{
  "metadata": {
    "pattern": "3hop_intra_doc_type1",
    "hop_count": "3hop",
    "category": "intra-doc",
    "connector_mode": "qualitative",
    "count": 250,
    "timestamp": "20260130_221007"
  },
  "questions": [
    {
      "question_id": 1,
      "question": "How does LLY's reliance on biologics data protection for Emgality in the U.S., which expires in 2030, align with their broader strategy of managing market exclusivity given the complex interaction between patent and regulatory protections?",
      "answer": "LLY relies on both compound patents and biologics data protection for Emgality, with U.S. data protection expiring in 2030 and compound patents extending until 2033. This staggered protection suggests a strategy to prolong market exclusivity by leveraging multiple forms of intellectual property. However, the company acknowledges on page 11 that predicting the actual length of exclusivity is difficult due to the complex interaction between patent and regulatory protections, as well as uncertainties in litigation and exclusivity extensions like pediatric or orphan drug designations. This implies that while LLY plans for extended exclusivity through layered protections, the real-world outcome may vary significantly from the estimated expiry dates.",
      "reasoning_steps": [
        "Hop 1: LLY(page_13) \u2192 Emgality: Emgality is protected by biologics data protection in the U.S. until 2030 and by compound patents until 2033.",
        "Hop 2: Emgality \u2192 Data Protection: Emgality is subject to multiple forms of intellectual property protection, including biologics data protection, which varies by territory and type.",
        "Hop 3: Data Protection \u2190 LLY(page_11): LLY acknowledges the complexity of predicting market exclusivity due to interactions between patent and regulatory protections, including uncertainties around litigation and exclusivity extensions."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Emgality",
        "node_3": "Data Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Emgality",
          "name": "Emgality",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 2,
      "question": "How does BMY's shared liability with AstraZeneca for Onglyza-related litigation risk, as disclosed in the legal proceedings section, reconcile with its continued financial stake in the product as indicated in the trademark disclosure?",
      "answer": "BMY shares potential liability with AstraZeneca for Onglyza-related litigation, as noted in the legal proceedings section where both companies are co-defendants in ongoing cardiovascular injury claims from the product's use. Despite divesting Onglyza to AstraZeneca in 2014, BMY still retains a financial stake in the product, as evidenced by the trademark disclosure in the document. This dual exposure\u2014both legal and financial\u2014suggests that while BMY no longer directly markets or profits from Onglyza, it remains vulnerable to legacy liabilities and maintains a residual economic interest in the product through its trademark rights.",
      "reasoning_steps": [
        "Hop 1: BMY(page_118) \u2192 AstraZeneca: BMY and AstraZeneca are co-defendants in ongoing litigation related to Onglyza, stemming from product liability claims of cardiovascular injuries, with the appeal still pending in the Sixth Circuit.",
        "Hop 2: AstraZeneca \u2192 Onglyza: AstraZeneca currently owns Onglyza, having acquired it from BMY in 2014, and is responsible for its ongoing commercialization.",
        "Hop 3: Onglyza \u2190 BMY(page_138): Despite the divestiture, BMY retains trademark rights to Onglyza, indicating a continued financial stake in the product\u2019s brand and market presence."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Produces]-> PRODUCT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "AstraZeneca",
        "node_3": "Onglyza",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_118",
          "chunk_id": "chunk_1",
          "chunk_text": "## Onglyza*\n\nBMS\t and\t AstraZeneca\t are\t co-defendants\t in\t product\t liability\t litigation\t related\t to Onglyza* .\t Plaintiffs\t assert\t claims, including\tclaims\tfor\twrongful\tdeath,\tas\ta\tresult\tof\theart\tfailure\tor\tother\tcardiovascular\tinjuries\tthey\tallege\twere\tcaused\tby their\t use\t of Onglyza* .\t In\t February\t 2018,\t the\t Judicial\t Panel\t on\t Multidistrict\t Litigation\t ordered\t all\t the\t federal Onglyza* cases\tto\tbe\ttransferred\tto\tan\tMDL\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tEastern\tDistrict\tof\tKentucky.\tA\tsignificant\tmajority\tof the\t claims\t were\t pending\t in\t the\t MDL,\t with\t others\t pending\t in\t a\t coordinated\t proceeding\t in\t California\t Superior\t Court\t in\t San Francisco\t(\"JCCP\").\tThe\tJCCP\tcourt\tgranted\tsummary\tjudgment\tto\tdefendants\tin\tMarch\t2022,\ta\tdecision\twhich\twas\taffirmed\tby\tthe California\tCourt\tof\tAppeal.\tThe\tCalifornia\tSupreme\tCourt\tdeclined\tto\treview\tthe\tdecision\tin\tJuly\t2023.\tIn\tthe\tMDL,\tthe\tcourt granted\t defendants'\t motion\t to\t exclude\t plaintiffs'\t only\t general\t causation\t expert\t on\t January\t 5,\t 2022\t and\t granted\t summary judgment\ton\tAugust\t2,\t2022.\tPlaintiffs\tfiled\ttheir\tNotice\tof\tAppeal\ton\tDecember\t2,\t2022.\tThe\tappeal\tremains\tpending\tin\tthe Sixth\tCircuit.\tAs\tpart\tof\tBMS's\tglobal\tdiabetes\tbusiness\tdivestiture,\tBMS\tsold Onglyza* to\tAstraZeneca\tin\tFebruary\t2014\tand any\tpotential\tliability\twith\trespect\tto Onglyza* is\texpected\tto\tbe\tshared\twith\tAstraZeneca.\n\n## SECURITIES\tLITIGATION\n\n## Celgene\tSecurities\tLitigations\n\nBeginning\t in\t March\t 2018,\t two\t putative\t class\t actions\t were\t filed\t against\t Celgene\t and\t certain\t of\t its\t officers\t in\t the\t U.S. District\t Court\t for\t the\t District\t of\t New\t Jersey\t (the\t \"Celgene\t Securities\t Class\t Action\").\t The\t complaints\t allege\t that\t the defendants\tviolated\tfederal\tsecurities\tlaws\tby\tmaking\tmisstatements\tand/or\tomissions\tconcerning\t(1)\ttrials\tof\tGED-0301,\t(2) Celgene's\t2020\toutlook\tand\tprojected\tsales\tof Otezla* ,\tand\t(3)\tthe\tNDA\tfor Zeposia .\tThe\tCourt\tconsolidated\tthe\ttwo\tactions and\tappointed\ta\tlead\tplaintiff,\tlead\tcounsel,\tand\tco-liaison\tcounsel\tfor\tthe\tputative\tclass.\tIn\tFebruary\t2019,\tthe\tdefendants filed\ta\tmotion\tto\tdismiss\tplaintiffs'\tamended\tcomplaint\tin\tfull.\tIn\tDecember\t2019,\tthe\tCourt\tdenied\tthe\tmotion\tto\tdismiss\tin part\tand\tgranted\tthe\tmotion\tto\tdismiss\tin\tpart\t(including\tall\tclaims\tarising\tfrom\talleged\tmisstatements\tregarding\tGED-0301). Although\tthe\tCourt\tgave\tthe\tplaintiff\tleave\tto\tre-plead\tthe\tdismissed\tclaims,\tit\telected\tnot\tto\tdo\tso,\tand\tthe\tdismissed claims\t are\t now\t dismissed\t with\t prejudice.\t In\t November\t 2020,\t the\t Court\t granted\t class\t certification\t with\t respect\t to\t the remaining\tclaims.\tIn\tMarch\t2023,\tthe\tCourt\tgranted\tthe\tdefendants\tleave\tto\tfile\ta\tmotion\tfor\tsummary\tjudgment,\tthe\tbriefing for\twhich\twas\tcompleted\tin\tJune\t2023.\tOn\tSeptember\t8,\t2023,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants'\tmotion for\t summary\t judgment\t as\t to\t the\t claims\t regarding\t statements\t made\t by\t the\t remaining\t officer\t defendants.\t As\t to\t the\t claims regarding\t Celgene's\t corporate\t statements,\t the\t Court\t denied\t the\t defendants'\t motion\t without\t prejudice\t and\t granted\t the defendants\tleave\tto\tre-raise\tthe\tissue.\tOn\tOctober\t27,\t2023,\tthe\tdefendants\tfiled\ta\tmotion\tfor\tpartial\tsummary\tjudgment\tas\tto Celgene's\tcorporate\tstatements.\n\nIn\tApril\t2020,\tcertain\tSchwab\tmanagement\tinvestment\tcompanies\ton\tbehalf\tof\tcertain\tSchwab\tfunds\tfiled\tan\tindividual\taction\tin the\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe\tsame\tallegations\tas\tthe\tCelgene\tSecurities\tClass Action\t against\t the\t same\t remaining\t defendants\t in\t that\t action\t (the\t \"Schwab\t Action\").\t In\t July\t 2020,\t the\t defendants\t filed\t a motion\tto\tdismiss\tthe\tplaintiffs'\tcomplaint\tin\tfull.\tIn\tMarch\t2021,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants' motion\tto\tdismiss\tconsistent\twith\tits\tdecision\tin\tthe\tCelgene\tSecurities\tClass\tAction.\n\nThe\t California\t Public\t Employees'\t Retirement\t System\t in\t April\t 2021\t (the\t \"CalPERS\t Action\");\t DFA\t Investment\t Dimensions\t Group Inc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds;\tand\tAmerican\tCentury\tMutual\tFunds,\tInc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds,\tin\tJuly 2021\t(respectively\tthe\t\"DFA\tAction\"\tand\tthe\t\"American\tCentury\tAction\"),\tand\tGIC\tPrivate\tLimited\tin\tSeptember\t2021\t(the\t\"GIC Action\"),\tfiled\tseparate\tindividual\tactions\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe same\t allegations\t as\t the\t Celgene\t Securities\t Class\t Action\t and\t the\t Schwab\t individual\t action\t against\t the\t same\t remaining defendants\t in\t those\t actions.\t In\t October\t 2021,\t these\t actions\t were\t consolidated\t for\t pre-trial\t proceedings\t with\t the\t Schwab Action.\tThe\tCourt\talso\tconsolidated\tany\tfuture\tdirect\tactions\traising\tcommon\tquestions\tof\tlaw\tand\tfact\twith\tthe\tSchwab\tAction (the\t \"Consolidated\t Schwab\t Action\").\t On\t October\t 2,\t 2023,\t defendants\t filed\t a\t motion\t for\t partial\t summary\t judgment\t in\t the Consolidated\tSchwab\tAction.\n\nNo\ttrial\tdates\thave\tbeen\tscheduled\tin\tany\tof\tthe\tabove\tCelgene\tSecurities\tLitigations.\n\n## Contingent\tValue\tRights\tLitigations\n\nIn\tJune\t2021,\tan\taction\twas\tfiled\tagainst\tBMS\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tSouthern\tDistrict\tof\tNew\tYork\tasserting claims\t of\t alleged\t breaches\t of\t a\t Contingent\t Value\t Rights\t Agreement\t (\"CVR\t Agreement\")\t entered\t into\t in\t connection\t with\t the closing\tof\tBMS's\tacquisition\tof\tCelgene\tCorporation\tin\tNovember\t2019.\tAn\tentity\tclaiming\tto\tbe\tthe\tsuccessor\ttrustee\tunder the\tCVR\tAgreement\talleges\tthat\tBMS\tbreached\tthe\tCVR\tAgreement\tby\tallegedly\tfailing\tto\tuse\t\"diligent\tefforts\"\tto\tobtain\tFDA approval\t of\t liso-cel\t ( Breyanzi )\t before\t a\t contractual\t milestone\t date,\t thereby\t allegedly\t avoiding\t a\t $6.4\t billion\t potential obligation\t to\t holders\t of\t the\t contingent\t value\t rights\t governed\t by\t the\t CVR\t Agreement\t and\t by\t allegedly\t failing\t to\t permit inspection\tof\trecords\tin\tresponse\tto\ta\trequest\tby\tthe\talleged\tsuccessor\ttrustee.\tThe\tplaintiff\tseeks\tdamages\tin\tan\tamount\tto be\tdetermined\tat\ttrial\tand\tother\trelief,\tincluding\tinterest\tand\tattorneys'\tfees.\tBMS\tdisputes\tthe\tallegations.\tBMS\tfiled\ta motion\tto\tdismiss\tthe\talleged\tsuccessor\ttrustee's\tcomplaint\tfor\tfailure\tto\tstate\ta\tclaim\tupon\twhich\trelief\tcan\tbe\tgranted, which\twas\tdenied\ton\tJune\t24,\t2022.\tOn\tFebruary\t2,\t2024,\tBMS\tfiled\ta\tmotion\tto\tdismiss\tthe\tcomplaint\tfor\tlack\tof\tsubject matter\tjurisdiction.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "AstraZeneca",
          "name": "AstraZeneca",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Onglyza",
          "name": "Onglyza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 3,
      "question": "How does the uncertainty around market exclusivity for Emgality, as influenced by data protection timelines in different territories, reflect the challenges LLY faces in maintaining long-term revenue stability for its neuroscience products?",
      "answer": "The 10-K filing acknowledges that the length of market exclusivity for products like Emgality is difficult to predict due to the complex interaction between patent and regulatory forms of exclusivity. Emgality benefits from biologics data protection expiring in 2030 in the U.S., 2028 in major European countries, and 2029 in Japan. However, this regulatory exclusivity is separate from patent protection, which extends to 2033 in the U.S. and Europe and 2035 in Japan. While data protection and patent protection work in parallel to extend exclusivity, the inherent unpredictability of patent litigation and regulatory decisions creates uncertainty in Emgality's long-term market position. This uncertainty, as noted in the intellectual property section, directly impacts LLY\u2019s ability to guarantee revenue stability for neuroscience products like Emgality, despite current protection timelines.",
      "reasoning_steps": [
        "Hop 1: LLY(page_11) \u2192 Data Protection: The company acknowledges the difficulty in predicting market exclusivity due to the complex interaction between patent and regulatory forms of protection, including data protection.",
        "Hop 2: Data Protection \u2192 Emgality: Emgality is subject to multiple forms of protection, including biologics data protection with expiry dates ranging from 2028 (Europe) to 2030 (U.S.) and compound patents extending to 2035 (Japan).",
        "Hop 3: Emgality \u2190 LLY(page_13): Emgality is listed as a key neuroscience product with specific protection timelines, highlighting its strategic importance and the risk associated with the expiration of exclusivity."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Data Protection",
        "node_3": "Emgality",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Emgality",
          "name": "Emgality",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 4,
      "question": "Given Trulicity's 32% U.S. revenue decline in 2024, how does the imminent expiration of its data protection align with Lilly's broader strategy to maintain market exclusivity for key products?",
      "answer": "The 32% U.S. revenue decline for Trulicity in 2024, driven by competitive dynamics and supply constraints, raises concerns about its sustainability as a revenue driver. This decline coincides with the disclosure that Trulicity will lose significant patent and data protections in the coming years, which typically leads to generic competition and further revenue erosion. However, Lilly emphasizes a broader intellectual property strategy that includes pending or granted patent term extensions, pediatric or orphan drug exclusivity, and complex interactions between patent and regulatory exclusivity to potentially extend market protection. Despite the uncertainty around Trulicity's future exclusivity, Lilly's IP portfolio management suggests an intent to strategically delay generic entry and maintain some level of market control, even as the product faces immediate competitive pressures.",
      "reasoning_steps": [
        "Hop 1: LLY(page_49) \u2192 Trulicity: Trulicity's U.S. revenue decreased by 32% in 2024 due to competitive dynamics and supply constraints.",
        "Hop 2: Trulicity \u2192 Data Protection: Trulicity is expected to lose significant patent and data protections in the next few years, increasing exposure to generic competition.",
        "Hop 3: Data Protection \u2190 LLY(page_11): Lilly outlines a strategy to extend market exclusivity through patent term extensions, pediatric/orphan drug exclusivity, and complex interactions between patent and regulatory protections."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Expires]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Trulicity",
        "node_3": "Data Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers m ay not add due to rounding.\n\nNM - not m eaningful\n\nJardiance revenue includes Glyxam bi,Synjardy, and Trijardy XR . (1)\n\nHumalog revenue includes insulin lispro. (2)\n\nBasaglar revenue includes R ezvoglar. (3)\n\nZyprexa revenue includes sale of the rights for the olanzapine portfolio in 2023. (4)\n\nRevenue of Mounjaro increased 85 percent in the U.S., primarily driv en by strong demand and increased supply. Rev enue outside of the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023, primarily driv en by v olume growth in launched markets.\n\nRevenue of Verzenio increased 36 percent in the U.S., driv en by increased demand, wholesaler buying patterns and, to a lesser extent, higher realized prices. Rev enue outside the U.S. increased 39 percent, driv en by increased demand.\n\nRevenue of Trulicity decreased 32 percent in the U.S., driv en by decreased v olume primarily due to competitiv e dynamics and supply constraints during the first half of 2024. Rev enue outside the U.S. decreased 8 percent, driv en by decreased v olume primarily due to competitiv e dynamics and actions we have taken to manage demand.\n\nRevenue of Zepbound in the U.S. in 2024 was $4.93 billion, compared to $175.8 million in 2023. Zepbound launched in the U.S. for the treatment of adult patients with obesity or ov erweight with weight-related comorbidities in Nov ember 2023.\n\nRevenue of Jardiance remained relativ ely flat in the U.S. as increased demand was offset by lower realized prices. Rev enue outside the U.S. increased 52 percent, driv en by increased v olume and a one-time payment receiv ed of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim. Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim inv olv ing Jardiance.\n\nRevenue of Taltz increased 18 percent in the U.S., driv en by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand. Revenue outside the U.S. increased 19 percent, primarily driv en by increased demand.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Trulicity",
          "name": "Trulicity",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain entities has increased due to consolidation, regulatory, and other market impacts, and they, along with gov ernments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or fav orable formulary placement. Such stakeholders hav e also increasingly imposed utilization management tools to limit access to our products. As these practices expand, including due to potential further consolidation of U.S. priv ate third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. We expect that consolidation of supply chain entities will continue to increase competitiv e and pricing pressures on pharmaceutical manufacturers.\n\nPharmacy benefit manager practices hav e come under increased scrutiny from U.S. policymakers at the federal and state lev el who hav e proposed legislation intended to address concerns regarding the impact that these intermediaries hav e on drug pricing and patients' out of pocket costs. If promulgated, such legislation could hav e resultant implications, costs, or consequences for our business and how we interact with these entities. For additional information on pricing and reimbursement for our pharmaceutical products, see Item 1, \"Business-U.S. Priv ate Sector Dynamics\" and \"Regulations and Priv ate Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.\"\n\n## Risks Related to Our Intellectual Property\n\n- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.\n\nIn the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time. For example, Trulicity will lose significant patent and remaining data protections in the next few years. Some products also lose patent protection as a result of successful third-party challenges. We hav e faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection.\n\nFor non-biologic products, loss of exclusiv ity typically results in the entry of one or more generic competitors, leading to a rapid and sev ere decline in rev enues, especially in the U.S. Generic pharmaceutical companies hav e in some cases introduced a generic product before resolution of any related patent litigation. For biologics, loss of exclusiv ity may or may not result in the near-term entry of competitor v ersions (i.e., biosimilars) due to many factors, including dev elopment timelines, manufacturing challenges, and/or uncertainties regarding the regulatory approv al pathways.\n\nOur success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often inv olv e complex legal, scientific and factual questions. There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found v alid and enforceable if challenged. Third parties may challenge, inv alidate, or circumv ent our patents and patent applications relating to our products, product candidates, and technologies. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not be deemed to infringe our patents. Moreover, patents relating to particular products, uses, formulations, or processes may not preclude other manufacturers from employing alternativ e processes or marketing alternativ e products or formulations that compete with our patented products. Patents held by third-parties hav e also contributed, and may in the future contribute, to a decision by us to not pursue all potential indications for a product candidate. In addition, competitors or other third parties may assert claims that our activ ities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis-Executiv e Ov erv iew-Other Matters-Patent Matters\" and Item 1, \"Business-Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.",
          "relationship": "Expires"
        },
        "node_3": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 5,
      "question": "How does the spin-off of Greenstone and its combination with Mylan impact Pfizer's segment reporting structure and revenue classification post-2020, particularly in relation to contract manufacturing and transitional supply agreements?",
      "answer": "Pfizer spun off its Upjohn Business, including Greenstone, on November 16, 2020, and combined it with Mylan to form Viatris. Following this transaction, Pfizer reorganized its commercial operations and began managing its business through two operating segments: Biopharma and PC1. PC1 includes revenues from contract manufacturing, such as Comirnaty-related manufacturing activities for BioNTech ($320 million in 2021), as well as revenues from manufacturing and supply agreements with former legacy Pfizer businesses, including transitional agreements with Viatris. This reorganization and the spin-off directly influenced how Pfizer classified its revenues post-2020, separating innovative biopharma operations from contract and transitional manufacturing activities.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_8) \u2192 [Greenstone]: Pfizer's Upjohn Business included Greenstone, a U.S.-based generics platform, which was spun off on November 16, 2020.",
        "Hop 2: [Greenstone] \u2192 [Mylan]: Greenstone was combined with Mylan to create Viatris as part of the spin-off transaction.",
        "Hop 3: [Mylan] \u2190 [PFE](page_113): Following the spin-off, Pfizer reorganized its commercial operations into two segments, including PC1 which manages contract manufacturing and transitional supply agreements with Viatris (formerly including Greenstone and Mylan)."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> COMP -[Involved_In]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Greenstone",
        "node_3": "Mylan",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "| U.K.            | United Kingdom                                                                                                                                                                                                                                                                                                                                            |\n|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Upjohn Business | Pfizer's former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris |\n| U.S.            | United States                                                                                                                                                                                                                                                                                                                                             |\n| Valneva         | Valneva SE                                                                                                                                                                                                                                                                                                                                                |\n| VBP             | volume-based procurement                                                                                                                                                                                                                                                                                                                                  |\n| Viatris         | Viatris Inc.                                                                                                                                                                                                                                                                                                                                              |\n| ViiV            | ViiV Healthcare Limited                                                                                                                                                                                                                                                                                                                                   |\n| WHO             | World Health Organization                                                                                                                                                                                                                                                                                                                                 |\n| WRDM            | Worldwide Research, Development and Medical                                                                                                                                                                                                                                                                                                               |\n| WTO             | World Trade Organization                                                                                                                                                                                                                                                                                                                                  |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Greenstone",
          "name": "Greenstone",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "| U.K.            | United Kingdom                                                                                                                                                                                                                                                                                                                                            |\n|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Upjohn Business | Pfizer's former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris |\n| U.S.            | United States                                                                                                                                                                                                                                                                                                                                             |\n| Valneva         | Valneva SE                                                                                                                                                                                                                                                                                                                                                |\n| VBP             | volume-based procurement                                                                                                                                                                                                                                                                                                                                  |\n| Viatris         | Viatris Inc.                                                                                                                                                                                                                                                                                                                                              |\n| ViiV            | ViiV Healthcare Limited                                                                                                                                                                                                                                                                                                                                   |\n| WHO             | World Health Organization                                                                                                                                                                                                                                                                                                                                 |\n| WRDM            | Worldwide Research, Development and Medical                                                                                                                                                                                                                                                                                                               |\n| WTO             | World Trade Organization                                                                                                                                                                                                                                                                                                                                  |\n",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Mylan",
          "name": "Mylan",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_113",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOn December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See Note 1A . (a)\n\nAt the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. (b)\n\n- Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). (c)\n- Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera. (d)\n- Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. (e)\n- On July 31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK's consumer healthcare business to form a new consumer healthcare JV. See Note 2C . (f)\n- Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals. (g)\n\n## Remaining Performance Obligations\n\nContracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totals $34.4 billion as of December 31, 2021, which includes amounts received in advance and deferred and amounts that will be invoiced as we deliver the product to our customers in future periods. Of this amount, we expect to recognize revenue of\n\nPfizer Inc.\n\n2021 Form 10-K\n\n104",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 6,
      "question": "How does the growth in EVENITY's contribution to Amgen's 2024 product sales align with the financial impact of Amgen's profit-sharing arrangement with UCB, given the $547 million global profit and loss share expense recorded in 2024?",
      "answer": "Amgen reported that EVENITY was among the brands contributing to a 26% U.S. volume growth and 17% ROW volume growth in 2024, indicating strong performance of the product. However, under Amgen's collaboration with UCB for EVENITY, Amgen shares global development costs and commercialization profits and losses equally with UCB. In 2024, this profit-sharing arrangement resulted in a $547 million expense recorded under Cost of Sales. Therefore, while EVENITY contributed positively to product sales volume, the financial benefit was partially offset by the shared profit obligations with UCB, reducing the net margin impact of EVENITY's growth.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_69) \u2192 EVENITY: EVENITY is listed among key products contributing to Amgen's 26% U.S. volume growth and 17% ROW volume growth in 2024.",
        "Hop 2: EVENITY \u2192 UCB: Amgen collaborates with UCB on EVENITY, sharing global development costs and commercialization profits and losses equally.",
        "Hop 3: UCB \u2190 AMGN(page_132): In 2024, Amgen recorded a $547 million profit and loss share expense related to the EVENITY collaboration with UCB, impacting cost of sales."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Includes]-> PRODUCT -[Introduces]-> COMP <-[Shares_Profits_Losses]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "EVENITY",
        "node_3": "UCB",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_69",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn the following discussion of changes in product sales, any reference to volume growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).\n\nTotal product sales increased 19% in 2024, primarily driven by volume growth of 23%, partially offset by declines in net selling price of 2%. U.S. volume grew 26% and ROW volume grew 17%. Product sales from acquired Horizon products contributed $4.2 billion in 2024 compared to $954 million in 2023, with volume growth of 11% from our other brands, including Repatha, TEZSPIRE, EVENITY, BLINCYTO and Prolia.\n\nFor 2025, we expect volume growth from certain brands to be partially offset by net selling price declines. Further, the first quarter of a year historically represents the  lowest  product  sales  quarter  for  the  year,  in  part  due  to  plan  changes,  insurance  reverifications  and  higher  co-pay  ex penses  as  U.S.  patients  work  through deductibles, particularly for products acquired through pharmacy benefit programs.\n\nUncertain macroeconomic conditions, changes in the healthcare ecosystem and geopolitical conflicts have the potential to introduce variability into product sales. Furthermore, product sales continue to be impacted by actions from governments and other entities to curb high inflation, provisions of the IRA, inappropriate expanded utilization of the 340B Program and growth in numbers of Medicaid enrollees and uninsured individuals. See Risk Factors in Part I, Item 1A. of this Form 10-K.\n\nOther revenues increased for 2024, primarily driven by higher corporate partner revenue from licensed products and royalty income.\n\nOperating expenses increased for 2024, driven by higher amortization expense from Horizon acquisition-related assets, higher R&amp;D and SG &amp;A expenses, including expenses from the acquired Horizon business, and higher profit share and royalty expense.",
          "relationship": "Includes"
        },
        "node_2": {
          "id": "EVENITY",
          "name": "EVENITY",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_29",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic  position  within  our  industry  by  strengthening  and  diversifying  our  R&amp;D  capabilities,  product  pipeline  and  marketed-product  base.  These  arrangements generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalties and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade  secret  protection  for  our  unpatented  confidential  and  proprietary  information  is  important  to  us.  To  protect  our  trade  secrets,  we  generally  require counterparties to execute confidentiality agreements upon commencement of a business relationship with us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## AstraZeneca plc\n\nWe are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE. Under our collaboration, both companies share global costs, profits and losses equally after payment by AstraZeneca of a mid-single-digit royalty to Amgen. AstraZeneca leads global development. In North America, Amgen, as the  principal,  recognizes  product  sales  of  TEZSPIRE  in  the  United  States,  and  AstraZeneca,  as  the  principal,  recognizes  product  sales  of  TEZSPIRE  in  Canada. AstraZeneca leads commercialization for TEZSPIRE outside North America. Amgen manufactures and supplies TEZSPIRE worldwide. 1\n\n## UCB\n\nWe are in a collaboration with UCB for the development and commercialization of EVENITY . Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY  and recognizes product sales in all other territories, including the United States. G lobal development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.\n\n## BeiGene, Ltd.\n\nIn January 2020, we acquired an equity stake in BeiG ene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For  additional  information  regarding  our  equity  investment  in  BeiG ene,  see  Part  IV -Note  10,  Investments,  to  the  Consolidated  Financial  Statements.  Under  the collaboration, BeiG ene began selling XGEV A in 2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to  BeiG ene on sales in  China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiG ene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiG ene will assume commercialization rights in China for a specified period, and Amgen and BeiG ene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiG ene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene.\n\nFor financial information about our significant collaborative arrangements, see Part IV-Note 9, Collaborations, to the Consolidated Financial Statements.\n\nWe are also in a collaboration w ith AstraZeneca for the development of AMG  104. S ee Research and Development and S elected Product Candidates section above. 1",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "UCB",
          "name": "UCB",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "## UCB\n\nWe are in a collaboration with UCB for the development and commercialization of EVENITY . Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY  and recognizes product sales in all other territories, including the United States. G lobal development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.\n\nDuring the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $547 million, $396 million and $255 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2024, 2023 and 2022, were not material.\n\n## BeiGene, Ltd.\n\nIn January 2020, we acquired an equity stake in BeiG ene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For  additional  information  regarding  our  equity  investment  in  BeiG ene,  see  Note  10,  Investments.  Under  the  collaboration,  BeiG ene  began  selling  XG EV A  in  2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to BeiG ene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiG ene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiG ene will assume commercialization rights in China for a specified period, and Amgen and BeiG ene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiG ene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene.\n\nDuring the years ended December 31, 2024, 2023 and 2022, net costs recovered from BeiG ene for oncology product candidates were $122 million, $109 million and $199 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2024, 2023 and 2022, product sales from Amgen to BeiG ene under the collaboration were $259 million, $125 million and $64 million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. Profit and loss share expenses related to the initial product-specific commercialization period were not material during the years ended December 31, 2024, 2023 and 2022.\n\n## Kyowa Kirin Co., Ltd.\n\nWe are in a collaboration and licensing agreement with Kyowa Kirin to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.\n\nUnder the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. Kyowa Kirin will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.\n\nWe made an upfront payment of $400 million to Kyowa Kirin that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and Kyowa Kirin share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by Kyowa Kirin will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay Kyowa Kirin significant double-digit royalties on global sales, except in Japan. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from Kyowa Kirin were $166 million, $93 million and $23 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income.\n\n## Other\n\nIn addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts, or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties, or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.",
          "relationship": "Shares_Profits_Losses"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 7,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as detailed in the separation agreements, impact the financial presentation of discontinued operations in the consolidated statement of income?",
      "answer": "Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, outlined in the manufacturing and supply agreements (MSAs), generated $219 million in sales and $195 million in cost of sales in 2021. Despite Organon being classified as a discontinued operation following the June 2, 2021 spin-off, these post-spin-off transactions continued to influence Merck\u2019s consolidated financial statements. The results of Organon\u2019s women\u2019s health, biosimilars, and established brands businesses were reflected as discontinued operations, yet the MSAs created a continued economic linkage. This dual treatment\u2014Organon as a spun-off entity while maintaining contractual supply obligations\u2014required Merck to separately disclose these transactions while also presenting Organon\u2019s historical results as discontinued operations, thereby affecting both income from discontinued operations and current asset/liability balances such as the $964 million due from Organon.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_94) \u2192 [Finished Pharmaceutical Products]: Merck entered into MSAs to manufacture and supply finished pharmaceutical products for Organon post-spin-off, with $219 million in sales and $195 million in cost of sales in 2021.",
        "Hop 2: [Finished Pharmaceutical Products] \u2192 [Organon]: These products are a core output of the post-spin-off supply relationship, indicating ongoing operational interdependence despite the separation.",
        "Hop 3: [Organon] \u2190 [MRK](page_146): Organon\u2019s historical operations were classified as discontinued in the consolidated income statement, with all periods presented recast accordingly, including the results of the businesses spun off to Organon."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Produces]-> COMP <-[Spins_Off]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Finished Pharmaceutical Products",
        "node_3": "Organon",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Finished_Pharmaceutical_Products",
          "name": "Finished Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_146",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmounts in the fourth quarter of 2020 include charges related to the acquisitions of VelosBio Inc. and OncoImmune (see Note 4) and an intangible asset impairment charge related to Zerbaxa (see Note 9). (1)\n\nAmounts in the third quarter of 2020 include charges related to transactions with Seagen Inc (see Note 4). (2)\n\nAmounts in the second quarter of 2021 include a charge related to the acquisition of Pandion Therapeutics, Inc. (see Note 4). (3)\n\nReflects the results of the businesses that were spun-off to Organon on June 2, 2021 as discontinued operations for all periods presented (see Note 3). (4)",
          "relationship": "Spins_Off"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 8,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as outlined in the separation agreements, impact the financial presentation of discontinued operations in Merck's consolidated income statement through June 2, 2021?",
      "answer": "Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as detailed in the manufacturing and supply agreements (MSAs), generated $219 million in sales and $195 million in cost of sales in 2021. Despite Organon being classified as a discontinued operation through June 2, 2021, the continuation of these supply agreements created a dual financial relationship\u2014where Merck both operated Organon\u2019s legacy businesses and provided critical manufacturing services post-spin-off. This duality complicates the clean separation of Organon\u2019s financial results from Merck\u2019s ongoing operations, suggesting that the discontinued operations presentation may not fully capture the interdependent financial impact of the spin-off and the continuing supply chain relationship.",
      "reasoning_steps": [
        "Hop 1: MRK(page_94) \u2192 Finished Pharmaceutical Products: Merck continues to manufacture and supply finished pharmaceutical products for Organon under MSAs, with $219 million in sales and $195 million in cost of sales recorded in 2021.",
        "Hop 2: Finished Pharmaceutical Products \u2192 Organon: These finished products represent a key output of the spun-off business and are central to Organon\u2019s post-spin-off operations, indicating a continued dependency on Merck\u2019s manufacturing infrastructure.",
        "Hop 3: Organon \u2190 MRK(page_146): Organon\u2019s results are reflected as discontinued operations in Merck\u2019s consolidated income statement through June 2, 2021, with prior periods recast accordingly."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Produces]-> COMP <-[Spins_Off]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Finished Pharmaceutical Products",
        "node_3": "Organon",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Finished_Pharmaceutical_Products",
          "name": "Finished Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_146",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmounts in the fourth quarter of 2020 include charges related to the acquisitions of VelosBio Inc. and OncoImmune (see Note 4) and an intangible asset impairment charge related to Zerbaxa (see Note 9). (1)\n\nAmounts in the third quarter of 2020 include charges related to transactions with Seagen Inc (see Note 4). (2)\n\nAmounts in the second quarter of 2021 include a charge related to the acquisition of Pandion Therapeutics, Inc. (see Note 4). (3)\n\nReflects the results of the businesses that were spun-off to Organon on June 2, 2021 as discontinued operations for all periods presented (see Note 3). (4)",
          "relationship": "Spins_Off"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 9,
      "question": "How does AbbVie's fair value accounting treatment for the Cerevel Therapeutics funding agreements, which include milestone-based repayment terms for tavapadon, relate to the deferred tax liabilities recognized as a result of the acquisition?",
      "answer": "AbbVie accounts for the Cerevel Therapeutics funding agreements under the fair value option, with a $246 million financing liability recognized at acquisition based on a probability-weighted model and Monte Carlo simulations for milestone and royalty payments. These agreements, which are contingent on FDA approval of tavapadon, represent a long-term financial obligation tied to the success of a specific drug candidate. Concurrently, AbbVie recognized deferred tax liabilities due to the acquisition, primarily stemming from the excess book basis over tax basis of intangible assets. This indicates that while AbbVie has assumed contingent financial obligations (like the funding agreements), it has also taken on long-term tax implications from the acquisition, suggesting a complex interplay between contingent liabilities and tax planning considerations. The fair value treatment of the funding agreements and the deferred tax liabilities both reflect the broader financial impact of the Cerevel acquisition on AbbVie\u2019s balance sheet.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_84) \u2192 [Funding Agreements]: Discussed in the context of fair value accounting, with a $246 million financing liability recognized using a probability-weighted model and Monte Carlo simulations for regulatory and sales milestones tied to tavapadon.",
        "Hop 2: [Funding Agreements] \u2192 [Cerevel Therapeutics]: Entered into by Cerevel prior to acquisition and assumed by AbbVie; these agreements are tied to the development and regulatory success of tavapadon.",
        "Hop 3: [Cerevel Therapeutics] \u2190 [ABBV](page_97): Acquisition of Cerevel resulted in deferred tax liabilities due to the excess book basis over tax basis of intangible assets."
      ],
      "difficulty": "hard",
      "idf_score": 6.115534801023568,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> FIN_INST -[Enters]-> COMP <-[Involved_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Funding Agreements",
        "node_3": "Cerevel Therapeutics",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Funding_Agreements",
          "name": "Funding Agreements",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_67",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIntangible assets relate to $8.1 billion of acquired in-process research and development (IPR&amp;D) associated with products that have not yet received regulatory approval. The estimated fair values of identifiable intangible assets were determined using the \"income approach\" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful l i fe. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors.\n\nThe current portion of long-term debt assumed by AbbVie consists of $345 million aggregate principal of 2.5% convertible senior notes due 2027. Upon acquisition, the convertible senior notes became callable and note holders could redeem the convertible senior notes for cash at a premium. As of the acquisition date, the convertible senior notes were recognized as current portion of long-term debt on the consolidated balance sheets at an aggregate fair value of $400 million. Following the acquisition date, the company repaid the convertible senior notes and there were no amounts outstanding as of December 31, 2024.\n\nLong-term debt assumed by AbbVie relates to funding agreements entered into by Cerevel Therapeutics prior to the acquisition. Under the agreements, Cerevel Therapeutics received funding to support development of tavapadon and agreed to repay regulatory milestones, sales milestones and royalties contingent upon approval of tavapadon by the U.S. Food and Drug Administration (FDA). The funding agreements were accounted for as financing arrangements and the fair value of the related financing liability was $246 million as of the acquisition date. The estimated fair value of the financing liability was determined using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Assumptions inherent in the development of fair value include discount rates, estimated probabilities and timing of achieving milestones and estimated amounts of future sales. See Note 10 and Note 11 for additional information.\n\nGoodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of Cerevel Therapeutics represents expected synergies, including the ability to: (i) expand AbbVie's neuroscience pipeline, (ii) leverage AbbVie's commercial, regulatory and clinical expertise to maximize Cerevel Therapeutic's assets and (iii) enhance AbbVie's existing neuroscience discovery capabilities. The goodwill is not deductible for tax purposes.\n\n2024 Form 10-K\n\n",
          "relationship": "Enters"
        },
        "node_3": {
          "id": "Cerevel_Therapeutics",
          "name": "Cerevel Therapeutics",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe decrease in deferred tax assets is primarily related to a decrease in compensation, employee benefits and advance payments. The increase in deferred tax liabilities is primarily due to the acquisition of Cerevel Therapeutics and ImmunoGen in which the company recorded the excess of book basis over tax basis of intangible assets, offset by amortization and impairment of intangible assets.\n\nThe company had valuation allowances of $14.8 billion as of December 31, 2024 and $13.5 billion as of December 31, 2023. These were principally related to foreign and state net operating losses and other credit carryforwards that are not expected to be realized.\n\nThe company incurred carryforward deductions in a foreign jurisdiction where realization of the future income tax benefit was, in previous reporting periods, considered so remote that the income tax benefit was not recognized as a deferred tax asset. In 2024, the company concluded that the future income tax benefit of the carryforward balances is no longer remote and therefore, a deferred tax asset was recognized. The company also recognized an offsetting valuation allowance, resulting in no net impact to deferred tax assets as such carryforward balances are not expected to be realized in the foreseeable future.\n\nAs of December 31, 2024, the company had U.S. federal, state and foreign credit carryforwards of $669 million as well as U.S. federal, state and foreign net operating loss carryforwards of $38.9 billion, which will expire at various times through 2044. The company also had foreign loss carryforwards of $33.3 billion that have no expiration.\n\nUnremitted foreign earnings subject to the Act's transition tax are not considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings or eligible for the 100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. However, the company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distributions) to be permanent in duration. The unrecognized tax liability is not practicable to determine.\n\n2024 Form 10-K\n\n",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 10,
      "question": "How does BMY's financial dependency on Ono for Opdivo royalties compare with the revenue-sharing structure of Tecentriq patent licensing agreements, and what does this reveal about BMY's strategic positioning in the PD-(L)1 immunotherapy space?",
      "answer": "BMY's financial dependency on Ono is evident through the royalty structure for Opdivo, where Ono receives 15% of sales outside North America and Japan, South Korea, and Taiwan, indicating a significant revenue-sharing obligation. Meanwhile, in the Tecentriq patent licensing agreement with Roche, BMY and Ono share single-digit royalties on global net sales through 2026, consistent with their existing arrangements. The contrast in royalty structures\u2014Opdivo's fixed percentages versus Tecentriq's single-digit terms\u2014suggests that BMY's strategic positioning in the PD-(L)1 immunotherapy space is shaped by both legacy partnerships and evolving licensing frameworks that balance revenue inflows with collaborative innovation.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_86) \u2192 [Ono]: BMY depends on Ono for Opdivo, with Ono receiving 15% royalties outside North America and the listed Asian territories.",
        "Hop 2: [Ono] \u2192 [Tecentriq]: Ono and BMY jointly benefit from Tecentriq licensing, with Roche paying single-digit royalties on global net sales through 2026, shared between BMY and Ono.",
        "Hop 3: [Tecentriq] \u2190 [BMY](page_90): BMY is a party to the Tecentriq patent licensing agreement with Roche, sharing royalties with Ono in alignment with prior agreements."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Receives]-> PRODUCT <-[Receives]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Ono",
        "node_3": "Tecentriq",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Tecentriq",
          "name": "Tecentriq",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 11,
      "question": "How does Merck's revenue growth from Verquvo in its own marketing territories compare with the potential future milestone payments tied to Verquvo's global sales performance under the Bayer collaboration agreement?",
      "answer": "Merck reported that sales of Verquvo and Adempas in its marketing territories grew 14% in 2021, primarily driven by higher demand in Europe. This growth indicates strong uptake of the product in Merck's commercialization regions. Meanwhile, under the collaboration agreement with Bayer, Merck determined in 2021 that future sales of Verquvo and Adempas would likely trigger an additional $400 million in sales-based milestone payments to Bayer. This suggests that while Verquvo is contributing positively to Merck's revenue in its territories, it is also expected to lead to significant future outflows tied to performance metrics. The interplay between these revenue gains and contingent liabilities highlights the dual-edged nature of the partnership from Merck's financial perspective.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_62) \u2192 [Verquvo]: Merck introduces Verquvo and reports a 14% growth in sales of Verquvo and Adempas in its marketing territories in 2021.",
        "Hop 2: [Verquvo] \u2192 [Bayer AG]: Bayer commercializes Verquvo outside the U.S., and Merck has a profit-sharing and cost-sharing arrangement with Bayer for the product.",
        "Hop 3: [Bayer AG] \u2190 [MRK](page_103): Merck disclosed that future sales of Verquvo are expected to trigger $400 million in additional sales-based milestone payments to Bayer."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Commercializes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Verquvo",
        "node_3": "Bayer AG",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5 to the consolidated financial statements). (1)\n\nAdempas  and  Verquvo  are  part  of  a  worldwide  collaboration  with  Bayer  to  market  and  develop  soluble  guanylate cyclase (sGC) modulators (see Note 5 to the consolidated financial statements). Adempas is approved for the treatment of certain types  of  PAH.  Verquvo  was  approved  in  the  U.S.  in  January  2021  to  reduce  the  risk  of  cardiovascular  death  and  heart  failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. These approvals were based on the results of the VICTORIA trial. Alliance revenue from the collaboration grew 22% in 2021 and rose 38% in 2020. Revenue from the collaboration also includes sales of Adempas and Verquvo in Merck's marketing territories. Sales of Adempas in Merck's marketing territories grew 14% in 2021 primarily reflecting higher demand in Europe.\n\n## Diabetes\n\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Verquvo",
          "name": "Verquvo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Bayer_AG",
          "name": "Bayer AG",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 12,
      "question": "How does Gilead's revenue recognition approach for Symtuza, which is commercialized by Janssen, reflect the contractual revenue-sharing terms and the accounting treatment of the intellectual property and supply obligations outlined in the collaboration agreement?",
      "answer": "Gilead recognizes its share of Symtuza revenue in the period when Janssen reports corresponding sales, as the license to the Gilead Compounds is deemed the predominant item in the agreement. This approach aligns with the contractual terms where Janssen sets the price of Symtuza and both parties share revenue based on the ratio of the net selling prices of their respective components, subject to restrictions and adjustments. Additionally, the intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation, which supports the timing and pattern of revenue recognition. This treatment reflects Gilead's role as the exclusive supplier of the Gilead Compounds and its ongoing involvement in the intellectual property underpinning Symtuza.",
      "reasoning_steps": [
        "Hop 1: GILD(page_40) \u2192 Symtuza: Gilead reports revenue from cobicistat, emtricitabine, and tenofovir alafenamide in Symtuza, a product commercialized by Janssen, and references the collaboration agreement for additional details.",
        "Hop 2: Symtuza \u2192 Janssen: Janssen is responsible for manufacturing, registration, distribution, and commercialization of Symtuza globally, while Gilead supplies the Gilead Compounds and retains intellectual property rights.",
        "Hop 3: Janssen \u2190 GILD(page_79): Gilead recognizes its share of Symtuza revenue as product sales when Janssen makes corresponding sales, due to the predominant nature of the intellectual property license. The revenue-sharing model is based on the net selling prices of each party\u2019s components."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Commercializes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Symtuza",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_40",
          "chunk_id": "chunk_5",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nRepresents\tour\trevenue\tfrom\tcobicistat\t('C'),\temtricitabine\t('FTC')\tand\ttenofovir\talafenamide\t('TAF')\tin\tSymtuza\t(darunavir/C/FTC/TAF),\ta\tfixed dose\t combination\t product\t commercialized\t by\t Janssen\t Sciences\t Ireland\t Unlimited\t Company\t ('Janssen').\t See\t Note\t 7.\t Collaborations\t and\t Other Arrangements\tof\tthe\tNotes\tto\tConsolidated\tFinancial\tStatements\tincluded\tin\tItem\t8\tof\tthis\tAnnual\tReport\ton\tForm\t10-K\tfor\tadditional\tinformation. Includes\tAtripla,\tEmtriva,\tSunlenca\tand\tTybost. (1) (2)\n\nHIV\t product\t sales\t increased\t 6%\t to\t $18.2\t billion\t in\t 2023,\t compared\t to\t 2022,\t primarily\t due\t to\t higher\t demand\t across treatment\t and\t prevention,\t in\t addition\t to\t higher\t average\t realized\t price\t and\t favorable\t channel\t inventory\t dynamics.\t In particular,\tBiktarvy\tsales\tincreased\tprimarily\treflecting\thigher\tdemand,\tincluding\tpatients\tswitching\tfrom\tother\tGilead\tHIV products,\t as\t well\t as\t higher\t average\t realized\t price.\t Also,\t Descovy\t sales\t increased\t primarily\t driven\t by\t favorable\t channel inventory\tdynamics\tand\thigher\tdemand.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen\t sets\t the\t price\t of\t Symtuza\t and\t the\t parties\t share\t revenue\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the party's\t component(s),\t subject\t to\t certain\t restrictions\t and\t adjustments.\t The\t intellectual\t property\t license\t and\t supply obligations\trelated\tto\tthe\tGilead\tCompounds\tare\taccounted\tfor\tas\ta\tsingle\tperformance\tobligation.\tAs\tthe\tlicense\twas\tdeemed to\tbe\tthe\tpredominant\titem\tto\twhich\tthe\trevenue\tshare\trelates,\twe\trecognize\tour\tshare\tof\tthe\tSymtuza\trevenue\tin\tthe\tperiod when\tthe\tcorresponding\tsales\tof\tSymtuza\tby\tJanssen\toccur.\tWe\trecord\tour\tshare\tof\tthe\tSymtuza\trevenue\tas\tProduct\tsales\ton\tour Consolidated\tStatements\tof\tIncome\tprimarily\tbecause\twe\tsupply\tthe\tGilead\tCompounds\tto\tJanssen\tfor\tSymtuza.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tJanssen may\tterminate\tthe\tagreement\twithout\tcause\ton\ta\tcountry-by-country\tbasis,\tin\twhich\tcase\tGilead\thas\tthe\tright\tto\tbecome\tthe selling\tparty\tfor\tsuch\tcountry(ies)\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10\tyears.\tJanssen may\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Japan\tTobacco\n\nIn\t2005,\tJapan\tTobacco,\tInc.\t('Japan\tTobacco')\tgranted\tus\texclusive\trights\tto\tdevelop\tand\tcommercialize\telvitegravir,\ta novel\t HIV\t integrase\t inhibitor,\t in\t all\t countries\t of\t the\t world,\t excluding\t Japan,\t where\t Japan\t Tobacco\t retained\t such\t rights. Effective\t December\t 2018,\t we\t entered\t into\t an\t agreement\t with\t Japan\t Tobacco\t to\t acquire\t the\t rights\t to\t market\t and\t distribute certain\tproducts\tin\tour\tHIV\tportfolio\tin\tJapan\tand\tto\texpand\tour\trights\tto\tdevelop\tand\tcommercialize\telvitegravir\tto\tinclude Japan.\tWe\tare\tresponsible\tfor\tthe\tmarketing\tof\tthe\tproducts\tas\tof\tJanuary\t1,\t2019.\n\nWe\t are\t responsible\t for\t seeking\t regulatory\t approval\t in\t our\t territories\t and\t are\t required\t to\t use\t diligent\t efforts\t to commercialize\t elvitegravir\t for\t the\t treatment\t of\t HIV\t infection.\t We\t bear\t all\t costs\t and\t expenses\t associated\t with\t such commercialization\tefforts\tand\tpay\ta\troyalty\tto\tJapan\tTobacco\tbased\ton\tour\tproduct\tsales.\tOur\tsales\tof\tthese\tproducts\tare included\tin\tProduct\tsales\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalties\tdue\tto\tJapan\tTobacco\tare\tincluded\tin\tCost\tof goods\tsold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalty\texpenses\trecognized\twere\t$167\tmillion,\t$198\tmillion\tand\t$250 million\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nUnder\tthe\tterms\tof\tthe\t2018\tagreement,\twe\tpaid\tJapan\tTobacco\t$559\tmillion\tin\tcash\tand\trecognized\tan\tintangible\tasset\tof $550\tmillion\treflecting\tthe\testimated\tfair\tvalue\tof\tthe\tmarketing-related\trights\tacquired\tfrom\tJapan\tTobacco.\tThe\tintangible asset\tis\tbeing\tamortized\tover\tnine\tyears,\trepresenting\tthe\tperiod\tover\twhich\tthe\tmajority\tof\tthe\tbenefits\tare\texpected\tto\tbe derived\t from\t the\t applicable\t products\t in\t our\t HIV\t portfolio.\t The\t amortization\t expense\t is\t classified\t as\t selling\t expense\t and recorded\tas\tSelling,\tgeneral\tand\tadministrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including material\tbreach\tby\teither\tparty\tor\texpiry\tof\troyalty\tpayment\tterm.\tWe\tmay\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Everest\n\nIn\tApril\t2019,\tEverest\tMedicines\t('Everest')\tand\tImmunomedics\tentered\tinto\tan\tagreement\tgranting\tEverest\tan\texclusive license\t to\t develop\t and\t commercialize\t Trodelvy\t in\t Greater\t China,\t South\t Korea,\t Singapore,\t Indonesia,\t Philippines,\t Vietnam, Thailand,\tMalaysia\tand\tMongolia\t(the\t'Territories').\tGilead\tsubsequently\tacquired\tImmunomedics\tin\tOctober\t2020\tand\tassumed the\tEverest\tlicense\tand\tsupply\tagreement,\twhich\tprovided\tfor\tcertain\tsales\tmilestones\tand\troyalties\tpayments\tto\tbe\tmade\tto Gilead\tand\twas\trecorded\tas\ta\t$175\tmillion\tfinite-lived\tasset\tas\tpart\tof\tthe\tpurchase\taccounting.\tIn\tthe\tfourth\tquarter\tof 2022,\t we\t reacquired\t all\t development\t and\t commercialization\t rights\t for\t Trodelvy\t from\t Everest\t and\t terminated\t the\t previous agreement.\tUnder\tthe\tterms\tof\tthe\tnew\tagreement,\tGilead\tmade\t$280\tmillion\tin\tupfront\ttermination\tpayments\tto\tEverest,\tof which\t$84\tmillion\twas\tmade\tin\t2022\tand\t$196\tmillion\twas\tmade\tin\t2023.\tIn\taddition,\tEverest\tis\teligible\tto\treceive\tup\tto\t$175 million\tin\tpotential\tadditional\tpayments\tupon\tachievement\tof\tcertain\tregulatory\tand\tcommercial\tmilestones.\tWe\taccounted\tfor the\tnew\tagreement\tas\ta\tcontract\ttermination,\twhich\tincludes\tthe\treacquisition\tof\tcommercial\trights\tand\tthe\tsettlement\tof\tour pre-existing\t relationship\t with\t Everest.\t As\t a\t result,\t we\t recorded\t an\t expense\t of\t $406\t million\t in\t Selling,\t general\t and administrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome\tduring\tthe\tyear\tended\tDecember\t31,\t2022,\twhich\tprimarily represents\tthe\tupfront\tcosts\tand\twrite-off\tof\tthe\tremaining\tvalue\tof\tthe\tpre-existing\tasset\trelated\tto\tthe\tprior\tagreement. Simultaneously,\t we\t recorded\t an\t acquired\t finite-lived\t asset\t with\t a\t fair\t value\t of\t $50\t million\t for\t the\t commercial\t rights reacquired\tfor\tproducts\tapproved\tin\tthe\tTerritories.\n\n## Abingworth\n\nIn\tDecember\t2023,\twe\tentered\tinto\tan\tarrangement\twith\tfunds\tmanaged\tby\tAbingworth\tLLP\t('Abingworth')\tunder\twhich\twe\twill receive\tup\tto\t$210\tmillion\tto\tco-fund\tour\tdevelopment\tcosts\tfor\tTrodelvy\tfor\tnon-small\tcell\tlung\tcancer\tin\t2023\tthrough\t2026. As\t there\t is\t substantive\t transfer\t of\t risk\t to\t the\t financial\t partner,\t the\t development\t funding\t is\t recognized\t by\t us\t as\t an obligation\tto\tperform\tcontractual\tservices.\tIn\t2023,\twe\treceived\t$50\tmillion\tfrom\tAbingworth.\tWe\tare\trecognizing\tthe\tfunding as\ta\treduction\tof\tResearch\tand\tdevelopment\texpenses\tusing\tan\tattribution\tmodel\tover\tthe\tperiod\tof\tthe\trelated\texpenses.\tIf successful,\t upon\t regulatory\t approval\t in\t the\t U.S.\t for\t the\t specified\t indication,\t Abingworth\t will\t be\t eligible\t to\t receive\t an approval-based\tfixed\tmilestone\tpayment\tof\tup\tto\t$84\tmillion\tand\troyalties\tbased\ton\tthe\tapplicable\tnet\tsales.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 13,
      "question": "How does AbbVie's ongoing exposure to securities litigation tied to Allergan's textured breast implants and generic drug pricing practices reconcile with the strategic rationale provided for the $120.30 per share cash and stock acquisition of Allergan in 2020?",
      "answer": "AbbVie's 2020 acquisition of Allergan for $120.30 per share in cash and stock aimed to diversify its business across multiple therapeutic areas, including aesthetics and generics. However, post-acquisition, AbbVie inherited ongoing securities litigation against Allergan related to its textured breast implants (In re: Allergan plc Securities Litigation) and alleged anticompetitive conduct in its former Actavis generics unit (In re: Allergan Generic Drug Pricing Securities Litigation), with class certification granted in both cases by 2021. These legal risks, which were still pending or recently settled as of 2022, could expose AbbVie to significant financial liabilities and reputational damage, potentially undermining the strategic benefits of diversification and commercial strength that the acquisition was intended to deliver.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_134) \u2192 Lawsuit: AbbVie faces multiple lawsuits, including those inherited from Allergan related to textured breast implants and generic drug pricing.",
        "Hop 2: Lawsuit \u2192 Allergan: Allergan was a defendant in shareholder lawsuits alleging misrepresentations regarding textured breast implants and anticompetitive conduct in its generics business, with class certification granted in both cases.",
        "Hop 3: Allergan \u2190 ABBV(page_91): AbbVie acquired Allergan in May 2020 for $120.30 per share in cash and stock, citing strategic diversification as a key rationale."
      ],
      "difficulty": "hard",
      "idf_score": 5.699080239556016,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Faces]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Lawsuit",
        "node_3": "Allergan",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Lawsuit",
          "name": "Lawsuit",
          "type": "LITIGATION",
          "idf_score": 4.131333131591441
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Allergan",
          "name": "Allergan",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_3",
          "chunk_text": "\nCertain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.\n\n## Note 5 Licensing, Acquisitions and Other Arrangements\n\n## Acquisition of Allergan\n\nOn May 8, 2020, AbbVie completed its acquisition of all outstanding equity interests in Allergan in a cash and stock transaction. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The combination created a diverse entity with leadership positions across immunology, hematologic oncology, aesthetics, neuroscience, eye care and women's health. AbbVie's existing product portfolio and pipeline is enhanced with numerous Allergan assets and Allergan's product portfolio benefits from AbbVie's commercial strength, expertise and international infrastructure. Under the terms of the acquisition, each ordinary share of Allergan common stock was converted into the right to receive (i) $120.30 in cash and (ii) 0.8660 of a share of AbbVie common stock.\n\nTotal consideration for the acquisition of Allergan is summarized as follows:\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 14,
      "question": "How does BMY's risk exposure to generic competition for Eliquis relate to its profit-sharing arrangement with Pfizer, particularly in light of the U.S. court rulings affirming Eliquis' patent validity through 2026?",
      "answer": "BMY faces significant risk from generic competition for Eliquis, as highlighted in the risk factors on page 38, where it notes that adverse litigation outcomes could allow generic apixaban products to enter the market before the estimated minimum exclusivity date. However, the partnership with Pfizer, detailed on page 112, involves shared global profits and losses, with Pfizer funding 50\u201360% of development costs. This joint commercialization model mitigates some of BMY's direct exposure to Eliquis-related risks. Furthermore, the U.S. court rulings in 2020 and 2021, referenced on page 157, affirmed the validity of Eliquis' composition of matter and formulation patents, extending exclusivity through 2026 and thereby reducing near-term generic threat in the U.S. market. Thus, the combination of a strong patent position and shared financial risk with Pfizer alters the nature of BMY's exposure to Eliquis' lifecycle risks, suggesting a more resilient revenue outlook than would be expected from the generic risk disclosures alone.",
      "reasoning_steps": [
        "Hop 1: BMY(page_38) \u2192 Eliquis: BMY discloses risk of generic competition for Eliquis, noting that adverse litigation outcomes could allow generic apixaban products to enter before the estimated exclusivity date.",
        "Hop 2: Eliquis \u2192 Pfizer: Eliquis is jointly developed and commercialized with Pfizer, with profits and losses shared equally globally, and Pfizer funding 50\u201360% of development costs.",
        "Hop 3: Pfizer \u2190 BMY(page_157): BMY and Pfizer successfully defended Eliquis patents in U.S. courts, with decisions affirming patent validity and extending exclusivity through 2026."
      ],
      "difficulty": "hard",
      "idf_score": 5.721306120841433,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> PRODUCT -[Commercializes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Eliquis",
        "node_3": "Pfizer",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "generic products, which negatively impacts the protections afforded the Company. Lower-priced generics or biosimilars for BMS biologic products or competing biologics could negatively impact our volumes and prices.\n\nIn  addition,  both  the  U.S.  Congress  and  the  U.S.  FDA  have  taken  steps  to  promote  the  development  and  approval  of generic drugs and biosimilar biologics. For example, in December 2019, the U.S. Congress enacted legislation intended to  facilitate  generic  companies'  access  to  drug  samples.  Section  610  of  the  Further  Consolidated  Appropriations  Act, 2020, provides generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from  the  reference  product' s  manufacturer  in  order  to  conduct  testing  necessary  to  obtain  approval  for  generic  or biosimilar products. This law has the potential to have an adverse impact on our business.\n\nThere is no assurance that a particular product will enjoy market exclusivity for the full time period that appears in the estimates disclosed in this 2021 Form 10-K or that we assume when we provide our financial guidance.\n\n## Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor ('CAR') T cell therapy, may present significant challenges and risks for us.\n\nThe  development  of  novel  approaches  for  the  treatment  of  diseases,  such  as  our  acquisition  in  November  2019  of Celgene's and Juno's CAR T cell therapy programs, including Breyanzi (liso-cel) and Abecma (ide-cel), presents many new challenges and risks due to the unique nature of genetic modification of patient cells ex vivo using certain viruses to reengineer  these  cells  to  ultimately  treat  diseases,  including  obtaining  regulatory  approval  from  U.S.  FDA  and  other regulatory agencies that have limited experience with the development of cellular therapies involving genetic modification of patient cells; developing and deploying consistent and reliable processes, while limiting contamination, for engineering a patient's cells ex vivo and infusing genetically modified cells back into the patient; developing processes for the safe administration of cellular therapies, including long-term follow-up for patients receiving cellular therapies; and sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process our potential CAR T products. The use of reengineered cells as a potential cancer treatment is a recent development and may not be broadly accepted by the regulatory, patient or medical communities.\n\nFurther, we may not be able to satisfactorily establish the safety and efficacy or the reliability of these therapies through health  authority  approval,  or  demonstrate  the  potential  advantages  and  side  effects  compared  to  existing  and  future therapies. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Furthermore, certain payment models could impact the financial feasibility of making CAR T cell therapies available in certain markets or by certain treatment sites, thereby limiting patient access. To date, only a few products  that  involve  the  genetic  modification  of  patient  cells  have  been  approved  for  commercial  sale.  Moreover,  the safety profiles of cellular therapies may adversely influence public perception and may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians and payers to subscribe to these novel treatment approaches. If we fail to overcome these and other challenges, or if significant adverse events are reported from similar therapies,  our  development  of  these  novel  treatment  approaches  may  be  hampered  or  delayed,  which  could  adversely affect our future anticipated revenues and/or profitability related to these therapeutic programs. In addition, we could also face  difficulties  in  manufacturing  CAR  T  cell  therapies,  which  could  adversely  affect  our  future  anticipated  revenues and/or profitability related to our CAR T cell therapies. See ' -We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.'\n\n## We face intense competition from other manufacturers and expect to see increasing market penetration of lower-priced generic products.\n\nThe future growth of BMS is dependent on the market access, uptake and expansion for marketed brands, new product introductions,  new  indications,  product  extensions  and  co-promotional  activities  with  alliance  partners.  Competition  is keen and as we lose exclusivity for some of our marketed brands lower-priced generic products will increasingly penetrate our  markets.  Generic  challenges  to  our  products  can  also  arise  at  any  time,  and  our  patents  may  not  prevent  the emergence of generic competition for our products. For example, if we receive an adverse litigation decision in a country in the EU where our Eliquis composition of matter patents and related Supplementary Protection Certificates are being challenged (see 'Item 8. Financial Statements and Supplementary Data-Note 19. Legal Proceedings and Contingencies'), we may not be able to prevent generic apixaban products from being introduced in such country prior to our estimated minimum market exclusivity date. In some countries, patent protection is significantly weaker than in the United States or in the EU; political and social pressure has also pushed legislation and other measures that promote the use  of  generic  and  biosimilar  products.  In  addition,  we  face  competition  from  new  products  entering  the  market, particularly in IO. New products may have (i) lower prices, (ii) superior efficacy (benefit) or safety (risk) profiles (whether actual  or  perceived),  (iii)  technological  advantages  that  may  make  such  products  more  convenient  to  use,  (iv)  better insurance coverage or reimbursement levels, (v) more effective marketing programs and/or other differentiating factors that make it harder for our products to compete. We also face intense competition for external partnerships, joint ventures and  acquisition  targets  that  can  help  develop  and  bring  new  products  to  markets.  Business  combinations  among  our competitors and major third-party payers may increase competition",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Eliquis",
          "name": "Eliquis",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n(a)    Includes unamortized up-front and milestone payments.\n\nSpecific information pertaining to significant alliances is discussed below, including their nature and purpose; the significant rights and obligations of the parties; specific accounting policy elections; and the statements of earnings classification of and amounts attributable to payments between the parties.\n\n## Pfizer\n\nBMS and Pfizer jointly develop and commercialize Eliquis , an anticoagulant discovered by BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis except in certain countries where Pfizer commercializes Eliquis and pays BMS a sales-based fee.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Pfizer",
          "name": "Pfizer",
          "type": "COMP",
          "idf_score": 4.8689320747222204
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_157",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eliquis - U.S.\n\nIn 2017, BMS received Notice Letters from twenty-five generic companies notifying BMS that they had filed aNDAs containing paragraph  IV  certifications  seeking  approval  of  generic  versions  of  Eliquis. As  a  result,  two  Eliquis  patents  listed  in  the  FDA Orange Book are being challenged: the composition of matter patent claiming apixaban specifically and a formulation patent. In response, BMS, along with its partner Pfizer, initiated patent infringement actions under the Hatch-Waxman Act against all generic filers in the U.S. District Court for the District of Delaware in April 2017. In August 2017, the U.S. Patent and Trademark Office granted patent term restoration to the composition of matter patent to November 2026, thereby restoring the term of the Eliquis composition of matter patent, which is BMS's basis for projected minimum market exclusivity dates. BMS settled with a number of aNDA filers.  These  settlements  do  not  affect  BMS's  projected  minimum  market  exclusivity  dates  for  Eliquis. A  trial  with  the remaining aNDA filers took place in late 2019. In August 2020, the U.S. District Court issued a decision finding that the remaining aNDA filers' products infringed the Eliquis composition of matter and formulation patents and that both Eliquis patents are not invalid. In September 2021, the Federal Circuit affirmed the lower court decision. The time by which the remaining aNDA filers could seek review of the Federal Circuit's decision has lapsed, and thus the decision is final.\n\n## Eliquis - Europe\n\nIn  November  2020  and  January  2021,  Sandoz  Limited  ('Sandoz')  and  Teva  Pharmaceutical  Industries  Ltd.  ('Teva  Limited'), respectively, filed lawsuits in the United Kingdom seeking revocation of the UK apixaban composition of matter patent and related Supplementary Protection Certificate. BMS subsequently filed counterclaims for infringement in both actions. A trial is scheduled to begin in early 2022.\n\nThere are similar lawsuits filed in France, Italy, the Netherlands, Portugal, the Republic of Ireland, and Sweden seeking revocation of a composition of matter patent relating to Eliquis .\n\nAdditional infringement and invalidity actions involving Eliquis patents may be filed in various countries in Europe in the coming months.\n\n## Onureg - U.S.\n\nIn November 2021, BMS received a Notice Letter from Accord notifying BMS that it had filed an aNDA containing a paragraph IV certification  seeking  approval  of  a  generic  version  of Onureg in  the  US  and  challenging  the  one  FDA  Orange  Book-listed formulation patent expiring in 2030. In response, BMS filed a patent infringement action against Accord in the U.S. District Court for the District of Delaware. No trial date has been scheduled.\n\n## Plavix* - Australia\n\nSanofi was notified that, in August 2007, GenRx Proprietary Limited ('GenRx') obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex  ('GenRx-Apotex').  In  August  2007,  GenRx-Apotex  filed  an  application  in  the  Federal  Court  of  Australia  seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a  revocation  suit  against  the  same  patent.  This  case  was  consolidated  with  the  GenRx-Apotex  case.  On August  12,  2008,  the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ('Full Court') appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($324 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages.  In  May  2020,  the Australian  government  appealed  the  Federal  Court's  decision  and  an  appeal  hearing  concluded  in February 2021.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 15,
      "question": "Given LLY's reliance on patent protection for revenue stability, how does the expected decline in Alimta's U.S. revenue due to patent expiration align with the historical revenue trends of Alimta outside the U.S., and what does this imply about the geographic divergence in product lifecycle management?",
      "answer": "LLY highlights on page 25 that Alimta is losing patent protection in the U.S., which is expected to result in a rapid and severe revenue decline due to generic competition. This contrasts with the revenue data from page 65, which shows that in 2021, Alimta generated $827.5 million in revenue outside the U.S., despite facing similar pressures in prior years. The divergence suggests that while U.S. revenue is highly sensitive to patent expiration due to rapid generic entry, international markets may offer more prolonged revenue stability, possibly due to differing regulatory timelines or market dynamics. This geographic disparity underscores the importance of regional intellectual property frameworks in shaping product lifecycle strategies.",
      "reasoning_steps": [
        "Hop 1: LLY(page_25) \u2192 Patent Protection: LLY depends heavily on intellectual property protection for revenue and faces a material adverse effect due to the expected generic entry for Alimta in the U.S.",
        "Hop 2: Patent Protection \u2192 Alimta: The loss of patent exclusivity for Alimta in the U.S. is expected to cause a rapid and severe revenue decline, as stated in the risk factors section.",
        "Hop 3: Alimta \u2190 LLY(page_65): Historical revenue data shows Alimta generated $827.5 million in 2021 from outside the U.S., indicating continued revenue contribution despite patent challenges."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT -[Negatively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Patent Protection",
        "node_3": "Alimta",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Alimta",
          "name": "Alimta",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                    | U.S.       | U.S.       | U.S.       | Outside U.S.   | Outside U.S.   | Outside U.S.   |\n|------------------------------------|------------|------------|------------|----------------|----------------|----------------|\n|                                    | 2021       | 2020       | 2019       | 2021           | 2020           | 2019           |\n| Revenue-to unaffiliated customers: |            |            |            |                |                |                |\n| Diabetes:                          |            |            |            |                |                |                |\n| Trulicity \u00ae                        | $ 4,914.4  | $ 3,835.9  | $ 3,155.2  | $ 1,557.6      | $ 1,232.2      | $ 972.7        |\n| Humalog \u00ae (1)                      | 1,320.7    | 1,485.6    | 1,669.7    | 1,132.3        | 1,140.3        | 1,151.0        |\n| Jardiance (2)                      | 807.3      | 620.8      | 565.9      | 683.5          | 533.0          | 378.3          |\n| Humulin \u00ae                          | 832.9      | 866.4      | 879.7      | 389.6          | 393.2          | 410.4          |\n| Basaglar \u00ae                         | 588.3      | 842.3      | 876.2      | 304.2          | 282.1          | 236.3          |\n| Trajenta (3)                       | 82.1       | 95.6       | 224.8      | 290.4          | 263.0          | 365.8          |\n| Other Diabetes                     | 173.6      | 162.5      | 158.0      | 111.2          | 81.5           | 88.1           |\n| Total Diabetes                     | 8,719.3    | 7,909.1    | 7,529.5    | 4,468.8        | 3,925.3        | 3,602.6        |\n| Oncology:                          |            |            |            |                |                |                |\n| Alimta \u00ae                           | 1,233.9    | 1,265.3    | 1,219.5    | 827.5          | 1,064.7        | 896.4          |\n| Verzenio \u00ae                         | 834.9      | 618.2      | 454.8      | 515.0          | 294.4          | 124.9          |\n| Cyramza \u00ae                          | 358.1      | 381.9      | 335.3      | 674.8          | 650.8          | 589.9          |\n| Erbitux \u00ae                          | 481.8      | 480.1      | 487.9      | 66.4           | 56.3           | 55.4           |\n| Tyvyt \u00ae                            | -          | -          | -          | 418.1          | 308.7          | 134.0          |\n| Other Oncology                     | 120.1      | 46.6       | 111.0      | 210.7          | 152.3          | 205.3          |\n| Total Oncology                     | 3,028.8    | 2,792.1    | 2,608.5    | 2,712.5        | 2,527.2        | 2,005.9        |\n| Immunology:                        |            |            |            |                |                |                |\n| Taltz \u00ae                            | 1,542.4    | 1,288.5    | 1,016.8    | 670.4          | 500.0          | 349.6          |\n| Olumiant \u00ae (4)                     | 324.1      | 63.8       | 42.2       | 791.0          | 575.0          | 384.7          |\n| Other Immunology                   | 15.3       | 20.0       | -          | 17.6           | 14.6           | -              |\n| Total Immunology                   | 1,881.8    | 1,372.3    | 1,059.0    | 1,479.0        | 1,089.6        | 734.3          |\n| Neuroscience:                      |            |            |            |                |                |                |\n| Cymbalta \u00ae                         | 38.7       | 42.1       | 49.6       | 542.8          | 725.6          | 675.8          |\n| Emgality \u00ae                         | 434.5      | 325.9      | 154.9      | 142.7          | 37.0           | 7.7            |\n| Zyprexa \u00ae                          | 39.6       | 46.1       | 41.0       | 390.7          | 360.5          | 377.6          |\n| Other Neuroscience                 | 102.0      | 73.2       | 111.0      | 207.5          | 220.9          | 305.3          |\n| Total Neuroscience                 | 614.8      | 487.3      | 356.5      | 1,283.7        | 1,344.0        | 1,366.4        |\n| Other:                             |            |            |            |                |                |                |\n| COVID-19 Antibodies (5)            | 1,978.0    | 850.0      | -          | 261.4          | 21.2           | -              |\n| Forteo \u00ae                           | 441.6      | 510.3      | 645.5      | 360.3          | 536.0          | 759.1          |\n| Cialis \u00ae                           | 10.6       | 61.8       | 231.7      | 707.9          | 545.4          | 658.8          |\n| Other                              | 136.1      | 246.4      | 291.9      | 233.9          | 321.8          | 469.7          |\n| Total Other                        | 2,566.4    | 1,668.4    | 1,169.1    | 1,563.5        | 1,424.4        | 1,887.7        |\n| Revenue                            | $ 16,811.0 | $ 14,229.3 | $ 12,722.6 | $ 11,507.4     | $ 10,310.5     | $ 9,596.8      |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 16,
      "question": "Given the importance of patent protection for revenue stability, how does the 32% U.S. revenue decline in Trulicity in 2024 reflect the risk associated with the anticipated expiration of its patent and data protections, as outlined in the intellectual property risk section?",
      "answer": "The 32% U.S. revenue decline in Trulicity in 2024 directly reflects the vulnerability of LLY's revenue streams when a product nears the end of its patent and data protection lifecycle. According to the intellectual property section, Trulicity is expected to lose significant patent and data protections in the next few years, which historically leads to rapid revenue erosion due to generic or biosimilar competition. This aligns with the observed revenue drop, likely driven by competitive dynamics and anticipation of reduced exclusivity. The connection between the loss of patent protection (as described on page 10) and Trulicity\u2019s current revenue trajectory (as reported on page 49) underscores the material financial risk posed by intellectual property expiration.",
      "reasoning_steps": [
        "Hop 1: LLY(page_10) \u2192 Patent Protection: LLY emphasizes the critical role of patent and data protection in maintaining market exclusivity and revenue, noting that loss of such protections typically results in rapid revenue decline for pharmaceutical products.",
        "Hop 2: Patent Protection \u2192 Trulicity: Trulicity is specifically cited as a product expected to lose significant patent and data protections in the near future, exposing it to generic or biosimilar competition and revenue erosion.",
        "Hop 3: Trulicity \u2190 LLY(page_49): Trulicity experienced a 32% decline in U.S. revenue in 2024, attributed to competitive dynamics and supply constraints, suggesting early signs of market pressure as its IP protections approach expiration."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT -[Expires]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Patent Protection",
        "node_3": "Trulicity",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_10",
          "chunk_id": "chunk_1",
          "chunk_text": "## Patents, Trademarks, and Other Intellectual Property Rights\n\n## Overview\n\nIntellectual property protection is critical to our ability to successfully commercialize our life sciences innov ations and inv est in the search for new medicines and uses. Loss of effectiv e patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effectiv e market exclusiv ity for the product, often leading to a sev ere and rapid decline in rev enues for the product. We own, hav e applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, for some products we hav e effectiv e intellectual property protection in the form of data protection under pharmaceutical regulatory laws.\n\nThe patent protection generally anticipated to be of most relev ance to pharmaceuticals is prov ided by patents claiming the activ e ingredient (the compound patent) for our products, particularly those in major markets such as the U.S., major European countries, and Japan. In general, patents in each relev ant country last for a period of 20 years from their filing date, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:\n\n- Patent term adjustment is av ailable to all U.S. patent applicants to prov ide relief in the ev ent that a patent grant is delayed during examination by the U.S. Patent and Trademark Office (USPTO).\n- Patent term restoration for a single patent for a pharmaceutical product is prov ided to U.S. patent holders to compensate for a portion of the time inv ested in clinical trials and the U.S. Food and Drug Administration (FDA) rev iew process. There is a fiv e-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from initial FDA approv al. Some countries outside the U.S. similarly offer forms of patent term restoration. For example, Supplementary Protection Certificates are av ailable to extend the life of a European patent up to an additional fiv e years (subject to a 15-year cap from European Medicines Agency (EMA) approv al) and in Japan patent terms can be extended up to fiv e years.\n\nIn some cases, the innov ator company may retain exclusiv ity despite approv al of the generic, biosimilar, or other follow-on v ersions of a new medicine beyond the expiration of the compound patent through market dynamics and challenges, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be av ailable under pharmaceutical regulatory laws. The primary forms of data protection are as follows:\n\n- Data package protection generally prohibits regulatory approv al of other manufacturers' applications for marketing approv al if they rely on the innov ator company's regulatory submission data for the drug. The base period is generally fiv e years in the U.S. (12 years for new biologics under the BPCIA, subject to certain conditions), effectiv ely 10 years in Europe, and eight years in Japan, which can be extended to 10 years with qualifying pediatric studies. The period begins on the date of product approv al and runs concurrently with the patent term for any relev ant patents. Legislativ e bodies in the European Union (EU) are discussing proposed reductions in data protection periods but it remains uncertain if, or when, these proposals might be adopted.\n- In the U.S., the FDA has the authority to grant additional data protection for approv ed drugs where the sponsor conducts specified testing in pediatric populations within a specified time period. If granted, this \"pediatric exclusiv ity\" prov ides an additional six months of exclusiv ity, which is added to the term of data protection, orphan drug exclusiv ity and, for products other than biologics, pediatric exclusiv ity is also added to the term of any relev ant and non-expired patents.\n- A specific use of a drug or biologic can receiv e \"orphan\" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recov er dev elopment and marketing costs through U.S. sales. Orphan designation entitles a particular use of the drug to sev en years of market exclusiv ity, which runs in parallel with any applicable patents.\n\nOutside the major markets, the adequacy and effectiv eness of intellectual property protection for pharmaceuticals v ary widely. International and U.S. free trade agreements like the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs Agreement) administered by the World Trade Organization prov ide global protection of certain intellectual property rights. But in a number of markets we are unable to patent our products or to enforce the patents that we receiv e for our products. Further, many dev eloping countries, and some dev eloped countries, do not prov ide effectiv e data package protection ev en though it is specified in the TRIPs Agreement.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain entities has increased due to consolidation, regulatory, and other market impacts, and they, along with gov ernments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or fav orable formulary placement. Such stakeholders hav e also increasingly imposed utilization management tools to limit access to our products. As these practices expand, including due to potential further consolidation of U.S. priv ate third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. We expect that consolidation of supply chain entities will continue to increase competitiv e and pricing pressures on pharmaceutical manufacturers.\n\nPharmacy benefit manager practices hav e come under increased scrutiny from U.S. policymakers at the federal and state lev el who hav e proposed legislation intended to address concerns regarding the impact that these intermediaries hav e on drug pricing and patients' out of pocket costs. If promulgated, such legislation could hav e resultant implications, costs, or consequences for our business and how we interact with these entities. For additional information on pricing and reimbursement for our pharmaceutical products, see Item 1, \"Business-U.S. Priv ate Sector Dynamics\" and \"Regulations and Priv ate Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.\"\n\n## Risks Related to Our Intellectual Property\n\n- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.\n\nIn the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time. For example, Trulicity will lose significant patent and remaining data protections in the next few years. Some products also lose patent protection as a result of successful third-party challenges. We hav e faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection.\n\nFor non-biologic products, loss of exclusiv ity typically results in the entry of one or more generic competitors, leading to a rapid and sev ere decline in rev enues, especially in the U.S. Generic pharmaceutical companies hav e in some cases introduced a generic product before resolution of any related patent litigation. For biologics, loss of exclusiv ity may or may not result in the near-term entry of competitor v ersions (i.e., biosimilars) due to many factors, including dev elopment timelines, manufacturing challenges, and/or uncertainties regarding the regulatory approv al pathways.\n\nOur success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often inv olv e complex legal, scientific and factual questions. There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found v alid and enforceable if challenged. Third parties may challenge, inv alidate, or circumv ent our patents and patent applications relating to our products, product candidates, and technologies. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not be deemed to infringe our patents. Moreover, patents relating to particular products, uses, formulations, or processes may not preclude other manufacturers from employing alternativ e processes or marketing alternativ e products or formulations that compete with our patented products. Patents held by third-parties hav e also contributed, and may in the future contribute, to a decision by us to not pursue all potential indications for a product candidate. In addition, competitors or other third parties may assert claims that our activ ities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis-Executiv e Ov erv iew-Other Matters-Patent Matters\" and Item 1, \"Business-Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.",
          "relationship": "Expires"
        },
        "node_3": {
          "id": "Trulicity",
          "name": "Trulicity",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers m ay not add due to rounding.\n\nNM - not m eaningful\n\nJardiance revenue includes Glyxam bi,Synjardy, and Trijardy XR . (1)\n\nHumalog revenue includes insulin lispro. (2)\n\nBasaglar revenue includes R ezvoglar. (3)\n\nZyprexa revenue includes sale of the rights for the olanzapine portfolio in 2023. (4)\n\nRevenue of Mounjaro increased 85 percent in the U.S., primarily driv en by strong demand and increased supply. Rev enue outside of the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023, primarily driv en by v olume growth in launched markets.\n\nRevenue of Verzenio increased 36 percent in the U.S., driv en by increased demand, wholesaler buying patterns and, to a lesser extent, higher realized prices. Rev enue outside the U.S. increased 39 percent, driv en by increased demand.\n\nRevenue of Trulicity decreased 32 percent in the U.S., driv en by decreased v olume primarily due to competitiv e dynamics and supply constraints during the first half of 2024. Rev enue outside the U.S. decreased 8 percent, driv en by decreased v olume primarily due to competitiv e dynamics and actions we have taken to manage demand.\n\nRevenue of Zepbound in the U.S. in 2024 was $4.93 billion, compared to $175.8 million in 2023. Zepbound launched in the U.S. for the treatment of adult patients with obesity or ov erweight with weight-related comorbidities in Nov ember 2023.\n\nRevenue of Jardiance remained relativ ely flat in the U.S. as increased demand was offset by lower realized prices. Rev enue outside the U.S. increased 52 percent, driv en by increased v olume and a one-time payment receiv ed of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim. Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim inv olv ing Jardiance.\n\nRevenue of Taltz increased 18 percent in the U.S., driv en by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand. Revenue outside the U.S. increased 19 percent, primarily driv en by increased demand.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 17,
      "question": "How does the Fast Track designation mentioned in the regulatory context relate to the financial risk and strategic value of PR006, given its inclusion in the Prevail acquisition and the contingent payment structure tied to regulatory approval?",
      "answer": "The Fast Track designation, referenced in the regulatory section, highlights the potential for expedited development and review of PR006, a product acquired through the Prevail acquisition. However, the contingent value right (CVR) structure tied to the regulatory approval of any Prevail product\u2014including PR006\u2014introduces financial risk, as the full $4.00 per share CVR payout is only realized if approval occurs by December 31, 2024. This creates a time-sensitive strategic imperative to secure FDA approval for PR006, which was granted Fast Track status, in order to maximize the value of the acquisition and justify the $747.4 million upfront cash payment and potential additional $160 million in CVR payouts.",
      "reasoning_steps": [
        "Hop 1: LLY(page_39) \u2192 Fast Track Designation: The company discusses Fast Track designation as a regulatory mechanism to expedite development and review of new therapies for serious conditions with unmet medical needs.",
        "Hop 2: Fast Track Designation \u2192 PR006: PR006, a gene therapy for frontotemporal dementia with GRN mutations, was granted Fast Track designation by the FDA, indicating its potential therapeutic significance and expedited regulatory pathway.",
        "Hop 3: PR006 \u2190 LLY(page_66): PR006 was acquired as part of Prevail Therapeutics, with a contingent payment structure (CVR) tied to regulatory approval, emphasizing the financial and strategic importance of achieving Fast Track milestones before the 2024 deadline."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Complies_With]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Fast Track Designation",
        "node_3": "PR006",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn collaboration with Boehringer Ingelheim. (1)\n\nBreakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. (2)\n\nFast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs. (3)\n\nThe FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients. (4)\n\nThere are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Complies_With"
        },
        "node_3": {
          "id": "PR006",
          "name": "PR006",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 18,
      "question": "How does Gilead's geographic revenue-sharing structure with Merck for long-acting HIV treatments align with the financial risks and collaboration terms outlined in their broader partnership agreement?",
      "answer": "Gilead and Merck have established a global cost- and revenue-sharing structure for long-acting HIV treatments, where Merck leads commercialization in the EU and Rest of World for oral formulations, while Gilead leads in the EU and Rest of World for injectable formulations. Gilead and Merck share global product revenues equally until thresholds of $2.0 billion (oral) and $3.5 billion (injectable) are surpassed, after which Gilead\u2019s share increases to 65%. Despite this, no revenues have been recognized under the agreement through 2023, and expenses were not material. This revenue-sharing model aligns with the broader partnership terms outlined in the collaboration agreement, which include joint development, cost-sharing, and mutual option rights for future integrase inhibitors. The financial risk appears balanced in terms of shared R&D and commercialization costs, but Gilead retains exclusive commercialization rights outside the U.S. for injectables, suggesting a strategic emphasis on global market control post-approval.",
      "reasoning_steps": [
        "Hop 1: GILD(page_76) \u2192 Rest of World: Gilead and Merck share global development and commercialization costs at 60% and 40%, respectively. Merck leads commercialization in the EU and Rest of World for long-acting oral products, while Gilead leads in the EU and Rest of World for injectables.",
        "Hop 2: Rest of World \u2192 Merck: The geographic split for commercialization responsibilities determines revenue-sharing dynamics, with equal revenue splits until thresholds are met, after which Gilead receives a larger share.",
        "Hop 3: Merck \u2190 GILD(page_75): The broader collaboration agreement outlines joint development and commercialization of long-acting HIV treatments combining lenacapavir and islatravir, with provisions for future formulation additions and mutual option rights."
      ],
      "difficulty": "hard",
      "idf_score": 5.566228656689513,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Leads_Commercialization]-> GPE -[Leads_Commercialization]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Rest of World",
        "node_3": "Merck",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "GPE",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Under\tthe\tterms\tof\tthe\tagreement,\tas\tamended,\tGilead\tand\tMerck\twill\tmostly\tshare\tglobal\tdevelopment\tand\tcommercialization costs\tat\t60%\tand\t40%,\trespectively,\tacross\tthe\toral\tand\tinjectable\tformulation\tprograms.\tFor\tlong-acting\toral\tproducts,\tif approved,\t Gilead\t would\t lead\t commercialization\t in\t the\t U.S.,\t and\t Merck\t would\t lead\t commercialization\t in\t the\t European\t Union ('EU')\tand\trest\tof\tthe\tworld.\tFor\tlong-acting\tinjectable\tproducts,\tif\tapproved,\tMerck\twould\tlead\tcommercialization\tin\tthe U.S.\tand\tGilead\twould\tlead\tcommercialization\tin\tthe\tEU\tand\trest\tof\tthe\tworld.\tUnder\tthe\tterms\tof\tthe\tagreement,\tGilead\tand Merck\twould\tjointly\tpromote\tthe\tcombination\tproducts\tin\tthe\tU.S.\tand\tcertain\tother\tmajor\tmarkets.\tIf\tsuccessful,\twe\twould share\t global\t product\t revenues\t with\t Merck\t equally\t until\t product\t revenues\t surpass\t certain\t pre-determined\t per\t formulation revenue\ttiers.\tUpon\tpassing\t$2.0\tbillion\tin\tnet\tproduct\tsales\tfor\tthe\toral\tcombination\tin\ta\tgiven\tcalendar\tyear,\tour\tshare\tof revenue\twould\tincrease\tto\t65%\tfor\tany\trevenues\tabove\tthe\tthreshold\tfor\tsuch\tcalendar\tyear.\tUpon\tpassing\t$3.5\tbillion\tin\tnet product\tsales\tfor\tthe\tinjectable\tcombination\tin\ta\tgiven\tcalendar\tyear,\tour\tshare\tof\trevenue\twill\tincrease\tto\t65%\tfor\tany revenues\t above\t the\t threshold\t for\t such\t calendar\t year.\t Reimbursements\t of\t R&amp;D\t costs\t to\t or\t from\t Merck\t are\t recorded\t within Research\tand\tdevelopment\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\tExpenses\trecognized\tunder\tthe\tagreement\twere\tnot material\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021.\tNo\trevenues\thave\tbeen\trecognized\tunder\tthe\tagreement\tfor\tthe years\tended\tDecember\t31,\t2023,\t2022\tand\t2021.\n\nWe\t will\t also\t have\t the\t option\t to\t license\t certain\t of\t Merck's\t investigational\t oral\t integrase\t inhibitors\t to\t develop\t in combination\twith\tlenacapavir.\tReciprocally,\tMerck\twill\thave\tthe\toption\tto\tlicense\tcertain\tof\tGilead's\tinvestigational\toral integrase\tinhibitors\tto\tdevelop\tin\tcombination\twith\tislatravir.\tEach\tcompany\tmay\texercise\tits\toption\tfor\tsuch\tinvestigational oral\t integrase\t inhibitor\t of\t the\t other\t company\t within\t the\t first\t five\t years\t after\t execution\t of\t the\t agreement,\t following completion\tof\tthe\tfirst\tPhase\t1\tclinical\ttrial\tof\tthat\tintegrase\tinhibitor.\tUpon\texercise\tof\tan\toption,\tthe\tcompanies\twill split\tdevelopment\tcosts\tand\trevenues,\tunless\tthe\tnon-exercising\tcompany\tdecides\tto\topt\tout,\tin\twhich\tcase\tthe\tnon-exercising company\twill\tbe\tpaid\ta\troyalty.\n\n## Arcus\n\nOn\tMay\t27,\t2020,\twe\tentered\tinto\ta\ttransaction\twith\tArcus,\ta\tpublicly\ttraded\toncology-focused\tbiopharmaceutical\tcompany, which\tincluded\tentry\tinto\tan\toption,\tlicense\tand\tcollaboration\tagreement\t(the\t'Collaboration\tAgreement'),\twith\tGilead\thaving the\tright\tto\topt\tin\tto\tall\tcurrent\tand\tfuture\tclinical-stage\tproduct\tcandidates\tfor\tup\tto\tten\tyears\tfollowing\tthe\tclosing\tof the\t transaction,\t and\t a\t common\t stock\t purchase\t agreement\t and\t an\t investor\t rights\t agreement\t (together,\t and\t as\t subsequently amended\tthe\t'Stock\tPurchase\tAgreements').\n\nIn\t November\t 2021,\t we\t exercised\t our\t options\t to\t three\t of\t Arcus'\t clinical\t stage\t programs\t and\t amended\t the\t Collaboration Agreement.\tThe\toption\texercise\tand\tamendment\ttransaction\tclosed\tin\tDecember\t2021,\ttriggering\tcollaboration\topt-in\tpayments\tof $725\tmillion\tand\twaiving\tthe\t$100\tmillion\toption\tcontinuation\tpayment\twhich\twould\thave\tbeen\tdue\tto\tArcus\tin\tthe\tthird\tquarter of\t2022.\tThe\tnet\toption\tcharge\tof\t$625\tmillion\twas\tincluded\twithin\tAcquired\tin-process\tresearch\tand\tdevelopment\texpenses\ton our\tConsolidated\tStatements\tof\tIncome\tfor\tthe\tyear\tended\tDecember\t31,\t2021.\tThe\tcollaboration\topt-in\tpayments\tof\t$725\tmillion were\trecorded\tin\tOther\tcurrent\tliabilities\ton\tour\tConsolidated\tBalance\tSheets\tas\tof\tDecember\t31,\t2021\tand\tpaid\tto\tArcus\tin January\t2022.\tOur\tpayments\tto\tArcus\twere\tincluded\twithin\tNet\tcash\tused\tin\tinvesting\tactivities\ton\tour\tConsolidated\tStatements of\tCash\tFlows\tin\tthe\tfirst\tquarter\tof\t2022.\n\nIn\t May\t 2023,\t we\t again\t amended\t the\t Collaboration\t Agreement\t to\t initiate\t research\t programs\t against\t up\t to\t four\t targets jointly\tselected\tby\tthe\tparties\tthat\tare\tapplicable\tto\tinflammatory\tdiseases.\tAs\tpart\tof\tthe\tamendment,\twe\tpaid\ta\t$35\tmillion upfront\tfee,\twhich\twas\tcharged\tto\tAcquired\tin-process\tresearch\tand\tdevelopment\texpenses\ton\tour\tConsolidated\tStatements\tof Income.\tGilead\tmay\texercise\tan\toption\tto\tlicense\teach\tprogram\tat\ttwo\tseparate,\tprespecified\ttime\tpoints.\tIf\tGilead\texercises its\toption\tat\tthe\tearlier\ttime\tpoint\tfor\tthe\tfirst\ttwo\ttarget\tprograms,\tArcus\twould\tbe\teligible\tto\treceive\tup\tto\t$420\tmillion in\tfuture\toption\tand\tmilestone\tpayments\tand\ttiered\troyalties\tfor\teach\toptioned\tprogram.\tFor\tany\tother\toption\texercise\tby Gilead\tfor\tthe\tfour\ttarget\tprograms,\tthe\tparties\twould\thave\trights\tto\tco-develop\tand\tshare\tglobal\tdevelopment\tcosts\tand\tto co-commercialize\tand\tshare\tprofits\tin\tthe\tU.S.\tfor\toptioned\tprograms.\n\nUnder\tthe\tamended\tCollaboration\tAgreement,\tthe\tcompanies\tco-develop\tand\tshare\tthe\tglobal\tcosts\trelated\tto\tthese\tclinical programs.\tWe\trecorded\t$189\tmillion\tand\t$187\tmillion\tof\tsuch\tcosts\tin\tResearch\tand\tdevelopment\texpenses\ton\tour\tConsolidated Statements\t of\t Income\t for\t the\t years\t ended\t December\t 31,\t 2023\t and\t 2022,\t respectively.\t If\t the\t optioned\t molecules\t achieve regulatory\tapproval,\tthe\tcompanies\twill\tco-commercialize\tand\tequally\tshare\tprofits\tin\tthe\tU.S.\tGilead\twill\thold\texclusive commercialization\trights\toutside\tthe\tU.S.,\tsubject\tto\tany\trights\tof\tArcus's\texisting\tcollaboration\tpartners,\tand\twill\tpay\tto Arcus\t tiered\t royalties\t as\t a\t percentage\t of\t net\t sales\t ranging\t from\t the\t mid\t teens\t to\t low\t twenties.\t Under\t the\t amended Collaboration\tAgreement,\twe\tmay\talso\tpay\tan\tadditional\t$100\tmillion\tat\tour\toption\ton\teach\tof\tthe\tfourth,\tsixth\tand\teighth anniversaries\tof\tthe\tagreement,\tunless\tterminated\tearly,\tto\tmaintain\tthe\trights\tto\topt\tin\tto\tfuture\tArcus\tprograms\tfor\tthe duration\tof\tthe\tcontact\tterm.",
          "relationship": "Leads_Commercialization"
        },
        "node_2": {
          "id": "Rest_of_World",
          "name": "Rest of World",
          "type": "GPE",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Under\tthe\tterms\tof\tthe\tagreement,\tas\tamended,\tGilead\tand\tMerck\twill\tmostly\tshare\tglobal\tdevelopment\tand\tcommercialization costs\tat\t60%\tand\t40%,\trespectively,\tacross\tthe\toral\tand\tinjectable\tformulation\tprograms.\tFor\tlong-acting\toral\tproducts,\tif approved,\t Gilead\t would\t lead\t commercialization\t in\t the\t U.S.,\t and\t Merck\t would\t lead\t commercialization\t in\t the\t European\t Union ('EU')\tand\trest\tof\tthe\tworld.\tFor\tlong-acting\tinjectable\tproducts,\tif\tapproved,\tMerck\twould\tlead\tcommercialization\tin\tthe U.S.\tand\tGilead\twould\tlead\tcommercialization\tin\tthe\tEU\tand\trest\tof\tthe\tworld.\tUnder\tthe\tterms\tof\tthe\tagreement,\tGilead\tand Merck\twould\tjointly\tpromote\tthe\tcombination\tproducts\tin\tthe\tU.S.\tand\tcertain\tother\tmajor\tmarkets.\tIf\tsuccessful,\twe\twould share\t global\t product\t revenues\t with\t Merck\t equally\t until\t product\t revenues\t surpass\t certain\t pre-determined\t per\t formulation revenue\ttiers.\tUpon\tpassing\t$2.0\tbillion\tin\tnet\tproduct\tsales\tfor\tthe\toral\tcombination\tin\ta\tgiven\tcalendar\tyear,\tour\tshare\tof revenue\twould\tincrease\tto\t65%\tfor\tany\trevenues\tabove\tthe\tthreshold\tfor\tsuch\tcalendar\tyear.\tUpon\tpassing\t$3.5\tbillion\tin\tnet product\tsales\tfor\tthe\tinjectable\tcombination\tin\ta\tgiven\tcalendar\tyear,\tour\tshare\tof\trevenue\twill\tincrease\tto\t65%\tfor\tany revenues\t above\t the\t threshold\t for\t such\t calendar\t year.\t Reimbursements\t of\t R&amp;D\t costs\t to\t or\t from\t Merck\t are\t recorded\t within Research\tand\tdevelopment\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\tExpenses\trecognized\tunder\tthe\tagreement\twere\tnot material\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021.\tNo\trevenues\thave\tbeen\trecognized\tunder\tthe\tagreement\tfor\tthe years\tended\tDecember\t31,\t2023,\t2022\tand\t2021.\n\nWe\t will\t also\t have\t the\t option\t to\t license\t certain\t of\t Merck's\t investigational\t oral\t integrase\t inhibitors\t to\t develop\t in combination\twith\tlenacapavir.\tReciprocally,\tMerck\twill\thave\tthe\toption\tto\tlicense\tcertain\tof\tGilead's\tinvestigational\toral integrase\tinhibitors\tto\tdevelop\tin\tcombination\twith\tislatravir.\tEach\tcompany\tmay\texercise\tits\toption\tfor\tsuch\tinvestigational oral\t integrase\t inhibitor\t of\t the\t other\t company\t within\t the\t first\t five\t years\t after\t execution\t of\t the\t agreement,\t following completion\tof\tthe\tfirst\tPhase\t1\tclinical\ttrial\tof\tthat\tintegrase\tinhibitor.\tUpon\texercise\tof\tan\toption,\tthe\tcompanies\twill split\tdevelopment\tcosts\tand\trevenues,\tunless\tthe\tnon-exercising\tcompany\tdecides\tto\topt\tout,\tin\twhich\tcase\tthe\tnon-exercising company\twill\tbe\tpaid\ta\troyalty.\n\n## Arcus\n\nOn\tMay\t27,\t2020,\twe\tentered\tinto\ta\ttransaction\twith\tArcus,\ta\tpublicly\ttraded\toncology-focused\tbiopharmaceutical\tcompany, which\tincluded\tentry\tinto\tan\toption,\tlicense\tand\tcollaboration\tagreement\t(the\t'Collaboration\tAgreement'),\twith\tGilead\thaving the\tright\tto\topt\tin\tto\tall\tcurrent\tand\tfuture\tclinical-stage\tproduct\tcandidates\tfor\tup\tto\tten\tyears\tfollowing\tthe\tclosing\tof the\t transaction,\t and\t a\t common\t stock\t purchase\t agreement\t and\t an\t investor\t rights\t agreement\t (together,\t and\t as\t subsequently amended\tthe\t'Stock\tPurchase\tAgreements').\n\nIn\t November\t 2021,\t we\t exercised\t our\t options\t to\t three\t of\t Arcus'\t clinical\t stage\t programs\t and\t amended\t the\t Collaboration Agreement.\tThe\toption\texercise\tand\tamendment\ttransaction\tclosed\tin\tDecember\t2021,\ttriggering\tcollaboration\topt-in\tpayments\tof $725\tmillion\tand\twaiving\tthe\t$100\tmillion\toption\tcontinuation\tpayment\twhich\twould\thave\tbeen\tdue\tto\tArcus\tin\tthe\tthird\tquarter of\t2022.\tThe\tnet\toption\tcharge\tof\t$625\tmillion\twas\tincluded\twithin\tAcquired\tin-process\tresearch\tand\tdevelopment\texpenses\ton our\tConsolidated\tStatements\tof\tIncome\tfor\tthe\tyear\tended\tDecember\t31,\t2021.\tThe\tcollaboration\topt-in\tpayments\tof\t$725\tmillion were\trecorded\tin\tOther\tcurrent\tliabilities\ton\tour\tConsolidated\tBalance\tSheets\tas\tof\tDecember\t31,\t2021\tand\tpaid\tto\tArcus\tin January\t2022.\tOur\tpayments\tto\tArcus\twere\tincluded\twithin\tNet\tcash\tused\tin\tinvesting\tactivities\ton\tour\tConsolidated\tStatements of\tCash\tFlows\tin\tthe\tfirst\tquarter\tof\t2022.\n\nIn\t May\t 2023,\t we\t again\t amended\t the\t Collaboration\t Agreement\t to\t initiate\t research\t programs\t against\t up\t to\t four\t targets jointly\tselected\tby\tthe\tparties\tthat\tare\tapplicable\tto\tinflammatory\tdiseases.\tAs\tpart\tof\tthe\tamendment,\twe\tpaid\ta\t$35\tmillion upfront\tfee,\twhich\twas\tcharged\tto\tAcquired\tin-process\tresearch\tand\tdevelopment\texpenses\ton\tour\tConsolidated\tStatements\tof Income.\tGilead\tmay\texercise\tan\toption\tto\tlicense\teach\tprogram\tat\ttwo\tseparate,\tprespecified\ttime\tpoints.\tIf\tGilead\texercises its\toption\tat\tthe\tearlier\ttime\tpoint\tfor\tthe\tfirst\ttwo\ttarget\tprograms,\tArcus\twould\tbe\teligible\tto\treceive\tup\tto\t$420\tmillion in\tfuture\toption\tand\tmilestone\tpayments\tand\ttiered\troyalties\tfor\teach\toptioned\tprogram.\tFor\tany\tother\toption\texercise\tby Gilead\tfor\tthe\tfour\ttarget\tprograms,\tthe\tparties\twould\thave\trights\tto\tco-develop\tand\tshare\tglobal\tdevelopment\tcosts\tand\tto co-commercialize\tand\tshare\tprofits\tin\tthe\tU.S.\tfor\toptioned\tprograms.\n\nUnder\tthe\tamended\tCollaboration\tAgreement,\tthe\tcompanies\tco-develop\tand\tshare\tthe\tglobal\tcosts\trelated\tto\tthese\tclinical programs.\tWe\trecorded\t$189\tmillion\tand\t$187\tmillion\tof\tsuch\tcosts\tin\tResearch\tand\tdevelopment\texpenses\ton\tour\tConsolidated Statements\t of\t Income\t for\t the\t years\t ended\t December\t 31,\t 2023\t and\t 2022,\t respectively.\t If\t the\t optioned\t molecules\t achieve regulatory\tapproval,\tthe\tcompanies\twill\tco-commercialize\tand\tequally\tshare\tprofits\tin\tthe\tU.S.\tGilead\twill\thold\texclusive commercialization\trights\toutside\tthe\tU.S.,\tsubject\tto\tany\trights\tof\tArcus's\texisting\tcollaboration\tpartners,\tand\twill\tpay\tto Arcus\t tiered\t royalties\t as\t a\t percentage\t of\t net\t sales\t ranging\t from\t the\t mid\t teens\t to\t low\t twenties.\t Under\t the\t amended Collaboration\tAgreement,\twe\tmay\talso\tpay\tan\tadditional\t$100\tmillion\tat\tour\toption\ton\teach\tof\tthe\tfourth,\tsixth\tand\teighth anniversaries\tof\tthe\tagreement,\tunless\tterminated\tearly,\tto\tmaintain\tthe\trights\tto\topt\tin\tto\tfuture\tArcus\tprograms\tfor\tthe duration\tof\tthe\tcontact\tterm.",
          "relationship": "Leads_Commercialization"
        },
        "node_3": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_1",
          "chunk_text": "## 7.\t\t\t\tCOLLABORATIONS\tAND\tOTHER\tARRANGEMENTS\n\nWe\tenter\tinto\tlicensing\tand\tstrategic\tcollaborations\tand\tother\tsimilar\tarrangements\twith\tthird\tparties\tfor\tthe\tresearch, development\t and\t commercialization\t of\t certain\t products\t and\t product\t candidates.\t These\t arrangements\t may\t involve\t two\t or\t more parties\twho\tare\tactive\tparticipants\tin\tthe\toperating\tactivities\tof\tthe\tcollaboration\tand\tare\texposed\tto\tsignificant\trisks\tand rewards\tdepending\ton\tthe\tcommercial\tsuccess\tof\tthe\tactivities.\tThe\tfinancial\tterms\tof\tthese\tarrangements\tmay\tinclude\tnonrefundable\t upfront\t payments,\t expense\t reimbursements\t or\t payments\t by\t us\t for\t options\t to\t acquire\t certain\t rights,\t contingent obligations\tby\tus\tfor\tpotential\tdevelopment\tand\tregulatory\tmilestone\tpayments\tand/or\tsales-based\tmilestone\tpayments,\troyalty payments,\t revenue\t or\t profit-sharing\t arrangements,\t cost-sharing\t arrangements\t and\t equity\t investments.\t Development\t milestone payments\tare\trecorded\tin\tour\tConsolidated\tStatements\tof\tIncome\tas\tincurred,\twhich\tis\tgenerally\twhen\tthe\tcorresponding\tevents become\tprobable.\tRegulatory\tmilestone\tpayments\tare\tcapitalized\tas\tintangible\tassets\tand\tamortized\tto\tCost\tof\tgoods\tsold\tover the\tterm\tof\tthe\trespective\tcollaboration\tarrangement.\tCertain\tpayments\tare\tcontingent\tupon\tthe\toccurrence\tof\tvarious\tfuture events\tthat\thave\ta\thigh\tdegree\tof\tuncertainty.\n\n## Arcellx\n\nIn\tJanuary\t2023,\twe\tclosed\tan\tagreement\tto\tenter\tinto\ta\tglobal\tstrategic\tcollaboration\twith\tArcellx,\ta\tpublic\tcompany,\tto co-develop\tand\tco-commercialize\tArcellx's\tlead\tlate-stage\tproduct\tcandidate,\tCART-ddBCMA,\tfor\tthe\ttreatment\tof\tpatients\twith relapsed\t or\t refractory\t multiple\t myeloma,\t and\t potential\t future\t next-generation\t autologous\t and\t non-autologous\t products.\t In December\t 2023,\t we\t expanded\t the\t scope\t of\t the\t collaboration\t to\t include\t lymphomas\t and\t exercised\t our\t option\t to\t negotiate\t a license\tfor\tArcellx's\tARC-SparX\tprogram,\tACLX-001,\tin\tmultiple\tmyeloma.\tIn\tconjunction\twith\tthese\tcollaboration\tagreements, we\t recorded\t a\t combined\t $313\t million\t charge\t to\t Acquired\t in-process\t research\t and\t development\t expenses\t on\t our\t Consolidated Statements\tof\tIncome\tin\t2023,\tprimarily\trelated\tto\tupfront\tpayments,\tas\twell\tas\ta\tcombined\tequity\tinvestment\tof\t$299\tmillion. Our\t equity\t investment\t is\t subject\t to\t lock-up\t provisions\t until\t June\t 2025\t and\t is\t included\t in\t Other\t long-term\t assets\t on\t our Consolidated Balance Sheets as of December 31, 2023. The companies will share development, clinical trial and commercialization\tcosts\tfor\tCART-ddBCMA\tand\twill\tjointly\tcommercialize\tthe\tproduct\tand\tsplit\tU.S.\tprofits\t50/50.\tOutside\tthe U.S.,\t we\t will\t commercialize\t the\t product\t and\t Arcellx\t will\t receive\t royalties\t on\t sales.\t Arcellx\t is\t eligible\t to\t receive performance-based\tdevelopment\tand\tregulatory\tmilestone\tpayments\tof\tup\tto\t$1.5\tbillion\trelated\tto\tCART-ddBCMA,\ta\tpotential future\tnext-generation\tautologous\tproduct\tand\ta\tpotential\tfuture\tnon-autologous\tproduct,\twith\tfurther\tcommercial\tmilestone payments,\tprofit\tsplit\tpayments\ton\tco-promoted\tproducts\tand\troyalties\ton\tat\tleast\ta\tportion\tof\tworldwide\tnet\tsales,\tdepending on\twhether\tArcellx\topts\tin\tto\tco-promote\tthe\tfuture\tproducts.\tIf\tadditional\tfuture\tproducts\tare\tdeveloped,\tArcellx\twould\tbe eligible\tto\treceive\tadditional\tmilestone\tpayments,\tprofit\tsplit\tpayments\ton\tco-promoted\tproducts\tand\troyalties\ton\tat\tleast\ta portion\tof\tworldwide\tnet\tsales,\tdepending\ton\twhether\tArcellx\topts\tin\tto\tco-promote\tthese\tadditional\tfuture\tproducts\tas\twell.\n\n## Dragonfly\n\nIn\t April\t 2022,\t we\t entered\t into\t a\t strategic\t research\t collaboration\t agreement\t (the\t 'Dragonfly\t Collaboration\t Agreement') with\t Dragonfly\t Therapeutics,\t Inc.\t ('Dragonfly')\t to\t develop\t natural\t killer\t ('NK')\t cell\t engager-based\t immunotherapies\t for oncology\tand\tinflammation\tindications.\tUnder\tthe\tterms\tof\tthe\tDragonfly\tCollaboration\tAgreement,\twe\treceived\tan\texclusive, worldwide\t license\t from\t Dragonfly\t for\t the\t 5T4-targeting\t investigational\t immunotherapy\t program,\t DF7001,\t as\t well\t as\t options, after\tthe\tcompletion\tof\tcertain\tpreclinical\tactivities,\tto\tlicense\texclusive,\tworldwide\trights\tto\tdevelop\tand\tcommercialize additional\tNK\tcell\tengager\tprograms\tusing\tthe\tDragonfly\tTri-specific\tNK\tEngager\tplatform.\tUpon\tthe\tclosing\tof\tthe\tDragonfly Collaboration\tAgreement,\twe\tmade\ta\t$300\tmillion\tupfront\tpayment\tto\tDragonfly,\tand\twe\tmade\tan\tadditional\t$15\tmillion\tpayment related\tto\ta\ttarget\tselection\tin\tconnection\twith\tan\tAugust\t2022\tamendment\tto\tthe\tagreement,\twhich\twere\trecorded\tin\tAcquired in-process\t research\t and\t development\t expenses\t on\t our\t Consolidated\t Statements\t of\t Income\t during\t the\t year\t ended\t December\t 31, 2022.\tIn\tJuly\t2023,\twe\tmutually\tagreed\tto\tterminate\tthe\tDF7001\tprogram.\tIf\twe\texercise\tour\toptions\ton\tadditional\tNK\tcell engager\tprograms,\tDragonfly\twould\tbe\teligible\tto\treceive\topt-in\tpayments\tand\tperformance-based\tdevelopment,\tregulatory\tand commercial\tmilestone\tpayments\tand\troyalties\ton\tworldwide\tnet\tsales\ton\tthese\toptioned\tprograms.\n\n## Merck\n\nOn\tMarch\t13,\t2021,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tMerck\tSharp\t&amp;\tDohme\tCorp.,\ta\tsubsidiary\tof Merck\t&amp;\tCo.,\tInc.\t('Merck')\tto\tjointly\tdevelop\tand\tcommercialize\tlong-acting\tinvestigational\ttreatments\tin\tHIV\tthat\tcombine Gilead's\t investigational\t capsid\t inhibitor,\t lenacapavir,\t and\t Merck's\t investigational\t nucleoside\t reverse\t transcriptase translocation\tinhibitor,\tislatravir,\twith\tother\tformulations\tpotentially\tadded\tto\tthe\tcollaboration\tas\tmutually\tagreed.\tThe collaboration\tis\tinitially\tfocused\ton\tlong-acting\toral\tand\tinjectable\tformulations.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 19,
      "question": "How does AbbVie's financial exposure to Imbruvica, including its collaboration with Janssen Biotech and the $3.6 billion intangible asset impairment charge, reflect both the strategic benefits and financial risks of co-commercializing a high-profile oncology product?",
      "answer": "AbbVie's collaboration with Janssen Biotech for the development and commercialization of Imbruvica involves shared costs and profits, with Janssen covering 60% of development costs and AbbVie 40%. In the U.S., AbbVie is the principal in end-customer sales and shares pre-tax profits and losses equally with Janssen, which is also reflected in AbbVie's cost of products sold. However, despite this cost-sharing structure, AbbVie reported a $3.6 billion intangible asset impairment charge in 2023 primarily related to Imbruvica, among other products, which significantly impacted gross margins. This impairment suggests that the long-term financial outlook for Imbruvica may be deteriorating, potentially outweighing the benefits of shared development and commercialization responsibilities. Thus, while the collaboration reduces direct financial burden, AbbVie still bears significant risk tied to Imbruvica\u2019s market performance.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_68) \u2192 Janssen Biotech: AbbVie shares development and commercialization responsibilities with Janssen Biotech for Imbruvica, with Janssen covering 60% of development costs and both parties sharing profits equally.",
        "Hop 2: Janssen Biotech \u2192 Imbruvica: Janssen Biotech was granted exclusive rights to commercialize Imbruvica outside the U.S. and co-exclusive rights within the U.S. under a long-term collaboration agreement with AbbVie.",
        "Hop 3: Imbruvica \u2190 ABBV(page_44): Imbruvica was a key contributor to a $3.6 billion intangible asset impairment charge in 2023, which significantly impacted AbbVie\u2019s gross margin."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Introduces]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Janssen Biotech",
        "node_3": "Imbruvica",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen_Biotech",
          "name": "Janssen Biotech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "Imbruvica",
          "name": "Imbruvica",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_3",
          "chunk_text": "\nGross\tmargin\tas\ta\tpercentage\tof\tnet\trevenues\tin\t2023\tdecreased\tcompared\tto\t2022.\tGross\tmargin\tpercentage\tfor\t2023\twas unfavorably\timpacted\tby\tintangible\tasset\timpairment\tcharges\tof\t$3.6\tbillion\tprimarily\trelated\tto\tImbruvica,\tCoolSculpting\tand Liletta,\thigher\tamortization\tof\tintangibles\tand\tchanges\tin\tproduct\tmix,\tpartially\toffset\tby\tthe\tfavorable\ttax\tlaw\tchanges\tin Puerto\tRico.\n\n## Selling,\tGeneral\tand\tAdministrative\n\n",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 20,
      "question": "How does BMY's increased royalty revenue from Keytruda in 2023 relate to Merck's reduced royalty payment obligation starting in 2024, and what implications does this have for BMY's future revenue streams tied to the product trademark?",
      "answer": "BMY reported increased royalty revenue from Keytruda in 2023 due to higher global sales, which directly contributed to the growth in royalties mentioned in the financial statements. However, the agreement with Merck specifies that the royalty rate will decrease from 6.5% to 2.5% starting in 2024, which could reduce future royalty inflows to BMY despite the product's ongoing commercial success. Additionally, while BMY benefits from the Keytruda trademark, it does not own the brand outright, limiting long-term control over the product\u2019s branding and potential revenue stability. This dynamic suggests that while BMY currently benefits from strong Keytruda performance, future revenue growth from the product may be constrained by the contractual royalty reduction.",
      "reasoning_steps": [
        "Hop 1: BMY(page_55) \u2192 Merck: BMY reported higher royalties in 2023 due to increased Keytruda sales, indicating a direct financial benefit from Merck's commercialization efforts.",
        "Hop 2: Merck \u2192 Keytruda: Merck's obligation to pay royalties on Keytruda sales to BMS and Ono was 6.5% through 2023, but will drop to 2.5% from 2024 through 2026, signaling a future decline in royalty income for BMY.",
        "Hop 3: Keytruda \u2190 BMY(page_138): BMY acknowledges that Keytruda is a trademark of Merck Sharp & Dohme Corp., not fully owned by BMY, which affects long-term brand control and potential revenue stability."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Pays]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Merck",
        "node_3": "Keytruda",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_55",
          "chunk_id": "chunk_4",
          "chunk_text": "\n\u00b7 Interest\t expense\t decreased\t in\t 2023\t due\t to\t additional\t debt\t maturities.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and Supplementary\tData-Note\t10.\tFinancing\tArrangements'\tfor\tfurther\tinformation.\n\n- Royalties\t increased\t in\t 2023\t primarily\t due\t to\t higher Keytruda *\t royalties.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and Supplementary\tData-Note\t4.\tAcquisitions,\tDivestitures,\tLicensing\tand\tOther\tArrangements'\tfor\tfurther\tinformation.\n- Equity\tinvestments\tgenerated\tlower\tlosses\tin\t2023\tcompared\tto\t2022\tdue\tto\tfair\tvalue\tadjustments\tfor\tinvestments\tthat\thave readily\t determinable\t fair\t value.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and\t Supplementary\t Data-Note\t 9.\t Financial Instruments\tand\tFair\tValue\tMeasurements'\tfor\tmore\tinformation.\n- Integration\texpenses\tdecreased\tin\t2023\tdue\tto\tlower\tconsulting\tfees\tto\timplement\tCelgene\tintegration\tinitiatives\trelated to\tprocesses\tand\tsystems.\n- Loss\ton\tdebt\tredemption\tresulted\tfrom\tthe\tearly\tredemption\tof\tlong-term\tdebt\tof\t$6.0\tbillion\tin\t2022.\n- Divestiture\tgains\tresulted\tfrom\tcertain\tmature\tproduct\trights\tdivested\tin\t2022.\n- Investment\tincome\tincreased\tin\t2023\tprimarily\tdue\tto\thigher\tinterest\trates.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Pays"
        },
        "node_3": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 21,
      "question": "How does Amgen's decision to terminate Novartis' U.S. commercialization rights for Aimovig in early 2022 relate to its competitive positioning against Novartis' Cosentyx in the U.S. and Europe, particularly in the context of their ongoing global development cost-sharing arrangement?",
      "answer": "Amgen's decision to end Novartis' U.S. commercialization rights for Aimovig in early 2022 severed the joint U.S. marketing arrangement, removing Novartis' ability to share in U.S. costs and profits or receive royalties on U.S. sales. However, Novartis retained global co-development rights and continued to share development expenses with Amgen. At the same time, Novartis' Cosentyx is listed in Amgen's 10-K as a direct competitor to Amgen's Otezla in both the U.S. and Europe. This dual relationship\u2014where Novartis is both a collaborator on Aimovig's global development and a competitor through Cosentyx\u2014creates a complex dynamic. Amgen's restructuring of the Aimovig partnership may reflect a strategic effort to reduce Novartis' influence in the U.S. market while still leveraging shared R&D resources globally, even as Cosentyx competes directly with Amgen's dermatology portfolio.",
      "reasoning_steps": [
        "Hop 1: AMGN (page_28) \u2192 Novartis: Amgen and Novartis modified their Aimovig collaboration in early 2022, ending Novartis' U.S. commercialization rights and royalty entitlement, while retaining shared global R&D cost obligations.",
        "Hop 2: Novartis \u2192 Cosentyx: Novartis is the producer of Cosentyx, a biologic drug used in dermatology and immunology.",
        "Hop 3: Cosentyx \u2190 AMGN (page_16): Cosentyx is explicitly listed in Amgen's 10-K as a competitor to Amgen's Otezla in both the U.S. and Europe, indicating direct market competition."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Produces]-> PRODUCT <-[Competes_Against]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Novartis",
        "node_3": "Cosentyx",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Novartis",
          "name": "Novartis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Cosentyx",
          "name": "Cosentyx",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 22,
      "question": "How does BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe align with the company's expressed risk regarding potential early generic entry of Eliquis and its impact on market exclusivity projections through 2026?",
      "answer": "BMY collaborates with Pfizer to litigate and defend Eliquis' patents in both the U.S. and Europe, as seen in the multiple lawsuits filed against generic challengers like Sandoz and Teva, and the successful U.S. court rulings affirming the validity of Eliquis' composition of matter and formulation patents through 2026. Despite these legal victories, BMY acknowledges in its risk factors that adverse litigation outcomes in Europe could still allow early generic entry of apixaban products before the estimated market exclusivity date, which would negatively affect revenue and market position. This creates a nuanced picture where, although BMY and Pfizer have secured strong legal wins in the U.S., the company remains exposed to risks in Europe that could undermine its exclusivity projections and financial planning tied to Eliquis.",
      "reasoning_steps": [
        "Hop 1: BMY (page_157) \u2192 Pfizer: BMY partners with Pfizer to defend Eliquis patents in the U.S. and Europe, including initiating litigation against generic challengers and securing court affirmations of patent validity through 2026.",
        "Hop 2: Pfizer \u2192 Eliquis: Pfizer is a joint commercialization partner of Eliquis, sharing development costs and global profits equally with BMY, making the defense of Eliquis' patents a shared strategic priority.",
        "Hop 3: Eliquis \u2190 BMY (page_38): BMY explicitly states in its risk factors that adverse litigation outcomes in Europe regarding Eliquis' patents could result in early generic entry, negatively impacting its market exclusivity projections and financial performance."
      ],
      "difficulty": "hard",
      "idf_score": 5.721306120841433,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Pfizer",
        "node_3": "Eliquis",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_157",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eliquis - U.S.\n\nIn 2017, BMS received Notice Letters from twenty-five generic companies notifying BMS that they had filed aNDAs containing paragraph  IV  certifications  seeking  approval  of  generic  versions  of  Eliquis. As  a  result,  two  Eliquis  patents  listed  in  the  FDA Orange Book are being challenged: the composition of matter patent claiming apixaban specifically and a formulation patent. In response, BMS, along with its partner Pfizer, initiated patent infringement actions under the Hatch-Waxman Act against all generic filers in the U.S. District Court for the District of Delaware in April 2017. In August 2017, the U.S. Patent and Trademark Office granted patent term restoration to the composition of matter patent to November 2026, thereby restoring the term of the Eliquis composition of matter patent, which is BMS's basis for projected minimum market exclusivity dates. BMS settled with a number of aNDA filers.  These  settlements  do  not  affect  BMS's  projected  minimum  market  exclusivity  dates  for  Eliquis. A  trial  with  the remaining aNDA filers took place in late 2019. In August 2020, the U.S. District Court issued a decision finding that the remaining aNDA filers' products infringed the Eliquis composition of matter and formulation patents and that both Eliquis patents are not invalid. In September 2021, the Federal Circuit affirmed the lower court decision. The time by which the remaining aNDA filers could seek review of the Federal Circuit's decision has lapsed, and thus the decision is final.\n\n## Eliquis - Europe\n\nIn  November  2020  and  January  2021,  Sandoz  Limited  ('Sandoz')  and  Teva  Pharmaceutical  Industries  Ltd.  ('Teva  Limited'), respectively, filed lawsuits in the United Kingdom seeking revocation of the UK apixaban composition of matter patent and related Supplementary Protection Certificate. BMS subsequently filed counterclaims for infringement in both actions. A trial is scheduled to begin in early 2022.\n\nThere are similar lawsuits filed in France, Italy, the Netherlands, Portugal, the Republic of Ireland, and Sweden seeking revocation of a composition of matter patent relating to Eliquis .\n\nAdditional infringement and invalidity actions involving Eliquis patents may be filed in various countries in Europe in the coming months.\n\n## Onureg - U.S.\n\nIn November 2021, BMS received a Notice Letter from Accord notifying BMS that it had filed an aNDA containing a paragraph IV certification  seeking  approval  of  a  generic  version  of Onureg in  the  US  and  challenging  the  one  FDA  Orange  Book-listed formulation patent expiring in 2030. In response, BMS filed a patent infringement action against Accord in the U.S. District Court for the District of Delaware. No trial date has been scheduled.\n\n## Plavix* - Australia\n\nSanofi was notified that, in August 2007, GenRx Proprietary Limited ('GenRx') obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex  ('GenRx-Apotex').  In  August  2007,  GenRx-Apotex  filed  an  application  in  the  Federal  Court  of  Australia  seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a  revocation  suit  against  the  same  patent.  This  case  was  consolidated  with  the  GenRx-Apotex  case.  On August  12,  2008,  the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ('Full Court') appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($324 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages.  In  May  2020,  the Australian  government  appealed  the  Federal  Court's  decision  and  an  appeal  hearing  concluded  in February 2021.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Pfizer",
          "name": "Pfizer",
          "type": "COMP",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n(a)    Includes unamortized up-front and milestone payments.\n\nSpecific information pertaining to significant alliances is discussed below, including their nature and purpose; the significant rights and obligations of the parties; specific accounting policy elections; and the statements of earnings classification of and amounts attributable to payments between the parties.\n\n## Pfizer\n\nBMS and Pfizer jointly develop and commercialize Eliquis , an anticoagulant discovered by BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis except in certain countries where Pfizer commercializes Eliquis and pays BMS a sales-based fee.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Eliquis",
          "name": "Eliquis",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "generic products, which negatively impacts the protections afforded the Company. Lower-priced generics or biosimilars for BMS biologic products or competing biologics could negatively impact our volumes and prices.\n\nIn  addition,  both  the  U.S.  Congress  and  the  U.S.  FDA  have  taken  steps  to  promote  the  development  and  approval  of generic drugs and biosimilar biologics. For example, in December 2019, the U.S. Congress enacted legislation intended to  facilitate  generic  companies'  access  to  drug  samples.  Section  610  of  the  Further  Consolidated  Appropriations  Act, 2020, provides generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from  the  reference  product' s  manufacturer  in  order  to  conduct  testing  necessary  to  obtain  approval  for  generic  or biosimilar products. This law has the potential to have an adverse impact on our business.\n\nThere is no assurance that a particular product will enjoy market exclusivity for the full time period that appears in the estimates disclosed in this 2021 Form 10-K or that we assume when we provide our financial guidance.\n\n## Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor ('CAR') T cell therapy, may present significant challenges and risks for us.\n\nThe  development  of  novel  approaches  for  the  treatment  of  diseases,  such  as  our  acquisition  in  November  2019  of Celgene's and Juno's CAR T cell therapy programs, including Breyanzi (liso-cel) and Abecma (ide-cel), presents many new challenges and risks due to the unique nature of genetic modification of patient cells ex vivo using certain viruses to reengineer  these  cells  to  ultimately  treat  diseases,  including  obtaining  regulatory  approval  from  U.S.  FDA  and  other regulatory agencies that have limited experience with the development of cellular therapies involving genetic modification of patient cells; developing and deploying consistent and reliable processes, while limiting contamination, for engineering a patient's cells ex vivo and infusing genetically modified cells back into the patient; developing processes for the safe administration of cellular therapies, including long-term follow-up for patients receiving cellular therapies; and sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process our potential CAR T products. The use of reengineered cells as a potential cancer treatment is a recent development and may not be broadly accepted by the regulatory, patient or medical communities.\n\nFurther, we may not be able to satisfactorily establish the safety and efficacy or the reliability of these therapies through health  authority  approval,  or  demonstrate  the  potential  advantages  and  side  effects  compared  to  existing  and  future therapies. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Furthermore, certain payment models could impact the financial feasibility of making CAR T cell therapies available in certain markets or by certain treatment sites, thereby limiting patient access. To date, only a few products  that  involve  the  genetic  modification  of  patient  cells  have  been  approved  for  commercial  sale.  Moreover,  the safety profiles of cellular therapies may adversely influence public perception and may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians and payers to subscribe to these novel treatment approaches. If we fail to overcome these and other challenges, or if significant adverse events are reported from similar therapies,  our  development  of  these  novel  treatment  approaches  may  be  hampered  or  delayed,  which  could  adversely affect our future anticipated revenues and/or profitability related to these therapeutic programs. In addition, we could also face  difficulties  in  manufacturing  CAR  T  cell  therapies,  which  could  adversely  affect  our  future  anticipated  revenues and/or profitability related to our CAR T cell therapies. See ' -We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.'\n\n## We face intense competition from other manufacturers and expect to see increasing market penetration of lower-priced generic products.\n\nThe future growth of BMS is dependent on the market access, uptake and expansion for marketed brands, new product introductions,  new  indications,  product  extensions  and  co-promotional  activities  with  alliance  partners.  Competition  is keen and as we lose exclusivity for some of our marketed brands lower-priced generic products will increasingly penetrate our  markets.  Generic  challenges  to  our  products  can  also  arise  at  any  time,  and  our  patents  may  not  prevent  the emergence of generic competition for our products. For example, if we receive an adverse litigation decision in a country in the EU where our Eliquis composition of matter patents and related Supplementary Protection Certificates are being challenged (see 'Item 8. Financial Statements and Supplementary Data-Note 19. Legal Proceedings and Contingencies'), we may not be able to prevent generic apixaban products from being introduced in such country prior to our estimated minimum market exclusivity date. In some countries, patent protection is significantly weaker than in the United States or in the EU; political and social pressure has also pushed legislation and other measures that promote the use  of  generic  and  biosimilar  products.  In  addition,  we  face  competition  from  new  products  entering  the  market, particularly in IO. New products may have (i) lower prices, (ii) superior efficacy (benefit) or safety (risk) profiles (whether actual  or  perceived),  (iii)  technological  advantages  that  may  make  such  products  more  convenient  to  use,  (iv)  better insurance coverage or reimbursement levels, (v) more effective marketing programs and/or other differentiating factors that make it harder for our products to compete. We also face intense competition for external partnerships, joint ventures and  acquisition  targets  that  can  help  develop  and  bring  new  products  to  markets.  Business  combinations  among  our competitors and major third-party payers may increase competition",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 23,
      "question": "How does Amgen's disclosure of performance unit compensation expense for 2024 relate to the maximum potential share issuance under the Amended 2009 Plan, considering the fungible share-counting formula and performance-based payout structure?",
      "answer": "Amgen reported $133 million in performance unit compensation expense for 2024, which is part of the broader Amended 2009 Plan that allows for up to 59 million shares available for future grants. The Plan uses a fungible share-counting formula where each performance unit counts as 1.9 shares. As of year-end 2024, there were 1,516,669 shares subject to outstanding 2022\u20132024 performance units, including dividend equivalents. However, these performance units are subject to a performance-based payout structure that could result in up to 200% of the target shares being issued if above-target performance goals are met. This means the actual share issuance\u2014and potentially the future compensation expense\u2014could be significantly higher than the current $133 million reflects, depending on performance outcomes. The expense figure on page 124, therefore, captures only the current-year accrual based on expected performance, while the Plan disclosure on page 92 reveals the full potential dilutive impact under the share-counting methodology and performance multipliers.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_124) \u2192 Performance Units: Reports $133 million in performance unit compensation expense for 2024, indicating the financial impact of these awards on the income statement.",
        "Hop 2: Performance Units \u2192 Amended 2009 Plan: Performance units are issued under the Amended 2009 Plan, which uses a 1.9 share reduction per unit for share pool accounting, and includes provisions for dividend equivalents and performance multipliers up to 200%.",
        "Hop 3: Amended 2009 Plan \u2190 AMGN(page_92): Details the Plan\u2019s fungible share-counting rules and performance-based payout mechanics, showing that the actual number of shares issued\u2014and thus the ultimate compensation cost\u2014could be significantly higher than the current expense suggests."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Includes]-> ACCOUNTING_POLICY <-[Subject_To]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Performance Units",
        "node_3": "Amended 2009 Plan",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                    | Years ended December 31,   | Years ended December 31,   | Years ended December 31,   |\n|----------------------------------------------------|----------------------------|----------------------------|----------------------------|\n|                                                    | 2024                       | 2023                       | 2022                       |\n| RSUs                                               | $ 351                      | $ 309                      | $ 227                      |\n| Performance units                                  | 133                        | 121                        | 132                        |\n| Stock options                                      | 46                         | 43                         | 42                         |\n| Total stock-based compensation expense, pretax     | 530                        | 473                        | 401                        |\n| Taxbenefit fromstock-based compensation expense    | (114)                      | (102)                      | (86)                       |\n| Total stock-based compensation expense, net of tax | $ 416                      | $ 371                      | $ 315                      |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Performance_Units",
          "name": "Performance Units",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_1",
          "chunk_text": "## 5. Stock-based compensation\n\nOur Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2024, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 59 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.\n\nThe following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):\n\n",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Amended_2009_Plan",
          "name": "Amended 2009 Plan",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. In accordance with this formula, each option or stock appreciation right counts as one share, while each RSU, performance unit or dividend equivalent counts as 1.9 shares. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the fungible share-counting formula. The number under column (c) represents the number of shares available for issuance under this plan based on each such available share counting as one share. Commencing with the grants made in April 2012, RSUs and performance units accrue dividend equivalents that are payable in shares only to the extent and when the underlying RSUs vest or underlying performance units have been earned and the related shares are issued to the grantee. The performance units granted under this plan are earned based on the accomplishment of specified performance goals at the end of their respective three-year performance periods; the number of performance  units  granted  represent  target  performance,  and  the  max imum  number  of  units  that  could  be  earned  based  on  our  performance  is  200%  of  the performance units granted in 2022, 2023 and 2024. (1)\n\nAs of December 31, 2024, the number of outstanding awards under column (a) includes (i) 5,909,018 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of $225.84; (ii) 3,289,089 shares issuable upon the vesting of outstanding RSUs, including 198,925 related dividend equivalents; and (iii) 1,516,669 shares subject to outstanding 2022, 2023 and 2024 performance units, including 91,901 related dividend equivalents. The weighted-average exercise price shown in column (b) is for the outstanding options only. The number of available shares under column (c) represents the number of shares that remain available for future issuance under this plan as of December 31, 2024, employing the fungible share formula and presumes the issuance of target shares under the performance units granted in 2022, 2023 and 2024 and related dividend equivalents. The numbers under columns (a) and (c) do not give effect to the additional shares  that  could  be  issuable  in  the  event  that  above  target  performance  on  the  performance  goals  under  these  outstanding  performance  units  is  achieved. Maximum performance under these goals could result in 200% of target shares being awarded for performance units granted in 2022, 2023 and 2024.\n\nThis plan has terminated as to future grants. The number under column (a) with respect to this plan includes 100 shares issuable upon the settlement of deferred RSUs. (2)\n\nThe Profit Sharing Plan was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company's subsidiaries located in Ireland who participate in the Profit Sharing Plan to apply a (3)",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 24,
      "question": "How does the inclusion of Eliquis in the Medicare Drug Price Negotiation Program, which could result in a new maximum fair price by 2026, reconcile with its 11% U.S. revenue growth in 2023 driven by market share gains in non-valvular atrial fibrillation?",
      "answer": "Eliquis experienced 11% U.S. revenue growth in 2023 due to increased adoption and market share gains in the non-valvular atrial fibrillation indication. However, its inclusion in the Medicare Drug Price Negotiation Program, which will set a new 'maximum fair price' by September 2024 for implementation in 2026, introduces potential pricing pressure that could impact future profitability. While Eliquis remains a high-performing asset in key therapeutic areas, the regulatory intervention under the IRA may constrain revenue growth or margin expansion in the medium term, particularly if the negotiated price is lower than current levels and applies broadly across Medicare beneficiaries and 340B Program entities.",
      "reasoning_steps": [
        "Hop 1: PFE(page_44) \u2192 Eliquis: Eliquis achieved 11% U.S. revenue growth in 2023 driven by oral anticoagulant adoption and market share gains in non-valvular atrial fibrillation.",
        "Hop 2: Eliquis \u2192 Medicare Drug Price Negotiation Program: Eliquis was selected as one of the first ten drugs under the Medicare Drug Price Negotiation Program, with a new maximum fair price to be set by CMS and effective in 2026.",
        "Hop 3: Medicare Drug Price Negotiation Program \u2190 PFE(page_38): The Medicare Drug Price Negotiation Program, part of the Inflation Reduction Act, introduces regulatory pricing constraints that could materially affect Pfizer's financial performance, with full impact uncertain due to ongoing legal challenges."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Involved_In]-> REGULATORY_REQUIREMENT <-[Faces]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Eliquis",
        "node_3": "Medicare Drug Price Negotiation Program",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_2",
          "chunk_text": "|                    |                        |                    | Revenue         | Revenue          |                |          |                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n|--------------------|------------------------|--------------------|-----------------|------------------|----------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (MILLIONS) Product | Global Revenues        | Region             | Year Ended 2023 | Dec. 31, 2022    | % Change Total | Oper.    | Operational Results Commentary                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Comirnaty          | $11,220                | U.S. $             | 2,404           | $ 8,775          | (73)           |          | Declines largely driven by lower contracted deliveries and demand in international markets and lower U.S. government contracted                                                                                                                                                                                                                                                                                                             |\n| Comirnaty          | Down 70%               | Int'l.             | 8,816           | 29,032           | (70)           | (69)     | deliveries, due to transition to new variant vaccines in most markets and the transition to traditional U.S. commercial market sales which began in September 2023.                                                                                                                                                                                                                                                                         |\n| Comirnaty          | (operationally)        | Worldwide          | $ 11,220        | $ 37,806         | (70)           | (70)     |                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Eliquis            | $6,747                 | U.S.               | $ 4,228         | $ 3,822          | 11             |          | Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to LOE and generic competition in certain international markets.                                                                                                                                                    |\n| Eliquis            | Up 5%                  | Int'l.             | 2,519           | 2,658            | (5)            | (3)      | Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to LOE and generic competition in certain international markets.                                                                                                                                                    |\n| Eliquis            | (operationally)        | Worldwide          | $ 6,747         | $ 6,480          | 4              | 5        | Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to LOE and generic competition in certain international markets.                                                                                                                                                    |\n| Prevnar family     | $6,440                 | U.S.               | $ 4,204         | $ 4,032          | 4              |          | Growth primarily driven by the adult indications in the U.S. due to strong patient demand for Prevnar 20 for the eligible adult population, partially offset by the Prevnar pediatric indication in the U.S. driven by lower market share due to competitor entry.                                                                                                                                                                          |\n| Prevnar family     | Up 3%                  | Int'l.             | 2,236           | 2,305            | (3)            | -        | Growth primarily driven by the adult indications in the U.S. due to strong patient demand for Prevnar 20 for the eligible adult population, partially offset by the Prevnar pediatric indication in the U.S. driven by lower market share due to competitor entry.                                                                                                                                                                          |\n| Prevnar family     | (operationally)        | Worldwide          | $ 6,440         | $ 6,337          | 2              | 3        | Growth primarily driven by the adult indications in the U.S. due to strong patient demand for Prevnar 20 for the eligible adult population, partially offset by the Prevnar pediatric indication in the U.S. driven by lower market share due to competitor entry.                                                                                                                                                                          |\n| Ibrance            | $4,753                 | U.S.               | $ 3,151         | $ 3,370          | (6)            |          | Declines primarily driven by lower demand globally due to competitive pressure, lower clinical trial purchases internationally, and planned price decreases in certain international developed markets.                                                                                                                                                                                                                                     |\n| Ibrance            | Down 6%                | Int'l.             | 1,602           | 1,751            | (8)            | (6)      | Declines primarily driven by lower demand globally due to competitive pressure, lower clinical trial purchases internationally, and planned price decreases in certain international developed markets.                                                                                                                                                                                                                                     |\n| Ibrance            | (operationally)        | Worldwide          | $ 4,753         | $ 5,120          | (7)            | (6)      | Declines primarily driven by lower demand globally due to competitive pressure, lower clinical trial purchases internationally, and planned price decreases in certain international developed markets.                                                                                                                                                                                                                                     |\n| Vyndaqel family    | $3,321                 | U.S.               | $ 1,863         | $ 1,245          | 50             |          | Growth largely driven by continued strong uptake of the ATTR-CM indication, primarily in the U.S. and developed Europe, partially offset by a planned price decrease that went into effect in Japan in the second quarter of 2022.                                                                                                                                                                                                          |\n| Vyndaqel family    | Up 36% (operationally) | Int'l. Worldwide $ | 1,458 3,321     | 1,202 $ 2,447    | 21 36          | 22 36    | Growth largely driven by continued strong uptake of the ATTR-CM indication, primarily in the U.S. and developed Europe, partially offset by a planned price decrease that went into effect in Japan in the second quarter of 2022.                                                                                                                                                                                                          |\n| Xeljanz            | $1,703                 | U.S.               | $ 1,154         | $ 1,129          | 2              |          | Decline driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to label changes, partially offset by higher net price in the U.S. due to favorable changes in channel mix.                                                                                                                                                                                               |\n| Xeljanz            | Down 4%                |                    |                 |                  | (18)           |          | Decline driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to label changes, partially offset by higher net price in the U.S. due to favorable changes in channel mix.                                                                                                                                                                                               |\n| Xeljanz            | (operationally)        | Int'l. Worldwide $ | 549 1,703       | 668 $ 1,796      | (5)            | (15) (4) | Declines primarily driven by: \u2022 a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with                                                                                                                                                                                                                                                                                  |\n| Paxlovid           | $1,279 Down 92%        |                    |                 |                  |                |          | sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory (see Note 17C ); and \u2022 lower contractual deliveries in most international markets, partially offset by: \u2022 strong demand in China under the temporary National Reimbursement Drug List (which ended on April 1, 2023) due to surge in COVID-19 infection during the first quarter of 2023; and |\n| Paxlovid           | (operationally)        | U.S.               | $ (1,289)       | $ 10,514         | * (69)         | (68)     | sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory (see Note 17C ); and \u2022 lower contractual deliveries in most international markets, partially offset by: \u2022 strong demand in China under the temporary National Reimbursement Drug List (which ended on April 1, 2023) due to surge in COVID-19 infection during the first quarter of 2023; and |\n| Paxlovid           |                        | Int'l.             | 2,568           | 8,419            | (93)           | (92)     | \u2022 fourth quarter sales under traditional commercial markets following transition, primarily in the U.S.                                                                                                                                                                                                                                                                                                                                     |\n| Paxlovid           | $1,191                 | Worldwide U.S. $   | $ 1,279 1,191   | $ 18,933 $ 1,198 | (1)            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Xtandi             | Down 1%                | Int'l.             | -               | -                | -              | -        | Decline driven by lower net price mainly due to unfavorable changes in channel mix, partially offset by higher demand.                                                                                                                                                                                                                                                                                                                      |\n| Paxlovid           | (operationally)        | Worldwide          | $ 1,191         | $ 1,198          | (1)            |          | Decline driven by lower net price mainly due to unfavorable changes in channel mix, partially offset by higher demand.                                                                                                                                                                                                                                                                                                                      |\n| Paxlovid           | $1,036                 |                    |                 |                  |                | (1)      | Decline driven by lower net price mainly due to unfavorable changes in channel mix, partially offset by higher demand.                                                                                                                                                                                                                                                                                                                      |\n| Inlyta             |                        | U.S.               | $ 642           | $ 618            | 4              |          | the U.S. driven by the adoption of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC, partially offset by lower volumes and lower net price in certain European markets.                                                                                                                                                                                           |\n| Inlyta             | Up 5%                  |                    |                 |                  |                |          | the U.S. driven by the adoption of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC, partially offset by lower volumes and lower net price in certain European markets.                                                                                                                                                                                           |\n|                    |                        | Int'l.             | 394             | 385              | 3              | 7        | Growth primarily reflects continued growth in emerging markets and                                                                                                                                                                                                                                                                                                                                                                          |\n|                    | (operationally)        | Worldwide          | $ 1,036         | $ 1,003          | 3              | 5        | Growth primarily reflects continued growth in emerging markets and                                                                                                                                                                                                                                                                                                                                                                          |\n| Nurtec ODT/Vydura  | $928                   | U.S. $ Int'l.      | 908 20          | $ 211 2          | * *            | *        | Growth primarily driven by timing of the acquisition of Biohaven (fourth quarter of 2022) as well as strong patient demand in the U.S. See Note 2A .                                                                                                                                                                                                                                                                                        |\n| Nurtec ODT/Vydura  | *                      | Worldwide $        | 928             | $ 213            | *              | *        | Growth primarily driven by timing of the acquisition of Biohaven (fourth quarter of 2022) as well as strong patient demand in the U.S. See Note 2A .                                                                                                                                                                                                                                                                                        |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Eliquis",
          "name": "Eliquis",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_2",
          "chunk_text": "The\tdrug\tpricing\tprovisions\tof\tthe\tIRA,\twhich\twas\tsigned\tinto\tlaw\tin\tAugust\t2022,\tbegan\tto\tbe\timplemented\tin\t2022\tand\timplementation\twill\tcontinue over\tthe\tnext\tseveral\tyears.\tThe\tIRA\tincludes\tseveral\tprovisions\tto\tlower\tprescription\tdrug\tcosts\tfor\tMedicare\tpatients\tand\tto\treduce\tdrug\tspending by\tthe\tfederal\tgovernment.\tAmong\tother\tthings,\tthe\tIRA\tenhances\tthe\tMedicare\tPart\tD\tbenefit\tby\teliminating\tthe\tcoverage\tgap\t('donut\thole')\tbeginning in\t2025,\tadds\ta\tmaximum\tout-of-pocket\tcap\tfor\tMedicare\tbeneficiaries\t(set\tat\t$2,000\tfor\t2025),\tand\tcreates\ta\tnew\tprogram\tthat\tallows\tpatients\tto\tpay their\tcost-sharing\tover\ttime.\tThe\tlaw\talso\trequires\tmanufacturers\tto\tprovide\ta\t10%\tdiscount\ton\tbranded\tprescriptions\tin\tthe\tinitial\tcoverage\tphase and\ta\t20%\tdiscount\tin\tthe\tcatastrophic\tphase,\timposes\trebates\tunder\tMedicare\tPart\tB\tand\tMedicare\tPart\tD\ton\tdrug\tprice\tincreases\tthat\toutpace inflation,\tand\tdirects\tHHS\tto\tset\tthe\tprices\tof\tcertain\thigh-expenditure,\tsingle-source\tdrugs\tand\tbiologics\tcovered\tunder\tMedicare\t(known\tas\tthe 'Medicare\tDrug\tPrice\tNegotiation\tProgram').\tIn\tAugust\t2023,\tthe\tBiden\tAdministration\tpublished\tthe\tfirst\tten\tmedicines\tsubject\tto\tthe\tMedicare\tDrug Price\tNegotiation\tProgram,\twhich\tincluded\tEliquis.\tAs\ta\tselected\tdrug,\tCMS\twill\testablish\ta\t'maximum\tfair\tprice'\tfor\tEliquis\tand\tthat\tprice\twill\tbe published\tby\tSeptember\t1,\t2024.\tThe\tprice\twill\tbe\tin\teffect\tin\t2026.\tThe\tmaximum\tfair\tprice\testablished\tby\tCMS\tis\trequired\tto\tbe\toffered\tto\tall Medicare\tbeneficiaries\tand\tto\tcovered\tentities\tparticipating\tin\tthe\t340B\tProgram\tif\tthat\tmaximum\tfair\tprice\tis\tlower\tthan\tthe\tdiscounted\tprice\tsuch entities\tare\toffered\tunder\tthe\t340B\tProgram\tceiling\tprice\tcalculation.\tIn\taddition,\tthere\twill\tbe\ta\tnew\tMedicare\tmanufacturer\tdiscount\tprogram agreement\texpected\tto\tbe\tsigned\tin\tMarch\t2024\tthat\twill\tchange\tour\tdiscounting\tobligations\tfor\tall\tmedicines\tin\tMedicare,\twith\tfew\texceptions, beginning\tin\t2025.\tThe\tMedicare\tDrug\tPrice\tNegotiation\tProgram\tis\tcurrently\tsubject\tto\tlegal\tchallenges\tand\ttherefore,\tthe\toutcome\tof\tthe\tProgram remains\tuncertain.\tWe\tcontinue\tto\tevaluate\tthe\timpact\tof\tthe\tIRA\ton\tour\tbusiness,\toperations\tand\tfinancial\tcondition\tand\tresults\tas\tthe\tfull\teffect of\tthe\tIRA\ton\tour\tbusiness\tand\tthe\tpharmaceutical\tindustry\tremains\tuncertain.\n\nChanges\tto\tthe\tMedicaid\tDrug\tRebate\tProgram\tor\tthe\t340B\tProgram\tcould\thave\ta\tmaterial\timpact\ton\tour\tbusiness.\tFor\texample,\tcertain\tchanges\tfinalized by\tCMS\tin\ta\tDecember\t2020\tfinal\trule,\tincluding\twhich\tproducts\tqualify\tas\tso-called\t'line\textension'\tdrugs\tsubject\tto\tincreased\trebate\tliability, may\thave\ta\tmaterial\timpact\ton\tour\tbusiness.\tAdditionally,\tin\tMay\t2023,\tCMS\tproposed\tnew\trules\tthat\tcould,\tif\tfinalized,\thave\ta\tmaterial\timpact\ton our\tbusiness.\tThose\tproposals\tinclude,\tfor\texample,\tnew\trules\tregarding\thow\tmanufacturers\twould\tbe\trequired\tto\taggregate\tdiscounts\tfor\tpurposes\tof determining\ttheir\tMedicaid\tBest\tPrice.\tAdditionally,\tvarious\tpotential\tchanges\tto\tthe\t340B\tProgram\tare\tundergoing\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n12",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Medicare_Drug_Price_Negotiation_Program",
          "name": "Medicare Drug Price Negotiation Program",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_2",
          "chunk_text": "Regulatory\tEnvironment/Pricing\tand\tAccess--Government\tand\tOther\tPayor\tGroup\tPressures-The\tpricing\tof\tmedicines\tand\tvaccines\tby\tpharmaceutical manufacturers\tand\tthe\tcost\tof\thealthcare,\twhich\tincludes\tmedicines,\tvaccines,\tmedical\tservices\tand\thospital\tservices,\tcontinues\tto\tbe\timportant\tto payors,\tgovernments,\tpatients,\tand\tother\tstakeholders.\tFederal\tand\tstate\tgovernments\tand\tprivate\tthird-party\tpayors\tin\tthe\tU.S.\tcontinue\tto\ttake action\tto\tmanage\tthe\tutilization\tand\tcost\tof\tdrugs,\tincluding\tincreasingly\temploying\tformularies\tto\tcontrol\tcosts\tand\tencourage\tutilization\tof certain\tdrugs,\tincluding\tthrough\tthe\tuse\tof\tdeductibles,\tutilization\tmanagement\ttools,\tcost\tsharing\tor\tformulary\tplacement.\tWe\tconsider\ta\tnumber\tof factors\timpacting\tthe\tpricing\tof\tour\tmedicines\tand\tvaccines.\tWithin\tthe\tU.S.,\twe\toften\tengage\twith\tpatients,\tdoctors\tand\thealthcare\tplans.\tWe\talso often\tprovide\tsignificant\tdiscounts\tfrom\tthe\tlist\tprice\tto\tinsurers,\tincluding\tPBMs\tand\tMCOs.\tThe\tprice\tthat\tpatients\tpay\tin\tthe\tU.S.\tfor\tprescribed medicines\tand\tvaccines\tis\tultimately\tset\tby\thealthcare\tproviders\tand\tinsurers.\tGovernments\tglobally,\tas\twell\tas\tprivate\tthird-party\tpayors\tin\tthe U.S.,\tmay\tuse\ta\tvariety\tof\tmeasures\tto\tcontrol\tcosts,\tincluding,\tamong\tothers,\tlegislative\tor\tregulatory\tpricing\treforms,\tdrug\tformularies (including\ttiering\tand\tutilization\tmanagement\ttools),\tcross\tcountry\tcollaboration\tand\tprocurement,\tprice\tcuts,\tmandatory\trebates,\thealth\ttechnology assessments,\tforced\tlocalization\tas\ta\tcondition\tof\tmarket\taccess,\t'international\treference\tpricing'\t(i.e.,\tthe\tpractice\tof\ta\tcountry\tlinking\tits regulated\tmedicine\tprices\tto\tthose\tof\tother\tcountries),\tQCE\tprocesses\tand\tVBP.\tWe\tanticipate\tthat\tthese\tand\tsimilar\tinitiatives\twill\tcontinue\tto increase\tpricing\tand\taccess\tpressures\tglobally.\tIn\tthe\tU.S.,\twe\texpect\tto\tsee\tcontinued\tfocus\tby\tCongress\tand\tthe\tBiden\tAdministration\ton\tregulating pricing.\tThe\tdrug\tpricing\tprovisions\tof\tthe\tIRA,\twhich\twas\tsigned\tinto\tlaw\tin\tAugust\t2022,\tbegan\tto\tbe\timplemented\tin\t2022\tand\timplementation efforts\twill\tcontinue\tover\tthe\tnext\tseveral\tyears.\tIn\tAugust\t2023,\tthe\tBiden\tAdministration\tunveiled\tthe\tfirst\tten\tmedicines\tsubject\tto\tthe 'Medicare\tDrug\tPrice\tNegotiation\tProgram,'\twhich\trequires\tmanufacturers\tof\tselect\tdrugs\tto\tengage\tin\ta\tprocess\twith\tthe\tfederal\tgovernment\tto\tset new\tMedicare\tprices\twhich\twould\tgo\tinto\teffect\tin\t2026.\tAmong\tthe\tfirst\tten\tmedicines\tsubject\tto\tthe\tProgram\tincluded\tEliquis.\tWe\tcontinue\tto evaluate\tthe\timpact\tof\tthe\tIRA\ton\tour\tbusiness,\toperations\tand\tfinancial\tcondition\tand\tresults\tas\tthe\tfull\teffect\tof\tthe\tIRA\ton\tour\tbusiness\tand\tthe pharmaceutical\tindustry\tremains\tuncertain.\tIn\taddition,\tchanges\tto\tthe\tMedicaid\tDrug\tRebate\tprogram\tor\tthe\t340B\tProgram,\tincluding\tlegal\tor legislative\tdevelopments\tat\tthe\tfederal\tor\tstate\tlevel\twith\trespect\tto\tthe\t340B\tprogram,\tcould\thave\ta\tmaterial\timpact\ton\tour\tbusiness.\tSee\tthe Item 1.\tBusiness --Pricing\tPressures\tand\tManaged\tCare\tOrganizations and --Government\tRegulation\tand\tPrice\tConstraints and\tthe Item\t1A.\tRisk Factors --Pricing\tand\tReimbursement sections.\n\nImpact\tof\tthe\tJuly\t2023\tTornado\tin\tRocky\tMount,\tNorth\tCarolina\t(NC)-Our\tmanufacturing\tfacility\tin\tRocky\tMount,\tNC\twas\tdamaged\tby\ta\ttornado\tin\tJuly 2023.\tThe\tfacility\tis\ta\tkey\tproducer\tof\tsterile\tinjectables\tand\tis\tresponsible\tfor\tmanufacturing\tnearly\t25\tpercent\tof\tall\tour\tsterile\tinjectablesincluding\tanesthesia,\tanalgesia,\tand\tmicronutrients-which\tis\tnearly\teight\tpercent\tof\tall\tthe\tsterile\tinjectables\tused\tin\tU.S.\thospitals.\tWhile manufacturing\thas\tresumed,\tthe\tsupply\tof\tmedicines\timpacted\tby\tthe\ttornado\tis\texpected\tto\tbe\taffected\tthrough\t2024.\n\nIn\t2023,\twe\trecorded\t$286\tmillion\tto Cost\tof\tsales for\tinventory\tlosses,\toverhead\tcosts\trelated\tto\tthe\tperiod\tin\twhich\tthe\tfacility\tcould\tnot operate,\tand\tincremental\tcosts\tresulting\tfrom\tthe\ttornado\tdamage.\tLosses\tincurred\tin\t2023\twere\tpartially\toffset\tby\tinsurance\trecoveries\treceived\tin the\tfourth\tquarter\tof\t2023.\tWe\tmay\trecord\tadditional\tlosses\tand/or\tcosts\tand/or\tinsurance\trecoveries\tin\tfuture\tperiods,\tbut\twe\tare\tunable\tto\tpredict them\twith\tcertainty\tat\tthis\ttime.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n32",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 25,
      "question": "How does the risk associated with Oak Street Health's participation in CMS Innovation Center models, such as ACO REACH, impact the long-term value of the goodwill recognized from its acquisition by CVS?",
      "answer": "The goodwill recognized from the acquisition of Oak Street Health by CVS was part of a broader acquisition strategy that included Signify Health in 2023, contributing to an increase in the carrying amount of goodwill during that year. Oak Street Health is subject to several risks tied to its participation in CMS Innovation Center models like ACO REACH, including annual changes that may reduce payments to participants and the lack of a long-term plan for ongoing participation in these models. These regulatory and financial risks could undermine the ability of Oak Street Health to generate consistent returns, which in turn could threaten the long-term value of the goodwill recognized in the acquisition. The annual impairment tests conducted by CVS in 2024 and 2023 found no impairment of goodwill, but the exposure of Oak Street Health to CMS model volatility raises concerns about the sustainability of its performance and, consequently, the durability of the goodwill value on CVS's balance sheet.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_150) \u2192 [Oak Street Health]: The acquisition of Oak Street Health contributed to an increase in the carrying amount of goodwill during 2023, which was disclosed in the goodwill section.",
        "Hop 2: [Oak Street Health] \u2192 [CMS Innovation Center Models]: Oak Street Health's operations are exposed to risks associated with CMS Innovation Center models, such as ACO REACH, including potential reductions in payments and lack of long-term model continuity.",
        "Hop 3: [CMS Innovation Center Models] \u2190 [CVS](page_44): CVS highlights the regulatory and business risks associated with participation in CMS Innovation Center models, which could affect the financial performance of Oak Street Health and the long-term value of the goodwill recognized from its acquisition."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> COMP -[Impacted_By]-> REGULATORY_REQUIREMENT <-[Impacted_By]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Oak Street Health",
        "node_3": "CMS Innovation Center Models",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_150",
          "chunk_id": "chunk_5",
          "chunk_text": "\nThere were no changes to the carrying amount of the Company's goodwill during the year ended December 31, 2024.\n\nDuring the year ended December 31, 2023, the increase in the carrying amount of goodwill was primarily driven by the acquisitions of Oak Street Health and Signify Health. See Note 2 ''Acquisitions, Divestitures and Asset Sales'' for additional information.\n\nDuring the fourth quarter of 2024 and 2023, and the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of these impairment tests indicated that there was no impairment of goodwill.\n\nAt December 31, 2024 and 2023, cumulative goodwill impairments were $6.6 billion.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Oak_Street_Health",
          "name": "Oak Street Health",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_1",
          "chunk_text": "- dependence on a concentrated number of key health plan customers;\n- the quality of the information received about plan members of such health plans for whom Signify Health will seek to provide in-home evaluations and other services, and the regulatory restrictions and requirements associated with directly contacting plan members;\n- ability to perform and ensure the quality of health risk assessments;\n- ability to achieve and receive shared health care cost savings;\n- the regulatory and business risks associated with participation in certain government health care programs, including, among others, the MSSP and ACO REACH models, and identification of diagnosis codes related to risk adjustment payments under Part C of the Medicare program;\n- health reform initiatives and changes in the rules governing government health care programs, including rules related to the use of in-home health risk assessments for the purpose of capturing individual risk use to calculate an individual's risk adjustment factor or a change to how patient-level risk is determined for CMS programs;\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;\n- impacts of fraud or anomalous billing on shared savings in CMS Innovation Center models;\n- use of 'open source' software in its technology, which may make it easier for others to gain access or compromise its proprietary technology;\n- success in large, national ACOs is dependent on the collective efforts and compliance of a wide range of participating clients, and for those clients to be able to meet new and changing requirements such as changes to interoperability and reporting requirements; and\n- challenges in rural and post-acute reimbursement due to their significant dependence on fee-for-service revenue.\n\nOur Oak Street Health business is subject to additional risks including, but not limited to, the following:\n\n- ability to attract new Medicare-eligible patients and credentialed, high-quality physicians and other providers for senior-focused primary care in a highly competitive market for such patients and providers;\n- satisfying the enrollment requirements under government health care programs for physicians and other providers in a timely manner;\n- dependence on a significant portion of revenue from Medicare or Medicare Advantage plans, which subjects Oak Street Health to reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;\n- dependence for a significant portion of revenue from agreements with a limited number of key payors with whom Oak Street Health contracts to provide services under terms that may permit a payor to amend the compensation arrangements or terminate the agreements without cause;\n- dependence on reimbursements from third-party payors, which can result in substantial delay, and on patients, through copayments and deductibles, which subjects Oak Street Health to additional reimbursement risk;\n- under the fix ed fee (or capitated) agreements Oak Street Health enters into with health plans, the assumption of the risk that the actual cost of a service it provides to a patient exceeds the reimbursement provided by the health plan;\n- reductions in the quality ratings of Medicare health plans Oak Street Health serves could result in a shift of patients from, or the termination of, a health plan Oak Street Health serves;\n- submission of inaccurate, incomplete or erroneous data, including risk adjustment data, to health plans and government payors could result in inaccuracies in the revenue Oak Street Health records or receipt of overpayments, which may subject it to repayment obligations and penalties;\n- geographic concentration of its primary care centers;\n- risks associated with its ex isting legal proceedings and litigations;\n- laws regulating the corporate practice of medicine and the associated agreements entered into with physician practice groups restrict the manner in which the Oak Street Health business is able to direct the operations and otherwise exercise control of its physician practice groups\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;",
          "relationship": "Impacted_By"
        },
        "node_3": {
          "id": "CMS_Innovation_Center_Models",
          "name": "CMS Innovation Center Models",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_1",
          "chunk_text": "- dependence on a concentrated number of key health plan customers;\n- the quality of the information received about plan members of such health plans for whom Signify Health will seek to provide in-home evaluations and other services, and the regulatory restrictions and requirements associated with directly contacting plan members;\n- ability to perform and ensure the quality of health risk assessments;\n- ability to achieve and receive shared health care cost savings;\n- the regulatory and business risks associated with participation in certain government health care programs, including, among others, the MSSP and ACO REACH models, and identification of diagnosis codes related to risk adjustment payments under Part C of the Medicare program;\n- health reform initiatives and changes in the rules governing government health care programs, including rules related to the use of in-home health risk assessments for the purpose of capturing individual risk use to calculate an individual's risk adjustment factor or a change to how patient-level risk is determined for CMS programs;\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;\n- impacts of fraud or anomalous billing on shared savings in CMS Innovation Center models;\n- use of 'open source' software in its technology, which may make it easier for others to gain access or compromise its proprietary technology;\n- success in large, national ACOs is dependent on the collective efforts and compliance of a wide range of participating clients, and for those clients to be able to meet new and changing requirements such as changes to interoperability and reporting requirements; and\n- challenges in rural and post-acute reimbursement due to their significant dependence on fee-for-service revenue.\n\nOur Oak Street Health business is subject to additional risks including, but not limited to, the following:\n\n- ability to attract new Medicare-eligible patients and credentialed, high-quality physicians and other providers for senior-focused primary care in a highly competitive market for such patients and providers;\n- satisfying the enrollment requirements under government health care programs for physicians and other providers in a timely manner;\n- dependence on a significant portion of revenue from Medicare or Medicare Advantage plans, which subjects Oak Street Health to reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;\n- dependence for a significant portion of revenue from agreements with a limited number of key payors with whom Oak Street Health contracts to provide services under terms that may permit a payor to amend the compensation arrangements or terminate the agreements without cause;\n- dependence on reimbursements from third-party payors, which can result in substantial delay, and on patients, through copayments and deductibles, which subjects Oak Street Health to additional reimbursement risk;\n- under the fix ed fee (or capitated) agreements Oak Street Health enters into with health plans, the assumption of the risk that the actual cost of a service it provides to a patient exceeds the reimbursement provided by the health plan;\n- reductions in the quality ratings of Medicare health plans Oak Street Health serves could result in a shift of patients from, or the termination of, a health plan Oak Street Health serves;\n- submission of inaccurate, incomplete or erroneous data, including risk adjustment data, to health plans and government payors could result in inaccuracies in the revenue Oak Street Health records or receipt of overpayments, which may subject it to repayment obligations and penalties;\n- geographic concentration of its primary care centers;\n- risks associated with its ex isting legal proceedings and litigations;\n- laws regulating the corporate practice of medicine and the associated agreements entered into with physician practice groups restrict the manner in which the Oak Street Health business is able to direct the operations and otherwise exercise control of its physician practice groups\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;",
          "relationship": "Impacted_By"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 26,
      "question": "How does Gilead's revenue-sharing structure with Merck for long-acting injectable HIV products align with the broader strategic options Gilead has negotiated with Merck, particularly regarding future combination therapies involving integrase inhibitors?",
      "answer": "Gilead's collaboration with Merck includes joint development and commercialization of long-acting injectable HIV products, with equal revenue sharing until a $3.5 billion sales threshold is reached, after which Gilead's share increases to 65%. Additionally, Gilead has broader strategic options to license Merck's investigational oral integrase inhibitors for combination with lenacapavir, with cost and revenue sharing or royalty arrangements depending on whether both parties opt in. This dual-layered partnership suggests a strategic alignment to expand the HIV portfolio through shared innovation and risk, while maintaining flexibility in revenue models based on product success and development participation.",
      "reasoning_steps": [
        "Hop 1: GILD(page_74) \u2192 Long-Acting Injectable Products: Gilead and Merck co-develop and commercialize long-acting injectable HIV treatments, with Gilead leading in the EU and rest of the world, and revenue sharing set at 50/50 until $3.5 billion in injectable product sales, after which Gilead receives 65% of additional revenues.",
        "Hop 2: Long-Acting Injectable Products \u2192 Merck: The collaboration centers on combining Gilead\u2019s lenacapavir with Merck\u2019s islatravir in both oral and injectable formulations, with defined cost and revenue-sharing structures.",
        "Hop 3: Merck \u2190 GILD(page_75): Gilead has the option to license Merck\u2019s investigational oral integrase inhibitors for development with lenacapavir, with reciprocal rights for Merck, and potential cost and revenue splits or royalty arrangements depending on option exercise."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Commercializes]-> PRODUCT -[Commercializes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Long-Acting Injectable Products",
        "node_3": "Merck",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "node_2": {
          "id": "Long-Acting_Injectable_Products",
          "name": "Long-Acting Injectable Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_1",
          "chunk_text": "We will also have the option to license certain of Merck's investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of G ilead's investigational oral integrase inhibitors to develop in combination with islatravir. Each company may ex ercise its option for such investigational oral integrase inhibitor of the other company within the first five years after ex ecution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon ex ercise of an option, the companies will split development costs and revenues, unless the non-ex ercising company decides to opt out, in which case the non-exercising company will be paid a royalty.\n\n## Arcus\n\nIn  May 2020, we entered into a transaction, and have since entered into various amending transactions, with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (as amended, the 'Collaboration Agreement'), with G ilead having the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the initial transaction, and a common stock purchase agreement and an investor rights agreement (together, as amended, the 'Stock Purchase Agreements').\n\nAs part of the November 2021 amendment, we exercised our options to three of Arcus' clinical stage programs and made related collaboration opt-in payments of $725 million to Arcus in 2022, which were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows.\n\nAs part of the May 2023 amendment, we paid a $35 million upfront fee to initiate research programs against up to four targets jointly selected by the parties that are  applicable  to  inflammatory  diseases,  which  was  charged  to  Acquired  in-process  research  and  development  ex penses  on  our  Consolidated  Statements  of Operations.\n\nAs part of the January 2024 amendment, we committed to a $100 million continuation fee, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations and paid later in 2024.\n\nUnder the Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $243 million, $189 million  and  $187  million  of  such  costs  primarily  in  Research  and  development  ex penses  on  our  Consolidated  Statements  of  Operations  for  the  years  ended December 31, 2024, 2023 and 2022, respectively. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. G ilead will hold ex clusive commercialization rights outside the U.S., subject to any rights of Arcus's ex isting collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. For the research programs applicable to inflammatory diseases, G ilead may exercise an option to license each program at two separate, prespecified time points. If G ilead exercises its option at the earlier time point for the first two target programs, Arcus would be eligible to receive up to $420 million in future option and milestone payments and tiered royalties for each optioned program. For any other option exercise by G ilead for the four target programs, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the U.S. for optioned programs. We may also pay as much as an additional $100 million at our option in 2026 and again in 2028, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term.\n\nUnder the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We have made various purchases of shares since the original closing of the agreement, including a purchase of shares at a premium for $320 million in 2024 whereby we recorded $233 million for the fair value of the equity investment in Prepaid and other current assets on our Consolidated Balance Sheets and $87 million for the premium in Other (income) expense, net on our Consolidated Statements of Operations for the year ended December 31, 2024. Following this transaction, we owned a total of 30.1 million shares, which represented approximately 33% of the issued and outstanding voting stock of Arcus at that time. As of December 31, 2024, we had three designees on Arcus' board of directors.\n\n## Galapagos\n\nIn August 2019, we closed a 10-year option, license and collaboration agreement (the 'OLCA') and a subscription agreement (the 'Subscription Agreement'), each with Galapagos, a clinical-stage biotechnology company based in Belgium, pursuant to which the parties entered into a global collaboration that covers certain programs in Galapagos' current and future product portfolio.\n\nUnder the OLCA, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, G alapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each G alapagos product optioned by us. If we exercise our option for a program, the parties will share  equally  in  development  costs  and  mutually  agreed  commercialization  costs  incurred  subsequent  to  our  ex ercise  of  the  option.  We  may  terminate  the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 27,
      "question": "What is the relationship between BMY's regulatory exclusivity risk for Opdualag and its strategic positioning as a treatment for unresectable or metastatic melanoma in patients aged 12 and older?",
      "answer": "BMY faces potential regulatory exclusivity risk for Opdualag, a biologic product listed on page 7, which is subject to a 12-year exclusivity period in the U.S. However, after the fourth year of this period, generic manufacturers may file an ANDA with a Paragraph IV certification, challenging the product's patent and potentially shortening its exclusivity. On page 4, Opdualag is specifically indicated for the treatment of unresectable or metastatic melanoma in patients aged 12 and older, highlighting its strategic importance in BMY's oncology portfolio. Given that melanoma is a high-impact disease with limited treatment options in advanced stages, the potential for early generic challenges could threaten BMY's ability to fully capitalize on Opdualag's exclusivity period, despite its critical therapeutic positioning.",
      "reasoning_steps": [
        "Hop 1: BMY(page_7) \u2192 Opdualag: BMY lists Opdualag as a biologic product with 12 years of regulatory exclusivity in the U.S., but notes that after the fourth year, generic manufacturers may file ANDAs with Paragraph IV certifications.",
        "Hop 2: Opdualag \u2192 Melanoma Treatment: Opdualag is indicated for the treatment of unresectable or metastatic melanoma in patients aged 12 and older, combining two immune checkpoint inhibitors for enhanced efficacy.",
        "Hop 3: Melanoma Treatment \u2190 BMY(page_4): BMY emphasizes Opdualag's indication for melanoma as part of its broader oncology strategy, highlighting its importance in treating a serious and life-threatening condition."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Indicated_For]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Opdualag",
        "node_3": "Melanoma Treatment",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an ANDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator's NDA is invalid, unenforceable, or will not be infringed by the generic product. This allegation is commonly known as a Paragraph IV  certification. The innovator then must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, ANDAs including Paragraph IV  certifications are filed with respect to certain of our products. We evaluate these ANDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines can also receive several types of regulatory exclusivity. An innovative chemical pharmaceutical product is entitled to five years of regulatory exclusivity in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, a generic manufacturer may file its ANDA after the fourth year  of  the  five-year  regulatory  ex clusivity  period.  Our  marketed  chemical  products  include Eliquis,  Revlimid,  Pomalyst,  Sprycel,  Zeposia,  Camzyos,  Sotyktu , Augtyro, Krazati, and Cobenfy .\n\n## Biologic products (includes CAR-T cell therapy products)\n\nQualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative  biological  product  was  first  approved  by  the  FDA.  Our  marketed  biologic  products  include Opdivo , Opdivo  Qvantig, Orencia, Yervoy,  Reblozyl, Opdualag, Breyanzi, Abecma and Abraxane.\n\nIn the U.S., medicines (chemically synthesized or biologically derived) may also receive an additional six months of market exclusivity (added to certain patent terms and regulatory exclusivities) if certain agreed-upon pediatric studies are completed by the applicant.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market ex clusivity. First, generic companies have increasingly sought to challenge innovators' patents covering major pharmaceutical products. Second, statutory and regulatory provisions may limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory ex clusivity.\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended for up to five years to compensate for the patent term lost during the regulatory review process, provided that the extension cannot cause the patent to be in effect for more than 15 years from the date of drug approval. Such extensions are granted on a country-by-country basis. The EU provides an additional six months of exclusivity added to the extended patent term if certain pediatric studies are completed by the applicant.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized  procedure.'  This  procedure  is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA.\n\nAfter obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout  the  EU,  all  products  for  which  marketing  authorizations  have  been  filed  after  October  and  November  2005  are  subject  to  an  '8+2+1'  regulatory exclusivity regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with ex isting treatments.",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Opdualag",
          "name": "Opdualag",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOpdualag Opdualag (nivolumab and relatlimab-rmbw) is a combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG -3 blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. \u00ae",
          "relationship": "Indicated_For"
        },
        "node_3": {
          "id": "Melanoma_Treatment",
          "name": "Melanoma Treatment",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOpdualag Opdualag (nivolumab and relatlimab-rmbw) is a combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG -3 blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. \u00ae",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 28,
      "question": "How does the revenue contribution from Symtuza in 2024 reflect Gilead's dependency on Janssen's manufacturing and commercialization capabilities, given the revenue-sharing model and Janssen's right to terminate the agreement?",
      "answer": "Symtuza generated $592 million in total revenue for Gilead in 2024, as reported in the product sales table. Under the collaboration agreement, Janssen is responsible for manufacturing, registration, distribution, and commercialization of Symtuza globally, while Gilead supplies the Gilead Compounds and retains intellectual property rights. Gilead recognizes its share of Symtuza revenue as Product Sales when Janssen makes corresponding sales, indicating a strong dependency on Janssen\u2019s global commercial infrastructure. However, Janssen has the right to terminate the agreement without cause, which could disrupt Gilead\u2019s revenue stream from Symtuza. This dependency is further underscored by the revenue-sharing model, where Gilead\u2019s income is contingent on Janssen\u2019s pricing decisions and market performance, highlighting a strategic risk in Gilead\u2019s reliance on Janssen for Symtuza\u2019s success.",
      "reasoning_steps": [
        "Hop 1: GILD(page_66) \u2192 Symtuza: Gilead reports Symtuza's revenue contribution of $592 million in 2024, broken down by region, as part of its HIV product sales.",
        "Hop 2: Symtuza \u2192 Janssen: Gilead granted Janssen an exclusive global license to Symtuza, with Janssen responsible for manufacturing, registration, distribution, and commercialization, while Gilead supplies the Gilead Compounds.",
        "Hop 3: Janssen \u2190 GILD(page_77): Gilead recognizes its share of Symtuza revenue as Product Sales when Janssen makes corresponding sales, and Janssen has the right to terminate the agreement without cause, which could impact Gilead\u2019s future revenue."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Manufactures]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Symtuza",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                  | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   |\n|----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|\n| (inm illions)                    | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         |\n| Productsales:                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| HIV                              |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Biktarvy                         | $ 10,855                      | $ 1,509                       | $ 1,060                       | $ 13,423                      | $ 9,692                       | $ 1,253                       | $ 905                         | $ 11,850                      | $ 8,510                       | $ 1,103                       | $ 777                         | $ 10,390                      |\n| Descovy                          | 1,902                         | 100                           | 110                           | 2,113                         | 1,771                         | 100                           | 114                           | 1,985                         | 1,631                         | 118                           | 123                           | 1,872                         |\n| Genvoya                          | 1,498                         | 180                           | 84                            | 1,762                         | 1,752                         | 205                           | 103                           | 2,060                         | 1,983                         | 284                           | 136                           | 2,404                         |\n| Odefsey                          | 957                           | 290                           | 41                            | 1,288                         | 1,012                         | 294                           | 44                            | 1,350                         | 1,058                         | 364                           | 47                            | 1,469                         |\n| Sym tuza-Revenueshare (1)        | 450                           | 130                           | 12                            | 592                           | 382                           | 133                           | 13                            | 529                           | 348                           | 168                           | 14                            | 530                           |\n| OtherHIV (2)                     | 257                           | 129                           | 48                            | 434                           | 238                           | 116                           | 47                            | 401                           | 290                           | 182                           | 59                            | 530                           |\n| Total HIV                        | 15,918                        | 2,339                         | 1,355                         | 19,612                        | 14,848                        | 2,102                         | 1,226                         | 18,175                        | 13,820                        | 2,219                         | 1,155                         | 17,194                        |\n| LiverD isease                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Sof osbuvir/V elpatasvir (3)     | 922                           | 299                           | 374                           | 1,596                         | 859                           | 323                           | 355                           | 1,537                         | 844                           | 355                           | 331                           | 1,530                         |\n| Vem lidy                         | 486                           | 44                            | 428                           | 959                           | 410                           | 38                            | 414                           | 862                           | 429                           | 35                            | 379                           | 842                           |\n| OtherLiverDisease (4)            | 192                           | 202                           | 73                            | 467                           | 152                           | 150                           | 83                            | 385                           | 167                           | 135                           | 124                           | 426                           |\n| Total LiverDisease               | 1,601                         | 545                           | 876                           | 3,021                         | 1,421                         | 511                           | 852                           | 2,784                         | 1,440                         | 525                           | 833                           | 2,798                         |\n| Veklury                          | 892                           | 284                           | 623                           | 1,799                         | 972                           | 408                           | 805                           | 2,184                         | 1,575                         | 702                           | 1,628                         | 3,905                         |\n| Oncology                         |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Cell Therapy                     |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Tecartus                         | 234                           | 138                           | 31                            | 403                           | 245                           | 110                           | 15                            | 370                           | 221                           | 75                            | 3                             | 299                           |\n| Yescarta                         | 662                           | 666                           | 242                           | 1,570                         | 811                           | 547                           | 140                           | 1,498                         | 747                           | 355                           | 57                            | 1,160                         |\n| Total Cell Therapy               | 896                           | 804                           | 274                           | 1,973                         | 1,055                         | 658                           | 156                           | 1,869                         | 968                           | 430                           | 60                            | 1,459                         |\n| Trodelvy                         | 902                           | 294                           | 119                           | 1,315                         | 777                           | 217                           | 68                            | 1,063                         | 525                           | 143                           | 12                            | 680                           |\n| Total Oncology                   | 1,798                         | 1,098                         | 393                           | 3,289                         | 1,833                         | 875                           | 224                           | 2,932                         | 1,494                         | 573                           | 73                            | 2,139                         |\n| Other                            |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| AmBisom e                        | 44                            | 276                           | 212                           | 533                           | 43                            | 260                           | 189                           | 492                           | 57                            | 258                           | 182                           | 497                           |\n| Other (5)                        | 255                           | 34                            | 68                            | 356                           | 261                           | 40                            | 66                            | 367                           | 331                           | 65                            | 53                            | 449                           |\n| Total Other                      | 299                           | 310                           | 280                           | 889                           | 304                           | 301                           | 255                           | 859                           | 388                           | 323                           | 235                           | 946                           |\n| Total product sales              | 20,508                        | 4,576                         | 3,526                         | 28,610                        | 19,377                        | 4,197                         | 3,361                         | 26,934                        | 18,716                        | 4,342                         | 3,924                         | 26,982                        |\n| Royalty,contractandotherrevenues | 82                            | 58                            | 4                             | 144                           | 62                            | 114                           | 7                             | 182                           | 168                           | 127                           | 4                             | 299                           |\n| Total revenues                   | $ 20,591                      | $ 4,634                       | $ 3,529                       | $ 28,754                      | $ 19,438                      | $ 4,310                       | $ 3,368                       | $ 27,116                      | $ 18,884                      | $ 4,469                       | $ 3,928                       | $ 27,281                      |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Manufactures"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 29,
      "question": "How does Merck's disclosure of data exclusivity timelines for biologic products align with the specific regulatory challenges and patent protection strategy for MK-7962 (sotatercept), particularly in light of its 2037 patent expiration and the Complete Response Letter received from the FDA in December 2023?",
      "answer": "Merck disclosed on page 15 that data exclusivity for MK-7962 (sotatercept) would last 12 years upon U.S. approval as a biologic product, with additional protection from patents covering methods of treating pulmonary arterial hypertension expiring in 2037. However, the company also noted on page 16 that MK-7962 received a Complete Response Letter from the FDA in December 2023, which introduces regulatory uncertainty that could delay approval and thus the start of the 12-year exclusivity period. This creates a potential misalignment between the expected exclusivity duration and the actual market availability timeline, especially given the importance of the 2037 patent expiration in providing long-term exclusivity. The interplay between regulatory feedback, exclusivity clock commencement, and patent life raises strategic considerations for Merck's product planning and risk mitigation.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_15) \u2192 [Data Exclusivity]: Merck explains data exclusivity timelines for biologics, noting that MK-7962 would be eligible for 12 years of exclusivity upon approval, with additional protection from patents expiring in 2037.",
        "Hop 2: [Data Exclusivity] \u2192 [MK-7962 (sotatercept)]: MK-7962 is a biologic drug candidate whose commercial viability is directly tied to the timing and duration of data exclusivity protections.",
        "Hop 3: [MK-7962 (sotatercept)] \u2190 [MRK](page_16): Merck reports that MK-7962 received a Complete Response Letter from the FDA in December 2023, which may delay its approval and thus the start of the 12-year exclusivity period."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Data Exclusivity",
        "node_3": "MK-7962 (sotatercept)",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNote:\t\t\t\tCompound\tpatent\tunless\totherwise\tnoted.\tCertain\tof\tthe\tproducts\tlisted\tmay\tbe\tthe\tsubject\tof\tpatent\tlitigation.\tSee\tItem\t8.\t'Financial\tStatements\tand\tSupplementary\tData,' Note\t11.\t'Contingencies\tand\tEnvironmental\tLiabilities'\tbelow.\n\nN/A:\t\t\t\tCurrently\tno\tmarketing\tapproval.\n\nThe\tEU\tdate\trepresents\tthe\texpiration\tdate\tfor\tthe\tfollowing\tfour\tcountries:\tFrance,\tGermany,\tItaly,\tand\tSpain\t(Major\tEU\tMarkets).\tIf\tSPC\tapplications\thave\tbeen\tfiled\tbut\thave not\tbeen\tgranted\tin\tall\tMajor\tEU\tMarkets,\tboth\tthe\tpatent\texpiry\tdate\tand\tthe\tSPC\texpiry\tdate\tare\tlisted. (1)\n\nThe\tPTE\tsystem\tin\tJapan\tallows\tfor\ta\tpatent\tto\tbe\textended\tmore\tthan\tonce\tprovided\tthe\tlater\tapproval\tis\tdirected\tto\ta\tdifferent\tindication\tfrom\tthat\tof\tthe\tprevious\tapproval. This\tmay\tresult\tin\tmultiple\tPTE\tapprovals\tfor\ta\tgiven\tpatent,\teach\twith\tits\town\texpiration\tdate. (2)\n\nAs\ta\tresult\tof\tsettlement\tagreements\trelated\tto\ta\tpatent\tdirected\tto\tthe\tspecific\tsitagliptin\tsalt\tform\tof\tthe\tproducts,\texclusivity\twill\textend\tthrough\tMay\t2026\tfor Januvia and Janumet ,\tand\tthrough\tJuly\t2026\tfor Janumet\tXR . (3)\n\nGeneric\tentry\tis\tnot\tanticipated\tin\t2024. (4)\n\nExpiry\tdate\treflects\tgranted\tPTE\tfor\tthe\t600\tmg\ttablet\tin\tJapan. (5)\n\nThe\tCompany\thas\tno\tmarketing\trights\tin\tthe\tU.S.,\tJapan\tor\tChina. (6)\n\nThe\tdistribution\tagreement\twith\tJohnson\t&amp;\tJohnson\tInnovative\tMedicine\texpires\ton\tOctober\t1,\t2024. (7)\n\nPart\tof\ta\tglobal\tstrategic\toncology\tcollaboration\twith\tEisai\tCo.,\tLtd. (8)\n\nEligible\tfor\tsix\tmonths\tpediatric\tmarket\texclusivity. (9)\n\nPart\tof\ta\tglobal\tstrategic\toncology\tcollaboration\twith\tAstraZeneca. (10)\n\nCommercialized\tunder\ta\tworldwide\tcollaboration\twith\tBayer\tAG. (11)\n\nThe\tCompany\thas\tno\tmarketing\trights\tin\tthe\tU.S. (12)\n\nPTE\tpending\tbut\tis\tnot\tincluded\tin\tthe\tlisted\tpatent\texpiry\tdate.\tData\texclusivity\thas\tbeen\tgranted\tin\tthe\tU.S.\tand\texpires\tJuly\t16,\t2033. (13)\n\nData\texclusivity\thas\tbeen\tgranted\tin\tthe\tEU\tand\tJapan,\tand\texpires\ton\tDecember\t13,\t2031\tand\tSeptember\t25,\t2030,\trespectively. (14)",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Data_Exclusivity",
          "name": "Data Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_3",
          "chunk_text": "\nReceived\ta\tComplete\tResponse\tLetter\tfrom\tthe\tFDA\tin\tDecember\t2023. (1)\n\nAs\ta\tbiologic\tproduct,\tMK-7962\t(sotatercept)\twill\tbe\teligible\tfor\t12\tyears\tof\tdata\texclusivity\tupon\tapproval\tin\tthe\tU.S.\tGranted\tpatents\tcovering\tmethods\tof\ttreating\tpulmonary arterial\thypertension\twith\tMK-7962\t(sotatercept),\twhich\twill\texpire\tin\t2037\t(absent\tPTE),\tmay\talso\tprovide\tadditional\texclusivity. (2)\n\nThe\tCompany\talso\thas\tthe\tfollowing\tkey\tU.S.\tpatent\tprotection\tfor\tdrug\tcandidates\tin\tPhase\t3\tdevelopment:\n\nCurrently\tAnticipated\n\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "MK-7962_(sotatercept)",
          "name": "MK-7962 (sotatercept)",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_3",
          "chunk_text": "\nReceived\ta\tComplete\tResponse\tLetter\tfrom\tthe\tFDA\tin\tDecember\t2023. (1)\n\nAs\ta\tbiologic\tproduct,\tMK-7962\t(sotatercept)\twill\tbe\teligible\tfor\t12\tyears\tof\tdata\texclusivity\tupon\tapproval\tin\tthe\tU.S.\tGranted\tpatents\tcovering\tmethods\tof\ttreating\tpulmonary arterial\thypertension\twith\tMK-7962\t(sotatercept),\twhich\twill\texpire\tin\t2037\t(absent\tPTE),\tmay\talso\tprovide\tadditional\texclusivity. (2)\n\nThe\tCompany\talso\thas\tthe\tfollowing\tkey\tU.S.\tpatent\tprotection\tfor\tdrug\tcandidates\tin\tPhase\t3\tdevelopment:\n\nCurrently\tAnticipated\n\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 30,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related claims relate to the ongoing mediation process involving Imerys and state attorneys general, particularly in light of the terminated mediation with 42 states and the separate path taken by New Mexico and Mississippi?",
      "answer": "Johnson & Johnson has established a $9 billion reserve, representing its best estimate of probable loss, to resolve current and future talc-related claims. This reserve is tied to ongoing legal proceedings involving Imerys, its former talc supplier, which filed for bankruptcy and proposed a plan to channel all talc-related claims against it into a trust, including its alleged indemnification rights against JNJ. Imerys and related parties, including Cyprus Mines Corporation, have been engaged in mediation since late 2021 to resolve these matters, with the mediation extended through December 2023. Separately, 42 states and the District of Columbia initiated a joint investigation into JNJ\u2019s marketing of talc products and agreed to mediation in the LTL Bankruptcy Case. However, that mediation was terminated in March 2023, with New Mexico and Mississippi opting to proceed in state court. The $9 billion reserve reflects the Company\u2019s attempt to quantify its exposure amid unresolved legal complexities, including the bifurcated legal landscape where some states pursue separate litigation while others were involved in now-terminated mediation.",
      "reasoning_steps": [
        "Hop 1: JNJ(page_97) \u2192 Imerys: JNJ's talc-related liabilities are linked to Imerys, its former talc supplier, which filed for bankruptcy and proposed a plan to channel all talc-related claims into a trust, including indemnification claims against JNJ.",
        "Hop 2: Imerys \u2192 Mediation: Imerys and related parties have been engaged in mediation since late 2021 to resolve talc-related claims, with the mediation extended through December 2023.",
        "Hop 3: Mediation \u2190 JNJ(page_98): JNJ was involved in a multi-state mediation with 42 states and DC regarding its marketing of talc products, which was terminated in March 2023, while New Mexico and Mississippi opted out to pursue state court litigation."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Engages]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Imerys",
        "node_3": "Mediation",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Imerys",
          "name": "Imerys",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Engages"
        },
        "node_3": {
          "id": "Mediation",
          "name": "Mediation",
          "type": "LITIGATION",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_2",
          "chunk_text": "Forty-two\tstates\tand\tthe\tDistrict\tof\tColumbia\t(including\tMississippi\tand\tNew\tMexico)\thave\tcommenced\ta\tjoint\tinvestigation\tinto\tthe Company's\tmarketing\tof\tits\ttalcum\tpowder\tproducts.\tAt\tthis\ttime,\tthe\tmulti-state\tgroup\thas\tnot\tasserted\tany\tclaims\tagainst\tthe\tCompany. Five\tstates\thave\tissued\tCivil\tInvestigative\tDemands\tseeking\tdocuments\tand\tother\tinformation.\tThe\tCompany\thas\tproduced\tdocuments\tto Arizona,\tNorth\tCarolina,\tTexas,\tand\tWashington\tand\tentered\tinto\tconfidentiality\tagreements.\tThe\tCompany\thas\tnot\treceived\tany\tfollow\tup requests\tfrom\tthose\tstates.\tIn\tMarch\t2022,\teach\tof\tthe\tforty-two\tstates\tagreed\tto\tmediation\tof\ttheir\tclaims\tin\tthe\tLTL\tBankruptcy\tCase. In\tJuly\t2022,\tNew\tMexico\tand\tMississippi\tindicated\tthey\twould\tno\tlonger\tvoluntarily\tsubmit\tto\tfurther\tmediation\tin\tthe\tLTL\tBankruptcy and\twould\tproceed\twith\ttheir\trespective\tcases\tin\tstate\tcourt.\tIn\tMarch\t2023,\tthe\tmediation\twas\tterminated.\tIn\tJanuary\t2024,\tthe\tCompany reached\tan\tagreement\tin\tprinciple\twith\tthe\tmulti-state\tgroup\tof\tstate\tAttorneys\tGeneral,\tsubject\tto\tongoing\tnegotiation\tof\tnon-monetary terms.\tThe\tunique\tprocedural\thistory\tand\tstatus\tof\tthe\tNew\tMexico\tand\tMississippi\tmatters\tspecifically\thave\tbeen\tdiscussed\tabove.\n\n## 92",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 31,
      "question": "How does Gilead's legal strategy of granting non-exclusive licenses to generic manufacturers like Lupin Ltd. relate to the timing of patent expirations and the company's broader intellectual property defense efforts, particularly in light of the Biktarvy and Symtuza litigation timelines?",
      "answer": "Gilead's legal strategy involves both aggressively defending its intellectual property and strategically settling patent litigation with generic manufacturers by granting non-exclusive licenses at future dates, as seen in the Biktarvy and Symtuza cases. In the case of Biktarvy, Gilead filed lawsuits against Lupin, Laurus, and Cipla in May 2022 after receiving their ANDAs challenging key patents. Similarly, for Symtuza, Gilead filed lawsuits against Lupin and Apotex in 2021 and 2022, respectively, and later entered into confidential settlement agreements in February 2025, granting Lupin and Apotex licenses to market generic versions starting on a future agreed-upon date or under certain conditions. This mirrors the broader approach outlined on page 9, where Gilead notes that settlement and license agreements with generic manufacturers (including Lupin Ltd.) are part of managing the risk of loss of exclusivity, which in the U.S. for some products is scheduled to expire in 2032. This dual approach\u2014litigation followed by controlled licensing\u2014allows Gilead to delay generic competition while managing legal risk and preserving some revenue stream beyond the immediate patent expiration.",
      "reasoning_steps": [
        "Hop 1: GILD(page_87) \u2192 License: Gilead entered into a non-exclusive license agreement with Apotex and MSN in February 2025, allowing them to market a generic version of Genvoya starting August 6, 2032, or earlier under certain conditions.",
        "Hop 2: License \u2192 Lupin Ltd.: Lupin is one of the generic manufacturers that challenged Gilead\u2019s patents for Biktarvy and Symtuza, leading to litigation and eventual settlement with future licensing rights, similar to Apotex.",
        "Hop 3: Lupin Ltd. \u2190 GILD(page_9): Gilead notes on page 9 that it has entered into settlement agreements with generic manufacturers, including Lupin Ltd., to resolve patent litigation concerning key products like TAF-containing therapies, and that U.S. regulatory exclusivity for some products extends to 2032."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> REGULATORY_REQUIREMENT -[Faces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "License",
        "node_3": "Lupin Ltd.",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_87",
          "chunk_id": "chunk_1",
          "chunk_text": "Starting in March 2022, we received letters from Lupin, Laurus Labs ('Laurus') and Cipla Ltd. ('Cipla'), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of the adult dosage strength of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of four of the six  patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of  Delaware  and  intend  to  enforce  and  defend  our  intellectual  property. Additionally,  in  November  2023,  we  received  a  letter  from  Cipla  indicating  that  it  has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of the pediatric dosage strength of Biktarvy. Cipla challenged the validity of two of the patents listed in the Orange Book as associated with Biktarvy. We filed a separate lawsuit against Cipla in December 2023 in the U.S. District Court of Delaware. This lawsuit has been consolidated with the first lawsuit, with a single trial scheduled for October 2025. In October 2024, Cipla separately filed a petition at the U.S. Patent &amp; Trademark Office ('USPTO') for Inter Partes Review (IPR) of one of the patents at issue in District Court litigation. We intend to defend this patent at the USPTO.\n\nIn June 2023, we received a letter from Apotex indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of  G envoya.  In  July  2023,  we  filed  a  patent  infringement  lawsuit  against Apotex   in  the  U.S.  District  Court  of  Delaware  and  to  enforce  and  defend  our intellectual property. This case was consolidated with the Symtuza matters discussed above, and a trial was scheduled for February 2025. In February 2025, we entered into a settlement agreement with Apotex and its manufacturer of cobicistat on silicon dioxide, MSN, to resolve the litigation and patent challenges associated with Genvoya in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex and MSN were granted a non-exclusive license for Apotex's ANDA product in the U.S. to certain of our patents on cobicistat on silicon dioxide and TAF relating to G envoya beginning on August 6, 2032, or earlier in certain circumstances. The settlement agreement has been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.\n\n## Antitrust and Consumer Protection\n\nWe, along with Bristol-Myers Squibb Company ('BMS'), Johnson &amp; Johnson, Inc. ('Johnson &amp; Johnson'), and Teva Pharmaceutical Industries Ltd. ('Teva') have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV , including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs consisting of retail pharmacies, individual health plans and United Healthcare, filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the classes. These cases have been coordinated with the class actions. In March 2023, the District Court granted our motion to hold separate trials as to (i) the allegations against us and Teva seeking monetary damages relating to Truvada and Atripla ('Phase I') and (ii) the allegations against us and, in part, Johnson &amp; Johnson, seeking monetary damages and injunctive relief relating to Complera ('Phase II'). In May 2023, we settled claims with the direct purchaser class and the retailer opt-out plaintiffs for $525 million, which we paid in the second half of 2023. The settlement agreements are not an admission of liability or fault by us. In June 2023, the jury returned a complete verdict in G ilead's favor on the remaining plaintiffs' Phase I allegations. In November 2023, the court denied plaintiffs' motion to set aside the verdict, and in February 2024, the court entered final judgment on the Phase I verdict and certain summary judgment rulings. In September 2024, plaintiffs filed their opening appellate briefs challenging the Phase I verdict and those summary judgment rulings. We filed our responsive briefs in January 2025. The court has stayed Phase II pending the appeal of Phase I. While we intend to vigorously oppose the appeal and defend against the Phase II claims, we cannot predict the ultimate outcome. If plaintiffs are successful in their appeal or Phase II claims, we could be required to pay monetary damages or could be subject to permanent injunctive relief in favor of plaintiffs.\n\nIn January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief. In March 2024, the court denied our motion for judgment on the pleadings to preclude Aetna from re-litigating claims that were dismissed at summary judgment in the above class action cases. We filed a writ petition appealing the denial of our motion for judgment on the pleadings, which the appellate court denied in May 2024. In April 2024, the court granted our motion to bifurcate the case to adjudicate the issue of preclusion before litigating the merits of the case. In July 2024, Aetna filed a request to voluntarily dismiss two of its claims with prejudice, which the court subsequently granted, leaving only the claims related to Truvada and Atripla. In September 2024, Aetna filed an amended complaint with respect to these claims. In October 2024, we filed a demurrer and motion to strike plaintiff's claims.",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "License",
          "name": "License",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_1",
          "chunk_text": "## Litigation Relating to Pre-Exposure Prophylaxis\n\nIn August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, 'HHS Patents') by the Patent Trial and Appeal Board ('PTAB'). The HHS Patents are assigned to the U.S. Department of Health and Human Services ('HHS') and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate ('TDF') or tenofovir alafenamide ('TAF') prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis ('PrEP'). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the use of Truvada and Descovy for PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a lawsuit against the U.S. federal government in the U.S. Court of Federal Claims ('CFC'), alleging breach of three material transfer agreements ('MTAs') related to the research underlying the HHS Patents and two clinical trial agreements ('CTAs') by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the CFC was held in June 2022, and in November 2022, the CFC determined that the government breached the MTAs. In January 2024, the CFC found the government liable for breach of both CTAs. In May 2023, the District Court held a trial regarding the government's patent infringement claims, and the jury rendered a full defense verdict in favor of G ilead, finding that the asserted claims of the HHS Patents are invalid and the HHS patents are not infringed. In March 2024, the District Court upheld the jury's verdict that the government's patents are invalid, denied the government's request for a new trial and then entered final judgment. In July 2024, the government filed a notice of appeal. In January 2025, we entered into a settlement agreement with the government to resolve these litigation matters relating to PrEP. The settlement includes the dismissal of both lawsuits, including the government's appeal of the jury verdict that its patents are invalid, as well as a license to the government's ex isting PrEP patents.\n\n## Litigation with Generic Manufacturers\n\nAs part of the approval process for some of our products, FDA granted us a New Chemical Entity ('NCE') exclusivity period during which other manufacturers' applications for approval of generic versions of our products will not be approved. G eneric manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application ('ANDA'), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product's approval.\n\nIn  October  2021,  we  received  a  letter  from  Lupin  Ltd.  ('Lupin')  indicating  that  it  has  submitted  an ANDA  to  FDA  requesting  permission  to  market  and manufacture a generic version of Symtuza, a product commercialized by Janssen Products L.P. and for which G ilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (together, 'Janssen'), filed a patent infringement lawsuit against Lupin as co-plaintiffs in  the  U.S.  District  Court  of  Delaware.  In  September  2022,  we  received  a  letter  from Apotex   Inc.  and Apotex   Corp.  (together,  'Apotex ')  stating  that  they  have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. The cases against Lupin and Apotex were consolidated into a single trial scheduled for February 2025. In February 2025, we, along with Janssen, entered into a settlement agreement with Lupin and its manufacturer of cobicistat on silicon dioxide, MSN Laboratories Private Limited, MSN Life Sciences Private  Ltd., and  MSN  Pharmaceuticals  Inc. (collectively, 'MSN'), to resolve the litigation and patent challenges associated with  Symtuza in the  U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Lupin and MSN were granted a non-exclusive license for Lupin's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. In February 2025, we, along with Janssen, entered into a settlement agreement with Apotex to resolve the litigation and patent challenges associated with Symtuza in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex was granted a non-exclusive license for Apotex's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. Both settlement agreements with Lupin and Apotex have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Lupin_Ltd.",
          "name": "Lupin Ltd.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nWhere applicable, settlement and license agreements w ith generic manufacturers relating to the patents that protect our principal products are noted. The nature and timing of loss of exclusivity for these products depends on a multitude of factors, and loss of exclusivity may be earlier under certain circumstances. For more information, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.' (1)\n\nIn S eptember 2022, G ilead and five generic manufacturers (Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.) reached agreements to settle the U.S . patent litigation concerning patents that protect TAF in our Descovy, V emlidy and Odefsey products. (2)\n\nThe composition of matter patent has expired in the EU. In the EU and the U.S ., patent applications are pending relating to our proprietary manufacturing processes. (3)\n\nIn 2018, G ilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our S tribild and G envoya products. (4)\n\nIn February 2025, G ilead reached an agreement w ith one generic manufacturer (Apotex, Inc., together w ith Apotex C orp., and its manufacturer of cobicistat, MS N Laboratories Private Limited, MS N Life S ciences Private Ltd., and MS N Pharmaceuticals Inc.) to settle the patent litigation concerning certain patents that protect cobicistat on silicon dioxide and TAF in our G envoya product. The Apotex/MS N agreement provides a non-exclusive license to those patents beginning on August 6, 2032, or earlier in certain circumstances. (5)\n\nIn January 2024, FDA granted pediatric exclusivity for V eklury, w hich extends all non-expired exclusivities by six months, and w hich is reflected in the presently reported date. (6)\n\nR eg u latory exclusivity in the U.S . expires in 2032. (7)\n\nOrphan exclusivity expires in 2031. (8)\n\nTen years of regulatory/market exclusivity expected on approval. (9)\n\n## Patent and Trade Secret Strategy\n\nFor a discussion of risks and challenges associated with our patent and trade secret strategy described below, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.'\n\n## Patents\n\nPatents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As  part  of  our  business  strategy,  we  actively  seek  patent  protection  both  in  the  U.S.  and  internationally  and  file  additional  patent  applications,  when appropriate, to cover improvements in our compounds, products and technology.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 32,
      "question": "How does Amgen's regulatory pathway for Repatha, which required a large phase 3 outcomes study to secure broader FDA approval, align with the payer-imposed access restrictions that have limited patient use despite price reductions, and how does this tension reflect against Amgen's stated commitment to facilitating patient access through partnerships and affordability programs?",
      "answer": "Amgen's development and regulatory approval of Repatha required a large phase 3 outcomes study to demonstrate cardiovascular risk reduction before the FDA granted broader approval, highlighting the significant investment and clinical evidence needed to support its value proposition. However, despite Amgen's efforts to reduce the net price of Repatha through discounts, rebates, and a lower list price via new National Drug Codes, commercial payers have imposed utilization management restrictions\u2014such as prior authorization and Step Therapy\u2014that have limited patient access and contributed to prescription abandonment. This dynamic contrasts with Amgen's public commitment to facilitating patient access through initiatives like patient support programs, biosimilar development, and risk-sharing partnerships with payers. While Amgen emphasizes its alignment with broader healthcare stakeholders to improve access, the payer-imposed barriers to Repatha access illustrate the real-world limitations of these efforts in the face of increasing payer cost-containment strategies and consolidation.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_52) \u2192 Repatha: Amgen describes the regulatory pathway for Repatha, which required a large phase 3 outcomes study to secure broader FDA approval for reducing cardiovascular risk, indicating the high bar for demonstrating clinical value.",
        "Hop 2: Repatha \u2192 Patient Access: Despite Amgen's price reductions and new NDCs to improve affordability, payers have imposed restrictions such as prior authorization and Step Therapy, limiting patient access and contributing to prescription abandonment.",
        "Hop 3: Patient Access \u2190 AMGN(page_17): Amgen asserts a strategic commitment to facilitating patient access through affordability programs, biosimilars, and partnerships with payers, even as it faces external pressures from payer consolidation and cost containment strategies."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Negatively_Impacts]-> RISK_FACTOR <-[Enables]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Repatha",
        "node_3": "Patient Access",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "RISK_FACTOR",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "outcomes study, as conditions for obtaining approval or obtaining an indication. For example, despite demonstrating that Repatha reduced LDL-C levels in a broad patient population, only after our large phase 3 outcomes study evaluating the ability of Repatha to prevent cardiovascular events met certain of its primary composite endpoint and key secondary composite endpoint did the FDA grant a broader approval of Repatha to reduce the risk of certain cardiovascular events. There may also be situations in which demonstrating the efficacy and safety of a product candidate may not be sufficient to gain regulatory approval unless superiority to other existing treatment options can be shown. The imposition of additional requirements or our inability to meet them in a timely fashion, or at all, has delayed, and may in the future delay, our clinical development and regulatory filing efforts, delay or prevent us from obtaining regulatory approval for new product candidates or new indications for existing products, or prevent us from maintaining our current product labels.\n\nSome of our products have been approved by U.S. and ex-U.S. regulatory authorities on an accelerated or conditional basis with full approval conditioned upon fulfilling the requirements of regulators. For example, the FDA has approved LUMAKRAS under accelerated approval for the treatment of adult patients with KRAS G12C-mutated local advanced or metastatic NSCLC. Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new post-marketing requirement for an additional confirmatory study to support full approval. Regulatory authorities are placing greater focus on whether the sponsors of products originally approved on an accelerated or conditional basis have met the conditions  of  the  accelerated  or  conditional  approvals.  If  we  are  unable  to  fulfill  the  regulators'  requirements  that  were  conditions  of  a  product's  accelerated  or conditional approval and/or if regulators reevaluate the data or risk-benefit profile of our product, the conditional approval may not result in full approval or may be revoked or not renewed. Alternatively, we may be required to change the product's labeled indications, conduct an additional confirmatory clinical trial, or even withdraw the product from the market.\n\nRegulatory authorities can also impose post-marketing pediatric study requirements. Failure to fulfill such requirements may result in regulatory or enforcement action, including financial penalties or the invalidation of a product's marketing authorization.\n\nSafety problems or signals can arise as our products and product candidates are evaluated in clinical trials, including investigator sponsored studies, or as our marketed products are used in clinical practice. We are required continuously to collect and assess adverse events reported to us and to communicate to regulatory agencies these adverse events and safety signals regarding our products. Regulatory agencies periodically perform inspections of our pharmacovigilance processes, including our adverse event reporting. In the United States, for our products with approved Risk Evaluation and Mitigation Strategies (REMS, see Part I, Item 1. Business -Government Regulation-Postapproval Phase), we are required to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. REMS and other risk management programs are designed to help ensure that a drug's benefits outweigh the risks and vary in the elements they contain. If the FDA is not satisfied with the results of the periodic assessment reports we submit for any of our REMS, the FDA may also modify our REMS or take other regulatory actions, such as  implementing  revised  or  restrictive  labeling.  The  drug  delivery  devices  approved  for  use  in  combination  with  our  products  are  also  subject  to  regulatory oversight  and  review  for  safety  and  malfunctions.  See Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks. If regulatory agencies determine that we or other parties (including our clinical trial investigators, those operating our patient support  programs  or  licensees  of  our  products)  have  not  complied  with  the  applicable  reporting,  other  pharmacovigilance  or  other  safety  or  quality  assessment requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including fines, marketing authorization withdrawal and other penalties. Our product candidates and marketed products can also be affected by safety problems or signals occurring with respect to products that are similar to ours or that implicate an entire class of products. Further, as a result of clinical trials, including sub-analyses or meta-analyses of earlier clinical trials (a meta-analysis involves the use of various statistical methods to combine results from previous separate but related studies) performed by us or others, concerns may arise about the sufficiency of the data or studies underlying a product's approved label. Such actual or perceived safety problems or concerns can lead to:\n\n- revised  or  restrictive  labeling  for  our  products,  or  the  potential  for  restrictive  labeling  that  has  resulted,  and  may  in  the  future  result,  in  our  decision  not  to commercialize a product candidate;\n- requirement of risk management or minimization activities or other regulatory agency compliance actions related to the promotion and sale of our products;\n- post-marketing commitments, mandated post-marketing requirements or pharmacovigilance programs for our approved products;\n- product recalls of our approved products;",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Repatha",
          "name": "Repatha",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_17",
          "chunk_id": "chunk_1",
          "chunk_text": "ENBREL's profitability in Medicare. In January 2025, CMS announced the next 15 drugs for Medicare price setting that will be applicable beginning on January 1, 2027, which includes Otezla. Also under the IRA, starting on January 1, 2024, Medicare Part D was redesigned to cap beneficiary out-of-pocket costs and, beginning on January 1, 2025, Federal reinsurance will become reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs). Further, the IRA created a mechanism for CMS to collect rebates from manufacturers if price increases outpace inflation. We began to accrue for rebate obligations on October 1, 2022 for Medicare Part D and on January 1, 2023 for Medicare Part B.\n\nOther potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; increasing transparency in drug pricing; using third-party value assessments to determine drug prices; referencing foreign prices; and changes to government rebate programs. For example, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, which excludes biologics. CMS also issued a proposed Medicaid Drug Rebate Program rule that would have required manufacturers to aggregate or 'stack' all rebates, discounts or other price concessions made to separate, unrelated entities across the pharmaceutical supply chain on a given unit of product to determine the 'Best Price,' a metric that is used to determine Medicaid rebates and 340B statutory rates. This proposal was not finalized but remains a policy that could be reconsidered in the future. Further, at the state level, eight states (Colorado, Maine, Maryland, Minnesota, New Hampshire, New Jersey, Oregon and Washington) have enacted laws that establish PDABs to identify drugs that pose affordability challenges, and in four states (Colorado, Maryland, Minnesota and Washington) include authority for the state PDAB to set upper payment limits on certain drugs for in-state patients, payers and providers.\n\nIn  many  countries  other  than  the  United  States,  government-sponsored  healthcare  systems  are  the  primary  payers  for  drugs  and  biologics.  With  increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in rebates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many governments use health technology assessment organizations to judge the added benefit of new treatments over existing ones, metrics which are then used to set reimbursement prices and/or set coverage limits. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that governments will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and revision of its pharmaceutical legislation. Various proposals are under consideration with the EU Council, followed by a negotiation among the EU government to agree to a final law. Full implementation is not expected until 2027 or later. The new legislation, if implemented, will likely have a significant impact on the landscape for access and pricing decisions within EU Member States.\n\nThe dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. G iven the diverse interests  in  play  between  payers,  biopharmaceutical  manufacturers,  policy  makers,  healthcare  providers  and  independent  organizations,  if  and  whether  the  parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:\n\n- investing billions of dollars annually in R&amp;D;\n- pricing our medicines to reflect the value they provide;\n- developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;\n- partnering with payers to share risk and accountability for health outcomes;\n- providing patient support and education programs;\n- helping patients in financial need access our medicines; and\n- working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.\n\nSee  Item  1A.  Risk  FactorsOur  sales  depend  on  coverage  and  reimbursement  from  government  and  commercial  third-party  payers,  and  pricing  and reimbursement pressures have affected, and are likely to continue to affect, our profitability and Item 1A. Risk FactorsGuidelines and recommendations published by various organizations can reduce the use of our products.",
          "relationship": "Enables"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 33,
      "question": "How does Pfizer's strategic focus on maximizing performance of new products reconcile with the dual pressures of biosimilar competition and payor-driven cost containment strategies outlined in the risk factors and regulatory sections?",
      "answer": "Pfizer's strategic focus in 2024 on 'maximizing performance of our new products' (page 36) faces significant headwinds from two interconnected pressures. First, the risk factors section identifies biosimilars as a competitive threat that could limit revenue growth (page 8). Second, the regulatory section explains that payors are actively promoting biosimilars as part of broader cost-containment strategies, which reduces demand for branded products (page 19). Together, these factors create a challenging environment where Pfizer must drive performance of new products while facing downward pricing pressure and substitution by lower-cost biosimilars encouraged by payors. This creates a direct tension between Pfizer's strategic priorities and external market forces affecting reimbursement and product adoption.",
      "reasoning_steps": [
        "Hop 1: PFE(page_8) \u2192 Biosimilars: Biosimilars are identified as a competitive threat that could limit revenue growth and market share for Pfizer\u2019s products.",
        "Hop 2: Biosimilars \u2192 Payors: Payors are actively promoting biosimilars as part of cost-containment strategies, encouraging substitution of branded products.",
        "Hop 3: Payors \u2190 PFE(page_36): Pfizer's 2024 strategic priority includes maximizing performance of new products, which must contend with payor-driven biosimilar adoption trends."
      ],
      "difficulty": "hard",
      "idf_score": 5.947298682712962,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Impacted_By]-> PRODUCT -[Promotes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Biosimilars",
        "node_3": "Payors",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "- the\tsuccess\tand\timpact\tof\texternal\tbusiness\tdevelopment\tactivities,\tsuch\tas\tthe\trecent\tacquisition\tof\tSeagen,\tincluding\tthe\tability\tto identify\tand\texecute\ton\tpotential\tbusiness\tdevelopment\topportunities;\tthe\tability\tto\tsatisfy\tthe\tconditions\tto\tclosing\tof\tannounced transactions\tin\tthe\tanticipated\ttime\tframe\tor\tat\tall;\tthe\tability\tto\trealize\tthe\tanticipated\tbenefits\tof\tany\tsuch\ttransactions\tin\tthe anticipated\ttime\tframe\tor\tat\tall;\tthe\tpotential\tneed\tfor\tand\timpact\tof\tadditional\tequity\tor\tdebt\tfinancing\tto\tpursue\tthese\topportunities, which\thas\tin\tthe\tpast\tand\tcould\tin\tthe\tfuture\tresult\tin\tincreased\tleverage\tand/or\ta\tdowngrade\tof\tour\tcredit\tratings\tand\tcould\tlimit\tour ability\tto\tobtain\tfuture\tfinancing;\tchallenges\tintegrating\tthe\tbusinesses\tand\toperations;\tdisruption\tto\tbusiness\tand\toperations relationships;\trisks\trelated\tto\tgrowing\trevenues\tfor\tcertain\tacquired\tor\tpartnered\tproducts;\tsignificant\ttransaction\tcosts;\tand\tunknown liabilities;\n- competition,\tincluding\tfrom\tnew\tproduct\tentrants,\tin-line\tbranded\tproducts,\tgeneric\tproducts,\tprivate\tlabel\tproducts,\tbiosimilars\tand product\tcandidates\tthat\ttreat\tor\tprevent\tdiseases\tand\tconditions\tsimilar\tto\tthose\ttreated\tor\tintended\tto\tbe\tprevented\tby\tour\tin-line products\tand\tproduct\tcandidates;\n- the\tability\tto\tsuccessfully\tmarket\tboth\tnew\tand\texisting\tproducts,\tincluding\tbiosimilars;\n- difficulties\tor\tdelays\tin\tmanufacturing,\tsales\tor\tmarketing;\tsupply\tdisruptions,\tshortages\tor\tstock-outs\tat\tour\tfacilities\tor\tthird-party facilities\tthat\twe\trely\ton;\tand\tlegal\tor\tregulatory\tactions;\n- the\timpact\tof\tpublic\thealth\toutbreaks,\tepidemics\tor\tpandemics\t(such\tas\tCOVID-19)\ton\tour\tbusiness,\toperations\tand\tfinancial\tcondition\tand results,\tincluding\timpacts\ton\tour\temployees,\tmanufacturing,\tsupply\tchain,\tsales\tand\tmarketing,\tR&amp;D\tand\tclinical\ttrials;\n- risks\tand\tuncertainties\trelated\tto\tour\tefforts\tto\tcontinue\tto\tdevelop\tand\tcommercialize\tComirnaty\tand\tPaxlovid\tor\tany\tpotential\tfuture COVID-19\tvaccines,\ttreatments\tor\tcombinations,\tas\twell\tas\tchallenges\trelated\tto\ttheir\tmanufacturing,\tsupply\tand\tdistribution,\tincluding, among\tothers,\tthe\trisk\tthat\tas\tthe\tmarket\tfor\tCOVID-19\tproducts\tcontinues\tto\tbecome\tmore\tendemic\tand\tseasonal,\tdemand\tfor\tour\tCOVID-19 products\thas\tand\tmay\tcontinue\tto\tbe\treduced\tor\tnot\tmeet\texpectations,\tor\tmay\tno\tlonger\texist,\twhich\thas\tand\tmay\tcontinue\tto\tlead\tto\treduced revenues,\texcess\tinventory\ton-hand\tand/or\tin\tthe\tchannel\twhich,\tfor\tPaxlovid\tand\tComirnaty,\tresulted\tin\tsignificant\tinventory\twrite-offs\tin 2023\tand\tcould\tcontinue\tto\tresult\tin\tinventory\twrite-offs,\tor\tother\tunanticipated\tcharges;\tchallenges\trelated\tto\tthe\ttransition\tto\tthe commercial\tmarket\tfor\tour\tCOVID-19\tproducts;\tuncertainties\trelated\tto\tthe\tpublic's\tadherence\tto\tvaccines,\tboosters,\ttreatments\tor combinations;\tand\trisks\trelated\tto\tour\tability\tto\taccurately\tpredict\tor\tachieve\tour\trevenue\tforecasts\tfor\tComirnaty\tand\tPaxlovid\tor\tany potential\tfuture\tCOVID-19\tvaccines\tor\ttreatments;\n- trends\ttoward\tmanaged\tcare\tand\thealthcare\tcost\tcontainment,\tand\tour\tability\tto\tobtain\tor\tmaintain\ttimely\tor\tadequate\tpricing\tor\tfavorable formulary\tplacement\tfor\tour\tproducts;\n- interest\trate\tand\tforeign\tcurrency\texchange\trate\tfluctuations,\tincluding\tthe\timpact\tof\tcurrency\tdevaluations\tand\tmonetary\tpolicy\tactions\tin countries\texperiencing\thigh\tinflation\tor\tdeflation\trates;\n- any\tsignificant\tissues\tinvolving\tour\tlargest\twholesale\tdistributors\tor\tgovernment\tcustomers,\twhich\taccount\tfor\ta\tsubstantial\tportion\tof\tour revenues;\n- the\timpact\tof\tthe\tincreased\tpresence\tof\tcounterfeit\tmedicines,\tvaccines\tor\tother\tproducts\tin\tthe\tpharmaceutical\tsupply\tchain;\n- any\tsignificant\tissues\trelated\tto\tthe\toutsourcing\tof\tcertain\toperational\tand\tstaff\tfunctions\tto\tthird\tparties;\n- any\tsignificant\tissues\trelated\tto\tour\tJVs\tand\tother\tthird-party\tbusiness\tarrangements,\tincluding\tmodifications\trelated\tto\tsupply\tagreements or\tother\tcontracts\twith\tcustomers\tincluding\tgovernments\tor\tother\tpayors;\n- uncertainties\trelated\tto\tgeneral\teconomic,\tpolitical,\tbusiness,\tindustry,\tregulatory\tand\tmarket\tconditions\tincluding,\twithout\tlimitation, uncertainties\trelated\tto\tthe\timpact\ton\tus,\tour\tcustomers,\tsuppliers\tand\tlenders\tand\tcounterparties\tto\tour\tforeign-exchange\tand\tinterestrate\tagreements\tof\tchallenging\tglobal\teconomic\tconditions,\tsuch\tas\tinflation\tor\tinterest\trate\tfluctuations,\tand\trecent\tand\tpossible\tfuture changes\tin\tglobal\tfinancial\tmarkets;\n- the\texposure\tof\tour\toperations\tglobally\tto\tpossible\tcapital\tand\texchange\tcontrols,\teconomic\tconditions,\texpropriation,\tsanctions\tand/or other\trestrictive\tgovernment\tactions,\tchanges\tin\tintellectual\tproperty\tlegal\tprotections\tand\tremedies,\tunstable\tgovernments\tand\tlegal systems\tand\tinter-governmental\tdisputes;\n- the\timpact\tof\tdisruptions\trelated\tto\tclimate\tchange\tand\tnatural\tdisasters,\tincluding\tuncertainties\trelated\tto\tthe\timpact\tof\tthe\ttornado\tat our\tmanufacturing\tfacility\tin\tRocky\tMount,\tNC\tin\t2023;\n- any\tchanges\tin\tbusiness,\tpolitical\tand\teconomic\tconditions\tdue\tto\tactual\tor\tthreatened\tterrorist\tactivity,\tgeopolitical\tinstability, political\tor\tcivil\tunrest\tor\tmilitary\taction,\tincluding\tthe\tongoing\tconflicts\tbetween\tRussia\tand\tUkraine\tand\tin\tthe\tMiddle\tEast\tand\tthe resulting\teconomic\tor\tother\tconsequences;\n- the\timpact\tof\tproduct\trecalls,\twithdrawals\tand\tother\tunusual\titems,\tincluding\tuncertainties\trelated\tto\tregulator-directed\trisk\tevaluations and\tassessments,\tincluding\tour\tongoing\tevaluation\tof\tour\tproduct\tportfolio\tfor\tthe\tpotential\tpresence\tor\tformation\tof\tnitrosamines;\n- trade\tbuying\tpatterns;\n- the\trisk\tof\tan\timpairment\tcharge\trelated\tto\tour\tintangible\tassets,\tgoodwill\tor\tequity-method\tinvestments;\n- the\timpact\tof,\tand\trisks\tand\tuncertainties\trelated\tto,\trestructurings\tand\tinternal\treorganizations,\tas\twell\tas\tany\tother\tcorporate strategic\tinitiatives\tand\tgrowth\tstrategies,\tand\tcost-reduction\tand\tproductivity\tinitiatives,\teach\tof\twhich\trequires\tupfront\tcosts\tbut\tmay fail\tto\tyield\tanticipated\tbenefits\tand\tmay\tresult\tin\tunexpected\tcosts,\torganizational\tdisruption,\tadverse\teffects\ton\temployee\tmorale, retention\tissues\tor\tother\tunintended\tconsequences;\n- the\tability\tto\tsuccessfully\tachieve\tour\tclimate\tgoals\tand\tprogress\tour\tenvironmental\tsustainability\tand\tother\tESG\tpriorities;\n\n## Risks\tRelated\tto\tGovernment\tRegulation\tand\tLegal\tProceedings :\n\n- the\timpact\tof\tany\tU.S.\thealthcare\treform\tor\tlegislation\tor\tany\tsignificant\tspending\treduction\tor\tcost\tcontrol\tefforts\taffecting\tMedicare, Medicaid\tor\tother\tpublicly\tfunded\tor\tsubsidized\thealth\tprograms,\tincluding\tthe\tIRA,\tor\tchanges\tin\tthe\ttax\ttreatment\tof\temployer-sponsored health\tinsurance\tthat\tmay\tbe\timplemented;\n- U.S.\tfederal\tor\tstate\tlegislation\tor\tregulatory\taction\tand/or\tpolicy\tefforts\taffecting,\tamong\tother\tthings,\tpharmaceutical\tproduct\tpricing, intellectual\tproperty,\treimbursement\tor\taccess\tor\trestrictions\ton\tU.S.\tdirect-to-consumer\tadvertising;\tlimitations\ton\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n2",
          "relationship": "Impacted_By"
        },
        "node_2": {
          "id": "Biosimilars",
          "name": "Biosimilars",
          "type": "PRODUCT",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "review\tor\tare\tthe\tsubject\tof\tcurrent\tregulatory\tactivity\tand/or\tlitigation,\tand\ttheir\tstatus\tis\tunclear.\tIn\t2022,\twe\timplemented\ta\tpolicy\tthat\twill help\timprove\tcontract\tpharmacy\tintegrity.\tThe\tHHS\tHealth\tResources\tand\tServices\tAdministration\t(HRSA),\twhich\tadministers\tthe\t340B\tProgram,\thas\tsent letters\tto\tnumerous\tmanufacturers\tthat\thave\talso\timplemented\tcontract\tpharmacy\tpolicies\tand\tintegrity\tinitiatives;\tthe\tletters\texpress\tHRSA's\tview that\tthose\tmanufacturers'\tpolicies\tare\tin\tviolation\tof\tthe\t340B\tstatute.\tHRSA\talso\thas\treferred\tsome\tof\tthose\tother\tmanufacturers\tto\tthe\tHHS\tOffice of\tInspector\tGeneral\t(OIG)\tfor\tpotential\tenforcement\taction.\tPfizer\thas\tnot\treceived\tan\tenforcement\tletter\tfrom\tHRSA\tto\tdate\trelating\tto\tour\t340B Program\tintegrity\tinitiative.\tSeveral\tmanufacturers\thave\tchallenged\tHRSA's\tenforcement\tletters\tin\tfederal\tcourt\tand\tlitigation\tis\tongoing\tin\tthose cases.\tWe\tbelieve\tthat\tour\tpolicy\tis\tconsistent\twith\tthe\tstatute.\tIn\taddition,\tsome\tstates\thave\tenacted\tlaws\tseeking\tto\trestrict\tmanufacturer policies\trelated\tto\tcontract\tpharmacy\ttransactions\tin\ttheir\tstates.\tAt\tleast\tone\tstate\thas\tbegun\tto\tpursue\tenforcement\tproceedings\tunder\tits\tlaw. Several\tstakeholders\thave\tchallenged\tsuch\tlaws\tin\tcertain\tstates.\tOther\tstates\thave\tconsidered\tand\tcould\tenact\tsimilar\tlaws\tgoing\tforward,\talthough any\tsuch\tlaws\talso\tmay\tbe\tsubject\tto\tlegal\tchallenges.\tAdditional\tlegal\tor\tlegislative\tdevelopments\tat\tthe\tfederal\tor\tstate\tlevel\twith\trespect\tto the\t340B\tProgram\tmay\thave\tan\tadverse\timpact\ton\tour\tintegrity\tinitiative,\tand\twe\tmay\tface\tenforcement\taction\tor\tpenalties,\tdepending\tupon\tsuch developments.\tThe\t340B\tProgram\tcontinues\tto\tbe\ta\tsubject\tof\tregulatory\tactivity,\tcongressional\tscrutiny\tand\tinquiries,\tlitigation,\tand\tother developments,\tany\tor\tall\tof\twhich\tcould\taffect\tthe\tscope\tof\tthe\tprogram\tand\tPfizer's\tobligation\tto\toffer\tdiscounts\tto\t340B\tProgram\tcovered\tentities under\tthe\tprogram.\tSee\tthe Item\t1A.\tRisk\tFactors -Pricing\tand\tReimbursement section.\n\nStates\tseek\tto\tcontrol\thealthcare\tcosts\trelated\tto\tMedicaid\tand\tother\tstate\tregulated\thealthcare\tprograms.\tA\tmajority\tof\tstates\tuse\tpreferred\tdrug lists\tto\tmanage\taccess\tto\tpharmaceutical\tproducts\tunder\tMedicaid,\tincluding\tsome\tof\tour\tproducts.\tStates\tmay\tseek\tto\tnegotiate\tsupplemental\trebate agreements\tthat\tare\tlarger\tthan\tthe\tminimum\tfederal\trequirement\tfor\tpreferred\tformulary\taccess.\tPreferred\taccess\tto\tour\tproducts\tunder\tthe\tMedicaid managed\tcare\tprograms\tare\toften\tdetermined\tby\tthe\tmanaged\tcare\thealth\tplans\tcontracted\tby\tthe\tstate\tto\tadminister\tbenefits,\twhich\tmay\talso\trequire supplemental\trebates\tfor\tpreferred\tformulary\taccess.\tWe\texpect\tstates\twill\tcontinue\tto\tseek\tcost\tcutting,\twhich\tmay\tfocus\ton\tmanaged\tcare\tcapitation payments,\tsupplemental\trebates,\tand/or\tformulary\tmanagement.\n\nWe\texpect\tto\tsee\tcontinued\tfocus\tby\tCongress\tand\tthe\tBiden\tAdministration\ton\tregulating\tpricing\tand\taccess\tto\tmedicine,\tin\taddition\tto\tactions already\ttaken,\twhich\tcould\tresult\tin\tlegislative\tand\tregulatory\tchanges.\tGovernment\tand\tprivate\tpayors\troutinely\tseek\tto\tmanage\tutilization\tand control\tthe\tcosts\tof\tour\tproducts.\tThere\tis\tconsiderable\tpublic\tand\tgovernment\tscrutiny\tof\tpharmaceutical\tpricing\tand\tactions\tbeing\ttaken\tat\tthe state\tand\tfederal\tlevel.\tFurther\tefforts\tby\tstates\tand\tthe\tfederal\tgovernment\tto\tregulate\tprices\tor\tpayment\tfor\tpharmaceutical\tproducts,\tincluding proposed\tactions\tto\tfacilitate\tdrug\timportation,\tsuch\tas\tFlorida's\tdrug\timportation\tprogram\twhich\twas\trecently\tauthorized\tby\tthe\tFDA,\tlimit reimbursement\tto\tlower\treference\tprices,\trequire\tdeep\tdiscounts,\timpose\tfinancial\tpenalties\trelated\tto\tpricing\tpractices,\tand\trequire\tmanufacturers to\treport\tand\tmake\tpublic\tprice\tincreases\tand\tsometimes\ta\twritten\tjustification\tfor\tthe\tincrease,\tcould\tadversely\taffect\tour\tbusiness\tif implemented.\tFurther,\tcommercial\tpayors\toften\tfollow\tMedicare\tcoverage\tand\treimbursement\tpolicies\twhen\tsetting\ttheir\town\tpayment\trates.\tAny reduction\tin\tcost\tor\tother\tcontainment\tmeasures\tmay\tsimilarly\tbe\tadopted\tby\tcommercial\tplans.\tPayors\tmay\tcontinue\tto\tpromote\tgeneric\tdrugs\tand biosimilars\tmore\taggressively\tto\tgenerate\tsavings\tand\tattempt\tto\tstimulate\tadditional\tprice\tcompetition.\tIn\taddition,\twe\texpect\tthat\tconsolidation and\tintegration\tamong\tpharmacy\tchains,\twholesalers\tand\tPBMs\twill\tincrease\tpricing\tpressures\tin\tthe\tindustry.\tSee\tthe Item\t1A.\tRisk\tFactors -Managed Care\tTrends section.\n\nAnti-Corruption. The\tFCPA\tprohibits\tU.S.\tcorporations\tand\ttheir\trepresentatives\tfrom\toffering,\tpromising,\tauthorizing\tor\tmaking\tpayments\tto\tany foreign\tgovernment\tofficial,\tgovernment\tstaff\tmember,\tpolitical\tparty\tor\tpolitical\tcandidate\tto\tobtain\tor\tretain\tbusiness\tabroad.\tThe\tscope\tof\tthe FCPA\tincludes\tinteractions\twith\tcertain\thealthcare\tprofessionals\tin\tmany\tcountries.\tOther\tcountries\thave\tenacted\tsimilar\tanti-corruption\tlaws\tand/or regulations.\n\nData\tPrivacy. The\tnumber\tof\tprivacy\tand\tdata\tsecurity\tlaws\tand\tregulations\tin\tthe\tU.S.\tto\twhich\twe\tare\tsubject\ton\tthe\tfederal\tand\tstate\tlevel continues\tto\tincrease.\tWe\troutinely\tcollect\tand\tuse\tsensitive\tpersonal\tinformation\trelating\tto\tdigital\thealth.\tThe\tlegislative,\tregulatory\tand litigation\tlandscape\tfor\tprivacy\tand\tdata\tprotection\trequirements\tis\trapidly\tevolving\tand\tchanging.\tThese\trequirements\tare\tnot\tuniversal\tand\tcan conflict\tbetween\tjurisdictions.\tCompliance\twith\tthose\tlaws\tand\tregulations\tis\tmade\tmore\tcomplex\tby\tthe\tlack\tof\tconsistent\tstandards,\tcommon definitions,\tor\tclear\tregulatory\texpectations.\tAt\tthe\tsame\ttime,\tenforcement\tof\tthese\tlaws\tand\tregulations\tis\tincreasing\tand\tlitigation\tis\tbecoming more\tcommon.\tAny\tfailure\tor\tperceived\tfailure\tby\tus\tto\tcomply\twith\tapplicable\tprivacy\tand\tdata\tprotection\tlaws\tand\tregulations,\tincluding cybersecurity\tbreaches\tor\tincidents,\tcould\tsubject\tus\tto\tsignificant\tfines\tand\tpenalties,\tlitigation,\tand\tnegatively\timpact\tour\treputation.\n\n## Outside\tthe\tU.S.\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Payors",
          "name": "Payors",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_1",
          "chunk_text": "## ITEM\t7.\n\n## GENERAL\n\nThe\tfollowing\tMD&amp;A\tis\tintended\tto\tassist\tthe\treader\tin\tunderstanding\tour\tfinancial\tcondition\tand\tresults\tof\toperations,\tincluding\tan\tevaluation\tof the\tamounts\tand\tcertainty\tof\tcash\tflows\tfrom\toperations\tand\tfrom\toutside\tsources,\tand\tis\tprovided\tas\ta\tsupplement\tto\tand\tshould\tbe\tread\tin conjunction\twith\tthe\tconsolidated\tfinancial\tstatements\tand\trelated\tnotes\tin Item\t8.\tFinancial\tStatements\tand\tSupplementary\tData in\tthis\tForm\t10-K. Discussions\tof\t2021\titems\tand\tyear-to-year\tcomparisons\tbetween\t2022\tand\t2021\tthat\tare\tnot\tincluded\tin\tthis\tForm\t10-K\tcan\tbe\tfound\twithin\tMD&amp;A\tin\tour 2022\tForm\t10-K.\n\n## OVERVIEW\tOF\tOUR\tPERFORMANCE,\tOPERATING\tENVIRONMENT,\tSTRATEGY\tAND\tOUTLOOK\n\nFinancial\tHighlights --The\tfollowing\tis\ta\tsummary\tof\tcertain\tfinancial\tperformance\tmetrics\t(in\tbillions,\texcept\tper\tshare\tdata):\n\n2023\tTotal\tRevenues--$58.5\tbillion\n\n2023\tNet\tCash\tFlow\tfrom\tOperations--$8.7\tbillion\n\nA\tdecrease\tof\t42%\tcompared\tto\t2022\n\n2023\tReported\tDiluted\tEPS--$0.37\n\nA\tdecrease\tof\t70%\tcompared\tto\t2022\n\n2023\tAdjusted\tDiluted\tEPS\t(Non-GAAP)--$1.84*\n\nA\tdecrease\tof\t93%\tcompared\tto\t2022\n\nA\tdecrease\tof\t72%\tcompared\tto\t2022\n\n* For\tadditional\tinformation\tregarding\tAdjusted\tdiluted\tEPS\t(which\tis\ta\tnon-GAAP\tfinancial\tmeasure),\tincluding\treconciliations\tof\tcertain\tGAAP\tReported\tto\tnon-GAAP\tAdjusted information,\tsee\tthe Non-GAAP\tFinancial\tMeasure:\tAdjusted\tIncome section\twithin\tMD&amp;A.\n\nReferences\tto\toperational\tvariances\tpertain\tto\tperiod-over-period\tchanges\tthat\texclude\tthe\timpact\tof\tforeign\texchange\trates.\tAlthough\tforeign exchange\trate\tchanges\tare\tpart\tof\tour\tbusiness,\tthey\tare\tnot\twithin\tour\tcontrol\tand\tsince\tthey\tcan\tmask\tpositive\tor\tnegative\ttrends\tin\tthe\tbusiness, we\tbelieve\tpresenting\toperational\tvariances\texcluding\tthese\tforeign\texchange\tchanges\tprovides\tuseful\tinformation\tto\tevaluate\tour\tresults.\n\nOur\tBusiness\tand\tStrategy --Pfizer\tInc.\tis\ta\tresearch-based,\tglobal\tbiopharmaceutical\tcompany.\tWe\tapply\tscience\tand\tour\tglobal\tresources\tto\tbring therapies\tto\tpeople\tthat\textend\tand\tsignificantly\timprove\ttheir\tlives.\tSee\tthe Item\t1.\tBusiness--About\tPfizer section.\tAs\ta\tscience-driven\tglobal biopharmaceutical\tcompany,\twe\tremain\tfocused\ton\tadvancing\tour\tpipeline,\tsupporting\tour\tmarketed\tbrands\tand\tdeploying\tcapital\tresponsibly,\twith\ta focus\ton\tinitiatives\tthat\tcan\thelp\tcontribute\tto\tour\tlong-term\trevenue\tand\tfuture\tgrowth.\tMost\tof\tour\trevenues\tcome\tfrom\tthe\tmanufacture\tand\tsale\tof biopharmaceutical\tproducts.\tWe\tbelieve\tthat\tour\tmedicines\tand\tvaccines\tprovide\tsignificant\tvalue\tfor\thealthcare\tproviders\tand\tpatients\tand continuously\tevaluate\thow\twe\tcan\tbest\tcollaborate\twith\tpatients,\tphysicians\tand\tpayors\tto\tsupport\tand\texpand\tpatient\taccess\tto\treliable,\taffordable healthcare\taround\tthe\tworld.\tIn\taddition,\twe\tcontinually\tseek\tto\texpand\tand\tbroaden\tour\tproduct\tportfolio\tofferings\tthrough\tprioritized\tdevelopment of\tour\tpipeline\tand\tbusiness\tdevelopment\topportunities\ttargeted\tat\tcritical\tunmet\tpatient\tneeds.\tAs\ta\tresult,\tour\tcommercial\torganizational structure\tand\tR&amp;D\toperations\tare\tcritical\tto\tthe\tsuccessful\texecution\tof\tour\tbusiness\tstrategy.\tOur\tability\tto\tfulfill\tour\tpurpose, Breakthroughs that\tchange\tpatients'\tlives ,\tremains\ta\tcore\tfocus\tand\tunderscores\tour\tcommitment\tto\taddressing\tthe\tneeds\tof\tsociety\tto\thelp\tsustain\tlong-term\tvalue creation\tfor\tall\tstakeholders.\tOur\t2024\tkey\tpriorities\tare:\n\n- Achieve\tworld-class\toncology\tleadership\n- Deliver\tnext\twave\tof\tpipeline\tinnovation\n- Maximize\tperformance\tof\tour\tnew\tproducts\n- Expand\tmargins\tby\trealigning\tour\tcost\tbase\n- Allocate\tcapital\tto\tenhance\tshareholder\tvalue\n\nPfizer\tInc.\n\n30",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 34,
      "question": "How does Merck's $11.5 billion acquisition of Acceleron Pharma align with its R&D focus on TGF-beta superfamily proteins and broader pipeline expansion strategy?",
      "answer": "Merck's $11.5 billion acquisition of Acceleron Pharma (page_52) aligns with its R&D focus on TGF-beta superfamily proteins, which Acceleron was evaluating for their role in regulating cell growth, differentiation, and repair (page_96). This acquisition brought sotatercept (MK-7962), a Phase 3 candidate for pulmonary arterial hypertension, and Reblozyl, a marketed erythroid maturation therapy, into Merck's portfolio. The research pipeline section (page_68) highlights Merck\u2019s strategic emphasis on expanding its late-stage clinical candidates and leveraging acquisitions to drive growth, which is exemplified by the integration of Acceleron\u2019s TGF-beta-focused pipeline into Merck\u2019s broader R&D strategy.",
      "reasoning_steps": [
        "Hop 1: MRK(page_52) \u2192 Acceleron Pharma Inc.: Merck acquired Acceleron for $11.5 billion in November 2021 to augment its pipeline.",
        "Hop 2: Acceleron Pharma Inc. \u2192 TGF-beta Superfamily Proteins: Acceleron was evaluating the TGF-beta superfamily of proteins for therapeutic applications, particularly in pulmonary and hematologic diseases.",
        "Hop 3: TGF-beta Superfamily Proteins \u2190 MRK(page_68): Merck\u2019s R&D section emphasizes pipeline expansion through acquisitions, including those targeting specific biological pathways like TGF-beta."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Acquires]-> COMP -[Evaluates]-> PRODUCT <-[Develops]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Acceleron Pharma Inc.",
        "node_3": "TGF-beta Superfamily Proteins",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_3",
          "chunk_text": "\n* Calculation not meaningful.\n\nNon-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see 'Non-GAAP Income and Non-GAAP EPS' below) . (1)\n\n## Executive Summary\n\nDuring 2021, Merck delivered on its strategic priorities by executing commercially to drive strong revenue and earnings growth  in  the  year,  completing  key  business  development  transactions,  accelerating  its  broad  pipeline,  and  achieving  notable regulatory milestones. Also, on June 2, 2021, Merck completed the spin-off of Organon. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company's consolidated financial statements through the date of the spin-off.\n\nWorldwide sales were $48.7 billion in 2021, an increase of 17% compared with 2020, or 16% excluding the favorable effect of foreign exchange. The sales increase was driven primarily by growth in oncology, vaccines, hospital acute care and animal health. Additionally,  revenue  in  2021  reflects  the  benefit  of  sales  of  molnupiravir,  an  investigational  oral  antiviral  COVID-19 treatment. As discussed below, COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth.\n\nMerck continues to execute scientifically  compelling  business  development  opportunities  to  augment  its  pipeline.  In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company evaluating the transforming growth factor (TGF)-beta superfamily of proteins through the development of pulmonary and hematologic therapies. In April  2021,  Merck  acquired  Pandion Therapeutics,  Inc.  (Pandion),  a  clinical-stage  biotechnology  company  developing  novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Additionally, Merck entered into a collaboration with Gilead Sciences, Inc. (Gilead) to jointly develop and commercialize long-acting treatments in HIV.\n\nIn  2021,  Merck  received  over  30  approvals  and  filed  over  20  New  Drug  Applications  (NDAs)  and  supplemental Biologics License Applications (BLAs) across the U.S., the EU, Japan and China. During 2021, the Company received numerous regulatory approvals within oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of breast, colorectal, cutaneous squamous cell, esophageal, melanoma and renal cell cancers, as  well  as  in  combination  with  chemotherapy  in  the  therapeutic  areas  of  breast,  cervical,  gastric  or  gastroesophageal  junction cancers. Keytruda was also approved in combination with Lenvima both for the treatment of certain adult patients with endometrial cancer  and  for  the  treatment  of  renal  cell  cancer.  Lenvima  is  being  developed  in  collaboration  with  Eisai  Co.,  Ltd.  (Eisai). Lynparza,  which  is  being  developed  in  collaboration  with  AstraZeneca  PLC  (AstraZeneca),  received  approval  in  China  as monotherapy for the treatment of certain adult patients with metastatic castration resistant prostate cancer. Additionally, the U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL)",
          "relationship": "Acquires"
        },
        "node_2": {
          "id": "Acceleron_Pharma_Inc.",
          "name": "Acceleron Pharma Inc.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_96",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nExpenses  for  curtailments,  settlements  and  termination  benefits  provided  to  certain  employees  were  incurred  in connection with the spin-off (see Note 14). Additionally, all outstanding Merck stock options, restricted stock units (RSUs) and performance share units (PSUs) (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees (see Note 13).\n\n## 4.    Acquisitions, Research Collaborations and License Agreements\n\nThe  Company  continues  to  pursue  acquisitions  and  the  establishment  of  external  alliances  such  as  research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent  upon  the  occurrence  of  certain  future  events  linked  to  the  success  of  the  asset  in  development.  The  Company  also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company's financial results.\n\n## 2021 Transactions\n\nIn November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron is evaluating the transforming growth factor (TGF)-beta superfamily of proteins that  is  known  to  play  a  central  role  in  the  regulation  of  cell  growth,  differentiation  and  repair.  Acceleron's  lead  therapeutic candidate,  sotatercept  (MK-7962),  has  a  novel  mechanism  of  action  with  the  potential  to  improve  short-term  and/or  long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard  of  care  for  the  treatment  of  PAH.  Under  a  previous  agreement  assumed  by  Merck,  Bristol  Myers  Squibb  (BMS)  was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS.\n\nIn  addition  to  sotatercept, Acceleron's  portfolio  includes Reblozyl (luspatercept),  a  first-in-class  erythroid  maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood  disorders  and  is  also  being  evaluated  in  Phase  2  and  Phase  3  trials  for  additional  indications  for  hematology  therapies. Reblozyl is  being  developed  and  commercialized  through  a  global  collaboration  with  BMS.  In  connection  with  this  ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Merck is eligible to receive future contingent milestone payments including up to $20 million in regulatory milestones and up to $80 million in sales-based milestones.\n\nThe transaction was accounted for as a business combination. The Company incurred $280 million of costs directly related  to  the  acquisition  of Acceleron,  consisting  primarily  of  share-based  compensation  payments  to  settle  non-vested  equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in Selling, general and administrative expenses and Research and development costs in 2021.",
          "relationship": "Evaluates"
        },
        "node_3": {
          "id": "TGF-beta_Superfamily_Proteins",
          "name": "TGF-beta Superfamily Proteins",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Restructuring Costs\n\nNon-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 6 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.\n\n## Income and Losses from Investments in Equity Securities\n\nNon-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.\n\n## Certain Other Items\n\nNon-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature,  significant  to  the  results  of  a  particular  period  or  not  indicative  of  future  operating  results.  Excluded  from  non-GAAP income and non-GAAP EPS are charges for the acquisitions of Pandion, VelosBio, OncoImmune and Peloton, as well as charges related to collaborations, including transactions with Seagen (see Note 4 to the consolidated financial statements). Also excluded from non-GAAP income and non-GAAP EPS are charges related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements). Additionally, excluded from non-GAAP income and non-GAAP EPS are certain tax items, including net tax benefits related to the settlement of certain federal income tax matters, an adjustment to tax benefits recorded  in  conjunction  with  the  2015  acquisition  of  Cubist  Pharmaceuticals,  Inc.,  a  tax  benefit  related  to  the  reversal  of  tax reserves established in connection with the 2014 divestiture of MCC, and a net tax charge related to the finalization of U.S. treasury regulations related to the TCJA (see Note 16 to the consolidated financial statements).\n\n## Research and Development\n\n## Research Pipeline\n\nThe Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in latestage  clinical  development.  A  chart  reflecting  the  Company's  current  research  pipeline  as  of  February  22,  2022  and  related discussion is set forth in Item 1. 'Business -Research and Development' above.\n\n## Acquisitions, Research Collaborations and License Agreements\n\nMerck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 4 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company's strategic criteria.\n\nIn  March  2021,  Merck  and  Gilead  entered  into  an  agreement  to  jointly  develop  and  commercialize  long-acting treatments  in  HIV  that  combine  Merck's  investigational  NRTTI,  islatravir,  and  Gilead's  investigational  capsid  inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.\n\nIn April 2021, Merck acquired Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to  address  the  unmet  needs  of  patients  living  with  autoimmune  diseases,  for  total  consideration  of  $1.9  billion.  Pandion  is advancing a pipeline of precision immune modulators targeting critical immune control nodes.\n\nIn November 2021, Merck acquired Acceleron, a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron is evaluating the TGF-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron's lead therapeutic candidate,",
          "relationship": "Develops"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 35,
      "question": "Given AMJEVITA's phase 3 initiation as a biosimilar to HUMIRA, and the competitive pressure Amgen faces from AbbVie's marketed HUMIRA, how does Amgen's biosimilar development strategy align with its need to offset revenue risks from HUMIRA's market dominance in psoriasis and TNF-alpha inhibition?",
      "answer": "Amgen initiated a phase 3 study for AMJEVITA, a biosimilar targeting HUMIRA, which is a monoclonal antibody that inhibits TNF-alpha binding and is widely used in psoriasis and other autoimmune conditions. This development aligns with Amgen's competitive response to HUMIRA's continued market strength, as HUMIRA is listed as a key competitor for both ENBREL and Otezla in the U.S. and Canada. Given that HUMIRA remains a dominant force in TNF-alpha inhibition and autoimmune disease treatment, Amgen's investment in AMJEVITA may serve dual purposes: capturing market share from AbbVie and potentially leveraging interchangeability to provide a cost-effective alternative. This strategy could help Amgen offset revenue risks associated with patent expiration timelines and competitive erosion of its own products, as outlined in the patent expiration and biosimilar development context.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_25) \u2192 AMJEVITA: Amgen initiated a phase 3 study for AMJEVITA, a biosimilar candidate targeting HUMIRA, indicating strategic development focus.",
        "Hop 2: AMJEVITA \u2192 HUMIRA: AMJEVITA is explicitly described as a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits TNF-alpha, a key therapeutic target in autoimmune diseases.",
        "Hop 3: HUMIRA \u2190 AMGN(page_16): HUMIRA is listed as a key competitor for Amgen's products ENBREL and Otezla in the U.S. and Canada, with AbbVie identified as the manufacturer, highlighting competitive pressure."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Related_To]-> PRODUCT <-[Competes_Against]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "AMJEVITA",
        "node_3": "HUMIRA",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                                | Program change                                                  |\n|-------------------|-----------------------------------------------------------|-----------------------------------------------------------------|\n| LUMAKRAS/LUMYKRAS | NSCLC with KRAS G12C mutations                            | Approved by the FDAand conditional marketing approval by the EC |\n| Otezla            | Mild-to-moderate psoriasis                                | Approved by the FDA                                             |\n| RIABNI            | Non-Hodgkin's lymphoma                                    | Approved by the FDA                                             |\n| AMJEVITA          | Interchangeability                                        | Initiated phase 3 study                                         |\n| Bemarituzumab     | GEJ adenocarcinoma                                        | Initiated phase 3 study                                         |\n| BLINCYTO          | Ph-negative B-cell precursor Acute lymphoblastic leukemia | Initiated phase 3 study                                         |\n| TEZSPIRE          | Chronic rhinosinusitis with nasal polyps                  | Initiated phase 3 study                                         |\n| Otezla            | COVID-19                                                  | Terminated                                                      |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "AMJEVITA",
          "name": "AMJEVITA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_5",
          "chunk_text": "\n* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.\n\n## Phases 3 and 2 Program Descriptions\n\nThe following provides additional information about selected product candidates that have advanced into human clinical trials.\n\n## AMJEVITA\n\nAMJEVITA is a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha.\n\n## Bemarituzumab\n\nBemarituzumab  is  a  monoclonal  antibody  that  inhibits  FGFR2b.  It  is  being  investigated  for  the  treatment  of  advanced  GEJ adenocarcinoma.\n\nIn April 2021, Amgen announced that the FDA had granted Breakthrough Therapy designation for bemarituzumab.",
          "relationship": "Related_To"
        },
        "node_3": {
          "id": "HUMIRA",
          "name": "HUMIRA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 36,
      "question": "How does BMY's exposure to the Inflation Reduction Act's price negotiation provisions for Pomalyst, selected for negotiation in 2027, interact with the company's reliance on patent exclusivity and regulatory protections for this product as outlined in its intellectual property strategy?",
      "answer": "BMY faces dual pressures on Pomalyst stemming from both regulatory pricing reforms and intellectual property risks. The Inflation Reduction Act (IRA), referenced in the 2024 10-K, subjects Pomalyst to government price negotiation starting in 2027, which could materially reduce revenue from this product. This pricing risk coincides with the company's strategic reliance on patent exclusivity and regulatory protections to maintain market exclusivity for Pomalyst. As noted in the document, BMY lists patents in the FDA's Orange Book and evaluates Paragraph IV certifications to defend against generic competition. However, the IRA's pricing negotiation mechanism introduces a new layer of financial pressure that may accelerate revenue erosion even before patent expiration. The combination of these factors suggests that BMY may face both reduced pricing power and increased competition for Pomalyst, potentially impacting long-term profitability and strategic planning for this asset.",
      "reasoning_steps": [
        "Hop 1: BMY(page_134) \u2192 IRA: The Inflation Reduction Act is listed as a regulatory requirement affecting BMY's business model and financial planning.",
        "Hop 2: IRA \u2192 Pomalyst: The IRA specifically targets Pomalyst for government price negotiation starting in 2027, as noted in the economic and market factors section of the 10-K.",
        "Hop 3: Pomalyst \u2190 BMY(page_7): Pomalyst is listed among BMY's key chemical products with regulatory exclusivity protections, and the company actively defends its patent rights against generic challenges."
      ],
      "difficulty": "hard",
      "idf_score": 5.912802246969486,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "IRA",
        "node_3": "Pomalyst",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "IRA",
          "name": "IRA",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.558777146418381
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Economic and Market Factors\n\n## Governmental Actions\n\nAs regulators continue to focus on prescription drugs, our products are facing increased pressures across the portfolio. These pressures stem from legislative and policy changes, including price controls, pharmaceutical market access, discounting, changes to tax and importation laws and other restrictions in the U.S., EU and other regions around the world. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which can negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. The IRA directs (i) the federal government to 'negotiate' prices for select high-cost Medicare Part D (beginning in 2026) and Part B (beginning in 2028) drugs that are more than nine years (for small-molecule drugs) or 13 years (for biological products) from their initial FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and  Part  D  drugs  when  prices  increase  faster  than  inflation  and  (iii)  the  formation  of  the  Part  D  Manufacturer  Program  which  replaced  the  Part  D  CG DP  and established a $2,000 cap for out-of-pocket costs for Medicare beneficiaries as of January 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is reached. In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the \"maximum fair  price\"  for  a  30-day  equivalent  supply  of Eliquis ,  which  applies  to  the  U.S.  Medicare  channel  effective  January  1,  2026.  In  January  2025,  the  HHS  selected Pomalyst as a medicine subject to \"negotiation\" for government-set prices beginning in 2027. It is possible that more of our products could be selected in future years, which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.\n\nIn  addition,  in  December  2023,  the  Biden  administration  released  a  proposed  framework  that  for  the  first  time  proposed  that  a  drug's  price  can  be  a  factor  in determining that the drug is not accessible to the public and, therefore, that the government could exercise 'march-in rights' and license it to a third party to manufacture.  We cannot predict whether the  Trump administration will finalize the draft framework or if the government will propose other drug pricing policy changes. If pursued and finalized, these policies could reduce prices and reimbursement for certain of our products and could significantly impact our business and consolidated results of operations.\n\nAt  the  state  level,  multiple  states  have  passed,  are  pursuing  or  are  considering  government  action  via  legislation  or  regulations  to  change  drug  pricing  and reimbursement (e.g., establishing prescription drug affordability boards, implementing manufacturer mandates tied to the Federal Public Health Service Act drug pricing program, etc.). Some of these state-level actions may also influence federal and other state policies and legislation. G iven the current uncertainty surrounding the adoption, timing and implementation of many of these measures, as well as pending litigation challenging such laws, we are unable to predict their full impact on our business. However, such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations. With respect to the Federal Public Health Service Act drug pricing program, certain states have enacted laws regulating manufacturer pricing obligations under the program to date. Several additional states are considering similar potential legislation or other government actions, and we expect other states may do the same in the future.\n\nAdditionally, in connection with the IRA, the following changes have been made to U.S. tax laws, including (i) a 15% minimum tax that generally applies to U.S. corporations on adjusted financial statement income beginning in 2023 and (ii) a non-deductible 1% excise tax provision on net stock repurchases after December 31, 2022. Furthermore, countries are in the process of enacting changes to their tax laws to implement the agreement by the OECD to establish a global minimum tax. See risk  factors  on  these  items  included  under  'Part  I-Item  1A.  Risk  Factors-Product,  Industry  and  Operational  Risks-Increased  pricing  pressure  and  other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins', '-We could lose market exclusivity of a product earlier than expected' and '-Changes to tax regulations could negatively impact our earnings.'",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Pomalyst",
          "name": "Pomalyst",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an ANDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator's NDA is invalid, unenforceable, or will not be infringed by the generic product. This allegation is commonly known as a Paragraph IV  certification. The innovator then must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, ANDAs including Paragraph IV  certifications are filed with respect to certain of our products. We evaluate these ANDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines can also receive several types of regulatory exclusivity. An innovative chemical pharmaceutical product is entitled to five years of regulatory exclusivity in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, a generic manufacturer may file its ANDA after the fourth year  of  the  five-year  regulatory  ex clusivity  period.  Our  marketed  chemical  products  include Eliquis,  Revlimid,  Pomalyst,  Sprycel,  Zeposia,  Camzyos,  Sotyktu , Augtyro, Krazati, and Cobenfy .\n\n## Biologic products (includes CAR-T cell therapy products)\n\nQualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative  biological  product  was  first  approved  by  the  FDA.  Our  marketed  biologic  products  include Opdivo , Opdivo  Qvantig, Orencia, Yervoy,  Reblozyl, Opdualag, Breyanzi, Abecma and Abraxane.\n\nIn the U.S., medicines (chemically synthesized or biologically derived) may also receive an additional six months of market exclusivity (added to certain patent terms and regulatory exclusivities) if certain agreed-upon pediatric studies are completed by the applicant.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market ex clusivity. First, generic companies have increasingly sought to challenge innovators' patents covering major pharmaceutical products. Second, statutory and regulatory provisions may limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory ex clusivity.\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended for up to five years to compensate for the patent term lost during the regulatory review process, provided that the extension cannot cause the patent to be in effect for more than 15 years from the date of drug approval. Such extensions are granted on a country-by-country basis. The EU provides an additional six months of exclusivity added to the extended patent term if certain pediatric studies are completed by the applicant.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized  procedure.'  This  procedure  is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA.\n\nAfter obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout  the  EU,  all  products  for  which  marketing  authorizations  have  been  filed  after  October  and  November  2005  are  subject  to  an  '8+2+1'  regulatory exclusivity regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with ex isting treatments.",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 37,
      "question": "How does the anticipated 2036 U.S. patent expiration for MK-1654, as listed under Merck's patent protection schedule, align with the company's strategic emphasis on long-term revenue generation given the product's current regulatory review status for RSV prophylaxis in infants?",
      "answer": "Merck lists MK-1654 (clesrovimab) with an anticipated 2036 U.S. patent expiration date, which provides a long-term intellectual property runway for the product. However, MK-1654 is currently under FDA and EU regulatory review as an investigational long-acting monoclonal antibody designed to protect infants from RSV disease. This means the product has not yet reached the market, and its commercialization timeline remains uncertain. While the patent protection extends well into the future, the delayed market entry due to ongoing regulatory processes may compress the effective revenue-generating period before patent expiration. This creates a strategic tension between the long patent life and the potential for a shorter commercial lifecycle, particularly for a product aimed at a seasonal and potentially competitive prophylactic market.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_15) \u2192 [Patent Law]: Merck discloses patent expiration schedules, including MK-1654 with a 2036 U.S. patent expiration date.",
        "Hop 2: [Patent Law] \u2192 [MK-1654]: MK-1654 is explicitly listed under the patent protection schedule, indicating its importance to Merck\u2019s IP portfolio.",
        "Hop 3: [MK-1654] \u2190 [MRK](page_50): MK-1654 is described as an investigational product currently under FDA and EU review for RSV prophylaxis in infants, with no indication of approval or commercial launch yet."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Patent Law",
        "node_3": "MK-1654",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nThe table below provides a list of expiration dates, which include any pending PTE and SPC periods where indicated, for the key patent protection in the U.S., the EU, Japan and China for the following marketed products:\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Patent_Law",
          "name": "Patent Law",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Under Review in the U.S.            |   Currently Anticipated Year of Expiration (in the U.S.) |\n|-------------------------------------|----------------------------------------------------------|\n| MK-1022 (patritum abderuxtecan) (1) |                                                     2035 |\n| MK-1654 (clesrovim ab)              |                                                     2036 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "MK-1654",
          "name": "MK-1654",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nbeing jointly developed by Daiichi Sankyo and M erck. M erck is working with Daiichi Sankyo to address FDA  feedback.\n\n- MK-6482 , Welireg, is under review in Japan both for the treatment of adults with V HL disease and for the treatment of certain adults with previously treated advanced renal cell carcinoma (RCC). Welireg is also under priority review in the U.S. for the treatment of certain patients with advanced, unresectable or metastatic pheochromocytoma and paraganglioma.\n- V116, Capvaxive ,  a  21-v alent  pneumococcal  conjugate  vaccine  designed  to  help  prevent  invasive  pneumococcal  disease  and  pneumococcal pneumonia caused by certain serotypes in adults, is under review in the EU and Japan.\n- MK-7962, Winrevair , M erck's novel activ in signaling inhibitor, is under rev iew in Japan for the treatment of adult patients with PA H.\n- MK-1654, clesrovimab, is an investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV  season under review by the FDA . Clesrovimab is also under review in the EU.\n- Additionally, Keytruda is under review in the EU and Japan for a supplemental indication for the treatment of certain patients with malignant pleural mesothelioma.\n\nDuring  2024,  the  Company  initiated  more  than  20  Phase  3  studies  spanning  cardiometabolic,  immunology ,  infectious  diseases,  oncology , ophthalmology and vaccines.\n\nThe Company is diversifying its oncology portfolio and executing on its strategy which is broadly based on three strategic pillars: immuno-oncology , precision molecular targeting and tissue targeting. M erck's Phase 3 oncology programs within these pillars are as follows:\n\n## Immuno-oncology\n\n- MK-1308A, the coformulation of quavonlimab, M erck's novel investigational anti-CTLA -4 antibody, in combination with pembrolizumab for RCC;\n- MK-3475, Keytruda , in the therapeutic areas of hepatocellular, ovarian and small-cell lung cancers;\n- MK-3475A, the subcutaneous coformulation of pembrolizumab in combination with hyaluronidase, being evaluated for comparability with intravenous pembrolizumab in metastatic NSCLC; and\n- V940 (mRNA-4157), an investigational individualized neoantigen therapy , in combination with Keytruda , as an adjuvant treatment in patients with certain ty pes of melanoma and NSCLC, being developed as part of a collaboration with M oderna, Inc.\n\n## Precision molecular targeting\n\n- MK-1026, nemtabrutinib, an oral, reversible, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, for hematological malignancies, including chronic ly mphocytic leukemia and small lymphocytic lymphoma;\n- MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with Keytruda , for metastatic NSCLC;\n- MK-3543, bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor for myeloproliferative disorders;\n- MK-5684, opevesostat, an investigational cytochrome P450 11A1 (CYP11A1) inhibitor for metastatic castration-resistant prostate cancer;\n- MK-7339, Lynparza, in combination with Keytruda , for non-small-cell lung and small-cell lung cancers; and\n- MK-7902, Lenvima, being developed as part of a collaboration with Eisai Co., Ltd. (Eisai), in combination with Keytruda , for esophageal cancer.\n\n## Tissue targeting\n\n- MK-1022, patritumab deruxtecan, being developed in collaboration wtih Daiichi Sankyo, for NSCLC as noted above;\n- MK-2140, zilovertamab vedotin, an A DC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) for hematological malignancies, including diffuse large B cell ly mphoma;\n- MK-2400, ifinatamab deruxtecan, an ADC being evaluated in patients with relapsed SCLC versus chemotherapy , being developed as part of a collaboration with Daiichi Sankyo; and",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 38,
      "question": "Given that Opdualag is indicated for melanoma treatment, how does the rapid revenue growth of Opdualag in the U.S. (41%) compared to non-U.S. markets relate to its therapeutic positioning in unresectable or metastatic melanoma?",
      "answer": "Opdualag, a combination therapy indicated for unresectable or metastatic melanoma, generated $870 million in U.S. revenue in 2024, reflecting a 41% increase from $615 million in 2023, compared to only $58 million in non-U.S. markets. This significant U.S. growth suggests strong adoption in a key market for advanced melanoma treatments. The drug\u2019s positioning as a dual PD-1 and LAG-3 inhibitor for a serious oncology indication aligns with its robust performance in the U.S., where access to innovative therapies and high disease prevalence likely drive usage. The disparity in growth between U.S. and non-U.S. markets may reflect regional differences in regulatory approvals, reimbursement, or clinical adoption patterns for melanoma therapies.",
      "reasoning_steps": [
        "Hop 1: BMY(page_4) \u2192 Melanoma Treatment: Opdualag is introduced as a treatment for unresectable or metastatic melanoma, indicating its therapeutic positioning in oncology.",
        "Hop 2: Melanoma Treatment \u2192 Opdualag: Opdualag is specifically indicated for melanoma, establishing a direct therapeutic link.",
        "Hop 3: Opdualag \u2190 BMY(page_50): Opdualag's revenue is reported at $928 million globally, with $870 million (41% growth) in the U.S. and only $58 million (48% growth) outside the U.S."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Indicated_For]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Melanoma Treatment",
        "node_3": "Opdualag",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOpdualag Opdualag (nivolumab and relatlimab-rmbw) is a combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG -3 blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. \u00ae",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Melanoma_Treatment",
          "name": "Melanoma Treatment",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOpdualag Opdualag (nivolumab and relatlimab-rmbw) is a combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG -3 blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. \u00ae",
          "relationship": "Indicated_For"
        },
        "node_3": {
          "id": "Opdualag",
          "name": "Opdualag",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_2",
          "chunk_text": "| Dollars in millions   | Year Ended December 31,   | Year Ended December 31,   | %Change   |\n|-----------------------|---------------------------|---------------------------|-----------|\n| Growth Portfolio      |                           |                           |           |\n| Opdivo                | 9,304                     | 9,009                     | 3 %       |\n| U.S.                  | 5,350                     | 5,246                     | 2 %       |\n| Non-U.S.              | 3,954                     | 3,763                     | 5 %       |\n| Orencia               | 3,682                     | 3,601                     | 2 %       |\n| U.S.                  | 2,770                     | 2,709                     | 2 %       |\n| Non-U.S.              | 912                       | 892                       | 2 %       |\n| Yervoy                | 2,530                     | 2,238                     | 13 %      |\n| U.S.                  | 1,599                     | 1,379                     | 16 %      |\n| Non-U.S.              | 931                       | 859                       | 8 %       |\n| Reblozyl              | 1,773                     | 1,008                     | 76 %      |\n| U.S.                  | 1,444                     | 804                       | 80 %      |\n| Non-U.S.              | 329                       | 204                       | 61 %      |\n| Opdualag              | 928                       | 627                       | 48 %      |\n| U.S.                  | 870                       | 615                       | 41 %      |\n| Non-U.S.              | 58                        | 12                        | >200%     |\n| Breyanzi              | 747                       | 364                       | 105 %     |\n| U.S.                  | 591                       | 303                       | 95 %      |\n| Non-U.S.              | 156                       | 61                        | 156 %     |\n| Camzyos               | 602                       | 231                       | 161 %     |\n| U.S.                  | 543                       | 225                       | 141 %     |\n| Non-U.S.              | 59                        | 6                         | >200%     |\n| Zeposia               | 566                       | 434                       | 30 %      |\n| U.S.                  | 403                       | 319                       | 26 %      |\n| Non-U.S.              | 163                       | 115                       | 42 %      |\n| Abecma                | 406                       | 472                       | (14) %    |\n| U.S.                  | 242                       | 358                       | (32) %    |\n| Non-U.S.              | 164                       | 114                       | 44 %      |\n| Sotyktu               | 246                       | 170                       | 45 %      |\n| U.S.                  | 190                       | 157                       | 21 %      |\n| Non-U.S.              | 56                        | 13                        | >200%     |\n| Krazati               | 126                       | -                         | N/A       |\n| U.S.                  | 118                       | -                         | N/A       |\n| Non-U.S.              | 8                         | -                         | N/A       |\n| Augtyro               | 38                        | 1                         | >200%     |\n| U.S.                  | 36                        | 1                         | >200%     |\n| Non-U.S.              | 2                         | -                         | N/A       |",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 39,
      "question": "How does the financial significance of Pfizer's Comirnaty manufacturing activities for BioNTech compare to the strategic depth of their broader mRNA vaccine collaboration, including equity stakes and cost-sharing arrangements?",
      "answer": "Pfizer's Comirnaty-related manufacturing activities for BioNTech generated only $33 million in revenue in 2023, indicating limited direct financial dependency between the two companies in this regard (page_112). However, the broader mRNA vaccine collaboration, including Comirnaty and the shingles vaccine candidate, reveals a deeper strategic relationship. Pfizer paid BioNTech a net upfront payment of $225 million (including a $150 million equity investment) for the shingles vaccine collaboration and shares development costs equally with BioNTech for these mRNA-based programs (page_76). As of December 31, 2023, Pfizer held a 2.7% equity stake in BioNTech, further cementing this strategic partnership. While the manufacturing relationship appears financially modest, the extensive cost-sharing, equity investment, and joint development approach demonstrate a significant strategic alignment between the companies in advancing mRNA vaccine technology.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_76) \u2192 [Comirnaty]: Details Pfizer's collaboration with BioNTech on Comirnaty, including cost-sharing arrangements and equity investment",
        "Hop 2: [Comirnaty] \u2192 [BioNTech]: Describes BioNTech's role in producing Comirnaty as part of their joint development and commercialization agreement",
        "Hop 3: [BioNTech] \u2190 [PFE](page_112): Reveals the limited financial scale of Comirnaty manufacturing activities ($33M in 2023) performed by Pfizer on behalf of BioNTech"
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Produces]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Comirnaty",
        "node_3": "BioNTech",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tSeptember\t2023,\tPfizer\tand\tBioNTech\tannounced\tthe\tFDA\tapproved\ta\tregulatory\tapplication\tfor\ttheir\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t12\tyears of\tage\tand\tolder\t(Comirnaty\t(COVID-19\tVaccine,\tmRNA,\t2023-2024\tFormula)).\tThe\tFDA\talso\tgranted\tEUA\tfor\tthe\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t6 months\tthrough\t11\tyears\tof\tage\t(Pfizer-BioNTech\tCOVID-19\tVaccine\t(2023-2024\tFormula)). (a)\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n41",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 40,
      "question": "How does Gilead's pursuit of Breakthrough Therapy Designation for Bulevirtide align with the drug's pending manufacturing resolution and its projected U.S. market exclusivity through 2030?",
      "answer": "Gilead's pursuit of Breakthrough Therapy Designation for Bulevirtide, aimed at expediting its development and review for treating chronic HDV infection, is strategically aligned with its efforts to resolve outstanding manufacturing and delivery concerns cited in the FDA's 2022 complete response letter. Despite these unresolved issues, the Breakthrough Therapy Designation underscores the drug's potential to address a serious unmet medical need. Furthermore, Gilead has projected U.S. market exclusivity for Bulevirtide through 2030, suggesting confidence in overcoming current regulatory hurdles and securing long-term commercial viability for the product.",
      "reasoning_steps": [
        "Hop 1: GILD(page_15) \u2192 Breakthrough Therapy Designation: Gilead describes the FDA's Breakthrough Therapy Designation as a mechanism to expedite drug development and review for serious conditions with preliminary evidence of substantial improvement over existing therapies.",
        "Hop 2: Breakthrough Therapy Designation \u2192 Bulevirtide: Bulevirtide has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic HDV infection, but its approval remains pending due to unresolved manufacturing and delivery concerns identified in an FDA complete response letter from October 2022.",
        "Hop 3: Bulevirtide \u2190 GILD(page_8): Gilead projects that Bulevirtide will maintain U.S. market exclusivity through 2030, indicating strategic confidence in its eventual regulatory approval and long-term commercial planning despite current delays."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Breakthrough Therapy Designation",
        "node_3": "Bulevirtide",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_1",
          "chunk_text": "At\t any\t point\t in\t this\t process,\t the\t development\t of\t a\t drug\t candidate\t can\t be\t stopped\t for\t a\t number\t of\t reasons,\t including safety\tconcerns,\tlack\tof\ttreatment\tbenefit\tor\tmanufacturing\tissues.\tWe\tcannot\tbe\tcertain\tthat\tany\tclinical\ttrials\tthat\twe\tare currently\tconducting\tor\tany\tthat\twe\tconduct\tin\tthe\tfuture\twill\tbe\tcompleted\tsuccessfully\tor\twithin\tany\tspecified\ttime\tperiod. We\tmay\tchoose,\tor\tFDA\tmay\trequire\tus,\tto\tdelay\tor\tsuspend\tour\tclinical\ttrials\tat\tany\ttime\tif\tit\tappears\tthat\tpatients\tare being\texposed\tto\tan\tunacceptable\thealth\trisk\tor\tif\tthe\tdrug\tcandidate\tdoes\tnot\tappear\tto\thave\tsufficient\ttreatment\tbenefit.\n\nEven\tafter\tapproving\ta\tdrug,\tFDA\tmay\talso\trequire\tPhase\t4\tnon-registrational\tstudies\tto\texplore\tscientific\tquestions\tto further\tcharacterize\tsafety\tand\tefficacy\tduring\tcommercial\tuse\tof\tour\tdrug.\tFDA\tmay\talso\trequire\tus\tto\tprovide\tadditional data\tor\tinformation,\timprove\tour\tmanufacturing\tprocesses,\tprocedures\tor\tfacilities\tor\tmay\trequire\textensive\tsurveillance\tto monitor\tthe\tsafety\tor\tbenefits\tof\tour\tproduct\tcandidates\tif\tit\tdetermines\tthat\tour\tfiling\tdoes\tnot\tcontain\tadequate\tevidence of\tthe\tsafety\tand\tbenefits\tof\tthe\tdrug.\tIn\taddition,\teven\tif\tFDA\tapproves\ta\tdrug,\tit\tcould\tlimit\tthe\tuses\tof\tthe\tdrug.\tFDA can\twithdraw\tapprovals\tif\tit\tdoes\tnot\tbelieve\tthat\twe\tare\tcomplying\twith\tregulatory\tstandards\tor\tif\tconcerns\tabout\tthe\tsafety or\tefficacy\tare\tuncovered\tor\toccur\tafter\tapproval.\n\nIn\taddition\tto\tobtaining\tFDA\tapproval\tfor\teach\tdrug,\twe\tobtain\tFDA\tapproval\tof\tthe\tmanufacturing\tfacilities\tfor\tany\tdrug we\t sell,\t including\t those\t of\t companies\t who\t manufacture\t our\t drugs\t for\t us.\t All\t of\t these\t facilities\t are\t subject\t to\t periodic inspections\tby\tFDA.\tFDA\tmust\talso\tapprove\tforeign\testablishments\tthat\tmanufacture\tproducts\tto\tbe\tsold\tin\tthe\tU.S.\tand\tthese facilities\tare\tsubject\tto\tperiodic\tregulatory\tinspection.\tOur\tmanufacturing\tfacilities\tlocated\tin\tCalifornia\talso\tmust\tbe licensed\tby\tthe\tState\tof\tCalifornia\tin\tcompliance\twith\tlocal\tregulatory\trequirements.\tOur\tmanufacturing\tfacilities\tin\tCanada, Ireland\tand\tNetherlands\talso\tmust\tobtain\tlocal\tlicenses\tand\tpermits\tin\tcompliance\twith\tlocal\tregulatory\trequirements.\n\nFDA\tmay\temploy\tone\tof\tseveral\ttools\tto\tfacilitate\tand\texpedite\tthe\tdevelopment\tand\treview\tof\ta\tdrug,\tincluding\tFast\tTrack designation,\tBreakthrough\tTherapy\tdesignation,\tAccelerated\tApproval\tdesignation\tand\tPriority\tReview\tdesignation.\tFast\tTrack designation\tis\tdesigned\tto\tfacilitate\tthe\tdevelopment\tand\treview\tof\ta\tdrug\tthat\ttreats\ta\tserious\tcondition\tand\tfills\tan\tunmet medical\tneed.\tBreakthrough\tTherapy\tdesignation\tis\tdesigned\tto\texpedite\tthe\tdevelopment\tand\treview\tof\ta\tdrug\tthat\ttreats\ta serious\t condition\t where\t preliminary\t clinical\t evidence\t demonstrates\t substantial\t improvement\t over\t available\t therapies. Accelerated\tApproval\tof\ta\tdrug\tmay\tbe\tgranted\tby\tFDA\twhere\tthe\tdrug\ttreats\ta\tserious\tcondition,\tfills\tan\tunmet\tmedical\tneed and\t has\t been\t studied\t for\t safety\t and\t efficacy.\t Priority\t Review\t designation\t means\t FDA's\t goal\t is\t to\t take\t action\t on\t an application\twithin\tsix\tmonths\tof\tfiling.\tFDA\tmay\tgrant\tPriority\tReview\tdesignation\tto\ta\tdrug\tthat\twould\tprovide\tsignificant improvement\tin\tthe\tsafety\tor\teffectiveness\tof\ta\ttreatment,\tdiagnosis\tor\tprevention\tof\ta\tserious\tcondition.\n\n## EU\tRegulatory\tSystem\tand\tApproval\tProce ss\n\nIn\t the\t EU,\t our\t products\t are\t subject\t to\t a\t variety\t of\t EU\t and\t EU\t member\t state\t regulations\t governing\t clinical\t trials, commercial\tsales\tand\tdistribution.\tWe\tare\trequired\tto\tobtain\ta\tmarketing\tauthorization\tin\tthe\tEU\tbefore\twe\tcan\tmarket\tour medicinal\tproducts\ton\tthe\trelevant\tmarket.\tThe\tconduct\tof\tclinical\ttrials\tin\tthe\tEU\tis\tgoverned\tby,\tamong\tothers,\tDirective 2001/20/EC\t and\t Directive\t 2005/28/EC\t and\t the\t ICH\t Good\t Clinical\t Practice\t guidelines.\t These\t impose\t legal\t and\t regulatory obligations\tthat\tare\tsimilar\tto\tthose\tprovided\tin\tapplicable\tU.S.\tlaws.\tThe\tconduct\tof\tclinical\ttrials\tin\tthe\tEU\tmust\tbe approved\t by\t the\t competent\t authorities\t of\t each\t EU\t member\t states\t in\t which\t the\t clinical\t trials\t take\t place,\t and\t a\t positive opinion\tmust\tbe\tobtained\tfrom\tthe\trelevant\tEthics\tCommittee\tin\tthe\trelevant\tmember\tstate.\tIn\t2014,\tthe\tEU\tlegislator\tadopted Regulation\t(EU)\tNo\t536/2014\tto\treplace\tDirective\t2001/20/EC\tand\tto\tintroduce\ta\tcoordinated\tprocedure\tfor\tauthorization\tof clinical\ttrials.\tThis\tRegulation\tentered\tinto\tapplication\tin\tJanuary\t2022.\n\nMarketing\tauthorization\tholders,\tmanufacturers,\timporters,\twholesalers\tand\tdistributors\tof\tmedicinal\tproducts\tplaced\ton the\t market\t in\t the\t EU\t are\t required\t to\t comply\t with\t a\t number\t of\t regulatory\t requirements\t including\t pharmacovigilance,\t GMP compliance\t and\t the\t requirement\t to\t obtain\t manufacturing,\t import\t and/or\t distribution\t licenses\t issued\t by\t the\t competent authorities\tof\tthe\tEU\tmember\tstates.\tFailure\tto\tcomply\twith\tthese\trequirements\tmay\tlead\tto\tthe\timposition\tof\tcivil,\tcriminal or\tadministrative\tsanctions,\tincluding\tsuspension\tof\tmarketing\tor\tmanufacturing\tauthorizations.\n\n## Pricing\tand\tReimbursement\n\nSuccessful\tcommercialization\tof\tour\tproducts\tdepends,\tin\tpart,\ton\tthe\tavailability\tof\tthird-party\tpayer\treimbursement\tfor the\tcost\tof\tsuch\tproducts\tand\trelated\ttreatments\tand\tmedical\tservices\tin\tthe\tmarkets\twhere\twe\tsell\tour\tproducts.\tGovernment health\tauthorities,\tprivate\thealth\tinsurers\tand\tother\torganizations\tgenerally\tprovide\treimbursement.\tIn\tthe\tU.S.,\tthe\tEU\tand other\t significant\t or\t potentially\t significant\t markets\t for\t our\t products\t and\t product\t candidates,\t government\t authorities\t and third-party\tpayers\tare\tincreasingly\tattempting\tto\tlimit\tor\tregulate\tthe\tprice\tof\tmedical\tproducts\tand\tservices.\tA\tsignificant portion\tof\tour\tsales\tof\tthe\tmajority\tof\tour\tproducts\tare\tsubject\tto\tsubstantial\tdiscounts\tfrom\ttheir\tlist\tprices,\tincluding rebates\twe\tmay\tbe\trequired\tto\tpay\tto\tMedicaid\tagencies\tor\tdiscounts\twe\tmay\tbe\trequired\tto\tpay\tto\tcovered\tentities\tunder Section\t340B\tof\tthe\tPublic\tHealth\tService\tAct\t('340B').\tAs\ta\tresult,\tthe\tprice\tincreases\twe\timplement\tfrom\ttime\tto\ttime\ton certain\tproducts\tmay\thave\ta\tlimited\teffect\ton\tour\tnet\tproduct\tsales\tin\tcertain\tmarkets.\tIn\taddition,\tstandard\treimbursement structures\tmay\tnot\tadequately\treimburse\tfor\tinnovative\ttherapies.",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "Breakthrough_Therapy_Designation",
          "name": "Breakthrough Therapy Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product Candidates   | Description                                                                                                                                                                                                                                                                                                                                                                                           |\n|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Regulatory Filings   |                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Bulevirtide          | A Biologics License Application has been filed with FDA for bulevirtide for the treatment of chronic hepatitis delta virus ('HDV') infection. It has been granted both Orphan Drug and Breakthrough Therapy designations by FDA for this indication. Approval is pending resolution of certain manufacturing and delivery concerns cited in a complete response letter issued by FDA in October 2022. |\n| Phase 3              |                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Lenacapavir          | Lenacapavir is being evaluated for an HIV PrEP indication.                                                                                                                                                                                                                                                                                                                                            |",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Bulevirtide",
          "name": "Bulevirtide",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_2",
          "chunk_text": "|                            | U.S.   |     | EU         |\n|----------------------------|--------|-----|------------|\n| Viral Diseases:            |        |     |            |\n| Lenacapavir                | 2037   |     | 2037       |\n| Bulevirtide                | 2030   |     | 2029       |\n| Oncology:                  |        |     |            |\n| Axicabtagene ciloleucel    | 2031   |     | - (1)      |\n| Sacituzumab govitecan-hziy | 2028   | (2) | 2029       |\n| Zimberelimab (3)           | 2036   |     | (2036) (4) |\n| Domvanalimab (3)           | 2037   |     | (2037) (4) |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 41,
      "question": "Given Merck's heavy dependence on key products like Lynparza for profitability, how does the company's strategy of combining Lynparza with Keytruda in Phase 3 clinical trials align with its exposure to sales volatility from loss of market exclusivity, especially as Keytruda is expected to lose U.S. exclusivity in 2028?",
      "answer": "Merck's 2023 10-K filing highlights that key products such as Lynparza and Keytruda contribute significantly to the company's profits and cash flows (page 28). However, the loss of market exclusivity for major products can lead to a rapid decline in sales, as seen with Bridion and expected for Keytruda in 2028. Despite this risk, the company is pursuing a strategic oncology initiative that includes combining Lynparza with Keytruda in Phase 3 trials for lung cancers (page 48). This suggests Merck is attempting to extend the lifecycle and value of Keytruda through novel therapeutic combinations, even as it anticipates a future decline in Keytruda sales due to generic competition. The success of this strategy would be critical to offsetting revenue losses and maintaining profitability from its key product portfolio.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_28) \u2192 [Key Products]: The company's financial health is heavily tied to key products, and loss of exclusivity for these products can materially impact revenue and profitability.",
        "Hop 2: [Key Products] \u2192 [Lynparza]: Lynparza is specifically listed as one of Merck\u2019s key products, which collectively drive a significant portion of the company\u2019s profits and cash flows.",
        "Hop 3: [Lynparza] \u2190 [MRK](page_48): Lynparza is being strategically combined with Keytruda in Phase 3 clinical trials, indicating a development effort to enhance its therapeutic value and potentially delay revenue erosion from Keytruda\u2019s impending loss of exclusivity."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> PRODUCT -[Includes]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Key Products",
        "node_3": "Lynparza",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Lynparza",
          "name": "Lynparza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- V116,\t an\t investigational\t 21-valent\t pneumococcal\t conjugate\t vaccine\t for\t the\t prevention\t of\t invasive\t pneumococcal\t disease\t and pneumococcal\tpneumonia\tin\tadults,\tis\talso\tunder\tpriority\treview\tby\tthe\tFDA.\n- MK-1022,\tpatritumab\tderuxtecan,\tis\tan\tADC\tbeing\tevaluated\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tNSCLC\tunder\tpriority\treview\tby the\tFDA.\tPatritumab\tderuxtecan\tis\tpart\tof\ta\tcollaboration\twith\tDaiichi\tSankyo.\n- Additionally, Keytruda is\t under\t review\t in\t the\t U.S.\t and/or\t in\t international\t markets\t for\t supplemental\t indications\t for\t the treatment\tof\tcertain\tpatients\twith\tbiliary\ttract,\tcervical,\tendometrial,\tgastric,\tnon-small-cell\tlung\tand\turothelial\tcancers.\n- Welireg is\tunder\treview\tin\tthe\tEU\tfor\tthe\ttreatment\tof\tcertain\tpatients\twith\tadvanced\tRCC\tand\tfor\tthe\ttreatment\tof\tvon\tHippelLindau\tdisease.\n\nDuring\t2023,\tthe\tCompany\tinitiated\tmore\tthan\t20\tPhase\t3\tstudies\tacross\tmultiple\tasset\tclasses,\tincluding\tthe\tprogression\tof eight\tnovel\tcandidates.\n\nThe\t Company\t is\t diversifying\t its\t oncology\t portfolio\t and\t executing\t on\t its\t strategy\t which\t is\t broadly\t based\t on\t three\t strategic pillars:\timmuno-oncology,\tprecision\tmolecular\ttargeting\tand\ttissue\ttargeting.\tMerck's\tPhase\t3\toncology\tprograms\twithin\tthese\tpillars\tare as\tfollows:\n\n## Immuno-oncology\n\n- Keytruda in\t the\t therapeutic\t areas\t of\t cutaneous\t squamous\t cell,\t hepatocellular,\t mesothelioma,\t ovarian\t and\t small-cell\t lung cancers;\n- MK-1308A,\tthe\tcoformulation\tof\tquavonlimab,\tMerck's\tnovel\tinvestigational\tanti-CTLA-4\tantibody,\tand\tpembrolizumab\tfor\tRCC;\n- MK-3475A,\tthe\tsubcutaneous\tcoformulation\tof\tpembrolizumab\twith\thyaluronidase\tfor\tcertain\ttypes\tof\tNSCLC;\n- MK-4280A,\tthe\tcoformulation\tof\tfavezelimab,\tMerck's\tnovel\tinvestigational\tanti-LAG3\ttherapy,\tand\tpembrolizumab\tfor\tcolorectal cancer\tand\thematological\tmalignancies;\n- MK-7684A,\t the\t coformulation\t of\t vibostolimab,\t an\t anti-TIGIT\t therapy,\t and\t pembrolizumab\t for\t certain\t types\t of\t melanoma,\t non-\n- small-cell\tand\tsmall-cell\tlung\tcancers;\tand\n- V940,\tan\tinvestigational\tindividualized\tneoantigen\ttherapy,\tin\tcombination\twith Keytruda ,\tfor\tcertain\ttypes\tof\tmelanoma\tand NSCLC,\tbeing\tdeveloped\tin\tcollaboration\twith\tModerna.\n\n## Precision\tmolecular\ttargeting\n\n- Lynparza\tin\tcombination\twith Keytruda for\tnon-small-cell\tlung\tand\tsmall-cell\tlung\tcancers;\n- Lenvima,\tbeing\tdeveloped\tin\tcollaboration\twith\tEisai\tCo.,\tLtd.\t(Eisai),\tin\tcombination\twith Keytruda for\tcertain\ttypes\tof esophageal\tand\tgastric\tcancers;\n- MK-1026,\t nemtabrutinib,\t an\t oral,\t reversible,\t non-covalent\t Bruton's\t tyrosine\t kinase\t (BTK)\t inhibitor,\t for\t hematological malignancies;\n- MK-3543,\t bomedemstat,\t an\t investigational\t orally\t available\t lysine-specific\t demethylase\t 1\t inhibitor\t for\t myeloproliferative disorders;\tand\n- MK-5684,\tan\tinvestigational\tcytochrome\tP450\t11A1\t(CYP11A1)\tinhibitor\tbeing\tdeveloped\tin\tcollaboration\twith\tOrion\tCorporation (Orion)\tfor\tmCRPC.\n\n## Tissue\ttargeting\n\n- MK-2870,\t an\t investigational\t trophoblast\t cell-surface\t antigen\t 2\t (TROP2)-directed\t ADC\t being\t developed\t in\t collaboration\t with Kelun-Biotech\tfor\tendometrial\tcarcinoma\tand\tcertain\ttypes\tof\tNSCLC.\n\nAdditionally,\tthe\tCompany\tcurrently\thas\tcandidates\tin\tPhase\t3\tclinical\tdevelopment\tin\tseveral\tother\ttherapeutic\tareas\tincluding:\n\n- MK-0616,\tan\tinvestigational,\toral\tproprotein\tconvertase\tsubtilisin/kexin\ttype\t9\t(PCSK9)\tinhibitor\tfor\thypercholesterolemia;\n- MK-1654,\tclesrovimab,\ta\thuman\tmonoclonal\tantibody\tfor\tthe\tprevention\tof\trespiratory\tsyncytial\tvirus\t(RSV);\n- MK-7240,\ttulisokibart,\ta\thumanized\tmonoclonal\tantibody\tdirected\tto\ttumor\tnecrosis\tfactor-like\tligand\t1A,\ta\ttarget\tassociated with\tboth\tintestinal\tinflammation\tand\tfibrosis,\tfor\tulcerative\tcolitis;",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 42,
      "question": "How does BMY's financial dependency on Ono for Opdivo royalties interact with the increasing regulatory approvals of Opdivo combination therapies and the risk of biosimilar competition threatening Opdivo's market exclusivity?",
      "answer": "BMY's financial dependency on Ono is highlighted by the royalty structure tied to Opdivo sales, where Ono receives 4% in North America and 15% elsewhere, subject to adjustments. During 2021, Opdivo combination therapies achieved multiple regulatory approvals globally, including for esophageal cancer in Japan and the EU, and for renal cell carcinoma (RCC) in the U.S. and EU, which likely boosted Opdivo sales and, by extension, Ono\u2019s royalties. However, BMY\u2019s own disclosures on page 9 indicate that Opdivo is among the marketed biologics vulnerable to biosimilar challenges, with the potential for biosimilar approval after 12 years of regulatory data protection. Given that Opdivo was first approved in 2014, the approach of the 12-year exclusivity window heightens the risk of biosimilar entry, which could erode Opdivo\u2019s market share and reduce royalty payments to Ono. Therefore, while recent regulatory approvals have likely strengthened Opdivo\u2019s commercial position in the short term, the looming threat of biosimilars poses a long-term risk to both BMY\u2019s revenue and Ono\u2019s royalty income.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_114) \u2192 [Ono]: BMY depends on Ono for Opdivo, with Ono receiving 4% in North America and 15% in other territories as royalties, subject to adjustments.",
        "Hop 2: [Ono] \u2192 [Opdivo]: Ono, as BMY\u2019s alliance partner in Japan, announced multiple regulatory approvals for Opdivo combination therapies in 2021, including for esophageal cancer and RCC, based on Phase III trials.",
        "Hop 3: [Opdivo] \u2190 [BMY](page_9): BMY discloses that Opdivo is among its marketed biologics facing potential biosimilar competition after 12 years of regulatory data protection, which is approaching given Opdivo\u2019s 2014 approval."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Announces]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Ono",
        "node_3": "Opdivo",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_114",
          "chunk_id": "chunk_3",
          "chunk_text": "\nBMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.\n\n## Nektar\n\nIn  2018,  BMS  and  Nektar  commenced  a  worldwide  license  and  collaboration  for  the  development  and  commercialization  of Bempegaldesleukin  (NKTR-214),  Nektar's  investigational  immuno-stimulatory  therapy  designed  to  selectively  expand  specific cancer-fighting T cells and natural killer cells directly in the tumor micro-environment. In January 2020, the parties amended the collaboration agreement. The Opdivo and NKTR-214 combination therapy is currently in Phase III clinical studies for metastatic melanoma, adjuvant melanoma, muscle-invasive bladder cancer and RCC. A joint development plan agreed by the parties as part of the original agreement, and updated as part of the January 2020 amendment, specifies development in certain indications and tumor types  with  each  party  responsible  for  the  supply  of  their  own  product.  BMS's  share  of  the  development  costs  associated  with therapies comprising a BMS medicine used in combination with NKTR-214 is 67.5%, subject to certain cost caps for Nektar. The January  2020  amendment  retains  the  cost  sharing  percentages  from  the  original  agreement.  The  parties  will  also  jointly commercialize  the  therapies,  subject  to  regulatory  approval.  BMS's  share  of  global  NKTR-214  profits  and  losses  will  be  35% subject to certain annual loss caps for Nektar.\n\nBMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.  BMS's equity  ownership  is  subject  to  certain  lock-up,  standstill  and  voting  provisions  for  a  five-year period. The amount of the up-front payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the up-front payment was allocated to the rights discussed above. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales-based milestones over the life of the alliance period. Research and development cost reimbursements were $98 million in 2021, $132 million in 2020 and $108 million in 2019.\n\n## 2seventy bio (formerly bluebird)\n\nOn November 4, 2021, bluebird completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company.\n\nThe  parties  jointly  develop  and  commercialize  novel  disease-altering  gene  therapy  product  candidates  targeting  BCMA.  The collaboration arrangement began in 2013 and included (i) a right for BMS to license any anti-BCMA products resulting from the collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and  commercialization  of  any  licensed  products resulting  from  the  collaboration  through  a  50/50  co-development  and  profit  share  in  the  U.S.  in  exchange  for  a  reduction  of milestone  payments,  and  (iii)  sales-based  milestones  and  royalties  payable  to  2seventy  bio  upon  the  commercialization  of  any licensed  products  resulting  from  the  collaboration  if  2seventy  bio  declined  to  exercise  their  co-development  and  profit  sharing rights. The options to license idecabtagene vicleucel (ide-cel, bb2121) and bb21217 were exercised in 2016 and 2017, respectively. In 2022, the parties elected to not pursue further development of bb21217.\n\nAll profits and losses relating to developing, commercializing and manufacturing ide-cel within the U.S. are shared equally. BMS is exclusively responsible for the development and commercialization of ide-cel outside the U.S.\n\nIn  2020,  terms  of  the  collaboration  were  amended  including  certain  manufacturing  obligations.  Both  parties  were  also  released from future exclusivity related to BCMA-directed T cell therapies. BMS paid $200 million to extinguish its obligation for future ex-U.S. milestones and royalties on ide-cel, which was included in Research and development expense in 2020.\n\nIn 2021, the FDA approved ide-cel (' Abecma ' ) for the treatment of relapsed or refractory multiple myeloma. Net product sales of Abecma  within  the  Alliance  territory  were  $158  million  and  related  profit  sharing  costs  were  $42  million  in  2021.  Cost reimbursements were not material.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product         | Indication                     | Date           | Developments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|-----------------|--------------------------------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Opdivo          | Hodgkin Lymphoma               | September 2021 | Ono, our alliance partner for Opdivo in Japan, announced that Japan's Ministry of Health, Labour and Welfare approved Opdivo for the treatment of pediatric patients with recurrent or refractory classical Hodgkin lymphoma, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase I PENGUIN trial.                                                                                                                                              |\n| Opdivo          | NSCLC                          | November 2021  | Announced the Phase III CheckMate-816 trial met the primary endpoint of improved event- free survival in patients with resectable stage IB to IIIA NSCLC. In a prespecified interim analysis, Opdivo plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone when given before surgery.                                                                                                                                                |\n| Opdivo          | RCC                            | August 2021    | Ono, our alliance partner for Opdivo in Japan, announced that Japan's Ministry of Health, Labour and Welfare approved the combination therapy of Opdivo and CABOMETYX * for the treatment of unresectable or metastatic RCC, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase III Checkmate-9ER trial.                                                                                                                                       |\n| Opdivo          | RCC                            | April 2021     | Announced EC approval of Opdivo in combination with CABOMETYX * for the first-line treatment of adults with advanced RCC. The approval is based on results from the Phase III CheckMate-9ER trial.                                                                                                                                                                                                                                                                                                                              |\n| Opdivo          | RCC                            | January 2021   | Announced FDA approval of Opdivo in combination with CABOMETYX * for the first-line treatment of patients with advanced RCC. The approval is based on the Phase III CheckMate-9ER trial.                                                                                                                                                                                                                                                                                                                                        |\n| Opdivo + Yervoy | CRC                            | June 2021      | Announced EC approval of Opdivo plus Yervoy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high mCRC after prior fluoropyrimidine-based combination chemotherapy. The approval is based on results from the Phase II CheckMate-142 trial.                                                                                                                                                                                                                              |\n| Opdivo + Yervoy | Melanoma                       | May 2021       | Announced new six-and-a-half year data from the Phase III CheckMate-067 trial demonstrating durable improvement in survival with first-line Opdivo plus Yervoy therapy and Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma.                                                                                                                                                                                                                                                                         |\n| Opdivo + Yervoy | Esophageal                     | September 2021 | Announced that the FDAhas accepted the sBLA for Opdivo in combination with Yervoy and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. The FDA assigned a PDUFA goal date of May 28, 2022. The sBLAsubmissions were based on the Phase III Checkmate-648 trial.                                                                                            |\n| Opdivo + Yervoy | Esophageal                     | September 2021 | Ono, our alliance partner for Opdivo in Japan, announced that the companies have submitted supplemental applications in Japan for Opdivo in combination with Yervoy and Opdivo in combination with chemotherapy for the first-line treatment of unresectable, advanced or recurrent esophageal cancer, for a partial change in approved items of the manufacturing and marketing approvals in Japan. The applications are based on results from the Phase III CheckMate-648 trial.                                              |\n| Opdivo + Yervoy | Esophageal                     | August 2021    | Announced that the EMA validated its MAA for both Opdivo in combination with Yervoy and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Validation of these applications confirm that the submissions are complete and begins the EMA's centralized review process. The applications are based on results from the pivotal Phase III CheckMate-648 trial. |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | September 2021 | Announced three-year data from the CheckMate-743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo plus Yervoy compared to platinum- based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma, regardless of histology.                                                                                                                                                                                                                          |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | June 2021      | Announced EC approval of Opdivo plus Yervoy for the first line treatment of adults with unresectable malignant pleural mesothelioma. The approval is based on results from the Phase III CheckMate-743 trial.                                                                                                                                                                                                                                                                                                                   |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | May 2021       | Ono, our alliance partner for Opdivo in Japan, announced that the companies received approval for combination therapy of Opdivo and Yervoy in Japan for the first-line treatment of unresectable advanced or recurrent malignant pleural mesothelioma, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase III CheckMate-743 trial.                                                                                                             |",
          "relationship": "Announces"
        },
        "node_3": {
          "id": "Opdivo",
          "name": "Opdivo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "## Biologic products\n\nThe  U.S.  healthcare  legislation  enacted  in  2010  created  an  approval  pathway  for  biosimilar  versions  of  innovative  biological products  that  did  not  previously  exist.  Prior  to  that  time,  innovative  biologics  had  essentially  unlimited  regulatory  exclusivity. Under the new regulatory mechanism, the FDA can approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. After an innovator has marketed its product for four years, any manufacturer may file an application for approval of a 'biosimilar' version of the innovator product. However, although an  application  for  approval  of  a  biosimilar  version  may  be  filed  four  years  after  approval  of  the  innovator  product,  qualified innovative  biological  products  will  receive  12  years  of  regulatory  data  protection,  meaning  that  the  FDA  may  not  approve  a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. The law also provides a mechanism  for  innovators  to  enforce  the  patents  that  protect  innovative  biological  products  and  for  biosimilar  applicants  to challenge  the  patents.  Such  patent  litigation  may  begin  as  early  as  four  years  after  the  innovative  biological  product  is  first approved by the FDA.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market exclusivity. First, generic companies have increasingly sought to challenge innovators' basic patents covering major  pharmaceutical  products.  Second,  statutory  and  regulatory  provisions  may  limit  the  ability  of  an  innovator  company  to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of all of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based  solely  on  the  expiration  of  the  relevant  patent(s)  or  the  current  forms  of  regulatory  exclusivity.  Our  marketed  biologic products include Opdivo , Yervoy , Orencia, Reblozyl and Empliciti .\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended to compensate for the patent term lost during the regulatory review process. Such extensions are granted on a country-by-country basis.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized procedure.' This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and  is  also  available  for  certain  new  chemical  compounds  and  products.  A  company  seeking  to  market  an  innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies  the  MAA. It  is  also  possible  for  new  chemical  products  to  obtain  marketing  authorization  in  the  EU  through  a  'mutual recognition  procedure,'  in  which  an  application  is  made  to  a  single  member  state,  and  if  the  member  state  approves  the pharmaceutical  product  under  a  national  procedure,  then  the  applicant  may  submit  that  approval  to  the  mutual  recognition procedure of some or all other member states.\n\nAfter  obtaining  marketing  authorization  approval,  a  company  must  obtain  pricing  and  reimbursement  for  the  pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout the EU, all products for which marketing authorizations have been filed after October/November 2005 are subject to an '8+2+1' regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator.  The  possible  extension  to  11  years  is  available  if  the  innovator,  during  the  first  eight  years  of  the  marketing authorization,  obtains  an  additional  indication  that  is  of  significant  clinical  benefit  in  comparison  with  existing  treatments.  For products  that  were  filed  prior  to  October/November  2005,  there  is  a  10-year  period  of  regulatory  data  protection  under  the centralized procedures and a period of either six or 10 years under the mutual recognition procedure (depending on the member state).\n\nIn contrast to the U.S., patents in the EU are not listed with regulatory authorities. Generic versions of pharmaceutical products can be approved after data protection expires, regardless of whether the innovator holds patents covering its drug. Thus, it is possible that an innovator may be seeking to enforce its patents against a generic competitor that is already marketing its product. Also, the European patent system has an opposition procedure in which generic manufacturers may challenge the validity of patents covering innovator products within nine months of grant.\n\nIn  general,  EU  law  treats  chemically-synthesized  drugs  and  biologically-derived  drugs  the  same  with  respect  to  intellectual property and data protection. In addition to the relevant legislation and annexes related to biologic medicinal products, the EMA has  issued  guidelines  that  outline  the  additional  information  to  be  provided  for  biosimilar  products,  also  known  as  generic biologics, in order to review an application for marketing approval.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 43,
      "question": "How does Merck's ongoing financial involvement with Organon, particularly through the manufacturing and supply agreements for formulated pharmaceutical products, reconcile with the fact that Organon was spun off and is now a separate entity with its own $9.5 billion debt obligation?",
      "answer": "Merck's ongoing involvement with Organon is maintained through a series of binding manufacturing and supply agreements (MSAs) under which Merck both supplies and receives formulated pharmaceutical products from Organon, generating $219 million in sales in 2021. Despite the spin-off of Organon\u2014which carried $9.5 billion in principal debt and was treated as a tax-free distribution\u2014Merck remains operationally connected through these agreements, which have initial terms ranging from four to ten years. Additionally, Merck had a net receivable of $964 million from Organon at year-end 2021, indicating continued financial exposure. This suggests that while Organon is now a separate, financially independent entity with its own debt obligations, Merck continues to maintain a strategic and financial relationship with it through contractual supply chain commitments.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_128) \u2192 [Organon]: Merck spun off Organon and adjusted employee stock awards to reflect the separation, indicating a structural and financial disentanglement.",
        "Hop 2: [Organon] \u2192 [Formulated Pharmaceutical Products]: Organon and Merck entered into mutual MSAs under which Merck manufactures and supplies formulated pharmaceutical products to Organon and vice versa, indicating ongoing interdependence.",
        "Hop 3: [Formulated Pharmaceutical Products] \u2190 [MRK](page_94): These MSAs generated $219 million in sales for Merck in 2021, and Merck had a net receivable of $964 million from Organon at year-end, showing that despite the spin-off, Merck remains financially tied to Organon through product manufacturing and supply commitments."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Produces]-> PRODUCT <-[Provides]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Formulated Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_128",
          "chunk_id": "chunk_3",
          "chunk_text": "\nActivity prior to the Organon spin-off has not been restated. (1)\n\nIn connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (2)\n\nAt December 31, 2021, there was $699 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.\n\n## 14.    Pension and Other Postretirement Benefit Plans\n\nThe  Company  has  defined  benefit  pension  plans  covering  eligible  employees  in  the  U.S.  and  in  certain  of  its international  subsidiaries.  In  addition,  the  Company  provides  medical  benefits,  principally  to  its  eligible  U.S.  retirees  and  their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.\n\n## Net Periodic Benefit Cost\n\nThe net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:\n\nPension Benefits\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Formulated_Pharmaceutical_Products",
          "name": "Formulated Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Provides"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 44,
      "question": "How does Merck's decision to grant royalty-free licenses to generic manufacturers for molnupiravir in low- and middle-income countries align with its collaboration structure with Ridgeback and the advance purchase agreements in more than 30 markets?",
      "answer": "Merck's decision to grant royalty-free licenses to generic manufacturers for molnupiravir in over 100 low- and middle-income countries aligns with its collaboration with Ridgeback, as both companies have agreed to forgo royalties under the Medicines Patent Pool (MPP) agreement for as long as COVID-19 remains a Public Health Emergency of International Concern by the WHO. This approach supports global access to the drug through tiered pricing and voluntary licensing. At the same time, Merck has entered into advance purchase and supply agreements in more than 30 markets, indicating a parallel strategy to secure revenue from higher-income countries. This dual approach allows Merck and Ridgeback to balance humanitarian goals with financial sustainability by leveraging different market segments and funding mechanisms.",
      "reasoning_steps": [
        "Hop 1: MRK(page_105) \u2192 Generic Manufacturers: Merck grants royalty-free licenses to generic manufacturers via the MPP to ensure access in over 100 low- and middle-income countries, with no royalties collected for as long as the WHO classifies COVID-19 as a Public Health Emergency of International Concern.",
        "Hop 2: Generic Manufacturers \u2192 Ridgeback: Ridgeback, as a co-collaborator with Merck on molnupiravir, shares the same royalty-free commitment under the MPP agreement, aligning both companies\u2019 access strategy for the drug in lower-income markets.",
        "Hop 3: Ridgeback \u2190 MRK(page_55): Merck is developing molnupiravir in collaboration with Ridgeback and has secured advance purchase agreements in more than 30 markets, which supports the financial viability of the partnership despite the royalty-free licensing in lower-income countries."
      ],
      "difficulty": "hard",
      "idf_score": 6.02437402262659,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Grants_License_To]-> COMP -[Grants_License_To]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Generic Manufacturers",
        "node_3": "Ridgeback",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_105",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nMerck  and  Ridgeback  are  committed  to  providing  timely  access  to  molnupiravir  globally  through  a  comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments as noted above; allocating up to 3 million courses of therapy to the United Nations Children's Fund (UNICEF) for use in adults; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool (MPP) to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. Merck, Ridgeback and Emory University will not receive royalties for sales of molnupiravir under the MPP agreement (molnupiravir was invented at Emory University and licensed to Ridgeback) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.\n\nSummarized financial information related to this collaboration is as follows:\n\n",
          "relationship": "Grants_License_To"
        },
        "node_2": {
          "id": "Generic_Manufacturers",
          "name": "Generic Manufacturers",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_105",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nMerck  and  Ridgeback  are  committed  to  providing  timely  access  to  molnupiravir  globally  through  a  comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments as noted above; allocating up to 3 million courses of therapy to the United Nations Children's Fund (UNICEF) for use in adults; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool (MPP) to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. Merck, Ridgeback and Emory University will not receive royalties for sales of molnupiravir under the MPP agreement (molnupiravir was invented at Emory University and licensed to Ridgeback) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.\n\nSummarized financial information related to this collaboration is as follows:\n\n",
          "relationship": "Grants_License_To"
        },
        "node_3": {
          "id": "Ridgeback",
          "name": "Ridgeback",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_55",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nEmergency  for  molnupiravir.  In  November  2021,  the  UK  Medicines  and  Healthcare  products  Regulatory  Agency  granted conditional  marketing  authorization  for  molnupiravir.  In  addition,  in  October  2021,  the  EMA  initiated  a  rolling  review  for molnupiravir. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review  process  to  facilitate  initiating  the  formal  review  of  the  Marketing  Authorization  Application.  Merck  is  developing molnupiravir in collaboration with Ridgeback. The companies are actively working with other regulatory agencies worldwide to submit applications for emergency use or marketing authorization. Merck has entered into advance purchase and supply agreements for molnupiravir in more than 30 markets. See Note 5 to the consolidated financial statements for additional information related to the collaboration with Ridgeback.\n\nIn March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, is providing Merck with funding to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. Merck has also entered into agreements to support the manufacturing and supply of Johnson &amp; Johnson's SARS-CoV-2/COVID-19 vaccine. Merck is using certain of its facilities in the U.S. to produce drug substance, formulate and fill vials of Johnson &amp; Johnson's vaccine.\n\n## Pricing\n\nGlobal  efforts  toward  health  care  cost  containment  continue  to  exert  pressure  on  product  pricing  and  market  access worldwide.  Changes  to  the  U.S.  health  care  system  as  part  of  health  care  reform  enacted  in  prior  years,  as  well  as  increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing  pressure.  In  several  international  markets,  government-mandated  pricing  actions  have  reduced  prices  of  generic  and patented drugs. In addition, the Company's revenue performance in 2021 was negatively affected by other cost-reduction measures taken  by  governments  and  other  third  parties  to  lower  health  care  costs.  In  the  U.S.,  the  Biden  Administration  and  Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.\n\n## Operating Results\n\n## Sales\n\n",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 45,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, relate to the legal challenges facing Comirnaty in the U.S. and Europe, and what potential impact could these legal risks have on the continuation of those international supply commitments?",
      "answer": "Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract extending through 2026 with rephased deliveries and volume reductions, is central to its international revenue commitments. However, Comirnaty faces multiple legal challenges: in April 2024, GSK Group sued Pfizer and BioNTech in the U.S., alleging infringement of five U.S. patents (later amended to include three additional patents), and in January 2025, Promosome LLC filed a complaint in the Unified Patent Court alleging infringement of a European patent in France, Germany, and Sweden. These legal risks could disrupt the manufacturing and distribution of Comirnaty in key markets, potentially jeopardizing Pfizer\u2019s ability to meet its contractual obligations under the amended EU agreement and impacting international revenue projections tied to the vaccine.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_107) \u2192 [BioNTech]: Pfizer depends on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026 with rephased deliveries and volume reductions.",
        "Hop 2: [BioNTech] \u2192 [Comirnaty]: BioNTech is a co-developer and co-defendant in legal actions related to Comirnaty, indicating its integral role in both the production and legal exposure of the product.",
        "Hop 3: [Comirnaty] \u2190 [PFE](page_101): Comirnaty is under legal scrutiny in both the U.S. and Europe, with multiple lawsuits alleging patent infringement, which could impact Pfizer\u2019s ability to fulfill international supply agreements tied to the product."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Impacts]-> PRODUCT <-[Impacts]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "BioNTech",
        "node_3": "Comirnaty",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_107",
          "chunk_id": "chunk_5",
          "chunk_text": "\nRevenues exceeded $500 m illion in each of 11, 14 and 24 countries outside the U .S. in 2024, 2023 and 2022, respectively. T he U .S. is the only country to contribute m ore than 10% of total revenue in 2024, 2023 and 2022. As a percentage of Total revenues , C hina was our largest m arket outside the U .S. (representing 4% of total revenues) in 2024, and Japan was our largest m arket outside the U .S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).\n\n## C. Other Revenue Information\n\n## Significant Customers\n\nWe and our collaboration partner, BioN T ech, have entered into agreem ents to supply pre-specified doses of C om irnaty with m ultiple developed and em erging nations around the world and are continuing to deliver doses of C om irnaty under such agreem ents. T his includes supply agreem ents entered into in N ovem ber 2020 and F ebruary and M ay 2021 with the E C  for Comirnaty on behalf of the different E U  m em ber states and certain other countries. E ach E U  m em ber state subm its its own C om irnaty vaccine order to us and is responsible for paym ent pursuant to term s of the supply agreem ents negotiated by the E C . In M ay 2023, we and BioN T ech am ended our contract with the E C  to deliver C O VID -19 vaccines to the E U . The am ended agreem ent includes rephasing of delivery of doses annually through 2026 and an aggregate volum e reduction, providing additional flexibility for those E U  m em ber states who agreed to the am ended agreem ent. The E C  will m aintain access to future adapted C O VID -19 vaccines and the ability to donate doses, in alignm ent with the original agreem ent.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 46,
      "question": "Given BMY's shared liability with AstraZeneca for Onglyza litigation and its financial stake in Farxiga (also an AstraZeneca product), how does this dual exposure to two different AstraZeneca drugs impact BMY's overall pharmaceutical partnership risk profile?",
      "answer": "BMY sold Onglyza to AstraZeneca in 2014 but still shares liability for ongoing litigation related to the drug, including a pending appeal in the Sixth Circuit (page_118). Meanwhile, BMY maintains a financial stake in Farxiga, another AstraZeneca product, through trademark rights documented in the 10-K (page_138). This dual exposure\u2014where BMY retains legal risk for a divested product and holds revenue exposure to a current product\u2014creates a complex risk profile in its partnership with AstraZeneca. The litigation risk from Onglyza could negatively impact BMY\u2019s financials, while its stake in Farxiga introduces revenue dependency on a product it does not fully control, highlighting a strategic tension in BMY\u2019s historical and ongoing collaboration with AstraZeneca.",
      "reasoning_steps": [
        "Hop 1: BMY(page_118) \u2192 AstraZeneca: BMY shares liability with AstraZeneca for Onglyza litigation despite selling the drug in 2014, with a pending appeal in the Sixth Circuit.",
        "Hop 2: AstraZeneca \u2192 Farxiga: Farxiga is explicitly identified as a trademark of AstraZeneca AB in the 10-K filing.",
        "Hop 3: Farxiga \u2190 BMY(page_138): BMY holds a financial stake in Farxiga through its trademark rights as referenced in the 10-K."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Produces]-> PRODUCT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "AstraZeneca",
        "node_3": "Farxiga",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_118",
          "chunk_id": "chunk_1",
          "chunk_text": "## Onglyza*\n\nBMS\t and\t AstraZeneca\t are\t co-defendants\t in\t product\t liability\t litigation\t related\t to Onglyza* .\t Plaintiffs\t assert\t claims, including\tclaims\tfor\twrongful\tdeath,\tas\ta\tresult\tof\theart\tfailure\tor\tother\tcardiovascular\tinjuries\tthey\tallege\twere\tcaused\tby their\t use\t of Onglyza* .\t In\t February\t 2018,\t the\t Judicial\t Panel\t on\t Multidistrict\t Litigation\t ordered\t all\t the\t federal Onglyza* cases\tto\tbe\ttransferred\tto\tan\tMDL\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tEastern\tDistrict\tof\tKentucky.\tA\tsignificant\tmajority\tof the\t claims\t were\t pending\t in\t the\t MDL,\t with\t others\t pending\t in\t a\t coordinated\t proceeding\t in\t California\t Superior\t Court\t in\t San Francisco\t(\"JCCP\").\tThe\tJCCP\tcourt\tgranted\tsummary\tjudgment\tto\tdefendants\tin\tMarch\t2022,\ta\tdecision\twhich\twas\taffirmed\tby\tthe California\tCourt\tof\tAppeal.\tThe\tCalifornia\tSupreme\tCourt\tdeclined\tto\treview\tthe\tdecision\tin\tJuly\t2023.\tIn\tthe\tMDL,\tthe\tcourt granted\t defendants'\t motion\t to\t exclude\t plaintiffs'\t only\t general\t causation\t expert\t on\t January\t 5,\t 2022\t and\t granted\t summary judgment\ton\tAugust\t2,\t2022.\tPlaintiffs\tfiled\ttheir\tNotice\tof\tAppeal\ton\tDecember\t2,\t2022.\tThe\tappeal\tremains\tpending\tin\tthe Sixth\tCircuit.\tAs\tpart\tof\tBMS's\tglobal\tdiabetes\tbusiness\tdivestiture,\tBMS\tsold Onglyza* to\tAstraZeneca\tin\tFebruary\t2014\tand any\tpotential\tliability\twith\trespect\tto Onglyza* is\texpected\tto\tbe\tshared\twith\tAstraZeneca.\n\n## SECURITIES\tLITIGATION\n\n## Celgene\tSecurities\tLitigations\n\nBeginning\t in\t March\t 2018,\t two\t putative\t class\t actions\t were\t filed\t against\t Celgene\t and\t certain\t of\t its\t officers\t in\t the\t U.S. District\t Court\t for\t the\t District\t of\t New\t Jersey\t (the\t \"Celgene\t Securities\t Class\t Action\").\t The\t complaints\t allege\t that\t the defendants\tviolated\tfederal\tsecurities\tlaws\tby\tmaking\tmisstatements\tand/or\tomissions\tconcerning\t(1)\ttrials\tof\tGED-0301,\t(2) Celgene's\t2020\toutlook\tand\tprojected\tsales\tof Otezla* ,\tand\t(3)\tthe\tNDA\tfor Zeposia .\tThe\tCourt\tconsolidated\tthe\ttwo\tactions and\tappointed\ta\tlead\tplaintiff,\tlead\tcounsel,\tand\tco-liaison\tcounsel\tfor\tthe\tputative\tclass.\tIn\tFebruary\t2019,\tthe\tdefendants filed\ta\tmotion\tto\tdismiss\tplaintiffs'\tamended\tcomplaint\tin\tfull.\tIn\tDecember\t2019,\tthe\tCourt\tdenied\tthe\tmotion\tto\tdismiss\tin part\tand\tgranted\tthe\tmotion\tto\tdismiss\tin\tpart\t(including\tall\tclaims\tarising\tfrom\talleged\tmisstatements\tregarding\tGED-0301). Although\tthe\tCourt\tgave\tthe\tplaintiff\tleave\tto\tre-plead\tthe\tdismissed\tclaims,\tit\telected\tnot\tto\tdo\tso,\tand\tthe\tdismissed claims\t are\t now\t dismissed\t with\t prejudice.\t In\t November\t 2020,\t the\t Court\t granted\t class\t certification\t with\t respect\t to\t the remaining\tclaims.\tIn\tMarch\t2023,\tthe\tCourt\tgranted\tthe\tdefendants\tleave\tto\tfile\ta\tmotion\tfor\tsummary\tjudgment,\tthe\tbriefing for\twhich\twas\tcompleted\tin\tJune\t2023.\tOn\tSeptember\t8,\t2023,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants'\tmotion for\t summary\t judgment\t as\t to\t the\t claims\t regarding\t statements\t made\t by\t the\t remaining\t officer\t defendants.\t As\t to\t the\t claims regarding\t Celgene's\t corporate\t statements,\t the\t Court\t denied\t the\t defendants'\t motion\t without\t prejudice\t and\t granted\t the defendants\tleave\tto\tre-raise\tthe\tissue.\tOn\tOctober\t27,\t2023,\tthe\tdefendants\tfiled\ta\tmotion\tfor\tpartial\tsummary\tjudgment\tas\tto Celgene's\tcorporate\tstatements.\n\nIn\tApril\t2020,\tcertain\tSchwab\tmanagement\tinvestment\tcompanies\ton\tbehalf\tof\tcertain\tSchwab\tfunds\tfiled\tan\tindividual\taction\tin the\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe\tsame\tallegations\tas\tthe\tCelgene\tSecurities\tClass Action\t against\t the\t same\t remaining\t defendants\t in\t that\t action\t (the\t \"Schwab\t Action\").\t In\t July\t 2020,\t the\t defendants\t filed\t a motion\tto\tdismiss\tthe\tplaintiffs'\tcomplaint\tin\tfull.\tIn\tMarch\t2021,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants' motion\tto\tdismiss\tconsistent\twith\tits\tdecision\tin\tthe\tCelgene\tSecurities\tClass\tAction.\n\nThe\t California\t Public\t Employees'\t Retirement\t System\t in\t April\t 2021\t (the\t \"CalPERS\t Action\");\t DFA\t Investment\t Dimensions\t Group Inc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds;\tand\tAmerican\tCentury\tMutual\tFunds,\tInc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds,\tin\tJuly 2021\t(respectively\tthe\t\"DFA\tAction\"\tand\tthe\t\"American\tCentury\tAction\"),\tand\tGIC\tPrivate\tLimited\tin\tSeptember\t2021\t(the\t\"GIC Action\"),\tfiled\tseparate\tindividual\tactions\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe same\t allegations\t as\t the\t Celgene\t Securities\t Class\t Action\t and\t the\t Schwab\t individual\t action\t against\t the\t same\t remaining defendants\t in\t those\t actions.\t In\t October\t 2021,\t these\t actions\t were\t consolidated\t for\t pre-trial\t proceedings\t with\t the\t Schwab Action.\tThe\tCourt\talso\tconsolidated\tany\tfuture\tdirect\tactions\traising\tcommon\tquestions\tof\tlaw\tand\tfact\twith\tthe\tSchwab\tAction (the\t \"Consolidated\t Schwab\t Action\").\t On\t October\t 2,\t 2023,\t defendants\t filed\t a\t motion\t for\t partial\t summary\t judgment\t in\t the Consolidated\tSchwab\tAction.\n\nNo\ttrial\tdates\thave\tbeen\tscheduled\tin\tany\tof\tthe\tabove\tCelgene\tSecurities\tLitigations.\n\n## Contingent\tValue\tRights\tLitigations\n\nIn\tJune\t2021,\tan\taction\twas\tfiled\tagainst\tBMS\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tSouthern\tDistrict\tof\tNew\tYork\tasserting claims\t of\t alleged\t breaches\t of\t a\t Contingent\t Value\t Rights\t Agreement\t (\"CVR\t Agreement\")\t entered\t into\t in\t connection\t with\t the closing\tof\tBMS's\tacquisition\tof\tCelgene\tCorporation\tin\tNovember\t2019.\tAn\tentity\tclaiming\tto\tbe\tthe\tsuccessor\ttrustee\tunder the\tCVR\tAgreement\talleges\tthat\tBMS\tbreached\tthe\tCVR\tAgreement\tby\tallegedly\tfailing\tto\tuse\t\"diligent\tefforts\"\tto\tobtain\tFDA approval\t of\t liso-cel\t ( Breyanzi )\t before\t a\t contractual\t milestone\t date,\t thereby\t allegedly\t avoiding\t a\t $6.4\t billion\t potential obligation\t to\t holders\t of\t the\t contingent\t value\t rights\t governed\t by\t the\t CVR\t Agreement\t and\t by\t allegedly\t failing\t to\t permit inspection\tof\trecords\tin\tresponse\tto\ta\trequest\tby\tthe\talleged\tsuccessor\ttrustee.\tThe\tplaintiff\tseeks\tdamages\tin\tan\tamount\tto be\tdetermined\tat\ttrial\tand\tother\trelief,\tincluding\tinterest\tand\tattorneys'\tfees.\tBMS\tdisputes\tthe\tallegations.\tBMS\tfiled\ta motion\tto\tdismiss\tthe\talleged\tsuccessor\ttrustee's\tcomplaint\tfor\tfailure\tto\tstate\ta\tclaim\tupon\twhich\trelief\tcan\tbe\tgranted, which\twas\tdenied\ton\tJune\t24,\t2022.\tOn\tFebruary\t2,\t2024,\tBMS\tfiled\ta\tmotion\tto\tdismiss\tthe\tcomplaint\tfor\tlack\tof\tsubject matter\tjurisdiction.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "AstraZeneca",
          "name": "AstraZeneca",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Farxiga",
          "name": "Farxiga",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 47,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene relate to the commercialization of BLINCYTO in China, and what does this imply about Amgen's strategic approach to oncology market expansion in the region?",
      "answer": "Amgen's $2.8 billion equity investment in BeiGene was part of a strategic collaboration aimed at expanding Amgen's oncology presence in China. As part of this arrangement, BeiGene began selling BLINCYTO in China in 2021, with Amgen sharing profits and losses equally during the initial commercialization period. BLINCYTO, an anti-CD19 x anti-CD3 BiTE molecule, represents a key oncology asset being leveraged through this partnership to penetrate the Chinese market. This approach reflects Amgen's broader strategy to utilize local partnerships for market access and shared risk in oncology development and commercialization.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_28) \u2192 [BeiGene]: Amgen invested $2.8 billion for a 20.5% stake in BeiGene to expand its oncology presence in China, with BeiGene commercializing BLINCYTO starting in 2021.",
        "Hop 2: [BeiGene] \u2192 [BLINCYTO]: BeiGene began selling BLINCYTO in China in 2021 under the collaboration agreement, sharing profits and losses with Amgen during the initial commercialization phase.",
        "Hop 3: [BLINCYTO] \u2190 [AMGN](page_26): BLINCYTO is described as an anti-CD19 x anti-CD3 BiTE molecule being investigated for adult patients with Ph-negative B-Cell precursor ALL, indicating its strategic importance in Amgen's oncology pipeline."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "BeiGene",
        "node_3": "BLINCYTO",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BeiGene",
          "name": "BeiGene",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_3",
          "chunk_text": "\nFor each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.\n\n## 8. Collaborations\n\nA collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.\n\nFrom time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or  product  candidates.  These  collaborations  generally  provide  for  nonrefundable  upfront  license  fees,  development  and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary  of  significant  accounting  policies,  for  additional  discussion  of  revenues  recognized  under  these  types  of  arrangements. Operating  expenses  for  costs  incurred  pursuant  to  these  arrangements  are  reported  in  their  respective  expense  line  items  in  the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand  our  oncology  presence  in  China.  For  additional  information  regarding  our  equity  investment  in  BeiGene,  see  Note  9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "BLINCYTO",
          "name": "BLINCYTO",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_1",
          "chunk_text": "## BLINCYTO\n\nBLINCYTO is an anti-CD19 x anti-CD3 BiTE molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor ALL. \u00ae\n\n## Efavaleukin alfa\n\nEfavaleukin alfa is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus and ulcerative colitis.\n\n## EVENITY\n\nEVENITY  is  a  monoclonal  antibody  that  inhibits  the  action  of  sclerostin.  It  is  being  evaluated  as  a  treatment  for  male osteoporosis. EVENITY is being developed in collaboration with UCB.\n\n## KYPROLIS\n\nKYPROLIS  is  a  small  molecule  proteasome  inhibitor.  It  is  being  investigated  for  weekly  dosing  in  combinations  with lenalidomide and dexamethasone for relapsed multiple myeloma.\n\nIn December 2021, we announced that the FDA had approved the expansion of the KYPROLIS prescribing information to include its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.\n\n## LUMAKRAS/LUMYKRAS\n\nLUMAKRAS is a KRAS G12C small  molecule  inhibitor.  It  is  being  investigated  as  treatment  for  a  variety  of  solid  tumors, including NSCLC, colorectal cancer and other solid tumor cancers.\n\nIn May 2021, we announced that the FDA had approved LUMAKRAS for the treatment of adult patients with KRAS G12Cmutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.\n\nIn November 2021, we announced that the EMA's CHMP had adopted a positive opinion and recommended conditional marketing authorization  of  LUMYKRAS,  known  as  LUMAKRAS  in  the  United  States,  for  the  treatment  of  adults  with  advanced  NSCLC with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.\n\nIn January 2022, we announced that the EC had granted conditional marketing authorization for LUMYKRAS for the treatment of adults with advanced NSCLC with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. We also  announced  that  LUMAKRAS  had  been  approved  in  Japan  for  the  treatment  of  KRAS  G12C-mutated  positive,  unresectable, advanced and/or recurrent NSCLC that has progressed after systemic anticancer therapy.\n\n## Nplate\n\nNplate is a TPO-RA. It is being investigated for the treatment of CIT.\n\n## Olpasiran\n\nOlpasiran is an siRNA that lowers lipoprotein(a), also known as Lp(a). It is being investigated in phase 2 for the treatment of atherosclerotic CV disease.\n\n## Ordesekimab\n\nOrdesekimab is a monoclonal antibody that inhibits the action of IL-15. It is being investigated for the treatment of celiac disease and is being developed in collaboration with Provention Bio, Inc.\n\n## Otezla\n\nOtezla  is  a  small  molecule  that  inhibits  PDE4.  It  is  being  investigated  in  phase  3  studies  for  the  treatment  of  patients  with moderate-to-severe genital psoriasis. It is being investigated in a phase 2 study for treatment of palmoplantar pustulosis.\n\nIn February 2021, we announced the submission of an sNDA to the FDA for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 48,
      "question": "Given Alimta's importance in Lilly's oncology portfolio, how does the company's reliance on patent protection for revenue stability align with the anticipated rapid revenue decline from Alimta following the loss of its patent exclusivity in the U.S. and other key markets?",
      "answer": "Lilly highlights Alimta as a key oncology product used in multiple treatment regimens for lung cancer and mesothelioma, underscoring its therapeutic significance. However, the company explicitly states that Alimta has recently lost or will soon lose significant patent protection in the U.S. and other key jurisdictions, which is expected to result in rapid and severe revenue declines due to generic competition. This creates a direct tension with Lilly's broader statement that its revenues, cash flows, and earnings depend heavily on products with intellectual property protection. The loss of exclusivity for Alimta, therefore, not only threatens the product\u2019s contribution to the oncology segment but also directly impacts Lilly\u2019s consolidated financial performance, revealing a critical vulnerability in the company\u2019s revenue model despite its strategic emphasis on patent-dependent innovation.",
      "reasoning_steps": [
        "Hop 1: LLY(page_5) \u2192 Alimta: Alimta is introduced as a core oncology product with multiple indications, including first-line and maintenance treatments for non-small cell lung cancer and malignant pleural mesothelioma.",
        "Hop 2: Alimta \u2192 Patent Protection: The loss of patent exclusivity for Alimta is cited as a key risk, with the company expecting rapid and severe revenue declines due to generic competition in the U.S. and other key jurisdictions.",
        "Hop 3: Patent Protection \u2190 LLY(page_25): The company emphasizes its dependence on intellectual property protection for most of its revenues and warns that the loss of such protection has already resulted and will continue to result in significant revenue declines."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Negatively_Impacts]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Alimta",
        "node_3": "Patent Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_1",
          "chunk_text": "## Part I\n\n## Item 1. Business\n\nEli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment-human pharmaceutical products.\n\nOur purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines.\n\nWe manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and 7 other countries. Our products are sold in approximately 120 countries.\n\n## Products\n\nOur products include:\n\n## Diabetes products , including:\n\n- Basaglar , in collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes. \u00ae\n- Humalog , Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 , insulin lispro, insulin lispro protamine , and insulin lispro mix 75/25, human insulin analogs for the treatment of diabetes. \u00ae\n- Humulin , Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 , human insulins of recombinant DNA origin for the treatment of diabetes. \u00ae\n- Jardiance , in collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; and to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults with heart failure and reduced ejection fraction. \u00ae\n- Trajenta , in collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes. \u00ae\n- Trulicit y , for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. \u00ae\n\n## Oncology products , including:\n\n- Alimta , for the first-line treatment, in combination with two other agents, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations; for the first-line treatment, in combination with another agent, of advanced non-squamous NSCLC; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent for the treatment of malignant pleural mesothelioma. \u00ae\n- Cyramza , for use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic NSCLC; in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor mutations. \u00ae\n- Erbitux , indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers. \u00ae",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Alimta",
          "name": "Alimta",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 49,
      "question": "How does the risk profile associated with Fast Track designations, as outlined in the regulatory challenges section, impact the valuation of PR006, one of the gene therapies acquired from Prevail with a Fast Track designation, given the time-sensitive regulatory approval conditions tied to the CVR payment?",
      "answer": "The risk profile associated with Fast Track designations, which includes uncertainties in regulatory approval and the high failure rate of drug candidates, directly impacts the valuation of PR006. As outlined in the regulatory challenges section, even with Fast Track designation, continued approval may be contingent on confirmatory Phase III trials, and failure can occur at any stage. PR006, acquired as part of the Prevail acquisition, is subject to a CVR that only pays out if regulatory approval occurs by December 31, 2024. This creates a time-sensitive risk, as any delay beyond that date reduces the CVR value, and the expiration of the CVR by December 1, 2028, without payment would result in no additional value. Therefore, the Fast Track designation, while beneficial, does not guarantee regulatory success or financial return, especially under the time-bound CVR structure.",
      "reasoning_steps": [
        "Hop 1: LLY(page_43) \u2192 Fast Track Designation: Discloses the regulatory framework and inherent risks associated with Fast Track designation, including the potential for failure at any stage and the need for confirmatory trials.",
        "Hop 2: Fast Track Designation \u2192 PR006: PR006 is one of the gene therapies acquired from Prevail that received Fast Track designation from the FDA, as noted in the acquisition overview.",
        "Hop 3: PR006 \u2190 LLY(page_70): PR006 is part of the Prevail acquisition, which includes a CVR structure contingent on regulatory approval by December 31, 2024, with financial implications tied to the timing of approval."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Receives]-> PRODUCT <-[Acquires]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Fast Track Designation",
        "node_3": "PR006",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_2",
          "chunk_text": "\nIn\tcollaboration\twith\tBoehringer\tIngelheim. (1)\n\nIn\tcollaboration\twith\tAlmirall,\tS.A.\tin\tEurope. (3)\n\nFast\tTrack\tdesignation\tis\tdesigned\tto\tfacilitate\tthe\tdevelopment\tand\texpedite\tthe\treview\tof\tmedicines\tto\ttreat\tserious\tconditions\tand\tfill\tan unmet\tmedical\tneed. (2)\n\nBreakthrough\tTherapy\tdesignation\tis\tdesigned\tto\texpedite\tthe\tdevelopment\tand\treview\tof\tpotential\tmedicines\tthat\tare\tintended\tto\ttreat\ta\tserious condition\twhere\tpreliminary\tclinical\tevidence\tindicates\tthat\tthe\ttreatment\tmay\tdemonstrate\tsubstantial\timprovement\tover\tavailable\ttherapy\ton\ta clinically\tsignificant\tendpoint. (4)\n\nContinued\tapproval\tmay\tbe\tcontingent\ton\tverification\tand\tdescription\tof\tclinical\tbenefit\tin\tconfirmatory\tPhase\tIII\ttrials. (5)\n\nThere\tare\tmany\tdifficulties\tand\tuncertainties\tinherent\tin\tpharmaceutical\tresearch\tand\tdevelopment,\tthe\tintroduction\tof\tnew products\tand\tindications,\tbusiness\tdevelopment\tactivities\tto\tenhance\tor\trefine\tor\tproduct\tpipeline,\tand\tcommercialization\tof our\tproducts.\tThere\tis\ta\thigh\trate\tof\tfailure\tinherent\tin\tdrug\tdiscovery\tand\tdevelopment.\tTo\tbring\ta\tproduct\tfrom\tthe discovery\tphase\tto\tmarket\ttakes\tconsiderable\ttime\tand\tentails\tsignificant\tcost.\tFailure\tcan\toccur\tat\tany\tpoint\tin\tthe process,\tincluding\tin\tlater\tstages\tafter\tsubstantial\tinvestment.\tAs\ta\tresult,\tmost\tfunds\tinvested\tin\tresearch\tand\tdevelopment programs\twill\tnot\tgenerate\tfinancial\treturns.\tNew\tproduct\tcandidates\tthat\tappear\tpromising\tin\tdevelopment\tor\tprior\tto\tbeing acquired\tmay\tfail\tto\treach\tthe\tmarket\tor\tmay\thave\tonly\tlimited\tcommercial\tsuccess\tbecause\tof\tefficacy\tor\tsafety\tconcerns, inability\tto\tobtain\tor\tmaintain\tnecessary\tregulatory\tapprovals\tor\tpayer\treimbursement\tor\tcoverage,\tfailure\tto\tobtain placement\ton\tguidelines\tor\trecommendations\tpublished\tby\tthird-party\torganizations\tthat\tare\tcommensurate\twith\tclinical\tdata, the\tapplication\tof\tpricing\tcontrols,\tlimited\tscope\tof\tapproved\tuses,\tlabel\tchanges,\tchanges\tin\tthe\trelevant\ttreatment standards\tor\tthe\tavailability\tof\tnewer,\tbetter,\tor\tmore\tcost-effective\tcompetitive\tproducts,\tdifficulty\tor\texcessive\tcosts\tto manufacture,\tinsufficient\tinfrastructure\tto\tsupport\tdetection,\tdiagnostic\tor\tother\trequisites\tfor\ttreatment,\tineffectiveness in\treaching\thealthcare\tprofessionals,\tincluding\tdigitally\tgiven\tthe\tincrease\tin\tvirtual\tengagements,\tor\tinfringement\tof\tthe patents\tor\tintellectual\tproperty\trights\tof\tothers.\tWe\tmay\talso\tfail\tto\tallocate\tresearch\tand\tdevelopment\tresources efficiently,\tfail\tto\tpursue\tor\tinvest\tsufficiently\tin\tproduct\tcandidates\tor\tindications\tthat\tmay\thave\tbeen\tsuccessful,\tor fail\tto\toptimally\tbalance\ttrial\tdesign,\tconduct,\tand\tspeed\tto\taccomplish\tdesired\toutcomes.\tRegulatory\tagencies\testablish\thigh hurdles\tfor\tthe\tefficacy\tand\tsafety\tof\tnew\tproducts\tand\tindications.\tDelay,\tuncertainty,\tunpredictability,\tand\tinconsistency in\tdrug\tapproval\tprocesses\tacross\tmarkets\tand\tagencies\tcan\tresult\tin\tdelays\tin\tproduct\tlaunches,\tlost\tmarket\topportunities, impairment\tof\tinventories,\tand\tother\tnegative\timpacts.\tIn\taddition,\tit\tcan\tbe\tvery\tdifficult\tto\tpredict\trevenue\tgrowth\trates of,\tor\tvariability\tin\tdemand\tfor,\tnew\tproducts\tand\tindications\twhich\tin\tsome\tcases\tleads\tto\tdifficulty\tmeeting\tproduct\tdemand or,\ton\tthe\tother\thand,\texcess\tinventory\tand\trelated\tfinancial\tcharges.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "PR006",
          "name": "PR006",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Acquires"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 50,
      "question": "How does the decline in Bridion sales following EU market exclusivity loss in 2023 impact MRK's overall revenue concentration risk, particularly given the company's reliance on a small set of key products like Keytruda and Gardasil that accounted for 56% of total sales in 2023?",
      "answer": "The loss of market exclusivity for Bridion in the EU in 2023 led to a substantial decline in its sales, which directly affects MRK's revenue stability. This decline occurs against the backdrop of MRK's heavy dependence on a small set of key products\u2014primarily Keytruda and Gardasil/Gardasil 9\u2014which together accounted for 56% of total sales in 2023. As Bridion was identified as one of the key products contributing to profits and cash flows, its weakening performance exacerbates the company's exposure to revenue volatility. This situation highlights the broader risk that the loss of exclusivity for any of its leading products could have a material adverse effect on MRK\u2019s financial condition and results of operations, especially in the absence of a robust pipeline to replace declining revenues.",
      "reasoning_steps": [
        "Hop 1: MRK(page_4) \u2192 Bridion: Bridion is introduced as a key product in the Hospital Acute Care segment, indicating its importance to MRK\u2019s pharmaceutical portfolio.",
        "Hop 2: Bridion \u2192 Key Products: Bridion is explicitly listed among the key products that contribute significantly to MRK\u2019s profits and cash flows, and its EU market exclusivity loss in 2023 is noted to have caused a substantial sales decline.",
        "Hop 3: Key Products \u2190 MRK(page_28): The company's dependence on key products is emphasized, noting that in 2023, Keytruda and Gardasil/Gardasil 9 alone represented 56% of total sales, and any adverse event affecting these products could materially impact financial performance."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Bridion",
        "node_3": "Key Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n## Pharmaceutical\n\nThe\t Pharmaceutical\t segment\t includes\t human\t health\t pharmaceutical\t and\t vaccine\t products.\t Human\t health\t pharmaceutical\t products consist\tof\ttherapeutic\tand\tpreventive\tagents,\tgenerally\tsold\tby\tprescription,\tfor\tthe\ttreatment\tof\thuman\tdisorders.\tHuman\thealth\tvaccine products\tconsist\tof\tpreventive\tpediatric,\tadolescent\tand\tadult\tvaccines.\tCertain\tof\tthe\tproducts\twithin\tthe\tCompany's\tfranchises\tare\tas follows:\n\n## Oncology\n\nKeytruda is\t an\t anti-PD-1\t (programmed\t death\t receptor-1)\t therapy\t that\t has\t been\t approved\t as\t monotherapy\t for\t the\t treatment\t of certain\tpatients\twith\tcervical\tcancer,\tclassical\tHodgkin\tlymphoma,\tcutaneous\tsquamous\tcell\tcarcinoma,\tesophageal\tor\tgastroesophageal junction\t (GEJ)\t carcinoma,\t head\t and\t neck\t squamous\t cell\t carcinoma\t (HNSCC),\t hepatocellular\t carcinoma\t (HCC),\t melanoma,\t Merkel\t cell carcinoma,\t microsatellite\t instability-high\t (MSI-H)\t or\t mismatch\t repair\t deficient\t (dMMR)\t solid\t tumors\t (including\t MSI-H/dMMR\t colorectal cancer\t and\t endometrial\t carcinoma),\t non-small-cell\t lung\t cancer\t (NSCLC),\t primary\t mediastinal\t large\t B-cell\t lymphoma\t (PMBCL),\t tumor mutational\t burden-high\t (TMB-H)\t solid\t tumors,\t and\t urothelial\t cancer\t including\t non-muscle\t invasive\t bladder\t cancer. Keytruda is\t also approved\tas\tmonotherapy\tfor\tthe\tadjuvant\ttreatment\tof\tcertain\tpatients\twith\tmelanoma,\tand\tfor\tcertain\tpatients\twith\trenal\tcell\tcarcinoma (RCC)\tpost-surgery. Keytruda is\tapproved\tfor\tadjuvant\ttreatment\tfollowing\tresection\tand\tplatinum-based\tchemotherapy\tfor\tcertain\tpatients with\tNSCLC.\tAdditionally, Keytruda is\tapproved\tfor\tpatients\twith\tcertain\ttypes\tof\tresectable\tNSCLC\tin\tcombination\twith\tchemotherapy\tas neoadjuvant\ttreatment,\tand\tthen\tcontinued\tas\ta\tsingle\tagent\tas\tadjuvant\ttreatment\tafter\tsurgery. Keytruda is\talso\tapproved\tfor\tpatients with\t high-risk\t early\t stage\t triple-negative\t breast\t cancer\t (TNBC)\t in\t combination\t with\t chemotherapy\t as\t neoadjuvant\t treatment,\t and\t then continued\tas\ta\tsingle\tagent\tas\tadjuvant\ttreatment\tafter\tsurgery.\tIn\taddition, Keytruda is\tapproved\tin\tcombination\twith\tchemotherapy\tfor the\ttreatment\tof\tcertain\tpatients\twith\tadvanced\tNSCLC,\tin\tcombination\twith\tchemotherapy\tfor\tcertain\ttypes\tof\tadvanced\tbiliary\ttract cancer,\tin\tcombination\twith\tchemotherapy\twith\tor\twithout\tbevacizumab\tfor\tadvanced\tcervical\tcancer,\tin\tcombination\twith\tchemotherapy\tfor advanced\tesophageal\tcancer,\tin\tcombination\twith\ttrastuzumab\tand\tchemotherapy\tfor\tcertain\tpatients\twith\tadvanced\thuman\tepidermal\tgrowth factor\treceptor\t2\t(HER2)-positive\tgastric\tor\tGEJ\tadenocarcinoma\twith\tPD-L1\t(CPS\t\u22651)\tand\tin\tcombination\twith\tchemotherapy\tfor\tadvanced HER2-negative\tgastric\tor\tGEJ\tadenocarcinoma,\tin\tcombination\twith\tchemotherapy\tfor\tHNSCC,\tin\tcombination\twith\tchemotherapy\tfor\tadvanced TNBC,\tin\tcombination\twith\taxitinib\tfor\tadvanced\tRCC,\tin\tcombination\twith\tLenvima\t(lenvatinib)\tfor\tpatients\twith\tadvanced\tRCC\tor\tcertain types\t of\t advanced\t endometrial\t carcinoma,\t and\t in\t combination\t with\t enfortumab\t vedotin\t for\t adult\t patients\t with\t locally\t advanced\t or metastatic\turothelial\tcancer. Welireg (belzutifan)\tis\ta\tmedication\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tcertain\tvon\tHippel-Lindau disease-associated\ttumors\tand\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tadvanced\tRCC\tfollowing\ta\tPD-1\tor\tprogrammed\tdeath-ligand\t1\t(PDL1)\tinhibitor\tand\ta\tvascular\tendothelial\tgrowth\tfactor\ttyrosine\tkinase\tinhibitor.\tIn\taddition,\tthe\tCompany\trecognizes\talliance\trevenue related\t to\t sales\t of\t Lynparza\t (olaparib),\t an\t oral\t poly\t (ADP-ribose)\t polymerase\t (PARP)\t inhibitor,\t for\t certain\t types\t of\t advanced\t or recurrent\t ovarian,\t early\t or\t metastatic\t breast,\t metastatic\t pancreatic,\t and\t metastatic\t castration-resistant\t prostate\t cancers;\t alliance revenue\trelated\tto\tsales\tof\tLenvima,\tan\toral\treceptor\ttyrosine\tkinase\tinhibitor,\tfor\tcertain\ttypes\tof\tthyroid\tcancer,\tRCC,\tHCC,\tin combination\twith\teverolimus\tfor\tcertain\tpatients\twith\tadvanced\tRCC,\tand\tin\tcombination\twith Keytruda for\tcertain\tpatients\twith\tadvanced endometrial\tcarcinoma\tor\tadvanced\tRCC;\tand\talliance\trevenue\trelated\tto\tReblozyl\t(luspatercept-aamt)\tfor\tthe\ttreatment\tof\tcertain\ttypes of\tanemia.\n\n## Vaccines\n\nGardasil (Human\tPapillomavirus\tQuadrivalent\t[Types\t6,\t11,\t16\tand\t18]\tVaccine,\tRecombinant)/ Gardasil 9\t(Human\tPapillomavirus\t9valent\tVaccine,\tRecombinant),\tvaccines\tto\thelp\tprevent\tcertain\tcancers\tand\tdiseases\tcaused\tby\tcertain\ttypes\tof\thuman\tpapillomavirus (HPV); ProQuad (Measles,\t Mumps,\t Rubella\t and\t Varicella\t Virus\t Vaccine\t Live),\t a\t pediatric\t combination\t vaccine\t to\t help\t protect\t against measles,\tmumps,\trubella\tand\tvaricella; M-M-R II\t(Measles,\tMumps\tand\tRubella\tVirus\tVaccine\tLive),\ta\tvaccine\tto\thelp\tprevent\tmeasles, mumps\tand\trubella; Varivax (Varicella\tVirus\tVaccine\tLive),\ta\tvaccine\tto\thelp\tprevent\tchickenpox\t(varicella); RotaTeq (Rotavirus\tVaccine, Live\tOral,\tPentavalent),\ta\tvaccine\tto\thelp\tprotect\tagainst\trotavirus\tgastroenteritis\tin\tinfants\tand\tchildren; Vaxneuvance (Pneumococcal 15-valent\tConjugate\tVaccine),\ta\tvaccine\tto\thelp\tprevent\tinvasive\tpneumococcal\tdisease\tin\tindividuals\t6\tweeks\tof\tage\tand\tolder; Pneumovax 23\t (pneumococcal\t vaccine\t polyvalent),\t a\t vaccine\t to\t help\t prevent\t pneumococcal\t disease;\t and Vaqta (hepatitis\t A\t vaccine,\t inactivated) indicated\tfor\tthe\tprevention\tof\tdisease\tcaused\tby\thepatitis\tA\tvirus\tin\tpersons\t12\tmonths\tof\tage\tand\tolder.\n\n## Hospital\tAcute\tCare\n\nBridion (sugammadex),\ta\tmedication\tfor\tthe\treversal\tof\ttwo\ttypes\tof\tneuromuscular\tblocking\tagents\tused\tduring\tsurgery; Prevymis (letermovir)\t for\t the\t prophylaxis\t of\t cytomegalovirus\t (CMV)\t infection\t and\t disease,\t or\t of\t CMV\t disease,\t in\t certain\t high\t risk\t adult recipients\tof\tan\tallogeneic\thematopoietic\tstem\tcell\ttransplant\tor\tof\ta\tkidney\ttransplant,\trespectively; Dificid (fidaxomicin)\tfor\tthe treatment\tof C.\tdifficile -associated\tdiarrhea; Zerbaxa (ceftolozane\tand\ttazobactam)\tfor\tinjection,\ta\tcombination\tantibacterial\tand\tbetalactamase\tinhibitor\tfor\tthe\ttreatment\tof\tcertain",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Bridion",
          "name": "Bridion",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 51,
      "question": "What does Merck's different branding and regulatory focus of its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, versus V114 in Japan, reveal about its geographic strategy in adult pneumococcal vaccine markets?",
      "answer": "Merck's decision to brand its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, where it received approvals in July 2021 and December 2021 respectively, and as V114 in Japan, where it is still under regulatory review, indicates a strategy of prioritizing established, high-volume markets first. The U.S. and EU approvals are significant given their size and regulatory influence, while Japan represents a later-stage opportunity. This phased approach suggests Merck is leveraging the vaccine's advanced development status and initial commercial success in major markets before expanding into other regions like Japan, which often requires additional localized data and regulatory processes.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_25) \u2192 [V114]: V114 is listed as an investigational pneumococcal vaccine in the company's development pipeline, specifically under review in Japan.",
        "Hop 2: [V114] \u2192 [Vaxneuvance]: V114 is the same product as Vaxneuvance, which is the branded version used in the U.S. and under priority review for pediatric use.",
        "Hop 3: [Vaxneuvance] \u2190 [MRK](page_9): Vaxneuvance is highlighted in the regulatory approvals section as having been approved in the U.S. (July 2021) and EU (December 2021) for adult immunization against pneumococcal disease."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Branded_As]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "V114",
        "node_3": "Vaxneuvance",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "## Cancer\n\nMK-0482 (2)\n\nNon-Small-Cell Lung\n\nMK-1026 (nemtabrutinib)\n\nHematological Malignancies\n\nMK-1308 (quavonlimab)\n\n(2)\n\nNon-Small-Cell Lung\n\nMK-1308A (quavonlimab+pembrolizumab)\n\nAdvanced Solid Tumors\n\nColorectal\n\nHepatocellular\n\nMelanoma\n\nSmall-Cell-Lung\n\nMK-2140 (zilovertamab vedotin)\n\nBreast\n\nHematological Malignancies\n\nNon-Small-Cell Lung\n\nMK-3475 Keytruda\n\nAdvanced Solid Tumors\n\nMK-4280 (favezelimab) (2)\n\nHematological Malignancies\n\nNon-Small-Cell Lung\n\nMK-4280A (favezelimab+pembrolizumab)\n\nRenal Cell\n\nSmall-Cell Lung\n\n## MK-4830 (2)\n\nNon-Small-Cell Lung\n\nRenal Cell\n\nSmall-Cell Lung\n\nMK-5890 (2)\n\nNon-Small-Cell Lung\n\nSmall-Cell Lung\n\nMK-6440 (ladiratuzumab vedotin) (1)(3)\n\nBreast\n\nEsophageal\n\nGastric\n\nHead and Neck\n\nMelanoma\n\nNon-Small-Cell Lung\n\nProstate\n\nSmall-Cell Lung\n\nMK-6482 Welireg (3)\n\nBiliary\n\nColorectal\n\nHepatocellular\n\nPancreatic\n\nRare cancers\n\nVon Hippel-Lindau Disease-Associated Tumors (EU)\n\n## MK-7119 Tukysa (1)\n\nAdvanced Solid Tumors\n\nBiliary\n\nBladder\n\nCervical Colorectal\n\nEndometrial\n\nGastric\n\nNon-Small-Cell Lung\n\nMK-7339 Lynparza (1)(3)\n\nAdvanced Solid Tumors\n\nMK-7684 (vibostolimab) (2)\n\nMelanoma\n\nMK-7684A (vibostolimab+pembrolizumab)\n\nBiliary\n\nBreast\n\nCervical\n\nEndometrial\n\nEsophageal\n\nHead and Neck\n\nHematological Malignancies\n\nHepatocellular\n\nProstate\n\nMK-7902 Lenvima\n\nBiliary\n\nGlioblastoma\n\nPancreatic\n\nProstate\n\nSmall-Cell Lung\n\nV937\n\nBreast\n\nCutaneous Squamous Cell\n\nHead and Neck\n\nMelanoma\n\nSolid Tumors\n\n## Cardiovascular\n\nMK-2060\n\nChikungunya Virus Vaccine\n\nV184\n\n## HIV-1 Infection\n\nMK-8591B (islatravir+MK-8507) (4)\n\nMK-8591D (islatravir+lenacapavir)\n\nNonalcoholic Steatohepatitis (NASH)\n\nMK-3655\n\nMK-6024\n\n## Overgrowth Syndrome\n\nMK-7075 (miransertib)\n\nPneumococcal Vaccine Adult\n\nV116\n\nPulmonary Arterial Hypertension\n\nMK-5475\n\nSchizophrenia MK-8189\n\nTreatment Resistant Depression\n\nMK-1942\n\n(1)(2)\n\n## Phase 2\n\n(1)(4)\n\n## Phase 3 (Phase 3 entry date)\n\n## Antiviral COVID-19\n\nMK-4482 (molnupiravir) (May 2021) (U.S) (1)(5)\n\n## Cancer\n\nMK-1308A (quavonlimab+pembrolizumab)\n\nRenal Cell (April 2021)\n\nMK-3475 Keytruda\n\nBiliary (September 2019)\n\nCutaneous Squamous Cell (August 2019) (EU)\n\nGastric (May 2015) (EU)\n\nHepatocellular (May 2016) (EU)\n\nMesothelioma (May 2018)\n\nOvarian (December 2018)\n\nProstate (May 2019)\n\nSmall-Cell Lung (May 2017)\n\nMK-3475 (pembrolizumab subcutaneous)\n\nNon-Small-Cell Lung (August 2021)\n\nMK-4280A (favezelimab+pembrolizumab)\n\nColorectal (November 2021)\n\nMK-6482 Welireg (3)\n\nRenal Cell (February 2020)\n\nMK-7119 Tukysa\n\n(1)\n\nBreast (October 2019)\n\nMK-7339 Lynparza (1)(3)\n\nColorectal (August 2020)\n\nNon-Small-Cell Lung (June 2019)\n\nSmall-Cell Lung (December 2020)\n\nMK-7684A (vibostolimab+pembrolizumab)\n\nNon-Small-Cell Lung (April 2021)\n\nMK-7902 Lenvima\n\n(1)(2)\n\nColorectal (April 2021)\n\nEsophageal (July 2021)\n\nGastric (December 2020)\n\nHead and Neck (February 2020)\n\nMelanoma (March 2019)\n\nNon-Small-Cell Lung (March 2019)\n\n## HIV-1 Infection\n\nMK-8591A (doravirine+islatravir) (February 2020) (4)\n\n## HIV-1 Prevention\n\nMK-8591 (islatravir) (February 2021) (4)\n\nPulmonary Arterial Hypertension\n\nMK-7962 (sotatercept) (January 2021)\n\nRespiratory Syncytial Virus\n\nMK-1654 (clesrovimab) (November 2021)\n\n## Under Review\n\nNew Molecular Entities/Vaccines Antiviral COVID-19 MK-4482 (molnupiravir) (EU) Cough MK-7264 (gefapixant) (U.S.) (EU) Pneumococcal Vaccine Adult (1) (6)\n\nV114 (JPN)\n\n## Certain Supplemental Filings\n\n## Cancer\n\nMK-3475 Keytruda\n\n- Adjuvant Treatment of Stage IIB or IIC Melanoma (KEYNOTE-716) (EU)\n\n\u2022 Adjuvent Renal Cell Cancer\n\n(KEYNOTE-564) (JPN)\n\n\u2022 MSI-H or dMMR Endometrial Cancer\n\n(KEYNOTE-158) (U.S.)\n\n- MSI-H or dMMR Six Tumor Basket\n\n(KEYNOTE-158) (EU)\n\n- High-Risk Early-Stage Triple-Negative Breast Cancer\n\n(KEYNOTE-522) (EU) (JPN)\n\n\u2022 Tumor Mutational Burden-High (KEYNOTE-158) (JPN)\n\n- Cervical Cancer (KEYNOTE-826) (EU) (JPN)\n\nMK-7339 Lynparza (1)\n\n\u2022\n\nBRCA\n\n-Mutated HER2-Negative Adjuvant Breast Cancer\n\n(OlympiA) (U.S.) (EU)\n\n- First-Line Metastatic Prostate Cancer\n\n(PROpel) (EU)\n\nMK-7902 Lenvima (1)(2)\n\n\u2022 First-Line Metastatic Hepatocellular Carcinoma\n\n(KEYNOTE-524) (U.S.)\n\n(7)\n\n\u2022 Advanced Unresectable Renal Cell Carcinoma\n\n(KEYNOTE-581) (JPN) (8)\n\n## Footnotes:\n\n- Being developed in a collaboration. (1)\n- Being developed in combination with Keytruda . (2)\n- Being developed as monotherapy and/or in combination with Keytruda. (3)\n- On FDA clinical hold. (4)\n- Available in the U.S. under Emergency Use Authorization. (5)\n- In January 2022, the FDA issued a CRL. Merck is reviewing the CRL and considering next steps. (6)\n- In July 2020, the FDA issued a CRL for Merck's and Eisai's applications. Merck and Eisai intend to submit additional data when available to the FDA. (7)\n- Approved on February 25, 2022. (8)",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "V114",
          "name": "V114",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_21",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nmust file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a 'mutual recognition  procedure'  in  which  an  application  is  made  to  a  single  member  state  and,  if  the  member  state  approves  the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU Member States.\n\nOutside  of  the  U.S.  and  the  EU,  the  Company  submits  marketing  applications  to  national  regulatory  authorities. Examples of such are the Ministry of Health, Labour and Welfare in Japan, the National Medical Products Administration in China, Health Canada, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanat\u00e1ria in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the U.S. or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.\n\n## Research and Development Update\n\nThe Company currently has several candidates under regulatory review in the U.S. and internationally or in late-stage clinical development.\n\nMK-4482, molnupiravir, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults  who  are  at  risk  for  progressing  to  severe  disease.  Merck  is  developing  molnupiravir  in  collaboration  with  Ridgeback Biotherapeutics LP. The FDA granted Emergency Use Authorization (EUA) for molnupiravir in December 2021; as updated in February 2022, to authorize molnupiravir for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. Molnupiravir is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. Molnupiravir has also received conditional marketing authorization in the UK and Special Approval for Emergency in Japan. In November 2021, the EMA issued a positive scientific opinion  for  molnupiravir,  which  is  intended  to  support  national  decision-making  on  the  possible  use  of  molnupiravir  prior  to marketing authorization. In October 2021, the EMA initiated a rolling review for molnupiravir for the treatment of COVID-19 in adults. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review process to facilitate  initiating  the  formal  review  of  the  MAA. Applications  to  other  regulatory  bodies  worldwide  are  underway. Molnupiravir is also being evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy  and  safety  of  molnupiravir  for  the  prevention  of  COVID-19  in  adults  who  reside  with  a  person  with  COVID-19. As previously announced, data from the MOVe-IN clinical trial indicated that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision was made not to proceed to Phase 3.\n\nMK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA. The NDA for gefapixant is based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck's NDA for gefapixant. In the CRL, the FDA requested additional information related to measurement of efficacy. The CRL was not related to the safety of gefapixant. Merck is reviewing the letter and considering next steps. Gefapixant is also under  review  in  the  EU,  although  the  review  period  has  been  extended  pending  the  receipt  of  additional  information  from  the Company.\n\nV114 is an investigational 15-valent pneumococcal conjugate vaccine under review in Japan for use in adults. V114 was approved in the U.S. in 2021 for use in adults where it is marketed as Vaxneuvance . Vaxneuvance is also under priority review by the FDA for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The FDA set a PDUFA date of April 1, 2022. The supplemental BLA is supported by results from Phase 2 and Phase 3 clinical studies in pediatric populations including infants, children, and adolescents.",
          "relationship": "Branded_As"
        },
        "node_3": {
          "id": "Vaxneuvance",
          "name": "Vaxneuvance",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "| Keytruda         | November 2021   | EC approved Keytruda plus Lenvima for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.                                                                                                    |\n|------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Keytruda         | November 2021   | PMDAapproved Keytruda in combination with chemotherapy (5-fluorouracil plus cisplatin) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma.                                                                                                                                                                                     |\n| Keytruda         | December 2021   | FDAapproved Keytruda as a monotherapy for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. The FDAalso expanded the indication for Keytruda as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).                            |\n| Keytruda         | December 2021   | Japan's Ministry of Health, Labor and Welfare (MHLW) approved Keytruda in combination with Lenvima for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy.                                                                                                                                                   |\n| Lynparza (1)     | June 2021       | NMPAapproved Lynparza as monotherapy for the treatment of adult patients with germline or somatic BRCA -mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent (abiraterone, enzalutamide).                                                                                                                |\n| molnupiravir (2) | December 2021   | FDAgranted Emergency Use Authorization (EUA) for molnupiravir to treat mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDAare not accessible or clinically appropriate. |\n| molnupiravir (2) | December 2021   | MHLWgranted molnupiravir Special Approval for Emergency for the treatment of infectious disease caused by SARS-CoV-2.                                                                                                                                                                                                                                                                        |\n| Vaxneuvance      | July 2021       | FDAapproved Vaxneuvance for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.                                                                                                                                                     |\n| Vaxneuvance      | December 2021   | EC approved Vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.                                                                                                                                                                                                            |\n| Verquvo (3)      | January 2021    | FDAapproved Verquvo to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.                                                                                                             |\n| Verquvo (3)      | July 2021       | EC approved Verquvo for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy.                                                                                                                                                                                     |\n| Welireg          | August 2021     | FDAapproved Welireg for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.                                                                                                                                                          |\n",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 52,
      "question": "How does Abbott Laboratories' treatment of 'awards to non-employee directors' under the 2017 Incentive Stock Program reflect the legacy structure and share availability rules established in the 2009 Program, particularly regarding the reuse of unissued or reacquired shares?",
      "answer": "Abbott Laboratories continues to issue awards to non-employee directors as part of the 2017 Incentive Stock Program, which builds upon the structure of the 2009 Program. The 2009 Program allowed for the reuse of shares that were subject to expired, canceled, or forfeited benefits, enabling those shares to be reallocated under the 2017 Program. This reuse mechanism, which includes both unissued shares and treasury shares (excluding restricted stock), ensures continuity in Abbott's equity compensation strategy while maintaining flexibility in share sourcing. The 2009 Program's rules on reacquired shares feeding into the 2017 Program directly support the ongoing availability of shares for awards to non-employee directors, highlighting how Abbott leverages legacy program provisions to sustain current governance incentives.",
      "reasoning_steps": [
        "Hop 1: ABT(page_84) \u2192 Awards to Non-Employee Directors: Discloses that the 2017 Program includes awards to non-employee directors and specifies that available shares may be either authorized but unissued or treasury shares (excluding restricted stock).",
        "Hop 2: Awards to Non-Employee Directors \u2192 2009 Program: The 2009 Program explicitly included awards to non-employee directors and established rules for share reuse when benefits lapsed or were canceled, feeding into the 2017 Program.",
        "Hop 3: 2009 Program \u2190 ABT(page_83): The 2009 Program is introduced with specific provisions allowing the reallocation of unissued or reacquired shares under the 2017 Program, directly influencing current share availability for non-employee director awards."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Contains]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "entities": {
        "start": "ABT",
        "node_2": "Awards to Non-Employee Directors",
        "node_3": "2009 Program",
        "end": "ABT"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "| (ii)   | Abbott Laboratories 2017 Incentive Stock Program . Benefits under the 2017 Programinclude non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non- employee directors, and foreign benefits. The shares that remain available for issuance under the 2017 Programmay be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied fromtreasury shares). If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2017 Programwithout the issuance of shares or payment                                                                                   |\n|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (iii)  | Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees . Eligible employees of participating non-U.S. affiliates of Abbott may participate in this plan.An eligible employee may authorize payroll deductions at the rate of1% to 10% of eligible compensation (in multiples of one percent) subject to a limit of US$12,500 during any purchase cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|        | Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The shares may be either authorized but unissued shares, treasury shares, or shares acquired on the open market. The purchase price is typically 85% of the lower of the fair market value of the shares on the purchase date or on the first day of that purchase cycle.As the number of shares subject to outstanding options is indeterminable, columns (a) and (b) of the above table do not include information on the Employee Stock Purchase Plan. As of December 31, 2024, an aggregate of 7,461,515 common shares were available for future issuance under the Employee Stock Purchase Plan, including shares subject to purchase during the current purchase cycle. |\n|        | In April 2017, the 2009 Employee Stock Purchase Plan for Non-U.S. Employees was amended and restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Awards_to_Non-Employee_Directors",
          "name": "Awards to Non-Employee Directors",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Contains"
        },
        "node_3": {
          "id": "2009_Program",
          "name": "2009 Program",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 53,
      "question": "How does Eli Lilly's emphasis on data protection as a strategic asset align with the specific regulatory exclusivity timelines for Emgality in different territories, particularly considering the variation in data protection expiry dates?",
      "answer": "Eli Lilly highlights the importance of intellectual property and data protection as strategic assets, noting the complexity of predicting market exclusivity due to interactions between patent and regulatory protections. Emgality, as one of the company's neuroscience products, benefits from both compound patents and data protection across multiple territories, with data protection expiry dates ranging from 2028 in major European countries to 2030 in the U.S. This variation in regulatory exclusivity timelines underscores the strategic importance of data protection in maintaining Emgality's market position across regions, aligning with the company's broader emphasis on navigating the uncertainties of exclusivity duration.",
      "reasoning_steps": [
        "Hop 1: LLY(page_11) \u2192 Data Protection: Eli Lilly emphasizes the importance of intellectual property and data protection, noting the difficulty in predicting market exclusivity due to interactions between patent and regulatory protections.",
        "Hop 2: Data Protection \u2192 Emgality: Emgality is subject to data protection with specific expiry dates, including 2030 in the U.S., 2028 in major European countries, and 2029 in Japan.",
        "Hop 3: Emgality \u2190 LLY(page_13): Emgality is a neuroscience product produced by Eli Lilly, with detailed regulatory protection timelines provided in the 10-K filing."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Data Protection",
        "node_3": "Emgality",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Emgality",
          "name": "Emgality",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 54,
      "question": "Given AMGN's exposure to biosimilar competition as a strategic risk, how does the decline in Aranesp sales during 2023 reflect the financial impact of biosimilar substitution, particularly in light of the reported drop in U.S. unit demand?",
      "answer": "The 2023 decline in Aranesp sales, driven by lower U.S. unit demand due to dialysis organizations transitioning to EPOGEN and its biosimilars, directly reflects the financial impact of biosimilar competition outlined in AMGN's risk factors. On page 15, AMGN highlights that biosimilars can significantly erode market share and revenue for its biologics, especially after loss of exclusivity. Page 74 confirms this risk is materializing: Aranesp sales dropped due to biosimilar competition from EPOGEN, with U.S. sales specifically falling as independent and medium-sized dialysis providers shifted to competing products. This aligns with the broader risk that biosimilars will continue to pressure both volume and net selling prices, indicating a clear financial manifestation of the strategic risk outlined earlier.",
      "reasoning_steps": [
        "Hop 1: AMGN (page_15) \u2192 Biosimilars: AMGN identifies biosimilars as a major competitive risk that can reduce both market share and pricing power, citing past examples like Sensipar.",
        "Hop 2: Biosimilars \u2192 Aranesp: EPOGEN and its biosimilars are directly cited as the cause of Aranesp's declining U.S. sales due to provider substitution.",
        "Hop 3: Aranesp \u2190 AMGN (page_74): Aranesp's 2023 sales performance is quantified as being negatively impacted by biosimilar competition, with specific mention of reduced unit demand in the U.S."
      ],
      "difficulty": "hard",
      "idf_score": 6.293872272992934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> PRODUCT -[Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Biosimilars",
        "node_3": "Aranesp",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_1",
          "chunk_text": "Although most of our products are biologics, some are small molecule products, including Otezla, KYPROLIS and LUMAKRAS/LUMYKRAS.\tBecause\tthe\tFDA\tapproval\tprocess\tpermits\tgeneric\tmanufacturers\tto\trely\ton\tthe\tsafety\tand\tefficacy\tdata\tof\tthe innovator\tproduct\trather\tthan\thaving\tto\tconduct\ttheir\town\tcostly\tand\ttime-consuming\tclinical\ttrials,\tgeneric\tmanufacturers\tcan often\tdevelop\tand\tmarket\ttheir\tcompeting\tversions\tof\tour\tsmall\tmolecule\tproducts\tat\tmuch\tlower\tprices.\tFor\texample,\tfollowing loss\tof\texclusivity\tof\tpatents\tdirected\tto\tcinacalcet,\tthe\tactive\tingredient\tin\tour\tsmall\tmolecule\tcalcimimetic\tSensipar,\twe lost\t a\t significant\t share\t of\t the\t market\t and\t corresponding\t revenues\t in\t a\t very\t short\t period\t of\t time.\t See\t Part\t IV-Note\t 20, Contingencies\tand\tcommitments,\tto\tthe\tConsolidated\tFinancial\tStatements.\n\nThe\tintroduction\tof\tnew\tproducts,\tthe\tdevelopment\tof\tnew\tprocesses\tor\ttechnologies\tby\tcompetitors\tor\tthe\temergence\tof\tnew information\tabout\texisting\tproducts\tmay\tresult\tin\t(i)\tincreased\tcompetition\tfor\tour\tmarketed\tproducts,\teven\tfor\tthose\tprotected by\t patents\t and/or\t (ii)\t reductions\t in\t the\t prices\t we\t receive\t from\t selling\t our\t products.\t In\t addition,\t the\t development\t of\t new treatment\toptions\tor\tstandards\tof\tcare\tmay\treduce\tthe\tuse\tof\tour\tproducts\tor\tmay\tlimit\tthe\tutility\tand\tapplication\tof\tongoing clinical\ttrials\tof\tour\tproduct\tcandidates.\t(As\tused\tin\tthis\tdocument,\tthe\tterm clinical\ttrials may\tinclude\tprospective\tclinical trials,\t observational\t studies,\t registries\t and\t other\t studies.)\t See\t Item\t 1A.\t Risk\t FactorsOur\t products\t face\t substantial competition\tand\tour\tproduct\tcandidates\tare\talso\tlikely\tto\tface\tsubstantial\tcompetition and\tItem\t1A.\tRisk\tFactorsWe\tcurrently face\tcompetition\tfrom\tbiosimilars\tand\tgenerics\tand\texpect\tto\tface\tincreasing\tcompetition\tfrom\tbiosimilars\tand\tgenerics\tin\tthe future .",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Biosimilars",
          "name": "Biosimilars",
          "type": "PRODUCT",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe\tdecrease\tin\tglobal\tAranesp\tsales\tfor\t2023\twas\tdriven\tby\tunfavorable\tchanges\tto\tforeign\tcurrency\texchange\trates\tand\tlower net\tselling\tprice.\tU.S.\tAranesp\tsales\tfor\t2023\tdecreased\tdue\tto\tlower\tunit\tdemand\tas\ta\tresult\tof\tindependent\tand\tmedium-sized dialysis\torganizations\ttransitioning\tfrom\tAranesp\tto\tEPOGEN.\n\nThe\t decrease\t in\t global\t Aranesp\t sales\t for\t 2022\t was\t driven\t by\t lower\t net\t selling\t price\t and\t unfavorable\t changes\t to\t foreign currency\texchange\trates,\tpartially\toffset\tby\tfavorable\tchanges\tto\testimated\tsales\tdeductions\tand\tvolume\tgrowth.\n\nWe\texpect\tAranesp\tto\tcontinue\tto\tface\tcompetition\tfrom\tEPOGEN\tand\tits\tbiosimilars,\twhich\twill\timpact\tvolume\tand\tnet\tselling price\tin\tthe\tfuture.\n\n## EVENITY\n\nTotal\tEVENITY\tsales\tby\tgeographic\tregion\twere\tas\tfollows\t(dollar\tamounts\tin\tmillions):\n\n",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Aranesp",
          "name": "Aranesp",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Aranesp\n\nTotal\tAranesp\tsales\tby\tgeographic\tregion\twere\tas\tfollows\t(dollar\tamounts\tin\tmillions):\n\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 55,
      "question": "How does Amgen's strategic emphasis on patient access programs reconcile with the payer-imposed restrictions that have negatively affected Repatha's sales, especially given the competitive landscape for Repatha in the U.S., Europe, and Asia Pacific?",
      "answer": "Amgen emphasizes patient access through initiatives like pricing strategies, co-pay assistance, and biosimilars, particularly in response to increasing payer pressures (page 17). However, despite these efforts, payer-imposed restrictions such as prior authorization requirements and formulary exclusions have significantly limited patient access to Repatha, contributing to prescription abandonment and reduced sales (page 37). This challenge is compounded by the competitive landscape where Repatha faces competition from products like Praluent, Leqvio, Skyrizi, and Humira in key markets (page 15), making it harder for Amgen to maintain market share even with price reductions and rebates. Thus, while Amgen is committed to improving access, the structural and competitive realities in the marketplace continue to constrain Repatha\u2019s commercial performance.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_17) \u2192 Patient Access: Amgen outlines its commitment to patient access through pricing strategies, co-pay assistance, and biosimilars, acknowledging increasing payer pressures and policy changes affecting affordability.",
        "Hop 2: Patient Access \u2192 Repatha: Despite Amgen\u2019s efforts, payer-imposed restrictions such as prior authorization and formulary limitations have negatively impacted Repatha\u2019s usage and sales, with affordability remaining a key barrier.",
        "Hop 3: Repatha \u2190 AMGN(page_15): Repatha operates in a highly competitive environment across the U.S., Europe, and Asia Pacific, facing direct competition from Praluent, Leqvio, Skyrizi, and Humira, which intensifies the challenge of maintaining sales despite access initiatives."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Enables]-> RISK_FACTOR -[Negatively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Patient Access",
        "node_3": "Repatha",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_17",
          "chunk_id": "chunk_1",
          "chunk_text": "ENBREL's profitability in Medicare. In January 2025, CMS announced the next 15 drugs for Medicare price setting that will be applicable beginning on January 1, 2027, which includes Otezla. Also under the IRA, starting on January 1, 2024, Medicare Part D was redesigned to cap beneficiary out-of-pocket costs and, beginning on January 1, 2025, Federal reinsurance will become reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs). Further, the IRA created a mechanism for CMS to collect rebates from manufacturers if price increases outpace inflation. We began to accrue for rebate obligations on October 1, 2022 for Medicare Part D and on January 1, 2023 for Medicare Part B.\n\nOther potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; increasing transparency in drug pricing; using third-party value assessments to determine drug prices; referencing foreign prices; and changes to government rebate programs. For example, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, which excludes biologics. CMS also issued a proposed Medicaid Drug Rebate Program rule that would have required manufacturers to aggregate or 'stack' all rebates, discounts or other price concessions made to separate, unrelated entities across the pharmaceutical supply chain on a given unit of product to determine the 'Best Price,' a metric that is used to determine Medicaid rebates and 340B statutory rates. This proposal was not finalized but remains a policy that could be reconsidered in the future. Further, at the state level, eight states (Colorado, Maine, Maryland, Minnesota, New Hampshire, New Jersey, Oregon and Washington) have enacted laws that establish PDABs to identify drugs that pose affordability challenges, and in four states (Colorado, Maryland, Minnesota and Washington) include authority for the state PDAB to set upper payment limits on certain drugs for in-state patients, payers and providers.\n\nIn  many  countries  other  than  the  United  States,  government-sponsored  healthcare  systems  are  the  primary  payers  for  drugs  and  biologics.  With  increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in rebates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many governments use health technology assessment organizations to judge the added benefit of new treatments over existing ones, metrics which are then used to set reimbursement prices and/or set coverage limits. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that governments will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and revision of its pharmaceutical legislation. Various proposals are under consideration with the EU Council, followed by a negotiation among the EU government to agree to a final law. Full implementation is not expected until 2027 or later. The new legislation, if implemented, will likely have a significant impact on the landscape for access and pricing decisions within EU Member States.\n\nThe dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. G iven the diverse interests  in  play  between  payers,  biopharmaceutical  manufacturers,  policy  makers,  healthcare  providers  and  independent  organizations,  if  and  whether  the  parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:\n\n- investing billions of dollars annually in R&amp;D;\n- pricing our medicines to reflect the value they provide;\n- developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;\n- partnering with payers to share risk and accountability for health outcomes;\n- providing patient support and education programs;\n- helping patients in financial need access our medicines; and\n- working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.\n\nSee  Item  1A.  Risk  FactorsOur  sales  depend  on  coverage  and  reimbursement  from  government  and  commercial  third-party  payers,  and  pricing  and reimbursement pressures have affected, and are likely to continue to affect, our profitability and Item 1A. Risk FactorsGuidelines and recommendations published by various organizations can reduce the use of our products.",
          "relationship": "Enables"
        },
        "node_2": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Repatha",
          "name": "Repatha",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product    | Territory                  | Competitor-marketed product         | Competitors                              |\n|------------|----------------------------|-------------------------------------|------------------------------------------|\n| Prolia (1) | U.S., Europe &Asia Pacific | Bisphosphonates, including generics | Various                                  |\n| ENBREL     | U.S.                       | HUMIRA (2)                          | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | HYRIMOZ                             | SandozGroup AG                           |\n| ENBREL     | U.S.                       | RINVOQ                              | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | Xeljanz                             | Pfizer Inc.                              |\n| ENBREL     | Canada                     | Etanercept biosimilars              | Various                                  |\n| XGEVA (1)  | U.S. &Europe               | Zoledronate generics                | Various                                  |\n| Repatha    | U.S., Europe &Asia Pacific | PRALUENT                            | Regeneron Sanofi                         |\n|            | U.S. &Europe               | LEQVIO                              | Novartis PharmaAG                        |\n|            | U.S. &Europe               | Skyrizi                             | AbbVie Inc.                              |\n|            | U.S. &Europe               | HUMIRA (2)                          | AbbVie Inc.                              |\n| Otezla     | U.S. &Europe               | Tremfya                             | Johnson &Johnson Innovative Medicine (3) |\n| Otezla     | U.S. &Europe               | Taltz                               | Lilly                                    |\n| Otezla     | U.S. &Europe               | Cosentyx                            | Novartis PharmaAG                        |\n| Otezla     | U.S. &Europe               | SOTYKTU                             | Bristol Myers Squibb Company             |\n|            | U.S. &Europe               | Topical products                    | Various                                  |\n|            | U.S.                       | Bisphosphonates, including generics |                                          |\n| EVENITY    | Japan                      | Teribone                            | Various Asahi Kasei Pharma               |\n|            | U.S. &Europe               | DARZALEX                            | Johnson &Johnson Innovative Medicine (3) |\n| KYPROLIS   | U.S. &Europe               | POMALYST/IMNOVID                    | Celgene Corporation (4)                  |\n|            | U.S. &Europe               | REVLIMID (5)                        | Various                                  |\n|            | U.S.                       | VELCADE                             | Takeda Oncology (6)                      |\n| Nplate     | U.S. &Europe               | PROMACTA/REVOLADE                   | Novartis PharmaAG                        |\n| Aranesp    | U.S.                       | PROCRIT (7)                         | Johnson &Johnson Innovative Medicine (3) |\n|            | U.S. &Europe               | Epoetin alfa biosimilars            | Various                                  |\n|            | U.S. &Europe               | BESPONSA                            | Pfizer Inc.                              |\n| BLINCYTO   | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S. &Europe               | Avastin                             | F. Hoffmann-La Roche Ltd. (Roche)        |\n| Vectibix   | U.S.                       | KEYTRUDA                            | Merck&Co., Inc.                          |\n|            | U.S. &Europe               | ERBITUX                             | Lilly                                    |\n|            | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S.                       | DUPIXENT                            | Regeneron Sanofi                         |\n|            | U.S.                       | FASENRA                             | AstraZeneca                              |\n| TEZSPIRE   | U.S.                       | XOLAIR                              | Genentech, Inc. Novartis PharmaAG        |\n|            | U.S.                       | NUCALA                              | GSKplc.                                  |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 56,
      "question": "How does Merck's $375 million milestone payment to Bayer AG in 2020 relate to the sales performance of Adempas, particularly in light of Merck's international sales of Adempas reaching $252 million in 2022?",
      "answer": "Merck's $375 million milestone payment to Bayer AG in 2020 reflects the success of their joint development and commercialization strategy for Adempas, which Merck commercializes internationally. By 2022, Adempas generated $252 million in international sales for Merck, indicating that the product was performing strongly in Merck\u2019s territory. This aligns with the rationale behind the milestone payment, which was tied to sales-based achievements under the collaboration agreement. The international sales figures demonstrate the financial contribution of Adempas to Merck, supporting the decision to make the milestone payment to Bayer.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_103) \u2192 [Bayer AG]: Merck made a $375 million milestone payment to Bayer in 2020 as part of their collaboration agreement tied to the sales performance of Adempas and Verquvo.",
        "Hop 2: [Bayer AG] \u2192 [Adempas]: Bayer developed Adempas and granted Merck the right to commercialize it internationally under the joint development and commercialization strategy.",
        "Hop 3: [Adempas] \u2190 [MRK](page_141): Adempas generated $252 million in international sales for Merck in 2022, reflecting its strong performance in Merck\u2019s marketing territory."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Bayer AG",
        "node_3": "Adempas",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Bayer_AG",
          "name": "Bayer AG",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Adempas",
          "name": "Adempas",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_141",
          "chunk_id": "chunk_2",
          "chunk_text": "| Years Ended December 31                | 2021     | 2021     | 2021     | 2020     | 2020     | 2020     | 2019     | 2019     | 2019     |\n|----------------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|\n|                                        | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    |\n| Pharmaceutical:                        |          |          |          |          |          |          |          |          |          |\n| Oncology                               |          |          |          |          |          |          |          |          |          |\n| Keytruda                               | $ 9,765  | $ 7,421  | $ 17,186 | $ 8,352  | $ 6,028  | $ 14,380 | $ 6,305  | $ 4,779  | $ 11,084 |\n| Alliance revenue - Lynparza (1)        | 515      | 473      | 989      | 417      | 308      | 725      | 269      | 176      | 444      |\n| Alliance revenue - Lenvima (1)         | 417      | 287      | 704      | 359      | 220      | 580      | 239      | 165      | 404      |\n| Vaccines                               |          |          |          |          |          |          |          |          |          |\n| Gardasil/Gardasil 9                    | 1,881    | 3,792    | 5,673    | 1,755    | 2,184    | 3,938    | 1,831    | 1,905    | 3,737    |\n| ProQuad/M-M-R II/Varivax               | 1,629    | 506      | 2,135    | 1,378    | 500      | 1,878    | 1,683    | 592      | 2,275    |\n| Pneumovax 23                           | 547      | 346      | 893      | 727      | 359      | 1,087    | 679      | 247      | 926      |\n| RotaTeq                                | 473      | 334      | 807      | 486      | 311      | 797      | 506      | 284      | 791      |\n| Vaqta                                  | 100      | 79       | 179      | 103      | 67       | 170      | 130      | 108      | 238      |\n| Hospital Acute Care                    |          |          |          |          |          |          |          |          |          |\n| Bridion                                | 762      | 770      | 1,532    | 583      | 615      | 1,198    | 533      | 598      | 1,131    |\n| Prevymis                               | 153      | 218      | 370      | 119      | 162      | 281      | 84       | 81       | 165      |\n| Primaxin                               | 2        | 258      | 259      | 2        | 248      | 251      | 2        | 271      | 273      |\n| Noxafil                                | 60       | 199      | 259      | 42       | 287      | 329      | 282      | 380      | 662      |\n| Cancidas                               | 4        | 208      | 212      | 7        | 207      | 213      | 6        | 242      | 249      |\n| Invanz                                 | (5)      | 207      | 202      | 9        | 202      | 211      | 30       | 233      | 263      |\n| Zerbaxa                                | 4        | (5)      | (1)      | 74       | 56       | 130      | 63       | 58       | 121      |\n| Immunology                             |          |          |          |          |          |          |          |          |          |\n| Simponi                                | -        | 825      | 825      | -        | 838      | 838      | -        | 830      | 830      |\n| Remicade                               | -        | 299      | 299      | -        | 330      | 330      | -        | 411      | 411      |\n| Neuroscience                           |          |          |          |          |          |          |          |          |          |\n| Belsomra                               | 78       | 241      | 318      | 81       | 247      | 327      | 92       | 214      | 306      |\n| Virology                               |          |          |          |          |          |          |          |          |          |\n| Molnupiravir                           | 632      | 320      | 952      | -        | -        | -        | -        | -        | -        |\n| Isentress/Isentress HD                 | 294      | 474      | 769      | 326      | 531      | 857      | 398      | 576      | 975      |\n| Cardiovascular                         |          |          |          |          |          |          |          |          |          |\n| Alliance revenue - Adempas/Verquvo (2) | 312      | 30       | 342      | 259      | 22       | 281      | 194      | 10       | 204      |\n| Adempas                                | -        | 252      | 252      | -        | 220      | 220      | -        | 215      | 215      |\n| Diabetes                               |          |          |          |          |          |          |          |          |          |\n| Januvia                                | 1,404    | 1,920    | 3,324    | 1,470    | 1,836    | 3,306    | 1,724    | 1,758    | 3,482    |\n| Janumet                                | 367      | 1,597    | 1,964    | 477      | 1,494    | 1,971    | 589      | 1,452    | 2,041    |\n| Other pharmaceutical (3)               | 1,007    | 1,302    | 2,310    | 984      | 1,328    | 2,312    | 1,215    | 1,661    | 2,873    |\n| Total Pharmaceutical segment sales     | 20,401   | 22,353   | 42,754   | 18,010   | 18,600   | 36,610   | 16,854   | 17,246   | 34,100   |\n| Animal Health:                         |          |          |          |          |          |          |          |          |          |\n| Livestock                              | 667      | 2,628    | 3,295    | 612      | 2,327    | 2,939    | 582      | 2,201    | 2,784    |\n| Companion Animals                      | 1,091    | 1,182    | 2,273    | 872      | 892      | 1,764    | 724      | 885      | 1,609    |\n| Total Animal Health segment sales      | 1,758    | 3,810    | 5,568    | 1,484    | 3,219    | 4,703    | 1,306    | 3,086    | 4,393    |\n| Other segment sales (4)                | -        | -        | -        | 23       | -        | 23       | 174      | 1        | 175      |\n| Total segment sales                    | 22,159   | 26,163   | 48,322   | 19,517   | 21,819   | 41,336   | 18,334   | 20,333   | 38,668   |\n| Other (5)                              | 266      | 116      | 382      | 71       | 111      | 182      | 86       | 368      | 453      |\n|                                        | $ 22,425 | $ 26,279 | $ 48,704 | $ 19,588 | $ 21,930 | $ 41,518 | $ 18,420 | $ 20,701 | $ 39,121 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 57,
      "question": "How does Amgen's exposure to generic competition risk for KYPROLIS relate to its collaboration and financial arrangements with BeiGene, Ltd., particularly considering Amgen's equity stake and profit-sharing structure in China?",
      "answer": "Amgen highlights KYPROLIS as one of its small molecule products facing significant generic competition risk on page 14, noting that such competition can rapidly erode market share and revenue. On page 132, it is revealed that BeiGene, Ltd. began selling KYPROLIS in China in 2022 under a collaboration where Amgen shares profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen with royalty obligations to BeiGene. Additionally, page 98 shows that Amgen has a long-standing equity stake in BeiGene, with multiple amendments to the Share Purchase Agreement and ongoing collaboration agreements, indicating a strategic and financially intertwined relationship. This suggests that while Amgen seeks to mitigate KYPROLIS's generic risk through geographic expansion via BeiGene, it also shares control and financial upside in the Chinese market, creating a complex trade-off between market access and revenue retention.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_14) \u2192 KYPROLIS: KYPROLIS is identified as a small molecule product vulnerable to generic competition, with Sensipar cited as a precedent where Amgen lost significant market share post-patent expiry.",
        "Hop 2: KYPROLIS \u2192 BeiGene, Ltd.: BeiGene began selling KYPROLIS in China in 2022 under a collaboration with Amgen, sharing profits and losses equally during the initial commercialization period, with potential reversion of rights and royalty obligations.",
        "Hop 3: BeiGene, Ltd. \u2190 AMGN(page_98): Amgen has a substantial equity stake in BeiGene and multiple contractual agreements, including amendments to collaboration and share purchase agreements, indicating a deep strategic and financial relationship."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Sells]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "KYPROLIS",
        "node_3": "BeiGene,Ltd.",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_14",
          "chunk_id": "chunk_1",
          "chunk_text": "Although most of our products are biologics, some are small molecule products, including Otezla, KYPROLIS and LUMAKRAS/LUMYKRAS. Because the FDA approval process permits generic manufacturers to rely on the safety and efficacy data of the innovator product rather than having to conduct their own costly and timeconsuming clinical trials, generic manufacturers can often develop and market their competing versions of our small molecule products at much lower prices. For example, following loss of exclusivity of patents directed to cinacalcet, the active ingredient in our small molecule calcimimetic Sensipar, we lost a significant share of the market and corresponding revenues in a very short period of time.\n\nThe introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in (i) increased competition for our marketed products, even for those protected by patents and/or (ii) reductions in the prices we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical  trials  of  our  product  candidates.  (As  used  in  this  document,  the  term clinical trials may  include  prospective  clinical  trials,  observational  studies, registries and other studies.) See Item 1A. Risk FactorsOur products face substantial competition and our product candidates are also likely to face substantial competition and Item 1A. Risk FactorsWe currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future .",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "KYPROLIS",
          "name": "KYPROLIS",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "## UCB\n\nWe are in a collaboration with UCB for the development and commercialization of EVENITY . Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY  and recognizes product sales in all other territories, including the United States. G lobal development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.\n\nDuring the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $547 million, $396 million and $255 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2024, 2023 and 2022, were not material.\n\n## BeiGene, Ltd.\n\nIn January 2020, we acquired an equity stake in BeiG ene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For  additional  information  regarding  our  equity  investment  in  BeiG ene,  see  Note  10,  Investments.  Under  the  collaboration,  BeiG ene  began  selling  XG EV A  in  2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to BeiG ene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiG ene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiG ene will assume commercialization rights in China for a specified period, and Amgen and BeiG ene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiG ene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene.\n\nDuring the years ended December 31, 2024, 2023 and 2022, net costs recovered from BeiG ene for oncology product candidates were $122 million, $109 million and $199 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2024, 2023 and 2022, product sales from Amgen to BeiG ene under the collaboration were $259 million, $125 million and $64 million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. Profit and loss share expenses related to the initial product-specific commercialization period were not material during the years ended December 31, 2024, 2023 and 2022.\n\n## Kyowa Kirin Co., Ltd.\n\nWe are in a collaboration and licensing agreement with Kyowa Kirin to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.\n\nUnder the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. Kyowa Kirin will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.\n\nWe made an upfront payment of $400 million to Kyowa Kirin that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and Kyowa Kirin share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by Kyowa Kirin will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay Kyowa Kirin significant double-digit royalties on global sales, except in Japan. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from Kyowa Kirin were $166 million, $93 million and $23 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income.\n\n## Other\n\nIn addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts, or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties, or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.",
          "relationship": "Sells"
        },
        "node_3": {
          "id": "BeiGene,Ltd.",
          "name": "BeiGene,Ltd.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_1",
          "chunk_text": "| Exhibit No.   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 10.15         | Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto. (Filed as an exhibit to Form8-Kon December 22, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                    |\n| 10.16         | Third Amended and Restated Credit Agreement, dated as of March 9, 2023, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent. (Filed as an exhibit to Form 8-K on March 9, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| 10.17         | Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited dated May 10, 2002 (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.) |\n| 10.17.1       | Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)                                                                                                                                                                                                                                                                            |\n| 10.18         | LetterAgreement, dated June 25, 2019, by and between Amgen Inc. and UCBCelltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                            |\n| 10.19         | Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                   |\n| 10.19.1       | First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                                                                      |\n| 10.19.2       | Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2023 on April 28, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                   |\n| 10.20         | Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| 10.21         | Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                            |\n| 10.21.1       | Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13Don January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| 10.21.2       | Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form10-Qfor the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| 10.21.3       | Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form8-Kon January 31, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 58,
      "question": "How does Gilead account for its share of Symtuza revenues given that Janssen holds exclusive global commercialization rights and sets the product's price?",
      "answer": "Gilead accounts for its share of Symtuza revenues as Product Sales on its Consolidated Statements of Income, even though Janssen holds exclusive global commercialization rights and sets the product\u2019s price. This revenue recognition occurs in the period when corresponding Symtuza sales by Janssen take place, as the intellectual property license related to Gilead\u2019s compounds is deemed the predominant item tied to the revenue share. Gilead does not directly set the product\u2019s price or control its global distribution but recognizes revenue based on the net selling prices of its compounds, which are components of Symtuza. This approach reflects the structure of the collaboration agreement, where the parties share revenue based on the ratio of the net selling prices of their respective components.",
      "reasoning_steps": [
        "Hop 1: GILD(page_79) \u2192 Janssen: Gilead recognizes its share of Symtuza revenue in the period when Janssen\u2019s sales occur, and this is recorded as Product Sales on the income statement because Gilead supplies the Gilead Compounds.",
        "Hop 2: Janssen \u2192 Symtuza: Janssen has exclusive global commercialization rights for Symtuza, including responsibility for manufacturing, registration, distribution, and pricing decisions.",
        "Hop 3: Symtuza \u2190 GILD(page_78): Symtuza was approved in the U.S. in July 2018 and the EU in September 2017 under a 2014 collaboration agreement amendment, with Gilead retaining intellectual property rights and supply responsibilities for its compounds."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Develops]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Symtuza",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen\t sets\t the\t price\t of\t Symtuza\t and\t the\t parties\t share\t revenue\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the party's\t component(s),\t subject\t to\t certain\t restrictions\t and\t adjustments.\t The\t intellectual\t property\t license\t and\t supply obligations\trelated\tto\tthe\tGilead\tCompounds\tare\taccounted\tfor\tas\ta\tsingle\tperformance\tobligation.\tAs\tthe\tlicense\twas\tdeemed to\tbe\tthe\tpredominant\titem\tto\twhich\tthe\trevenue\tshare\trelates,\twe\trecognize\tour\tshare\tof\tthe\tSymtuza\trevenue\tin\tthe\tperiod when\tthe\tcorresponding\tsales\tof\tSymtuza\tby\tJanssen\toccur.\tWe\trecord\tour\tshare\tof\tthe\tSymtuza\trevenue\tas\tProduct\tsales\ton\tour Consolidated\tStatements\tof\tIncome\tprimarily\tbecause\twe\tsupply\tthe\tGilead\tCompounds\tto\tJanssen\tfor\tSymtuza.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tJanssen may\tterminate\tthe\tagreement\twithout\tcause\ton\ta\tcountry-by-country\tbasis,\tin\twhich\tcase\tGilead\thas\tthe\tright\tto\tbecome\tthe selling\tparty\tfor\tsuch\tcountry(ies)\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10\tyears.\tJanssen may\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Japan\tTobacco\n\nIn\t2005,\tJapan\tTobacco,\tInc.\t('Japan\tTobacco')\tgranted\tus\texclusive\trights\tto\tdevelop\tand\tcommercialize\telvitegravir,\ta novel\t HIV\t integrase\t inhibitor,\t in\t all\t countries\t of\t the\t world,\t excluding\t Japan,\t where\t Japan\t Tobacco\t retained\t such\t rights. Effective\t December\t 2018,\t we\t entered\t into\t an\t agreement\t with\t Japan\t Tobacco\t to\t acquire\t the\t rights\t to\t market\t and\t distribute certain\tproducts\tin\tour\tHIV\tportfolio\tin\tJapan\tand\tto\texpand\tour\trights\tto\tdevelop\tand\tcommercialize\telvitegravir\tto\tinclude Japan.\tWe\tare\tresponsible\tfor\tthe\tmarketing\tof\tthe\tproducts\tas\tof\tJanuary\t1,\t2019.\n\nWe\t are\t responsible\t for\t seeking\t regulatory\t approval\t in\t our\t territories\t and\t are\t required\t to\t use\t diligent\t efforts\t to commercialize\t elvitegravir\t for\t the\t treatment\t of\t HIV\t infection.\t We\t bear\t all\t costs\t and\t expenses\t associated\t with\t such commercialization\tefforts\tand\tpay\ta\troyalty\tto\tJapan\tTobacco\tbased\ton\tour\tproduct\tsales.\tOur\tsales\tof\tthese\tproducts\tare included\tin\tProduct\tsales\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalties\tdue\tto\tJapan\tTobacco\tare\tincluded\tin\tCost\tof goods\tsold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalty\texpenses\trecognized\twere\t$167\tmillion,\t$198\tmillion\tand\t$250 million\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nUnder\tthe\tterms\tof\tthe\t2018\tagreement,\twe\tpaid\tJapan\tTobacco\t$559\tmillion\tin\tcash\tand\trecognized\tan\tintangible\tasset\tof $550\tmillion\treflecting\tthe\testimated\tfair\tvalue\tof\tthe\tmarketing-related\trights\tacquired\tfrom\tJapan\tTobacco.\tThe\tintangible asset\tis\tbeing\tamortized\tover\tnine\tyears,\trepresenting\tthe\tperiod\tover\twhich\tthe\tmajority\tof\tthe\tbenefits\tare\texpected\tto\tbe derived\t from\t the\t applicable\t products\t in\t our\t HIV\t portfolio.\t The\t amortization\t expense\t is\t classified\t as\t selling\t expense\t and recorded\tas\tSelling,\tgeneral\tand\tadministrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including material\tbreach\tby\teither\tparty\tor\texpiry\tof\troyalty\tpayment\tterm.\tWe\tmay\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Everest\n\nIn\tApril\t2019,\tEverest\tMedicines\t('Everest')\tand\tImmunomedics\tentered\tinto\tan\tagreement\tgranting\tEverest\tan\texclusive license\t to\t develop\t and\t commercialize\t Trodelvy\t in\t Greater\t China,\t South\t Korea,\t Singapore,\t Indonesia,\t Philippines,\t Vietnam, Thailand,\tMalaysia\tand\tMongolia\t(the\t'Territories').\tGilead\tsubsequently\tacquired\tImmunomedics\tin\tOctober\t2020\tand\tassumed the\tEverest\tlicense\tand\tsupply\tagreement,\twhich\tprovided\tfor\tcertain\tsales\tmilestones\tand\troyalties\tpayments\tto\tbe\tmade\tto Gilead\tand\twas\trecorded\tas\ta\t$175\tmillion\tfinite-lived\tasset\tas\tpart\tof\tthe\tpurchase\taccounting.\tIn\tthe\tfourth\tquarter\tof 2022,\t we\t reacquired\t all\t development\t and\t commercialization\t rights\t for\t Trodelvy\t from\t Everest\t and\t terminated\t the\t previous agreement.\tUnder\tthe\tterms\tof\tthe\tnew\tagreement,\tGilead\tmade\t$280\tmillion\tin\tupfront\ttermination\tpayments\tto\tEverest,\tof which\t$84\tmillion\twas\tmade\tin\t2022\tand\t$196\tmillion\twas\tmade\tin\t2023.\tIn\taddition,\tEverest\tis\teligible\tto\treceive\tup\tto\t$175 million\tin\tpotential\tadditional\tpayments\tupon\tachievement\tof\tcertain\tregulatory\tand\tcommercial\tmilestones.\tWe\taccounted\tfor the\tnew\tagreement\tas\ta\tcontract\ttermination,\twhich\tincludes\tthe\treacquisition\tof\tcommercial\trights\tand\tthe\tsettlement\tof\tour pre-existing\t relationship\t with\t Everest.\t As\t a\t result,\t we\t recorded\t an\t expense\t of\t $406\t million\t in\t Selling,\t general\t and administrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome\tduring\tthe\tyear\tended\tDecember\t31,\t2022,\twhich\tprimarily represents\tthe\tupfront\tcosts\tand\twrite-off\tof\tthe\tremaining\tvalue\tof\tthe\tpre-existing\tasset\trelated\tto\tthe\tprior\tagreement. Simultaneously,\t we\t recorded\t an\t acquired\t finite-lived\t asset\t with\t a\t fair\t value\t of\t $50\t million\t for\t the\t commercial\t rights reacquired\tfor\tproducts\tapproved\tin\tthe\tTerritories.\n\n## Abingworth\n\nIn\tDecember\t2023,\twe\tentered\tinto\tan\tarrangement\twith\tfunds\tmanaged\tby\tAbingworth\tLLP\t('Abingworth')\tunder\twhich\twe\twill receive\tup\tto\t$210\tmillion\tto\tco-fund\tour\tdevelopment\tcosts\tfor\tTrodelvy\tfor\tnon-small\tcell\tlung\tcancer\tin\t2023\tthrough\t2026. As\t there\t is\t substantive\t transfer\t of\t risk\t to\t the\t financial\t partner,\t the\t development\t funding\t is\t recognized\t by\t us\t as\t an obligation\tto\tperform\tcontractual\tservices.\tIn\t2023,\twe\treceived\t$50\tmillion\tfrom\tAbingworth.\tWe\tare\trecognizing\tthe\tfunding as\ta\treduction\tof\tResearch\tand\tdevelopment\texpenses\tusing\tan\tattribution\tmodel\tover\tthe\tperiod\tof\tthe\trelated\texpenses.\tIf successful,\t upon\t regulatory\t approval\t in\t the\t U.S.\t for\t the\t specified\t indication,\t Abingworth\t will\t be\t eligible\t to\t receive\t an approval-based\tfixed\tmilestone\tpayment\tof\tup\tto\t$84\tmillion\tand\troyalties\tbased\ton\tthe\tapplicable\tnet\tsales.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Develops"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 59,
      "question": "What does Merck disclose about the anticipated patent expiration for MK-1654 in the U.S., and how does this relate to their broader disclosure about patent protections across key global markets?",
      "answer": "Merck discloses that MK-1654 has an anticipated U.S. patent expiration date of 2036. This information is presented in a list of products under review in the U.S. with their respective expected expiration years. Separately, Merck also discloses the existence of a table that includes patent expiration dates for key products across multiple jurisdictions, including the U.S., EU, Japan, and China. While the specific expiration details for MK-1654 in non-U.S. markets are not provided in the referenced sections, the structure of the disclosures indicates that Merck tracks and reports patent protections across several key global markets.",
      "reasoning_steps": [
        "Hop 1: MRK(page_16) \u2192 MK-1654: Merck discloses that MK-1654 has an anticipated U.S. patent expiration in 2036.",
        "Hop 2: MK-1654 \u2192 Patent Law: The anticipated expiration date of MK-1654 is governed by U.S. patent law and regulatory frameworks for biopharmaceuticals.",
        "Hop 3: Patent Law \u2190 MRK(page_15): Merck references a table that includes patent expiration dates for key products across the U.S., EU, Japan, and China, indicating a broader disclosure framework for global patent protections."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "MK-1654",
        "node_3": "Patent Law",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Under Review in the U.S.            |   Currently Anticipated Year of Expiration (in the U.S.) |\n|-------------------------------------|----------------------------------------------------------|\n| MK-1022 (patritum abderuxtecan) (1) |                                                     2035 |\n| MK-1654 (clesrovim ab)              |                                                     2036 |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "MK-1654",
          "name": "MK-1654",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Under Review in the U.S.            |   Currently Anticipated Year of Expiration (in the U.S.) |\n|-------------------------------------|----------------------------------------------------------|\n| MK-1022 (patritum abderuxtecan) (1) |                                                     2035 |\n| MK-1654 (clesrovim ab)              |                                                     2036 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Patent_Law",
          "name": "Patent Law",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nThe table below provides a list of expiration dates, which include any pending PTE and SPC periods where indicated, for the key patent protection in the U.S., the EU, Japan and China for the following marketed products:\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 60,
      "question": "How does the $266 million investment in Common Collective Trusts reported in the pension investments section relate to the $1.3 billion in guaranteed obligations associated with Separate Accounts assets, given that these trusts are used to fund the underlying investments in the Separate Accounts structure?",
      "answer": "CVS reports a $266 million investment in Common Collective Trusts as part of its pension investments on page 166. According to page 151, these Common Collective Trusts are components of Separate Accounts assets, which are used to meet specific pension obligations where contract holders bear the investment risk. On page 177, the company discloses that it guarantees $1.3 billion in minimum contractual obligations tied to these Separate Accounts assets. Therefore, while the contract holders bear the investment risk, the company remains liable if the value of these assets, including those invested in Common Collective Trusts, falls below the guaranteed benefit levels. This creates a contingent liability for CVS tied directly to the performance of these underlying investments.",
      "reasoning_steps": [
        "Hop 1: CVS(page_166) \u2192 Common Collective Trusts: CVS holds $266 million in Common Collective Trusts as part of its pension investments, which are categorized under 'Other investments' and valued at fair value.",
        "Hop 2: Common Collective Trusts \u2192 Separate Accounts Assets: Common Collective Trusts are used as investments within Separate Accounts, which are legally segregated funds where contract holders bear the investment risk and which are used to meet guaranteed pension obligations.",
        "Hop 3: Separate Accounts Assets \u2190 CVS(page_177): CVS guarantees $1.3 billion in minimum contractual obligations tied to these Separate Accounts, meaning the company could be liable if the assets (including those in Common Collective Trusts) fall below required levels to fund guaranteed benefits."
      ],
      "difficulty": "hard",
      "idf_score": 6.293872272992934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST -[Comprises]-> FIN_INST <-[Guarantees]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Common Collective Trusts",
        "node_3": "Separate Accounts Assets",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_2",
          "chunk_text": "| In millions                                       | Level 1   | Level 2   | Level 3   | Total   |\n|---------------------------------------------------|-----------|-----------|-----------|---------|\n| Cash and cash equivalents                         | $ 118     | $ 81      | $ -       | $ 199   |\n| Debt securities:                                  |           |           |           |         |\n| U.S. government securities                        | 575       | 36        | -         | 611     |\n| States, municipalities and political subdivisions | -         | 170       | -         | 170     |\n| U.S. corporate securities                         | -         | 2,006     | -         | 2,006   |\n| Foreign securities                                | -         | 167       | -         | 167     |\n| Residential mortgage-backed securities            | -         | 287       | -         | 287     |\n| Commercial mortgage-backed securities             | -         | 83        | -         | 83      |\n| Other asset-backed securities                     | -         | 133       | -         | 133     |\n| Redeemable preferred securities                   | -         | 5         | -         | 5       |\n| Total debt securities                             | 575       | 2,887     | -         | 3,462   |\n| Equity securities:                                |           |           |           |         |\n| U.S. domestic                                     | 1,046     | -         | -         | 1,046   |\n| International                                     | 537       | -         | -         | 537     |\n| Domestic real estate                              | 15        | -         | -         | 15      |\n| Total equity securities                           | 1,598     | -         | -         | 1,598   |\n| Other investments:                                |           |           |           |         |\n| Real estate                                       | -         | -         | 343       | 343     |\n| Common/collective trusts (1)                      | -         | 266       | -         | 266     |\n| Derivatives                                       | -         | (3)       | -         | (3)     |\n| Total other investments                           | -         | 263       | 343       | 606     |\n| Total pension investments (2)                     | $ 2,291   | $ 3,231   | $ 343     | $ 5,865 |\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Common_Collective_Trusts",
          "name": "Common Collective Trusts",
          "type": "FIN_INST",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_151",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ''Significant Accounting Policies'' for additional information regarding the valuation of cost method investments.\n\n## Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets\n\nSeparate Accounts assets relate to the Company's large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company's other businesses. Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders' equity or cash flows.\n\nSeparate Accounts assets include debt and equity securities. The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 ''Fair Value.'' Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts' interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value ('NAV') per share/unit on the valuation date.",
          "relationship": "Comprises"
        },
        "node_3": {
          "id": "Separate_Accounts_Assets",
          "name": "Separate Accounts Assets",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_177",
          "chunk_id": "chunk_5",
          "chunk_text": "\nThere is not a material difference between premiums on a written basis versus an earned basis.\n\nThe Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company's capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December 31, 2021 or 2020.\n\n## 16. Commitments and Contingencies\n\n## COVID-19\n\nThe COVID-19 pandemic continues to evolve. The Company believes COVID-19's impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic's impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company's knowledge and control. As a result, the impact COVID-19 will have on the Company's businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.\n\n## Guarantees\n\nThe Company has the following significant guarantee arrangements at December 31, 2021:\n\n- ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company's ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank.\n- Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $1.3 billion and $1.4 billion at December 31, 2021 and 2020, respectively. See Note 1 ''Significant Accounting Policies'' for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account's investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would",
          "relationship": "Guarantees"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 61,
      "question": "How does Pfizer's financial dependency on BioNTech for Comirnaty manufacturing compare with its strategic investment and cost-sharing structure for the mRNA shingles vaccine collaboration?",
      "answer": "Pfizer's dependency on BioNTech for Comirnaty manufacturing is reflected in the $33 million in 2023 revenue recorded under contract manufacturing activities performed on behalf of BioNTech, indicating a transactional and operational relationship. In contrast, the mRNA shingles vaccine collaboration represents a deeper strategic partnership where Pfizer paid a total of $225 million upfront (including $75 million in cash and a $150 million equity investment), and agreed to share development costs equally with BioNTech. This reflects a fundamentally different financial structure\u2014one characterized by joint investment, shared risk, and long-term profit-sharing rather than fee-for-service manufacturing. The contrast highlights how Pfizer engages with BioNTech across different modalities: as a contract manufacturer in one context and as a co-developer and commercialization partner in another.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_112) \u2192 [BioNTech]: Pfizer records $33 million in 2023 revenue from Comirnaty-related manufacturing activities performed on behalf of BioNTech, indicating an operational dependency.",
        "Hop 2: [BioNTech] \u2192 [mRNA Shingles Vaccine]: Pfizer entered a collaboration with BioNTech to develop an mRNA-based shingles vaccine, paying $225 million upfront and agreeing to share development costs.",
        "Hop 3: [mRNA Shingles Vaccine] \u2190 [PFE](page_76): Pfizer holds global commercialization rights (excluding certain regions) and will share gross profits with BioNTech from any future product, indicating a strategic and financial partnership."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Commercializes]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "BioNTech",
        "node_3": "mRNA Shingles Vaccine",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "mRNA_Shingles_Vaccine",
          "name": "mRNA Shingles Vaccine",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 62,
      "question": "How does the Fast Track designation for PR006, acquired through the Prevail acquisition, align with Eli Lilly's broader disclosures about the risks and uncertainties associated with regulatory designations and drug development timelines?",
      "answer": "Eli Lilly acquired PR006 as part of the Prevail acquisition in January 2021, which included a $747.4 million upfront payment and a contingent value right (CVR) worth up to $160 million if regulatory approval is achieved by December 31, 2024. PR006, a gene therapy for frontotemporal dementia with GRN mutations, received Fast Track designation from the FDA, a status intended to expedite development and review for serious conditions with unmet medical needs. However, in another section of the 10-K, Lilly highlights the inherent uncertainties in drug development, noting that even promising candidates may fail due to efficacy or safety concerns, regulatory hurdles, or competitive dynamics. This creates a tension between the optimism implied by the Fast Track status and the cautionary tone around regulatory and developmental risks, particularly given the CVR's time-bound nature, which incentivizes rapid regulatory progress despite the acknowledged unpredictability of drug approval timelines.",
      "reasoning_steps": [
        "Hop 1: LLY(page_70) \u2192 PR006: Eli Lilly acquired PR006 through the Prevail acquisition in January 2021, with a purchase structure including a CVR contingent on regulatory approval by December 31, 2024.",
        "Hop 2: PR006 \u2192 Fast Track Designation: PR006 received Fast Track designation from the FDA, indicating its potential to treat a serious condition with unmet medical need.",
        "Hop 3: Fast Track Designation \u2190 LLY(page_43): In a different section, Lilly emphasizes the high failure rate in drug development, regulatory unpredictability, and the risk that even promising candidates may not reach the market or achieve commercial success."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Acquires]-> PRODUCT -[Receives]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "PR006",
        "node_3": "Fast Track Designation",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Acquires"
        },
        "node_2": {
          "id": "PR006",
          "name": "PR006",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_2",
          "chunk_text": "\nIn\tcollaboration\twith\tBoehringer\tIngelheim. (1)\n\nIn\tcollaboration\twith\tAlmirall,\tS.A.\tin\tEurope. (3)\n\nFast\tTrack\tdesignation\tis\tdesigned\tto\tfacilitate\tthe\tdevelopment\tand\texpedite\tthe\treview\tof\tmedicines\tto\ttreat\tserious\tconditions\tand\tfill\tan unmet\tmedical\tneed. (2)\n\nBreakthrough\tTherapy\tdesignation\tis\tdesigned\tto\texpedite\tthe\tdevelopment\tand\treview\tof\tpotential\tmedicines\tthat\tare\tintended\tto\ttreat\ta\tserious condition\twhere\tpreliminary\tclinical\tevidence\tindicates\tthat\tthe\ttreatment\tmay\tdemonstrate\tsubstantial\timprovement\tover\tavailable\ttherapy\ton\ta clinically\tsignificant\tendpoint. (4)\n\nContinued\tapproval\tmay\tbe\tcontingent\ton\tverification\tand\tdescription\tof\tclinical\tbenefit\tin\tconfirmatory\tPhase\tIII\ttrials. (5)\n\nThere\tare\tmany\tdifficulties\tand\tuncertainties\tinherent\tin\tpharmaceutical\tresearch\tand\tdevelopment,\tthe\tintroduction\tof\tnew products\tand\tindications,\tbusiness\tdevelopment\tactivities\tto\tenhance\tor\trefine\tor\tproduct\tpipeline,\tand\tcommercialization\tof our\tproducts.\tThere\tis\ta\thigh\trate\tof\tfailure\tinherent\tin\tdrug\tdiscovery\tand\tdevelopment.\tTo\tbring\ta\tproduct\tfrom\tthe discovery\tphase\tto\tmarket\ttakes\tconsiderable\ttime\tand\tentails\tsignificant\tcost.\tFailure\tcan\toccur\tat\tany\tpoint\tin\tthe process,\tincluding\tin\tlater\tstages\tafter\tsubstantial\tinvestment.\tAs\ta\tresult,\tmost\tfunds\tinvested\tin\tresearch\tand\tdevelopment programs\twill\tnot\tgenerate\tfinancial\treturns.\tNew\tproduct\tcandidates\tthat\tappear\tpromising\tin\tdevelopment\tor\tprior\tto\tbeing acquired\tmay\tfail\tto\treach\tthe\tmarket\tor\tmay\thave\tonly\tlimited\tcommercial\tsuccess\tbecause\tof\tefficacy\tor\tsafety\tconcerns, inability\tto\tobtain\tor\tmaintain\tnecessary\tregulatory\tapprovals\tor\tpayer\treimbursement\tor\tcoverage,\tfailure\tto\tobtain placement\ton\tguidelines\tor\trecommendations\tpublished\tby\tthird-party\torganizations\tthat\tare\tcommensurate\twith\tclinical\tdata, the\tapplication\tof\tpricing\tcontrols,\tlimited\tscope\tof\tapproved\tuses,\tlabel\tchanges,\tchanges\tin\tthe\trelevant\ttreatment standards\tor\tthe\tavailability\tof\tnewer,\tbetter,\tor\tmore\tcost-effective\tcompetitive\tproducts,\tdifficulty\tor\texcessive\tcosts\tto manufacture,\tinsufficient\tinfrastructure\tto\tsupport\tdetection,\tdiagnostic\tor\tother\trequisites\tfor\ttreatment,\tineffectiveness in\treaching\thealthcare\tprofessionals,\tincluding\tdigitally\tgiven\tthe\tincrease\tin\tvirtual\tengagements,\tor\tinfringement\tof\tthe patents\tor\tintellectual\tproperty\trights\tof\tothers.\tWe\tmay\talso\tfail\tto\tallocate\tresearch\tand\tdevelopment\tresources efficiently,\tfail\tto\tpursue\tor\tinvest\tsufficiently\tin\tproduct\tcandidates\tor\tindications\tthat\tmay\thave\tbeen\tsuccessful,\tor fail\tto\toptimally\tbalance\ttrial\tdesign,\tconduct,\tand\tspeed\tto\taccomplish\tdesired\toutcomes.\tRegulatory\tagencies\testablish\thigh hurdles\tfor\tthe\tefficacy\tand\tsafety\tof\tnew\tproducts\tand\tindications.\tDelay,\tuncertainty,\tunpredictability,\tand\tinconsistency in\tdrug\tapproval\tprocesses\tacross\tmarkets\tand\tagencies\tcan\tresult\tin\tdelays\tin\tproduct\tlaunches,\tlost\tmarket\topportunities, impairment\tof\tinventories,\tand\tother\tnegative\timpacts.\tIn\taddition,\tit\tcan\tbe\tvery\tdifficult\tto\tpredict\trevenue\tgrowth\trates of,\tor\tvariability\tin\tdemand\tfor,\tnew\tproducts\tand\tindications\twhich\tin\tsome\tcases\tleads\tto\tdifficulty\tmeeting\tproduct\tdemand or,\ton\tthe\tother\thand,\texcess\tinventory\tand\trelated\tfinancial\tcharges.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 63,
      "question": "How does Amgen's characterization of RINVOQ as a competitive threat align with its legal partnership with AbbVie regarding Humira biosimilars, particularly in light of the alleged market division agreements involving delayed U.S. biosimilar entry?",
      "answer": "Amgen lists RINVOQ as a competitor to its product ENBREL in both the U.S. and Canada (page 16), indicating direct market pressure from AbbVie's product. However, the filing also reveals that AbbVie and Amgen entered into a settlement agreement where Amgen agreed to delay its U.S. market entry with AMGEVITA, its Humira biosimilar, in exchange for alleged exclusivity starting in January 2023 (page 150). This suggests a strategic alignment where Amgen accepted short-term competitive pressure from RINVOQ in exchange for structured market access benefits tied to the Humira biosimilar landscape, as part of a broader set of agreements that included market division terms with AbbVie and other biosimilar developers.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_16) \u2192 RINVOQ: Amgen explicitly identifies RINVOQ as a competitor to ENBREL in the U.S. and Canada, indicating competitive market pressure.",
        "Hop 2: RINVOQ \u2192 AbbVie: RINVOQ is a product owned by AbbVie, as noted in the list of third-party trademarks referenced in the filing (page 7).",
        "Hop 3: AbbVie \u2190 AMGN(page_150): Amgen is named in legal proceedings related to AbbVie\u2019s alleged market division agreements involving delayed U.S. entry of Humira biosimilars, including Amgen\u2019s own AMGEVITA."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Competes_Against]-> PRODUCT -[Produces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "RINVOQ",
        "node_3": "AbbVie",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "node_2": {
          "id": "RINVOQ",
          "name": "RINVOQ",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "AbbVie",
          "name": "AbbVie",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_150",
          "chunk_id": "chunk_1",
          "chunk_text": "2019); Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. (April 9, 2019) (Law Enforcement); Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. (April 16, 2019); Sheet Metal Workers' Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al. (April 19, 2019) (Sheet Metal Workers'); Locals 302 &amp; 612 of The International Union of Operating EngineersEmployers  Construction  Industry  Health  And  Security  Trust  Fund  v.  AbbVie  Inc.,  et  al. (April  25,  2019)  (Construction  Industry); Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc. , et al. (April 30, 2019) (Louisiana Health); and Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al. (May 10, 2019) (Cleveland Bakers) (collectively, Humira Antitrust Class Actions).\n\nIn  each  of  the  Humira Antitrust  Class Actions,  the  plaintiffs  bring  federal  antitrust  claims  along  with  various  state  law  claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully  monopolized  the  alleged  market  for  Humira  and  biosimilars  of  Humira,  including  by  creating  an  allegedly unlawful  so-called  patent  thicket  around  Humira.  In  the  Local  1500,  Sheet  Metal  Workers'  and  Construction  Industry  cases,  the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira biosimilars, including Bioepis, Mylan, Sandoz, Fresenius Kabi USA, LLC (Fresenius), Pfizer Inc. and Momenta Pharmaceuticals,  Inc.,  in  connection  with  the  settlement  of  patent  litigation  relating  to  Humira,  whereby  Amgen  and  the  other defendants that have developed Humira biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA, its Humira biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira biosimilar in that market for five months, beginning in January 2023. In each of the Humira Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney's fees on behalf of a putative class of thirdparty payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira in the United States. Defendants' responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes.\n\nOn August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz and Fresenius. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual  motions),  challenging  the  legal  sufficiency  of  the  plaintiffs'  allegations  to  state  any  claim  for  relief  under  the  law.  On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support  of  the  motion  to  dismiss.  On  June  8,  2020,  the  Illinois  Northern  District  Court  issued  an  order  granting  the  motion  by  the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the FTC and one on behalf  of  20  states,  each  filed  on  October  13,  2020.  On  December  21,  2020,  the  defendants-appellees  filed  their opposition brief. Defendants-appellees amicus briefs, including one by the DoJ, were filed on December 28, 2020. On February 25, 2021, oral argument was held by the U.S. Court of Appeals for the Seventh Circuit on the appeal by plaintiffs-appellants of the lower court's dismissal of the consolidated complaint with prejudice.\n\n## U.S. Tax Litigation\n\nAmgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue\n\nSee Note 6, Income taxes, for discussion of the IRS tax dispute and the Company's petition in the U.S. Tax Court.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 64,
      "question": "How does Amgen's equity stake in BeiGene, Ltd., acquired for $2.8 billion in 2020, influence the commercialization and competitive risk profile of KYPROLIS, especially given that KYPROLIS is a small molecule product vulnerable to generic competition and is already being sold by BeiGene in China under a profit-sharing arrangement?",
      "answer": "Amgen acquired a $2.8 billion equity stake in BeiGene, Ltd. in 2020 to expand its oncology presence in China. As part of the collaboration, BeiGene began selling KYPROLIS in China in 2022, with Amgen and BeiGene sharing profits and losses equally during the initial commercialization period. KYPROLIS, being a small molecule product, is particularly vulnerable to generic competition following patent expiration, as seen with Sensipar, where Amgen lost significant market share and revenue quickly after generic entry. This dual exposure\u2014through both equity investment and joint commercialization\u2014heightens Amgen's risk, as a loss of exclusivity for KYPROLIS could not only erode its own sales but also impact the financial returns from its strategic stake in BeiGene.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_98) \u2192 BeiGene,Ltd.: Amgen made a $2.8 billion equity investment in BeiGene in 2020 as part of a collaboration to expand oncology presence in China.",
        "Hop 2: BeiGene,Ltd. \u2192 KYPROLIS: BeiGene began selling KYPROLIS in China in 2022 under a collaboration where Amgen and BeiGene share profits and losses equally during the initial commercialization period.",
        "Hop 3: KYPROLIS \u2190 AMGN(page_14): KYPROLIS is a small molecule product, making it vulnerable to generic competition post-patent expiration, similar to Sensipar, which led to a rapid loss of market share and revenue."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Sells]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "BeiGene,Ltd.",
        "node_3": "KYPROLIS",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_1",
          "chunk_text": "| Exhibit No.   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 10.15         | Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto. (Filed as an exhibit to Form8-Kon December 22, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                    |\n| 10.16         | Third Amended and Restated Credit Agreement, dated as of March 9, 2023, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent. (Filed as an exhibit to Form 8-K on March 9, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| 10.17         | Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited dated May 10, 2002 (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.) |\n| 10.17.1       | Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)                                                                                                                                                                                                                                                                            |\n| 10.18         | LetterAgreement, dated June 25, 2019, by and between Amgen Inc. and UCBCelltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                            |\n| 10.19         | Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                   |\n| 10.19.1       | First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                                                                      |\n| 10.19.2       | Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2023 on April 28, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                   |\n| 10.20         | Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| 10.21         | Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                            |\n| 10.21.1       | Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13Don January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| 10.21.2       | Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form10-Qfor the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| 10.21.3       | Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form8-Kon January 31, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "BeiGene,Ltd.",
          "name": "BeiGene,Ltd.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "## UCB\n\nWe are in a collaboration with UCB for the development and commercialization of EVENITY . Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY  and recognizes product sales in all other territories, including the United States. G lobal development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.\n\nDuring the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $547 million, $396 million and $255 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2024, 2023 and 2022, were not material.\n\n## BeiGene, Ltd.\n\nIn January 2020, we acquired an equity stake in BeiG ene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For  additional  information  regarding  our  equity  investment  in  BeiG ene,  see  Note  10,  Investments.  Under  the  collaboration,  BeiG ene  began  selling  XG EV A  in  2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to BeiG ene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiG ene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiG ene will assume commercialization rights in China for a specified period, and Amgen and BeiG ene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiG ene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene.\n\nDuring the years ended December 31, 2024, 2023 and 2022, net costs recovered from BeiG ene for oncology product candidates were $122 million, $109 million and $199 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2024, 2023 and 2022, product sales from Amgen to BeiG ene under the collaboration were $259 million, $125 million and $64 million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. Profit and loss share expenses related to the initial product-specific commercialization period were not material during the years ended December 31, 2024, 2023 and 2022.\n\n## Kyowa Kirin Co., Ltd.\n\nWe are in a collaboration and licensing agreement with Kyowa Kirin to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.\n\nUnder the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. Kyowa Kirin will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.\n\nWe made an upfront payment of $400 million to Kyowa Kirin that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and Kyowa Kirin share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by Kyowa Kirin will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay Kyowa Kirin significant double-digit royalties on global sales, except in Japan. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from Kyowa Kirin were $166 million, $93 million and $23 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income.\n\n## Other\n\nIn addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts, or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties, or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.",
          "relationship": "Sells"
        },
        "node_3": {
          "id": "KYPROLIS",
          "name": "KYPROLIS",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_14",
          "chunk_id": "chunk_1",
          "chunk_text": "Although most of our products are biologics, some are small molecule products, including Otezla, KYPROLIS and LUMAKRAS/LUMYKRAS. Because the FDA approval process permits generic manufacturers to rely on the safety and efficacy data of the innovator product rather than having to conduct their own costly and timeconsuming clinical trials, generic manufacturers can often develop and market their competing versions of our small molecule products at much lower prices. For example, following loss of exclusivity of patents directed to cinacalcet, the active ingredient in our small molecule calcimimetic Sensipar, we lost a significant share of the market and corresponding revenues in a very short period of time.\n\nThe introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in (i) increased competition for our marketed products, even for those protected by patents and/or (ii) reductions in the prices we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical  trials  of  our  product  candidates.  (As  used  in  this  document,  the  term clinical trials may  include  prospective  clinical  trials,  observational  studies, registries and other studies.) See Item 1A. Risk FactorsOur products face substantial competition and our product candidates are also likely to face substantial competition and Item 1A. Risk FactorsWe currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future .",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 65,
      "question": "How does the expected loss of market exclusivity for Bridion in the U.S. in 2026 impact Merck's strategic positioning in its key market, given the company's reliance on major products and alliance revenue growth in the U.S. territory?",
      "answer": "The expected loss of market exclusivity for Bridion in the U.S. in 2026 poses a significant risk to Merck's revenue base, especially as Bridion is listed among key products contributing to the company's profits and cash flows. This risk is compounded by the fact that Merck's U.S. operations, a major marketing territory, are central to alliance revenue growth, as evidenced by the 8% growth in alliance revenue in 2023 driven by demand in Bayer's territories and sales of products like Adempas and Verquvo in Merck's own markets. Given that the company's oncology and vaccines portfolios, led by Keytruda and Gardasil/Gardasil 9, already represent 56% of total sales, the anticipated decline in Bridion sales after 2026 could further strain Merck's ability to maintain revenue stability unless offset by new product launches or growth in alliance-derived profits.",
      "reasoning_steps": [
        "Hop 1: MRK(page_4) \u2192 Bridion: Bridion is introduced as a key product in the Hospital Acute Care segment, indicating its importance in Merck's pharmaceutical portfolio.",
        "Hop 2: Bridion \u2192 US: Bridion is expected to lose market exclusivity in the U.S. in 2026, which will likely result in a substantial sales decline due to generic competition.",
        "Hop 3: US \u2190 MRK(page_54): The U.S. is a core part of Merck's operations and marketing territories, with alliance revenue growing by 8% in 2023, highlighting the strategic importance of maintaining strong product sales and partnerships in this region."
      ],
      "difficulty": "hard",
      "idf_score": 5.74456612865888,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Impacted_By]-> GPE <-[Operates_In]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Bridion",
        "node_3": "US",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "GPE",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n## Pharmaceutical\n\nThe\t Pharmaceutical\t segment\t includes\t human\t health\t pharmaceutical\t and\t vaccine\t products.\t Human\t health\t pharmaceutical\t products consist\tof\ttherapeutic\tand\tpreventive\tagents,\tgenerally\tsold\tby\tprescription,\tfor\tthe\ttreatment\tof\thuman\tdisorders.\tHuman\thealth\tvaccine products\tconsist\tof\tpreventive\tpediatric,\tadolescent\tand\tadult\tvaccines.\tCertain\tof\tthe\tproducts\twithin\tthe\tCompany's\tfranchises\tare\tas follows:\n\n## Oncology\n\nKeytruda is\t an\t anti-PD-1\t (programmed\t death\t receptor-1)\t therapy\t that\t has\t been\t approved\t as\t monotherapy\t for\t the\t treatment\t of certain\tpatients\twith\tcervical\tcancer,\tclassical\tHodgkin\tlymphoma,\tcutaneous\tsquamous\tcell\tcarcinoma,\tesophageal\tor\tgastroesophageal junction\t (GEJ)\t carcinoma,\t head\t and\t neck\t squamous\t cell\t carcinoma\t (HNSCC),\t hepatocellular\t carcinoma\t (HCC),\t melanoma,\t Merkel\t cell carcinoma,\t microsatellite\t instability-high\t (MSI-H)\t or\t mismatch\t repair\t deficient\t (dMMR)\t solid\t tumors\t (including\t MSI-H/dMMR\t colorectal cancer\t and\t endometrial\t carcinoma),\t non-small-cell\t lung\t cancer\t (NSCLC),\t primary\t mediastinal\t large\t B-cell\t lymphoma\t (PMBCL),\t tumor mutational\t burden-high\t (TMB-H)\t solid\t tumors,\t and\t urothelial\t cancer\t including\t non-muscle\t invasive\t bladder\t cancer. Keytruda is\t also approved\tas\tmonotherapy\tfor\tthe\tadjuvant\ttreatment\tof\tcertain\tpatients\twith\tmelanoma,\tand\tfor\tcertain\tpatients\twith\trenal\tcell\tcarcinoma (RCC)\tpost-surgery. Keytruda is\tapproved\tfor\tadjuvant\ttreatment\tfollowing\tresection\tand\tplatinum-based\tchemotherapy\tfor\tcertain\tpatients with\tNSCLC.\tAdditionally, Keytruda is\tapproved\tfor\tpatients\twith\tcertain\ttypes\tof\tresectable\tNSCLC\tin\tcombination\twith\tchemotherapy\tas neoadjuvant\ttreatment,\tand\tthen\tcontinued\tas\ta\tsingle\tagent\tas\tadjuvant\ttreatment\tafter\tsurgery. Keytruda is\talso\tapproved\tfor\tpatients with\t high-risk\t early\t stage\t triple-negative\t breast\t cancer\t (TNBC)\t in\t combination\t with\t chemotherapy\t as\t neoadjuvant\t treatment,\t and\t then continued\tas\ta\tsingle\tagent\tas\tadjuvant\ttreatment\tafter\tsurgery.\tIn\taddition, Keytruda is\tapproved\tin\tcombination\twith\tchemotherapy\tfor the\ttreatment\tof\tcertain\tpatients\twith\tadvanced\tNSCLC,\tin\tcombination\twith\tchemotherapy\tfor\tcertain\ttypes\tof\tadvanced\tbiliary\ttract cancer,\tin\tcombination\twith\tchemotherapy\twith\tor\twithout\tbevacizumab\tfor\tadvanced\tcervical\tcancer,\tin\tcombination\twith\tchemotherapy\tfor advanced\tesophageal\tcancer,\tin\tcombination\twith\ttrastuzumab\tand\tchemotherapy\tfor\tcertain\tpatients\twith\tadvanced\thuman\tepidermal\tgrowth factor\treceptor\t2\t(HER2)-positive\tgastric\tor\tGEJ\tadenocarcinoma\twith\tPD-L1\t(CPS\t\u22651)\tand\tin\tcombination\twith\tchemotherapy\tfor\tadvanced HER2-negative\tgastric\tor\tGEJ\tadenocarcinoma,\tin\tcombination\twith\tchemotherapy\tfor\tHNSCC,\tin\tcombination\twith\tchemotherapy\tfor\tadvanced TNBC,\tin\tcombination\twith\taxitinib\tfor\tadvanced\tRCC,\tin\tcombination\twith\tLenvima\t(lenvatinib)\tfor\tpatients\twith\tadvanced\tRCC\tor\tcertain types\t of\t advanced\t endometrial\t carcinoma,\t and\t in\t combination\t with\t enfortumab\t vedotin\t for\t adult\t patients\t with\t locally\t advanced\t or metastatic\turothelial\tcancer. Welireg (belzutifan)\tis\ta\tmedication\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tcertain\tvon\tHippel-Lindau disease-associated\ttumors\tand\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tadvanced\tRCC\tfollowing\ta\tPD-1\tor\tprogrammed\tdeath-ligand\t1\t(PDL1)\tinhibitor\tand\ta\tvascular\tendothelial\tgrowth\tfactor\ttyrosine\tkinase\tinhibitor.\tIn\taddition,\tthe\tCompany\trecognizes\talliance\trevenue related\t to\t sales\t of\t Lynparza\t (olaparib),\t an\t oral\t poly\t (ADP-ribose)\t polymerase\t (PARP)\t inhibitor,\t for\t certain\t types\t of\t advanced\t or recurrent\t ovarian,\t early\t or\t metastatic\t breast,\t metastatic\t pancreatic,\t and\t metastatic\t castration-resistant\t prostate\t cancers;\t alliance revenue\trelated\tto\tsales\tof\tLenvima,\tan\toral\treceptor\ttyrosine\tkinase\tinhibitor,\tfor\tcertain\ttypes\tof\tthyroid\tcancer,\tRCC,\tHCC,\tin combination\twith\teverolimus\tfor\tcertain\tpatients\twith\tadvanced\tRCC,\tand\tin\tcombination\twith Keytruda for\tcertain\tpatients\twith\tadvanced endometrial\tcarcinoma\tor\tadvanced\tRCC;\tand\talliance\trevenue\trelated\tto\tReblozyl\t(luspatercept-aamt)\tfor\tthe\ttreatment\tof\tcertain\ttypes of\tanemia.\n\n## Vaccines\n\nGardasil (Human\tPapillomavirus\tQuadrivalent\t[Types\t6,\t11,\t16\tand\t18]\tVaccine,\tRecombinant)/ Gardasil 9\t(Human\tPapillomavirus\t9valent\tVaccine,\tRecombinant),\tvaccines\tto\thelp\tprevent\tcertain\tcancers\tand\tdiseases\tcaused\tby\tcertain\ttypes\tof\thuman\tpapillomavirus (HPV); ProQuad (Measles,\t Mumps,\t Rubella\t and\t Varicella\t Virus\t Vaccine\t Live),\t a\t pediatric\t combination\t vaccine\t to\t help\t protect\t against measles,\tmumps,\trubella\tand\tvaricella; M-M-R II\t(Measles,\tMumps\tand\tRubella\tVirus\tVaccine\tLive),\ta\tvaccine\tto\thelp\tprevent\tmeasles, mumps\tand\trubella; Varivax (Varicella\tVirus\tVaccine\tLive),\ta\tvaccine\tto\thelp\tprevent\tchickenpox\t(varicella); RotaTeq (Rotavirus\tVaccine, Live\tOral,\tPentavalent),\ta\tvaccine\tto\thelp\tprotect\tagainst\trotavirus\tgastroenteritis\tin\tinfants\tand\tchildren; Vaxneuvance (Pneumococcal 15-valent\tConjugate\tVaccine),\ta\tvaccine\tto\thelp\tprevent\tinvasive\tpneumococcal\tdisease\tin\tindividuals\t6\tweeks\tof\tage\tand\tolder; Pneumovax 23\t (pneumococcal\t vaccine\t polyvalent),\t a\t vaccine\t to\t help\t prevent\t pneumococcal\t disease;\t and Vaqta (hepatitis\t A\t vaccine,\t inactivated) indicated\tfor\tthe\tprevention\tof\tdisease\tcaused\tby\thepatitis\tA\tvirus\tin\tpersons\t12\tmonths\tof\tage\tand\tolder.\n\n## Hospital\tAcute\tCare\n\nBridion (sugammadex),\ta\tmedication\tfor\tthe\treversal\tof\ttwo\ttypes\tof\tneuromuscular\tblocking\tagents\tused\tduring\tsurgery; Prevymis (letermovir)\t for\t the\t prophylaxis\t of\t cytomegalovirus\t (CMV)\t infection\t and\t disease,\t or\t of\t CMV\t disease,\t in\t certain\t high\t risk\t adult recipients\tof\tan\tallogeneic\thematopoietic\tstem\tcell\ttransplant\tor\tof\ta\tkidney\ttransplant,\trespectively; Dificid (fidaxomicin)\tfor\tthe treatment\tof C.\tdifficile -associated\tdiarrhea; Zerbaxa (ceftolozane\tand\ttazobactam)\tfor\tinjection,\ta\tcombination\tantibacterial\tand\tbetalactamase\tinhibitor\tfor\tthe\ttreatment\tof\tcertain",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Bridion",
          "name": "Bridion",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Impacted_By"
        },
        "node_3": {
          "id": "US",
          "name": "US",
          "type": "GPE",
          "idf_score": 4.222304909797168
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance\trevenue\trepresents\tMerck's\tshare\tof\tprofits\tfrom\tsales\tin\tBayer's\tmarketing\tterritories,\twhich\tare\tproduct\tsales\tnet\tof\tcost\tof\tsales\tand\tcommercialization\tcosts\t(see Note\t4\tto\tthe\tconsolidated\tfinancial\tstatements). (1)\n\nAdempas\tand\tVerquvo\tare\tpart\tof\ta\tworldwide\tcollaboration\twith\tBayer\tAG\t(Bayer)\tto\tmarket\tand\tdevelop\tsoluble\tguanylate\tcyclase (sGC)\tmodulators\t(see\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements).\tAdempas\tis\tapproved\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tPAH and\tchronic\tpulmonary\thypertension.\tVerquvo\tis\tapproved\tto\treduce\tthe\trisk\tof\tcardiovascular\tdeath\tand\theart\tfailure\thospitalization following\ta\thospitalization\tfor\theart\tfailure\tor\tneed\tfor\toutpatient\tintravenous\tdiuretics\tin\tadults\twith\tsymptomatic\tchronic\theart failure\tand\treduced\tejection\tfraction.\tVerquvo\twas\tapproved\tin\tthe\tU.S.,\tthe\tEU\tand\tJapan\tin\t2021\tand\thas\tsince\tbeen\tapproved\tin\tseveral other\tmarkets.\tAlliance\trevenue\tfrom\tthe\tcollaboration\tgrew\t8%\tin\t2023\treflecting\thigher\tprofit\tsharing,\twhich\treflects\tincreased\tdemand in\tBayer's\tmarketing\tterritories.\tRevenue\talso\tincludes\tsales\tof\tAdempas\tand\tVerquvo\tin\tMerck's\tmarketing\tterritories.\tSales\tof\tAdempas in\tMerck's\tmarketing\tterritories\tgrew\t7%\tin\t2023\tprimarily\treflecting\thigher\tdemand.\n\n## Virology\n\n",
          "relationship": "Operates_In"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 66,
      "question": "How does Amgen's inclusion of PROCRIT in its trademarked product list relate to its competitive positioning against Aranesp, given the reimbursement challenges described in the context of biosimilar competition?",
      "answer": "Amgen lists PROCRIT as one of its trademarked products, indicating its importance to the company's portfolio. However, in the competitive landscape, Amgen notes that Aranesp competes directly with PROCRIT in supportive cancer care and predialysis settings. Despite this competition, Amgen faces additional pressure as both products contend with biosimilars and increasingly restrictive reimbursement policies that emphasize cost containment and require higher clinical evidence for coverage. This creates a dual challenge where Amgen must defend PROCRIT's market position against Aranesp while also navigating a broader environment of payer scrutiny and biosimilar competition.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_7) \u2192 [PROCRIT]: Amgen lists PROCRIT as one of its trademarked products, indicating its strategic importance to the company's portfolio.",
        "Hop 2: [PROCRIT] \u2192 [Aranesp]: PROCRIT competes with Aranesp in supportive cancer care and predialysis settings, as noted in the competitive landscape section.",
        "Hop 3: [Aranesp] \u2190 [AMGN](page_16): Aranesp is listed as one of Amgen\u2019s products facing biosimilar competition, and the broader reimbursement section highlights increasing payer scrutiny and cost containment pressures affecting all products, including PROCRIT and Aranesp."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Negatively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "PROCRIT",
        "node_3": "Aranesp",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "PROCRIT",
          "name": "PROCRIT",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_3",
          "chunk_text": "\nApproved biosimilars available in Europe and Canada. \u2020\n\nA subsidiary of J&amp;J. (1)\n\nDermatology only. (2)\n\nOther biosimilars under regulatory review in the United States and Europe. (3)\n\nPROCRIT competes with Aranesp in supportive cancer care and predialysis settings. (4)\n\nKYPROLIS is facing increased competition from several recently approved products. (5)\n\nA subsidiary of Takeda. (6)\n\nA subsidiary of BMS. (7)\n\n## Reimbursement\n\nSales  of  our  principal  products  are  dependent  on  the  availability  and  extent  of  coverage  and  reimbursement  from  third-party payers.  In  many  markets  around  the  world,  these  payers,  including  government  health  systems,  private  health  insurers  and  other organizations, remain focused on reducing the cost of healthcare; and their efforts have intensified as a result of rising healthcare costs, economic  pressures  and  broader  challenges  generated  by  the  COVID-19  pandemic.  Drugs  remain  heavily  scrutinized  for  cost containment. As a result, payers are becoming more restrictive regarding the use of biopharmaceutical products and are scrutinizing the prices of these products while requiring a higher level of clinical evidence to support the benefits such products bring to patients and the broader  healthcare  system.  These  pressures  become  intensified  when  our  products  become  subject  to  competition,  including  from biosimilars.",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Aranesp",
          "name": "Aranesp",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 67,
      "question": "Given that BMY completed its acquisition of Celgene in November 2019, how might the ongoing litigation with Molina\u2014initiated in May 2021 over claims related to Thalomid and Revlimid\u2014affect BMY's financial exposure, particularly since these liabilities arose after the acquisition was finalized and are not included in the initial valuation?",
      "answer": "The litigation with Molina, which began in May 2021, centers on claims related to Celgene\u2019s products Thalomid and Revlimid. Since the acquisition of Celgene by BMY was finalized in November 2019, these liabilities arose post-acquisition and would not have been included in the initial fair value assessment of assets and liabilities assumed at the time of the $35.7 billion transaction. As a result, any potential damages or settlements from this litigation would directly impact BMY\u2019s current financial position rather than being absorbed as part of the acquisition accounting. The complaint also references off-label marketing allegations, which could carry significant financial or reputational risks, further exposing BMY to unforeseen costs not accounted for in the original acquisition valuation.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_166) \u2192 [Molina]: BMY (through its subsidiary Celgene) is named in litigation initiated by Molina in May 2021 over claims related to Thalomid and Revlimid, including off-label marketing allegations.",
        "Hop 2: [Molina] \u2192 [Celgene]: Molina sued Celgene and BMS over contractual and marketing-related claims, indicating Celgene's products and practices are central to the litigation.",
        "Hop 3: [Celgene] \u2190 [BMY](page_116): BMY acquired Celgene in November 2019 for $35.7 billion, and the valuation was based on the fair value of assets and liabilities as of that date, excluding post-acquisition liabilities such as the Molina litigation."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> COMP -[Involved_In]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Molina",
        "node_3": "Celgene",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Molina",
          "name": "Molina",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 68,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene to commercialize XGEVA in China align with the competitive pressures facing XGEVA in the U.S. and Europe, and what implications does this have for Amgen's revenue diversification strategy?",
      "answer": "Amgen's $2.8 billion equity investment in BeiGene (page 28) was part of a strategic collaboration to expand its oncology footprint in China, where BeiGene began selling XGEVA in 2020. Under the arrangement, Amgen and BeiGene share profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen (page 121). Meanwhile, XGEVA faces direct competition in the U.S. and Europe from zoledronate generics (page 16), which typically erode branded drug revenues due to lower-cost alternatives entering the market. This suggests Amgen is strategically shifting focus toward growth markets like China to offset declining revenue potential in mature markets due to generic competition. The financial commitment to BeiGene underscores Amgen\u2019s intent to diversify XGEVA\u2019s revenue base geographically, mitigating the impact of competitive pressures in developed markets.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_28) \u2192 [BeiGene]: Amgen invested $2.8 billion for a 20.5% stake in BeiGene to expand oncology presence in China and commercialize XGEVA.",
        "Hop 2: [BeiGene] \u2192 [XGEVA]: BeiGene began selling XGEVA in China in 2020 under a joint profit-sharing and commercialization agreement.",
        "Hop 3: [XGEVA] \u2190 [AMGN](page_16): XGEVA faces competitive threats in the U.S. and Europe from zoledronate generics, which can significantly reduce revenue from the branded product."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "BeiGene",
        "node_3": "XGEVA",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BeiGene",
          "name": "BeiGene",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_3",
          "chunk_text": "\nFor each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.\n\n## 8. Collaborations\n\nA collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.\n\nFrom time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or  product  candidates.  These  collaborations  generally  provide  for  nonrefundable  upfront  license  fees,  development  and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary  of  significant  accounting  policies,  for  additional  discussion  of  revenues  recognized  under  these  types  of  arrangements. Operating  expenses  for  costs  incurred  pursuant  to  these  arrangements  are  reported  in  their  respective  expense  line  items  in  the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand  our  oncology  presence  in  China.  For  additional  information  regarding  our  equity  investment  in  BeiGene,  see  Note  9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "XGEVA",
          "name": "XGEVA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 69,
      "question": "How does LLY reconcile the 2030 biologics data protection expiry with the 2033 compound patent expiry for Emgality in the U.S., especially in light of their broader statements about the uncertainty of market exclusivity duration?",
      "answer": "LLY reports that Emgality, a neuroscience product, benefits from both compound patent protection and biologics data protection in the U.S., with expiry dates of 2033 and 2030 respectively. However, in a separate section discussing the broader context of intellectual property, LLY emphasizes that the duration of market exclusivity is inherently uncertain due to the complex interplay between patent and regulatory exclusivity, as well as potential litigation outcomes. This suggests that while Emgality has defined protection timelines listed, the company acknowledges that these dates may not fully determine the actual market exclusivity period. Therefore, investors and analysts should consider the 2030 and 2033 dates as potential benchmarks, but also factor in LLY\u2019s own caution that these may not guarantee uninterrupted exclusivity or competitive advantage.",
      "reasoning_steps": [
        "Hop 1: LLY(page_13) \u2192 Emgality: Emgality has U.S. biologics data protection expiring in 2030 and compound patent protection expiring in 2033.",
        "Hop 2: Emgality \u2192 Data Protection: Emgality is subject to multiple forms of data protection across different jurisdictions, including biologics data protection and compound patents.",
        "Hop 3: Data Protection \u2190 LLY(page_11): LLY acknowledges that market exclusivity duration is uncertain due to the complex interaction between patent and regulatory protections, and the unpredictability of litigation outcomes."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Emgality",
        "node_3": "Data Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Emgality",
          "name": "Emgality",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 70,
      "question": "What percentage of CVS's total assets at year-end 2022 were represented by investments in Common Collective Trusts, and how does this allocation reflect the role of Separate Accounts in the company's pension investment strategy?",
      "answer": "At year-end 2022, CVS reported $5,087 million in Separate Accounts Assets, which included investments in Common Collective Trusts valued at $266 million. These Common Collective Trusts represented approximately 0.9% of the company\u2019s total assets of $232,999 million. The Separate Accounts Assets are specifically tied to large case pension products, where contract holders bear the investment risk, and the corresponding liability mirrors the asset value. The allocation to Common Collective Trusts, which are classified as Level 2 investments based on NAV per share/unit, indicates a measured exposure to diversified pooled funds while maintaining legal segregation of these assets from other business risks. This aligns with CVS's broader pension investment strategy, which includes $5,865 million in total pension investments, showing a diversified but cautious approach to managing contract holder funds.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_114) \u2192 [Separate Accounts Assets]: Discloses $5,087 million in Separate Accounts Assets as part of total assets, specifically tied to large case pension products.",
        "Hop 2: [Separate Accounts Assets] \u2192 [Common Collective Trusts]: These assets include investments in Common Collective Trusts, which are valued at NAV per share/unit and classified as Level 2 investments.",
        "Hop 3: [Common Collective Trusts] \u2190 [CVS](page_166): Reports $266 million invested in Common Collective Trusts as part of $5,865 million in total pension investments, with details on valuation levels."
      ],
      "difficulty": "hard",
      "idf_score": 6.293872272992934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Comprises]-> FIN_INST <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Separate Accounts Assets",
        "node_3": "Common Collective Trusts",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_114",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                                                                                                                             | At December 31,   | At December 31,   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|\n| In millions, except per share amounts                                                                                                                                                                                       | 2021              | 2020              |\n| Assets:                                                                                                                                                                                                                     |                   |                   |\n| Cash and cash equivalents                                                                                                                                                                                                   | $ 9,408           | $ 7,854           |\n| Investments                                                                                                                                                                                                                 | 3,117             | 3,000             |\n| Accounts receivable, net                                                                                                                                                                                                    | 24,431            | 21,742            |\n| Inventories                                                                                                                                                                                                                 | 17,760            | 18,496            |\n| Other current assets                                                                                                                                                                                                        | 5,292             | 5,277             |\n| Total current assets                                                                                                                                                                                                        | 60,008            | 56,369            |\n| Long-term investments                                                                                                                                                                                                       | 23,025            | 20,812            |\n| Property and equipment, net                                                                                                                                                                                                 | 12,896            | 12,606            |\n| Operating lease right-of-use assets                                                                                                                                                                                         | 19,122            | 20,729            |\n| Goodwill                                                                                                                                                                                                                    | 79,121            | 79,552            |\n| Intangible assets, net                                                                                                                                                                                                      | 29,026            | 31,142            |\n| Separate accounts assets                                                                                                                                                                                                    | 5,087             | 4,881             |\n| Other assets                                                                                                                                                                                                                | 4,714             | 4,624             |\n| Total assets                                                                                                                                                                                                                | $ 232,999         | $ 230,715         |\n| Liabilities:                                                                                                                                                                                                                |                   |                   |\n| Accounts payable                                                                                                                                                                                                            | $ 12,544          | $ 11,138          |\n| Pharmacy claims and discounts payable                                                                                                                                                                                       | 17,330            | 15,795            |\n| Health care costs payable                                                                                                                                                                                                   | 8,808             | 7,936             |\n| Policyholders' funds                                                                                                                                                                                                        | 4,301             | 4,270             |\n| Accrued expenses                                                                                                                                                                                                            | 17,670            | 14,243            |\n| Other insurance liabilities                                                                                                                                                                                                 | 1,303             | 1,557             |\n| Current portion of operating lease liabilities                                                                                                                                                                              | 1,646             | 1,638             |\n| Current portion of long-term debt                                                                                                                                                                                           | 4,205             | 5,440             |\n| Total current liabilities                                                                                                                                                                                                   | 67,807            | 62,017            |\n| Long-term operating lease liabilities                                                                                                                                                                                       | 18,177            | 18,757            |\n| Long-term debt                                                                                                                                                                                                              | 51,971            | 59,207            |\n| Deferred income taxes                                                                                                                                                                                                       | 6,270             | 6,794             |\n| Separate accounts liabilities                                                                                                                                                                                               | 5,087             | 4,881             |\n| Other long-term insurance liabilities                                                                                                                                                                                       | 6,402             | 7,007             |\n| Other long-term liabilities                                                                                                                                                                                                 | 1,904             | 2,351             |\n| Total liabilities                                                                                                                                                                                                           | 157,618           | 161,014           |\n| Commitments and contingencies (Note 16)                                                                                                                                                                                     |                   |                   |\n| Shareholders' equity:                                                                                                                                                                                                       |                   |                   |\n| Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding                                                                                                                                         | -                 | -                 |\n| Common stock, par value $0.01: 3,200 shares authorized; 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and 1,733 shares issued and 1,310 shares outstanding at December 31, 2020 and capital surplus | 47,377            | 46,513            |\n| Treasury stock, at cost: 422 and 423 shares at December 31, 2021 and 2020                                                                                                                                                   | (28,173)          | (28,178)          |\n| Retained earnings                                                                                                                                                                                                           | 54,906            | 49,640            |\n| Accumulated other comprehensive income                                                                                                                                                                                      | 965               | 1,414             |\n| Total CVS Health shareholders' equity                                                                                                                                                                                       | 75,075            | 69,389            |\n| Noncontrolling interests                                                                                                                                                                                                    | 306               | 312               |\n| Total shareholders' equity                                                                                                                                                                                                  | 75,381            | 69,701            |\n| Total liabilities and shareholders' equity                                                                                                                                                                                  | $ 232,999         | $ 230,715         |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Separate_Accounts_Assets",
          "name": "Separate Accounts Assets",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_151",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ''Significant Accounting Policies'' for additional information regarding the valuation of cost method investments.\n\n## Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets\n\nSeparate Accounts assets relate to the Company's large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company's other businesses. Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders' equity or cash flows.\n\nSeparate Accounts assets include debt and equity securities. The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 ''Fair Value.'' Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts' interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value ('NAV') per share/unit on the valuation date.",
          "relationship": "Comprises"
        },
        "node_3": {
          "id": "Common_Collective_Trusts",
          "name": "Common Collective Trusts",
          "type": "FIN_INST",
          "idf_score": 5.320917198465278
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_2",
          "chunk_text": "| In millions                                       | Level 1   | Level 2   | Level 3   | Total   |\n|---------------------------------------------------|-----------|-----------|-----------|---------|\n| Cash and cash equivalents                         | $ 118     | $ 81      | $ -       | $ 199   |\n| Debt securities:                                  |           |           |           |         |\n| U.S. government securities                        | 575       | 36        | -         | 611     |\n| States, municipalities and political subdivisions | -         | 170       | -         | 170     |\n| U.S. corporate securities                         | -         | 2,006     | -         | 2,006   |\n| Foreign securities                                | -         | 167       | -         | 167     |\n| Residential mortgage-backed securities            | -         | 287       | -         | 287     |\n| Commercial mortgage-backed securities             | -         | 83        | -         | 83      |\n| Other asset-backed securities                     | -         | 133       | -         | 133     |\n| Redeemable preferred securities                   | -         | 5         | -         | 5       |\n| Total debt securities                             | 575       | 2,887     | -         | 3,462   |\n| Equity securities:                                |           |           |           |         |\n| U.S. domestic                                     | 1,046     | -         | -         | 1,046   |\n| International                                     | 537       | -         | -         | 537     |\n| Domestic real estate                              | 15        | -         | -         | 15      |\n| Total equity securities                           | 1,598     | -         | -         | 1,598   |\n| Other investments:                                |           |           |           |         |\n| Real estate                                       | -         | -         | 343       | 343     |\n| Common/collective trusts (1)                      | -         | 266       | -         | 266     |\n| Derivatives                                       | -         | (3)       | -         | (3)     |\n| Total other investments                           | -         | 263       | 343       | 606     |\n| Total pension investments (2)                     | $ 2,291   | $ 3,231   | $ 343     | $ 5,865 |\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 71,
      "question": "Given that DaVita accounts for approximately 90% of all EPOGEN sales and is bound by a supply agreement requiring them to purchase at least 90% of their ESA requirements from Amgen through December 2022, how does Amgen's strategic positioning of EPOGEN in its marketed product portfolio align with the risks posed by DaVita's dominant purchasing role and the potential for biosimilar competition post-2022?",
      "answer": "Amgen positions EPOGEN as a key marketed product within its nephrology portfolio, highlighting its historical significance and continued relevance in treating anemia in dialysis patients. However, the company faces a dual risk: first, its reliance on DaVita for nearly 90% of EPOGEN sales creates a concentration risk, especially as the 2017 supply agreement was set to expire in December 2022, introducing uncertainty in continued volume guarantees. Second, the broader risk of biosimilar competition looms over EPOGEN, as noted in the risk factors section, where Amgen acknowledges that the expiration or weakening of exclusivity protections could accelerate market entry of biosimilars. This dual exposure\u2014contractual dependency on a single customer and vulnerability to biosimilars\u2014suggests that while EPOGEN remains strategically important, its future contribution to revenue is increasingly precarious without renewed contractual assurance or competitive differentiation.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_29) \u2192 DaVita: Amgen discloses a supply agreement with DaVita requiring them to purchase at least 90% of their ESA requirements through December 2022.",
        "Hop 2: DaVita \u2192 EPOGEN: DaVita accounts for approximately 90% of all EPOGEN sales, indicating a high degree of revenue concentration tied to this customer relationship.",
        "Hop 3: EPOGEN \u2190 AMGN(page_62): EPOGEN is listed among Amgen\u2019s marketed products, indicating its strategic presence in the nephrology segment despite facing biosimilar and contractual risks."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Purchases]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "DaVita",
        "node_3": "EPOGEN",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_29",
          "chunk_id": "chunk_1",
          "chunk_text": "## DaVita Inc.\n\nIn January 2017, we entered into a six-year supply agreement with DaVita, which superseded the previously existing, seven-year supply agreement that commenced in 2012. Pursuant to the 2017 agreement, we supply EPOGEN and Aranesp in amounts necessary to meet specified annual percentages of DaVita's and its affiliates' requirements for ESAs used in providing dialysis services in the United States and Puerto Rico. Such percentages vary during the term of the agreement, but in each year are at least 90%. The agreement expires  in  December  2022.  The  agreement  may  be  terminated  by  either  party  before  expiration  of  its  term  in  the  event  of  certain breaches of the agreement by the other party.\n\nFor  financial  information  about  our  significant  collaborative  arrangements,  see  Part  IV-Note  8,  Collaborations,  to  the Consolidated Financial Statements.\n\n## Human Capital Resources\n\n## Overview\n\nAmgen's approach to human capital resource management starts with our mission to serve patients. We strive to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. The way we approach our business is guided by our Amgen Values:\n\n",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "DaVita",
          "name": "DaVita",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_46",
          "chunk_id": "chunk_1",
          "chunk_text": "products receive data exclusivity. In late 2019, the previous Administration agreed to remove from the United States-Mexico-Canada Agreement  a  requirement  for  at  least  10  years  of  data  exclusivity  for  biologic  products.  Also,  the  FDA  is  considering  whether subsequent changes to a licensed biologic would be protected by the remainder of the reference product's original 12-year exclusivity period (a concept known in the generic drug context as 'umbrella exclusivity'). If the FDA were to decide that umbrella exclusivity does  not  apply  to  biological  reference  products  or  were  to  make  other  changes  to  the  exclusivity  period,  this  could  expose  us  to biosimilar competition at an earlier time. There also have been, and may continue to be, legislative and regulatory efforts to promote competition  through  policies  enabling  easier  generic  and  biosimilar  approval  and  commercialization,  including  efforts  to  lower standards for demonstrating biosimilarity or interchangeability, limit patents that may be litigated and/or patent settlements, implement preferential  reimbursement  policies  for  biosimilars  and  pass  new  laws  requiring  more  disclosure  in  the  FDA's  Orange  and  Purple Books. For example, in 2021 the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offered  training  to  help  identify  prior  art,  and  seeking  USPTO's  views  on  practices  that  extend  market  exclusivities,  whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents.\n\nUpon the expiration or loss of patent protection and/or applicable exclusivity for one of our small molecule products, we can lose the majority of revenues for that product in a very short period of time. See Item 1. Business-Marketing, Distribution and Selected Marketed Products-Competition. Additionally, if one of our small molecule products is the subject of an FDA Written Request for pediatric studies and we are unable to adequately complete these studies, we may not obtain the pediatric exclusivity award that extends existing patents and unexpired regulatory exclusivity for the product by an additional six months.\n\nWhile we are unable to predict the precise effects of biosimilars and generics on our products, we are currently facing and expect to face greater competition in the United States, Europe and elsewhere as a result of biosimilar and generic competition and, in turn, downward pressure on our product prices and sales. This competition has had, and could increasingly have, a material adverse effect on our product sales, business and results of operations. State laws may also have an impact on our business. For example, California is the first  state  to  have passed legislation, effective on January 1, 2020, against 'pay for delay' settlements of patent infringement claims filed by manufacturers of generics or biosimilars where anything of value is given in exchange for settlement. Under this law, such settlement  agreements  are  presumptively  anticompetitive.  The  law  may  result  in  prolonged  litigation  and  fewer  settlements.  Other states, including Connecticut, New York, Illinois and Minnesota, may adopt similar laws or a similar law could be adopted at the federal level.\n\nConcentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.\n\nCertain of our distributors, customers and payers have substantial purchasing leverage, due to the volume of our products they purchase or the number of patient lives for which they provide coverage. The substantial majority of our U.S. product sales is made to three  pharmaceutical  product  wholesaler  distributors:  McKesson  Corporation, AmerisourceBergen  Corporation  and  Cardinal  Health, Inc. These distributors, in turn, sell our products to their customers, which include physicians or their clinics, dialysis centers, hospitals and pharmacies. One of our products, EPOGEN, is sold primarily to free-standing dialysis clinics. DaVita owns or manages a large number of the outpatient dialysis  facilities  located  in  the  United  States  and  accounts  for  approximately  90%  of  all  EPOGEN sales. Similarly, as discussed above, there has been significant consolidation in the health insurance industry, including that a small number of PBMs  now  oversee  a  substantial  percentage  of  total  covered  lives  in  the  United  States.  See Our  sales  depend  on  coverage  and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely  to  continue  to  affect,  our  profitability. The  three  largest  PBMs  in  the  United  States  are  now  part  of  major  health  insurance providers. The growing concentration of purchasing and negotiating power by these entities has, and may continue to, put pressure on our pricing due to their ability to extract price discounts on our products, fees for other services or rebates, negatively affecting our bargaining position, sales and/or profit margins. In addition, decisions by these entities to purchase or cover less or none of our products in favor of competing products could have a material adverse effect on our product sales, business and results of operations due to their purchasing  volume.  Further,  if  one  of  our  significant  wholesale  distributors  encounters  financial  or  other  difficulties  and  becomes unable or unwilling to pay us all amounts that such distributor owes us on a timely basis, or at all, it could negatively affect our business and results of operations. In addition, if one of our significant wholesale distributors becomes insolvent or otherwise unable to continue its commercial relationship with us in its present form, it could significantly disrupt our business and adversely affect our product sales, our business and results of operations unless suitable alternatives are timely found or lost sales are absorbed by another distributor.\n\n## RISKS RELATED TO RESEARCH AND DEVELOPMENT\n\nWe may not be able to develop commercial products despite significant investments in R&amp;D.\n\nAmgen invests heavily in R&amp;D. Successful product development in the biotechnology industry is highly uncertain, and very few R&amp;D projects yield approved and commercially viable products. Product candidates, including biosimilar product",
          "relationship": "Purchases"
        },
        "node_3": {
          "id": "EPOGEN",
          "name": "EPOGEN",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_1",
          "chunk_text": "## Overview\n\nAmgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.\n\nOur  principal  products  are  ENBREL,  Prolia,  Otezla,  XGEVA,  Neulasta, Aranesp,  Repatha,  KYPROLIS  and  Nplate.  We  also market  a  number  of  other  products,  including  MVASI,  Vectibix,  KANJINTI,  EVENITY,  EPOGEN,  BLINCYTO,  AMGEVITA, Aimovig, Parsabiv, NEUPOGEN, LUMAKRAS/LUMYKRAS, Sensipar/Mimpara and TEZSPIRE. For additional information about our products, see Part I, Item 1. Business-Marketing, Distribution and Selected Marketed Products.\n\nOur strategy includes integrated activities intended to maintain and strengthen our competitive position in the industry. We focus on six commercial areas: inflammation, oncology/hematology, bone health, CV disease, nephrology and neuroscience. And we conduct discovery  research  primarily  in  three  therapeutic  areas:  inflammation,  oncology/hematology  and  general  medicine.  In  2021,  we advanced our innovative pipeline, launched new products, completed several strategic transactions to augment our pipeline and research capabilities,  and  continued  providing  uninterrupted  supplies  of  our  medicines  globally  through  the  second  year  of  the  COVID-19 pandemic. We accomplished these objectives while maintaining a strategic and disciplined approach to capital allocation and while advancing our ESG efforts.\n\nIn 2021, we continued to advance our pipeline, including achieving key regulatory approvals for LUMAKRAS and TEZSPIRE. Our  external  business  development  activities  for  2021  included:  (i)  acquiring  Five  Prime,  including  a  later-stage  gastric  cancer bemarituzumab program; (ii) entering into a license agreement with KKC to develop a later-stage molecule for atopic dermatitis and other diseases; and (iii) acquiring Teneobio for its proprietary technologies and oncology programs in development. We also continued to  advance  our  biosimilar  program  with  the  launch  of  RIABNI  in  the  United  States  and  introduced  our  other  biosimilars  into  new markets. Our biosimilars are expected to continue launching in new markets throughout 2022.\n\nDuring 2021, while meeting the challenges of a global pandemic and facing increased competition from biosimilars and generics, total  product  sales  were  relatively  flat  as  volume  growth  was  offset  by  lower  net  selling  prices.  Product  sales  decreased  4%  in  the United  States,  driven  by  lower  net  selling  prices,  partially  offset  by  volume  growth,  and  increased  12%  ROW,  driven  by  volume growth, partially offset by lower net selling prices. Total operating expenses increased 13%, driven by IPR&amp;D expense from the Five Prime acquisition and the upfront payment associated with the KKC licensing agreement.\n\nCash flows from operating activities totaled $9.3 billion, which supported investment in our business while returning capital to shareholders through the payment of cash dividends and stock repurchases. For 2021, we increased our quarterly cash dividend by 10% to $1.76 per share of common stock. In December 2021, we declared a cash dividend of $1.94 per share of common stock for the first quarter of 2022, an increase of 10% for this period, to be paid in March 2022. We also repurchased 21.7 million shares of our common stock during 2021 at an aggregate cost of $5.0 billion. In 2021, we issued $4.9 billion and repaid $4.2 billion of debt that was coming due in 2022.\n\nAmgen's approach to, and investment in, human capital resource management is directed at attracting, motivating, developing and retaining  talent  to  tackle  the  challenges  of  running  an  enterprise  focused  on  the  discovery,  development  and  commercialization  of innovative  medicines.  Our  compensation,  benefits  and  development  programs  are  designed  to  encourage  performance,  promote accountability and adherence to Company values, and align with the interests of the Company's shareholders. Further, we believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. We are engaging in activities and setting goals to improve our focus on diversity, inclusion and belonging. For further information on these and other efforts, see Part I, Item 1. Business-Human Capital Resources.\n\nWe have a long-standing ambition to be environmentally responsible, and we regularly set targets to challenge ourselves to deliver further improvements. In 2020, we met or exceeded our environmental sustainability targets set out in 2013 that called for reducing fleet carbon output by up to 20%, facility carbon output by 10%, water consumption by 10% and waste disposal by 35%.  We achieved our 2020 targets while growing revenues, increasing production capacity and expanding to approximately 100 countries over the same 2013-20 period. To continue on our path to greater environmental sustainability, in January 2021 we announced a new set of long-term environmental targets to achieve by 2027, including achieving carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%. 2 2, 3\n\nRepresents reductions against established baselines, taking into account only verified reduction projects, and does not take into account changes associated with contraction or expansion of the Company. 2\n\nCarbon neutrality goal refers to Scope 1 and 2. 3",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 72,
      "question": "What does BMY's $650 million up-front payment and up to $2.5 billion in contingent milestone payments to Eisai for MORAb-202 development indicate about its strategic prioritization of oncology, given the drug's inclusion in the global pipeline and co-commercialization scope across multiple high-prevalence cancer indications?",
      "answer": "BMY's significant financial commitment to Eisai, including a $650 million up-front payment and potential milestone payments of up to $2.5 billion, signals a strong strategic emphasis on oncology, particularly in the development of MORAb-202 for high-burden cancers like endometrial, ovarian, lung, and breast. Despite MORAb-202 being in Phase I/II clinical trials, BMY's investment underscores its confidence in the drug's potential and its intent to jointly develop and commercialize the therapy across a broad geographic footprint (U.S., Canada, Europe, Russia, Japan, China, and Asia-Pacific). This aligns with BMY\u2019s broader licensing and collaboration strategy highlighted elsewhere in the 10-K, which includes prioritizing global oncology innovation through partnerships, as seen with Eisai and other collaborators like Agenus and Prothena.",
      "reasoning_steps": [
        "Hop 1: BMY(page_116) \u2192 Eisai: BMY paid a $650 million up-front fee and committed to up to $2.5 billion in contingent milestone payments for a global strategic collaboration with Eisai focused on MORAb-202.",
        "Hop 2: Eisai \u2192 MORAb-202: Eisai is responsible for global manufacturing and supply of MORAb-202, which is in Phase I/II clinical trials for multiple solid tumors including endometrial, ovarian, lung, and breast cancers.",
        "Hop 3: MORAb-202 \u2190 BMY(page_66): BMY describes the Eisai collaboration as part of its broader strategic licensing and alliance activity, which includes MORAb-202 in its global pipeline of oncology-focused development programs."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> COMP -[Supplies]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Eisai",
        "node_3": "MORAb-202",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "Eisai",
          "name": "Eisai",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "MORAb-202",
          "name": "MORAb-202",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_1",
          "chunk_text": "## Acquisitions, Divestitures, Licensing and Other Arrangements\n\nSignificant  acquisitions,  divestitures,  licensing  and  other  arrangements  during  2021  are  summarized  below.  Refer  to  'Item  8. Financial Statements and Supplementary Data -Note 3. Alliances' and '-Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements' for further information.\n\nAgenus  -  We  obtained  a  global  exclusive  license  to Agenus'  proprietary  bispecific  antibody  program, AGEN1777,  that  blocks TIGIT and an additional target. AGEN1777 is currently in a Phase I clinical trial.\n\nEisai - We commenced an exclusive global strategic collaboration with Eisai for the co-development and co-commercialization of MORAb-202, a selective folate receptor alpha antibody-drug conjugate being investigated in endometrial, ovarian, lung and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nProthena - We exercised our option under the global neuroscience research and development collaboration for the exclusive U.S. rights  to  PRX005,  an  anti-tau  antibody  that  specifically  targets  an  area  within  the  microtubule  binding  region  for  the  potential treatment of Alzheimer's disease. PRX005 is currently in a Phase I clinical trial.\n\nRockefeller  University  -  We  obtained  a  global  exclusive  license  to  develop,  manufacture  and  commercialize  Rockefeller University's  novel  monoclonal  antibody  duo  treatment  that  neutralizes  the  SARS-CoV-2  virus  for  treatment  and  potentially  for prevention of COVID-19. Phase I clinical trials to assess dosing for IV and subcutaneous formulations and to assess safety have been  completed  by  Rockefeller  University.  In  May  2021,  enrollment  initiated  in  the  Phase  II  study  within  the  NIH ACTIV-2 protocol at a network of sites within the U.S. Phase II enrollment was completed in August 2021 and topline data is expected in the first quarter of 2022.",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 73,
      "question": "How does the expiration of the 2012 Long-Term Incentive Plan and the transition to the 2022 Long-Term Incentive Plan affect the valuation methodology and grant pricing assumptions for stock options, particularly in terms of volatility and grant-date pricing?",
      "answer": "The expiration of the 2012 Long-Term Incentive Plan in April 2022 and the transition to the 2022 Long-Term Incentive Plan introduced a change in the grant-date pricing methodology, with options now being granted at the closing price of JNJ stock rather than the average of the high and low prices. Additionally, the fair value of options granted in 2023 was $27.85, up from $23.23 in 2022 and $20.86 in 2021, reflecting updated volatility assumptions that blend a 10-year weekly historical volatility rate with a 5-week average implied volatility rate based on traded options. This shift in valuation methodology and pricing aligns with the new plan\u2019s structure and reflects a more dynamic approach to volatility estimation.",
      "reasoning_steps": [
        "Hop 1: JNJ(page_85) \u2192 2022 Long-Term Incentive Plan: Stock options under the 2022 plan are granted at the closing price of JNJ stock, and the fair value of options granted in 2023 was $27.85, using a blended volatility assumption that includes both historical and implied volatility.",
        "Hop 2: 2022 Long-Term Incentive Plan \u2192 2012 Long-Term Incentive Plan: The 2012 plan expired in April 2022, after which all new grants were made under the 2022 plan. The 2012 plan previously used the average of the high and low stock prices for grant pricing.",
        "Hop 3: 2012 Long-Term Incentive Plan \u2190 JNJ(page_124): The 2012 plan is referenced in the exhibit list as a formal compensation plan with specific award agreements, indicating its historical role in structuring executive incentives."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY -[Replaces]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "2022 Long-Term Incentive Plan",
        "node_3": "2012 Long-Term Incentive Plan",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "ACCOUNTING_POLICY",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_85",
          "chunk_id": "chunk_1",
          "chunk_text": "## Stock\toptions\n\nStock\toptions\texpire\t10\tyears\tfrom\tthe\tdate\tof\tgrant\tand\tvest\tover\tservice\tperiods\tthat\trange\tfrom\t6\tmonths\tto\t4\tyears. Options\tgranted\tunder\tthe\t2012\tLong-Term\tIncentive\tPlan\twere\tgranted\tat\tthe\taverage\tof\tthe\thigh\tand\tlow\tprices\tof\tthe\tCompany's\tCommon Stock\ton\tthe\tNew\tYork\tStock\tExchange\ton\tthe\tdate\tof\tgrant.\tOptions\tgranted\tunder\tthe\t2022\tLong-Term\tincentive\tPlan\twere\tgranted\tat\tthe closing\tprice\tof\tthe\tCompany's\tCommon\tStock\ton\tthe\tNew\tYork\tStock\tExchange\ton\tthe\tdate\tof\tgrant.\n\nThe\tfair\tvalue\tof\teach\toption\taward\twas\testimated\ton\tthe\tdate\tof\tgrant\tusing\tthe\tBlack-Scholes\toption\tvaluation\tmodel\tthat\tuses\tthe assumptions\tnoted\tin\tthe\tfollowing\ttable.\tFor\t2023,\t2022,\tand\t2021\tgrants,\texpected\tvolatility\trepresents\ta\tblended\trate\tof\t10-year weekly\thistorical\toverall\tvolatility\trate,\tand\ta\t5-week\taverage\timplied\tvolatility\trate\tbased\ton\tat-the-money\ttraded\tJohnson\t&amp;\tJohnson options\twith\ta\tlife\tof\t2\tyears.\tFor\tall\tgrants,\thistorical\tdata\tis\tused\tto\tdetermine\tthe\texpected\tlife\tof\tthe\toption.\tThe\trisk-free\trate was\tbased\ton\tthe\tU.S.\tTreasury\tyield\tcurve\tin\teffect\tat\tthe\ttime\tof\tgrant.\n\nThe\taverage\tfair\tvalue\tof\toptions\tgranted\twas\t$27.85,\t$23.23\tand\t$20.86,\tin\tfiscal\tyears\t2023,\t2022\tand\t2021,\trespectively.\tThe\tfair value\twas\testimated\tbased\ton\tthe\tweighted\taverage\tassumptions\tof:\n\n",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "2022_Long-Term_Incentive_Plan",
          "name": "2022 Long-Term Incentive Plan",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_120",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIncluded\tin\tthis\tcategory\tare\tthe\tfollowing\tequity\tcompensation\tplans\twhich\thave\tbeen\tapproved\tby\tthe\tCompany's\tshareholders:\t2012\tLong-Term Incentive\tPlan\tand\t2022\tLong-Term\tIncentive\tPlan. (1)\n\nThis\tcolumn\texcludes\tshares\treflected\tunder\tthe\tcolumn\t'Number\tof\tSecurities\tto\tbe\tIssued\tUpon\tExercise\tof\tOutstanding\tOptions\tand\tRights.' (2)\n\nThe\t2012\tLong-Term\tIncentive\tPlan\texpired\tApril\t26,\t2022.\tAll\toptions\tand\trestricted\tshares\tgranted\tsubsequent\tto\tthat\tdate\twere\tunder\tthe\t2022 Long-Term\tIncentive\tPlan. (3)\n\n## Item\t13.\tCertain\trelationships\tand\trelated\ttransactions,\tand director\tindependence\n\nThe\tinformation\tcalled\tfor\tby\tthis\titem\tis\tincorporated\therein\tby\treference\tto\tthe\tmaterial\tunder\tthe\tcaptions\tItem\t1.\tElection\tof Directors\t-\tRelated\tperson\ttransactions\t&amp;\tDirector\tindependence\tin\tthe\tProxy\tStatement.\n\n## Item\t14.\tPrincipal\taccountant\tfees\tand\tservices\n\nThe\tinformation\tcalled\tfor\tby\tthis\titem\tis\tincorporated\therein\tby\treference\tto\tthe\tmaterial\tunder\tthe\tcaption\tItem\t3.\tRatification\tof appointment\tof\tindependent\tregistered\tpublic\taccounting\tfirm\tin\tthe\tProxy\tStatement.\n\n## 114",
          "relationship": "Replaces"
        },
        "node_3": {
          "id": "2012_Long-Term_Incentive_Plan",
          "name": "2012 Long-Term Incentive Plan",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "| Reg. S-K Exhibit Table   | Description                                                                                                                                                                                                                                                         |\n|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Item No.                 | of Exhibit                                                                                                                                                                                                                                                          |\n| 2(i)                     | Agreement and Plan of Merger, dated as of October 31, 2022, by and among Johnson & Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc. - Incorporated herein by reference to Exhibit 2.1 of the Registrant's Form 8-K Current Report filed November 1, 2022.\u2020         |\n| 3(i)                     | Restated Certificate of Incorporation effective February 19, 2016 - Incorporated herein by reference to Exhibit 3(i) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.                                                         |\n| 3(ii)                    | Certificate of Amendment to the Certificate of Incorporation of Johnson & Johnson effective April 30, 2020 - Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020.                                      |\n| 3(iii)                   | By-Laws of the Company, as amended effective June 9, 2020 - Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed June 10, 2020.                                                                                        |\n| 4(a)                     | Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.                                                                               |\n| 4(b)                     | Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 - Incorporated herein by reference to Exhibit 4.1 of the Registrant's Form 8-K Current Report filed August 12, 2020.                                             |\n| 10(a)                    | 2012 Long-Term Incentive Plan - Incorporated herein by reference to Appendix A of the Registrant's Proxy Statement filed on March 15, 2012.* Form of Stock Option Certificate under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit |\n| 10(b)                    | 10.2 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*                                                                                                                                                                           |\n| 10(c)                    | Form of Restricted Share Unit Certificate under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit 10.3 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*                                           |\n| 10(d)                    | Form of Performance Share Unit Certificate under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit 10.4 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*                                          |\n| 10(e)                    | Global NonQualified Stock Option Award Agreement under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*                                    |\n| 10(f)                    | Global Restricted Share Unit Award Agreement under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit 10.2 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*                                        |\n| 10(g)                    | Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan - Incorporated herein by reference to Exhibit 10.3 of the Registrant's Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*                                       |\n| 10(h)                    | Global Restricted Share Unit Award Agreement granted to John Reed on May 1, 2023 under the 2022 Long-Term Incentive Plan - Filed with this document.*                                                                                                               |\n| 10(i)                    | Domestic Deferred Compensation (Certificate of Extra Compensation) Plan - Incorporated herein by reference to Exhibit 10(g) of the Registrant's Form 10-K Annual Report for the year ended December 28, 2003.*                                                      |\n| 10(j)                    | Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009 - Incorporated herein by reference to Exhibit 10(j) of the Registrant's Form 10-K Annual Report for the year ended December 28, 2008.*                                     |\n| 10(k)                    | 2009 Certificates of Long-Term Performance Plan - Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*                                                                        |\n",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 74,
      "question": "How does Amgen's appeal of the PTAB's decision on the '138 Patent relate to its litigation strategy against Sandoz regarding the '638 and '101 Patents, particularly in terms of protecting market exclusivity for its apremilast product?",
      "answer": "Amgen's appeal of the PTAB's decision on the '138 Patent demonstrates its aggressive defense of intellectual property rights, particularly in response to biosimilar challenges. This aligns with its litigation strategy against Sandoz, where Amgen successfully enforced the '638 and '101 Patents, resulting in injunctions that prevent Sandoz from marketing its generic apremilast until after the expiration of those patents. Both legal actions reflect Amgen's broader approach to delay or block market entry of competing products, thereby preserving its market exclusivity and revenue stream for key drugs like apremilast.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_147) \u2192 [Notice of Appeal (PTAB decision on '138 Patent)]: Amgen filed a notice of appeal to the Federal Circuit Court challenging the PTAB's decision that invalidated claims of the '138 Patent, showing its commitment to defending patent validity.",
        "Hop 2: [Notice of Appeal] \u2192 [Sandoz]: Amgen filed a notice of appeal to the Federal Circuit Court after the New Jersey District Court ruled in favor of Amgen against Sandoz on the '638 and '101 Patents, indicating continued legal engagement to enforce patent rights.",
        "Hop 3: [Sandoz] \u2190 [AMGN](page_145): Amgen successfully obtained injunctions against Sandoz, preventing the launch of its generic apremilast until after the expiration of the '638 and '101 Patents, reinforcing its market protection strategy."
      ],
      "difficulty": "hard",
      "idf_score": 5.051418948098934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Files]-> COMP <-[Faces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Notice of Appeal",
        "node_3": "Sandoz",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_147",
          "chunk_id": "chunk_1",
          "chunk_text": "In  February  2016,  the  European  Patent  Office  (EPO)  granted  European  Patent  No.  2,215,124  (EP  2,215,124)  to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the  EPO  seeking  to  invalidate  it.  In  November  2016,  Sanofi-Aventis  Deutschland  GmbH,  Sanofi-Aventis  Groupe  S.A.  and  Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen's patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen's patent. In November 2018, the EPO confirmed the validity of Amgen's EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA's decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA's October 29, 2020 ruling.\n\nOn April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.'s appeals making final the Japanese High Court's decisions  that  PRALUENT  infringes Amgen's  valid  patent  rights  in  Japan.  On  June  24,  2020, Amgen  filed  written  answers  to  the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen's Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron's invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan.\n\n## NEUPOGEN (filgrastim)/Neulasta Patent Litigation\n\n## Amgen Inc., et al. v. Hospira Inc. et al.\n\nOn February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit  in  the  Delaware  District  Court  against  Hospira  Inc.  and  Pfizer  Inc.  (collectively,  Pfizer).  This  lawsuit  stems  from  Pfizer's submission of an application  for  FDA  licensure  of  a  pegfilgrastim  product  as  biosimilar  to Amgen's  Neulasta. Amgen  has  asserted infringement of U.S. Patent No. 8,273,707 (the '707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the '707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the '707 Patent. In June 2020, the FDA approved Pfizer's NYVEPRIA, a biosimilar to Amgen's Neulasta.\n\nOn April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction. Currently pending before the Delaware District Court is Pfizer's motion for summary judgment of noninfringement, which has been fully briefed. No date has been set for argument on the motion.\n\n## Patent Trial and Appeal Board (PTAB) Challenge\n\n## Apotex PTAB Challenge\n\nIn February 2017, the PTAB of the USPTO granted Apotex's petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the '138 Patent), challenging claims of the '138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the '138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018.\n\nOn May 20, 2019, the PTAB issued a decision denying Apotex's request for rehearing on the PTAB's finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen's '138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court's decision in Arthrex Inc. v. Smith &amp; Nephew, Inc ., 941 F.3d 1320 (Fed. Cir. 2019).\n\nOn July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the '138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the '138 Patent, for proceedings consistent with its decision in Arthrex Inc. v. Smith &amp; Nephew, Inc. ,  requesting  that  such  remanded  cases  be  held  pending  the  U.S. Supreme Court's disposition of the petition for writ of certiorari in United States v. Arthrex, Inc. ,  No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government's petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Notice_of_Appeal",
          "name": "Notice of Appeal",
          "type": "LITIGATION",
          "idf_score": 4.222304909797168
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Files"
        },
        "node_3": {
          "id": "Sandoz",
          "name": "Sandoz",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 75,
      "question": "How does BMY's exposure to product liability litigation risk related to Byetta* connect to their prior ownership of Amylin, and how does this affect the financial implications of their diabetes business divestiture?",
      "answer": "BMY's exposure to product liability litigation risk related to Byetta* stems from their prior ownership of Amylin, the original developer of the drug, which was divested in 2014 as part of BMY\u2019s global diabetes business. Despite the divestiture, BMY remains a co-defendant alongside Lilly in litigation alleging Byetta* caused pancreatic cancer, with nearly 60% of JCCP plaintiffs having submitted dismissals with prejudice as of December 31, 2021. While BMY sold the product to AstraZeneca, any additional liability related to Byetta* is expected to be shared with AstraZeneca, creating ongoing financial risk tied to the divestiture. This litigation exposure contrasts with BMY\u2019s earlier statement on page 48 that divestitures could result in continued financial exposure through guarantees or other arrangements, and highlights the long-term liabilities that may persist even after asset sales, affecting the net financial benefit of the $1.9 billion in pretax royalty income generated from such divestitures in 2021.",
      "reasoning_steps": [
        "Hop 1: BMY(page_48) \u2192 Amylin: BMY discusses the divestiture of their diabetes business, including Amylin, and notes the potential adverse financial impact if royalty streams decline, referencing $1.9 billion in pretax income from royalties in 2021.",
        "Hop 2: Amylin \u2192 Byetta*: Byetta* is identified as a product previously owned by Amylin, which was part of the diabetes business divested by BMY.",
        "Hop 3: Byetta* \u2190 BMY(page_160): BMY remains a co-defendant in Byetta*-related litigation, with financial exposure continuing post-divestiture, and liability expected to be shared with AstraZeneca."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Relates_To]-> COMP -[Owns]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Amylin",
        "node_3": "Byetta*",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "related  to  the  divestiture  of  our  diabetes  business  (including  the  transfer  of  certain  future  royalty  rights  pertaining  to Amylin,  Onglyza*  and  Farxiga*  product  sales),  out-licensed  intellectual  property  and  the  Merck  patent  infringement settlement. Pretax income generated from royalties was approximately $1.9 billion in 2021. Our pretax income could be adversely affected if the royalty streams decline in future periods.\n\nFailure  to  effectively  manage  acquisitions,  divestitures,  alliances,  joint  ventures  and  other  portfolio  actions  could adversely  impact  our  future  results.  In  addition,  any  businesses  or  assets  that  we  acquire  in  the  future  may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.\n\nWe have acquired, or in-licensed, a number of assets and we expect to continue to support our pipeline with compounds or products obtained through licensing and acquisitions. Future revenues, profits and cash flows of an acquired company's products, technologies and pipeline candidates may not materialize due to low product uptake, delayed or missed pipeline opportunities,  the  inability  to  capture  expected  synergies  resulting  from  cost  savings  and  avoidance,  increased competition, safety concerns, regulatory issues, supply chain problems or other factors beyond our control. Substantial difficulties,  costs  and  delays  could  result  from  integrating  our  acquisitions,  including  for  (i)  R&amp;D,  manufacturing, distribution,  sales,  marketing,  promotion  and  information  technology  activities;  (ii)  policies,  procedures,  processes, controls and compliance; and (iii) tax considerations. Where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with a joint venture or acquisition, the value of those  securities  will  fluctuate  and  may  depreciate  in  value.  We  may  not  control  the  company  in  which  we  acquire securities,  such  as  in  connection  with  a  collaborative  arrangement,  and  as  a  result,  we  will  have  limited  ability  to determine its management, operational decisions, internal controls and compliance and other policies, which can result in additional financial and reputational risks.\n\nWe may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect our earnings. Our divestitures also may result in continued financial exposure to the divested businesses, such as through guarantees or other financial arrangements, continued supply and services arrangements, or potential litigation, following the transaction. Under these arrangements, nonperformance by us could result in obligations being imposed on us that could have a material adverse effect on our competitive position, cash flows, results of operations, financial condition or reputation. In particular, we divested Otezla* in connection with obtaining regulatory approval for our acquisition of Celgene. If the FTC determines that we violated the consent order that we agreed to in connection with the divestiture, the FTC may seek a civil penalty and our reputation may be adversely affected.\n\nWe might also incur asset impairment charges related to acquisitions or divestitures that reduce our earnings. The value allocated to certain of our assets could be substantially impaired due to a number of factors beyond our control. New or revised accounting standards, rules and interpretations could result in changes to the recognition of income and expense that may materially and adversely affect our financial results.\n\nIf the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact our financial condition, cash flows and results of operations. Moreover, due to the substantial amount of debt that we incurred to finance the cash portion of the Celgene and MyoKardia acquisitions, there can be no assurance of when we will be able to expand our business development capacity. Although we are committed to reducing our debt, pursuing strategic transaction opportunities in future may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings.\n\n## Failure  to  attract  and  retain  highly  qualified  workforce  could  affect  our  ability  to  successfully  develop  and commercialize products.\n\nOur success is largely dependent on our continued ability to (i) attract and retain highly qualified scientific, technical and management workforce, including people with expertise in clinical R&amp;D, governmental regulation and commercialization, and  (ii)  in  connection  with  our  Celgene  acquisition,  integrate  two  unique  corporate  cultures  and  maintain  employee morale. We are facing increasing competition for a limited pool of qualified individuals from numerous pharmaceutical and  biotechnology  companies,  universities,  government  entities,  research  institutions,  companies  seeking  to  enter  the healthcare space, and companies in other industries. We cannot be sure that we will be able to retain quality talent or that the costs of doing so will not materially increase.\n\n## Market, Liquidity and Credit Risks\n\nOur significant additional indebtedness that we incurred in connection with the Celgene and MyoKardia acquisitions could have negative consequences.\n\nOur acquisitions of Celgene and MyoKardia increased the amount of our debt resulting in additional interest expense. This  could  reduce  our  financial  flexibility  to  continue  capital  investments,  develop  new  products  and  declare  future dividends.",
          "relationship": "Relates_To"
        },
        "node_2": {
          "id": "Amylin",
          "name": "Amylin",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_185",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Commission.\n* Indicates,  in  this  2021  Form  10-K,  brand  names  of  products,  which  are  registered  trademarks  not  solely  owned  by  the Company or  its  subsidiaries. Abilify is  a  trademark  of  Otsuka  Pharmaceutical  Co.,  Ltd.; Atripla is  a  trademark  of  Gilead Sciences,  LLC; Avapro/Avalide (known  in  the  EU  as Aprovel/Karvea )  and Plavix are  trademarks  of  Sanofi; Byetta is  a trademark of Amylin Pharmaceuticals, LLC; CABOMETYX is a trademark of Exelixis, Inc.; Erbitux is a trademark of ImClone LLC; Farxiga and Onglyza are  trademarks  of  AstraZeneca  AB; Gleevec is  a  trademark  of  Novartis  AG; Keytruda is  a trademark of Merck Sharp &amp; Dohme Corp.; Otezla is a trademark of Amgen Inc.; Tecentriq is a trademark of Genetech, Inc.; and Yescarta is a trademark of Kite Pharma, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.",
          "relationship": "Owns"
        },
        "node_3": {
          "id": "Byetta*",
          "name": "Byetta*",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 76,
      "question": "How does Merck's strategic emphasis on Lynparza in combination with Keytruda for lung cancers align with its financial exposure to patent expiration risks, particularly given the product's role among key revenue-generating products and the anticipated 2028 U.S. market exclusivity loss for Keytruda?",
      "answer": "Merck's strategic emphasis on Lynparza, highlighted in its combination therapy with Keytruda for lung cancers, positions the product as a core component of its oncology pipeline (page_48). This aligns with Lynparza's status as one of Merck's key revenue-generating products, which collectively accounted for a significant portion of the company's profits and cash flows (page_30). However, the financial exposure to patent expiration risks looms large, particularly given the anticipated 2028 loss of U.S. market exclusivity for Keytruda, which alone contributed to 56% of Merck's total sales in 2023 when combined with Gardasil/Gardasil 9 (page_28). This creates a dual vulnerability: Lynparza's strategic value depends on Keytruda\u2019s continued market presence, yet the impending patent expiration of Keytruda threatens to erode the revenue base that supports Merck\u2019s pipeline investments. Therefore, while Lynparza is positioned as a key growth driver, its strategic alignment is at risk if Merck cannot mitigate the anticipated revenue decline from Keytruda\u2019s loss of exclusivity.",
      "reasoning_steps": [
        "Hop 1: MRK(page_48) \u2192 Lynparza: Introduces Lynparza as a strategic component in Merck's oncology pipeline, particularly in combination with Keytruda for lung cancers.",
        "Hop 2: Lynparza \u2192 Key Products: Lynparza is explicitly listed among Merck's key products, which are critical to generating profits and operating cash flow.",
        "Hop 3: Key Products \u2190 MRK(page_28): Highlights the financial risk associated with patent expiration, especially noting Keytruda's anticipated U.S. market exclusivity loss in 2028, which poses a material threat to Merck's revenue base."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Lynparza",
        "node_3": "Key Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- V116,\t an\t investigational\t 21-valent\t pneumococcal\t conjugate\t vaccine\t for\t the\t prevention\t of\t invasive\t pneumococcal\t disease\t and pneumococcal\tpneumonia\tin\tadults,\tis\talso\tunder\tpriority\treview\tby\tthe\tFDA.\n- MK-1022,\tpatritumab\tderuxtecan,\tis\tan\tADC\tbeing\tevaluated\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tNSCLC\tunder\tpriority\treview\tby the\tFDA.\tPatritumab\tderuxtecan\tis\tpart\tof\ta\tcollaboration\twith\tDaiichi\tSankyo.\n- Additionally, Keytruda is\t under\t review\t in\t the\t U.S.\t and/or\t in\t international\t markets\t for\t supplemental\t indications\t for\t the treatment\tof\tcertain\tpatients\twith\tbiliary\ttract,\tcervical,\tendometrial,\tgastric,\tnon-small-cell\tlung\tand\turothelial\tcancers.\n- Welireg is\tunder\treview\tin\tthe\tEU\tfor\tthe\ttreatment\tof\tcertain\tpatients\twith\tadvanced\tRCC\tand\tfor\tthe\ttreatment\tof\tvon\tHippelLindau\tdisease.\n\nDuring\t2023,\tthe\tCompany\tinitiated\tmore\tthan\t20\tPhase\t3\tstudies\tacross\tmultiple\tasset\tclasses,\tincluding\tthe\tprogression\tof eight\tnovel\tcandidates.\n\nThe\t Company\t is\t diversifying\t its\t oncology\t portfolio\t and\t executing\t on\t its\t strategy\t which\t is\t broadly\t based\t on\t three\t strategic pillars:\timmuno-oncology,\tprecision\tmolecular\ttargeting\tand\ttissue\ttargeting.\tMerck's\tPhase\t3\toncology\tprograms\twithin\tthese\tpillars\tare as\tfollows:\n\n## Immuno-oncology\n\n- Keytruda in\t the\t therapeutic\t areas\t of\t cutaneous\t squamous\t cell,\t hepatocellular,\t mesothelioma,\t ovarian\t and\t small-cell\t lung cancers;\n- MK-1308A,\tthe\tcoformulation\tof\tquavonlimab,\tMerck's\tnovel\tinvestigational\tanti-CTLA-4\tantibody,\tand\tpembrolizumab\tfor\tRCC;\n- MK-3475A,\tthe\tsubcutaneous\tcoformulation\tof\tpembrolizumab\twith\thyaluronidase\tfor\tcertain\ttypes\tof\tNSCLC;\n- MK-4280A,\tthe\tcoformulation\tof\tfavezelimab,\tMerck's\tnovel\tinvestigational\tanti-LAG3\ttherapy,\tand\tpembrolizumab\tfor\tcolorectal cancer\tand\thematological\tmalignancies;\n- MK-7684A,\t the\t coformulation\t of\t vibostolimab,\t an\t anti-TIGIT\t therapy,\t and\t pembrolizumab\t for\t certain\t types\t of\t melanoma,\t non-\n- small-cell\tand\tsmall-cell\tlung\tcancers;\tand\n- V940,\tan\tinvestigational\tindividualized\tneoantigen\ttherapy,\tin\tcombination\twith Keytruda ,\tfor\tcertain\ttypes\tof\tmelanoma\tand NSCLC,\tbeing\tdeveloped\tin\tcollaboration\twith\tModerna.\n\n## Precision\tmolecular\ttargeting\n\n- Lynparza\tin\tcombination\twith Keytruda for\tnon-small-cell\tlung\tand\tsmall-cell\tlung\tcancers;\n- Lenvima,\tbeing\tdeveloped\tin\tcollaboration\twith\tEisai\tCo.,\tLtd.\t(Eisai),\tin\tcombination\twith Keytruda for\tcertain\ttypes\tof esophageal\tand\tgastric\tcancers;\n- MK-1026,\t nemtabrutinib,\t an\t oral,\t reversible,\t non-covalent\t Bruton's\t tyrosine\t kinase\t (BTK)\t inhibitor,\t for\t hematological malignancies;\n- MK-3543,\t bomedemstat,\t an\t investigational\t orally\t available\t lysine-specific\t demethylase\t 1\t inhibitor\t for\t myeloproliferative disorders;\tand\n- MK-5684,\tan\tinvestigational\tcytochrome\tP450\t11A1\t(CYP11A1)\tinhibitor\tbeing\tdeveloped\tin\tcollaboration\twith\tOrion\tCorporation (Orion)\tfor\tmCRPC.\n\n## Tissue\ttargeting\n\n- MK-2870,\t an\t investigational\t trophoblast\t cell-surface\t antigen\t 2\t (TROP2)-directed\t ADC\t being\t developed\t in\t collaboration\t with Kelun-Biotech\tfor\tendometrial\tcarcinoma\tand\tcertain\ttypes\tof\tNSCLC.\n\nAdditionally,\tthe\tCompany\tcurrently\thas\tcandidates\tin\tPhase\t3\tclinical\tdevelopment\tin\tseveral\tother\ttherapeutic\tareas\tincluding:\n\n- MK-0616,\tan\tinvestigational,\toral\tproprotein\tconvertase\tsubtilisin/kexin\ttype\t9\t(PCSK9)\tinhibitor\tfor\thypercholesterolemia;\n- MK-1654,\tclesrovimab,\ta\thuman\tmonoclonal\tantibody\tfor\tthe\tprevention\tof\trespiratory\tsyncytial\tvirus\t(RSV);\n- MK-7240,\ttulisokibart,\ta\thumanized\tmonoclonal\tantibody\tdirected\tto\ttumor\tnecrosis\tfactor-like\tligand\t1A,\ta\ttarget\tassociated with\tboth\tintestinal\tinflammation\tand\tfibrosis,\tfor\tulcerative\tcolitis;",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Lynparza",
          "name": "Lynparza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 77,
      "question": "How does CVS account for its Red Oak Sourcing joint venture with Cardinal Health in its consolidated financial statements, given the quarterly payments received from Cardinal and the 50% ownership structure?",
      "answer": "CVS consolidates Red Oak Sourcing, LLC in its financial statements despite the 50% ownership because it has determined that it is the primary beneficiary of the VIE, with the ability to direct Red Oak's activities. Although Red Oak is jointly owned with Cardinal Health and neither company holds inventory on behalf of the other, CVS receives quarterly payments from Cardinal that began in October 2014 and are tied to milestones, with payments increasing as those milestones are met. These payments, which totaled $183 million annually from 2019 to 2021, reduce CVS\u2019s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. This accounting treatment reflects CVS\u2019s control over the entity\u2019s operations despite equal ownership, and the financial impact of the payments is directly tied to inventory cost recognition rather than revenue or equity method accounting.",
      "reasoning_steps": [
        "Hop 1: CVS (page 18) \u2192 Red Oak Sourcing, LLC: CVS and Cardinal Health each own 50% of Red Oak Sourcing, a generic pharmaceutical sourcing entity, and use it to negotiate supply contracts without holding inventory.",
        "Hop 2: Red Oak Sourcing, LLC \u2192 Cardinal Health, Inc.: The joint venture arrangement results in Cardinal making quarterly payments to CVS, which are tied to milestone achievements and increase over time.",
        "Hop 3: Cardinal Health, Inc. \u2190 CVS (page 138): CVS consolidates Red Oak in its financial statements because it controls the entity\u2019s activities and recognizes the payments from Cardinal as reductions in inventory cost when the related products are sold."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Depends_On]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Red Oak Sourcing,LLC",
        "node_3": "Cardinal Health, Inc.",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_1",
          "chunk_text": "## Generic Sourcing Venture\n\nThe Company and Cardinal Health, Inc. ('Cardinal') each have a 50% ownership in Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.\n\n## Working Capital Practices\n\nThe Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, proceeds from sale-leaseback transactions and long-term borrowings. For additional information on the Company's working capital practices, see 'Liquidity and Capital Resources' in the MD&amp;A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS. Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company's consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company's consolidated pharmacy revenues are paid in cash, or with debit or credit cards.\n\n## Human Capital\n\n## Overview\n\nAt CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December 31, 2021, we employed approximately 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 72% of whom were full-time.\n\nWe believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help our Board and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2021, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.\n\nThe Board and our chief executive officer ('CEO') provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.\n\n## Total Rewards\n\nWe recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility.\n\nIn recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company's minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company's competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Red_Oak_Sourcing,LLC",
          "name": "Red Oak Sourcing,LLC",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_1",
          "chunk_text": "## Generic Sourcing Venture\n\nThe Company and Cardinal Health, Inc. ('Cardinal') each have a 50% ownership in Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.\n\n## Working Capital Practices\n\nThe Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, proceeds from sale-leaseback transactions and long-term borrowings. For additional information on the Company's working capital practices, see 'Liquidity and Capital Resources' in the MD&amp;A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS. Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company's consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company's consolidated pharmacy revenues are paid in cash, or with debit or credit cards.\n\n## Human Capital\n\n## Overview\n\nAt CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December 31, 2021, we employed approximately 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 72% of whom were full-time.\n\nWe believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help our Board and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2021, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.\n\nThe Board and our chief executive officer ('CEO') provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.\n\n## Total Rewards\n\nWe recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility.\n\nIn recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company's minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company's competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Cardinal_Health,_Inc.",
          "name": "Cardinal Health, Inc.",
          "type": "COMP",
          "idf_score": 5.069602770184371
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "## Shares Held in Trust\n\nThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.\n\n## Variable Interest Entities\n\nThe Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE's economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE.\n\n## Variable Interest Entities - Primary Beneficiary\n\nIn 2014, the Company and Cardinal Health, Inc. ('Cardinal') established Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment.\n\nCardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company's carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.\n\n## Variable Interest Entities - Other Variable Interest Holder\n\nThe Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:\n\n- Hedge fund and private equity investments - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.\n- Real estate partnerships - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.\n\nThe Company is not the primary beneficiary of these VIEs because the nature of the Company's involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE's income or losses in net income (loss). The Company's maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.\n\nThe total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:\n\n",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 78,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related liabilities relate to the Cyprus Mines Corporation's involvement in the Imerys bankruptcy mediation, and what does this imply about the company's exposure to the multi-state investigation into talcum powder marketing?",
      "answer": "Johnson & Johnson has established a $9 billion reserve, payable over 25 years, to resolve current and future talc-related claims, which encompasses actual and contemplated settlements, including those tied to the Imerys bankruptcy proceedings. Cyprus Mines Corporation, which previously owned certain Imerys talc mines, filed for bankruptcy and proposed a plan that would allow it to contribute to a trust under the Imerys Plan in exchange for legal protection from talc claims. Cyprus, along with Imerys and claimants\u2019 representatives, has been engaged in ongoing mediation since late 2021, with the Bankruptcy Court extending the mediation through December 2023. This indicates that J&J's liability exposure is being managed through structured legal frameworks involving third-party entities like Cyprus and Imerys, which seek to consolidate and channel talc claims through trusts. However, despite these mediation efforts, forty-two states and the District of Columbia have pursued a separate multi-state investigation into J&J\u2019s marketing of talcum powder products. Although the states agreed to mediation in the LTL Bankruptcy Case in March 2022, New Mexico and Mississippi later opted out and resumed their cases in state court, with the broader mediation ultimately being terminated in March 2023. This suggests that while J&J has attempted to consolidate and manage talc-related liabilities through structured bankruptcy and mediation processes involving entities like Cyprus, it still faces parallel regulatory scrutiny that is not fully addressed through those mechanisms.",
      "reasoning_steps": [
        "Hop 1: JNJ(page_97) \u2192 Cyprus Mines Corporation: JNJ has a $9 billion reserve tied to talc-related claims, which includes potential indemnification obligations arising from the Imerys bankruptcy, where Cyprus Mines Corporation is a key involved party.",
        "Hop 2: Cyprus Mines Corporation \u2192 Mediation: Cyprus is a central participant in the ongoing bankruptcy mediation with Imerys and claimants, seeking to resolve talc-related liabilities through a trust mechanism.",
        "Hop 3: Mediation \u2190 JNJ(page_98): Despite the mediation efforts involving Cyprus and Imerys, JNJ still faces a multi-state investigation into its talcum powder marketing, with some states opting out of the mediation and pursuing independent legal action."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Engages]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Cyprus Mines Corporation",
        "node_3": "Mediation",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Cyprus_Mines_Corporation",
          "name": "Cyprus Mines Corporation",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Engages"
        },
        "node_3": {
          "id": "Mediation",
          "name": "Mediation",
          "type": "LITIGATION",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_2",
          "chunk_text": "Forty-two\tstates\tand\tthe\tDistrict\tof\tColumbia\t(including\tMississippi\tand\tNew\tMexico)\thave\tcommenced\ta\tjoint\tinvestigation\tinto\tthe Company's\tmarketing\tof\tits\ttalcum\tpowder\tproducts.\tAt\tthis\ttime,\tthe\tmulti-state\tgroup\thas\tnot\tasserted\tany\tclaims\tagainst\tthe\tCompany. Five\tstates\thave\tissued\tCivil\tInvestigative\tDemands\tseeking\tdocuments\tand\tother\tinformation.\tThe\tCompany\thas\tproduced\tdocuments\tto Arizona,\tNorth\tCarolina,\tTexas,\tand\tWashington\tand\tentered\tinto\tconfidentiality\tagreements.\tThe\tCompany\thas\tnot\treceived\tany\tfollow\tup requests\tfrom\tthose\tstates.\tIn\tMarch\t2022,\teach\tof\tthe\tforty-two\tstates\tagreed\tto\tmediation\tof\ttheir\tclaims\tin\tthe\tLTL\tBankruptcy\tCase. In\tJuly\t2022,\tNew\tMexico\tand\tMississippi\tindicated\tthey\twould\tno\tlonger\tvoluntarily\tsubmit\tto\tfurther\tmediation\tin\tthe\tLTL\tBankruptcy and\twould\tproceed\twith\ttheir\trespective\tcases\tin\tstate\tcourt.\tIn\tMarch\t2023,\tthe\tmediation\twas\tterminated.\tIn\tJanuary\t2024,\tthe\tCompany reached\tan\tagreement\tin\tprinciple\twith\tthe\tmulti-state\tgroup\tof\tstate\tAttorneys\tGeneral,\tsubject\tto\tongoing\tnegotiation\tof\tnon-monetary terms.\tThe\tunique\tprocedural\thistory\tand\tstatus\tof\tthe\tNew\tMexico\tand\tMississippi\tmatters\tspecifically\thave\tbeen\tdiscussed\tabove.\n\n## 92",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 79,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related claims reflect its exposure through both direct litigation and potential indemnification obligations arising from the Imerys bankruptcy mediation?",
      "answer": "Johnson & Johnson has established a $9 billion reserve to address current and future talc-related claims, which includes both direct litigation exposure and potential indemnification obligations. This reserve reflects the company's estimate of probable loss following the dismissal of the LTL 2 bankruptcy case. Separately, Imerys, JNJ's former talc supplier, filed for bankruptcy and proposed a plan that would channel all talc-related claims against it into a trust, along with its alleged indemnification rights against JNJ. Mediation involving Imerys, Cyprus, and claimants has been ongoing since late 2021, with amended plans filed in 2023 and revised trust distribution procedures in early 2024. The continuation of this mediation, combined with unresolved direct litigation in federal and state courts\u2014including the multi-district litigation expected to go to trial in early 2025\u2014suggests that JNJ\u2019s $9 billion reserve may not fully capture the long-term financial impact of these interconnected legal challenges.",
      "reasoning_steps": [
        "Hop 1: JNJ (page 98) \u2192 Mediation: JNJ faces multi-state investigation into its talc products and participated in mediation that was terminated in March 2023, with some states proceeding in state court.",
        "Hop 2: Mediation \u2192 Imerys: The Mediation Parties include Imerys, which filed for bankruptcy and seeks to channel talc claims into a trust alongside its indemnification rights against JNJ.",
        "Hop 3: Imerys \u2190 JNJ (page 97): JNJ depends on the outcome of Imerys\u2019s bankruptcy proceedings, where Imerys and Cyprus have filed revised plans and trust distribution procedures, directly impacting JNJ\u2019s potential indemnification liabilities."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Engages]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Mediation",
        "node_3": "Imerys",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_2",
          "chunk_text": "Forty-two\tstates\tand\tthe\tDistrict\tof\tColumbia\t(including\tMississippi\tand\tNew\tMexico)\thave\tcommenced\ta\tjoint\tinvestigation\tinto\tthe Company's\tmarketing\tof\tits\ttalcum\tpowder\tproducts.\tAt\tthis\ttime,\tthe\tmulti-state\tgroup\thas\tnot\tasserted\tany\tclaims\tagainst\tthe\tCompany. Five\tstates\thave\tissued\tCivil\tInvestigative\tDemands\tseeking\tdocuments\tand\tother\tinformation.\tThe\tCompany\thas\tproduced\tdocuments\tto Arizona,\tNorth\tCarolina,\tTexas,\tand\tWashington\tand\tentered\tinto\tconfidentiality\tagreements.\tThe\tCompany\thas\tnot\treceived\tany\tfollow\tup requests\tfrom\tthose\tstates.\tIn\tMarch\t2022,\teach\tof\tthe\tforty-two\tstates\tagreed\tto\tmediation\tof\ttheir\tclaims\tin\tthe\tLTL\tBankruptcy\tCase. In\tJuly\t2022,\tNew\tMexico\tand\tMississippi\tindicated\tthey\twould\tno\tlonger\tvoluntarily\tsubmit\tto\tfurther\tmediation\tin\tthe\tLTL\tBankruptcy and\twould\tproceed\twith\ttheir\trespective\tcases\tin\tstate\tcourt.\tIn\tMarch\t2023,\tthe\tmediation\twas\tterminated.\tIn\tJanuary\t2024,\tthe\tCompany reached\tan\tagreement\tin\tprinciple\twith\tthe\tmulti-state\tgroup\tof\tstate\tAttorneys\tGeneral,\tsubject\tto\tongoing\tnegotiation\tof\tnon-monetary terms.\tThe\tunique\tprocedural\thistory\tand\tstatus\tof\tthe\tNew\tMexico\tand\tMississippi\tmatters\tspecifically\thave\tbeen\tdiscussed\tabove.\n\n## 92",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Mediation",
          "name": "Mediation",
          "type": "LITIGATION",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Engages"
        },
        "node_3": {
          "id": "Imerys",
          "name": "Imerys",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 80,
      "question": "How do Amgen's challenges with payer-imposed access restrictions for Repatha in the U.S. compare with the access limitations experienced for Prolia due to healthcare provider capacity constraints during the pandemic, and what do these dynamics reveal about the company's overall patient access risk exposure?",
      "answer": "Amgen faces distinct but significant patient access challenges from two different systemic pressures. On one side, U.S. commercial payers have imposed access restrictions on Repatha through formulary limitations, prior authorization requirements, and high patient cost-sharing, which have historically led to reduced prescription fills and lower sales. In response, Amgen cut both net and list prices for Repatha, including discontinuing the higher-priced version in 2019, yet access remains constrained due to payer utilization management criteria and rebate negotiations, particularly among the top five integrated health plans and PBMs that control approximately 85% of U.S. pharmacy prescriptions. On the other side, Prolia's administration model \u2014 requiring in-office healthcare provider visits \u2014 made it vulnerable to pandemic-related healthcare system disruptions. With many patients delaying care and oncology treatment preferences shifting toward less immunosuppressive or non-injectable therapies, Prolia's usage and sales were negatively impacted. These two access risk profiles \u2014 payer-driven for Repatha and healthcare delivery system-driven for Prolia \u2014 reveal that Amgen\u2019s commercial performance is highly sensitive to structural barriers beyond product efficacy or pricing, underscoring a broader systemic patient access risk that spans both payer dynamics and healthcare delivery infrastructure.",
      "reasoning_steps": [
        "Hop 1: [AMGN] \u2192 [Payers]: Amgen's business is heavily influenced by commercial and government payers in the U.S., who impose restrictions such as prior authorization, formulary exclusions, and high patient cost-sharing, especially affecting Repatha access and sales.",
        "Hop 2: [Payers] \u2192 [Patient Access]: These payer actions, including the use of copay accumulator programs and restrictive utilization management criteria, directly limit patient access to Repatha, despite Amgen\u2019s efforts to reduce prices and rebates.",
        "Hop 3: [Patient Access] \u2190 [AMGN]: During the pandemic, patient access to Prolia was also limited due to healthcare provider capacity constraints and shifts in treatment preferences, showing a different but equally impactful access risk stemming from healthcare delivery system disruptions."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Negatively_Impacts]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Payers",
        "node_3": "Patient Access",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "RISK_FACTOR",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_41",
          "chunk_id": "chunk_1",
          "chunk_text": "## -U.S. commercial payer actions have affected and may continue to affect access to and sales of our products\n\nPayers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from the consolidation of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With  increasing  frequency,  payers  are  adopting  benefit  plan  changes  that  shift  a  greater  proportion  of  drug  costs  to  patients.  Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant  limitations  on  patients'  use  of  manufacturer  commercial  copay  assistance  programs.  Further,  government  regulation  of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, and  remains  standing  policy  for  2022)  that  has  caused  commercial  payers  to  more  widely  adopt  copay  accumulator  adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their  formularies or those they manage, particularly in treatment areas where the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer's prior authorization before covering the product or that patients use a mailorder  pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain  indications  for  which  our  products  are  approved  or  chosen  to  exclude  coverage  entirely.  For  example,  some  payers  require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria,  and  these  requirements  have  limited,  and  may  continue  to  limit,  patient  access  to  Repatha  treatment.  In  an  effort  to  reduce barriers  to  access,  we  reduced  the  net  price  of  Repatha  by  providing  greater  discounts  and  rebates  to  payers,  including  PBMs  that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than pay their co-pay payment, we introduced a set of new National Drug Codes to make Repatha available at a lower list price to attempt to address affordability for patients, particularly those on Medicare, and on December 31,  2019,  we  discontinued  the  higher  list  price  option  for  Repatha.  Despite  these  net  and  list  price  reductions,  some  payers  have restricted,  and  may  continue  to  restrict,  patient  access  and  have  and  may  continue  to  change  formulary  coverage  for  Repatha,  seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, and negatively affect Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements  and  limiting  patient  access  and  usage.  For  example,  in  the  United  States,  as  of  the  beginning  of  2021,  the  top  five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage or plan changes, restrictions or exclusions imposed by these commercial  payers  could  have  a  material  adverse  effect  on  our  product  sales,  business  and  results  of  operations.  Policy  reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or  consequences  for  our  business  and  how  we  interact  with  these  entities.  See Concentration  of  sales  at  certain  of  our  wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.\n\n-Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products\n\nOutside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1.  Business-Reimbursement. IRP has been widely used by many countries outside the United States to control costs based on an external  benchmark  of  a  product's  price  in  other  countries.  IRP  policies  can  change  quickly  and  frequently  and  may  not  reflect differences  in  the  burden  of  disease,  indications,  market  structures,  or  affordability  differences  across  countries  or  regions.  Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are  used  in  various  foreign  jurisdictions  as  well.  In  addition,  countries  may  refuse  to  reimburse  or  may  restrict  the  reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA's approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to 2020 was limited to a narrower patient population (such as those with HoFH) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Payers",
          "name": "Payers",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_41",
          "chunk_id": "chunk_1",
          "chunk_text": "## -U.S. commercial payer actions have affected and may continue to affect access to and sales of our products\n\nPayers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from the consolidation of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With  increasing  frequency,  payers  are  adopting  benefit  plan  changes  that  shift  a  greater  proportion  of  drug  costs  to  patients.  Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant  limitations  on  patients'  use  of  manufacturer  commercial  copay  assistance  programs.  Further,  government  regulation  of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, and  remains  standing  policy  for  2022)  that  has  caused  commercial  payers  to  more  widely  adopt  copay  accumulator  adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their  formularies or those they manage, particularly in treatment areas where the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer's prior authorization before covering the product or that patients use a mailorder  pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain  indications  for  which  our  products  are  approved  or  chosen  to  exclude  coverage  entirely.  For  example,  some  payers  require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria,  and  these  requirements  have  limited,  and  may  continue  to  limit,  patient  access  to  Repatha  treatment.  In  an  effort  to  reduce barriers  to  access,  we  reduced  the  net  price  of  Repatha  by  providing  greater  discounts  and  rebates  to  payers,  including  PBMs  that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than pay their co-pay payment, we introduced a set of new National Drug Codes to make Repatha available at a lower list price to attempt to address affordability for patients, particularly those on Medicare, and on December 31,  2019,  we  discontinued  the  higher  list  price  option  for  Repatha.  Despite  these  net  and  list  price  reductions,  some  payers  have restricted,  and  may  continue  to  restrict,  patient  access  and  have  and  may  continue  to  change  formulary  coverage  for  Repatha,  seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, and negatively affect Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements  and  limiting  patient  access  and  usage.  For  example,  in  the  United  States,  as  of  the  beginning  of  2021,  the  top  five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage or plan changes, restrictions or exclusions imposed by these commercial  payers  could  have  a  material  adverse  effect  on  our  product  sales,  business  and  results  of  operations.  Policy  reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or  consequences  for  our  business  and  how  we  interact  with  these  entities.  See Concentration  of  sales  at  certain  of  our  wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.\n\n-Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products\n\nOutside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1.  Business-Reimbursement. IRP has been widely used by many countries outside the United States to control costs based on an external  benchmark  of  a  product's  price  in  other  countries.  IRP  policies  can  change  quickly  and  frequently  and  may  not  reflect differences  in  the  burden  of  disease,  indications,  market  structures,  or  affordability  differences  across  countries  or  regions.  Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are  used  in  various  foreign  jurisdictions  as  well.  In  addition,  countries  may  refuse  to  reimburse  or  may  restrict  the  reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA's approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to 2020 was limited to a narrower patient population (such as those with HoFH) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_35",
          "chunk_id": "chunk_1",
          "chunk_text": "appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. For example, an NPR/Harvard poll in 2021 found that, with hospitals crowded from COVID-19, one in five U.S. households has had to delay care for serious illnesses. These measures and challenges will likely continue to varying degrees for the duration of the pandemic and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia requires administration by a healthcare provider in doctors' offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia instructs healthcare professionals who discontinue Prolia to transition  the  patient  to  an  alternative  antiresorptive,  including  oral  treatments  that  do  not  require  administration  by  a  healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive or therapies that do not require administration in a hospital setting, potentially adversely affecting sales of certain of our products. Also, new patients have been, and are expected to continue to be, less likely to be diagnosed and/or to start therapeutics during the pandemic, and these effects, together with the lower treatment rates during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decrease in diagnoses over the course  of  the  pandemic  has  suppressed  the  volume  of  new  patients  starting  treatment,  which  we  expect  to  continue  to  impact  our business. Once the pandemic subsides, we anticipate there could be a backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate lower provider capacity, and this lower provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences  among  healthcare  professionals  and  patients  toward  treatments  that  do  not  require  administration  by  healthcare professionals or visits to medical facilities.\n\nAs  the  pandemic  continues,  and  if  conditions  worsen  or  if  the  duration  of  the  pandemic  extends  significantly,  we  expect  to experience  additional  adverse  effects  on  our  development,  operational  and  commercial  activities,  customer  purchases  and  our collections of accounts receivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections as conditions begin to improve. There was a resurgence in COVID19 infections in numerous jurisdictions in 2021, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions, including in the United States, Europe and Asia Pacific regions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. New variants of the SARS-CoV-2 virus have emerged, including the delta and omicron variants, and have been shown to be present in many geographies and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain  their  efficacy  against  future  variants  of  the  virus.  Further,  even  while  vaccine  booster  shots  are  available  for  certain  patients, persistent vaccine hesitancy may result in under-vaccinated populations which may prolong the duration of the COVID-19 pandemic and  continue  to  disrupt  the  availability  of  healthcare  services  to  the  patients  we  serve.  Jurisdictions  may  implement,  continue  or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity. These measures could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain,  and  further  prevent  or  discourage  patients  from  participating  in  our  clinical  trials,  seeking  healthcare  services  and  the administration of certain of our products. The increased availability of remote working arrangements in response to the COVID-19 pandemic has expanded the pool of companies that can compete for our employees and employment candidates. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the United States, on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 (including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of COVID-19 antibody therapies for Lilly) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of,  materials  or  components  used  in  the  development,  manufacturing,  distribution,  or  administration  of  our  products.  For  example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our clinical trials has developed that we are actively monitoring and managing. We have also experienced challenges in obtaining certain COVID-19-related supplies, including COVID-19 antigen rapid test kits for our staff, as a result of high demand and limited supplies during the omicron variant surge. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.\n\nThe COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in this 'Risk Factors' section, which could materially adversely affect our business, operations and",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 81,
      "question": "How does Amgen's filing of a notice of appeal against Zydus in the U.S. regarding the '638 Patent relate to its defense of European Patent No. EP 2,215,124 in Europe, and what does this reveal about its global strategy to maintain market exclusivity?",
      "answer": "Amgen's filing of a notice of appeal against Zydus on October 27, 2021, regarding the '638 Patent in the U.S. reflects its aggressive defense of intellectual property to delay generic competition for apremilast. This aligns with its broader global strategy seen in the defense of European Patent No. EP 2,215,124, which protects Repatha and was upheld by the Technical Board of Appeal (TBA) in part on October 29, 2020. While the TBA invalidated broader claims covering PRALUENT, Amgen continued to enforce the valid claims across Europe, including through litigation in Germany and Japan. The coordinated legal actions in both jurisdictions demonstrate Amgen\u2019s intent to extend market exclusivity through robust patent enforcement, even as it faces partial invalidation and appeals in certain regions. This dual approach underscores the company's reliance on litigation and appeals to maximize product lifecycle management globally.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_145) \u2192 [Zydus]: Amgen secured a final judgment against Zydus on September 28, 2021, for infringing the '638 Patent, leading Zydus to file a notice of appeal on October 27, 2021.",
        "Hop 2: [Zydus] \u2192 [Notice of Appeal]: Zydus filed a notice of appeal to the Federal Circuit Court regarding the '638 Patent infringement ruling.",
        "Hop 3: [Notice of Appeal] \u2190 [AMGN](page_147): Amgen defended European Patent EP 2,215,124 through appeals and litigation in Europe and Japan, including enforcement actions following the TBA\u2019s partial uphold of the patent on October 29, 2020."
      ],
      "difficulty": "hard",
      "idf_score": 5.397992538378906,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> COMP -[Files]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Zydus",
        "node_3": "Notice of Appeal",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Zydus",
          "name": "Zydus",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Files"
        },
        "node_3": {
          "id": "Notice_of_Appeal",
          "name": "Notice of Appeal",
          "type": "LITIGATION",
          "idf_score": 4.222304909797168
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_147",
          "chunk_id": "chunk_1",
          "chunk_text": "In  February  2016,  the  European  Patent  Office  (EPO)  granted  European  Patent  No.  2,215,124  (EP  2,215,124)  to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the  EPO  seeking  to  invalidate  it.  In  November  2016,  Sanofi-Aventis  Deutschland  GmbH,  Sanofi-Aventis  Groupe  S.A.  and  Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen's patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen's patent. In November 2018, the EPO confirmed the validity of Amgen's EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA's decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA's October 29, 2020 ruling.\n\nOn April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.'s appeals making final the Japanese High Court's decisions  that  PRALUENT  infringes Amgen's  valid  patent  rights  in  Japan.  On  June  24,  2020, Amgen  filed  written  answers  to  the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen's Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron's invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan.\n\n## NEUPOGEN (filgrastim)/Neulasta Patent Litigation\n\n## Amgen Inc., et al. v. Hospira Inc. et al.\n\nOn February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit  in  the  Delaware  District  Court  against  Hospira  Inc.  and  Pfizer  Inc.  (collectively,  Pfizer).  This  lawsuit  stems  from  Pfizer's submission of an application  for  FDA  licensure  of  a  pegfilgrastim  product  as  biosimilar  to Amgen's  Neulasta. Amgen  has  asserted infringement of U.S. Patent No. 8,273,707 (the '707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the '707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the '707 Patent. In June 2020, the FDA approved Pfizer's NYVEPRIA, a biosimilar to Amgen's Neulasta.\n\nOn April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction. Currently pending before the Delaware District Court is Pfizer's motion for summary judgment of noninfringement, which has been fully briefed. No date has been set for argument on the motion.\n\n## Patent Trial and Appeal Board (PTAB) Challenge\n\n## Apotex PTAB Challenge\n\nIn February 2017, the PTAB of the USPTO granted Apotex's petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the '138 Patent), challenging claims of the '138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the '138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018.\n\nOn May 20, 2019, the PTAB issued a decision denying Apotex's request for rehearing on the PTAB's finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen's '138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court's decision in Arthrex Inc. v. Smith &amp; Nephew, Inc ., 941 F.3d 1320 (Fed. Cir. 2019).\n\nOn July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the '138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the '138 Patent, for proceedings consistent with its decision in Arthrex Inc. v. Smith &amp; Nephew, Inc. ,  requesting  that  such  remanded  cases  be  held  pending  the  U.S. Supreme Court's disposition of the petition for writ of certiorari in United States v. Arthrex, Inc. ,  No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government's petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 82,
      "question": "How does Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, impact Amgen's competitive positioning in the U.S. market, especially given Novartis's direct competition with Otezla and Nplate in key therapeutic areas?",
      "answer": "Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, removed U.S. cost-sharing and royalty obligations, giving Amgen full control over Aimovig\u2019s U.S. commercialization. This change likely strengthens Amgen\u2019s ability to directly compete in the U.S. market. However, Novartis remains a competitor to Amgen in several therapeutic areas, including with Otezla and Nplate, where Novartis markets Cosentyx and PROMACTA/REVOLADE, respectively. This dual relationship\u2014where Novartis both collaborates globally on Aimovig and competes directly in other product lines\u2014creates a complex competitive dynamic that could influence Amgen\u2019s market strategy and performance in neurology and hematology.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_28) \u2192 [Aimovig]: Amgen discloses the revised collaboration with Novartis on Aimovig effective January 1, 2022, under which Amgen no longer pays U.S. royalties or shares commercialization costs, and Novartis retains only ex-U.S. rights.",
        "Hop 2: [Aimovig] \u2192 [Novartis]: Novartis retains global co-development rights and exclusive commercial rights outside the U.S. and Japan for Aimovig, and continues to pay double-digit royalties on ex-U.S. sales, indicating a continued financial stake in the product.",
        "Hop 3: [Novartis] \u2190 [AMGN](page_16): Amgen lists Novartis as a direct competitor in the U.S. and Europe for products like Otezla (with Cosentyx) and Nplate (with PROMACTA/REVOLADE), highlighting competitive pressure in therapeutic areas where Amgen has significant revenue exposure."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Retains_Rights_To]-> COMP <-[Competes_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Aimovig",
        "node_3": "Novartis",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Aimovig",
          "name": "Aimovig",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Retains_Rights_To"
        },
        "node_3": {
          "id": "Novartis",
          "name": "Novartis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 83,
      "question": "How does Amgen's patent protection timeline for polypeptide-based molecules, including Tarlatamab, align with the company's strategic investment in advancing Tarlatamab into phase 3 trials for small cell lung cancer?",
      "answer": "Amgen has disclosed that Tarlatamab, an investigational polypeptide-based molecule for small cell lung cancer, is protected by patents expiring in 2036 in both the U.S. and Europe. This long-duration patent protection aligns with Amgen's decision to invest in initiating phase 3 trials for Tarlatamab, indicating a strategic commitment to its development and commercialization. The extended IP protection provides Amgen with a competitive window to recoup R&D investments and establish market positioning in a high-need therapeutic area.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_13) \u2192 Polypeptides: Amgen discloses patent expiration timelines for various polypeptide-based molecules, including Tarlatamab, which is protected until 2036 in both U.S. and Europe.",
        "Hop 2: Polypeptides \u2192 Tarlatamab: Tarlatamab is specifically listed as a polypeptide-based molecule in Amgen\u2019s pipeline with patent protection extending to 2036, indicating its importance in the company\u2019s portfolio.",
        "Hop 3: Tarlatamab \u2190 AMGN(page_26): Amgen has initiated phase 3 trials for Tarlatamab in small cell lung cancer, signaling a major strategic investment in its development."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Polypeptides",
        "node_3": "Tarlatamab",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product                           | Territory   | General subject matter                                                    | Expiration         |\n|-----------------------------------|-------------|---------------------------------------------------------------------------|--------------------|\n|                                   | U.S.        | Formulations and methods of preparing formulations                        | 10/19/2037         |\n| Enbrel (etanercept) \u00ae             | U.S.        | Fusion protein and pharmaceutical compositions                            | 11/22/2028         |\n|                                   | U.S.        | DNA encoding fusion protein and methods of making fusion protein          | 4/24/2029          |\n| Otezla (apremilast) \u00ae             | U.S.        | Compositions and compounds                                                | 2/16/2028          |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 3/20/2023          |\n| \u00ae                                 | U.S.        | Antibodies (2)                                                            | 8/22/2028          |\n|                                   | U.S.        | Methods of treatment                                                      | 11/22/2030         |\n| Repatha (evolocumab)              | Europe      | Compositions (1)                                                          | 8/22/2028          |\n| Repatha (evolocumab)              | Europe      | Methods of treatment                                                      | 5/10/2032          |\n|                                   | Europe      | Formulation                                                               | 5/3/2033           |\n| Nplate (romiplostim) \u00ae            | U.S.        | Formulation                                                               | 2/12/2028          |\n|                                   | Europe      | Thrombopoietic compounds (1)                                              | 10/22/2019         |\n|                                   | Europe      | Formulation                                                               | 4/20/2027          |\n|                                   | U.S.        | Compositions and compounds                                                | 12/7/2027          |\n| \u00ae                                 | U.S.        | Methods of treatment                                                      | 4/14/2025          |\n| KYPROLIS (carfilzomib)            | U.S.        | Methods of making                                                         | 5/8/2033           |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 12/7/2025          |\n| Aranesp (darbepoetin alfa) \u00ae      | U.S.        | Glycosylation analogs of erythropoietin proteins                          | 5/15/2024          |\n|                                   | U.S.        | Antibodies                                                                | 4/25/2026          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/9/2033           |\n| EVENITY (romosozumab-aqqg) \u00ae      | Europe      | Antibodies (1)                                                            | 4/28/2026          |\n|                                   | Europe      | Methods of treatment                                                      | 4/18/2032          |\n|                                   | Europe      | Formulation and methods of using formulation                              | 5/11/2031          |\n|                                   | U.S.        | Pharmaceutical compositions and bifunctional polypeptides                 | 4/6/2030           |\n| \u00ae                                 | U.S.        | Method of administration                                                  | 9/28/2027          |\n| BLINCYTO (blinatumomab)           | Europe      | Bifunctional polypeptides (1)                                             | 11/26/2024         |\n|                                   | Europe      | Method of administration                                                  | 11/6/2029          |\n| TEZSPIRE (tezepelumab-ekko) \u00ae     | U.S.        | Polypeptides (2)                                                          | 2/3/2029           |\n|                                   | U.S.        | Methods of treatment                                                      | 8/23/2038          |\n|                                   | Europe      | Polypeptides (1)                                                          | 9/9/2028           |\n| TEPEZZA (teprotumumab-trbw) \u00ae     | U.S.        | IGF-1R antibodies (3)                                                     | 3/3/2029           |\n| \u00ae                                 | U.S.        | Compound and pharmaceutical composition                                   | 2/7/2031           |\n| Parsabiv (etelcalcetide)          | U.S.        | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | Methods of making                                                         | 8/9/2035           |\n|                                   | Europe      | Compound and pharmaceutical composition (1)                               | 7/29/2030          |\n|                                   | Europe      | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | CGRP receptor antibodies                                                  | 5/17/2032          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/22/2036          |\n| Aimovig (erenumab-aooe) \u00ae         | U.S.        | Compositions and pharmaceutical formulations                              | 4/1/2039           |\n|                                   | Europe      | CGRP receptor antibodies (1)                                              | 12/18/2029         |\n|                                   | Europe      | Methods of treatment                                                      | 8/10/2035          |\n|                                   | U.S.        | Compounds and pharmaceutical compositions                                 | 5/21/2038          |\n| LUMAKRAS /LUMYKRAS\u2122 (sotorasib) \u00ae | U.S.        | Crystalline form, pharmaceutical compositions and methods of treatment    | 5/20/2040          |\n|                                   | U.S.        | Methods of treatment                                                      | 9/15/2040          |\n|                                   | Europe      | Compounds, pharmaceutical compositions and methods of treatment           | 5/21/2038          |\n|                                   | U.S.        | Polypeptides and pharmaceutical compositions                              | 4/11/2026          |\n| KRYSTEXXA (pegloticase) \u00ae         | U.S.        | Methods of treatment                                                      |                    |\n|                                   | U.S.        | Compounds and pharmaceutical compositions (2)                             | 6/25/2030 2/3/2031 |\n| TAVNEOS (avacopan) \u00ae              | U.S.        | Crystalline and amorphous forms and pharmaceutical compositions           | 5/29/2041          |\n| UPLIZNA (inebilizumab-cdon) \u00ae     | U.S.        | CD19 antibodies and pharmaceutical compositions (2)                       | 3/7/2030           |\n|                                   | Europe      | CD19 antibodies, pharmaceutical compositions and methods of treatment (1) | 9/7/2027           |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Polypeptides",
          "name": "Polypeptides",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_4",
          "chunk_text": "| Molecule      | Territory   | General subject matter   |   Estimated expiration* |\n|---------------|-------------|--------------------------|-------------------------|\n| Bemarituzumab | U.S.        | Polypeptides             |                    2029 |\n| Bemarituzumab | Europe      | Polypeptides             |                    2029 |\n| Dazodalibep   | U.S.        | Polypeptides             |                    2034 |\n| Dazodalibep   | Europe      | Polypeptides             |                    2032 |\n| Olpasiran     | U.S.        | Compounds                |                    2036 |\n| Olpasiran     | Europe      | Compounds                |                    2036 |\n| Rocatinlimab  | U.S.        | Polypeptides             |                    2027 |\n| Rocatinlimab  | Europe      | Polypeptides             |                    2026 |\n| Tarlatamab    | U.S.        | Polypeptides             |                    2036 |\n| Tarlatamab    | Europe      | Polypeptides             |                    2036 |\n",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Tarlatamab",
          "name": "Tarlatamab",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                         | Program change                                      |\n|-------------------|----------------------------------------------------|-----------------------------------------------------|\n| Dazodalibep       | Sj\u00f6gren's Syndrome                                 | Horizon acquired program                            |\n| KYPROLIS          | Weekly dosing for relapsed multiple myeloma        | Concluded-program did not meet its primary endpoint |\n| LUMAKRAS/LUMYKRAS | NSCLC in combination with chemotherapy             | Initiated phase 3 study                             |\n| Otezla            | Genital psoriasis                                  | Approved by the FDA                                 |\n| Tarlatamab        | Small cell lung cancer                             | Initiated phase 3 study                             |\n| TEPEZZA           | Active TED (OPTIC-J); Chronic/Low CAS TED in Japan | Horizon acquired programs                           |\n| UPLIZNA           | IgG4-related disease; Myasthenia gravis            | Horizon acquired programs                           |\n| ABP 206           | Biosimilar to OPDIVO                               | Initiated phase 3 study                             |\n",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 84,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products factor into the financial impact of the spin-off as reflected in Merck's discontinued operations reporting?",
      "answer": "Merck's spin-off of Organon involved a complex transition framework including multi-year manufacturing and supply agreements (MSAs), under which Merck agreed to toll manufacture and supply certain formulated pharmaceutical products for Organon. These agreements generated $219 million in sales and $195 million in cost of sales in 2021, indicating continued economic interaction post-spin-off. However, the spin-off also resulted in the classification of Organon's businesses (including women's health, biosimilars, and established brands) as discontinued operations, with Merck incurring $556 million in separation costs in 2021 and $743 million in 2020. The continuation of manufacturing relationships under the MSAs suggests that while Organon was spun off as a separate entity, Merck retained a strategic role in its supply chain, which complicates the clean separation of financial results and raises questions about the long-term implications of these interdependencies on Merck's reported discontinued operations.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_94) \u2192 [Formulated Pharmaceutical Products]: Merck entered into MSAs to manufacture and supply formulated pharmaceutical products for Organon post-spin-off, with $219 million in sales and $195 million in cost of sales in 2021.",
        "Hop 2: [Formulated Pharmaceutical Products] \u2192 [Organon]: Organon is both a recipient and provider of formulated pharmaceutical products under these MSAs, indicating a mutual dependency post-spin-off.",
        "Hop 3: [Organon] \u2190 [MRK](page_146): Organon's businesses were classified as discontinued operations in Merck's financial statements, with Merck incurring significant separation costs and reflecting the spin-off's financial impact in discontinued operations."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Provides]-> PRODUCT -[Produces]-> COMP <-[Spins_Off]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Formulated Pharmaceutical Products",
        "node_3": "Organon",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Provides"
        },
        "node_2": {
          "id": "Formulated_Pharmaceutical_Products",
          "name": "Formulated Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_146",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmounts in the fourth quarter of 2020 include charges related to the acquisitions of VelosBio Inc. and OncoImmune (see Note 4) and an intangible asset impairment charge related to Zerbaxa (see Note 9). (1)\n\nAmounts in the third quarter of 2020 include charges related to transactions with Seagen Inc (see Note 4). (2)\n\nAmounts in the second quarter of 2021 include a charge related to the acquisition of Pandion Therapeutics, Inc. (see Note 4). (3)\n\nReflects the results of the businesses that were spun-off to Organon on June 2, 2021 as discontinued operations for all periods presented (see Note 3). (4)",
          "relationship": "Spins_Off"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 85,
      "question": "How does BMY's strategic partnership with 2seventy bio, which includes profit-sharing on U.S. sales of anti-BCMA products like Abecma, reflect in both the collaborative agreement terms and the financial performance metrics reported for 2024?",
      "answer": "BMY's strategic partnership with 2seventy bio involves joint development and commercialization of anti-BCMA products, including Abecma, which received FDA approval in 2021 for treating relapsed or refractory multiple myeloma. Under the agreement, 2seventy bio has the right to participate in the U.S. development and commercialization of licensed products, including a 50/50 profit share in exchange for reduced milestone payments. This arrangement is directly reflected in BMY's financial performance for 2024, where U.S. net product sales of Abecma were $242 million, and the related profit-sharing costs amounted to $43 million. This demonstrates how the collaborative structure with 2seventy bio directly impacts BMY's financials through shared profitability and cost obligations.",
      "reasoning_steps": [
        "Hop 1: BMY(page_134) \u2192 2seventy bio: BMY partners with 2seventy bio for joint development and commercialization of anti-BCMA gene therapy products.",
        "Hop 2: 2seventy bio \u2192 Anti-BCMA Products: The collaboration includes profit-sharing and co-commercialization rights for anti-BCMA products such as Abecma.",
        "Hop 3: Anti-BCMA Products \u2190 BMY(page_91): BMY reports U.S. net sales of Abecma at $242 million in 2024, with $43 million in profit-sharing costs to 2seventy bio."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Has_Stake_In]-> PRODUCT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "2seventy bio",
        "node_3": "Anti-BCMA Products",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "2seventy_bio",
          "name": "2seventy bio",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## 2seventy bio\n\nBMS and 2seventy bio jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration includes (i) a right  for  BMS  to  license  any  anti-BCMA  products  resulting  from  the  collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to 2seventy bio upon the commercialization of any licensed products resulting from the collaboration should 2seventy bio decline to exercise their co-development and profit sharing rights.\n\nBMS exercised its option to license idecabtagene vicleucel ( Abecma ) in 2016 and 2seventy bio elected to participate in development and commercialization of Abecma in the U.S. in 2018. The terms of the collaboration have since been amended to transfer substantially all manufacturing obligations to BMS and eliminate ex-U.S. milestones and royalties payable to 2seventy bio for Abecma .\n\nIn  2021,  the  FDA  approved Abecma for  the  treatment  of  relapsed  or  refractory  multiple  myeloma.  Net  product  sales  of Abecma in  the  U.S.  were  $242  million, $358  million  and  $297  million;  and  the  related  profit  sharing  costs  were  $43  million,  $109  million  and  $49  million  in  2024,  2023  and  2022,  respectively.  Cost reimbursements were not material.\n\n## Eisai\n\nIn 2024, BMS and Eisai agreed to end the global strategic collaboration for the co-development and co-commercialization of MORAb-202 due to the ongoing portfolio prioritization efforts within BMS. All rights and obligations for MORAb-202 were transferred to Eisai, and BMS is to receive $90 million as part of the termination, which was included in Other (income)/expense, net during the twelve months ended December 31, 2024, of which $85 million was received during the third quarter of 2024.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Asset Acquisition\n\n## Karuna\n\nOn March 18, 2024, BMS acquired Karuna, a clinical-stage biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living  with  psychiatric  and  neurological  conditions.  The  acquisition  provided  BMS  with  rights  to Cobenfy (x anomeline  and  trospium  chloride),  formerly  KarXT. Cobenfy is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety, which was approved by the FDA on September 26, 2024 for the treatment of schizophrenia in adults. Cobenfy is also in registrational trials for both adjunctive therapy to ex isting standard of care agents in schizophrenia and the treatment of psychosis in patients with Alzheimer's Disease.\n\nBMS acquired  all  of  the  issued  and  outstanding  shares  of  Karuna's  common  stock  for  $330.00  per  share  in  an  all-cash  transaction  for  total  consideration  of $14.0 billion, or $12.9 billion net of cash acquired. The acquisition was funded primarily with debt proceeds (see \"-Note 10. Financing Arrangements\" for further detail). The transaction was accounted for as an asset acquisition since Cobenfy represented substantially all of the fair value of the gross assets acquired. As a result, $12.1 billion was ex pensed to Acquired IPRD during the twelve months ended December 31, 2024.\n\nThe following summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and Acquired IPRD expense:",
          "relationship": "Has_Stake_In"
        },
        "node_3": {
          "id": "Anti-BCMA_Products",
          "name": "Anti-BCMA Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## 2seventy bio\n\nBMS and 2seventy bio jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration includes (i) a right  for  BMS  to  license  any  anti-BCMA  products  resulting  from  the  collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to 2seventy bio upon the commercialization of any licensed products resulting from the collaboration should 2seventy bio decline to exercise their co-development and profit sharing rights.\n\nBMS exercised its option to license idecabtagene vicleucel ( Abecma ) in 2016 and 2seventy bio elected to participate in development and commercialization of Abecma in the U.S. in 2018. The terms of the collaboration have since been amended to transfer substantially all manufacturing obligations to BMS and eliminate ex-U.S. milestones and royalties payable to 2seventy bio for Abecma .\n\nIn  2021,  the  FDA  approved Abecma for  the  treatment  of  relapsed  or  refractory  multiple  myeloma.  Net  product  sales  of Abecma in  the  U.S.  were  $242  million, $358  million  and  $297  million;  and  the  related  profit  sharing  costs  were  $43  million,  $109  million  and  $49  million  in  2024,  2023  and  2022,  respectively.  Cost reimbursements were not material.\n\n## Eisai\n\nIn 2024, BMS and Eisai agreed to end the global strategic collaboration for the co-development and co-commercialization of MORAb-202 due to the ongoing portfolio prioritization efforts within BMS. All rights and obligations for MORAb-202 were transferred to Eisai, and BMS is to receive $90 million as part of the termination, which was included in Other (income)/expense, net during the twelve months ended December 31, 2024, of which $85 million was received during the third quarter of 2024.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Asset Acquisition\n\n## Karuna\n\nOn March 18, 2024, BMS acquired Karuna, a clinical-stage biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living  with  psychiatric  and  neurological  conditions.  The  acquisition  provided  BMS  with  rights  to Cobenfy (x anomeline  and  trospium  chloride),  formerly  KarXT. Cobenfy is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety, which was approved by the FDA on September 26, 2024 for the treatment of schizophrenia in adults. Cobenfy is also in registrational trials for both adjunctive therapy to ex isting standard of care agents in schizophrenia and the treatment of psychosis in patients with Alzheimer's Disease.\n\nBMS acquired  all  of  the  issued  and  outstanding  shares  of  Karuna's  common  stock  for  $330.00  per  share  in  an  all-cash  transaction  for  total  consideration  of $14.0 billion, or $12.9 billion net of cash acquired. The acquisition was funded primarily with debt proceeds (see \"-Note 10. Financing Arrangements\" for further detail). The transaction was accounted for as an asset acquisition since Cobenfy represented substantially all of the fair value of the gross assets acquired. As a result, $12.1 billion was ex pensed to Acquired IPRD during the twelve months ended December 31, 2024.\n\nThe following summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and Acquired IPRD expense:",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 86,
      "question": "How does Gilead's revenue recognition model for Symtuza, which is manufactured and distributed by Janssen, compare with its cost-sharing arrangement with Janssen for Odefsey, and what does this reveal about Gilead's strategic control and financial exposure across these two HIV products?",
      "answer": "Gilead recognizes its share of Symtuza revenue in the period when Janssen sells the product, as the license to Janssen is deemed the predominant item in the performance obligation. This contrasts with Odefsey, where Gilead retains manufacturing responsibility and leads commercialization in most markets, sharing revenues with Janssen based on the net selling prices of each party's components. For Odefsey, Gilead records Janssen's share of revenue as a cost of goods sold, which totaled $403 million in 2024. This difference shows that Gilead has more direct control and visibility over Odefsey's revenue and cost structure, whereas Symtuza's financial performance is more dependent on Janssen's commercial execution. The arrangement for Symtuza reflects a more passive revenue model, while Odefsey involves active operational and strategic involvement by Gilead.",
      "reasoning_steps": [
        "Hop 1: GILD(page_77) \u2192 Janssen: Gilead recognizes Symtuza revenue as Product Sales when Janssen sells the product, with the license deemed predominant in the performance obligation.",
        "Hop 2: Janssen \u2192 Odefsey: Janssen retains distribution rights in certain countries for Odefsey, a product co-developed with Gilead, under a revenue-sharing model tied to component net selling prices.",
        "Hop 3: Odefsey \u2190 GILD(page_76): Gilead leads manufacturing and commercialization of Odefsey in most markets and records Janssen's share of revenue as a cost of goods sold, which was $403 million in 2024."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Distributes]-> PRODUCT <-[Distributes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Odefsey",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Odefsey",
          "name": "Odefsey",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 87,
      "question": "How does AbbVie's ongoing litigation exposure related to Allergan's textured breast implants and generic drug pricing practices influence the financial or strategic rationale behind the $120.30 per share cash component of the Allergan acquisition?",
      "answer": "The litigation exposure from Allergan's textured breast implants, which are the subject of consolidated securities litigation in New York with class certification granted in September 2021, and the generics pricing litigation settled in November 2021, introduces significant legal and reputational risk post-acquisition. Given that AbbVie paid $120.30 in cash per Allergan share as part of the acquisition consideration finalized in May 2020, this financial commitment must have factored in known litigation liabilities at the time. However, the continued litigation activity post-acquisition suggests that AbbVie may have underestimated or under-reserved for these liabilities, potentially affecting the long-term value realization of the acquisition despite its strategic intent to diversify AbbVie\u2019s business across new therapeutic areas.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_134) \u2192 Lawsuit: AbbVie faces litigation tied to Allergan's products, including textured breast implants and generics pricing practices.",
        "Hop 2: Lawsuit \u2192 Allergan: These lawsuits were filed against Allergan prior to or shortly after the acquisition and were part of its legacy liabilities.",
        "Hop 3: Allergan \u2190 ABBV(page_91): AbbVie paid $120.30 in cash per Allergan share as part of the 2020 acquisition, which implies that these legal exposures were factored into the valuation and risk assessment."
      ],
      "difficulty": "hard",
      "idf_score": 5.699080239556016,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Faces]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Lawsuit",
        "node_3": "Allergan",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Lawsuit",
          "name": "Lawsuit",
          "type": "LITIGATION",
          "idf_score": 4.131333131591441
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Allergan",
          "name": "Allergan",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_3",
          "chunk_text": "\nCertain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.\n\n## Note 5 Licensing, Acquisitions and Other Arrangements\n\n## Acquisition of Allergan\n\nOn May 8, 2020, AbbVie completed its acquisition of all outstanding equity interests in Allergan in a cash and stock transaction. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The combination created a diverse entity with leadership positions across immunology, hematologic oncology, aesthetics, neuroscience, eye care and women's health. AbbVie's existing product portfolio and pipeline is enhanced with numerous Allergan assets and Allergan's product portfolio benefits from AbbVie's commercial strength, expertise and international infrastructure. Under the terms of the acquisition, each ordinary share of Allergan common stock was converted into the right to receive (i) $120.30 in cash and (ii) 0.8660 of a share of AbbVie common stock.\n\nTotal consideration for the acquisition of Allergan is summarized as follows:\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 88,
      "question": "How does AbbVie's acquisition-related goodwill from Cerevel Therapeutics connect with the financing liability associated with tavapadon's development, and how is the fair value of this liability updated post-acquisition?",
      "answer": "AbbVie recognized goodwill from the acquisition of Cerevel Therapeutics, which included expectations of synergies and pipeline expansion (page 72). This acquisition brought with it funding agreements tied to the development of tavapadon, which require AbbVie to make contingent payments based on regulatory and sales milestones (page 67). Post-acquisition, the financing liability associated with these agreements is measured at fair value using unobservable inputs, including probability-weighted models and Monte Carlo simulations, with changes in fair value reflected in earnings (page 84). This shows how AbbVie not only assumed contingent liabilities through the acquisition but also actively manages and updates their valuation based on evolving probabilities and market conditions.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_72) \u2192 Cerevel Therapeutics: AbbVie recognized goodwill from the acquisition of Cerevel Therapeutics, which included expectations of synergies and pipeline expansion.",
        "Hop 2: Cerevel Therapeutics \u2192 Funding Agreements: Cerevel had entered into funding agreements tied to the development of tavapadon, which AbbVie assumed upon acquisition. These agreements require AbbVie to make contingent payments based on regulatory and sales milestones.",
        "Hop 3: Funding Agreements \u2190 ABBV(page_84): Post-acquisition, the financing liability associated with these agreements is measured at fair value using unobservable inputs, with changes in fair value recognized in earnings."
      ],
      "difficulty": "hard",
      "idf_score": 6.115534801023568,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Enters]-> FIN_INST <-[Involved_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Cerevel Therapeutics",
        "node_3": "Funding Agreements",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_7",
          "chunk_text": "\n(a) Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5).\n\nThe company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of December 31, 2024 and 2023, there were no accumulated goodwill impairment losses.\n\n## 69 | 2024 Form 10-K",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Cerevel_Therapeutics",
          "name": "Cerevel Therapeutics",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_67",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIntangible assets relate to $8.1 billion of acquired in-process research and development (IPR&amp;D) associated with products that have not yet received regulatory approval. The estimated fair values of identifiable intangible assets were determined using the \"income approach\" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful l i fe. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors.\n\nThe current portion of long-term debt assumed by AbbVie consists of $345 million aggregate principal of 2.5% convertible senior notes due 2027. Upon acquisition, the convertible senior notes became callable and note holders could redeem the convertible senior notes for cash at a premium. As of the acquisition date, the convertible senior notes were recognized as current portion of long-term debt on the consolidated balance sheets at an aggregate fair value of $400 million. Following the acquisition date, the company repaid the convertible senior notes and there were no amounts outstanding as of December 31, 2024.\n\nLong-term debt assumed by AbbVie relates to funding agreements entered into by Cerevel Therapeutics prior to the acquisition. Under the agreements, Cerevel Therapeutics received funding to support development of tavapadon and agreed to repay regulatory milestones, sales milestones and royalties contingent upon approval of tavapadon by the U.S. Food and Drug Administration (FDA). The funding agreements were accounted for as financing arrangements and the fair value of the related financing liability was $246 million as of the acquisition date. The estimated fair value of the financing liability was determined using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Assumptions inherent in the development of fair value include discount rates, estimated probabilities and timing of achieving milestones and estimated amounts of future sales. See Note 10 and Note 11 for additional information.\n\nGoodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of Cerevel Therapeutics represents expected synergies, including the ability to: (i) expand AbbVie's neuroscience pipeline, (ii) leverage AbbVie's commercial, regulatory and clinical expertise to maximize Cerevel Therapeutic's assets and (iii) enhance AbbVie's existing neuroscience discovery capabilities. The goodwill is not deductible for tax purposes.\n\n2024 Form 10-K\n\n",
          "relationship": "Enters"
        },
        "node_3": {
          "id": "Funding_Agreements",
          "name": "Funding Agreements",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 89,
      "question": "How does Merck's expectation of declining U.S. sales for Keytruda due to IRA-mandated government price setting in 2028 align with its broader concerns about the long-term impact of the IRA on pharmaceutical innovation and new treatment development?",
      "answer": "Merck anticipates that Keytruda, a major revenue driver, will face a government-set price effective January 1, 2028, which the company expects will lead to a decline in its U.S. sales. This expectation is detailed in the context of the Inflation Reduction Act (IRA), which introduces government price setting for certain Medicare Part B drugs starting in 2028. On page 10, Merck expresses broader concerns that the IRA could harm innovation in the pharmaceutical industry, potentially resulting in fewer new treatments being developed and approved over time. The company is actively working to mitigate these harmful effects, particularly the risk of reduced innovation. Therefore, the anticipated decline in Keytruda sales serves as a concrete example of how the IRA's pricing provisions could undermine the financial incentives for pharmaceutical innovation that Merck highlights as a systemic risk to the industry.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_38) \u2192 [Government Price Setting]: Merck explicitly states that Keytruda is expected to be selected for IRA-mandated government price setting in 2026, with the price becoming effective in 2028, leading to a projected decline in U.S. sales.",
        "Hop 2: [Government Price Setting] \u2192 [Keytruda]: Keytruda is one of the products specifically identified by Merck as being subject to future government price setting under the IRA, making it a focal point for how this policy will directly affect the company\u2019s revenue.",
        "Hop 3: [Keytruda] \u2190 [MRK](page_10): On page 10, Merck raises concerns about the long-term implications of the IRA on innovation in the pharmaceutical industry, suggesting that reduced pricing power could lead to fewer new treatments being developed, which aligns with the specific risk posed to Keytruda\u2019s revenue stream."
      ],
      "difficulty": "hard",
      "idf_score": 6.227106576680673,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Impacted_By]-> REGULATORY_REQUIREMENT -[Negatively_Impacted_By]-> PRODUCT <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Government Price Setting",
        "node_3": "Keytruda",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Risks Relating to G overnment Regulation and Legal Proceedings\n\n## The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.\n\nAs discussed above in Item 1. 'Competition and the Health Care Environment,' the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive Branch, Congress and state legislatures.\n\nIn 2022, Congress passed the IRA , which makes significant changes to how drugs are covered and paid for under the M edicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the M edicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, which has taken effect in 2025, and government price setting for certain M edicare Part D drugs, starting in 2026, and  M edicare  Part  B  drugs  starting  in  2028.  Furthermore,  government  price  setting  may  also  impact  pricing  in  the  private  market,  negatively  affecting  the Company's performance. A s noted in Item 1. 'Competition and the Health Care Environment,' in 2023, HHS selected Januvia for the first y ear of the IRA 's price setting program, which will result in a government set price becoming effective on January 1, 2026. On January 17, 2025, HHS announced that Janumet and Janumet XR have been selected for government price setting, which will become effective on January 1, 2027. Furthermore, the Company expects that in 2026 HHS will include Keytruda in a subsequent selection of products to undergo IRA  price setting, with such price to become effective on January 1, 2028 and the Company expects that, as a result, U.S. sales of Keytruda will decline after that time.\n\nIn addition, in 2021, Congress passed the A merican Rescue Plan A ct, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to M edicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to M edicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the A verage M anufacturer Price (AMP) in rebates to state M edicaid programs for M edicaid-covered drugs. A s a result of this provision, manufacturers may have to pay state M edicaid programs more in rebates than they received on sales of particular products. This change presents a risk to M erck for drugs that have high M edicaid utilization and rebate exposure that is more than 100% of the AM P . A dditionally , increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company's ability  to identify  inappropriate discounts are having a negative impact on the Company's performance. A lso, the Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug A ffordability Boards that have the authority to conduct affordability rev iews and establish upper payment limits and that Company products may be selected for such reviews.\n\nIn the U.S., members of the government have made public statements in favor of, and may take steps to implement, various regulatory changes that could  negatively  impact  the  pharmaceutical  industry ,  including  the  Company .  Those  potential  changes  include  some  related  to  vaccines  and  vaccine development, as well as personnel and policy changes at the FDA and other government agencies and programs. For example, HHS could undergo changes that could make it more difficult for the FDA  to grant regulatory approvals for drugs and vaccines and the U.S. Centers for Disease Control and Prevention (CDC) to issue or maintain recommendations for vaccines. A dditionally , if the FDA  drug user fee programs were eliminated, that could cause significant delays to facility inspections and approvals of new products. It is too early for the Company to assess which, if any , of the policy changes that have been publicly referenced would be implemented, and the Company cannot predict what additional future changes in the health care industry in general, or the pharmaceutical industry in particular,  will  occur;  howev er,  any   changes  could  hav e  a  material  adv erse  effect  on  the  Company 's  business,  cash  flows,  results  of  operations,  financial condition and prospects.\n\n## The  Company's  products,  including  products  in  development,  cannot  be  marketed  unless  the  Company  obtains  and  maintains  regulatory approval.\n\nThe Company's activities, including research, preclinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S., including the FDA , and by foreign regulatory authorities, including in the EU, Japan and China. In the U.S., the FDA  administers requirements covering the testing, approval, safety , effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals and vaccines. In some cases, the FDA  requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. Regulation outside the U.S. also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA  and foreign regulatory authorities, including in the EU, Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.",
          "relationship": "Impacted_By"
        },
        "node_2": {
          "id": "Government_Price_Setting",
          "name": "Government Price Setting",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nIn  addressing global cost containment pressures, the  Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens' access to appropriate health care, including medicines.\n\nOperating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company's business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.\n\n## United States\n\nThe Company faces increasing pricing pressure from managed care organizations, government agencies and programs that could negatively affect the Company's sales and profit margins, including, through (i) practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii) federal laws and regulations related to M edicare and M edicaid, including the M edicare Prescription Drug, Improvement, and Modernization A ct of 2003, the Patient Protection and A ffordable Care A ct of 2010 (A CA ), the A merican Rescue Plan A ct of 2021 (A merican Rescue Plan A ct), and the Inflation Reduction A ct of 2022 (IRA ). A dditionally , increased utiliz ation of the 340B Federal Drug Discount Program and restrictions on the Company's ability to identify  inappropriate discounts are having a negative impact on Company performance.\n\nIn the U.S., federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay . For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by M edicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, V eterans A ffairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.\n\nAdditionally in the U.S., consolidation and integration among health care entities is a major factor in the competitive marketplace for pharmaceutical products.  Health plans and pharmacy benefit managers have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for M erck's products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been increasing the cost-sharing required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies, as well as governments, also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in  treatment  areas  in  which  the  payor  has  taken  the  position  that  multiple  branded  products  are  therapeutically  comparable.  A s  the  U.S.  payor  market concentrates further, the Company may face greater pricing pressure from private third-party payors.\n\n## Legislative Changes\n\nIn 2022, Congress passed the IRA , which makes significant changes to how drugs are covered and paid for under the M edicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the M edicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, which has taken effect in 2025, and government price setting for certain M edicare Part D drugs, starting in 2026, and  M edicare  Part  B  drugs  starting  in  2028.  Government  price  setting  may  also  impact  pricing  in  the  private  market  negatively  affecting  the  Company's performance. In A ugust 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for M edicare &amp; M edicaid Services (CM S), selected Januvia for the first y ear of the IRA 's 'Drug Price Negotiation Program' (Program). Pursuant to the IRA 's Program, a government price was set for Januvia , which will become effective on January 1, 2026. In January 2025, HHS announced that Janumet and Janumet XR have been selected for government price setting, which will become effective on January 1, 2027. In addition, the Company expects that Keytruda will be selected in 2026 for government price setting, which would become effective on January 1, 2028 and the Company expects that, as a result, U.S. sales of Keytruda will decline after that time. The Company has sued the U.S.  government  regarding  the  IRA 's  Program  (see  Item  8  'Financial  Statements  and  Supplementary  Data,'  Note  10.  'Contingencies  and  Environmental Liabilities' below). Furthermore,",
          "relationship": "Negatively_Impacted_By"
        },
        "node_3": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_10",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nthe Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs.\n\nThe long-term implications of the IRA  remain uncertain and subject to various factors, including the manner in which HHS decides to implement the statute. M any experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time. M erck is working to mitigate the potentially harmful effects that the law could have, which could include a detrimental impact on innovation.\n\nIn addition, in 2021, Congress passed the A merican Rescue Plan A ct, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to M edicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to M edicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the A verage M anufacturer Price (AMP) in rebates to state M edicaid programs for M edicaid-covered drugs. A s a result of this provision, manufacturers may have to pay state M edicaid programs more in rebates than they received on sales of particular products. This change presents a risk to M erck for drugs that have high M edicaid utilization and rebate exposure that is more than 100% of the A M P.\n\nThe Company also faces increasing pricing pressure in the states, which are looking to exert greater influence over the price of prescription drugs. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that  states  will  continue  their  focus  on  pharmaceutical  pricing  and  will  increasingly   shift  to  more  aggressiv e  price  control  tools  such  as  Prescription  Drug Affordability  Boards that have the authority to conduct affordability reviews and establish upper payment limits and that Company products may be selected for such reviews. In addition, in 2024, the FDA  authorized, for a two-year period, Florida's application to import prescription drugs from Canada.\n\n## Regulatory Changes\n\nThe pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls.\n\n## European Union\n\nEfforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product's prices in other markets (external reference pricing), or compare a product's price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company's drugs. Reference pricing mechanisms are usually set at the national level and can be changed pursuant to local regulations or guidance.\n\nSome EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans.  Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class.\n\nThe downward pressure on health care costs in general, particularly prescription drugs, has become intense. A s a result, increasingly high barriers are being erected to the entry of new products. In some EU M ember States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU M ember State.\n\nAdditionally , EU M ember States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from M ember State to M ember State. Some EU M ember States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU M ember States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or a so-called health technology assessment (HTA ), in order to obtain reimbursement or pricing approval. The HTA  of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in most EU M ember States. The HTA  process, which is currently governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country in",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 90,
      "question": "How does Amgen's financial exposure to EVENITY through its collaboration with UCB, as reflected in profit and loss sharing, align with the geographic commercialization responsibilities outlined in the partnership?",
      "answer": "Amgen's financial exposure to EVENITY through its collaboration with UCB is significant, as evidenced by global profit and loss share expenses of $396 million in 2023, $255 million in 2022, and $186 million in 2021, which were recorded in Cost of Sales. This financial commitment aligns with Amgen's responsibility to lead commercialization in all territories outside of Europe, including the United States, while UCB leads in most European countries. Despite UCB's leadership in Europe, Amgen retains global manufacturing and supply responsibilities and shares development and commercialization profits and losses equally with UCB, indicating a balanced but financially substantial partnership structure.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_132) \u2192 UCB: Amgen reports significant profit and loss sharing expenses related to EVENITY with UCB, totaling $396 million in 2023, indicating substantial financial exposure.",
        "Hop 2: UCB \u2192 EVENITY: UCB is a key collaborator in the development and commercialization of EVENITY, with defined geographic commercialization responsibilities\u2014UCB leads in Europe, while Amgen leads elsewhere.",
        "Hop 3: EVENITY \u2190 AMGN(page_30): EVENITY is highlighted as a major collaborative product with UCB, and Amgen's role includes global manufacturing and supply, with equal sharing of profits and losses, reinforcing the financial exposure already noted."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "UCB",
        "node_3": "EVENITY",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "share\tpayments\twere\t$44\tmillion\tand\t$47\tmillion\tas\tof\tDecember\t31,\t2023\tand\t2022,\trespectively,\twhich\tare\tincluded\tin\tOther current\tassets\tin\tthe\tConsolidated\tBalance\tSheets.\n\n## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\nDuring\t the\t years\t ended\t December\t 31,\t 2023,\t 2022\t and\t 2021,\t net\t costs\t due\t to\t AstraZeneca\t for\t global\t development\t were $77\t million,\t $74\t million\t and\t $49\t million,\t respectively,\t and\t were\t recorded\t in\t R&amp;D\t expense\t in\t the\t Consolidated\t Statements\t of Income.\tDuring\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\tnet\tcosts\tdue\tto\tAstraZeneca\tfor\tglobal\tcommercialization\twere $73\tmillion,\t$60\tmillion\tand\t$39\tmillion,\trespectively,\tand\twere\trecorded\tin\tSG&amp;A\texpense\tin\tthe\tConsolidated\tStatements\tof Income.\tDuring\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022,\tglobal\tprofit\tand\tloss\tshare\texpenses\twere\t$310\tmillion\tand\t$119 million,\trespectively,\tand\twere\trecorded\tprimarily\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tTEZSPIRE\tlaunched in\tthe\tUnited\tStates\tin\tJanuary\t2022.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nDuring\t the\t years\t ended\t December\t 31,\t 2023,\t 2022\t and\t 2021,\t global\t profit\t and\t loss\t share\t expenses\t were\t $396\t million,\t $255 million\tand\t$186\tmillion,\trespectively,\tand\twere\trecorded\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tNet\tcosts recovered\tfrom\tand\tdue\tto\tUCB\tduring\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\twere\tnot\tmaterial.\n\n## Novartis\tPharma\tAG\n\nWe\tare\tin\ta\tcollaboration\twith\tNovartis\tto\tjointly\tdevelop\tand\tcommercialize\tAimovig.\tOn\tJanuary\t31,\t2022,\twe\tmodified\tthe terms\tof\tthe\tcollaboration.\tEffective\tJanuary\t1,\t2022,\tin\tthe\tUnited\tStates,\tNovartis\tno\tlonger\tcollaborates\twith\tAmgen,\tshares Aimovig\tcommercialization\tcosts\tor\tis\trequired\tto\tpay\tmilestones,\tand\tAmgen\tno\tlonger\tpays\troyalties\tto\tNovartis\ton\tU.S.\tsales of\tAimovig.\tNovartis\tcontinues\tto\thold\tglobal\tco-development\trights\tand\texclusive\tcommercial\trights\toutside\tthe\tUnited\tStates and\tJapan\tfor\tAimovig.\tAmgen\tand\tNovartis\tshare\tglobal\tdevelopment\texpenses,\tand\tNovartis\tpays\tAmgen\tdouble-digit\troyalties\ton net\tsales\tof\tthe\tproduct\toutside\tthe\tUnited\tStates\tand\tJapan.\tAmgen\tmanufactures\tand\tsupplies\tAimovig\tworldwide.\n\nDuring\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022,\tnet\tcosts\trecovered\tfrom\tNovartis\tfor\tmigraine\tproducts\twere\t$42\tmillion and\t$53\tmillion,\trespectively,\tand\twere\trecorded\tin\tR&amp;D\texpense\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyear\tended December\t31,\t2021,\tnet\tcosts\trecovered\tfrom\tNovartis\tfor\tmigraine\tproducts\twere\t$160\tmillion\tand\twere\trecorded\tprimarily\tin\tSG&amp;A expense\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyear\tended\tDecember\t31,\t2021,\troyalties\tdue\tto\tNovartis\tfor\tAimovig were\t$116\tmillion\tand\twere\trecorded\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyears\tended\tDecember 31,\t2023,\t2022\tand\t2021,\troyalties\tdue\tfrom\tNovartis\tfor\tAimovig\twere\tnot\tmaterial.\n\n## Kyowa\tKirin\tCo.,\tLtd.\n\nWe\tare\tin\ta\tcollaboration\tand\tlicensing\tagreement\twith\tKyowa\tKirin\tto\tjointly\tdevelop\tand\tcommercialize\trocatinlimab,\tan anti-OX40\tfully\thuman\tmonoclonal\tantibody,\tworldwide,\texcept\tin\tJapan.\tRocatinlimab\tis\tfor\tthe\ttreatment\tof\tatopic\tdermatitis, with\tpotential\tfor\ttreatment\tof\tother\tautoimmune\tdiseases.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tlead\tthe\tglobal\tdevelopment,\tmanufacture\tand\tcommercialization\tof\trocatinlimab,\texcept in\t Japan.\t Kyowa\t Kirin\t will\t co-promote\t rocatinlimab\t with\t Amgen\t in\t the\t United\t States\t and\t have\t opt\t in\t rights\t to\t co-promote rocatinlimab\tin\tvarious\tother\tmarkets\toutside\tthe\tUnited\tStates,\tincluding\tin\tEurope\tand\tAsia.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "UCB",
          "name": "UCB",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nFor\t financial\t information\t about\t our\t significant\t collaborative\t arrangements,\t see\t Part\t IV-Note\t 9,\t Collaborations,\t to\t the Consolidated\tFinancial\tStatements.",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "EVENITY",
          "name": "EVENITY",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nFor\t financial\t information\t about\t our\t significant\t collaborative\t arrangements,\t see\t Part\t IV-Note\t 9,\t Collaborations,\t to\t the Consolidated\tFinancial\tStatements.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 91,
      "question": "How does Johnson & Johnson's classification of reverse repurchase agreements (RRAs) with maturities over three months align with its accounting treatment of held-to-maturity investments, given the company's policy of maintaining collateral at 102% of RRA value?",
      "answer": "Johnson & Johnson classifies reverse repurchase agreements (RRAs) with maturities over three months from the date of purchase as marketable securities, while held-to-maturity investments are reported at amortized cost with realized gains or losses recognized in earnings. The company maintains a policy that the collateral backing RRAs must be at least 102% of their value and rated at least A (or equivalent), which reflects a conservative approach to liquidity and credit risk. This policy aligns with the accounting treatment of held-to-maturity investments, which also emphasizes credit quality and long-term holding, suggesting a consistent strategy of risk mitigation across both investment types. However, the classification of longer-term RRAs as marketable securities indicates a more liquid or potentially shorter-duration intent compared to held-to-maturity investments.",
      "reasoning_steps": [
        "Hop 1: JNJ(page_54) \u2192 Held-to-Maturity Investments: Discloses classification of RRAs with maturities over three months as marketable securities and outlines collateral policy at 102% with minimum A rating",
        "Hop 2: Held-to-Maturity Investments \u2192 Held to Maturity Policy: Regulates the accounting treatment of such investments at amortized cost with realized gains/losses in earnings",
        "Hop 3: Held to Maturity Policy \u2190 JNJ(page_59): Subject_To the policy that held-to-maturity investments are reported at amortized cost and realized gains or losses are reported in earnings"
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Regulates]-> ACCOUNTING_POLICY <-[Subject_To]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Held-to-Maturity Investments",
        "node_3": "Held to Maturity Policy",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_1",
          "chunk_text": "at  least  an  investment  grade  credit  rating.  The  Company  invests  its  cash  primarily  in  government  securities  and  obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).\n\nRRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a  daily  basis.  RRAs  with  stated  maturities  of  greater  than  three  months  from  the  date  of  purchase  are  classified  as marketable securities.\n\n## Investments\n\nInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.\n\n## Property, Plant and Equipment and Depreciation\n\nProperty, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Held-to-Maturity_Investments",
          "name": "Held-to-Maturity Investments",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_5",
          "chunk_text": "\nHeld to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (1)\n\nAvailable for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. (2)",
          "relationship": "Regulates"
        },
        "node_3": {
          "id": "Held_to_Maturity_Policy",
          "name": "Held to Maturity Policy",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_5",
          "chunk_text": "\nHeld to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (1)\n\nAvailable for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. (2)",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 92,
      "question": "How does Amgen's commitment to facilitating patient access through pricing and support programs reconcile with the negative impact on product sales caused by commercial payers like Express Scripts leveraging their market dominance to extract deeper discounts and impose access restrictions?",
      "answer": "Amgen emphasizes its commitment to facilitating patient access through responsible pricing, co-pay assistance, and biosimilar development (page 17). However, despite these efforts, payers like Express Scripts\u2014part of the top six integrated health plans and PBMs controlling 94% of U.S. pharmacy prescriptions\u2014use their market dominance to negotiate deeper discounts and impose access restrictions, such as prior authorization and step therapy, which have negatively affected Repatha sales and could continue to impact other products (page 37). This dynamic shows that while Amgen is actively trying to improve access, structural market forces and payer strategies significantly constrain the effectiveness of those efforts in practice.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_17) \u2192 [Patient Access]: Amgen outlines its commitment to patient access through responsible pricing, co-pay assistance, and biosimilars, while acknowledging pricing pressures from Medicare reforms and Medicaid rebate proposals.",
        "Hop 2: [Patient Access] \u2192 [Express Scripts]: Commercial payers like Express Scripts are shown to impose access restrictions and negotiate deeper discounts due to their dominant market position, directly impacting patient access and utilization of Amgen products.",
        "Hop 3: [Express Scripts] \u2190 [AMGN](page_37): Amgen reports that payer actions, including those by Express Scripts, have materially affected product sales, particularly for Repatha, due to formulary restrictions, co-pay requirements, and increased rebate demands."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Enables]-> RISK_FACTOR -[Negatively_Impacts]-> COMP <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Patient Access",
        "node_3": "Express Scripts",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_17",
          "chunk_id": "chunk_1",
          "chunk_text": "ENBREL's profitability in Medicare. In January 2025, CMS announced the next 15 drugs for Medicare price setting that will be applicable beginning on January 1, 2027, which includes Otezla. Also under the IRA, starting on January 1, 2024, Medicare Part D was redesigned to cap beneficiary out-of-pocket costs and, beginning on January 1, 2025, Federal reinsurance will become reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs). Further, the IRA created a mechanism for CMS to collect rebates from manufacturers if price increases outpace inflation. We began to accrue for rebate obligations on October 1, 2022 for Medicare Part D and on January 1, 2023 for Medicare Part B.\n\nOther potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; increasing transparency in drug pricing; using third-party value assessments to determine drug prices; referencing foreign prices; and changes to government rebate programs. For example, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, which excludes biologics. CMS also issued a proposed Medicaid Drug Rebate Program rule that would have required manufacturers to aggregate or 'stack' all rebates, discounts or other price concessions made to separate, unrelated entities across the pharmaceutical supply chain on a given unit of product to determine the 'Best Price,' a metric that is used to determine Medicaid rebates and 340B statutory rates. This proposal was not finalized but remains a policy that could be reconsidered in the future. Further, at the state level, eight states (Colorado, Maine, Maryland, Minnesota, New Hampshire, New Jersey, Oregon and Washington) have enacted laws that establish PDABs to identify drugs that pose affordability challenges, and in four states (Colorado, Maryland, Minnesota and Washington) include authority for the state PDAB to set upper payment limits on certain drugs for in-state patients, payers and providers.\n\nIn  many  countries  other  than  the  United  States,  government-sponsored  healthcare  systems  are  the  primary  payers  for  drugs  and  biologics.  With  increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in rebates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many governments use health technology assessment organizations to judge the added benefit of new treatments over existing ones, metrics which are then used to set reimbursement prices and/or set coverage limits. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that governments will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and revision of its pharmaceutical legislation. Various proposals are under consideration with the EU Council, followed by a negotiation among the EU government to agree to a final law. Full implementation is not expected until 2027 or later. The new legislation, if implemented, will likely have a significant impact on the landscape for access and pricing decisions within EU Member States.\n\nThe dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. G iven the diverse interests  in  play  between  payers,  biopharmaceutical  manufacturers,  policy  makers,  healthcare  providers  and  independent  organizations,  if  and  whether  the  parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:\n\n- investing billions of dollars annually in R&amp;D;\n- pricing our medicines to reflect the value they provide;\n- developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;\n- partnering with payers to share risk and accountability for health outcomes;\n- providing patient support and education programs;\n- helping patients in financial need access our medicines; and\n- working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.\n\nSee  Item  1A.  Risk  FactorsOur  sales  depend  on  coverage  and  reimbursement  from  government  and  commercial  third-party  payers,  and  pricing  and reimbursement pressures have affected, and are likely to continue to affect, our profitability and Item 1A. Risk FactorsGuidelines and recommendations published by various organizations can reduce the use of our products.",
          "relationship": "Enables"
        },
        "node_2": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Express_Scripts",
          "name": "Express Scripts",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 93,
      "question": "How does BMY's financial treatment of Celgene in amortization adjustments relate to the legal risks posed by the Pomalyst antitrust class action, particularly in light of the ongoing litigation and potential damages under federal and state laws?",
      "answer": "BMY's financial treatment of Celgene includes amortization of purchase price adjustments to Celgene debt, indicating a continued financial linkage post-acquisition. This financial integration contrasts with the legal exposure arising from the Pomalyst antitrust class action, where Celgene and BMS are defendants in a lawsuit alleging anticompetitive conduct related to pomalidomide, including fraudulent patent practices and unlawful settlements with generic manufacturers. Although no trial date has been set, the plaintiffs have filed an amended complaint expanding the scope, which heightens the risk of potential damages under federal antitrust laws and state consumer protection statutes. The litigation risk could result in significant financial liabilities, which may not yet be fully captured in BMY\u2019s amortization adjustments or segment-specific financial disclosures, highlighting a potential misalignment between financial integration and legal risk exposure.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_58) \u2192 [Celgene]: BMY includes amortization of purchase price adjustments to Celgene debt, indicating ongoing financial integration post-acquisition.",
        "Hop 2: [Celgene] \u2192 [Complaint]: Celgene faces a Pomalyst antitrust class action alleging fraud before the USPTO, sham litigation, and unlawful patent settlements.",
        "Hop 3: [Complaint] \u2190 [BMY](page_121): BMY is jointly named in the litigation, with exposure to damages under federal antitrust and state laws, which could materially affect financial position."
      ],
      "difficulty": "hard",
      "idf_score": 5.637779078509849,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> COMP -[Faces]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Celgene",
        "node_3": "Complaint",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_58",
          "chunk_id": "chunk_3",
          "chunk_text": "\n(a)\t\t\t\tIncludes\tamortization\tof\tpurchase\tprice\tadjustments\tto\tCelgene\tdebt.",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_1",
          "chunk_text": "In\tOctober\tand\tNovember\t2023,\tthree\thealthcare\tsystems-the\tMayo\tClinic,\tLifePoint\tCorporate\tServices,\tG.P.\tand\tIntermountain Health,\tInc.-filed\ttwo\tnew\tlawsuits\tagainst\tCelgene,\tBMS\tand\tcertain\tgeneric\tmanufacturers\tmaking\tlargely\tthe\tsame\tclaims\tand allegations\tagainst\tCelgene\tand\tBMS\tas\twere\tmade\twith\trespect\tto Revlimid in\tthe\tnow-settled\tclass\taction\tlitigation,\tand seeking\tinjunctive\trelief\tand\tdamages\tunder\tthe\tSherman\tAntitrust\tAct\tand\tparallel\tstate\tlaws.\tThose\tactions\tare\tpending\tin the\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey.\tNo\ttrial\tdates\thave\tbeen\tscheduled.\n\n## MSK\tContract\tLitigation\n\nOn\tApril\t1,\t2022,\tMemorial\tSloan\tKettering\tCancer\tCenter\tand\tEureka\tTherapeutics,\tInc.\t(collectively,\t\"Plaintiffs\")\tfiled\ta complaint\tagainst\tBMS,\tCelgene\tand\tJuno\t(collectively,\t\"Defendants\").\tIn\tJune\t2022,\tPlaintiffs\tfiled\tan\tamended\tcomplaint. Plaintiffs\tallege\tthat\tDefendants\tbreached\ta\tlicense\tagreement\tby\tallegedly\tfailing\tto\tuse\tcommercially\treasonable\tefforts\tto develop,\t manufacture,\t and\t commercialize\t a\t certain\t chimeric\t antigen\t receptor\t product\t and\t by\t failing\t to\t pay\t Plaintiffs\t a running\t royalty\t of\t at\t least\t 1.5%\t of\t worldwide\t sales\t of Abecma allegedly\t owed\t to\t Plaintiffs\t under\t the\t license\t agreement. Defendants\tdisagree\twith\tplaintiffs'\tclaims,\tand\tfiled\ta\tmotion\tto\tdismiss\tthe\tamended\tcomplaint\tin\tJuly\t2022.\tOn\tJanuary\t24, 2024,\tthe\tCourt\tgranted\tDefendants'\tmotion\tto\tdismiss\tas\tto\tBMS\tand\tCelgene,\tremoving\tthem\tfrom\tthe\tcase.\tThe\tcase\tagainst Juno\twill\tcontinue.\tNo\ttrial\tdate\thas\tbeen\tscheduled.\n\n## Pomalyst\tAntitrust\tClass\tAction\n\nIn\tSeptember\t2023,\tcertain\thealth\tplan\tentities\tfiled\tan\taction\ton\tbehalf\tof\ta\tputative\tclass\tof\tend-payor\tplaintiffs\tagainst Celgene,\tBMS,\tand\tcertain\tgeneric\tpharmaceutical\tmanufacturers\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tSouthern\tDistrict\tof\tNew York.\tThe\tclass\tcomplaint\tasserts\tclaims\tunder\tfederal\tantitrust\tlaw\tand\tstate\tantitrust,\tconsumer\tprotection,\tand\tunjust enrichment\tlaws\tbased\ton\tallegations\tthat\tCelgene\tand\tBMS\tengaged\tin\tanticompetitive\tconduct\trelated\tto\tpomalidomide\tin\tthe U.S.,\t including\t by\t allegedly\t engaging\t in\t fraud\t before\t the\t USPTO\t in\t the\t acquisition\t of\t patents\t related\t to\t the\t use\t of pomalidomide,\tby\tfiling\talleged\tsham\tpatent\tlitigations\tagainst\tgeneric\tpharmaceutical\tcompanies\tseeking\tto\tmarket\tgeneric pomalidomide,\t and\t by\t entering\t into\t allegedly\t unlawful\t patent\t litigation\t settlements\t with\t certain\t generic\t pharmaceutical companies\tseeking\tto\tmarket\tgeneric\tpomalidomide.\tIn\tDecember\t2023,\tthe\tplaintiffs\tfiled\tan\tamended\tcomplaint\tthat\tadded\tone individual\t Pomalyst\t patient\t as\t a\t plaintiff,\t removed\t the\t generic\t manufacturer\t defendants,\t and\t added\t two\t individuals\t as defendants.\tNo\ttrial\tdate\thas\tbeen\tscheduled.\n\n## GOVERNMENT\tINVESTIGATIONS\n\nLike\tother\tpharmaceutical\tcompanies,\tBMS\tand\tcertain\tof\tits\tsubsidiaries\tare\tsubject\tto\textensive\tregulation\tby\tnational, state\tand\tlocal\tauthorities\tin\tthe\tU.S.\tand\tother\tcountries\tin\twhich\tBMS\toperates.\tAs\ta\tresult,\tBMS,\tfrom\ttime\tto\ttime,\tis subject\t to\t various\t governmental\t and\t regulatory\t inquiries\t and\t investigations\t as\t well\t as\t threatened\t legal\t actions\t and proceedings.\tIt\tis\tpossible\tthat\tcriminal\tcharges,\tsubstantial\tfines\tand/or\tcivil\tpenalties,\tcould\tresult\tfrom\tgovernment\tor regulatory\tinvestigations.\n\n## ENVIRONMENTAL\tPROCEEDINGS\n\nAs\t previously\t reported,\t BMS\t is\t a\t party\t to\t several\t environmental\t proceedings\t and\t other\t matters,\t and\t is\t responsible\t under various\t state,\t federal\t and\t foreign\t laws,\t including\t CERCLA,\t for\t certain\t costs\t of\t investigating\t and/or\t remediating contamination\tresulting\tfrom\tpast\tindustrial\tactivity\tat\tBMS's\tcurrent\tor\tformer\tsites\tor\tat\twaste\tdisposal\tor\treprocessing facilities\toperated\tby\tthird\tparties.\n\n## CERCLA\tand\tOther\tRemediation\tMatters\n\nWith\t respect\t to\t CERCLA\t and\t other\t remediation\t matters\t for\t which\t BMS\t is\t responsible\t under\t various\t state,\t federal\t and international\t laws,\t BMS\t typically\t estimates\t potential\t costs\t based\t on\t information\t obtained\t from\t the\t U.S.\t Environmental Protection\tAgency,\tor\tcounterpart\tstate\tor\tforeign\tagency\tand/or\tstudies\tprepared\tby\tindependent\tconsultants,\tincluding\tthe total\testimated\tcosts\tfor\tthe\tsite\tand\tthe\texpected\tcost-sharing,\tif\tany,\twith\tother\t\"potentially\tresponsible\tparties,\"\tand BMS\taccrues\tliabilities\twhen\tthey\tare\tprobable\tand\treasonably\testimable.\tBMS\testimated\tits\tshare\tof\tfuture\tcosts\tfor\tthese sites\tto\tbe\t$80\tmillion\tas\tof\tDecember\t31,\t2023,\twhich\trepresents\tthe\tsum\tof\tbest\testimates\tor,\twhere\tno\tbest\testimate\tcan reasonably\tbe\tmade,\testimates\tof\tthe\tminimal\tprobable\tamount\tamong\ta\trange\tof\tsuch\tcosts\t(without\ttaking\tinto\taccount\tany potential\trecoveries\tfrom\tother\tparties).\tThe\tamount\tincludes\tthe\testimated\tcosts\tfor\tany\tadditional\tprobable\tloss\tassociated with\tthe\tpreviously\tdisclosed\tNorth\tBrunswick\tTownship\tHigh\tSchool\tRemediation\tSite.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Complaint",
          "name": "Complaint",
          "type": "LITIGATION",
          "idf_score": 4.701877990059054
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_1",
          "chunk_text": "In\tOctober\tand\tNovember\t2023,\tthree\thealthcare\tsystems-the\tMayo\tClinic,\tLifePoint\tCorporate\tServices,\tG.P.\tand\tIntermountain Health,\tInc.-filed\ttwo\tnew\tlawsuits\tagainst\tCelgene,\tBMS\tand\tcertain\tgeneric\tmanufacturers\tmaking\tlargely\tthe\tsame\tclaims\tand allegations\tagainst\tCelgene\tand\tBMS\tas\twere\tmade\twith\trespect\tto Revlimid in\tthe\tnow-settled\tclass\taction\tlitigation,\tand seeking\tinjunctive\trelief\tand\tdamages\tunder\tthe\tSherman\tAntitrust\tAct\tand\tparallel\tstate\tlaws.\tThose\tactions\tare\tpending\tin the\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey.\tNo\ttrial\tdates\thave\tbeen\tscheduled.\n\n## MSK\tContract\tLitigation\n\nOn\tApril\t1,\t2022,\tMemorial\tSloan\tKettering\tCancer\tCenter\tand\tEureka\tTherapeutics,\tInc.\t(collectively,\t\"Plaintiffs\")\tfiled\ta complaint\tagainst\tBMS,\tCelgene\tand\tJuno\t(collectively,\t\"Defendants\").\tIn\tJune\t2022,\tPlaintiffs\tfiled\tan\tamended\tcomplaint. Plaintiffs\tallege\tthat\tDefendants\tbreached\ta\tlicense\tagreement\tby\tallegedly\tfailing\tto\tuse\tcommercially\treasonable\tefforts\tto develop,\t manufacture,\t and\t commercialize\t a\t certain\t chimeric\t antigen\t receptor\t product\t and\t by\t failing\t to\t pay\t Plaintiffs\t a running\t royalty\t of\t at\t least\t 1.5%\t of\t worldwide\t sales\t of Abecma allegedly\t owed\t to\t Plaintiffs\t under\t the\t license\t agreement. Defendants\tdisagree\twith\tplaintiffs'\tclaims,\tand\tfiled\ta\tmotion\tto\tdismiss\tthe\tamended\tcomplaint\tin\tJuly\t2022.\tOn\tJanuary\t24, 2024,\tthe\tCourt\tgranted\tDefendants'\tmotion\tto\tdismiss\tas\tto\tBMS\tand\tCelgene,\tremoving\tthem\tfrom\tthe\tcase.\tThe\tcase\tagainst Juno\twill\tcontinue.\tNo\ttrial\tdate\thas\tbeen\tscheduled.\n\n## Pomalyst\tAntitrust\tClass\tAction\n\nIn\tSeptember\t2023,\tcertain\thealth\tplan\tentities\tfiled\tan\taction\ton\tbehalf\tof\ta\tputative\tclass\tof\tend-payor\tplaintiffs\tagainst Celgene,\tBMS,\tand\tcertain\tgeneric\tpharmaceutical\tmanufacturers\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tSouthern\tDistrict\tof\tNew York.\tThe\tclass\tcomplaint\tasserts\tclaims\tunder\tfederal\tantitrust\tlaw\tand\tstate\tantitrust,\tconsumer\tprotection,\tand\tunjust enrichment\tlaws\tbased\ton\tallegations\tthat\tCelgene\tand\tBMS\tengaged\tin\tanticompetitive\tconduct\trelated\tto\tpomalidomide\tin\tthe U.S.,\t including\t by\t allegedly\t engaging\t in\t fraud\t before\t the\t USPTO\t in\t the\t acquisition\t of\t patents\t related\t to\t the\t use\t of pomalidomide,\tby\tfiling\talleged\tsham\tpatent\tlitigations\tagainst\tgeneric\tpharmaceutical\tcompanies\tseeking\tto\tmarket\tgeneric pomalidomide,\t and\t by\t entering\t into\t allegedly\t unlawful\t patent\t litigation\t settlements\t with\t certain\t generic\t pharmaceutical companies\tseeking\tto\tmarket\tgeneric\tpomalidomide.\tIn\tDecember\t2023,\tthe\tplaintiffs\tfiled\tan\tamended\tcomplaint\tthat\tadded\tone individual\t Pomalyst\t patient\t as\t a\t plaintiff,\t removed\t the\t generic\t manufacturer\t defendants,\t and\t added\t two\t individuals\t as defendants.\tNo\ttrial\tdate\thas\tbeen\tscheduled.\n\n## GOVERNMENT\tINVESTIGATIONS\n\nLike\tother\tpharmaceutical\tcompanies,\tBMS\tand\tcertain\tof\tits\tsubsidiaries\tare\tsubject\tto\textensive\tregulation\tby\tnational, state\tand\tlocal\tauthorities\tin\tthe\tU.S.\tand\tother\tcountries\tin\twhich\tBMS\toperates.\tAs\ta\tresult,\tBMS,\tfrom\ttime\tto\ttime,\tis subject\t to\t various\t governmental\t and\t regulatory\t inquiries\t and\t investigations\t as\t well\t as\t threatened\t legal\t actions\t and proceedings.\tIt\tis\tpossible\tthat\tcriminal\tcharges,\tsubstantial\tfines\tand/or\tcivil\tpenalties,\tcould\tresult\tfrom\tgovernment\tor regulatory\tinvestigations.\n\n## ENVIRONMENTAL\tPROCEEDINGS\n\nAs\t previously\t reported,\t BMS\t is\t a\t party\t to\t several\t environmental\t proceedings\t and\t other\t matters,\t and\t is\t responsible\t under various\t state,\t federal\t and\t foreign\t laws,\t including\t CERCLA,\t for\t certain\t costs\t of\t investigating\t and/or\t remediating contamination\tresulting\tfrom\tpast\tindustrial\tactivity\tat\tBMS's\tcurrent\tor\tformer\tsites\tor\tat\twaste\tdisposal\tor\treprocessing facilities\toperated\tby\tthird\tparties.\n\n## CERCLA\tand\tOther\tRemediation\tMatters\n\nWith\t respect\t to\t CERCLA\t and\t other\t remediation\t matters\t for\t which\t BMS\t is\t responsible\t under\t various\t state,\t federal\t and international\t laws,\t BMS\t typically\t estimates\t potential\t costs\t based\t on\t information\t obtained\t from\t the\t U.S.\t Environmental Protection\tAgency,\tor\tcounterpart\tstate\tor\tforeign\tagency\tand/or\tstudies\tprepared\tby\tindependent\tconsultants,\tincluding\tthe total\testimated\tcosts\tfor\tthe\tsite\tand\tthe\texpected\tcost-sharing,\tif\tany,\twith\tother\t\"potentially\tresponsible\tparties,\"\tand BMS\taccrues\tliabilities\twhen\tthey\tare\tprobable\tand\treasonably\testimable.\tBMS\testimated\tits\tshare\tof\tfuture\tcosts\tfor\tthese sites\tto\tbe\t$80\tmillion\tas\tof\tDecember\t31,\t2023,\twhich\trepresents\tthe\tsum\tof\tbest\testimates\tor,\twhere\tno\tbest\testimate\tcan reasonably\tbe\tmade,\testimates\tof\tthe\tminimal\tprobable\tamount\tamong\ta\trange\tof\tsuch\tcosts\t(without\ttaking\tinto\taccount\tany potential\trecoveries\tfrom\tother\tparties).\tThe\tamount\tincludes\tthe\testimated\tcosts\tfor\tany\tadditional\tprobable\tloss\tassociated with\tthe\tpreviously\tdisclosed\tNorth\tBrunswick\tTownship\tHigh\tSchool\tRemediation\tSite.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 94,
      "question": "How does AbbVie's profit-sharing arrangement with Janssen Biotech on Imbruvica sales, as detailed in the collaboration note, reconcile with the company's broader accounting policy on collaboration revenues and milestone payments?",
      "answer": "AbbVie's collaboration with Janssen Biotech on Imbruvica involves a profit- and cost-sharing structure where both parties share pre-tax profits and losses equally, with Janssen covering approximately 60% of development costs and AbbVie 40%. This arrangement is consistent with AbbVie's broader accounting policy, as outlined in the financial statements, which recognizes collaboration revenues and expenses based on the nature of the payments\u2014development milestones are expensed upfront, while regulatory and commercial milestones are capitalized and amortized. The profit-sharing from Imbruvica is reflected in AbbVie\u2019s net revenues and cost of products sold, aligning with the company\u2019s stated approach to recognizing revenue and expenses from collaborative arrangements.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_68) \u2192 Imbruvica: Introduces Imbruvica as a jointly developed and commercialized product with Janssen Biotech, outlining a profit- and cost-sharing arrangement where both parties share pre-tax profits and losses equally and Janssen covers 60% of development costs.",
        "Hop 2: Imbruvica \u2192 Janssen Biotech: The collaboration agreement establishes Janssen Biotech as a key partner in the development and commercialization of Imbruvica, with defined financial responsibilities and revenue-sharing terms.",
        "Hop 3: Janssen Biotech \u2190 ABBV(page_60): The company\u2019s accounting policy on collaboration revenues and milestone payments explains how such arrangements are recognized in financial statements, including expensing development milestones and capitalizing regulatory/commercial milestones."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Introduces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Imbruvica",
        "node_3": "Janssen Biotech",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Imbruvica",
          "name": "Imbruvica",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "Janssen_Biotech",
          "name": "Janssen Biotech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_60",
          "chunk_id": "chunk_1",
          "chunk_text": "products\tsubject\tto\tthe\trebate,\tthe\tapplicable\tprice\tterms\tand\tthe\testimated\tlag\ttime\tbetween\tsale\tand\tpayment\tof\tthe\trebate, which\tcan\tbe\tsignificant.\n\nIn\taddition\tto\trevenue\tfrom\tcontracts\twith\tcustomers,\tthe\tcompany\talso\trecognizes\tcertain\tcollaboration\trevenues.\tSee\tNote\t6 for\tadditional\tinformation\trelated\tto\tthe\tcollaborations\twith\tJanssen\tBiotech,\tInc.\tand\tGenentech,\tInc.\tAdditionally,\tsee\tNote\t16 for\tdisaggregation\tof\trevenue\tby\tproduct\tand\tgeography.\n\n## Research\tand\tDevelopment\tExpenses\n\nInternal\tR&amp;D\tcosts\tare\texpensed\tas\tincurred.\tClinical\ttrial\tcosts\tincurred\tby\tthird\tparties\tare\texpensed\tas\tthe\tcontracted work\tis\tperformed.\n\n## Acquired\tIPR&amp;D\tand\tMilestones\tExpenses\n\nIn\tan\tasset\tacquisition,\tpayments\tincurred\tprior\tto\tregulatory\tapproval\tto\tacquire\trights\tto\tin-process\tR&amp;D\tprojects\tare expensed\tas\tacquired\tIPR&amp;D\tand\tmilestones\texpense\tin\tthe\tconsolidated\tstatements\tof\tearnings\tunless\tthe\tproject\thas\tan\talternative future\tuse.\tThese\tcosts\tinclude\tupfront\tand\tdevelopment\tmilestone\tpayments\trelated\tto\tR&amp;D\tcollaborations,\tlicensing\tarrangements, or\tother\tasset\tacquisitions\tthat\tprovide\trights\tto\tdevelop,\tmanufacture\tand/or\tsell\tpharmaceutical\tproducts.\tWhere\tcontingent development\tmilestone\tpayments\tare\tdue\tto\tthird\tparties,\tprior\tto\tregulatory\tapproval,\tthe\tpayment\tobligations\tare\texpensed\twhen the\tmilestone\tresults\tare\tachieved.\tRegulatory\tand\tcommercial\tmilestone\tpayments\tmade\tto\tthird\tparties\tsubsequent\tto\tregulatory approval\tare\tcapitalized\tas\tintangible\tassets\tand\tamortized\tto\tcost\tof\tproducts\tsold\tover\tthe\tremaining\tuseful\tlife\tof\tthe\trelated product.\n\n## Business\tCombinations\n\nAbbVie\tutilizes\tthe\tacquisition\tmethod\tof\taccounting\tfor\tbusiness\tcombinations.\tThis\tmethod\trequires,\tamong\tother\tthings,\tthat results\tof\toperations\tof\tacquired\tcompanies\tare\tincluded\tin\tAbbVie's\tresults\tof\toperations\tbeginning\ton\tthe\tacquisition\tdate\tand that\tassets\tacquired\tand\tliabilities\tassumed\tare\trecognized\tat\tfair\tvalue\tas\tof\tthe\tacquisition\tdate.\tAny\texcess\tof\tthe\tfair\tvalue of\tconsideration\ttransferred\tover\tthe\tfair\tvalue\tof\tthe\tnet\tassets\tacquired\tis\trecognized\tas\tgoodwill.\tContingent\tconsideration liabilities\tare\trecognized\tat\tthe\testimated\tfair\tvalue\ton\tthe\tacquisition\tdate.\tSubsequent\tchanges\tto\tthe\tfair\tvalue\tof\tcontingent consideration\tliabilities\tare\trecognized\tin\tother\texpense,\tnet\tin\tthe\tconsolidated\tstatements\tof\tearnings.\tThe\tfair\tvalue\tof assets\tacquired\tand\tliabilities\tassumed\tin\tcertain\tcases\tmay\tbe\tsubject\tto\trevision\tbased\ton\tthe\tfinal\tdetermination\tof\tfair\tvalue during\ta\tperiod\tof\ttime\tnot\tto\texceed\t12\tmonths\tfrom\tthe\tacquisition\tdate.\tLegal\tcosts,\tdue\tdiligence\tcosts,\tbusiness\tvaluation costs\tand\tall\tother\tbusiness\tacquisition\tcosts\tare\texpensed\twhen\tincurred.\n\nIn\ta\tbusiness\tcombination,\tthe\tfair\tvalue\tof\tIPR&amp;D\tprojects\tacquired\tis\tcapitalized\tand\taccounted\tfor\tas\tindefinite-lived intangible\tassets\tuntil\tthe\tunderlying\tproject\treceives\tregulatory\tapproval,\tat\twhich\tpoint\tthe\tintangible\tasset\twill\tbe\taccounted for\tas\ta\tdefinite-lived\tintangible\tasset,\tor\tdiscontinuation,\tat\twhich\tpoint\tthe\tintangible\tasset\twill\tbe\twritten\toff.\tR&amp;D\tcosts incurred\tby\tthe\tcompany\tafter\tthe\tacquisition\tare\texpensed\tto\tR&amp;D\tas\tincurred.\n\n## Collaborations\tand\tOther\tArrangements\n\nThe\tcompany\tenters\tinto\tcollaborative\tagreements\twith\tthird\tparties\tto\tdevelop\tand\tcommercialize\tdrug\tcandidates. Collaborative\tactivities\tmay\tinclude\tjoint\tresearch\tand\tdevelopment\tand\tcommercialization\tof\tnew\tproducts.\tAbbVie\tgenerally receives\tcertain\tlicensing\trights\tunder\tthese\tarrangements.\tThese\tcollaborations\toften\trequire\tupfront\tpayments\tand\tmay\tinclude additional\tmilestone,\tresearch\tand\tdevelopment\tcost\tsharing,\troyalty\tor\tprofit\tshare\tpayments,\tcontingent\tupon\tthe\toccurrence\tof certain\tfuture\tevents\tlinked\tto\tthe\tsuccess\tof\tthe\tasset\tin\tdevelopment\tand\tcommercialization.\tUpfront\tpayments\tassociated\twith collaborative\tarrangements\tand\tsubsequent\tpayments\tmade\tto\tthe\tpartner\tfor\tthe\tachievement\tof\tdevelopment\tmilestones\tprior\tto regulatory\tapproval\tare\texpensed\tto\tacquired\tIPR&amp;D\tand\tmilestones\texpense\tin\tthe\tconsolidated\tstatements\tof\tearnings.\tRegulatory and\tcommercial\tmilestone\tpayments\tmade\tto\tthe\tpartner\tsubsequent\tto\tregulatory\tapproval\tare\tcapitalized\tas\tintangible\tassets\tand amortized\tto\tcost\tof\tproducts\tsold\tover\tthe\testimated\tuseful\tlife\tof\tthe\trelated\tasset.\tRoyalties\tare\texpensed\tto\tcost\tof\tproducts sold\tin\tthe\tconsolidated\tstatements\tof\tearnings\twhen\tincurred.\n\n## Advertising\n\nCosts\tassociated\twith\tadvertising\tare\texpensed\tas\tincurred\tand\tare\tincluded\tin\tselling,\tgeneral\tand\tadministrative\t(SG&amp;A) expense\tin\tthe\tconsolidated\tstatements\tof\tearnings.\tAdvertising\texpenses\twere\t$2.2\tbillion\tin\t2023,\t$2.0\tbillion\tin\t2022\tand\t$2.1 billion\tin\t2021.\n\n## 57 | 2023\tForm\t10-K",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 95,
      "question": "How does AbbVie's financial benefit from the Allergan acquisition, particularly the reduction in inventory fair value step-up adjustment, reconcile with the ongoing litigation risks associated with Allergan's legacy businesses, such as the shareholder lawsuits over textured breast implants and generic drug pricing?",
      "answer": "AbbVie reported a gross margin improvement in 2021 due to lower amortization of inventory fair value step-up adjustment from the Allergan acquisition, indicating a positive financial impact. However, this benefit is juxtaposed with ongoing litigation risks tied to Allergan's legacy operations, including shareholder lawsuits over textured breast implants and anticompetitive conduct allegations related to the Actavis generics unit. These legal challenges, some of which have been certified as class actions, pose potential financial liabilities and reputational risks that could offset the acquisition's financial gains. The coexistence of these factors suggests a complex risk-reward profile for AbbVie post-Allergan acquisition.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_65) \u2192 [Allergan]: AbbVie's gross margin improvement in 2021 was attributed to lower amortization of inventory fair value step-up adjustment from the Allergan acquisition.",
        "Hop 2: [Allergan] \u2192 [Lawsuit]: Allergan faces multiple lawsuits, including those from shareholders related to textured breast implants and generic drug pricing, indicating legacy legal risks.",
        "Hop 3: [Lawsuit] \u2190 [ABBV](page_134): AbbVie continues to face litigation stemming from Allergan's legacy businesses, including class action lawsuits that have been certified, highlighting ongoing exposure."
      ],
      "difficulty": "hard",
      "idf_score": 5.699080239556016,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Faces]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Allergan",
        "node_3": "Lawsuit",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_3",
          "chunk_text": "\nGross margin as a percentage of net revenues in 2021 increased from 2020 primarily due to lower amortization of inventory fair value step-up adjustment associated with the Allergan acquisition and favorable changes in product mix, partially offset by higher amortization of intangible assets associated with the Allergan acquisition.\n\n## Selling, General and Administrative\n\n",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Allergan",
          "name": "Allergan",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Lawsuit",
          "name": "Lawsuit",
          "type": "LITIGATION",
          "idf_score": 4.131333131591441
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 96,
      "question": "How does Amgen's use of interest rate swap contracts to hedge $1.4 billion of the 3.625% 2024 Notes relate to the full repayment of those notes in 2024, and what does this imply about their debt management strategy?",
      "answer": "Amgen used interest rate swap contracts to hedge $1.4 billion of the 3.625% 2024 Notes, effectively converting fixed-rate coupons to floating-rate SOFR-based coupons. This hedging activity was disclosed on page 148. The company fully repaid the $1.4 billion aggregate principal amount of the 3.625% 2024 Notes in 2024, as noted in the debt repayments section on page 142. This indicates a strategic approach to managing interest rate exposure on specific debt instruments before their retirement, aligning hedging activities with debt repayment schedules to mitigate financial risk.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_149) \u2192 Interest Rate Swap Contracts: Amgen discloses the notional amounts and interest rates of interest rate swap contracts, including those associated with the 3.625% 2024 Notes.",
        "Hop 2: Interest Rate Swap Contracts \u2192 3.625% 2024 Notes: Interest rate swaps were used to hedge the 3.625% 2024 Notes, converting fixed-rate debt to floating-rate debt as part of Amgen\u2019s fair value hedging strategy.",
        "Hop 3: 3.625% 2024 Notes \u2190 AMGN(page_142): Amgen fully repaid the $1.4 billion of 3.625% 2024 Notes in 2024, aligning with the maturity of the associated interest rate swap contracts."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Impacts]-> FIN_INST <-[Decreases]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Interest Rate Swap Contracts",
        "node_3": "3.625% 2024 Notes",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_149",
          "chunk_id": "chunk_1",
          "chunk_text": "As of December 31, 2024 and 2023, the interest rates on the portion of notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Interest_Rate_Swap_Contracts",
          "name": "Interest Rate Swap Contracts",
          "type": "FIN_INST",
          "idf_score": 5.069602770184371
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_148",
          "chunk_id": "chunk_5",
          "chunk_text": "\n## Fair value hedges\n\nTo achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that qualify for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate SOFR-based coupons over the terms of the related hedge contracts. As of both December 31, 2024 and 2023, we had interest rate swap contracts with an aggregate notional amount of $6.7 billion that hedge certain portions of our long-term debt issuances.\n\nDuring the year ended December 31, 2024, interest rate swap contracts with an aggregate notional amount of $1.4 billion matured in connection with the repayment of  the 3.625% 2024 Notes. In addition, we entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%.",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "3.625%_2024_Notes",
          "name": "3.625% 2024 Notes",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_142",
          "chunk_id": "chunk_1",
          "chunk_text": "## Debt extinguishment\n\nIn 2024, we repurchased an aggregate principal amount of our debt of $875 million, including portions of the 3.15% 2040  Notes, 2.80% 2041  Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $659 million, which resulted in a $215 million gain on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income.\n\nIn 2023, we repurchased an aggregate principal amount of our debt of $881 million, including portions of the 2.00% 2032 Notes, 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375%  2050  Notes, 3.00%  2052  Notes, 4.20%  2052  Notes  and 4.40%  2062  Notes,  for  an  aggregate  cost  of  $647  million,  which  resulted  in  a  $225  million  gain  on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income.\n\nIn 2022, we repurchased an aggregate principal amount of our debt of $378 million, including portions of the 2.20% 2027 Notes, 1.65% 2028 Notes, 2.00% 2032 Notes, 2.80% 2041 Notes and 3.00% 2052 Notes, for an aggregate cost of $297 million, which resulted in a $78 million gain on extinguishment of debt recorded in Other income (expense), net, in the Consolidated Statements of Income.\n\n## Debt repayments\n\nIn 2024, we repaid the full $2.0 billion aggregate principal amount on the term loan due April 2025, $200 million of the aggregate principal amount on the term loan due October 2026 and the full $1.4 billion aggregate principal amount of the 3.625% 2024 Notes.\n\nIn 2023, we repaid the full $750 million aggregate principal amount of the 2.25% 2023 Notes and the full CHF700 million aggregate principal amount ($704 million upon settlement of the related cross-currency swap) of the 0.41% 2023 Swiss franc Bonds.\n\n## In 2022, no debt was repaid or redeemed.\n\n## Interest rate swaps\n\nTo achieve a desired mix of fix ed-rate and floating-rate debt, we enter into interest rate swap contracts that effectively convert fix ed-rate interest coupons for certain of our debt instruments to floating SOFR-based coupons over the terms of the respective debt instruments. These interest rate swap contracts qualify and are designated as fair value hedges. For information regarding the terms of these contracts, see Note 19, Derivative instruments.\n\n## Cross-currency swaps\n\nTo hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts outstanding as of December 31, 2024, effectively convert the interest payments and principal repayments on our 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros and pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 19, Derivative instruments. Cross-currency swap contracts associated with other foreign denominated debt previously outstanding were settled in connection with the repayment of such debt, as discussed above.\n\n## Shelf registration statement and other facilities\n\nAs of December 31, 2024, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2024 and 2023, we had no amounts outstanding under our commercial paper program.\n\nIn the first quarter of 2023, we amended and restated our syndicated, unsecured, revolving credit agreement, under which we may borrow up to $4.0 billion for general corporate purposes, including as a liquidity backstop for our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $1.25 billion with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. G enerally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) SOFR plus 1.01% or (ii) the highest of (A) the administrative agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month SOFR plus 1.1%. As of December 31, 2024 and 2023, no amounts were outstanding under this facility.\n\nIn February 2023, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary",
          "relationship": "Decreases"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 97,
      "question": "How does BMY's strategic emphasis on expanding Opdivo into earlier lines of therapy and new tumor types align with the shorter market exclusivity timeline of its combination partner Yervoy, particularly given Yervoy's minimum exclusivity expiration in the U.S. by 2025?",
      "answer": "BMY's strategy emphasizes expanding Opdivo into earlier lines of therapy and new tumor types, including combinations with Yervoy and other anti-cancer agents (page_43). However, Yervoy, a key combination partner for Opdivo, has a minimum estimated market exclusivity date of 2025 in the U.S., significantly earlier than Opdivo\u2019s 2028 exclusivity date (page_8). This raises a strategic challenge, as the loss of Yervoy\u2019s exclusivity could limit the long-term commercial viability of the Opdivo + Yervoy regimen despite BMY\u2019s efforts to broaden its use in oncology (page_4).",
      "reasoning_steps": [
        "Hop 1: BMY(page_8) \u2192 Yervoy: Yervoy has a minimum estimated market exclusivity date of 2025 in the U.S., indicating a near-term risk of generic or biosimilar competition.",
        "Hop 2: Yervoy \u2192 Opdivo: Yervoy is frequently used in combination with Opdivo, as noted in the product descriptions, particularly for indications like NSCLC, melanoma, and CRC.",
        "Hop 3: Opdivo \u2190 BMY(page_43): BMY\u2019s strategy emphasizes expanding Opdivo into earlier lines of therapy and new tumor types, including continued use in combination with Yervoy, despite Yervoy\u2019s earlier exclusivity expiration."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Combines_With]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Yervoy",
        "node_3": "Opdivo",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                              | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   |\n|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|\n|                                              | U.S.                                        | EU (p)                                      | Japan                                       |\n| Abecma (idecabtagene vicleucel)              | 2036                                        | 2035                                        | 2035                                        |\n| Abraxane (paclitaxel) (a)                    | ^^                                          | ^^                                          | ^^                                          |\n| Augtyro (repotrectinib) (b)                  | 2035                                        | ++                                          | ++                                          |\n| Breyanzi (lisocabtagene maraleucel) (c)      | 2033                                        | 2033                                        | 2033                                        |\n| Camzyos (mavacamten) (d)                     | 2034                                        | 2034                                        | ++                                          |\n| Eliquis (apixaban) (e)                       | 2026                                        | ^^                                          | 2026                                        |\n| Inrebic (fedratinib) (f)                     | 2031                                        | 2031                                        | ++                                          |\n| Onureg (azacitidine) (g)                     | 2027                                        | ^^                                          | ++                                          |\n| Opdivo (nivolumab)                           | 2028                                        | 2030                                        | 2031                                        |\n| Opdualag (nivolumab and relatlimab-rmbw) (h) | 2034                                        | 2033                                        | ++                                          |\n| Orencia (abatacept) (i)                      | ^^                                          | ^^                                          | ^^                                          |\n| Pomalyst/Imnovid (pomalidomide) (j)          | ^^                                          | 2024                                        | ^^                                          |\n| Reblozyl (luspatercept-aamt) (k)             | 2031                                        | 2030                                        | ++                                          |\n| Revlimid (lenalidomide) (l)                  | ^^                                          | ^^                                          | ^^                                          |\n| Sotyktu (deucravacitinib) (m)                | 2033                                        | 2033                                        | 2033                                        |\n| Sprycel (dasatinib) (n)                      | ^^                                          | ^^                                          | ^^                                          |\n| Yervoy (ipilimumab)                          | 2025                                        | 2026                                        | 2025                                        |\n| Zeposia (ozanimod) (o)                       | 2029                                        | 2034                                        | ++                                          |",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Yervoy",
          "name": "Yervoy",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_2",
          "chunk_text": "| Eliquis \u00ae           | Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Opdivo \u00ae            | Opdivo (nivolumab) is a biological product and a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer. The Opdivo + Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and various gastric and esophageal cancers. There are several ongoing potentially registrational studies for Opdivo across other tumor types and disease areas, in monotherapy and in combination with Yervoy and various anti-cancer agents. |\n| Orencia \u00ae           | Orencia (abatacept) is a biological product, is a fusion protein indicated for adult patients with moderate to severe active RA and PsA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular JIA and for the treatment of aGVHD, in combination with a calcineurin inhibitor and methotrexate.                                                                                                                                                                                                                                                                                      |\n| Pomalyst /Imnovid \u00ae | Pomalyst/Imnovid (pomalidomide) is a small molecule that is administered orally and modulates the immune system and other biologically important targets. Pomalyst/Imnovid is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. \u00ae                                                                                                                                                                                                                                     |\n| Yervoy \u00ae            | Yervoy (ipilimumab) is a biological product and is a CTLA4 immune checkpoint inhibitor. Yervoy is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. The Opdivo + Yervoy regimen is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and esophageal cancer.                                                                                                                                                                                                                                                                                                                              |\n| Sprycel \u00ae           | Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosome-positive CML in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including Gleevec* (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome-positive CML.                                                                                                                                                             |",
          "relationship": "Combines_With"
        },
        "node_3": {
          "id": "Opdivo",
          "name": "Opdivo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Strategy\n\nOur\tprincipal\tstrategy\tis\tto\tcombine\tthe\tresources,\tscale\tand\tcapability\tof\ta\tlarge\tpharmaceutical\tcompany\twith\tthe\tspeed, agility\tand\tfocus\ton\tinnovation\ttypically\tfound\tin\tthe\tbiotech\tindustry.\tOur\tpriorities\tare\t(i)\tto\tcontinue\tto\trenew\tand diversify\t our\t portfolio\t through\t launching\t new\t medicines,\t (ii)\t advancing\t our\t early,\t mid\t and\t late-stage\t pipeline\t and\t (iii) executing\tdisciplined\tbusiness\tdevelopment.\tAs\twe\tundergo\ta\tperiod\tof\trenewal,\tour\tstrategy\twill\tbe\tfocused\ton\tdriving\tnearterm\t growth,\t minimizing\t the\t impact\t of\t a\t transition\t period\t that\t follows\t and\t delivering\t growth\t in\t the\t late\t 2020s\t by accelerating\t opportunities\t that\t enhance\t productivity\t and\t efficiency,\t advance\t our\t pipeline,\t and\t drive\t strong\t commercial execution\tthat\tmove\tour\tbusiness\tforward.\tWe\tremain\tcommitted\tto\ta\tstrategic\tbusiness\tdevelopment\tand\tmaintaining\ta\tstrong investment\tgrade\tcredit\trating,\tgrowing\tthe\tdividend\tand\treducing\tadditional\tdebt\tthat\twill\tbe\tissued\tin\tsupport\tof\trecent transactions.\n\nOur\tfocus\tis\ton\tdiscovering,\tdeveloping\tand\tdelivering\ttransformational\tmedicines\tfor\tpatients\tfacing\tserious\tdiseases\tin\tthe following\tfive\tcore\ttherapeutic\tareas:\t(i)\toncology\twith\ta\tpriority\tin\tcertain\ttumor\ttypes,\tincluding\tdiversification\tbeyond IO;\t(ii)\thematology\twith\topportunities\tto\texpand\tleadership\tposition\tin\tmultiple\tmyeloma,\tas\twell\tas\tbroaden\tour\tportfolio across\t leukemias,\t lymphomas\t and\t non-malignant\t hematologic\t diseases;\t (iii)\t immunology\t with\t priorities\t in\t strengthening presence\tin\tdermatology,\trheumatology\tand\tgastrointestinal\tdisorders,\testablishing\tnew\tstandards\tof\tcare\tin\tpulmonology\tand rapidly\t advance\t cell\t therapy\t into\t immunology\t diseases;\t (iv)\t cardiovascular\t diseases\t with\t focus\t on\t cardiomyopathies,\t heart failures and thrombotic diseases; and (v) neuroscience with a focus on neuropsychiatry, neurodegenerative and neuroinflammation\tdiseases.\n\nWe\t are\t working\t towards\t expanding\t our\t pipeline\t of\t registrational\t assets\t from\t six\t to\t up\t to\t twelve.\t In\t addition,\t we\t are positioned\t to\t support\t continued\t innovation\t and\t expand\t treatment\t options\t across\t several\t different\t diseases\t based\t on\t our differentiated\tresearch\tplatforms.\tWe\thave\ta\tbroad\tportfolio\tand\tpipeline\twhen\tit\tcomes\tto\tautologous\tCAR-T\tcell\ttherapies. We\thave\ttwo\tapproved\tcell\ttherapies\tagainst\ttwo\tdistinct\ttargets\tand\tare\tcontinuing\tto\tbuild\tour\tleadership\tin\tthis\tspace.\tWe are\t expanding\t manufacturing\t capacity,\t exploring\t innovative\t technologies\t such\t as\t dual-targeting\t CAR-Ts\t and\t allogenic approaches,\tadvancing\tmultiple\tnext-generation\tassets\tincluding\tnew\ttargets\tand\trapidly\texpanding\tinto\timmunology,\tincluding lupus\tand\tmultiple\tsclerosis.\tWe\talso\thave\ta\tstrong\tposition\tin\tthe\tprotein\tdegradation\tfield\tand\thave\tbeen\tadvancing\tour pipeline\twith\tan\texpansive\tlibrary\tof\tassets\twith\ttwo\tin\tregistrational\ttrials,\tan\tadditional\tfive\tin\tclinical\tphase\tstudies and\t more\t than\t fifteen\t being\t studied\t pre-clinically.\t This\t growing\t platform\t has\t potential\t across\t several\t diseases\t and\t is positioned\tto\tdeliver\tapproximately\tfour\tINDs\teach\tyear.\tTogether\twith\tour\tproven\ttrack\trecord,\trapidly\tadvancing\tpipeline and\tgrowth\twith\tmarketed\tproducts,\twe\tincreased\tand\tsustained\tour\tR&amp;D\tproductivity\tenabling\tus\tto\tidentify\tmore\thigh-quality candidates\t and\t increase\t their\t probability\t of\t reaching\t patients\t in\t need.\t Specifically,\t our\t ambition\t is\t to:\t (i)\t deliver approximately\tten\tINDs\tper\tyear;\t(ii)\tincrease\tsuccess\trates\tfrom\tfirst-in-human\ttrials\tto\tapproval\tto\tapproximately\t20%; (iii)\treduce\ttimelines\tto\tachieve\ta\tmedian\tof\t6.5\tyears\tfrom\tfirst-in-human\ttrials\tto\tapproval.\tOur\tR&amp;D\tstrategy\twill\thelp ensure\t we\t maintain\t a\t strong\t legacy\t of\t scientific\t innovation,\t bringing\t first-in\t class\t and/or\t best-in-class\t treatments\t to patients\tat\tan\taccelerated\tspeed.\n\nOur\tcommercial\tmodel\thas\tbeen\tsuccessful\twith\trevenues\tfrom\tour\tin-line\tbrands\tand\tnew\tproduct\tportfolio\tcontinuing\tto\tgrow, which\tdemonstrates\tstrong\texecution\tof\tour\tstrategy.\tWe\tremain\tfocused\tand\twell-resourced\tin\tour\tcancer\tdevelopment\tprograms and\tseek\tto\tbroaden\tthe\tuse\tof Opdivo in\tearlier\tlines\tof\ttherapy,\texpand\tinto\tnew\ttumors,\taccelerate\tnext\twave\toncology mechanisms\t and\t develop\t treatment\t options\t for\t refractory\t oncology\t patients.\t We\t are\t encouraged\t that\t our\t investigational subcutaneous\t formulation\t for Opdivo has\t the\t potential\t to\t bring\t enhanced\t benefits\t to\t patients\t into\t the\t next\t decade,\t with positive\tregistrational\tdata\tnow\tin-house.\tWe\tcontinue\tto\tdrive\tadoption\tof Opdivo by\texpanding\tinto\tadditional\tindications and\t tumor\t types\t both\t as\t a\t monotherapy\t and\t in\t combination\t with Yervoy and\t other\t anti-cancer\t agents.\t We\t are\t further strengthening\t our\t IO\t portfolio\t with Opdualag for\t the\t treatment\t of\t melanoma\t and\t potential\t expanded\t opportunities\t in\t other indications.\t We\t are\t growing\t a\t differentiated\t NSCLC\t portfolio,\t which\t includes\t the\t launch\t of Augtyro and\t includes Krazati , (acquired\t through\t Mirati),\t which\t demonstrates\t a\t strategic\t fit\t into\t our\t oncology\t portfolio.\t We\t are\t also\t strengthening\t our neuroscience\tportfolio\twith\tthe\tplanned\tacquisition\tof\tKaruna.\tMoreover, Eliquis continues\tto\tgrow,\tleveraging\tits\tbest\tin class\t clinical\t profile\t and\t extensive\t real\t world\t data\t and\t remains\t the\t number\t one\t novel\t oral\t anticoagulant\t in\t total prescriptions\tglobally. Camzyos continues\tto\tdemonstrate\tbenefits\tas\tshared\tthrough\tour\tlong-term\tfollow-up\tdata\tfrom\ttwo Phase\tIII\tstudies.\tIn\timmunology, Sotyktu is\tthe\tkey\tgrowth\tdriver\tfor\tBMS\tand\twe\tcontinue\tto\tmake\tfurther\tinvestments\tto accelerate\t the\t launch\t through\t direct\t to\t consumer\t advertising\t and\t adding\t field\t force\t support.\t In\t addition,\t our\t Phase\t III registrational\t clinical\t trials\t are\t underway\t for Sotyktu in\t PsA,\t SLE\t and\t Sj\u00f6gren's\t Syndrome.\t We\t are\t able\t to\t leverage\t our leading\tcapabilities\tin\thematological\tmalignancies\tand\tour\trobust\tpipeline\tto\tprovide\topportunities\tfor\tlong-term\tgrowth\tto offset\tthe\timpact\tof\tcurrent\tand\tfuture\tpatent\texpiries\tfor Revlimid and Pomalyst .\tAs\twe\tlook\tat\tour\tcell\ttherapy\tfranchise, we\tcontinue\tto\texplore\tnew\tindications\twith Breyanzi to\tinclude\tthe\ttreatment\tof\tCLL,\tFL\tand\tMCL.\tIf\tindication\tfor\tCLL\tis approved,\t it\t would\t be\t the\t first\t and\t only\t CAR-T\t available\t for\t this\t patient\t population. Reblozyl is\t advancing\t into\t new indications\twith\tan\tongoing\tregistrational\ttrial\tfor\tchronic\tanemia\tassociated\twith\tmyelofibrosis.\n\nThe\t evolution\t in\t our\t operating\t model,\t which\t focuses\t on\t maintaining\t a\t disciplined\t approach\t in\t marketing,\t selling\t and administrative\texpenses,\twill\tenable\tus\tto\tdeliver\tthe\tnecessary\tstrategic,\tfinancial\tand\toperational\tflexibility\tto\tinvest in\tthe\thighest\tpriority\topportunities\twithin\tour\tportfolio.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 98,
      "question": "How does BMY's early generic entry for Revlimid in Europe illustrate the limitations of regulatory data protection in preventing market exclusivity loss, given that regulatory data protection typically prevents reliance on innovator data for generic approval?",
      "answer": "BMY experienced early generic entry for Revlimid in the UK starting January 18, 2022, and in other European countries beginning February 18, 2022, due to patent settlements, which shows that patent challenges can lead to earlier-than-expected market exclusivity loss. While market exclusivity is generally determined by patent rights and regulatory data protection (RDP), which prevents regulatory agencies from relying on innovator data to approve generic versions during the exclusivity period, the evidence from page 8 clarifies that RDP does not prevent competitors from gaining approval based on their own clinical data. This distinction reveals a key limitation of RDP: it only restricts reliance on the innovator's data, not independent development by competitors. Thus, even with RDP in place, BMY faced generic competition earlier than expected due to patent settlements, highlighting how regulatory data protection alone cannot fully safeguard market exclusivity when patent rights are challenged or expire prematurely.",
      "reasoning_steps": [
        "Hop 1: BMY(page_36) \u2192 Patent Rights: BMY discloses that patent settlements led to early generic entry for Revlimid in Europe, with specific dates in the UK and other European countries.",
        "Hop 2: Patent Rights \u2192 Market Exclusivity: Market exclusivity is determined by both patent rights and regulatory data protection, as outlined in the document, with patents being a key determinant of exclusivity duration.",
        "Hop 3: Market Exclusivity \u2190 BMY(page_8): Regulatory data protection does not prevent competitors from gaining approval using their own data, which means that even with RDP in place, a product can face competition if patent rights are compromised."
      ],
      "difficulty": "hard",
      "idf_score": 5.128494288012563,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> RISK_FACTOR -[Determined_By]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Patent Rights",
        "node_3": "Market Exclusivity",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_1",
          "chunk_text": "## meet one or more of its primary endpoints, our stock price could decline significantly and there may be an adverse impact on our business, financial condition or results of operations.\n\nWe are focusing our efforts and resources in disease areas of high unmet need. With our more focused portfolio, investors are  placing  heightened  scrutiny  on  some  of  our  products  or  late-stage  compounds.  We  have,  however,  experienced setbacks and may continue to do so as there are further developments in our clinical studies. For example, in October 2021,  we  announced  that  the  Phase  2  LATTICE-UC  study  evaluating  deucravacitinib,  a  first-in-class,  oral,  selective tyrosine kinase 2 (TYK2) inhibitor, compared to placebo in moderate to severe ulcerative colitis (UC) did not meet the primary efficacy endpoint of clinical remission at Week 12, nor secondary efficacy endpoints. Additionally, we obtained many late-stage compounds as well as prioritized brand portfolio in hematology and immunology through our acquisition of Celgene that may not meet expectations.\n\nThe announcement of data from our clinical studies, or those of our competitors, or news of any developments related to our, or our competitors', products or late-stage compounds, such as Opdivo, has and will continue to cause significant volatility  in  our  stock  price  and,  depending  on  the  news,  may  result  in  an  adverse  impact  on  our  business,  financial condition  or  results  of  operations.  Furthermore,  the  announcement  of  any  negative  or  unexpected  data  or  the discontinuation of development of any of our key late-stage product candidates, any delay in our anticipated timelines for filing for regulatory approval or a significant advancement of a competitor, has and will continue to cause our stock price to  decline  significantly  and  may  have  an  adverse  impact  on  our  business,  financial  condition  or  results  of  operations. There is no assurance that data from our clinical studies will support filings for regulatory approval, that our key product candidates may prove to be effective or as effective as other competing products, that, even if approved, any such products will become commercially successful for all approved indications, or that the indications of key products approved under the U.S. FDA ' s Accelerated Approval Program that continued approval is contingent upon verification and description of clinical benefit in confirmatory trials will be withdrawn.\n\n## We could lose market exclusivity of a product earlier than expected.\n\nIn the pharmaceutical and biotechnology industries, the majority of an innovative product's commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product's revenues.\n\nMarket exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights, if any, varies from country to country and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain or maintain patent and other intellectual property rights, or limitations on the use or loss of such rights, could result in a rapid loss of sales for any affected products which could be material to us. In some countries,  including  certain  EU  member  states,  basic  patent  protections  for  our  products  may  not  exist  because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file  in  those  countries.  In  addition,  the  patent  environment  can  be  unpredictable  and  the  validity  and  enforceability  of patents  cannot  be  predicted  with  certainty.  In  addition,  manufacturers  of  innovative  drugs  as  well  as  generic  drug manufacturers may be able to design their products around our owned or licensed patents and compete with us using the resulting alternative technology. Absent relevant patent protection for a product, once the data exclusivity period expires, generic or alternative versions can be approved and marketed.\n\nGeneric and biosimilar product manufacturers as well as other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we could face earlier-than-expected competition for any products at any time. Patents  covering  our  key  products  have  been,  and  are  likely  to  continue  to  be,  subject  to  validity,  enforceability  and infringement challenges in patent litigations and post-grant review patent office proceedings. Although we are confident in the strength of our intellectual property rights, it may be possible for generic drug companies to successfully challenge our rights and launch their generic versions of our drugs prior to the expiration of our intellectual property rights. In addition, in order to avoid the uncertainty and expense of litigation, among other reasons, we may decide to enter into settlements with generic manufacturers that permit generic market entry prior to the expiration of our intellectual property rights. For example, we expect that some generic drug companies may market generic versions of Revlimid in the major European markets before the expiration of our intellectual property rights. In particular, as a result of patent settlements, we  expect  generic  entry  for  Revlimid  in  the  United  Kingdom  beginning  on  January  18,  2022,  and  in  various  other European countries where our Supplemental Protection Certificate is in force beginning on February 18, 2022. Similarly, in  the  U.S.,  following  patent  settlements,  certain  companies  have  been  granted  volume-limited  licenses  to  sell  generic lenalidomide in the U.S. commencing in March 2022 or thereafter.\n\nIn  some  cases,  manufacturers  may  seek  regulatory  approval  by  submitting  their  own  clinical  study  data  to  obtain marketing  approval  or  choose  to  launch  a  generic  product  'at  risk'  before  the  expiration  of  the  applicable  patent(s) and/or before the final resolution of related patent litigation. In addition, some countries are allowing manufacturers to manufacture and sell",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "Patent_Rights",
          "name": "Patent Rights",
          "type": "RISK_FACTOR",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_2",
          "chunk_text": "\nWe own or license a number of patents in the U.S. and foreign countries primarily covering our products. We have also developed many brand names and trademarks for our products. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement.\n\nIn the pharmaceutical industry, the majority of an innovative product's commercial value is usually realized during the period in which  the  product  has  market  exclusivity. A  product's  market  exclusivity  is  generally  determined  by  two  forms  of  intellectual property:  patent  rights  held  by  the  innovator  company  and  any  regulatory  forms  of  exclusivity  to  which  the  innovative  drug  is entitled.\n\nPatents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to  exclude  others  from  practicing  an  invention  related  to  the  medicine.  Patents  may  cover,  among  other  things,  the  active ingredient(s),  various  uses  of  a  drug  product,  pharmaceutical  formulations,  drug  delivery  mechanisms  and  processes  for  (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.\n\nMarket exclusivity is also sometimes influenced by regulatory data protection exclusivity rights. Many developed countries provide certain non-patent incentives for the development of medicines. For example, in the U.S., EU, Japan and certain other countries, RDP exclusivity rights are offered as incentives for research on medicines for rare diseases, or orphan drugs, and on medicines useful in treating pediatric patients. These incentives can provide a market exclusivity period on a product that expires beyond the patent term.",
          "relationship": "Determined_By"
        },
        "node_3": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "The U.S., EU and Japan each provide regulatory data protection, a period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator's data to approve a competitor's generic copy. In certain markets where patent protection  and  other  forms  of  market  exclusivity  may  have  expired,  regulatory  data  protection  can  be  of  particular  importance. However, most regulatory forms of exclusivity do not prevent a competitor from gaining regulatory approval prior to the expiration of regulatory data protection exclusivity on the basis of the competitor's own safety and efficacy data on its drug, even when that drug is identical to  that  marketed  by  the  innovator. When  these  patent  rights  and  other  forms  of  exclusivity  expire  and  generic versions  of  a  medicine  are  approved  and  marketed,  there  are  often  substantial  and  rapid  declines  in  the  sales  of  the  original innovative product. For further discussion of the impact of generic competition on our business, refer to '-Competition' below.\n\nSpecific aspects of the law governing market exclusivity and data regulatory protection for pharmaceuticals vary from country to country. The following summarizes key exclusivity rules in markets representing significant sales:\n\n## United States\n\nIn the U.S., most of our key products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product's patent life, however, is lost during the time it takes an innovative company to develop and obtain regulatory approval of a new drug. As compensation at least in part for the lost patent term due to regulatory review periods, the  innovator  may,  depending  on  a  number  of  factors,  apply  to  the  government  to  restore  lost  patent  term  by  extending  the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval.\n\nA company seeking to market an innovative pharmaceutical in the U.S. must submit a complete set of safety and efficacy data to the  FDA.  If  the  innovative  pharmaceutical  is  a  chemical  product,  the  company  files  an  NDA.  If  the  medicine  is  a  biological product, a BLA is filed. Both types of applications can receive certain periods of regulatory exclusivity. An NDA or a BLA for a compound that is designated as an orphan drug can receive seven years of exclusivity for an orphan drug indication. During this period, the FDA generally may not approve another application for the same drug product for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic exclusivity. The type of application filed can affect regulatory data protection exclusivity rights as discussed below.\n\n## Chemical products\n\nA competitor seeking to launch a generic substitute of a chemical innovative drug in the U.S. must file an aNDA with the FDA. In the aNDA, the generic manufacturer needs to demonstrate only 'bioequivalence' between the generic substitute and the approved NDA drug. The aNDA relies upon the safety and efficacy data previously filed by the innovator in its NDA.\n\nAn innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an aNDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an aNDA and allege that  one  or  more  of  the  patents  listed  in  the  Orange  Book  under  an  innovator's  NDA  is  invalid,  unenforceable,  or  will  not  be infringed  by  the  generic  product. This  allegation  is  commonly  known  as  a  Paragraph  IV  certification. The  innovator  then  must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, aNDAs including Paragraph IV certifications are filed with respect to certain of our products. We evaluate these aNDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines  approved  under  an  NDA  can  also  receive  several  types  of  regulatory  data  protection.  An  innovative  chemical pharmaceutical product is entitled to five years of regulatory data protection in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, as described above, a generic manufacturer may file its aNDA after the fourth year of the five-year regulatory data protection period. A pharmaceutical drug product that contains an active ingredient that has been previously approved in an NDA, but is approved in, for example, a new formulation or a new route of administration, but not  for  the  drug  itself,  or  for  a  new  indication  on  the  basis  of  new  clinical  studies,  may  receive  three  years  of  regulatory  data protection for that formulation, route of administration, or indication.",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 99,
      "question": "How does BMY's reliance on Abilify\u2014a product whose trademark is owned by Otsuka\u2014affect BMY's financial obligations to Otsuka, particularly in light of the historical co-promotion agreement for Sprycel?",
      "answer": "BMY's use of the Abilify trademark, which is owned by Otsuka, highlights BMY's dependence on Otsuka for commercializing certain products, even though no direct financial obligation related to Abilify is mentioned in the filing. In contrast, BMY had a clear financial relationship with Otsuka through the co-promotion of Sprycel, under which BMY paid Otsuka fees based on net sales\u2014$294 million on the first $1.0 billion of annual net sales plus 1% beyond that. Although the co-promotion ended in 2019, payments to Otsuka in 2020 and 2021 were still substantial, indicating a significant financial linkage. This raises the question of whether BMY's use of Otsuka-owned intellectual property, such as the Abilify trademark, indirectly supports Otsuka's market position and could influence future financial arrangements or negotiations between the two companies.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_185) \u2192 [Abilify]: BMY references Abilify as a product it produces but notes that the trademark is owned by Otsuka.",
        "Hop 2: [Abilify] \u2192 [Otsuka]: Otsuka is the trademark owner of Abilify, indicating intellectual property control despite BMY's production and commercialization.",
        "Hop 3: [Otsuka] \u2190 [BMY](page_116): BMY had a co-promotion agreement with Otsuka for Sprycel, under which BMY paid significant fees, showing a financial dependency and collaboration history."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Owns]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Abilify",
        "node_3": "Otsuka",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_185",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Commission.\n* Indicates,  in  this  2021  Form  10-K,  brand  names  of  products,  which  are  registered  trademarks  not  solely  owned  by  the Company or  its  subsidiaries. Abilify is  a  trademark  of  Otsuka  Pharmaceutical  Co.,  Ltd.; Atripla is  a  trademark  of  Gilead Sciences,  LLC; Avapro/Avalide (known  in  the  EU  as Aprovel/Karvea )  and Plavix are  trademarks  of  Sanofi; Byetta is  a trademark of Amylin Pharmaceuticals, LLC; CABOMETYX is a trademark of Exelixis, Inc.; Erbitux is a trademark of ImClone LLC; Farxiga and Onglyza are  trademarks  of  AstraZeneca  AB; Gleevec is  a  trademark  of  Novartis  AG; Keytruda is  a trademark of Merck Sharp &amp; Dohme Corp.; Otezla is a trademark of Amgen Inc.; Tecentriq is a trademark of Genetech, Inc.; and Yescarta is a trademark of Kite Pharma, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Abilify",
          "name": "Abilify",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_185",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Commission.\n* Indicates,  in  this  2021  Form  10-K,  brand  names  of  products,  which  are  registered  trademarks  not  solely  owned  by  the Company or  its  subsidiaries. Abilify is  a  trademark  of  Otsuka  Pharmaceutical  Co.,  Ltd.; Atripla is  a  trademark  of  Gilead Sciences,  LLC; Avapro/Avalide (known  in  the  EU  as Aprovel/Karvea )  and Plavix are  trademarks  of  Sanofi; Byetta is  a trademark of Amylin Pharmaceuticals, LLC; CABOMETYX is a trademark of Exelixis, Inc.; Erbitux is a trademark of ImClone LLC; Farxiga and Onglyza are  trademarks  of  AstraZeneca  AB; Gleevec is  a  trademark  of  Novartis  AG; Keytruda is  a trademark of Merck Sharp &amp; Dohme Corp.; Otezla is a trademark of Amgen Inc.; Tecentriq is a trademark of Genetech, Inc.; and Yescarta is a trademark of Kite Pharma, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.",
          "relationship": "Owns"
        },
        "node_3": {
          "id": "Otsuka",
          "name": "Otsuka",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 100,
      "question": "Given the 32% global decline in Humira sales due to biosimilar competition in 2023, how does AbbVie's strategic focus on maintaining formulary access align with the product's continued dominance in revenue contribution, representing 27% of total net revenues for the year?",
      "answer": "AbbVie reported a 32% global decline in Humira sales in 2023 due to biosimilar competition following the loss of exclusivity in January 2023. Despite this significant drop, Humira still accounted for 27% of AbbVie's total net revenues in 2023, down from 37% in both 2022 and 2021. The company actively pursued strategies to maintain broad formulary access for Humira to mitigate biosimilar erosion. This dual narrative suggests that while biosimilars have had a material impact on Humira's revenue, AbbVie's proactive market access strategies have preserved its position as the company's largest product, albeit at a reduced revenue share. This alignment reflects a strategic balance between managing competitive pressures and sustaining revenue contribution from a historically dominant product.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_43) \u2192 Biosimilar Competition: Humira faced direct biosimilar competition globally after losing exclusivity in January 2023, leading to a 32% decline in global sales.",
        "Hop 2: Biosimilar Competition \u2192 Humira: The document explicitly states that Humira is facing direct biosimilar competition, which is a key driver of its declining revenues.",
        "Hop 3: Humira \u2190 ABBV(page_81): Despite the decline, Humira still accounted for 27% of AbbVie\u2019s total net revenues in 2023, maintaining its position as the company\u2019s largest product."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR -[Faces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Biosimilar Competition",
        "node_3": "Humira",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_2",
          "chunk_text": "\n## n/m\t-\tNot\tmeaningful\n\nThe\tfollowing\tdiscussion\tand\tanalysis\tof\tAbbVie's\tnet\trevenues\tby\tproduct\tis\tpresented\ton\ta\tconstant\tcurrency\tbasis.\n\nGlobal\tHumira\tsales\tdecreased\t32%\tin\t2023.\tIn\tthe\tUnited\tStates,\tHumira\tsales\tdecreased\t35%\tin\t2023\tprimarily\tdriven\tby\tdirect biosimilar\tcompetition\tfollowing\tloss\tof\texclusivity\ton\tJanuary\t31,\t2023.\tInternationally,\tHumira\trevenues\tdecreased\t12%\tin\t2023 primarily\tdriven\tby\tthe\tcontinued\timpact\tof\tdirect\tbiosimilar\tcompetition.\tAbbVie\tcontinues\tto\tpursue\tstrategies\tto\tmaintain\tbroad formulary\taccess\tof\tHumira\tand\tmanage\tthe\timpact\tof\tbiosimilar\terosion.\n\nNet\trevenues\tfor\tSkyrizi\tincreased\t51%\tin\t2023\tprimarily\tdriven\tby\tcontinued\tstrong\tmarket\tshare\tuptake\tas\twell\tas\tmarket growth\tacross\tall\tindications,\tpartially\toffset\tby\tunfavorable\tpricing.\n\nNet\trevenues\tfor\tRinvoq\tincreased\t58%\tin\t2023\tprimarily\tdriven\tby\tcontinued\tstrong\tmarket\tshare\tuptake\tas\twell\tas\tmarket growth\tacross\tall\tindications,\tpartially\toffset\tby\tunfavorable\tpricing.\n\nNet\trevenues\tfor\tImbruvica\trepresent\tproduct\trevenues\tin\tthe\tUnited\tStates\tand\tcollaboration\trevenues\toutside\tof\tthe\tUnited States\trelated\tto\tAbbVie's\t50%\tshare\tof\tImbruvica\tprofit.\tAbbVie's\tglobal\tImbruvica\trevenues\tdecreased\t21%\tin\t2023\tprimarily driven\tby\tdecreased\tdemand\tand\tlower\tmarket\tshare\tin\tthe\tUnited\tStates\tas\twell\tas\tdecreased\tcollaboration\trevenues.\n\nNet\trevenues\tfor\tVenclexta\tincreased\t15%\tin\t2023.\tIn\tthe\tUnited\tStates,\tVenclexta\tnet\trevenues\tincreased\t8%\tdriven\tby continued\tmarket\tgrowth\tacross\tall\tindications,\tmarket\tshare\tuptake\tas\twell\tas\tfavorable\tpricing.\tInternationally,\tVenclexta\tnet revenues\tincreased\t22%\tprimarily\tdriven\tby\tcontinued\tmarket\tshare\tuptake\tand\tmarket\tgrowth\tacross\tall\tindications.\n\nNet\trevenues\tfor\tBotox\tCosmetic\tincreased\t4%\tin\t2023.\tIn\tthe\tUnited\tStates,\tBotox\tCosmetic\tnet\trevenues\tincreased\t1%\tdriven\tby increased\tconsumer\tdemand\tdue\tto\teconomic\trecovery\tin\tthe\ttoxin\tmarket.\tInternationally,\tBotox\tCosmetic\tnet\trevenues\tincreased\t10% primarily\tdriven\tby\trecovery\tfrom\tCOVID-19\tin\tChina\tand\tincreased\tconsumer\tdemand\tacross\tother\tkey\tinternational\tmarkets.",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Biosimilar_Competition",
          "name": "Biosimilar Competition",
          "type": "RISK_FACTOR",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "## Marketing,\tSales\tand\tDistribution\tCapabilities\n\nAbbVie\tutilizes\ta\tcombination\tof\tdedicated\tcommercial\tresources,\tregional\tcommercial\tresources\tand\tdistributorships\tto\tmarket, sell\tand\tdistribute\tits\tproducts\tworldwide.\tAbbVie\tdirects\tits\tprimary\tmarketing\tefforts\ttoward\tsecuring\tthe\tprescription,\tor recommendation,\tof\tits\tbrand\tof\tproducts\tby\tphysicians,\texternal\texperts\tand\tother\thealth\tcare\tproviders.\tManaged\tcare\tproviders (for\texample,\thealth\tmaintenance\torganizations\tand\tpharmacy\tbenefit\tmanagers),\thospitals\tand\tstate\tand\tfederal\tgovernment\tagencies (for\texample,\tState\tMedicaid\tprograms,\tthe\tUnited\tStates\tDepartment\tof\tVeterans\tAffairs\tand\tthe\tUnited\tStates\tDepartment\tof Defense)\tare\talso\timportant\tcustomers.\tAbbVie\talso\tmarkets\tdirectly\tto\tconsumers\tthemselves,\talthough\tin\tthe\tUnited\tStates\tmany\tof the\tcompany's\tproducts\tmust\tbe\tsold\tpursuant\tto\ta\tprescription.\tOutside\tof\tthe\tUnited\tStates,\tAbbVie\tfocuses\tits\tpromotional\tand market\taccess\tefforts\ton\texternal\texperts,\tpayers,\tphysicians\tand\thealth\tsystems.\tAbbVie\talso\tprovides\tpatient\tsupport\tprograms closely\trelated\tto\tits\tproducts.\n\nAbbVie's\tproducts\tare\tgenerally\tsold\tworldwide\tdirectly\tto\twholesalers,\tdistributors,\tgovernment\tagencies,\thealth\tcare facilities,\tspecialty\tpharmacies\tand\tindependent\tretailers\tfrom\tAbbVie-owned\tdistribution\tcenters\tand\tpublic\twarehouses.\tCertain products\t(including\taesthetic\tproducts\tand\tdevices)\tare\talso\tsold\tdirectly\tto\tphysicians\tand\tother\tlicensed\thealthcare\tproviders. Although\tAbbVie's\tbusiness\tdoes\tnot\thave\tsignificant\tseasonality,\tAbbVie's\tproduct\trevenues\tmay\tbe\taffected\tby\tend\tcustomer\tand retail\tbuying\tpatterns,\tfluctuations\tin\twholesaler\tinventory\tlevels\tand\tother\tfactors.\n\nIn\tthe\tUnited\tStates,\tAbbVie\tdistributes\tpharmaceutical\tproducts\tprincipally\tthrough\tindependent\twholesale\tdistributors,\twith some\tsales\tdirectly\tto\tretailers,\tpharmacies,\tpatients\tor\tother\tcustomers.\tIn\t2023,\tthree\twholesale\tdistributors\t(McKesson Corporation,\tCardinal\tHealth,\tInc.\tand\tAmerisourceBergen\tCorporation)\taccounted\tfor\tsubstantially\tall\tof\tAbbVie's\tpharmaceutical product\tsales\tin\tthe\tUnited\tStates.\tNo\tindividual\twholesaler\taccounted\tfor\tgreater\tthan\t39%\tof\tAbbVie's\t2023\tgross\trevenues\tin\tthe United\tStates.\tOutside\tthe\tUnited\tStates,\tAbbVie\tsells\tproducts\tprimarily\tto\twholesalers\tor\tthrough\tdistributors,\tand\tdepending\ton the\tmarket\tworks\tthrough\tlargely\tcentralized\tnational\tpayers\tsystems\tto\tagree\ton\treimbursement\tterms.\n\nCertain\tproducts\tare\tco-marketed\tor\tco-promoted\twith\tother\tcompanies.\tAbbVie\thas\tno\tsingle\tcustomer\tthat,\tif\tthe\tcustomer\twere lost,\twould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tcompany's\tbusiness.\tNo\tmaterial\tportion\tof\tAbbVie's\tbusiness\tis\tsubject\tto renegotiation\tof\tprofits\tor\ttermination\tof\tcontracts\tat\tthe\telection\tof\tthe\tgovernment.\tOrders\tare\tgenerally\tfilled\ton\ta\tcurrent basis\tand\torder\tbacklog\tis\tnot\tmaterial\tto\tAbbVie's\tbusiness.\n\n## Competition\n\nThe\tmarkets\tfor\tAbbVie's\tproducts\tare\thighly\tcompetitive.\tAbbVie\tcompetes\twith\tother\tresearch-based\tpharmaceuticals\tand biotechnology\tcompanies\tthat\tdiscover,\tmanufacture,\tmarket\tand\tsell\tproprietary\tpharmaceutical\tproducts,\ttherapies\tand\tbiologics. For\texample,\tAbbVie's\timmunology\tproducts\tcompete\twith\tanti-TNF\tproducts,\tJAK\tinhibitors\tand\tother\tcompetitive\tproducts\tintended to\ttreat\ta\tnumber\tof\tdisease\tstates,\tand\tAbbVie's\toncology\tproducts\tcompete\twith\tBTK\tinhibitors\tand\tother\tcompetitive\tproducts intended\tto\ttreat\tcertain\tcancers.\tIn\taddition,\tin\tthe\tpast\tfew\tyears,\ta\tnumber\tof\tother\tcompanies\thave\tstarted\tto\tdevelop,\thave successfully\tdeveloped\tand/or\tare\tcurrently\tmarketing\tproducts\tthat\tare\tbeing\tpositioned\tas\tcompetitors\tto\tBotox.\tThe\tsearch\tfor technological\tinnovations\tin\tpharmaceutical\tproducts\tis\ta\tsignificant\taspect\tof\tcompetition.\tThe\tintroduction\tof\tnew\tproducts\tby competitors\tand\tchanges\tin\tmedical\tpractices\tand\tprocedures\tcan\tresult\tin\tproduct\tobsolescence.\tPrice\tis\talso\ta\tcompetitive factor.\tIn\taddition,\tthe\tsubstitution\tof\tgeneric\tand\tbiosimilar\tpharmaceutical\tproducts\tfor\tbranded\tpharmaceutical\tproducts creates\tcompetitive\tpressures\ton\tAbbVie's\tproducts\tthat\tdo\tnot\thave\tpatent\tprotection.\tNew\tproducts\tor\ttreatments\tbrought\tto market\tby\tAbbVie's\tcompetitors\tcould\tcause\trevenues\tfor\tAbbVie's\tproducts\tto\tdecrease\tdue\tto\tprice\treductions\tand\tsales\tvolume decreases.\n\nBiosimilars. Competition\tfor\tAbbVie's\tbiologic\tproducts\tis\taffected\tby\tthe\tapproval\tof\tfollow-on\tbiologics,\talso\tknown\tas 'biosimilars.'\tBiologics\thave\tadded\tmajor\ttherapeutic\toptions\tfor\tthe\ttreatment\tof\tmany\tdiseases,\tincluding\tsome\tfor\twhich therapies\twere\tunavailable\tor\tinadequate.\tThe\tcost\tof\tdeveloping\tand\tproducing\tbiologic\ttherapies\tis\ttypically\tdramatically\thigher than\tfor\tsmall\tmolecule\tmedications,\tand\tmany\tbiologic\tmedications\tare\tused\tfor\tongoing\ttreatment\tof\tchronic\tdiseases,\tsuch\tas rheumatoid\tarthritis\tor\tinflammatory\tbowel\tdisease,\tor\tfor\tthe\ttreatment\tof\tpreviously\tuntreatable\tcancer.\tSignificant\tinvestments in\tbiologics\tinfrastructure\tand\tmanufacturing\tare\tnecessary\tto\tproduce\tbiologic\tproducts.\n\nHumira\tis\tfacing\tdirect\tbiosimilar\tcompetition\tglobally,\tand\tAbbVie\twill\tcontinue\tto\tface\tcompetitive\tpressure\tfrom\tthese biologics\tand\tfrom\torally\tadministered\tproducts.\n\nIn\tthe\tUnited\tStates,\tthe\tFDA\tregulates\tbiologics\tunder\tthe\tFederal\tFood,\tDrug,\tand\tCosmetic\tAct\t(the\tFFDCA),\tthe\tPublic Health\tService\tAct\t(PHSA)\tand\tthe\tregulations\timplementing\tthese\tstatutes.\tThe\tenactment\tof\tfederal\thealth\tcare\treform\tlegislation in\tMarch\t2010\tprovided\ta\tpathway\tfor\tapproval\tof\tbiosimilars\tunder\tthe\tPHSA,\tbut\tthe\tapproval\tprocess\tfor,\tand\tscience\tbehind, biosimilars\tis\tcomplex.\tApproval\tby\tthe\tFDA\tis\tdependent\tupon\tmany\tfactors,\tincluding\ta\tshowing\tthat\tthe\tbiosimilar\tis\t\"highly similar\"\tto\tthe\toriginal\tproduct\tand\thas\tno\tclinically\tmeaningful\tdifferences\tfrom\tthe\toriginal\tproduct\tin\n\n5\n\n",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Humira",
          "name": "Humira",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_81",
          "chunk_id": "chunk_5",
          "chunk_text": "\nAbbVie\talso\tholds\tinvestments\tin\tequity\tsecurities\tthat\tdo\tnot\thave\treadily\tdeterminable\tfair\tvalues.\tThe\tcompany\trecords these\tinvestments\tat\tcost\tand\tremeasures\tthem\tto\tfair\tvalue\tbased\ton\tcertain\tobservable\tprice\tchanges\tor\timpairment\tevents\tas\tthey occur.\tThe\tcarrying\tamount\tof\tthese\tinvestments\twas\t$159\tmillion\tas\tof\tDecember\t31,\t2023\tand\t$129\tmillion\tas\tof\tDecember\t31,\t2022. No\tsignificant\tcumulative\tupward\tor\tdownward\tadjustments\thave\tbeen\trecorded\tfor\tthese\tinvestments\tas\tof\tDecember\t31,\t2023.\n\n## Concentrations\tof\tRisk\n\nOf\ttotal\tnet\taccounts\treceivable,\tthree\tU.S.\twholesalers\taccounted\tfor\t81%\tas\tof\tDecember\t31,\t2023\tand\t82%\tas\tof\tDecember\t31, 2022,\tand\tsubstantially\tall\tof\tAbbVie's\tpharmaceutical\tproduct\tnet\trevenues\tin\tthe\tUnited\tStates\twere\tto\tthese\tthree\twholesalers.\n\nHumira\t(adalimumab)\tis\tAbbVie's\tsingle\tlargest\tproduct\tand\taccounted\tfor\tapproximately\t27%\tof\tAbbVie's\ttotal\tnet\trevenues\tin 2023,\t37%\tin\t2022\tand\t37%\tin\t2021.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 101,
      "question": "With the phase 3 NSCLC trial for zimberelimab-domvanalimab discontinued in January 2024, how does Gilead's 2037 patent protection for domvanalimab influence its potential future investment decisions for this oncology asset?",
      "answer": "The discontinuation of the phase 3 trial for the zimberelimab-domvanalimab combination in first-line NSCLC in January 2024 marks a significant setback in its clinical development pathway. However, the 10-K filing shows that domvanalimab has U.S. and EU patent protection extending to 2037, which preserves its long-term commercial potential. This extended patent life could justify continued investment in alternative indications or reformulated strategies for domvanalimab, especially if Gilead identifies new therapeutic contexts where the molecule may still offer clinical value. The combination therapy's earlier-stage development in upper gastrointestinal tract cancer remains open for exploration, suggesting that while the NSCLC program has paused, the asset itself remains strategically relevant due to its patent longevity and potential repurposing.",
      "reasoning_steps": [
        "Hop 1: GILD(page_7) \u2192 Zimberelimab: Gilead is evaluating zimberelimab in combination with domvanalimab as a first-line treatment for NSCLC, but enrollment was discontinued in January 2024.",
        "Hop 2: Zimberelimab \u2192 Domvanalimab: The two are being studied together in oncology trials, particularly in NSCLC and upper gastrointestinal cancers, indicating a shared therapeutic strategy.",
        "Hop 3: Domvanalimab \u2190 GILD(page_8): Domvanalimab has U.S. and EU patent protection extending to 2037, suggesting long-term asset value despite the NSCLC trial discontinuation."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Partners_With]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Zimberelimab",
        "node_3": "Domvanalimab",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product Candidates            | Description                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Phase 3                       |                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Axicabtagene ciloleucel       | Axicabtagene ciloleucel, a CAR T-cell therapy, is being evaluated as (i) a second-line and later treatment for high-risk FL and (ii) a first-line treatment for high risk LBCL.                                                                                                                                                                                                                                                              |\n| Sacituzumab govitecan- hziy   | In breast cancer, sacituzumab govitecan-hziy is being evaluated as (i) a first-line treatment for PD-L1 negative metastatic TNBC and (ii) HR+/HER2- chemo-naive metastatic breast cancer. In collaboration with Merck Sharpe & Dohme LLC ('Merck'), it is also being evaluated in combination with Merck's pembrolizumab as (i) a first-line treatment for PD-L1 positive metastatic TNBC and (ii) an adjuvant treatment for early TNBC. (1) |\n|                               | In lung and thoracic cancer, sacituzumab govitecan-hziy is being evaluated as a second- or third-line treatment for non-small cell lung cancer ('NSCLC'). It is also being evaluated in combination with Merck's pembrolizumab as a first-line treatment for PD-L1 positive NSCLC.                                                                                                                                                           |\n|                               | In genitourinary cancer, sacituzumab govitecan-hziy is being evaluated as a second-line treatment for metastatic UC. FDA granted accelerated approval for Trodelvy in second-line metastatic UC in April 2021.                                                                                                                                                                                                                               |\n| Domvanalimab and zimberelimab | In collaboration with Arcus Biosciences, Inc. ('Arcus'), the combination of zimberelimab, an anti-PD-1 monoclonal antibody, and domvanalimab, an Fc-silent anti-TIGIT antibody, with chemotherapy is being evaluated as (i) a first-line treatment for NSCLC and (ii) a first-line treatment for upper gastrointestinal tract cancer. (1)                                                                                                    |\n|                               | In collaboration with Arcus, the combination of zimberelimab and domvanalimab is being evaluated as a first-line treatment for NSCLC. In January 2024, we announced discontinuation of further enrollment in this study. (1)                                                                                                                                                                                                                 |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Zimberelimab",
          "name": "Zimberelimab",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product Candidates            | Description                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Phase 3                       |                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Axicabtagene ciloleucel       | Axicabtagene ciloleucel, a CAR T-cell therapy, is being evaluated as (i) a second-line and later treatment for high-risk FL and (ii) a first-line treatment for high risk LBCL.                                                                                                                                                                                                                                                              |\n| Sacituzumab govitecan- hziy   | In breast cancer, sacituzumab govitecan-hziy is being evaluated as (i) a first-line treatment for PD-L1 negative metastatic TNBC and (ii) HR+/HER2- chemo-naive metastatic breast cancer. In collaboration with Merck Sharpe & Dohme LLC ('Merck'), it is also being evaluated in combination with Merck's pembrolizumab as (i) a first-line treatment for PD-L1 positive metastatic TNBC and (ii) an adjuvant treatment for early TNBC. (1) |\n|                               | In lung and thoracic cancer, sacituzumab govitecan-hziy is being evaluated as a second- or third-line treatment for non-small cell lung cancer ('NSCLC'). It is also being evaluated in combination with Merck's pembrolizumab as a first-line treatment for PD-L1 positive NSCLC.                                                                                                                                                           |\n|                               | In genitourinary cancer, sacituzumab govitecan-hziy is being evaluated as a second-line treatment for metastatic UC. FDA granted accelerated approval for Trodelvy in second-line metastatic UC in April 2021.                                                                                                                                                                                                                               |\n| Domvanalimab and zimberelimab | In collaboration with Arcus Biosciences, Inc. ('Arcus'), the combination of zimberelimab, an anti-PD-1 monoclonal antibody, and domvanalimab, an Fc-silent anti-TIGIT antibody, with chemotherapy is being evaluated as (i) a first-line treatment for NSCLC and (ii) a first-line treatment for upper gastrointestinal tract cancer. (1)                                                                                                    |\n|                               | In collaboration with Arcus, the combination of zimberelimab and domvanalimab is being evaluated as a first-line treatment for NSCLC. In January 2024, we announced discontinuation of further enrollment in this study. (1)                                                                                                                                                                                                                 |\n",
          "relationship": "Partners_With"
        },
        "node_3": {
          "id": "Domvanalimab",
          "name": "Domvanalimab",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_2",
          "chunk_text": "|                            | U.S.   |     | EU         |\n|----------------------------|--------|-----|------------|\n| Viral Diseases:            |        |     |            |\n| Lenacapavir                | 2037   |     | 2037       |\n| Bulevirtide                | 2030   |     | 2029       |\n| Oncology:                  |        |     |            |\n| Axicabtagene ciloleucel    | 2031   |     | - (1)      |\n| Sacituzumab govitecan-hziy | 2028   | (2) | 2029       |\n| Zimberelimab (3)           | 2036   |     | (2036) (4) |\n| Domvanalimab (3)           | 2037   |     | (2037) (4) |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 102,
      "question": "How does Merck's full guarantee of MSD Netherlands Capital B.V.'s \u20ac3.4 billion Euronotes offering relate to the company's compliance with debt covenants as of December 31, 2024, and what does this imply about the consolidated treatment of this finance subsidiary?",
      "answer": "Merck's full and unconditional guarantee of MSD Netherlands Capital B.V.'s \u20ac3.4 billion Euronotes offering (comprising four tranches with maturities between 2032 and 2054) creates a direct liability for the parent company, despite MSD Netherlands Capital B.V. being a finance subsidiary with no independent assets or operations. This guarantee is significant because the subsidiary exists solely to issue, administer, and repay these notes. Despite the magnitude of this long-term debt obligation, Merck was in compliance with all applicable debt covenants as of December 31, 2024, indicating that the company's overall financial position remains strong enough to absorb this liability without breaching its borrowing agreements. Furthermore, the consolidated financial treatment of MSD Netherlands Capital B.V. ensures that its financial condition, results of operations, and cash flows are fully integrated into Merck's financial statements, reinforcing the rationale behind the covenant compliance. This consolidated approach provides transparency into how the parent company manages and accounts for its structured finance vehicles.",
      "reasoning_steps": [
        "Hop 1: MRK(page_107) \u2192 Euronotes: Merck fully guarantees \u20ac3.4 billion in Euronotes issued by MSD Netherlands Capital B.V., with specific tranches maturing between 2032 and 2054.",
        "Hop 2: Euronotes \u2192 MSD Netherlands Capital B.V.: The Euronotes were issued by MSD Netherlands Capital B.V., a finance subsidiary with no independent assets or operations, solely for the purpose of debt issuance.",
        "Hop 3: MSD Netherlands Capital B.V. \u2190 MRK(page_140): MSD Netherlands Capital B.V. is a wholly owned subsidiary of Merck, as evidenced by the filing of an indenture agreement dated May 30, 2024, and its financials are consolidated into Merck\u2019s financial statements."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> FIN_INST -[Issues]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Euronotes",
        "node_3": "MSD Netherlands Capital B.V.",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_107",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.\n\nIn M ay 2024, M SD Netherlands Capital B.V ., a wholly owned finance subsidiary of M erck, completed a registered public offering of \u20ac3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of \u20ac850 million of 3.25% senior notes due 2032, \u20ac850 million of 3.50% senior notes due 2037, \u20ac850 million of 3.70% senior notes due 2044 and \u20ac850 million of 3.75% senior notes due 2054 (collectively , the Euronotes). The Company has fully and unconditionally guaranteed all of M SD Netherlands Capital B.V .'s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. M SD Netherlands Capital B.V . is a 'finance subsidiary' as defined in Rule 13-01(a)(4)(vi) of Regulation S-X  of the Exchange A ct, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of M SD Netherlands Capital B.V . are consolidated in the financial statements of the Company . The net cash proceeds from the offering were used for general corporate purposes.\n\nCertain of the Company's borrowings require that M erck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.\n\nThe aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.\n\nThe Company has a $6.0 billion credit facility that matures in M ay 2028. The facility provides backup liquidity for the Company's commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.\n\n## Leases\n\nThe Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if M erck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that M erck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. V ehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.\n\nLease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company's leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company's pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck  includes  both  the  lease  and  non-lease  components  for  purposes  of  calculating  the  right-of-use  asset  and  related  lease  liability  (if  the  non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.\n\nCertain of the Company's lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. M erck's lease agreements do not contain any material residual value guarantees or material restrictive covenants.\n\nOperating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022.",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Euronotes",
          "name": "Euronotes",
          "type": "FIN_INST",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_107",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.\n\nIn M ay 2024, M SD Netherlands Capital B.V ., a wholly owned finance subsidiary of M erck, completed a registered public offering of \u20ac3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of \u20ac850 million of 3.25% senior notes due 2032, \u20ac850 million of 3.50% senior notes due 2037, \u20ac850 million of 3.70% senior notes due 2044 and \u20ac850 million of 3.75% senior notes due 2054 (collectively , the Euronotes). The Company has fully and unconditionally guaranteed all of M SD Netherlands Capital B.V .'s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. M SD Netherlands Capital B.V . is a 'finance subsidiary' as defined in Rule 13-01(a)(4)(vi) of Regulation S-X  of the Exchange A ct, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of M SD Netherlands Capital B.V . are consolidated in the financial statements of the Company . The net cash proceeds from the offering were used for general corporate purposes.\n\nCertain of the Company's borrowings require that M erck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.\n\nThe aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.\n\nThe Company has a $6.0 billion credit facility that matures in M ay 2028. The facility provides backup liquidity for the Company's commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.\n\n## Leases\n\nThe Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if M erck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that M erck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. V ehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.\n\nLease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company's leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company's pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck  includes  both  the  lease  and  non-lease  components  for  purposes  of  calculating  the  right-of-use  asset  and  related  lease  liability  (if  the  non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.\n\nCertain of the Company's lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. M erck's lease agreements do not contain any material residual value guarantees or material restrictive covenants.\n\nOperating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022.",
          "relationship": "Issues"
        },
        "node_3": {
          "id": "MSD_Netherlands_Capital_B.V.",
          "name": "MSD Netherlands Capital B.V.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "page_id": "page_140",
          "chunk_id": "chunk_2",
          "chunk_text": "| Exhibit Number   |    | Description                                                                                                                                                                                                                                                                                                                                 |\n|------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 3.1              | -  | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) -Incorporated by reference to Merck & Co., Inc.'s Current Reporton Form 8-Kfiled November 4,2009 (No. 1-6571)                                                                                                                                                 |\n| 3.2              | -  | By-Laws of Merck &Co., Inc. (effective March 22, 2022) -Incorporated byreference to Merck &Co., Inc.'s Current Report on Form 8-K filed March 25,2022 (No. 1-6571)                                                                                                                                                                          |\n| 4.1              | -  | Indenture, dated as of April 1, 1991, between Merck Sharp &Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New Y ork), as Trustee (the 1991 Indenture) -Incorporated by reference to Exhibit4 to MSD's Registration Statementon Form S-3 (No. 33-39349) |\n| 4.2              | -  | First Supplemental Indenture to the 1991 Indenture, dated as of October 1, 1997 -Incorporated byreference to Exhibit 4(b) to MSD's Registration Statementon Form S-3 filed September 25,1997 (No. 333-36383)                                                                                                                                |\n| 4.3              | -  | Second Supplemental Indenture to the 1991 Indenture, dated November 3,2009 -Incorporated byreference to Exhibit 4.3 to Merck& Co., Inc.'s Current Reporton Form 8-Kfiled November 4,2009 (No.1-6571)                                                                                                                                        |\n| 4.4              | -  | Third Supplemental Indenture to the 1991 Indenture, dated May 1, 2012 -Incorporated by reference to Exhibit 4.1 to Merck & Co., Inc.'s Form 10-QQuarterlyReport for the period ended March 31,2012 (No. 1-6571)                                                                                                                             |\n| 4.5              | -  | Indenture, dated November 26, 2003, between Merck & Co., Inc. (f/k/a Schering-Plough Corporation) and The Bank of New Y ork as Trustee (the 2003 Indenture) -Incorporated by reference to Exhibit 4.1 to Schering-Plough's Current Report on Form 8 - K filed November 28,2003 (No. 1-6571)                                                 |\n| 4.6              | -  | Second Supplemental Indenture to the 2003 Indenture (including Form of Note), dated November 26, 2003 - Incorporated by reference to Exhibit 4.3 to Schering-Plough's Current Reporton Form 8 - Kfiled November 28,2003 (No. 1-6571)                                                                                                        |\n| 4.7              | -  | Third Supplemental Indenture to the 2003 Indenture (including Form of Note), dated September 17,2007 -Incorporated byreference to Exhibit 4.1 to Schering-Plough's Current Reporton Form 8 - Kfiled September 17,2007 (No. 1-6571)                                                                                                          |\n| 4.8              | -  | Fifth Supplemental Indenture to the 2003 Indenture, dated November 3, 2009 -Incorporated by reference to Exhibit 4.4 to Merck & Co., Inc.'s Current Reporton Form 8-Kfiled November 4,2009 (No. 1-6571)                                                                                                                                     |\n| 4.9              | -  | Indenture, dated as of January 6, 2010, between Merck & Co., Inc. and U.S. Bank Trust National Association, as Trustee -Incorporated byreference to Exhibit 4.1 to Merck &Co., Inc.'s Current Report on Form 8-Kfiled December 10, 2010 (No. 1- 6571)                                                                                       |\n| 4.10             | -  | Indenture, dated as of May 30, 2024, among MSD Netherlands Capital B.V ., Merck & Co., Inc. and U.S. Bank Trust National Association, as Trustee -Incorporated by reference to Exhibit 4.1 to Merck & Co., Inc.'s Current Report on Form 8-K filed May 30, 2024 (No. 1-6571)                                                                |\n| 4.11             | -  | Description of the Registrant's Securities                                                                                                                                                                                                                                                                                                  |\n| *10.1            | -  | Merck &Co., Inc. Executive Incentive Plan (as amended and restated effective January1, 2025)                                                                                                                                                                                                                                                |\n| *10.2            | -  | Merck & Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019)- Incorporated byreference to Exhibit 10.2 to Merck &Co., Inc.'s Form 10-KAnnual Report for the fiscal year ended December 31, 2019 filed February26,2020 (No. 1-6571)                                          |\n| *10.3            | -  | Merck & Co., Inc. 2010 Incentive Stock Plan (as amended and restated June 1, 2015) -Incorporated by reference to Merck & Co., Inc.'s Schedule 14Afiled April 13,2015 (No. 1-6571)                                                                                                                                                           |\n| *10.4            | -  | Form of stock option terms for 2013 quarterlyand annual non-qualified option grants under the Merck &Co., Inc. 2010 Incentive Stock Plan -Incorporated byreference to Exhibit 10.19 to Merck &Co., Inc.'s Form 10-KAnnual Report for the fiscal year ended December 31,2012 filed February28,2013 (No. 1-6571)                              |\n| *10.5            | -  | Form of stock option terms for 2014 quarterlyand annual non-qualified option grants under the Merck &Co., Inc. 2010 Incentive Stock Plan - Incorporated by reference to Exhibit 10.18 to Merck & Co., Inc.'s Form 10-K Annual Report for the fiscal year ended December 31,2014 filed February27,2015 (No. 1-6571)                          |",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 103,
      "question": "How does Merck's financial exposure to Lenvima through alliance revenue relate to the strategic importance of Keytruda's combination therapies, given Merck's collaborative development framework with Eisai and AstraZeneca?",
      "answer": "Merck's alliance revenue model, which includes Lenvima as a partnered product developed with Eisai, reflects its financial stake in the drug's performance. This revenue stream is tied to the success of Lenvima in combination therapies, such as with Keytruda, which is strategically emphasized in regulatory approvals and oncology growth. Additionally, Merck's collaboration with AstraZeneca on Lynparza and Keytruda combination therapies illustrates a broader strategic framework where co-development and co-commercialization agreements amplify Merck's oncology portfolio and revenue potential, linking Lenvima\u2019s commercial success directly to Keytruda\u2019s therapeutic expansion.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_5) \u2192 [Lenvima]: Merck discloses Lenvima as part of its oncology product portfolio and mentions alliance revenue related to its sales, indicating a financial stake in the drug's performance.",
        "Hop 2: [Lenvima] \u2192 [Keytruda]: Lenvima is used in combination with Keytruda for treating endometrial and renal cell cancers, showing a direct therapeutic and strategic linkage between the two drugs.",
        "Hop 3: [Keytruda] \u2190 [MRK](page_101): Merck's collaboration with AstraZeneca on Lynparza and Keytruda combination therapies highlights the strategic importance of Keytruda in Merck's oncology pipeline and revenue generation."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Partners_With]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Lenvima",
        "node_3": "Keytruda",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs. (1)\n\nOther revenues are primarily comprised of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. (2)\n\n## Pharmaceutical\n\nThe Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company's franchises are as follows:\n\n## Oncology\n\nKeytruda (pembrolizumab), the Company's anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment  of  certain  patients  with  cervical  cancer,  classical  Hodgkin  Lymphoma  (cHL),  cutaneous  squamous  cell  carcinoma (cSCC),  esophageal  or  gastroesophageal  junction  (GEJ)  carcinoma,  head  and  neck  squamous  cell  carcinoma  (HNSCC), hepatocellular  carcinoma  (HCC),  non-small-cell  lung  cancer  (NSCLC),  melanoma,  Merkel  cell  carcinoma,  microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. Keytruda is also approved for the treatment of certain patients in  combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with platinum-and fluoropyrimidine-based chemotherapy for  esophageal  or  GEJ  carcinoma,  in  combination  with  chemotherapy,  with  or  without  bevacizumab,  for  cervical  cancer,  in combination with chemotherapy for triple-negative breast cancer (TNBC), in combination with axitinib for advanced renal cell carcinoma (RCC), and in combination with lenvatinib for endometrial carcinoma or RCC. Keytruda is  also  approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Keytruda is also approved as a monotherapy for the adjuvant treatment of certain patients  with  RCC.  In  addition,  the  Company  recognizes  alliance  revenue  related  to  sales  of  Lynparza  (olaparib),  an  oral  poly (ADP-ribose) polymerase (PARP) inhibitor, for certain  types  of  advanced  ovarian,  breast,  pancreatic,  and  prostate  cancers;  and Lenvima (lenvatinib) for certain types of",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Lenvima",
          "name": "Lenvima",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_3",
          "chunk_text": "\n* Calculation not meaningful.\n\nNon-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see 'Non-GAAP Income and Non-GAAP EPS' below) . (1)\n\n## Executive Summary\n\nDuring 2021, Merck delivered on its strategic priorities by executing commercially to drive strong revenue and earnings growth  in  the  year,  completing  key  business  development  transactions,  accelerating  its  broad  pipeline,  and  achieving  notable regulatory milestones. Also, on June 2, 2021, Merck completed the spin-off of Organon. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company's consolidated financial statements through the date of the spin-off.\n\nWorldwide sales were $48.7 billion in 2021, an increase of 17% compared with 2020, or 16% excluding the favorable effect of foreign exchange. The sales increase was driven primarily by growth in oncology, vaccines, hospital acute care and animal health. Additionally,  revenue  in  2021  reflects  the  benefit  of  sales  of  molnupiravir,  an  investigational  oral  antiviral  COVID-19 treatment. As discussed below, COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth.\n\nMerck continues to execute scientifically  compelling  business  development  opportunities  to  augment  its  pipeline.  In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company evaluating the transforming growth factor (TGF)-beta superfamily of proteins through the development of pulmonary and hematologic therapies. In April  2021,  Merck  acquired  Pandion Therapeutics,  Inc.  (Pandion),  a  clinical-stage  biotechnology  company  developing  novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Additionally, Merck entered into a collaboration with Gilead Sciences, Inc. (Gilead) to jointly develop and commercialize long-acting treatments in HIV.\n\nIn  2021,  Merck  received  over  30  approvals  and  filed  over  20  New  Drug  Applications  (NDAs)  and  supplemental Biologics License Applications (BLAs) across the U.S., the EU, Japan and China. During 2021, the Company received numerous regulatory approvals within oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of breast, colorectal, cutaneous squamous cell, esophageal, melanoma and renal cell cancers, as  well  as  in  combination  with  chemotherapy  in  the  therapeutic  areas  of  breast,  cervical,  gastric  or  gastroesophageal  junction cancers. Keytruda was also approved in combination with Lenvima both for the treatment of certain adult patients with endometrial cancer  and  for  the  treatment  of  renal  cell  cancer.  Lenvima  is  being  developed  in  collaboration  with  Eisai  Co.,  Ltd.  (Eisai). Lynparza,  which  is  being  developed  in  collaboration  with  AstraZeneca  PLC  (AstraZeneca),  received  approval  in  China  as monotherapy for the treatment of certain adult patients with metastatic castration resistant prostate cancer. Additionally, the U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL)",
          "relationship": "Partners_With"
        },
        "node_3": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe  estimated  fair  values  of  identifiable  intangible  assets  relate  primarily  to  trade  names  and  were  determined  using  an  income  approach.  The  future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. (1)\n\nThe goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes. (2)\n\nThe Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in Selling, general and administrative expenses in 2019.\n\nAlso  in  April  2019,  Merck  acquired  Immune  Design,  a  late-stage  immunotherapy  company  employing  nextgeneration in vivo approaches to enable the body's immune system to fight disease, for $301 million in cash. The transaction was accounted for as a business combination. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets  of  $42  million. The  excess  of  the  consideration  transferred  over  the  fair  value  of  net  assets  acquired  of  $20  million  was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable  intangible  assets  related  to  IPR&amp;D  were  determined  using  an  income  approach. Actual  cash  flows  are  likely  to  be different than those assumed.\n\n## 5.    Collaborative Arrangements\n\nMerck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to  significant  risks  and  rewards  dependent  on  the  commercial  success  of  the  activities  of  the  collaboration.  Merck's  more significant collaborative arrangements are discussed below.\n\n## AstraZeneca\n\nIn  2017,  Merck  and  AstraZeneca  PLC  (AstraZeneca)  entered  into  a  global  strategic  oncology  collaboration  to  codevelop and co-commercialize AstraZeneca's Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 104,
      "question": "What is the relationship between BMY's legal exposure in the Cigna lawsuit and the financial obligations it assumed from acquiring Celgene for $35.7 billion?",
      "answer": "BMY's legal exposure in the Cigna lawsuit is directly tied to liabilities it assumed as part of the $35.7 billion Celgene acquisition. The litigation involves Cigna suing both Celgene and BMS over claims related to contractual breaches and drug reimbursements, which originated during Celgene's operations. Since BMY acquired Celgene in 2019, it inherited these legal obligations, including potential damages and defense costs. The acquisition agreement included the assumption of Celgene's liabilities, which now expose BMY to financial risks from ongoing litigation like the Cigna case. This underscores how BMY's substantial investment in the Celgene acquisition continues to carry forward legal and financial exposure in high-stakes litigation matters.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_166) \u2192 [Cigna]: BMY is named in a lawsuit by Cigna over claims related to Celgene's drug reimbursement practices.",
        "Hop 2: [Cigna] \u2192 [Celgene]: Cigna's lawsuit specifically targets Celgene for alleged contractual breaches and reimbursement claims tied to Thalomid and Revlimid.",
        "Hop 3: [Celgene] \u2190 [BMY](page_116): BMY acquired Celgene in 2019 for $35.7 billion, assuming all liabilities including those from ongoing litigation like the Cigna case."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> COMP -[Involved_In]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Cigna",
        "node_3": "Celgene",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Cigna",
          "name": "Cigna",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 105,
      "question": "How does Merck's strategic collaboration with Moderna on V940 (mRNA-4157), which is being evaluated in combination with Keytruda, align with the anticipated decline in Keytruda sales in the U.S. post-2028, especially in light of the company's current alliance revenue growth in U.S. virology and sGC modulator markets?",
      "answer": "Merck's collaboration with Moderna on V940 (mRNA-4157), an individualized neoantigen therapy being tested in combination with Keytruda, represents a forward-looking investment in oncology innovation aimed at extending Keytruda\u2019s therapeutic value and potentially mitigating the anticipated decline in U.S. sales post-2028. However, this strategic move must be weighed against the expected drop in Keytruda revenue following the loss of U.S. market exclusivity, as disclosed in the risk factors. Meanwhile, Merck is experiencing current growth in alliance revenue from virology products like Adempas and Verquvo in the U.S., which grew by 7% and 8% respectively in 2023. This juxtaposition suggests that while Merck is attempting to future-proof its oncology portfolio through mRNA innovation, it is also currently leveraging growth opportunities in other therapeutic areas to offset anticipated oncology revenue erosion.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_90) \u2192 [Keytruda]: Merck discloses its collaboration with Moderna on V940 (mRNA-4157), an investigational neoantigen therapy currently in Phase 3 trials in combination with Keytruda, with shared costs and profits.",
        "Hop 2: [Keytruda] \u2192 [US]: Merck anticipates a substantial decline in Keytruda sales in the U.S. after 2028 due to the loss of market exclusivity, which will significantly impact revenue and profitability.",
        "Hop 3: [US] \u2190 [MRK](page_54): Merck reports current growth in alliance revenue from virology products Adempas and Verquvo in the U.S., with 7% and 8% growth in 2023, respectively."
      ],
      "difficulty": "hard",
      "idf_score": 5.051418948098934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Impacted_By]-> GPE <-[Operates_In]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Keytruda",
        "node_3": "US",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "GPE",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n## Bristol-Myers\tSquibb\tCompany\n\nReblozyl\t(luspatercept-aamt)\tis\ta\tfirst-in-class\terythroid\tmaturation\trecombinant\tfusion\tprotein\tobtained\tas\tpart\tof\tMerck's November\t2021\tacquisition\tof\tAcceleron\tthat\tis\tbeing\tcommercialized\tthrough\ta\tglobal\tcollaboration\twith\tBMS.\tReblozyl\tis\tapproved\tin\tthe U.S.,\tEurope,\tand\tcertain\tother\tmarkets\tfor\tthe\ttreatment\tof\tanemia\tin\tcertain\trare\tblood\tdisorders\tand\tis\talso\tbeing\tevaluated\tfor additional\tindications\tfor\thematology\ttherapies.\tBMS\tis\tthe\tprincipal\ton\tsales\ttransactions\tfor\tReblozyl;\thowever,\tMerck\tco-promotes Reblozyl\t(and\twill\tco-promote\tall\tfuture\tproducts\tapproved\tunder\tthis\tcollaboration)\tin\tNorth\tAmerica,\twhich\tis\treimbursed\tby\tBMS.\tMerck receives\ta\t20%\tsales\troyalty\tfrom\tBMS\twhich\tcould\tincrease\tto\ta\tmaximum\tof\t24%\tbased\ton\tsales\tlevels.\tThis\troyalty\twill\tbe\treduced\tby 50%\t upon\t the\t earlier\t of\t patent\t expiry\t or\t generic\t entry\t on\t an\t indication-by-indication\t basis\t in\t each\t market.\t Additionally,\t Merck\t is eligible\t to\t receive\t future\t contingent\t sales-based\t milestone\t payments\t of\t up\t to\t $80\t million.\t Alliance\t revenue\t related\t to\t this collaboration\t(recorded\twithin Sales )\tconsists\tof\troyalties\tand,\tfor\t2022,\talso\tincludes\tthe\treceipt\tof\ta\tregulatory\tapproval\tmilestone payment\tof\t$20\tmillion.\tMerck\trecorded\talliance\trevenue\trelated\tto\tthis\tcollaboration\tof\t$212\tmillion\tin\t2023,\t$166\tmillion\tin\t2022\tand $17\tmillion\tin\t2021.\n\n## Moderna,\tInc.\n\nIn\t September\t 2022,\t Merck\t exercised\t its\t option\t to\t jointly\t develop\t and\t commercialize\t V940\t (mRNA-4157),\t an\t investigational individualized\tneoantigen\ttherapy,\tpursuant\tto\tthe\tterms\tof\tan\texisting\tcollaboration\tand\tlicense\tagreement\twith\tModerna,\twhich\tresulted in\ta\t$250\tmillion\tpayment\tthat\twas\tcharged\tto Research\tand\tdevelopment expenses\tin\t2022.\tV940\t(mRNA-4157)\tis\tcurrently\tbeing\tevaluated in\tcombination\twith Keytruda in\tmultiple\tPhase\t3\tclinical\ttrials.\tMerck\tand\tModerna\twill\tshare\tcosts\tand\tany\tprofits\tequally\tunder\tthis worldwide\t collaboration.\t Merck\t records\t its\t share\t of\t development\t costs\t associated\t with\t the\t collaboration\t as\t part\t of Research\t and development expenses.\tAny\treimbursements\treceived\tfrom\tModerna\tfor\tresearch\tand\tdevelopment\texpenses\twill\tbe\trecognized\tas\treductions\tto Research\tand\tdevelopment costs.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\tcollaboration\tis\tas\tfollows:\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Impacted_By"
        },
        "node_3": {
          "id": "US",
          "name": "US",
          "type": "GPE",
          "idf_score": 4.222304909797168
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance\trevenue\trepresents\tMerck's\tshare\tof\tprofits\tfrom\tsales\tin\tBayer's\tmarketing\tterritories,\twhich\tare\tproduct\tsales\tnet\tof\tcost\tof\tsales\tand\tcommercialization\tcosts\t(see Note\t4\tto\tthe\tconsolidated\tfinancial\tstatements). (1)\n\nAdempas\tand\tVerquvo\tare\tpart\tof\ta\tworldwide\tcollaboration\twith\tBayer\tAG\t(Bayer)\tto\tmarket\tand\tdevelop\tsoluble\tguanylate\tcyclase (sGC)\tmodulators\t(see\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements).\tAdempas\tis\tapproved\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tPAH and\tchronic\tpulmonary\thypertension.\tVerquvo\tis\tapproved\tto\treduce\tthe\trisk\tof\tcardiovascular\tdeath\tand\theart\tfailure\thospitalization following\ta\thospitalization\tfor\theart\tfailure\tor\tneed\tfor\toutpatient\tintravenous\tdiuretics\tin\tadults\twith\tsymptomatic\tchronic\theart failure\tand\treduced\tejection\tfraction.\tVerquvo\twas\tapproved\tin\tthe\tU.S.,\tthe\tEU\tand\tJapan\tin\t2021\tand\thas\tsince\tbeen\tapproved\tin\tseveral other\tmarkets.\tAlliance\trevenue\tfrom\tthe\tcollaboration\tgrew\t8%\tin\t2023\treflecting\thigher\tprofit\tsharing,\twhich\treflects\tincreased\tdemand in\tBayer's\tmarketing\tterritories.\tRevenue\talso\tincludes\tsales\tof\tAdempas\tand\tVerquvo\tin\tMerck's\tmarketing\tterritories.\tSales\tof\tAdempas in\tMerck's\tmarketing\tterritories\tgrew\t7%\tin\t2023\tprimarily\treflecting\thigher\tdemand.\n\n## Virology\n\n",
          "relationship": "Operates_In"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 106,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related claims relate to the ongoing mediation involving Cyprus Mines Corporation, and what implications does this have for the company's potential future liabilities beyond the amount accrued?",
      "answer": "Johnson & Johnson has established a $9 billion reserve, which encompasses actual and contemplated settlements, to resolve current and future talc-related claims. This reserve is linked to the ongoing mediation involving Cyprus Mines Corporation, as Cyprus is a key party in the bankruptcy proceedings and has been engaged in mediation since late 2021. The mediation involves Imerys, Cyprus, and claimants' representatives, and contemplates a trust mechanism to channel all talc-related claims against these parties, including indemnification rights against JNJ. Despite the mediation extending into late 2023 and the filing of revised plans and trust distribution procedures in early 2024, the parties have not yet reached a resolution. As a result, JNJ acknowledges it cannot estimate the possible loss or range of loss beyond the $9 billion already accrued, highlighting significant uncertainty and potential for increased liability depending on the outcome of the mediation and trust implementation.",
      "reasoning_steps": [
        "Hop 1: JNJ (page_98) \u2192 Mediation: JNJ is involved in multi-state mediation related to talc claims, which was terminated in March 2023, but has reached an agreement in principle with state attorneys general.",
        "Hop 2: Mediation \u2192 Cyprus Mines Corporation: Cyprus Mines Corporation is a key participant in the bankruptcy-related mediation with Imerys and talc claimants, with mediation extended through December 2023 and involving trust-based resolution mechanisms.",
        "Hop 3: Cyprus Mines Corporation \u2190 JNJ (page_97): JNJ depends on the outcome of Cyprus and Imerys\u2019s bankruptcy plans, which propose channelling all talc claims to a trust that may pursue indemnification from JNJ, directly impacting JNJ\u2019s future liability."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Engages]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Mediation",
        "node_3": "Cyprus Mines Corporation",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_2",
          "chunk_text": "Forty-two\tstates\tand\tthe\tDistrict\tof\tColumbia\t(including\tMississippi\tand\tNew\tMexico)\thave\tcommenced\ta\tjoint\tinvestigation\tinto\tthe Company's\tmarketing\tof\tits\ttalcum\tpowder\tproducts.\tAt\tthis\ttime,\tthe\tmulti-state\tgroup\thas\tnot\tasserted\tany\tclaims\tagainst\tthe\tCompany. Five\tstates\thave\tissued\tCivil\tInvestigative\tDemands\tseeking\tdocuments\tand\tother\tinformation.\tThe\tCompany\thas\tproduced\tdocuments\tto Arizona,\tNorth\tCarolina,\tTexas,\tand\tWashington\tand\tentered\tinto\tconfidentiality\tagreements.\tThe\tCompany\thas\tnot\treceived\tany\tfollow\tup requests\tfrom\tthose\tstates.\tIn\tMarch\t2022,\teach\tof\tthe\tforty-two\tstates\tagreed\tto\tmediation\tof\ttheir\tclaims\tin\tthe\tLTL\tBankruptcy\tCase. In\tJuly\t2022,\tNew\tMexico\tand\tMississippi\tindicated\tthey\twould\tno\tlonger\tvoluntarily\tsubmit\tto\tfurther\tmediation\tin\tthe\tLTL\tBankruptcy and\twould\tproceed\twith\ttheir\trespective\tcases\tin\tstate\tcourt.\tIn\tMarch\t2023,\tthe\tmediation\twas\tterminated.\tIn\tJanuary\t2024,\tthe\tCompany reached\tan\tagreement\tin\tprinciple\twith\tthe\tmulti-state\tgroup\tof\tstate\tAttorneys\tGeneral,\tsubject\tto\tongoing\tnegotiation\tof\tnon-monetary terms.\tThe\tunique\tprocedural\thistory\tand\tstatus\tof\tthe\tNew\tMexico\tand\tMississippi\tmatters\tspecifically\thave\tbeen\tdiscussed\tabove.\n\n## 92",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Mediation",
          "name": "Mediation",
          "type": "LITIGATION",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Engages"
        },
        "node_3": {
          "id": "Cyprus_Mines_Corporation",
          "name": "Cyprus Mines Corporation",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_1",
          "chunk_text": "Following\tthe\tdismissal\tof\tLTL\t2,\tnew\tlawsuits\twere\tfiled\tand\tcases\tacross\tthe\tcountry\tthat\thad\tbeen\tstayed\twere\treactivated.\tThe majority\tof\tthe\tcases\tare\tpending\tin\tfederal\tcourt,\torganized\tin\ta\tmulti-district\tlitigation\t(MDL)\tin\tthe\tUnited\tStates\tDistrict\tCourt for\tthe\tDistrict\tof\tNew\tJersey.\tIn\tthe\tMDL,\tcase-specific\tdiscovery\tis\tproceeding\twith\tan\texpectation\tthat\ta\ttrial\twill\toccur\tin\tearly 2025.\tSeparately,\tdiscovery\tand\tpre-trial\tactivity\tis\tunderway\tin\tvarious\tindividually\tfiled\tand\tset\tcases\taround\tthe\tcountry,\twith\tmost activity\tfor\tsuch\tcases\tcentralized\tin\tNew\tJersey\tand\tCalifornia.\n\nIn\tthe\toriginal\tbankruptcy\tcase,\tthe\tCompany\tagreed\tto\tprovide\tfunding\tto\tLTL\tfor\tthe\tpayment\tof\tamounts\tthe\tNew\tJersey\tBankruptcy\tCourt determines\tare\towed\tby\tLTL\tand\tthe\testablishment\tof\ta\t$2\tbillion\ttrust\tin\tfurtherance\tof\tthis\tpurpose.\tThe\tCompany\testablished\ta\treserve for\tapproximately\t$2\tbillion\tin\tconnection\twith\tthe\taforementioned\ttrust.\tDuring\tthe\tbankruptcy\tproceedings\tLTL\thad\tbeen\tde-consolidated by\tthe\tCompany.\tIn\tthe\tLTL\t2\tBankruptcy\tCase,\tthe\tCompany\thad\tagreed\tto\tcontribute\tan\tadditional\tamount\twhich,\twhen\tadded\tto\tthe\tprior $2\tbillion,\twould\tbe\ta\ttotal\treserve\tof\tapproximately\t$9\tbillion\tpayable\tover\t25\tyears\t(nominal\tvalue\tapproximately\t$12\tbillion discounted\tat\ta\trate\tof\t4.41%),\tto\tresolve\tall\tthe\tcurrent\tand\tfuture\ttalc\tclaims.\tThe\tapproximate\t$9\tbillion\treserve\tencompasses\tactual and\tcontemplated\tsettlements,\tof\twhich\tapproximately\tone-third\tis\trecorded\tas\ta\tcurrent\tliability.\tThe\trecorded\tamount\tremains\tthe Company's\tbest\testimate\tof\tprobable\tloss\tafter\tthe\tdismissal.\n\nThe\tparties\thave\tnot\tyet\treached\ta\tresolution\tof\tall\ttalc\tmatters\tand\tthe\tCompany\tis\tunable\tto\testimate\tthe\tpossible\tloss\tor\trange\tof loss\tbeyond\tthe\tamount\taccrued.\n\nA\tclass\taction\tadvancing\tclaims\trelating\tto\tindustrial\ttalc\twas\tfiled\tagainst\tthe\tCompany\tand\tothers\tin\tNew\tJersey\tstate\tcourt\tin\tMay 2022\t(the\tEdley\tClass\tAction).\tThe\tEdley\tClass\tAction\tasserts,\tamong\tother\tthings,\tthat\tthe\tCompany\tfraudulently\tdefended\tpast\tasbestos personal\tinjury\tlawsuits\tarising\tfrom\texposure\tto\tindustrial\ttalc\tmined,\tmilled,\tand\tmanufactured\tbefore\tJanuary\t6,\t1989\tby\tthe Company's\tthen\twholly\towned\tsubsidiary,\tWindsor\tMinerals,\tInc.,\twhich\tis\tcurrently\ta\tdebtor\tin\tthe\tImerys\tBankruptcy\tdescribed hereafter.\tThe\tCompany\tremoved\tthe\tEdley\tClass\tAction\tto\tfederal\tcourt\tin\tthe\tDistrict\tof\tNew\tJersey.\tIn\tOctober\t2022,\tthe\tCompany\tfiled motions\tto\tdismiss\tand\tto\tdeny\tcertification\tof\ta\tclass\tto\tpursue\tthe\tEdley\tClass\tAction\tin\tthe\tNew\tJersey\tDistrict\tCourt.\tArgument\ton the\tmotions\twas\theard\tin\tNovember\t2023.\tThereafter,\tthe\tCompany\tresolved\tthis\tmatter.\n\nIn\tFebruary\t2019,\tthe\tCompany's\ttalc\tsupplier,\tImerys\tTalc\tAmerica,\tInc.\tand\ttwo\tof\tits\taffiliates,\tImerys\tTalc\tVermont,\tInc.\tand\tImerys Talc\tCanada,\tInc.\t(collectively,\tImerys)\tfiled\ta\tvoluntary\tpetition\tfor\trelief\tunder\tchapter\t11\tof\tthe\tUnited\tStates\tCode\t(the Bankruptcy\tCode)\tin\tthe\tUnited\tStates\tBankruptcy\tCourt\tfor\tthe\tDistrict\tof\tDelaware\t(Imerys\tBankruptcy).\tThe\tImerys\tBankruptcy\trelates to\tImerys's\tpotential\tliability\tfor\tpersonal\tinjury\tfrom\texposure\tto\ttalcum\tpowder\tsold\tby\tImerys.\tIn\tits\tbankruptcy,\tImerys\talleges\tit has\tclaims\tagainst\tthe\tCompany\tfor\tindemnification\tand\trights\tto\tjoint\tinsurance\tproceeds.\tIn\tits\tbankruptcy,\tImerys\tproposed\ta\tchapter 11\tplan\t(the\tImerys\tPlan)\tthat\tcontemplated\tall\ttalc-related\tclaims\tagainst\tit\tbeing\tchanneled\tto\ta\ttrust\talong\twith\tits\talleged indemnification\trights\tagainst\tthe\tCompany.\tFollowing\tconfirmation\tand\tconsummation\tof\tthe\tplan,\tthe\ttrust\twould\tpay\ttalc\tclaims pursuant\tto\tproposed\ttrust\tdistribution\tprocedures\t(the\tTDP)\tand\tthen\tseek\tindemnification\tfrom\tthe\tCompany.\n\nIn\tFebruary\t2021,\tCyprus\tMines\tCorporation\t(Cyprus),\twhich\thad\towned\tcertain\tImerys\ttalc\tmines,\tfiled\ta\tvoluntary\tpetition\tfor\trelief under\tchapter\t11\tof\tthe\tBankruptcy\tCode\tand\tfiled\tits\tDisclosure\tStatement\tand\tPlan\t(the\tCyprus\tPlan).\tThe\tCyprus\tPlan\tcontemplates\ta settlement\twith\tImerys\tand\ttalc\tclaimants\twhere\tCyprus\twould\tmake\ta\tmonetary\tcontribution\tto\ta\ttrust\testablished\tunder\tthe\tImerys\tPlan in\texchange\tfor\tan\tinjunction\tagainst\ttalc\tclaims\tasserted\tagainst\tit\tand\tcertain\taffiliated\tparties.\n\nThe\tImerys\tPlan\tproceeded\tto\tsolicitation\tin\tearly\t2021.\tHowever,\tthe\tImerys\tPlan\tdid\tnot\treceive\tthe\trequisite\tnumber\tof\tvotes\tto\tbe confirmed\tafter\tthe\tBankruptcy\tCourt\truled\tcertain\tvotes\tcast\tin\tfavor\tof\tthe\tImerys\tPlan\tshould\tbe\tdisregarded.\tImerys\tsubsequently canceled\tits\tconfirmation\thearing.\n\nImerys,\tthe\tImerys\tTort\tClaimants'\tCommittee,\tand\tthe\tImerys\tFuture\tClaimants'\tRepresentative,\talong\twith\tCyprus,\tthe\tCyprus\tTort Claimants'\tCommittee,\tand\tthe\tCyprus\tFuture\tClaimants'\tRepresentative\t(collectively\tthe\tMediation\tParties)\thave\tbeen\tengaged\tin mediation\tsince\tshortly\tafter\tthe\tconfirmation\thearing\twas\tcanceled\tin\tOctober\t2021.\tIn\tSeptember\t2023,\tthe\tBankruptcy\tCourt\tentered\tan order\textending\tthe\tterm\tof\tthe\tmediation\tamong\tthe\tMediation\tParties\tthrough\tthe\tend\tof\tDecember\t2023.\tThe\tBankruptcy\tCourt\talso authorized\tImerys\tand\tCyprus\tto\tproceed\twith\tmediation\twith\tcertain\tof\ttheir\tinsurers\tthrough\tthe\tend\tof\tDecember\t2023.\n\nIn\tSeptember\t2023,\tImerys\tand\tCyprus\tfiled\tamended\tplans\tof\treorganization.\tThe\tamended\tplans\tcontemplate\ta\tsimilar\tconstruct\tas\tthe prior\tImerys\tand\tCyprus\tPlans,\tincluding\tall\ttalc\tclaims\tagainst\tImerys\tand\tCyprus\t(and\tcertain\tother\tprotected\tparties)\tbeing\tchanneled to\ta\ttrust\talong\twith\tImerys's\tand\tCyprus's\talleged\tindemnification\trights\tagainst\tthe\tCompany.\tIn\tJanuary\t2024,\tImerys\tand\tCyprus\tfiled revised\tTDP.\tIn\tFebruary\t2024,\tImerys\tand\tCyprus\tfiled\tcertain\tmotions\trelated\tto\ttheir\tDisclosure\tStatement.\n\nIn\tFebruary\t2018,\ta\tsecurities\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tcertain\tnamed\tofficers\tin\tthe\tUnited\tStates District\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey,\talleging\tthat\tthe\tCompany\tviolated\tthe\tfederal\tsecurities\tlaws\tby\tfailing\tto\tdisclose alleged\tasbestos\tcontamination\tin\tbody\tpowders\tcontaining\ttalc,\tprimarily\tJOHNSON'S\tBaby\tPowder,\tand\tthat\tpurchasers\tof\tthe\tCompany's shares\tsuffered\tlosses\tas\ta\tresult.\tIn\tApril\t2019,\tthe\tCompany\tmoved\tto\tdismiss\tthe\tcomplaint.\tIn\n\n2023\tAnnual\tReport 91",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 107,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the 2023 amendment with the EC, intersect with the patent litigation risks involving Comirnaty in the U.S. and Europe, and what implications might this have for Pfizer's international revenue streams, particularly in the EU and key non-U.S. markets like China and Japan?",
      "answer": "Pfizer depends on BioNTech for the supply of Comirnaty, as evidenced by their ongoing agreements with the European Commission (EC) for delivering pre-specified doses through 2026, with flexibility for EU member states and access to future adapted vaccines. However, Comirnaty faces significant legal challenges, including a U.S. lawsuit from GSK Group alleging infringement of eight patents and a European case by Promosome LLC concerning patents in France, Germany, and Sweden. These legal risks could disrupt the production and sale of Comirnaty, which is a critical product for Pfizer\u2019s international revenue. Given that China (4% of total revenue in 2024) and Japan (6% in 2023) are key non-U.S. markets, and the EU remains a central region under the EC agreements, any adverse legal outcome could impact Pfizer\u2019s ability to fulfill these contracts and maintain revenue stability in these jurisdictions.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_107) \u2192 [BioNTech]: Pfizer relies on BioNTech for Comirnaty supply agreements, including a 2023 amendment with the EC that rephased deliveries through 2026 and allowed for volume reductions.",
        "Hop 2: [BioNTech] \u2192 [Comirnaty]: BioNTech is a co-developer and co-defendant in litigation involving Comirnaty, indicating a deep legal and operational linkage between the two entities.",
        "Hop 3: [Comirnaty] \u2190 [PFE](page_101): Comirnaty is the subject of multiple patent infringement lawsuits in both the U.S. and Europe, which could impact Pfizer\u2019s ability to continue manufacturing and selling the vaccine."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Impacts]-> PRODUCT <-[Impacts]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "BioNTech",
        "node_3": "Comirnaty",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_107",
          "chunk_id": "chunk_5",
          "chunk_text": "\nRevenues exceeded $500 m illion in each of 11, 14 and 24 countries outside the U .S. in 2024, 2023 and 2022, respectively. T he U .S. is the only country to contribute m ore than 10% of total revenue in 2024, 2023 and 2022. As a percentage of Total revenues , C hina was our largest m arket outside the U .S. (representing 4% of total revenues) in 2024, and Japan was our largest m arket outside the U .S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).\n\n## C. Other Revenue Information\n\n## Significant Customers\n\nWe and our collaboration partner, BioN T ech, have entered into agreem ents to supply pre-specified doses of C om irnaty with m ultiple developed and em erging nations around the world and are continuing to deliver doses of C om irnaty under such agreem ents. T his includes supply agreem ents entered into in N ovem ber 2020 and F ebruary and M ay 2021 with the E C  for Comirnaty on behalf of the different E U  m em ber states and certain other countries. E ach E U  m em ber state subm its its own C om irnaty vaccine order to us and is responsible for paym ent pursuant to term s of the supply agreem ents negotiated by the E C . In M ay 2023, we and BioN T ech am ended our contract with the E C  to deliver C O VID -19 vaccines to the E U . The am ended agreem ent includes rephasing of delivery of doses annually through 2026 and an aggregate volum e reduction, providing additional flexibility for those E U  m em ber states who agreed to the am ended agreem ent. The E C  will m aintain access to future adapted C O VID -19 vaccines and the ability to donate doses, in alignm ent with the original agreem ent.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 108,
      "question": "How does the decline in Odefsey sales from 2022 to 2024 reconcile with Gilead's ongoing revenue-sharing arrangement with Janssen, and what implications does this have for Gilead's cost of goods sold?",
      "answer": "Odefsey sales declined from $1,469 million in 2022 to $1,288 million in 2024, as reported on page 66. Despite this decline, Gilead continues to share revenues with Janssen under their collaboration agreement, where Janssen retains a portion of the net selling price of Odefsey, and Gilead retains up to 30% of Janssen's share in major markets. This revenue-sharing arrangement directly affects Gilead's cost of goods sold, which includes Janssen's portion of the revenue from Odefsey sales. As seen on page 77, Gilead's cost of goods sold related to Janssen's share was $403 million in 2024, down from $483 million in 2022, reflecting the reduced sales volume of Odefsey and Symtuza. Therefore, while Odefsey sales have declined, Gilead still bears a significant cost burden from its ongoing partnership with Janssen, which impacts gross margins.",
      "reasoning_steps": [
        "Hop 1: GILD(page_66) \u2192 Odefsey: GILD reports declining sales of Odefsey from $1,469 million in 2022 to $1,288 million in 2024.",
        "Hop 2: Odefsey \u2192 Janssen: GILD has a revenue-sharing agreement with Janssen for Odefsey, where Janssen retains a portion of the net selling price, and Gilead retains up to 30% in major markets.",
        "Hop 3: Janssen \u2190 GILD(page_77): GILD's cost of goods sold includes Janssen's share of revenue from Odefsey and Symtuza, which declined from $483 million in 2022 to $403 million in 2024."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Distributes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Odefsey",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                  | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   |\n|----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|\n| (inm illions)                    | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         |\n| Productsales:                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| HIV                              |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Biktarvy                         | $ 10,855                      | $ 1,509                       | $ 1,060                       | $ 13,423                      | $ 9,692                       | $ 1,253                       | $ 905                         | $ 11,850                      | $ 8,510                       | $ 1,103                       | $ 777                         | $ 10,390                      |\n| Descovy                          | 1,902                         | 100                           | 110                           | 2,113                         | 1,771                         | 100                           | 114                           | 1,985                         | 1,631                         | 118                           | 123                           | 1,872                         |\n| Genvoya                          | 1,498                         | 180                           | 84                            | 1,762                         | 1,752                         | 205                           | 103                           | 2,060                         | 1,983                         | 284                           | 136                           | 2,404                         |\n| Odefsey                          | 957                           | 290                           | 41                            | 1,288                         | 1,012                         | 294                           | 44                            | 1,350                         | 1,058                         | 364                           | 47                            | 1,469                         |\n| Sym tuza-Revenueshare (1)        | 450                           | 130                           | 12                            | 592                           | 382                           | 133                           | 13                            | 529                           | 348                           | 168                           | 14                            | 530                           |\n| OtherHIV (2)                     | 257                           | 129                           | 48                            | 434                           | 238                           | 116                           | 47                            | 401                           | 290                           | 182                           | 59                            | 530                           |\n| Total HIV                        | 15,918                        | 2,339                         | 1,355                         | 19,612                        | 14,848                        | 2,102                         | 1,226                         | 18,175                        | 13,820                        | 2,219                         | 1,155                         | 17,194                        |\n| LiverD isease                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Sof osbuvir/V elpatasvir (3)     | 922                           | 299                           | 374                           | 1,596                         | 859                           | 323                           | 355                           | 1,537                         | 844                           | 355                           | 331                           | 1,530                         |\n| Vem lidy                         | 486                           | 44                            | 428                           | 959                           | 410                           | 38                            | 414                           | 862                           | 429                           | 35                            | 379                           | 842                           |\n| OtherLiverDisease (4)            | 192                           | 202                           | 73                            | 467                           | 152                           | 150                           | 83                            | 385                           | 167                           | 135                           | 124                           | 426                           |\n| Total LiverDisease               | 1,601                         | 545                           | 876                           | 3,021                         | 1,421                         | 511                           | 852                           | 2,784                         | 1,440                         | 525                           | 833                           | 2,798                         |\n| Veklury                          | 892                           | 284                           | 623                           | 1,799                         | 972                           | 408                           | 805                           | 2,184                         | 1,575                         | 702                           | 1,628                         | 3,905                         |\n| Oncology                         |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Cell Therapy                     |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Tecartus                         | 234                           | 138                           | 31                            | 403                           | 245                           | 110                           | 15                            | 370                           | 221                           | 75                            | 3                             | 299                           |\n| Yescarta                         | 662                           | 666                           | 242                           | 1,570                         | 811                           | 547                           | 140                           | 1,498                         | 747                           | 355                           | 57                            | 1,160                         |\n| Total Cell Therapy               | 896                           | 804                           | 274                           | 1,973                         | 1,055                         | 658                           | 156                           | 1,869                         | 968                           | 430                           | 60                            | 1,459                         |\n| Trodelvy                         | 902                           | 294                           | 119                           | 1,315                         | 777                           | 217                           | 68                            | 1,063                         | 525                           | 143                           | 12                            | 680                           |\n| Total Oncology                   | 1,798                         | 1,098                         | 393                           | 3,289                         | 1,833                         | 875                           | 224                           | 2,932                         | 1,494                         | 573                           | 73                            | 2,139                         |\n| Other                            |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| AmBisom e                        | 44                            | 276                           | 212                           | 533                           | 43                            | 260                           | 189                           | 492                           | 57                            | 258                           | 182                           | 497                           |\n| Other (5)                        | 255                           | 34                            | 68                            | 356                           | 261                           | 40                            | 66                            | 367                           | 331                           | 65                            | 53                            | 449                           |\n| Total Other                      | 299                           | 310                           | 280                           | 889                           | 304                           | 301                           | 255                           | 859                           | 388                           | 323                           | 235                           | 946                           |\n| Total product sales              | 20,508                        | 4,576                         | 3,526                         | 28,610                        | 19,377                        | 4,197                         | 3,361                         | 26,934                        | 18,716                        | 4,342                         | 3,924                         | 26,982                        |\n| Royalty,contractandotherrevenues | 82                            | 58                            | 4                             | 144                           | 62                            | 114                           | 7                             | 182                           | 168                           | 127                           | 4                             | 299                           |\n| Total revenues                   | $ 20,591                      | $ 4,634                       | $ 3,529                       | $ 28,754                      | $ 19,438                      | $ 4,310                       | $ 3,368                       | $ 27,116                      | $ 18,884                      | $ 4,469                       | $ 3,928                       | $ 27,281                      |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Odefsey",
          "name": "Odefsey",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 109,
      "question": "Given Forteo's declining U.S. revenue trend in 2021 and 2022, how does Eli Lilly's reliance on patent protection for revenue stability align with the imminent loss of intellectual property rights for this product?",
      "answer": "Forteo, which generated $441.6 million in U.S. revenue in 2022, has been experiencing a steady decline in sales over the past two years. This decline aligns with Eli Lilly's disclosure that Forteo is among the products losing significant patent protection in the U.S. and globally. The company explicitly states that the loss of intellectual property rights has resulted and will continue to result in rapid and severe revenue declines. Despite this, Eli Lilly emphasizes its dependence on patent-protected products for the majority of its revenues, cash flows, and earnings, highlighting a strategic vulnerability as Forteo's patent protection expires. This creates a direct tension between the company's stated reliance on protected product portfolios and the reality of Forteo's diminishing revenue trajectory as exclusivity erodes.",
      "reasoning_steps": [
        "Hop 1: LLY(page_65) \u2192 Forteo: Forteo's U.S. revenue declined from $510.3 million in 2021 to $441.6 million in 2022, indicating a downward trend.",
        "Hop 2: Forteo \u2192 Patent Protection: The company discloses that Forteo has recently lost or will soon lose significant patent protection in the U.S. and key international markets, exposing it to generic competition.",
        "Hop 3: Patent Protection \u2190 LLY(page_25): Eli Lilly states that it depends on intellectual property protection for most of its revenues and that the loss of exclusivity leads to rapid and severe revenue declines, as seen with Forteo."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Negatively_Impacts]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Forteo",
        "node_3": "Patent Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                    | U.S.       | U.S.       | U.S.       | Outside U.S.   | Outside U.S.   | Outside U.S.   |\n|------------------------------------|------------|------------|------------|----------------|----------------|----------------|\n|                                    | 2021       | 2020       | 2019       | 2021           | 2020           | 2019           |\n| Revenue-to unaffiliated customers: |            |            |            |                |                |                |\n| Diabetes:                          |            |            |            |                |                |                |\n| Trulicity \u00ae                        | $ 4,914.4  | $ 3,835.9  | $ 3,155.2  | $ 1,557.6      | $ 1,232.2      | $ 972.7        |\n| Humalog \u00ae (1)                      | 1,320.7    | 1,485.6    | 1,669.7    | 1,132.3        | 1,140.3        | 1,151.0        |\n| Jardiance (2)                      | 807.3      | 620.8      | 565.9      | 683.5          | 533.0          | 378.3          |\n| Humulin \u00ae                          | 832.9      | 866.4      | 879.7      | 389.6          | 393.2          | 410.4          |\n| Basaglar \u00ae                         | 588.3      | 842.3      | 876.2      | 304.2          | 282.1          | 236.3          |\n| Trajenta (3)                       | 82.1       | 95.6       | 224.8      | 290.4          | 263.0          | 365.8          |\n| Other Diabetes                     | 173.6      | 162.5      | 158.0      | 111.2          | 81.5           | 88.1           |\n| Total Diabetes                     | 8,719.3    | 7,909.1    | 7,529.5    | 4,468.8        | 3,925.3        | 3,602.6        |\n| Oncology:                          |            |            |            |                |                |                |\n| Alimta \u00ae                           | 1,233.9    | 1,265.3    | 1,219.5    | 827.5          | 1,064.7        | 896.4          |\n| Verzenio \u00ae                         | 834.9      | 618.2      | 454.8      | 515.0          | 294.4          | 124.9          |\n| Cyramza \u00ae                          | 358.1      | 381.9      | 335.3      | 674.8          | 650.8          | 589.9          |\n| Erbitux \u00ae                          | 481.8      | 480.1      | 487.9      | 66.4           | 56.3           | 55.4           |\n| Tyvyt \u00ae                            | -          | -          | -          | 418.1          | 308.7          | 134.0          |\n| Other Oncology                     | 120.1      | 46.6       | 111.0      | 210.7          | 152.3          | 205.3          |\n| Total Oncology                     | 3,028.8    | 2,792.1    | 2,608.5    | 2,712.5        | 2,527.2        | 2,005.9        |\n| Immunology:                        |            |            |            |                |                |                |\n| Taltz \u00ae                            | 1,542.4    | 1,288.5    | 1,016.8    | 670.4          | 500.0          | 349.6          |\n| Olumiant \u00ae (4)                     | 324.1      | 63.8       | 42.2       | 791.0          | 575.0          | 384.7          |\n| Other Immunology                   | 15.3       | 20.0       | -          | 17.6           | 14.6           | -              |\n| Total Immunology                   | 1,881.8    | 1,372.3    | 1,059.0    | 1,479.0        | 1,089.6        | 734.3          |\n| Neuroscience:                      |            |            |            |                |                |                |\n| Cymbalta \u00ae                         | 38.7       | 42.1       | 49.6       | 542.8          | 725.6          | 675.8          |\n| Emgality \u00ae                         | 434.5      | 325.9      | 154.9      | 142.7          | 37.0           | 7.7            |\n| Zyprexa \u00ae                          | 39.6       | 46.1       | 41.0       | 390.7          | 360.5          | 377.6          |\n| Other Neuroscience                 | 102.0      | 73.2       | 111.0      | 207.5          | 220.9          | 305.3          |\n| Total Neuroscience                 | 614.8      | 487.3      | 356.5      | 1,283.7        | 1,344.0        | 1,366.4        |\n| Other:                             |            |            |            |                |                |                |\n| COVID-19 Antibodies (5)            | 1,978.0    | 850.0      | -          | 261.4          | 21.2           | -              |\n| Forteo \u00ae                           | 441.6      | 510.3      | 645.5      | 360.3          | 536.0          | 759.1          |\n| Cialis \u00ae                           | 10.6       | 61.8       | 231.7      | 707.9          | 545.4          | 658.8          |\n| Other                              | 136.1      | 246.4      | 291.9      | 233.9          | 321.8          | 469.7          |\n| Total Other                        | 2,566.4    | 1,668.4    | 1,169.1    | 1,563.5        | 1,424.4        | 1,887.7        |\n| Revenue                            | $ 16,811.0 | $ 14,229.3 | $ 12,722.6 | $ 11,507.4     | $ 10,310.5     | $ 9,596.8      |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Forteo",
          "name": "Forteo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 110,
      "question": "How does Merck's financial treatment of its stake in Verquvo reflect the sales-based milestone payments made to Bayer AG, and how does this compare with the amortization schedule for Adempas given their respective commercialization roles?",
      "answer": "Merck's financial treatment of its stake in Verquvo includes a portion of the final $400 million sales-based milestone payment made to Bayer AG in January 2022, with $68 million attributed to Verquvo and capitalized as an intangible asset. This contrasts with the $806 million attributed to Adempas, which includes both acquired intangible balances and milestone payments. Verquvo\u2019s intangible asset is being amortized through 2031, while Adempas is amortized through 2027, reflecting different projected cash flow timelines despite both being part of the same collaboration. The $375 million milestone paid in 2020 and the subsequent $153 million catch-up amortization expense in 2021 further illustrate the evolving financial commitment tied to product approvals and sales performance.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_103) \u2192 [Bayer AG]: Merck entered into a collaboration with Bayer AG in 2014 to develop and commercialize sGC modulators, including Adempas and Verquvo, with shared development costs and profits.",
        "Hop 2: [Bayer AG] \u2192 [Verquvo]: Bayer AG developed Verquvo, which Merck commercializes in the U.S., and both companies share profits; Merck made a $375 million milestone payment in 2020 and recognized a $400 million liability in 2021 due to probable future sales milestones.",
        "Hop 3: [Verquvo] \u2190 [MRK](page_104): Merck capitalized $68 million of the final $400 million milestone payment to Bayer as an intangible asset related to Verquvo, amortizing it through 2031, compared to Adempas\u2019s $806 million balance amortized through 2027."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Bayer AG",
        "node_3": "Verquvo",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Bayer_AG",
          "name": "Bayer AG",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Verquvo",
          "name": "Verquvo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_104",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\npayment that was outstanding under this agreement. Accordingly, Merck recorded a liability of $400 million and a corresponding increase to the intangible assets related to this collaboration. Merck also recognized $153 million of cumulative amortization catchup  expense  related  to  the  recognition  of  this  milestone  in  2021.  In  January  2022,  Merck  made  this  final  milestone  payment  to Bayer.\n\nThe  intangible  asset  balances  related  to Adempas  (which  includes  the  acquired  intangible  asset  balance,  as  well  as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $806 million and $68 million, respectively, at December 31, 2021 and are included in Other Intangibles, Net . The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.\n\nSummarized financial information related to this collaboration is as follows:\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 111,
      "question": "How does the maturity of the 3.625% 2024 Notes impact the fair value and liability treatment of Amgen's interest rate swap contracts as disclosed in the derivative instruments section?",
      "answer": "The maturity of the $1.4 billion 3.625% 2024 Notes resulted in the termination of associated interest rate swap contracts during the year ended December 31, 2024. This event reduced the notional amount of active interest rate swaps from $6.7 billion at the beginning of the year. As of December 31, 2024, Amgen no longer held any derivative assets related to these terminated interest rate swaps, and the remaining liability related to interest rate swaps stood at $571 million as per the consolidated balance sheets. This reflects the dynamic relationship between debt maturities and the corresponding hedging instruments, which directly affects the fair value and liability recognition of derivatives.",
      "reasoning_steps": [
        "Hop 1: AMGN(page149) \u2192 3.625% 2024 Notes: Discloses that the 3.625% 2024 Notes had a notional amount of $1,400 million as of December 31, 2023, and were fully repaid by December 31, 2024.",
        "Hop 2: 3.625% 2024 Notes \u2192 Interest Rate Swap Contracts: The repayment of the 3.625% 2024 Notes caused the associated $1.4 billion in interest rate swap contracts to mature and terminate during 2024.",
        "Hop 3: Interest Rate Swap Contracts \u2190 AMGN(page151): As of December 31, 2024, the fair value of interest rate swap contracts no longer included any asset component, and the liability component stood at $571 million, reflecting the termination of the 3.625% 2024 Notes-linked swaps."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Impacts]-> FIN_INST <-[Discloses]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "3.625% 2024 Notes",
        "node_3": "Interest Rate Swap Contracts",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_149",
          "chunk_id": "chunk_2",
          "chunk_text": "|                        | December 31,     | December 31,   | December 31,     | December 31,   |\n|------------------------|------------------|----------------|------------------|----------------|\n|                        | 2024             | 2024           | 2023             | 2023           |\n| Notes                  | Notional amounts | Interest rates | Notional amounts | Interest rates |\n| 3.625% 2024 Notes      | $ -              | N/A            | $ 1,400          | SOFR+3.4%      |\n| 3.125% 2025 Notes      | 1,000            | SOFR+2.1%      | 1,000            | SOFR+2.1%      |\n| 2.60% 2026 Notes       | 1,250            | SOFR+2.1%      | 1,250            | SOFR+2.1%      |\n| 2.45% 2030 Notes       | 1,000            | SOFR+1.3%      | 1,000            | SOFR+1.3%      |\n| 2.30% 2031 Notes       | 500              | SOFR+1.1%      | 500              | SOFR+1.1%      |\n| 5.25% 2033 Notes       | 1,400            | SOFR+1.8%      | -                | N/A            |\n| 4.663% 2051 Notes      | 1,500            | SOFR+4.3%      | 1,500            | SOFR+4.3%      |\n| Total notional amounts | $ 6,650          |                | $ 6,650          |                |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "3.625%_2024_Notes",
          "name": "3.625% 2024 Notes",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_148",
          "chunk_id": "chunk_5",
          "chunk_text": "\n## Fair value hedges\n\nTo achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that qualify for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate SOFR-based coupons over the terms of the related hedge contracts. As of both December 31, 2024 and 2023, we had interest rate swap contracts with an aggregate notional amount of $6.7 billion that hedge certain portions of our long-term debt issuances.\n\nDuring the year ended December 31, 2024, interest rate swap contracts with an aggregate notional amount of $1.4 billion matured in connection with the repayment of  the 3.625% 2024 Notes. In addition, we entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%.",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Interest_Rate_Swap_Contracts",
          "name": "Interest Rate Swap Contracts",
          "type": "FIN_INST",
          "idf_score": 5.069602770184371
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_151",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                     | Derivative assets                             | Derivative assets   | Derivative liabilities                            | Derivative liabilities   |\n|-----------------------------------------------------|-----------------------------------------------|---------------------|---------------------------------------------------|--------------------------|\n| December 31, 2023                                   | Consolidated Balance Sheets locations         | Fair values         | Consolidated Balance Sheets locations             | Fair values              |\n| Derivatives designated as hedging instruments:      |                                               |                     |                                                   |                          |\n| Foreign currency forward contracts                  | Other current assets/ Other noncurrent assets | $ 145               | Accrued liabilities/ Other noncurrent liabilities | $ 116                    |\n| Cross-currency swap contracts                       | Other current assets/ Other noncurrent assets | -                   | Accrued liabilities/ Other noncurrent liabilities | 405                      |\n| Interest rate swap contracts                        | Other current assets/ Other noncurrent assets | -                   | Accrued liabilities/ Other noncurrent liabilities | 571                      |\n| Total derivatives designated as hedging instruments |                                               | 145                 |                                                   | 1,092                    |\n| Total derivatives                                   |                                               | $ 145               |                                                   | $ 1,092                  |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 48
    },
    {
      "question_id": 112,
      "question": "How does Gilead's exclusive licensing arrangement with Janssen for Symtuza, where Janssen sets the price and controls global commercialization, align with Gilead's financial dependency on Symtuza revenue shares and the risk of unilateral termination by Janssen?",
      "answer": "Gilead granted Janssen an exclusive global license for Symtuza, making Janssen responsible for pricing, manufacturing, and commercialization. Despite this, Gilead recognizes its share of Symtuza revenue as Product sales, which totaled hundreds of millions annually (e.g., $403 million in 2024 for Janssen's share across Complera/Eviplera and Odefsey, indicating similar scale for Symtuza). However, the agreement allows Janssen to terminate without cause on a country-by-country basis or entirely, posing a material risk to Gilead\u2019s revenue stream. This creates a dependency dynamic where Gilead\u2019s financial performance is tied to Janssen\u2019s commercial decisions without full control over the product\u2019s market trajectory.",
      "reasoning_steps": [
        "Hop 1: GILD(page_76) \u2192 Exclusive License: Gilead granted Janssen an exclusive license to Symtuza globally, with Janssen taking full responsibility for development, manufacturing, and commercialization.",
        "Hop 2: Exclusive License \u2192 Janssen: This licensing structure vests Janssen with control over pricing and market strategy, while Gilead remains the exclusive supplier of Gilead Compounds and retains IP rights.",
        "Hop 3: Janssen \u2190 GILD(page_77): Gilead recognizes Symtuza revenue shares as Product sales, but faces risk due to Janssen\u2019s ability to terminate the agreement unilaterally, which could materially affect Gilead\u2019s revenue."
      ],
      "difficulty": "hard",
      "idf_score": 6.02437402262659,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Amends]-> ACCOUNTING_POLICY -[Amends]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Exclusive License",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "ACCOUNTING_POLICY",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Amends"
        },
        "node_2": {
          "id": "Exclusive_License",
          "name": "Exclusive License",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Amends"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 113,
      "question": "How does Eli Lilly's increased capital expenditure of $3.45 billion in 2023 relate to its reliance on Global Systemically Important Banks (G-SIBs) for cash management, given the regulatory capital requirements these institutions must meet?",
      "answer": "Eli Lilly's capital expenditures rose significantly to $3.45 billion in 2023, driven by investments in new manufacturing facilities and strategic business development activities. To finance these outflows, the company relies on cash held at major financial institutions, many of which are classified as Global Systemically Important Banks (G-SIBs). These G-SIBs are subject to stringent regulatory oversight and must meet specific capital requirements, which Eli Lilly acknowledges in its risk management disclosures. By choosing to deposit cash with these highly regulated institutions, Lilly mitigates counterparty risk while ensuring liquidity to support its elevated capital spending. This strategic alignment between capital deployment and secure cash management reflects a coordinated approach to financial risk and operational growth.",
      "reasoning_steps": [
        "Hop 1: [LLY](page_50) \u2192 [Capital Requirements]: LLY's capital expenditures increased to $3.45 billion in 2023, driven by investments in new facilities and business development activities.",
        "Hop 2: [Capital Requirements] \u2192 [G-SIBs]: The company's ability to fund these capital outflows depends on its cash holdings, which are concentrated in financial institutions identified as G-SIBs.",
        "Hop 3: [G-SIBs] \u2190 [LLY](page_78): G-SIBs are subject to rigorous regulatory capital requirements, which LLY cites as a reason for confidence in their ability to meet obligations, thereby supporting LLY\u2019s cash management and funding strategy."
      ],
      "difficulty": "hard",
      "idf_score": 5.657389435086491,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT -[Meets]-> FIN_INST <-[Depends_On]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Capital Requirements",
        "node_3": "G-SIBs",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_1",
          "chunk_text": "## Operating\tResults-2022\n\nFor\ta\tdiscussion\tof\tour\tresults\tof\toperations\tpertaining\tto\t2022\tand\t2021\tsee\tItem\t7,\t\"Management's\tDiscussion\tand\tAnalysis of\tResults\tof\tOperations\tand\tFinancial\tCondition\"\tin\tour\tAnnual\tReport\ton\tForm\t10-K\tfor\tthe\tyear\tended\tDecember\t31,\t2022.\n\n## FINANCIAL\tCONDITION\tAND\tLIQUIDITY\n\nWe\tbelieve\tour\tavailable\tcash\tand\tcash\tequivalents,\ttogether\twith\tour\tability\tto\tgenerate\toperating\tcash\tflow\tand\tour\taccess to\tshort-term\tand\tlong-term\tborrowings,\tare\tsufficient\tto\tfund\tour\texisting\tand\tplanned\tcapital\trequirements,\twhich\tinclude:\n\n- working\tcapital\trequirements,\tincluding\trelated\tto\temployee\tpayroll\tand\tbenefits,\tclinical\ttrials,\tmanufacturing materials,\tand\ttaxes;\n- capital\texpenditures;\n- share\trepurchases\tand\tdividends;\n- repayment\tof\toutstanding\tshort-term\tand\tlong-term\tborrowings;\n- milestone\tand\troyalty\tpayments;\n- potential\tbusiness\tdevelopment\tactivities,\tincluding\tacquisitions,\tcollaborations,\tinvestments,\tand\tlicensing arrangements;\tand\n- contributions\tto\tour\tdefined\tbenefit\tpension\tand\tretiree\thealth\tbenefit\tplans.\n\nOur\tmanagement\tcontinuously\tevaluates\tour\tliquidity\tand\tcapital\tresources,\tincluding\tour\taccess\tto\texternal\tcapital,\tto ensure\twe\tcan\tadequately\tand\tefficiently\tfinance\tour\tcapital\trequirements.\tAs\tof\tDecember\t31,\t2023,\tour\tmaterial\tcash requirements\tprimarily\trelated\tto\tpurchases\tof\tgoods\tand\tservices\tto\tproduce\tour\tproducts\tand\tconduct\tour\toperations,\tcapital expenditures,\tdividends,\trepayment\tof\toutstanding\tborrowings,\tmilestone\tand\troyalty\tpayments,\tbusiness\tdevelopment activities,\tand\tthe\tremaining\tobligations\tfor\tthe\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\tfrom the\t2017\tTax\tAct,\t(see\tNotes\t11,\t4,\t3,\tand\t14\tto\tthe\tconsolidated\tfinancial\tstatements).\tWe\tanticipate\tour\tcash\trequirements related\tto\tordinary\tcourse\tpurchases\tof\tgoods\tand\tservices\twill\tbe\tconsistent\twith\tour\tpast\tlevels\trelative\tto\trevenues.\n\nCapital\texpenditures\twere\t$3.45\tbillion\tduring\t2023,\tcompared\tto\t$1.85\tbillion\tin\t2022.\tWe\tare\tmaking\tinvestments\tin\tnew facilities\tin\tIndiana,\tNorth\tCarolina,\tAlzey,\tRhineland-Palatinate,\tGermany,\tand\tLimerick,\tIreland\tto\tmanufacture\texisting and\tfuture\tproducts.\tThese\tinvestments,\tand\tother\tcapital\tinvestments\tthat\tsupport\tour\toperations,\thave\tincreased\tour\tcapital expenditures\tand\twill\tresult\tin\thigher\tcapital\texpenditures\tover\tthe\tnext\tseveral\tyears.\n\nCash\tand\tcash\tequivalents\tincreased\tto\t$2.82\tbillion\tas\tof\tDecember\t31,\t2023,\tcompared\twith\t$2.07\tbillion\tat\tDecember\t31, 2022.\tNet\tcash\tprovided\tby\toperating\tactivities\tdecreased\tto\t$4.24\tbillion\tin\t2023,\tcompared\twith\t$7.59\tbillion\tin\t2022.\tThe decrease\tin\tnet\tcash\tprovided\tby\toperating\tactivities\twas\tprimarily\tdriven\tby\tan\tincrease\tin\tcash\tpayments\tfor\tincome\ttaxes. See\tNote\t14\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tadditional\tinformation.\tRefer\tto\tthe\tconsolidated\tstatements\tof\tcash flows\tfor\tadditional\tinformation\ton\tthe\tsignificant\tsources\tand\tuses\tof\tcash\tfor\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022.\n\nIn\taddition\tto\tour\tcash\tand\tcash\tequivalents,\twe\theld\ttotal\tinvestments\tof\t$3.16\tbillion\tand\t$3.05\tbillion\tas\tof\tDecember\t31, 2023\tand\t2022,\trespectively.\tSee\tNote\t7\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tadditional\tinformation.\n\nIn\t2023,\twe\treceived\tcash\tproceeds\tof\t$1.60\tbillion\tfor\tthe\tsale\tof\tproduct\trights,\tprimarily\trelated\tto\tthe\tsales\tof\tthe rights\tfor\tthe\tolanzapine\tportfolio,\tincluding\tZyprexa,\tand\tBaqsimi.\tSee\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements\tfor additional\tinformation.\n\nFor\tinvestments\tthat\twere\taccounted\tfor\tas\tasset\tacquisitions,\twe\tpaid\t$3.94\tbillion\tin\t2023\tfor\tacquired\tIPR&amp;D\tprimarily related\tto\tacquisitions\tof\tDICE,\tVersanis,\tEmergence,\tand\tMablink.\tFor\tinvestments\tthat\twere\taccounted\tfor\tas\tbusiness combinations,\twe\tpaid\t$1.04\tbillion\tin\t2023\tprimarily\trelated\tto\tthe\tacquisition\tof\tPOINT.\tSee\tNote\t3\tto\tthe\tconsolidated financial\tstatements\tfor\tadditional\tinformation.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Capital_Requirements",
          "name": "Capital Requirements",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.04795152265239
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Risk\tManagement\tand\tRelated\tFinancial\tInstruments\n\nFinancial\tinstruments\tthat\tpotentially\tsubject\tus\tto\tcredit\trisk\tconsist\tprincipally\tof\ttrade\treceivables\tand\tinterestbearing\tinvestments.\tWholesale\tdistributors\tof\tlife\tscience\tproducts\taccount\tfor\ta\tsubstantial\tportion\tof\tour\ttrade receivables;\tcollateral\tis\tgenerally\tnot\trequired.\tWe\tseek\tto\tmitigate\tthe\trisk\tassociated\twith\tthis\tconcentration\tthrough our\tongoing\tcredit-review\tprocedures\tand\tinsurance.\tThe\tmajority\tof\tour\tcash\tis\theld\tby\ta\tfew\tmajor\tfinancial\tinstitutions that\thave\tbeen\tidentified\tas\tGlobal\tSystemically\tImportant\tBanks\t(G-SIBs)\tby\tthe\tFinancial\tStability\tBoard.\tG-SIBs\tare subject\tto\trigorous\tregulatory\ttesting\tand\toversight\tand\tmust\tmeet\tcertain\tcapital\trequirements.\tWe\tmonitor\tour\texposures with\tthese\tinstitutions\tand\tdo\tnot\texpect\tany\tof\tthese\tinstitutions\tto\tfail\tto\tmeet\ttheir\tobligations.\tIn\taccordance\twith documented\tcorporate\trisk-management\tpolicies,\twe\tmonitor\tthe\tamount\tof\tcredit\texposure\tto\tany\tone\tfinancial\tinstitution\tor corporate\tissuer\tbased\ton\tcredit\trating\tof\tour\tcounterparty.\tWe\tare\texposed\tto\tcredit-related\tlosses\tin\tthe\tevent\tof nonperformance\tby\tcounterparties\tto\trisk-management\tinstruments\tbut\tdo\tnot\texpect\tsignificant\tcounterparties\tto\tfail\tto\tmeet their\tobligations\tgiven\ttheir\tinvestment\tgrade\tcredit\tratings.\n\nWe\thave\tentered\tinto\taccounts\treceivable\tfactoring\tagreements\twith\tfinancial\tinstitutions\tto\tsell\tcertain\tof\tour\tnon-U.S. accounts\treceivable.\tThese\ttransactions\tare\taccounted\tfor\tas\tsales\tand\tresult\tin\ta\treduction\tin\taccounts\treceivable\tbecause the\tagreements\ttransfer\teffective\tcontrol\tover,\tand\trisk\trelated\tto,\tthe\treceivables\tto\tthe\tbuyers.\tOur\tfactoring\tagreements do\tnot\tallow\tfor\trecourse\tin\tthe\tevent\tof\tuncollectibility,\tand\twe\tdo\tnot\tretain\tany\tinterest\tin\tthe\tunderlying\taccounts receivable\tonce\tsold.\tWe\tderecognized\t$431.9\tmillion\tand\t$422.1\tmillion\tof\taccounts\treceivable\tas\tof\tDecember\t31,\t2023\tand 2022,\trespectively,\tunder\tthese\tfactoring\tarrangements.\tThe\tcosts\tof\tfactoring\tsuch\taccounts\treceivable\twere\tnot\tmaterial\tfor the\tyears\tended\tDecember\t31,\t2023,\t2022,\tand\t2021.\n\nOur\tderivative\tactivities\tare\tinitiated\twithin\tthe\tguidelines\tof\tdocumented\tcorporate\trisk-management\tpolicies\tand\tare intended\tto\toffset\tlosses\tand\tgains\ton\tthe\tassets,\tliabilities,\tand\ttransactions\tbeing\thedged.\tManagement\treviews\tthe correlation\tand\teffectiveness\tof\tour\tderivatives\ton\ta\tquarterly\tbasis.",
          "relationship": "Meets"
        },
        "node_3": {
          "id": "G-SIBs",
          "name": "G-SIBs",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Risk\tManagement\tand\tRelated\tFinancial\tInstruments\n\nFinancial\tinstruments\tthat\tpotentially\tsubject\tus\tto\tcredit\trisk\tconsist\tprincipally\tof\ttrade\treceivables\tand\tinterestbearing\tinvestments.\tWholesale\tdistributors\tof\tlife\tscience\tproducts\taccount\tfor\ta\tsubstantial\tportion\tof\tour\ttrade receivables;\tcollateral\tis\tgenerally\tnot\trequired.\tWe\tseek\tto\tmitigate\tthe\trisk\tassociated\twith\tthis\tconcentration\tthrough our\tongoing\tcredit-review\tprocedures\tand\tinsurance.\tThe\tmajority\tof\tour\tcash\tis\theld\tby\ta\tfew\tmajor\tfinancial\tinstitutions that\thave\tbeen\tidentified\tas\tGlobal\tSystemically\tImportant\tBanks\t(G-SIBs)\tby\tthe\tFinancial\tStability\tBoard.\tG-SIBs\tare subject\tto\trigorous\tregulatory\ttesting\tand\toversight\tand\tmust\tmeet\tcertain\tcapital\trequirements.\tWe\tmonitor\tour\texposures with\tthese\tinstitutions\tand\tdo\tnot\texpect\tany\tof\tthese\tinstitutions\tto\tfail\tto\tmeet\ttheir\tobligations.\tIn\taccordance\twith documented\tcorporate\trisk-management\tpolicies,\twe\tmonitor\tthe\tamount\tof\tcredit\texposure\tto\tany\tone\tfinancial\tinstitution\tor corporate\tissuer\tbased\ton\tcredit\trating\tof\tour\tcounterparty.\tWe\tare\texposed\tto\tcredit-related\tlosses\tin\tthe\tevent\tof nonperformance\tby\tcounterparties\tto\trisk-management\tinstruments\tbut\tdo\tnot\texpect\tsignificant\tcounterparties\tto\tfail\tto\tmeet their\tobligations\tgiven\ttheir\tinvestment\tgrade\tcredit\tratings.\n\nWe\thave\tentered\tinto\taccounts\treceivable\tfactoring\tagreements\twith\tfinancial\tinstitutions\tto\tsell\tcertain\tof\tour\tnon-U.S. accounts\treceivable.\tThese\ttransactions\tare\taccounted\tfor\tas\tsales\tand\tresult\tin\ta\treduction\tin\taccounts\treceivable\tbecause the\tagreements\ttransfer\teffective\tcontrol\tover,\tand\trisk\trelated\tto,\tthe\treceivables\tto\tthe\tbuyers.\tOur\tfactoring\tagreements do\tnot\tallow\tfor\trecourse\tin\tthe\tevent\tof\tuncollectibility,\tand\twe\tdo\tnot\tretain\tany\tinterest\tin\tthe\tunderlying\taccounts receivable\tonce\tsold.\tWe\tderecognized\t$431.9\tmillion\tand\t$422.1\tmillion\tof\taccounts\treceivable\tas\tof\tDecember\t31,\t2023\tand 2022,\trespectively,\tunder\tthese\tfactoring\tarrangements.\tThe\tcosts\tof\tfactoring\tsuch\taccounts\treceivable\twere\tnot\tmaterial\tfor the\tyears\tended\tDecember\t31,\t2023,\t2022,\tand\t2021.\n\nOur\tderivative\tactivities\tare\tinitiated\twithin\tthe\tguidelines\tof\tdocumented\tcorporate\trisk-management\tpolicies\tand\tare intended\tto\toffset\tlosses\tand\tgains\ton\tthe\tassets,\tliabilities,\tand\ttransactions\tbeing\thedged.\tManagement\treviews\tthe correlation\tand\teffectiveness\tof\tour\tderivatives\ton\ta\tquarterly\tbasis.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 114,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene expose the company to financial risk, given BLINCYTO's phase 3 development status in 2022 and the shared profit arrangement for commercialization in China?",
      "answer": "Amgen's $2.8 billion equity investment in BeiGene creates significant financial exposure, particularly for BLINCYTO, which was still in phase 3 development in 2022 and therefore not yet generating revenue. Under the collaboration agreement, Amgen shares profits and losses equally with BeiGene during the initial commercialization period in China, meaning Amgen bears 50% of any losses if BLINCYTO underperforms. Additionally, Amgen may have to pay royalties to BeiGene on future sales in China if product rights revert back to Amgen after the initial period. This dual exposure\u2014both through upfront capital investment and ongoing profit-sharing\u2014creates a layered financial risk structure tied to BLINCYTO's uncertain development and commercial trajectory.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_25) \u2192 BLINCYTO: BLINCYTO was in phase 3 development in 2022 for Ph-negative B-cell precursor Acute lymphoblastic leukemia, indicating it was not yet commercially viable and carried development risk.",
        "Hop 2: BLINCYTO \u2192 BeiGene: BeiGene is responsible for BLINCYTO\u2019s commercialization in China under a collaboration with Amgen, which includes shared development and commercialization costs and risks.",
        "Hop 3: BeiGene \u2190 AMGN(page_28): Amgen made a $2.8 billion equity investment in BeiGene in 2020 and shares profits and losses equally during the initial commercialization period, exposing Amgen to financial risk if BLINCYTO fails or underperforms in the Chinese market."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Supplies]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "BLINCYTO",
        "node_3": "BeiGene",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                                | Program change                                                  |\n|-------------------|-----------------------------------------------------------|-----------------------------------------------------------------|\n| LUMAKRAS/LUMYKRAS | NSCLC with KRAS G12C mutations                            | Approved by the FDAand conditional marketing approval by the EC |\n| Otezla            | Mild-to-moderate psoriasis                                | Approved by the FDA                                             |\n| RIABNI            | Non-Hodgkin's lymphoma                                    | Approved by the FDA                                             |\n| AMJEVITA          | Interchangeability                                        | Initiated phase 3 study                                         |\n| Bemarituzumab     | GEJ adenocarcinoma                                        | Initiated phase 3 study                                         |\n| BLINCYTO          | Ph-negative B-cell precursor Acute lymphoblastic leukemia | Initiated phase 3 study                                         |\n| TEZSPIRE          | Chronic rhinosinusitis with nasal polyps                  | Initiated phase 3 study                                         |\n| Otezla            | COVID-19                                                  | Terminated                                                      |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "BLINCYTO",
          "name": "BLINCYTO",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_3",
          "chunk_text": "\nFor each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.\n\n## 8. Collaborations\n\nA collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.\n\nFrom time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or  product  candidates.  These  collaborations  generally  provide  for  nonrefundable  upfront  license  fees,  development  and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary  of  significant  accounting  policies,  for  additional  discussion  of  revenues  recognized  under  these  types  of  arrangements. Operating  expenses  for  costs  incurred  pursuant  to  these  arrangements  are  reported  in  their  respective  expense  line  items  in  the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand  our  oncology  presence  in  China.  For  additional  information  regarding  our  equity  investment  in  BeiGene,  see  Note  9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "BeiGene",
          "name": "BeiGene",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 115,
      "question": "How does AbbVie's legal enforcement of Vraylar's patent rights through Forest Laboratories Holdings Limited relate to the drug's U.S. revenue growth between 2020 and 2021?",
      "answer": "AbbVie, through its subsidiary Forest Laboratories Holdings Limited, actively enforces patent rights for Vraylar, as seen in the 2019 litigation against multiple generic drug manufacturers to block their entry into the market. This legal protection is critical for maintaining exclusivity and revenue generation. On page 137, Vraylar's U.S. revenue is reported to have grown from $951 million in 2020 to $1,728 million in 2021, indicating a significant year-over-year increase. The enforcement of patents through litigation likely contributed to preserving market exclusivity during this period, thereby supporting the substantial revenue growth by preventing generic competition from eroding sales.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_136) \u2192 Forest Laboratories Holdings Limited: AbbVie uses this subsidiary to enforce patent rights for Vraylar, including litigation filed in 2019 against potential generic competitors.",
        "Hop 2: Forest Laboratories Holdings Limited \u2192 Vraylar: The subsidiary is directly involved in the legal protection of Vraylar, a key drug in AbbVie\u2019s neuroscience portfolio.",
        "Hop 3: Vraylar \u2190 ABBV(page_137): Vraylar\u2019s U.S. revenue grew from $951 million in 2020 to $1,728 million in 2021, showing strong financial performance that may be tied to ongoing patent enforcement."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Produces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Forest Laboratories Holdings Limited",
        "node_3": "Vraylar",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Forest_Laboratories_Holdings_Limited",
          "name": "Forest Laboratories Holdings Limited",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Vraylar",
          "name": "Vraylar",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_137",
          "chunk_id": "chunk_2",
          "chunk_text": "| years ended December 31 (in millions)   | years ended December 31 (in millions)   | 2021        | 2020        | 2019     |\n|-----------------------------------------|-----------------------------------------|-------------|-------------|----------|\n| Immunology                              |                                         |             |             |          |\n| Humira                                  | United States                           | $ 17,330    | $ 16,112    | $ 14,864 |\n|                                         | International                           | 3,364       | 3,720       | 4,305    |\n|                                         | Total                                   | $ 20,694    | $ 19,832    | $ 19,169 |\n| Skyrizi                                 | United States                           | $ 2,486     | $ 1,385     | $ 311    |\n|                                         | International                           | 453         | 205         | 44       |\n|                                         | Total                                   | $ 2,939     | $ 1,590     | $ 355    |\n| Rinvoq                                  | United States                           | $ 1,271     | $ 653       | $ 47     |\n|                                         | International                           | 380         | 78          | -        |\n|                                         | Total                                   | $ 1,651     | $ 731       | $ 47     |\n| Hematologic Oncology                    |                                         |             |             |          |\n| Imbruvica                               | United States                           | $ 4,321     | $ 4,305     | $ 3,830  |\n|                                         | Collaboration revenues                  | 1,087       | 1,009       | 844      |\n|                                         | Total                                   | $ 5,408     | $ 5,314     | $ 4,674  |\n| Venclexta                               | United States                           | $ 934       | $ 804       | $ 521    |\n|                                         | International                           | 886         | 533         | 271      |\n|                                         | Total                                   | $ 1,820     | $ 1,337     | $ 792    |\n| Aesthetics                              |                                         |             |             |          |\n| Botox Cosmetic (a)                      | United States                           | $ 1,424     | $ 687       | $ -      |\n|                                         | International                           | 808         | 425         | -        |\n|                                         | Total                                   | $ 2,232     | $ 1,112     | $ -      |\n| Juvederm Collection (a)                 | United States                           | $ 658       | $ 318       | $ -      |\n|                                         | International                           | 877         | 400         | -        |\n|                                         | Total                                   | $ 1,535     | $ 718       | $ -      |\n| Other Aesthetics (a)                    | United States                           | $ 1,268     | $ 666       | $ -      |\n|                                         | International                           | 198         | 94          | -        |\n|                                         | Total                                   | $ 1,466     | $ 760       | $ -      |\n| Neuroscience                            |                                         |             |             |          |\n| Botox Therapeutic (a)                   | United States                           | $ 2,012     | $ 1,155     | $ -      |\n|                                         | International                           | 439         | 232         | -        |\n|                                         | Total                                   | $ 2,451     | $ 1,387     | $ -      |\n| Vraylar (a)                             | United States                           | $ 1,728     | $ 951       | $ -      |\n| Duodopa                                 | United States                           | $ 102       | $ 103       | $ 97     |\n|                                         | International                           | $           | 494         |          |\n| Ubrelvy (a)                             | Total                                   | 511         | $           | $ 461    |\n| Other Neuroscience (a)                  | United States United States             | $ 552 $ 667 | $ 125 $ 528 | $ - $ -  |\n|                                         | International                           | 18          | 11          | -        |\n|                                         | Total                                   | $ 685       | $ 539       | $ -      |",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 116,
      "question": "Given the potential material financial impact of the RADV Audit Rule on Medicare reimbursement and Oak Street Health's operations, how does this regulatory risk reconcile with CVS's strategic decision to finance a $5.0 billion acquisition of Oak Street Health just one year before the rule's January 2023 implementation?",
      "answer": "CVS's acquisition of Oak Street Health for $5.0 billion in May 2023 occurred after the RADV Audit Rule was issued in January 2023, which the company explicitly notes could 'materially affect the amount of our Medicare reimbursement' and 'impact the services provided by, or the financial performance of, Oak Street Health.' Despite this risk, CVS proceeded with the acquisition to advance its value-based care strategy and expand into senior-focused primary care. The timing suggests that while CVS was aware of the regulatory uncertainty introduced by the RADV Audit Rule, it prioritized strategic growth in Medicare-focused care over short-term financial risks, potentially betting on long-term integration benefits to offset regulatory pressures.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_184) \u2192 [RADV Audit Rule]: The company explicitly identifies the RADV Audit Rule as a regulatory risk that could materially affect Medicare reimbursement and operational performance.",
        "Hop 2: [RADV Audit Rule] \u2192 [Oak Street Health]: The rule is noted to 'impact the services provided by, or the financial performance of, Oak Street Health,' directly linking the regulation to the acquired entity\u2019s operational risk.",
        "Hop 3: [Oak Street Health] \u2190 [CVS](page_133): CVS acquired Oak Street Health in May 2023 for $5.0 billion, despite the RADV Audit Rule having been issued just months earlier in January 2023."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> REGULATORY_REQUIREMENT -[Negatively_Impacts]-> COMP <-[Acquires]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "RADV Audit Rule",
        "node_3": "Oak Street Health",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_184",
          "chunk_id": "chunk_1",
          "chunk_text": "from regulatory audits, whether as a result of RADV, Public Exchange-related or other audits by CMS, the OIG or otherwise, including audits of the Company's minimum loss ratio rebates, methodology and/or reports, could be material and could adversely affect the Company's operating results, cash flows and/or financial condition.\n\nThe RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS RADV programs.\n\n## Medicare and Medicaid Litigation and Investigations\n\nThe Company has received CIDs from the Civil Division of the DOJ in connection with investigations of the Company's identification and/or submission of diagnosis codes related to risk adjustment payments, including patient chart review processes, under Parts C and D of the Medicare program. The Company is cooperating with the government and providing documents and information in response to these CIDs.\n\nIn May 2017, the Company received a CID from the U.S. Attorney's Office for the Southern District of New York requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.\n\nSince January 2022, the U.S. Attorney's Office for the District of Massachusetts has issued subpoenas to Aetna Life Insurance Company seeking, among other things, information in connection with its relationship and compensation arrangements with certain brokers, and the Company may receive similar inquiries in the future. The Company is cooperating with the investigation.\n\n## Stockholder Matters\n\nBeginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company's LTC business unit. Since filing, several of the cases have been consolidated, and two have resolved. In February 2025, the District of Rhode Island granted the Company's motion to dismiss In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford ). A derivative case in the District of Rhode Island, Lovoi v. Aguirre , had been stayed pending the outcome of the Waterford case, and the court has scheduled a status conference. In In re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich ), the Rhode Island Supreme Court affirmed the superior court's order granting the Company's motion to dismiss in January 2025. The Company and its current and former officers and directors are defending themselves against remaining claims.\n\nBeginning in December 2021, the Company has received three demands for inspection of books and records pursuant to Delaware General Corporation Law Section 220 ('Section 220 demands'), as well as a derivative complaint ( Vladimir Gusinsky Revocable Trust v. Lynch, et al. ) that was filed in January 2023, which the defendants moved to dismiss. The Section 220 demands and the complaint purport to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids. Following the Company's response to the Section 220 demands, two of the three stockholders sent demand letters to the Board containing allegations substantially similar to those made in the earlier Section 220 demands and the derivative matter, and requested that it take certain actions, including consideration of its governance and policies with respect to controlled substances. The Board deferred consideration of these two demands until after the motion to dismiss the Gusinsky case was decided. In July 2024, the court granted the defendants' motion to dismiss the Gusinsky case. In September 2024, the Board received a third demand letter containing similar allegations and requesting the Board take action. The Board has formed a demand review committee to evaluate the demands.\n\nIn January 2022, a shareholder class action complaint was filed in the Northern District of Illinois, Allison v. Oak Street Health, Inc., et al. Defendants include Oak Street Health and certain of its pre-acquisition officers and directors. The putative plaintiffs assert causes of action under various securities laws premised on allegations that defendants made omissions and misrepresentations to investors relating to marketing conduct they allege may violate the False Claims Act. In May 2024, the parties reached agreement in principle to settle this action for an amount immaterial to the Company. The court granted approval of the settlement in December 2024.\n\nBeginning in July 2024, two purported class action complaints, as well as multiple derivative complaints, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws and state law that are premised on allegations that the defendants made certain",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "RADV_Audit_Rule",
          "name": "RADV Audit Rule",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_53",
          "chunk_id": "chunk_1",
          "chunk_text": "- Data Validation Audits ('RADV Audit Rule') issued in January 2023 or other changes that may result from enforcement or audit actions, could: materially affect the amount of our Medicare reimbursement, require us to raise prices or reduce the benefits we offer to Medicare beneficiaries, impact the services provided by, or the financial performance of, Oak Street Health and Signify Health and potentially limit our (and the industry's) participation in the Medicare program.\n- The RADV Audit Rule creates uncertainty for Medicare Advantage plans. The lack of detail provided with respect to how CMS will select contracts and claims to audit, the methodology CMS will use, and how it will extrapolate as part of the RADV Audit Rule may impact future Medicare Advantage bids and result in other implications. The RADV Audit Rule also permits extrapolation of OIG contract level audits for payment years 2018 forward. The RADV Audit Rule is subject to ongoing litigation and the outcome and future impacts are uncertain.\n- Medicare Part D has resulted in increased utilization of prescription medications and puts pressure on our pharmacy gross margin rates due to regulatory and competitive pressures. Further, as a result of the ACA and changes to the retiree drug subsidy rules, clients of our PBM business could decide to discontinue providing prescription drug benefits to their Medicare-eligible members. To the extent this phenomenon occurs, the adverse effects of increasing customer migration into Medicare Part D may outweigh the benefits we realize from growth of our Medicare Part D products.\n- Our Medicare Part D operating results and our ability to expand our Medicare Part D business could be adversely affected if: the cost and complexity of Medicare Part D exceed management's expectations or prevent effective program implementation or administration; further changes to the regulations regarding how drug costs are reported for Medicare Part D (including changes related to the IRA) are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the applicable regulations impact our ability to retain fees from third parties including network pharmacies; the government alters Medicare Part D program requirements or reduces funding because of the higher-than-anticipated cost to taxpayers of Medicare Part D or for other reasons; or reinsurance thresholds are reduced.\n- The IRA contains significant changes to the Part D program that began in 2023 and will continue to 2032 that shifts more of the claim liability to plans and away from the government, including a complete redesign of the Part D standard benefit effective in 2025.\n- We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, and some states mandate that certain amounts be included or excluded from encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to bid for, and continue to participate in, certain Medicaid programs.\n- If we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs, and on our operating results, cash flows and financial condition.\n- The resumption of Medicaid eligibility redeterminations after being suspended during the COVID-19 pandemic has negatively impacted the number of members eligible for the Company's Medicaid plans, which could impact our operating results and cash flows from the Medicaid business.\n- Certain of our Medicaid contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our Medicaid programs because more states are using encounter data to determine compliance with performance standards and, in part, to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect accurate, or to correct inaccurate or incomplete, encounter data and have been and could be exposed to premium withholding, operating sanctions and financial fines and penalties for noncompliance.\n- CMS has proposed requiring that health plans offering certain dual eligible programs must also offer Medicaid programs, which could further impact the Company's ability to obtain or retain membership in its dual eligible programs. In addition, states are increasingly requiring companies to offer Medicaid within a state and conducting competitive bid processes to qualify to offer dual eligible products.\n\nPrograms funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase.",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Oak_Street_Health",
          "name": "Oak Street Health",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_133",
          "chunk_id": "chunk_1",
          "chunk_text": "addition, the standard also requires disclosure of the CODM's title and position, as well as detail on how the CODM uses the reported measure of segment operating results to evaluate segment performance and allocate resources. The standard also aligns interim segment reporting disclosure requirements with annual segment reporting disclosure requirements. The Company adopted the standard on January 1, 2024 for fiscal year reporting and the standard became effective for interim reporting periods in fiscal years beginning after December 15, 2024. The standard requires retrospective application to all prior periods presented. While the standard requires additional disclosures related to the Company's reportable segments, the standard did not have any impact on the Company's consolidated operating results, financial condition or cash flows as of the date of adoption. Refer to Note 19 ''Segment Reporting'' for the Company's segment reporting disclosures, including those newly required by this standard.\n\n## New Accounting Pronouncements Not Yet Adopted\n\n## Income Taxes\n\nIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The standard requires the Company to provide further disaggregated income tax disclosures for specific categories on the effective tax rate reconciliation, as well as additional information about federal, state/local and foreign income taxes. The standard also requires the Company to annually disclose its income taxes paid (net of refunds received), disaggregated by jurisdiction. The Company adopted the standard on January 1, 2025 for fiscal year reporting. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. While the standard requires additional disclosures related to the Company's income taxes, the standard did not have any impact on the Company's consolidated operating results, financial condition or cash flows.\n\n## Disaggregation of Income Statement Expenses\n\nIn November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The standard requires the Company to provide further disaggregated information of relevant expense captions within its consolidated statements of operations, including the purchases of inventory, employee compensation, depreciation and intangible asset amortization, as well as the inclusion of other specific ex penses, gains and losses required by ex isting G AAP. The new standard also requires the Company to disclose its total selling expenses and, on an annual basis, provide a qualitative description of its selling ex penses. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The standard may be applied prospectively or retrospectively. While the standard will require additional disclosures related to certain ex penses included in the consolidated statements of operations, the standard is not ex pected to have any impact on the Company's consolidated operating results, financial condition or cash flows.\n\n## 2. Acquisitions, Divestitures and Asset Sales\n\n## Oak Street Health Acquisition\n\nOn May 2, 2023 (the 'Oak Street Health Acquisition Date'), the Company acquired 100% of the outstanding shares and voting interest of Oak Street Health for cash ('Oak Street Health Acquisition'). Under the terms of the merger agreement, Oak Street Health stockholders received $39.00 per share in cash. The Company financed the transaction with borrowings of $5.0 billion from a term loan agreement entered into on May 1, 2023 as described in Note 10 ''Borrowings and Credit Agreements'' and cash on hand. Oak Street Health is a leading multi-payor, senior focused value-based primary care company. Oak Street Health is included within the Health Services segment. The Company acquired Oak Street Health to advance its value-based care strategy and broaden its platform into primary care.\n\nThe fair value of the consideration transferred on the date of acquisition consisted of the following:\n\n",
          "relationship": "Acquires"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 117,
      "question": "What is the impact of Amgen's new interest rate swap contracts on the $4.25 billion principal amount of 5.25% 2033 Notes, and how does this hedging activity reflect a strategic shift in their debt management approach?",
      "answer": "Amgen entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%. This hedging activity affects a portion of the $4.25 billion principal amount of the 5.25% 2033 Notes, effectively converting fixed-rate coupons to floating-rate SOFR-based coupons. This reflects a strategic shift in Amgen's debt management approach, where they actively manage interest rate exposure by adjusting the mix of fixed-rate and floating-rate debt, as evidenced by the $6.7 billion total interest rate swap contracts outstanding as of December 31, 2024.",
      "reasoning_steps": [
        "Hop 1: AMGN(page page_141) \u2192 5.25% 2033 Notes: Amgen discloses the $4.25 billion principal amount of the 5.25% 2033 Notes as part of its long-term debt structure.",
        "Hop 2: 5.25% 2033 Notes \u2192 New Interest Rate Swap Contracts: Amgen entered into new interest rate swap contracts with a notional amount of $1.4 billion related to the 5.25% 2033 Notes to convert fixed-rate coupons to floating-rate SOFR-based coupons.",
        "Hop 3: New Interest Rate Swap Contracts \u2190 AMGN(page page_148): Amgen actively manages its debt portfolio using fair value hedges, with $6.7 billion in total interest rate swap contracts outstanding as of December 31, 2024, indicating a strategic approach to interest rate risk management."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Impacts]-> FIN_INST <-[Invests_In]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "5.25% 2033 Notes",
        "node_3": "New Interest Rate Swap Contracts",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_141",
          "chunk_id": "chunk_3",
          "chunk_text": "|                   | Principal Amount   |\n|-------------------|--------------------|\n| 5.25% 2025 Notes  | $ 2,000            |\n| 5.507% 2026 Notes | 1,500              |\n| 5.15% 2028 Notes  | 3,750              |\n| 5.25% 2030 Notes  | 2,750              |\n| 5.25% 2033 Notes  | 4,250              |\n| 5.60% 2043 Notes  | 2,750              |\n| 5.65% 2053 Notes  | 4,250              |\n| 5.75% 2063 Notes  | 2,750              |\n| Total             | $ 24,000           |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "5.25%_2033_Notes",
          "name": "5.25% 2033 Notes",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_148",
          "chunk_id": "chunk_5",
          "chunk_text": "\n## Fair value hedges\n\nTo achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that qualify for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate SOFR-based coupons over the terms of the related hedge contracts. As of both December 31, 2024 and 2023, we had interest rate swap contracts with an aggregate notional amount of $6.7 billion that hedge certain portions of our long-term debt issuances.\n\nDuring the year ended December 31, 2024, interest rate swap contracts with an aggregate notional amount of $1.4 billion matured in connection with the repayment of  the 3.625% 2024 Notes. In addition, we entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%.",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "New_Interest_Rate_Swap_Contracts",
          "name": "New Interest Rate Swap Contracts",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_148",
          "chunk_id": "chunk_5",
          "chunk_text": "\n## Fair value hedges\n\nTo achieve a desired mix of fixed-rate and floating-rate debt, we enter into interest rate swap contracts that qualify for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate SOFR-based coupons over the terms of the related hedge contracts. As of both December 31, 2024 and 2023, we had interest rate swap contracts with an aggregate notional amount of $6.7 billion that hedge certain portions of our long-term debt issuances.\n\nDuring the year ended December 31, 2024, interest rate swap contracts with an aggregate notional amount of $1.4 billion matured in connection with the repayment of  the 3.625% 2024 Notes. In addition, we entered into new interest rate swap contracts with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 118,
      "question": "How does the Fast Track designation for PR006, acquired through the Prevail acquisition, align with Eli Lilly's broader commentary on the risks and uncertainties associated with fast-tracked drug development programs?",
      "answer": "Eli Lilly acquired PR006 through the $747.4 million Prevail acquisition in January 2021, and the drug received Fast Track designation from the FDA. This designation is intended to expedite development and review for therapies addressing serious conditions with unmet medical needs. However, in another section of the 10-K, Lilly acknowledges the significant risks and uncertainties inherent in pharmaceutical R&D, noting that fast-tracked drugs like PR006 still face high failure rates, regulatory hurdles, and commercialization challenges despite accelerated pathways. This highlights the tension between the strategic value of Fast Track assets and the reality of development risk.",
      "reasoning_steps": [
        "Hop 1: LLY(page_66) \u2192 PR006: LLY acquired PR006 through the $747.4 million acquisition of Prevail in 2021, with PR006 receiving Fast Track designation from the FDA.",
        "Hop 2: PR006 \u2192 Fast Track Designation: PR006 was granted Fast Track status by the FDA, indicating its potential to treat a serious condition with unmet medical need.",
        "Hop 3: Fast Track Designation \u2190 LLY(page_39): LLY discusses Fast Track designation in the context of broader R&D risks, noting that despite expedited pathways, most drug candidates fail to generate returns due to safety, efficacy, or regulatory hurdles."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Complies_With]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "PR006",
        "node_3": "Fast Track Designation",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "PR006",
          "name": "PR006",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Complies_With"
        },
        "node_3": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn collaboration with Boehringer Ingelheim. (1)\n\nBreakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. (2)\n\nFast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs. (3)\n\nThe FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients. (4)\n\nThere are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 119,
      "question": "How does Amgen's legal involvement with AbbVie in the Humira antitrust litigation relate to its competitive positioning against AbbVie's product RINVOQ in the U.S. market?",
      "answer": "Amgen is named in the Humira Antitrust Class Actions alongside AbbVie, where plaintiffs allege that Amgen and AbbVie entered into an unlawful settlement agreement delaying Amgen's U.S. market entry with its Humira biosimilar, AMGEVITA, until 2023. Meanwhile, RINVOQ is listed in Amgen's 10-K as one of AbbVie\u2019s marketed products that directly competes with Amgen\u2019s ENBREL in the U.S. and Canada. This indicates that while Amgen collaborates with AbbVie in legal settlements around biosimilar market timing, it also faces competitive pressure from AbbVie\u2019s newer products like RINVOQ, which may benefit from the delayed biosimilar competition to Humira. The legal dynamics and competitive landscape together shape Amgen\u2019s strategic positioning in the TNF inhibitor market.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_150) \u2192 [AbbVie]: Amgen is named in antitrust litigation with AbbVie, where plaintiffs allege a settlement delaying Amgen's U.S. entry with AMGEVITA (Humira biosimilar) until January 2023.",
        "Hop 2: [AbbVie] \u2192 [RINVOQ]: AbbVie is the manufacturer of RINVOQ, a product listed in Amgen\u2019s 10-K as a competitor to ENBREL in the U.S. and Canada.",
        "Hop 3: [RINVOQ] \u2190 [AMGN](page_16): RINVOQ is listed in Amgen\u2019s competitive landscape table as a competing product to ENBREL, indicating direct market rivalry between Amgen and AbbVie."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Produces]-> PRODUCT <-[Competes_Against]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "AbbVie",
        "node_3": "RINVOQ",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_150",
          "chunk_id": "chunk_1",
          "chunk_text": "2019); Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. (April 9, 2019) (Law Enforcement); Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. (April 16, 2019); Sheet Metal Workers' Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al. (April 19, 2019) (Sheet Metal Workers'); Locals 302 &amp; 612 of The International Union of Operating EngineersEmployers  Construction  Industry  Health  And  Security  Trust  Fund  v.  AbbVie  Inc.,  et  al. (April  25,  2019)  (Construction  Industry); Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc. , et al. (April 30, 2019) (Louisiana Health); and Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al. (May 10, 2019) (Cleveland Bakers) (collectively, Humira Antitrust Class Actions).\n\nIn  each  of  the  Humira Antitrust  Class Actions,  the  plaintiffs  bring  federal  antitrust  claims  along  with  various  state  law  claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully  monopolized  the  alleged  market  for  Humira  and  biosimilars  of  Humira,  including  by  creating  an  allegedly unlawful  so-called  patent  thicket  around  Humira.  In  the  Local  1500,  Sheet  Metal  Workers'  and  Construction  Industry  cases,  the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira biosimilars, including Bioepis, Mylan, Sandoz, Fresenius Kabi USA, LLC (Fresenius), Pfizer Inc. and Momenta Pharmaceuticals,  Inc.,  in  connection  with  the  settlement  of  patent  litigation  relating  to  Humira,  whereby  Amgen  and  the  other defendants that have developed Humira biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA, its Humira biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira biosimilar in that market for five months, beginning in January 2023. In each of the Humira Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney's fees on behalf of a putative class of thirdparty payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira in the United States. Defendants' responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes.\n\nOn August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz and Fresenius. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual  motions),  challenging  the  legal  sufficiency  of  the  plaintiffs'  allegations  to  state  any  claim  for  relief  under  the  law.  On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support  of  the  motion  to  dismiss.  On  June  8,  2020,  the  Illinois  Northern  District  Court  issued  an  order  granting  the  motion  by  the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the FTC and one on behalf  of  20  states,  each  filed  on  October  13,  2020.  On  December  21,  2020,  the  defendants-appellees  filed  their opposition brief. Defendants-appellees amicus briefs, including one by the DoJ, were filed on December 28, 2020. On February 25, 2021, oral argument was held by the U.S. Court of Appeals for the Seventh Circuit on the appeal by plaintiffs-appellants of the lower court's dismissal of the consolidated complaint with prejudice.\n\n## U.S. Tax Litigation\n\nAmgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue\n\nSee Note 6, Income taxes, for discussion of the IRS tax dispute and the Company's petition in the U.S. Tax Court.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "AbbVie",
          "name": "AbbVie",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "RINVOQ",
          "name": "RINVOQ",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 120,
      "question": "How does Bristol-Myers Squibb's exposure to Byetta* litigation risk, inherited through its former subsidiary Amylin, align with the company's broader financial risk disclosures related to divestitures, particularly considering the $1.9 billion in 2021 pretax royalty income tied to the diabetes business?",
      "answer": "Bristol-Myers Squibb's exposure to Byetta* litigation, which stems from its former subsidiary Amylin, remains a liability despite the 2014 divestiture of the diabetes business to AstraZeneca. Although the majority of claims alleging pancreatic cancer have been dismissed due to summary judgment rulings in favor of the defendants, BMS still faces potential shared liability with AstraZeneca. This litigation risk is part of a broader set of financial risks outlined in the company's disclosures regarding divestitures, which include the possibility of adverse effects on pretax income if royalty streams decline. Notably, in 2021, BMS received approximately $1.9 billion in pretax income from royalties tied to the diabetes business, including Byetta*, Onglyza*, and Farxiga*. The continued financial benefit from these royalty rights contrasts with the lingering legal exposure, highlighting a complex trade-off between retained revenue streams and residual liabilities from divested assets.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_48) \u2192 [Amylin]: BMY references the divestiture of its diabetes business, which included Amylin, and notes that pretax income from royalties was approximately $1.9 billion in 2021, indicating ongoing financial exposure to the business post-divestiture.",
        "Hop 2: [Amylin] \u2192 [Byetta* Litigation]: Amylin, as a former subsidiary of BMS, is a co-defendant in Byetta* litigation related to alleged pancreatic cancer injuries, with BMS retaining shared liability through the divestiture agreement.",
        "Hop 3: [Byetta* Litigation] \u2190 [BMY](page_160): BMY faces ongoing litigation risk from Byetta*, despite the dismissal of many claims, with potential appeals and continued exposure due to its historical ownership and contractual obligations post-divestiture."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Relates_To]-> COMP -[Involved_In]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Amylin",
        "node_3": "Byetta* Litigation",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "related  to  the  divestiture  of  our  diabetes  business  (including  the  transfer  of  certain  future  royalty  rights  pertaining  to Amylin,  Onglyza*  and  Farxiga*  product  sales),  out-licensed  intellectual  property  and  the  Merck  patent  infringement settlement. Pretax income generated from royalties was approximately $1.9 billion in 2021. Our pretax income could be adversely affected if the royalty streams decline in future periods.\n\nFailure  to  effectively  manage  acquisitions,  divestitures,  alliances,  joint  ventures  and  other  portfolio  actions  could adversely  impact  our  future  results.  In  addition,  any  businesses  or  assets  that  we  acquire  in  the  future  may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.\n\nWe have acquired, or in-licensed, a number of assets and we expect to continue to support our pipeline with compounds or products obtained through licensing and acquisitions. Future revenues, profits and cash flows of an acquired company's products, technologies and pipeline candidates may not materialize due to low product uptake, delayed or missed pipeline opportunities,  the  inability  to  capture  expected  synergies  resulting  from  cost  savings  and  avoidance,  increased competition, safety concerns, regulatory issues, supply chain problems or other factors beyond our control. Substantial difficulties,  costs  and  delays  could  result  from  integrating  our  acquisitions,  including  for  (i)  R&amp;D,  manufacturing, distribution,  sales,  marketing,  promotion  and  information  technology  activities;  (ii)  policies,  procedures,  processes, controls and compliance; and (iii) tax considerations. Where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with a joint venture or acquisition, the value of those  securities  will  fluctuate  and  may  depreciate  in  value.  We  may  not  control  the  company  in  which  we  acquire securities,  such  as  in  connection  with  a  collaborative  arrangement,  and  as  a  result,  we  will  have  limited  ability  to determine its management, operational decisions, internal controls and compliance and other policies, which can result in additional financial and reputational risks.\n\nWe may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect our earnings. Our divestitures also may result in continued financial exposure to the divested businesses, such as through guarantees or other financial arrangements, continued supply and services arrangements, or potential litigation, following the transaction. Under these arrangements, nonperformance by us could result in obligations being imposed on us that could have a material adverse effect on our competitive position, cash flows, results of operations, financial condition or reputation. In particular, we divested Otezla* in connection with obtaining regulatory approval for our acquisition of Celgene. If the FTC determines that we violated the consent order that we agreed to in connection with the divestiture, the FTC may seek a civil penalty and our reputation may be adversely affected.\n\nWe might also incur asset impairment charges related to acquisitions or divestitures that reduce our earnings. The value allocated to certain of our assets could be substantially impaired due to a number of factors beyond our control. New or revised accounting standards, rules and interpretations could result in changes to the recognition of income and expense that may materially and adversely affect our financial results.\n\nIf the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact our financial condition, cash flows and results of operations. Moreover, due to the substantial amount of debt that we incurred to finance the cash portion of the Celgene and MyoKardia acquisitions, there can be no assurance of when we will be able to expand our business development capacity. Although we are committed to reducing our debt, pursuing strategic transaction opportunities in future may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings.\n\n## Failure  to  attract  and  retain  highly  qualified  workforce  could  affect  our  ability  to  successfully  develop  and commercialize products.\n\nOur success is largely dependent on our continued ability to (i) attract and retain highly qualified scientific, technical and management workforce, including people with expertise in clinical R&amp;D, governmental regulation and commercialization, and  (ii)  in  connection  with  our  Celgene  acquisition,  integrate  two  unique  corporate  cultures  and  maintain  employee morale. We are facing increasing competition for a limited pool of qualified individuals from numerous pharmaceutical and  biotechnology  companies,  universities,  government  entities,  research  institutions,  companies  seeking  to  enter  the healthcare space, and companies in other industries. We cannot be sure that we will be able to retain quality talent or that the costs of doing so will not materially increase.\n\n## Market, Liquidity and Credit Risks\n\nOur significant additional indebtedness that we incurred in connection with the Celgene and MyoKardia acquisitions could have negative consequences.\n\nOur acquisitions of Celgene and MyoKardia increased the amount of our debt resulting in additional interest expense. This  could  reduce  our  financial  flexibility  to  continue  capital  investments,  develop  new  products  and  declare  future dividends.",
          "relationship": "Relates_To"
        },
        "node_2": {
          "id": "Amylin",
          "name": "Amylin",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Byetta*_Litigation",
          "name": "Byetta* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 121,
      "question": "How does the financial impact of BMY's ongoing litigation exposure with Otsuka over Abilify* compare to the historical revenue benefits BMY derived from its co-promotion agreement with Otsuka for Sprycel?",
      "answer": "BMY faced ongoing litigation exposure as of 2022 related to Abilify*, where it and Otsuka were co-defendants in 11 remaining cases in Canada, with two active class actions certified in Quebec and Ontario. This litigation followed over 2,500 cases filed in the U.S., most of which were resolved through a master settlement program initiated in 2019. In contrast, BMY's prior co-promotion agreement with Otsuka for Sprycel generated $1.8 billion in revenues in 2019, with Otsuka receiving $302 million in fees based on net sales. While the litigation represents a liability risk, the co-promotion agreement was a source of significant revenue, suggesting a complex relationship where financial gains from collaboration were substantial, yet offset by significant legal exposure on another product.",
      "reasoning_steps": [
        "Hop 1: BMY(page_160) \u2192 Abilify* Litigation: BMY and Otsuka are co-defendants in ongoing litigation over Abilify*, with 11 cases remaining in Canada and two active class actions.",
        "Hop 2: Abilify* Litigation \u2192 Otsuka: Otsuka is a co-defendant with BMY in the Abilify* litigation, indicating shared legal exposure.",
        "Hop 3: Otsuka \u2190 BMY(page_116): BMY and Otsuka co-promoted Sprycel through 2019, with BMY earning $1.8 billion in revenues and paying Otsuka $302 million in fees that year."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> LITIGATION -[Involved_In]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Abilify* Litigation",
        "node_3": "Otsuka",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Abilify*_Litigation",
          "name": "Abilify* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Otsuka",
          "name": "Otsuka",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 122,
      "question": "How does BMY's exposure to ongoing Byetta* litigation risk, through its former subsidiary Amylin, reconcile with the financial benefits it continues to receive from the divestiture of its diabetes business, including Amylin-related royalties?",
      "answer": "BMY, although no longer directly owning Byetta*, remains exposed to litigation risk through its former subsidiary Amylin, which co-defends Byetta*-related lawsuits alongside Lilly. Despite the dismissal of most pancreatic cancer claims due to federal preemption and plaintiffs dismissing many remaining cases, there is still potential for appeals and residual liability. On the other hand, BMY continues to benefit financially from the 2014 divestiture of its diabetes business, which included Amylin, through ongoing royalty income\u2014approximately $1.9 billion in pretax income in 2021\u2014related to Amylin, Onglyza*, and Farxiga* product sales. The continued litigation risk from Byetta* creates a dual dynamic where BMY retains financial upside from the divestiture but also faces residual legal exposure, highlighting the complex interplay between divestiture benefits and long-tail liabilities.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_160) \u2192 [Byetta*]: BMY faces litigation exposure through Byetta*, a product it no longer owns but which was developed under its former subsidiary Amylin, with ongoing legal risks despite significant dismissals.",
        "Hop 2: [Byetta*] \u2192 [Amylin]: Byetta* is a trademark of Amylin Pharmaceuticals, LLC, which was a former subsidiary of BMY, linking the litigation risk back to BMY's historical ownership and corporate structure.",
        "Hop 3: [Amylin] \u2190 [BMY](page_48): BMY continues to receive substantial pretax royalty income (e.g., $1.9 billion in 2021) from the divestiture of its diabetes business, which included Amylin, showing a direct financial benefit from the same entity that now carries litigation risk."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Owns]-> COMP <-[Relates_To]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Byetta*",
        "node_3": "Amylin",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Byetta*",
          "name": "Byetta*",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_185",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Commission.\n* Indicates,  in  this  2021  Form  10-K,  brand  names  of  products,  which  are  registered  trademarks  not  solely  owned  by  the Company or  its  subsidiaries. Abilify is  a  trademark  of  Otsuka  Pharmaceutical  Co.,  Ltd.; Atripla is  a  trademark  of  Gilead Sciences,  LLC; Avapro/Avalide (known  in  the  EU  as Aprovel/Karvea )  and Plavix are  trademarks  of  Sanofi; Byetta is  a trademark of Amylin Pharmaceuticals, LLC; CABOMETYX is a trademark of Exelixis, Inc.; Erbitux is a trademark of ImClone LLC; Farxiga and Onglyza are  trademarks  of  AstraZeneca  AB; Gleevec is  a  trademark  of  Novartis  AG; Keytruda is  a trademark of Merck Sharp &amp; Dohme Corp.; Otezla is a trademark of Amgen Inc.; Tecentriq is a trademark of Genetech, Inc.; and Yescarta is a trademark of Kite Pharma, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.",
          "relationship": "Owns"
        },
        "node_3": {
          "id": "Amylin",
          "name": "Amylin",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "related  to  the  divestiture  of  our  diabetes  business  (including  the  transfer  of  certain  future  royalty  rights  pertaining  to Amylin,  Onglyza*  and  Farxiga*  product  sales),  out-licensed  intellectual  property  and  the  Merck  patent  infringement settlement. Pretax income generated from royalties was approximately $1.9 billion in 2021. Our pretax income could be adversely affected if the royalty streams decline in future periods.\n\nFailure  to  effectively  manage  acquisitions,  divestitures,  alliances,  joint  ventures  and  other  portfolio  actions  could adversely  impact  our  future  results.  In  addition,  any  businesses  or  assets  that  we  acquire  in  the  future  may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.\n\nWe have acquired, or in-licensed, a number of assets and we expect to continue to support our pipeline with compounds or products obtained through licensing and acquisitions. Future revenues, profits and cash flows of an acquired company's products, technologies and pipeline candidates may not materialize due to low product uptake, delayed or missed pipeline opportunities,  the  inability  to  capture  expected  synergies  resulting  from  cost  savings  and  avoidance,  increased competition, safety concerns, regulatory issues, supply chain problems or other factors beyond our control. Substantial difficulties,  costs  and  delays  could  result  from  integrating  our  acquisitions,  including  for  (i)  R&amp;D,  manufacturing, distribution,  sales,  marketing,  promotion  and  information  technology  activities;  (ii)  policies,  procedures,  processes, controls and compliance; and (iii) tax considerations. Where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with a joint venture or acquisition, the value of those  securities  will  fluctuate  and  may  depreciate  in  value.  We  may  not  control  the  company  in  which  we  acquire securities,  such  as  in  connection  with  a  collaborative  arrangement,  and  as  a  result,  we  will  have  limited  ability  to determine its management, operational decisions, internal controls and compliance and other policies, which can result in additional financial and reputational risks.\n\nWe may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect our earnings. Our divestitures also may result in continued financial exposure to the divested businesses, such as through guarantees or other financial arrangements, continued supply and services arrangements, or potential litigation, following the transaction. Under these arrangements, nonperformance by us could result in obligations being imposed on us that could have a material adverse effect on our competitive position, cash flows, results of operations, financial condition or reputation. In particular, we divested Otezla* in connection with obtaining regulatory approval for our acquisition of Celgene. If the FTC determines that we violated the consent order that we agreed to in connection with the divestiture, the FTC may seek a civil penalty and our reputation may be adversely affected.\n\nWe might also incur asset impairment charges related to acquisitions or divestitures that reduce our earnings. The value allocated to certain of our assets could be substantially impaired due to a number of factors beyond our control. New or revised accounting standards, rules and interpretations could result in changes to the recognition of income and expense that may materially and adversely affect our financial results.\n\nIf the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact our financial condition, cash flows and results of operations. Moreover, due to the substantial amount of debt that we incurred to finance the cash portion of the Celgene and MyoKardia acquisitions, there can be no assurance of when we will be able to expand our business development capacity. Although we are committed to reducing our debt, pursuing strategic transaction opportunities in future may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings.\n\n## Failure  to  attract  and  retain  highly  qualified  workforce  could  affect  our  ability  to  successfully  develop  and commercialize products.\n\nOur success is largely dependent on our continued ability to (i) attract and retain highly qualified scientific, technical and management workforce, including people with expertise in clinical R&amp;D, governmental regulation and commercialization, and  (ii)  in  connection  with  our  Celgene  acquisition,  integrate  two  unique  corporate  cultures  and  maintain  employee morale. We are facing increasing competition for a limited pool of qualified individuals from numerous pharmaceutical and  biotechnology  companies,  universities,  government  entities,  research  institutions,  companies  seeking  to  enter  the healthcare space, and companies in other industries. We cannot be sure that we will be able to retain quality talent or that the costs of doing so will not materially increase.\n\n## Market, Liquidity and Credit Risks\n\nOur significant additional indebtedness that we incurred in connection with the Celgene and MyoKardia acquisitions could have negative consequences.\n\nOur acquisitions of Celgene and MyoKardia increased the amount of our debt resulting in additional interest expense. This  could  reduce  our  financial  flexibility  to  continue  capital  investments,  develop  new  products  and  declare  future dividends.",
          "relationship": "Relates_To"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 123,
      "question": "How does GILD's settlement timeline with Apotex Inc. for Symtuza and Genvoya relate to the company's strategic use of licensing agreements to manage patent risk and maintain revenue streams through 2032?",
      "answer": "GILD entered into settlement agreements with Apotex in February 2025, granting the generic manufacturer a non-exclusive license for Symtuza and Genvoya, with market entry beginning on August 6, 2032, or earlier under certain conditions. This aligns with GILD's broader strategy of using licensing agreements to manage patent litigation risk and control the timing of generic competition, particularly for key HIV products. The structured licensing approach allows GILD to extend revenue visibility through 2032 while mitigating the immediate financial impact of generic entry, as seen in the context of other patent disputes involving Biktarvy and the pediatric exclusivity extension for Veklury. This reflects a calculated balance between defending intellectual property and managing market exclusivity through negotiated settlements.",
      "reasoning_steps": [
        "Hop 1: GILD(page_9) \u2192 Apotex Inc.: GILD entered into a settlement with Apotex in February 2025, granting a non-exclusive license for Symtuza and Genvoya with market entry starting August 6, 2032.",
        "Hop 2: Apotex Inc. \u2192 License: The settlement agreement with Apotex involves a non-exclusive license to certain patents, allowing Apotex to market generic versions of Genvoya and Symtuza under defined terms.",
        "Hop 3: License \u2190 GILD(page_87): GILD strategically uses licensing agreements as part of its IP defense and revenue management framework, as evidenced by similar settlements with Lupin and MSN, and ongoing litigation with Cipla and Laurus over Biktarvy patents."
      ],
      "difficulty": "hard",
      "idf_score": 6.02437402262659,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Faces]-> REGULATORY_REQUIREMENT <-[Invests_In]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Apotex Inc.",
        "node_3": "License",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nWhere applicable, settlement and license agreements w ith generic manufacturers relating to the patents that protect our principal products are noted. The nature and timing of loss of exclusivity for these products depends on a multitude of factors, and loss of exclusivity may be earlier under certain circumstances. For more information, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.' (1)\n\nIn S eptember 2022, G ilead and five generic manufacturers (Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.) reached agreements to settle the U.S . patent litigation concerning patents that protect TAF in our Descovy, V emlidy and Odefsey products. (2)\n\nThe composition of matter patent has expired in the EU. In the EU and the U.S ., patent applications are pending relating to our proprietary manufacturing processes. (3)\n\nIn 2018, G ilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our S tribild and G envoya products. (4)\n\nIn February 2025, G ilead reached an agreement w ith one generic manufacturer (Apotex, Inc., together w ith Apotex C orp., and its manufacturer of cobicistat, MS N Laboratories Private Limited, MS N Life S ciences Private Ltd., and MS N Pharmaceuticals Inc.) to settle the patent litigation concerning certain patents that protect cobicistat on silicon dioxide and TAF in our G envoya product. The Apotex/MS N agreement provides a non-exclusive license to those patents beginning on August 6, 2032, or earlier in certain circumstances. (5)\n\nIn January 2024, FDA granted pediatric exclusivity for V eklury, w hich extends all non-expired exclusivities by six months, and w hich is reflected in the presently reported date. (6)\n\nR eg u latory exclusivity in the U.S . expires in 2032. (7)\n\nOrphan exclusivity expires in 2031. (8)\n\nTen years of regulatory/market exclusivity expected on approval. (9)\n\n## Patent and Trade Secret Strategy\n\nFor a discussion of risks and challenges associated with our patent and trade secret strategy described below, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.'\n\n## Patents\n\nPatents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As  part  of  our  business  strategy,  we  actively  seek  patent  protection  both  in  the  U.S.  and  internationally  and  file  additional  patent  applications,  when appropriate, to cover improvements in our compounds, products and technology.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Apotex_Inc.",
          "name": "Apotex Inc.",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_1",
          "chunk_text": "## Litigation Relating to Pre-Exposure Prophylaxis\n\nIn August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, 'HHS Patents') by the Patent Trial and Appeal Board ('PTAB'). The HHS Patents are assigned to the U.S. Department of Health and Human Services ('HHS') and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate ('TDF') or tenofovir alafenamide ('TAF') prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis ('PrEP'). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the use of Truvada and Descovy for PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a lawsuit against the U.S. federal government in the U.S. Court of Federal Claims ('CFC'), alleging breach of three material transfer agreements ('MTAs') related to the research underlying the HHS Patents and two clinical trial agreements ('CTAs') by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the CFC was held in June 2022, and in November 2022, the CFC determined that the government breached the MTAs. In January 2024, the CFC found the government liable for breach of both CTAs. In May 2023, the District Court held a trial regarding the government's patent infringement claims, and the jury rendered a full defense verdict in favor of G ilead, finding that the asserted claims of the HHS Patents are invalid and the HHS patents are not infringed. In March 2024, the District Court upheld the jury's verdict that the government's patents are invalid, denied the government's request for a new trial and then entered final judgment. In July 2024, the government filed a notice of appeal. In January 2025, we entered into a settlement agreement with the government to resolve these litigation matters relating to PrEP. The settlement includes the dismissal of both lawsuits, including the government's appeal of the jury verdict that its patents are invalid, as well as a license to the government's ex isting PrEP patents.\n\n## Litigation with Generic Manufacturers\n\nAs part of the approval process for some of our products, FDA granted us a New Chemical Entity ('NCE') exclusivity period during which other manufacturers' applications for approval of generic versions of our products will not be approved. G eneric manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application ('ANDA'), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product's approval.\n\nIn  October  2021,  we  received  a  letter  from  Lupin  Ltd.  ('Lupin')  indicating  that  it  has  submitted  an ANDA  to  FDA  requesting  permission  to  market  and manufacture a generic version of Symtuza, a product commercialized by Janssen Products L.P. and for which G ilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (together, 'Janssen'), filed a patent infringement lawsuit against Lupin as co-plaintiffs in  the  U.S.  District  Court  of  Delaware.  In  September  2022,  we  received  a  letter  from Apotex   Inc.  and Apotex   Corp.  (together,  'Apotex ')  stating  that  they  have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. The cases against Lupin and Apotex were consolidated into a single trial scheduled for February 2025. In February 2025, we, along with Janssen, entered into a settlement agreement with Lupin and its manufacturer of cobicistat on silicon dioxide, MSN Laboratories Private Limited, MSN Life Sciences Private  Ltd., and  MSN  Pharmaceuticals  Inc. (collectively, 'MSN'), to resolve the litigation and patent challenges associated with  Symtuza in the  U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Lupin and MSN were granted a non-exclusive license for Lupin's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. In February 2025, we, along with Janssen, entered into a settlement agreement with Apotex to resolve the litigation and patent challenges associated with Symtuza in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex was granted a non-exclusive license for Apotex's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. Both settlement agreements with Lupin and Apotex have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "License",
          "name": "License",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_87",
          "chunk_id": "chunk_1",
          "chunk_text": "Starting in March 2022, we received letters from Lupin, Laurus Labs ('Laurus') and Cipla Ltd. ('Cipla'), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of the adult dosage strength of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of four of the six  patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of  Delaware  and  intend  to  enforce  and  defend  our  intellectual  property. Additionally,  in  November  2023,  we  received  a  letter  from  Cipla  indicating  that  it  has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of the pediatric dosage strength of Biktarvy. Cipla challenged the validity of two of the patents listed in the Orange Book as associated with Biktarvy. We filed a separate lawsuit against Cipla in December 2023 in the U.S. District Court of Delaware. This lawsuit has been consolidated with the first lawsuit, with a single trial scheduled for October 2025. In October 2024, Cipla separately filed a petition at the U.S. Patent &amp; Trademark Office ('USPTO') for Inter Partes Review (IPR) of one of the patents at issue in District Court litigation. We intend to defend this patent at the USPTO.\n\nIn June 2023, we received a letter from Apotex indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of  G envoya.  In  July  2023,  we  filed  a  patent  infringement  lawsuit  against Apotex   in  the  U.S.  District  Court  of  Delaware  and  to  enforce  and  defend  our intellectual property. This case was consolidated with the Symtuza matters discussed above, and a trial was scheduled for February 2025. In February 2025, we entered into a settlement agreement with Apotex and its manufacturer of cobicistat on silicon dioxide, MSN, to resolve the litigation and patent challenges associated with Genvoya in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex and MSN were granted a non-exclusive license for Apotex's ANDA product in the U.S. to certain of our patents on cobicistat on silicon dioxide and TAF relating to G envoya beginning on August 6, 2032, or earlier in certain circumstances. The settlement agreement has been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.\n\n## Antitrust and Consumer Protection\n\nWe, along with Bristol-Myers Squibb Company ('BMS'), Johnson &amp; Johnson, Inc. ('Johnson &amp; Johnson'), and Teva Pharmaceutical Industries Ltd. ('Teva') have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV , including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs consisting of retail pharmacies, individual health plans and United Healthcare, filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the classes. These cases have been coordinated with the class actions. In March 2023, the District Court granted our motion to hold separate trials as to (i) the allegations against us and Teva seeking monetary damages relating to Truvada and Atripla ('Phase I') and (ii) the allegations against us and, in part, Johnson &amp; Johnson, seeking monetary damages and injunctive relief relating to Complera ('Phase II'). In May 2023, we settled claims with the direct purchaser class and the retailer opt-out plaintiffs for $525 million, which we paid in the second half of 2023. The settlement agreements are not an admission of liability or fault by us. In June 2023, the jury returned a complete verdict in G ilead's favor on the remaining plaintiffs' Phase I allegations. In November 2023, the court denied plaintiffs' motion to set aside the verdict, and in February 2024, the court entered final judgment on the Phase I verdict and certain summary judgment rulings. In September 2024, plaintiffs filed their opening appellate briefs challenging the Phase I verdict and those summary judgment rulings. We filed our responsive briefs in January 2025. The court has stayed Phase II pending the appeal of Phase I. While we intend to vigorously oppose the appeal and defend against the Phase II claims, we cannot predict the ultimate outcome. If plaintiffs are successful in their appeal or Phase II claims, we could be required to pay monetary damages or could be subject to permanent injunctive relief in favor of plaintiffs.\n\nIn January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief. In March 2024, the court denied our motion for judgment on the pleadings to preclude Aetna from re-litigating claims that were dismissed at summary judgment in the above class action cases. We filed a writ petition appealing the denial of our motion for judgment on the pleadings, which the appellate court denied in May 2024. In April 2024, the court granted our motion to bifurcate the case to adjudicate the issue of preclusion before litigating the merits of the case. In July 2024, Aetna filed a request to voluntarily dismiss two of its claims with prejudice, which the court subsequently granted, leaving only the claims related to Truvada and Atripla. In September 2024, Aetna filed an amended complaint with respect to these claims. In October 2024, we filed a demurrer and motion to strike plaintiff's claims.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 124,
      "question": "How does BMY's ongoing litigation to enforce patent rights for Eliquis in Europe relate to the potential loss of market exclusivity, and what impact could this have on the company's revenue realization during the exclusivity period?",
      "answer": "BMY's ongoing litigation to enforce patent rights for Eliquis in Europe is critical to maintaining market exclusivity, which is essential for maximizing revenue during the exclusivity period. In jurisdictions like the UK, Finland, and Slovakia, adverse judicial decisions have already allowed generic manufacturers to market competing products, reducing BMY's ability to capture full commercial value. The company is actively litigating in multiple European countries to prevent early generic entry, as the expiration or invalidation of patents before the natural end of exclusivity could lead to rapid revenue declines. Given that the majority of an innovative product\u2019s value is realized during the exclusivity period, any early loss of exclusivity due to unsuccessful patent enforcement could materially affect BMY\u2019s financial performance, especially for high-revenue products like Eliquis.",
      "reasoning_steps": [
        "Hop 1: BMY(page_121) \u2192 Patent Rights: BMY is actively involved in litigation across Europe to defend Eliquis' composition-of-matter patent and SPCs, with mixed outcomes including losses in the UK, Finland, and Slovakia, allowing generic entry.",
        "Hop 2: Patent Rights \u2192 Market Exclusivity: Patent rights are a primary determinant of market exclusivity, which allows innovator companies to realize the majority of a product's commercial value before generic competition enters.",
        "Hop 3: Market Exclusivity \u2190 BMY(page_28): The loss of market exclusivity\u2014either through patent expiration, legal challenges, or settlements\u2014can result in rapid and substantial declines in product revenues, as seen with Eliquis in certain European markets."
      ],
      "difficulty": "hard",
      "idf_score": 5.128494288012563,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> RISK_FACTOR -[Provides]-> REGULATORY_REQUIREMENT <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Patent Rights",
        "node_3": "Market Exclusivity",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_1",
          "chunk_text": "We are vigorously defending against the legal proceedings in which we are named as defendants and we believe we have substantial claims and/or defenses in each matter. While the outcomes of these proceedings and other contingencies BMS is subject to are inherently unpredictable and uncertain, we do not believe that any of these matters will have a material adverse effect on  BMS' financial position or liquidity, though they could possibly be material to our consolidated results of operations in any one accounting period. There can be no assurance that there will not be an increase in the scope of one or more of the matters described below or that any other or future lawsuits, claims, government investigations, or other legal proceedings will not be material to BMS's financial position, results of operations, or cash flows for a particular period. Furthermore, failure to successfully enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably  estimated.  Developments  in  legal  proceedings  and  other  matters  that  could  cause  changes  in  the  amounts  previously  accrued  are  evaluated  each reporting period. For a discussion of BMS's tax contingencies, see \" - Note 7. Income Taxes.\"\n\n## INTELLECTUAL PROPERTY\n\n## Eliquis - E urope\n\nBMS is involved in litigations throughout Europe against companies seeking to launch generic apixaban products prior to the expiration of the composition-of-matter patent for Eliquis and its associated SPCs. Litigations are pending or have been concluded in: Belgium, Bulgaria, Croatia, Czech Republic, France, Denmark, Finland, Greece, Hungary, Ireland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, and the UK.\n\nTrials or preliminary proceedings on the merits have been held in: Czech Republic, Finland, France, Ireland, Netherlands, Norway, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, and the UK. To date BMS has obtained decisions in the following countries:\n\n- BMS obtained a final negative decision in the UK, and generics are now on the market in this country.\n- BMS obtained final positive decisions in Norway, Sweden, and Switzerland.\n- BMS obtained initial  negative  decisions  in  Finland,  Ireland,  and  Slovakia.  In  Finland  and  Slovakia,  appeals  are  pending.  In  Ireland,  the  appeals  court remanded the case to the lower court for rehearing.\n- BMS obtained initial positive decisions in the Czech Republic, France, and Netherlands, and appeals are pending in all three countries.\n- In  Spain,  the  Barcelona  Commercial  Court  found  the  composition-of-matter  patent  for Eliquis and  its  associated  SPC  invalid.  BMS  appealed,  and  the Barcelona Court of Appeal overturned the decision. The generic products that launched at risk after the Barcelona Commercial Court were either enjoined or removed from the market as a result of the Barcelona Court of Appeal ruling. An appeal is pending before the Supreme Court.\n- In  Finland,  generics  have  entered  the  market  while  proceedings  are  pending.  In  Portugal,  BMS  obtained  preliminary  injunctions  against  two  generic companies, but one generic company remains on the market while proceedings are pending.\n\nGeneric manufacturers may seek to market generic versions of Eliquis in additional countries in Europe prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe.\n\n## Plavix* - Australia\n\nFrom 2007 to 2010, BMS and Sanofi were involved in patent litigation with a generic company seeking to launch clopidogrel bisulfate 75 mg tablets in Australia. While BMS and Sanofi obtained an initially favorable decision and an injunction, that decision was overturned on appeal. In 2013, the Australian government intervened seeking damages, which would have been split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi disputed that the Australian government is entitled to any damages. The trial court issued a decision dismissing the Australian government's claim for damages, the Australian government appealed, and the Federal Court issued a ruling in BMS and Sanofi's favor, which was affirmed in December 2024, by the High Court of Australia.\n\n## Pomalyst - U.S.\n\nIn  December  2024,  Celgene  received  a  Notice  Letter  from  Cipla  USA,  Inc.  ('Cipla')  notifying  Celgene  that  Cipla  had  filed  an ANDA  containing  paragraph  IV certifications seeking approval to market generic pomalidomide products in the U.S. In response, Celgene initiated a patent infringement action against Cipla in the U.S. District Court for the District of New Jersey, asserting certain FDA Orange Book-listed patents. No trial date has been scheduled.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Patent_Rights",
          "name": "Patent Rights",
          "type": "RISK_FACTOR",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "Abraxane Abraxane (paclitax el albumin-bound particles for injectable suspension) is a solvent-free protein-bound chemotherapy product that combines paclitaxel with  albumin  using  our  proprietary Nab technology platform, and is used to treat breast cancer,  NSCLC and pancreatic cancer, among others. \u00ae \u00ae\n\nWe own or license a number of patents in the U.S. and foreign countries primarily covering our products. We have also developed many brand names and trademarks for our products. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement.\n\nIn  the  pharmaceutical industry, the majority of an innovative product's commercial value is usually realized during the period in which the product has market exclusivity. A product's market exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovative drug is entitled.\n\nPatents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.\n\nMarket exclusivity is also sometimes provided by regulatory exclusivity, a period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator's data to approve a competitor's generic or biosimilar copy. Regulatory exclusivity can provide a market exclusivity period on a product that expires beyond the patent term.\n\nWhen these patent rights and other forms of exclusivity expire and generic versions of a medicine are approved and marketed, there are often substantial and rapid declines in the sales of the original innovative product. For further discussion of the impact of generic medicines on our business, refer to '-Competition' below.\n\nSpecific  aspects  of  the  law  governing  market  patent  protection  and  regulatory  ex clusivity  for  pharmaceuticals  vary  from  country  to  country.  The  following summarizes key exclusivity rules in markets representing significant sales:\n\n## United States\n\nIn the U.S., most of our key products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product's patent life, however, is lost during the time it takes an innovator company to develop and obtain regulatory approval of a new drug. As compensation at least in part for the lost patent term due to regulatory review periods, the innovator may, depending on a number of factors, apply to the government to restore lost patent term by extending the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval.\n\nA company seeking to market an innovative pharmaceutical in the  U.S. must submit a complete set of safety and efficacy data to the  FDA.  If the innovative pharmaceutical is a chemical product, the company files an NDA. If the medicine is a biological product, a BLA is filed. Both types of applications can receive certain periods of regulatory exclusivity as discussed below. An NDA or a BLA for a compound that is designated as an orphan drug can receive seven years of exclusivity for an orphan drug indication. During this period, the FDA generally may not approve another application for the same drug product for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic ex clusivity.\n\n## Chemical products\n\nA competitor  seeking  to  launch  a  generic  substitute  of  a  chemical  innovative  drug  in  the  U.S.  must  file  an ANDA  with  the  FDA.  In  the ANDA,  the  generic manufacturer needs to demonstrate only 'bioequivalence' between the generic substitute and the approved NDA drug. The ANDA relies upon the safety and efficacy data previously filed by the innovator in its NDA.",
          "relationship": "Provides"
        },
        "node_3": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "a REMS program. The inability to bring a product to market or a significant delay in the expected regulatory approval and related launch date of a new product could negatively impact our revenues and earnings. In addition, if certain acquired pipeline programs are canceled or we believe their commercial prospects have  been  reduced,  we  may  recognize  material  non-cash  impairment  charges  for  those  programs.  Finally,  losing  key  molecules  and  intermediaries  or  our compound library through a natural or man-made disaster or act of sabotage could negatively impact the product development cycle.\n\nWe can provide no assurance when or whether any of our products under development will be approved or launched or whether any products, once launched, will be commercially successful. The public announcement of data from our clinical studies, or those of our competitors, or news of any developments related to our, or our competitors', products or late-stage compounds may cause significant volatility in our stock price and depending on the data, may result in an adverse impact on our business, financial condition or results of operations. If the development of any of our key late-stage product candidates is delayed or discontinued or a clinical study does not meet one or more of its primary endpoints, our stock price could decline significantly and there may be an adverse impact on our business, financial condition or results of operations.\n\nWe must maintain a continuous flow of successful new products and successful new indications for existing products sufficient both to cover our substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short-term or long-term can have a material adverse effect on our business, results of operations, cash flow, financial condition and prospects. W e may also choose to no longer pursue certain programs from time to time as we periodically review our research and development programs and seek to prioritize our pipeline investments. This may result in further uncertainty as to when potential new products will be approved and commercialized. There can be no assurance that our key product candidates would prove to be safe and effective or as safe and effective as other competing products, or that, even if approved, any such products will become commercially successful for all approved indications.\n\n## We could lose market exclusivity of a product earlier than expected.\n\nIn the pharmaceutical and biotechnology industries, the majority of an innovative product' s commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product's revenues.\n\nMarket exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights, if any, varies from country to country and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain or maintain patent and other intellectual property rights, or limitations on the use or loss of such rights, could result in a rapid loss of sales for any affected products which could be material to  us.  In  some  countries,  including  certain  EU  member  states,  basic  patent  protections  for  our  products  may  not  exist  because  certain  countries  did  not historically offer the right to obtain specific types of patents, and/or we (or our licensors) did not file in those countries. In addition, the patent environment can be unpredictable, and the validity and enforceability of patents cannot be predicted with certainty.  For example, for  Eliquis, generics have challenged the composition of matter patents and related  SPCs in various jurisdictions, and trials have taken place, or are scheduled to take place, in certain  European countries. While these legal proceedings are pending, generic manufacturers have begun marketing generic versions of Eliquis in certain EU countries and may seek to market generic versions of Eliquis in other EU countries prior to the expiration date of applicable patents and related SPCs. Furthermore, manufacturers of innovative drugs as well as generic drug manufacturers may be able to design their products around our owned or licensed patents and compete with us using the resulting alternative technology. Absent relevant patent protection for a product, once the data exclusivity period expires, generic or alternative versions can be approved and marketed.\n\nGeneric and biosimilar product manufacturers as well as other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we have faced and may continue to face earlier-than-expected competition for any products at any time. Patents covering our key products have been, and  are  likely  to  continue  to  be,  subject  to  validity,  enforceability  and  infringement  challenges  in  patent  litigations  and  post-grant  review  patent  office proceedings. Although we are confident in the strength of our intellectual property rights, it may be possible for generic drug companies to successfully challenge our rights and launch their generic versions of our drugs prior to the expiration of our intellectual property rights. For example, following certain adverse judicial decisions in the UK, Finland and Slovakia, generic manufacturers have begun marketing generic versions of Eliquis in these countries, and may seek to market generic versions of Eliquis in additional countries in Europe, prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe. In addition, in order to avoid the uncertainty and expense of litigation, among other  reasons,  we  may  decide  to  enter  into  settlements  with  generic  manufacturers  that  permit  generic  market  entry  prior  to  the  expiration  of  our intellectual property rights. For example, as a result of patent settlements, generic entry for Revlimid in the UK began on January 18, 2022, and in various other European countries on February 18, 2022. Similarly, in the U.S., following patent settlements, certain companies have begun marketing generic lenalidomide pursuant to volume-limited licenses. The licenses will no longer be volume-limited beginning on January 31, 2026.",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 125,
      "question": "How does Pfizer's competitive challenge from generic drugs, as outlined in the Competition section, align with the company's strategic collaboration with payors to promote affordable healthcare, given the reported 42% decline in net cash flow from operations in 2023?",
      "answer": "Pfizer faces significant competitive pressure from generic drug manufacturers, particularly after patent expirations, which has led to price cuts and volume loss, as noted in the Competition section. This pressure is compounded by payors promoting generic drugs to reduce healthcare costs, as outlined in the Managed Care Trends section. Despite these challenges, Pfizer collaborates with payors to support affordable healthcare access, as stated in the MD&A section, while navigating a 42% decline in net cash flow from operations in 2023. This financial strain underscores the importance of strategic partnerships with payors to maintain market access and patient affordability while managing the impact of generic competition.",
      "reasoning_steps": [
        "Hop 1: PFE(page_16) \u2192 Generic Drugs: Pfizer identifies generic pharmaceutical manufacturers as a major competitive challenge, noting that they can market competing versions of Pfizer's products after patent expiration and often charge significantly less, leading to price cuts and volume loss.",
        "Hop 2: Generic Drugs \u2192 Payors: Payors typically encourage the use of generic drugs as cost-saving measures, often through Medicaid and other managed care programs, which can reduce Pfizer's market share and revenue.",
        "Hop 3: Payors \u2190 PFE(page_36): Pfizer collaborates with payors to support patient access to affordable healthcare, even as the company faces a 42% decline in net cash flow from operations in 2023, highlighting the strategic importance of maintaining relationships with payors amid financial pressures."
      ],
      "difficulty": "hard",
      "idf_score": 6.227106576680673,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Promotes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Generic Drugs",
        "node_3": "Payors",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_1",
          "chunk_text": "## COMPETITION\n\nOur\tbusiness\tis\tconducted\tin\tintensely\tcompetitive\tand\thighly\tregulated\tmarkets.\tMany\tof\tour\tproducts\tface\tcompetition\tin\tthe\tform\tof\tbranded\tor generic\tdrugs\tor\tbiosimilars\tthat\ttreat\tsimilar\tdiseases\tor\tindications.\tThe\tprincipal\tforms\tof\tcompetition\tinclude\tefficacy,\tsafety,\tease\tof\tuse and\tcost.\tThough\tthe\tmeans\tof\tcompetition\tvary\tamong\tour\tproducts,\tdemonstrating\tthe\tvalue\tof\tour\tproducts\tis\ta\tcritical\tfactor\tfor\tsuccess.\n\nWe\tcompete\twith\tother\tcompanies\tthat\tmanufacture\tand\tsell\tproducts\tthat\ttreat\tor\tprevent\tdiseases\tor\tindications\tsimilar\tto\tthose\ttreated\tor prevented\tby\tour\tmajor\tproducts.\tThese\tcompetitors\tinclude\tother\tworldwide\tresearch-based\tbiopharmaceutical\tcompanies,\tsmaller\tresearch\tcompanies with\tmore\tlimited\ttherapeutic\tfocus\tand\tgeneric\tdrug\tand\tbiosimilar\tmanufacturers.\tOur\tcompetitors\talso\tmay\tdevote\tsubstantial\tfunds\tand\tresources to\tR&amp;D\tand\ttheir\tsuccessful\tR&amp;D\tcould\tresult\tin\terosion\tof\tthe\tsales\tof\tour\texisting\tproducts\tand\tpotential\tsales\tof\tour\tproducts\tin\tdevelopment,\tas well\tas\tproduct\tobsolescence.\tIn\taddition,\tseveral\tof\tour\tcompetitors\toperate\twithout\tlarge\tR&amp;D\texpenses\tand\tmake\ta\tregular\tpractice\tof\tchallenging our\tproduct\tpatents\tbefore\ttheir\texpiration.\n\nTo\thelp\taddress\tcompetitive\ttrends\twe\tcontinually\temphasize\tinnovation,\twhich\tis\tunderscored\tby\tour\tmulti-billion-dollar\tinvestment\tin\tR&amp;D,\tas\twell as\tour\tbusiness\tdevelopment\ttransactions,\tboth\tdesigned\tto\tresult\tin\ta\tstrong\tand\tdifferentiated\tproduct\tpipeline.\tOur\tinvestment\tin\tresearch continues\teven\tafter\tdrug\tor\tvaccine\tapproval\tas\twe\tseek\tto\tfurther\tdemonstrate\tthe\tvalue\tof\tour\tproducts\tfor\tthe\tconditions\tthey\ttreat\tor\tprevent, as\twell\tas\tinvestigating\tpotential\tnew\tapplications.\tWe\teducate\tpatients,\tphysicians,\tpayors\tand\tglobal\thealth\tauthorities\ton\tthe\tbenefits\tand\trisks of\tour\tmedicines\tand\tvaccines,\tand\tseek\tto\tcontinually\tenhance\tthe\torganizational\teffectiveness\tof\tour\tbiopharmaceutical\tfunctions,\tincluding\tour efforts\tto\teffectively\tlaunch\tand\tmarket\tour\tproducts\tto\tour\tcustomers.\n\nOperating\tconditions\thave\talso\tshifted\tas\ta\tresult\tof\tincreased\tglobal\tcompetitive\tpressures,\tindustry\tregulation\tand\tcost\tcontainment.\tWe\tcontinue to\tevaluate,\tadapt\tand\timprove\tour\torganization\tand\tbusiness\tpractices\tin\tan\teffort\tto\tbetter\tmeet\tcustomer\tand\tpublic\tneeds.\tWe\tbelieve\tthat\twe have\ttaken\tan\tindustry-leading\trole\tin\tevolving\tour\tethical\tapproaches\tto\tU.S.\tdirect-to-consumer\tadvertising,\tinteractions\twith,\tand\tpayments\tto, healthcare\tprofessionals\tand\tmedical\teducation\tgrants.\tWe\talso\tcontinue\tto\tsupport\tprograms\tto\taddress\tpatient\taffordability\tand\taccess\tbarriers,\tas we\tstrive\tto\tadvance\tfundamental\thealth\tsystem\tchange\tthrough\tour\tsupport\tfor\tbetter\thealthcare\tsolutions.\tFor\texample,\tin\tMay\t2022,\twe\tlaunched An Accord\tfor\ta\tHealthier\tWorld, which\taims\tto\tprovide\tour\tfull\tportfolio\tof\tpatented\tand\toff-patent\tmedicines\tand\tvaccines\tfor\twhich\tPfizer\tholds global\trights\ton\ta\tnot-for-profit\tbasis\tto\t1.2\tbillion\tpeople\tliving\tin\t45\tlower-income\tcountries\taround\tthe\tworld.\n\nOur\tvaccines\thave\tand\tmay\tcontinue\tto\tface\tcompetition,\tincluding\tfrom\tthe\tintroduction\tof\talternative\tvaccines\tor\t'next-generation'\tvaccines\tprior to\tor\tafter\tthe\texpiration\tof\ttheir\tpatents,\twhich\tmay\tadversely\taffect\tour\tfuture\tresults.\n\nOur\tbiosimilars,\twhich\tinclude\tbiosimilars\tof\tcertain\tinflammation\t&amp;\timmunology\tand\toncology\tbiologic\tmedicines,\tcompete\twith\tbranded\tproducts\tfrom competitors,\tas\twell\tas\tother\tgenerics\tand\tbiosimilars\tmanufacturers.\tWe\tseek\tto\tmaximize\tthe\topportunity\tto\testablish\ta\t'first-to-market'\tor\tearly market\tposition\tfor\tour\tbiosimilars\tto\tprovide\tcustomers\ta\tlower-cost\talternative\timmediately\twhen\tavailable\tand\talso\tto\tpotentially\tprovide\tus\twith higher\tlevels\tof\tsales\tand\tprofitability\tuntil\tother\tcompetitors\tenter\tthe\tmarket.\n\nGeneric\tProducts .\tGeneric\tpharmaceutical\tmanufacturers\tpose\tone\tof\tthe\tbiggest\tcompetitive\tchallenges\tto\tour\tbranded\tsmall\tmolecule\tproducts\tbecause they\tcan\tmarket\ta\tcompeting\tversion\tof\tour\tproduct\tafter\tthe\texpiration\tor\tloss\tof\tour\tpatent\tprotection\tand\toften\tcharge\tmuch\tless.\tSeveral competitors\tregularly\tchallenge\tour\tproduct\tpatents\tbefore\ttheir\texpiration.\tGeneric\tcompetitors\toften\toperate\twithout\tlarge\tR&amp;D\texpenses,\tas\twell as\twithout\tcosts\tof\tconveying\tmedical\tinformation\tabout\tproducts\tto\tthe\tmedical\tcommunity.\tIn\taddition,\tthe\tapproval\tprocess\tin\tthe\tU.S.\tand\tin\tthe EU\texempts\tgenerics\tfrom\tcostly\tand\ttime-consuming\tclinical\ttrials\tto\tdemonstrate\ttheir\tsafety\tand\tefficacy,\tallowing\tgeneric\tmanufacturers\tto\trely on\tthe\tsafety\tand\tefficacy\tdata\tof\tthe\tinnovator\tproduct.\tIn\tChina,\tfor\texample,\tgiven\tthe\texpansion\tof\tthe\tQCE\tprocess\tand\tcontinuation\tof\tthe\tVBP program,\twe\texpect\tto\tcontinue\tto\tface\tintensified\tcompetition\tby\tcertain\tgeneric\tmanufacturers\tin\t2024\tand\tbeyond,\twhich\thas\tand\tmay\tcontinue\tto result\tin\tprice\tcuts\tand\tvolume\tloss\tof\tsome\tof\tour\tproducts.\tIn\taddition,\tgeneric\tversions\tof\tcompetitors'\tbranded\tproducts\thave\tand\tmay\tcontinue to\tcompete\twith\tour\tproducts.\n\nCommercial\tand\tgovernment\tpayors\ttypically\tencourage\tthe\tuse\tof\tgenerics\tas\talternatives\tto\tbrand-name\tdrugs\tin\ttheir\thealthcare\tprograms,\tincluding Medicaid\tin\tthe\tU.S.,\tand\tU.S.\tlaws\tgenerally\tallow,\tand\tin\tsome\tcases\trequire,\tpharmacists\tto\tsubstitute\tgeneric\tdrugs\tfor\tbrand-name\tdrugs.\tIn\ta small\tsubset\tof\tstates,\tprescribing\tphysicians\tare\table\tto\texpressly\tprevent\tsuch\tsubstitution.\tSimilar\trules\talso\tapply\tin\tseveral\tEU\tmember states,\twhere\tnational\tauthorities\ttypically\tencourage\tand\tincentivize\tthe\tuse\tof\tgeneric\tproducts.\n\nBiosimilars. Certain\tof\tour\tbiologic\tproducts,\tincluding\tEnbrel\t(we\tmarket\tEnbrel\toutside\tthe\tU.S.\tand\tCanada),\talready\tface,\tor\tmay\tface\tin\tthe future,\tcompetition\tfrom\tbiosimilars\t(also\treferred\tto\tas\tfollow-on\tbiologics).\tBiosimilars\tare\tversions\tof\tbiologic\tmedicines\tthat\thave\tbeen developed\tand\tproven\tto\tbe\thighly\tsimilar\tto\tthe\toriginal\tbiologic\tin\tterms\tof\tsafety\tand\tefficacy\tand\tthat\thave\tno\tclinically\tmeaningful differences\tin\tsafety,\tpurity\tor\tpotency.\tBiosimilars\thave\tthe\tpotential\tto\toffer\thigh-quality,\tlower-cost\talternatives\tto\tinnovative\tbiologic medicines.\tIn\tthe\tU.S.,\tbiosimilars\treferencing\tinnovative\tbiologic\tproducts\tare\tapproved\tby\tthe\tFDA\tunder\tthe\tU.S.\tPublic\tHealth\tService\tAct, whereas\tin\tthe\tEU\tthe\tEMA\tis\tresponsible\tfor\tevaluating\tthe\tmajority\tof\tapplications\tfor\tbiosimilars\tthrough\tthe\tcentralized\tprocedure.\n\n## PRICING\tPRESSURES\tAND\tMANAGED\tCARE\tORGANIZATIONS\n\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Generic_Drugs",
          "name": "Generic Drugs",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "review\tor\tare\tthe\tsubject\tof\tcurrent\tregulatory\tactivity\tand/or\tlitigation,\tand\ttheir\tstatus\tis\tunclear.\tIn\t2022,\twe\timplemented\ta\tpolicy\tthat\twill help\timprove\tcontract\tpharmacy\tintegrity.\tThe\tHHS\tHealth\tResources\tand\tServices\tAdministration\t(HRSA),\twhich\tadministers\tthe\t340B\tProgram,\thas\tsent letters\tto\tnumerous\tmanufacturers\tthat\thave\talso\timplemented\tcontract\tpharmacy\tpolicies\tand\tintegrity\tinitiatives;\tthe\tletters\texpress\tHRSA's\tview that\tthose\tmanufacturers'\tpolicies\tare\tin\tviolation\tof\tthe\t340B\tstatute.\tHRSA\talso\thas\treferred\tsome\tof\tthose\tother\tmanufacturers\tto\tthe\tHHS\tOffice of\tInspector\tGeneral\t(OIG)\tfor\tpotential\tenforcement\taction.\tPfizer\thas\tnot\treceived\tan\tenforcement\tletter\tfrom\tHRSA\tto\tdate\trelating\tto\tour\t340B Program\tintegrity\tinitiative.\tSeveral\tmanufacturers\thave\tchallenged\tHRSA's\tenforcement\tletters\tin\tfederal\tcourt\tand\tlitigation\tis\tongoing\tin\tthose cases.\tWe\tbelieve\tthat\tour\tpolicy\tis\tconsistent\twith\tthe\tstatute.\tIn\taddition,\tsome\tstates\thave\tenacted\tlaws\tseeking\tto\trestrict\tmanufacturer policies\trelated\tto\tcontract\tpharmacy\ttransactions\tin\ttheir\tstates.\tAt\tleast\tone\tstate\thas\tbegun\tto\tpursue\tenforcement\tproceedings\tunder\tits\tlaw. Several\tstakeholders\thave\tchallenged\tsuch\tlaws\tin\tcertain\tstates.\tOther\tstates\thave\tconsidered\tand\tcould\tenact\tsimilar\tlaws\tgoing\tforward,\talthough any\tsuch\tlaws\talso\tmay\tbe\tsubject\tto\tlegal\tchallenges.\tAdditional\tlegal\tor\tlegislative\tdevelopments\tat\tthe\tfederal\tor\tstate\tlevel\twith\trespect\tto the\t340B\tProgram\tmay\thave\tan\tadverse\timpact\ton\tour\tintegrity\tinitiative,\tand\twe\tmay\tface\tenforcement\taction\tor\tpenalties,\tdepending\tupon\tsuch developments.\tThe\t340B\tProgram\tcontinues\tto\tbe\ta\tsubject\tof\tregulatory\tactivity,\tcongressional\tscrutiny\tand\tinquiries,\tlitigation,\tand\tother developments,\tany\tor\tall\tof\twhich\tcould\taffect\tthe\tscope\tof\tthe\tprogram\tand\tPfizer's\tobligation\tto\toffer\tdiscounts\tto\t340B\tProgram\tcovered\tentities under\tthe\tprogram.\tSee\tthe Item\t1A.\tRisk\tFactors -Pricing\tand\tReimbursement section.\n\nStates\tseek\tto\tcontrol\thealthcare\tcosts\trelated\tto\tMedicaid\tand\tother\tstate\tregulated\thealthcare\tprograms.\tA\tmajority\tof\tstates\tuse\tpreferred\tdrug lists\tto\tmanage\taccess\tto\tpharmaceutical\tproducts\tunder\tMedicaid,\tincluding\tsome\tof\tour\tproducts.\tStates\tmay\tseek\tto\tnegotiate\tsupplemental\trebate agreements\tthat\tare\tlarger\tthan\tthe\tminimum\tfederal\trequirement\tfor\tpreferred\tformulary\taccess.\tPreferred\taccess\tto\tour\tproducts\tunder\tthe\tMedicaid managed\tcare\tprograms\tare\toften\tdetermined\tby\tthe\tmanaged\tcare\thealth\tplans\tcontracted\tby\tthe\tstate\tto\tadminister\tbenefits,\twhich\tmay\talso\trequire supplemental\trebates\tfor\tpreferred\tformulary\taccess.\tWe\texpect\tstates\twill\tcontinue\tto\tseek\tcost\tcutting,\twhich\tmay\tfocus\ton\tmanaged\tcare\tcapitation payments,\tsupplemental\trebates,\tand/or\tformulary\tmanagement.\n\nWe\texpect\tto\tsee\tcontinued\tfocus\tby\tCongress\tand\tthe\tBiden\tAdministration\ton\tregulating\tpricing\tand\taccess\tto\tmedicine,\tin\taddition\tto\tactions already\ttaken,\twhich\tcould\tresult\tin\tlegislative\tand\tregulatory\tchanges.\tGovernment\tand\tprivate\tpayors\troutinely\tseek\tto\tmanage\tutilization\tand control\tthe\tcosts\tof\tour\tproducts.\tThere\tis\tconsiderable\tpublic\tand\tgovernment\tscrutiny\tof\tpharmaceutical\tpricing\tand\tactions\tbeing\ttaken\tat\tthe state\tand\tfederal\tlevel.\tFurther\tefforts\tby\tstates\tand\tthe\tfederal\tgovernment\tto\tregulate\tprices\tor\tpayment\tfor\tpharmaceutical\tproducts,\tincluding proposed\tactions\tto\tfacilitate\tdrug\timportation,\tsuch\tas\tFlorida's\tdrug\timportation\tprogram\twhich\twas\trecently\tauthorized\tby\tthe\tFDA,\tlimit reimbursement\tto\tlower\treference\tprices,\trequire\tdeep\tdiscounts,\timpose\tfinancial\tpenalties\trelated\tto\tpricing\tpractices,\tand\trequire\tmanufacturers to\treport\tand\tmake\tpublic\tprice\tincreases\tand\tsometimes\ta\twritten\tjustification\tfor\tthe\tincrease,\tcould\tadversely\taffect\tour\tbusiness\tif implemented.\tFurther,\tcommercial\tpayors\toften\tfollow\tMedicare\tcoverage\tand\treimbursement\tpolicies\twhen\tsetting\ttheir\town\tpayment\trates.\tAny reduction\tin\tcost\tor\tother\tcontainment\tmeasures\tmay\tsimilarly\tbe\tadopted\tby\tcommercial\tplans.\tPayors\tmay\tcontinue\tto\tpromote\tgeneric\tdrugs\tand biosimilars\tmore\taggressively\tto\tgenerate\tsavings\tand\tattempt\tto\tstimulate\tadditional\tprice\tcompetition.\tIn\taddition,\twe\texpect\tthat\tconsolidation and\tintegration\tamong\tpharmacy\tchains,\twholesalers\tand\tPBMs\twill\tincrease\tpricing\tpressures\tin\tthe\tindustry.\tSee\tthe Item\t1A.\tRisk\tFactors -Managed Care\tTrends section.\n\nAnti-Corruption. The\tFCPA\tprohibits\tU.S.\tcorporations\tand\ttheir\trepresentatives\tfrom\toffering,\tpromising,\tauthorizing\tor\tmaking\tpayments\tto\tany foreign\tgovernment\tofficial,\tgovernment\tstaff\tmember,\tpolitical\tparty\tor\tpolitical\tcandidate\tto\tobtain\tor\tretain\tbusiness\tabroad.\tThe\tscope\tof\tthe FCPA\tincludes\tinteractions\twith\tcertain\thealthcare\tprofessionals\tin\tmany\tcountries.\tOther\tcountries\thave\tenacted\tsimilar\tanti-corruption\tlaws\tand/or regulations.\n\nData\tPrivacy. The\tnumber\tof\tprivacy\tand\tdata\tsecurity\tlaws\tand\tregulations\tin\tthe\tU.S.\tto\twhich\twe\tare\tsubject\ton\tthe\tfederal\tand\tstate\tlevel continues\tto\tincrease.\tWe\troutinely\tcollect\tand\tuse\tsensitive\tpersonal\tinformation\trelating\tto\tdigital\thealth.\tThe\tlegislative,\tregulatory\tand litigation\tlandscape\tfor\tprivacy\tand\tdata\tprotection\trequirements\tis\trapidly\tevolving\tand\tchanging.\tThese\trequirements\tare\tnot\tuniversal\tand\tcan conflict\tbetween\tjurisdictions.\tCompliance\twith\tthose\tlaws\tand\tregulations\tis\tmade\tmore\tcomplex\tby\tthe\tlack\tof\tconsistent\tstandards,\tcommon definitions,\tor\tclear\tregulatory\texpectations.\tAt\tthe\tsame\ttime,\tenforcement\tof\tthese\tlaws\tand\tregulations\tis\tincreasing\tand\tlitigation\tis\tbecoming more\tcommon.\tAny\tfailure\tor\tperceived\tfailure\tby\tus\tto\tcomply\twith\tapplicable\tprivacy\tand\tdata\tprotection\tlaws\tand\tregulations,\tincluding cybersecurity\tbreaches\tor\tincidents,\tcould\tsubject\tus\tto\tsignificant\tfines\tand\tpenalties,\tlitigation,\tand\tnegatively\timpact\tour\treputation.\n\n## Outside\tthe\tU.S.\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Payors",
          "name": "Payors",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_1",
          "chunk_text": "## ITEM\t7.\n\n## GENERAL\n\nThe\tfollowing\tMD&amp;A\tis\tintended\tto\tassist\tthe\treader\tin\tunderstanding\tour\tfinancial\tcondition\tand\tresults\tof\toperations,\tincluding\tan\tevaluation\tof the\tamounts\tand\tcertainty\tof\tcash\tflows\tfrom\toperations\tand\tfrom\toutside\tsources,\tand\tis\tprovided\tas\ta\tsupplement\tto\tand\tshould\tbe\tread\tin conjunction\twith\tthe\tconsolidated\tfinancial\tstatements\tand\trelated\tnotes\tin Item\t8.\tFinancial\tStatements\tand\tSupplementary\tData in\tthis\tForm\t10-K. Discussions\tof\t2021\titems\tand\tyear-to-year\tcomparisons\tbetween\t2022\tand\t2021\tthat\tare\tnot\tincluded\tin\tthis\tForm\t10-K\tcan\tbe\tfound\twithin\tMD&amp;A\tin\tour 2022\tForm\t10-K.\n\n## OVERVIEW\tOF\tOUR\tPERFORMANCE,\tOPERATING\tENVIRONMENT,\tSTRATEGY\tAND\tOUTLOOK\n\nFinancial\tHighlights --The\tfollowing\tis\ta\tsummary\tof\tcertain\tfinancial\tperformance\tmetrics\t(in\tbillions,\texcept\tper\tshare\tdata):\n\n2023\tTotal\tRevenues--$58.5\tbillion\n\n2023\tNet\tCash\tFlow\tfrom\tOperations--$8.7\tbillion\n\nA\tdecrease\tof\t42%\tcompared\tto\t2022\n\n2023\tReported\tDiluted\tEPS--$0.37\n\nA\tdecrease\tof\t70%\tcompared\tto\t2022\n\n2023\tAdjusted\tDiluted\tEPS\t(Non-GAAP)--$1.84*\n\nA\tdecrease\tof\t93%\tcompared\tto\t2022\n\nA\tdecrease\tof\t72%\tcompared\tto\t2022\n\n* For\tadditional\tinformation\tregarding\tAdjusted\tdiluted\tEPS\t(which\tis\ta\tnon-GAAP\tfinancial\tmeasure),\tincluding\treconciliations\tof\tcertain\tGAAP\tReported\tto\tnon-GAAP\tAdjusted information,\tsee\tthe Non-GAAP\tFinancial\tMeasure:\tAdjusted\tIncome section\twithin\tMD&amp;A.\n\nReferences\tto\toperational\tvariances\tpertain\tto\tperiod-over-period\tchanges\tthat\texclude\tthe\timpact\tof\tforeign\texchange\trates.\tAlthough\tforeign exchange\trate\tchanges\tare\tpart\tof\tour\tbusiness,\tthey\tare\tnot\twithin\tour\tcontrol\tand\tsince\tthey\tcan\tmask\tpositive\tor\tnegative\ttrends\tin\tthe\tbusiness, we\tbelieve\tpresenting\toperational\tvariances\texcluding\tthese\tforeign\texchange\tchanges\tprovides\tuseful\tinformation\tto\tevaluate\tour\tresults.\n\nOur\tBusiness\tand\tStrategy --Pfizer\tInc.\tis\ta\tresearch-based,\tglobal\tbiopharmaceutical\tcompany.\tWe\tapply\tscience\tand\tour\tglobal\tresources\tto\tbring therapies\tto\tpeople\tthat\textend\tand\tsignificantly\timprove\ttheir\tlives.\tSee\tthe Item\t1.\tBusiness--About\tPfizer section.\tAs\ta\tscience-driven\tglobal biopharmaceutical\tcompany,\twe\tremain\tfocused\ton\tadvancing\tour\tpipeline,\tsupporting\tour\tmarketed\tbrands\tand\tdeploying\tcapital\tresponsibly,\twith\ta focus\ton\tinitiatives\tthat\tcan\thelp\tcontribute\tto\tour\tlong-term\trevenue\tand\tfuture\tgrowth.\tMost\tof\tour\trevenues\tcome\tfrom\tthe\tmanufacture\tand\tsale\tof biopharmaceutical\tproducts.\tWe\tbelieve\tthat\tour\tmedicines\tand\tvaccines\tprovide\tsignificant\tvalue\tfor\thealthcare\tproviders\tand\tpatients\tand continuously\tevaluate\thow\twe\tcan\tbest\tcollaborate\twith\tpatients,\tphysicians\tand\tpayors\tto\tsupport\tand\texpand\tpatient\taccess\tto\treliable,\taffordable healthcare\taround\tthe\tworld.\tIn\taddition,\twe\tcontinually\tseek\tto\texpand\tand\tbroaden\tour\tproduct\tportfolio\tofferings\tthrough\tprioritized\tdevelopment of\tour\tpipeline\tand\tbusiness\tdevelopment\topportunities\ttargeted\tat\tcritical\tunmet\tpatient\tneeds.\tAs\ta\tresult,\tour\tcommercial\torganizational structure\tand\tR&amp;D\toperations\tare\tcritical\tto\tthe\tsuccessful\texecution\tof\tour\tbusiness\tstrategy.\tOur\tability\tto\tfulfill\tour\tpurpose, Breakthroughs that\tchange\tpatients'\tlives ,\tremains\ta\tcore\tfocus\tand\tunderscores\tour\tcommitment\tto\taddressing\tthe\tneeds\tof\tsociety\tto\thelp\tsustain\tlong-term\tvalue creation\tfor\tall\tstakeholders.\tOur\t2024\tkey\tpriorities\tare:\n\n- Achieve\tworld-class\toncology\tleadership\n- Deliver\tnext\twave\tof\tpipeline\tinnovation\n- Maximize\tperformance\tof\tour\tnew\tproducts\n- Expand\tmargins\tby\trealigning\tour\tcost\tbase\n- Allocate\tcapital\tto\tenhance\tshareholder\tvalue\n\nPfizer\tInc.\n\n30",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 126,
      "question": "How does BMY's strategic emphasis on expanding the use of Opdivo in combination with Yervoy across new tumor types align with the financial and operational structure of the BMY-Ono partnership for these products in Asia-Pacific markets?",
      "answer": "BMY's strategic focus on expanding Opdivo's use in combination with Yervoy across multiple tumor types, as detailed in the strategy section on page 43, is operationally and financially intertwined with the joint development and commercialization agreement with Ono in Japan, South Korea, and Taiwan. According to page 86, BMY and Ono equally share profits, losses, and development costs for combination therapies involving both parties\u2019 compounds, which includes Opdivo and Yervoy. This equal sharing aligns with BMY\u2019s broader objective to accelerate commercial execution and expand treatment options, as the partnership likely reduces the financial burden and risk of global expansion, particularly in the Asia-Pacific region. The product supply is managed entirely by BMY, which supports their control over the manufacturing and distribution aspects of these therapies, reinforcing their ability to execute on the strategic goal of expanding into new indications and markets.",
      "reasoning_steps": [
        "Hop 1: BMY(page_43) \u2192 Opdivo: BMY emphasizes expanding Opdivo's use in combination with Yervoy across new tumor types and earlier lines of therapy as part of its commercial and pipeline growth strategy.",
        "Hop 2: Opdivo \u2192 Yervoy: Opdivo and Yervoy are frequently used together in approved regimens for multiple cancers, including NSCLC, melanoma, and CRC, as detailed in the product descriptions.",
        "Hop 3: Yervoy \u2190 BMY(page_86): BMY jointly develops and commercializes Yervoy with Ono in Asia-Pacific markets, with equal profit and cost sharing for combination therapies, and BMY manages the product supply."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Combines_With]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Opdivo",
        "node_3": "Yervoy",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Strategy\n\nOur\tprincipal\tstrategy\tis\tto\tcombine\tthe\tresources,\tscale\tand\tcapability\tof\ta\tlarge\tpharmaceutical\tcompany\twith\tthe\tspeed, agility\tand\tfocus\ton\tinnovation\ttypically\tfound\tin\tthe\tbiotech\tindustry.\tOur\tpriorities\tare\t(i)\tto\tcontinue\tto\trenew\tand diversify\t our\t portfolio\t through\t launching\t new\t medicines,\t (ii)\t advancing\t our\t early,\t mid\t and\t late-stage\t pipeline\t and\t (iii) executing\tdisciplined\tbusiness\tdevelopment.\tAs\twe\tundergo\ta\tperiod\tof\trenewal,\tour\tstrategy\twill\tbe\tfocused\ton\tdriving\tnearterm\t growth,\t minimizing\t the\t impact\t of\t a\t transition\t period\t that\t follows\t and\t delivering\t growth\t in\t the\t late\t 2020s\t by accelerating\t opportunities\t that\t enhance\t productivity\t and\t efficiency,\t advance\t our\t pipeline,\t and\t drive\t strong\t commercial execution\tthat\tmove\tour\tbusiness\tforward.\tWe\tremain\tcommitted\tto\ta\tstrategic\tbusiness\tdevelopment\tand\tmaintaining\ta\tstrong investment\tgrade\tcredit\trating,\tgrowing\tthe\tdividend\tand\treducing\tadditional\tdebt\tthat\twill\tbe\tissued\tin\tsupport\tof\trecent transactions.\n\nOur\tfocus\tis\ton\tdiscovering,\tdeveloping\tand\tdelivering\ttransformational\tmedicines\tfor\tpatients\tfacing\tserious\tdiseases\tin\tthe following\tfive\tcore\ttherapeutic\tareas:\t(i)\toncology\twith\ta\tpriority\tin\tcertain\ttumor\ttypes,\tincluding\tdiversification\tbeyond IO;\t(ii)\thematology\twith\topportunities\tto\texpand\tleadership\tposition\tin\tmultiple\tmyeloma,\tas\twell\tas\tbroaden\tour\tportfolio across\t leukemias,\t lymphomas\t and\t non-malignant\t hematologic\t diseases;\t (iii)\t immunology\t with\t priorities\t in\t strengthening presence\tin\tdermatology,\trheumatology\tand\tgastrointestinal\tdisorders,\testablishing\tnew\tstandards\tof\tcare\tin\tpulmonology\tand rapidly\t advance\t cell\t therapy\t into\t immunology\t diseases;\t (iv)\t cardiovascular\t diseases\t with\t focus\t on\t cardiomyopathies,\t heart failures and thrombotic diseases; and (v) neuroscience with a focus on neuropsychiatry, neurodegenerative and neuroinflammation\tdiseases.\n\nWe\t are\t working\t towards\t expanding\t our\t pipeline\t of\t registrational\t assets\t from\t six\t to\t up\t to\t twelve.\t In\t addition,\t we\t are positioned\t to\t support\t continued\t innovation\t and\t expand\t treatment\t options\t across\t several\t different\t diseases\t based\t on\t our differentiated\tresearch\tplatforms.\tWe\thave\ta\tbroad\tportfolio\tand\tpipeline\twhen\tit\tcomes\tto\tautologous\tCAR-T\tcell\ttherapies. We\thave\ttwo\tapproved\tcell\ttherapies\tagainst\ttwo\tdistinct\ttargets\tand\tare\tcontinuing\tto\tbuild\tour\tleadership\tin\tthis\tspace.\tWe are\t expanding\t manufacturing\t capacity,\t exploring\t innovative\t technologies\t such\t as\t dual-targeting\t CAR-Ts\t and\t allogenic approaches,\tadvancing\tmultiple\tnext-generation\tassets\tincluding\tnew\ttargets\tand\trapidly\texpanding\tinto\timmunology,\tincluding lupus\tand\tmultiple\tsclerosis.\tWe\talso\thave\ta\tstrong\tposition\tin\tthe\tprotein\tdegradation\tfield\tand\thave\tbeen\tadvancing\tour pipeline\twith\tan\texpansive\tlibrary\tof\tassets\twith\ttwo\tin\tregistrational\ttrials,\tan\tadditional\tfive\tin\tclinical\tphase\tstudies and\t more\t than\t fifteen\t being\t studied\t pre-clinically.\t This\t growing\t platform\t has\t potential\t across\t several\t diseases\t and\t is positioned\tto\tdeliver\tapproximately\tfour\tINDs\teach\tyear.\tTogether\twith\tour\tproven\ttrack\trecord,\trapidly\tadvancing\tpipeline and\tgrowth\twith\tmarketed\tproducts,\twe\tincreased\tand\tsustained\tour\tR&amp;D\tproductivity\tenabling\tus\tto\tidentify\tmore\thigh-quality candidates\t and\t increase\t their\t probability\t of\t reaching\t patients\t in\t need.\t Specifically,\t our\t ambition\t is\t to:\t (i)\t deliver approximately\tten\tINDs\tper\tyear;\t(ii)\tincrease\tsuccess\trates\tfrom\tfirst-in-human\ttrials\tto\tapproval\tto\tapproximately\t20%; (iii)\treduce\ttimelines\tto\tachieve\ta\tmedian\tof\t6.5\tyears\tfrom\tfirst-in-human\ttrials\tto\tapproval.\tOur\tR&amp;D\tstrategy\twill\thelp ensure\t we\t maintain\t a\t strong\t legacy\t of\t scientific\t innovation,\t bringing\t first-in\t class\t and/or\t best-in-class\t treatments\t to patients\tat\tan\taccelerated\tspeed.\n\nOur\tcommercial\tmodel\thas\tbeen\tsuccessful\twith\trevenues\tfrom\tour\tin-line\tbrands\tand\tnew\tproduct\tportfolio\tcontinuing\tto\tgrow, which\tdemonstrates\tstrong\texecution\tof\tour\tstrategy.\tWe\tremain\tfocused\tand\twell-resourced\tin\tour\tcancer\tdevelopment\tprograms and\tseek\tto\tbroaden\tthe\tuse\tof Opdivo in\tearlier\tlines\tof\ttherapy,\texpand\tinto\tnew\ttumors,\taccelerate\tnext\twave\toncology mechanisms\t and\t develop\t treatment\t options\t for\t refractory\t oncology\t patients.\t We\t are\t encouraged\t that\t our\t investigational subcutaneous\t formulation\t for Opdivo has\t the\t potential\t to\t bring\t enhanced\t benefits\t to\t patients\t into\t the\t next\t decade,\t with positive\tregistrational\tdata\tnow\tin-house.\tWe\tcontinue\tto\tdrive\tadoption\tof Opdivo by\texpanding\tinto\tadditional\tindications and\t tumor\t types\t both\t as\t a\t monotherapy\t and\t in\t combination\t with Yervoy and\t other\t anti-cancer\t agents.\t We\t are\t further strengthening\t our\t IO\t portfolio\t with Opdualag for\t the\t treatment\t of\t melanoma\t and\t potential\t expanded\t opportunities\t in\t other indications.\t We\t are\t growing\t a\t differentiated\t NSCLC\t portfolio,\t which\t includes\t the\t launch\t of Augtyro and\t includes Krazati , (acquired\t through\t Mirati),\t which\t demonstrates\t a\t strategic\t fit\t into\t our\t oncology\t portfolio.\t We\t are\t also\t strengthening\t our neuroscience\tportfolio\twith\tthe\tplanned\tacquisition\tof\tKaruna.\tMoreover, Eliquis continues\tto\tgrow,\tleveraging\tits\tbest\tin class\t clinical\t profile\t and\t extensive\t real\t world\t data\t and\t remains\t the\t number\t one\t novel\t oral\t anticoagulant\t in\t total prescriptions\tglobally. Camzyos continues\tto\tdemonstrate\tbenefits\tas\tshared\tthrough\tour\tlong-term\tfollow-up\tdata\tfrom\ttwo Phase\tIII\tstudies.\tIn\timmunology, Sotyktu is\tthe\tkey\tgrowth\tdriver\tfor\tBMS\tand\twe\tcontinue\tto\tmake\tfurther\tinvestments\tto accelerate\t the\t launch\t through\t direct\t to\t consumer\t advertising\t and\t adding\t field\t force\t support.\t In\t addition,\t our\t Phase\t III registrational\t clinical\t trials\t are\t underway\t for Sotyktu in\t PsA,\t SLE\t and\t Sj\u00f6gren's\t Syndrome.\t We\t are\t able\t to\t leverage\t our leading\tcapabilities\tin\thematological\tmalignancies\tand\tour\trobust\tpipeline\tto\tprovide\topportunities\tfor\tlong-term\tgrowth\tto offset\tthe\timpact\tof\tcurrent\tand\tfuture\tpatent\texpiries\tfor Revlimid and Pomalyst .\tAs\twe\tlook\tat\tour\tcell\ttherapy\tfranchise, we\tcontinue\tto\texplore\tnew\tindications\twith Breyanzi to\tinclude\tthe\ttreatment\tof\tCLL,\tFL\tand\tMCL.\tIf\tindication\tfor\tCLL\tis approved,\t it\t would\t be\t the\t first\t and\t only\t CAR-T\t available\t for\t this\t patient\t population. Reblozyl is\t advancing\t into\t new indications\twith\tan\tongoing\tregistrational\ttrial\tfor\tchronic\tanemia\tassociated\twith\tmyelofibrosis.\n\nThe\t evolution\t in\t our\t operating\t model,\t which\t focuses\t on\t maintaining\t a\t disciplined\t approach\t in\t marketing,\t selling\t and administrative\texpenses,\twill\tenable\tus\tto\tdeliver\tthe\tnecessary\tstrategic,\tfinancial\tand\toperational\tflexibility\tto\tinvest in\tthe\thighest\tpriority\topportunities\twithin\tour\tportfolio.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Opdivo",
          "name": "Opdivo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_2",
          "chunk_text": "| Eliquis \u00ae           | Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Opdivo \u00ae            | Opdivo (nivolumab) is a biological product and a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer. The Opdivo + Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and various gastric and esophageal cancers. There are several ongoing potentially registrational studies for Opdivo across other tumor types and disease areas, in monotherapy and in combination with Yervoy and various anti-cancer agents. |\n| Orencia \u00ae           | Orencia (abatacept) is a biological product, is a fusion protein indicated for adult patients with moderate to severe active RA and PsA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular JIA and for the treatment of aGVHD, in combination with a calcineurin inhibitor and methotrexate.                                                                                                                                                                                                                                                                                      |\n| Pomalyst /Imnovid \u00ae | Pomalyst/Imnovid (pomalidomide) is a small molecule that is administered orally and modulates the immune system and other biologically important targets. Pomalyst/Imnovid is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. \u00ae                                                                                                                                                                                                                                     |\n| Yervoy \u00ae            | Yervoy (ipilimumab) is a biological product and is a CTLA4 immune checkpoint inhibitor. Yervoy is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. The Opdivo + Yervoy regimen is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and esophageal cancer.                                                                                                                                                                                                                                                                                                                              |\n| Sprycel \u00ae           | Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosome-positive CML in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including Gleevec* (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome-positive CML.                                                                                                                                                             |",
          "relationship": "Combines_With"
        },
        "node_3": {
          "id": "Yervoy",
          "name": "Yervoy",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Ono\n\nBMS\tand\tOno\tjointly\tdevelop\tand\tcommercialize Opdivo , Yervoy and\tseveral\tBMS\tinvestigational\tcompounds\tin\tJapan,\tSouth\tKorea and\tTaiwan.\tBMS\tis\tresponsible\tfor\tsupply\tof\tthe\tproducts.\tProfits,\tlosses\tand\tdevelopment\tcosts\tare\tshared\tequally\tfor\tall combination\ttherapies\tinvolving\tcompounds\tof\tboth\tparties.\tOtherwise,\tsharing\tis\t80%\tand\t20%\tfor\tactivities\tinvolving\tonly one\tof\tthe\tparty's\tcompounds.\n\nBMS\t and\t Ono\t also\t jointly\t develop\t and\t commercialize Orencia in\t Japan.\t BMS\t is\t responsible\t for\t the\t order\t fulfillment\t and distribution\tof\tthe\tintravenous\tformulation\tand\tOno\tis\tresponsible\tfor\tthe\tsubcutaneous\tformulation.\tBoth\tformulations\tare jointly\t promoted\t by\t both\t parties\t with\t assigned\t customer\t accounts\t and\t BMS\t is\t responsible\t for\t the\t product\t supply.\t A\t copromotion\tfee\tof\t60%\tis\tpaid\twhen\ta\tsale\tis\tmade\tto\tthe\tother\tparty's\tassigned\tcustomer.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\talliance\twas\tas\tfollows:\n\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 127,
      "question": "How does the uncertainty around U.S. tax changes scheduled for 2026 under the 2017 Tax Act reconcile with the structured eight-year Toll Tax payment schedule LLY is currently following through 2025?",
      "answer": "LLY acknowledges in its 2023 10-K (page 46) that U.S. tax changes scheduled to occur in 2026 as part of the 2017 Tax Act could affect its future tax expense and assessment of global minimum tax impacts. Meanwhile, the company is currently complying with the eight-year Toll Tax payment period introduced by the 2017 Tax Act, with scheduled payments extending through 2025. This creates a tension between the structured near-term tax payment obligations and the potential for significant changes in the U.S. tax regime just as those obligations are concluding. The uncertainty around 2026 tax changes could materially affect LLY\u2019s effective tax rate and cash tax payments at a time when the company is nearing completion of its Toll Tax payments, highlighting a critical timing mismatch in tax planning and financial forecasting.",
      "reasoning_steps": [
        "Hop 1: LLY(page_46) \u2192 2017 Tax Act: LLY notes that U.S. tax changes under the 2017 Tax Act are scheduled to occur in 2026 and could materially affect its future tax expense and assessment of global minimum tax impacts.",
        "Hop 2: 2017 Tax Act \u2192 Eight-Year Payment Period: The 2017 Tax Act introduced the Toll Tax with an eight-year payment schedule, allowing companies to spread payments from 2018 through 2025.",
        "Hop 3: Eight-Year Payment Period \u2190 LLY(page_92): LLY is currently complying with this structured eight-year payment schedule, with future cash payments extending through 2025."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Introduces]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "2017 Tax Act",
        "node_3": "Eight-Year Payment Period",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_46",
          "chunk_id": "chunk_1",
          "chunk_text": "In\tresponse\tto\tthe\tOECD/G20\tInclusive\tFramework\ton\tBase\tErosion\tand\tProfit\tShifting\t(Framework),\twhich\tset\tforth\ta\ttwo-pillar solution\tto\treform\tthe\tinternational\ttax\tframework,\tand\tthe\tEU's\tadoption\tof\tDirective\t2022/2523\t(known\tas\t\"Pillar\tTwo\") (Directive)\twithin\tthe\tEU\tto\timplement\tthe\tFramework,\tmultiple\tcountries,\tboth\twithin\tand\toutside\tof\tthe\tEU,\thave\tenacted legislation\tthat\tprovides\tfor\ta\tminimum\tlevel\tof\ttaxation\tof\tmultinational\tcompanies.\tThe\tDirective\trequired\tEU\tmember\tstates to\tenact\tlegislation\teffective\tfor\tyears\tbeginning\ton\tor\tafter\tDecember\t31,\t2023.\tFor\tcertain\tprovisions\twithin\tthe Framework,\tthe\tOECD\tpublished\tguidance\tduring\t2023\tthat\textends\tthe\teffective\tdates\tfor\tenactment.\tWhile\twe\texpect\tan increase\tin\tfuture\tyears'\ttax\texpense\tas\ta\tresult\tof\tthe\tglobal\tminimum\ttax,\twe\tdo\tnot\tanticipate\ta\tmaterial\timpact\tto\tour 2024\tconsolidated\tresults\tof\toperations.\tOur\tassessment\tof\tthe\timpact\tfor\t2024\tand\tsubsequent\tyears\tcould\tbe\taffected\tby legislative\tguidance,\tfuture\tenactment\tof\tadditional\tprovisions\twithin\tthe\tPillar\tTwo\tframework,\tand\tU.S.\ttax\tchanges scheduled\tto\toccur\tin\t2026\tas\tpart\tof\tthe\tTax\tCuts\tand\tJobs\tAct\t(2017\tTax\tAct).\n\nA\tbipartisan\ttax\tbill,\tthe\tTax\tRelief\tfor\tAmerican\tFamilies\tand\tWorkers\tAct,\twas\tpassed\tby\tthe\tU.S.\tHouse\tof\tRepresentatives in\tJanuary\t2024.\tThe\tbill\tcontains\tcertain\tbusiness\ttax\tprovisions\tincluding\tthe\tretroactive\trepeal\tfor\t2022\tand\t2023\tand deferral\tof\tthe\trequirement\tto\tcapitalize\tU.S.\tresearch\tand\tdevelopment\texpenses\tfor\ttax\tpurposes\tthat\twas\ta\tprovision enacted\tin\tthe\t2017\tTax\tAct.\tUncertainty\texists\tas\tto\twhether\tthe\tbill\twill\tbe\tenacted\tinto\tlaw;\thowever,\tif\tthe\tbill\tis enacted\tas\tcurrently\tdrafted,\twe\twould\texpect\tour\teffective\ttax\trate\tfor\t2024\tto\tbe\tmoderately\thigher,\tand\ta\tnet\tdiscrete\ttax detriment\tin\tthe\tquarter\tof\tenactment\trelated\tto\t2022\tand\t2023.\tIn\taddition,\twe\twould\texpect\ta\tdecrease\tin\tcash\ttax\tpayments.\n\n## Acquisitions\n\nWe\tinvest\tin\texternal\tresearch\tand\ttechnologies\tthat\twe\tbelieve\tcomplement\tand\tstrengthen\tour\town\tefforts.\tThese\tinvestments can\ttake\tmany\tforms,\tincluding\tacquisitions,\tcollaborations,\tinvestments,\tand\tlicensing\tarrangements.\tWe\tview\tour\tbusiness development\tactivity\tas\ta\tway\tto\tenhance\tor\trefine\tour\tpipeline\tand\tstrengthen\tour\tbusiness.\n\nFor\tinvestments\tthat\twere\taccounted\tfor\tas\tasset\tacquisitions,\twe\tpaid\t$3.94\tbillion\tin\t2023\tfor\tacquired\tIPR&amp;D\tprimarily related\tto\tacquisitions\tof\tDICE,\tVersanis,\tEmergence\tTherapeutics\tAG\t(Emergence),\tand\tMablink\tBiosciences\tSAS\t(Mablink).\tFor investments\tthat\twere\taccounted\tfor\tas\tbusiness\tcombinations,\twe\tpaid\t$1.04\tbillion\tin\t2023\tprimarily\trelated\tto\tthe acquisition\tof\tPOINT\tBiopharma\tGlobal\tInc.\t(POINT).\n\nSee\tNote\t3\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tfurther\tdiscussion\tregarding\tour\trecent\tacquisitions.\n\nFor\tdiscussion\tof\trisks\trelated\tto\tbusiness\tdevelopment\tactivities,\tsee\tItem\t1A,\t\"Risk\tFactors-Pharmaceutical\tresearch\tand development\tis\tvery\tcostly\tand\thighly\tuncertain;\twe\tmay\tnot\tsucceed\tin\tdeveloping,\tlicensing,\tor\tacquiring\tcommercially successful\tproducts\tsufficient\tin\tnumber\tor\tvalue\tto\treplace\trevenues\tof\tproducts\tthat\thave\tlost\tor\twill\tlose\tintellectual property\tprotection\tor\tare\tdisplaced\tby\tcompeting\tproducts\tor\ttherapies.\"\n\n## Foreign\tCurrency\tExchange\tRates\n\nAs\ta\tglobal\tcompany,\twe\tface\tforeign\tcurrency\trisk\texposure\tfrom\tfluctuating\tcurrency\texchange\trates,\tprimarily\tthe\tU.S. dollar\tagainst\tthe\teuro,\tJapanese\tyen,\tand\tChinese\tyuan.\tWhile\twe\tseek\tto\tmanage\ta\tportion\tof\tthese\texposures\tthrough\thedging and\tother\trisk\tmanagement\ttechniques,\tsignificant\tfluctuations\tin\tcurrency\trates\tcan\thave\ta\tmaterial\timpact,\teither\tpositive or\tnegative,\ton\tour\tconsolidated\tresults\tof\toperations\tin\tany\tgiven\tperiod.\tThere\tis\tuncertainty\tin\tthe\tfuture\tmovements\tin foreign\tcurrency\texchange\trates,\tand\tfluctuations\tin\tthese\trates\tcould\tadversely\timpact\tour\tconsolidated\tresults\tof operations\tand\tcash\tflows.\n\n## Other\tFactors\n\nOther\tfactors\thave\thad,\tand\tmay\tcontinue\tto\thave,\tan\timpact\ton\tour\tconsolidated\tresults\tof\toperations.\tThese\tfactors\tinclude cost\tand\twage\tinflation,\tavailability\tof\tadequate\tcapacity\tin\tglobal\ttransportation,\tsupply\tchain\tand\tlabor\tmarket complexities,\tinternational\ttension\tand\tconflicts,\tuneven\teconomic\tgrowth\tor\tdownturns\tor\tuncertainty,\tand\tan\tincrease\tin overall\tdemand\tin\tour\tindustry\tfor\tcertain\tproducts\tand\tmaterials.\n\nSee\tItem\t1A,\t\"Risk\tFactors\"\tfor\tadditional\tinformation\ton\trisk\tfactors\tthat\tcould\timpact\tour\tbusiness\tand\toperations.",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "2017_Tax_Act",
          "name": "2017 Tax Act",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tDecember\t2017,\tthe\tTax\tCuts\tand\tJob\tAct\t(2017\tTax\tAct)\twas\tsigned\tinto\tlaw.\tThe\t2017\tTax\tAct\tincluded\tsignificant\tchanges to\tthe\tU.S.\tcorporate\tincome\ttax\tsystem,\tincluding\ta\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\ton unremitted\tforeign\tearnings.\tThe\t2017\tTax\tAct\tprovided\tan\telection\tto\ttaxpayers\tsubject\tto\tthe\tToll\tTax\tto\tmake\tpayments\tover an\teight-year\tperiod\tbeginning\tin\t2018\tthrough\t2025.\tHaving\tmade\tthis\telection,\tour\tfuture\tcash\tpayments\trelating\tto\tthe\tToll Tax\tas\tof\tDecember\t31,\t2023\tare\tas\tfollows:\n\n",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "Eight-Year_Payment_Period",
          "name": "Eight-Year Payment Period",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tDecember\t2017,\tthe\tTax\tCuts\tand\tJob\tAct\t(2017\tTax\tAct)\twas\tsigned\tinto\tlaw.\tThe\t2017\tTax\tAct\tincluded\tsignificant\tchanges to\tthe\tU.S.\tcorporate\tincome\ttax\tsystem,\tincluding\ta\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\ton unremitted\tforeign\tearnings.\tThe\t2017\tTax\tAct\tprovided\tan\telection\tto\ttaxpayers\tsubject\tto\tthe\tToll\tTax\tto\tmake\tpayments\tover an\teight-year\tperiod\tbeginning\tin\t2018\tthrough\t2025.\tHaving\tmade\tthis\telection,\tour\tfuture\tcash\tpayments\trelating\tto\tthe\tToll Tax\tas\tof\tDecember\t31,\t2023\tare\tas\tfollows:\n\n",
          "relationship": "Complies_With"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 128,
      "question": "How does Merck's recognition of Lenvima-related alliance revenue on its income statement align with its $1.0 billion intangible asset valuation for Lenvima, given Eisai's role as the principal on global product sales?",
      "answer": "Merck recognizes its share of Lenvima profits as alliance revenue, which is derived from Eisai's global product sales where Eisai acts as the principal. Despite not directly recording Lenvima sales, Merck holds a $1.0 billion intangible asset tied to its collaboration with Eisai on Lenvima, reflecting the long-term strategic value of the partnership. This asset valuation, disclosed in the intangible assets section, underscores Merck's financial stake in Lenvima's success, even though revenue recognition is profit-based rather than sales-based. The $1.0 billion valuation aligns with Merck's forward-looking expectations of profitability through the collaboration, despite Eisai's control over direct sales.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_5) \u2192 [Lenvima]: Merck discloses that it recognizes alliance revenue from Lenvima, which is based on Eisai's product sales net of cost of sales and commercialization costs.",
        "Hop 2: [Lenvima] \u2192 [Eisai]: Eisai is the principal on all Lenvima sales globally and is responsible for recording product sales, while Merck receives a share of the profits.",
        "Hop 3: [Eisai] \u2190 [MRK](page_115): Merck reports a $1.0 billion intangible asset related to the Lenvima collaboration with Eisai, indicating the strategic and financial significance of the partnership despite Eisai's control over direct sales."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Produces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Lenvima",
        "node_3": "Eisai",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs. (1)\n\nOther revenues are primarily comprised of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. (2)\n\n## Pharmaceutical\n\nThe Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company's franchises are as follows:\n\n## Oncology\n\nKeytruda (pembrolizumab), the Company's anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment  of  certain  patients  with  cervical  cancer,  classical  Hodgkin  Lymphoma  (cHL),  cutaneous  squamous  cell  carcinoma (cSCC),  esophageal  or  gastroesophageal  junction  (GEJ)  carcinoma,  head  and  neck  squamous  cell  carcinoma  (HNSCC), hepatocellular  carcinoma  (HCC),  non-small-cell  lung  cancer  (NSCLC),  melanoma,  Merkel  cell  carcinoma,  microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. Keytruda is also approved for the treatment of certain patients in  combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with platinum-and fluoropyrimidine-based chemotherapy for  esophageal  or  GEJ  carcinoma,  in  combination  with  chemotherapy,  with  or  without  bevacizumab,  for  cervical  cancer,  in combination with chemotherapy for triple-negative breast cancer (TNBC), in combination with axitinib for advanced renal cell carcinoma (RCC), and in combination with lenvatinib for endometrial carcinoma or RCC. Keytruda is  also  approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Keytruda is also approved as a monotherapy for the adjuvant treatment of certain patients  with  RCC.  In  addition,  the  Company  recognizes  alliance  revenue  related  to  sales  of  Lynparza  (olaparib),  an  oral  poly (ADP-ribose) polymerase (PARP) inhibitor, for certain  types  of  advanced  ovarian,  breast,  pancreatic,  and  prostate  cancers;  and Lenvima (lenvatinib) for certain types of",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Lenvima",
          "name": "Lenvima",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_102",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone payments. (2)\n\n## Eisai\n\nIn 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization  of  Lenvima  (lenvatinib),  an  orally  available  tyrosine  kinase  inhibitor  discovered  by  Eisai.  Under  the agreement,  Merck  and  Eisai  will  develop  and  commercialize  Lenvima  jointly,  both  as  monotherapy  and  in  combination  with Keytruda . Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as  alliance  revenue.  Expenses  incurred  during  co-development  are  shared  by  the  two  companies  in  accordance  with  the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Eisai",
          "name": "Eisai",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_115",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAcquired intangibles include products and product rights, IPR&amp;D, trade names and patents, licenses and other, which are  initially  recorded  at  fair  value,  assigned  an  estimated  useful  life,  and  amortized  primarily  on  a  straight-line  basis  over  their estimated useful lives. Some of the more significant acquired intangibles, on a net basis, related to human health marketed products (included  in  products  and  product  rights  above)  at  December  31,  2021  include Reblozyl ,  $3.8  billion; Zerbaxa ,  $478  million; Gardasil/Gardasil 9, $191 million; Bridion , $145 million; Dificid , $145 million; Sivextro , $138 million; and Simponi , $101 million. Additionally, the Company had $5.0 billion of net acquired intangibles related to animal health marketed products at December 31, 2021,  of  which  $2.3  billion  relate  primarily  to  trade  names  obtained  through  the  2019  acquisition  of Antelliq  (see  Note  4). At December 31, 2021, IPR&amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-1026 (nemtabrutinib), $2.0 billion, obtained through the acquisition of ArQule in 2020 (see below and Note 4); and MK-7264 (gefapixant) $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016. Some of the more significant net intangible assets included in licenses and other above at December 31, 2021 include Lynparza, $1.1 billion, related to a collaboration with AstraZeneca; Lenvima, $1.0 billion, related to a collaboration with Eisai; Adempas, $806 million related  to  a  collaboration  with  Bayer;  and  Verquvo,  $68  million,  also  related  to  a  collaboration  with  Bayer.  See  Note  5  for additional information related to the intangible assets associated with these collaborations.\n\nIn  2020,  the  Company  recorded  an  impairment  charge  of  $1.6  billion  within Cost  of  sales related  to Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of Zerbaxa , and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the Zerbaxa intangible asset for impairment. The Company revised its cash flow forecasts for Zerbaxa utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the Zerbaxa intangible  asset  value  was  not  fully  recoverable  on  an  undiscounted  cash  flows  basis.  The  Company  utilized  market participant  assumptions  to  determine  its  best  estimate  of  the  fair  value  of  the  intangible  asset  related  to Zerbaxa that,  when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120 million to Cost of sales in 2020 related to the Zerbaxa recall. A phased resupply of Zerbaxa was initiated in the fourth quarter of 2021.\n\nIn 2019, the Company recorded impairment charges related to marketed products and other intangibles of $705 million. Of this amount, $612 million related to Sivextro (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of Sivextro in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for Sivextro , which indicated that the Sivextro intangible asset value was not fully recoverable  on  an  undiscounted  cash  flows  basis.  The  Company  utilized  market  participant  assumptions  to  determine  its  best estimate of the fair value of the intangible asset related to Sivextro that, when compared with its related carrying value, resulted in the impairment charge noted above.\n\nIPR&amp;D that  the  Company  acquires  through  business  combinations  represents  the  fair  value  assigned  to  incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 129,
      "question": "How does Amgen's competitive positioning of XGEVA in the U.S. and Europe relate to its strategic financial stake in BeiGene, Ltd., and how does this partnership influence Amgen's oncology revenue growth in China?",
      "answer": "Amgen's competitive positioning of XGEVA in the U.S. and Europe, where it faces competition from zoledronate generics, is supported through its strategic partnership with BeiGene, Ltd., under which BeiGene sells XGEVA in China. This collaboration allows Amgen to expand its oncology footprint in the Chinese market, where BeiGene assumes commercialization rights and shares profits and losses equally during the initial commercialization period. Amgen's $2.8 billion equity stake in BeiGene, as disclosed in their 10-K, reflects a long-term strategic investment to strengthen its oncology portfolio and market access in China, which is further reinforced by the multiple amendments and agreements filed under Exhibit 10.19 through 10.21.3. In 2024, Amgen recorded $259 million in product sales from XGEVA to BeiGene, contributing directly to Amgen's oncology revenue growth and demonstrating how the financial stake and product collaboration together support Amgen\u2019s broader oncology strategy in high-growth markets.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_15) \u2192 [XGEVA]: XGEVA is listed as a product facing competition from zoledronate generics in the U.S. and Europe.",
        "Hop 2: [XGEVA] \u2192 [BeiGene, Ltd.]: BeiGene sells XGEVA in China under a collaboration agreement with Amgen, with profit and loss sharing and eventual royalty payments to BeiGene.",
        "Hop 3: [BeiGene, Ltd.] \u2190 [AMGN](page_98): Amgen holds a $2.8 billion equity stake in BeiGene and has multiple binding agreements, including amendments to the collaboration and share purchase agreements, filed as exhibits in the 10-K."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Sells]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "XGEVA",
        "node_3": "BeiGene,Ltd.",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product    | Territory                  | Competitor-marketed product         | Competitors                              |\n|------------|----------------------------|-------------------------------------|------------------------------------------|\n| Prolia (1) | U.S., Europe &Asia Pacific | Bisphosphonates, including generics | Various                                  |\n| ENBREL     | U.S.                       | HUMIRA (2)                          | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | HYRIMOZ                             | SandozGroup AG                           |\n| ENBREL     | U.S.                       | RINVOQ                              | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | Xeljanz                             | Pfizer Inc.                              |\n| ENBREL     | Canada                     | Etanercept biosimilars              | Various                                  |\n| XGEVA (1)  | U.S. &Europe               | Zoledronate generics                | Various                                  |\n| Repatha    | U.S., Europe &Asia Pacific | PRALUENT                            | Regeneron Sanofi                         |\n|            | U.S. &Europe               | LEQVIO                              | Novartis PharmaAG                        |\n|            | U.S. &Europe               | Skyrizi                             | AbbVie Inc.                              |\n|            | U.S. &Europe               | HUMIRA (2)                          | AbbVie Inc.                              |\n| Otezla     | U.S. &Europe               | Tremfya                             | Johnson &Johnson Innovative Medicine (3) |\n| Otezla     | U.S. &Europe               | Taltz                               | Lilly                                    |\n| Otezla     | U.S. &Europe               | Cosentyx                            | Novartis PharmaAG                        |\n| Otezla     | U.S. &Europe               | SOTYKTU                             | Bristol Myers Squibb Company             |\n|            | U.S. &Europe               | Topical products                    | Various                                  |\n|            | U.S.                       | Bisphosphonates, including generics |                                          |\n| EVENITY    | Japan                      | Teribone                            | Various Asahi Kasei Pharma               |\n|            | U.S. &Europe               | DARZALEX                            | Johnson &Johnson Innovative Medicine (3) |\n| KYPROLIS   | U.S. &Europe               | POMALYST/IMNOVID                    | Celgene Corporation (4)                  |\n|            | U.S. &Europe               | REVLIMID (5)                        | Various                                  |\n|            | U.S.                       | VELCADE                             | Takeda Oncology (6)                      |\n| Nplate     | U.S. &Europe               | PROMACTA/REVOLADE                   | Novartis PharmaAG                        |\n| Aranesp    | U.S.                       | PROCRIT (7)                         | Johnson &Johnson Innovative Medicine (3) |\n|            | U.S. &Europe               | Epoetin alfa biosimilars            | Various                                  |\n|            | U.S. &Europe               | BESPONSA                            | Pfizer Inc.                              |\n| BLINCYTO   | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S. &Europe               | Avastin                             | F. Hoffmann-La Roche Ltd. (Roche)        |\n| Vectibix   | U.S.                       | KEYTRUDA                            | Merck&Co., Inc.                          |\n|            | U.S. &Europe               | ERBITUX                             | Lilly                                    |\n|            | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S.                       | DUPIXENT                            | Regeneron Sanofi                         |\n|            | U.S.                       | FASENRA                             | AstraZeneca                              |\n| TEZSPIRE   | U.S.                       | XOLAIR                              | Genentech, Inc. Novartis PharmaAG        |\n|            | U.S.                       | NUCALA                              | GSKplc.                                  |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "XGEVA",
          "name": "XGEVA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "## UCB\n\nWe are in a collaboration with UCB for the development and commercialization of EVENITY . Under our collaboration, UCB has rights to lead commercialization for EVENITY in most countries in Europe. Amgen, as the principal, leads commercialization for EVENITY  and recognizes product sales in all other territories, including the United States. G lobal development costs and commercialization profits and losses related to the collaboration are shared equally. Amgen manufactures and supplies EVENITY worldwide.\n\nDuring the years ended December 31, 2024, 2023 and 2022, global profit and loss share expenses were $547 million, $396 million and $255 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. Net costs recovered from and due to UCB during the years ended December 31, 2024, 2023 and 2022, were not material.\n\n## BeiGene, Ltd.\n\nIn January 2020, we acquired an equity stake in BeiG ene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. For  additional  information  regarding  our  equity  investment  in  BeiG ene,  see  Note  10,  Investments.  Under  the  collaboration,  BeiG ene  began  selling  XG EV A  in  2020, BLINCYTO in 2021 and KYPROLIS in 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen would pay royalties to BeiG ene on sales in China of such products for a specified period. Amgen manufactures and supplies the collaboration products to BeiGene.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiG ene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiG ene will assume commercialization rights in China for a specified period, and Amgen and BeiG ene will share profits and losses equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiG ene on sales in China for a specified period. For product sales outside China, Amgen also pays royalties to BeiGene.\n\nDuring the years ended December 31, 2024, 2023 and 2022, net costs recovered from BeiG ene for oncology product candidates were $122 million, $109 million and $199 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the years ended December 31, 2024, 2023 and 2022, product sales from Amgen to BeiG ene under the collaboration were $259 million, $125 million and $64 million, respectively, and were recorded in Product sales in the Consolidated Statements of Income. Profit and loss share expenses related to the initial product-specific commercialization period were not material during the years ended December 31, 2024, 2023 and 2022.\n\n## Kyowa Kirin Co., Ltd.\n\nWe are in a collaboration and licensing agreement with Kyowa Kirin to jointly develop and commercialize rocatinlimab, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. Rocatinlimab is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.\n\nUnder the terms of the agreement, we lead the global development, manufacture and commercialization of rocatinlimab, except in Japan. Kyowa Kirin will co-promote rocatinlimab with Amgen in the United States and have opt in rights to co-promote rocatinlimab in various other markets outside the United States, including in Europe and Asia.\n\nWe made an upfront payment of $400 million to Kyowa Kirin that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and Kyowa Kirin share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by Kyowa Kirin will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850 million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay Kyowa Kirin significant double-digit royalties on global sales, except in Japan. During the years ended December 31, 2024, 2023 and 2022, net costs recovered from Kyowa Kirin were $166 million, $93 million and $23 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income.\n\n## Other\n\nIn addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts, or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties, or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.",
          "relationship": "Sells"
        },
        "node_3": {
          "id": "BeiGene,Ltd.",
          "name": "BeiGene,Ltd.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_1",
          "chunk_text": "| Exhibit No.   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 10.15         | Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto. (Filed as an exhibit to Form8-Kon December 22, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                    |\n| 10.16         | Third Amended and Restated Credit Agreement, dated as of March 9, 2023, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent. (Filed as an exhibit to Form 8-K on March 9, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| 10.17         | Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited dated May 10, 2002 (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&DLimited (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.) |\n| 10.17.1       | Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)                                                                                                                                                                                                                                                                            |\n| 10.18         | LetterAgreement, dated June 25, 2019, by and between Amgen Inc. and UCBCelltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                            |\n| 10.19         | Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                   |\n| 10.19.1       | First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)                                                                                                                                                                                                                                                                      |\n| 10.19.2       | Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2023 on April 28, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                   |\n| 10.20         | Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| 10.21         | Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                            |\n| 10.21.1       | Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13Don January 8, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| 10.21.2       | Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form10-Qfor the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| 10.21.3       | Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form8-Kon January 31, 2023 and incorporated herein by reference.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 130,
      "question": "How does Pfizer's financial dependency on BioNTech for Comirnaty-related manufacturing activities reconcile with the shared commercialization rights and profit-sharing structure defined in their collaboration agreement?",
      "answer": "Pfizer depends on BioNTech for certain Comirnaty-related manufacturing activities, which generated $33 million in revenue for Pfizer in 2023. Despite this dependency, the collaboration agreement signed in April 2020 (amended January 2021) outlines that Pfizer holds global commercialization rights for Comirnaty, excluding Germany, Turkey, and certain regions in China, where BioNTech markets and distributes the vaccine. Pfizer recognizes its share of gross profits from BioNTech's sales in Germany and Turkey as 'Alliance revenues'. This interdependency shows that while Pfizer relies on BioNTech for manufacturing in certain regions, the shared commercialization framework and profit-sharing mechanism ensure both parties benefit financially based on their respective roles in the vaccine's global distribution.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_112) \u2192 [BioNTech]: Pfizer depends on BioNTech for certain Comirnaty-related manufacturing activities, which generated $33 million in 2023 revenue for the PC1 contract development and manufacturing organization.",
        "Hop 2: [BioNTech] \u2192 [Comirnaty]: Pfizer and BioNTech co-developed Comirnaty under a global agreement, with Pfizer holding commercialization rights worldwide except in Germany, Turkey, and parts of China, where BioNTech distributes the vaccine.",
        "Hop 3: [Comirnaty] \u2190 [PFE](page_76): Pfizer recognizes its share of gross profits from BioNTech's sales of Comirnaty in Germany and Turkey under 'Alliance revenues', reflecting the shared financial benefits despite regional manufacturing and distribution roles."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Commercializes]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "BioNTech",
        "node_3": "Comirnaty",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 131,
      "question": "How does the reported revenue growth of Eliquis in 2024 compare with the potential revenue impact of the Inflation Reduction Act's (IRA) price negotiation provisions, particularly given the announced 'maximum fair price' for Eliquis effective in 2026?",
      "answer": "Eliquis generated $13.333 billion in total revenue in 2024, with U.S. sales growing 14% to $9.631 billion. However, the Inflation Reduction Act (IRA) has introduced significant pricing pressures, including the announcement in August 2024 of a 'maximum fair price' for Eliquis that will apply to the U.S. Medicare channel starting January 1, 2026. This government-determined pricing mechanism is expected to reduce revenue from Eliquis, especially in the Medicare segment, which accounted for a large portion of its U.S. growth. The IRA's provisions, such as rebates for inflation-driven price increases and the Part D Manufacturer Program, further constrain revenue potential beyond 2025. Therefore, while Eliquis remains a top revenue driver in 2024, the IRA's regulatory interventions signal a material risk to its future profitability and revenue trajectory.",
      "reasoning_steps": [
        "Hop 1: BMY (page_51) \u2192 Eliquis: Eliquis generated $13.333 billion in total revenue in 2024, with U.S. sales growing 14% to $9.631 billion.",
        "Hop 2: Eliquis \u2192 IRA: In August 2024, HHS announced a 'maximum fair price' for Eliquis under the IRA, effective January 1, 2026, which will cap pricing in the U.S. Medicare channel.",
        "Hop 3: IRA \u2190 BMY (page_134): The IRA is explicitly listed in the glossary as a key regulatory framework impacting drug pricing, confirming its relevance to Eliquis and other products."
      ],
      "difficulty": "hard",
      "idf_score": 5.566228656689513,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Increases]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Eliquis",
        "node_3": "IRA",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_51",
          "chunk_id": "chunk_1",
          "chunk_text": "| Dollars in millions       | 2024     | 2023     | %Change   |     |\n|---------------------------|----------|----------|-----------|-----|\n| Growth Portfolio (cont.)  |          |          |           |     |\n| Cobenfy                   | 10       | -        |           | N/A |\n| U.S.                      | 10       | -        |           | N/A |\n| Non-U.S.                  | -        | -        |           | N/A |\n| Other Growth Products (a) | 1,605    | 1,211    | 33        | %   |\n| U.S.                      | 674      | 620      | 9         | %   |\n| Non-U.S.                  | 931      | 591      | 58        | %   |\n| Total Growth Portfolio    | $ 22,563 | $ 19,366 | 17        | %   |\n| U.S.                      | 14,840   | 12,736   | 17        | %   |\n| Non-U.S.                  | 7,723    | 6,630    | 16        | %   |\n| Legacy Portfolio          |          |          |           |     |\n| Eliquis                   | $ 13,333 | $ 12,206 | 9         | %   |\n| U.S.                      | 9,631    | 8,482    | 14        | %   |\n| Non-U.S.                  | 3,702    | 3,724    | (1)       | %   |\n| Revlimid                  | 5,773    | 6,097    | (5)       | %   |\n| U.S.                      | 4,999    | 5,195    | (4)       | %   |\n| Non-U.S.                  | 774      | 902      | (14)      | %   |\n| Pomalyst/Imnovid          | 3,545    | 3,441    | 3         | %   |\n| U.S.                      | 2,695    | 2,339    | 15        | %   |\n| Non-U.S.                  | 850      | 1,102    | (23)      | %   |\n| Sprycel                   | 1,286    | 1,930    | (33)      | %   |\n| U.S.                      | 983      | 1,422    | (31)      | %   |\n| Non-U.S.                  | 303      | 508      | (40)      | %   |\n| Abraxane                  | 875      | 1,004    | (13)      | %   |\n| U.S.                      | 541      | 702      | (23)      | %   |\n| Non-U.S.                  | 334      | 302      | 11        | %   |\n| Other Legacy Products (b) | 925      | 962      | (4)       | %   |\n| U.S.                      | 416      | 334      | 25        | %   |\n| Non-U.S.                  | 509      | 628      | (19)      | %   |\n| Total Legacy Portfolio    | $ 25,737 | $ 25,640 | -         | %   |\n| U.S.                      | 19,265   | 18,474   | 4         | %   |\n| Non-U.S.                  | 6,472    | 7,166    | (10)      | %   |\n| Total Revenues            | $ 48,300 | $ 45,006 | 7         | %   |\n| U.S.                      | 34,105   | 31,210   | 9         | %   |\n",
          "relationship": "Increases"
        },
        "node_2": {
          "id": "Eliquis",
          "name": "Eliquis",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Economic and Market Factors\n\n## Governmental Actions\n\nAs regulators continue to focus on prescription drugs, our products are facing increased pressures across the portfolio. These pressures stem from legislative and policy changes, including price controls, pharmaceutical market access, discounting, changes to tax and importation laws and other restrictions in the U.S., EU and other regions around the world. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which can negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. The IRA directs (i) the federal government to 'negotiate' prices for select high-cost Medicare Part D (beginning in 2026) and Part B (beginning in 2028) drugs that are more than nine years (for small-molecule drugs) or 13 years (for biological products) from their initial FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and  Part  D  drugs  when  prices  increase  faster  than  inflation  and  (iii)  the  formation  of  the  Part  D  Manufacturer  Program  which  replaced  the  Part  D  CG DP  and established a $2,000 cap for out-of-pocket costs for Medicare beneficiaries as of January 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is reached. In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the \"maximum fair  price\"  for  a  30-day  equivalent  supply  of Eliquis ,  which  applies  to  the  U.S.  Medicare  channel  effective  January  1,  2026.  In  January  2025,  the  HHS  selected Pomalyst as a medicine subject to \"negotiation\" for government-set prices beginning in 2027. It is possible that more of our products could be selected in future years, which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.\n\nIn  addition,  in  December  2023,  the  Biden  administration  released  a  proposed  framework  that  for  the  first  time  proposed  that  a  drug's  price  can  be  a  factor  in determining that the drug is not accessible to the public and, therefore, that the government could exercise 'march-in rights' and license it to a third party to manufacture.  We cannot predict whether the  Trump administration will finalize the draft framework or if the government will propose other drug pricing policy changes. If pursued and finalized, these policies could reduce prices and reimbursement for certain of our products and could significantly impact our business and consolidated results of operations.\n\nAt  the  state  level,  multiple  states  have  passed,  are  pursuing  or  are  considering  government  action  via  legislation  or  regulations  to  change  drug  pricing  and reimbursement (e.g., establishing prescription drug affordability boards, implementing manufacturer mandates tied to the Federal Public Health Service Act drug pricing program, etc.). Some of these state-level actions may also influence federal and other state policies and legislation. G iven the current uncertainty surrounding the adoption, timing and implementation of many of these measures, as well as pending litigation challenging such laws, we are unable to predict their full impact on our business. However, such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations. With respect to the Federal Public Health Service Act drug pricing program, certain states have enacted laws regulating manufacturer pricing obligations under the program to date. Several additional states are considering similar potential legislation or other government actions, and we expect other states may do the same in the future.\n\nAdditionally, in connection with the IRA, the following changes have been made to U.S. tax laws, including (i) a 15% minimum tax that generally applies to U.S. corporations on adjusted financial statement income beginning in 2023 and (ii) a non-deductible 1% excise tax provision on net stock repurchases after December 31, 2022. Furthermore, countries are in the process of enacting changes to their tax laws to implement the agreement by the OECD to establish a global minimum tax. See risk  factors  on  these  items  included  under  'Part  I-Item  1A.  Risk  Factors-Product,  Industry  and  Operational  Risks-Increased  pricing  pressure  and  other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins', '-We could lose market exclusivity of a product earlier than expected' and '-Changes to tax regulations could negatively impact our earnings.'",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "IRA",
          "name": "IRA",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.558777146418381
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 132,
      "question": "How does the acquisition of Turning Point and the subsequent FDA approval of repotrectinib as Augtyro reflect on BMY's strategic investment in oncology, especially considering its minimal 2023 revenue contribution despite being marketed?",
      "answer": "BMY's acquisition of Turning Point in 2022 for $4.1 billion provided rights to repotrectinib, which was later approved by the FDA and marketed as Augtyro in November 2023. Despite this strategic move to expand BMY's oncology portfolio, Augtyro contributed only $1 million in revenue in 2023, as noted in the financial tables. This highlights a lag between acquisition integration, product launch, and revenue generation, suggesting that the expected financial return from this asset may take time to materialize, even after regulatory approval.",
      "reasoning_steps": [
        "Hop 1: BMY (page_88) \u2192 Repotrectinib: BMY acquired Turning Point in 2022 for $4.1 billion, gaining rights to repotrectinib, an investigational oncology drug.",
        "Hop 2: Repotrectinib \u2192 Augtyro: Repotrectinib was approved by the FDA in November 2023 and rebranded as Augtyro, indicating BMY's intent to commercialize the drug in the oncology market.",
        "Hop 3: Augtyro \u2190 BMY (page_83): In the 2023 financial tables, Augtyro is listed under the New Product Portfolio with only $1 million in revenue, showing minimal financial impact despite its approval and marketing."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Related_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Repotrectinib",
        "node_3": "Augtyro",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_88",
          "chunk_id": "chunk_1",
          "chunk_text": "BMS\t acquired\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Mirati's\t common\t stock\t for\t $58.00\t per\t share\t in\t an\t all-cash transaction\tfor\ta\ttotal\tconsideration\tof\t$4.8\tbillion\tor\t$4.1\tbillion,\tnet\tof\testimated\tcash\tacquired.\tMirati\tstockholders will\t also\t receive\t one\t non-tradeable\t contingent\t value\t right\t for\t each\t share\t of\t Mirati\t common\t stock\t held,\t potentially\t worth $12.00\tper\tshare\tin\tcash\tfor\ta\ttotal\tvalue\tof\tapproximately\t$1.0\tbillion.\tThe\tpayout\tof\tthe\tcontingent\tvalue\tright\tis\tsubject to\tthe\tFDA\tacceptance\tof\tan\tNDA\tfor\tMRTX1719\tfor\tthe\ttreatment\tof\tspecific\tindications\twithin\tseven\tyears\tof\tthe\tclosing\tof the\ttransaction.\tThe\ttransaction\twill\tbe\taccounted\tfor\tas\ta\tbusiness\tcombination\tin\twhich\tall\tassets\tacquired\tand\tliabilities assumed\t will\t be\t recognized\t at\t fair\t value\t as\t of\t the\t acquisition\t date.\t The\t purchase\t price\t allocation\t of\t the\t consideration transferred\tto\tthe\tassets\tacquired\tand\tliabilities\tassumed\thas\tnot\tyet\tbeen\tfinalized.\tThe\tacquisition\twas\tfunded\tthrough\ta combination\tof\tcash\ton\thand\tand\tdebt\tproceeds.\n\n## Karuna\n\nIn\t December\t 2023,\t BMS\t entered\t into\t a\t definitive\t merger\t agreement\t to\t acquire\t Karuna,\t a\t clinical-stage\t biopharmaceutical company\tdriven\tto\tdiscover,\tdevelop,\tand\tdeliver\ttransformative\tmedicines\tfor\tpeople\tliving\twith\tpsychiatric\tand\tneurological conditions.\tThe\tacquisition\twill\tprovide\tBMS\twith\trights\tto\tKaruna's\tlead\tasset,\tKarXT\t(xanomeline-trospium).\tKarXT\tis\tan antipsychotic\twith\ta\tnovel\tmechanism\tof\taction\tand\tdifferentiated\tefficacy\tand\tsafety,\tis\tcurrently\tunder\treview\tby\tthe\tFDA for\tthe\ttreatment\tof\tschizophrenia\tin\tadults\twith\ta\tPDUFA\tdate\tof\tSeptember\t26,\t2024.\tKarXT\tis\talso\tin\tregistrational\ttrials for\t both\t adjunctive\t therapy\t to\t existing\t standard\t of\t care\t agents\t in\t schizophrenia\t and\t for\t the\t treatment\t of\t psychosis\t in patients\twith\tAlzheimer's\tdisease.\n\nBMS\t will\t acquire\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Karuna's\t common\t stock\t for\t $330.00\t per\t share\t in\t an\t all-cash transaction\t for\t a\t total\t consideration\t of\t $14.0\t billion.\t The\t accounting\t treatment\t as\t a\t business\t combination\t or\t asset acquisition\twill\tbe\tdetermined\tin\tthe\tperiod\tthe\ttransaction\tcloses.\tThe\ttransaction\tis\texpected\tto\tclose\tin\tthe\tfirst\thalf of\t 2024,\t subject\t to\t customary\t closing\t conditions,\t including\t approval\t of\t Karuna\t stockholders\t and\t receipt\t of\t regulatory approvals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## RayzeBio\n\nIn\tDecember\t2023,\tBMS\tentered\tinto\ta\tdefinitive\tmerger\tagreement\tto\tacquire\tRayzeBio,\ta\tclinical-stage\tradiopharmaceutical therapeutics\t (RPT)\t company\t with\t actinium-based\t RPTs\t for\t solid\t tumors.\t The\t acquisition\t will\t provide\t BMS\t with\t rights\t to RayzeBio's\t actinium-based\t radiopharmaceutical\t platform\t and\t lead\t asset,\t RYZ101,\t which\t is\t in\t Phase\t III\t development\t for treatment\tof\tgastroenteropancreatic\tneuroendocrine\ttumors.\n\nBMS\twill\tacquire\tall\tof\tthe\tissued\tand\toutstanding\tshares\tof\tRayzeBio's\tcommon\tstock\tfor\t$62.50\tper\tshare\tin\tan\tall-cash transaction\t for\t a\t total\t consideration\t of\t $4.1\t billion.\t The\t transaction\t is\t expected\t to\t be\t accounted\t for\t as\t a\t business combination\tand\tis\tanticipated\tto\tclose\tin\tthe\tfirst\thalf\tof\t2024,\tsubject\tto\tfulfillment\tof\tcustomary\tclosing\tconditions, including\treceipt\tof\trequired\tregulatory\tapprovals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## Orum\n\nIn\tNovember\t2023,\tBMS\tacquired\tthe\trights\tto\tOrum's\tORM-6151\tprogram,\twhich\tis\tin\tpreclinical\tdevelopment.\tORM-6151\tis\ta anti-CD33\tantibody-enabled\tGSPT1\tdegrader\tthat\thas\treceived\tthe\tFDA's\tclearance\tfor\tPhase\tI\tfor\tthe\ttreatment\tof\tpatients with\t acute\t myeloid\t leukemia\t or\t high-risk\t myelodysplastic\t syndromes.\t The\t consideration\t included\t an\t upfront\t payment\t of $100\tmillion,\tas\twell\tas\tcontingent\tdevelopment\tmilestone\tpayments\tup\tto\t$80\tmillion.\tThe\tupfront\tpayment\twas\texpensed\tto Acquired\tIPRD.\n\n## Turning\tPoint\n\nIn\t2022,\tBMS\tacquired\tTurning\tPoint\tfor\t$4.1\tbillion\tof\tcash\t(or\t$3.3\tbillion\tnet\tof\tcash\tacquired).\tTurning\tPoint\twas\ta clinical-stage\t precision\t oncology\t company\t with\t a\t pipeline\t of\t investigational\t medicines\t designed\t to\t target\t the\t common mutations\t and\t alterations\t that\t drive\t cancer\t growth.\t The\t acquisition\t provided\t BMS\t rights\t to\t Turning\t Point's\t lead\t asset, repotrectinib,\tand\tother\tclinical\tand\tpre-clinical\tstage\tassets.\tRepotrectinib\twas\tapproved\tby\tthe\tFDA\tin\tNovember\t2023\tand is\tmarketed\tunder\tthe\tbrand\tname Augtyro.\n\nThe\t transaction\t was\t accounted\t for\t as\t a\t business\t combination\t in\t which\t all\t assets\t acquired\t and\t liabilities\t assumed\t were recognized\tat\tfair\tvalue\tas\tof\tthe\tacquisition\tdate.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Repotrectinib",
          "name": "Repotrectinib",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_88",
          "chunk_id": "chunk_1",
          "chunk_text": "BMS\t acquired\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Mirati's\t common\t stock\t for\t $58.00\t per\t share\t in\t an\t all-cash transaction\tfor\ta\ttotal\tconsideration\tof\t$4.8\tbillion\tor\t$4.1\tbillion,\tnet\tof\testimated\tcash\tacquired.\tMirati\tstockholders will\t also\t receive\t one\t non-tradeable\t contingent\t value\t right\t for\t each\t share\t of\t Mirati\t common\t stock\t held,\t potentially\t worth $12.00\tper\tshare\tin\tcash\tfor\ta\ttotal\tvalue\tof\tapproximately\t$1.0\tbillion.\tThe\tpayout\tof\tthe\tcontingent\tvalue\tright\tis\tsubject to\tthe\tFDA\tacceptance\tof\tan\tNDA\tfor\tMRTX1719\tfor\tthe\ttreatment\tof\tspecific\tindications\twithin\tseven\tyears\tof\tthe\tclosing\tof the\ttransaction.\tThe\ttransaction\twill\tbe\taccounted\tfor\tas\ta\tbusiness\tcombination\tin\twhich\tall\tassets\tacquired\tand\tliabilities assumed\t will\t be\t recognized\t at\t fair\t value\t as\t of\t the\t acquisition\t date.\t The\t purchase\t price\t allocation\t of\t the\t consideration transferred\tto\tthe\tassets\tacquired\tand\tliabilities\tassumed\thas\tnot\tyet\tbeen\tfinalized.\tThe\tacquisition\twas\tfunded\tthrough\ta combination\tof\tcash\ton\thand\tand\tdebt\tproceeds.\n\n## Karuna\n\nIn\t December\t 2023,\t BMS\t entered\t into\t a\t definitive\t merger\t agreement\t to\t acquire\t Karuna,\t a\t clinical-stage\t biopharmaceutical company\tdriven\tto\tdiscover,\tdevelop,\tand\tdeliver\ttransformative\tmedicines\tfor\tpeople\tliving\twith\tpsychiatric\tand\tneurological conditions.\tThe\tacquisition\twill\tprovide\tBMS\twith\trights\tto\tKaruna's\tlead\tasset,\tKarXT\t(xanomeline-trospium).\tKarXT\tis\tan antipsychotic\twith\ta\tnovel\tmechanism\tof\taction\tand\tdifferentiated\tefficacy\tand\tsafety,\tis\tcurrently\tunder\treview\tby\tthe\tFDA for\tthe\ttreatment\tof\tschizophrenia\tin\tadults\twith\ta\tPDUFA\tdate\tof\tSeptember\t26,\t2024.\tKarXT\tis\talso\tin\tregistrational\ttrials for\t both\t adjunctive\t therapy\t to\t existing\t standard\t of\t care\t agents\t in\t schizophrenia\t and\t for\t the\t treatment\t of\t psychosis\t in patients\twith\tAlzheimer's\tdisease.\n\nBMS\t will\t acquire\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Karuna's\t common\t stock\t for\t $330.00\t per\t share\t in\t an\t all-cash transaction\t for\t a\t total\t consideration\t of\t $14.0\t billion.\t The\t accounting\t treatment\t as\t a\t business\t combination\t or\t asset acquisition\twill\tbe\tdetermined\tin\tthe\tperiod\tthe\ttransaction\tcloses.\tThe\ttransaction\tis\texpected\tto\tclose\tin\tthe\tfirst\thalf of\t 2024,\t subject\t to\t customary\t closing\t conditions,\t including\t approval\t of\t Karuna\t stockholders\t and\t receipt\t of\t regulatory approvals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## RayzeBio\n\nIn\tDecember\t2023,\tBMS\tentered\tinto\ta\tdefinitive\tmerger\tagreement\tto\tacquire\tRayzeBio,\ta\tclinical-stage\tradiopharmaceutical therapeutics\t (RPT)\t company\t with\t actinium-based\t RPTs\t for\t solid\t tumors.\t The\t acquisition\t will\t provide\t BMS\t with\t rights\t to RayzeBio's\t actinium-based\t radiopharmaceutical\t platform\t and\t lead\t asset,\t RYZ101,\t which\t is\t in\t Phase\t III\t development\t for treatment\tof\tgastroenteropancreatic\tneuroendocrine\ttumors.\n\nBMS\twill\tacquire\tall\tof\tthe\tissued\tand\toutstanding\tshares\tof\tRayzeBio's\tcommon\tstock\tfor\t$62.50\tper\tshare\tin\tan\tall-cash transaction\t for\t a\t total\t consideration\t of\t $4.1\t billion.\t The\t transaction\t is\t expected\t to\t be\t accounted\t for\t as\t a\t business combination\tand\tis\tanticipated\tto\tclose\tin\tthe\tfirst\thalf\tof\t2024,\tsubject\tto\tfulfillment\tof\tcustomary\tclosing\tconditions, including\treceipt\tof\trequired\tregulatory\tapprovals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## Orum\n\nIn\tNovember\t2023,\tBMS\tacquired\tthe\trights\tto\tOrum's\tORM-6151\tprogram,\twhich\tis\tin\tpreclinical\tdevelopment.\tORM-6151\tis\ta anti-CD33\tantibody-enabled\tGSPT1\tdegrader\tthat\thas\treceived\tthe\tFDA's\tclearance\tfor\tPhase\tI\tfor\tthe\ttreatment\tof\tpatients with\t acute\t myeloid\t leukemia\t or\t high-risk\t myelodysplastic\t syndromes.\t The\t consideration\t included\t an\t upfront\t payment\t of $100\tmillion,\tas\twell\tas\tcontingent\tdevelopment\tmilestone\tpayments\tup\tto\t$80\tmillion.\tThe\tupfront\tpayment\twas\texpensed\tto Acquired\tIPRD.\n\n## Turning\tPoint\n\nIn\t2022,\tBMS\tacquired\tTurning\tPoint\tfor\t$4.1\tbillion\tof\tcash\t(or\t$3.3\tbillion\tnet\tof\tcash\tacquired).\tTurning\tPoint\twas\ta clinical-stage\t precision\t oncology\t company\t with\t a\t pipeline\t of\t investigational\t medicines\t designed\t to\t target\t the\t common mutations\t and\t alterations\t that\t drive\t cancer\t growth.\t The\t acquisition\t provided\t BMS\t rights\t to\t Turning\t Point's\t lead\t asset, repotrectinib,\tand\tother\tclinical\tand\tpre-clinical\tstage\tassets.\tRepotrectinib\twas\tapproved\tby\tthe\tFDA\tin\tNovember\t2023\tand is\tmarketed\tunder\tthe\tbrand\tname Augtyro.\n\nThe\t transaction\t was\t accounted\t for\t as\t a\t business\t combination\t in\t which\t all\t assets\t acquired\t and\t liabilities\t assumed\t were recognized\tat\tfair\tvalue\tas\tof\tthe\tacquisition\tdate.",
          "relationship": "Related_To"
        },
        "node_3": {
          "id": "Augtyro",
          "name": "Augtyro",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_2",
          "chunk_text": "| Dollars in millions                              | 2023     | 2022     | 2021     |\n|--------------------------------------------------|----------|----------|----------|\n| In-Line Products                                 |          |          |          |\n| Eliquis                                          | 12,206   | $ 11,789 | $ 10,762 |\n| Opdivo                                           | 9,009    | 8,249    | 7,523    |\n| Orencia                                          | 3,601    | 3,464    | 3,306    |\n| Pomalyst/Imnovid                                 | 3,441    | 3,497    | 3,332    |\n| Yervoy                                           | 2,238    | 2,131    | 2,026    |\n| Sprycel                                          | 1,930    | 2,165    | 2,117    |\n| Mature and other brands                          | 1,895    | 2,045    | 2,234    |\n| Total In-Line Products                           | 34,320   | 33,340   | 31,300   |\n| New Product Portfolio                            |          |          |          |\n| Reblozyl                                         | 1,008    | 717      | 551      |\n| Opdualag                                         | 627      | 252      | -        |\n| Abecma                                           | 472      | 388      | 164      |\n| Zeposia                                          | 434      | 250      | 134      |\n| Breyanzi                                         | 364      | 182      | 87       |\n| Camzyos                                          | 231      | 24       | -        |\n| Sotyktu                                          | 170      | 8        | -        |\n| Onureg                                           | 168      | 124      | 73       |\n| Inrebic                                          | 110      | 85       | 74       |\n| Augtyro                                          | 1        | -        | -        |\n| Total New Product Portfolio                      | 3,585    | 2,030    | 1,083    |\n| Total In-Line Products and New Product Portfolio | 37,905   | 35,370   | 32,383   |\n| Recent LOE Products (a)                          |          |          |          |\n| Revlimid                                         | 6,097    | 9,978    | 12,821   |\n| Abraxane                                         | 1,004    | 811      | 1,181    |\n| Total Recent LOE Products                        | 7,101    | 10,789   | 14,002   |\n| Total revenues                                   | $ 45,006 | $ 46,159 | $ 46,385 |\n| United States                                    | $ 31,555 | $ 31,828 | $ 29,214 |\n| International                                    | 12,752   | 13,497   | 16,319   |\n| Other (b)                                        | 699      | 834      | 852      |\n| Total revenues                                   | $ 45,006 | $ 46,159 | $ 46,385 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 133,
      "question": "How does Amgen's financial exposure to EVENITY through its collaboration with UCB compare to the costs and profit-sharing obligations disclosed in the financial statements?",
      "answer": "Amgen's collaboration with UCB for EVENITY involves shared global development costs and equal sharing of commercialization profits and losses, with Amgen leading commercialization outside Europe and manufacturing worldwide. In 2023, Amgen incurred $396 million in global profit and loss share expenses related to the EVENITY collaboration, which were recorded in Cost of Sales. This financial exposure highlights Amgen\u2019s significant commitment to the partnership, with direct implications on profitability and cost structure as disclosed in the Consolidated Statements of Income.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_30) \u2192 EVENITY: Amgen discloses its collaboration with UCB for EVENITY, including shared development and commercialization responsibilities and profit/loss sharing.",
        "Hop 2: EVENITY \u2192 UCB: The collaboration with UCB gives the latter rights to lead commercialization in most European countries, while Amgen leads in other territories and handles global manufacturing.",
        "Hop 3: UCB \u2190 AMGN(page_132): Amgen reports $396 million in global profit and loss share expenses for EVENITY in 2023, recorded in Cost of Sales, reflecting the financial impact of the UCB collaboration."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Introduces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "EVENITY",
        "node_3": "UCB",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nFor\t financial\t information\t about\t our\t significant\t collaborative\t arrangements,\t see\t Part\t IV-Note\t 9,\t Collaborations,\t to\t the Consolidated\tFinancial\tStatements.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "EVENITY",
          "name": "EVENITY",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nFor\t financial\t information\t about\t our\t significant\t collaborative\t arrangements,\t see\t Part\t IV-Note\t 9,\t Collaborations,\t to\t the Consolidated\tFinancial\tStatements.",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "UCB",
          "name": "UCB",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_132",
          "chunk_id": "chunk_1",
          "chunk_text": "share\tpayments\twere\t$44\tmillion\tand\t$47\tmillion\tas\tof\tDecember\t31,\t2023\tand\t2022,\trespectively,\twhich\tare\tincluded\tin\tOther current\tassets\tin\tthe\tConsolidated\tBalance\tSheets.\n\n## AstraZeneca\tplc\n\nWe\tare\tin\ta\tcollaboration\twith\tAstraZeneca\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tTEZSPIRE.\tUnder\tour\tcollaboration, both\t companies\t share\t global\t costs,\t profits\t and\t losses\t equally\t after\t payment\t by\t AstraZeneca\t of\t a\t mid-single-digit\t royalty\t to Amgen.\tAstraZeneca\tleads\tglobal\tdevelopment,\tand\tboth\tAmgen\tand\tAstraZeneca\tjointly\tcommercialize\tTEZSPIRE\tin\tNorth\tAmerica.\tIn North\t America,\t Amgen,\t as\t the\t principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t the\t United\t States,\t and\t AstraZeneca,\t as\t the principal,\t recognizes\t product\t sales\t of\t TEZSPIRE\t in\t Canada.\t AstraZeneca\t leads\t commercialization\t for\t TEZSPIRE\t outside\t North America.\tAmgen\tmanufactures\tand\tsupplies\tTEZSPIRE\tworldwide.\n\nDuring\t the\t years\t ended\t December\t 31,\t 2023,\t 2022\t and\t 2021,\t net\t costs\t due\t to\t AstraZeneca\t for\t global\t development\t were $77\t million,\t $74\t million\t and\t $49\t million,\t respectively,\t and\t were\t recorded\t in\t R&amp;D\t expense\t in\t the\t Consolidated\t Statements\t of Income.\tDuring\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\tnet\tcosts\tdue\tto\tAstraZeneca\tfor\tglobal\tcommercialization\twere $73\tmillion,\t$60\tmillion\tand\t$39\tmillion,\trespectively,\tand\twere\trecorded\tin\tSG&amp;A\texpense\tin\tthe\tConsolidated\tStatements\tof Income.\tDuring\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022,\tglobal\tprofit\tand\tloss\tshare\texpenses\twere\t$310\tmillion\tand\t$119 million,\trespectively,\tand\twere\trecorded\tprimarily\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tTEZSPIRE\tlaunched in\tthe\tUnited\tStates\tin\tJanuary\t2022.\n\n## UCB\n\nWe\tare\tin\ta\tcollaboration\twith\tUCB\tfor\tthe\tdevelopment\tand\tcommercialization\tof\tEVENITY.\tUnder\tour\tcollaboration,\tUCB\thas rights\tto\tlead\tcommercialization\tfor\tEVENITY\tin\tmost\tcountries\tin\tEurope.\tAmgen,\tas\tthe\tprincipal,\tleads\tcommercialization\tfor EVENITY\t and\t recognizes\t product\t sales\t in\t all\t other\t territories,\t including\t the\t United\t States.\t Global\t development\t costs\t and commercialization\tprofits\tand\tlosses\trelated\tto\tthe\tcollaboration\tare\tshared\tequally.\tAmgen\tmanufactures\tand\tsupplies\tEVENITY worldwide.\n\nDuring\t the\t years\t ended\t December\t 31,\t 2023,\t 2022\t and\t 2021,\t global\t profit\t and\t loss\t share\t expenses\t were\t $396\t million,\t $255 million\tand\t$186\tmillion,\trespectively,\tand\twere\trecorded\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tNet\tcosts recovered\tfrom\tand\tdue\tto\tUCB\tduring\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\twere\tnot\tmaterial.\n\n## Novartis\tPharma\tAG\n\nWe\tare\tin\ta\tcollaboration\twith\tNovartis\tto\tjointly\tdevelop\tand\tcommercialize\tAimovig.\tOn\tJanuary\t31,\t2022,\twe\tmodified\tthe terms\tof\tthe\tcollaboration.\tEffective\tJanuary\t1,\t2022,\tin\tthe\tUnited\tStates,\tNovartis\tno\tlonger\tcollaborates\twith\tAmgen,\tshares Aimovig\tcommercialization\tcosts\tor\tis\trequired\tto\tpay\tmilestones,\tand\tAmgen\tno\tlonger\tpays\troyalties\tto\tNovartis\ton\tU.S.\tsales of\tAimovig.\tNovartis\tcontinues\tto\thold\tglobal\tco-development\trights\tand\texclusive\tcommercial\trights\toutside\tthe\tUnited\tStates and\tJapan\tfor\tAimovig.\tAmgen\tand\tNovartis\tshare\tglobal\tdevelopment\texpenses,\tand\tNovartis\tpays\tAmgen\tdouble-digit\troyalties\ton net\tsales\tof\tthe\tproduct\toutside\tthe\tUnited\tStates\tand\tJapan.\tAmgen\tmanufactures\tand\tsupplies\tAimovig\tworldwide.\n\nDuring\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022,\tnet\tcosts\trecovered\tfrom\tNovartis\tfor\tmigraine\tproducts\twere\t$42\tmillion and\t$53\tmillion,\trespectively,\tand\twere\trecorded\tin\tR&amp;D\texpense\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyear\tended December\t31,\t2021,\tnet\tcosts\trecovered\tfrom\tNovartis\tfor\tmigraine\tproducts\twere\t$160\tmillion\tand\twere\trecorded\tprimarily\tin\tSG&amp;A expense\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyear\tended\tDecember\t31,\t2021,\troyalties\tdue\tto\tNovartis\tfor\tAimovig were\t$116\tmillion\tand\twere\trecorded\tin\tCost\tof\tsales\tin\tthe\tConsolidated\tStatements\tof\tIncome.\tDuring\tthe\tyears\tended\tDecember 31,\t2023,\t2022\tand\t2021,\troyalties\tdue\tfrom\tNovartis\tfor\tAimovig\twere\tnot\tmaterial.\n\n## Kyowa\tKirin\tCo.,\tLtd.\n\nWe\tare\tin\ta\tcollaboration\tand\tlicensing\tagreement\twith\tKyowa\tKirin\tto\tjointly\tdevelop\tand\tcommercialize\trocatinlimab,\tan anti-OX40\tfully\thuman\tmonoclonal\tantibody,\tworldwide,\texcept\tin\tJapan.\tRocatinlimab\tis\tfor\tthe\ttreatment\tof\tatopic\tdermatitis, with\tpotential\tfor\ttreatment\tof\tother\tautoimmune\tdiseases.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tlead\tthe\tglobal\tdevelopment,\tmanufacture\tand\tcommercialization\tof\trocatinlimab,\texcept in\t Japan.\t Kyowa\t Kirin\t will\t co-promote\t rocatinlimab\t with\t Amgen\t in\t the\t United\t States\t and\t have\t opt\t in\t rights\t to\t co-promote rocatinlimab\tin\tvarious\tother\tmarkets\toutside\tthe\tUnited\tStates,\tincluding\tin\tEurope\tand\tAsia.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 134,
      "question": "Given MRK's reliance on key products like Bravecto for profits and cash flows, and the recent EC approval of Bravecto's injectable formulation for dogs, how does the extension of Bravecto's market exclusivity align with MRK's broader strategy to offset revenue declines from other key products losing exclusivity, such as Bridion in the EU and Keytruda expected to lose exclusivity in the U.S. in 2028?",
      "answer": "Merck (MRK) emphasizes in its risk factors that the loss of market exclusivity for key products like Bridion in the EU and the anticipated loss for Keytruda in the U.S. in 2028 can significantly reduce sales and impact financial performance. However, the recent EC approval of Bravecto's injectable formulation for dogs in January 2024 extends the product's market exclusivity and provides a new avenue for revenue generation. Since key products like Bravecto, Keytruda, and Gardasil account for a large portion of MRK's profits, the strategic extension of Bravecto's exclusivity helps offset expected revenue declines from other products. This aligns with MRK\u2019s broader approach to maintain profitability through lifecycle management and regulatory approvals that expand indications or formulations of existing products, especially in the absence of immediate pipeline replacements.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_28) \u2192 [Key Products]: MRK depends heavily on key products like Keytruda, Gardasil, Lynparza, Bravecto, and Bridion for profits and cash flows, and the loss of market exclusivity for these products can materially affect the company.",
        "Hop 2: [Key Products] \u2192 [Bravecto]: Bravecto is specifically listed among MRK\u2019s key products, contributing to profitability and cash flow, and is thus subject to the same market exclusivity risks and strategic importance as other key products.",
        "Hop 3: [Bravecto] \u2190 [MRK](page_7): The EC approval of Bravecto's injectable formulation for dogs in January 2024 extends its market exclusivity and creates a new revenue opportunity, helping to offset declines from other products losing exclusivity."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> PRODUCT -[Includes]-> PRODUCT <-[Announces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Key Products",
        "node_3": "Bravecto",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Bravecto",
          "name": "Bravecto",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "| Keytruda     | November 2023   | FDA approval in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.                                                                                                               |\n|--------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Keytruda     | December 2023   | FDA full approval in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer) and Astellas. |\n| Keytruda     | December 2023   | EC approval in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1, based on the KEYNOTE- 859 trial.                                                                                      |\n| Keytruda     | December 2023   | EC approval in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on the KEYNOTE-966 trial.                                                                                                                                                                    |\n| Keytruda     | December 2023   | China's NMPA approval in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.                                                                                                     |\n| Keytruda     | January 2024    | FDA approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.                                                                                                                                                           |\n| Keytruda     | January 2024    | FDA full approval for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an accelerated to full (regular) approval is based on the KEYNOTE-394 trial.                                                                                                     |\n| Keytruda     | February 2024   | China's NMPA approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the KEYNOTE-966 trial.                                                                                                                                                                   |\n| Lynparza (1) | May 2023        | FDA approval in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated ( BRCAm ) metastatic castration-resistant prostate cancer (mCRPC), based on the PROpel trial.                                                                                                        |\n| Lynparza (1) | August 2023     | Japan's MHLW approval in combination with abiraterone and prednisolone for treatment of adult patients with BRCAm mCRPC with distant metastasis, based on the PROpel trial.                                                                                                                                                                                                 |\n| Prevymis     | June 2023       | FDA approval for CMV prophylaxis in Donor CMV-seropositive/Recipient CMV-seronegative adult kidney transplant recipients, based on the P002 trial.                                                                                                                                                                                                                          |\n| Prevymis     | November 2023   | EC approval for CMV prophylaxis Donor CMV-seropositive/Recipient CMV-seronegative adult kidney transplant recipients, based on the P002 trial.                                                                                                                                                                                                                              |\n| Ervebo       | August 2023     | FDA approval of an expanded indication for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older.                                                                                                                                            |\n| Ervebo       | September 2023  | EC approval of an expanded indication for active immunization of individuals one year of age or older to protect against Ebola Virus Disease caused by Zaire ebolavirus . The vaccine was previously approved for use in the EU for individuals 18 years of age or older.                                                                                                   |\n| Welireg      | December 2023   | FDA approval for the treatment of adult patients with advanced RCC following both a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor, based on the LITESPARK-005 trial.                                                                                                                                                           |\n| Bravecto     | January 2024    | EC approval of injectable formulation for dogs for the persistent killing of fleas and ticks for 12 months after treatment.                                                                                                                                                                                                                                                 |\n",
          "relationship": "Announces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 135,
      "question": "How does the Pharmacy & Consumer Wellness segment's reported $189 million decrease in adjusted operating income due to pharmacy reimbursement pressure reconcile with the strategic rationale for acquiring Oak Street Health, given Oak Street's reliance on third-party payors for a significant portion of its revenue?",
      "answer": "The Pharmacy & Consumer Wellness segment experienced a $189 million decrease in adjusted operating income in 2024, driven in part by continued pharmacy reimbursement pressure from third-party payors. This pressure stems from efforts by managed care organizations, PBMs, and other payors to reduce prescription drug costs, including the use of restrictive networks and changes in the mix of business. Despite this, CVS proceeded with the acquisition of Oak Street Health, a company that is significantly dependent on reimbursements from the same class of third-party payors for its revenue. Oak Street Health's business model assumes risk related to service costs exceeding reimbursement rates under fixed-fee agreements and faces additional risk from potential reductions in Medicare reimbursement rates or changes in government program rules. The strategic rationale for the acquisition was to advance CVS's value-based care strategy and expand into primary care, suggesting a calculated bet that the long-term benefits of vertical integration and population health management could offset the short-term reimbursement challenges evident in both the Pharmacy segment and Oak Street Health's operations.",
      "reasoning_steps": [
        "Hop 1: CVS(page_86) \u2192 Third-Party Payors: The Pharmacy & Consumer Wellness segment's adjusted operating income decreased by $189 million in 2024, partly due to reimbursement pressure from third-party payors, including PBMs and managed care organizations.",
        "Hop 2: Third-Party Payors \u2192 Oak Street Health: Oak Street Health is heavily reliant on third-party payors, including Medicare and Medicare Advantage plans, for a significant portion of its revenue and faces risks related to reimbursement delays, changes in government program rules, and potential reductions in payment rates.",
        "Hop 3: Oak Street Health \u2190 CVS(page_133): CVS acquired Oak Street Health in May 2023 to advance its value-based care strategy and expand into senior-focused primary care, despite Oak Street's exposure to the same reimbursement risks affecting the Pharmacy segment."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> COMP -[Depends_On]-> COMP <-[Acquires]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Third-Party Payors",
        "node_3": "Oak Street Health",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_1",
          "chunk_text": "- front store volume, including the impact of a decrease in store count and lower contributions from COVID-19 over-the-counter ('OTC') test kits since the expiration of the public health emergency in May 2023.\n- Pharmacy same store sales increased 12.3% in 2024 compared to 2023. The increase was primarily driven by the 6.8% increase in pharmacy same store prescription volume on a 30-day equivalent basis, including increased contributions from vaccinations, and pharmacy drug mix, including branded GLP-1 drugs. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions.\n- Front store same store sales decreased 2.1% in 2024 compared to 2023 primarily due to general softening of consumer demand and lower contributions from COVID-19 OTC test kits compared to the prior year.\n\n## Operating expenses\n\n- Operating expenses in the Pharmacy &amp; Consumer Wellness segment include payroll, employee benefits and occupancy costs associated with the segment's stores and pharmacy fulfillment operations; selling expenses; advertising expenses; depreciation and amortization expense and certain administrative expenses.\n- Operating expenses remained relatively consistent in 2024 compared to the prior year at $19.6 billion, as the absence of gains from anti-trust legal settlements and increased investments in the segment's operations and capabilities were substantially offset by the decrease in store count.\n\n## Restructuring charges\n\n- During 2024, the Company recorded $747 million of restructuring charges related to the write-down of lease right-of-use assets and property and equipment in connection with the Company's restructuring program. See Note 3 ''Restructuring'' included in Item 8 of this 10-K for additional information.\n\n## Loss on assets held for sale\n\n- During 2023, the Company recorded losses on assets held for sale of $349 million related to the write-down of its LTC business. See Note 2 ''Acquisitions, Divestitures and Asset Sales'' included in Item 8 of this 10-K for additional information.\n\n## Adjusted operating income\n\n- Adjusted operating income decreased $189 million, or 3.2%, in 2024 compared to 2023 primarily driven by continued pharmacy reimbursement pressure and decreased front store volume, including lower contributions from COVID-19 OTC test kits, largely offset by increased prescription volume, including increased contributions from vaccinations, as well as improved drug purchasing.\n- As you review the Pharmacy &amp; Consumer Wellness segment's performance in this area, you should consider the following important information about the business:\n- The segment's adjusted operating income has been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix  of business within the pharmacy portion of the Pharmacy &amp; Consumer Wellness segment. If the pharmacy reimbursement pressure accelerates, the segment may not be able to grow revenues, and its adjusted operating income could be adversely affected.\n\n## Prescriptions filled\n\n- Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy &amp; Consumer Wellness segment's retail and long-term care pharmacies and infusion services operations. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.\n- Prescriptions filled increased 4.0% on a 30-day equivalent basis in 2024 compared to 2023 primarily driven by increased utilization, partially offset by the decrease in store count.\n\n## Generic dispensing rate\n\n- Generic dispensing rate is calculated by dividing the Pharmacy &amp; Consumer Wellness segment's generic drug prescriptions filled by its total prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Third-Party_Payors",
          "name": "Third-Party Payors",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_1",
          "chunk_text": "- dependence on a concentrated number of key health plan customers;\n- the quality of the information received about plan members of such health plans for whom Signify Health will seek to provide in-home evaluations and other services, and the regulatory restrictions and requirements associated with directly contacting plan members;\n- ability to perform and ensure the quality of health risk assessments;\n- ability to achieve and receive shared health care cost savings;\n- the regulatory and business risks associated with participation in certain government health care programs, including, among others, the MSSP and ACO REACH models, and identification of diagnosis codes related to risk adjustment payments under Part C of the Medicare program;\n- health reform initiatives and changes in the rules governing government health care programs, including rules related to the use of in-home health risk assessments for the purpose of capturing individual risk use to calculate an individual's risk adjustment factor or a change to how patient-level risk is determined for CMS programs;\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;\n- impacts of fraud or anomalous billing on shared savings in CMS Innovation Center models;\n- use of 'open source' software in its technology, which may make it easier for others to gain access or compromise its proprietary technology;\n- success in large, national ACOs is dependent on the collective efforts and compliance of a wide range of participating clients, and for those clients to be able to meet new and changing requirements such as changes to interoperability and reporting requirements; and\n- challenges in rural and post-acute reimbursement due to their significant dependence on fee-for-service revenue.\n\nOur Oak Street Health business is subject to additional risks including, but not limited to, the following:\n\n- ability to attract new Medicare-eligible patients and credentialed, high-quality physicians and other providers for senior-focused primary care in a highly competitive market for such patients and providers;\n- satisfying the enrollment requirements under government health care programs for physicians and other providers in a timely manner;\n- dependence on a significant portion of revenue from Medicare or Medicare Advantage plans, which subjects Oak Street Health to reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;\n- dependence for a significant portion of revenue from agreements with a limited number of key payors with whom Oak Street Health contracts to provide services under terms that may permit a payor to amend the compensation arrangements or terminate the agreements without cause;\n- dependence on reimbursements from third-party payors, which can result in substantial delay, and on patients, through copayments and deductibles, which subjects Oak Street Health to additional reimbursement risk;\n- under the fix ed fee (or capitated) agreements Oak Street Health enters into with health plans, the assumption of the risk that the actual cost of a service it provides to a patient exceeds the reimbursement provided by the health plan;\n- reductions in the quality ratings of Medicare health plans Oak Street Health serves could result in a shift of patients from, or the termination of, a health plan Oak Street Health serves;\n- submission of inaccurate, incomplete or erroneous data, including risk adjustment data, to health plans and government payors could result in inaccuracies in the revenue Oak Street Health records or receipt of overpayments, which may subject it to repayment obligations and penalties;\n- geographic concentration of its primary care centers;\n- risks associated with its ex isting legal proceedings and litigations;\n- laws regulating the corporate practice of medicine and the associated agreements entered into with physician practice groups restrict the manner in which the Oak Street Health business is able to direct the operations and otherwise exercise control of its physician practice groups\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Oak_Street_Health",
          "name": "Oak Street Health",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_133",
          "chunk_id": "chunk_1",
          "chunk_text": "addition, the standard also requires disclosure of the CODM's title and position, as well as detail on how the CODM uses the reported measure of segment operating results to evaluate segment performance and allocate resources. The standard also aligns interim segment reporting disclosure requirements with annual segment reporting disclosure requirements. The Company adopted the standard on January 1, 2024 for fiscal year reporting and the standard became effective for interim reporting periods in fiscal years beginning after December 15, 2024. The standard requires retrospective application to all prior periods presented. While the standard requires additional disclosures related to the Company's reportable segments, the standard did not have any impact on the Company's consolidated operating results, financial condition or cash flows as of the date of adoption. Refer to Note 19 ''Segment Reporting'' for the Company's segment reporting disclosures, including those newly required by this standard.\n\n## New Accounting Pronouncements Not Yet Adopted\n\n## Income Taxes\n\nIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The standard requires the Company to provide further disaggregated income tax disclosures for specific categories on the effective tax rate reconciliation, as well as additional information about federal, state/local and foreign income taxes. The standard also requires the Company to annually disclose its income taxes paid (net of refunds received), disaggregated by jurisdiction. The Company adopted the standard on January 1, 2025 for fiscal year reporting. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. While the standard requires additional disclosures related to the Company's income taxes, the standard did not have any impact on the Company's consolidated operating results, financial condition or cash flows.\n\n## Disaggregation of Income Statement Expenses\n\nIn November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The standard requires the Company to provide further disaggregated information of relevant expense captions within its consolidated statements of operations, including the purchases of inventory, employee compensation, depreciation and intangible asset amortization, as well as the inclusion of other specific ex penses, gains and losses required by ex isting G AAP. The new standard also requires the Company to disclose its total selling expenses and, on an annual basis, provide a qualitative description of its selling ex penses. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The standard may be applied prospectively or retrospectively. While the standard will require additional disclosures related to certain ex penses included in the consolidated statements of operations, the standard is not ex pected to have any impact on the Company's consolidated operating results, financial condition or cash flows.\n\n## 2. Acquisitions, Divestitures and Asset Sales\n\n## Oak Street Health Acquisition\n\nOn May 2, 2023 (the 'Oak Street Health Acquisition Date'), the Company acquired 100% of the outstanding shares and voting interest of Oak Street Health for cash ('Oak Street Health Acquisition'). Under the terms of the merger agreement, Oak Street Health stockholders received $39.00 per share in cash. The Company financed the transaction with borrowings of $5.0 billion from a term loan agreement entered into on May 1, 2023 as described in Note 10 ''Borrowings and Credit Agreements'' and cash on hand. Oak Street Health is a leading multi-payor, senior focused value-based primary care company. Oak Street Health is included within the Health Services segment. The Company acquired Oak Street Health to advance its value-based care strategy and broaden its platform into primary care.\n\nThe fair value of the consideration transferred on the date of acquisition consisted of the following:\n\n",
          "relationship": "Acquires"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 136,
      "question": "How does Tarlatamab's patent protection timeline position it within Amgen's polypeptide therapy portfolio, especially considering near-term patent expirations for BLINCYTO and TEZSPIRE?",
      "answer": "Tarlatamab, an investigational polypeptide therapy for small cell lung cancer, has U.S. and European patent protections that are set to expire in 2036\u2014significantly later than many other polypeptide therapies in Amgen's portfolio. This contrasts with BLINCYTO, which has a bifunctional polypeptide patent expiring in 2024 (Europe) and TEZSPIRE, with polypeptide patents expiring in 2029 (U.S.) and 2028 (Europe). Positioned as a phase 3-initiated asset, Tarlatamab's longer patent runway could provide Amgen with extended market exclusivity and revenue potential in the polypeptide space, offsetting the near-term loss of exclusivity for existing therapies like BLINCYTO and TEZSPIRE.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_26) \u2192 Tarlatamab: Tarlatamab is an investigational polypeptide therapy for small cell lung cancer that has initiated a phase 3 study.",
        "Hop 2: Tarlatamab \u2192 Polypeptides: Tarlatamab is classified under the general subject matter of 'Polypeptides' with patent protection in the U.S. and Europe expiring in 2036.",
        "Hop 3: Polypeptides \u2190 AMGN(page_13): Amgen discloses patent expiration dates for various polypeptide therapies, including BLINCYTO (2024 in Europe) and TEZSPIRE (2028\u20132029), showing Tarlatamab's longer exclusivity window."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Depends_On]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Tarlatamab",
        "node_3": "Polypeptides",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                         | Program change                                      |\n|-------------------|----------------------------------------------------|-----------------------------------------------------|\n| Dazodalibep       | Sj\u00f6gren's Syndrome                                 | Horizon acquired program                            |\n| KYPROLIS          | Weekly dosing for relapsed multiple myeloma        | Concluded-program did not meet its primary endpoint |\n| LUMAKRAS/LUMYKRAS | NSCLC in combination with chemotherapy             | Initiated phase 3 study                             |\n| Otezla            | Genital psoriasis                                  | Approved by the FDA                                 |\n| Tarlatamab        | Small cell lung cancer                             | Initiated phase 3 study                             |\n| TEPEZZA           | Active TED (OPTIC-J); Chronic/Low CAS TED in Japan | Horizon acquired programs                           |\n| UPLIZNA           | IgG4-related disease; Myasthenia gravis            | Horizon acquired programs                           |\n| ABP 206           | Biosimilar to OPDIVO                               | Initiated phase 3 study                             |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Tarlatamab",
          "name": "Tarlatamab",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_4",
          "chunk_text": "| Molecule      | Territory   | General subject matter   |   Estimated expiration* |\n|---------------|-------------|--------------------------|-------------------------|\n| Bemarituzumab | U.S.        | Polypeptides             |                    2029 |\n| Bemarituzumab | Europe      | Polypeptides             |                    2029 |\n| Dazodalibep   | U.S.        | Polypeptides             |                    2034 |\n| Dazodalibep   | Europe      | Polypeptides             |                    2032 |\n| Olpasiran     | U.S.        | Compounds                |                    2036 |\n| Olpasiran     | Europe      | Compounds                |                    2036 |\n| Rocatinlimab  | U.S.        | Polypeptides             |                    2027 |\n| Rocatinlimab  | Europe      | Polypeptides             |                    2026 |\n| Tarlatamab    | U.S.        | Polypeptides             |                    2036 |\n| Tarlatamab    | Europe      | Polypeptides             |                    2036 |\n",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Polypeptides",
          "name": "Polypeptides",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product                           | Territory   | General subject matter                                                    | Expiration         |\n|-----------------------------------|-------------|---------------------------------------------------------------------------|--------------------|\n|                                   | U.S.        | Formulations and methods of preparing formulations                        | 10/19/2037         |\n| Enbrel (etanercept) \u00ae             | U.S.        | Fusion protein and pharmaceutical compositions                            | 11/22/2028         |\n|                                   | U.S.        | DNA encoding fusion protein and methods of making fusion protein          | 4/24/2029          |\n| Otezla (apremilast) \u00ae             | U.S.        | Compositions and compounds                                                | 2/16/2028          |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 3/20/2023          |\n| \u00ae                                 | U.S.        | Antibodies (2)                                                            | 8/22/2028          |\n|                                   | U.S.        | Methods of treatment                                                      | 11/22/2030         |\n| Repatha (evolocumab)              | Europe      | Compositions (1)                                                          | 8/22/2028          |\n| Repatha (evolocumab)              | Europe      | Methods of treatment                                                      | 5/10/2032          |\n|                                   | Europe      | Formulation                                                               | 5/3/2033           |\n| Nplate (romiplostim) \u00ae            | U.S.        | Formulation                                                               | 2/12/2028          |\n|                                   | Europe      | Thrombopoietic compounds (1)                                              | 10/22/2019         |\n|                                   | Europe      | Formulation                                                               | 4/20/2027          |\n|                                   | U.S.        | Compositions and compounds                                                | 12/7/2027          |\n| \u00ae                                 | U.S.        | Methods of treatment                                                      | 4/14/2025          |\n| KYPROLIS (carfilzomib)            | U.S.        | Methods of making                                                         | 5/8/2033           |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 12/7/2025          |\n| Aranesp (darbepoetin alfa) \u00ae      | U.S.        | Glycosylation analogs of erythropoietin proteins                          | 5/15/2024          |\n|                                   | U.S.        | Antibodies                                                                | 4/25/2026          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/9/2033           |\n| EVENITY (romosozumab-aqqg) \u00ae      | Europe      | Antibodies (1)                                                            | 4/28/2026          |\n|                                   | Europe      | Methods of treatment                                                      | 4/18/2032          |\n|                                   | Europe      | Formulation and methods of using formulation                              | 5/11/2031          |\n|                                   | U.S.        | Pharmaceutical compositions and bifunctional polypeptides                 | 4/6/2030           |\n| \u00ae                                 | U.S.        | Method of administration                                                  | 9/28/2027          |\n| BLINCYTO (blinatumomab)           | Europe      | Bifunctional polypeptides (1)                                             | 11/26/2024         |\n|                                   | Europe      | Method of administration                                                  | 11/6/2029          |\n| TEZSPIRE (tezepelumab-ekko) \u00ae     | U.S.        | Polypeptides (2)                                                          | 2/3/2029           |\n|                                   | U.S.        | Methods of treatment                                                      | 8/23/2038          |\n|                                   | Europe      | Polypeptides (1)                                                          | 9/9/2028           |\n| TEPEZZA (teprotumumab-trbw) \u00ae     | U.S.        | IGF-1R antibodies (3)                                                     | 3/3/2029           |\n| \u00ae                                 | U.S.        | Compound and pharmaceutical composition                                   | 2/7/2031           |\n| Parsabiv (etelcalcetide)          | U.S.        | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | Methods of making                                                         | 8/9/2035           |\n|                                   | Europe      | Compound and pharmaceutical composition (1)                               | 7/29/2030          |\n|                                   | Europe      | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | CGRP receptor antibodies                                                  | 5/17/2032          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/22/2036          |\n| Aimovig (erenumab-aooe) \u00ae         | U.S.        | Compositions and pharmaceutical formulations                              | 4/1/2039           |\n|                                   | Europe      | CGRP receptor antibodies (1)                                              | 12/18/2029         |\n|                                   | Europe      | Methods of treatment                                                      | 8/10/2035          |\n|                                   | U.S.        | Compounds and pharmaceutical compositions                                 | 5/21/2038          |\n| LUMAKRAS /LUMYKRAS\u2122 (sotorasib) \u00ae | U.S.        | Crystalline form, pharmaceutical compositions and methods of treatment    | 5/20/2040          |\n|                                   | U.S.        | Methods of treatment                                                      | 9/15/2040          |\n|                                   | Europe      | Compounds, pharmaceutical compositions and methods of treatment           | 5/21/2038          |\n|                                   | U.S.        | Polypeptides and pharmaceutical compositions                              | 4/11/2026          |\n| KRYSTEXXA (pegloticase) \u00ae         | U.S.        | Methods of treatment                                                      |                    |\n|                                   | U.S.        | Compounds and pharmaceutical compositions (2)                             | 6/25/2030 2/3/2031 |\n| TAVNEOS (avacopan) \u00ae              | U.S.        | Crystalline and amorphous forms and pharmaceutical compositions           | 5/29/2041          |\n| UPLIZNA (inebilizumab-cdon) \u00ae     | U.S.        | CD19 antibodies and pharmaceutical compositions (2)                       | 3/7/2030           |\n|                                   | Europe      | CD19 antibodies, pharmaceutical compositions and methods of treatment (1) | 9/7/2027           |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 137,
      "question": "How does Eli Lilly's election to pay the Toll Tax over an eight-year period, as outlined in their accounting policy, influence their forward-looking tax expense projections given the anticipated U.S. tax changes under the 2017 Tax Act scheduled for 2026?",
      "answer": "Eli Lilly elected to pay the Toll Tax over an eight-year period from 2018 through 2025, which spreads out their cash payments related to the one-time repatriation transition tax on unremitted foreign earnings introduced by the 2017 Tax Act. This structured payment plan likely provides short-term liquidity benefits. However, the company also notes that U.S. tax changes under the 2017 Tax Act, scheduled to occur in 2026, may increase their future tax expense. Therefore, while the eight-year payment plan reduces immediate financial pressure, the long-term tax burden could rise due to these upcoming changes, affecting future cash flows and effective tax rates.",
      "reasoning_steps": [
        "Hop 1: LLY(page_92) \u2192 Eight-Year Payment Period: LLY elected to pay the Toll Tax over an eight-year period from 2018 through 2025, affecting future cash payments.",
        "Hop 2: Eight-Year Payment Period \u2192 2017 Tax Act: The 2017 Tax Act introduced the Toll Tax and provided the option for taxpayers to pay over eight years.",
        "Hop 3: 2017 Tax Act \u2190 LLY(page_46): LLY notes that U.S. tax changes under the 2017 Tax Act, scheduled for 2026, may increase future tax expense and affect cash tax payments."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY -[Introduces]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Eight-Year Payment Period",
        "node_3": "2017 Tax Act",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "ACCOUNTING_POLICY",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tDecember\t2017,\tthe\tTax\tCuts\tand\tJob\tAct\t(2017\tTax\tAct)\twas\tsigned\tinto\tlaw.\tThe\t2017\tTax\tAct\tincluded\tsignificant\tchanges to\tthe\tU.S.\tcorporate\tincome\ttax\tsystem,\tincluding\ta\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\ton unremitted\tforeign\tearnings.\tThe\t2017\tTax\tAct\tprovided\tan\telection\tto\ttaxpayers\tsubject\tto\tthe\tToll\tTax\tto\tmake\tpayments\tover an\teight-year\tperiod\tbeginning\tin\t2018\tthrough\t2025.\tHaving\tmade\tthis\telection,\tour\tfuture\tcash\tpayments\trelating\tto\tthe\tToll Tax\tas\tof\tDecember\t31,\t2023\tare\tas\tfollows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Eight-Year_Payment_Period",
          "name": "Eight-Year Payment Period",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tDecember\t2017,\tthe\tTax\tCuts\tand\tJob\tAct\t(2017\tTax\tAct)\twas\tsigned\tinto\tlaw.\tThe\t2017\tTax\tAct\tincluded\tsignificant\tchanges to\tthe\tU.S.\tcorporate\tincome\ttax\tsystem,\tincluding\ta\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\ton unremitted\tforeign\tearnings.\tThe\t2017\tTax\tAct\tprovided\tan\telection\tto\ttaxpayers\tsubject\tto\tthe\tToll\tTax\tto\tmake\tpayments\tover an\teight-year\tperiod\tbeginning\tin\t2018\tthrough\t2025.\tHaving\tmade\tthis\telection,\tour\tfuture\tcash\tpayments\trelating\tto\tthe\tToll Tax\tas\tof\tDecember\t31,\t2023\tare\tas\tfollows:\n\n",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "2017_Tax_Act",
          "name": "2017 Tax Act",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_46",
          "chunk_id": "chunk_1",
          "chunk_text": "In\tresponse\tto\tthe\tOECD/G20\tInclusive\tFramework\ton\tBase\tErosion\tand\tProfit\tShifting\t(Framework),\twhich\tset\tforth\ta\ttwo-pillar solution\tto\treform\tthe\tinternational\ttax\tframework,\tand\tthe\tEU's\tadoption\tof\tDirective\t2022/2523\t(known\tas\t\"Pillar\tTwo\") (Directive)\twithin\tthe\tEU\tto\timplement\tthe\tFramework,\tmultiple\tcountries,\tboth\twithin\tand\toutside\tof\tthe\tEU,\thave\tenacted legislation\tthat\tprovides\tfor\ta\tminimum\tlevel\tof\ttaxation\tof\tmultinational\tcompanies.\tThe\tDirective\trequired\tEU\tmember\tstates to\tenact\tlegislation\teffective\tfor\tyears\tbeginning\ton\tor\tafter\tDecember\t31,\t2023.\tFor\tcertain\tprovisions\twithin\tthe Framework,\tthe\tOECD\tpublished\tguidance\tduring\t2023\tthat\textends\tthe\teffective\tdates\tfor\tenactment.\tWhile\twe\texpect\tan increase\tin\tfuture\tyears'\ttax\texpense\tas\ta\tresult\tof\tthe\tglobal\tminimum\ttax,\twe\tdo\tnot\tanticipate\ta\tmaterial\timpact\tto\tour 2024\tconsolidated\tresults\tof\toperations.\tOur\tassessment\tof\tthe\timpact\tfor\t2024\tand\tsubsequent\tyears\tcould\tbe\taffected\tby legislative\tguidance,\tfuture\tenactment\tof\tadditional\tprovisions\twithin\tthe\tPillar\tTwo\tframework,\tand\tU.S.\ttax\tchanges scheduled\tto\toccur\tin\t2026\tas\tpart\tof\tthe\tTax\tCuts\tand\tJobs\tAct\t(2017\tTax\tAct).\n\nA\tbipartisan\ttax\tbill,\tthe\tTax\tRelief\tfor\tAmerican\tFamilies\tand\tWorkers\tAct,\twas\tpassed\tby\tthe\tU.S.\tHouse\tof\tRepresentatives in\tJanuary\t2024.\tThe\tbill\tcontains\tcertain\tbusiness\ttax\tprovisions\tincluding\tthe\tretroactive\trepeal\tfor\t2022\tand\t2023\tand deferral\tof\tthe\trequirement\tto\tcapitalize\tU.S.\tresearch\tand\tdevelopment\texpenses\tfor\ttax\tpurposes\tthat\twas\ta\tprovision enacted\tin\tthe\t2017\tTax\tAct.\tUncertainty\texists\tas\tto\twhether\tthe\tbill\twill\tbe\tenacted\tinto\tlaw;\thowever,\tif\tthe\tbill\tis enacted\tas\tcurrently\tdrafted,\twe\twould\texpect\tour\teffective\ttax\trate\tfor\t2024\tto\tbe\tmoderately\thigher,\tand\ta\tnet\tdiscrete\ttax detriment\tin\tthe\tquarter\tof\tenactment\trelated\tto\t2022\tand\t2023.\tIn\taddition,\twe\twould\texpect\ta\tdecrease\tin\tcash\ttax\tpayments.\n\n## Acquisitions\n\nWe\tinvest\tin\texternal\tresearch\tand\ttechnologies\tthat\twe\tbelieve\tcomplement\tand\tstrengthen\tour\town\tefforts.\tThese\tinvestments can\ttake\tmany\tforms,\tincluding\tacquisitions,\tcollaborations,\tinvestments,\tand\tlicensing\tarrangements.\tWe\tview\tour\tbusiness development\tactivity\tas\ta\tway\tto\tenhance\tor\trefine\tour\tpipeline\tand\tstrengthen\tour\tbusiness.\n\nFor\tinvestments\tthat\twere\taccounted\tfor\tas\tasset\tacquisitions,\twe\tpaid\t$3.94\tbillion\tin\t2023\tfor\tacquired\tIPR&amp;D\tprimarily related\tto\tacquisitions\tof\tDICE,\tVersanis,\tEmergence\tTherapeutics\tAG\t(Emergence),\tand\tMablink\tBiosciences\tSAS\t(Mablink).\tFor investments\tthat\twere\taccounted\tfor\tas\tbusiness\tcombinations,\twe\tpaid\t$1.04\tbillion\tin\t2023\tprimarily\trelated\tto\tthe acquisition\tof\tPOINT\tBiopharma\tGlobal\tInc.\t(POINT).\n\nSee\tNote\t3\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tfurther\tdiscussion\tregarding\tour\trecent\tacquisitions.\n\nFor\tdiscussion\tof\trisks\trelated\tto\tbusiness\tdevelopment\tactivities,\tsee\tItem\t1A,\t\"Risk\tFactors-Pharmaceutical\tresearch\tand development\tis\tvery\tcostly\tand\thighly\tuncertain;\twe\tmay\tnot\tsucceed\tin\tdeveloping,\tlicensing,\tor\tacquiring\tcommercially successful\tproducts\tsufficient\tin\tnumber\tor\tvalue\tto\treplace\trevenues\tof\tproducts\tthat\thave\tlost\tor\twill\tlose\tintellectual property\tprotection\tor\tare\tdisplaced\tby\tcompeting\tproducts\tor\ttherapies.\"\n\n## Foreign\tCurrency\tExchange\tRates\n\nAs\ta\tglobal\tcompany,\twe\tface\tforeign\tcurrency\trisk\texposure\tfrom\tfluctuating\tcurrency\texchange\trates,\tprimarily\tthe\tU.S. dollar\tagainst\tthe\teuro,\tJapanese\tyen,\tand\tChinese\tyuan.\tWhile\twe\tseek\tto\tmanage\ta\tportion\tof\tthese\texposures\tthrough\thedging and\tother\trisk\tmanagement\ttechniques,\tsignificant\tfluctuations\tin\tcurrency\trates\tcan\thave\ta\tmaterial\timpact,\teither\tpositive or\tnegative,\ton\tour\tconsolidated\tresults\tof\toperations\tin\tany\tgiven\tperiod.\tThere\tis\tuncertainty\tin\tthe\tfuture\tmovements\tin foreign\tcurrency\texchange\trates,\tand\tfluctuations\tin\tthese\trates\tcould\tadversely\timpact\tour\tconsolidated\tresults\tof operations\tand\tcash\tflows.\n\n## Other\tFactors\n\nOther\tfactors\thave\thad,\tand\tmay\tcontinue\tto\thave,\tan\timpact\ton\tour\tconsolidated\tresults\tof\toperations.\tThese\tfactors\tinclude cost\tand\twage\tinflation,\tavailability\tof\tadequate\tcapacity\tin\tglobal\ttransportation,\tsupply\tchain\tand\tlabor\tmarket complexities,\tinternational\ttension\tand\tconflicts,\tuneven\teconomic\tgrowth\tor\tdownturns\tor\tuncertainty,\tand\tan\tincrease\tin overall\tdemand\tin\tour\tindustry\tfor\tcertain\tproducts\tand\tmaterials.\n\nSee\tItem\t1A,\t\"Risk\tFactors\"\tfor\tadditional\tinformation\ton\trisk\tfactors\tthat\tcould\timpact\tour\tbusiness\tand\toperations.",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 138,
      "question": "How does Merck's $4.0 billion upfront investment in Daiichi Sankyo's DXd ADC candidates align with its strategic business development focus on oncology pipeline expansion as highlighted in the 2023 annual results?",
      "answer": "Merck's $4.0 billion upfront investment in Daiichi Sankyo's DXd ADC candidates (patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan) reflects a significant commitment to expanding its oncology pipeline through external innovation. This strategic move aligns with Merck's stated focus in its 2023 annual results on augmenting its internal pipeline with compelling external science, particularly in oncology. The agreement grants Merck global rights (excluding Japan) to develop and commercialize these potentially first-in-class ADCs for multiple solid tumors. The investment underscores Merck\u2019s prioritization of oncology, a key growth driver in 2023, alongside other business development activities such as the acquisitions of Prometheus Biosciences and Imago BioSciences.",
      "reasoning_steps": [
        "Hop 1: MRK(page_90) \u2192 DXd ADC Candidates: Merck made a $4.0 billion upfront investment in Daiichi Sankyo's DXd ADC candidates, with potential additional payments of up to $5.5 billion per ADC upon sales milestones.",
        "Hop 2: DXd ADC Candidates \u2192 Daiichi Sankyo: Daiichi Sankyo retains manufacturing and supply responsibility for the DXd ADCs, while Merck shares development and commercialization rights globally (excluding Japan).",
        "Hop 3: Daiichi Sankyo \u2190 MRK(page_47): Merck highlighted its strategic business development focus in 2023, including the Daiichi Sankyo ADC partnership as a key transaction to bolster its oncology pipeline."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> PRODUCT -[Supplies]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "DXd ADC Candidates",
        "node_3": "Daiichi Sankyo",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\nExpenses\tin\t2022\tinclude\tthe\t$250\tmillion\toption\tpayment\tnoted\tabove. (1)\n\n## Daiichi\tSankyo\n\nIn\tOctober\t2023,\tMerck\tand\tDaiichi\tSankyo\tentered\tinto\ta\tglobal\tdevelopment\tand\tcommercialization\tagreement\tfor\tthree\tof\tDaiichi Sankyo's\t DXd\t ADC\t candidates:\t patritumab\t deruxtecan\t (HER3-DXd)\t (MK-1022),\t ifinatamab\t deruxtecan\t (I-DXd)\t (MK-2400)\t and\t raludotatug deruxtecan\t (R-DXd)\t (MK-5909).\t All\t three\t potentially\t first-in-class\t DXd\t ADCs\t are\t in\t various\t stages\t of\t clinical\t development\t for\t the treatment\tof\tmultiple\tsolid\ttumors\tboth\tas\tmonotherapy\tand/or\tin\tcombination\twith\tother\ttreatments.\tThe\tcompanies\twill\tjointly\tdevelop and\t potentially\t commercialize\t these\t ADC\t candidates\t worldwide,\t except\t in\t Japan\t where\t Daiichi\t Sankyo\t will\t maintain\t exclusive\t rights. Daiichi\tSankyo\twill\tbe\tsolely\tresponsible\tfor\tmanufacturing\tand\tsupply.\n\nUnder\t the\t terms\t of\t the\t agreement,\t Merck\t made\t payments\t to\t Daiichi\t Sankyo\t totaling\t $4.0\t billion.\t These\t payments\t included $1.0\tbillion\t($500\tmillion\teach\tfor\tpatritumab\tderuxtecan\tand\tifinatamab\tderuxtecan)\twhich\tmay\tbe\trefundable\ton\ta\tpro-rated\tbasis\tin\tthe event\tof\tearly\ttermination\tof\tdevelopment\twith\trespect\tto\teither\tprogram.\tIn\taddition,\tthe\tagreement\tprovides\tfor\ta\tcontinuation\tpayment of\t$750\tmillion\trelated\tto\tpatritumab\tderuxtecan\tdue\tfrom\tMerck\tin\tOctober\t2024\tand\ta\tcontinuation\tpayment\tof\t$750\tmillion\trelated\tto raludotatug\tderuxtecan\tdue\tfrom\tMerck\tin\tOctober\t2025.\tIf\tMerck\tdoes\tnot\tmake\tthe\tcontinuation\tpayments\ton\tthe\tdates\tnoted\tfor\teither patritumab\t deruxtecan\t or\t raludotatug\t deruxtecan,\t the\t rights\t for\t the\t applicable\t program\t will\t revert\t to\t Daiichi\t Sankyo\t and\t the\t nonrefundable\tupfront\tpayments\talready\tpaid\twill\tbe\tretained\tby\tDaiichi\tSankyo.\tThe\tagreement\talso\tprovides\tfor\tcontingent\tpayments\tfrom Merck\tto\tDaiichi\tSankyo\tof\tup\tto\tan\tadditional\t$5.5\tbillion\tfor\teach\tDXd\tADC\tupon\tthe\tsuccessful\tachievement\tof\tcertain\tsales-based milestones.\n\nFollowing\tregulatory\tapproval,\tDaiichi\tSankyo\twill\tgenerally\trecord\tsales\tworldwide\t(Daiichi\tSankyo\twill\tbe\tthe\tprincipal\ton sales\ttransactions)\tand\tthe\tcompanies\twill\tequally\tshare\texpenses\tas\twell\tas\tprofits\tworldwide\texcept\tfor\tJapan\twhere\tDaiichi\tSankyo retains\texclusive\trights\tand\tMerck\twill\treceive\ta\t5%\tsales-based\troyalty.\tMerck\twill\trecord\tits\tshare\tof\tproduct\tsales,\tnet\tof\tcost\tof sales\t and\t commercialization\t costs,\t as\t alliance\t revenue.\t For\t raludotatug\t deruxtecan,\t Merck\t will\t be\t responsible\t for\t 75%\t of\t the\t first $2.0\tbillion\tof\tresearch\tand\tdevelopment\texpenses\tand\t50%\tof\texcess\tallowable\tresearch\tand\tdevelopment\texpenses;\tthe\tcompanies\twill share\tequally\tall",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "DXd_ADC_Candidates",
          "name": "DXd ADC Candidates",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\nExpenses\tin\t2022\tinclude\tthe\t$250\tmillion\toption\tpayment\tnoted\tabove. (1)\n\n## Daiichi\tSankyo\n\nIn\tOctober\t2023,\tMerck\tand\tDaiichi\tSankyo\tentered\tinto\ta\tglobal\tdevelopment\tand\tcommercialization\tagreement\tfor\tthree\tof\tDaiichi Sankyo's\t DXd\t ADC\t candidates:\t patritumab\t deruxtecan\t (HER3-DXd)\t (MK-1022),\t ifinatamab\t deruxtecan\t (I-DXd)\t (MK-2400)\t and\t raludotatug deruxtecan\t (R-DXd)\t (MK-5909).\t All\t three\t potentially\t first-in-class\t DXd\t ADCs\t are\t in\t various\t stages\t of\t clinical\t development\t for\t the treatment\tof\tmultiple\tsolid\ttumors\tboth\tas\tmonotherapy\tand/or\tin\tcombination\twith\tother\ttreatments.\tThe\tcompanies\twill\tjointly\tdevelop and\t potentially\t commercialize\t these\t ADC\t candidates\t worldwide,\t except\t in\t Japan\t where\t Daiichi\t Sankyo\t will\t maintain\t exclusive\t rights. Daiichi\tSankyo\twill\tbe\tsolely\tresponsible\tfor\tmanufacturing\tand\tsupply.\n\nUnder\t the\t terms\t of\t the\t agreement,\t Merck\t made\t payments\t to\t Daiichi\t Sankyo\t totaling\t $4.0\t billion.\t These\t payments\t included $1.0\tbillion\t($500\tmillion\teach\tfor\tpatritumab\tderuxtecan\tand\tifinatamab\tderuxtecan)\twhich\tmay\tbe\trefundable\ton\ta\tpro-rated\tbasis\tin\tthe event\tof\tearly\ttermination\tof\tdevelopment\twith\trespect\tto\teither\tprogram.\tIn\taddition,\tthe\tagreement\tprovides\tfor\ta\tcontinuation\tpayment of\t$750\tmillion\trelated\tto\tpatritumab\tderuxtecan\tdue\tfrom\tMerck\tin\tOctober\t2024\tand\ta\tcontinuation\tpayment\tof\t$750\tmillion\trelated\tto raludotatug\tderuxtecan\tdue\tfrom\tMerck\tin\tOctober\t2025.\tIf\tMerck\tdoes\tnot\tmake\tthe\tcontinuation\tpayments\ton\tthe\tdates\tnoted\tfor\teither patritumab\t deruxtecan\t or\t raludotatug\t deruxtecan,\t the\t rights\t for\t the\t applicable\t program\t will\t revert\t to\t Daiichi\t Sankyo\t and\t the\t nonrefundable\tupfront\tpayments\talready\tpaid\twill\tbe\tretained\tby\tDaiichi\tSankyo.\tThe\tagreement\talso\tprovides\tfor\tcontingent\tpayments\tfrom Merck\tto\tDaiichi\tSankyo\tof\tup\tto\tan\tadditional\t$5.5\tbillion\tfor\teach\tDXd\tADC\tupon\tthe\tsuccessful\tachievement\tof\tcertain\tsales-based milestones.\n\nFollowing\tregulatory\tapproval,\tDaiichi\tSankyo\twill\tgenerally\trecord\tsales\tworldwide\t(Daiichi\tSankyo\twill\tbe\tthe\tprincipal\ton sales\ttransactions)\tand\tthe\tcompanies\twill\tequally\tshare\texpenses\tas\twell\tas\tprofits\tworldwide\texcept\tfor\tJapan\twhere\tDaiichi\tSankyo retains\texclusive\trights\tand\tMerck\twill\treceive\ta\t5%\tsales-based\troyalty.\tMerck\twill\trecord\tits\tshare\tof\tproduct\tsales,\tnet\tof\tcost\tof sales\t and\t commercialization\t costs,\t as\t alliance\t revenue.\t For\t raludotatug\t deruxtecan,\t Merck\t will\t be\t responsible\t for\t 75%\t of\t the\t first $2.0\tbillion\tof\tresearch\tand\tdevelopment\texpenses\tand\t50%\tof\texcess\tallowable\tresearch\tand\tdevelopment\texpenses;\tthe\tcompanies\twill share\tequally\tall",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "Daiichi_Sankyo",
          "name": "Daiichi Sankyo",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nleading\tedge\tscience,\tand\tadvanced\tits\tbroad\tpipeline\twhich\tincludes\tgrowing\tdiversity\tacross\tnew\ttherapeutic\tareas\tand\tmodalities. Additionally,\t Merck\t completed\t several\t strategic\t business\t development\t transactions\t and\t returned\t capital\t to\t shareholders,\t primarily through\tdividends.\n\nWorldwide\tsales\twere\t$60.1\tbillion\tin\t2023,\tan\tincrease\tof\t1%\tcompared\twith\t2022,\tor\t4%\texcluding\tthe\tunfavorable\teffect\tof foreign\texchange.\tThe\tsales\tincrease\twas\tprimarily\tdue\tto\tgrowth\tin\toncology,\tvaccines,\thospital\tacute\tcare\tand\tanimal\thealth,\tpartially offset\tby\tdeclines\tin\tvirology\t(driven\tby\tlower\tsales\tof\tCOVID-19\tmedication Lagevrio )\tand\tdiabetes.\n\nMerck\tcontinues\tto\texecute\tstrategic\tbusiness\tdevelopment\topportunities\tto\taugment\tits\trobust\tinternal\tpipeline\twith\tcompelling external\tscience.\tHighlights\tof\t2023\tactivity\tinclude\tthe\tfollowing:\n\n- Entered\tinto\ta\tglobal\tdevelopment\tand\tcommercialization\tagreement\tfor\tthree\tof\tDaiichi\tSankyo's\tderuxtecan\t(DXd)\tantibody\tdrug conjugate\t(ADC)\tcandidates,\twhich\tare\tin\tvarious\tstages\tof\tclinical\tdevelopment\tfor\tthe\ttreatment\tof\tmultiple\tsolid\ttumors both\tas\tmonotherapy\tand/or\tin\tcombination\twith\tother\ttreatments.\n- Acquired\t Prometheus\t Biosciences,\t Inc.\t (Prometheus),\t a\t clinical-stage\t biotechnology\t company\t pioneering\t a\t precision\t medicine approach\tfor\tthe\tdiscovery,\tdevelopment,\tand\tcommercialization\tof\tnovel\ttherapeutic\tand\tcompanion\tdiagnostic\tproducts\tfor\tthe treatment\tof\timmune-mediated\tdiseases\tincluding\tulcerative\tcolitis,\tCrohn's\tdisease,\tand\tother\tautoimmune\tconditions.\n- Closed\ta\tlicense\tand\tcollaboration\tagreement\texpanding\tthe\tCompany's\trelationship\twith\tKelun-Biotech\tpursuant\tto\twhich\tMerck gained\texclusive\trights\tfor\tthe\tresearch,\tdevelopment,\tmanufacture\tand\tcommercialization\tof\tup\tto\tnow\tfive\tinvestigational preclinical\tADCs\tfor\tthe\ttreatment\tof\tcancer\t(Kelun-Biotech\tretained\trights\tfor\tcertain\tlicensed\tand\toption\tADCs\tfor\tChinese mainland,\tHong\tKong\tand\tMacau).\n- Acquired\t Imago\t BioSciences,\t Inc.\t (Imago),\t a\t clinical-stage\t biopharmaceutical\t company\t developing\t new\t medicines\t for\t the treatment\tof\tmyeloproliferative\tneoplasms\tand\tother\tbone\tmarrow\tdiseases.\n\nDuring\t2023,\tthe\tCompany\treceived\tmore\tthan\t25\tregulatory\tapprovals\tin\tmajor\tmarkets,\tincluding\tnumerous\tregulatory\tapprovals within\t oncology. Keytruda received\t approval\t for\t additional\t indications\t in\t the\t U.S.\t and/or\t internationally\t as\t monotherapy\t in\t the therapeutic\t areas\t of\t non-small-cell\t lung\t cancer\t (NSCLC)\t and\t primary\t mediastinal\t large\t B-cell\t lymphoma\t (PMBCL),\t in\t combination\t with chemotherapy\tin\tthe\ttherapeutic\tareas\tof\tbiliary\ttract\tcancer,\tgastric\tor\tgastroesophageal\tjunction\t(GEJ)\tadenocarcinoma\tand\tNSCLC,\tas well\t as\t in\t combination\t with\t Padcev\t (enfortunab\t vedotin-ejfv)\t for\t advanced\t urothelial\t cancer.\t Lynparza,\t which\t is\t being\t developed\t in collaboration\t with\t AstraZeneca\t PLC\t (AstraZeneca),\t received\t approvals\t in\t the\t U.S.\t in\t combination\t with\t abiraterone\t and\t prednisone\t or prednisolone\tand\tin\tJapan\tin\tcombination\twith\tabiraterone\tand\tprednisolone\t-\tboth\tfor\tthe\ttreatment\tof\tcertain\tadult\tpatients\twith BRCA -mutated\t( BRCA m)\tmetastatic\tcastration-resistant\tprostate\tcancer\t(mCRPC). Welireg was\tapproved\tfor\ta\tsupplemental\tindication\tin\tthe\tU.S. for\t the\t treatment\t of\t adult\t patients\t with\t advanced\t renal\t cell\t carcinoma\t (RCC)\t following\t a\t programmed\t death\t receptor-1\t (PD-1)\t or programmed\tdeath-ligand\t(PD-L1)\tinhibitor\tand\ta\tvascular\tendothelial\tgrowth\tfactor\ttyrosine\tkinase\tinhibitor\t(VEGF-TKI).\n\nAdditionally,\t in\t 2023, Prevymis was\t approved\t for\t a\t supplemental\t indication\t in\t both\t the\t U.S.\t and\t the\t EU\t for\t prophylaxis (prevention)\tof\tcytomegalovirus\t(CMV)\tdisease\tin\tcertain\tadult\tkidney\ttransplant\trecipients\tat\thigh\trisk.\n\nIn\t addition\t to\t the\t recent\t regulatory\t approvals\t discussed\t above,\t the\t Company\t advanced\t its\t late-stage\t pipeline\t with\t several regulatory\tsubmissions.\n\n- MK-7962,\tsotatercept,\ta\tnovel\tinvestigational\tactivin\tsignaling\tinhibitor\tis\tunder\tpriority\treview\tby\tthe\tU.S.\tFood\tand\tDrug Administration\t(FDA)\tand\tunder\treview\tby\tthe\tEuropean\tMedicines\tAgency\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tpulmonary arterial\thypertension\t(PAH).",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 139,
      "question": "How does GILD's financial dependency on Janssen's pricing decisions for Symtuza affect its revenue recognition strategy, given the structure of their revenue-sharing agreement and Janssen's exclusive global commercialization rights?",
      "answer": "GILD recognizes its share of Symtuza revenue in the period when Janssen sells the product, as the intellectual property license to Janssen is deemed the predominant item in the agreement. Janssen sets the price globally and is responsible for manufacturing, registration, and commercialization, while GILD supplies the Gilead Compounds. This revenue-sharing model, where GILD\u2019s revenue is directly influenced by Janssen\u2019s pricing and sales performance, creates a dependency that could impact GILD's financial predictability and requires close alignment with Janssen\u2019s market strategy. The structure also allows for potential termination by Janssen on a country-by-country basis, which could further affect GILD\u2019s revenue stream if GILD chooses to assume commercialization responsibilities in those markets.",
      "reasoning_steps": [
        "Hop 1: GILD(page_77) \u2192 Janssen: GILD recognizes Symtuza revenue based on Janssen's sales and the license is the predominant item in the agreement.",
        "Hop 2: Janssen \u2192 Symtuza: Janssen holds exclusive global commercialization rights and sets the price for Symtuza, while GILD supplies the Gilead Compounds.",
        "Hop 3: Symtuza \u2190 GILD(page_76): GILD's revenue recognition is tied to Janssen's sales performance and pricing decisions, with potential impacts from termination rights and market dynamics."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Distributes]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Symtuza",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 140,
      "question": "How does Merck's regulatory strategy for Welireg, particularly the August 2021 FDA approval, align with the financial incentives tied to its commercialization, including the $50 million milestone payment triggered by its first commercial sale in 2021?",
      "answer": "Merck's regulatory strategy for Welireg, as outlined in the research and development section, emphasizes a structured clinical development process culminating in FDA approval, which is a critical step for commercialization. This process directly enabled the FDA's August 2021 approval of Welireg as a monotherapy. Following this approval, Merck made a $50 million milestone payment to former Peloton shareholders upon the first commercial sale of Welireg in 2021. This payment was part of a broader agreement that also includes potential future payments tied to regulatory and sales milestones, illustrating how Merck's regulatory achievements are directly linked to financial obligations and incentives in its product development strategy.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_19) \u2192 [FDA Approval]: The Company's R&D section details the regulatory pathway for new drugs, including the requirement for FDA approval following clinical trials.",
        "Hop 2: [FDA Approval] \u2192 [Welireg]: Welireg received FDA approval in August 2021 as a treatment for von Hippel-Lindau disease, marking a key regulatory milestone.",
        "Hop 3: [Welireg] \u2190 [MRK](page_101): Following the FDA approval and first commercial sale in 2021, Merck triggered a $50 million milestone payment to former Peloton shareholders as part of the acquisition agreement."
      ],
      "difficulty": "hard",
      "idf_score": 5.8805329864007,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Receives]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "FDA Approval",
        "node_3": "Welireg",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nRoyalty  income  in  2021  on  patent  and  know-how  licenses  and  other  rights  amounted  to  $286  million.  Merck  also incurred royalty expenses amounting to $2.4 billion in 2021 under patent and know-how licenses it holds.\n\n## Research and Development\n\nThe Company's business is characterized by the introduction of new products or new uses for existing products through a  strong  research  and  development  program.  At  December  31,  2021,  approximately  17,500  people  were  employed  in  the Company's research  activities. The  Company  prioritizes  its  research  and  development  efforts  and  focuses  on  candidates  that  it believes represent breakthrough science that will make a difference for patients and payers.\n\nThe  Company  maintains  a  number  of  long-term  exploratory  and  fundamental  research  programs  in  biology  and chemistry as well as research programs directed toward product development. The Company's research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company's research and development resources  on  candidates  the  Company  believes  are  capable  of  providing  unambiguous,  promotable  advantages  to  patients  and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck  is  pursuing  emerging  product  opportunities  independent  of  therapeutic  area  or  modality  (small  molecule,  biologics  and vaccines) and is building its biologics capabilities. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research with a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.\n\nThe  Company's  clinical  pipeline  includes  candidates  in  multiple  disease  areas,  including  cancer,  cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, respiratory diseases, and vaccines.\n\nIn  the  development  of  human  health  products,  industry  practice  and  government  regulations  in  the  U.S.  and  most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through pre-clinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the U.S., recorded data on pre-clinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.\n\nOnce the Company's scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences pre-clinical testing with that compound. Pre-clinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable pre-clinical  data,  the  Company  will  initiate  clinical  testing  in  accordance  with  established  regulatory  requirements. The  clinical testing  begins  with  Phase  1  studies,  which  are  designed  to  assess  safety,  tolerability,  pharmacokinetics,  and  preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase 2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects  that  could  limit  the  compound's  usefulness.  In  some  situations,  the  clinical  program  incorporates  adaptive  design methodology  to  use  accumulating  data  to  decide  how  to  modify  aspects  of  the  ongoing  clinical  study  as  it  continues,  without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a twostage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase 2 trials are satisfactory, the Company commences large-scale Phase 3 trials to confirm the compound's efficacy and safety. Another  type  of  adaptive  clinical  trial  is  an  adaptive  Phase  2/3  trial  design,  a  study  that  includes  an  interim  analysis  and  an adaptation that changes the trial from having features common in a Phase 2 study (e.g. multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate  study.  Upon  completion  of  Phase  3  trials,  if  satisfactory,  the  Company  submits  regulatory  filings  with  the  appropriate regulatory  agencies  around  the  world  to  have  the  product  candidate  approved  for  marketing.  There  can  be  no  assurance  that  a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "FDA_Approval",
          "name": "FDA Approval",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.4942386252808095
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_3",
          "chunk_text": "\n* Calculation not meaningful.\n\nNon-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see 'Non-GAAP Income and Non-GAAP EPS' below) . (1)\n\n## Executive Summary\n\nDuring 2021, Merck delivered on its strategic priorities by executing commercially to drive strong revenue and earnings growth  in  the  year,  completing  key  business  development  transactions,  accelerating  its  broad  pipeline,  and  achieving  notable regulatory milestones. Also, on June 2, 2021, Merck completed the spin-off of Organon. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company's consolidated financial statements through the date of the spin-off.\n\nWorldwide sales were $48.7 billion in 2021, an increase of 17% compared with 2020, or 16% excluding the favorable effect of foreign exchange. The sales increase was driven primarily by growth in oncology, vaccines, hospital acute care and animal health. Additionally,  revenue  in  2021  reflects  the  benefit  of  sales  of  molnupiravir,  an  investigational  oral  antiviral  COVID-19 treatment. As discussed below, COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth.\n\nMerck continues to execute scientifically  compelling  business  development  opportunities  to  augment  its  pipeline.  In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company evaluating the transforming growth factor (TGF)-beta superfamily of proteins through the development of pulmonary and hematologic therapies. In April  2021,  Merck  acquired  Pandion Therapeutics,  Inc.  (Pandion),  a  clinical-stage  biotechnology  company  developing  novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Additionally, Merck entered into a collaboration with Gilead Sciences, Inc. (Gilead) to jointly develop and commercialize long-acting treatments in HIV.\n\nIn  2021,  Merck  received  over  30  approvals  and  filed  over  20  New  Drug  Applications  (NDAs)  and  supplemental Biologics License Applications (BLAs) across the U.S., the EU, Japan and China. During 2021, the Company received numerous regulatory approvals within oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of breast, colorectal, cutaneous squamous cell, esophageal, melanoma and renal cell cancers, as  well  as  in  combination  with  chemotherapy  in  the  therapeutic  areas  of  breast,  cervical,  gastric  or  gastroesophageal  junction cancers. Keytruda was also approved in combination with Lenvima both for the treatment of certain adult patients with endometrial cancer  and  for  the  treatment  of  renal  cell  cancer.  Lenvima  is  being  developed  in  collaboration  with  Eisai  Co.,  Ltd.  (Eisai). Lynparza,  which  is  being  developed  in  collaboration  with  AstraZeneca  PLC  (AstraZeneca),  received  approval  in  China  as monotherapy for the treatment of certain adult patients with metastatic castration resistant prostate cancer. Additionally, the U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL)",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Welireg",
          "name": "Welireg",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndate, as well as Research and development expenses of $993 million in 2019 related to the transaction. Former Peloton shareholders received a $50 million milestone payment from Merck in 2021 upon first commercial sale of Peloton's lead candidate, Welireg (belzutifan),  which  was  approved as monotherapy in the U.S. in August 2021. Former Peloton shareholders are also eligible to receive  $50  million  upon  U.S.  regulatory  approval  as  a  combination  therapy,  as  well  as  up  to  $1.05  billion  of  sales-based milestones.\n\nOn April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq's debt. The transaction was accounted for as a business combination.\n\nThe estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:\n\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 141,
      "question": "How does Merck's ongoing financial involvement with Finished Pharmaceutical Products through manufacturing agreements reflect the legacy relationship with Organon, particularly in light of the $964 million receivable from Organon at year-end 2021?",
      "answer": "Merck's continued financial involvement with Finished Pharmaceutical Products, as outlined in the manufacturing and supply agreements (MSAs), reflects the legacy relationship with Organon post-spin-off. Despite Organon being spun off in June 2021, Merck still manufactures, packages, and labels certain Finished Pharmaceutical Products for Organon under multi-year MSAs. This ongoing relationship is evidenced by the $964 million receivable from Organon at December 31, 2021, indicating that Merck had provided significant services or delivered products under these agreements shortly after the spin-off. The financial entanglement persists despite the separation, showing that the spin-off did not immediately sever operational ties, and Merck remains integral to the production and distribution of Organon's Finished Pharmaceutical Products in the short to medium term.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_128) \u2192 [Organon]: Merck spun off Organon in 2021 and incurred $556 million in separation costs that year, indicating a major restructuring of their relationship.",
        "Hop 2: [Organon] \u2192 [Finished Pharmaceutical Products]: Organon relies on Merck to manufacture and supply certain Finished Pharmaceutical Products under multi-year MSAs post-spin-off.",
        "Hop 3: [Finished Pharmaceutical Products] \u2190 [MRK](page_94): Merck continues to produce and package Finished Pharmaceutical Products for Organon, with $219 million in MSA-related sales recorded in 2021, and a $964 million receivable from Organon at year-end."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Produces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Finished Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_128",
          "chunk_id": "chunk_3",
          "chunk_text": "\nActivity prior to the Organon spin-off has not been restated. (1)\n\nIn connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (2)\n\nAt December 31, 2021, there was $699 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.\n\n## 14.    Pension and Other Postretirement Benefit Plans\n\nThe  Company  has  defined  benefit  pension  plans  covering  eligible  employees  in  the  U.S.  and  in  certain  of  its international  subsidiaries.  In  addition,  the  Company  provides  medical  benefits,  principally  to  its  eligible  U.S.  retirees  and  their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.\n\n## Net Periodic Benefit Cost\n\nThe net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:\n\nPension Benefits\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Finished_Pharmaceutical_Products",
          "name": "Finished Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndistribution  is  expected  to  qualify  and  has  been  treated  as  tax  free  to  Merck  and  its  shareholders  for  U.S.  federal  income  tax purposes.  Indebtedness  of  $9.5  billion  principal  amount,  consisting  of  term  loans  and  senior  notes,  was  issued  in  2021  in connection  with  the  spin-off  and  assumed  by  Organon.  Merck  is  no  longer  the  obligor  of  any  Organon  debt  or  financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.\n\nAlso in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered  into  various  other  agreements  to  effect  the  spin-off  and  provide  a  framework  for  the  relationship  between  Merck  and Organon  after  the  spin-off,  including  a  transition  services  agreement  (TSA),  manufacturing  and  supply  agreements  (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the  spin-off.  Merck  and  Organon  also  entered  into  a  series  of  interim  operating  agreements  pursuant  to  which  in  various jurisdictions  where  Merck  held  licenses,  permits  and  other  rights  in  connection  with  marketing,  import  and/or  distribution  of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant  licenses  and  permits  are  transferred  to  Organon.  Under  such  interim  operating  agreements  and  in  accordance  with  the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture  and  supply  certain  formulated  pharmaceutical  products  for  Organon,  and  (c)  package  and  label  certain  finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.\n\nAmounts  included  in  the  consolidated  statement  of  income  for  the  above  MSAs  include  sales  of  $219  million  and related  cost  of  sales  of  $195  million  in  2021.  Amounts  included  in  the  consolidated  statement  of  income  for  the  TSAs  was immaterial in 2021. The amount due from Organon under the above agreements was $964 million at December 31, 2021 and is reflected in Other current assets . The amount due to Organon under these agreements was $400 million at December 31, 2021 and is included in A ccrued and other current liabilities .\n\nThe  results  of  the  women's  health,  biosimilars  and  established  brands  businesses  (previously  included  in  the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021,  have  been  reflected  as  discontinued  operations  in  the  Company's  consolidated  statement  of  income  as Income  from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off.  Prior  periods  have  been  recast  to  reflect  this  presentation.  As  a  result  of  the  spin-off  of  Organon,  Merck  incurred separation  costs  of  $556  million  in  2021  and  $743  million  in  2020,  which  are  also  included  in Income  from  Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests . These costs primarily relate to professional fees for separation  activities  within  finance,  tax,  legal  and  information  technology  functions,  as  well  as  investment  banking  fees. As  of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 142,
      "question": "How does the absence of defined market exclusivity dates for Orencia in BMY's exclusivity table impact the long-term financial dynamics of BMY's joint commercialization arrangement with Ono in Japan?",
      "answer": "The absence of defined market exclusivity dates for Orencia in BMY's exclusivity table (page 8) introduces uncertainty regarding the duration of market protection for the product in key territories. This uncertainty becomes significant when viewed in light of BMY's joint commercialization arrangement with Ono in Japan (page 86), where the two companies co-promote Orencia with distinct distribution responsibilities: BMY handles the intravenous formulation and Ono manages the subcutaneous formulation. Furthermore, BMY receives a 60% co-promotion fee when a sale is made to the other party's assigned customer, indicating a structured financial dependency on the continued commercial success of Orencia in Japan. Given that BMY also pays Ono a 15% royalty on Opdivo sales outside of Japan and North America, the lack of clarity around Orencia's exclusivity dates raises questions about the long-term profitability and stability of this joint arrangement, especially as generic competition could erode revenue streams without defined exclusivity protections.",
      "reasoning_steps": [
        "Hop 1: BMY(page_8) \u2192 Orencia: Orencia's market exclusivity dates are conspicuously absent in the exclusivity table, unlike other products which have defined dates.",
        "Hop 2: Orencia \u2192 Ono: BMY and Ono jointly develop and commercialize Orencia in Japan, with defined roles for each formulation and a co-promotion fee structure.",
        "Hop 3: Ono \u2190 BMY(page_86): BMY pays Ono royalties on Opdivo sales outside Japan and depends on Ono for the Japanese market, creating a complex financial interdependency."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Promotes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Orencia",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                              | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   |\n|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|\n|                                              | U.S.                                        | EU (p)                                      | Japan                                       |\n| Abecma (idecabtagene vicleucel)              | 2036                                        | 2035                                        | 2035                                        |\n| Abraxane (paclitaxel) (a)                    | ^^                                          | ^^                                          | ^^                                          |\n| Augtyro (repotrectinib) (b)                  | 2035                                        | ++                                          | ++                                          |\n| Breyanzi (lisocabtagene maraleucel) (c)      | 2033                                        | 2033                                        | 2033                                        |\n| Camzyos (mavacamten) (d)                     | 2034                                        | 2034                                        | ++                                          |\n| Eliquis (apixaban) (e)                       | 2026                                        | ^^                                          | 2026                                        |\n| Inrebic (fedratinib) (f)                     | 2031                                        | 2031                                        | ++                                          |\n| Onureg (azacitidine) (g)                     | 2027                                        | ^^                                          | ++                                          |\n| Opdivo (nivolumab)                           | 2028                                        | 2030                                        | 2031                                        |\n| Opdualag (nivolumab and relatlimab-rmbw) (h) | 2034                                        | 2033                                        | ++                                          |\n| Orencia (abatacept) (i)                      | ^^                                          | ^^                                          | ^^                                          |\n| Pomalyst/Imnovid (pomalidomide) (j)          | ^^                                          | 2024                                        | ^^                                          |\n| Reblozyl (luspatercept-aamt) (k)             | 2031                                        | 2030                                        | ++                                          |\n| Revlimid (lenalidomide) (l)                  | ^^                                          | ^^                                          | ^^                                          |\n| Sotyktu (deucravacitinib) (m)                | 2033                                        | 2033                                        | 2033                                        |\n| Sprycel (dasatinib) (n)                      | ^^                                          | ^^                                          | ^^                                          |\n| Yervoy (ipilimumab)                          | 2025                                        | 2026                                        | 2025                                        |\n| Zeposia (ozanimod) (o)                       | 2029                                        | 2034                                        | ++                                          |",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Orencia",
          "name": "Orencia",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Ono\n\nBMS\tand\tOno\tjointly\tdevelop\tand\tcommercialize Opdivo , Yervoy and\tseveral\tBMS\tinvestigational\tcompounds\tin\tJapan,\tSouth\tKorea and\tTaiwan.\tBMS\tis\tresponsible\tfor\tsupply\tof\tthe\tproducts.\tProfits,\tlosses\tand\tdevelopment\tcosts\tare\tshared\tequally\tfor\tall combination\ttherapies\tinvolving\tcompounds\tof\tboth\tparties.\tOtherwise,\tsharing\tis\t80%\tand\t20%\tfor\tactivities\tinvolving\tonly one\tof\tthe\tparty's\tcompounds.\n\nBMS\t and\t Ono\t also\t jointly\t develop\t and\t commercialize Orencia in\t Japan.\t BMS\t is\t responsible\t for\t the\t order\t fulfillment\t and distribution\tof\tthe\tintravenous\tformulation\tand\tOno\tis\tresponsible\tfor\tthe\tsubcutaneous\tformulation.\tBoth\tformulations\tare jointly\t promoted\t by\t both\t parties\t with\t assigned\t customer\t accounts\t and\t BMS\t is\t responsible\t for\t the\t product\t supply.\t A\t copromotion\tfee\tof\t60%\tis\tpaid\twhen\ta\tsale\tis\tmade\tto\tthe\tother\tparty's\tassigned\tcustomer.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\talliance\twas\tas\tfollows:\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 143,
      "question": "How does BMY's revenue from Orencia in 2023 reflect the joint commercialization and promotional responsibilities shared with Ono in Japan?",
      "answer": "BMY reported $3,601 million in revenue from Orencia in 2023, which reflects its joint commercialization agreement with Ono. Under the arrangement, BMY is responsible for product supply and order fulfillment for the intravenous formulation, while Ono handles the subcutaneous formulation. Both parties jointly promote the drug in Japan, with a co-promotion fee of 60% paid when a sale is made to the other party's assigned customer. This structure directly influences how Orencia\u2019s revenue is generated and distributed between the two companies, making the $3.6 billion figure a result of their collaborative yet segmented commercialization model.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_86) \u2192 [Ono]: BMY and Ono jointly develop and commercialize Orencia in Japan, with BMY responsible for product supply and order fulfillment for the intravenous formulation.",
        "Hop 2: [Ono] \u2192 [Orencia]: Ono is responsible for the subcutaneous formulation of Orencia and shares joint promotion responsibilities with BMY in Japan, including a 60% co-promotion fee.",
        "Hop 3: [Orencia] \u2190 [BMY](page_83): BMY reported $3,601 million in 2023 revenue from Orencia, indicating the financial outcome of the joint commercialization and promotional dynamics with Ono."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Promotes]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Ono",
        "node_3": "Orencia",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Ono\n\nBMS\tand\tOno\tjointly\tdevelop\tand\tcommercialize Opdivo , Yervoy and\tseveral\tBMS\tinvestigational\tcompounds\tin\tJapan,\tSouth\tKorea and\tTaiwan.\tBMS\tis\tresponsible\tfor\tsupply\tof\tthe\tproducts.\tProfits,\tlosses\tand\tdevelopment\tcosts\tare\tshared\tequally\tfor\tall combination\ttherapies\tinvolving\tcompounds\tof\tboth\tparties.\tOtherwise,\tsharing\tis\t80%\tand\t20%\tfor\tactivities\tinvolving\tonly one\tof\tthe\tparty's\tcompounds.\n\nBMS\t and\t Ono\t also\t jointly\t develop\t and\t commercialize Orencia in\t Japan.\t BMS\t is\t responsible\t for\t the\t order\t fulfillment\t and distribution\tof\tthe\tintravenous\tformulation\tand\tOno\tis\tresponsible\tfor\tthe\tsubcutaneous\tformulation.\tBoth\tformulations\tare jointly\t promoted\t by\t both\t parties\t with\t assigned\t customer\t accounts\t and\t BMS\t is\t responsible\t for\t the\t product\t supply.\t A\t copromotion\tfee\tof\t60%\tis\tpaid\twhen\ta\tsale\tis\tmade\tto\tthe\tother\tparty's\tassigned\tcustomer.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\talliance\twas\tas\tfollows:\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Orencia",
          "name": "Orencia",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_2",
          "chunk_text": "| Dollars in millions                              | 2023     | 2022     | 2021     |\n|--------------------------------------------------|----------|----------|----------|\n| In-Line Products                                 |          |          |          |\n| Eliquis                                          | 12,206   | $ 11,789 | $ 10,762 |\n| Opdivo                                           | 9,009    | 8,249    | 7,523    |\n| Orencia                                          | 3,601    | 3,464    | 3,306    |\n| Pomalyst/Imnovid                                 | 3,441    | 3,497    | 3,332    |\n| Yervoy                                           | 2,238    | 2,131    | 2,026    |\n| Sprycel                                          | 1,930    | 2,165    | 2,117    |\n| Mature and other brands                          | 1,895    | 2,045    | 2,234    |\n| Total In-Line Products                           | 34,320   | 33,340   | 31,300   |\n| New Product Portfolio                            |          |          |          |\n| Reblozyl                                         | 1,008    | 717      | 551      |\n| Opdualag                                         | 627      | 252      | -        |\n| Abecma                                           | 472      | 388      | 164      |\n| Zeposia                                          | 434      | 250      | 134      |\n| Breyanzi                                         | 364      | 182      | 87       |\n| Camzyos                                          | 231      | 24       | -        |\n| Sotyktu                                          | 170      | 8        | -        |\n| Onureg                                           | 168      | 124      | 73       |\n| Inrebic                                          | 110      | 85       | 74       |\n| Augtyro                                          | 1        | -        | -        |\n| Total New Product Portfolio                      | 3,585    | 2,030    | 1,083    |\n| Total In-Line Products and New Product Portfolio | 37,905   | 35,370   | 32,383   |\n| Recent LOE Products (a)                          |          |          |          |\n| Revlimid                                         | 6,097    | 9,978    | 12,821   |\n| Abraxane                                         | 1,004    | 811      | 1,181    |\n| Total Recent LOE Products                        | 7,101    | 10,789   | 14,002   |\n| Total revenues                                   | $ 45,006 | $ 46,159 | $ 46,385 |\n| United States                                    | $ 31,555 | $ 31,828 | $ 29,214 |\n| International                                    | 12,752   | 13,497   | 16,319   |\n| Other (b)                                        | 699      | 834      | 852      |\n| Total revenues                                   | $ 45,006 | $ 46,159 | $ 46,385 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 144,
      "question": "What is the implication of Abbott's ability to reuse shares from forfeited or canceled benefits under the 2009 Program for the design and flexibility of performance-based equity awards under the 2017 Program?",
      "answer": "Abbott's ability to reuse shares from forfeited or canceled benefits under the 2009 Program provides flexibility in managing the overall equity compensation pool, directly supporting the design and administration of performance-based awards under the 2017 Program. The 2009 Program allows shares that were previously subject to canceled or forfeited benefits to be reused for new awards, including performance awards, under the 2017 Program. This recycling mechanism enhances Abbott\u2019s capacity to offer ongoing incentives without requiring additional authorized shares, aligning with the broader set of benefits under the 2017 Program, which explicitly includes performance awards among its available instruments. This dynamic enables Abbott to maintain a consistent and adaptable equity compensation strategy across multiple incentive programs.",
      "reasoning_steps": [
        "Hop 1: ABT (page_84) \u2192 Performance Awards: The 2017 Incentive Stock Program includes performance awards as part of its equity compensation offerings, indicating Abbott\u2019s active use of such instruments to incentivize employees.",
        "Hop 2: Performance Awards \u2192 2009 Program: The 2009 Program also includes performance awards and specifies that shares from canceled or forfeited awards can be reused under the 2017 Program, establishing a direct link between the two programs.",
        "Hop 3: 2009 Program \u2190 ABT (page_83): The 2009 Program explicitly allows for the reuse of shares from expired or canceled benefits under the 2017 Program, creating a flexible framework for Abbott to manage its equity compensation pool over time."
      ],
      "difficulty": "hard",
      "idf_score": 6.293872272992934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Contains]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "entities": {
        "start": "ABT",
        "node_2": "Performance Awards",
        "node_3": "2009 Program",
        "end": "ABT"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "| (ii)   | Abbott Laboratories 2017 Incentive Stock Program . Benefits under the 2017 Programinclude non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non- employee directors, and foreign benefits. The shares that remain available for issuance under the 2017 Programmay be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied fromtreasury shares). If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2017 Programwithout the issuance of shares or payment                                                                                   |\n|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (iii)  | Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees . Eligible employees of participating non-U.S. affiliates of Abbott may participate in this plan.An eligible employee may authorize payroll deductions at the rate of1% to 10% of eligible compensation (in multiples of one percent) subject to a limit of US$12,500 during any purchase cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|        | Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The shares may be either authorized but unissued shares, treasury shares, or shares acquired on the open market. The purchase price is typically 85% of the lower of the fair market value of the shares on the purchase date or on the first day of that purchase cycle.As the number of shares subject to outstanding options is indeterminable, columns (a) and (b) of the above table do not include information on the Employee Stock Purchase Plan. As of December 31, 2024, an aggregate of 7,461,515 common shares were available for future issuance under the Employee Stock Purchase Plan, including shares subject to purchase during the current purchase cycle. |\n|        | In April 2017, the 2009 Employee Stock Purchase Plan for Non-U.S. Employees was amended and restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Performance_Awards",
          "name": "Performance Awards",
          "type": "FIN_INST",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Contains"
        },
        "node_3": {
          "id": "2009_Program",
          "name": "2009 Program",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 145,
      "question": "How does AbbVie's legal strategy through Allergan Sales, LLC to protect Vraylar's intellectual property relate to the drug's U.S. revenue performance in 2021?",
      "answer": "AbbVie, through its subsidiary Allergan Sales, LLC, actively pursued litigation in the U.S. District Court for the District of Delaware to enforce patent rights for Vraylar (cariprazine), seeking to block generic competition from companies like Sun Pharma and Aurobindo. This legal action reflects a strategic effort to maintain market exclusivity for Vraylar. In 2021, Vraylar generated $1.728 billion in U.S. revenue, indicating strong market performance that likely benefits from the protection of these patents. The litigation underscores AbbVie's commitment to defending a high-performing asset in its neuroscience portfolio, aligning legal and commercial strategies to sustain revenue from key products.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_136) \u2192 Allergan Sales, LLC: AbbVie's subsidiary is actively involved in litigation to enforce patent rights for Vraylar against generic competitors.",
        "Hop 2: Allergan Sales, LLC \u2192 Vraylar: The litigation centers on Vraylar, a key neuroscience product developed and marketed by Allergan Sales, LLC.",
        "Hop 3: Vraylar \u2190 ABBV(page_137): Vraylar generated $1.728 billion in U.S. revenue in 2021, reflecting its importance in AbbVie's portfolio."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Produces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Allergan Sales,LLC",
        "node_3": "Vraylar",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Allergan_Sales,LLC",
          "name": "Allergan Sales,LLC",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Vraylar",
          "name": "Vraylar",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_137",
          "chunk_id": "chunk_2",
          "chunk_text": "| years ended December 31 (in millions)   | years ended December 31 (in millions)   | 2021        | 2020        | 2019     |\n|-----------------------------------------|-----------------------------------------|-------------|-------------|----------|\n| Immunology                              |                                         |             |             |          |\n| Humira                                  | United States                           | $ 17,330    | $ 16,112    | $ 14,864 |\n|                                         | International                           | 3,364       | 3,720       | 4,305    |\n|                                         | Total                                   | $ 20,694    | $ 19,832    | $ 19,169 |\n| Skyrizi                                 | United States                           | $ 2,486     | $ 1,385     | $ 311    |\n|                                         | International                           | 453         | 205         | 44       |\n|                                         | Total                                   | $ 2,939     | $ 1,590     | $ 355    |\n| Rinvoq                                  | United States                           | $ 1,271     | $ 653       | $ 47     |\n|                                         | International                           | 380         | 78          | -        |\n|                                         | Total                                   | $ 1,651     | $ 731       | $ 47     |\n| Hematologic Oncology                    |                                         |             |             |          |\n| Imbruvica                               | United States                           | $ 4,321     | $ 4,305     | $ 3,830  |\n|                                         | Collaboration revenues                  | 1,087       | 1,009       | 844      |\n|                                         | Total                                   | $ 5,408     | $ 5,314     | $ 4,674  |\n| Venclexta                               | United States                           | $ 934       | $ 804       | $ 521    |\n|                                         | International                           | 886         | 533         | 271      |\n|                                         | Total                                   | $ 1,820     | $ 1,337     | $ 792    |\n| Aesthetics                              |                                         |             |             |          |\n| Botox Cosmetic (a)                      | United States                           | $ 1,424     | $ 687       | $ -      |\n|                                         | International                           | 808         | 425         | -        |\n|                                         | Total                                   | $ 2,232     | $ 1,112     | $ -      |\n| Juvederm Collection (a)                 | United States                           | $ 658       | $ 318       | $ -      |\n|                                         | International                           | 877         | 400         | -        |\n|                                         | Total                                   | $ 1,535     | $ 718       | $ -      |\n| Other Aesthetics (a)                    | United States                           | $ 1,268     | $ 666       | $ -      |\n|                                         | International                           | 198         | 94          | -        |\n|                                         | Total                                   | $ 1,466     | $ 760       | $ -      |\n| Neuroscience                            |                                         |             |             |          |\n| Botox Therapeutic (a)                   | United States                           | $ 2,012     | $ 1,155     | $ -      |\n|                                         | International                           | 439         | 232         | -        |\n|                                         | Total                                   | $ 2,451     | $ 1,387     | $ -      |\n| Vraylar (a)                             | United States                           | $ 1,728     | $ 951       | $ -      |\n| Duodopa                                 | United States                           | $ 102       | $ 103       | $ 97     |\n|                                         | International                           | $           | 494         |          |\n| Ubrelvy (a)                             | Total                                   | 511         | $           | $ 461    |\n| Other Neuroscience (a)                  | United States United States             | $ 552 $ 667 | $ 125 $ 528 | $ - $ -  |\n|                                         | International                           | 18          | 11          | -        |\n|                                         | Total                                   | $ 685       | $ 539       | $ -      |",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 146,
      "question": "How does the arbitration outcome with Genmab A/S over Darzalex FASPRO impact JNJ's amortization strategy for intangible assets tied to co-developed products, especially considering the milestone-based capitalization policy described in the financial statements?",
      "answer": "The arbitration panel ruled in Janssen's favor in April 2023, dismissing Genmab A/S\u2019s claims for milestones and an extended royalty term for Darzalex FASPRO, which likely avoided additional intangible asset recognition. Given that milestones are capitalized as intangible assets and amortized to cost of products sold over their useful life, as noted on page 60, this favorable outcome may have limited JNJ\u2019s future amortization expenses related to Darzalex FASPRO. In contrast, JNJ\u2019s broader portfolio includes co-developed products like XARELTO and IMBRUVICA, where milestone payments may have been capitalized and amortized under the same policy, indicating a strategic reliance on partnership-driven asset creation without long-term royalty escalation risks in this specific case.",
      "reasoning_steps": [
        "Hop 1: JNJ(page_106) \u2192 Arbitration Notice: Janssen faced an arbitration initiated by Genmab A/S in June 2022 seeking milestones and an extended royalty term for Darzalex FASPRO, but the claims were dismissed in April 2023.",
        "Hop 2: Arbitration Notice \u2192 Genmab A/S: The arbitration centered around financial obligations and intellectual property terms between Janssen and Genmab A/S related to Darzalex FASPRO.",
        "Hop 3: Genmab A/S \u2190 JNJ(page_60): JNJ disclosed that milestones from licensing arrangements, including Darzalex licensed from Genmab A/S, are capitalized as intangible assets and amortized over their useful life."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Files]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "JNJ",
        "node_2": "Arbitration Notice",
        "node_3": "Genmab A/S",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_106",
          "chunk_id": "chunk_1",
          "chunk_text": "## Innovative\tMedicine\n\nIn\tJune\t2019,\tthe\tUnited\tStates\tFederal\tTrade\tCommission\t(FTC)\tissued\ta\tCivil\tInvestigative\tDemand\tto\tthe\tCompany\tand\tJanssen\tBiotech, Inc.\t(collectively,\tJanssen)\tin\tconnection\twith\tits\tinvestigation\tof\twhether\tJanssen's\tREMICADE\tcontracting\tpractices\tviolate\tfederal antitrust\tlaws.\tThe\tCompany\thas\tproduced\tdocuments\tand\tinformation\tresponsive\tto\tthe\tCivil\tInvestigative\tDemand.\tJanssen\tis\tin\tongoing discussions\twith\tthe\tFTC\tstaff\tregarding\tits\tinquiry.\n\nIn\tFebruary\t2022,\tthe\tUnited\tStates\tFederal\tTrade\tCommission\t(FTC)\tissued\tCivil\tInvestigative\tDemands\tto\tJohnson\t&amp;\tJohnson\tand\tJanssen Biotech,\tInc.\t(collectively,\tJanssen)\tin\tconnection\twith\tits\tinvestigation\tof\twhether\tadvertising\tpractices\tfor\tREMICADE\tviolate\tfederal law.\tJanssen\thas\tproduced\tdocuments\tand\tinformation\tresponsive\tto\tthe\tCivil\tInvestigative\tDemands.\tJanssen\tis\tin\tongoing\tdiscussions with\tthe\tFTC\tstaff\tregarding\tthe\tinquiry.\n\nIn\tJune\t2022,\tGenmab\tA/S\tfiled\ta\tNotice\tfor\tArbitration\twith\tInternational\tInstitute\tfor\tConflict\tPrevention\tand\tResolution\t(CPR) against\tJanssen\tBiotech,\tInc.\tseeking\tmilestones\tand\tan\textended\troyalty\tterm\tfor\tDarzalex\tFASPRO.\tIn\tApril\t2023,\tthe\tArbitration\tPanel ruled\tin\tJanssen's\tfavor\tand\tdismissed\tGenmab's\tclaims.\tIn\tJanuary\t2024,\tGenmab's\tappeal\tof\tthis\tdismissal\twas\tdenied.\n\nIn\tOctober\t2018,\ttwo\tseparate\tputative\tclass\tactions\twere\tfiled\tagainst\tActelion\tPharmaceutical\tLtd.,\tActelion\tPharmaceuticals\tU.S., Inc.,\tand\tActelion\tClinical\tResearch,\tInc.\t(collectively\tActelion)\tin\tUnited\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tMaryland\tand United\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tColumbia.\tThe\tcomplaints\tallege\tthat\tActelion\tviolated\tstate\tand\tfederal\tantitrust\tand unfair\tcompetition\tlaws\tby\tallegedly\trefusing\tto\tsupply\tgeneric\tpharmaceutical\tmanufacturers\twith\tsamples\tof\tTRACLEER.\tTRACLEER\tis subject\tto\ta\tRisk\tEvaluation\tand\tMitigation\tStrategy\trequired\tby\tthe\tU.S.\tFood\tand\tDrug\tAdministration,\twhich\timposes\trestrictions\ton distribution\tof\tthe\tproduct.\tIn\tJanuary\t2019,\tthe\tplaintiffs\tdismissed\tthe\tDistrict\tof\tColumbia\tcase\tand\tfiled\ta\tconsolidated\tcomplaint in\tthe\tUnited\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tMaryland.\n\nIn\tDecember\t2023,\ta\tputative\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tJanssen\tBiotech\tInc.\t(collectively\t'Janssen')\tin\tthe United\tStates\tDistrict\tCourt\tfor\tthe\tEastern\tDistrict\tof\tVirginia.\tThe\tcomplaint\talleges\tthat\tJanssen\tviolated\tfederal\tand\tstate antitrust\tlaws\tand\tother\tstate\tlaws\tby\tdelaying\tbiosimilar\tcompetition\twith\tSTELARA\tthrough\tthe\tJanssen's\tenforcement\tof\tpatent\trights covering\tSTELARA.\tThe\tcomplaint\tseeks\tdamages\tand\tother\trelief.\n\nIn\tJune\t2022,\tJanssen\tPharmaceuticals,\tInc.\tfiled\ta\tDemand\tfor\tArbitration\tagainst\tEmergent\tBiosolutions\tInc.\tet\tal.\t(EBSI)\twith\tthe American\tArbitration\tAssociation,\talleging\tthat\tEBSI\tbreached\tthe\tparties'\tManufacturing\tServices\tAgreement\tfor\tthe\tCompany's\tCOVID-19 vaccine.\tIn\tJuly\t2022,\tEmergent\tfiled\tits\tanswering\tstatement\tand\tcounterclaims.\tThe\thearing\tis\tscheduled\tfor\tJuly\t2024.\n\n## 100",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Arbitration_Notice",
          "name": "Arbitration Notice",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_106",
          "chunk_id": "chunk_1",
          "chunk_text": "## Innovative\tMedicine\n\nIn\tJune\t2019,\tthe\tUnited\tStates\tFederal\tTrade\tCommission\t(FTC)\tissued\ta\tCivil\tInvestigative\tDemand\tto\tthe\tCompany\tand\tJanssen\tBiotech, Inc.\t(collectively,\tJanssen)\tin\tconnection\twith\tits\tinvestigation\tof\twhether\tJanssen's\tREMICADE\tcontracting\tpractices\tviolate\tfederal antitrust\tlaws.\tThe\tCompany\thas\tproduced\tdocuments\tand\tinformation\tresponsive\tto\tthe\tCivil\tInvestigative\tDemand.\tJanssen\tis\tin\tongoing discussions\twith\tthe\tFTC\tstaff\tregarding\tits\tinquiry.\n\nIn\tFebruary\t2022,\tthe\tUnited\tStates\tFederal\tTrade\tCommission\t(FTC)\tissued\tCivil\tInvestigative\tDemands\tto\tJohnson\t&amp;\tJohnson\tand\tJanssen Biotech,\tInc.\t(collectively,\tJanssen)\tin\tconnection\twith\tits\tinvestigation\tof\twhether\tadvertising\tpractices\tfor\tREMICADE\tviolate\tfederal law.\tJanssen\thas\tproduced\tdocuments\tand\tinformation\tresponsive\tto\tthe\tCivil\tInvestigative\tDemands.\tJanssen\tis\tin\tongoing\tdiscussions with\tthe\tFTC\tstaff\tregarding\tthe\tinquiry.\n\nIn\tJune\t2022,\tGenmab\tA/S\tfiled\ta\tNotice\tfor\tArbitration\twith\tInternational\tInstitute\tfor\tConflict\tPrevention\tand\tResolution\t(CPR) against\tJanssen\tBiotech,\tInc.\tseeking\tmilestones\tand\tan\textended\troyalty\tterm\tfor\tDarzalex\tFASPRO.\tIn\tApril\t2023,\tthe\tArbitration\tPanel ruled\tin\tJanssen's\tfavor\tand\tdismissed\tGenmab's\tclaims.\tIn\tJanuary\t2024,\tGenmab's\tappeal\tof\tthis\tdismissal\twas\tdenied.\n\nIn\tOctober\t2018,\ttwo\tseparate\tputative\tclass\tactions\twere\tfiled\tagainst\tActelion\tPharmaceutical\tLtd.,\tActelion\tPharmaceuticals\tU.S., Inc.,\tand\tActelion\tClinical\tResearch,\tInc.\t(collectively\tActelion)\tin\tUnited\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tMaryland\tand United\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tColumbia.\tThe\tcomplaints\tallege\tthat\tActelion\tviolated\tstate\tand\tfederal\tantitrust\tand unfair\tcompetition\tlaws\tby\tallegedly\trefusing\tto\tsupply\tgeneric\tpharmaceutical\tmanufacturers\twith\tsamples\tof\tTRACLEER.\tTRACLEER\tis subject\tto\ta\tRisk\tEvaluation\tand\tMitigation\tStrategy\trequired\tby\tthe\tU.S.\tFood\tand\tDrug\tAdministration,\twhich\timposes\trestrictions\ton distribution\tof\tthe\tproduct.\tIn\tJanuary\t2019,\tthe\tplaintiffs\tdismissed\tthe\tDistrict\tof\tColumbia\tcase\tand\tfiled\ta\tconsolidated\tcomplaint in\tthe\tUnited\tStates\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tMaryland.\n\nIn\tDecember\t2023,\ta\tputative\tclass\taction\tlawsuit\twas\tfiled\tagainst\tthe\tCompany\tand\tJanssen\tBiotech\tInc.\t(collectively\t'Janssen')\tin\tthe United\tStates\tDistrict\tCourt\tfor\tthe\tEastern\tDistrict\tof\tVirginia.\tThe\tcomplaint\talleges\tthat\tJanssen\tviolated\tfederal\tand\tstate antitrust\tlaws\tand\tother\tstate\tlaws\tby\tdelaying\tbiosimilar\tcompetition\twith\tSTELARA\tthrough\tthe\tJanssen's\tenforcement\tof\tpatent\trights covering\tSTELARA.\tThe\tcomplaint\tseeks\tdamages\tand\tother\trelief.\n\nIn\tJune\t2022,\tJanssen\tPharmaceuticals,\tInc.\tfiled\ta\tDemand\tfor\tArbitration\tagainst\tEmergent\tBiosolutions\tInc.\tet\tal.\t(EBSI)\twith\tthe American\tArbitration\tAssociation,\talleging\tthat\tEBSI\tbreached\tthe\tparties'\tManufacturing\tServices\tAgreement\tfor\tthe\tCompany's\tCOVID-19 vaccine.\tIn\tJuly\t2022,\tEmergent\tfiled\tits\tanswering\tstatement\tand\tcounterclaims.\tThe\thearing\tis\tscheduled\tfor\tJuly\t2024.\n\n## 100",
          "relationship": "Files"
        },
        "node_3": {
          "id": "Genmab_A/S",
          "name": "Genmab A/S",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_60",
          "chunk_id": "chunk_3",
          "chunk_text": "\n* \t\t\tMilestones\tare\tcapitalized\tas\tintangible\tassets\tand\tamortized\tto\tcost\tof\tproducts\tsold\tover\tthe\tuseful\tlife.\n\nFor\tall\tyears\tpresented,\tthere\twas\tno\tindividual\tproject\tthat\trepresented\tgreater\tthan\t5%\tof\tthe\ttotal\tannual\tconsolidated\tresearch\tand development\texpense.\n\nThe\tCompany\thas\ta\tnumber\tof\tproducts\tand\tcompounds\tdeveloped\tin\tcollaboration\twith\tstrategic\tpartners\tincluding\tXARELTO,\tco-developed with\tBayer\tHealthCare\tAG\tand\tIMBRUVICA,\tdeveloped\tin\tcollaboration\tand\tco-marketed\twith\tPharmacyclics\tLLC,\tan\tAbbVie\tcompany.\n\nSeparately,\tthe\tCompany\thas\ta\tnumber\tof\tlicensing\tarrangements\tfor\tproducts\tand\tcompounds\tincluding\tDARZALEX,\tlicensed\tfrom\tGenmab\tA/S.\n\n## Advertising\n\nCosts\tassociated\twith\tadvertising\tare\texpensed\tin\tthe\tyear\tincurred\tand\tare\tincluded\tin\tselling,\tmarketing\tand\tadministrative\texpenses. Advertising\texpenses\tworldwide,\twhich\tcomprised\ttelevision,\tradio,\tprint\tmedia\tand\tInternet\tadvertising,\twere\t$0.5\tbillion,\t$0.7\tbillion and\t$1.2\tbillion\tin\tfiscal\tyears\t2023,\t2022\tand\t2021,\trespectively.\n\n## Income\ttaxes\n\nIncome\ttaxes\tare\trecorded\tbased\ton\tamounts\trefundable\tor\tpayable\tfor\tthe\tcurrent\tyear\tand\tinclude\tthe\tresults\tof\tany\tdifference\tbetween U.S.\tGAAP\taccounting\tand\ttax\treporting,\trecorded\tas\tdeferred\ttax\tassets\tor\tliabilities.\tThe\tCompany\n\n## 54",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 147,
      "question": "How does Eli Lilly's reliance on Global Systemically Important Banks (G-SIBs) for cash management reconcile with its capital expenditure commitments and liquidity planning, given the regulatory capital requirements these institutions must meet?",
      "answer": "Eli Lilly places the majority of its cash with Global Systemically Important Banks (G-SIBs), which are subject to stringent regulatory oversight and must meet specific capital requirements to ensure financial stability. The company monitors its exposures to these institutions and does not expect any of them to fail to meet their obligations, given their investment-grade credit ratings. This risk management approach aligns with the company's broader liquidity planning, where it assesses its ability to fund capital requirements\u2014including $3.45 billion in capital expenditures for 2023\u2014through available cash, operating cash flow, and access to short- and long-term borrowings. Despite a decline in net cash from operating activities to $4.24 billion in 2023, Eli Lilly maintains confidence in its liquidity position, with $2.82 billion in cash and $3.16 billion in total investments as of year-end, supporting its strategic investments and capital outlays. This synthesis shows that the company's trust in G-SIBs is underpinned by both regulatory safeguards and its own robust liquidity planning.",
      "reasoning_steps": [
        "Hop 1: [LLY](page_78) \u2192 [G-SIBs]: Eli Lilly holds the majority of its cash with G-SIBs, which are subject to rigorous regulatory oversight and capital requirements, mitigating credit risk.",
        "Hop 2: [G-SIBs] \u2192 [Capital Requirements]: G-SIBs must meet specific capital requirements set by global regulators, which enhances their financial stability and reduces the likelihood of default.",
        "Hop 3: [Capital Requirements] \u2190 [LLY](page_50): Eli Lilly evaluates its liquidity and capital resources to ensure it can meet its capital requirements, including $3.45 billion in capital expenditures for 2023, through cash, operating cash flow, and financing."
      ],
      "difficulty": "hard",
      "idf_score": 5.657389435086491,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> FIN_INST -[Meets]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "G-SIBs",
        "node_3": "Capital Requirements",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Risk\tManagement\tand\tRelated\tFinancial\tInstruments\n\nFinancial\tinstruments\tthat\tpotentially\tsubject\tus\tto\tcredit\trisk\tconsist\tprincipally\tof\ttrade\treceivables\tand\tinterestbearing\tinvestments.\tWholesale\tdistributors\tof\tlife\tscience\tproducts\taccount\tfor\ta\tsubstantial\tportion\tof\tour\ttrade receivables;\tcollateral\tis\tgenerally\tnot\trequired.\tWe\tseek\tto\tmitigate\tthe\trisk\tassociated\twith\tthis\tconcentration\tthrough our\tongoing\tcredit-review\tprocedures\tand\tinsurance.\tThe\tmajority\tof\tour\tcash\tis\theld\tby\ta\tfew\tmajor\tfinancial\tinstitutions that\thave\tbeen\tidentified\tas\tGlobal\tSystemically\tImportant\tBanks\t(G-SIBs)\tby\tthe\tFinancial\tStability\tBoard.\tG-SIBs\tare subject\tto\trigorous\tregulatory\ttesting\tand\toversight\tand\tmust\tmeet\tcertain\tcapital\trequirements.\tWe\tmonitor\tour\texposures with\tthese\tinstitutions\tand\tdo\tnot\texpect\tany\tof\tthese\tinstitutions\tto\tfail\tto\tmeet\ttheir\tobligations.\tIn\taccordance\twith documented\tcorporate\trisk-management\tpolicies,\twe\tmonitor\tthe\tamount\tof\tcredit\texposure\tto\tany\tone\tfinancial\tinstitution\tor corporate\tissuer\tbased\ton\tcredit\trating\tof\tour\tcounterparty.\tWe\tare\texposed\tto\tcredit-related\tlosses\tin\tthe\tevent\tof nonperformance\tby\tcounterparties\tto\trisk-management\tinstruments\tbut\tdo\tnot\texpect\tsignificant\tcounterparties\tto\tfail\tto\tmeet their\tobligations\tgiven\ttheir\tinvestment\tgrade\tcredit\tratings.\n\nWe\thave\tentered\tinto\taccounts\treceivable\tfactoring\tagreements\twith\tfinancial\tinstitutions\tto\tsell\tcertain\tof\tour\tnon-U.S. accounts\treceivable.\tThese\ttransactions\tare\taccounted\tfor\tas\tsales\tand\tresult\tin\ta\treduction\tin\taccounts\treceivable\tbecause the\tagreements\ttransfer\teffective\tcontrol\tover,\tand\trisk\trelated\tto,\tthe\treceivables\tto\tthe\tbuyers.\tOur\tfactoring\tagreements do\tnot\tallow\tfor\trecourse\tin\tthe\tevent\tof\tuncollectibility,\tand\twe\tdo\tnot\tretain\tany\tinterest\tin\tthe\tunderlying\taccounts receivable\tonce\tsold.\tWe\tderecognized\t$431.9\tmillion\tand\t$422.1\tmillion\tof\taccounts\treceivable\tas\tof\tDecember\t31,\t2023\tand 2022,\trespectively,\tunder\tthese\tfactoring\tarrangements.\tThe\tcosts\tof\tfactoring\tsuch\taccounts\treceivable\twere\tnot\tmaterial\tfor the\tyears\tended\tDecember\t31,\t2023,\t2022,\tand\t2021.\n\nOur\tderivative\tactivities\tare\tinitiated\twithin\tthe\tguidelines\tof\tdocumented\tcorporate\trisk-management\tpolicies\tand\tare intended\tto\toffset\tlosses\tand\tgains\ton\tthe\tassets,\tliabilities,\tand\ttransactions\tbeing\thedged.\tManagement\treviews\tthe correlation\tand\teffectiveness\tof\tour\tderivatives\ton\ta\tquarterly\tbasis.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "G-SIBs",
          "name": "G-SIBs",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Risk\tManagement\tand\tRelated\tFinancial\tInstruments\n\nFinancial\tinstruments\tthat\tpotentially\tsubject\tus\tto\tcredit\trisk\tconsist\tprincipally\tof\ttrade\treceivables\tand\tinterestbearing\tinvestments.\tWholesale\tdistributors\tof\tlife\tscience\tproducts\taccount\tfor\ta\tsubstantial\tportion\tof\tour\ttrade receivables;\tcollateral\tis\tgenerally\tnot\trequired.\tWe\tseek\tto\tmitigate\tthe\trisk\tassociated\twith\tthis\tconcentration\tthrough our\tongoing\tcredit-review\tprocedures\tand\tinsurance.\tThe\tmajority\tof\tour\tcash\tis\theld\tby\ta\tfew\tmajor\tfinancial\tinstitutions that\thave\tbeen\tidentified\tas\tGlobal\tSystemically\tImportant\tBanks\t(G-SIBs)\tby\tthe\tFinancial\tStability\tBoard.\tG-SIBs\tare subject\tto\trigorous\tregulatory\ttesting\tand\toversight\tand\tmust\tmeet\tcertain\tcapital\trequirements.\tWe\tmonitor\tour\texposures with\tthese\tinstitutions\tand\tdo\tnot\texpect\tany\tof\tthese\tinstitutions\tto\tfail\tto\tmeet\ttheir\tobligations.\tIn\taccordance\twith documented\tcorporate\trisk-management\tpolicies,\twe\tmonitor\tthe\tamount\tof\tcredit\texposure\tto\tany\tone\tfinancial\tinstitution\tor corporate\tissuer\tbased\ton\tcredit\trating\tof\tour\tcounterparty.\tWe\tare\texposed\tto\tcredit-related\tlosses\tin\tthe\tevent\tof nonperformance\tby\tcounterparties\tto\trisk-management\tinstruments\tbut\tdo\tnot\texpect\tsignificant\tcounterparties\tto\tfail\tto\tmeet their\tobligations\tgiven\ttheir\tinvestment\tgrade\tcredit\tratings.\n\nWe\thave\tentered\tinto\taccounts\treceivable\tfactoring\tagreements\twith\tfinancial\tinstitutions\tto\tsell\tcertain\tof\tour\tnon-U.S. accounts\treceivable.\tThese\ttransactions\tare\taccounted\tfor\tas\tsales\tand\tresult\tin\ta\treduction\tin\taccounts\treceivable\tbecause the\tagreements\ttransfer\teffective\tcontrol\tover,\tand\trisk\trelated\tto,\tthe\treceivables\tto\tthe\tbuyers.\tOur\tfactoring\tagreements do\tnot\tallow\tfor\trecourse\tin\tthe\tevent\tof\tuncollectibility,\tand\twe\tdo\tnot\tretain\tany\tinterest\tin\tthe\tunderlying\taccounts receivable\tonce\tsold.\tWe\tderecognized\t$431.9\tmillion\tand\t$422.1\tmillion\tof\taccounts\treceivable\tas\tof\tDecember\t31,\t2023\tand 2022,\trespectively,\tunder\tthese\tfactoring\tarrangements.\tThe\tcosts\tof\tfactoring\tsuch\taccounts\treceivable\twere\tnot\tmaterial\tfor the\tyears\tended\tDecember\t31,\t2023,\t2022,\tand\t2021.\n\nOur\tderivative\tactivities\tare\tinitiated\twithin\tthe\tguidelines\tof\tdocumented\tcorporate\trisk-management\tpolicies\tand\tare intended\tto\toffset\tlosses\tand\tgains\ton\tthe\tassets,\tliabilities,\tand\ttransactions\tbeing\thedged.\tManagement\treviews\tthe correlation\tand\teffectiveness\tof\tour\tderivatives\ton\ta\tquarterly\tbasis.",
          "relationship": "Meets"
        },
        "node_3": {
          "id": "Capital_Requirements",
          "name": "Capital Requirements",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.04795152265239
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_1",
          "chunk_text": "## Operating\tResults-2022\n\nFor\ta\tdiscussion\tof\tour\tresults\tof\toperations\tpertaining\tto\t2022\tand\t2021\tsee\tItem\t7,\t\"Management's\tDiscussion\tand\tAnalysis of\tResults\tof\tOperations\tand\tFinancial\tCondition\"\tin\tour\tAnnual\tReport\ton\tForm\t10-K\tfor\tthe\tyear\tended\tDecember\t31,\t2022.\n\n## FINANCIAL\tCONDITION\tAND\tLIQUIDITY\n\nWe\tbelieve\tour\tavailable\tcash\tand\tcash\tequivalents,\ttogether\twith\tour\tability\tto\tgenerate\toperating\tcash\tflow\tand\tour\taccess to\tshort-term\tand\tlong-term\tborrowings,\tare\tsufficient\tto\tfund\tour\texisting\tand\tplanned\tcapital\trequirements,\twhich\tinclude:\n\n- working\tcapital\trequirements,\tincluding\trelated\tto\temployee\tpayroll\tand\tbenefits,\tclinical\ttrials,\tmanufacturing materials,\tand\ttaxes;\n- capital\texpenditures;\n- share\trepurchases\tand\tdividends;\n- repayment\tof\toutstanding\tshort-term\tand\tlong-term\tborrowings;\n- milestone\tand\troyalty\tpayments;\n- potential\tbusiness\tdevelopment\tactivities,\tincluding\tacquisitions,\tcollaborations,\tinvestments,\tand\tlicensing arrangements;\tand\n- contributions\tto\tour\tdefined\tbenefit\tpension\tand\tretiree\thealth\tbenefit\tplans.\n\nOur\tmanagement\tcontinuously\tevaluates\tour\tliquidity\tand\tcapital\tresources,\tincluding\tour\taccess\tto\texternal\tcapital,\tto ensure\twe\tcan\tadequately\tand\tefficiently\tfinance\tour\tcapital\trequirements.\tAs\tof\tDecember\t31,\t2023,\tour\tmaterial\tcash requirements\tprimarily\trelated\tto\tpurchases\tof\tgoods\tand\tservices\tto\tproduce\tour\tproducts\tand\tconduct\tour\toperations,\tcapital expenditures,\tdividends,\trepayment\tof\toutstanding\tborrowings,\tmilestone\tand\troyalty\tpayments,\tbusiness\tdevelopment activities,\tand\tthe\tremaining\tobligations\tfor\tthe\tone-time\trepatriation\ttransition\ttax\t(also\tknown\tas\tthe\t'Toll\tTax')\tfrom the\t2017\tTax\tAct,\t(see\tNotes\t11,\t4,\t3,\tand\t14\tto\tthe\tconsolidated\tfinancial\tstatements).\tWe\tanticipate\tour\tcash\trequirements related\tto\tordinary\tcourse\tpurchases\tof\tgoods\tand\tservices\twill\tbe\tconsistent\twith\tour\tpast\tlevels\trelative\tto\trevenues.\n\nCapital\texpenditures\twere\t$3.45\tbillion\tduring\t2023,\tcompared\tto\t$1.85\tbillion\tin\t2022.\tWe\tare\tmaking\tinvestments\tin\tnew facilities\tin\tIndiana,\tNorth\tCarolina,\tAlzey,\tRhineland-Palatinate,\tGermany,\tand\tLimerick,\tIreland\tto\tmanufacture\texisting and\tfuture\tproducts.\tThese\tinvestments,\tand\tother\tcapital\tinvestments\tthat\tsupport\tour\toperations,\thave\tincreased\tour\tcapital expenditures\tand\twill\tresult\tin\thigher\tcapital\texpenditures\tover\tthe\tnext\tseveral\tyears.\n\nCash\tand\tcash\tequivalents\tincreased\tto\t$2.82\tbillion\tas\tof\tDecember\t31,\t2023,\tcompared\twith\t$2.07\tbillion\tat\tDecember\t31, 2022.\tNet\tcash\tprovided\tby\toperating\tactivities\tdecreased\tto\t$4.24\tbillion\tin\t2023,\tcompared\twith\t$7.59\tbillion\tin\t2022.\tThe decrease\tin\tnet\tcash\tprovided\tby\toperating\tactivities\twas\tprimarily\tdriven\tby\tan\tincrease\tin\tcash\tpayments\tfor\tincome\ttaxes. See\tNote\t14\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tadditional\tinformation.\tRefer\tto\tthe\tconsolidated\tstatements\tof\tcash flows\tfor\tadditional\tinformation\ton\tthe\tsignificant\tsources\tand\tuses\tof\tcash\tfor\tthe\tyears\tended\tDecember\t31,\t2023\tand\t2022.\n\nIn\taddition\tto\tour\tcash\tand\tcash\tequivalents,\twe\theld\ttotal\tinvestments\tof\t$3.16\tbillion\tand\t$3.05\tbillion\tas\tof\tDecember\t31, 2023\tand\t2022,\trespectively.\tSee\tNote\t7\tto\tthe\tconsolidated\tfinancial\tstatements\tfor\tadditional\tinformation.\n\nIn\t2023,\twe\treceived\tcash\tproceeds\tof\t$1.60\tbillion\tfor\tthe\tsale\tof\tproduct\trights,\tprimarily\trelated\tto\tthe\tsales\tof\tthe rights\tfor\tthe\tolanzapine\tportfolio,\tincluding\tZyprexa,\tand\tBaqsimi.\tSee\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements\tfor additional\tinformation.\n\nFor\tinvestments\tthat\twere\taccounted\tfor\tas\tasset\tacquisitions,\twe\tpaid\t$3.94\tbillion\tin\t2023\tfor\tacquired\tIPR&amp;D\tprimarily related\tto\tacquisitions\tof\tDICE,\tVersanis,\tEmergence,\tand\tMablink.\tFor\tinvestments\tthat\twere\taccounted\tfor\tas\tbusiness combinations,\twe\tpaid\t$1.04\tbillion\tin\t2023\tprimarily\trelated\tto\tthe\tacquisition\tof\tPOINT.\tSee\tNote\t3\tto\tthe\tconsolidated financial\tstatements\tfor\tadditional\tinformation.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 148,
      "question": "How does the selection of Pomalyst under the IRA for government price negotiation in 2027 reconcile with BMY's reliance on five-year U.S. regulatory exclusivity for chemical products like Pomalyst, and what implications does this have under the IRA's broader framework of Medicare Part D pricing controls?",
      "answer": "BMY markets Pomalyst, a chemical product that is entitled to five years of U.S. regulatory exclusivity, which typically delays generic approval until after this period. However, despite this exclusivity, Pomalyst was selected in January 2025 under the IRA for government price negotiation, with pricing controls set to begin in 2027\u2014well before the potential expiration of its exclusivity period. The IRA imposes a framework that allows the federal government to negotiate prices for select high-cost Medicare Part D drugs more than nine years from initial FDA approval. This creates a tension between the traditional regulatory exclusivity protections and the new pricing pressures introduced by the IRA. The selection of Pomalyst under this framework signals that regulatory exclusivity alone may not insulate high-cost branded drugs from significant revenue erosion due to government intervention in pricing, particularly under the IRA\u2019s Part D pricing controls and the $2,000 out-of-pocket cap with manufacturer cost-sharing responsibilities.",
      "reasoning_steps": [
        "Hop 1: BMY(page_7) \u2192 Pomalyst: Pomalyst is listed among BMY\u2019s marketed chemical products that are entitled to five years of U.S. regulatory exclusivity, delaying generic approval.",
        "Hop 2: Pomalyst \u2192 IRA: Pomalyst was selected in January 2025 under the IRA for government price negotiation, with pricing controls set to begin in 2027, despite its regulatory exclusivity.",
        "Hop 3: IRA \u2190 BMY(page_134): The IRA introduces Medicare Part D pricing controls, including negotiated prices for drugs more than nine years from FDA approval, which applies to Pomalyst and accelerates revenue erosion risk."
      ],
      "difficulty": "hard",
      "idf_score": 5.912802246969486,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Pomalyst",
        "node_3": "IRA",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an ANDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator's NDA is invalid, unenforceable, or will not be infringed by the generic product. This allegation is commonly known as a Paragraph IV  certification. The innovator then must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, ANDAs including Paragraph IV  certifications are filed with respect to certain of our products. We evaluate these ANDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines can also receive several types of regulatory exclusivity. An innovative chemical pharmaceutical product is entitled to five years of regulatory exclusivity in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, a generic manufacturer may file its ANDA after the fourth year  of  the  five-year  regulatory  ex clusivity  period.  Our  marketed  chemical  products  include Eliquis,  Revlimid,  Pomalyst,  Sprycel,  Zeposia,  Camzyos,  Sotyktu , Augtyro, Krazati, and Cobenfy .\n\n## Biologic products (includes CAR-T cell therapy products)\n\nQualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative  biological  product  was  first  approved  by  the  FDA.  Our  marketed  biologic  products  include Opdivo , Opdivo  Qvantig, Orencia, Yervoy,  Reblozyl, Opdualag, Breyanzi, Abecma and Abraxane.\n\nIn the U.S., medicines (chemically synthesized or biologically derived) may also receive an additional six months of market exclusivity (added to certain patent terms and regulatory exclusivities) if certain agreed-upon pediatric studies are completed by the applicant.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market ex clusivity. First, generic companies have increasingly sought to challenge innovators' patents covering major pharmaceutical products. Second, statutory and regulatory provisions may limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory ex clusivity.\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended for up to five years to compensate for the patent term lost during the regulatory review process, provided that the extension cannot cause the patent to be in effect for more than 15 years from the date of drug approval. Such extensions are granted on a country-by-country basis. The EU provides an additional six months of exclusivity added to the extended patent term if certain pediatric studies are completed by the applicant.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized  procedure.'  This  procedure  is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA.\n\nAfter obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout  the  EU,  all  products  for  which  marketing  authorizations  have  been  filed  after  October  and  November  2005  are  subject  to  an  '8+2+1'  regulatory exclusivity regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with ex isting treatments.",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Pomalyst",
          "name": "Pomalyst",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Economic and Market Factors\n\n## Governmental Actions\n\nAs regulators continue to focus on prescription drugs, our products are facing increased pressures across the portfolio. These pressures stem from legislative and policy changes, including price controls, pharmaceutical market access, discounting, changes to tax and importation laws and other restrictions in the U.S., EU and other regions around the world. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which can negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. The IRA directs (i) the federal government to 'negotiate' prices for select high-cost Medicare Part D (beginning in 2026) and Part B (beginning in 2028) drugs that are more than nine years (for small-molecule drugs) or 13 years (for biological products) from their initial FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and  Part  D  drugs  when  prices  increase  faster  than  inflation  and  (iii)  the  formation  of  the  Part  D  Manufacturer  Program  which  replaced  the  Part  D  CG DP  and established a $2,000 cap for out-of-pocket costs for Medicare beneficiaries as of January 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is reached. In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the \"maximum fair  price\"  for  a  30-day  equivalent  supply  of Eliquis ,  which  applies  to  the  U.S.  Medicare  channel  effective  January  1,  2026.  In  January  2025,  the  HHS  selected Pomalyst as a medicine subject to \"negotiation\" for government-set prices beginning in 2027. It is possible that more of our products could be selected in future years, which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.\n\nIn  addition,  in  December  2023,  the  Biden  administration  released  a  proposed  framework  that  for  the  first  time  proposed  that  a  drug's  price  can  be  a  factor  in determining that the drug is not accessible to the public and, therefore, that the government could exercise 'march-in rights' and license it to a third party to manufacture.  We cannot predict whether the  Trump administration will finalize the draft framework or if the government will propose other drug pricing policy changes. If pursued and finalized, these policies could reduce prices and reimbursement for certain of our products and could significantly impact our business and consolidated results of operations.\n\nAt  the  state  level,  multiple  states  have  passed,  are  pursuing  or  are  considering  government  action  via  legislation  or  regulations  to  change  drug  pricing  and reimbursement (e.g., establishing prescription drug affordability boards, implementing manufacturer mandates tied to the Federal Public Health Service Act drug pricing program, etc.). Some of these state-level actions may also influence federal and other state policies and legislation. G iven the current uncertainty surrounding the adoption, timing and implementation of many of these measures, as well as pending litigation challenging such laws, we are unable to predict their full impact on our business. However, such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations. With respect to the Federal Public Health Service Act drug pricing program, certain states have enacted laws regulating manufacturer pricing obligations under the program to date. Several additional states are considering similar potential legislation or other government actions, and we expect other states may do the same in the future.\n\nAdditionally, in connection with the IRA, the following changes have been made to U.S. tax laws, including (i) a 15% minimum tax that generally applies to U.S. corporations on adjusted financial statement income beginning in 2023 and (ii) a non-deductible 1% excise tax provision on net stock repurchases after December 31, 2022. Furthermore, countries are in the process of enacting changes to their tax laws to implement the agreement by the OECD to establish a global minimum tax. See risk  factors  on  these  items  included  under  'Part  I-Item  1A.  Risk  Factors-Product,  Industry  and  Operational  Risks-Increased  pricing  pressure  and  other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins', '-We could lose market exclusivity of a product earlier than expected' and '-Changes to tax regulations could negatively impact our earnings.'",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "IRA",
          "name": "IRA",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.558777146418381
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Subject_To"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 149,
      "question": "How does the elimination of the FFS Adjuster in the RADV Audit Rule impact the financial outlook for CVS's Medicare Advantage Plans, especially given the elevated utilization trends noted in the Outlook section?",
      "answer": "The elimination of the FFS Adjuster in the RADV Audit Rule increases the potential liability for CVS's Medicare Advantage Plans during CMS audits, as the company is now subject to extrapolated payment errors without a benchmark error rate from Original Medicare. This regulatory change, combined with elevated utilization levels in Medicare Advantage programs persisting into late 2023, creates a heightened risk of retroactive adjustments and financial penalties. In the Outlook section, the company acknowledges the difficulty in predicting continued utilization trends, which compounds the uncertainty introduced by the RADV Audit Rule. This interplay between regulatory changes and operational challenges could materially affect the profitability and financial performance of CVS's Medicare Advantage business.",
      "reasoning_steps": [
        "Hop 1: CVS(page_27) \u2192 RADV Audit Rule: The final RADV Audit Rule eliminates the FFS Adjuster, increasing liability risk for Medicare Advantage payment errors through extrapolation without a benchmark.",
        "Hop 2: RADV Audit Rule \u2192 Medicare Advantage Plans: The rule impacts how risk adjustment data is audited, directly affecting reimbursement accuracy and exposing plans to potential financial penalties.",
        "Hop 3: Medicare Advantage Plans \u2190 CVS(page_81): The Outlook section notes that Medicare Advantage utilization remained elevated into late 2023, which increases the volume of claims subject to audit and heightens the financial risk under the new RADV Audit Rule."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Impacts]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "RADV Audit Rule",
        "node_3": "Medicare Advantage Plans",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2023.pdf",
          "page_id": "page_27",
          "chunk_id": "chunk_1",
          "chunk_text": "sharing\tor\tpayment\tlevels,\tand\tchanges\tto\tbenefits,\treimbursement,\teligibility\tcriteria,\tprovider\tnetwork\tadequacy requirements\t(including\trequiring\tthe\tinclusion\tof\tspecified\thigh\tcost\tproviders\tin\tthe\tCompany's\tnetworks)\tand\tprogram structure.\tIn\tsome\tstates,\tcurrent\tMedicaid\tand\tdual\teligible\tfunding\tand\tpremium\trevenue\tmay\tnot\tbe\tadequate\tfor\tthe\tCompany to\tcontinue\tprogram\tparticipation.\tThe\tCompany's\tMedicaid\tand\tdual\teligible\tcontracts\twith\tstates\t(or\tsponsors\tof\tMedicaid managed\tcare\tplans)\tare\tsubject\tto\tcancellation\tby\tthe\tstate\t(or\tthe\tsponsors\tof\tthe\tmanaged\tcare\tplans)\tafter\ta\tshort\tnotice period\twithout\tcause\t(e.g.,\twhen\ta\tstate\tdiscontinues\ta\tmanaged\tcare\tprogram)\tor\tin\tthe\tevent\tof\tinsufficient\tstate\tfunding.\n\nThe\tCompany's\tMedicaid,\tdual\teligible\tand\tdual\teligible\tspecial\tneeds\tplan\tproducts\talso\tare\theavily\tregulated\tby\tCMS\tand state\tMedicaid\tagencies,\twhich\thave\tthe\tright\tto\taudit\tthe\tCompany's\tperformance\tto\tdetermine\tcompliance\twith\tCMS\tcontracts and\tregulations.\tThe\tCompany's\tMedicaid\tproducts,\tdual\teligible\tproducts\tand\tCHIP\tcontracts\talso\tare\tsubject\tto\tcomplex federal\tand\tstate\tregulations\tand\toversight\tby\tstate\tMedicaid\tagencies\tregarding\tthe\tservices\tprovided\tto\tMedicaid\tenrollees, payment\tfor\tthose\tservices,\tnetwork\trequirements\t(including\tmandatory\tinclusion\tof\tspecified\thigh-cost\tproviders),\tand\tother aspects\tof\tthese\tprograms,\tand\tby\texternal\treview\torganizations\twhich\taudit\tMedicaid\tplans\ton\tbehalf\tof\tstate\tMedicaid agencies.\tThe\tlaws,\tregulations\tand\tcontractual\trequirements\tapplicable\tto\tthe\tCompany\tand\tother\tparticipants\tin\tMedicaid\tand dual\teligible\tprograms,\tincluding\trequirements\tthat\tthe\tCompany\tsubmit\tencounter\tdata\tto\tthe\tapplicable\tstate\tagency,\tare extensive,\tcomplex\tand\tsubject\tto\tchange.\tThe\tCompany\thas\tinvested\tsignificant\tresources\tto\tcomply\twith\tthese\tstandards,\tand its\tMedicaid\tand\tdual\teligible\tprogram\tcompliance\tefforts\twill\tcontinue\tto\trequire\tsignificant\tresources.\tCMS\tand/or\tstate Medicaid\tagencies\tmay\tfine\tthe\tCompany,\twithhold\tpayments\tto\tthe\tCompany,\tseek\tpremium\tand\tother\trefunds,\tterminate\tthe Company's\texisting\tcontracts,\telect\tnot\tto\taward\tthe\tCompany\tnew\tcontracts\tor\tnot\tto\trenew\tthe\tCompany's\texisting\tcontracts, prohibit\tthe\tCompany\tfrom\tcontinuing\tto\tmarket\tand/or\tenroll\tmembers\tin\tor\trefuse\tto\tautomatically\tassign\tmembers\tto\tone\tor more\tof\tthe\tCompany's\tMedicaid\tor\tdual\teligible\tproducts,\texclude\tthe\tCompany\tfrom\tparticipating\tin\tone\tor\tmore\tMedicaid\tor dual\teligible\tprograms\tand/or\tinstitute\tother\tsanctions\tand/or\tcivil\tmonetary\tpenalties\tagainst\tthe\tCompany\tif\tit\tfails\tto comply\twith\tCMS\tor\tstate\tregulations\tor\tcontractual\trequirements.\tCMS\thas\tproposed\trequiring\tthat\thealth\tplans\toffering certain\tdual\teligible\tprograms\tmust\talso\toffer\tMedicaid\tprograms,\twhich\tcould\timpact\tthe\tCompany's\tability\tto\tobtain\tor retain\tmembership\tin\tits\tdual\teligible\tprograms.\n\nThe\tCompany\tcannot\tpredict\twhether\tpending\tor\tfuture\tfederal\tor\tstate\tlegislation\tor\tcourt\tproceedings\twill\tchange\tvarious aspects\tof\tthe\tMedicaid\tprogram,\tnor\tcan\tit\tpredict\tthe\timpact\tthose\tchanges\twill\thave\ton\tits\tbusiness\toperations\tor operating\tresults,\tbut\tthe\teffects\tcould\tbe\tmaterially\tadverse.\n\nMedicare\tand\tMedicaid\tAudits -\tCMS\tregularly\taudits\tthe\tCompany's\tperformance\tto\tdetermine\tits\tcompliance\twith\tCMS's regulations\tand\tits\tcontracts\twith\tCMS\tand\tto\tassess\tthe\tquality\tof\tservices\tit\tprovides\tto\tMedicare\tAdvantage\tand\tPDP beneficiaries.\tFor\texample,\tCMS\tconducts\trisk\tadjustment\tdata\tvalidation\t('RADV')\taudits\tof\ta\tsubset\tof\tMedicare\tAdvantage contracts\tfor\teach\tcontract\tyear.\tSince\t2011,\tCMS\thas\tselected\tcertain\tof\tthe\tCompany's\tMedicare\tAdvantage\tcontracts\tfor various\tyears\tfor\tRADV\taudit,\tand\tthe\tnumber\tof\tRADV\taudits\tcontinues\tto\tincrease.\tThe\tOIG\talso\tis\tauditing\tthe\tCompany's risk\tadjustment\tdata\tand\tthat\tof\tother\tcompanies,\tand\tthe\tCompany\texpects\tCMS\tand\tthe\tOIG\tto\tcontinue\tauditing\trisk adjustment\tdata.\tThe\tCompany\talso\thas\treceived\tCivil\tInvestigative\tDemands\t('CIDs')\tfrom,\tand\tprovided\tdocuments\tand information\tto,\tthe\tCivil\tDivision\tof\tthe\tDOJ\tin\tconnection\twith\tinvestigations\tof\tthe\tCompany's\tidentification\tand/or submission\tof\tdiagnosis\tcodes\trelated\tto\trisk\tadjustment\tpayments,\tincluding\tpatient\tchart\treview\tprocesses,\tunder\tParts\tC and\tD\tof\tthe\tMedicare\tprogram.\n\nOn\tJanuary\t30,\t2023,\tCMS\treleased\tthe\tfinal\trule\tconcerning\tPart\tC\tcontract-level\tRisk\tAdjustment\tData\tValidation\tAudits\t(the 'RADV\tAudit\tRule').\tThe\tRADV\tAudit\tRule\teliminated\tthe\tapplication\tof\ta\tfee-for-service\tadjuster\t('FFS\tAdjuster')\tin contract-level\tRADV\taudits\tbut\tcontinued\tthe\tuse\tof\textrapolation\tin\tsuch\taudits\tof\tMedicare\tAdvantage\torganizations.\tThe\tFFS Adjuster\tthat\twas\tannounced\tin\t2012\twas\tto\tbe\tused\tby\tCMS\tto\tdetermine\ta\tpermissible\tlevel\tof\tpayment\terror.\tBy\tapplying\tthe FFS\tAdjuster,\tMedicare\tAdvantage\torganizations\twould\thave\tbeen\tliable\tfor\trepayments\tonly\tto\tthe\textent\tthat\ttheir extrapolated\tpayment\terrors\texceeded\tthe\terror\trate\tin\tOriginal\tMedicare,\twhich\tcould\thave\timpacted\tthe\textrapolated repayments\tto\twhich\tMedicare\tAdvantage\torganizations\tare\tsubject.\tUnder\tthe\tRADV\tAudit\tRule,\tCMS\tis\tnow\tconducting\tRADV audits\tof\tMedicare\tAdvantage\torganizations,\tincluding\tthe\tCompany's\tMedicare\tAdvantage\tplans,\tfor\tpayment\tyear\t2018\tand subsequent\tpayment\tyears\tusing\textrapolation\twithout\tthe\tapplication\tof\ta\tFFS\tAdjuster.\tThe\tRADV\tAudit\tRule\tmay\thave potential\tadverse\teffects,\twhich\tcould\tbe\tmaterial,\ton\tthe\tCompany's\toperating\tresults,\tfinancial\tcondition,\tand\tcash\tflows. CMS\talso\thas\tannounced\tthat\tit\twill\tnot\tconduct\tRADV\taudits\ton\tall\tcontracts;\tinstead,\tit\twill\tonly\taudit\tcontracts\tit believes\tare\tat\tthe\thighest\trisk\tfor\toverpayments\tbased\ton\tits\tstatistical\tmodeling.\tThe\tRADV\tAudit\tRule\tis\tsubject\tto ongoing\tlitigation\tand\tthe\toutcome\tand\tfuture\timpacts\tare\tuncertain.\n\nIn\taddition,\tstate\tMedicaid\tagencies\tregularly\taudit\tthe\tCompany's\tperformance\tacross\tall\tareas\tof\tits\tcontractual obligations\tto\tthe\tstate\tto\tdetermine\tcompliance\tand\tquality\tof\tservices.\tThe\tCompany\tmay\tbe\tsubject\tto,\tamong\tother penalties,\tsignificant\tfines,\tsanctions,\tcorrective\tactions,\tand\tenrollment\tfreezes\tdepending\ton\tthe\tfindings\tof\tthese\taudits and\treviews.\tThe",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "RADV_Audit_Rule",
          "name": "RADV Audit Rule",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "- risk\tscore\ttrend.\tCMS\tintends\tto\tpublish\tthe\tfinal\t2025\trate\tannouncement\tno\tlater\tthan\tApril\t1,\t2024.\tThe\tCompany\tfaces challenges\tfrom\tthe\timpact\tof\tthe\tincreasing\tcost\tof\tmedical\tcare\t(including\tprescription\tmedications),\tchanges\tto methodologies\tfor\tdetermining\tpayments\tand\tCMS\tlocal\tand\tnational\tcoverage\tdecisions\tthat\trequire\tthe\tCompany\tto\tpay\tfor services\tand\tsupplies\tthat\tare\tnot\tfactored\tinto\tthe\tCompany's\tbids.\tWe\tcannot\tpredict\thow\tthe\trates\twill\tbe\tfinalized, future\tMedicare\tfunding\tlevels,\tthe\timpact\tof\tfuture\tfederal\tbudget\tactions\tor\tensure\tthat\tsuch\tchanges\tor\tactions\twill not\thave\ta\tmaterial\tadverse\teffect\ton\tour\tMedicare\toperating\tresults.\n- The\torganic\texpansion\tof\tour\tMedicare\tAdvantage\tand\tMedicare\tPart\tD\tservice\tarea\tis\tsubject\tto\tthe\tability\tof\tCMS\tto process\tour\trequests\tfor\tservice\tarea\texpansions\tand\tour\tability\tto\tbuild\tcost\tcompetitive\tprovider\tnetworks\tin\tthe expanded\tservice\tareas\tthat\tmeet\tapplicable\tnetwork\tadequacy\trequirements.\tCMS'\tdecisions\ton\tour\trequests\tfor\tservice\tarea expansions\talso\tmay\tbe\taffected\tadversely\tby\tcompliance\tissues\tthat\tarise\teach\tyear\tin\tour\tMedicare\toperations.\n- CMS\tregularly\taudits\tour\tperformance\tto\tdetermine\tour\tcompliance\twith\tCMS's\tregulations\tand\tour\tcontracts\twith\tCMS\tand\tto assess\tthe\tquality\tof\tthe\tservices\twe\tprovide\tto\tour\tMedicare\tmembers,\tand\tstate\tregulators\tare\tincreasingly\tconducting audits\tto\tassess\tthe\tquality\tof\tservices\twe\tprovide\tto\tour\tMedicaid\tmembers.\tAs\ta\tresult\tof\tthese\taudits,\twe\tmay\tbe subject\tto\tsignificant\tor\tmaterial\tretroactive\tadjustments\tto\tand/or\twithholding\tof\tcertain\tpremiums\tand\tfees,\tfines, criminal\tliability,\tcivil\tmonetary\tpenalties,\tCMS-\tor\tstate-imposed\tsanctions\t(including\tsuspension\tor\texclusion\tfrom participation\tin\tgovernment\tprograms)\tor\tother\trestrictions\ton\tour\tMedicare,\tMedicaid\tand\tother\tbusinesses,\tincluding suspension\tor\tloss\tof\tlicensure.\n- 'Star\tratings'\tfrom\tCMS\tfor\tour\tMedicare\tAdvantage\tplans\twill\tcontinue\tto\thave\ta\tsignificant\teffect\ton\tour\tplans' operating\tresults.\tOnly\tMedicare\tAdvantage\tplans\twith\ta\tstar\trating\tof\t4\tor\thigher\t(out\tof\t5)\tare\teligible\tfor\ta\tquality bonus\tin\ttheir\tbasic\tpremium\trates.\tCMS\tcontinues\tto\tchange\tits\trating\tsystem\tto\tmake\tachieving\tand\tmaintaining\ta\tfour\tor higher\tstar\trating\tmore\tdifficult.\tIf\tour\tstar\tratings\tfall\tor\tremain\tbelow\tfour\tfor\ta\tsignificant\tportion\tof\tour\tMedicare Advantage\tmembership,\tor\tdo\tnot\tmatch\tthe\tperformance\tof\tour\tcompetitors,\tor\tthe\tstar\trating\tquality\tbonuses\tare\treduced or\teliminated,\tour\trevenues,\toperating\tresults\tand\tcash\tflows\tmay\tbe\tsignificantly\tadversely\taffected.\tIn\taddition,\tdue\tto uncertainties\twith\tCMS\tcut-points,\tno\tMedicare\tAdvantage\tplan\tcan\tguarantee\ttheir\toverall\tstar\tratings.\tThere\tcan\tbe\tno assurances\tthat\tthe\tCompany\twill\tbe\tsuccessful\tin\tmaintaining\tor\timproving\tits\tstar\tratings\tin\tfuture\tyears.\n- The\tCompany's\t2023\tstar\tratings\twere\tused\tto\tdetermine\twhich\tof\tits\tMedicare\tAdvantage\tplans\thave\tratings\tof\t4\tstars or\thigher\tand\tqualify\tfor\tbonus\tpayments\tin\t2024.\tBased\ton\tthe\t2023\tstar\tratings,\tthe\tCompany's\tMedicare\tAdvantage plans\tare\tnot\teligible\tfor\tfull\tlevel\tquality\tbonuses\tin\t2024,\twhich\tcould\treduce\tprofit\tmargin.\tCMS\treleased\tthe Company's\t2024\tstar\tratings\tin\tOctober\t2023,\twhich\twill\timpact\trevenues\tin\t2025.\tThe\tpercentage\tof\tAetna\tMedicare Advantage\tmembers\tin\t4+\tstar\tplans\tis\texpected\tto\treturn\tto\t87%\t(based\ton\tenrollment\tand\tcontract\taffiliation\tas\tof December\t31,\t2023),\tas\tcompared\tto\tthe\tunmitigated\t21%\tbased\ton\tthe\t2023\tstar\tratings.\tThe\tmain\tdriver\tof\tthis increase\twas\ta\thalf\tstar\timprovement\tin\tthe\tAetna\tNational\tPPO,\twhich\tincreased\tfrom\t3.5\tstars\tto\t4.0\tstars.\tThis means\tthat\twe\texpect\tthat\tthe\tCompany's\tMedicare\tAdvantage\tplans\twill\tagain\tbe\teligible\tfor\tfull\tlevel\tquality bonuses\tin\t2025.\n- Payments\twe\treceive\tfrom\tCMS\tfor\tour\tMedicare\tAdvantage\tand\tMedicare\tPart\tD\tbusinesses\talso\tare\tsubject\tto\trisk\tadjustment based\ton\tthe\thealth\tstatus\tof\tthe\tindividuals\twe\tenroll.\tElements\tof\tthat\trisk\tadjustment\tmechanism\tcontinue\tto\tbe challenged\tby\tthe\tDOJ,\tthe\tOIG\tand\tCMS\titself.\tFor\texample,\tCMS\tmade\tsignificant\tchanges\tto\tthe\tstructure\tof\tthe hierarchical\tcondition\tcategory\tmodel\tin\tversion\t28,\twhich\tmay\timpact\tRAF\tscores\tfor\ta\tlarger\tpercentage\tof\tMedicare Advantage\tbeneficiaries\tand\tcould\tresult\tin\tchanges\tto\tbeneficiary\tRAF\tscores\twith\tor\twithout\ta\tchange\tin\tthe\tpatient's health\tstatus.\tSubstantial\tchanges\tin\tthe\trisk\tadjustment\tmechanism,\tincluding\tthose\tthat\tresult\tfrom\tthe\tfinal\tPart\tC contract-level\tRisk\tAdjustment\tData\tValidation\tAudits\t('RADV\tAudit\tRule')\tissued\tin\tJanuary\t2023\tor\tother\tchanges\tthat\tmay result\tfrom\tenforcement\tor\taudit\tactions,\tcould\tmaterially\taffect\tthe\tamount\tof\tour\tMedicare\treimbursement,\trequire\tus\tto raise\tprices\tor\treduce\tthe\tbenefits\twe\toffer\tto\tMedicare\tbeneficiaries,\timpact\tthe\tservices\tprovided\tby,\tor\tthe\tfinancial performance\tof,\tOak\tStreet\tHealth\tand\tSignify\tHealth\tand\tpotentially\tlimit\tour\t(and\tthe\tindustry's)\tparticipation\tin\tthe Medicare\tprogram.\n- The\tRADV\tAudit\tRule\tcreates\tuncertainty\tfor\tMedicare\tAdvantage\tplans.\tThe\tlack\tof\tdetail\tprovided\twith\trespect\tto\thow\tCMS will\tselect\tcontracts\tand\tclaims\tto\taudit,\tthe\tmethodology\tCMS\twill\tuse,\tand\thow\tit\twill\textrapolate\tas\tpart\tof\tthe\tRADV Audit\tRule\tmay\timpact\tfuture\tMedicare\tAdvantage\tbids\tand\tresult\tin\tother\timplications.\tThe\tRADV\tAudit\tRule\talso\tpermits extrapolation\tof\tOIG\tcontract\tlevel\taudits\tfor\tpayment\tyears\t2018\tforward.\tThe\tRADV\tAudit\tRule\tis\tsubject\tto\tongoing litigation\tand\tthe\toutcome\tand\tfuture\timpacts\tare\tuncertain.\n- Changes\tto\tthe\tability\tof\tPBMs\tto\thave\tpharmacy\tperformance\tprograms\tin\tplace\tfor\tclients\tand\treport\tpayments\tvia\tdirect and\tindirect\treporting\tmechanisms,\tincluding\trequiring\tall\tpharmacy\tpayments\tto\tbe\tincluded\tin\tpoint-of-sale\tpricing, could\timpact\tthe\tHealth\tServices\tbusiness.\n- Medicare\tPart\tD\thas\tresulted\tin\tincreased\tutilization\tof\tprescription\tmedications\tand\tputs\tpressure\ton\tour\tpharmacy\tgross margin\trates\tdue\tto\tregulatory\tand\tcompetitive\tpressures.\tFurther,\tas\ta\tresult\tof\tthe\tACA\tand\tchanges\tto\tthe\tretiree\tdrug subsidy\trules,\tclients\tof\tour\tPBM\tbusiness\tcould\tdecide\tto\tdiscontinue\tproviding\tprescription\tdrug\tbenefits\tto\ttheir",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Medicare_Advantage_Plans",
          "name": "Medicare Advantage Plans",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2023.pdf",
          "page_id": "page_81",
          "chunk_id": "chunk_1",
          "chunk_text": "## Outlook\n\nThe\tCompany\tbelieves\tyou\tshould\tconsider\tthe\tfollowing\tkey\tbusiness\tand\tregulatory\ttrends\tand\tuncertainties:\n\n## Key\tBusiness\tTrends\tand\tUncertainties\n\n- Membership\tenrollment\tin\tMedicare\tAdvantage\tplans\texceeded\texpectations.\n- Utilization,\tparticularly\tin\tMedicare\tAdvantage\tprograms,\tpersisted\tat\televated\tlevels\tinto\tthe\tend\tof\t2023.\tAt\tthis time,\tthe\tlevel\tof\tcontinued\tutilization\tis\tdifficult\tto\taccurately\tpredict.\n- The\tCompany\texpects\tgrowth\tin\tits\tnew\tCordavis,\tOak\tStreet\tHealth\tand\tSignify\tHealth\tbusinesses.\n- Competitive\tpressures\tin\tthe\tPBM\tindustry\thave\tcaused\tthe\tCompany\tto\tcontinue\tto\tshare\twith\tclients\ta\tlarger\tportion\tof rebates,\tfees\tand/or\tdiscounts\treceived\tfrom\tpharmaceutical\tmanufacturers.\tIn\taddition,\tmarketplace\tdynamics\tand regulatory\tchanges\thave\tlimited\tthe\tCompany's\tability\tto\toffer\tplan\tsponsors\tpricing\tthat\tincludes\tretail\tnetwork 'differential'\tor\t'spread.'\tThe\tCompany\texpects\tthese\ttrends\tto\tcontinue.\n- Competitive\tpressures\tin\tthe\tretail\tpharmacy\tindustry\tare\tincreasing,\tresulting\tin\taggressive\tgeneric\tpricing\tprograms, the\tgrowth\tof\tdiscount\tcards\tand\tincreased\tutilization\tof\tdigital\tcommerce.\n- Future\tcosts\tare\tinfluenced\tby\ta\tnumber\tof\tfactors\tincluding\tcompetitive\tdemand\tfor\tproducts\tand\tservices,\tlegislative and\tregulatory\tconsiderations,\tand\tlabor\tand\tother\tmarket\tdynamics,\tincluding\tinflation.\tWe\tevaluate\tand\tadjust\tour approach\tin\teach\tof\tthe\tmarkets\twe\tserve,\tconsidering\tall\trelevant\tfactors.\n- The\tCompany\texpects\tbenefits\tfrom\tenterprise-wide\tcost\tsavings\tinitiatives\tand\tinvestments\tin\tefficiencies,\twhich\taim to\treduce\tthe\tCompany's\toperating\tcost\tstructure\tin\ta\tway\tthat\timproves\tthe\tconsumer\texperience\tand\tis\tsustainable.\n\n## Key\tRegulatory\tTrends\tand\tUncertainties\n\n- The\tCompany\tis\texposed\tto\tfunding\tand\tregulation\tof,\tand\tchanges\tin\tgovernment\tpolicy\twith\trespect\tto\tand/or\tfunding\tor regulation\tof,\tthe\tvarious\tMedicare\tprograms\tin\twhich\tthe\tCompany\tparticipates,\tincluding\tchanges\tin\tthe\tamounts payable\tto\tus\tunder\tthose\tprograms\tand/or\tnew\treforms\tor\tsurcharges\ton\texisting\tprograms,\tincluding\tchanges\tto applicable\trisk\tadjustment\tmechanisms.\n- Legislation\tand/or\tregulations\tseeking\tto\tregulate\tPBM\tactivities\tin\ta\tcomprehensive\tmanner\thave\tbeen\tproposed\tor enacted\tin\ta\tmajority\tof\tstates\tand\ton\tthe\tfederal\tlevel.\tThis\tlegislative\tand\tregulatory\tactivity\tcould\tadversely affect\tthe\tCompany's\tability\tto\tconduct\tbusiness\ton\tcommercially\treasonable\tterms\tand\tthe\tCompany's\tability\tto standardize\tits\tPBM\tproducts\tand\tservices\tacross\tstate\tlines.\n\nFor\tadditional\tinformation\tregarding\tthese\tand\tother\ttrends\tand\tuncertainties,\tsee\tItem\t1A,\t'Risk\tFactors'\tand\tPart\tI,\tItem\t1 'Business\t-\tGovernment\tRegulation.'",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 150,
      "question": "How does Merck's acquisition of Acceleron Pharma for $11.5 billion relate to the strategic value of TGF-beta superfamily proteins, given that these proteins are central to the development of therapies like sotatercept, which is being evaluated in Phase 3 trials for pulmonary arterial hypertension?",
      "answer": "Merck's acquisition of Acceleron Pharma for $11.5 billion was driven by the strategic value of the TGF-beta superfamily proteins, which are central to the development of therapies such as sotatercept (MK-7962), currently in Phase 3 trials for pulmonary arterial hypertension (PAH). Acceleron was specifically evaluating this protein family's role in regulating cell growth, differentiation, and repair, with sotatercept representing a lead candidate that could significantly improve clinical outcomes in PAH patients. The acquisition aligns with Merck\u2019s broader R&D strategy to invest in scientifically compelling platforms with near- and long-term growth potential, particularly in areas like pulmonary and hematologic diseases where TGF-beta signaling plays a pivotal role.",
      "reasoning_steps": [
        "Hop 1: MRK(page_68) \u2192 TGF-beta Superfamily Proteins: Merck acquired Acceleron, which was evaluating the TGF-beta superfamily of proteins for their role in regulating cell growth and repair, with a focus on sotatercept for PAH.",
        "Hop 2: TGF-beta Superfamily Proteins \u2192 Acceleron Pharma Inc.: Acceleron was specifically evaluating this protein family as the foundation of its therapeutic pipeline, including sotatercept and Reblozyl.",
        "Hop 3: Acceleron Pharma Inc. \u2190 MRK(page_52): Merck acquired Acceleron for $11.5 billion in 2021, recognizing its strategic value in advancing therapies targeting the TGF-beta superfamily."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Develops]-> PRODUCT -[Evaluates]-> COMP <-[Acquires]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "TGF-beta Superfamily Proteins",
        "node_3": "Acceleron Pharma Inc.",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Restructuring Costs\n\nNon-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 6 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.\n\n## Income and Losses from Investments in Equity Securities\n\nNon-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.\n\n## Certain Other Items\n\nNon-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature,  significant  to  the  results  of  a  particular  period  or  not  indicative  of  future  operating  results.  Excluded  from  non-GAAP income and non-GAAP EPS are charges for the acquisitions of Pandion, VelosBio, OncoImmune and Peloton, as well as charges related to collaborations, including transactions with Seagen (see Note 4 to the consolidated financial statements). Also excluded from non-GAAP income and non-GAAP EPS are charges related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements). Additionally, excluded from non-GAAP income and non-GAAP EPS are certain tax items, including net tax benefits related to the settlement of certain federal income tax matters, an adjustment to tax benefits recorded  in  conjunction  with  the  2015  acquisition  of  Cubist  Pharmaceuticals,  Inc.,  a  tax  benefit  related  to  the  reversal  of  tax reserves established in connection with the 2014 divestiture of MCC, and a net tax charge related to the finalization of U.S. treasury regulations related to the TCJA (see Note 16 to the consolidated financial statements).\n\n## Research and Development\n\n## Research Pipeline\n\nThe Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in latestage  clinical  development.  A  chart  reflecting  the  Company's  current  research  pipeline  as  of  February  22,  2022  and  related discussion is set forth in Item 1. 'Business -Research and Development' above.\n\n## Acquisitions, Research Collaborations and License Agreements\n\nMerck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 4 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company's strategic criteria.\n\nIn  March  2021,  Merck  and  Gilead  entered  into  an  agreement  to  jointly  develop  and  commercialize  long-acting treatments  in  HIV  that  combine  Merck's  investigational  NRTTI,  islatravir,  and  Gilead's  investigational  capsid  inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.\n\nIn April 2021, Merck acquired Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to  address  the  unmet  needs  of  patients  living  with  autoimmune  diseases,  for  total  consideration  of  $1.9  billion.  Pandion  is advancing a pipeline of precision immune modulators targeting critical immune control nodes.\n\nIn November 2021, Merck acquired Acceleron, a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron is evaluating the TGF-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron's lead therapeutic candidate,",
          "relationship": "Develops"
        },
        "node_2": {
          "id": "TGF-beta_Superfamily_Proteins",
          "name": "TGF-beta Superfamily Proteins",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_96",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nExpenses  for  curtailments,  settlements  and  termination  benefits  provided  to  certain  employees  were  incurred  in connection with the spin-off (see Note 14). Additionally, all outstanding Merck stock options, restricted stock units (RSUs) and performance share units (PSUs) (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees (see Note 13).\n\n## 4.    Acquisitions, Research Collaborations and License Agreements\n\nThe  Company  continues  to  pursue  acquisitions  and  the  establishment  of  external  alliances  such  as  research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent  upon  the  occurrence  of  certain  future  events  linked  to  the  success  of  the  asset  in  development.  The  Company  also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company's financial results.\n\n## 2021 Transactions\n\nIn November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron is evaluating the transforming growth factor (TGF)-beta superfamily of proteins that  is  known  to  play  a  central  role  in  the  regulation  of  cell  growth,  differentiation  and  repair.  Acceleron's  lead  therapeutic candidate,  sotatercept  (MK-7962),  has  a  novel  mechanism  of  action  with  the  potential  to  improve  short-term  and/or  long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard  of  care  for  the  treatment  of  PAH.  Under  a  previous  agreement  assumed  by  Merck,  Bristol  Myers  Squibb  (BMS)  was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS.\n\nIn  addition  to  sotatercept, Acceleron's  portfolio  includes Reblozyl (luspatercept),  a  first-in-class  erythroid  maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood  disorders  and  is  also  being  evaluated  in  Phase  2  and  Phase  3  trials  for  additional  indications  for  hematology  therapies. Reblozyl is  being  developed  and  commercialized  through  a  global  collaboration  with  BMS.  In  connection  with  this  ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Merck is eligible to receive future contingent milestone payments including up to $20 million in regulatory milestones and up to $80 million in sales-based milestones.\n\nThe transaction was accounted for as a business combination. The Company incurred $280 million of costs directly related  to  the  acquisition  of Acceleron,  consisting  primarily  of  share-based  compensation  payments  to  settle  non-vested  equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in Selling, general and administrative expenses and Research and development costs in 2021.",
          "relationship": "Evaluates"
        },
        "node_3": {
          "id": "Acceleron_Pharma_Inc.",
          "name": "Acceleron Pharma Inc.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_3",
          "chunk_text": "\n* Calculation not meaningful.\n\nNon-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see 'Non-GAAP Income and Non-GAAP EPS' below) . (1)\n\n## Executive Summary\n\nDuring 2021, Merck delivered on its strategic priorities by executing commercially to drive strong revenue and earnings growth  in  the  year,  completing  key  business  development  transactions,  accelerating  its  broad  pipeline,  and  achieving  notable regulatory milestones. Also, on June 2, 2021, Merck completed the spin-off of Organon. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company's consolidated financial statements through the date of the spin-off.\n\nWorldwide sales were $48.7 billion in 2021, an increase of 17% compared with 2020, or 16% excluding the favorable effect of foreign exchange. The sales increase was driven primarily by growth in oncology, vaccines, hospital acute care and animal health. Additionally,  revenue  in  2021  reflects  the  benefit  of  sales  of  molnupiravir,  an  investigational  oral  antiviral  COVID-19 treatment. As discussed below, COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth.\n\nMerck continues to execute scientifically  compelling  business  development  opportunities  to  augment  its  pipeline.  In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company evaluating the transforming growth factor (TGF)-beta superfamily of proteins through the development of pulmonary and hematologic therapies. In April  2021,  Merck  acquired  Pandion Therapeutics,  Inc.  (Pandion),  a  clinical-stage  biotechnology  company  developing  novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Additionally, Merck entered into a collaboration with Gilead Sciences, Inc. (Gilead) to jointly develop and commercialize long-acting treatments in HIV.\n\nIn  2021,  Merck  received  over  30  approvals  and  filed  over  20  New  Drug  Applications  (NDAs)  and  supplemental Biologics License Applications (BLAs) across the U.S., the EU, Japan and China. During 2021, the Company received numerous regulatory approvals within oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of breast, colorectal, cutaneous squamous cell, esophageal, melanoma and renal cell cancers, as  well  as  in  combination  with  chemotherapy  in  the  therapeutic  areas  of  breast,  cervical,  gastric  or  gastroesophageal  junction cancers. Keytruda was also approved in combination with Lenvima both for the treatment of certain adult patients with endometrial cancer  and  for  the  treatment  of  renal  cell  cancer.  Lenvima  is  being  developed  in  collaboration  with  Eisai  Co.,  Ltd.  (Eisai). Lynparza,  which  is  being  developed  in  collaboration  with  AstraZeneca  PLC  (AstraZeneca),  received  approval  in  China  as monotherapy for the treatment of certain adult patients with metastatic castration resistant prostate cancer. Additionally, the U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL)",
          "relationship": "Acquires"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 151,
      "question": "How does BMY's acquisition of Juno's CAR T cell therapy programs, which are associated with significant development risks, relate to the company's ongoing litigation over CAR T-related patents, and how might the outcome of this litigation affect BMY's financial exposure or strategic positioning in cellular therapies?",
      "answer": "BMY acquired Juno\u2019s CAR T cell therapy programs, including Breyanzi and Abecma, which are described as presenting significant development risks due to regulatory, manufacturing, and market adoption challenges. Juno was also involved in a high-stakes litigation over U.S. Patent No. 7,446,190, where a jury initially awarded $1.2 billion in royalties and damages against Kite for infringement related to its Yescarta product. However, this decision was later overturned on appeal, with the patent being ruled invalid. BMY, as the current owner of Juno's assets, is continuing to pursue legal remedies, including a potential petition to the U.S. Supreme Court. The outcome of this litigation could materially affect BMY\u2019s financial exposure and strategic positioning in the CAR T space, particularly given the company\u2019s emphasis on novel therapies and the importance of patent protection in maintaining market exclusivity and revenue potential. If the litigation fails to yield a favorable result, BMY may face increased competition and reduced revenue potential for its CAR T portfolio, despite the high development risks already acknowledged.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_38) \u2192 [Juno]: BMY acquired Juno\u2019s CAR T cell therapy programs, which are described as presenting significant development and regulatory risks.",
        "Hop 2: [Juno] \u2192 [CAR T Litigation]: Juno was a co-plaintiff in a major patent infringement lawsuit over CAR T technology, which resulted in a $1.2 billion award before being overturned on appeal.",
        "Hop 3: [CAR T Litigation] \u2190 [BMY](page_156): BMY is continuing to pursue legal remedies in the CAR T litigation, indicating strategic and financial stake in the outcome of this case."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> COMP -[Involved_In]-> LITIGATION <-[Involved_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Juno",
        "node_3": "CAR T Litigation",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "generic products, which negatively impacts the protections afforded the Company. Lower-priced generics or biosimilars for BMS biologic products or competing biologics could negatively impact our volumes and prices.\n\nIn  addition,  both  the  U.S.  Congress  and  the  U.S.  FDA  have  taken  steps  to  promote  the  development  and  approval  of generic drugs and biosimilar biologics. For example, in December 2019, the U.S. Congress enacted legislation intended to  facilitate  generic  companies'  access  to  drug  samples.  Section  610  of  the  Further  Consolidated  Appropriations  Act, 2020, provides generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from  the  reference  product' s  manufacturer  in  order  to  conduct  testing  necessary  to  obtain  approval  for  generic  or biosimilar products. This law has the potential to have an adverse impact on our business.\n\nThere is no assurance that a particular product will enjoy market exclusivity for the full time period that appears in the estimates disclosed in this 2021 Form 10-K or that we assume when we provide our financial guidance.\n\n## Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor ('CAR') T cell therapy, may present significant challenges and risks for us.\n\nThe  development  of  novel  approaches  for  the  treatment  of  diseases,  such  as  our  acquisition  in  November  2019  of Celgene's and Juno's CAR T cell therapy programs, including Breyanzi (liso-cel) and Abecma (ide-cel), presents many new challenges and risks due to the unique nature of genetic modification of patient cells ex vivo using certain viruses to reengineer  these  cells  to  ultimately  treat  diseases,  including  obtaining  regulatory  approval  from  U.S.  FDA  and  other regulatory agencies that have limited experience with the development of cellular therapies involving genetic modification of patient cells; developing and deploying consistent and reliable processes, while limiting contamination, for engineering a patient's cells ex vivo and infusing genetically modified cells back into the patient; developing processes for the safe administration of cellular therapies, including long-term follow-up for patients receiving cellular therapies; and sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process our potential CAR T products. The use of reengineered cells as a potential cancer treatment is a recent development and may not be broadly accepted by the regulatory, patient or medical communities.\n\nFurther, we may not be able to satisfactorily establish the safety and efficacy or the reliability of these therapies through health  authority  approval,  or  demonstrate  the  potential  advantages  and  side  effects  compared  to  existing  and  future therapies. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Furthermore, certain payment models could impact the financial feasibility of making CAR T cell therapies available in certain markets or by certain treatment sites, thereby limiting patient access. To date, only a few products  that  involve  the  genetic  modification  of  patient  cells  have  been  approved  for  commercial  sale.  Moreover,  the safety profiles of cellular therapies may adversely influence public perception and may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians and payers to subscribe to these novel treatment approaches. If we fail to overcome these and other challenges, or if significant adverse events are reported from similar therapies,  our  development  of  these  novel  treatment  approaches  may  be  hampered  or  delayed,  which  could  adversely affect our future anticipated revenues and/or profitability related to these therapeutic programs. In addition, we could also face  difficulties  in  manufacturing  CAR  T  cell  therapies,  which  could  adversely  affect  our  future  anticipated  revenues and/or profitability related to our CAR T cell therapies. See ' -We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.'\n\n## We face intense competition from other manufacturers and expect to see increasing market penetration of lower-priced generic products.\n\nThe future growth of BMS is dependent on the market access, uptake and expansion for marketed brands, new product introductions,  new  indications,  product  extensions  and  co-promotional  activities  with  alliance  partners.  Competition  is keen and as we lose exclusivity for some of our marketed brands lower-priced generic products will increasingly penetrate our  markets.  Generic  challenges  to  our  products  can  also  arise  at  any  time,  and  our  patents  may  not  prevent  the emergence of generic competition for our products. For example, if we receive an adverse litigation decision in a country in the EU where our Eliquis composition of matter patents and related Supplementary Protection Certificates are being challenged (see 'Item 8. Financial Statements and Supplementary Data-Note 19. Legal Proceedings and Contingencies'), we may not be able to prevent generic apixaban products from being introduced in such country prior to our estimated minimum market exclusivity date. In some countries, patent protection is significantly weaker than in the United States or in the EU; political and social pressure has also pushed legislation and other measures that promote the use  of  generic  and  biosimilar  products.  In  addition,  we  face  competition  from  new  products  entering  the  market, particularly in IO. New products may have (i) lower prices, (ii) superior efficacy (benefit) or safety (risk) profiles (whether actual  or  perceived),  (iii)  technological  advantages  that  may  make  such  products  more  convenient  to  use,  (iv)  better insurance coverage or reimbursement levels, (v) more effective marketing programs and/or other differentiating factors that make it harder for our products to compete. We also face intense competition for external partnerships, joint ventures and  acquisition  targets  that  can  help  develop  and  bring  new  products  to  markets.  Business  combinations  among  our competitors and major third-party payers may increase competition",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Juno",
          "name": "Juno",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_156",
          "chunk_id": "chunk_1",
          "chunk_text": "While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that  there  will  not  be  an  increase  in  the  scope  of  one  or  more  of  these  pending  matters  or  any  other  or  future  lawsuits,  claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will  be  incurred  and  the  amount  of  the  related  loss  can  be  reasonably  estimated.  Developments  in  legal  proceedings  and  other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS's tax contingencies, see '-Note 7. Income Taxes'.\n\n## INTELLECTUAL PROPERTY\n\n## Anti-PD-1 Antibody Litigation\n\nIn September 2015, Dana-Farber Cancer Institute ('Dana-Farber') filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer  was  allowed  to  intervene  in  this  case  alleging  that  one  of  the  scientists  identified  by  Dana-Farber  was  employed  by  a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the District Court issued an opinion ruling that the two scientists should be added as inventors to the patents which was affirmed on appeal. In May 2021, the U.S. Supreme Court declined to consider the case. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the District Court's decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss the complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber's claims for damages before May 17, 2019-the date of the District Court's ruling that Dana-Farber was a co-inventor of the patents-are preempted by federal patent law. No trial date has been scheduled.\n\n## CAR T\n\nIn October 2017, Juno and Sloan Kettering Institute for Cancer Research ('SKI') filed a complaint for patent infringement against Kite  Pharma,  Inc.  ('Kite')  in  the  U.S.  District  Court  for  the  Central  District  of  California.  The  complaint  alleged  that  Kite's Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the ''190 Patent') concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the '190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite's defenses, finding that Kite willfully infringed the '190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite's sales of Yescarta* through the expiration of the '190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite's motions in their entirety. In April 2020, the Court granted in part Juno's motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest  and  enhanced damages and a 27.6% running royalty on Kite's sales of Yescarta * from December 13, 2019 through the expiration of the '190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the '190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit  for  panel  and  en  banc  rehearing  which  the  Federal  Circuit  denied  on  January  14,  2022. The  Company  intends  to  file  a petition for a writ of certiorari with the U.S. Supreme Court.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "CAR_T_Litigation",
          "name": "CAR T Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_156",
          "chunk_id": "chunk_1",
          "chunk_text": "While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that  there  will  not  be  an  increase  in  the  scope  of  one  or  more  of  these  pending  matters  or  any  other  or  future  lawsuits,  claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will  be  incurred  and  the  amount  of  the  related  loss  can  be  reasonably  estimated.  Developments  in  legal  proceedings  and  other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS's tax contingencies, see '-Note 7. Income Taxes'.\n\n## INTELLECTUAL PROPERTY\n\n## Anti-PD-1 Antibody Litigation\n\nIn September 2015, Dana-Farber Cancer Institute ('Dana-Farber') filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer  was  allowed  to  intervene  in  this  case  alleging  that  one  of  the  scientists  identified  by  Dana-Farber  was  employed  by  a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the District Court issued an opinion ruling that the two scientists should be added as inventors to the patents which was affirmed on appeal. In May 2021, the U.S. Supreme Court declined to consider the case. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the District Court's decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss the complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber's claims for damages before May 17, 2019-the date of the District Court's ruling that Dana-Farber was a co-inventor of the patents-are preempted by federal patent law. No trial date has been scheduled.\n\n## CAR T\n\nIn October 2017, Juno and Sloan Kettering Institute for Cancer Research ('SKI') filed a complaint for patent infringement against Kite  Pharma,  Inc.  ('Kite')  in  the  U.S.  District  Court  for  the  Central  District  of  California.  The  complaint  alleged  that  Kite's Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the ''190 Patent') concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the '190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite's defenses, finding that Kite willfully infringed the '190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite's sales of Yescarta* through the expiration of the '190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite's motions in their entirety. In April 2020, the Court granted in part Juno's motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest  and  enhanced damages and a 27.6% running royalty on Kite's sales of Yescarta * from December 13, 2019 through the expiration of the '190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the '190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit  for  panel  and  en  banc  rehearing  which  the  Federal  Circuit  denied  on  January  14,  2022. The  Company  intends  to  file  a petition for a writ of certiorari with the U.S. Supreme Court.",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 152,
      "question": "How does the share reuse mechanism in Abbott's 2009 Incentive Stock Program affect the availability of shares for future issuance under the Employee Stock Purchase Plan as of December 31, 2024?",
      "answer": "The share reuse mechanism in Abbott's 2009 Incentive Stock Program allows shares from canceled or forfeited benefits under that program to be repurposed for new awards under the 2017 Incentive Stock Program. This recycled share availability directly contributes to the 7,461,515 common shares that were available for future issuance under the Employee Stock Purchase Plan as of December 31, 2024. This mechanism enables Abbott to maintain its equity compensation offerings without requiring new share authorizations, as shares not utilized in the 2009 Program can be reallocated to support ongoing employee purchase cycles and other incentive awards under the 2017 Program.",
      "reasoning_steps": [
        "Hop 1: ABT(page_84) \u2192 Non-Qualified Stock Options: Discloses the availability of 7,461,515 common shares for future issuance under the Employee Stock Purchase Plan as of December 31, 2024",
        "Hop 2: Non-Qualified Stock Options \u2192 2009 Program: The 2009 Program includes non-qualified stock options as part of its incentive benefits",
        "Hop 3: 2009 Program \u2190 ABT(page_83): Details how shares from canceled/forfeited benefits under the 2009 Program can be reused for new awards under the 2017 Program"
      ],
      "difficulty": "hard",
      "idf_score": 5.947298682712962,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Contains]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "entities": {
        "start": "ABT",
        "node_2": "Non-Qualified Stock Options",
        "node_3": "2009 Program",
        "end": "ABT"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "| (ii)   | Abbott Laboratories 2017 Incentive Stock Program . Benefits under the 2017 Programinclude non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non- employee directors, and foreign benefits. The shares that remain available for issuance under the 2017 Programmay be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied fromtreasury shares). If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2017 Programwithout the issuance of shares or payment                                                                                   |\n|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (iii)  | Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees . Eligible employees of participating non-U.S. affiliates of Abbott may participate in this plan.An eligible employee may authorize payroll deductions at the rate of1% to 10% of eligible compensation (in multiples of one percent) subject to a limit of US$12,500 during any purchase cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|        | Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The shares may be either authorized but unissued shares, treasury shares, or shares acquired on the open market. The purchase price is typically 85% of the lower of the fair market value of the shares on the purchase date or on the first day of that purchase cycle.As the number of shares subject to outstanding options is indeterminable, columns (a) and (b) of the above table do not include information on the Employee Stock Purchase Plan. As of December 31, 2024, an aggregate of 7,461,515 common shares were available for future issuance under the Employee Stock Purchase Plan, including shares subject to purchase during the current purchase cycle. |\n|        | In April 2017, the 2009 Employee Stock Purchase Plan for Non-U.S. Employees was amended and restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Non-Qualified_Stock_Options",
          "name": "Non-Qualified Stock Options",
          "type": "FIN_INST",
          "idf_score": 4.627770017905332
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Contains"
        },
        "node_3": {
          "id": "2009_Program",
          "name": "2009 Program",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 153,
      "question": "How might the anticipated decline in Bridion sales after losing U.S. market exclusivity in 2026 affect Merck's growing reliance on alliance revenue from collaborations like the Bayer sGC modulator partnership?",
      "answer": "Merck's alliance revenue from the Bayer collaboration grew 8% in 2023, reflecting increased demand for Adempas and Verquvo in Bayer's marketing territories. However, Bridion, which generated $1.156 billion in U.S. sales in 2023, is set to lose market exclusivity in the U.S. in 2026, following similar losses in the EU and Japan that already caused substantial declines. Given Bridion\u2019s historical contribution to Merck\u2019s revenue and the expected drop in sales post-exclusivity loss, the company may face pressure to rely more heavily on growing alliance revenue streams to offset the decline. This dynamic highlights a potential interplay between the lifecycle of proprietary products and the strategic importance of collaborative partnerships in maintaining revenue growth.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_54) \u2192 [US]: Merck operates in the U.S. and generates alliance revenue from the Bayer collaboration, which includes sales of Adempas and Verquvo, growing 8% in 2023.",
        "Hop 2: [US] \u2192 [Bridion]: Bridion is expected to lose U.S. market exclusivity in 2026, which will likely lead to a substantial decline in sales similar to what occurred in the EU and Japan.",
        "Hop 3: [Bridion] \u2190 [MRK](page_126): Bridion generated $1.156 billion in U.S. sales in 2023, making it a significant contributor to Merck\u2019s revenue before the anticipated drop post-2026."
      ],
      "difficulty": "hard",
      "idf_score": 5.74456612865888,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Operates_In]-> GPE -[Impacted_By]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "US",
        "node_3": "Bridion",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "GPE",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance\trevenue\trepresents\tMerck's\tshare\tof\tprofits\tfrom\tsales\tin\tBayer's\tmarketing\tterritories,\twhich\tare\tproduct\tsales\tnet\tof\tcost\tof\tsales\tand\tcommercialization\tcosts\t(see Note\t4\tto\tthe\tconsolidated\tfinancial\tstatements). (1)\n\nAdempas\tand\tVerquvo\tare\tpart\tof\ta\tworldwide\tcollaboration\twith\tBayer\tAG\t(Bayer)\tto\tmarket\tand\tdevelop\tsoluble\tguanylate\tcyclase (sGC)\tmodulators\t(see\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements).\tAdempas\tis\tapproved\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tPAH and\tchronic\tpulmonary\thypertension.\tVerquvo\tis\tapproved\tto\treduce\tthe\trisk\tof\tcardiovascular\tdeath\tand\theart\tfailure\thospitalization following\ta\thospitalization\tfor\theart\tfailure\tor\tneed\tfor\toutpatient\tintravenous\tdiuretics\tin\tadults\twith\tsymptomatic\tchronic\theart failure\tand\treduced\tejection\tfraction.\tVerquvo\twas\tapproved\tin\tthe\tU.S.,\tthe\tEU\tand\tJapan\tin\t2021\tand\thas\tsince\tbeen\tapproved\tin\tseveral other\tmarkets.\tAlliance\trevenue\tfrom\tthe\tcollaboration\tgrew\t8%\tin\t2023\treflecting\thigher\tprofit\tsharing,\twhich\treflects\tincreased\tdemand in\tBayer's\tmarketing\tterritories.\tRevenue\talso\tincludes\tsales\tof\tAdempas\tand\tVerquvo\tin\tMerck's\tmarketing\tterritories.\tSales\tof\tAdempas in\tMerck's\tmarketing\tterritories\tgrew\t7%\tin\t2023\tprimarily\treflecting\thigher\tdemand.\n\n## Virology\n\n",
          "relationship": "Operates_In"
        },
        "node_2": {
          "id": "US",
          "name": "US",
          "type": "GPE",
          "idf_score": 4.222304909797168
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Impacted_By"
        },
        "node_3": {
          "id": "Bridion",
          "name": "Bridion",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_126",
          "chunk_id": "chunk_2",
          "chunk_text": "| Years Ended December 31                | 2023     | 2023     | 2023     | 2022     | 2022     | 2022     | 2021     | 2021     | 2021     |\n|----------------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|\n|                                        | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    |\n| Pharmaceutical:                        |          |          |          |          |          |          |          |          |          |\n| Oncology                               |          |          |          |          |          |          |          |          |          |\n| Keytruda                               | $ 15,114 | $ 9,897  | $ 25,011 | $ 12,686 | $ 8,251  | $ 20,937 | $ 9,765  | $ 7,421  | $ 17,186 |\n| Alliance revenue - Lynparza (1)        | 607      | 592      | 1,199    | 584      | 532      | 1,116    | 515      | 473      | 989      |\n| Alliance revenue - Lenvima (1)         | 657      | 303      | 960      | 579      | 297      | 876      | 417      | 287      | 704      |\n| Welireg                                | 209      | 10       | 218      | 123      | -        | 123      | 13       | -        | 13       |\n| Alliance revenue - Reblozyl (2)        | 168      | 43       | 212      | 123      | 43       | 166      | -        | 17       | 17       |\n| Vaccines                               |          |          |          |          |          |          |          |          |          |\n| Gardasil/Gardasil 9                    | 2,083    | 6,803    | 8,886    | 2,065    | 4,832    | 6,897    | 1,881    | 3,792    | 5,673    |\n| ProQuad/M-M-R II/Varivax               | 1,837    | 531      | 2,368    | 1,724    | 518      | 2,241    | 1,629    | 506      | 2,135    |\n| RotaTeq                                | 493      | 276      | 769      | 508      | 275      | 783      | 473      | 334      | 807      |\n| Vaxneuvance                            | 561      | 103      | 665      | 163      | 7        | 170      | 3        | -        | 3        |\n| Pneumovax 23                           | 127      | 285      | 412      | 346      | 256      | 602      | 547      | 346      | 893      |\n| Vaqta                                  | 119      | 61       | 180      | 95       | 78       | 173      | 100      | 79       | 179      |\n| Hospital Acute Care                    |          |          |          |          |          |          |          |          |          |\n| Bridion                                | 1,156    | 686      | 1,842    | 922      | 762      | 1,685    | 762      | 770      | 1,532    |\n| Prevymis                               | 264      | 341      | 605      | 188      | 240      | 428      | 153      | 218      | 370      |\n| Dificid                                | 274      | 28       | 302      | 241      | 22       | 263      | 166      | 10       | 175      |\n| Zerbaxa                                | 119      | 100      | 218      | 89       | 79       | 169      | 4        | (5)      | (1)      |\n| Noxafil                                | 32       | 181      | 213      | 51       | 187      | 238      | 60       | 199      | 259      |\n| Primaxin                               | 1        | 211      | 213      | 1        | 238      | 239      | 2        | 258      | 259      |\n| Cardiovascular                         |          |          |          |          |          |          |          |          |          |\n| Alliance revenue - Adempas/Verquvo (3) | 350      | 16       | 367      | 329      | 12       | 341      | 312      | 30       | 342      |\n| Adempas                                | -        | 255      | 255      | -        | 238      | 238      | -        | 252      | 252      |\n| Virology                               |          |          |          |          |          |          |          |          |          |\n| Lagevrio                               | 10       | 1,418    | 1,428    | 1,523    | 4,161    | 5,684    | 632      | 320      | 952      |\n| Isentress/Isentress HD                 | 215      | 268      | 483      | 274      | 359      | 633      | 294      | 474      | 769      |\n| Neuroscience                           |          |          |          |          |          |          |          |          |          |\n| Belsomra                               | 81       | 150      | 231      | 79       | 179      | 258      | 78       | 241      | 318      |\n| Immunology                             |          |          |          |          |          |          |          |          |          |\n| Simponi                                | -        | 710      | 710      | -        | 706      | 706      | -        | 825      | 825      |\n| Remicade                               | -        | 187      | 187      | -        | 207      | 207      | -        | 299      | 299      |\n| Diabetes                               |          |          |          |          |          |          |          |          |          |\n| Januvia                                | 1,151    | 1,039    | 2,189    | 1,248    | 1,565    | 2,813    | 1,404    | 1,920    | 3,324    |\n| Janumet                                | 223      | 954      | 1,177    | 355      | 1,344    | 1,700    | 367      | 1,597    | 1,964    |\n| Other pharmaceutical (4)               | 688      | 1,596    | 2,283    | 693      | 1,628    | 2,319    | 824      | 1,690    | 2,516    |\n| Total Pharmaceutical segment sales     | 26,539   | 27,044   | 53,583   | 24,989   | 27,016   | 52,005   | 20,401   | 22,353   | 42,754   |\n| Animal Health:                         |          |          |          |          |          |          |          |          |          |\n| Livestock                              | 700      | 2,637    | 3,337    | 710      | 2,590    | 3,300    | 667      | 2,628    | 3,295    |\n| Companion Animal                       | 1,104    | 1,184    | 2,288    | 1,112    | 1,138    | 2,250    | 1,091    | 1,182    | 2,273    |\n| Total Animal Health segment sales      | 1,804    | 3,821    | 5,625    | 1,822    | 3,728    | 5,550    | 1,758    | 3,810    | 5,568    |\n| Total segment sales                    | 28,343   | 30,865   | 59,208   | 26,811   | 30,744   | 57,555   | 22,159   | 26,163   | 48,322   |\n| Other (5)                              | 137      | 770      | 907      | 395      | 1,333    | 1,728    | 266      | 116      | 382      |\n|                                        | $ 28,480 | $ 31,635 | $ 60,115 | $ 27,206 | $ 32,077 | $ 59,283 | $ 22,425 | $ 26,279 | $ 48,704 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 154,
      "question": "Given Merck's joint development of Keytruda with Moderna and its critical role as one of the company's key products contributing to 56% of total sales in 2023, how does the anticipated loss of U.S. market exclusivity for Keytruda in 2028 align with Merck's ability to sustain profitability and replace revenue from products losing patent protection, especially considering the high-risk, long-cycle nature of its R&D efforts?",
      "answer": "Merck's joint development of Keytruda with Moderna, which includes cost and profit sharing, positions Keytruda as a major revenue driver, contributing to 56% of Merck's total sales in 2023. However, the anticipated loss of U.S. market exclusivity for Keytruda in 2028 poses a significant risk to future revenue streams, as seen with other products like Bridion, which experienced a substantial sales decline after losing exclusivity. Given that Merck's R&D pipeline carries a high failure rate and long development cycles, the company may struggle to replace the revenue lost from Keytruda in a timely manner. This raises concerns about Merck's ability to sustain profitability and manage cash flow as its key products, including Keytruda, face increasing market pressures and patent expirations.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_90) \u2192 [Keytruda]: Merck jointly develops and commercializes Keytruda with Moderna, sharing costs and profits, and Keytruda is a major contributor to alliance revenue.",
        "Hop 2: [Keytruda] \u2192 [Key Products]: Keytruda is one of Merck\u2019s key products, representing a significant portion of total sales (56% in 2023) and is central to the company\u2019s profitability and cash flow.",
        "Hop 3: [Key Products] \u2190 [MRK](page_28): The company acknowledges that the loss of market exclusivity for key products like Keytruda in 2028 could materially impact results, especially given the high risk and long investment cycles in R&D that may not yield timely replacements."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Keytruda",
        "node_3": "Key Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n## Bristol-Myers\tSquibb\tCompany\n\nReblozyl\t(luspatercept-aamt)\tis\ta\tfirst-in-class\terythroid\tmaturation\trecombinant\tfusion\tprotein\tobtained\tas\tpart\tof\tMerck's November\t2021\tacquisition\tof\tAcceleron\tthat\tis\tbeing\tcommercialized\tthrough\ta\tglobal\tcollaboration\twith\tBMS.\tReblozyl\tis\tapproved\tin\tthe U.S.,\tEurope,\tand\tcertain\tother\tmarkets\tfor\tthe\ttreatment\tof\tanemia\tin\tcertain\trare\tblood\tdisorders\tand\tis\talso\tbeing\tevaluated\tfor additional\tindications\tfor\thematology\ttherapies.\tBMS\tis\tthe\tprincipal\ton\tsales\ttransactions\tfor\tReblozyl;\thowever,\tMerck\tco-promotes Reblozyl\t(and\twill\tco-promote\tall\tfuture\tproducts\tapproved\tunder\tthis\tcollaboration)\tin\tNorth\tAmerica,\twhich\tis\treimbursed\tby\tBMS.\tMerck receives\ta\t20%\tsales\troyalty\tfrom\tBMS\twhich\tcould\tincrease\tto\ta\tmaximum\tof\t24%\tbased\ton\tsales\tlevels.\tThis\troyalty\twill\tbe\treduced\tby 50%\t upon\t the\t earlier\t of\t patent\t expiry\t or\t generic\t entry\t on\t an\t indication-by-indication\t basis\t in\t each\t market.\t Additionally,\t Merck\t is eligible\t to\t receive\t future\t contingent\t sales-based\t milestone\t payments\t of\t up\t to\t $80\t million.\t Alliance\t revenue\t related\t to\t this collaboration\t(recorded\twithin Sales )\tconsists\tof\troyalties\tand,\tfor\t2022,\talso\tincludes\tthe\treceipt\tof\ta\tregulatory\tapproval\tmilestone payment\tof\t$20\tmillion.\tMerck\trecorded\talliance\trevenue\trelated\tto\tthis\tcollaboration\tof\t$212\tmillion\tin\t2023,\t$166\tmillion\tin\t2022\tand $17\tmillion\tin\t2021.\n\n## Moderna,\tInc.\n\nIn\t September\t 2022,\t Merck\t exercised\t its\t option\t to\t jointly\t develop\t and\t commercialize\t V940\t (mRNA-4157),\t an\t investigational individualized\tneoantigen\ttherapy,\tpursuant\tto\tthe\tterms\tof\tan\texisting\tcollaboration\tand\tlicense\tagreement\twith\tModerna,\twhich\tresulted in\ta\t$250\tmillion\tpayment\tthat\twas\tcharged\tto Research\tand\tdevelopment expenses\tin\t2022.\tV940\t(mRNA-4157)\tis\tcurrently\tbeing\tevaluated in\tcombination\twith Keytruda in\tmultiple\tPhase\t3\tclinical\ttrials.\tMerck\tand\tModerna\twill\tshare\tcosts\tand\tany\tprofits\tequally\tunder\tthis worldwide\t collaboration.\t Merck\t records\t its\t share\t of\t development\t costs\t associated\t with\t the\t collaboration\t as\t part\t of Research\t and development expenses.\tAny\treimbursements\treceived\tfrom\tModerna\tfor\tresearch\tand\tdevelopment\texpenses\twill\tbe\trecognized\tas\treductions\tto Research\tand\tdevelopment costs.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\tcollaboration\tis\tas\tfollows:\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 155,
      "question": "How does BMY's reduced royalty share from Keytruda sales (2024\u20132026) impact its revenue position, especially considering its royalty dependency on Opdivo through its agreement with Ono?",
      "answer": "BMY receives a declining royalty share from Keytruda sales, dropping from 6.5% to 2.5% starting in 2024 through 2026, which will reduce its future revenue from this blockbuster product. At the same time, BMY depends on Ono to receive royalties from Opdivo sales, where Ono earns 15% outside North America and 4% in North America. Given that both Keytruda and Opdivo are PD-1 inhibitors and key revenue drivers, the reduction in Keytruda royalties could place pressure on BMY\u2019s oncology revenue stream, which is partially offset by its royalty entitlement through Opdivo. However, the interdependence between BMY and Ono across these two competing PD-1 products creates a complex revenue dynamic that may influence BMY\u2019s strategic decisions in oncology.",
      "reasoning_steps": [
        "Hop 1: BMY(page_138) \u2192 Keytruda(PRODUCT): BMY co-owns the rights to Keytruda and receives a portion of the royalties from its sales.",
        "Hop 2: Keytruda(PRODUCT) \u2192 Ono(COMP): BMY and Ono share royalties from Keytruda sales, with BMY receiving 75% and Ono 25% under a global patent license agreement with Merck.",
        "Hop 3: Ono(COMP) \u2190 BMY(page_86): BMY depends on Ono for royalties from Opdivo sales, where Ono receives 15% outside Japan, South Korea, and Taiwan and 4% in North America, with BMY receiving the remainder."
      ],
      "difficulty": "hard",
      "idf_score": 6.227106576680673,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Receives]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Keytruda",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 156,
      "question": "How does the change in Amgen's collaboration terms with Novartis on Aimovig in 2022 impact Amgen's financial exposure and strategic control over the product, especially in light of the global manufacturing responsibilities Amgen retains?",
      "answer": "The change in Amgen's collaboration terms with Novartis in 2022 significantly reduced Amgen's financial exposure in the U.S. market by eliminating royalty payments to Novartis and shifting full commercialization responsibility to Amgen. Previously, Amgen paid Novartis $116 million in royalties in 2021 alone for U.S. sales of Aimovig. At the same time, Amgen retains global manufacturing responsibilities, which means it continues to manage supply chain operations and likely maintains cost control and quality oversight. This shift gives Amgen greater strategic control over Aimovig\u2019s commercial trajectory in the U.S., while still benefiting from Novartis\u2019s international distribution under the ex-U.S. rights, where Novartis continues to pay double-digit royalties. The change aligns with a more centralized control model for Amgen, reducing shared cost structures domestically while maintaining global R&D cost sharing and international royalty inflows.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_28) \u2192 [Novartis]: Amgen entered into a modified collaboration with Novartis in 2022, under which Novartis no longer shares U.S. commercialization costs or receives royalties from Amgen on U.S. sales of Aimovig.",
        "Hop 2: [Novartis] \u2192 [Aimovig]: Novartis retains exclusive commercial rights outside the U.S. and Japan for Aimovig and continues to pay double-digit royalties on net sales in those territories.",
        "Hop 3: [Aimovig] \u2190 [AMGN](page_122): Amgen continues to manufacture and supply Aimovig worldwide and in 2021 paid $116 million in royalties to Novartis for U.S. sales, while also recovering $160 million in net costs from Novartis for migraine products globally."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Holds_Rights_To]-> PRODUCT <-[Supplies]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Novartis",
        "node_3": "Aimovig",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Novartis",
          "name": "Novartis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Holds_Rights_To"
        },
        "node_3": {
          "id": "Aimovig",
          "name": "Aimovig",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_122",
          "chunk_id": "chunk_1",
          "chunk_text": "In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\nDuring the years ended December 31, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $220 million and $225 million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the year ended December 31, 2021, product sales from Amgen to BeiGene under the collaboration were $72 million and were recorded in Product sales in the Consolidated Statements of Income. During the year ended December 31, 2021, profit and loss share expenses  related  to  the  initial  product-specific  commercialization  period  were  $64  million  and  were  recorded  primarily  in  SG&amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $21 million and $22 million as of December 31, 2021 and 2020, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $61 million and $99 million as of December 31, 2021 and 2020, respectively, which are included in Other current assets in the Consolidated Balance Sheets.\n\n## Novartis Pharma AG\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Note 19, Contingencies and commitments.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide. In the United States, Novartis will no longer collaborate  with Amgen or share Aimovig commercialization costs and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\n## Amgen manufactures and supplies Aimovig worldwide.\n\nDuring the years ended December 31, 2021, 2020 and 2019, net costs recovered from Novartis for migraine products were $160 million, $192 million and $187 million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due to Novartis for Aimovig were $116 million, $139 million and $115 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due from Novartis for Aimovig were not material.\n\n## Kyowa Kirin Co., Ltd.\n\nOn July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize an antiOX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.\n\nUnder the terms of the agreement, we will lead the global development, manufacture and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia.",
          "relationship": "Supplies"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 157,
      "question": "How does Pfizer's $6 billion in remaining performance obligations for Comirnaty as of December 31, 2023, reflect the geographic commercialization rights established in the April 2020 agreement with BioNTech, particularly in light of the FDA's September 2023 approval of the updated Omicron XBB.1.5-adapted formulation?",
      "answer": "Pfizer's $6 billion in remaining performance obligations for Comirnaty reflects its exclusive commercialization rights in most global markets outside Germany and Turkey, as established in the April 2020 agreement with BioNTech. The FDA's September 2023 approval of the updated Omicron XBB.1.5-adapted formulation supports continued vaccine demand in Pfizer's authorized markets, directly impacting the company\u2019s obligation to deliver under firm contracts. The geographic split\u2014where BioNTech handles Germany and Turkey\u2014explains why Pfizer\u2019s obligations are tied to markets where it has full commercial control. Additionally, Pfizer performs Comirnaty-related manufacturing activities on behalf of BioNTech, generating $33 million in 2023, which underscores the ongoing interdependence in production despite the division of commercialization rights.",
      "reasoning_steps": [
        "Hop 1: PFE(page_76) \u2192 Comirnaty: Discloses the April 2020 agreement with BioNTech, outlining Pfizer\u2019s global commercialization rights for Comirnaty excluding Germany and Turkey, with shared development costs and profit-sharing.",
        "Hop 2: Comirnaty \u2192 BioNTech: The September 2023 FDA approval of the Omicron XBB.1.5-adapted formulation indicates ongoing development and regulatory momentum for Comirnaty, which supports continued commercial obligations.",
        "Hop 3: BioNTech \u2190 PFE(page_112): Notes Pfizer\u2019s $6 billion in remaining performance obligations tied to Comirnaty supply contracts and highlights the $33 million in 2023 contract manufacturing performed on behalf of BioNTech, reflecting the ongoing collaboration dynamics."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Produces]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Comirnaty",
        "node_3": "BioNTech",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tSeptember\t2023,\tPfizer\tand\tBioNTech\tannounced\tthe\tFDA\tapproved\ta\tregulatory\tapplication\tfor\ttheir\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t12\tyears of\tage\tand\tolder\t(Comirnaty\t(COVID-19\tVaccine,\tmRNA,\t2023-2024\tFormula)).\tThe\tFDA\talso\tgranted\tEUA\tfor\tthe\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t6 months\tthrough\t11\tyears\tof\tage\t(Pfizer-BioNTech\tCOVID-19\tVaccine\t(2023-2024\tFormula)). (a)\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n41",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 158,
      "question": "What implications does Merck's ownership of the Keytruda trademark have for BMY's financial dependency on Merck through its Keytruda royalty payments?",
      "answer": "Merck owns the Keytruda trademark, as noted in the product listing on page 138, and BMY depends on Merck through a royalty agreement tied to Keytruda sales. According to the agreement detailed on page 90, Merck pays ongoing royalties on global sales of Keytruda to BMY and Ono, with a 75/25 split. On page 55, BMY notes that its royalty income increased in 2023 primarily due to higher Keytruda royalties. This creates a financial dependency where BMY's revenue from Keytruda is directly tied to Merck's ability to market and sell the product under its trademark. If Merck were to face challenges related to the Keytruda brand or its market position, it could directly impact BMY's royalty income, highlighting a key risk in BMY's revenue stream tied to both intellectual property ownership and Merck's commercial execution.",
      "reasoning_steps": [
        "Hop 1: BMY(page_138) \u2192 Keytruda: BMY references Keytruda as a trademark owned by Merck, indicating its dependence on Merck's intellectual property.",
        "Hop 2: Keytruda \u2192 Merck: BMY and Ono receive royalties from Merck based on global sales of Keytruda under a patent license agreement.",
        "Hop 3: Merck \u2190 BMY(page_55): BMY's financial statements show that royalty income increased in 2023 primarily due to higher Keytruda royalties, demonstrating financial dependency on Merck."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Pays]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Keytruda",
        "node_3": "Merck",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Pays"
        },
        "node_3": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_55",
          "chunk_id": "chunk_4",
          "chunk_text": "\n\u00b7 Interest\t expense\t decreased\t in\t 2023\t due\t to\t additional\t debt\t maturities.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and Supplementary\tData-Note\t10.\tFinancing\tArrangements'\tfor\tfurther\tinformation.\n\n- Royalties\t increased\t in\t 2023\t primarily\t due\t to\t higher Keytruda *\t royalties.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and Supplementary\tData-Note\t4.\tAcquisitions,\tDivestitures,\tLicensing\tand\tOther\tArrangements'\tfor\tfurther\tinformation.\n- Equity\tinvestments\tgenerated\tlower\tlosses\tin\t2023\tcompared\tto\t2022\tdue\tto\tfair\tvalue\tadjustments\tfor\tinvestments\tthat\thave readily\t determinable\t fair\t value.\t Refer\t to\t 'Item\t 8.\t Financial\t Statements\t and\t Supplementary\t Data-Note\t 9.\t Financial Instruments\tand\tFair\tValue\tMeasurements'\tfor\tmore\tinformation.\n- Integration\texpenses\tdecreased\tin\t2023\tdue\tto\tlower\tconsulting\tfees\tto\timplement\tCelgene\tintegration\tinitiatives\trelated to\tprocesses\tand\tsystems.\n- Loss\ton\tdebt\tredemption\tresulted\tfrom\tthe\tearly\tredemption\tof\tlong-term\tdebt\tof\t$6.0\tbillion\tin\t2022.\n- Divestiture\tgains\tresulted\tfrom\tcertain\tmature\tproduct\trights\tdivested\tin\t2022.\n- Investment\tincome\tincreased\tin\t2023\tprimarily\tdue\tto\thigher\tinterest\trates.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 159,
      "question": "How does Merck's financial treatment of the spin-off of Organon in 2021, including the packaging and labeling of finished pharmaceutical products for Organon under the manufacturing agreements, reflect on Merck's consolidated income and balance sheet as of December 31, 2023?",
      "answer": "Merck's spin-off of Organon in 2021 resulted in a $9.0 billion cash distribution to Merck and the transfer of $9.5 billion in debt obligations to Organon. As of December 31, 2023, Merck reported $632 million due from Organon under the manufacturing and supply agreements (MSAs), while also owing $598 million to Organon, both reflected in current assets and liabilities, respectively. In 2023, Merck recorded $394 million in sales and $422 million in cost of sales related to these MSAs, indicating that despite the spin-off, Merck continues to maintain a significant operational relationship with Organon through the packaging and labeling of finished pharmaceutical products. This ongoing relationship contributes to Merck\u2019s consolidated income and balance sheet, even though Organon is now a separate entity.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_124) \u2192 [Organon]: Merck's consolidated balance sheet as of December 31, 2023, reflects accumulated losses and adjustments related to the spin-off of Organon, including a $449 million adjustment directly tied to the transaction.",
        "Hop 2: [Organon] \u2192 [Finished Pharmaceutical Products]: Following the spin-off, Merck and Organon entered into MSAs under which Merck packages and labels finished pharmaceutical products for Organon, indicating a continued operational linkage.",
        "Hop 3: [Finished Pharmaceutical Products] \u2190 [MRK](page_91): In 2023, Merck recorded $394 million in sales and $422 million in cost of sales related to the MSAs, with $632 million due from Organon and $598 million due to Organon as of year-end, showing the financial impact of this ongoing relationship."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> COMP -[Packages]-> PRODUCT <-[Labels]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Finished Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                     | Derivatives   |     | Employee Benefit Plans   |     | Foreign Currency Translation Adjustment   | Accumulated Other Comprehensive Loss   |\n|-------------------------------------------------------------------------------------|---------------|-----|--------------------------|-----|-------------------------------------------|----------------------------------------|\n| Balance January 1, 2021, net of taxes                                               | (266)         |     | (4,540)                  | $   | (1,828)                                   | $ (6,634)                              |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 333           |     | 1,737                    |     | (304)                                     | 1,766                                  |\n| Tax                                                                                 | (75)          |     | (332)                    |     | (119)                                     | (526)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 258           |     | 1,405                    |     | (423)                                     | 1,240                                  |\n| Reclassification adjustments, pretax                                                | 192           | (1) | 466                      | (2) | -                                         | 658                                    |\n| Tax                                                                                 | (40)          |     | (102)                    |     | -                                         | (142)                                  |\n| Reclassification adjustments, net of taxes                                          | 152           |     | 364                      |     | -                                         | 516                                    |\n| Other comprehensive income (loss), net of taxes                                     | 410           |     | 1,769                    |     | (423)                                     | 1,756                                  |\n| Spin-off of Organon (see Note 5)                                                    | -             |     | 28                       |     | 421                                       | 449                                    |\n| Balance at December 31, 2021, net of taxes                                          | 144           |     | (2,743)                  |     | (1,830)                                   | (4,429)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 684           |     | 70                       |     | (584)                                     | 170                                    |\n| Tax                                                                                 | (143)         |     | 12                       |     | (19)                                      | (150)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 541           |     | 82                       |     | (603)                                     | 20                                     |\n| Reclassification adjustments, pretax                                                | (775)         | (1) | 329                      | (2) | -                                         | (446)                                  |\n| Tax                                                                                 | 163           |     | (76)                     |     | -                                         | 87                                     |\n| Reclassification adjustments, net of taxes                                          | (612)         |     | 253                      |     | -                                         | (359)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (71)          |     | 335                      |     | (603)                                     | (339)                                  |\n| Balance at December 31, 2022, net of taxes                                          | 73            |     | (2,408)                  | (3) | (2,433)                                   | (4,768)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 114           |     | (413)                    |     | 17                                        | (282)                                  |\n| Tax                                                                                 | (24)          |     | 86                       |     | 63                                        | 125                                    |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 90            |     | (327)                    |     | 80                                        | (157)                                  |\n| Reclassification adjustments, pretax                                                | (237)         | (1) | (64)                     | (2) | 9                                         | (292)                                  |\n| Tax                                                                                 | 50            |     | 6                        |     | -                                         | 56                                     |\n| Reclassification adjustments, net of taxes                                          | (187)         |     | (58)                     |     | 9                                         | (236)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (97)          |     | (385)                    |     | 89                                        | (393)                                  |\n| Balance at December 31, 2023, net of taxes                                          | (24)          |     | (2,793) (3)              | $   | (2,344)                                   | $ (5,161)                              |\n",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Packages"
        },
        "node_3": {
          "id": "Finished_Pharmaceutical_Products",
          "name": "Finished Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Labels"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 160,
      "question": "How does Amgen's competitive positioning against HUMIRA in key therapeutic areas relate to its development and patent strategy for AMJEVITA, particularly given the biosimilar's mechanism of action and potential exclusivity period?",
      "answer": "Amgen directly competes with HUMIRA in multiple therapeutic areas such as rheumatology and immunology, as seen in the list of competitor products on page 16. AMJEVITA, a biosimilar to HUMIRA (monoclonal antibody that inhibits TNF-alpha), is part of Amgen\u2019s strategy to enter this competitive space. The company's patent expiration estimates and ongoing clinical trials for AMJEVITA, as disclosed on page 25, suggest a strategic effort to secure market exclusivity and extend competitive advantage despite HUMIRA's established position and AbbVie's other competing products like RINVOQ.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_16) \u2192 HUMIRA: Amgen lists HUMIRA as a key competitor for products like ENBREL and Otezla in the U.S. and Europe, indicating strong market overlap in immunology and inflammatory disease areas.",
        "Hop 2: HUMIRA \u2192 AMJEVITA: AMJEVITA is explicitly described as a biosimilar to HUMIRA, targeting the same biological pathway (TNF-alpha inhibition), which positions it as a direct competitor to HUMIRA.",
        "Hop 3: AMJEVITA \u2190 AMGN(page_25): Amgen is developing AMJEVITA through clinical trials and is seeking patent protection that could extend its exclusivity period, despite the risk of patent challenges and expiration timelines outlined in the filing."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Competes_Against]-> PRODUCT -[Related_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "HUMIRA",
        "node_3": "AMJEVITA",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "node_2": {
          "id": "HUMIRA",
          "name": "HUMIRA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_5",
          "chunk_text": "\n* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.\n\n## Phases 3 and 2 Program Descriptions\n\nThe following provides additional information about selected product candidates that have advanced into human clinical trials.\n\n## AMJEVITA\n\nAMJEVITA is a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha.\n\n## Bemarituzumab\n\nBemarituzumab  is  a  monoclonal  antibody  that  inhibits  FGFR2b.  It  is  being  investigated  for  the  treatment  of  advanced  GEJ adenocarcinoma.\n\nIn April 2021, Amgen announced that the FDA had granted Breakthrough Therapy designation for bemarituzumab.",
          "relationship": "Related_To"
        },
        "node_3": {
          "id": "AMJEVITA",
          "name": "AMJEVITA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_5",
          "chunk_text": "\n* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.\n\n## Phases 3 and 2 Program Descriptions\n\nThe following provides additional information about selected product candidates that have advanced into human clinical trials.\n\n## AMJEVITA\n\nAMJEVITA is a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha.\n\n## Bemarituzumab\n\nBemarituzumab  is  a  monoclonal  antibody  that  inhibits  FGFR2b.  It  is  being  investigated  for  the  treatment  of  advanced  GEJ adenocarcinoma.\n\nIn April 2021, Amgen announced that the FDA had granted Breakthrough Therapy designation for bemarituzumab.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 161,
      "question": "How does BMY's royalty entitlement from Keytruda sales through its agreement with Ono compare to its commercial rights for Opdivo in Asia, and what does this reveal about its strategic positioning in the PD-1 inhibitor market?",
      "answer": "BMY receives a 75% share of the royalties from Keytruda sales under a global patent license with Ono, where Merck pays 6.5% through 2023 and 2.5% through 2026 on global sales. In contrast, BMY has exclusive rights to develop, manufacture, and commercialize Opdivo globally except in Japan, South Korea, and Taiwan, where Ono receives royalties of 15% outside North America. This shows that BMY strategically leverages partnerships like the one with Ono to maintain a strong presence in the PD-1 inhibitor space, even in regions where it does not directly commercialize the drug, thereby maximizing revenue through both direct sales and royalty streams.",
      "reasoning_steps": [
        "Hop 1: BMY(page_86) \u2192 Ono: BMY has exclusive rights to Opdivo globally except in Japan, South Korea, and Taiwan, where Ono receives 15% royalties.",
        "Hop 2: Ono \u2192 Keytruda: BMY and Ono share royalties from Keytruda sales globally at a 75/25 split after legal fees, with Merck paying 6.5% through 2023 and 2.5% through 2026.",
        "Hop 3: Keytruda \u2190 BMY(page_138): BMY acknowledges Keytruda as a trademark of Merck Sharp & Dohme Corp., indicating it does not own the product but benefits from it via licensing agreements."
      ],
      "difficulty": "hard",
      "idf_score": 6.227106576680673,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Receives]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Ono",
        "node_3": "Keytruda",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 162,
      "question": "How do the financial structures of Gilead's collaboration with Merck on long-acting HIV treatments compare to the Arcellx partnership in oncology, and what do these structures imply about Gilead's strategic risk-sharing and revenue participation in each therapeutic area?",
      "answer": "Gilead's collaboration with Merck on long-acting HIV treatments involves shared development and commercialization costs at a 60/40 split (Gilead/Merck), with joint promotion in the U.S. and profit-sharing that transitions to a 65/35 split for Gilead once the injectable formulation exceeds $3.5 billion in annual sales. No revenues have yet been recognized under this agreement. In contrast, the Arcellx partnership involves a $313 million upfront charge and a $299 million equity investment, with joint development and commercialization costs and a 50/50 U.S. profit split for CART-ddBCMA, plus potential milestone payments up to $1.5 billion and international royalties. These structures indicate that Gilead assumes more upfront financial exposure in oncology through the Arcellx deal, while in HIV, the Merck collaboration spreads risk more evenly with cost-sharing and delayed revenue participation until performance thresholds are met.",
      "reasoning_steps": [
        "Hop 1: GILD(page_75) \u2192 Merck: Gilead has a joint development and commercialization agreement with Merck for long-acting HIV treatments, with a 60/40 cost split and revenue-sharing thresholds for increased Gilead participation.",
        "Hop 2: Merck \u2192 Long-Acting Injectable Products: Merck co-develops and co-commercializes long-acting injectable HIV products with Gilead, with Merck leading U.S. commercialization and Gilead leading outside the U.S.",
        "Hop 3: Long-Acting Injectable Products \u2190 GILD(page_74): The long-acting injectable HIV products are part of a broader set of collaboration agreements detailed on page 74, which include cost and revenue-sharing arrangements and are contrasted with other therapeutic partnerships like Arcellx in oncology."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Merck",
        "node_3": "Long-Acting Injectable Products",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_1",
          "chunk_text": "We will also have the option to license certain of Merck's investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of G ilead's investigational oral integrase inhibitors to develop in combination with islatravir. Each company may ex ercise its option for such investigational oral integrase inhibitor of the other company within the first five years after ex ecution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon ex ercise of an option, the companies will split development costs and revenues, unless the non-ex ercising company decides to opt out, in which case the non-exercising company will be paid a royalty.\n\n## Arcus\n\nIn  May 2020, we entered into a transaction, and have since entered into various amending transactions, with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (as amended, the 'Collaboration Agreement'), with G ilead having the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the initial transaction, and a common stock purchase agreement and an investor rights agreement (together, as amended, the 'Stock Purchase Agreements').\n\nAs part of the November 2021 amendment, we exercised our options to three of Arcus' clinical stage programs and made related collaboration opt-in payments of $725 million to Arcus in 2022, which were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows.\n\nAs part of the May 2023 amendment, we paid a $35 million upfront fee to initiate research programs against up to four targets jointly selected by the parties that are  applicable  to  inflammatory  diseases,  which  was  charged  to  Acquired  in-process  research  and  development  ex penses  on  our  Consolidated  Statements  of Operations.\n\nAs part of the January 2024 amendment, we committed to a $100 million continuation fee, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations and paid later in 2024.\n\nUnder the Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $243 million, $189 million  and  $187  million  of  such  costs  primarily  in  Research  and  development  ex penses  on  our  Consolidated  Statements  of  Operations  for  the  years  ended December 31, 2024, 2023 and 2022, respectively. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. G ilead will hold ex clusive commercialization rights outside the U.S., subject to any rights of Arcus's ex isting collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. For the research programs applicable to inflammatory diseases, G ilead may exercise an option to license each program at two separate, prespecified time points. If G ilead exercises its option at the earlier time point for the first two target programs, Arcus would be eligible to receive up to $420 million in future option and milestone payments and tiered royalties for each optioned program. For any other option exercise by G ilead for the four target programs, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the U.S. for optioned programs. We may also pay as much as an additional $100 million at our option in 2026 and again in 2028, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term.\n\nUnder the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We have made various purchases of shares since the original closing of the agreement, including a purchase of shares at a premium for $320 million in 2024 whereby we recorded $233 million for the fair value of the equity investment in Prepaid and other current assets on our Consolidated Balance Sheets and $87 million for the premium in Other (income) expense, net on our Consolidated Statements of Operations for the year ended December 31, 2024. Following this transaction, we owned a total of 30.1 million shares, which represented approximately 33% of the issued and outstanding voting stock of Arcus at that time. As of December 31, 2024, we had three designees on Arcus' board of directors.\n\n## Galapagos\n\nIn August 2019, we closed a 10-year option, license and collaboration agreement (the 'OLCA') and a subscription agreement (the 'Subscription Agreement'), each with Galapagos, a clinical-stage biotechnology company based in Belgium, pursuant to which the parties entered into a global collaboration that covers certain programs in Galapagos' current and future product portfolio.\n\nUnder the OLCA, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, G alapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each G alapagos product optioned by us. If we exercise our option for a program, the parties will share  equally  in  development  costs  and  mutually  agreed  commercialization  costs  incurred  subsequent  to  our  ex ercise  of  the  option.  We  may  terminate  the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Long-Acting_Injectable_Products",
          "name": "Long-Acting Injectable Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 163,
      "question": "How does the financial structure of the Red Oak Sourcing, LLC venture with Cardinal Health, Inc. impact CVS's Retail/LTC segment profitability, particularly in light of the quarterly payments received from Cardinal and the consolidation of Red Oak into CVS's financial statements?",
      "answer": "The financial structure of the Red Oak Sourcing, LLC venture positively impacts CVS's Retail/LTC segment profitability through the quarterly payments received from Cardinal Health, Inc., which reduce the carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Specifically, CVS received $183 million annually from Cardinal during 2019\u20132021 under this arrangement. Since CVS consolidates Red Oak as the primary beneficiary, the benefits from this generic pharmaceutical sourcing venture flow directly into the Retail/LTC segment. However, Red Oak does not hold inventory or have physical assets, meaning the financial benefits are derived solely from the contractual payments and cost efficiencies in sourcing. This structure aligns with CVS\u2019s broader working capital practices, where pharmacy revenues\u2014largely settled within 30 days\u2014support efficient cash flow cycles, further enhancing the segment\u2019s financial performance.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_138) \u2192 [Cardinal Health, Inc.]: CVS discloses receiving $183 million annually from Cardinal under the Red Oak Sourcing arrangement, which reduces inventory carrying costs and flows into cost of products sold.",
        "Hop 2: [Cardinal Health, Inc.] \u2192 [Red Oak Sourcing, LLC]: The relationship is structured such that both CVS and Cardinal jointly own Red Oak, a generic pharmaceutical sourcing entity that negotiates supply contracts for both companies but holds no inventory.",
        "Hop 3: [Red Oak Sourcing, LLC] \u2190 [CVS](page_18): CVS consolidates Red Oak in its financials as the primary beneficiary, and the arrangement is described in the context of sourcing strategy and supply chain efficiency within the Retail/LTC segment."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Depends_On]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Cardinal Health, Inc.",
        "node_3": "Red Oak Sourcing,LLC",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "## Shares Held in Trust\n\nThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.\n\n## Variable Interest Entities\n\nThe Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE's economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE.\n\n## Variable Interest Entities - Primary Beneficiary\n\nIn 2014, the Company and Cardinal Health, Inc. ('Cardinal') established Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment.\n\nCardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company's carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.\n\n## Variable Interest Entities - Other Variable Interest Holder\n\nThe Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:\n\n- Hedge fund and private equity investments - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.\n- Real estate partnerships - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.\n\nThe Company is not the primary beneficiary of these VIEs because the nature of the Company's involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE's income or losses in net income (loss). The Company's maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.\n\nThe total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:\n\n",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Cardinal_Health,_Inc.",
          "name": "Cardinal Health, Inc.",
          "type": "COMP",
          "idf_score": 5.069602770184371
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_1",
          "chunk_text": "## Generic Sourcing Venture\n\nThe Company and Cardinal Health, Inc. ('Cardinal') each have a 50% ownership in Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.\n\n## Working Capital Practices\n\nThe Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, proceeds from sale-leaseback transactions and long-term borrowings. For additional information on the Company's working capital practices, see 'Liquidity and Capital Resources' in the MD&amp;A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS. Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company's consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company's consolidated pharmacy revenues are paid in cash, or with debit or credit cards.\n\n## Human Capital\n\n## Overview\n\nAt CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December 31, 2021, we employed approximately 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 72% of whom were full-time.\n\nWe believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help our Board and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2021, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.\n\nThe Board and our chief executive officer ('CEO') provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.\n\n## Total Rewards\n\nWe recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility.\n\nIn recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company's minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company's competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Red_Oak_Sourcing,LLC",
          "name": "Red Oak Sourcing,LLC",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_1",
          "chunk_text": "## Generic Sourcing Venture\n\nThe Company and Cardinal Health, Inc. ('Cardinal') each have a 50% ownership in Red Oak Sourcing, LLC ('Red Oak'), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.\n\n## Working Capital Practices\n\nThe Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, proceeds from sale-leaseback transactions and long-term borrowings. For additional information on the Company's working capital practices, see 'Liquidity and Capital Resources' in the MD&amp;A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS. Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company's consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company's consolidated pharmacy revenues are paid in cash, or with debit or credit cards.\n\n## Human Capital\n\n## Overview\n\nAt CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December 31, 2021, we employed approximately 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 72% of whom were full-time.\n\nWe believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help our Board and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2021, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.\n\nThe Board and our chief executive officer ('CEO') provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.\n\n## Total Rewards\n\nWe recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility.\n\nIn recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company's minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company's competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 164,
      "question": "How does Merck's financial treatment of the spin-off of Organon on page 124 reconcile with the ongoing supply relationship involving formulated pharmaceutical products, including the $394 million in 2023 sales under manufacturing and supply agreements?",
      "answer": "Merck's spin-off of Organon was reflected in the equity section on page 124, where the balance of accumulated other comprehensive loss included a $449 million adjustment related to the spin-off. Despite the separation, Merck and Organon maintained a significant supply relationship, as evidenced by $394 million in 2023 sales from manufacturing and supply agreements (MSAs) detailed on page 91. These agreements include mutual obligations for manufacturing formulated pharmaceutical products, indicating that while Organon was spun off as a separate entity, Merck continues to derive revenue and incur costs from ongoing supply arrangements, which are reflected in both the income statement and balance sheet accounts such as 'Other current assets' and 'Accrued and other current liabilities'.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_124) \u2192 [Organon]: The spin-off of Organon is reflected in the equity section, with a specific adjustment of $449 million included in accumulated other comprehensive loss.",
        "Hop 2: [Organon] \u2192 [Formulated Pharmaceutical Products]: Following the spin-off, Merck and Organon entered into manufacturing and supply agreements (MSAs) under which Merck supplies formulated pharmaceutical products to Organon.",
        "Hop 3: [Formulated Pharmaceutical Products] \u2190 [MRK](page_91): The MSAs are detailed in the notes, showing that Merck recorded $394 million in sales from these agreements in 2023, with corresponding cost of sales and receivables recorded on the balance sheet."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> COMP -[Supplies]-> PRODUCT <-[Supplies]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Formulated Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                     | Derivatives   |     | Employee Benefit Plans   |     | Foreign Currency Translation Adjustment   | Accumulated Other Comprehensive Loss   |\n|-------------------------------------------------------------------------------------|---------------|-----|--------------------------|-----|-------------------------------------------|----------------------------------------|\n| Balance January 1, 2021, net of taxes                                               | (266)         |     | (4,540)                  | $   | (1,828)                                   | $ (6,634)                              |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 333           |     | 1,737                    |     | (304)                                     | 1,766                                  |\n| Tax                                                                                 | (75)          |     | (332)                    |     | (119)                                     | (526)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 258           |     | 1,405                    |     | (423)                                     | 1,240                                  |\n| Reclassification adjustments, pretax                                                | 192           | (1) | 466                      | (2) | -                                         | 658                                    |\n| Tax                                                                                 | (40)          |     | (102)                    |     | -                                         | (142)                                  |\n| Reclassification adjustments, net of taxes                                          | 152           |     | 364                      |     | -                                         | 516                                    |\n| Other comprehensive income (loss), net of taxes                                     | 410           |     | 1,769                    |     | (423)                                     | 1,756                                  |\n| Spin-off of Organon (see Note 5)                                                    | -             |     | 28                       |     | 421                                       | 449                                    |\n| Balance at December 31, 2021, net of taxes                                          | 144           |     | (2,743)                  |     | (1,830)                                   | (4,429)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 684           |     | 70                       |     | (584)                                     | 170                                    |\n| Tax                                                                                 | (143)         |     | 12                       |     | (19)                                      | (150)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 541           |     | 82                       |     | (603)                                     | 20                                     |\n| Reclassification adjustments, pretax                                                | (775)         | (1) | 329                      | (2) | -                                         | (446)                                  |\n| Tax                                                                                 | 163           |     | (76)                     |     | -                                         | 87                                     |\n| Reclassification adjustments, net of taxes                                          | (612)         |     | 253                      |     | -                                         | (359)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (71)          |     | 335                      |     | (603)                                     | (339)                                  |\n| Balance at December 31, 2022, net of taxes                                          | 73            |     | (2,408)                  | (3) | (2,433)                                   | (4,768)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 114           |     | (413)                    |     | 17                                        | (282)                                  |\n| Tax                                                                                 | (24)          |     | 86                       |     | 63                                        | 125                                    |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 90            |     | (327)                    |     | 80                                        | (157)                                  |\n| Reclassification adjustments, pretax                                                | (237)         | (1) | (64)                     | (2) | 9                                         | (292)                                  |\n| Tax                                                                                 | 50            |     | 6                        |     | -                                         | 56                                     |\n| Reclassification adjustments, net of taxes                                          | (187)         |     | (58)                     |     | 9                                         | (236)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (97)          |     | (385)                    |     | 89                                        | (393)                                  |\n| Balance at December 31, 2023, net of taxes                                          | (24)          |     | (2,793) (3)              | $   | (2,344)                                   | $ (5,161)                              |\n",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "Formulated_Pharmaceutical_Products",
          "name": "Formulated Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Supplies"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 165,
      "question": "How does BMY's royalty-sharing arrangement with Ono for Tecentriq sales compare with Ono's royalty entitlement for Opdivo sales, and what does this reveal about the relative financial stakes for Ono in these two PD-related partnerships?",
      "answer": "BMY and Ono share royalties from Tecentriq sales through a single-digit percentage of worldwide net sales from Roche, with the split between them consistent with existing agreements. Meanwhile, Ono receives a fixed 4% royalty in North America and 15% in other territories (excluding Japan, South Korea, and Taiwan) from BMY on Opdivo sales. This suggests that Ono has a more direct and potentially higher guaranteed stake in Opdivo, whereas Tecentriq royalties depend on Roche's performance and the unspecified split under existing agreements, highlighting differing financial incentives and dependencies in these PD-related partnerships.",
      "reasoning_steps": [
        "Hop 1: BMY(page_90) \u2192 Tecentriq: BMS and Ono have a global patent license agreement with Roche related to Tecentriq, under which Roche pays single-digit royalties on worldwide net sales through 2026, shared between BMS and Ono according to existing agreements.",
        "Hop 2: Tecentriq \u2192 Ono: Ono is a co-licensee with BMS in the Tecentriq agreement, receiving a portion of Roche\u2019s royalty payments, though the exact percentage is not disclosed and is governed by prior arrangements.",
        "Hop 3: Ono \u2190 BMY(page_86): Ono receives fixed royalty rates (4% in North America, 15% elsewhere) from BMY on Opdivo sales, indicating a more structured and transparent revenue model for Ono in this partnership."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Receives]-> PRODUCT -[Receives]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Tecentriq",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "node_2": {
          "id": "Tecentriq",
          "name": "Tecentriq",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## LianBio\t(mavacamten)\n\nIn\tOctober\t2023,\tBMS\treacquired\tthe\trights\tfor\tmavacamten\tin\tChina\tand\tcertain\tother\tAsian\tterritories\tfrom\tLianBio.\tThe transaction\t resulted\t in\t a\t $445\t million\t Acquired\t IPRD\t charge\t which\t included\t the\t cash\t transferred\t of\t $350\t million\t and\t the carrying\tvalue\tof\tpreviously\testablished\tLicense\tintangible\tasset.\n\n## Keytruda*\tPatent\tLicense\tAgreement\n\nBMS\tand\tOno\tare\tparties\tto\ta\tglobal\tpatent\tlicense\tagreement\twith\tMerck\trelated\tto\tMerck's\tPD-1\tantibody Keytruda *.\tUnder\tthe agreement,\tMerck\twas\tobligated\tto\tpay\tongoing\troyalties\ton\tglobal\tsales\tof Keytruda *\tof\t6.5%\tthrough\tDecember\t31,\t2023,\tand will\tpay\t2.5%\tfrom\tJanuary\t1,\t2024\tthrough\tDecember\t31,\t2026.\tThe\tcompanies\talso\tgranted\tcertain\trights\tto\teach\tother\tunder their\t respective\t patent\t portfolios\t pertaining\t to\t PD-1.\t Payments\t and\t royalties\t are\t shared\t between\t BMS\t and\t Ono\t on\t a\t 75/25 percent\tallocation,\trespectively\tafter\tadjusting\tfor\teach\tparties'\tlegal\tfees.\n\n## Tecentriq*\tPatent\tLicense\tAgreement\n\nBMS\t and\t Ono\t are\t parties\t to\t a\t global\t patent\t license\t agreement\t with\t Roche\t Group\t related\t to Tecentriq *,\t Roche's\t anti-PD-L1 antibody.\tUnder\tthe\tagreement,\tRoche\tis\tobligated\tto\tpay\tsingle-digit\troyalties\ton\tworldwide\tnet\tsales\tof Tecentriq *\tthrough December\t31,\t2026.\tThe\troyalties\tare\tshared\tbetween\tBMS\tand\tOno\tconsistent\twith\texisting\tagreements.",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_5",
          "chunk_text": "\nBMS\tis\tthe\tprincipal\tin\tthe\tend\tcustomer\tproduct\tsales\tand\thas\tthe\texclusive\tright\tto\tdevelop,\tmanufacture\tand\tcommercialize Opdivo worldwide\texcept\tin\tJapan,\tSouth\tKorea\tand\tTaiwan.\tOno\tis\tentitled\tto\treceive\troyalties\tof\t4%\tin\tNorth\tAmerica\tand\t15% in\tall\tterritories\texcluding\tthe\tthree\tcountries\tlisted\tabove,\tsubject\tto\tcustomary\tadjustments.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 166,
      "question": "How does AbbVie's acquisition of ImmunoGen for $9.8 billion in total fair value relate to the strategic positioning of Elahere, given its inclusion in the core oncology product portfolio and the associated goodwill implications?",
      "answer": "AbbVie acquired ImmunoGen for $9.8 billion in total fair value, gaining access to Elahere, an approved antibody-drug conjugate (ADC) for platinum-resistant ovarian cancer, which is now part of AbbVie\u2019s core oncology portfolio. Despite the acquisition being accounted for under the acquisition method with finalized valuations by December 2024, the company reported no accumulated goodwill impairment losses as of year-end. This suggests that while Elahere is strategically positioned as a key oncology asset, its long-term value realization remains contingent on commercial success and integration outcomes, which could influence future goodwill assessments.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_72) \u2192 ImmunoGen: AbbVie acquired ImmunoGen for $9.8 billion in total fair value, with no accumulated goodwill impairment losses as of December 31, 2024.",
        "Hop 2: ImmunoGen \u2192 Elahere: ImmunoGen developed Elahere, a first-in-class ADC for platinum-resistant ovarian cancer, which is a flagship asset in their oncology pipeline.",
        "Hop 3: Elahere \u2190 ABBV(page_6): Elahere is listed among AbbVie\u2019s core oncology products, approved in both the U.S. and EU, and is positioned as a treatment for FR\u03b1-positive, platinum-resistant epithelial ovarian cancer."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Develops]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "ImmunoGen",
        "node_3": "Elahere",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_7",
          "chunk_text": "\n(a) Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5).\n\nThe company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of December 31, 2024 and 2023, there were no accumulated goodwill impairment losses.\n\n## 69 | 2024 Form 10-K",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "ImmunoGen",
          "name": "ImmunoGen",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "AbbVie also assumed a licensing agreement entered into by Cerevel Therapeutics with Pfizer Inc. (Pfizer) prior to the acquisition. Under the agreement, Cerevel Therapeutics was granted an exclusive global license under certain Pfizer patent rights to develop, manufacture and commercialize compounds included i n Cerevel Therapeutic's pipeline. AbbVie could make additional payments of up to $1.6 billion upon achievement of certain regulatory and commercial milestones for all programs. Additionally, AbbVie will pay tiered royalties on net revenues.\n\nFollowing the acquisition date, the operating results of Cerevel Therapeutics have been included in the consolidated financial statements. For the period from the acquisition date through December 31, 2024, operating losses attributable to Cerevel Therapeutics were $4.9 billion, inclusive of an intangible asset i mpairment charge of $4.5 billion related to emraclidine. See Note 7 for additional information. Operating losses attributable to Cerevel Therapeutics also i ncluded $161 million of cash-settled, post-closing expense for Cerevel Therapeutics employee incentive awards. AbbVie issued 0.3 million RSUs to holders of Cerevel Therapeutics equity awards based on a conversion factor described in the transaction agreement. Stock compensation expense related to RSUs issued at the acquisition date was not significant.\n\nAcquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $44 million for the year ended December 31, 2024 and were included in selling, general and administrative (SG&amp;A) expense in the consolidated statements of earnings.\n\n## Acquisition of ImmunoGen, Inc.\n\nOn February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen. ImmunoGen is a commercial-stage biotechnology company focused on the discovery, development and commercialization of antibody-drug conjugates (ADC) for cancer patients. ImmunoGen's oncology portfolio includes i ts  fl a gs hi p cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. The combination accelerates AbbVie's entry into the solid tumor space and strengthens its oncology pipeline. Under the terms of the agreement, AbbVie acquired all outstanding shares of ImmunoGen for $31.26 per share in cash. The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired).\n\nThe acquisition of ImmunoGen has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed was finalized during the three months ended December 31, 2024.\n\nThe following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date:\n\n",
          "relationship": "Develops"
        },
        "node_3": {
          "id": "Elahere",
          "name": "Elahere",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "3\n\nOncology products. AbbVie's oncology products target some of the most complex and difficult-to-treat cancers. These products are:\n\nImbruvica. Imbruvica (ibrutinib) is an oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one of the first medicines to receive a United States Food and Drug Administration (FDA) approval after being granted a Breakthrough Therapy Designation and is one of the few therapies to receive four separate designations. Imbruvica currently is approved for the treatment of adult patients with blood cancers such as chronic l ymphocytic leukemia (CLL), as well as certain forms of non-Hodgkin lymphoma. Imbruvica is approved in adult and pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy.\n\nVenclexta/Venclyxto. Venclexta (venetoclax) is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers. Venclexta is approved by the FDA for adults with CLL or small lymphocytic lymphoma. In addition, Venclexta is approved in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia who are 75 years of age or older or have other medical conditions that prevent the use of standard chemotherapy.\n\nElahere. Elahere (mirvetuximab soravtansine-gynx) is an anObody-drug conjugate (ADC) used to treat certain types of cancer. Elahere is approved in both the United States and the European Union for the treatment of adult paOents with FR\u03b1 posiOve, plaOnum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.\n\nEpkinly .  Epkinly  (epcoritamab)  is  a  product  used  to  treat  adults  with  certain  types  of  diffuse  large  B-cell  lymphoma  (DLBCL)  and  high-grade  B-cell l ymphoma that has recurred or that does not respond to previous treatment aRer receiving two or more treatments. Epkinly is administered as a subcutaneous i njection. Epkinly is also approved to treat adults with relapsed or refractory follicular lymphoma.\n\nAesthetics products. AbbVie's Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring and skincare products, which hold market-leading positions in the U.S. and in key markets around the world. These products are:\n\nBotox Cosmetic. Botox Cosmetic is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for treatment in four areas: temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows), moderate to severe crow's feet, moderate to severe forehead lines in adults and moderate to severe platysma bands. Botox Cosmetic is approved for use in all major markets around the world and is approved for the treatment of masseter muscle prominence in China.\n\nThe Juvederm Collection of Fillers. The Juvederm Collection of Fillers is a portfolio of hyaluronic acid-based dermal fillers with a variety of approved i ndications in the U.S. and in other major markets around the world to augment or treat volume loss in the temples, undereye, cheeks, chin, lips and lower face.\n\nOther aesthetics. Other aesthetics products include, but are not limited to, Alloderm regenerative dermal tissue, CoolSculpting body contouring technology, Natrelle breast implants, the SkinMedica skincare line, Latisse eyelash solution and DiamondGlow dermabrasion technology.\n\nNeuroscience products. AbbVie's neuroscience products address some of the most difficult-to-treat neurologic diseases. These products are:\n\nBotox Therapeutic. Botox Therapeutic (onabotulinumtoxinA injection) is an acetylcholine release inhibitor and a neuromuscular blocking agent that is i njected into muscle tissue. In the United States, it is approved to treat numerous indications, including chronic migraine, overactive bladder in adults who have an inadequate response to an anticholinergic medication, and urinary incontinence due to detrusor overactivity associated with a neurologic condition i n adults who have an inadequate response to an anticholinergic medication. In addition, Botox Therapeutic is approved to treat spasticity in patients two years of age and older, cervical dystonia in adults, as well as other conditions. Botox is marketed in other countries around the world and licenses will vary. Botox Therapeutic is marketed by GSK in Japan.\n\nVraylar. Vraylar (cariprazine) is a dopamine D3-preferring D3/D2 receptor partial agonist and a 5-HT1A receptor partial agonist. Vraylar is indicated for acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar disorder in adults, acute treatment of depressive episodes associated with bipolar I disorder in adults and as an adjunctive treatment in major depressive disorder.\n\nDuopa and Duodopa (carbidopa and levodopa).    AbbVie's levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States.\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 167,
      "question": "How does Gilead's settlement with Lupin Ltd. regarding Symtuza relate to the broader licensing strategy reflected in the Biktarvy litigation and settlement agreements, particularly in terms of timing and exclusivity conditions?",
      "answer": "Gilead's settlement with Lupin Ltd. in September 2022 involved granting a non-exclusive license for Symtuza, beginning on a future agreed-upon date or earlier under certain conditions. This mirrors the broader licensing strategy seen in the Biktarvy litigation, where multiple generic manufacturers, including Cipla and Laurus, challenged Gilead's patents, leading to lawsuits and potential settlements involving similar non-exclusive licenses. The timing of these licenses\u2014often deferred to a future date unless specific conditions are met\u2014suggests a strategic effort to delay generic competition while managing litigation risk and maintaining revenue exclusivity for as long as possible.",
      "reasoning_steps": [
        "Hop 1: GILD(page_9) \u2192 Lupin Ltd.: Gilead entered into a settlement agreement with Lupin Ltd. in September 2022, granting a non-exclusive license for Symtuza with a deferred effective date.",
        "Hop 2: Lupin Ltd. \u2192 License: Lupin's ANDA submission and subsequent litigation led to a licensing resolution, indicating a strategic approach to generic challenges.",
        "Hop 3: License \u2190 GILD(page_87): Gilead's broader pattern of handling generic challenges includes litigation and settlement with other manufacturers (e.g., Cipla and Laurus) over Biktarvy, also resulting in deferred non-exclusive licenses."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Faces]-> REGULATORY_REQUIREMENT <-[Invests_In]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Lupin Ltd.",
        "node_3": "License",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nWhere applicable, settlement and license agreements w ith generic manufacturers relating to the patents that protect our principal products are noted. The nature and timing of loss of exclusivity for these products depends on a multitude of factors, and loss of exclusivity may be earlier under certain circumstances. For more information, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.' (1)\n\nIn S eptember 2022, G ilead and five generic manufacturers (Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.) reached agreements to settle the U.S . patent litigation concerning patents that protect TAF in our Descovy, V emlidy and Odefsey products. (2)\n\nThe composition of matter patent has expired in the EU. In the EU and the U.S ., patent applications are pending relating to our proprietary manufacturing processes. (3)\n\nIn 2018, G ilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our S tribild and G envoya products. (4)\n\nIn February 2025, G ilead reached an agreement w ith one generic manufacturer (Apotex, Inc., together w ith Apotex C orp., and its manufacturer of cobicistat, MS N Laboratories Private Limited, MS N Life S ciences Private Ltd., and MS N Pharmaceuticals Inc.) to settle the patent litigation concerning certain patents that protect cobicistat on silicon dioxide and TAF in our G envoya product. The Apotex/MS N agreement provides a non-exclusive license to those patents beginning on August 6, 2032, or earlier in certain circumstances. (5)\n\nIn January 2024, FDA granted pediatric exclusivity for V eklury, w hich extends all non-expired exclusivities by six months, and w hich is reflected in the presently reported date. (6)\n\nR eg u latory exclusivity in the U.S . expires in 2032. (7)\n\nOrphan exclusivity expires in 2031. (8)\n\nTen years of regulatory/market exclusivity expected on approval. (9)\n\n## Patent and Trade Secret Strategy\n\nFor a discussion of risks and challenges associated with our patent and trade secret strategy described below, see Item 1A. Risk Factors 'Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.'\n\n## Patents\n\nPatents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As  part  of  our  business  strategy,  we  actively  seek  patent  protection  both  in  the  U.S.  and  internationally  and  file  additional  patent  applications,  when appropriate, to cover improvements in our compounds, products and technology.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Lupin_Ltd.",
          "name": "Lupin Ltd.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_1",
          "chunk_text": "## Litigation Relating to Pre-Exposure Prophylaxis\n\nIn August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, 'HHS Patents') by the Patent Trial and Appeal Board ('PTAB'). The HHS Patents are assigned to the U.S. Department of Health and Human Services ('HHS') and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate ('TDF') or tenofovir alafenamide ('TAF') prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis ('PrEP'). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the use of Truvada and Descovy for PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a lawsuit against the U.S. federal government in the U.S. Court of Federal Claims ('CFC'), alleging breach of three material transfer agreements ('MTAs') related to the research underlying the HHS Patents and two clinical trial agreements ('CTAs') by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the CFC was held in June 2022, and in November 2022, the CFC determined that the government breached the MTAs. In January 2024, the CFC found the government liable for breach of both CTAs. In May 2023, the District Court held a trial regarding the government's patent infringement claims, and the jury rendered a full defense verdict in favor of G ilead, finding that the asserted claims of the HHS Patents are invalid and the HHS patents are not infringed. In March 2024, the District Court upheld the jury's verdict that the government's patents are invalid, denied the government's request for a new trial and then entered final judgment. In July 2024, the government filed a notice of appeal. In January 2025, we entered into a settlement agreement with the government to resolve these litigation matters relating to PrEP. The settlement includes the dismissal of both lawsuits, including the government's appeal of the jury verdict that its patents are invalid, as well as a license to the government's ex isting PrEP patents.\n\n## Litigation with Generic Manufacturers\n\nAs part of the approval process for some of our products, FDA granted us a New Chemical Entity ('NCE') exclusivity period during which other manufacturers' applications for approval of generic versions of our products will not be approved. G eneric manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application ('ANDA'), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product's approval.\n\nIn  October  2021,  we  received  a  letter  from  Lupin  Ltd.  ('Lupin')  indicating  that  it  has  submitted  an ANDA  to  FDA  requesting  permission  to  market  and manufacture a generic version of Symtuza, a product commercialized by Janssen Products L.P. and for which G ilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (together, 'Janssen'), filed a patent infringement lawsuit against Lupin as co-plaintiffs in  the  U.S.  District  Court  of  Delaware.  In  September  2022,  we  received  a  letter  from Apotex   Inc.  and Apotex   Corp.  (together,  'Apotex ')  stating  that  they  have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. The cases against Lupin and Apotex were consolidated into a single trial scheduled for February 2025. In February 2025, we, along with Janssen, entered into a settlement agreement with Lupin and its manufacturer of cobicistat on silicon dioxide, MSN Laboratories Private Limited, MSN Life Sciences Private  Ltd., and  MSN  Pharmaceuticals  Inc. (collectively, 'MSN'), to resolve the litigation and patent challenges associated with  Symtuza in the  U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Lupin and MSN were granted a non-exclusive license for Lupin's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. In February 2025, we, along with Janssen, entered into a settlement agreement with Apotex to resolve the litigation and patent challenges associated with Symtuza in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex was granted a non-exclusive license for Apotex's ANDA product in the U.S. to our patent, jointly owned with Janssen, relating to a use of Symtuza, beginning on an agreed-upon date in the future, or earlier in certain circumstances. The terms of the settlement agreement are confidential. Both settlement agreements with Lupin and Apotex have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "License",
          "name": "License",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_87",
          "chunk_id": "chunk_1",
          "chunk_text": "Starting in March 2022, we received letters from Lupin, Laurus Labs ('Laurus') and Cipla Ltd. ('Cipla'), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of the adult dosage strength of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of four of the six  patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of  Delaware  and  intend  to  enforce  and  defend  our  intellectual  property. Additionally,  in  November  2023,  we  received  a  letter  from  Cipla  indicating  that  it  has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of the pediatric dosage strength of Biktarvy. Cipla challenged the validity of two of the patents listed in the Orange Book as associated with Biktarvy. We filed a separate lawsuit against Cipla in December 2023 in the U.S. District Court of Delaware. This lawsuit has been consolidated with the first lawsuit, with a single trial scheduled for October 2025. In October 2024, Cipla separately filed a petition at the U.S. Patent &amp; Trademark Office ('USPTO') for Inter Partes Review (IPR) of one of the patents at issue in District Court litigation. We intend to defend this patent at the USPTO.\n\nIn June 2023, we received a letter from Apotex indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of  G envoya.  In  July  2023,  we  filed  a  patent  infringement  lawsuit  against Apotex   in  the  U.S.  District  Court  of  Delaware  and  to  enforce  and  defend  our intellectual property. This case was consolidated with the Symtuza matters discussed above, and a trial was scheduled for February 2025. In February 2025, we entered into a settlement agreement with Apotex and its manufacturer of cobicistat on silicon dioxide, MSN, to resolve the litigation and patent challenges associated with Genvoya in the U.S. District Court for the District of Delaware. Pursuant to the settlement agreement, Apotex and MSN were granted a non-exclusive license for Apotex's ANDA product in the U.S. to certain of our patents on cobicistat on silicon dioxide and TAF relating to G envoya beginning on August 6, 2032, or earlier in certain circumstances. The settlement agreement has been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.\n\n## Antitrust and Consumer Protection\n\nWe, along with Bristol-Myers Squibb Company ('BMS'), Johnson &amp; Johnson, Inc. ('Johnson &amp; Johnson'), and Teva Pharmaceutical Industries Ltd. ('Teva') have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV , including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs consisting of retail pharmacies, individual health plans and United Healthcare, filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the classes. These cases have been coordinated with the class actions. In March 2023, the District Court granted our motion to hold separate trials as to (i) the allegations against us and Teva seeking monetary damages relating to Truvada and Atripla ('Phase I') and (ii) the allegations against us and, in part, Johnson &amp; Johnson, seeking monetary damages and injunctive relief relating to Complera ('Phase II'). In May 2023, we settled claims with the direct purchaser class and the retailer opt-out plaintiffs for $525 million, which we paid in the second half of 2023. The settlement agreements are not an admission of liability or fault by us. In June 2023, the jury returned a complete verdict in G ilead's favor on the remaining plaintiffs' Phase I allegations. In November 2023, the court denied plaintiffs' motion to set aside the verdict, and in February 2024, the court entered final judgment on the Phase I verdict and certain summary judgment rulings. In September 2024, plaintiffs filed their opening appellate briefs challenging the Phase I verdict and those summary judgment rulings. We filed our responsive briefs in January 2025. The court has stayed Phase II pending the appeal of Phase I. While we intend to vigorously oppose the appeal and defend against the Phase II claims, we cannot predict the ultimate outcome. If plaintiffs are successful in their appeal or Phase II claims, we could be required to pay monetary damages or could be subject to permanent injunctive relief in favor of plaintiffs.\n\nIn January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief. In March 2024, the court denied our motion for judgment on the pleadings to preclude Aetna from re-litigating claims that were dismissed at summary judgment in the above class action cases. We filed a writ petition appealing the denial of our motion for judgment on the pleadings, which the appellate court denied in May 2024. In April 2024, the court granted our motion to bifurcate the case to adjudicate the issue of preclusion before litigating the merits of the case. In July 2024, Aetna filed a request to voluntarily dismiss two of its claims with prejudice, which the court subsequently granted, leaving only the claims related to Truvada and Atripla. In September 2024, Aetna filed an amended complaint with respect to these claims. In October 2024, we filed a demurrer and motion to strike plaintiff's claims.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 168,
      "question": "How does Amgen's concern about Express Scripts' influence on patient access to Repatha relate to the company's broader commitment to facilitating patient access through pricing adjustments and support programs?",
      "answer": "Amgen identifies Express Scripts, along with other major PBMs, as contributing to restricted patient access to Repatha due to their significant negotiating leverage, which results in deeper discounts and formulary restrictions. Despite Amgen\u2019s efforts to improve access by reducing Repatha\u2019s list price and offering new National Drug Codes to lower co-pay costs, payers like Express Scripts have continued to impose utilization criteria and prior authorization requirements that limit patient use. In contrast, on page 17, Amgen emphasizes its commitment to ensuring patient access through initiatives such as co-pay assistance programs, biosimilar development, and risk-sharing partnerships with payers. The tension between these two perspectives reveals that while Amgen is actively working to enhance access, structural market forces\u2014particularly the dominance of large PBMs like Express Scripts\u2014are undermining these efforts, highlighting a key risk to the company\u2019s commercial success and strategic goals.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_37) \u2192 [Express Scripts]: Amgen identifies Express Scripts as a major PBM exerting pricing pressure and restricting patient access to Repatha through formulary exclusions and utilization management.",
        "Hop 2: [Express Scripts] \u2192 [Patient Access]: Express Scripts\u2019 formulary restrictions and prior authorization requirements directly limit patient access to Repatha, despite Amgen\u2019s pricing adjustments.",
        "Hop 3: [Patient Access] \u2190 [AMGN](page_17): Amgen states a strategic commitment to improving patient access through co-pay programs, biosimilars, and partnerships, yet acknowledges the challenges posed by payer practices."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> COMP -[Negatively_Impacts]-> RISK_FACTOR <-[Enables]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Express Scripts",
        "node_3": "Patient Access",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "RISK_FACTOR",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Express_Scripts",
          "name": "Express Scripts",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "expected to continue to have, a negative impact on the Company's product sales, business and results of operations. Louisiana, Arkansas, West V irginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B Program, and, in 2024, no fewer than 25 states considered similar legislation. These bills vary, but typically include provisions on restricting a manufacturer's ability to direct drugs in 340B channels, recognizing 340B contract  pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers.  In  March 2024, the  U.S.  Court of Appeals for the 8th  Circuit ruled that Arkansas' Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision contributed to an increase in the number of states considering similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisiana's 340B contract pharmacy mandate law, and the U.S. District Court for the  District of  Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of who is considered a patient under the 340B Program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.\n\nAdditionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, though the state has not completed any significant steps towards importation within the one-year authorization window. Colorado, Maine, New Hampshire, New Mexico, Texas and V ermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.\n\nUltimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.\n\n## -U.S. commercial payer actions have affected, and may continue to affect, access to and sales of our products\n\nPayers, including healthcare insurers,  PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, are continuing to seek ways to further reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patients' use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, and to also impose restrictions on access to, or usage of, our products (such as Step Therapy), require that patients receive the payer's prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list  price.  However,  affordability  of  patient  out-of-pocket  co-pay  cost  has  limited,  and  may  continue  to  limit,  patient  use.  Further,  despite  these  net  and  list  price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce its sales. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in  the  United  States,  the  FTC's  interim  report  released  in  2024  showed  that  the  top  six   integrated  health  plans  and  PBMs  controlled  about  94%  of  all  pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mailorder pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health G roup (among the top six integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts on their behalf and for the benefit of their other customers. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_17",
          "chunk_id": "chunk_1",
          "chunk_text": "ENBREL's profitability in Medicare. In January 2025, CMS announced the next 15 drugs for Medicare price setting that will be applicable beginning on January 1, 2027, which includes Otezla. Also under the IRA, starting on January 1, 2024, Medicare Part D was redesigned to cap beneficiary out-of-pocket costs and, beginning on January 1, 2025, Federal reinsurance will become reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs). Further, the IRA created a mechanism for CMS to collect rebates from manufacturers if price increases outpace inflation. We began to accrue for rebate obligations on October 1, 2022 for Medicare Part D and on January 1, 2023 for Medicare Part B.\n\nOther potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; increasing transparency in drug pricing; using third-party value assessments to determine drug prices; referencing foreign prices; and changes to government rebate programs. For example, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal, which excludes biologics. CMS also issued a proposed Medicaid Drug Rebate Program rule that would have required manufacturers to aggregate or 'stack' all rebates, discounts or other price concessions made to separate, unrelated entities across the pharmaceutical supply chain on a given unit of product to determine the 'Best Price,' a metric that is used to determine Medicaid rebates and 340B statutory rates. This proposal was not finalized but remains a policy that could be reconsidered in the future. Further, at the state level, eight states (Colorado, Maine, Maryland, Minnesota, New Hampshire, New Jersey, Oregon and Washington) have enacted laws that establish PDABs to identify drugs that pose affordability challenges, and in four states (Colorado, Maryland, Minnesota and Washington) include authority for the state PDAB to set upper payment limits on certain drugs for in-state patients, payers and providers.\n\nIn  many  countries  other  than  the  United  States,  government-sponsored  healthcare  systems  are  the  primary  payers  for  drugs  and  biologics.  With  increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in rebates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many governments use health technology assessment organizations to judge the added benefit of new treatments over existing ones, metrics which are then used to set reimbursement prices and/or set coverage limits. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that governments will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and revision of its pharmaceutical legislation. Various proposals are under consideration with the EU Council, followed by a negotiation among the EU government to agree to a final law. Full implementation is not expected until 2027 or later. The new legislation, if implemented, will likely have a significant impact on the landscape for access and pricing decisions within EU Member States.\n\nThe dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. G iven the diverse interests  in  play  between  payers,  biopharmaceutical  manufacturers,  policy  makers,  healthcare  providers  and  independent  organizations,  if  and  whether  the  parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:\n\n- investing billions of dollars annually in R&amp;D;\n- pricing our medicines to reflect the value they provide;\n- developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;\n- partnering with payers to share risk and accountability for health outcomes;\n- providing patient support and education programs;\n- helping patients in financial need access our medicines; and\n- working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.\n\nSee  Item  1A.  Risk  FactorsOur  sales  depend  on  coverage  and  reimbursement  from  government  and  commercial  third-party  payers,  and  pricing  and reimbursement pressures have affected, and are likely to continue to affect, our profitability and Item 1A. Risk FactorsGuidelines and recommendations published by various organizations can reduce the use of our products.",
          "relationship": "Enables"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 169,
      "question": "How does Gilead's revenue share from Symtuza sales relate to its contractual dependency on Janssen's pricing and commercialization decisions, given the structure of their collaboration agreement?",
      "answer": "Gilead's revenue share from Symtuza is directly tied to Janssen's pricing and commercialization decisions, as Janssen sets the price of Symtuza and is responsible for its global distribution. Gilead supplies the Gilead Compounds and receives a share of the revenue based on the ratio of net selling prices of each party's components. This revenue share is recognized by Gilead as Product Sales when Janssen makes corresponding sales. However, because Janssen controls the commercialization and pricing strategy, Gilead's financial performance from Symtuza is contingent on Janssen's market approach, including pricing decisions and sales execution. This dependency creates a risk for Gilead, as changes in Janssen's strategy or termination of the agreement could directly impact Gilead\u2019s revenue from Symtuza, despite Gilead\u2019s exclusive supply role.",
      "reasoning_steps": [
        "Hop 1: GILD(page_66) \u2192 Symtuza: Gilead reports Symtuza revenueshare as $592 million in total product sales for 2024, indicating its financial significance.",
        "Hop 2: Symtuza \u2192 Janssen: Gilead granted Janssen an exclusive global license to Symtuza, under which Janssen is responsible for manufacturing, registration, distribution, and commercialization.",
        "Hop 3: Janssen \u2190 GILD(page_77): Gilead recognizes Symtuza revenue based on Janssen\u2019s sales and pricing decisions, with revenue share recognized as Product Sales, highlighting Gilead\u2019s dependency on Janssen\u2019s commercial execution."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Commercializes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Symtuza",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                  | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2024   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2023   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   | YearEndedDecem ber 31, 2022   |\n|----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|\n| (inm illions)                    | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         | U.S.                          | Europe (6 )                   | Rest of World (6 )            | Total                         |\n| Productsales:                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| HIV                              |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Biktarvy                         | $ 10,855                      | $ 1,509                       | $ 1,060                       | $ 13,423                      | $ 9,692                       | $ 1,253                       | $ 905                         | $ 11,850                      | $ 8,510                       | $ 1,103                       | $ 777                         | $ 10,390                      |\n| Descovy                          | 1,902                         | 100                           | 110                           | 2,113                         | 1,771                         | 100                           | 114                           | 1,985                         | 1,631                         | 118                           | 123                           | 1,872                         |\n| Genvoya                          | 1,498                         | 180                           | 84                            | 1,762                         | 1,752                         | 205                           | 103                           | 2,060                         | 1,983                         | 284                           | 136                           | 2,404                         |\n| Odefsey                          | 957                           | 290                           | 41                            | 1,288                         | 1,012                         | 294                           | 44                            | 1,350                         | 1,058                         | 364                           | 47                            | 1,469                         |\n| Sym tuza-Revenueshare (1)        | 450                           | 130                           | 12                            | 592                           | 382                           | 133                           | 13                            | 529                           | 348                           | 168                           | 14                            | 530                           |\n| OtherHIV (2)                     | 257                           | 129                           | 48                            | 434                           | 238                           | 116                           | 47                            | 401                           | 290                           | 182                           | 59                            | 530                           |\n| Total HIV                        | 15,918                        | 2,339                         | 1,355                         | 19,612                        | 14,848                        | 2,102                         | 1,226                         | 18,175                        | 13,820                        | 2,219                         | 1,155                         | 17,194                        |\n| LiverD isease                    |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Sof osbuvir/V elpatasvir (3)     | 922                           | 299                           | 374                           | 1,596                         | 859                           | 323                           | 355                           | 1,537                         | 844                           | 355                           | 331                           | 1,530                         |\n| Vem lidy                         | 486                           | 44                            | 428                           | 959                           | 410                           | 38                            | 414                           | 862                           | 429                           | 35                            | 379                           | 842                           |\n| OtherLiverDisease (4)            | 192                           | 202                           | 73                            | 467                           | 152                           | 150                           | 83                            | 385                           | 167                           | 135                           | 124                           | 426                           |\n| Total LiverDisease               | 1,601                         | 545                           | 876                           | 3,021                         | 1,421                         | 511                           | 852                           | 2,784                         | 1,440                         | 525                           | 833                           | 2,798                         |\n| Veklury                          | 892                           | 284                           | 623                           | 1,799                         | 972                           | 408                           | 805                           | 2,184                         | 1,575                         | 702                           | 1,628                         | 3,905                         |\n| Oncology                         |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Cell Therapy                     |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| Tecartus                         | 234                           | 138                           | 31                            | 403                           | 245                           | 110                           | 15                            | 370                           | 221                           | 75                            | 3                             | 299                           |\n| Yescarta                         | 662                           | 666                           | 242                           | 1,570                         | 811                           | 547                           | 140                           | 1,498                         | 747                           | 355                           | 57                            | 1,160                         |\n| Total Cell Therapy               | 896                           | 804                           | 274                           | 1,973                         | 1,055                         | 658                           | 156                           | 1,869                         | 968                           | 430                           | 60                            | 1,459                         |\n| Trodelvy                         | 902                           | 294                           | 119                           | 1,315                         | 777                           | 217                           | 68                            | 1,063                         | 525                           | 143                           | 12                            | 680                           |\n| Total Oncology                   | 1,798                         | 1,098                         | 393                           | 3,289                         | 1,833                         | 875                           | 224                           | 2,932                         | 1,494                         | 573                           | 73                            | 2,139                         |\n| Other                            |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |\n| AmBisom e                        | 44                            | 276                           | 212                           | 533                           | 43                            | 260                           | 189                           | 492                           | 57                            | 258                           | 182                           | 497                           |\n| Other (5)                        | 255                           | 34                            | 68                            | 356                           | 261                           | 40                            | 66                            | 367                           | 331                           | 65                            | 53                            | 449                           |\n| Total Other                      | 299                           | 310                           | 280                           | 889                           | 304                           | 301                           | 255                           | 859                           | 388                           | 323                           | 235                           | 946                           |\n| Total product sales              | 20,508                        | 4,576                         | 3,526                         | 28,610                        | 19,377                        | 4,197                         | 3,361                         | 26,934                        | 18,716                        | 4,342                         | 3,924                         | 26,982                        |\n| Royalty,contractandotherrevenues | 82                            | 58                            | 4                             | 144                           | 62                            | 114                           | 7                             | 182                           | 168                           | 127                           | 4                             | 299                           |\n| Total revenues                   | $ 20,591                      | $ 4,634                       | $ 3,529                       | $ 28,754                      | $ 19,438                      | $ 4,310                       | $ 3,368                       | $ 27,116                      | $ 18,884                      | $ 4,469                       | $ 3,928                       | $ 27,281                      |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 170,
      "question": "How does the launch of Cordavis in 2024 as a biosimilar-focused subsidiary align with CVS's broader negotiated relationships with pharmaceutical manufacturers, particularly in light of the Health Services segment's reported 90 million plan members?",
      "answer": "CVS launched Cordavis in 2024 to work directly with pharmaceutical manufacturers to commercialize and/or co-produce high-quality biosimilar products, aiming to increase access and reduce costs for clients. This initiative aligns with the Health Services segment's broader role in negotiating pricing and rebates with pharmaceutical manufacturers on behalf of its participants, as noted in the segment overview. With approximately 90 million plan members served by the PBM solutions, the integration of Cordavis supports CVS\u2019s strategy to enhance cost management and improve health outcomes across its extensive client base. This alignment demonstrates a strategic and operational synergy between a newly created subsidiary and long-standing manufacturer partnerships, both aimed at delivering value-based health care solutions.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_72) \u2192 [Cordavis]: CVS launched Cordavis as a wholly owned subsidiary focused on biosimilars, aiming to increase access and reduce costs for clients.",
        "Hop 2: [Cordavis] \u2192 [Pharmaceutical Manufacturers]: Cordavis works directly with pharmaceutical manufacturers to commercialize and/or co-produce biosimilar products.",
        "Hop 3: [Pharmaceutical Manufacturers] \u2190 [CVS](page_112): The Health Services segment negotiates pricing and rebates with pharmaceutical manufacturers on behalf of its participants and serves approximately 90 million plan members."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> COMP -[Works_With]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Cordavis",
        "node_3": "Pharmaceutical Manufacturers",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. ('MD&amp;A')\n\nThe following discussion and analysis should be read in conjunction with the audited consolidated financial statements and related notes included in Item 8 of this Annual Report on Form 10-K (this '10-K'), 'Risk Factors' included in Item 1A of this 10-K and the 'Cautionary Statement Concerning Forward-Looking Statements' in this 10-K.\n\n## Overview of Business\n\nCVS Health Corporation, together with its subsidiaries (collectively, 'CVS Health,' the 'Company,' 'we,' 'our' or 'us'), is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of December 31, 2024, the Company had more than 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members and expanding specialty pharmacy solutions, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan ('PDP'). The Company is creating new sources of value through its integrated model allowing it to ex pand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.\n\nThe Company has four reportable segments: Health Care Benefits, Health Services, Pharmacy &amp; Consumer Wellness and Corporate/Other, which are described below.\n\n## Overview of the Health Care Benefits Segment\n\nThe Health Care Benefits segment operates as one of the nation's leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs and Medicaid health care management services. The Health Care Benefits segment's primary customers, its members, primarily access the segment's products and services through employer groups, government-sponsored plans or individually. The Health Care Benefits segment also serves customers who purchase products and services that are ancillary to its health insurance products. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as 'Insured' and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as 'ASC.' The Company sold Insured plans directly to individual consumers through the individual public health insurance exchanges ('Public Exchanges') in 17 states as of December 31, 2024.\n\n## Overview of the Health Services Segment\n\nThe Health Services segment provides a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. PBM solutions include plan design offerings and administration, formulary management, retail pharmacy network management services, and specialty and mail order pharmacy services. In addition, the Company provides clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities ('Covered Entities'). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants and provides various administrative, management and reporting services to pharmaceutical manufacturers. During 2023, the Company completed the acquisition of two key health care delivery assets - Signify Health, Inc. ('Signify Health'), a leader in health risk assessments, value-based care and provider enablement services, and Oak Street Health, Inc. ('Oak Street Health'), a leading multi-payor operator of value-based primary care centers serving Medicare eligible patients. The Company also launched Cordavis , a wholly owned subsidiary that works directly with pharmaceutical manufacturers to commercialize and/or coproduce high quality biosimilar products. The Health Services segment's clients and customers are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public and private health insurance exchanges and other sponsors of health benefit plans throughout the U.S., patients who receive care in the Health Services segment's medical clinics, virtually or in the home, as well as Covered Entities. TM",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Cordavis",
          "name": "Cordavis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_12",
          "chunk_id": "chunk_1",
          "chunk_text": "two programs administered by CMS, the Accountable Care Organization ('ACO') Realizing Equity, Access, and Community Health ('REACH') Model (collectively, 'ACO REACH') and the Medicare Shared Savings Program ('MSSP'), under which the Company served a total of more than 1 million covered lives as of December 31, 2024.\n\nACOs are networks of healthcare providers and suppliers that work together to invest in infrastructure and redesign delivery processes to attempt to achieve high quality and efficient delivery of services. ACOs that achieve performance standards established by the U.S. Department of Health and Human Services ('HHS') are eligible to share in a portion of the amounts saved by the Medicare program.\n\n## In-Home Health Evaluations\n\nAs a complement to its value-based care delivery, the Company operates a large mobile network of credentialed providers in the U.S. through its Signify Health business. These credentialed providers are deployed into the home primarily to conduct in-home health evaluations ('IHEs') and perform select diagnostic services. IHEs may also be performed virtually or at a healthcare provider facility. During the year ended December 31, 2024, the Company performed more than 3 million IHEs. While in the home, providers perform IHEs with the assistance of the Company's longitudinal patient records and proprietary clinical workflow software with its integrated device hub. The Company's software guides clinical workflows as well as in-home diagnostic screenings, yielding a rich patient report of hundreds of data points. The Company also offers diagnostic and preventive services and provides comprehensive medication review services while in the home. Through its IHEs, the Company creates a comprehensive, documented record of the clinical, social and behavioral needs of its health plan customers' medically complex populations and seek to further engage them with the healthcare system.\n\nThe evaluation results of IHEs are provided to individuals' primary care physicians. The Company believes sharing these results helps to fill gaps in care, while encouraging individuals who have not regularly visited their PCP to schedule a visit. The IHEs also provide health plans with insights into member health without taking members out of the home and contribute to health plans' ability to effectively participate in value-based and risk-adjusted government programs such as Medicare Advantage. The data gathered during an IHE is also a resource that can be used by health plans to improve their Healthcare Effectiveness Data and Information Set ('HEDIS') scores and Medicare Advantage star ratings.\n\n## MinuteClinic\n\nAs of December 31, 2024, the Company operated more than 900 MinuteClinic locations in the U.S. The clinics are staffed by nurse practitioners and physician assistants who utilize nationally established guidelines to deliver a variety of health care services. Payors value these clinics because they provide convenient, highquality, cost-effective care, in many cases offering an attractive alternative to more ex pensive sites of care. MinuteClinic also offers virtual care services to connect customers with licensed providers to provide access to health services remotely. MinuteClinic is collaborating with the Company's medical and pharmacy members to help meet the needs of the Company's health plan and client plan members by offering programs that can improve member health and lower costs. MinuteClinic also maintains relationships with leading hospitals, clinics and physicians in the communities we serve to support and enhance quality, access and continuity of care.\n\n## Cordavis\n\nThe Company launched Cordavis, a wholly owned subsidiary that works directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products. Through Cordavis, the Company intends to develop a portfolio of products that will provide broader access to biosimilars in the U.S. As access to biosimilars increases, it is ex pected to generate more competition in the market which should lead to lower costs and result in higher savings for our clients.\n\n## Health Services Information Systems\n\nThe Health Services segment's claim adjudication platform incorporates architecture that centralizes the data generated from adjudicating retail pharmacy, specialty and mail order claims and delivering other solutions to PBM clients. The Health Engagement Engine technology and proprietary clinical algorithms help connect various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices. This capability transforms pharmacy data into actionable interventions at key points of care, including in retail, mail and specialty pharmacies as well as in customer care call center operations, leveraging our enterprise data platform to improve the quality of care. The technology leverages assisted artificial intelligence to deliver insights to the business and bring automation to otherwise manual tasks. Specialty services also connects with our claim adjudication platform and various health plan adjudication platforms with a centralized architecture servicing many clients and members. Operating services, such as Specialty Expedite , provide an interconnected onboarding solution for specialty medications and branding solutions ranging from fulfillment to total patient management. These services are managed through our new innovative specialty workflow and web platform. \u00ae \u00ae",
          "relationship": "Works_With"
        },
        "node_3": {
          "id": "Pharmaceutical_Manufacturers",
          "name": "Pharmaceutical Manufacturers",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_1",
          "chunk_text": "## Index to Consolidated Financial Statements\n\n## Notes to Consolidated Financial Statements\n\n## 1. Significant Accounting Policies\n\n## Description of Business\n\nCVS Health Corporation, together with its subsidiaries (collectively, 'CVS Health' or the 'Company'), is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of December 31, 2024, the Company had more than 9,000 retail locations, more than 1,000 walk-in and primary medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members and expanding specialty pharmacy solutions, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan ('PDP'). The Company is creating new sources of value through its integrated model allowing it to ex pand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.\n\nThe Company has four reportable segments: Health Care Benefits, Health Services, Pharmacy &amp; Consumer Wellness and Corporate/Other, which are described below.\n\n## Health Care Benefits Segment\n\nThe Health Care Benefits segment operates as one of the nation's leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs and Medicaid health care management services. The Health Care Benefits segment's primary customers, its members, primarily access the segment's products and services through employer groups, government-sponsored plans or individually. The Health Care Benefits segment also serves customers who purchase products and services that are ancillary to its health insurance products. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as 'Insured' and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as 'ASC.' The Company sold Insured plans directly to individual consumers through the individual public health insurance exchanges ('Public Exchanges') in 17 states as of December 31, 2024.\n\n## Health Services Segment\n\nThe Health Services segment provides a full range of pharmacy benefit management ('PBM') solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. PBM solutions include plan design offerings and administration, formulary management, retail pharmacy network management services, and specialty and mail order pharmacy services. In addition, the Company provides clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities ('Covered Entities'). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants and provides various administrative, management and reporting services to pharmaceutical manufacturers. During 2023, the Company completed the acquisition of two key health care delivery assets - Signify Health, Inc. ('Signify Health'), a leader in health risk assessments, valuebased care and provider enablement services, and Oak Street Health, Inc. ('Oak Street Health'), a leading multi-payor operator of value-based primary care centers serving Medicare eligible patients. The Company also launched Cordavis , a wholly owned subsidiary that works directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products. The Health Services segment's clients and customers are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, the U.S. Centers for Medicare &amp; Medicaid Services ('CMS'), plans offered on public and private health insurance exchanges and other sponsors of health benefit plans throughout the U.S., patients who receive care in the Health Services segment's medical clinics, virtually or in the home, as well as Covered Entities. TM\n\n## Pharmacy &amp; Consumer Wellness Segment\n\nThe Pharmacy &amp; Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also conducts long-term care pharmacy ('LTC') operations, which distribute prescription drugs and provide related pharmacy",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 171,
      "question": "How does BMY's reliance on patent rights to secure market exclusivity for its innovative drugs align with the financial risks disclosed from ongoing patent litigation, such as the CAR T cell technology case involving a $1.2 billion royalty judgment and subsequent reversal?",
      "answer": "BMY's market exclusivity strategy, particularly in the U.S., heavily depends on patent rights to protect the commercial value of its innovative drugs during their lifecycle. For instance, the company emphasizes that the majority of an innovative product's value is realized during the period of market exclusivity, which is largely determined by the strength and enforceability of its patent portfolio. However, this strategy is directly challenged by the litigation risks highlighted in the legal proceedings section. Specifically, the CAR T cell technology case involving Juno, SKI, and Kite demonstrates the financial exposure BMY faces when patent rights are contested. Initially, a jury awarded Juno and SKI approximately $1.2 billion in royalties, interest, and enhanced damages, with an ongoing 27.6% running royalty on Kite's Yescarta* sales. Although this judgment was later reversed on appeal, the case underscores the uncertainty and potential financial impact of patent litigation. This dynamic reveals a critical misalignment: while BMY depends on strong patent rights to maintain exclusivity and revenue generation, its ability to enforce these rights is subject to unpredictable legal outcomes that could materially affect its financial position or results of operations.",
      "reasoning_steps": [
        "Hop 1: BMY(page_8) \u2192 Market Exclusivity: BMY relies on patent rights and regulatory data protection to maintain market exclusivity for its innovative drugs, with the majority of a product's commercial value realized during this period.",
        "Hop 2: Market Exclusivity \u2192 Patent Rights: Patent rights are a key determinant of market exclusivity, covering active ingredients, formulations, and methods of use, and are critical to preventing generic competition.",
        "Hop 3: Patent Rights \u2190 BMY(page_156): Ongoing litigation, such as the CAR T cell case, highlights the financial and operational risks associated with enforcing patent rights, as seen in the $1.2 billion judgment that was later overturned on appeal."
      ],
      "difficulty": "hard",
      "idf_score": 5.128494288012563,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Determined_By]-> RISK_FACTOR <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Market Exclusivity",
        "node_3": "Patent Rights",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "RISK_FACTOR",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "The U.S., EU and Japan each provide regulatory data protection, a period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator's data to approve a competitor's generic copy. In certain markets where patent protection  and  other  forms  of  market  exclusivity  may  have  expired,  regulatory  data  protection  can  be  of  particular  importance. However, most regulatory forms of exclusivity do not prevent a competitor from gaining regulatory approval prior to the expiration of regulatory data protection exclusivity on the basis of the competitor's own safety and efficacy data on its drug, even when that drug is identical to  that  marketed  by  the  innovator. When  these  patent  rights  and  other  forms  of  exclusivity  expire  and  generic versions  of  a  medicine  are  approved  and  marketed,  there  are  often  substantial  and  rapid  declines  in  the  sales  of  the  original innovative product. For further discussion of the impact of generic competition on our business, refer to '-Competition' below.\n\nSpecific aspects of the law governing market exclusivity and data regulatory protection for pharmaceuticals vary from country to country. The following summarizes key exclusivity rules in markets representing significant sales:\n\n## United States\n\nIn the U.S., most of our key products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product's patent life, however, is lost during the time it takes an innovative company to develop and obtain regulatory approval of a new drug. As compensation at least in part for the lost patent term due to regulatory review periods, the  innovator  may,  depending  on  a  number  of  factors,  apply  to  the  government  to  restore  lost  patent  term  by  extending  the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval.\n\nA company seeking to market an innovative pharmaceutical in the U.S. must submit a complete set of safety and efficacy data to the  FDA.  If  the  innovative  pharmaceutical  is  a  chemical  product,  the  company  files  an  NDA.  If  the  medicine  is  a  biological product, a BLA is filed. Both types of applications can receive certain periods of regulatory exclusivity. An NDA or a BLA for a compound that is designated as an orphan drug can receive seven years of exclusivity for an orphan drug indication. During this period, the FDA generally may not approve another application for the same drug product for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic exclusivity. The type of application filed can affect regulatory data protection exclusivity rights as discussed below.\n\n## Chemical products\n\nA competitor seeking to launch a generic substitute of a chemical innovative drug in the U.S. must file an aNDA with the FDA. In the aNDA, the generic manufacturer needs to demonstrate only 'bioequivalence' between the generic substitute and the approved NDA drug. The aNDA relies upon the safety and efficacy data previously filed by the innovator in its NDA.\n\nAn innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an aNDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an aNDA and allege that  one  or  more  of  the  patents  listed  in  the  Orange  Book  under  an  innovator's  NDA  is  invalid,  unenforceable,  or  will  not  be infringed  by  the  generic  product. This  allegation  is  commonly  known  as  a  Paragraph  IV  certification. The  innovator  then  must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, aNDAs including Paragraph IV certifications are filed with respect to certain of our products. We evaluate these aNDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines  approved  under  an  NDA  can  also  receive  several  types  of  regulatory  data  protection.  An  innovative  chemical pharmaceutical product is entitled to five years of regulatory data protection in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, as described above, a generic manufacturer may file its aNDA after the fourth year of the five-year regulatory data protection period. A pharmaceutical drug product that contains an active ingredient that has been previously approved in an NDA, but is approved in, for example, a new formulation or a new route of administration, but not  for  the  drug  itself,  or  for  a  new  indication  on  the  basis  of  new  clinical  studies,  may  receive  three  years  of  regulatory  data protection for that formulation, route of administration, or indication.",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_2",
          "chunk_text": "\nWe own or license a number of patents in the U.S. and foreign countries primarily covering our products. We have also developed many brand names and trademarks for our products. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement.\n\nIn the pharmaceutical industry, the majority of an innovative product's commercial value is usually realized during the period in which  the  product  has  market  exclusivity. A  product's  market  exclusivity  is  generally  determined  by  two  forms  of  intellectual property:  patent  rights  held  by  the  innovator  company  and  any  regulatory  forms  of  exclusivity  to  which  the  innovative  drug  is entitled.\n\nPatents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to  exclude  others  from  practicing  an  invention  related  to  the  medicine.  Patents  may  cover,  among  other  things,  the  active ingredient(s),  various  uses  of  a  drug  product,  pharmaceutical  formulations,  drug  delivery  mechanisms  and  processes  for  (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.\n\nMarket exclusivity is also sometimes influenced by regulatory data protection exclusivity rights. Many developed countries provide certain non-patent incentives for the development of medicines. For example, in the U.S., EU, Japan and certain other countries, RDP exclusivity rights are offered as incentives for research on medicines for rare diseases, or orphan drugs, and on medicines useful in treating pediatric patients. These incentives can provide a market exclusivity period on a product that expires beyond the patent term.",
          "relationship": "Determined_By"
        },
        "node_3": {
          "id": "Patent_Rights",
          "name": "Patent Rights",
          "type": "RISK_FACTOR",
          "idf_score": 4.78192069773259
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_156",
          "chunk_id": "chunk_1",
          "chunk_text": "While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that  there  will  not  be  an  increase  in  the  scope  of  one  or  more  of  these  pending  matters  or  any  other  or  future  lawsuits,  claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will  be  incurred  and  the  amount  of  the  related  loss  can  be  reasonably  estimated.  Developments  in  legal  proceedings  and  other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS's tax contingencies, see '-Note 7. Income Taxes'.\n\n## INTELLECTUAL PROPERTY\n\n## Anti-PD-1 Antibody Litigation\n\nIn September 2015, Dana-Farber Cancer Institute ('Dana-Farber') filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer  was  allowed  to  intervene  in  this  case  alleging  that  one  of  the  scientists  identified  by  Dana-Farber  was  employed  by  a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the District Court issued an opinion ruling that the two scientists should be added as inventors to the patents which was affirmed on appeal. In May 2021, the U.S. Supreme Court declined to consider the case. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the District Court's decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss the complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber's claims for damages before May 17, 2019-the date of the District Court's ruling that Dana-Farber was a co-inventor of the patents-are preempted by federal patent law. No trial date has been scheduled.\n\n## CAR T\n\nIn October 2017, Juno and Sloan Kettering Institute for Cancer Research ('SKI') filed a complaint for patent infringement against Kite  Pharma,  Inc.  ('Kite')  in  the  U.S.  District  Court  for  the  Central  District  of  California.  The  complaint  alleged  that  Kite's Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the ''190 Patent') concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the '190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite's defenses, finding that Kite willfully infringed the '190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite's sales of Yescarta* through the expiration of the '190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite's motions in their entirety. In April 2020, the Court granted in part Juno's motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest  and  enhanced damages and a 27.6% running royalty on Kite's sales of Yescarta * from December 13, 2019 through the expiration of the '190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the '190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit  for  panel  and  en  banc  rehearing  which  the  Federal  Circuit  denied  on  January  14,  2022. The  Company  intends  to  file  a petition for a writ of certiorari with the U.S. Supreme Court.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 172,
      "question": "How did Pfizer's financial dependency on BioNTech for Comirnaty manufacturing in 2023 relate to the collaborative development and profit-sharing structure outlined in their global agreement?",
      "answer": "In 2023, Pfizer reported $33 million in revenues from Comirnaty-related manufacturing activities performed on behalf of BioNTech, indicating a material financial dependency on the collaboration (page 112). This manufacturing relationship is part of a broader partnership where both companies co-develop and co-commercialize Comirnaty under a global agreement signed in April 2020 and amended in January 2021 (page 76). Under this agreement, Pfizer recognizes revenues and cost of sales on a gross basis in markets where it commercializes the vaccine, and it records its share of gross profits from BioNTech's sales in Germany and Turkey via 'Alliance revenues.' The manufacturing activities, therefore, are not standalone but integrated into a deeper partnership involving joint development, shared costs, and profit-sharing. The $33 million in contract manufacturing revenues from BioNTech thus reflects a financial component of a broader strategic and operational alignment, rather than a simple vendor-client relationship.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_112) \u2192 [BioNTech]: Pfizer reports $33 million in Comirnaty-related manufacturing revenues from BioNTech, indicating a dependency on the collaboration for production activities.",
        "Hop 2: [BioNTech] \u2192 [Comirnaty]: BioNTech co-developed Comirnaty with Pfizer and holds commercialization rights in Germany and Turkey under their global agreement.",
        "Hop 3: [Comirnaty] \u2190 [PFE](page_76): Pfizer recognizes revenues and cost of sales on a gross basis for Comirnaty and records its share of gross profits from BioNTech\u2019s sales in certain markets under the collaborative agreement."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "BioNTech",
        "node_3": "Comirnaty",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn\tSeptember\t2023,\tPfizer\tand\tBioNTech\tannounced\tthe\tFDA\tapproved\ta\tregulatory\tapplication\tfor\ttheir\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t12\tyears of\tage\tand\tolder\t(Comirnaty\t(COVID-19\tVaccine,\tmRNA,\t2023-2024\tFormula)).\tThe\tFDA\talso\tgranted\tEUA\tfor\tthe\tOmicron\tXBB.1.5-adapted\tmonovalent\tCOVID-19\tvaccine\tfor\tindividuals\t6 months\tthrough\t11\tyears\tof\tage\t(Pfizer-BioNTech\tCOVID-19\tVaccine\t(2023-2024\tFormula)). (a)\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n41",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 173,
      "question": "How does Amgen's competitive positioning against REVLIMID, a product manufactured by Celgene, relate to the legal actions Amgen pursued against Celgene's partners following the acquisition of Otezla-related patents?",
      "answer": "Amgen lists REVLIMID, manufactured by Celgene, as a competitor to KYPROLIS in both the U.S. and Europe, indicating direct market competition. However, after acquiring Otezla and its associated patents from Celgene in 2020, Amgen pursued multiple legal actions against third-party manufacturers (e.g., Glenmark, Unichem, Emcure, and others), securing consent judgments and injunctions to prevent these companies from producing apremilast (the active ingredient in Otezla) during the term of the acquired patents. This suggests that while Celgene was a competitor through REVLIMID, Amgen transitioned into a successor role post-acquisition, leveraging Celgene\u2019s former legal positions to protect Otezla\u2019s exclusivity and limit competition, including from generic manufacturers previously partnered with Celgene.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_16) \u2192 REVLIMID: Amgen identifies REVLIMID as a competitive product to KYPROLIS in both U.S. and Europe, manufactured by Celgene.",
        "Hop 2: REVLIMID \u2192 Celgene: REVLIMID is a product developed and marketed by Celgene, as noted in the list of trademarks in the filing.",
        "Hop 3: Celgene \u2190 AMGN(page_144): Amgen acquired Otezla and related patents from Celgene in 2020 and pursued legal actions against multiple third-party manufacturers, previously partnered with Celgene, to block apremilast production during the patent term."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Competes_Against]-> PRODUCT -[Produces]-> COMP <-[Discontinues_Partnership]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "REVLIMID",
        "node_3": "Celgene",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "node_2": {
          "id": "REVLIMID",
          "name": "REVLIMID",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_144",
          "chunk_id": "chunk_1",
          "chunk_text": "Ltd,  DRL,  Emcure,  Glenmark,  Macleods,  Mankind,  Pharmascience,  Sandoz,  Shilpa,  Actavis,  Torrent,  Unichem  and  Zydus  filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark's apremilast product during the term of the '940, '638, '302, '101, '536, '243, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nFollowing Amgen's acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey  District  Court  issued  an  order  substituting Amgen  for  Celgene  as  plaintiff  in  the  consolidated  action  and  all  related  actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.\n\nOn March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem's apremilast product during the term of the '940, '638, '302, '101, '536, '243, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero's apremilast product during the term of the '940, '516, '638, '302, '101, '536, '717, '243, '330, '854 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On May  28,  2020,  based  on  a  joint  request  by  Amgen  and  Emcure,  the  New  Jersey  District  Court  entered  a  consent  judgment  and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure's apremilast product during the term of the '638, '101, '854 and '541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the '717, '516 and '854 Patents, leaving the '940, '302, '536,  '243,  '330,  '638,  '101  and  '541  Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind's  apremilast  product  during  the  term  of  the  '940,  '302,  '536,  '243,  '330,  '638,  '101  and  '541  Patents,  unless  authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District  Court  entered  a  consent  judgment  and  injunction  prohibiting  the  making,  using,  selling,  offering  to  sell,  or  importing  of Macleods' apremilast product during the term of the '638 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.  On  October  7,  2020,  based  on  a  joint  request  by Amgen  and Amneal,  the  New  Jersey  District  Court  entered  a  consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal's apremilast product during the term of the '101, '940, '638, '302, '536, '243, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa's apremilast product during the term of the '638, '101 and '854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis' apremilast product during the term of the '940, '516, '638, '302, '536, '717, '330, '854 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston's apremilast product during the term of the '638 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo's apremilast product during the term of the '940, '516, '638, '302, '101, '536, '717, '243, '330, '854 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nOn May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla's apremilast product during the term of the '940, '638, '302, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent's apremilast product during the term of the '101, '638, '854 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New  Jersey  District  Court  entered  a  consent  judgment  and  injunction  prohibiting  the  making,  using,  selling,  offering  to  sell,  or importing  of Alkem's  apremilast  product  during  the  term  of  the  '940,  '638,  '302,  '536,  '330  and  '541  Patents,  unless  authorized pursuant  to  a  confidential  settlement  agreement.  On  May  25,  2021,  based  on  a  joint  request  by Amgen  and  MSN,  the  New  Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN's apremilast product during the term of the '940, '638, '302, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and",
          "relationship": "Discontinues_Partnership"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 174,
      "question": "How does Merck's acquisition of Peloton Therapeutics, Inc. in 2019 align with the 2021 FDA approval of Welireg for von Hippel-Lindau disease, and what does this imply about the strategic value of the acquisition in advancing Merck's rare disease oncology portfolio?",
      "answer": "Merck's acquisition of Peloton Therapeutics, Inc. in 2019 provided access to Welireg, an oral HIF-2\u03b1 inhibitor, which received FDA approval in August 2021 for treating adult patients with von Hippel-Lindau (VHL) disease\u2014a rare genetic disorder. This approval, based on results from the open-label Study 004 trial, demonstrates the successful integration and development of Peloton's pipeline asset into Merck\u2019s oncology portfolio. The acquisition was strategically aligned with Merck\u2019s focus on rare and high-impact diseases, particularly in oncology, as evidenced by the subsequent regulatory success of Welireg. This highlights how the Peloton acquisition contributed directly to Merck\u2019s ability to bring innovative therapies for rare cancers to market, reinforcing the value of the investment.",
      "reasoning_steps": [
        "Hop 1: MRK(page_9) \u2192 Welireg: Welireg is introduced as a newly FDA-approved product in August 2021 for VHL disease, indicating its importance in Merck's therapeutic pipeline.",
        "Hop 2: Welireg \u2192 Peloton Therapeutics,Inc.: Welireg was obtained through Merck\u2019s 2019 acquisition of Peloton, as noted in the narrative on page 59, linking the product to the acquisition strategy.",
        "Hop 3: Peloton Therapeutics,Inc. \u2190 MRK(page_59): The acquisition is referenced in the context of product development and regulatory progress, specifically noting that Welireg's FDA approval in 2021 was based on Study 004 and was part of Merck\u2019s strategic portfolio expansion."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Supplies]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Welireg",
        "node_3": "Peloton Therapeutics,Inc.",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "| Keytruda         | November 2021   | EC approved Keytruda plus Lenvima for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.                                                                                                    |\n|------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Keytruda         | November 2021   | PMDAapproved Keytruda in combination with chemotherapy (5-fluorouracil plus cisplatin) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma.                                                                                                                                                                                     |\n| Keytruda         | December 2021   | FDAapproved Keytruda as a monotherapy for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. The FDAalso expanded the indication for Keytruda as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).                            |\n| Keytruda         | December 2021   | Japan's Ministry of Health, Labor and Welfare (MHLW) approved Keytruda in combination with Lenvima for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy.                                                                                                                                                   |\n| Lynparza (1)     | June 2021       | NMPAapproved Lynparza as monotherapy for the treatment of adult patients with germline or somatic BRCA -mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent (abiraterone, enzalutamide).                                                                                                                |\n| molnupiravir (2) | December 2021   | FDAgranted Emergency Use Authorization (EUA) for molnupiravir to treat mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDAare not accessible or clinically appropriate. |\n| molnupiravir (2) | December 2021   | MHLWgranted molnupiravir Special Approval for Emergency for the treatment of infectious disease caused by SARS-CoV-2.                                                                                                                                                                                                                                                                        |\n| Vaxneuvance      | July 2021       | FDAapproved Vaxneuvance for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.                                                                                                                                                     |\n| Vaxneuvance      | December 2021   | EC approved Vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.                                                                                                                                                                                                            |\n| Verquvo (3)      | January 2021    | FDAapproved Verquvo to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.                                                                                                             |\n| Verquvo (3)      | July 2021       | EC approved Verquvo for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy.                                                                                                                                                                                     |\n| Welireg          | August 2021     | FDAapproved Welireg for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.                                                                                                                                                          |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Welireg",
          "name": "Welireg",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndecreased 63% in 2020 primarily due to lower demand and pricing in the U.S. due to generic competition for Emend for Injection following U.S. patent expiry in September 2019. Also contributing to the Emend sales decline in 2020 was lower demand in Europe and Japan as a result of generic competition for the oral formulation of Emend following loss of market exclusivity in May 2019 and December 2019, respectively.\n\nIn June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive  results  from  the  National  Cancer  Institute  Cancer  Therapy  Evaluation  Program-sponsored  SPRINT  Stratum  1  trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration with AstraZeneca referenced above that includes Lynparza.\n\nIn August  2021,  the  FDA  approved Welireg ,  an  oral  HIF-2\u03b1  inhibitor,  for  the  treatment  of  adult  patients  with  VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. Welireg was obtained as part of Merck's 2019 acquisition of Peloton Therapeutics, Inc. (Peloton). See Note 4 to the consolidated financial statements.\n\n## Vaccines\n\n",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "Peloton_Therapeutics,Inc.",
          "name": "Peloton Therapeutics,Inc.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndecreased 63% in 2020 primarily due to lower demand and pricing in the U.S. due to generic competition for Emend for Injection following U.S. patent expiry in September 2019. Also contributing to the Emend sales decline in 2020 was lower demand in Europe and Japan as a result of generic competition for the oral formulation of Emend following loss of market exclusivity in May 2019 and December 2019, respectively.\n\nIn June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive  results  from  the  National  Cancer  Institute  Cancer  Therapy  Evaluation  Program-sponsored  SPRINT  Stratum  1  trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration with AstraZeneca referenced above that includes Lynparza.\n\nIn August  2021,  the  FDA  approved Welireg ,  an  oral  HIF-2\u03b1  inhibitor,  for  the  treatment  of  adult  patients  with  VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. Welireg was obtained as part of Merck's 2019 acquisition of Peloton Therapeutics, Inc. (Peloton). See Note 4 to the consolidated financial statements.\n\n## Vaccines\n\n",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 175,
      "question": "Given the resolution of most Byetta* litigation claims and the expectation that remaining liability would be shared with AstraZeneca, how does this potential ongoing exposure align with Bristol-Myers Squibb's broader financial risk related to divestitures, particularly regarding 'continued financial exposure through guarantees or other financial arrangements' noted in the risk factors?",
      "answer": "The Byetta* litigation, largely resolved with over 60% of plaintiffs in the JCCP submitting dismissals and a final decision in the MDL, represents a significantly reduced liability for Bristol-Myers Squibb. However, the company notes that any remaining liability to Amylin (a former subsidiary and co-defendant) is expected to be shared with AstraZeneca, the buyer of the diabetes business in 2014. This shared liability creates a form of continued financial exposure for BMY, which aligns with the broader risk outlined in the risk factors section on page 48. There, the company warns that divestitures like the sale of its diabetes business may result in ongoing financial exposure, such as through guarantees or other financial arrangements. The Byetta* litigation therefore serves as a concrete example of how legacy liabilities from divested assets can persist and potentially affect BMY\u2019s financial condition, even after the business unit has been sold and litigation appears largely resolved.",
      "reasoning_steps": [
        "Hop 1: BMY(page_160) \u2192 Byetta* Litigation: BMY discusses the litigation status, noting that over 60% of plaintiffs have submitted dismissals and that remaining liability is expected to be shared with AstraZeneca.",
        "Hop 2: Byetta* Litigation \u2192 Amylin: Amylin, a former BMY subsidiary, is a co-defendant in the Byetta* litigation, and any remaining liability is tied to its involvement in the litigation.",
        "Hop 3: Amylin \u2190 BMY(page_48): BMY references financial risks related to divestitures, including 'continued financial exposure through guarantees or other financial arrangements,' which applies to Amylin\u2019s litigation liability post-sale."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Involved_In]-> COMP <-[Relates_To]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Byetta* Litigation",
        "node_3": "Amylin",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Byetta*_Litigation",
          "name": "Byetta* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Amylin",
          "name": "Amylin",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "related  to  the  divestiture  of  our  diabetes  business  (including  the  transfer  of  certain  future  royalty  rights  pertaining  to Amylin,  Onglyza*  and  Farxiga*  product  sales),  out-licensed  intellectual  property  and  the  Merck  patent  infringement settlement. Pretax income generated from royalties was approximately $1.9 billion in 2021. Our pretax income could be adversely affected if the royalty streams decline in future periods.\n\nFailure  to  effectively  manage  acquisitions,  divestitures,  alliances,  joint  ventures  and  other  portfolio  actions  could adversely  impact  our  future  results.  In  addition,  any  businesses  or  assets  that  we  acquire  in  the  future  may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.\n\nWe have acquired, or in-licensed, a number of assets and we expect to continue to support our pipeline with compounds or products obtained through licensing and acquisitions. Future revenues, profits and cash flows of an acquired company's products, technologies and pipeline candidates may not materialize due to low product uptake, delayed or missed pipeline opportunities,  the  inability  to  capture  expected  synergies  resulting  from  cost  savings  and  avoidance,  increased competition, safety concerns, regulatory issues, supply chain problems or other factors beyond our control. Substantial difficulties,  costs  and  delays  could  result  from  integrating  our  acquisitions,  including  for  (i)  R&amp;D,  manufacturing, distribution,  sales,  marketing,  promotion  and  information  technology  activities;  (ii)  policies,  procedures,  processes, controls and compliance; and (iii) tax considerations. Where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with a joint venture or acquisition, the value of those  securities  will  fluctuate  and  may  depreciate  in  value.  We  may  not  control  the  company  in  which  we  acquire securities,  such  as  in  connection  with  a  collaborative  arrangement,  and  as  a  result,  we  will  have  limited  ability  to determine its management, operational decisions, internal controls and compliance and other policies, which can result in additional financial and reputational risks.\n\nWe may not be successful in separating underperforming or non-strategic assets, and gains or losses on the divestiture of, or lost operating income from, such assets may affect our earnings. Our divestitures also may result in continued financial exposure to the divested businesses, such as through guarantees or other financial arrangements, continued supply and services arrangements, or potential litigation, following the transaction. Under these arrangements, nonperformance by us could result in obligations being imposed on us that could have a material adverse effect on our competitive position, cash flows, results of operations, financial condition or reputation. In particular, we divested Otezla* in connection with obtaining regulatory approval for our acquisition of Celgene. If the FTC determines that we violated the consent order that we agreed to in connection with the divestiture, the FTC may seek a civil penalty and our reputation may be adversely affected.\n\nWe might also incur asset impairment charges related to acquisitions or divestitures that reduce our earnings. The value allocated to certain of our assets could be substantially impaired due to a number of factors beyond our control. New or revised accounting standards, rules and interpretations could result in changes to the recognition of income and expense that may materially and adversely affect our financial results.\n\nIf the execution or implementation of acquisitions, divestitures, alliances, joint ventures and other portfolio actions is not successful, it could adversely impact our financial condition, cash flows and results of operations. Moreover, due to the substantial amount of debt that we incurred to finance the cash portion of the Celgene and MyoKardia acquisitions, there can be no assurance of when we will be able to expand our business development capacity. Although we are committed to reducing our debt, pursuing strategic transaction opportunities in future may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings.\n\n## Failure  to  attract  and  retain  highly  qualified  workforce  could  affect  our  ability  to  successfully  develop  and commercialize products.\n\nOur success is largely dependent on our continued ability to (i) attract and retain highly qualified scientific, technical and management workforce, including people with expertise in clinical R&amp;D, governmental regulation and commercialization, and  (ii)  in  connection  with  our  Celgene  acquisition,  integrate  two  unique  corporate  cultures  and  maintain  employee morale. We are facing increasing competition for a limited pool of qualified individuals from numerous pharmaceutical and  biotechnology  companies,  universities,  government  entities,  research  institutions,  companies  seeking  to  enter  the healthcare space, and companies in other industries. We cannot be sure that we will be able to retain quality talent or that the costs of doing so will not materially increase.\n\n## Market, Liquidity and Credit Risks\n\nOur significant additional indebtedness that we incurred in connection with the Celgene and MyoKardia acquisitions could have negative consequences.\n\nOur acquisitions of Celgene and MyoKardia increased the amount of our debt resulting in additional interest expense. This  could  reduce  our  financial  flexibility  to  continue  capital  investments,  develop  new  products  and  declare  future dividends.",
          "relationship": "Relates_To"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 176,
      "question": "Given the loss of patent protection for Forteo as highlighted in the risk factors, how does the historical revenue decline of Forteo between 2019 and 2022 align with Eli Lilly's concerns about generic competition impacting products like Forteo?",
      "answer": "Eli Lilly's risk factors on page 25 indicate that Forteo has recently lost or will soon lose significant patent protection in the U.S. and key international jurisdictions, exposing it to generic competition and likely resulting in rapid and severe revenue declines. This aligns with the financial data on page 65, which shows Forteo's global revenue declining from $645.5 million in the U.S. and $759.1 million outside the U.S. in 2019 to $441.6 million in the U.S. and $360.3 million outside the U.S. in 2021. This represents a 31.6% drop in U.S. revenue and a 52.6% drop in non-U.S. revenue over two years, supporting the company's expressed concern about the material adverse impact of patent expiration on consolidated results.",
      "reasoning_steps": [
        "Hop 1: LLY(page_25) \u2192 Patent Protection: The company states that Forteo has recently lost or will soon lose significant patent protection in the U.S. and key jurisdictions outside the U.S., exposing it to generic competition and likely resulting in rapid revenue declines.",
        "Hop 2: Patent Protection \u2192 Forteo: The loss of patent protection for Forteo is directly linked to the risk of generic competition entering the market, which the company expects will cause a material adverse effect on revenues and earnings.",
        "Hop 3: Forteo \u2190 LLY(page_65): Financial data shows Forteo's revenue declining from $645.5 million (U.S.) and $759.1 million (non-U.S.) in 2019 to $441.6 million (U.S.) and $360.3 million (non-U.S.) in 2021, reflecting the early impact of patent expiration consistent with the risk factors."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT -[Negatively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Patent Protection",
        "node_3": "Forteo",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.\n\nA number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.\n\nCertain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.\n\nThere is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,\" and Item 1, \"Business Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.\n\n- Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.\n\nOur long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, \"Business -",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Forteo",
          "name": "Forteo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                    | U.S.       | U.S.       | U.S.       | Outside U.S.   | Outside U.S.   | Outside U.S.   |\n|------------------------------------|------------|------------|------------|----------------|----------------|----------------|\n|                                    | 2021       | 2020       | 2019       | 2021           | 2020           | 2019           |\n| Revenue-to unaffiliated customers: |            |            |            |                |                |                |\n| Diabetes:                          |            |            |            |                |                |                |\n| Trulicity \u00ae                        | $ 4,914.4  | $ 3,835.9  | $ 3,155.2  | $ 1,557.6      | $ 1,232.2      | $ 972.7        |\n| Humalog \u00ae (1)                      | 1,320.7    | 1,485.6    | 1,669.7    | 1,132.3        | 1,140.3        | 1,151.0        |\n| Jardiance (2)                      | 807.3      | 620.8      | 565.9      | 683.5          | 533.0          | 378.3          |\n| Humulin \u00ae                          | 832.9      | 866.4      | 879.7      | 389.6          | 393.2          | 410.4          |\n| Basaglar \u00ae                         | 588.3      | 842.3      | 876.2      | 304.2          | 282.1          | 236.3          |\n| Trajenta (3)                       | 82.1       | 95.6       | 224.8      | 290.4          | 263.0          | 365.8          |\n| Other Diabetes                     | 173.6      | 162.5      | 158.0      | 111.2          | 81.5           | 88.1           |\n| Total Diabetes                     | 8,719.3    | 7,909.1    | 7,529.5    | 4,468.8        | 3,925.3        | 3,602.6        |\n| Oncology:                          |            |            |            |                |                |                |\n| Alimta \u00ae                           | 1,233.9    | 1,265.3    | 1,219.5    | 827.5          | 1,064.7        | 896.4          |\n| Verzenio \u00ae                         | 834.9      | 618.2      | 454.8      | 515.0          | 294.4          | 124.9          |\n| Cyramza \u00ae                          | 358.1      | 381.9      | 335.3      | 674.8          | 650.8          | 589.9          |\n| Erbitux \u00ae                          | 481.8      | 480.1      | 487.9      | 66.4           | 56.3           | 55.4           |\n| Tyvyt \u00ae                            | -          | -          | -          | 418.1          | 308.7          | 134.0          |\n| Other Oncology                     | 120.1      | 46.6       | 111.0      | 210.7          | 152.3          | 205.3          |\n| Total Oncology                     | 3,028.8    | 2,792.1    | 2,608.5    | 2,712.5        | 2,527.2        | 2,005.9        |\n| Immunology:                        |            |            |            |                |                |                |\n| Taltz \u00ae                            | 1,542.4    | 1,288.5    | 1,016.8    | 670.4          | 500.0          | 349.6          |\n| Olumiant \u00ae (4)                     | 324.1      | 63.8       | 42.2       | 791.0          | 575.0          | 384.7          |\n| Other Immunology                   | 15.3       | 20.0       | -          | 17.6           | 14.6           | -              |\n| Total Immunology                   | 1,881.8    | 1,372.3    | 1,059.0    | 1,479.0        | 1,089.6        | 734.3          |\n| Neuroscience:                      |            |            |            |                |                |                |\n| Cymbalta \u00ae                         | 38.7       | 42.1       | 49.6       | 542.8          | 725.6          | 675.8          |\n| Emgality \u00ae                         | 434.5      | 325.9      | 154.9      | 142.7          | 37.0           | 7.7            |\n| Zyprexa \u00ae                          | 39.6       | 46.1       | 41.0       | 390.7          | 360.5          | 377.6          |\n| Other Neuroscience                 | 102.0      | 73.2       | 111.0      | 207.5          | 220.9          | 305.3          |\n| Total Neuroscience                 | 614.8      | 487.3      | 356.5      | 1,283.7        | 1,344.0        | 1,366.4        |\n| Other:                             |            |            |            |                |                |                |\n| COVID-19 Antibodies (5)            | 1,978.0    | 850.0      | -          | 261.4          | 21.2           | -              |\n| Forteo \u00ae                           | 441.6      | 510.3      | 645.5      | 360.3          | 536.0          | 759.1          |\n| Cialis \u00ae                           | 10.6       | 61.8       | 231.7      | 707.9          | 545.4          | 658.8          |\n| Other                              | 136.1      | 246.4      | 291.9      | 233.9          | 321.8          | 469.7          |\n| Total Other                        | 2,566.4    | 1,668.4    | 1,169.1    | 1,563.5        | 1,424.4        | 1,887.7        |\n| Revenue                            | $ 16,811.0 | $ 14,229.3 | $ 12,722.6 | $ 11,507.4     | $ 10,310.5     | $ 9,596.8      |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 177,
      "question": "How does BMY's exposure to biosimilar risk for Orencia, as outlined in the biologics section, intersect with its joint commercialization and supply arrangement with Ono in Japan, and how does this compare to BMY's broader dependency on collaboration partners like Ono for revenue and operational execution?",
      "answer": "BMY identifies Orencia as one of its marketed biologic products facing increased biosimilar risk due to regulatory changes that allow for earlier filings of biosimilars and limit the ability to enforce patent protection during ongoing litigation. This uncertainty around market exclusivity is particularly relevant given that Orencia is jointly commercialized with Ono in Japan, where BMY is responsible for product supply and order fulfillment for the intravenous formulation, while Ono handles the subcutaneous version. In this co-promotion arrangement, BMY receives a 60% co-promotion fee when a sale is made to the other party's assigned customer, indicating a significant revenue dependency on this partnership. Furthermore, BMY's broader dependency on collaboration partners like Ono is evident in other areas\u2014such as the royalty structure for Opdivo outside of North America\u2014where BMY pays Ono 15% of sales, highlighting a strategic reliance on external partners for both revenue and operational execution in key markets.",
      "reasoning_steps": [
        "Hop 1: BMY(page_9) \u2192 Orencia: Discloses Orencia as a marketed biologic product facing increased risk from biosimilar competition due to regulatory changes, including earlier biosimilar filing timelines and limited patent enforcement during litigation.",
        "Hop 2: Orencia \u2192 Ono: BMY and Ono jointly develop and commercialize Orencia in Japan, with BMY responsible for supply and Ono handling the subcutaneous formulation; both parties jointly promote the product, with a 60% co-promotion fee paid when a sale is made to the other's assigned customer.",
        "Hop 3: Ono \u2190 BMY(page_114): BMY depends on Ono for revenue and market access, particularly in Japan, South Korea, and Taiwan, where BMY pays Ono 15% royalties on Opdivo sales outside North America, demonstrating a broader strategic dependency on collaboration partners."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Promotes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Orencia",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "## Biologic products\n\nThe  U.S.  healthcare  legislation  enacted  in  2010  created  an  approval  pathway  for  biosimilar  versions  of  innovative  biological products  that  did  not  previously  exist.  Prior  to  that  time,  innovative  biologics  had  essentially  unlimited  regulatory  exclusivity. Under the new regulatory mechanism, the FDA can approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. After an innovator has marketed its product for four years, any manufacturer may file an application for approval of a 'biosimilar' version of the innovator product. However, although an  application  for  approval  of  a  biosimilar  version  may  be  filed  four  years  after  approval  of  the  innovator  product,  qualified innovative  biological  products  will  receive  12  years  of  regulatory  data  protection,  meaning  that  the  FDA  may  not  approve  a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. The law also provides a mechanism  for  innovators  to  enforce  the  patents  that  protect  innovative  biological  products  and  for  biosimilar  applicants  to challenge  the  patents.  Such  patent  litigation  may  begin  as  early  as  four  years  after  the  innovative  biological  product  is  first approved by the FDA.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market exclusivity. First, generic companies have increasingly sought to challenge innovators' basic patents covering major  pharmaceutical  products.  Second,  statutory  and  regulatory  provisions  may  limit  the  ability  of  an  innovator  company  to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of all of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based  solely  on  the  expiration  of  the  relevant  patent(s)  or  the  current  forms  of  regulatory  exclusivity.  Our  marketed  biologic products include Opdivo , Yervoy , Orencia, Reblozyl and Empliciti .\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended to compensate for the patent term lost during the regulatory review process. Such extensions are granted on a country-by-country basis.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized procedure.' This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and  is  also  available  for  certain  new  chemical  compounds  and  products.  A  company  seeking  to  market  an  innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies  the  MAA. It  is  also  possible  for  new  chemical  products  to  obtain  marketing  authorization  in  the  EU  through  a  'mutual recognition  procedure,'  in  which  an  application  is  made  to  a  single  member  state,  and  if  the  member  state  approves  the pharmaceutical  product  under  a  national  procedure,  then  the  applicant  may  submit  that  approval  to  the  mutual  recognition procedure of some or all other member states.\n\nAfter  obtaining  marketing  authorization  approval,  a  company  must  obtain  pricing  and  reimbursement  for  the  pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout the EU, all products for which marketing authorizations have been filed after October/November 2005 are subject to an '8+2+1' regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator.  The  possible  extension  to  11  years  is  available  if  the  innovator,  during  the  first  eight  years  of  the  marketing authorization,  obtains  an  additional  indication  that  is  of  significant  clinical  benefit  in  comparison  with  existing  treatments.  For products  that  were  filed  prior  to  October/November  2005,  there  is  a  10-year  period  of  regulatory  data  protection  under  the centralized procedures and a period of either six or 10 years under the mutual recognition procedure (depending on the member state).\n\nIn contrast to the U.S., patents in the EU are not listed with regulatory authorities. Generic versions of pharmaceutical products can be approved after data protection expires, regardless of whether the innovator holds patents covering its drug. Thus, it is possible that an innovator may be seeking to enforce its patents against a generic competitor that is already marketing its product. Also, the European patent system has an opposition procedure in which generic manufacturers may challenge the validity of patents covering innovator products within nine months of grant.\n\nIn  general,  EU  law  treats  chemically-synthesized  drugs  and  biologically-derived  drugs  the  same  with  respect  to  intellectual property and data protection. In addition to the relevant legislation and annexes related to biologic medicinal products, the EMA has  issued  guidelines  that  outline  the  additional  information  to  be  provided  for  biosimilar  products,  also  known  as  generic biologics, in order to review an application for marketing approval.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Orencia",
          "name": "Orencia",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_113",
          "chunk_id": "chunk_5",
          "chunk_text": "\n## Ono\n\nBMS and Ono jointly develop and commercialize Opdivo , Yervoy and  several  BMS investigational compounds in Japan, South Korea and Taiwan. BMS is responsible for supply of the products. Profits, losses and development costs are shared equally for all combination therapies involving compounds of both parties. Otherwise, sharing is 80% and 20% for activities involving only one of the party's compounds.\n\nBMS  and  Ono  also  jointly  develop  and  commercialize Orencia in  Japan.  BMS  is  responsible  for  the  order  fulfillment  and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. A co-promotion fee of 60% is paid when a sale is made to the other party's assigned customer.\n\nIn 2019, Ono exercised the right to accept NKTR-214 into the alliance with BMS upon completion of a Phase I clinical study of Opdivo and NKTR-214 in the Ono Territory. Ono partially reimbursed BMS for development costs incurred with the study and shares in certain future development costs, contingent milestone payments, profits and losses under the collaboration with Nektar.\n\nIn 2017, Ono granted BMS an exclusive license for the development and commercialization of ONO-4578, Ono's Prostaglandin E2 receptor 4 antagonist. In 2020, the rights were terminated by both parties.",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_114",
          "chunk_id": "chunk_3",
          "chunk_text": "\nBMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.\n\n## Nektar\n\nIn  2018,  BMS  and  Nektar  commenced  a  worldwide  license  and  collaboration  for  the  development  and  commercialization  of Bempegaldesleukin  (NKTR-214),  Nektar's  investigational  immuno-stimulatory  therapy  designed  to  selectively  expand  specific cancer-fighting T cells and natural killer cells directly in the tumor micro-environment. In January 2020, the parties amended the collaboration agreement. The Opdivo and NKTR-214 combination therapy is currently in Phase III clinical studies for metastatic melanoma, adjuvant melanoma, muscle-invasive bladder cancer and RCC. A joint development plan agreed by the parties as part of the original agreement, and updated as part of the January 2020 amendment, specifies development in certain indications and tumor types  with  each  party  responsible  for  the  supply  of  their  own  product.  BMS's  share  of  the  development  costs  associated  with therapies comprising a BMS medicine used in combination with NKTR-214 is 67.5%, subject to certain cost caps for Nektar. The January  2020  amendment  retains  the  cost  sharing  percentages  from  the  original  agreement.  The  parties  will  also  jointly commercialize  the  therapies,  subject  to  regulatory  approval.  BMS's  share  of  global  NKTR-214  profits  and  losses  will  be  35% subject to certain annual loss caps for Nektar.\n\nBMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.  BMS's equity  ownership  is  subject  to  certain  lock-up,  standstill  and  voting  provisions  for  a  five-year period. The amount of the up-front payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the up-front payment was allocated to the rights discussed above. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales-based milestones over the life of the alliance period. Research and development cost reimbursements were $98 million in 2021, $132 million in 2020 and $108 million in 2019.\n\n## 2seventy bio (formerly bluebird)\n\nOn November 4, 2021, bluebird completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company.\n\nThe  parties  jointly  develop  and  commercialize  novel  disease-altering  gene  therapy  product  candidates  targeting  BCMA.  The collaboration arrangement began in 2013 and included (i) a right for BMS to license any anti-BCMA products resulting from the collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and  commercialization  of  any  licensed  products resulting  from  the  collaboration  through  a  50/50  co-development  and  profit  share  in  the  U.S.  in  exchange  for  a  reduction  of milestone  payments,  and  (iii)  sales-based  milestones  and  royalties  payable  to  2seventy  bio  upon  the  commercialization  of  any licensed  products  resulting  from  the  collaboration  if  2seventy  bio  declined  to  exercise  their  co-development  and  profit  sharing rights. The options to license idecabtagene vicleucel (ide-cel, bb2121) and bb21217 were exercised in 2016 and 2017, respectively. In 2022, the parties elected to not pursue further development of bb21217.\n\nAll profits and losses relating to developing, commercializing and manufacturing ide-cel within the U.S. are shared equally. BMS is exclusively responsible for the development and commercialization of ide-cel outside the U.S.\n\nIn  2020,  terms  of  the  collaboration  were  amended  including  certain  manufacturing  obligations.  Both  parties  were  also  released from future exclusivity related to BCMA-directed T cell therapies. BMS paid $200 million to extinguish its obligation for future ex-U.S. milestones and royalties on ide-cel, which was included in Research and development expense in 2020.\n\nIn 2021, the FDA approved ide-cel (' Abecma ' ) for the treatment of relapsed or refractory multiple myeloma. Net product sales of Abecma  within  the  Alliance  territory  were  $158  million  and  related  profit  sharing  costs  were  $42  million  in  2021.  Cost reimbursements were not material.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 178,
      "question": "How does Amgen's competitive positioning of Otezla against Novartis's Cosentyx in the U.S. and Europe align with the financial terms of their Aimovig collaboration, particularly following the restructuring of the U.S. commercialization agreement effective January 1, 2022?",
      "answer": "Amgen lists Otezla as directly competing against Novartis's Cosentyx in the U.S. and Europe, indicating a strategic focus on capturing market share in these regions. However, despite this competitive dynamic, Amgen and Novartis maintain a significant collaborative relationship through the Aimovig partnership. Under the revised agreement effective January 1, 2022, Amgen no longer pays U.S. royalties or shares commercialization costs with Novartis for Aimovig, while Novartis retains ex-U.S. rights and continues to pay double-digit royalties on international sales. This dual dynamic\u2014competition on one product and collaboration on another\u2014suggests a nuanced strategic balance between market rivalry and shared financial incentives.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_16) \u2192 Cosentyx: Amgen lists Otezla as competing against Novartis's Cosentyx in the U.S. and Europe, signaling a direct competitive threat.",
        "Hop 2: Cosentyx \u2192 Novartis: Cosentyx is a Novartis-marketed product, as noted in the trademark list, confirming its ownership and strategic importance to Novartis.",
        "Hop 3: Novartis \u2190 AMGN(page_28): Amgen and Novartis have a joint development and commercialization agreement for Aimovig, with Novartis continuing to pay double-digit royalties on ex-U.S. sales post-2022 restructuring, while U.S. royalty obligations from Amgen to Novartis were eliminated."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Competes_Against]-> PRODUCT -[Produces]-> COMP <-[Pays_Royalties_To]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Cosentyx",
        "node_3": "Novartis",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "node_2": {
          "id": "Cosentyx",
          "name": "Cosentyx",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Novartis",
          "name": "Novartis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Pays_Royalties_To"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 179,
      "question": "How does BMY's strategic partnership with Lilly, as reflected in their shared commercialization rights for Erbitux*, relate to the litigation exposure BMY faces through its former subsidiary Amylin in the Byetta* litigation, particularly given the divestiture of these assets to AstraZeneca in 2014?",
      "answer": "BMY's strategic partnership with Lilly involved shared commercialization rights for Erbitux*, including a distribution fee for 39% of Erbitux* net sales in North America, indicating a deep commercial relationship (page_121). This partnership context is important when considering the Byetta* litigation, where BMY\u2019s former subsidiary Amylin and Lilly are co-defendants in lawsuits alleging personal injury from Byetta*, primarily pancreatic cancer (page_160). Although BMY sold Byetta* to AstraZeneca in 2014, the company still faces indirect liability, as any additional liability to Amylin is expected to be shared with AstraZeneca. This demonstrates how legacy partnerships and product divestitures can create long-term legal exposure even after formal ownership transfer.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_121) \u2192 [Lilly]: BMY had a co-commercialization agreement with Lilly for Erbitux*, receiving a distribution fee for 39% of North American sales, indicating a significant commercial partnership.",
        "Hop 2: [Lilly] \u2192 [Byetta* Litigation]: Lilly is a co-defendant with Amylin (a former BMY subsidiary) in Byetta* litigation, where plaintiffs allege pancreatic cancer and wrongful death from the drug.",
        "Hop 3: [Byetta* Litigation] \u2190 [BMY](page_160): Despite selling Byetta* to AstraZeneca in 2014, BMY notes that any additional liability to Amylin is expected to be shared with AstraZeneca, indicating continued exposure."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Involved_In]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Lilly",
        "node_3": "Byetta* Litigation",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_1",
          "chunk_text": "In September 2015, BMS transferred a percentage of its future royalty rights on Amylin net product sales in the U.S. to CPPIB. The transferred rights represent approximately 70% of potential future royalties BMS is entitled to in 2019 to 2025. In exchange for the transfer, BMS received an additional tiered-based royalty on Amylin net  product  sales  in  the  U.S.  from  CPPIB in 2016 through 2018. In 2021, CPPIB transferred its future royalty rights on Amylin net product sales in the U.S. to OCM Healthcare. As a result of these transfers of rights, royalty income for Amylin net product sales in the U.S. were reduced by $28 million in 2021, $39 million in 2020 and $48 million in 2019.\n\nIn November 2017, BMS transferred a percentage of its future royalty rights on a portion of Onglyza* and Farxiga* net product sales to Royalty Pharma. The transferred rights represent approximately 20% to 25% of potential future royalties BMS is entitled to for those products in 2020 to 2025. As a result of these transfers of rights, royalty income for Onglyza* and Farxiga* net product sales were increased by $165 million in 2019, and reduced by $75 million in 2021 and $67 million in 2020.\n\n## Otezla*\n\nIn order to complete the Celgene acquisition, BMS was required by the FTC to divest certain products. In 2019, BMS completed the divestiture of Otezla* (apremilast) to Amgen for $13.4 billion of cash. The transaction was accounted for as an asset divestiture. Otezla* was acquired as part of the Celgene acquisition and was classified as held-for-sale at the time of the acquisition. The fair value of Otezla* net assets consisted of $13.0 billion of developed product rights and $381 million of inventory.\n\n## UPSA Business\n\nIn 2019, BMS sold its UPSA consumer health business, including the shares of UPSA SAS and BMS's assets and liabilities relating to the UPSA product portfolio. The transaction was accounted for as the sale of a business.\n\n## Mature Brands and Other\n\n## Erbitux* Business\n\nBMS had a commercialization agreement with Lilly through Lilly's subsidiary ImClone for the co-development and promotion of Erbitux * in the U.S., Canada and Japan. BMS was the principal in the end customer product sales in North America and paid Lilly a distribution fee for 39% of Erbitux * net sales in North America plus a share of certain royalties paid by Lilly.\n\nBMS transferred its co-commercialization rights in Japan to Merck KGaA in 2015 in exchange for sales-based royalties through 2032. As a result of the adoption of ASC 610 in 2018, estimated future royalties resulting from the transfer of rights to Merck KGaA were recorded as a cumulative effect adjustment in Retained earnings. Royalty income was increased by $32 million in 2021 and $23 million in 2019 as a result of changes in estimated future royalties.\n\n## Manufacturing Operations\n\nIn 2019, BMS sold its manufacturing and packaging facility in Anagni, Italy to Catalent Inc. The transaction was accounted for as the  sale  of  a  business.  The  assets  were  reduced  to  their  relative  fair  value  after  considering  the  purchase  price  resulting  in  an impairment charge of $121 million that was included in Cost of products sold in 2019.\n\n## Other\n\nIn 2020, the product rights to a mature brand were sold resulting in proceeds of $50 million and divestiture gain of $49 million.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Lilly",
          "name": "Lilly",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Byetta*_Litigation",
          "name": "Byetta* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 180,
      "question": "How does Eli Lilly's intellectual property strategy for Kisunla, particularly around data protection, align with the estimated exclusivity timelines in different markets?",
      "answer": "Eli Lilly emphasizes the importance of intellectual property protection, noting that market exclusivity is influenced by both patent and regulatory forms of protection, and that the duration of exclusivity can be uncertain due to potential litigation and regulatory complexities (page 11). For Kisunla specifically, the company has secured biologics data protection in the U.S. with an estimated expiry date of 2036, and data protection in Japan expiring in 2032 (page 13). This aligns with the broader IP strategy by leveraging both patent and data protection mechanisms to extend market exclusivity in key territories, although the actual duration may vary due to the factors outlined in the IP portfolio section.",
      "reasoning_steps": [
        "Hop 1: LLY(page_11) \u2192 Data Protection: The company discusses its broader intellectual property strategy, emphasizing the importance of both patents and data protection, while acknowledging uncertainties in predicting exclusivity duration due to litigation and regulatory dynamics.",
        "Hop 2: Data Protection \u2192 Kisunla: Kisunla benefits from data protection in the U.S. and Japan, with expiry dates of 2036 and 2032 respectively, indicating a strategic use of regulatory exclusivity.",
        "Hop 3: Kisunla \u2190 LLY(page_13): The product-specific table reveals the estimated exclusivity timelines, showing how data protection is applied practically to Kisunla in key markets."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Data Protection",
        "node_3": "Kisunla",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Kisunla",
          "name": "Kisunla",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 181,
      "question": "How does AbbVie's financial benefit from the Allergan acquisition, including the lower amortization of inventory fair value step-up adjustment, reconcile with the ongoing litigation risks from Allergan's legacy businesses, including the class action lawsuits and settlements related to textured breast implants and generic drug pricing?",
      "answer": "AbbVie realized financial benefits from the Allergan acquisition, including a reduction in amortization of inventory fair value step-up adjustments that contributed to an increase in gross margin as a percentage of net revenues in 2021. However, the acquisition also brought significant litigation risks tied to Allergan\u2019s legacy businesses. Specifically, lawsuits alleging misrepresentations regarding textured breast implants have been consolidated in the Southern District of New York, with class certification granted in September 2021. Additionally, Allergan faced shareholder lawsuits over its former Actavis generics unit\u2019s alleged anticompetitive conduct, which were consolidated in the District of New Jersey and settled in July 2021, with court approval received in November 2021. These ongoing legal matters pose financial and reputational risks that could offset some of the benefits AbbVie gained from the acquisition, particularly if settlements or damages are substantial.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_65) \u2192 [Allergan]: AbbVie benefited from lower amortization of inventory fair value step-up adjustments linked to the Allergan acquisition, improving gross margin percentages.",
        "Hop 2: [Allergan] \u2192 [Lawsuit]: Allergan faces multiple lawsuits tied to legacy products and business practices, including securities litigation over textured breast implants and generic drug pricing.",
        "Hop 3: [Lawsuit] \u2190 [ABBV](page_134): These lawsuits, detailed in AbbVie\u2019s 10-K, include class action settlements and ongoing litigation that could result in financial liabilities for AbbVie as the acquiring company."
      ],
      "difficulty": "hard",
      "idf_score": 5.699080239556016,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Faces]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Allergan",
        "node_3": "Lawsuit",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_3",
          "chunk_text": "\nGross margin as a percentage of net revenues in 2021 increased from 2020 primarily due to lower amortization of inventory fair value step-up adjustment associated with the Allergan acquisition and favorable changes in product mix, partially offset by higher amortization of intangible assets associated with the Allergan acquisition.\n\n## Selling, General and Administrative\n\n",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Allergan",
          "name": "Allergan",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "node_3": {
          "id": "Lawsuit",
          "name": "Lawsuit",
          "type": "LITIGATION",
          "idf_score": 4.131333131591441
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_1",
          "chunk_text": "In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.\n\n## Shareholder and Securities Litigation\n\nIn June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.\n\nIn October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys' fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.\n\nLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.\n\n## Product Liability and General Litigation\n\nIn 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit.\n\n## Intellectual Property Litigation\n\nAbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District  Court  for  the  Northern  District  of  Illinois  against Alvotech  hf. AbbVie  alleges  defendant's  proposed  biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court  denied  Defendant's  motion  to  dismiss  on  jurisdictional  grounds  in  the  first  case;  a  motion  in  the  second  case remains  pending.  The  court  has  set  a  trial  on  a  subset  of  patents  for August  2022.  The  court  order  provides  that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.\n\nPharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 182,
      "question": "How does AbbVie's financial treatment of development-stage milestone payments in collaboration agreements, such as the one with Janssen Biotech, Inc., align with the strategic value and revenue potential of Imbruvica as a co-commercialized oncology product in the U.S.?",
      "answer": "AbbVie's collaboration with Janssen Biotech, Inc. involves joint development and co-commercialization of Imbruvica, a key oncology product in the U.S. According to the financial treatment outlined in the disclosures, AbbVie expenses milestone payments made during the development stage to R&D expense when the milestone is achieved. Post-approval payments are capitalized as intangible assets and amortized over the product's useful life. This treatment aligns with the strategic value of Imbruvica, which is co-commercialized in the U.S. with shared profit responsibilities and generates ongoing revenue potential through its co-exclusive arrangement. The financial structure reflects AbbVie\u2019s long-term commitment to the product, given its importance in the oncology portfolio and the shared global revenue model with tiered royalty structures outside the U.S.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_84) \u2192 [Janssen Biotech, Inc.]: Disclosure on financial treatment of collaboration agreements, including expensing of development-stage milestones to R&D and capitalization of post-approval payments.",
        "Hop 2: [Janssen Biotech, Inc.] \u2192 [Imbruvica]: Janssen and AbbVie co-develop and co-commercialize Imbruvica under a global collaboration agreement, with shared U.S. commercialization rights and Janssen responsible for 60% of development costs.",
        "Hop 3: [Imbruvica] \u2190 [ABBV](page_90): Imbruvica is positioned as a core oncology asset with strategic importance, as indicated by its co-exclusive U.S. commercialization and global revenue-sharing model with tiered royalties."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Announces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Janssen Biotech, Inc.",
        "node_3": "Imbruvica",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_1",
          "chunk_text": "typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. Sales incentives to customers are insignificant.\n\nIn addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography.\n\n## Research and Development Expenses\n\nInternal research and development (R&amp;D) costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaborations, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.\n\n## Collaborations and Other Arrangements\n\nThe company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements during the development stage are expensed to acquired in-process research and development (IPR&amp;D) expenses in the consolidated statements of earnings. Subsequent payments made to the partner for the achievement of milestones during the development stage are expensed to R&amp;D expense in the consolidated statements of earnings when the milestone is achieved. Milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred.\n\n## Advertising\n\nCosts associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&amp;A) expense in the consolidated statements of earnings. Advertising expenses were $2.1 billion in 2021, $1.8 billion in 2020 and $1.1 billion in 2019.\n\n## Pension and Other Post-Employment Benefits\n\nAbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions, including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive income (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period.\n\n## Income Taxes\n\nIncome taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pretax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized.\n\n## Cash and Equivalents\n\nCash and equivalents include money market funds and time deposits with original maturities of three months or less.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Janssen_Biotech,_Inc.",
          "name": "Janssen Biotech, Inc.",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_98",
          "chunk_id": "chunk_1",
          "chunk_text": "commercial milestones, and AbbVie will pay tiered royalties from low-to-mid teen percentages on global net revenues outside of greater China.\n\n## Genmab A/S\n\nIn June 2020, AbbVie and Genmab A/S (Genmab) entered into a collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody therapeutics and entered into a discovery research collaboration for future differentiated antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab granted to AbbVie an exclusive license to its epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 programs. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will record net revenues in the U.S. and Japan, and the parties will share equally in pre-tax profits from these sales. Genmab will receive tiered royalties on remaining global sales. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs and AbbVie retains the right to opt-in to program development. During 2020, AbbVie made an upfront payment of $750 million, which was recorded to IPR&amp;D in the consolidated statement of earnings. AbbVie could make additional payments of up to $3.2 billion upon the achievement of certain development, regulatory and commercial milestones for all programs.\n\n## Reata Pharmaceuticals, Inc.\n\nIn October 2019, AbbVie and Reata Pharmaceuticals, Inc. (Reata) entered into an amended and restated license agreement. Under the terms of the agreement, Reata reacquired exclusive development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie for territories outside of the United States with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As consideration for the rights reacquired by Reata, AbbVie received a total of $250 million as of December 31, 2020 and $80 million in cash in 2021. Total consideration of $330 million was recognized in other operating (income) expense in the consolidated statement of earnings in 2019. In addition, AbbVie will receive low single-digit, tiered royalties from worldwide sales of omaveloxolone and certain nextgeneration Nrf2 activators.\n\n## Other Arrangements\n\nIn addition to the significant arrangements described above, AbbVie entered into several other arrangements resulting in charges to IPR&amp;D of $192 million in 2021, $248 million in 2020 and $385 million in 2019. In connection with the other individually insignificant early-stage arrangements entered into in 2021, AbbVie could make additional payments of up to $5.5 billion upon the achievement of certain development, regulatory and commercial milestones.\n\n## Note 6 Collaborations\n\nThe company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2021, 2020 and 2019.\n\n## Collaboration with Janssen Biotech, Inc.\n\nIn December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson &amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.\n\nThe collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Imbruvica",
          "name": "Imbruvica",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_8",
          "chunk_text": "|\n",
          "relationship": "Announces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 183,
      "question": "Given the expiration timeline of data protection for Trulicity mentioned in the intellectual property risks section, how does the decline in Trulicity's U.S. revenue reported in the financial results align with Eli Lilly's strategy for managing revenue volatility as data exclusivity nears expiration?",
      "answer": "Eli Lilly's 10-K highlights that Trulicity will lose significant patent and data protections in the coming years, which poses a risk of rapid revenue decline due to generic competition. This is corroborated by the reported 32% decrease in Trulicity's U.S. revenue in 2024, attributed to competitive dynamics and supply constraints. The decline suggests that market exclusivity erosion is already impacting Trulicity's performance, even before full expiration of protections. This aligns with the company's broader concern in the IP risk section about the difficulty in maintaining pricing and formulary access in a consolidating payer landscape. The financial results and IP risk disclosures together indicate that the company is already experiencing the anticipated revenue volatility tied to Trulicity\u2019s lifecycle stage, necessitating strategic responses such as portfolio diversification and lifecycle management.",
      "reasoning_steps": [
        "Hop 1: LLY(page_11) \u2192 Data Protection: LLY discusses the importance of data protection for market exclusivity and notes the uncertainty around the duration of such protections due to litigation and regulatory factors.",
        "Hop 2: Data Protection \u2192 Trulicity: The IP risk section explicitly identifies Trulicity as a product facing imminent loss of data and patent protections, increasing exposure to generic competition and revenue erosion.",
        "Hop 3: Trulicity \u2190 LLY(page_49): The financial results show a 32% decline in Trulicity's U.S. revenue in 2024, driven by competitive dynamics and supply constraints, signaling early effects of reduced exclusivity."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT -[Expires]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Data Protection",
        "node_3": "Trulicity",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain entities has increased due to consolidation, regulatory, and other market impacts, and they, along with gov ernments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or fav orable formulary placement. Such stakeholders hav e also increasingly imposed utilization management tools to limit access to our products. As these practices expand, including due to potential further consolidation of U.S. priv ate third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. We expect that consolidation of supply chain entities will continue to increase competitiv e and pricing pressures on pharmaceutical manufacturers.\n\nPharmacy benefit manager practices hav e come under increased scrutiny from U.S. policymakers at the federal and state lev el who hav e proposed legislation intended to address concerns regarding the impact that these intermediaries hav e on drug pricing and patients' out of pocket costs. If promulgated, such legislation could hav e resultant implications, costs, or consequences for our business and how we interact with these entities. For additional information on pricing and reimbursement for our pharmaceutical products, see Item 1, \"Business-U.S. Priv ate Sector Dynamics\" and \"Regulations and Priv ate Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.\"\n\n## Risks Related to Our Intellectual Property\n\n- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.\n\nIn the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time. For example, Trulicity will lose significant patent and remaining data protections in the next few years. Some products also lose patent protection as a result of successful third-party challenges. We hav e faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection.\n\nFor non-biologic products, loss of exclusiv ity typically results in the entry of one or more generic competitors, leading to a rapid and sev ere decline in rev enues, especially in the U.S. Generic pharmaceutical companies hav e in some cases introduced a generic product before resolution of any related patent litigation. For biologics, loss of exclusiv ity may or may not result in the near-term entry of competitor v ersions (i.e., biosimilars) due to many factors, including dev elopment timelines, manufacturing challenges, and/or uncertainties regarding the regulatory approv al pathways.\n\nOur success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often inv olv e complex legal, scientific and factual questions. There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found v alid and enforceable if challenged. Third parties may challenge, inv alidate, or circumv ent our patents and patent applications relating to our products, product candidates, and technologies. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not be deemed to infringe our patents. Moreover, patents relating to particular products, uses, formulations, or processes may not preclude other manufacturers from employing alternativ e processes or marketing alternativ e products or formulations that compete with our patented products. Patents held by third-parties hav e also contributed, and may in the future contribute, to a decision by us to not pursue all potential indications for a product candidate. In addition, competitors or other third parties may assert claims that our activ ities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis-Executiv e Ov erv iew-Other Matters-Patent Matters\" and Item 1, \"Business-Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.",
          "relationship": "Expires"
        },
        "node_3": {
          "id": "Trulicity",
          "name": "Trulicity",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers m ay not add due to rounding.\n\nNM - not m eaningful\n\nJardiance revenue includes Glyxam bi,Synjardy, and Trijardy XR . (1)\n\nHumalog revenue includes insulin lispro. (2)\n\nBasaglar revenue includes R ezvoglar. (3)\n\nZyprexa revenue includes sale of the rights for the olanzapine portfolio in 2023. (4)\n\nRevenue of Mounjaro increased 85 percent in the U.S., primarily driv en by strong demand and increased supply. Rev enue outside of the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023, primarily driv en by v olume growth in launched markets.\n\nRevenue of Verzenio increased 36 percent in the U.S., driv en by increased demand, wholesaler buying patterns and, to a lesser extent, higher realized prices. Rev enue outside the U.S. increased 39 percent, driv en by increased demand.\n\nRevenue of Trulicity decreased 32 percent in the U.S., driv en by decreased v olume primarily due to competitiv e dynamics and supply constraints during the first half of 2024. Rev enue outside the U.S. decreased 8 percent, driv en by decreased v olume primarily due to competitiv e dynamics and actions we have taken to manage demand.\n\nRevenue of Zepbound in the U.S. in 2024 was $4.93 billion, compared to $175.8 million in 2023. Zepbound launched in the U.S. for the treatment of adult patients with obesity or ov erweight with weight-related comorbidities in Nov ember 2023.\n\nRevenue of Jardiance remained relativ ely flat in the U.S. as increased demand was offset by lower realized prices. Rev enue outside the U.S. increased 52 percent, driv en by increased v olume and a one-time payment receiv ed of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim. Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim inv olv ing Jardiance.\n\nRevenue of Taltz increased 18 percent in the U.S., driv en by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand. Revenue outside the U.S. increased 19 percent, primarily driv en by increased demand.",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 184,
      "question": "How does Merck's capital allocation strategy in oncology and other therapeutic areas reconcile with the anticipated government price-setting under the IRA for Keytruda, which is central to its oncology portfolio and expected to face binding pricing constraints starting in 2028?",
      "answer": "Merck's capital allocation strategy emphasizes investment in therapeutic areas such as oncology, where Keytruda\u2014a key growth driver\u2014plays a central role. However, the company anticipates that Keytruda will be subject to government price-setting under the IRA, with pricing constraints expected to take effect in early 2028. This regulatory pressure on pricing directly challenges the return on investment for Keytruda, which is a major component of Merck's oncology R&D spending. The company also faces current pricing pressures, with gross U.S. sales reduced by 37% due to rebates and discounts, further constraining revenue potential. Therefore, the anticipated price-setting risk for Keytruda introduces uncertainty into the viability of Merck\u2019s capital allocation decisions in oncology, where increased R&D spending is currently justified by the commercial success of products like Keytruda.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_31) \u2192 [IRA]: Merck notes that the Inflation Reduction Act introduces government price-setting, with Keytruda expected to be included in future selections under the IRA\u2019s program, impacting future revenue potential.",
        "Hop 2: [IRA] \u2192 [Government Price Setting]: The IRA mandates government price-setting for certain Medicare Part D and B drugs, with Keytruda anticipated to be included, starting in 2028.",
        "Hop 3: [Government Price Setting] \u2190 [MRK](page_49): Merck\u2019s capital allocation strategy emphasizes oncology investment, including Keytruda, even as the company faces increasing pricing pressures from the IRA and existing rebate structures."
      ],
      "difficulty": "hard",
      "idf_score": 5.566228656689513,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT -[Introduces]-> REGULATORY_REQUIREMENT <-[Faces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "IRA",
        "node_3": "Government Price Setting",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_31",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nThe\tCompany\tcannot\tstate\twith\tcertainty\twhen\tor\twhether\tany\tof\tits\tproducts\tnow\tunder\tdevelopment\twill\tbe\tapproved\tor\tlaunched; whether\tit\twill\tbe\table\tto\tdevelop,\tlicense\tor\totherwise\tacquire\tcompounds,\tproduct\tcandidates\tor\tproducts;\tor\twhether\tany\tproducts, once\tlaunched,\twill\tbe\tcommercially\tsuccessful.\tThe\tCompany\tmust\tmaintain\ta\tcontinuous\tflow\tof\tsuccessful\tnew\tproducts\tand\tsuccessful new\tindications\tfor\texisting\tproducts\tsufficient\tboth\tto\tcover\tits\tsubstantial\tresearch\tand\tdevelopment\tcosts\tand\tto\treplace\tsales\tthat are\tlost\tas\tprofitable\tproducts\tlose\tmarket\texclusivity\tor\tare\tdisplaced\tby\tcompeting\tproducts\tor\ttherapies.\tFailure\tto\tdo\tso\tin\tthe short\tterm\tor\tlong\tterm\twould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tresults\tof\toperations,\tcash\tflow,\tfinancial condition\tand\tprospects.\n\n## The\tCompany's\tsuccess\tis\tdependent\ton\tthe\tsuccessful\tdevelopment\tand\tmarketing\tof\tnew\tproducts,\twhich\tare\tsubject\tto\tsubstantial risks.\n\nProducts\tthat\tappear\tpromising\tin\tdevelopment\tmay\tfail\tto\treach\tthe\tmarket\tor\tfail\tto\tsucceed\tfor\tnumerous\treasons,\tincluding the\tfollowing:\n\n- findings\t of\t ineffectiveness,\t superior\t safety\t or\t efficacy\t of\t competing\t products,\t or\t harmful\t side\t effects\t in\t clinical\t or preclinical\ttesting;\n- failure\tto\treceive\tthe\tnecessary\tregulatory\tapprovals,\tincluding\tdelays\tin\tthe\tapproval\tof\tnew\tproducts\tand\tnew\tindications, or\tthe\tanticipated\tlabeling,\tand\tuncertainties\tabout\tthe\ttime\trequired\tto\tobtain\tregulatory\tapprovals\tand\tthe\tbenefit/risk standards\tapplied\tby\tregulatory\tagencies\tin\tdetermining\twhether\tto\tgrant\tapprovals;\n- failure\tin\tcertain\tmarkets\tto\tobtain\treimbursement\tcommensurate\twith\tthe\tlevel\tof\tinnovation\tand\tclinical\tbenefit\tpresented by\tthe\tproduct;\n- lack\tof\teconomic\tfeasibility\tdue\tto\tmanufacturing\tcosts\tor\tother\tfactors;\tand\n- preclusion\tfrom\tcommercialization\tby\tthe\tproprietary\trights\tof\tothers.\n\nIn\tthe\tfuture,\tif\tcertain\tpipeline\tprograms\tare\tcancelled\tor\tif\tthe\tCompany\tbelieves\tthat\ttheir\tcommercial\tprospects\thave\tbeen reduced,\t the\t Company\t may\t recognize\t material\t non-cash\t impairment\t charges\t for\t those\t programs\t that\t were\t measured\t at\t fair\t value\t and capitalized\tin\tconnection\twith\tacquisitions\tor\tcertain\tcollaborations.\n\nFailure\tto\tsuccessfully\tdevelop\tand\tmarket\tnew\tproducts\tin\tthe\tshort\tterm\tor\tlong\tterm\twould\thave\ta\tmaterial\tadverse\teffect\ton the\tCompany's\tbusiness,\tresults\tof\toperations,\tcash\tflow,\tfinancial\tcondition\tand\tprospects.\n\n## The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n\nThe\t Company\t faces\t continued\t pricing\t pressure\t globally\t and,\t particularly\t in\t mature\t markets,\t from\t managed\t care\t organizations, government\t agencies\t and\t programs\t that\t could\t negatively\t affect\t the\t Company's\t sales\t and\t profit\t margins.\t In\t the\t U.S.,\t these\t include (i)\t U.S.\t federal\t laws\t and\t regulations\t related\t to\t Medicare\t and\t Medicaid,\t including\t the\t Medicare\t Prescription\t Drug\t Improvement\t and Modernization\tAct\tof\t2003,\tthe\tACA,\tand\tthe\tIRA,\t(ii)\tpractices\tof\tmanaged\tcare\tgroups\tand\tinstitutional\tand\tgovernmental\tpurchasers, and\t(iii)\tstate\tactivities\taimed\tat\tincreasing\tprice\ttransparency,\tincluding\tnew\tlaws\tas\tnoted\tabove\tin\tItem\t1.\t'Competition\tand\tthe Health\tCare\tEnvironment.'\tChanges\tto\tthe\thealth\tcare\tsystem\tenacted\tas\tpart\tof\thealth\tcare\treform\tin\tthe\tU.S.,\tas\twell\tas\tincreased purchasing\tpower\tof\tentities\tthat\tnegotiate\ton\tbehalf\tof\tMedicare,\tMedicaid,\tand\tprivate\tsector\tbeneficiaries,\tcould\tresult\tin\tfurther pricing\tpressures.\tAs\tnoted\tin\tItem\t1.\t'Competition\tand\tthe\tHealth\tCare\tEnvironment,'\tin\t2023,\tHHS\tincluded Januvia in\tthe\tfirst\tyear\tof the\tIRA's\tprice\tsetting\tprogram,\twhich\tabsent\tfurther\tlegislative\tor\tcourt\tintervention\twill\tresult\tin\ta\tgovernment\tset\tprice\tbecoming effective\ton\tJanuary\t1,\t2026.\tFurthermore,\tthe\tCompany\tanticipates\tthat\tHHS\twill\tinclude Keytruda in\ta\tsubsequent\tselection\tof\tproducts to\tundergo\tIRA\tprice\tsetting,\twith\tsuch\tprice\tlikely\tto\tbe\teffective\tin\tearly\t2028.\tIn\taddition,\tin\tthe\tU.S.,\tlarger\tcustomers\thave received\thigher\trebates\ton\tdrugs\tin\tcertain\thighly\tcompetitive\tcategories.\tThe\tCompany\tmust\talso\tcompete\tto\tbe\tplaced\ton\tformularies\tof managed\tcare\torganizations.\tExclusion\tof\ta\tproduct\tfrom\ta\tformulary\tcan\tlead\tto\treduced\tusage\tin\tthe\tmanaged\tcare\torganization.\n\nIn\torder\tto\tprovide\tinformation\tabout\tthe\tCompany's\tpricing\tpractices,\tthe\tCompany\tannually\tposts\ton\tits\twebsite\tits\tPricing Transparency\t Report\t for\t the\t U.S.\t The\t report\t provides\t the\t Company's\t average\t annual\t list\t price\t and\t net\t price\t increases\t across\t the Company's\t U.S.\t portfolio\t dating\t back\t to\t 2010.\t In\t 2023,\t the\t Company's\t gross\t U.S.\t sales\t were\t reduced\t by\t 37%\t as\t a\t result\t of\t rebates, discounts\tand\treturns.\n\nOutside\tthe\tU.S.,\tnumerous\tmajor\tmarkets,\tincluding\tthe\tEU,\tJapan\tand\tChina\thave\tpervasive\tgovernment\tinvolvement\tin\tfunding health\t care\t and,\t in\t that\t regard,\t fix\t the\t pricing\t and\t reimbursement\t of\t pharmaceutical\t and\t vaccine\t products.\t Consequently,\t in\t those markets,\tthe\tCompany\tis\tsubject\tto\tgovernment",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "IRA",
          "name": "IRA",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.558777146418381
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\t use\t of\t biologically\t derived\t ingredients\t can\t lead\t to\t variability\t in\t the\t manufacturing\t process\t and\t could\t lead\t to allegations\t of\t harm,\t including\t infections\t or\t allergic\t reactions,\t which\t allegations\t would\t be\t reviewed\t through\t a\t standard investigation\tprocess\tthat\tcould\tlead\tto\tclosure\tof\tproduct\tfacilities\tdue\tto\tpossible\tcontamination.\tAny\tof\tthese\tevents could\tresult\tin\tsubstantial\tcosts.\n\n## Risks\tRelating\tto\tGovernment\tRegulation\tand\tLegal\tProceedings\n\n## The\thealth\tcare\tindustry\tin\tthe\tU.S.\thas\tbeen,\tand\twill\tcontinue\tto\tbe,\tsubject\tto\tincreasing\tregulation\tand\tpolitical\taction.\n\nAs\tdiscussed\tabove\tin\tItem\t1.\t'Competition\tand\tthe\tHealth\tCare\tEnvironment,'\tthe\tCompany\tbelieves\tthat\tthe\thealth\tcare\tindustry will\tcontinue\tto\tbe\tsubject\tto\tincreasing\tregulation\tas\twell\tas\tpolitical\tand\tlegal\taction,\tas\tfuture\tproposals\tto\treform\tthe\thealth care\tsystem\tare\tconsidered\tby\tthe\tExecutive\tbranch,\tCongress\tand\tstate\tlegislatures.\n\nIn\t2022,\tCongress\tpassed\tthe\tIRA,\twhich\tmakes\tsignificant\tchanges\tto\thow\tdrugs\tare\tcovered\tand\tpaid\tfor\tunder\tthe\tMedicare program,\tincluding\tthe\tcreation\tof\tfinancial\tpenalties\tfor\tdrugs\twhose\tprices\trise\tfaster\tthan\tthe\trate\tof\tinflation,\tredesign\tof\tthe Medicare\tPart\tD\tprogram\tto\trequire\tmanufacturers\tto\tbear\tmore\tof\tthe\tliability\tfor\tcertain\tdrug\tbenefits,\tand\tgovernment\tprice-setting for\tcertain\tMedicare\tPart\tD\tdrugs,\tstarting\tin\t2026,\tand\tMedicare\tPart\tB\tdrugs\tstarting\tin\t2028.\tAs\tnoted\tin\tItem\t1.\t'Competition\tand the\tHealth\tCare\tEnvironment,'\tin\t2023,\tHHS\tincluded Januvia in\tthe\tfirst\tyear\tof\tthe\tIRA's\tprice\tsetting\tprogram,\twhich\tabsent\tfurther legislative\tor\tcourt\tintervention\twill\tresult\tin\ta\tgovernment\tset\tprice\tbecoming\teffective\ton\tJanuary\t1,\t2026.\tFurthermore,\tthe\tCompany anticipates\tthat\tHHS\twill\tinclude Keytruda in\ta\tsubsequent\tselection\tof\tproducts\tto\tundergo\tIRA\tprice\tsetting,\twith\tsuch\tprice\tlikely\tto be\teffective\tin\tearly\t2028.\n\nIn\taddition,\tin\t2021,\tCongress\tpassed\tthe\tAmerican\tRescue\tPlan\tAct,\twhich\tincluded\ta\tprovision\tthat\teliminates\tthe\tstatutory\tcap on\t rebates\t drug\t manufacturers\t pay\t to\t Medicaid\t beginning\t in\t January\t 2024.\t These\t rebates\t act\t as\t a\t discount\t off\t the\t list\t price\t and eliminating\tthe\tcap\tmeans\tthat\tmanufacturer\tdiscounts\tpaid\tto\tMedicaid\tcan\tincrease.\tPrior\tto\tthis\tchange,\tmanufacturers\thave\tnot\tbeen required\tto\tpay\tmore\tthan\t100%\tof\tthe\tAverage\tManufacturer\tPrice\t(AMP)\tin\trebates\tto\tstate\tMedicaid\tprograms\tfor\tMedicaid-covered\tdrugs. As\t a\t result\t of\t this\t provision,\t beginning\t in\t 2024,\t manufacturers\t may\t have\t to\t pay\t state\t Medicaid\t programs\t more\t in\t rebates\t than\t they received\ton\tsales\tof\tparticular\tproducts.\tThis\tchange\tpresents\ta\trisk\tto\tMerck\tfor\tdrugs\tthat\thave\thigh\tMedicaid\tutilization\tand\trebate exposure\tthat\tis\tmore\tthan\t100%\tof\tthe\tAMP.\n\nIn\t the\t U.S.,\t the\t Biden\t Administration\t and\t Congress\t continue\t to\t discuss\t legislation\t designed\t to\t control\t health\t care\t costs, including\tthe\tcost\tof\tdrugs.\tThe\tCompany\tcannot\tpredict\twhat\tadditional\tfuture\tchanges\tin\tthe\thealth\tcare\tindustry\tin\tgeneral,\tor\tthe pharmaceutical\tindustry\tin\tparticular,\twill\toccur;\thowever,\tany\tchanges\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness, cash\tflow,\tresults\tof\toperations,\tfinancial\tcondition\tand\tprospects.\n\n## The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n\nThe\tCompany's\tactivities,\tincluding\tresearch,\tpreclinical\ttesting,\tclinical\ttrials\tand\tthe\tmanufacturing\tand\tmarketing\tof\tits products,\tare\tsubject\tto\textensive\tregulation\tby\tnumerous\tfederal,\tstate\tand\tlocal\tgovernmental\tauthorities\tin\tthe\tU.S.,\tincluding\tthe FDA,\tand\tby\tforeign\tregulatory\tauthorities,\tincluding\tin\tthe\tEU,\tJapan\tand\tChina.\tIn\tthe\tU.S.,\tthe\tFDA\tadministers\trequirements\tcovering the\ttesting,\tapproval,\tsafety,\teffectiveness,\tmanufacturing,\tlabeling\tand\tmarketing\tof\tprescription\tpharmaceuticals\tand\tvaccines.\tIn some\tcases,\tthe\tFDA\trequirements\thave\tincreased\tthe\tamount\tof\ttime\tand\tresources\tnecessary\tto\tdevelop\tnew\tproducts\tand\tbring\tthem\tto market\tin\tthe\tU.S.\tRegulation\toutside\tthe\tU.S.\talso\tis\tprimarily\tfocused\ton\tdrug\tsafety\tand\teffectiveness\tand,\tin\tmany\tcases,\treduction in\tthe\tcost\tof\tdrugs.\tThe\tFDA\tand\tforeign\tregulatory\tauthorities,\tincluding\tin\tthe\tEU,\tJapan\tand\tChina,\thave\tsubstantial\tdiscretion\tto require\tadditional\ttesting,\tto\tdelay\tor\twithhold\tregistration\tand\tmarketing\tapproval\tand\tto\totherwise\tpreclude\tdistribution\tand\tsale\tof a\tproduct.\n\nEven\tif\tthe\tCompany\tis\tsuccessful\tin\tdeveloping\tnew\tproducts,\tit\twill\tnot\tbe\table\tto\tmarket\tany\tof\tthose\tproducts\tunless\tand until\tit\thas\tobtained\tall\trequired\tregulatory\tapprovals\t(which\tin\tlimited\tcircumstances\tmay\tinclude\tauthorizations\tfor\temergency\tuse)\tin each\tjurisdiction\twhere\tit\tproposes\tto\tmarket\tthe\tnew\tproducts.\tOnce\tobtained,\tthe\tCompany\tmust\tmaintain\tapproval\tas\tlong\tas\tit\tplans\tto market\tits\tnew\tproducts\tin\teach\tjurisdiction\twhere\tapproval\tis\trequired.\tThe\tCompany's\tfailure\tto\tobtain\tapproval,\tsignificant\tdelays\tin the\t approval\t process,\t or\t its\t failure\t to\t maintain\t approval\t in\t any\t jurisdiction\t will\t prevent\t it\t from\t selling\t the\t products\t in\t that jurisdiction\tand\trealizing\tsales.",
          "relationship": "Introduces"
        },
        "node_3": {
          "id": "Government_Price_Setting",
          "name": "Government Price Setting",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- MK-8591A,\t islatravir,\t an\t investigational\t nucleoside\t reverse\t transcriptase\t translocation\t inhibitor,\t in\t combination\t with doravirine\tfor\tthe\ttreatment\tof\tHIV-1\tinfection\t(which\tis\ton\tpartial\tclinical\thold\tfor\thigher\tdoses\tthan\tthose\tused\tin\tcurrent clinical\ttrials);\tand\n- MK-4482, Lagevrio ,\twhich\tis\treflected\tin\tPhase\t3\tdevelopment\tin\tthe\tU.S.\tas\tit\tremains\tinvestigational\tfollowing\tEmergency\tUse Authorization\t(EUA)\tin\t2021.\n\nMerck's\tcapital\tallocation\tstrategy\tcontinues\tto\tprioritize\tinvestments\tin\tits\tbusiness\tto\tdrive\tnear-\tand\tlong-term\tgrowth, including\tinvesting\tin\topportunities\tto\taddress\timportant\tunmet\tmedical\tneeds\tand\tsupporting\tthe\tCompany's\tcommercial\topportunities.\tIn addition,\tMerck\tremains\tcommitted\tto\tits\tdividend\tand\twill\tcontinue\tto\tpursue\tthe\tmost\tcompelling\texternal\tscience\tand\ttechnologies through\tvalue-enhancing\tbusiness\tdevelopment\ttransactions.\tResearch\tand\tdevelopment\texpenses\tin\t2023\treflect\thigher\tcharges\tfor\tbusiness development\t transactions\t and\t increased\t development\t spending\t particularly\t in\t the\t therapeutic\t areas\t of\t oncology,\t cardiovascular, infectious\tdiseases\tand\tvaccines.\n\nIn\tNovember\t2023,\tMerck's\tBoard\tof\tDirectors\tapproved\tan\tincrease\tto\tthe\tCompany's\tquarterly\tdividend,\traising\tit\tto\t$0.77\tper share\tfrom\t$0.73\tper\tshare\ton\tthe\tCompany's\toutstanding\tcommon\tstock.\tDuring\t2023,\tthe\tCompany\treturned\t$8.8\tbillion\tto\tshareholders through\tdividends\tof\t$7.4\tbillion\tand\tshare\trepurchases\tof\t$1.3\tbillion.\n\nGAAP\tand\tNon-GAAP\tEPS\twere\tnegatively\taffected\tin\t2023,\t2022\tand\t2021\tby\t$6.21,\t$0.22,\tand\t$0.65,\trespectively,\tof\tcharges\tfor\tcertain\tupfront\tand\tpre-approval\tmilestone\tpayments related\tto\tcollaborations\tand\tlicensing\tagreements,\tas\twell\tas\tcharges\trelated\tto\tpre-approval\tassets\tobtained\tin\ttransactions\taccounted\tfor\tas\tasset\tacquisitions.\n\n## Pricing\n\nGlobal\tefforts\ttoward\thealth\tcare\tcost\tcontainment\tcontinue\tto\texert\tpressure\ton\tproduct\tpricing\tand\tmarket\taccess\tworldwide. Changes\tto\tthe\tU.S.\thealth\tcare\tsystem\tenacted\tin\tprior\tyears\tas\tpart\tof\thealth\tcare\treform,\tas\twell\tas\tincreased\tpurchasing\tpower\tof entities\tthat\tnegotiate\ton\tbehalf\tof\tMedicare,\tMedicaid,\tand\tprivate\tsector\tbeneficiaries,\thave\tcontributed\tto\tpricing\tpressure.\tIn several\tinternational\tmarkets,\tgovernment-mandated\tpricing\tactions\thave\treduced\tprices\tof\tgeneric\tand\tpatented\tdrugs.\tIn\taddition,\tthe Company's\t sales\t performance\t in\t 2023\t was\t negatively\t affected\t by\t other\t cost-reduction\t measures\t taken\t by\t governments\t and\t other\t third parties\tto\tlower\thealth\tcare\tcosts.\tIn\t2022,\tthe\tU.S.\tCongress\tpassed\tthe\tInflation\tReduction\tAct\t(IRA),\twhich\tmakes\tsignificant\tchanges to\thow\tdrugs\tare\tcovered\tand\tpaid\tfor\tunder\tthe\tMedicare\tprogram,\tincluding\tthe\tcreation\tof\tfinancial\tpenalties\tfor\tdrugs\twhose\tprices rise\tfaster\tthan\tthe\trate\tof\tinflation,\tredesign\tof\tthe\tMedicare\tPart\tD\tprogram\tto\trequire\tmanufacturers\tto\tbear\tmore\tof\tthe\tliability for\tcertain\tdrug\tbenefits,\tand\tgovernment\tprice-setting\tfor\tcertain\tMedicare\tPart\tD\tdrugs\t(starting\tin\t2026)\tand\tMedicare\tPart\tB\tdrugs (starting\tin\t2028).\tIn\tAugust\t2023,\tthe\tU.S.\tDepartment\tof\tHealth\tand\tHuman\tServices\t(HHS),\tthrough\tthe\tCenters\tfor\tMedicare\t&amp;\tMedicaid Services\t (CMS),\t announced\t that Januvia will\t be\t included\t in\t the\t first\t year\t of\t the\t IRA's\t 'Drug\t Price\t Negotiation\t Program'\t (Program). Pursuant\tto\tthe\tIRA's\tProgram,\tdiscussions\twith\tthe\tgovernment\toccurred\tin\t2023\tand\twill\tcontinue\tin\t2024,\twith\tgovernment\tprice-setting becoming\t effective\t on\t January\t 1,\t 2026.\t The\t Company\t has\t sued\t the\t U.S.\t government\t regarding\t the\t IRA's\t Program\t (see\t Note\t 11\t to\t the consolidated\tfinancial\tstatements).\tFurthermore,\tthe\tBiden",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 185,
      "question": "How does the potential maximum share issuance from performance units granted under the Amended 2009 Plan impact Amgen's stock-based compensation expense trends over the past three years, considering the plan's fungible share-counting formula?",
      "answer": "The Amended 2009 Plan allows for performance units to be earned up to 200% of the target grant, which could significantly increase the number of shares issued if above-target performance is achieved. Despite this potential dilution, Amgen's stock-based compensation expense for performance units remained relatively stable at $133 million in 2024, $121 million in 2023, and $132 million in 2022. This suggests that the expense recognition is based on the expected achievement of performance goals rather than the maximum possible payout. Additionally, the plan's fungible share-counting formula reduces the available share pool by 1.9 shares for each performance unit granted, which affects how remaining shares are allocated for future awards and influences long-term equity compensation planning.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_92) \u2192 Amended 2009 Plan: The plan allows performance units to be earned up to 200% of target, with a fungible share-counting formula that counts each performance unit as 1.9 shares for share pool depletion purposes.",
        "Hop 2: Amended 2009 Plan \u2192 Performance Units: Performance units are a type of equity award under the Amended 2009 Plan, subject to the same fungible share-counting rules and performance-based vesting conditions.",
        "Hop 3: Performance Units \u2190 AMGN(page_124): Performance unit expenses have remained relatively flat over the past three years, indicating consistent performance expectations despite the potential for 200% payout."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY -[Includes]-> FIN_INST <-[Discloses]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Amended 2009 Plan",
        "node_3": "Performance Units",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "ACCOUNTING_POLICY",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe Amended 2009 Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. In accordance with this formula, each option or stock appreciation right counts as one share, while each RSU, performance unit or dividend equivalent counts as 1.9 shares. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the fungible share-counting formula. The number under column (c) represents the number of shares available for issuance under this plan based on each such available share counting as one share. Commencing with the grants made in April 2012, RSUs and performance units accrue dividend equivalents that are payable in shares only to the extent and when the underlying RSUs vest or underlying performance units have been earned and the related shares are issued to the grantee. The performance units granted under this plan are earned based on the accomplishment of specified performance goals at the end of their respective three-year performance periods; the number of performance  units  granted  represent  target  performance,  and  the  max imum  number  of  units  that  could  be  earned  based  on  our  performance  is  200%  of  the performance units granted in 2022, 2023 and 2024. (1)\n\nAs of December 31, 2024, the number of outstanding awards under column (a) includes (i) 5,909,018 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of $225.84; (ii) 3,289,089 shares issuable upon the vesting of outstanding RSUs, including 198,925 related dividend equivalents; and (iii) 1,516,669 shares subject to outstanding 2022, 2023 and 2024 performance units, including 91,901 related dividend equivalents. The weighted-average exercise price shown in column (b) is for the outstanding options only. The number of available shares under column (c) represents the number of shares that remain available for future issuance under this plan as of December 31, 2024, employing the fungible share formula and presumes the issuance of target shares under the performance units granted in 2022, 2023 and 2024 and related dividend equivalents. The numbers under columns (a) and (c) do not give effect to the additional shares  that  could  be  issuable  in  the  event  that  above  target  performance  on  the  performance  goals  under  these  outstanding  performance  units  is  achieved. Maximum performance under these goals could result in 200% of target shares being awarded for performance units granted in 2022, 2023 and 2024.\n\nThis plan has terminated as to future grants. The number under column (a) with respect to this plan includes 100 shares issuable upon the settlement of deferred RSUs. (2)\n\nThe Profit Sharing Plan was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company's subsidiaries located in Ireland who participate in the Profit Sharing Plan to apply a (3)",
          "relationship": "Subject_To"
        },
        "node_2": {
          "id": "Amended_2009_Plan",
          "name": "Amended 2009 Plan",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_1",
          "chunk_text": "## 5. Stock-based compensation\n\nOur Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2024, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 59 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.\n\nThe following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):\n\n",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Performance_Units",
          "name": "Performance Units",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                    | Years ended December 31,   | Years ended December 31,   | Years ended December 31,   |\n|----------------------------------------------------|----------------------------|----------------------------|----------------------------|\n|                                                    | 2024                       | 2023                       | 2022                       |\n| RSUs                                               | $ 351                      | $ 309                      | $ 227                      |\n| Performance units                                  | 133                        | 121                        | 132                        |\n| Stock options                                      | 46                         | 43                         | 42                         |\n| Total stock-based compensation expense, pretax     | 530                        | 473                        | 401                        |\n| Taxbenefit fromstock-based compensation expense    | (114)                      | (102)                      | (86)                       |\n| Total stock-based compensation expense, net of tax | $ 416                      | $ 371                      | $ 315                      |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 186,
      "question": "How does the availability of 7,461,515 common shares for future issuance under the Employee Stock Purchase Plan for Non-U.S. Employees relate to the share recycling provisions in the 2009 Program and their continued use in the 2017 Program?",
      "answer": "The Employee Stock Purchase Plan for Non-U.S. Employees had 7,461,515 common shares available for future issuance as of December 31, 2024. These shares may come from authorized but unissued shares, treasury shares, or shares acquired on the open market. The 2009 Program includes a provision that allows shares reserved for benefits that lapse, expire, terminate, or are forfeited or canceled without issuance to be reused in the 2017 Program. This recycling mechanism supports the availability of shares in plans like the Employee Stock Purchase Plan for Non-U.S. Employees, which was previously known as the 2009 Employee Stock Purchase Plan for Non-U.S. Employees before being amended and restated in 2017. Therefore, the 7,461,515 shares available for future issuance could potentially include shares that were previously reserved under the 2009 Program but became available again due to unexercised or canceled benefits.",
      "reasoning_steps": [
        "Hop 1: [ABT](page_84) \u2192 [Foreign Benefits]: Discloses the Employee Stock Purchase Plan for Non-U.S. Employees, including the 7,461,515 shares available for future issuance and the plan's operational details.",
        "Hop 2: [Foreign Benefits] \u2192 [2009 Program]: The 2009 Program includes foreign benefits and contains provisions that allow shares reserved for canceled or unexercised benefits to be reused in the 2017 Program.",
        "Hop 3: [2009 Program] \u2190 [ABT](page_83): Introduces the 2009 Program and its share recycling provisions, which are carried forward into the 2017 Program, directly influencing the availability of shares for plans like the Employee Stock Purchase Plan for Non-U.S. Employees."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_INST -[Contains]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "entities": {
        "start": "ABT",
        "node_2": "Foreign Benefits",
        "node_3": "2009 Program",
        "end": "ABT"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "ACCOUNTING_POLICY",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "| (ii)   | Abbott Laboratories 2017 Incentive Stock Program . Benefits under the 2017 Programinclude non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non- employee directors, and foreign benefits. The shares that remain available for issuance under the 2017 Programmay be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied fromtreasury shares). If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2017 Programwithout the issuance of shares or payment                                                                                   |\n|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (iii)  | Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees . Eligible employees of participating non-U.S. affiliates of Abbott may participate in this plan.An eligible employee may authorize payroll deductions at the rate of1% to 10% of eligible compensation (in multiples of one percent) subject to a limit of US$12,500 during any purchase cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|        | Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The shares may be either authorized but unissued shares, treasury shares, or shares acquired on the open market. The purchase price is typically 85% of the lower of the fair market value of the shares on the purchase date or on the first day of that purchase cycle.As the number of shares subject to outstanding options is indeterminable, columns (a) and (b) of the above table do not include information on the Employee Stock Purchase Plan. As of December 31, 2024, an aggregate of 7,461,515 common shares were available for future issuance under the Employee Stock Purchase Plan, including shares subject to purchase during the current purchase cycle. |\n|        | In April 2017, the 2009 Employee Stock Purchase Plan for Non-U.S. Employees was amended and restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Foreign_Benefits",
          "name": "Foreign Benefits",
          "type": "FIN_INST",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Contains"
        },
        "node_3": {
          "id": "2009_Program",
          "name": "2009 Program",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "page_id": "page_83",
          "chunk_id": "chunk_3",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\n(1) (i) Abbott Laboratories 2009 Incentive Stock Program .  Benefits under the Abbott Laboratories 2009 Incentive Stock Program (the '2009 Program') include non-qualified stock options, restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).\n\nIf there is a lapse, ex piration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the Abbott Laboratories 2017 Incentive Stock Program (the '2017 Program'). If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott,",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "ABT",
          "name": "ABT",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 187,
      "question": "How does Gilead's revenue recognition policy for Symtuza align with its financial treatment of Complera/Eviplera and Odefsey, given the differing manufacturing and commercialization responsibilities in these Janssen collaborations?",
      "answer": "Gilead recognizes its share of Symtuza revenue as Product Sales on its Consolidated Statements of Income, primarily because it supplies the Gilead Compounds to Janssen for Symtuza. This mirrors the treatment of Complera/Eviplera and Odefsey, where Gilead also recognizes revenue shares as Product Sales. However, there are operational differences: Gilead is responsible for manufacturing Complera/Eviplera and Odefsey and leads registration, distribution, and commercialization, while Janssen handles these activities for Symtuza globally. Despite these differences, the financial structure is consistent\u2014revenue shares are based on the ratio of net selling prices of each party's components, and Janssen's share of revenue from these products is recorded as Cost of Goods Sold, totaling $430 million for Symtuza-related products in 2023. This alignment in financial treatment contrasts with the differing operational models, suggesting a consistent revenue recognition policy across Janssen collaborations regardless of Gilead's level of direct involvement in manufacturing or commercialization.",
      "reasoning_steps": [
        "Hop 1: GILD(page_79) \u2192 Janssen: Gilead and Janssen share revenue based on the ratio of net selling prices for Symtuza, with Gilead recognizing its share as Product Sales due to supplying the Gilead Compounds.",
        "Hop 2: Janssen \u2192 Symtuza: Janssen is responsible for manufacturing, registration, distribution, and commercialization of Symtuza globally under the 2014 amendment, while Gilead retains intellectual property rights for the Gilead Compounds.",
        "Hop 3: Symtuza \u2190 GILD(page_78): Gilead's financial treatment of Symtuza aligns with Complera/Eviplera and Odefsey, where Gilead also recognizes revenue shares as Product Sales and records Janssen's share as Cost of Goods Sold, despite having more direct involvement in manufacturing and commercialization for those products."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Manufactures]-> PRODUCT <-[Develops]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Symtuza",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen\t sets\t the\t price\t of\t Symtuza\t and\t the\t parties\t share\t revenue\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the party's\t component(s),\t subject\t to\t certain\t restrictions\t and\t adjustments.\t The\t intellectual\t property\t license\t and\t supply obligations\trelated\tto\tthe\tGilead\tCompounds\tare\taccounted\tfor\tas\ta\tsingle\tperformance\tobligation.\tAs\tthe\tlicense\twas\tdeemed to\tbe\tthe\tpredominant\titem\tto\twhich\tthe\trevenue\tshare\trelates,\twe\trecognize\tour\tshare\tof\tthe\tSymtuza\trevenue\tin\tthe\tperiod when\tthe\tcorresponding\tsales\tof\tSymtuza\tby\tJanssen\toccur.\tWe\trecord\tour\tshare\tof\tthe\tSymtuza\trevenue\tas\tProduct\tsales\ton\tour Consolidated\tStatements\tof\tIncome\tprimarily\tbecause\twe\tsupply\tthe\tGilead\tCompounds\tto\tJanssen\tfor\tSymtuza.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tJanssen may\tterminate\tthe\tagreement\twithout\tcause\ton\ta\tcountry-by-country\tbasis,\tin\twhich\tcase\tGilead\thas\tthe\tright\tto\tbecome\tthe selling\tparty\tfor\tsuch\tcountry(ies)\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10\tyears.\tJanssen may\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Japan\tTobacco\n\nIn\t2005,\tJapan\tTobacco,\tInc.\t('Japan\tTobacco')\tgranted\tus\texclusive\trights\tto\tdevelop\tand\tcommercialize\telvitegravir,\ta novel\t HIV\t integrase\t inhibitor,\t in\t all\t countries\t of\t the\t world,\t excluding\t Japan,\t where\t Japan\t Tobacco\t retained\t such\t rights. Effective\t December\t 2018,\t we\t entered\t into\t an\t agreement\t with\t Japan\t Tobacco\t to\t acquire\t the\t rights\t to\t market\t and\t distribute certain\tproducts\tin\tour\tHIV\tportfolio\tin\tJapan\tand\tto\texpand\tour\trights\tto\tdevelop\tand\tcommercialize\telvitegravir\tto\tinclude Japan.\tWe\tare\tresponsible\tfor\tthe\tmarketing\tof\tthe\tproducts\tas\tof\tJanuary\t1,\t2019.\n\nWe\t are\t responsible\t for\t seeking\t regulatory\t approval\t in\t our\t territories\t and\t are\t required\t to\t use\t diligent\t efforts\t to commercialize\t elvitegravir\t for\t the\t treatment\t of\t HIV\t infection.\t We\t bear\t all\t costs\t and\t expenses\t associated\t with\t such commercialization\tefforts\tand\tpay\ta\troyalty\tto\tJapan\tTobacco\tbased\ton\tour\tproduct\tsales.\tOur\tsales\tof\tthese\tproducts\tare included\tin\tProduct\tsales\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalties\tdue\tto\tJapan\tTobacco\tare\tincluded\tin\tCost\tof goods\tsold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalty\texpenses\trecognized\twere\t$167\tmillion,\t$198\tmillion\tand\t$250 million\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nUnder\tthe\tterms\tof\tthe\t2018\tagreement,\twe\tpaid\tJapan\tTobacco\t$559\tmillion\tin\tcash\tand\trecognized\tan\tintangible\tasset\tof $550\tmillion\treflecting\tthe\testimated\tfair\tvalue\tof\tthe\tmarketing-related\trights\tacquired\tfrom\tJapan\tTobacco.\tThe\tintangible asset\tis\tbeing\tamortized\tover\tnine\tyears,\trepresenting\tthe\tperiod\tover\twhich\tthe\tmajority\tof\tthe\tbenefits\tare\texpected\tto\tbe derived\t from\t the\t applicable\t products\t in\t our\t HIV\t portfolio.\t The\t amortization\t expense\t is\t classified\t as\t selling\t expense\t and recorded\tas\tSelling,\tgeneral\tand\tadministrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including material\tbreach\tby\teither\tparty\tor\texpiry\tof\troyalty\tpayment\tterm.\tWe\tmay\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Everest\n\nIn\tApril\t2019,\tEverest\tMedicines\t('Everest')\tand\tImmunomedics\tentered\tinto\tan\tagreement\tgranting\tEverest\tan\texclusive license\t to\t develop\t and\t commercialize\t Trodelvy\t in\t Greater\t China,\t South\t Korea,\t Singapore,\t Indonesia,\t Philippines,\t Vietnam, Thailand,\tMalaysia\tand\tMongolia\t(the\t'Territories').\tGilead\tsubsequently\tacquired\tImmunomedics\tin\tOctober\t2020\tand\tassumed the\tEverest\tlicense\tand\tsupply\tagreement,\twhich\tprovided\tfor\tcertain\tsales\tmilestones\tand\troyalties\tpayments\tto\tbe\tmade\tto Gilead\tand\twas\trecorded\tas\ta\t$175\tmillion\tfinite-lived\tasset\tas\tpart\tof\tthe\tpurchase\taccounting.\tIn\tthe\tfourth\tquarter\tof 2022,\t we\t reacquired\t all\t development\t and\t commercialization\t rights\t for\t Trodelvy\t from\t Everest\t and\t terminated\t the\t previous agreement.\tUnder\tthe\tterms\tof\tthe\tnew\tagreement,\tGilead\tmade\t$280\tmillion\tin\tupfront\ttermination\tpayments\tto\tEverest,\tof which\t$84\tmillion\twas\tmade\tin\t2022\tand\t$196\tmillion\twas\tmade\tin\t2023.\tIn\taddition,\tEverest\tis\teligible\tto\treceive\tup\tto\t$175 million\tin\tpotential\tadditional\tpayments\tupon\tachievement\tof\tcertain\tregulatory\tand\tcommercial\tmilestones.\tWe\taccounted\tfor the\tnew\tagreement\tas\ta\tcontract\ttermination,\twhich\tincludes\tthe\treacquisition\tof\tcommercial\trights\tand\tthe\tsettlement\tof\tour pre-existing\t relationship\t with\t Everest.\t As\t a\t result,\t we\t recorded\t an\t expense\t of\t $406\t million\t in\t Selling,\t general\t and administrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome\tduring\tthe\tyear\tended\tDecember\t31,\t2022,\twhich\tprimarily represents\tthe\tupfront\tcosts\tand\twrite-off\tof\tthe\tremaining\tvalue\tof\tthe\tpre-existing\tasset\trelated\tto\tthe\tprior\tagreement. Simultaneously,\t we\t recorded\t an\t acquired\t finite-lived\t asset\t with\t a\t fair\t value\t of\t $50\t million\t for\t the\t commercial\t rights reacquired\tfor\tproducts\tapproved\tin\tthe\tTerritories.\n\n## Abingworth\n\nIn\tDecember\t2023,\twe\tentered\tinto\tan\tarrangement\twith\tfunds\tmanaged\tby\tAbingworth\tLLP\t('Abingworth')\tunder\twhich\twe\twill receive\tup\tto\t$210\tmillion\tto\tco-fund\tour\tdevelopment\tcosts\tfor\tTrodelvy\tfor\tnon-small\tcell\tlung\tcancer\tin\t2023\tthrough\t2026. As\t there\t is\t substantive\t transfer\t of\t risk\t to\t the\t financial\t partner,\t the\t development\t funding\t is\t recognized\t by\t us\t as\t an obligation\tto\tperform\tcontractual\tservices.\tIn\t2023,\twe\treceived\t$50\tmillion\tfrom\tAbingworth.\tWe\tare\trecognizing\tthe\tfunding as\ta\treduction\tof\tResearch\tand\tdevelopment\texpenses\tusing\tan\tattribution\tmodel\tover\tthe\tperiod\tof\tthe\trelated\texpenses.\tIf successful,\t upon\t regulatory\t approval\t in\t the\t U.S.\t for\t the\t specified\t indication,\t Abingworth\t will\t be\t eligible\t to\t receive\t an approval-based\tfixed\tmilestone\tpayment\tof\tup\tto\t$84\tmillion\tand\troyalties\tbased\ton\tthe\tapplicable\tnet\tsales.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Manufactures"
        },
        "node_3": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Develops"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 188,
      "question": "How does BMY's exposure to early market exclusivity loss for Eliquis in Europe relate to the company's reliance on patent rights enforcement, given the ongoing legal proceedings and the potential for additional generic competition in other EU countries?",
      "answer": "BMY faces early market exclusivity loss for Eliquis in several European countries due to adverse legal decisions and ongoing patent litigation, which directly challenges the company's reliance on patent rights enforcement to maintain revenue stability. In countries like the UK, Finland, and Slovakia, generic versions of Eliquis have already entered the market despite pending appeals, reducing BMY\u2019s control over the product's commercial lifecycle. This exposure is compounded by the fact that BMY is currently involved in litigation across more than 20 European jurisdictions, with mixed outcomes\u2014some favorable (e.g., Norway, Sweden, Switzerland) and some unfavorable (e.g., UK, Ireland, Spain). The company's ability to enforce its patent rights is critical to delaying generic entry and preserving revenue, yet the unpredictable nature of these legal proceedings and the potential for further adverse rulings suggest that additional generic competition may emerge before patent expiration. This dynamic undermines BMY\u2019s broader strategy of relying on strong patent rights to protect key revenue-generating products and highlights the financial risk posed by early market exclusivity erosion.",
      "reasoning_steps": [
        "Hop 1: BMY(page_28) \u2192 Market Exclusivity: The document highlights the risk of losing market exclusivity earlier than expected, particularly for Eliquis, which could lead to rapid revenue decline due to generic competition.",
        "Hop 2: Market Exclusivity \u2192 Patent Rights: Market exclusivity is directly tied to patent rights, which are described as a key determinant of commercial value for innovative pharmaceuticals. The strength and enforceability of these rights dictate the duration of exclusivity.",
        "Hop 3: Patent Rights \u2190 BMY(page_121): The document details ongoing litigation across Europe regarding Eliquis' patent rights, with mixed outcomes and active generic market entries in several countries, indicating a real and immediate threat to BMY's revenue protection strategy."
      ],
      "difficulty": "hard",
      "idf_score": 5.128494288012563,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> REGULATORY_REQUIREMENT -[Provides]-> RISK_FACTOR <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Market Exclusivity",
        "node_3": "Patent Rights",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "RISK_FACTOR",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "a REMS program. The inability to bring a product to market or a significant delay in the expected regulatory approval and related launch date of a new product could negatively impact our revenues and earnings. In addition, if certain acquired pipeline programs are canceled or we believe their commercial prospects have  been  reduced,  we  may  recognize  material  non-cash  impairment  charges  for  those  programs.  Finally,  losing  key  molecules  and  intermediaries  or  our compound library through a natural or man-made disaster or act of sabotage could negatively impact the product development cycle.\n\nWe can provide no assurance when or whether any of our products under development will be approved or launched or whether any products, once launched, will be commercially successful. The public announcement of data from our clinical studies, or those of our competitors, or news of any developments related to our, or our competitors', products or late-stage compounds may cause significant volatility in our stock price and depending on the data, may result in an adverse impact on our business, financial condition or results of operations. If the development of any of our key late-stage product candidates is delayed or discontinued or a clinical study does not meet one or more of its primary endpoints, our stock price could decline significantly and there may be an adverse impact on our business, financial condition or results of operations.\n\nWe must maintain a continuous flow of successful new products and successful new indications for existing products sufficient both to cover our substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short-term or long-term can have a material adverse effect on our business, results of operations, cash flow, financial condition and prospects. W e may also choose to no longer pursue certain programs from time to time as we periodically review our research and development programs and seek to prioritize our pipeline investments. This may result in further uncertainty as to when potential new products will be approved and commercialized. There can be no assurance that our key product candidates would prove to be safe and effective or as safe and effective as other competing products, or that, even if approved, any such products will become commercially successful for all approved indications.\n\n## We could lose market exclusivity of a product earlier than expected.\n\nIn the pharmaceutical and biotechnology industries, the majority of an innovative product' s commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product's revenues.\n\nMarket exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights, if any, varies from country to country and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain or maintain patent and other intellectual property rights, or limitations on the use or loss of such rights, could result in a rapid loss of sales for any affected products which could be material to  us.  In  some  countries,  including  certain  EU  member  states,  basic  patent  protections  for  our  products  may  not  exist  because  certain  countries  did  not historically offer the right to obtain specific types of patents, and/or we (or our licensors) did not file in those countries. In addition, the patent environment can be unpredictable, and the validity and enforceability of patents cannot be predicted with certainty.  For example, for  Eliquis, generics have challenged the composition of matter patents and related  SPCs in various jurisdictions, and trials have taken place, or are scheduled to take place, in certain  European countries. While these legal proceedings are pending, generic manufacturers have begun marketing generic versions of Eliquis in certain EU countries and may seek to market generic versions of Eliquis in other EU countries prior to the expiration date of applicable patents and related SPCs. Furthermore, manufacturers of innovative drugs as well as generic drug manufacturers may be able to design their products around our owned or licensed patents and compete with us using the resulting alternative technology. Absent relevant patent protection for a product, once the data exclusivity period expires, generic or alternative versions can be approved and marketed.\n\nGeneric and biosimilar product manufacturers as well as other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we have faced and may continue to face earlier-than-expected competition for any products at any time. Patents covering our key products have been, and  are  likely  to  continue  to  be,  subject  to  validity,  enforceability  and  infringement  challenges  in  patent  litigations  and  post-grant  review  patent  office proceedings. Although we are confident in the strength of our intellectual property rights, it may be possible for generic drug companies to successfully challenge our rights and launch their generic versions of our drugs prior to the expiration of our intellectual property rights. For example, following certain adverse judicial decisions in the UK, Finland and Slovakia, generic manufacturers have begun marketing generic versions of Eliquis in these countries, and may seek to market generic versions of Eliquis in additional countries in Europe, prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe. In addition, in order to avoid the uncertainty and expense of litigation, among other  reasons,  we  may  decide  to  enter  into  settlements  with  generic  manufacturers  that  permit  generic  market  entry  prior  to  the  expiration  of  our intellectual property rights. For example, as a result of patent settlements, generic entry for Revlimid in the UK began on January 18, 2022, and in various other European countries on February 18, 2022. Similarly, in the U.S., following patent settlements, certain companies have begun marketing generic lenalidomide pursuant to volume-limited licenses. The licenses will no longer be volume-limited beginning on January 31, 2026.",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "Abraxane Abraxane (paclitax el albumin-bound particles for injectable suspension) is a solvent-free protein-bound chemotherapy product that combines paclitaxel with  albumin  using  our  proprietary Nab technology platform, and is used to treat breast cancer,  NSCLC and pancreatic cancer, among others. \u00ae \u00ae\n\nWe own or license a number of patents in the U.S. and foreign countries primarily covering our products. We have also developed many brand names and trademarks for our products. We consider the overall protection of our patents, trademarks, licenses and other intellectual property rights to be of material value and act to protect these rights from infringement.\n\nIn  the  pharmaceutical industry, the majority of an innovative product's commercial value is usually realized during the period in which the product has market exclusivity. A product's market exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovative drug is entitled.\n\nPatents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.\n\nMarket exclusivity is also sometimes provided by regulatory exclusivity, a period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator's data to approve a competitor's generic or biosimilar copy. Regulatory exclusivity can provide a market exclusivity period on a product that expires beyond the patent term.\n\nWhen these patent rights and other forms of exclusivity expire and generic versions of a medicine are approved and marketed, there are often substantial and rapid declines in the sales of the original innovative product. For further discussion of the impact of generic medicines on our business, refer to '-Competition' below.\n\nSpecific  aspects  of  the  law  governing  market  patent  protection  and  regulatory  ex clusivity  for  pharmaceuticals  vary  from  country  to  country.  The  following summarizes key exclusivity rules in markets representing significant sales:\n\n## United States\n\nIn the U.S., most of our key products are protected by patents with varying terms depending on the type of patent and the filing date. A significant portion of a product's patent life, however, is lost during the time it takes an innovator company to develop and obtain regulatory approval of a new drug. As compensation at least in part for the lost patent term due to regulatory review periods, the innovator may, depending on a number of factors, apply to the government to restore lost patent term by extending the expiration date of one patent up to a maximum term of five years, provided that the extension cannot cause the patent to be in effect for more than 14 years from the date of drug approval.\n\nA company seeking to market an innovative pharmaceutical in the  U.S. must submit a complete set of safety and efficacy data to the  FDA.  If the innovative pharmaceutical is a chemical product, the company files an NDA. If the medicine is a biological product, a BLA is filed. Both types of applications can receive certain periods of regulatory exclusivity as discussed below. An NDA or a BLA for a compound that is designated as an orphan drug can receive seven years of exclusivity for an orphan drug indication. During this period, the FDA generally may not approve another application for the same drug product for the same orphan use. A company may also earn six months of additional exclusivity for a drug where specific clinical studies are conducted at the written request of the FDA to study the use of the medicine to treat pediatric patients, and submission to the FDA is made prior to the loss of basic ex clusivity.\n\n## Chemical products\n\nA competitor  seeking  to  launch  a  generic  substitute  of  a  chemical  innovative  drug  in  the  U.S.  must  file  an ANDA  with  the  FDA.  In  the ANDA,  the  generic manufacturer needs to demonstrate only 'bioequivalence' between the generic substitute and the approved NDA drug. The ANDA relies upon the safety and efficacy data previously filed by the innovator in its NDA.",
          "relationship": "Provides"
        },
        "node_3": {
          "id": "Patent_Rights",
          "name": "Patent Rights",
          "type": "RISK_FACTOR",
          "idf_score": 4.78192069773259
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_1",
          "chunk_text": "We are vigorously defending against the legal proceedings in which we are named as defendants and we believe we have substantial claims and/or defenses in each matter. While the outcomes of these proceedings and other contingencies BMS is subject to are inherently unpredictable and uncertain, we do not believe that any of these matters will have a material adverse effect on  BMS' financial position or liquidity, though they could possibly be material to our consolidated results of operations in any one accounting period. There can be no assurance that there will not be an increase in the scope of one or more of the matters described below or that any other or future lawsuits, claims, government investigations, or other legal proceedings will not be material to BMS's financial position, results of operations, or cash flows for a particular period. Furthermore, failure to successfully enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably  estimated.  Developments  in  legal  proceedings  and  other  matters  that  could  cause  changes  in  the  amounts  previously  accrued  are  evaluated  each reporting period. For a discussion of BMS's tax contingencies, see \" - Note 7. Income Taxes.\"\n\n## INTELLECTUAL PROPERTY\n\n## Eliquis - E urope\n\nBMS is involved in litigations throughout Europe against companies seeking to launch generic apixaban products prior to the expiration of the composition-of-matter patent for Eliquis and its associated SPCs. Litigations are pending or have been concluded in: Belgium, Bulgaria, Croatia, Czech Republic, France, Denmark, Finland, Greece, Hungary, Ireland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, and the UK.\n\nTrials or preliminary proceedings on the merits have been held in: Czech Republic, Finland, France, Ireland, Netherlands, Norway, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, and the UK. To date BMS has obtained decisions in the following countries:\n\n- BMS obtained a final negative decision in the UK, and generics are now on the market in this country.\n- BMS obtained final positive decisions in Norway, Sweden, and Switzerland.\n- BMS obtained initial  negative  decisions  in  Finland,  Ireland,  and  Slovakia.  In  Finland  and  Slovakia,  appeals  are  pending.  In  Ireland,  the  appeals  court remanded the case to the lower court for rehearing.\n- BMS obtained initial positive decisions in the Czech Republic, France, and Netherlands, and appeals are pending in all three countries.\n- In  Spain,  the  Barcelona  Commercial  Court  found  the  composition-of-matter  patent  for Eliquis and  its  associated  SPC  invalid.  BMS  appealed,  and  the Barcelona Court of Appeal overturned the decision. The generic products that launched at risk after the Barcelona Commercial Court were either enjoined or removed from the market as a result of the Barcelona Court of Appeal ruling. An appeal is pending before the Supreme Court.\n- In  Finland,  generics  have  entered  the  market  while  proceedings  are  pending.  In  Portugal,  BMS  obtained  preliminary  injunctions  against  two  generic companies, but one generic company remains on the market while proceedings are pending.\n\nGeneric manufacturers may seek to market generic versions of Eliquis in additional countries in Europe prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe.\n\n## Plavix* - Australia\n\nFrom 2007 to 2010, BMS and Sanofi were involved in patent litigation with a generic company seeking to launch clopidogrel bisulfate 75 mg tablets in Australia. While BMS and Sanofi obtained an initially favorable decision and an injunction, that decision was overturned on appeal. In 2013, the Australian government intervened seeking damages, which would have been split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi disputed that the Australian government is entitled to any damages. The trial court issued a decision dismissing the Australian government's claim for damages, the Australian government appealed, and the Federal Court issued a ruling in BMS and Sanofi's favor, which was affirmed in December 2024, by the High Court of Australia.\n\n## Pomalyst - U.S.\n\nIn  December  2024,  Celgene  received  a  Notice  Letter  from  Cipla  USA,  Inc.  ('Cipla')  notifying  Celgene  that  Cipla  had  filed  an ANDA  containing  paragraph  IV certifications seeking approval to market generic pomalidomide products in the U.S. In response, Celgene initiated a patent infringement action against Cipla in the U.S. District Court for the District of New Jersey, asserting certain FDA Orange Book-listed patents. No trial date has been scheduled.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 189,
      "question": "How does Amgen's decision to amortize the developed product technology rights related to Otezla over 8.5 years align with its lifecycle management strategy given Otezla's status as an approved therapy for mild-to-moderate psoriasis with no new program changes in 2022?",
      "answer": "Amgen reports Otezla as an approved therapy for mild-to-moderate psoriasis with no new program changes in 2022, indicating it is in a mature phase of its lifecycle. The company allocated its acquisition costs to the 'developed product technology rights' for Otezla, which is being amortized over a weighted-average period of 8.5 years using the straight-line method. This amortization schedule reflects a long-term view of Otezla's value generation, despite its mature status, suggesting Amgen anticipates sustained cash flows from the asset. The use of a multiperiod excess earnings model to determine fair value further supports this forward-looking revenue expectation, even in the absence of active development changes.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_25) \u2192 Otezla: Otezla is listed as an approved therapy for mild-to-moderate psoriasis with no program changes in 2022, indicating a mature product lifecycle stage.",
        "Hop 2: Otezla \u2192 Developed Product Technology Rights: The developed product technology rights are specifically tied to Otezla, with fair value derived from projected after-tax cash flows using a multiperiod excess earnings model.",
        "Hop 3: Developed Product Technology Rights \u2190 AMGN(page_112): These rights are being amortized over 8.5 years via straight-line method, signaling long-term value expectation despite Otezla's current maturity."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Relates_To]-> PRODUCT <-[Amortizes]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Otezla",
        "node_3": "Developed Product Technology Rights",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                                | Program change                                                  |\n|-------------------|-----------------------------------------------------------|-----------------------------------------------------------------|\n| LUMAKRAS/LUMYKRAS | NSCLC with KRAS G12C mutations                            | Approved by the FDAand conditional marketing approval by the EC |\n| Otezla            | Mild-to-moderate psoriasis                                | Approved by the FDA                                             |\n| RIABNI            | Non-Hodgkin's lymphoma                                    | Approved by the FDA                                             |\n| AMJEVITA          | Interchangeability                                        | Initiated phase 3 study                                         |\n| Bemarituzumab     | GEJ adenocarcinoma                                        | Initiated phase 3 study                                         |\n| BLINCYTO          | Ph-negative B-cell precursor Acute lymphoblastic leukemia | Initiated phase 3 study                                         |\n| TEZSPIRE          | Chronic rhinosinusitis with nasal polyps                  | Initiated phase 3 study                                         |\n| Otezla            | COVID-19                                                  | Terminated                                                      |\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Otezla",
          "name": "Otezla",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset  acquisition.  Rather,  the  excess  of  the  accumulated  cost  over  the  fair  value  of  the  net  assets  acquired  is  reallocated  to  the nonfinancial assets acquired.\n\nThe developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multiperiod excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.",
          "relationship": "Relates_To"
        },
        "node_3": {
          "id": "Developed_Product_Technology_Rights",
          "name": "Developed Product Technology Rights",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset  acquisition.  Rather,  the  excess  of  the  accumulated  cost  over  the  fair  value  of  the  net  assets  acquired  is  reallocated  to  the nonfinancial assets acquired.\n\nThe developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multiperiod excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.",
          "relationship": "Amortizes"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 190,
      "question": "How does AbbVie's fair value accounting treatment of the financing liability from Cerevel Therapeutics' pre-acquisition funding agreements impact the deferred tax liabilities recognized post-acquisition?",
      "answer": "AbbVie assumed Cerevel Therapeutics' funding agreements, which are accounted for under the fair value option using unobservable inputs and complex models for milestone and royalty payments. This fair value treatment has led to changes in the liability\u2019s valuation over time, directly impacting AbbVie's balance sheet. Post-acquisition, AbbVie recorded an increase in deferred tax liabilities primarily due to the acquisition of Cerevel Therapeutics, specifically related to the excess book basis over tax basis of intangible assets. Therefore, the fair value fluctuations of the financing liability from the funding agreements influence the overall balance sheet exposure, which in turn affects the deferred tax liabilities tied to the acquired intangible assets.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_84) \u2192 Funding Agreements: AbbVie assumed Cerevel Therapeutics' funding agreements and applied fair value accounting using unobservable inputs and Monte Carlo simulations for sales milestones and royalty payments.",
        "Hop 2: Funding Agreements \u2192 Cerevel Therapeutics: The funding agreements were originally entered into by Cerevel Therapeutics prior to acquisition and represent a financial obligation now managed by AbbVie.",
        "Hop 3: Cerevel Therapeutics \u2190 ABBV(page_97): AbbVie recorded an increase in deferred tax liabilities primarily due to the acquisition of Cerevel Therapeutics, related to the excess book basis over tax basis of intangible assets."
      ],
      "difficulty": "hard",
      "idf_score": 6.115534801023568,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> FIN_INST -[Involved_In]-> COMP <-[Involved_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Funding Agreements",
        "node_3": "Cerevel Therapeutics",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "FIN_INST",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Funding_Agreements",
          "name": "Funding Agreements",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Cerevel_Therapeutics",
          "name": "Cerevel Therapeutics",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe decrease in deferred tax assets is primarily related to a decrease in compensation, employee benefits and advance payments. The increase in deferred tax liabilities is primarily due to the acquisition of Cerevel Therapeutics and ImmunoGen in which the company recorded the excess of book basis over tax basis of intangible assets, offset by amortization and impairment of intangible assets.\n\nThe company had valuation allowances of $14.8 billion as of December 31, 2024 and $13.5 billion as of December 31, 2023. These were principally related to foreign and state net operating losses and other credit carryforwards that are not expected to be realized.\n\nThe company incurred carryforward deductions in a foreign jurisdiction where realization of the future income tax benefit was, in previous reporting periods, considered so remote that the income tax benefit was not recognized as a deferred tax asset. In 2024, the company concluded that the future income tax benefit of the carryforward balances is no longer remote and therefore, a deferred tax asset was recognized. The company also recognized an offsetting valuation allowance, resulting in no net impact to deferred tax assets as such carryforward balances are not expected to be realized in the foreseeable future.\n\nAs of December 31, 2024, the company had U.S. federal, state and foreign credit carryforwards of $669 million as well as U.S. federal, state and foreign net operating loss carryforwards of $38.9 billion, which will expire at various times through 2044. The company also had foreign loss carryforwards of $33.3 billion that have no expiration.\n\nUnremitted foreign earnings subject to the Act's transition tax are not considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings or eligible for the 100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. However, the company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distributions) to be permanent in duration. The unrecognized tax liability is not practicable to determine.\n\n2024 Form 10-K\n\n",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 191,
      "question": "How does AbbVie's acquisition-related goodwill addition for Cerevel Therapeutics connect with the company's fair value accounting treatment of the assumed funding agreements, particularly given the use of unobservable inputs and milestone-based payment models in their valuation?",
      "answer": "AbbVie added goodwill as part of its acquisition of Cerevel Therapeutics, indicating strategic investment in expanding its neuroscience portfolio. Cerevel had previously entered into funding agreements that were assumed by AbbVie during the acquisition. These funding agreements are accounted for under the fair value option, with valuation based on complex models involving unobservable inputs, including probability-weighted regulatory milestones and Monte Carlo simulations for sales milestones and royalties. This creates a dual-layer exposure: the initial goodwill reflects confidence in the acquired business, while the fair value treatment of the assumed liabilities introduces ongoing financial volatility tied to uncertain future events. Therefore, the acquisition decision (reflected in the goodwill) and the subsequent accounting for the funding liabilities (with high estimation uncertainty) must be viewed together to assess the risk-adjusted value of the Cerevel acquisition.",
      "reasoning_steps": [
        "Hop 1: ABBV(page_72) \u2192 Cerevel Therapeutics: AbbVie added goodwill from the acquisition of Cerevel Therapeutics, signaling strategic value placed on the company.",
        "Hop 2: Cerevel Therapeutics \u2192 Funding Agreements: Cerevel had existing funding agreements involving complex financial instruments tied to milestone payments and royalties.",
        "Hop 3: Funding Agreements \u2190 ABBV(page_84): AbbVie assumed these funding agreements and accounts for them using the fair value option, with valuation based on unobservable inputs and probabilistic models."
      ],
      "difficulty": "hard",
      "idf_score": 6.115534801023568,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Involved_In]-> FIN_INST <-[Involved_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Cerevel Therapeutics",
        "node_3": "Funding Agreements",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "FIN_INST",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_7",
          "chunk_text": "\n(a) Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5).\n\nThe company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of December 31, 2024 and 2023, there were no accumulated goodwill impairment losses.\n\n## 69 | 2024 Form 10-K",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Cerevel_Therapeutics",
          "name": "Cerevel Therapeutics",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Funding_Agreements",
          "name": "Funding Agreements",
          "type": "FIN_INST",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_5",
          "chunk_text": "\nMoney market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs i ncluding published interest rate curves and both forward and spot prices for foreign currencies.\n\nThe financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one\n\n## 81 | 2024 Form 10-K",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 192,
      "question": "How does Amgen's competitive positioning against Celgene's POMALYST/IMNOVID in the multiple myeloma market align with its broader strategic involvement with Celgene through the 2017 acquisition activity?",
      "answer": "Amgen's competitive positioning against Celgene's POMALYST/IMNOVID, as listed in the product competition table, reveals that KYPROLIS competes directly with these Celgene-developed therapies in both the U.S. and Europe. This competitive dynamic exists despite Amgen's broader strategic involvement with Celgene, referenced in the glossary on page 4, which indicates a prior acquisition relationship. The juxtaposition of direct competition with historical acquisition activity suggests a complex market landscape where Amgen both competes with and builds upon prior Celgene assets in the oncology space.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_4) \u2192 Celgene: Celgene is listed in Amgen\u2019s glossary, indicating a significant relationship, potentially through prior acquisition activity.",
        "Hop 2: Celgene \u2192 POMALYST/IMNOVID: Celgene is identified as the marketer of POMALYST/IMNOVID, a key oncology product referenced in the product trademark list.",
        "Hop 3: POMALYST/IMNOVID \u2190 AMGN(page_16): POMALYST/IMNOVID is listed as a competitor to Amgen\u2019s KYPROLIS in the multiple myeloma market across both U.S. and Europe."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> COMP -[Produces]-> PRODUCT <-[Competes_Against]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Celgene",
        "node_3": "POMALYST/IMNOVID",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_2",
          "chunk_text": "| Term              | Description                                                      |\n|-------------------|------------------------------------------------------------------|\n| 2017 Tax Act      | Tax Cuts and Jobs Act of 2017                                    |\n| AbbVie            | AbbVie Inc.                                                      |\n| ACA               | Affordable Care Act                                              |\n| aHUS              | atypical hemolytic uremic syndrome                               |\n| ALL               | acute lymphoblastic leukemia                                     |\n| AMD               | age-related macular degeneration                                 |\n| Amended 2009 Plan | Amended and Restated 2009 Equity Incentive Plan                  |\n| ANDA              | Abbreviated New Drug Application                                 |\n| AOCI              | accumulated other comprehensive income (loss)                    |\n| AstraZeneca       | AstraZeneca plc                                                  |\n| BAFF              | B-cell activating factor                                         |\n| BeiGene           | BeiGene, Ltd.                                                    |\n| BiTE \u00ae            | bispecific T-cell engager                                        |\n| BLA               | Biologics License Application                                    |\n| BMS               | Bristol Myers Squibb Company                                     |\n| BPCIA             | Biologics Price Competition and Innovation Act of 2009           |\n| Celgene           | Celgene Corporation                                              |\n| CGRP              | calcitonin gene-related peptide                                  |\n| chemotherapy      | anticancer medicines                                             |\n| CHMP              | Committee for Medicinal Products for Human Use                   |\n| CIT               | chemotherapy-induced thrombocytopenia                            |\n| CKD               | chronic kidney disease                                           |\n| CMS               | Centers for Medicare &Medicaid Services                          |\n| COSO              | Committee of Sponsoring Organizations of the Treadway Commission |\n| COVID-19          | coronavirus disease 2019                                         |\n| CV                | cardiovascular                                                   |\n| DaVita            | DaVita Inc.                                                      |\n| DLL3              | delta-like ligand 3                                              |\n| DOJ               | U.S. Department of Justice                                       |\n| DoR               | duration of response                                             |\n| EC                | European Commission                                              |\n| EMA               | European Medicines Agency                                        |\n| EPS               | earnings per share                                               |\n| ERG               | employee resource group                                          |\n| ESA               | erythropoiesis-stimulating agent                                 |\n| ESG               | environmental, social and governance                             |\n| ESRD              | end-stage renal disease                                          |\n| EU                | European Union                                                   |\n| FASB              | Financial Accounting Standards Board                             |\n| FCPA              | U.S. Foreign Corrupt Practices Act                               |\n| FDA               | U.S. Food and Drug Administration                                |\n| FDCA              | Federal Food, Drug, and Cosmetic Act                             |\n| FGFR2b            | fibroblast growth factor receptor 2b                             |\n| Fitch             | Fitch Ratings, Inc.                                              |",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_3",
          "chunk_text": "\nProducts  referenced  in  this  report  that  are  not  included  in  the  above  list  are  trademarks  of  their  respective  owners.  They  are Avastin , Cosentyx , DARZALEX , DARZALEX FASPRO , EYLEA , Fulphila , Herceptin , HUMIRA , POMALYST /IMNOVID ,  PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE , Remicade , REVLIMID ,  RINVOQ , Rituxan /MabThera , Skyrizi , SOLIRIS , STELARA , Taltz , Tremfya , UDENYCA , VELCADE  and Xeljanz . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "POMALYST/IMNOVID",
          "name": "POMALYST/IMNOVID",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_Against"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 193,
      "question": "How does Amgen's strategic investment in BeiGene align with the commercialization performance and risk-sharing structure for XGEVA in China, particularly considering the profit-sharing and royalty arrangements?",
      "answer": "Amgen's strategic $2.8 billion investment in BeiGene was aimed at expanding its oncology presence in China, with XGEVA being one of the first products commercialized by BeiGene under the collaboration. According to the 10-K, BeiGene began selling XGEVA in 2020 and Amgen shares profits and losses equally during the initial product-specific commercialization periods. This profit-sharing model suggests a risk-mitigation strategy for Amgen, allowing it to leverage BeiGene\u2019s local market expertise while sharing upfront commercialization costs and uncertainties. However, after the initial period, product rights may revert to Amgen, at which point it would pay royalties to BeiGene on sales in China. This structure indicates that Amgen is not only relying on BeiGene for market entry but also structuring financial exposure to balance long-term control with near-term risk-sharing, particularly for a high-value product like XGEVA, which is used for preventing skeletal-related events in patients with bone metastases.",
      "reasoning_steps": [
        "Hop 1: [AMGN](page_12) \u2192 [XGEVA]: XGEVA is introduced as a key oncology product launched in 2010, used for preventing skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma.",
        "Hop 2: [XGEVA] \u2192 [BeiGene]: Amgen's collaboration with BeiGene includes the commercialization of XGEVA in China starting in 2020, with equal profit and loss sharing during the initial commercialization period.",
        "Hop 3: [BeiGene] \u2190 [AMGN](page_28): Amgen\u2019s $2.8 billion equity investment in BeiGene in 2020 was part of a broader strategic collaboration to expand oncology presence in China, with detailed profit-sharing and eventual royalty arrangements tied to product sales."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Supplies]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "XGEVA",
        "node_3": "BeiGene",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_12",
          "chunk_id": "chunk_1",
          "chunk_text": "## ENBREL\n\nWe market ENBREL, a tumor necrosis factor blocker, in the United States and Canada. ENBREL was launched in 1998 and is used primarily in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis.\n\n## Prolia\n\nWe market Prolia in many countries around the world. Prolia contains the same active ingredient as XGEVA but is approved for different indications, patient populations, doses and frequencies of administration. Prolia was launched in the United States and Europe in 2010. In the United States, it is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant  to  other  available  osteoporosis  therapy.  In  Europe,  Prolia  is  used  primarily  for  the  treatment  of  osteoporosis  in postmenopausal women at increased risk of fracture.\n\n## Otezla\n\nWe market Otezla, a small molecule that inhibits PDE4, in many countries around the world. Otezla was acquired from BMS in November 2019 after their acquisition of Celgene. Otezla is an oral therapy approved for the treatment of adult patients with plaque psoriasis  across  all  severities  for  whom  phototherapy  or  systemic  therapy  is  appropriate,  patients  with  active  psoriatic  arthritis  and patients with oral ulcers associated with Beh\u00e7et's disease. In Europe, Otezla is approved for second-line use in the treatment of psoriatic arthritis and psoriasis and for patients with oral ulcers associated with Beh\u00e7et's disease who are candidates for systemic therapy.\n\n## XGEVA\n\nWe market XGEVA in many countries around the world. XGEVA was launched in 2010 and is used primarily in the indication for prevention  of  SREs  (pathological  fracture,  radiation  to  bone,  spinal  cord  compression  or  surgery  to  bone)  in  patients  with  bone metastases from solid tumors and multiple myeloma.\n\n## Neulasta\n\nWe market Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta was launched in 2002 and is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer (nonmyeloid) who receive anticancer medicines (chemotherapy) that can cause fever and a low blood cell count. In 2015, the Neulasta Onpro kit became available in the United States. The Neulasta Onpro kit provides physicians the opportunity to initiate administration of Neulasta on the same day as chemotherapy, with drug delivery of the recommended dose of Neulasta at home the day after chemotherapy, thereby saving the patient a trip back to the doctor.\n\n## Aranesp\n\nWe market Aranesp primarily in the United States and Europe. It was launched in 2001 and is indicated to treat a lower-thannormal number of red blood cells (anemia) caused by CKD in both patients on dialysis and patients not on dialysis. Aranesp is also indicated  for  the  treatment  of  anemia  due  to  concomitant  myelosuppressive  chemotherapy  in  certain  patients  with  nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp.\n\n## Repatha\n\nWe market Repatha, a PCSK9 inhibitor, in many countries around the world. Repatha was launched in 2015 and is indicated to reduce the risks of myocardial infarction, stroke and coronary revascularization in adults with established CV disease. Repatha is also indicated to reduce LDL-C in adults with primary hyperlipidemia, including HeFH; in pediatric patients aged 10 years and older with HeFH; and in adults and pediatric patients aged 10 years and older with HoFH.\n\n## KYPROLIS\n\nWe  market  KYPROLIS  primarily  in  the  United  States  and  Europe.  KYPROLIS was  launched  in  2012  and  is  indicated  in combination with (i) dexamethasone, (ii) lenalidomide plus dexamethasone and (iii) DARZALEX plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. It is also approved as a single agent for patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "XGEVA",
          "name": "XGEVA",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_3",
          "chunk_text": "\nFor each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.\n\n## 8. Collaborations\n\nA collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.\n\nFrom time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or  product  candidates.  These  collaborations  generally  provide  for  nonrefundable  upfront  license  fees,  development  and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary  of  significant  accounting  policies,  for  additional  discussion  of  revenues  recognized  under  these  types  of  arrangements. Operating  expenses  for  costs  incurred  pursuant  to  these  arrangements  are  reported  in  their  respective  expense  line  items  in  the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand  our  oncology  presence  in  China.  For  additional  information  regarding  our  equity  investment  in  BeiGene,  see  Note  9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "BeiGene",
          "name": "BeiGene",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 194,
      "question": "How does Amgen's customer concentration risk, where 77% of gross revenues come from three customers, interact with its indirect competitive exposure to Pfizer through Xeljanz in the ENBREL market?",
      "answer": "Amgen's customer concentration risk is significant, with 77% of its gross revenues in 2024 derived from just three customers, indicating a high level of channel dependency. One of Amgen\u2019s key products, ENBREL, faces indirect competition from Xeljanz, a product manufactured by Pfizer. This competitive dynamic suggests that Amgen's revenue stability is not only tied to the continued purchasing behavior of a small group of customers but also to market pressures exerted by Pfizer's product. Thus, Amgen's financial exposure is twofold: it faces risk from over-concentration in its customer base and from competitive pressure in the TNF inhibitor market, where Xeljanz competes directly with ENBREL.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_120) \u2192 Pfizer: Amgen's revenue is highly concentrated, with 77% coming from just three customers, indicating a strong dependency on a limited number of channels for product distribution.",
        "Hop 2: Pfizer \u2192 Xeljanz: Pfizer is the manufacturer of Xeljanz, a product listed in the company's trademark disclosures, which places it in the same therapeutic class as ENBREL.",
        "Hop 3: Xeljanz \u2190 AMGN(page_15): Xeljanz is listed in Amgen\u2019s 10-K as a competitor to ENBREL in the U.S. market, indicating that Amgen views Xeljanz as a direct market threat to one of its major products."
      ],
      "difficulty": "hard",
      "idf_score": 5.721306120841433,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Produces]-> PRODUCT <-[Competes_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Pfizer",
        "node_3": "Xeljanz",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_120",
          "chunk_id": "chunk_1",
          "chunk_text": "For each of the years ended December 31, 2024, 2023 and 2022, we had product sales to three customers that individually accounted for more than 10% of total revenues. For the year ended December 31, 2024, on a combined basis, these customers accounted for 77% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):\n\n",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Pfizer",
          "name": "Pfizer",
          "type": "COMP",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_2",
          "chunk_text": "\nProducts referenced in this report that are not included in the above list are trademarks of their respective owners. They are Avastin , BESPONSA , Cosentyx , DARZALEX , DUPIXENT , ERBITUX , EYLEA , FASENRA , Herceptin ,  HUMIRA ,  HYRIMOZ , KEYTRUDA , LEQVIO ,  Nucala ,  POMALYST /IMNOVID , PRALUENT ,  PROCRIT ,  PROMACTA /REVOLADE ,  Remicade ,  REVLIMID ,  RINVOQ ,  Rituxan /MabThera ,  Skyrizi ,  SOLIRIS ,  SOTYKTU ,  STELARA , Taltz , Teribone , Tremfya , VELCADE , Xeljanz and XOLAIR . \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u00ae \u2122 \u00ae \u00ae \u00ae \u00ae",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Xeljanz",
          "name": "Xeljanz",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product    | Territory                  | Competitor-marketed product         | Competitors                              |\n|------------|----------------------------|-------------------------------------|------------------------------------------|\n| Prolia (1) | U.S., Europe &Asia Pacific | Bisphosphonates, including generics | Various                                  |\n| ENBREL     | U.S.                       | HUMIRA (2)                          | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | HYRIMOZ                             | SandozGroup AG                           |\n| ENBREL     | U.S.                       | RINVOQ                              | AbbVie Inc.                              |\n| ENBREL     | U.S.                       | Xeljanz                             | Pfizer Inc.                              |\n| ENBREL     | Canada                     | Etanercept biosimilars              | Various                                  |\n| XGEVA (1)  | U.S. &Europe               | Zoledronate generics                | Various                                  |\n| Repatha    | U.S., Europe &Asia Pacific | PRALUENT                            | Regeneron Sanofi                         |\n|            | U.S. &Europe               | LEQVIO                              | Novartis PharmaAG                        |\n|            | U.S. &Europe               | Skyrizi                             | AbbVie Inc.                              |\n|            | U.S. &Europe               | HUMIRA (2)                          | AbbVie Inc.                              |\n| Otezla     | U.S. &Europe               | Tremfya                             | Johnson &Johnson Innovative Medicine (3) |\n| Otezla     | U.S. &Europe               | Taltz                               | Lilly                                    |\n| Otezla     | U.S. &Europe               | Cosentyx                            | Novartis PharmaAG                        |\n| Otezla     | U.S. &Europe               | SOTYKTU                             | Bristol Myers Squibb Company             |\n|            | U.S. &Europe               | Topical products                    | Various                                  |\n|            | U.S.                       | Bisphosphonates, including generics |                                          |\n| EVENITY    | Japan                      | Teribone                            | Various Asahi Kasei Pharma               |\n|            | U.S. &Europe               | DARZALEX                            | Johnson &Johnson Innovative Medicine (3) |\n| KYPROLIS   | U.S. &Europe               | POMALYST/IMNOVID                    | Celgene Corporation (4)                  |\n|            | U.S. &Europe               | REVLIMID (5)                        | Various                                  |\n|            | U.S.                       | VELCADE                             | Takeda Oncology (6)                      |\n| Nplate     | U.S. &Europe               | PROMACTA/REVOLADE                   | Novartis PharmaAG                        |\n| Aranesp    | U.S.                       | PROCRIT (7)                         | Johnson &Johnson Innovative Medicine (3) |\n|            | U.S. &Europe               | Epoetin alfa biosimilars            | Various                                  |\n|            | U.S. &Europe               | BESPONSA                            | Pfizer Inc.                              |\n| BLINCYTO   | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S. &Europe               | Avastin                             | F. Hoffmann-La Roche Ltd. (Roche)        |\n| Vectibix   | U.S.                       | KEYTRUDA                            | Merck&Co., Inc.                          |\n|            | U.S. &Europe               | ERBITUX                             | Lilly                                    |\n|            | U.S. &Europe               | Chemotherapy regime                 | Various                                  |\n|            | U.S.                       | DUPIXENT                            | Regeneron Sanofi                         |\n|            | U.S.                       | FASENRA                             | AstraZeneca                              |\n| TEZSPIRE   | U.S.                       | XOLAIR                              | Genentech, Inc. Novartis PharmaAG        |\n|            | U.S.                       | NUCALA                              | GSKplc.                                  |\n",
          "relationship": "Competes_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 195,
      "question": "How does Pfizer's financial exposure to BioNTech through the mRNA Shingles Vaccine collaboration compare with its contractual manufacturing dependency on BioNTech for Comirnaty, as reflected in both the collaborative arrangements and contract manufacturing disclosures?",
      "answer": "Pfizer's exposure to BioNTech through the mRNA Shingles Vaccine involves an upfront payment of $225 million, an equity stake of 2.7%, and shared development and commercialization rights globally (excluding certain regions), with potential future milestone payments of up to $200 million. In contrast, Pfizer's dependency on BioNTech for Comirnaty manufacturing is reflected in contract development and manufacturing revenues of $33 million in 2023, indicating a more transactional and operational relationship. The former reflects a strategic R&D and commercial partnership, while the latter is a supply chain dependency tied to production activities.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_76) \u2192 [mRNA Shingles Vaccine]: Describes Pfizer's collaboration with BioNTech to develop the mRNA Shingles Vaccine, including a $225 million upfront investment and 2.7% equity stake in BioNTech.",
        "Hop 2: [mRNA Shingles Vaccine] \u2192 [BioNTech]: BioNTech provides proprietary mRNA technology for the vaccine, and the two companies share development and commercialization rights and profits, excluding certain regions.",
        "Hop 3: [BioNTech] \u2190 [PFE](page_112): Pfizer discloses Comirnaty-related contract manufacturing activities performed for BioNTech, totaling $33 million in 2023, indicating a separate and distinct dependency on BioNTech in manufacturing logistics."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Commercializes]-> PRODUCT -[Commercializes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "mRNA Shingles Vaccine",
        "node_3": "BioNTech",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Commercializes"
        },
        "node_2": {
          "id": "mRNA_Shingles_Vaccine",
          "name": "mRNA Shingles Vaccine",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## D.\tLicensing\tArrangement\n\nAgreement\twith\tValneva-In\tJune\t2022,\twe\tentered\tinto\tan\tEquity\tSubscription\tAgreement,\tunder\twhich\twe\tinvested\t\u20ac90.5\tmillion\t($95\tmillion)\tin Valneva\tto\tfurther\tsupport\tour\tarrangement\tto\tco-develop\tand\tcommercialize\tLyme\tdisease\tvaccine\tcandidate,\tVLA15,\twhich\twe\toriginally\tentered\tinto with\tValneva\tin\t2020.\tIn\taddition,\twe\tupdated\tthe\tterms\tof\tour\texisting\tco-development\tand\tcommercialization\tagreement\tfor\tVLA15.\tValneva\twill\tnow fund\t40%\tof\tthe\tremaining\tshared\tdevelopment\tcosts,\tand\twe\twill\tpay\tValneva\ttiered\troyalties\tranging\tfrom\t14%\tto\t22%,\tcompared\tto\troyalties\tstarting at\t19%\tin\tthe\tinitial\tagreement.\tIn\taddition,\tthe\troyalties\twill\tbe\tcomplemented\tby\tup\tto\t$100\tmillion\tin\tmilestones\tpayable\tto\tValneva\tbased\ton cumulative\tsales.\tOther\tearly\tcommercialization\tmilestones\tare\tunchanged.\tAs\tof\tDecember\t31,\t2023,\twe\theld\ta\t6.9%\tequity\tstake\tof\tValneva.\n\n## E.\tCollaborative\tArrangements\n\nWe\tenter\tinto\tcollaborative\tarrangements\twith\trespect\tto\tin-line\tmedicines,\tas\twell\tas\tmedicines\tin\tdevelopment\tthat\trequire\tcompletion\tof\tresearch and\tregulatory\tapproval.\tCollaborative\tarrangements\tare\tcontractual\tagreements\twith\tthird\tparties\tthat\tinvolve\ta\tjoint\toperating\tactivity,\ttypically a\tresearch\tand/or\tcommercialization\teffort,\twhere\tboth\twe\tand\tour\tpartner\tare\tactive\tparticipants\tin\tthe\tactivity\tand\tare\texposed\tto\tthe\tsignificant risks\tand\trewards\tof\tthe\tactivity.\tOur\trights\tand\tobligations\tunder\tour\tcollaborative\tarrangements\tvary.\tFor\texample,\twe\thave\tagreements\tto\tcopromote\tpharmaceutical\tproducts\tdiscovered\tby\tus\tor\tother\tcompanies,\tand\twe\thave\tagreements\twhere\twe\tpartner\tto\tco-develop\tand/or\tparticipate together\tin\tcommercializing,\tmarketing,\tpromoting,\tmanufacturing\tand/or\tdistributing\ta\tdrug\tproduct\tor\tvaccine.\n\nCollaboration\twith\tBiohaven-In\tNovember\t2021,\twe\tentered\tinto\ta\tcollaboration\tand\tlicense\tagreement\tand\trelated\tsublicense\tagreement\twith\tBiohaven and\tcertain\tof\tits\tsubsidiaries\tto\tcommercialize\trimegepant\tand\tzavegepant\tfor\tthe\ttreatment\tand\tprevention\tof\tmigraines\toutside\tof\tthe\tU.S., subject\tto\tregulatory\tapproval.\tUnder\tthe\tterms\tof\tthe\tagreement,\tBiohaven\twould\tlead\tR&amp;D\tglobally\tand\twe\twould\thave\tthe\texclusive\tright\tto commercialization\tglobally,\toutside\tof\tthe\tU.S.\tUpon\tthe\tclosing\tof\tthe\ttransaction\ton\tJanuary\t4,\t2022,\twe\tpaid\tBiohaven\t$500\tmillion,\tincluding\tan upfront\tpayment\tof\t$150\tmillion\tand\tan\tequity\tinvestment\tof\t$350\tmillion.\tWe\trecognized\t$263\tmillion\tfor\tthe\tupfront\tpayment\tand\tpremium\tpaid\ton\tour equity\tinvestment\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses .\tIn\tOctober\t2022,\twe\tacquired\tall\toutstanding\tcommon\tshares\tof\tBiohaven not\talready\towned\tby\tus\tfor\t$148.50\tper\tshare,\tin\tcash,\tfor\tpayments\tof\tapproximately\t$11.5\tbillion.\tSee Note\t2A. This\tacquisition\trepresented\ta settlement\tof\tthe\tpre-existing\trelationship,\tand\twe\tdetermined\tthat\tno\tgain\tor\tloss\twas\trequired\tto\tbe\trecognized.\n\nCollaborations\twith\tBioNTech-On\tDecember\t30,\t2021,\twe\tentered\tinto\ta\tresearch,\tdevelopment\tand\tcommercialization\tagreement\tto\tdevelop\ta\tpotential first\tmRNA-based\tvaccine\tfor\tthe\tprevention\tof\tshingles\t(herpes\tzoster\tvirus)\tbased\ton\tBioNTech's\tproprietary\tmRNA\ttechnology\tand\tour\tantigen technology.\tUnder\tthe\tterms\tof\tthe\tagreement,\twe\tagreed\tto\tpay\tBioNTech\t$225\tmillion,\tincluding\tan\tupfront\tcash\tpayment\tof\t$75\tmillion\tand\tan\tequity investment\tof\t$150\tmillion.\tBioNTech\tis\teligible\tto\treceive\tfuture\tregulatory\tand\tsales\tmilestone\tpayments\tof\tup\tto\t$200\tmillion.\tIn\treturn, BioNTech\tagreed\tto\tpay\tus\t$25\tmillion\tfor\tour\tproprietary\tantigen\ttechnology.\tThe\tnet\tupfront\tpayment\tto\tBioNTech\twas\trecorded\tto Acquired\tinprocess\tresearch\tand\tdevelopment\texpenses in\tour\tfourth\tquarter\tof\t2021.\tWe\tand\tBioNTech\tshare\tdevelopment\tcosts.\tWe\twill\thave\tcommercialization rights\tto\tthe\tpotential\tvaccine\tworldwide,\texcluding\tGermany,\tTurkey\tand\tcertain\tdeveloping\tcountries\twhere\tBioNTech\twill\thave\tcommercialization rights.\tWe\tand\tBioNTech\twill\tshare\tgross\tprofits\tfrom\tcommercialization\tof\tany\tproduct.\tAs\tof\tDecember\t31,\t2023,\twe\theld\tan\tequity\tstake\tof\t2.7%\tof BioNTech.\n\nOn\tApril\t9,\t2020,\twe\tsigned\ta\tglobal\tagreement\twith\tBioNTech\tto\tco-develop\ta\tmRNA-based\tcoronavirus\tvaccine\tprogram\taimed\tat\tpreventing\tCOVID-19 infection,\twhich\tresulted\tin\tthe\tdevelopment\tof\tComirnaty.\tOn\tJanuary\t29,\t2021,\twe\tand\tBioNTech\tsigned\tan\tamended\tversion\tof\tthe\tApril\t2020 agreement.\tUnder\tthe\tJanuary\t2021\tagreement,\tBioNTech\tpaid\tus\ttheir\t50\tpercent\tshare\tof\tprior\tdevelopment\tcosts\tin\ta\tlump\tsum\tpayment\tduring\tthe first\tquarter\tof\t2021.\tFurther\tR&amp;D\tcosts\tare\tbeing\tshared\tequally.\tWe\thave\tcommercialization\trights\tto\tthe\tvaccine\tworldwide,\texcluding\tGermany\tand Turkey\twhere\tBioNTech\tmarkets\tand\tdistributes\tthe\tvaccine\tunder\tthe\tagreement\twith\tus,\tand\texcluding\tChina,\tHong\tKong,\tMacau\tand\tTaiwan,\twhich\tare subject\tto\ta\tseparate\tcollaboration\tbetween\tBioNTech\tand\tShanghai\tFosun\tPharmaceutical\t(Group)\tCo.,\tLtd.\tWe\trecognize\trevenues\tand\tcost\tof\tsales\ton a\tgross\tbasis\tin\tmarkets\twhere\twe\tare\tcommercializing\tthe\tvaccine\tand\twe\trecord\tour\tshare\tof\tgross\tprofits\trelated\tto\tsales\tof\tthe\tvaccine\tby BioNTech\tin\tGermany\tand\tTurkey\tin Alliance\trevenues .\n\n",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Excludes\trevenues\tfor\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech,\twhich\tare\tincluded\tin\tthe\tPC1\tcontract\tdevelopment\tand\tmanufacturing organization.\tSee\tfootnote\t(h)\tbelow. (a)\n- Includes\ta\tnon-cash\trevenue\treversal\tof\t$3.5\tbillion\trecorded\tin\tthe\tfourth\tquarter\tof\t2023,\tof\twhich\ta\tportion\twas\tassociated\twith\tsales\trecorded\tin\t2022,\trelated\tto\tthe expected\treturn\tof\tan\testimated\t6.5\tmillion\ttreatment\tcourses\tof\tEUA-labeled\tU.S.\tgovernment\tinventory. (b) (c)\n\n(d)\n\nImmunoglobulin\t(Ig)\tportfolio\tincludes\tthe\trevenues\tfrom\tPanzyga,\tOctagam\tand\tCutaquig.\n\nErbitux\tis\ta\tregistered\ttrademark\tof\tImClone\tLLC.\n\n- Represents\trevenues\tfrom\tlegacy\tSeagen\tproducts\tsubsequent\tto\tthe\tacquisition\ton\tDecember\t14,\t2023.\tSee Note\t2A . (f)\n- In\tMarch\t2023,\tit\twas\tannounced\tthat\tour\talliance\twith\tMerck\tKGaA\tto\tco-develop\tand\tco-commercialize\tBavencio\t(avelumab)\twould\tterminate.\tEffective\tJune\t30,\t2023,\tMerck\tKGaA\ttook full\tcontrol\tof\tthe\tglobal\tcommercialization\tof\tBavencio.\tBeginning\tin\tthe\tthird\tquarter\tof\t2023,\tthe\trelated\tprofit\tshare\twas\treplaced\tby\ta\t15%\troyalty\tto\tPfizer\ton\tnet\tsales\tof Bavencio,\twhich\twas\trecorded\tin Other\t(income)/deductions--net .\tWe\tand\tMerck\tKGaA\tcontinue\tto\toperationalize\tour\trespective\tongoing\tclinical\ttrials\tfor\tBavencio;\tand\tMerck\tKGaA controls\tall\tfuture\tR&amp;D\tactivities.\tBavencio\tis\ta\tregistered\ttrademark\tof\tMerck\tKGaA. (e)\n- See Note\t17A above\tfor\tinformation\tabout\tBusiness\tInnovation.\tPrior-period\tfinancial\tinformation\thas\tbeen\trevised\tto\treflect\tthe\tcurrent\tperiod\tpresentation. (g)\n- PC1\tincludes\trevenues\tfrom\tour\tcontract\tmanufacturing,\tincluding\tcertain\tComirnaty-related\tmanufacturing\tactivities\tperformed\ton\tbehalf\tof\tBioNTech\t($33\tmillion\tfor\t2023,\t$188 million\tfor\t2022,\tand\t$320\tmillion\tfor\t2021),\tand\trevenues\tfrom\tour\tactive\tpharmaceutical\tingredient\tsales\toperation,\tas\twell\tas\trevenues\trelated\tto\tour\tmanufacturing\tand\tsupply agreements\twith\tformer\tlegacy\tPfizer\tbusinesses/partnerships. (h)\n\nRemaining\tPerformance\tObligations-Contracted\trevenue\texpected\tto\tbe\trecognized\tfrom\tremaining\tperformance\tobligations\tfor\tfirm\torders\tin\tlong-term contracts\tto\tsupply\tComirnaty\tand\tPaxlovid\tto\tour\tcustomers\ttotaled\tapproximately\t$6\tbillion\tand\t$3.4\tbillion,\trespectively,\tas\tof\tDecember\t31, 2023,\twhich\tincludes\tamounts\treceived\tin\tadvance\tand\tdeferred,\tas\twell\tas\tamounts\tthat\twill\tbe\tinvoiced\tas\twe\tdeliver\tthese\tproducts\tto\tour customers\tin\tfuture\tperiods.\tOf\tthese\tamounts,\tcurrent\tcontract\tterms\tprovide\tfor\texpected\tdelivery\tof\tproduct\twith\tcontracted\trevenue\tfrom\t2024 through\t2028,\tthe\ttiming\tof\twhich\tmay\tbe\trenegotiated.\tRemaining\tperformance\tobligations\tare\tbased\ton\tforeign\texchange\trates\tas\tof\tthe\tend\tof\tour fiscal\tfourth\tquarter\tof\t2023\tand\texclude\tarrangements\twith\tan\toriginal\texpected\tcontract\tduration\tof\tless\tthan\tone\tyear.\tRemaining\tperformance obligations\tassociated\twith\tcontracts\tfor\tother\tproducts\tand\tservices\twere\tnot\tsignificant\tas\tof\tDecember\t31,\t2023\tor\t2022.\n\nDeferred\tRevenues-Our\tdeferred\trevenues\tprimarily\trelate\tto\tadvance\tpayments\treceived\tor\treceivable\tfrom\tvarious\tgovernment\tor\tgovernment\tsponsored customers\tfor\tsupply\tof\tPaxlovid\tand\tComirnaty.\n\nThe\tdeferred\trevenues\trelated\tto\tPaxlovid\ttotaled\t$3.4\tbillion\tas\tof\tDecember\t31,\t2023,\twith\t$1.5\tbillion\tand\t$1.9\tbillion\trecorded\tin\tcurrent liabilities\tand\tnoncurrent\tliabilities,\trespectively,\twhile\tdeferred\trevenues\trelated\tto\tPaxlovid\twere\tnot\tmaterial\tas\tof\tDecember\t31,\t2022.\tThe increase\tin\tPaxlovid\tdeferred\trevenues\tduring\t2023\twas\tprimarily\tdriven\tby\tthe\treversal\tof\tPaxlovid\trevenues\tand\tconversion\tof\tpreviously\tpurchased EUA-labeled\tPaxlovid\ttreatment\tcourses\tinto\ta\tvolume-based\tcredit\tunder\tour\tOctober\t2023\tamended\tagreement\twith\tthe\tU.S.\tgovernment.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n106",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 196,
      "question": "How does the $6.6 billion in cumulative goodwill impairments, including those tied to the acquisition of Oak Street Health, expose CVS to the financial risks associated with the RADV Audit Rule, particularly in light of potential Medicare reimbursement cuts and ongoing litigation involving risk adjustment coding practices?",
      "answer": "CVS has reported $6.6 billion in cumulative goodwill impairments, with a significant portion linked to the acquisitions of Oak Street Health and Signify Health. These entities are particularly vulnerable to regulatory changes such as the RADV Audit Rule, which could materially affect Medicare reimbursement and the financial performance of Oak Street Health. The RADV Audit Rule introduces uncertainty around risk adjustment payments and allows for extrapolation in audits dating back to 2018, increasing the potential for financial penalties. This risk is compounded by ongoing litigation and Civil Investigative Demands (CIDs) from the DOJ related to diagnosis coding and risk adjustment payments, which directly involve Oak Street Health\u2019s operations. Thus, the goodwill tied to these acquisitions exposes CVS to both regulatory and legal risks that could lead to financial liabilities and operational constraints under the RADV framework.",
      "reasoning_steps": [
        "Hop 1: CVS(page_150) \u2192 Oak Street Health: Introduction of Oak Street Health as part of goodwill from acquisitions, with $6.6 billion in cumulative impairments.",
        "Hop 2: Oak Street Health \u2192 RADV Audit Rule: The RADV Audit Rule negatively impacts Oak Street Health's financial performance due to potential Medicare reimbursement reductions and audit-related liabilities.",
        "Hop 3: RADV Audit Rule \u2190 CVS(page_184): CVS faces exposure from RADV-related audits and litigation, including DOJ investigations into risk adjustment coding practices, which could lead to material financial penalties."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> COMP -[Negatively_Impacts]-> REGULATORY_REQUIREMENT <-[Faces]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Oak Street Health",
        "node_3": "RADV Audit Rule",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_150",
          "chunk_id": "chunk_5",
          "chunk_text": "\nThere were no changes to the carrying amount of the Company's goodwill during the year ended December 31, 2024.\n\nDuring the year ended December 31, 2023, the increase in the carrying amount of goodwill was primarily driven by the acquisitions of Oak Street Health and Signify Health. See Note 2 ''Acquisitions, Divestitures and Asset Sales'' for additional information.\n\nDuring the fourth quarter of 2024 and 2023, and the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of these impairment tests indicated that there was no impairment of goodwill.\n\nAt December 31, 2024 and 2023, cumulative goodwill impairments were $6.6 billion.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Oak_Street_Health",
          "name": "Oak Street Health",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_53",
          "chunk_id": "chunk_1",
          "chunk_text": "- Data Validation Audits ('RADV Audit Rule') issued in January 2023 or other changes that may result from enforcement or audit actions, could: materially affect the amount of our Medicare reimbursement, require us to raise prices or reduce the benefits we offer to Medicare beneficiaries, impact the services provided by, or the financial performance of, Oak Street Health and Signify Health and potentially limit our (and the industry's) participation in the Medicare program.\n- The RADV Audit Rule creates uncertainty for Medicare Advantage plans. The lack of detail provided with respect to how CMS will select contracts and claims to audit, the methodology CMS will use, and how it will extrapolate as part of the RADV Audit Rule may impact future Medicare Advantage bids and result in other implications. The RADV Audit Rule also permits extrapolation of OIG contract level audits for payment years 2018 forward. The RADV Audit Rule is subject to ongoing litigation and the outcome and future impacts are uncertain.\n- Medicare Part D has resulted in increased utilization of prescription medications and puts pressure on our pharmacy gross margin rates due to regulatory and competitive pressures. Further, as a result of the ACA and changes to the retiree drug subsidy rules, clients of our PBM business could decide to discontinue providing prescription drug benefits to their Medicare-eligible members. To the extent this phenomenon occurs, the adverse effects of increasing customer migration into Medicare Part D may outweigh the benefits we realize from growth of our Medicare Part D products.\n- Our Medicare Part D operating results and our ability to expand our Medicare Part D business could be adversely affected if: the cost and complexity of Medicare Part D exceed management's expectations or prevent effective program implementation or administration; further changes to the regulations regarding how drug costs are reported for Medicare Part D (including changes related to the IRA) are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the applicable regulations impact our ability to retain fees from third parties including network pharmacies; the government alters Medicare Part D program requirements or reduces funding because of the higher-than-anticipated cost to taxpayers of Medicare Part D or for other reasons; or reinsurance thresholds are reduced.\n- The IRA contains significant changes to the Part D program that began in 2023 and will continue to 2032 that shifts more of the claim liability to plans and away from the government, including a complete redesign of the Part D standard benefit effective in 2025.\n- We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, and some states mandate that certain amounts be included or excluded from encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to bid for, and continue to participate in, certain Medicaid programs.\n- If we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs, and on our operating results, cash flows and financial condition.\n- The resumption of Medicaid eligibility redeterminations after being suspended during the COVID-19 pandemic has negatively impacted the number of members eligible for the Company's Medicaid plans, which could impact our operating results and cash flows from the Medicaid business.\n- Certain of our Medicaid contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our Medicaid programs because more states are using encounter data to determine compliance with performance standards and, in part, to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect accurate, or to correct inaccurate or incomplete, encounter data and have been and could be exposed to premium withholding, operating sanctions and financial fines and penalties for noncompliance.\n- CMS has proposed requiring that health plans offering certain dual eligible programs must also offer Medicaid programs, which could further impact the Company's ability to obtain or retain membership in its dual eligible programs. In addition, states are increasingly requiring companies to offer Medicaid within a state and conducting competitive bid processes to qualify to offer dual eligible products.\n\nPrograms funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase.",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "RADV_Audit_Rule",
          "name": "RADV Audit Rule",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_184",
          "chunk_id": "chunk_1",
          "chunk_text": "from regulatory audits, whether as a result of RADV, Public Exchange-related or other audits by CMS, the OIG or otherwise, including audits of the Company's minimum loss ratio rebates, methodology and/or reports, could be material and could adversely affect the Company's operating results, cash flows and/or financial condition.\n\nThe RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS RADV programs.\n\n## Medicare and Medicaid Litigation and Investigations\n\nThe Company has received CIDs from the Civil Division of the DOJ in connection with investigations of the Company's identification and/or submission of diagnosis codes related to risk adjustment payments, including patient chart review processes, under Parts C and D of the Medicare program. The Company is cooperating with the government and providing documents and information in response to these CIDs.\n\nIn May 2017, the Company received a CID from the U.S. Attorney's Office for the Southern District of New York requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.\n\nSince January 2022, the U.S. Attorney's Office for the District of Massachusetts has issued subpoenas to Aetna Life Insurance Company seeking, among other things, information in connection with its relationship and compensation arrangements with certain brokers, and the Company may receive similar inquiries in the future. The Company is cooperating with the investigation.\n\n## Stockholder Matters\n\nBeginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company's LTC business unit. Since filing, several of the cases have been consolidated, and two have resolved. In February 2025, the District of Rhode Island granted the Company's motion to dismiss In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford ). A derivative case in the District of Rhode Island, Lovoi v. Aguirre , had been stayed pending the outcome of the Waterford case, and the court has scheduled a status conference. In In re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich ), the Rhode Island Supreme Court affirmed the superior court's order granting the Company's motion to dismiss in January 2025. The Company and its current and former officers and directors are defending themselves against remaining claims.\n\nBeginning in December 2021, the Company has received three demands for inspection of books and records pursuant to Delaware General Corporation Law Section 220 ('Section 220 demands'), as well as a derivative complaint ( Vladimir Gusinsky Revocable Trust v. Lynch, et al. ) that was filed in January 2023, which the defendants moved to dismiss. The Section 220 demands and the complaint purport to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids. Following the Company's response to the Section 220 demands, two of the three stockholders sent demand letters to the Board containing allegations substantially similar to those made in the earlier Section 220 demands and the derivative matter, and requested that it take certain actions, including consideration of its governance and policies with respect to controlled substances. The Board deferred consideration of these two demands until after the motion to dismiss the Gusinsky case was decided. In July 2024, the court granted the defendants' motion to dismiss the Gusinsky case. In September 2024, the Board received a third demand letter containing similar allegations and requesting the Board take action. The Board has formed a demand review committee to evaluate the demands.\n\nIn January 2022, a shareholder class action complaint was filed in the Northern District of Illinois, Allison v. Oak Street Health, Inc., et al. Defendants include Oak Street Health and certain of its pre-acquisition officers and directors. The putative plaintiffs assert causes of action under various securities laws premised on allegations that defendants made omissions and misrepresentations to investors relating to marketing conduct they allege may violate the False Claims Act. In May 2024, the parties reached agreement in principle to settle this action for an amount immaterial to the Company. The court granted approval of the settlement in December 2024.\n\nBeginning in July 2024, two purported class action complaints, as well as multiple derivative complaints, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws and state law that are premised on allegations that the defendants made certain",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 197,
      "question": "How does the use of reinsurance agreements to reduce capital requirements connect with the legacy Aetna stock appreciation rights (SARs) obligations and their impact on CVS's capital structure?",
      "answer": "CVS utilizes reinsurance agreements, such as the four-year agreements entered in January 2022, to reduce required capital and manage surplus requirements in its Health Care Benefits segment. These agreements are part of a broader capital management strategy. Separately, the company inherited legacy Aetna SARs through its acquisition, which were converted into CVS Health Corporation SARs and are settled in stock, impacting equity and compensation expenses. While reinsurance agreements directly affect capital efficiency by transferring risk, the SARs influence capital structure through share-based compensation and dilution. Together, both elements reflect different dimensions of capital management: one through risk transfer and the other through employee compensation tied to equity, both of which are essential to understanding the company\u2019s overall capital allocation and financial flexibility.",
      "reasoning_steps": [
        "Hop 1: [CVS](page_177) \u2192 [Reinsurance Agreements]: Discloses that reinsurance agreements are used to reduce capital and surplus requirements, including a new four-year agreement in 2022 for group Commercial Insured business.",
        "Hop 2: [Reinsurance Agreements] \u2192 [Aetna]: Aetna was involved in reinsurance agreements, particularly in 2018 when it assumed risk for WellCare's Medicare Part D plans, showing a historical and structural link between reinsurance and Aetna's risk profile.",
        "Hop 3: [Aetna] \u2190 [CVS](page_172): Aetna's unvested SARs were converted into CVS SARs upon acquisition, which are settled in stock and affect equity and compensation expense, tying into broader capital structure considerations."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY -[Enters_Into]-> COMP <-[Involved_In]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Reinsurance Agreements",
        "node_3": "Aetna",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "ACCOUNTING_POLICY",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_177",
          "chunk_id": "chunk_5",
          "chunk_text": "\nThere is not a material difference between premiums on a written basis versus an earned basis.\n\nThe Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company's capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December 31, 2021 or 2020.\n\n## 16. Commitments and Contingencies\n\n## COVID-19\n\nThe COVID-19 pandemic continues to evolve. The Company believes COVID-19's impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic's impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company's knowledge and control. As a result, the impact COVID-19 will have on the Company's businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.\n\n## Guarantees\n\nThe Company has the following significant guarantee arrangements at December 31, 2021:\n\n- ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company's ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank.\n- Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $1.3 billion and $1.4 billion at December 31, 2021 and 2020, respectively. See Note 1 ''Significant Accounting Policies'' for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account's investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Reinsurance_Agreements",
          "name": "Reinsurance Agreements",
          "type": "ACCOUNTING_POLICY",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_176",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## 15. Reinsurance\n\nThe Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company's primary liability as the direct insurer of the risks reinsured.\n\nOn November 30, 2018, the Company completed the sale of Aetna's standalone Medicare Part D prescription drug plans to a subsidiary of WellCare Health Plans, Inc. ('WellCare'), effective December 31, 2018. In connection with that sale, subsidiaries of WellCare and Aetna entered into reinsurance agreements under which WellCare ceded to Aetna 100% of the insurance risk related to the divested standalone Medicare Part D prescription drug plans for the 2019 PDP plan year.\n\nIn January 2022, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment's group Commercial Insured business.\n\nReinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:\n\n",
          "relationship": "Enters_Into"
        },
        "node_3": {
          "id": "Aetna",
          "name": "Aetna",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "page_id": "page_172",
          "chunk_id": "chunk_1",
          "chunk_text": "service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.\n\nAll unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.\n\nThe following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:\n\n",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 198,
      "question": "How does BMY's exposure to biosimilar risk for Opdivo, as outlined in the regulatory exclusivity section, interact with the geographic partnership structure involving Ono and the associated royalty terms in Japan, South Korea, and Taiwan?",
      "answer": "BMY identifies Opdivo as one of its key marketed biologic products, facing heightened risk from biosimilar challenges due to evolving regulatory frameworks in both the U.S. and EU, which may limit the company's ability to prevent biosimilar approvals during ongoing patent litigation. This uncertainty around market exclusivity duration could impact BMY\u2019s revenue protection strategy for Opdivo globally. However, in Japan, South Korea, and Taiwan, Opdivo is managed by Ono, BMY\u2019s alliance partner, under a licensing agreement that excludes BMY from commercialization rights in these territories. Despite this geographic carve-out, BMY still receives a 15% royalty on Opdivo sales outside of North America, including these territories, subject to customary adjustments. This structure implies that while BMY benefits from Opdivo\u2019s success in these markets through royalty income, it has limited control over how Opdivo is positioned or defended against biosimilar competition in those regions, creating a potential misalignment between risk exposure and strategic control.",
      "reasoning_steps": [
        "Hop 1: BMY(page_9) \u2192 Opdivo: BMY discloses Opdivo as a key biologic product facing increased biosimilar risk due to shortened market exclusivity periods under U.S. and EU regulatory frameworks.",
        "Hop 2: Opdivo \u2192 Ono: Ono is BMY\u2019s alliance partner for Opdivo in Japan, where Ono handles regulatory and commercial activities, including recent approvals for new indications such as pediatric Hodgkin lymphoma and unresectable RCC.",
        "Hop 3: Ono \u2190 BMY(page_114): BMY depends on Ono for Opdivo commercialization in Japan, South Korea, and Taiwan, and receives a 15% royalty on sales in those territories, excluding North America."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Announces]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Opdivo",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "## Biologic products\n\nThe  U.S.  healthcare  legislation  enacted  in  2010  created  an  approval  pathway  for  biosimilar  versions  of  innovative  biological products  that  did  not  previously  exist.  Prior  to  that  time,  innovative  biologics  had  essentially  unlimited  regulatory  exclusivity. Under the new regulatory mechanism, the FDA can approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. After an innovator has marketed its product for four years, any manufacturer may file an application for approval of a 'biosimilar' version of the innovator product. However, although an  application  for  approval  of  a  biosimilar  version  may  be  filed  four  years  after  approval  of  the  innovator  product,  qualified innovative  biological  products  will  receive  12  years  of  regulatory  data  protection,  meaning  that  the  FDA  may  not  approve  a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. The law also provides a mechanism  for  innovators  to  enforce  the  patents  that  protect  innovative  biological  products  and  for  biosimilar  applicants  to challenge  the  patents.  Such  patent  litigation  may  begin  as  early  as  four  years  after  the  innovative  biological  product  is  first approved by the FDA.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market exclusivity. First, generic companies have increasingly sought to challenge innovators' basic patents covering major  pharmaceutical  products.  Second,  statutory  and  regulatory  provisions  may  limit  the  ability  of  an  innovator  company  to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of all of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based  solely  on  the  expiration  of  the  relevant  patent(s)  or  the  current  forms  of  regulatory  exclusivity.  Our  marketed  biologic products include Opdivo , Yervoy , Orencia, Reblozyl and Empliciti .\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended to compensate for the patent term lost during the regulatory review process. Such extensions are granted on a country-by-country basis.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized procedure.' This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and  is  also  available  for  certain  new  chemical  compounds  and  products.  A  company  seeking  to  market  an  innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies  the  MAA. It  is  also  possible  for  new  chemical  products  to  obtain  marketing  authorization  in  the  EU  through  a  'mutual recognition  procedure,'  in  which  an  application  is  made  to  a  single  member  state,  and  if  the  member  state  approves  the pharmaceutical  product  under  a  national  procedure,  then  the  applicant  may  submit  that  approval  to  the  mutual  recognition procedure of some or all other member states.\n\nAfter  obtaining  marketing  authorization  approval,  a  company  must  obtain  pricing  and  reimbursement  for  the  pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout the EU, all products for which marketing authorizations have been filed after October/November 2005 are subject to an '8+2+1' regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator.  The  possible  extension  to  11  years  is  available  if  the  innovator,  during  the  first  eight  years  of  the  marketing authorization,  obtains  an  additional  indication  that  is  of  significant  clinical  benefit  in  comparison  with  existing  treatments.  For products  that  were  filed  prior  to  October/November  2005,  there  is  a  10-year  period  of  regulatory  data  protection  under  the centralized procedures and a period of either six or 10 years under the mutual recognition procedure (depending on the member state).\n\nIn contrast to the U.S., patents in the EU are not listed with regulatory authorities. Generic versions of pharmaceutical products can be approved after data protection expires, regardless of whether the innovator holds patents covering its drug. Thus, it is possible that an innovator may be seeking to enforce its patents against a generic competitor that is already marketing its product. Also, the European patent system has an opposition procedure in which generic manufacturers may challenge the validity of patents covering innovator products within nine months of grant.\n\nIn  general,  EU  law  treats  chemically-synthesized  drugs  and  biologically-derived  drugs  the  same  with  respect  to  intellectual property and data protection. In addition to the relevant legislation and annexes related to biologic medicinal products, the EMA has  issued  guidelines  that  outline  the  additional  information  to  be  provided  for  biosimilar  products,  also  known  as  generic biologics, in order to review an application for marketing approval.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Opdivo",
          "name": "Opdivo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product         | Indication                     | Date           | Developments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|-----------------|--------------------------------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Opdivo          | Hodgkin Lymphoma               | September 2021 | Ono, our alliance partner for Opdivo in Japan, announced that Japan's Ministry of Health, Labour and Welfare approved Opdivo for the treatment of pediatric patients with recurrent or refractory classical Hodgkin lymphoma, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase I PENGUIN trial.                                                                                                                                              |\n| Opdivo          | NSCLC                          | November 2021  | Announced the Phase III CheckMate-816 trial met the primary endpoint of improved event- free survival in patients with resectable stage IB to IIIA NSCLC. In a prespecified interim analysis, Opdivo plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone when given before surgery.                                                                                                                                                |\n| Opdivo          | RCC                            | August 2021    | Ono, our alliance partner for Opdivo in Japan, announced that Japan's Ministry of Health, Labour and Welfare approved the combination therapy of Opdivo and CABOMETYX * for the treatment of unresectable or metastatic RCC, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase III Checkmate-9ER trial.                                                                                                                                       |\n| Opdivo          | RCC                            | April 2021     | Announced EC approval of Opdivo in combination with CABOMETYX * for the first-line treatment of adults with advanced RCC. The approval is based on results from the Phase III CheckMate-9ER trial.                                                                                                                                                                                                                                                                                                                              |\n| Opdivo          | RCC                            | January 2021   | Announced FDA approval of Opdivo in combination with CABOMETYX * for the first-line treatment of patients with advanced RCC. The approval is based on the Phase III CheckMate-9ER trial.                                                                                                                                                                                                                                                                                                                                        |\n| Opdivo + Yervoy | CRC                            | June 2021      | Announced EC approval of Opdivo plus Yervoy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high mCRC after prior fluoropyrimidine-based combination chemotherapy. The approval is based on results from the Phase II CheckMate-142 trial.                                                                                                                                                                                                                              |\n| Opdivo + Yervoy | Melanoma                       | May 2021       | Announced new six-and-a-half year data from the Phase III CheckMate-067 trial demonstrating durable improvement in survival with first-line Opdivo plus Yervoy therapy and Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma.                                                                                                                                                                                                                                                                         |\n| Opdivo + Yervoy | Esophageal                     | September 2021 | Announced that the FDAhas accepted the sBLA for Opdivo in combination with Yervoy and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. The FDA assigned a PDUFA goal date of May 28, 2022. The sBLAsubmissions were based on the Phase III Checkmate-648 trial.                                                                                            |\n| Opdivo + Yervoy | Esophageal                     | September 2021 | Ono, our alliance partner for Opdivo in Japan, announced that the companies have submitted supplemental applications in Japan for Opdivo in combination with Yervoy and Opdivo in combination with chemotherapy for the first-line treatment of unresectable, advanced or recurrent esophageal cancer, for a partial change in approved items of the manufacturing and marketing approvals in Japan. The applications are based on results from the Phase III CheckMate-648 trial.                                              |\n| Opdivo + Yervoy | Esophageal                     | August 2021    | Announced that the EMA validated its MAA for both Opdivo in combination with Yervoy and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Validation of these applications confirm that the submissions are complete and begins the EMA's centralized review process. The applications are based on results from the pivotal Phase III CheckMate-648 trial. |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | September 2021 | Announced three-year data from the CheckMate-743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo plus Yervoy compared to platinum- based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma, regardless of histology.                                                                                                                                                                                                                          |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | June 2021      | Announced EC approval of Opdivo plus Yervoy for the first line treatment of adults with unresectable malignant pleural mesothelioma. The approval is based on results from the Phase III CheckMate-743 trial.                                                                                                                                                                                                                                                                                                                   |\n| Opdivo + Yervoy | Malignant Pleural Mesothelioma | May 2021       | Ono, our alliance partner for Opdivo in Japan, announced that the companies received approval for combination therapy of Opdivo and Yervoy in Japan for the first-line treatment of unresectable advanced or recurrent malignant pleural mesothelioma, for a partial change in approved items of the manufacturing and marketing approval. The approval is based on results from the Phase III CheckMate-743 trial.                                                                                                             |",
          "relationship": "Announces"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_114",
          "chunk_id": "chunk_3",
          "chunk_text": "\nBMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments.\n\n## Nektar\n\nIn  2018,  BMS  and  Nektar  commenced  a  worldwide  license  and  collaboration  for  the  development  and  commercialization  of Bempegaldesleukin  (NKTR-214),  Nektar's  investigational  immuno-stimulatory  therapy  designed  to  selectively  expand  specific cancer-fighting T cells and natural killer cells directly in the tumor micro-environment. In January 2020, the parties amended the collaboration agreement. The Opdivo and NKTR-214 combination therapy is currently in Phase III clinical studies for metastatic melanoma, adjuvant melanoma, muscle-invasive bladder cancer and RCC. A joint development plan agreed by the parties as part of the original agreement, and updated as part of the January 2020 amendment, specifies development in certain indications and tumor types  with  each  party  responsible  for  the  supply  of  their  own  product.  BMS's  share  of  the  development  costs  associated  with therapies comprising a BMS medicine used in combination with NKTR-214 is 67.5%, subject to certain cost caps for Nektar. The January  2020  amendment  retains  the  cost  sharing  percentages  from  the  original  agreement.  The  parties  will  also  jointly commercialize  the  therapies,  subject  to  regulatory  approval.  BMS's  share  of  global  NKTR-214  profits  and  losses  will  be  35% subject to certain annual loss caps for Nektar.\n\nBMS paid Nektar $1.85 billion for the rights discussed above and 8.3 million shares of Nektar common stock which represented a 4.8% ownership interest.  BMS's equity  ownership  is  subject  to  certain  lock-up,  standstill  and  voting  provisions  for  a  five-year period. The amount of the up-front payment allocated to the equity investment was $800 million after considering Nektar's stock price on the date of closing and current limitations on trading the securities. The remaining $1.05 billion of the up-front payment was allocated to the rights discussed above. BMS will also pay up to $1.8 billion upon the achievement of contingent development, regulatory and sales-based milestones over the life of the alliance period. Research and development cost reimbursements were $98 million in 2021, $132 million in 2020 and $108 million in 2019.\n\n## 2seventy bio (formerly bluebird)\n\nOn November 4, 2021, bluebird completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company.\n\nThe  parties  jointly  develop  and  commercialize  novel  disease-altering  gene  therapy  product  candidates  targeting  BCMA.  The collaboration arrangement began in 2013 and included (i) a right for BMS to license any anti-BCMA products resulting from the collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and  commercialization  of  any  licensed  products resulting  from  the  collaboration  through  a  50/50  co-development  and  profit  share  in  the  U.S.  in  exchange  for  a  reduction  of milestone  payments,  and  (iii)  sales-based  milestones  and  royalties  payable  to  2seventy  bio  upon  the  commercialization  of  any licensed  products  resulting  from  the  collaboration  if  2seventy  bio  declined  to  exercise  their  co-development  and  profit  sharing rights. The options to license idecabtagene vicleucel (ide-cel, bb2121) and bb21217 were exercised in 2016 and 2017, respectively. In 2022, the parties elected to not pursue further development of bb21217.\n\nAll profits and losses relating to developing, commercializing and manufacturing ide-cel within the U.S. are shared equally. BMS is exclusively responsible for the development and commercialization of ide-cel outside the U.S.\n\nIn  2020,  terms  of  the  collaboration  were  amended  including  certain  manufacturing  obligations.  Both  parties  were  also  released from future exclusivity related to BCMA-directed T cell therapies. BMS paid $200 million to extinguish its obligation for future ex-U.S. milestones and royalties on ide-cel, which was included in Research and development expense in 2020.\n\nIn 2021, the FDA approved ide-cel (' Abecma ' ) for the treatment of relapsed or refractory multiple myeloma. Net product sales of Abecma  within  the  Alliance  territory  were  $158  million  and  related  profit  sharing  costs  were  $42  million  in  2021.  Cost reimbursements were not material.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 199,
      "question": "How did Merck's spin-off of Organon in 2021 continue to impact its 2023 operating margin through ongoing manufacturing and labeling agreements for finished pharmaceutical products?",
      "answer": "Merck's spin-off of Organon in 2021 continued to affect its 2023 financials through post-spin-off manufacturing and labeling agreements. Specifically, Merck incurred $422 million in cost of sales related to packaging and labeling finished pharmaceutical products for Organon in 2023, despite no longer being the obligor of Organon's $9.5 billion in debt. These agreements, which range in duration from four to ten years, generated $394 million in sales for Merck in 2023. The $394 million in sales offset some of the $5.5 billion pretax charge Merck recorded in 2023 for collaboration-related research and development expenses, though the cost of sales directly impacted the company's operating margin.",
      "reasoning_steps": [
        "Hop 1: MRK(page_124) \u2192 Organon: Merck spun off Organon in 2021, transferring $9.5 billion in debt and receiving $9.0 billion in cash, with residual financial impacts tracked in accumulated other comprehensive loss.",
        "Hop 2: Organon \u2192 Finished Pharmaceutical Products: Post-spin-off agreements included Merck manufacturing, packaging, and labeling finished pharmaceutical products for Organon under multi-year supply contracts.",
        "Hop 3: Finished Pharmaceutical Products \u2190 MRK(page_91): In 2023, Merck recorded $394 million in sales and $422 million in related cost of sales from these agreements, directly affecting its operating margin despite the spin-off being completed in 2021."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> COMP -[Labels]-> PRODUCT <-[Labels]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Finished Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                     | Derivatives   |     | Employee Benefit Plans   |     | Foreign Currency Translation Adjustment   | Accumulated Other Comprehensive Loss   |\n|-------------------------------------------------------------------------------------|---------------|-----|--------------------------|-----|-------------------------------------------|----------------------------------------|\n| Balance January 1, 2021, net of taxes                                               | (266)         |     | (4,540)                  | $   | (1,828)                                   | $ (6,634)                              |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 333           |     | 1,737                    |     | (304)                                     | 1,766                                  |\n| Tax                                                                                 | (75)          |     | (332)                    |     | (119)                                     | (526)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 258           |     | 1,405                    |     | (423)                                     | 1,240                                  |\n| Reclassification adjustments, pretax                                                | 192           | (1) | 466                      | (2) | -                                         | 658                                    |\n| Tax                                                                                 | (40)          |     | (102)                    |     | -                                         | (142)                                  |\n| Reclassification adjustments, net of taxes                                          | 152           |     | 364                      |     | -                                         | 516                                    |\n| Other comprehensive income (loss), net of taxes                                     | 410           |     | 1,769                    |     | (423)                                     | 1,756                                  |\n| Spin-off of Organon (see Note 5)                                                    | -             |     | 28                       |     | 421                                       | 449                                    |\n| Balance at December 31, 2021, net of taxes                                          | 144           |     | (2,743)                  |     | (1,830)                                   | (4,429)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 684           |     | 70                       |     | (584)                                     | 170                                    |\n| Tax                                                                                 | (143)         |     | 12                       |     | (19)                                      | (150)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 541           |     | 82                       |     | (603)                                     | 20                                     |\n| Reclassification adjustments, pretax                                                | (775)         | (1) | 329                      | (2) | -                                         | (446)                                  |\n| Tax                                                                                 | 163           |     | (76)                     |     | -                                         | 87                                     |\n| Reclassification adjustments, net of taxes                                          | (612)         |     | 253                      |     | -                                         | (359)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (71)          |     | 335                      |     | (603)                                     | (339)                                  |\n| Balance at December 31, 2022, net of taxes                                          | 73            |     | (2,408)                  | (3) | (2,433)                                   | (4,768)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 114           |     | (413)                    |     | 17                                        | (282)                                  |\n| Tax                                                                                 | (24)          |     | 86                       |     | 63                                        | 125                                    |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 90            |     | (327)                    |     | 80                                        | (157)                                  |\n| Reclassification adjustments, pretax                                                | (237)         | (1) | (64)                     | (2) | 9                                         | (292)                                  |\n| Tax                                                                                 | 50            |     | 6                        |     | -                                         | 56                                     |\n| Reclassification adjustments, net of taxes                                          | (187)         |     | (58)                     |     | 9                                         | (236)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (97)          |     | (385)                    |     | 89                                        | (393)                                  |\n| Balance at December 31, 2023, net of taxes                                          | (24)          |     | (2,793) (3)              | $   | (2,344)                                   | $ (5,161)                              |\n",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Labels"
        },
        "node_3": {
          "id": "Finished_Pharmaceutical_Products",
          "name": "Finished Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Labels"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 200,
      "question": "How does BMY's financial stake in Farxiga and its shared liability with AstraZeneca for Onglyza-related litigation reflect its ongoing exposure to AstraZeneca's pharmaceutical risks despite the 2014 divestiture of Onglyza?",
      "answer": "BMY maintains a financial stake in Farxiga, a product trademarked by AstraZeneca, indicating continued commercial alignment with AstraZeneca\u2019s pharmaceutical portfolio. Despite divesting Onglyza in 2014, BMY remains exposed to litigation risks tied to the drug, as it is co-defending product liability lawsuits alongside AstraZeneca in ongoing federal appeals. This dual exposure\u2014through both current product revenue sharing (Farxiga) and legacy liability (Onglyza litigation)\u2014demonstrates how BMY's financial and legal risks remain interlinked with AstraZeneca's pharmaceutical operations even after the divestiture.",
      "reasoning_steps": [
        "Hop 1: BMY(page_138) \u2192 Farxiga: BMY holds a financial stake in Farxiga, a product trademarked by AstraZeneca, indicating ongoing commercial exposure to AstraZeneca\u2019s pharmaceutical business.",
        "Hop 2: Farxiga \u2192 AstraZeneca: Farxiga is a trademark of AstraZeneca, making it a direct product of the company and linking BMY\u2019s revenue exposure to AstraZeneca\u2019s product performance.",
        "Hop 3: AstraZeneca \u2190 BMY(page_118): Despite selling Onglyza to AstraZeneca in 2014, BMY is still co-defendant in product liability litigation related to the drug, with potential liability shared between the two companies."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Produces]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Farxiga",
        "node_3": "AstraZeneca",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Farxiga",
          "name": "Farxiga",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_138",
          "chunk_id": "chunk_1",
          "chunk_text": "- \u2020 Confidential\ttreatment\thas\tbeen\tgranted\tfor\tcertain\tportions\twhich\tare\tomitted\tin\tthe\tcopy\tof\tthe\texhibit\telectronically filed\twith\tthe\tCommission.\n* Indicates,\t in\t this\t 2023\t Form\t 10-K,\t brand\t names\t of\t products,\t which\t are\t registered\t trademarks\t not\t solely\t owned\t by\t the Company\t or\t its\t subsidiaries. Abilify is\t a\t trademark\t of\t Otsuka\t Pharmaceutical\t Co.,\t Ltd.; Cabometyx is\t a\t trademark\t of Exelixis,\tInc.; Farxiga and Onglyza are\ttrademarks\tof\tAstraZeneca\tAB; Gleevec is\ta\ttrademark\tof\tNovartis\tAG; Keytruda is a\ttrademark\tof\tMerck\tSharp\t&amp;\tDohme\tCorp.; Otezla is\ta\ttrademark\tof\tAmgen\tInc.; Plavix is\ta\ttrademark\tof\tSanofi;\tand Tecentriq is\t a\t trademark\t of\t Genentech,\t Inc.\t Brand\t names\t of\t products\t that\t are\t in\t all\t italicized\t letters,\t without\t an asterisk,\tare\tregistered\ttrademarks\tof\tBMS\tand/or\tone\tof\tits\tsubsidiaries.",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "AstraZeneca",
          "name": "AstraZeneca",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_118",
          "chunk_id": "chunk_1",
          "chunk_text": "## Onglyza*\n\nBMS\t and\t AstraZeneca\t are\t co-defendants\t in\t product\t liability\t litigation\t related\t to Onglyza* .\t Plaintiffs\t assert\t claims, including\tclaims\tfor\twrongful\tdeath,\tas\ta\tresult\tof\theart\tfailure\tor\tother\tcardiovascular\tinjuries\tthey\tallege\twere\tcaused\tby their\t use\t of Onglyza* .\t In\t February\t 2018,\t the\t Judicial\t Panel\t on\t Multidistrict\t Litigation\t ordered\t all\t the\t federal Onglyza* cases\tto\tbe\ttransferred\tto\tan\tMDL\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tEastern\tDistrict\tof\tKentucky.\tA\tsignificant\tmajority\tof the\t claims\t were\t pending\t in\t the\t MDL,\t with\t others\t pending\t in\t a\t coordinated\t proceeding\t in\t California\t Superior\t Court\t in\t San Francisco\t(\"JCCP\").\tThe\tJCCP\tcourt\tgranted\tsummary\tjudgment\tto\tdefendants\tin\tMarch\t2022,\ta\tdecision\twhich\twas\taffirmed\tby\tthe California\tCourt\tof\tAppeal.\tThe\tCalifornia\tSupreme\tCourt\tdeclined\tto\treview\tthe\tdecision\tin\tJuly\t2023.\tIn\tthe\tMDL,\tthe\tcourt granted\t defendants'\t motion\t to\t exclude\t plaintiffs'\t only\t general\t causation\t expert\t on\t January\t 5,\t 2022\t and\t granted\t summary judgment\ton\tAugust\t2,\t2022.\tPlaintiffs\tfiled\ttheir\tNotice\tof\tAppeal\ton\tDecember\t2,\t2022.\tThe\tappeal\tremains\tpending\tin\tthe Sixth\tCircuit.\tAs\tpart\tof\tBMS's\tglobal\tdiabetes\tbusiness\tdivestiture,\tBMS\tsold Onglyza* to\tAstraZeneca\tin\tFebruary\t2014\tand any\tpotential\tliability\twith\trespect\tto Onglyza* is\texpected\tto\tbe\tshared\twith\tAstraZeneca.\n\n## SECURITIES\tLITIGATION\n\n## Celgene\tSecurities\tLitigations\n\nBeginning\t in\t March\t 2018,\t two\t putative\t class\t actions\t were\t filed\t against\t Celgene\t and\t certain\t of\t its\t officers\t in\t the\t U.S. District\t Court\t for\t the\t District\t of\t New\t Jersey\t (the\t \"Celgene\t Securities\t Class\t Action\").\t The\t complaints\t allege\t that\t the defendants\tviolated\tfederal\tsecurities\tlaws\tby\tmaking\tmisstatements\tand/or\tomissions\tconcerning\t(1)\ttrials\tof\tGED-0301,\t(2) Celgene's\t2020\toutlook\tand\tprojected\tsales\tof Otezla* ,\tand\t(3)\tthe\tNDA\tfor Zeposia .\tThe\tCourt\tconsolidated\tthe\ttwo\tactions and\tappointed\ta\tlead\tplaintiff,\tlead\tcounsel,\tand\tco-liaison\tcounsel\tfor\tthe\tputative\tclass.\tIn\tFebruary\t2019,\tthe\tdefendants filed\ta\tmotion\tto\tdismiss\tplaintiffs'\tamended\tcomplaint\tin\tfull.\tIn\tDecember\t2019,\tthe\tCourt\tdenied\tthe\tmotion\tto\tdismiss\tin part\tand\tgranted\tthe\tmotion\tto\tdismiss\tin\tpart\t(including\tall\tclaims\tarising\tfrom\talleged\tmisstatements\tregarding\tGED-0301). Although\tthe\tCourt\tgave\tthe\tplaintiff\tleave\tto\tre-plead\tthe\tdismissed\tclaims,\tit\telected\tnot\tto\tdo\tso,\tand\tthe\tdismissed claims\t are\t now\t dismissed\t with\t prejudice.\t In\t November\t 2020,\t the\t Court\t granted\t class\t certification\t with\t respect\t to\t the remaining\tclaims.\tIn\tMarch\t2023,\tthe\tCourt\tgranted\tthe\tdefendants\tleave\tto\tfile\ta\tmotion\tfor\tsummary\tjudgment,\tthe\tbriefing for\twhich\twas\tcompleted\tin\tJune\t2023.\tOn\tSeptember\t8,\t2023,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants'\tmotion for\t summary\t judgment\t as\t to\t the\t claims\t regarding\t statements\t made\t by\t the\t remaining\t officer\t defendants.\t As\t to\t the\t claims regarding\t Celgene's\t corporate\t statements,\t the\t Court\t denied\t the\t defendants'\t motion\t without\t prejudice\t and\t granted\t the defendants\tleave\tto\tre-raise\tthe\tissue.\tOn\tOctober\t27,\t2023,\tthe\tdefendants\tfiled\ta\tmotion\tfor\tpartial\tsummary\tjudgment\tas\tto Celgene's\tcorporate\tstatements.\n\nIn\tApril\t2020,\tcertain\tSchwab\tmanagement\tinvestment\tcompanies\ton\tbehalf\tof\tcertain\tSchwab\tfunds\tfiled\tan\tindividual\taction\tin the\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe\tsame\tallegations\tas\tthe\tCelgene\tSecurities\tClass Action\t against\t the\t same\t remaining\t defendants\t in\t that\t action\t (the\t \"Schwab\t Action\").\t In\t July\t 2020,\t the\t defendants\t filed\t a motion\tto\tdismiss\tthe\tplaintiffs'\tcomplaint\tin\tfull.\tIn\tMarch\t2021,\tthe\tCourt\tgranted\tin\tpart\tand\tdenied\tin\tpart\tdefendants' motion\tto\tdismiss\tconsistent\twith\tits\tdecision\tin\tthe\tCelgene\tSecurities\tClass\tAction.\n\nThe\t California\t Public\t Employees'\t Retirement\t System\t in\t April\t 2021\t (the\t \"CalPERS\t Action\");\t DFA\t Investment\t Dimensions\t Group Inc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds;\tand\tAmerican\tCentury\tMutual\tFunds,\tInc.,\ton\tbehalf\tof\tcertain\tof\tits\tfunds,\tin\tJuly 2021\t(respectively\tthe\t\"DFA\tAction\"\tand\tthe\t\"American\tCentury\tAction\"),\tand\tGIC\tPrivate\tLimited\tin\tSeptember\t2021\t(the\t\"GIC Action\"),\tfiled\tseparate\tindividual\tactions\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tDistrict\tof\tNew\tJersey\tasserting\tlargely\tthe same\t allegations\t as\t the\t Celgene\t Securities\t Class\t Action\t and\t the\t Schwab\t individual\t action\t against\t the\t same\t remaining defendants\t in\t those\t actions.\t In\t October\t 2021,\t these\t actions\t were\t consolidated\t for\t pre-trial\t proceedings\t with\t the\t Schwab Action.\tThe\tCourt\talso\tconsolidated\tany\tfuture\tdirect\tactions\traising\tcommon\tquestions\tof\tlaw\tand\tfact\twith\tthe\tSchwab\tAction (the\t \"Consolidated\t Schwab\t Action\").\t On\t October\t 2,\t 2023,\t defendants\t filed\t a\t motion\t for\t partial\t summary\t judgment\t in\t the Consolidated\tSchwab\tAction.\n\nNo\ttrial\tdates\thave\tbeen\tscheduled\tin\tany\tof\tthe\tabove\tCelgene\tSecurities\tLitigations.\n\n## Contingent\tValue\tRights\tLitigations\n\nIn\tJune\t2021,\tan\taction\twas\tfiled\tagainst\tBMS\tin\tthe\tU.S.\tDistrict\tCourt\tfor\tthe\tSouthern\tDistrict\tof\tNew\tYork\tasserting claims\t of\t alleged\t breaches\t of\t a\t Contingent\t Value\t Rights\t Agreement\t (\"CVR\t Agreement\")\t entered\t into\t in\t connection\t with\t the closing\tof\tBMS's\tacquisition\tof\tCelgene\tCorporation\tin\tNovember\t2019.\tAn\tentity\tclaiming\tto\tbe\tthe\tsuccessor\ttrustee\tunder the\tCVR\tAgreement\talleges\tthat\tBMS\tbreached\tthe\tCVR\tAgreement\tby\tallegedly\tfailing\tto\tuse\t\"diligent\tefforts\"\tto\tobtain\tFDA approval\t of\t liso-cel\t ( Breyanzi )\t before\t a\t contractual\t milestone\t date,\t thereby\t allegedly\t avoiding\t a\t $6.4\t billion\t potential obligation\t to\t holders\t of\t the\t contingent\t value\t rights\t governed\t by\t the\t CVR\t Agreement\t and\t by\t allegedly\t failing\t to\t permit inspection\tof\trecords\tin\tresponse\tto\ta\trequest\tby\tthe\talleged\tsuccessor\ttrustee.\tThe\tplaintiff\tseeks\tdamages\tin\tan\tamount\tto be\tdetermined\tat\ttrial\tand\tother\trelief,\tincluding\tinterest\tand\tattorneys'\tfees.\tBMS\tdisputes\tthe\tallegations.\tBMS\tfiled\ta motion\tto\tdismiss\tthe\talleged\tsuccessor\ttrustee's\tcomplaint\tfor\tfailure\tto\tstate\ta\tclaim\tupon\twhich\trelief\tcan\tbe\tgranted, which\twas\tdenied\ton\tJune\t24,\t2022.\tOn\tFebruary\t2,\t2024,\tBMS\tfiled\ta\tmotion\tto\tdismiss\tthe\tcomplaint\tfor\tlack\tof\tsubject matter\tjurisdiction.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 201,
      "question": "How does the Fast Track designation mentioned in the regulatory context relate to LLY's investment in PR001, and what implications does this have for the company's financial exposure tied to the contingent value rights from the Prevail acquisition?",
      "answer": "The Fast Track designation, mentioned in the regulatory section on page 39, is intended to expedite the development and review of new therapies for serious conditions with unmet medical needs. PR001, a gene therapy acquired through the Prevail acquisition (page 66), was granted this designation by the FDA, indicating its potential significance in treating Parkinson\u2019s disease with GBA1 mutations and neuronopathic Gaucher disease. The acquisition of Prevail included contingent value rights (CVRs) that could pay up to $160 million if regulatory approval of a Prevail product like PR001 occurs by December 31, 2024. However, the high failure rate in drug development, as noted in the risk factors on page 39, introduces significant uncertainty around whether PR001 will meet regulatory approval in time to trigger the CVR payment, thereby affecting LLY's financial exposure and potential future liabilities tied to this acquisition.",
      "reasoning_steps": [
        "Hop 1: LLY(page_39) \u2192 Fast Track Designation: Disclosed in the regulatory context as a mechanism to expedite development of therapies for serious conditions with unmet needs.",
        "Hop 2: Fast Track Designation \u2192 PR001: PR001 was granted Fast Track designation by the FDA, indicating its potential therapeutic importance and alignment with regulatory priorities.",
        "Hop 3: PR001 \u2190 LLY(page_66): PR001 is a key asset acquired from Prevail, with its regulatory progress directly tied to contingent value rights worth up to $160 million."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Complies_With]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Fast Track Designation",
        "node_3": "PR001",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn collaboration with Boehringer Ingelheim. (1)\n\nBreakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. (2)\n\nFast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs. (3)\n\nThe FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients. (4)\n\nThere are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Complies_With"
        },
        "node_3": {
          "id": "PR001",
          "name": "PR001",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 202,
      "question": "How does the spin-off of Organon impact Merck's financial obligations and revenue streams related to formulated pharmaceutical products, particularly in light of the manufacturing and supply agreements between the two companies?",
      "answer": "The spin-off of Organon in 2021 transferred $9.5 billion in principal debt to Organon, removing it from Merck's balance sheet and reducing Merck\u2019s long-term financial obligations. Despite this separation, Merck continues to maintain a supply relationship with Organon through multi-year manufacturing and supply agreements (MSAs), under which Merck both supplies and receives formulated pharmaceutical products. In 2023, Merck reported $394 million in sales related to these agreements, with a corresponding cost of sales of $422 million, indicating a slight loss on these transactions. This suggests that while Merck no longer owns Organon, it remains operationally intertwined with it, particularly in the formulated pharmaceutical products segment, and continues to derive revenue (albeit at a cost) from these post-spin-off arrangements.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_124) \u2192 [Organon]: Merck completed the spin-off of Organon in 2021, transferring $9.5 billion in debt to the new entity and receiving $9.0 billion in cash proceeds.",
        "Hop 2: [Organon] \u2192 [Formulated Pharmaceutical Products]: Following the spin-off, Merck and Organon entered into MSAs under which Merck manufactures and supplies formulated pharmaceutical products to Organon.",
        "Hop 3: [Formulated Pharmaceutical Products] \u2190 [MRK](page_91): In 2023, Merck reported $394 million in sales and $422 million in cost of sales related to these MSAs, indicating ongoing financial activity tied to formulated pharmaceutical products post-spin-off."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> COMP -[Manufactures]-> PRODUCT <-[Supplies]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Organon",
        "node_3": "Formulated Pharmaceutical Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_124",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                     | Derivatives   |     | Employee Benefit Plans   |     | Foreign Currency Translation Adjustment   | Accumulated Other Comprehensive Loss   |\n|-------------------------------------------------------------------------------------|---------------|-----|--------------------------|-----|-------------------------------------------|----------------------------------------|\n| Balance January 1, 2021, net of taxes                                               | (266)         |     | (4,540)                  | $   | (1,828)                                   | $ (6,634)                              |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 333           |     | 1,737                    |     | (304)                                     | 1,766                                  |\n| Tax                                                                                 | (75)          |     | (332)                    |     | (119)                                     | (526)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 258           |     | 1,405                    |     | (423)                                     | 1,240                                  |\n| Reclassification adjustments, pretax                                                | 192           | (1) | 466                      | (2) | -                                         | 658                                    |\n| Tax                                                                                 | (40)          |     | (102)                    |     | -                                         | (142)                                  |\n| Reclassification adjustments, net of taxes                                          | 152           |     | 364                      |     | -                                         | 516                                    |\n| Other comprehensive income (loss), net of taxes                                     | 410           |     | 1,769                    |     | (423)                                     | 1,756                                  |\n| Spin-off of Organon (see Note 5)                                                    | -             |     | 28                       |     | 421                                       | 449                                    |\n| Balance at December 31, 2021, net of taxes                                          | 144           |     | (2,743)                  |     | (1,830)                                   | (4,429)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 684           |     | 70                       |     | (584)                                     | 170                                    |\n| Tax                                                                                 | (143)         |     | 12                       |     | (19)                                      | (150)                                  |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 541           |     | 82                       |     | (603)                                     | 20                                     |\n| Reclassification adjustments, pretax                                                | (775)         | (1) | 329                      | (2) | -                                         | (446)                                  |\n| Tax                                                                                 | 163           |     | (76)                     |     | -                                         | 87                                     |\n| Reclassification adjustments, net of taxes                                          | (612)         |     | 253                      |     | -                                         | (359)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (71)          |     | 335                      |     | (603)                                     | (339)                                  |\n| Balance at December 31, 2022, net of taxes                                          | 73            |     | (2,408)                  | (3) | (2,433)                                   | (4,768)                                |\n| Other comprehensive income (loss) before reclassification adjustments, pretax       | 114           |     | (413)                    |     | 17                                        | (282)                                  |\n| Tax                                                                                 | (24)          |     | 86                       |     | 63                                        | 125                                    |\n| Other comprehensive income (loss) before reclassification adjustments, net of taxes | 90            |     | (327)                    |     | 80                                        | (157)                                  |\n| Reclassification adjustments, pretax                                                | (237)         | (1) | (64)                     | (2) | 9                                         | (292)                                  |\n| Tax                                                                                 | 50            |     | 6                        |     | -                                         | 56                                     |\n| Reclassification adjustments, net of taxes                                          | (187)         |     | (58)                     |     | 9                                         | (236)                                  |\n| Other comprehensive income (loss), net of taxes                                     | (97)          |     | (385)                    |     | 89                                        | (393)                                  |\n| Balance at December 31, 2023, net of taxes                                          | (24)          |     | (2,793) (3)              | $   | (2,344)                                   | $ (5,161)                              |\n",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Manufactures"
        },
        "node_3": {
          "id": "Formulated_Pharmaceutical_Products",
          "name": "Formulated Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Supplies"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 203,
      "question": "How does the Fast Track designation for PR001, acquired through LLY's acquisition of Prevail for $747.4 million net of cash, align with LLY's broader disclosure on the uncertainties and risks associated with Fast Track and other accelerated regulatory pathways?",
      "answer": "LLY acquired Prevail in January 2021 for $747.4 million net of cash, gaining PR001, which had received Fast Track designation from the FDA. The Fast Track designation was a key asset, as it was intended to expedite development and review of therapies for serious conditions with unmet medical needs. However, in another section of the 10-K, LLY acknowledges the inherent uncertainties in drug development, particularly noting that even with Fast Track or Breakthrough Therapy designations, continued approval may be contingent on confirmatory trials, and there is a high rate of failure across the R&D pipeline. This suggests that while PR001's Fast Track status offers a potential development advantage, LLY still faces significant risk in translating this into commercial success before the CVR deadline of December 31, 2024.",
      "reasoning_steps": [
        "Hop 1: LLY(page_70) \u2192 PR001: LLY acquired Prevail in 2021 for $747.4 million net of cash, gaining PR001, a gene therapy for Parkinson\u2019s and Gaucher disease.",
        "Hop 2: PR001 \u2192 Fast Track Designation: PR001 was granted Fast Track designation by the FDA, indicating its potential to treat serious conditions with unmet needs.",
        "Hop 3: Fast Track Designation \u2190 LLY(page_43): LLY disclosed that Fast Track and Breakthrough Therapy designations come with uncertainties, including the need for confirmatory trials and the high failure rate in drug development."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Acquires]-> PRODUCT -[Receives]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "PR001",
        "node_3": "Fast Track Designation",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Acquires"
        },
        "node_2": {
          "id": "PR001",
          "name": "PR001",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_70",
          "chunk_id": "chunk_1",
          "chunk_text": "## Prevail\tAcquisition\n\n## Overview\tof\tTransaction\n\nIn\tJanuary\t2021,\twe\tacquired\tall\tshares\tof\tPrevail\tfor\ta\tpurchase\tprice\tthat\tincluded\t$22.50\tper\tshare\tin\tcash\t(or\tan aggregate\tof\t$747.4\tmillion,\tnet\tof\tcash\tacquired)\tplus\tone\tnon-tradable\tCVR\tper\tshare.\tThe\tCVR\tentitles\tPrevail\tstockholders up\tto\tan\tadditional\t$4.00\tper\tshare\tin\tcash\t(or\tan\taggregate\tof\tapproximately\t$160\tmillion)\tpayable,\tsubject\tto\tcertain\tterms and\tconditions,\tupon\tthe\tfirst\tregulatory\tapproval\tof\ta\tPrevail\tproduct\tin\tone\tof\tthe\tfollowing\tcountries:\tU.S.,\tJapan, United\tKingdom,\tGermany,\tFrance,\tItaly,\tor\tSpain.\tTo\tachieve\tthe\tfull\tvalue\tof\tthe\tCVR,\tsuch\tregulatory\tapproval\tmust\toccur by\tDecember\t31,\t2024.\tIf\tsuch\tregulatory\tapproval\toccurs\tafter\tDecember\t31,\t2024,\tthe\tvalue\tof\tthe\tCVR\twill\tbe\treduced\tby approximately\t8.3\tcents\tper\tmonth\tuntil\tDecember\t1,\t2028,\tat\twhich\tpoint\tthe\tCVR\twill\texpire\twithout\tpayment.\n\nUnder\tthe\tterms\tof\tthe\tagreement,\twe\tacquired\tpotentially\tdisease-modifying\tAAV9-based\tgene\ttherapies\tfor\tpatients\twith neurodegenerative\tdiseases.\tThe\tacquisition\testablished\ta\tnew\tmodality\tfor\tdrug\tdiscovery\tand\tdevelopment,\textending\tour research\tefforts\tthrough\tthe\tcreation\tof\ta\tgene\ttherapy\tprogram\tthat\tis\tbeing\tanchored\tby\tPrevail's\tportfolio\tof\tassets.\tThe lead\tgene\ttherapies\tin\tclinical\tdevelopment\tthat\twe\tacquired\twere\tPR001\t(GBA1\tGene\tTherapy)\tfor\tpatients\twith\tParkinson's disease\twith\tGBA1\tmutations\tand\tneuronopathic\tGaucher\tdisease\tand\tPR006\tfor\tpatients\twith\tfrontotemporal\tdementia\twith\tGRN mutations.\tBoth\tPR001\tand\tPR006\twere\tgranted\tFast\tTrack\tdesignation\tfrom\tthe\tU.S.\tFood\tand\tDrug\tAdministration.\n\n## Assets\tAcquired\tand\tLiabilities\tAssumed\n\nThe\tfollowing\ttable\tsummarizes\tthe\tamounts\trecognized\tfor\tassets\tacquired\tand\tliabilities\tassumed\tas\tof\tthe\tacquisition\tdate:\n\n",
          "relationship": "Receives"
        },
        "node_3": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_2",
          "chunk_text": "\nIn\tcollaboration\twith\tBoehringer\tIngelheim. (1)\n\nIn\tcollaboration\twith\tAlmirall,\tS.A.\tin\tEurope. (3)\n\nFast\tTrack\tdesignation\tis\tdesigned\tto\tfacilitate\tthe\tdevelopment\tand\texpedite\tthe\treview\tof\tmedicines\tto\ttreat\tserious\tconditions\tand\tfill\tan unmet\tmedical\tneed. (2)\n\nBreakthrough\tTherapy\tdesignation\tis\tdesigned\tto\texpedite\tthe\tdevelopment\tand\treview\tof\tpotential\tmedicines\tthat\tare\tintended\tto\ttreat\ta\tserious condition\twhere\tpreliminary\tclinical\tevidence\tindicates\tthat\tthe\ttreatment\tmay\tdemonstrate\tsubstantial\timprovement\tover\tavailable\ttherapy\ton\ta clinically\tsignificant\tendpoint. (4)\n\nContinued\tapproval\tmay\tbe\tcontingent\ton\tverification\tand\tdescription\tof\tclinical\tbenefit\tin\tconfirmatory\tPhase\tIII\ttrials. (5)\n\nThere\tare\tmany\tdifficulties\tand\tuncertainties\tinherent\tin\tpharmaceutical\tresearch\tand\tdevelopment,\tthe\tintroduction\tof\tnew products\tand\tindications,\tbusiness\tdevelopment\tactivities\tto\tenhance\tor\trefine\tor\tproduct\tpipeline,\tand\tcommercialization\tof our\tproducts.\tThere\tis\ta\thigh\trate\tof\tfailure\tinherent\tin\tdrug\tdiscovery\tand\tdevelopment.\tTo\tbring\ta\tproduct\tfrom\tthe discovery\tphase\tto\tmarket\ttakes\tconsiderable\ttime\tand\tentails\tsignificant\tcost.\tFailure\tcan\toccur\tat\tany\tpoint\tin\tthe process,\tincluding\tin\tlater\tstages\tafter\tsubstantial\tinvestment.\tAs\ta\tresult,\tmost\tfunds\tinvested\tin\tresearch\tand\tdevelopment programs\twill\tnot\tgenerate\tfinancial\treturns.\tNew\tproduct\tcandidates\tthat\tappear\tpromising\tin\tdevelopment\tor\tprior\tto\tbeing acquired\tmay\tfail\tto\treach\tthe\tmarket\tor\tmay\thave\tonly\tlimited\tcommercial\tsuccess\tbecause\tof\tefficacy\tor\tsafety\tconcerns, inability\tto\tobtain\tor\tmaintain\tnecessary\tregulatory\tapprovals\tor\tpayer\treimbursement\tor\tcoverage,\tfailure\tto\tobtain placement\ton\tguidelines\tor\trecommendations\tpublished\tby\tthird-party\torganizations\tthat\tare\tcommensurate\twith\tclinical\tdata, the\tapplication\tof\tpricing\tcontrols,\tlimited\tscope\tof\tapproved\tuses,\tlabel\tchanges,\tchanges\tin\tthe\trelevant\ttreatment standards\tor\tthe\tavailability\tof\tnewer,\tbetter,\tor\tmore\tcost-effective\tcompetitive\tproducts,\tdifficulty\tor\texcessive\tcosts\tto manufacture,\tinsufficient\tinfrastructure\tto\tsupport\tdetection,\tdiagnostic\tor\tother\trequisites\tfor\ttreatment,\tineffectiveness in\treaching\thealthcare\tprofessionals,\tincluding\tdigitally\tgiven\tthe\tincrease\tin\tvirtual\tengagements,\tor\tinfringement\tof\tthe patents\tor\tintellectual\tproperty\trights\tof\tothers.\tWe\tmay\talso\tfail\tto\tallocate\tresearch\tand\tdevelopment\tresources efficiently,\tfail\tto\tpursue\tor\tinvest\tsufficiently\tin\tproduct\tcandidates\tor\tindications\tthat\tmay\thave\tbeen\tsuccessful,\tor fail\tto\toptimally\tbalance\ttrial\tdesign,\tconduct,\tand\tspeed\tto\taccomplish\tdesired\toutcomes.\tRegulatory\tagencies\testablish\thigh hurdles\tfor\tthe\tefficacy\tand\tsafety\tof\tnew\tproducts\tand\tindications.\tDelay,\tuncertainty,\tunpredictability,\tand\tinconsistency in\tdrug\tapproval\tprocesses\tacross\tmarkets\tand\tagencies\tcan\tresult\tin\tdelays\tin\tproduct\tlaunches,\tlost\tmarket\topportunities, impairment\tof\tinventories,\tand\tother\tnegative\timpacts.\tIn\taddition,\tit\tcan\tbe\tvery\tdifficult\tto\tpredict\trevenue\tgrowth\trates of,\tor\tvariability\tin\tdemand\tfor,\tnew\tproducts\tand\tindications\twhich\tin\tsome\tcases\tleads\tto\tdifficulty\tmeeting\tproduct\tdemand or,\ton\tthe\tother\thand,\texcess\tinventory\tand\trelated\tfinancial\tcharges.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 204,
      "question": "How does BMY's exposure to legal risk around patent enforcement on specific products, such as those facing Paragraph IV certifications, reconcile with their strategic reliance on market exclusivity for revenue stability, particularly in light of the potential for early loss of exclusivity and increased generic competition?",
      "answer": "BMY faces legal risks related to patent enforcement, including challenges from generic manufacturers filing ANDAs with Paragraph IV certifications, which could result in substantial revenue declines if exclusivity is lost prematurely. Patents are a key determinant of market exclusivity, which is crucial for realizing commercial value from innovative products. However, BMY acknowledges in their risk factors that there is no assurance that a product will enjoy market exclusivity for the full period disclosed, and generic competition could emerge earlier than expected. This creates a strategic tension between BMY's reliance on patent rights to maintain exclusivity and the reality that such rights may not fully prevent generic competition, especially in markets with weaker patent protections or increasing regulatory pressure to promote generics. The combination of these factors highlights a material risk to BMY\u2019s revenue stability and long-term earnings potential.",
      "reasoning_steps": [
        "Hop 1: BMY(page_114) \u2192 Patent Rights: BMY notes that failure to successfully enforce patent rights would likely result in substantial decreases in product revenues due to generic competition, specifically referencing Paragraph IV certifications as a recurring legal challenge.",
        "Hop 2: Patent Rights \u2192 Market Exclusivity: Patents are described as a key determinant of market exclusivity, which is essential for realizing the commercial value of innovative pharmaceuticals, with specific reference to the Orange Book listing and Paragraph IV certification process.",
        "Hop 3: Market Exclusivity \u2190 BMY(page_28): BMY warns that there is no assurance a product will enjoy market exclusivity for the full time period disclosed, and generic challenges could arise at any time, undermining revenue projections and financial guidance."
      ],
      "difficulty": "hard",
      "idf_score": 5.128494288012563,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> RISK_FACTOR -[Positively_Impacts]-> REGULATORY_REQUIREMENT <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Patent Rights",
        "node_3": "Market Exclusivity",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_114",
          "chunk_id": "chunk_4",
          "chunk_text": "\nThe\taggregate\tintrinsic\tvalue\tin\tthe\tpreceding\ttable\trepresents\tthe\ttotal\tpretax\tintrinsic\tvalue,\tbased\ton\tthe\tclosing\tstock price\tof\t$51.31\ton\tDecember\t29,\t2023,\twhich\twas\tthe\tlast\ttrading\tday\tof\t2023.\n\n## Note\t20.\tLEGAL\tPROCEEDINGS\tAND\tCONTINGENCIES\n\nBMS\t and\t certain\t of\t its\t subsidiaries\t are\t involved\t in\t various\t lawsuits,\t claims,\t government\t investigations\t and\t other\t legal proceedings\tthat\tarise\tin\tthe\tordinary\tcourse\tof\tbusiness.\tThese\tclaims\tor\tproceedings\tcan\tinvolve\tvarious\ttypes\tof\tparties, including\t governments,\t competitors,\t customers,\t partners,\t suppliers,\t service\t providers,\t licensees,\t licensors,\t employees,\t or shareholders,\t among\t others.\t These\t matters\t may\t involve\t patent\t infringement,\t antitrust,\t securities,\t pricing,\t sales\t and marketing\t practices,\t environmental,\t commercial,\t contractual\t rights,\t licensing\t obligations,\t health\t and\t safety\t matters, consumer\tfraud,\temployment\tmatters,\tproduct\tliability\tand\tinsurance\tcoverage,\tamong\tothers.\tThe\tresolution\tof\tthese\tmatters often\t develops\t over\t a\t long\t period\t of\t time\t and\t expectations\t can\t change\t as\t a\t result\t of\t new\t findings,\t rulings,\t appeals\t or settlement\tarrangements.\tLegal\tproceedings\tthat\tare\tsignificant\tor\tthat\tBMS\tbelieves\tcould\tbecome\tsignificant\tor\tmaterial\tare described\tbelow.\n\nWhile\tBMS\tdoes\tnot\tbelieve\tthat\tany\tof\tthese\tmatters,\texcept\tas\totherwise\tspecifically\tnoted\tbelow,\twill\thave\ta\tmaterial adverse\t effect\t on\t its\t financial\t position\t or\t liquidity\t as\t BMS\t believes\t it\t has\t substantial\t claims\t and/or\t defenses\t in\t the matters,\t the\t outcomes\t of\t BMS's\t legal\t proceedings\t and\t other\t contingencies\t are\t inherently\t unpredictable\t and\t subject\t to significant\tuncertainties.\tThere\tcan\tbe\tno\tassurance\tthat\tthere\twill\tnot\tbe\tan\tincrease\tin\tthe\tscope\tof\tone\tor\tmore\tof\tthese pending\tmatters\tor\tany\tother\tor\tfuture\tlawsuits,\tclaims,\tgovernment\tinvestigations\tor\tother\tlegal\tproceedings\twill\tnot\tbe material\tto\tBMS's\tfinancial\tposition,\tresults\tof\toperations\tor\tcash\tflows\tfor\ta\tparticular\tperiod.\tFurthermore,\tfailure\tto successfully\tenforce\tBMS's\tpatent\trights\twould\tlikely\tresult\tin\tsubstantial\tdecreases\tin\tthe\trespective\tproduct\trevenues\tfrom generic\tcompetition.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Patent_Rights",
          "name": "Patent Rights",
          "type": "RISK_FACTOR",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "In\t the\t pharmaceutical\t industry,\t the\t majority\t of\t an\t innovative\t product's\t commercial\t value\t is\t usually\t realized\t during\t the period\tin\twhich\tthe\tproduct\thas\tmarket\texclusivity.\tA\tproduct's\tmarket\texclusivity\tis\tgenerally\tdetermined\tby\ttwo\tforms\tof intellectual\t property:\t patent\t rights\t held\t by\t the\t innovator\t company\t and\t any\t regulatory\t forms\t of\t exclusivity\t to\t which\t the innovative\tdrug\tis\tentitled.\n\nPatents\tare\ta\tkey\tdeterminant\tof\tmarket\texclusivity\tfor\tmost\tbranded\tpharmaceuticals.\tPatents\tprovide\tthe\tinnovator\twith\tthe right\tto\texclude\tothers\tfrom\tpracticing\tan\tinvention\trelated\tto\tthe\tmedicine.\tPatents\tmay\tcover,\tamong\tother\tthings,\tthe active\tingredient(s),\tvarious\tuses\tof\ta\tdrug\tproduct,\tpharmaceutical\tformulations,\tdrug\tdelivery\tmechanisms\tand\tprocesses\tfor (or\tintermediates\tuseful\tin)\tthe\tmanufacture\tof\tproducts.\tProtection\tfor\tindividual\tproducts\textends\tfor\tvarying\tperiods\tin accordance\twith\tthe\texpiration\tdates\tof\tpatents\tin\tthe\tvarious\tcountries.\tThe\tprotection\tafforded,\twhich\tmay\talso\tvary\tfrom country\tto\tcountry,\tdepends\tupon\tthe\ttype\tof\tpatent,\tits\tscope\tof\tcoverage\tand\tthe\tavailability\tof\tmeaningful\tlegal\tremedies in\tthe\tcountry.\n\nMarket\texclusivity\tis\talso\tsometimes\tprovided\tby\tRDP,\ta\tperiod\tof\ttime\tafter\tthe\tapproval\tof\ta\tnew\tdrug\tduring\twhich\tthe regulatory\tagency\tmay\tnot\trely\tupon\tthe\tinnovator's\tdata\tto\tapprove\ta\tcompetitor's\tgeneric\tcopy.\tMany\tdeveloped\tcountries provide\tcertain\tnon-patent\tincentives\tfor\tthe\tdevelopment\tof\tmedicines.\tFor\texample,\tin\tthe\tU.S.,\tEU,\tJapan\tand\tcertain\tother countries,\tRDP\texclusivity\trights\tare\toffered\tas\tincentives\tfor\tresearch\ton\tmedicines\tfor\trare\tdiseases,\tor\torphan\tdrugs,\tand on\tmedicines\tuseful\tin\ttreating\tpediatric\tpatients.\tThese\tincentives\tcan\tprovide\ta\tmarket\texclusivity\tperiod\ton\ta\tproduct that\texpires\tbeyond\tthe\tpatent\tterm.\n\nWhen\tthese\tpatent\trights\tand\tother\tforms\tof\texclusivity\texpire\tand\tgeneric\tversions\tof\ta\tmedicine\tare\tapproved\tand\tmarketed, there\tare\toften\tsubstantial\tand\trapid\tdeclines\tin\tthe\tsales\tof\tthe\toriginal\tinnovative\tproduct.\tFor\tfurther\tdiscussion\tof\tthe impact\tof\tgeneric\tmedicines\ton\tour\tbusiness,\trefer\tto\t'-Competition'\tbelow.\n\nSpecific\taspects\tof\tthe\tlaw\tgoverning\tmarket\tpatent\tprotection\tand\tRDP\tfor\tpharmaceuticals\tvary\tfrom\tcountry\tto\tcountry.\tThe following\tsummarizes\tkey\texclusivity\trules\tin\tmarkets\trepresenting\tsignificant\tsales:\n\n## United\tStates\n\nIn\tthe\tU.S.,\tmost\tof\tour\tkey\tproducts\tare\tprotected\tby\tpatents\twith\tvarying\tterms\tdepending\ton\tthe\ttype\tof\tpatent\tand\tthe filing\tdate.\tA\tsignificant\tportion\tof\ta\tproduct's\tpatent\tlife,\thowever,\tis\tlost\tduring\tthe\ttime\tit\ttakes\tan\tinnovator\tcompany to\tdevelop\tand\tobtain\tregulatory\tapproval\tof\ta\tnew\tdrug.\tAs\tcompensation\tat\tleast\tin\tpart\tfor\tthe\tlost\tpatent\tterm\tdue\tto regulatory\t review\t periods,\t the\t innovator\t may,\t depending\t on\t a\t number\t of\t factors,\t apply\t to\t the\t government\t to\t restore\t lost patent\tterm\tby\textending\tthe\texpiration\tdate\tof\tone\tpatent\tup\tto\ta\tmaximum\tterm\tof\tfive\tyears,\tprovided\tthat\tthe\textension cannot\tcause\tthe\tpatent\tto\tbe\tin\teffect\tfor\tmore\tthan\t14\tyears\tfrom\tthe\tdate\tof\tdrug\tapproval.\n\nA\tcompany\tseeking\tto\tmarket\tan\tinnovative\tpharmaceutical\tin\tthe\tU.S.\tmust\tsubmit\ta\tcomplete\tset\tof\tsafety\tand\tefficacy\tdata to\tthe\tFDA.\tIf\tthe\tinnovative\tpharmaceutical\tis\ta\tchemical\tproduct,\tthe\tcompany\tfiles\tan\tNDA.\tIf\tthe\tmedicine\tis\ta\tbiological product,\ta\tBLA\tis\tfiled.\tBoth\ttypes\tof\tapplications\tcan\treceive\tcertain\tperiods\tof\tregulatory\texclusivity.\tAn\tNDA\tor\ta\tBLA for\ta\tcompound\tthat\tis\tdesignated\tas\tan\torphan\tdrug\tcan\treceive\tseven\tyears\tof\texclusivity\tfor\tan\torphan\tdrug\tindication. During\tthis\tperiod,\tthe\tFDA\tgenerally\tmay\tnot\tapprove\tanother\tapplication\tfor\tthe\tsame\tdrug\tproduct\tfor\tthe\tsame\torphan\tuse. A\tcompany\tmay\talso\tearn\tsix\tmonths\tof\tadditional\texclusivity\tfor\ta\tdrug\twhere\tspecific\tclinical\tstudies\tare\tconducted\tat\tthe written\trequest\tof\tthe\tFDA\tto\tstudy\tthe\tuse\tof\tthe\tmedicine\tto\ttreat\tpediatric\tpatients,\tand\tsubmission\tto\tthe\tFDA\tis\tmade prior\t to\t the\t loss\t of\t basic\t exclusivity.\t The\t type\t of\t application\t filed\t (NDA\t or\t BLA)\t can\t affect\t RDP\t exclusivity\t rights\t as discussed\tbelow.\n\n## Chemical\tproducts\n\nA\tcompetitor\tseeking\tto\tlaunch\ta\tgeneric\tsubstitute\tof\ta\tchemical\tinnovative\tdrug\tin\tthe\tU.S.\tmust\tfile\tan\tANDA\twith\tthe\tFDA. In\t the\t ANDA,\t the\t generic\t manufacturer\t needs\t to\t demonstrate\t only\t 'bioequivalence'\t between\t the\t generic\t substitute\t and\t the approved\tNDA\tdrug.\tThe\tANDA\trelies\tupon\tthe\tsafety\tand\tefficacy\tdata\tpreviously\tfiled\tby\tthe\tinnovator\tin\tits\tNDA.\n\nAn\tinnovator\tcompany\tis\trequired\tto\tlist\tcertain\tof\tits\tpatents\tcovering\tthe\tmedicine\twith\tthe\tFDA\tin\twhat\tis\tcommonly\tknown as\tthe\tOrange\tBook.\tAbsent\ta\tsuccessful\tpatent\tchallenge,\tthe\tFDA\tcannot\tapprove\tan\tANDA\tuntil\tafter\tthe\tinnovator's\tlisted patents\texpire.\tHowever,\tafter\tthe\tinnovator\thas\tmarketed\tits\tproduct\tfor\tfour\tyears,\ta\tgeneric\tmanufacturer\tmay\tfile\tan\tANDA and\tallege\tthat\tone\tor\tmore\tof\tthe\tpatents\tlisted\tin\tthe\tOrange\tBook\tunder\tan\tinnovator's\tNDA\tis\tinvalid,\tunenforceable,\tor will\t not\t be\t infringed\t by\t the\t generic\t product.\t This\t allegation\t is\t commonly\t known\t as\t a\t Paragraph\t IV\t certification.\t The innovator\tthen\tmust\tdecide\twhether\tto\tfile\ta\tpatent\tinfringement\tsuit\tagainst\tthe\tgeneric\tmanufacturer.\tFrom\ttime\tto\ttime, ANDAs\tincluding\tParagraph\tIV\tcertifications\tare\tfiled\twith\trespect\tto\tcertain\tof\tour\tproducts.\tWe\tevaluate\tthese\tANDAs\ton\ta case-by-case\tbasis\tand,\twhere\twarranted,\tfile\tsuit\tagainst\tthe\tgeneric\tmanufacturer\tto\tprotect\tour\tpatent\trights.",
          "relationship": "Positively_Impacts"
        },
        "node_3": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "and\twe\tare\tnot\table\tto\tpredict\twhether\ta\tfinal\trule\twill\tbe\tadopted\talong\tthe\tlines\tproposed\tand,\tif\tadopted,\twhether\tthe government\twould\tseek\tto\texercise\tmarch-in\trights\tfor\tany\tof\tour\tproducts.\n\nThere\tis\tno\tassurance\tthat\ta\tparticular\tproduct\twill\tenjoy\tmarket\texclusivity\tfor\tthe\tfull\ttime\tperiod\tthat\tappears\tin\tthe estimates\tdisclosed\tin\tthis\t2023\tForm\t10-K\tor\tthat\twe\tassume\twhen\twe\tprovide\tour\tfinancial\tguidance.\n\n## We\tface\tintense\tcompetition\tfrom\tother\tmanufacturers\tand\texpect\tto\tsee\tincreasing\tmarket\tpenetration\tof\tlower-priced\tgeneric products.\n\nThe\t future\t growth\t of\t BMS\t is\t dependent\t on\t the\t market\t access,\t uptake\t and\t expansion\t for\t marketed\t brands,\t new\t product introductions,\tnew\tindications,\tproduct\textensions\tand\tco-promotional\tactivities\twith\talliance\tpartners.\tCompetition\tis\tkeen and\t as\t we\t lose\t exclusivity\t for\t some\t of\t our\t marketed\t brands\t lower-priced\t generic\t products\t will\t increasingly\t penetrate\t our markets.\tGeneric\tchallenges\tto\tour\tproducts\tcan\talso\tarise\tat\tany\ttime,\tand\tour\tpatents\tmay\tnot\tprevent\tthe\temergence\tof generic\tcompetition\tfor\tour\tproducts.\tIn\tsome\tcountries,\tpatent\tprotection\tis\tsignificantly\tweaker\tthan\tin\tthe\tU.S.\tor\tin\tthe EU;\t political\t and\t social\t pressure\t has\t also\t pushed\t legislation\t and\t other\t measures\t that\t promote\t the\t use\t of\t generic\t and biosimilar\tproducts.\tFor\tadditional\tinformation,\tsee\t'Item\t1A.\tRisk\tFactors-We\tcould\tlose\tmarket\texclusivity\tof\ta\tproduct earlier\tthan\texpected.'\n\nIn\taddition,\twe\tface\tcompetition\tfrom\tnew\tproducts\tentering\tthe\tmarket,\tparticularly\tin\tIO.\tNew\tproducts\tmay\thave\t(i)\tlower prices,\t (ii)\t superior\t efficacy\t (benefit)\t or\t safety\t (risk)\t profiles\t (whether\t actual\t or\t perceived),\t (iii)\t technological advantages\tthat\tmay\tmake\tsuch\tproducts\tmore\tconvenient\tto\tuse,\t(iv)\tbetter\tinsurance\tcoverage\tor\treimbursement\tlevels,\t(v) more\teffective\tmarketing\tprograms\tand/or\tother\tdifferentiating\tfactors\tthat\tmake\tit\tharder\tfor\tour\tproducts\tto\tcompete.\tWe cannot\t predict\t with\t accuracy\t the\t timing\t or\t impact\t of\t the\t introduction\t of\t competitive\t products\t that\t treat\t diseases\t and conditions\tlike\tthose\ttreated\tby\tour\tproducts\tand\tproduct\tcandidates.\tBusiness\tcombinations\tamong\tour\tcompetitors\tand\tmajor third-party\t payers\t may\t also\t increase\t competition\t for\t our\t products.\t If\t we\t are\t unable\t to\t compete\t successfully\t against\t our competitors'\tproducts\tin\tthe\tmarketplace,\tthis\tcould\thave\ta\tmaterial\tnegative\timpact\ton\tour\trevenues\tand\tearnings.\n\n## We\tcould\texperience\tdifficulties,\tdelays\tand\tdisruptions\tin\tour\tsupply\tchain\tas\twell\tas\tin\tthe\tmanufacturing,\tdistribution and\tsale\tof\tour\tproducts.\n\nOur\tproduct\tsupply\tand\trelated\tpatient\taccess\thas\tbeen,\tand\tcould\tin\tthe\tfuture\tbe,\tnegatively\timpacted\tby\tdifficulties, delays\t and\t disruptions\t in\t the\t manufacturing,\t distribution\t and\t sale\t of\t our\t products.\t Some\t of\t the\t difficulties,\t delays\t and disruptions\tinclude:\t(i)\tproduct\tseizures\tor\trecalls\tor\tforced\tclosings\tof\tmanufacturing\tplants;\t(ii)\tour\tfailure,\tor\tthe failure\t of\t any\t of\t our\t vendors\t or\t suppliers,\t to\t comply\t with\t cGMP\t and\t other\t applicable\t regulations\t or\t quality\t assurance guidelines\t that\t could\t lead\t to\t manufacturing\t shutdowns,\t product\t shortages\t or\t delays\t in\t product\t manufacturing;\t (iii) manufacturing,\t quality\t assurance/quality\t control,\t supply\t problems\t or\t governmental\t approval\t delays;\t (iv)\t the\t failure\t of\t a supplier,\t including\t sole\t source\t or\t single\t source\t suppliers,\t to\t provide\t us\t with\t the\t necessary\t raw\t materials,\t supplies\t or finished\t goods\t within\t a\t reasonable\t timeframe\t and\t with\t required\t quality;\t (v)\t the\t failure\t of\t a\t third-party\t manufacturer\t to supply\tus\twith\tbulk\tactive\tor\tfinished\tproduct\ton\ttime;\t(vi)\tconstruction\tor\tregulatory\tapproval\tdelays\tfor\tnew\tfacilities\tor the\texpansion\tof\texisting\tfacilities,\tincluding\tthose\tintended\tto\tsupport\tfuture\tdemand\tfor\tour\tbiologics\tproducts,\tsuch\tas Opdivo;\t(vii)\tthe\tfailure\tto\tmeet\tnew\tand\temerging\tregulations\trequiring\tproducts\tto\tbe\ttracked\tthroughout\tthe\tdistribution channels\t using\t unique\t identifiers\t to\t verify\t their\t authenticity\t in\t the\t supply\t chain;\t (viii)\t other\t manufacturing\t or distribution\t issues,\t including\t limits\t to\t manufacturing\t capacity\t and\t changes\t in\t the\t types\t of\t products\t produced,\t such\t as biologics,\tphysical\tlimitations,\tlabor\tdisputes\tor\tshortages,\tor\tother\tbusiness\tinterruptions;\tand\t(ix)\tdisruptions\tin\tsupply chain\tcontinuity,\tincluding\tfrom\tmarket\tforces\t(such\tas\tthe\trecent\tstress\ton\tglobal\tlogistics),\tnatural\tdisasters,\tglobal disease\toutbreaks\tor\tpandemics\t(including\tCOVID-19),\tacts\tof\twar\tor\tterrorism\tor\tother\tunforeseeable\tor\tunavoidable\tevents that\tmaterially\timpact\tone\tor\tmore\tof\tour\tfacilities\tor\ta\tcritical\tsupplier.\n\nIn\taddition,\tmanufacturing\tprocesses\tfor\tnovel\tcell-based\ttherapies,\tsuch\tas\tCAR-T\tcell\ttherapies,\tare\tstill\tevolving,\tand our\tprocesses\tmay\tbe\tmore\tcomplicated\tor\tmore\texpensive\tthan\tthe\tapproaches\ttaken\tby\tour\tcurrent\tand\tfuture\tcompetitors.\tOur ability\t to\t source\t raw\t materials\t and\t supplies\t used\t to\t manufacture\t our\t CAR-T\t cell\t therapies\t and\t to\t develop\t consistent\t and reliable\tmanufacturing\tprocesses\tand\tdistribution\tnetworks\twith\tan\tattractive\tcost\tof\tgoods\tcould\timpact\tfuture\tanticipated revenue\tand\tgross\tprofit\tfor\tour\tCAR-T\tcell\ttherapies.\tFurthermore,\twe\tmay\tface\tchallenges\twith\tsourcing\traw\tmaterials\tand supplies\tfor\tclinical\tand,\tif\tapproved,\tcommercial\tmanufacturing.\tLogistical\tand\tshipment\tdelays\tand\tother\tfactors\tnot\tin\tour control\tcould\tprevent\tor\tdelay\tthe\tdelivery\tof\tour\tproduct\tcandidates\tand\tmarketed\tproducts\tto\tpatients.\tAdditionally,\twe\tare required\tto\tmaintain\ta\tcomplex\tchain\tof\tidentity\tand\tcustody\twith\trespect\tto\tpatient\tmaterial\tas\tsuch\tmaterial\tenters\tinto and\tmoves\tthrough\tthe\tmanufacturing\tprocess.\tAs\ta\tresult,\teven\tslight\tdeviations\tat\tany\tpoint\tin\tthe\tproduction\tprocess\tfor our\t CAR-T\t cell\t therapies\t or\t in\t material\t used\t in\t our\t CAR-T\t cell\t therapies\t could\t result\t in\t loss\t of\t product\t or\t regulatory remedial\taction,\twhich\tcould\tadversely\taffect\tour\tfuture\tanticipated\trevenues\tand/or\tprofitability\trelated\tto\tour\tCAR-T\tcell therapies.",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 205,
      "question": "How does Eli Lilly's reliance on data protection for Reyvow\u00ae align with their broader intellectual property strategy, particularly given the acknowledged unpredictability of maintaining market exclusivity due to patent litigation and regulatory interactions?",
      "answer": "Eli Lilly emphasizes the importance of intellectual property protection across its portfolio, noting on page 11 that market exclusivity can be difficult to predict due to the complex interplay between patent and regulatory protections, as well as uncertainties in patent litigation. Despite this, the company relies on both compound patents and data protection for Reyvow\u00ae, with data protection set to expire in 2032 in major European countries and Japan. This indicates a strategic use of regulatory exclusivity to extend commercial advantages beyond patent coverage, even while acknowledging the risks of relying on such protections in a litigious and evolving regulatory environment.",
      "reasoning_steps": [
        "Hop 1: [LLY](page_11) \u2192 [Data Protection]: The company highlights the importance of data protection as part of its IP strategy but notes the unpredictability of market exclusivity due to litigation and regulatory interactions.",
        "Hop 2: [Data Protection] \u2192 [Reyvow \u00ae]: Reyvow\u00ae benefits from data protection in Europe and Japan, with expiry dates in 2032, indicating strategic reliance on this form of IP for market exclusivity.",
        "Hop 3: [Reyvow \u00ae] \u2190 [LLY](page_13): Reyvow\u00ae is listed among key neuroscience products with defined IP expiry dates, showing how the company structures its lifecycle management around both patents and regulatory protections."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT -[Subject_To]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Data Protection",
        "node_3": "Reyvow \u00ae",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Our Intellectual Property Portfolio\n\nWe consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, dev ices, or uses that prov ide protection beyond the estimated dates shown below. For approv ed products, estimated dates include, where applicable, pending or granted patent term extensions. Where granted, estimated dates for approv ed products also reflect pediatric or orphan drug exclusiv ity. The length of market exclusiv ity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusiv ity and the inherent uncertainties regarding patent litigation. There can be no assurance that a particular product will maintain market exclusiv ity for the duration of the estimated expiry or that exclusiv ity will be limited to that time frame.\n\nThe most relev ant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:\n\n",
          "relationship": "Complies_With"
        },
        "node_2": {
          "id": "Data_Protection",
          "name": "Data Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Reyvow_\u00ae",
          "name": "Reyvow \u00ae",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Therapeutic Area      | Product   | Protection                | Territory                |   Estimated Expiry Date |\n|-----------------------|-----------|---------------------------|--------------------------|-------------------------|\n| Neuroscience products | Emgality  | compound patent           | U.S.                     |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | major European countries |                    2033 |\n| Neuroscience products | Emgality  | compound patent           | Japan                    |                    2035 |\n| Neuroscience products | Emgality  | biologics data protection | U.S.                     |                    2030 |\n| Neuroscience products | Emgality  | data protection           | major European countries |                    2028 |\n| Neuroscience products | Emgality  | data protection           | Japan                    |                    2029 |\n| Neuroscience products | Kisunla   | compound patent           | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | compound patent           | Japan                    |                    2036 |\n| Neuroscience products | Kisunla   | biologics data protection | U.S.                     |                    2036 |\n| Neuroscience products | Kisunla   | data protection           | Japan                    |                    2032 |\n| Neuroscience products | Reyvow    | compound patent           | U.S.                     |                    2028 |\n| Neuroscience products | Reyvow    | compound patent           | Japan                    |                    2028 |\n| Neuroscience products | Reyvow    | data protection           | major European countries |                    2032 |\n| Neuroscience products | Reyvow    | data protection           | Japan                    |                    2032 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 206,
      "question": "How does the financial performance of Eliquis, which contributed $13.3 billion in revenue for BMY in 2024, align with the strategic partnership structure involving Pfizer, where BMS supplies the product at cost plus a percentage of net sales in certain smaller countries?",
      "answer": "Eliquis generated $13.3 billion in total revenue for BMY in 2024, with $9.6 billion coming from the U.S. and $3.7 billion from non-U.S. markets. Under the co-commercialization agreement with Pfizer, BMS is the principal in end-customer sales in major markets, including the U.S., Europe, Canada, Australia, China, Japan, and South Korea. In smaller countries, Pfizer has full commercialization rights, and BMS supplies the product at cost plus a percentage of net sales, which is recorded in full upon transfer of control to Pfizer. This structure suggests that while BMS retains significant control and revenue generation in major markets, its financial exposure and operational involvement in smaller markets are more limited, potentially affecting overall profitability and strategic prioritization of Eliquis in those regions.",
      "reasoning_steps": [
        "Hop 1: BMY(page_51) \u2192 Eliquis: Eliquis generated $13.3 billion in total revenue for BMY in 2024, with $9.6 billion from the U.S. and $3.7 billion from non-U.S. markets.",
        "Hop 2: Eliquis \u2192 Pfizer: BMS and Pfizer co-commercialize Eliquis, with BMS supplying the product at cost plus a percentage of net sales in smaller countries, where Pfizer holds full commercialization rights.",
        "Hop 3: Pfizer \u2190 BMY(page_134): Pfizer is listed as a key partner in BMY\u2019s 2024 10-K, indicating the strategic importance of the alliance and the structured financial and operational responsibilities between the two companies."
      ],
      "difficulty": "hard",
      "idf_score": 5.721306120841433,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Increases]-> PRODUCT -[Supplies]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Eliquis",
        "node_3": "Pfizer",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_51",
          "chunk_id": "chunk_1",
          "chunk_text": "| Dollars in millions       | 2024     | 2023     | %Change   |     |\n|---------------------------|----------|----------|-----------|-----|\n| Growth Portfolio (cont.)  |          |          |           |     |\n| Cobenfy                   | 10       | -        |           | N/A |\n| U.S.                      | 10       | -        |           | N/A |\n| Non-U.S.                  | -        | -        |           | N/A |\n| Other Growth Products (a) | 1,605    | 1,211    | 33        | %   |\n| U.S.                      | 674      | 620      | 9         | %   |\n| Non-U.S.                  | 931      | 591      | 58        | %   |\n| Total Growth Portfolio    | $ 22,563 | $ 19,366 | 17        | %   |\n| U.S.                      | 14,840   | 12,736   | 17        | %   |\n| Non-U.S.                  | 7,723    | 6,630    | 16        | %   |\n| Legacy Portfolio          |          |          |           |     |\n| Eliquis                   | $ 13,333 | $ 12,206 | 9         | %   |\n| U.S.                      | 9,631    | 8,482    | 14        | %   |\n| Non-U.S.                  | 3,702    | 3,724    | (1)       | %   |\n| Revlimid                  | 5,773    | 6,097    | (5)       | %   |\n| U.S.                      | 4,999    | 5,195    | (4)       | %   |\n| Non-U.S.                  | 774      | 902      | (14)      | %   |\n| Pomalyst/Imnovid          | 3,545    | 3,441    | 3         | %   |\n| U.S.                      | 2,695    | 2,339    | 15        | %   |\n| Non-U.S.                  | 850      | 1,102    | (23)      | %   |\n| Sprycel                   | 1,286    | 1,930    | (33)      | %   |\n| U.S.                      | 983      | 1,422    | (31)      | %   |\n| Non-U.S.                  | 303      | 508      | (40)      | %   |\n| Abraxane                  | 875      | 1,004    | (13)      | %   |\n| U.S.                      | 541      | 702      | (23)      | %   |\n| Non-U.S.                  | 334      | 302      | 11        | %   |\n| Other Legacy Products (b) | 925      | 962      | (4)       | %   |\n| U.S.                      | 416      | 334      | 25        | %   |\n| Non-U.S.                  | 509      | 628      | (19)      | %   |\n| Total Legacy Portfolio    | $ 25,737 | $ 25,640 | -         | %   |\n| U.S.                      | 19,265   | 18,474   | 4         | %   |\n| Non-U.S.                  | 6,472    | 7,166    | (10)      | %   |\n| Total Revenues            | $ 48,300 | $ 45,006 | 7         | %   |\n| U.S.                      | 34,105   | 31,210   | 9         | %   |\n",
          "relationship": "Increases"
        },
        "node_2": {
          "id": "Eliquis",
          "name": "Eliquis",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_1",
          "chunk_text": "The co-exclusive license rights granted to Pfizer in exchange for an upfront payment and potential milestone payments were recorded to Deferred income and are being  amortized  in  Other  (income)/ex pense,  net,  as Eliquis was not a commercial product at the commencement of the alliance.  The upfront payment and any subsequent contingent milestone proceeds are amortized over the expected period of BMS's co-promotion obligation through the market exclusivity period. Both parties assumed certain obligations to actively participate in a joint ex ecutive committee and various other operating committees and have joint responsibilities for the research, development, distribution, sales and marketing activities of the alliance using resources in their own infrastructures.  BMS and  Pfizer manufacture the product in the alliance and BMS is the principal in the end customer product sales in the U.S., significant countries in Europe, as well as Canada, Australia, China, Japan and South Korea. In certain smaller countries, Pfizer has full commercialization rights and BMS supplies the product to Pfizer at cost plus a percentage of the net sales price to end-customers, which is recorded in full upon transfer of control of the product to Pfizer.\n\nSummarized financial information related to this alliance was as follows:\n\n",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "Pfizer",
          "name": "Pfizer",
          "type": "COMP",
          "idf_score": 4.8689320747222204
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 207,
      "question": "How does Merck's acquisition of Peloton Therapeutics in 2019 align with the subsequent commercialization and milestone payments tied to Welireg following its FDA approval in August 2021?",
      "answer": "Merck's 2019 acquisition of Peloton Therapeutics provided access to Welireg, an oral HIF-2\u03b1 inhibitor, which received FDA approval in August 2021 for treating adult patients with VHL disease. Following this approval, Merck paid a $50 million milestone payment to former Peloton shareholders, with potential for additional payments tied to U.S. regulatory approvals for combination therapy and up to $1.05 billion in sales-based milestones. This demonstrates how the strategic acquisition of Peloton was directly linked to the development and commercial success of Welireg, as the product's regulatory progress triggered financial obligations and opportunities tied to its lifecycle management.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_59) \u2192 [Peloton Therapeutics, Inc.]: Merck acquired Peloton in 2019, gaining rights to Welireg.",
        "Hop 2: [Peloton Therapeutics, Inc.] \u2192 [Welireg]: Peloton's lead candidate, Welireg, was the key asset transferred to Merck through the acquisition.",
        "Hop 3: [Welireg] \u2190 [MRK](page_101): Following Welireg's FDA approval in August 2021, Merck made a $50 million milestone payment to former Peloton shareholders, with potential for additional payments."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> COMP -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Peloton Therapeutics,Inc.",
        "node_3": "Welireg",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndecreased 63% in 2020 primarily due to lower demand and pricing in the U.S. due to generic competition for Emend for Injection following U.S. patent expiry in September 2019. Also contributing to the Emend sales decline in 2020 was lower demand in Europe and Japan as a result of generic competition for the oral formulation of Emend following loss of market exclusivity in May 2019 and December 2019, respectively.\n\nIn June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive  results  from  the  National  Cancer  Institute  Cancer  Therapy  Evaluation  Program-sponsored  SPRINT  Stratum  1  trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration with AstraZeneca referenced above that includes Lynparza.\n\nIn August  2021,  the  FDA  approved Welireg ,  an  oral  HIF-2\u03b1  inhibitor,  for  the  treatment  of  adult  patients  with  VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. Welireg was obtained as part of Merck's 2019 acquisition of Peloton Therapeutics, Inc. (Peloton). See Note 4 to the consolidated financial statements.\n\n## Vaccines\n\n",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "Peloton_Therapeutics,Inc.",
          "name": "Peloton Therapeutics,Inc.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndecreased 63% in 2020 primarily due to lower demand and pricing in the U.S. due to generic competition for Emend for Injection following U.S. patent expiry in September 2019. Also contributing to the Emend sales decline in 2020 was lower demand in Europe and Japan as a result of generic competition for the oral formulation of Emend following loss of market exclusivity in May 2019 and December 2019, respectively.\n\nIn June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive  results  from  the  National  Cancer  Institute  Cancer  Therapy  Evaluation  Program-sponsored  SPRINT  Stratum  1  trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration with AstraZeneca referenced above that includes Lynparza.\n\nIn August  2021,  the  FDA  approved Welireg ,  an  oral  HIF-2\u03b1  inhibitor,  for  the  treatment  of  adult  patients  with  VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. Welireg was obtained as part of Merck's 2019 acquisition of Peloton Therapeutics, Inc. (Peloton). See Note 4 to the consolidated financial statements.\n\n## Vaccines\n\n",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "Welireg",
          "name": "Welireg",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\ndate, as well as Research and development expenses of $993 million in 2019 related to the transaction. Former Peloton shareholders received a $50 million milestone payment from Merck in 2021 upon first commercial sale of Peloton's lead candidate, Welireg (belzutifan),  which  was  approved as monotherapy in the U.S. in August 2021. Former Peloton shareholders are also eligible to receive  $50  million  upon  U.S.  regulatory  approval  as  a  combination  therapy,  as  well  as  up  to  $1.05  billion  of  sales-based milestones.\n\nOn April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq's debt. The transaction was accounted for as a business combination.\n\nThe estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:\n\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 208,
      "question": "Given that Yervoy's estimated market exclusivity in the U.S. ends in 2025, how does BMY's strategic focus on expanding the use of Opdivo in combination with Yervoy align with their long-term oncology growth plans, especially considering ongoing efforts to broaden Opdivo into new tumor types and earlier lines of therapy?",
      "answer": "BMY faces an impending loss of market exclusivity for Yervoy in the U.S. in 2025, which could threaten revenue from the Opdivo + Yervoy regimen. However, BMY's strategy emphasizes expanding Opdivo\u2019s use across new tumor types and earlier lines of therapy, both as a monotherapy and in combination with Yervoy and other agents. This suggests a deliberate effort to extend the commercial lifecycle of the combination therapy by increasing its applicability and adoption before Yervoy\u2019s exclusivity expires. Additionally, BMY is advancing next-wave oncology mechanisms and developing treatment options for refractory patients, indicating a broader plan to maintain oncology leadership despite the looming Yervoy patent expiration.",
      "reasoning_steps": [
        "Hop 1: BMY(page_8) \u2192 Yervoy: Yervoy's U.S. market exclusivity is set to expire in 2025, signaling a near-term risk to revenue from the drug and its combination therapies.",
        "Hop 2: Yervoy \u2192 Opdivo: Yervoy is frequently used in combination with Opdivo across multiple oncology indications, as noted in the product descriptions and treatment regimens.",
        "Hop 3: Opdivo \u2190 BMY(page_43): BMY's strategic focus includes expanding Opdivo into new tumor types and earlier lines of therapy, both as monotherapy and in combination with Yervoy and other agents, to drive long-term oncology growth."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Combines_With]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Yervoy",
        "node_3": "Opdivo",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                              | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   | Estimated Minimum Market Exclusivity Date   |\n|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|\n|                                              | U.S.                                        | EU (p)                                      | Japan                                       |\n| Abecma (idecabtagene vicleucel)              | 2036                                        | 2035                                        | 2035                                        |\n| Abraxane (paclitaxel) (a)                    | ^^                                          | ^^                                          | ^^                                          |\n| Augtyro (repotrectinib) (b)                  | 2035                                        | ++                                          | ++                                          |\n| Breyanzi (lisocabtagene maraleucel) (c)      | 2033                                        | 2033                                        | 2033                                        |\n| Camzyos (mavacamten) (d)                     | 2034                                        | 2034                                        | ++                                          |\n| Eliquis (apixaban) (e)                       | 2026                                        | ^^                                          | 2026                                        |\n| Inrebic (fedratinib) (f)                     | 2031                                        | 2031                                        | ++                                          |\n| Onureg (azacitidine) (g)                     | 2027                                        | ^^                                          | ++                                          |\n| Opdivo (nivolumab)                           | 2028                                        | 2030                                        | 2031                                        |\n| Opdualag (nivolumab and relatlimab-rmbw) (h) | 2034                                        | 2033                                        | ++                                          |\n| Orencia (abatacept) (i)                      | ^^                                          | ^^                                          | ^^                                          |\n| Pomalyst/Imnovid (pomalidomide) (j)          | ^^                                          | 2024                                        | ^^                                          |\n| Reblozyl (luspatercept-aamt) (k)             | 2031                                        | 2030                                        | ++                                          |\n| Revlimid (lenalidomide) (l)                  | ^^                                          | ^^                                          | ^^                                          |\n| Sotyktu (deucravacitinib) (m)                | 2033                                        | 2033                                        | 2033                                        |\n| Sprycel (dasatinib) (n)                      | ^^                                          | ^^                                          | ^^                                          |\n| Yervoy (ipilimumab)                          | 2025                                        | 2026                                        | 2025                                        |\n| Zeposia (ozanimod) (o)                       | 2029                                        | 2034                                        | ++                                          |",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Yervoy",
          "name": "Yervoy",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_2",
          "chunk_text": "| Eliquis \u00ae           | Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Opdivo \u00ae            | Opdivo (nivolumab) is a biological product and a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer. The Opdivo + Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and various gastric and esophageal cancers. There are several ongoing potentially registrational studies for Opdivo across other tumor types and disease areas, in monotherapy and in combination with Yervoy and various anti-cancer agents. |\n| Orencia \u00ae           | Orencia (abatacept) is a biological product, is a fusion protein indicated for adult patients with moderate to severe active RA and PsA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular JIA and for the treatment of aGVHD, in combination with a calcineurin inhibitor and methotrexate.                                                                                                                                                                                                                                                                                      |\n| Pomalyst /Imnovid \u00ae | Pomalyst/Imnovid (pomalidomide) is a small molecule that is administered orally and modulates the immune system and other biologically important targets. Pomalyst/Imnovid is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. \u00ae                                                                                                                                                                                                                                     |\n| Yervoy \u00ae            | Yervoy (ipilimumab) is a biological product and is a CTLA4 immune checkpoint inhibitor. Yervoy is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma. The Opdivo + Yervoy regimen is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and esophageal cancer.                                                                                                                                                                                                                                                                                                                              |\n| Sprycel \u00ae           | Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromosome-positive CML in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including Gleevec* (imatinib mesylate) and the treatment of children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome-positive CML.                                                                                                                                                             |",
          "relationship": "Combines_With"
        },
        "node_3": {
          "id": "Opdivo",
          "name": "Opdivo",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Strategy\n\nOur\tprincipal\tstrategy\tis\tto\tcombine\tthe\tresources,\tscale\tand\tcapability\tof\ta\tlarge\tpharmaceutical\tcompany\twith\tthe\tspeed, agility\tand\tfocus\ton\tinnovation\ttypically\tfound\tin\tthe\tbiotech\tindustry.\tOur\tpriorities\tare\t(i)\tto\tcontinue\tto\trenew\tand diversify\t our\t portfolio\t through\t launching\t new\t medicines,\t (ii)\t advancing\t our\t early,\t mid\t and\t late-stage\t pipeline\t and\t (iii) executing\tdisciplined\tbusiness\tdevelopment.\tAs\twe\tundergo\ta\tperiod\tof\trenewal,\tour\tstrategy\twill\tbe\tfocused\ton\tdriving\tnearterm\t growth,\t minimizing\t the\t impact\t of\t a\t transition\t period\t that\t follows\t and\t delivering\t growth\t in\t the\t late\t 2020s\t by accelerating\t opportunities\t that\t enhance\t productivity\t and\t efficiency,\t advance\t our\t pipeline,\t and\t drive\t strong\t commercial execution\tthat\tmove\tour\tbusiness\tforward.\tWe\tremain\tcommitted\tto\ta\tstrategic\tbusiness\tdevelopment\tand\tmaintaining\ta\tstrong investment\tgrade\tcredit\trating,\tgrowing\tthe\tdividend\tand\treducing\tadditional\tdebt\tthat\twill\tbe\tissued\tin\tsupport\tof\trecent transactions.\n\nOur\tfocus\tis\ton\tdiscovering,\tdeveloping\tand\tdelivering\ttransformational\tmedicines\tfor\tpatients\tfacing\tserious\tdiseases\tin\tthe following\tfive\tcore\ttherapeutic\tareas:\t(i)\toncology\twith\ta\tpriority\tin\tcertain\ttumor\ttypes,\tincluding\tdiversification\tbeyond IO;\t(ii)\thematology\twith\topportunities\tto\texpand\tleadership\tposition\tin\tmultiple\tmyeloma,\tas\twell\tas\tbroaden\tour\tportfolio across\t leukemias,\t lymphomas\t and\t non-malignant\t hematologic\t diseases;\t (iii)\t immunology\t with\t priorities\t in\t strengthening presence\tin\tdermatology,\trheumatology\tand\tgastrointestinal\tdisorders,\testablishing\tnew\tstandards\tof\tcare\tin\tpulmonology\tand rapidly\t advance\t cell\t therapy\t into\t immunology\t diseases;\t (iv)\t cardiovascular\t diseases\t with\t focus\t on\t cardiomyopathies,\t heart failures and thrombotic diseases; and (v) neuroscience with a focus on neuropsychiatry, neurodegenerative and neuroinflammation\tdiseases.\n\nWe\t are\t working\t towards\t expanding\t our\t pipeline\t of\t registrational\t assets\t from\t six\t to\t up\t to\t twelve.\t In\t addition,\t we\t are positioned\t to\t support\t continued\t innovation\t and\t expand\t treatment\t options\t across\t several\t different\t diseases\t based\t on\t our differentiated\tresearch\tplatforms.\tWe\thave\ta\tbroad\tportfolio\tand\tpipeline\twhen\tit\tcomes\tto\tautologous\tCAR-T\tcell\ttherapies. We\thave\ttwo\tapproved\tcell\ttherapies\tagainst\ttwo\tdistinct\ttargets\tand\tare\tcontinuing\tto\tbuild\tour\tleadership\tin\tthis\tspace.\tWe are\t expanding\t manufacturing\t capacity,\t exploring\t innovative\t technologies\t such\t as\t dual-targeting\t CAR-Ts\t and\t allogenic approaches,\tadvancing\tmultiple\tnext-generation\tassets\tincluding\tnew\ttargets\tand\trapidly\texpanding\tinto\timmunology,\tincluding lupus\tand\tmultiple\tsclerosis.\tWe\talso\thave\ta\tstrong\tposition\tin\tthe\tprotein\tdegradation\tfield\tand\thave\tbeen\tadvancing\tour pipeline\twith\tan\texpansive\tlibrary\tof\tassets\twith\ttwo\tin\tregistrational\ttrials,\tan\tadditional\tfive\tin\tclinical\tphase\tstudies and\t more\t than\t fifteen\t being\t studied\t pre-clinically.\t This\t growing\t platform\t has\t potential\t across\t several\t diseases\t and\t is positioned\tto\tdeliver\tapproximately\tfour\tINDs\teach\tyear.\tTogether\twith\tour\tproven\ttrack\trecord,\trapidly\tadvancing\tpipeline and\tgrowth\twith\tmarketed\tproducts,\twe\tincreased\tand\tsustained\tour\tR&amp;D\tproductivity\tenabling\tus\tto\tidentify\tmore\thigh-quality candidates\t and\t increase\t their\t probability\t of\t reaching\t patients\t in\t need.\t Specifically,\t our\t ambition\t is\t to:\t (i)\t deliver approximately\tten\tINDs\tper\tyear;\t(ii)\tincrease\tsuccess\trates\tfrom\tfirst-in-human\ttrials\tto\tapproval\tto\tapproximately\t20%; (iii)\treduce\ttimelines\tto\tachieve\ta\tmedian\tof\t6.5\tyears\tfrom\tfirst-in-human\ttrials\tto\tapproval.\tOur\tR&amp;D\tstrategy\twill\thelp ensure\t we\t maintain\t a\t strong\t legacy\t of\t scientific\t innovation,\t bringing\t first-in\t class\t and/or\t best-in-class\t treatments\t to patients\tat\tan\taccelerated\tspeed.\n\nOur\tcommercial\tmodel\thas\tbeen\tsuccessful\twith\trevenues\tfrom\tour\tin-line\tbrands\tand\tnew\tproduct\tportfolio\tcontinuing\tto\tgrow, which\tdemonstrates\tstrong\texecution\tof\tour\tstrategy.\tWe\tremain\tfocused\tand\twell-resourced\tin\tour\tcancer\tdevelopment\tprograms and\tseek\tto\tbroaden\tthe\tuse\tof Opdivo in\tearlier\tlines\tof\ttherapy,\texpand\tinto\tnew\ttumors,\taccelerate\tnext\twave\toncology mechanisms\t and\t develop\t treatment\t options\t for\t refractory\t oncology\t patients.\t We\t are\t encouraged\t that\t our\t investigational subcutaneous\t formulation\t for Opdivo has\t the\t potential\t to\t bring\t enhanced\t benefits\t to\t patients\t into\t the\t next\t decade,\t with positive\tregistrational\tdata\tnow\tin-house.\tWe\tcontinue\tto\tdrive\tadoption\tof Opdivo by\texpanding\tinto\tadditional\tindications and\t tumor\t types\t both\t as\t a\t monotherapy\t and\t in\t combination\t with Yervoy and\t other\t anti-cancer\t agents.\t We\t are\t further strengthening\t our\t IO\t portfolio\t with Opdualag for\t the\t treatment\t of\t melanoma\t and\t potential\t expanded\t opportunities\t in\t other indications.\t We\t are\t growing\t a\t differentiated\t NSCLC\t portfolio,\t which\t includes\t the\t launch\t of Augtyro and\t includes Krazati , (acquired\t through\t Mirati),\t which\t demonstrates\t a\t strategic\t fit\t into\t our\t oncology\t portfolio.\t We\t are\t also\t strengthening\t our neuroscience\tportfolio\twith\tthe\tplanned\tacquisition\tof\tKaruna.\tMoreover, Eliquis continues\tto\tgrow,\tleveraging\tits\tbest\tin class\t clinical\t profile\t and\t extensive\t real\t world\t data\t and\t remains\t the\t number\t one\t novel\t oral\t anticoagulant\t in\t total prescriptions\tglobally. Camzyos continues\tto\tdemonstrate\tbenefits\tas\tshared\tthrough\tour\tlong-term\tfollow-up\tdata\tfrom\ttwo Phase\tIII\tstudies.\tIn\timmunology, Sotyktu is\tthe\tkey\tgrowth\tdriver\tfor\tBMS\tand\twe\tcontinue\tto\tmake\tfurther\tinvestments\tto accelerate\t the\t launch\t through\t direct\t to\t consumer\t advertising\t and\t adding\t field\t force\t support.\t In\t addition,\t our\t Phase\t III registrational\t clinical\t trials\t are\t underway\t for Sotyktu in\t PsA,\t SLE\t and\t Sj\u00f6gren's\t Syndrome.\t We\t are\t able\t to\t leverage\t our leading\tcapabilities\tin\thematological\tmalignancies\tand\tour\trobust\tpipeline\tto\tprovide\topportunities\tfor\tlong-term\tgrowth\tto offset\tthe\timpact\tof\tcurrent\tand\tfuture\tpatent\texpiries\tfor Revlimid and Pomalyst .\tAs\twe\tlook\tat\tour\tcell\ttherapy\tfranchise, we\tcontinue\tto\texplore\tnew\tindications\twith Breyanzi to\tinclude\tthe\ttreatment\tof\tCLL,\tFL\tand\tMCL.\tIf\tindication\tfor\tCLL\tis approved,\t it\t would\t be\t the\t first\t and\t only\t CAR-T\t available\t for\t this\t patient\t population. Reblozyl is\t advancing\t into\t new indications\twith\tan\tongoing\tregistrational\ttrial\tfor\tchronic\tanemia\tassociated\twith\tmyelofibrosis.\n\nThe\t evolution\t in\t our\t operating\t model,\t which\t focuses\t on\t maintaining\t a\t disciplined\t approach\t in\t marketing,\t selling\t and administrative\texpenses,\twill\tenable\tus\tto\tdeliver\tthe\tnecessary\tstrategic,\tfinancial\tand\toperational\tflexibility\tto\tinvest in\tthe\thighest\tpriority\topportunities\twithin\tour\tportfolio.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 209,
      "question": "How does the expiration of Complera/Eviplera's U.S. patent in 2025 impact Gilead's revenue-sharing arrangement with Janssen, particularly in light of Janssen's role in setting Symtuza's price and the associated revenue recognition practices?",
      "answer": "The expiration of Complera/Eviplera's U.S. patent in 2025 will likely increase competitive pressure from generics, potentially reducing Gilead's revenue from this product, which is co-developed and co-distributed with Janssen. Under the agreement, Gilead and Janssen share revenues based on the ratio of the net selling prices of their respective components. As patent protection wanes, Gilead may face declining sales volumes, which would directly affect the revenue pool shared with Janssen. In contrast, Gilead's arrangement with Janssen for Symtuza involves Janssen setting the price globally, with Gilead recognizing its share of Symtuza revenue as Product sales due to its role as the exclusive supplier of the Gilead Compounds. This difference in revenue dynamics\u2014where Janssen controls pricing for Symtuza but shares revenue on Complera/Eviplera\u2014creates a nuanced dependency where Gilead's financial exposure to Complera/Eviplera's patent cliff is more direct, while Symtuza's revenue is influenced by Janssen's pricing strategy and market performance.",
      "reasoning_steps": [
        "Hop 1: GILD(page_9) \u2192 Complera/Eviplera: Complera/Eviplera's U.S. patent expires in 2025, which is listed in the table of patent expirations, signaling future generic competition.",
        "Hop 2: Complera/Eviplera \u2192 Janssen: Gilead and Janssen co-developed and co-distribute Complera/Eviplera globally, with revenue shared based on the net selling prices of each party's components, as detailed in the collaboration agreement.",
        "Hop 3: Janssen \u2190 GILD(page_77): For Symtuza, Janssen sets the global price and Gilead recognizes its share of revenue as Product sales due to its supply role, highlighting a different revenue dependency model compared to Complera/Eviplera."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Distributes]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Complera/Eviplera",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_2",
          "chunk_text": "|                   | Patent Expiration (1)   | Patent Expiration (1)   | Patent Expiration (1)   | Patent Expiration (1)   |\n|-------------------|-------------------------|-------------------------|-------------------------|-------------------------|\n|                   | U.S.                    | U.S.                    | EU                      | EU                      |\n| Descovy           | 2031                    | (2)                     | 2027                    |                         |\n| Vemlidy           | 2031                    | (2)                     | 2027                    |                         |\n| Complera/Eviplera | 2025                    |                         | 2026                    |                         |\n| Zydelig           | 2025                    |                         | 2029                    |                         |\n| Odefsey           | 2032                    | (2)                     | 2027                    | (3)                     |\n| Yescarta          | 2031                    |                         | -                       |                         |\n| Stribild          | 2029                    | (4)                     | 2028                    |                         |\n| Genvoya           | 2029                    | (4), (5)                | 2028                    |                         |\n| Harvoni           | 2030                    |                         | 2030                    |                         |\n| Epclusa           | 2033                    |                         | 2032                    |                         |\n| Biktarvy          | 2033                    |                         | 2033                    |                         |\n| Vosevi            | 2034                    |                         | 2033                    |                         |\n| Veklury           | 2036                    | (6)                     | 2035                    |                         |\n| Tecartus          | 2027                    |                         | -                       | (3)                     |\n| Trodelvy          | 2028                    | (7)                     | 2029                    |                         |\n| Hepcludex         | 2030                    |                         | 2029                    |                         |\n| Sunlenca          | 2037                    |                         | 2037                    |                         |\n| Livdelzi          | 2025                    | (8)                     | -                       | (9)                     |\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Complera/Eviplera",
          "name": "Complera/Eviplera",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 210,
      "question": "How does BMY's financial exposure to 2seventy bio through profit-sharing on Abecma sales relate to the strategic importance of anti-BCMA products in their oncology pipeline, especially in light of BMY's broader partnership structure as reflected in their 10-K glossary?",
      "answer": "BMY's financial exposure to 2seventy bio is significant, with $43 million in profit-sharing costs in 2024 alone tied to Abecma sales, which are a key anti-BCMA product developed jointly. This reflects the strategic importance of anti-BCMA products in BMY\u2019s oncology portfolio, particularly in treating relapsed or refractory multiple myeloma. The inclusion of 2seventy bio in the 10-K glossary on page 134 further underscores the partnership's prominence in BMY\u2019s broader collaboration ecosystem, highlighting its role alongside other major biopharma partners. This synthesis reveals that BMY not only financially depends on 2seventy bio for revenue contributions but also strategically positions the collaboration as a core component of its oncology innovation framework.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_91) \u2192 [Anti-BCMA Products]: BMY and 2seventy bio jointly develop anti-BCMA products, including Abecma, which generated $242 million in U.S. net sales in 2024, with BMY incurring $43 million in profit-sharing costs.",
        "Hop 2: [Anti-BCMA Products] \u2192 [2seventy bio]: The anti-BCMA products are central to the collaboration with 2seventy bio, which gives them co-development rights and profit-sharing in the U.S., indicating a deep strategic and financial linkage.",
        "Hop 3: [2seventy bio] \u2190 [BMY](page_134): 2seventy bio is listed in the 10-K glossary, indicating its recognized strategic importance among BMY\u2019s key partners, reinforcing the centrality of the anti-BCMA collaboration in BMY\u2019s broader oncology strategy."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Has_Stake_In]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Anti-BCMA Products",
        "node_3": "2seventy bio",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## 2seventy bio\n\nBMS and 2seventy bio jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration includes (i) a right  for  BMS  to  license  any  anti-BCMA  products  resulting  from  the  collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to 2seventy bio upon the commercialization of any licensed products resulting from the collaboration should 2seventy bio decline to exercise their co-development and profit sharing rights.\n\nBMS exercised its option to license idecabtagene vicleucel ( Abecma ) in 2016 and 2seventy bio elected to participate in development and commercialization of Abecma in the U.S. in 2018. The terms of the collaboration have since been amended to transfer substantially all manufacturing obligations to BMS and eliminate ex-U.S. milestones and royalties payable to 2seventy bio for Abecma .\n\nIn  2021,  the  FDA  approved Abecma for  the  treatment  of  relapsed  or  refractory  multiple  myeloma.  Net  product  sales  of Abecma in  the  U.S.  were  $242  million, $358  million  and  $297  million;  and  the  related  profit  sharing  costs  were  $43  million,  $109  million  and  $49  million  in  2024,  2023  and  2022,  respectively.  Cost reimbursements were not material.\n\n## Eisai\n\nIn 2024, BMS and Eisai agreed to end the global strategic collaboration for the co-development and co-commercialization of MORAb-202 due to the ongoing portfolio prioritization efforts within BMS. All rights and obligations for MORAb-202 were transferred to Eisai, and BMS is to receive $90 million as part of the termination, which was included in Other (income)/expense, net during the twelve months ended December 31, 2024, of which $85 million was received during the third quarter of 2024.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Asset Acquisition\n\n## Karuna\n\nOn March 18, 2024, BMS acquired Karuna, a clinical-stage biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living  with  psychiatric  and  neurological  conditions.  The  acquisition  provided  BMS  with  rights  to Cobenfy (x anomeline  and  trospium  chloride),  formerly  KarXT. Cobenfy is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety, which was approved by the FDA on September 26, 2024 for the treatment of schizophrenia in adults. Cobenfy is also in registrational trials for both adjunctive therapy to ex isting standard of care agents in schizophrenia and the treatment of psychosis in patients with Alzheimer's Disease.\n\nBMS acquired  all  of  the  issued  and  outstanding  shares  of  Karuna's  common  stock  for  $330.00  per  share  in  an  all-cash  transaction  for  total  consideration  of $14.0 billion, or $12.9 billion net of cash acquired. The acquisition was funded primarily with debt proceeds (see \"-Note 10. Financing Arrangements\" for further detail). The transaction was accounted for as an asset acquisition since Cobenfy represented substantially all of the fair value of the gross assets acquired. As a result, $12.1 billion was ex pensed to Acquired IPRD during the twelve months ended December 31, 2024.\n\nThe following summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and Acquired IPRD expense:",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Anti-BCMA_Products",
          "name": "Anti-BCMA Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## 2seventy bio\n\nBMS and 2seventy bio jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration includes (i) a right  for  BMS  to  license  any  anti-BCMA  products  resulting  from  the  collaboration,  (ii)  a  right  for  2seventy  bio  to  participate  in  the  development  and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to 2seventy bio upon the commercialization of any licensed products resulting from the collaboration should 2seventy bio decline to exercise their co-development and profit sharing rights.\n\nBMS exercised its option to license idecabtagene vicleucel ( Abecma ) in 2016 and 2seventy bio elected to participate in development and commercialization of Abecma in the U.S. in 2018. The terms of the collaboration have since been amended to transfer substantially all manufacturing obligations to BMS and eliminate ex-U.S. milestones and royalties payable to 2seventy bio for Abecma .\n\nIn  2021,  the  FDA  approved Abecma for  the  treatment  of  relapsed  or  refractory  multiple  myeloma.  Net  product  sales  of Abecma in  the  U.S.  were  $242  million, $358  million  and  $297  million;  and  the  related  profit  sharing  costs  were  $43  million,  $109  million  and  $49  million  in  2024,  2023  and  2022,  respectively.  Cost reimbursements were not material.\n\n## Eisai\n\nIn 2024, BMS and Eisai agreed to end the global strategic collaboration for the co-development and co-commercialization of MORAb-202 due to the ongoing portfolio prioritization efforts within BMS. All rights and obligations for MORAb-202 were transferred to Eisai, and BMS is to receive $90 million as part of the termination, which was included in Other (income)/expense, net during the twelve months ended December 31, 2024, of which $85 million was received during the third quarter of 2024.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Asset Acquisition\n\n## Karuna\n\nOn March 18, 2024, BMS acquired Karuna, a clinical-stage biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living  with  psychiatric  and  neurological  conditions.  The  acquisition  provided  BMS  with  rights  to Cobenfy (x anomeline  and  trospium  chloride),  formerly  KarXT. Cobenfy is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety, which was approved by the FDA on September 26, 2024 for the treatment of schizophrenia in adults. Cobenfy is also in registrational trials for both adjunctive therapy to ex isting standard of care agents in schizophrenia and the treatment of psychosis in patients with Alzheimer's Disease.\n\nBMS acquired  all  of  the  issued  and  outstanding  shares  of  Karuna's  common  stock  for  $330.00  per  share  in  an  all-cash  transaction  for  total  consideration  of $14.0 billion, or $12.9 billion net of cash acquired. The acquisition was funded primarily with debt proceeds (see \"-Note 10. Financing Arrangements\" for further detail). The transaction was accounted for as an asset acquisition since Cobenfy represented substantially all of the fair value of the gross assets acquired. As a result, $12.1 billion was ex pensed to Acquired IPRD during the twelve months ended December 31, 2024.\n\nThe following summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and Acquired IPRD expense:",
          "relationship": "Has_Stake_In"
        },
        "node_3": {
          "id": "2seventy_bio",
          "name": "2seventy bio",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_134",
          "chunk_id": "chunk_2",
          "chunk_text": "| 2024Form10-K              | Annual Report onForm10-Kforthefiscal yearendedDecem ber31,2024                                 | MAA           | Marketing Authorization Application                                                 |\n|---------------------------|------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|\n| 2021Plan                  | 2021StockAwardandIncentivePlan                                                                 | MCL           | mantlecell lym phom a                                                               |\n| 2seventy bio              | 2seventy bio, Inc.                                                                             | MCO           | ManagedCareOrganization                                                             |\n| 340BProgram               | 340BDrugPricingProgram                                                                         | MDS           | myelodysplasticsyndrom es                                                           |\n| 2024SeniorUnsecured Notes | Aggregateprincipalam ount of$13.0 billion ofunsecured senior notes issuedbyBMS in February2024 | Merck         | Merck &Co.,Inc.                                                                     |\n| AbbVie                    | AbbVieInc.                                                                                     | MF            | myelof ibrosis                                                                      |\n| ADC                       | antibody-drug conjugate                                                                        | Mirati        | Mirati Therapeutics,Inc.                                                            |\n| aGVHD                     | acutegraf t-versus-host disease                                                                | MPM           | Malignant Pleural Mesotheliom a                                                     |\n| Amgen                     | AmgenInc.                                                                                      | MS            | MultipleSclerosis                                                                   |\n| Amylin                    | AmylinPharm aceuticals,                                                                        | MSI-High      | microsatelliteinstability-high                                                      |\n| ANDA                      | Inc. abbreviatedNewDrugApplication                                                             | MyoKardia     | MyoKardia,Inc.                                                                      |\n| ASC                       | Accounting Standards Codif ication                                                             | NAV           | net asset value                                                                     |\n| ASR                       | Accelerated ShareRepurchase                                                                    | NDA           | NewDrugApplication                                                                  |\n| AstraZ eneca              | AstraZenecaPLC                                                                                 | Nim bus       | Nim bus Therapeutics,LLC                                                            |\n| BCMA                      | B-cell maturation antigen                                                                      | NKT           | natural killerT                                                                     |\n| Biogen                    | Biogen,Inc.                                                                                    | Novartis      | Novartis Pharm aceutical Corporation                                                |\n| Biohaven                  | BiohavenPharm aceutical HoldingCom pany Ltd.                                                   | NSCLC         | non-sm all cell lung cancer                                                         |\n| BLA                       | Biologics LicenseApplication                                                                   | NVAF          | non-valvular atrial f ibrillation                                                   |\n| CAR-T                     | Chim ericAntigen ReceptorTcells                                                                | OCE           | Oncology Center ofExcellence                                                        |\n| Celgene                   | CelgeneCorporationacquiredbyBMSonNovem ber20,2019                                              | OECD          | OrganizationforEconom icCo-operationandDevelopm ent                                 |\n| CERCLA                    | U.S.Com prehensiveEnvironm ental Response,Com pensation and Liability Act                      | oHCM          | obstructivehypertrophiccardiom yopathy                                              |\n| CGDP                      | CoverageGapDiscount Program                                                                    | OIG           | Off iceofInspector General oftheU.S.Departm ent ofHealthandHum an Services          |\n| cGMP                      | current GoodManufacturing Practices                                                            | Ono           | OnoPharm aceutical Co.,Ltd.                                                         |\n| Cheplapharm               | CheplapharmArzneim ittelGmbH                                                                   | Orum          | OrumTherapeutics                                                                    |\n| CHMP                      | Com mitteef orMedicinal Products forHum anUse                                                  | Otsuka        | OtsukaPharm aceutical Co.,Ltd.                                                      |\n| CLL                       | Chroniclym phocyticleukem ia                                                                   | PBMs          | Pharm acy Benef it Managers                                                         |\n| CML COSO                  | chronicm yeloid leukem ia Com mitteeofSponsoring Organizations oftheTreadwayCom mission        | PCAOB PD-1    | PublicCom pany Accounting Oversight Board                                           |\n| CRC                       |                                                                                                | PDMA          | program meddeath receptor-1                                                         |\n| DLBCL                     | colorectal carcinom a                                                                          | PDUFA         | Prescription DrugMarketing Act PrescriptionDrugUserFeeAct                           |\n| Dragonf ly                | dif f uselargeB-cell lym phom a Dragonf ly Therapeutics,Inc.                                   | Pfizer        | Pfizer, Inc.                                                                        |\n|                           | ent                                                                                            |               | Pharm aceutical Research and ManufacturersofAm erica's Prof essional Practices Code |\n| DSA                       | Distribution Services Agreem                                                                   | PhRMACode     |                                                                                     |\n| EC EGFR                   | EuropeanCom mission estim atedglom erular f iltration rate                                     | PPF Prothena  | progressivepulm onary f ibrosis ProthenaCorporation                                 |\n| Eisai                     | Eisai Co.,Ltd.                                                                                 | PRP           | potentially responsibleparty                                                        |\n| EMA                       | European Medicines                                                                             | PsA           | psoriaticarthritis                                                                  |\n| EPS                       | Agency earnings per share                                                                      | PTR           | patent termrestoration                                                              |\n| ESA                       | erythoropoiesis-stim ulating agent                                                             | R&D           | research and developm ent                                                           |\n|                           | except as otherwisenoted,EUref ers to thecountries that arem em bers oftheEuropean             | RA            | rheum atoid arthritis                                                               |\n| EU                        | Unionplus theUnitedKingdom                                                                     | RayzeBio      |                                                                                     |\n| Evotec ExchangeAct        | EvotecSE theSecurities ExchangeAct o1934                                                       | RCC           | RayzeBio,Inc.                                                                       |\n| FASB                      | Financial Accounting Standards Board                                                           | RDP           | renal cell carcinom a Regulatory DataProtection                                     |\n| FDA                       | U.S.FoodandDrugAdm inistration                                                                 | REMS          | Risk Evaluation and Mitigation Strategy                                             |\n| FL                        | f ollicularlym phom a                                                                          | Roche         | RocheHoldingAG                                                                      |\n| GAAP                      | U.S.generally accepted accounting principles                                                   | ROS1          | c-ros oncogene1                                                                     |\n| Gilead                    | Gilead Sciences, Inc.                                                                          | RS            | ring sideroblast                                                                    |\n| GILTI                     | global intangiblelowtaxedincom e                                                               | Sanof i       | Sanof i S.A.                                                                        |\n| GlaxoSm ithKline          | GlaxoSm ithKlinePLC                                                                            | SEC           | U.S.Securities andExchangeCom mission                                               |\n| GTN                       | gross-to-net                                                                                   | SLE           | system iclupus erythem                                                              |\n| Halozym e                 | Halozym                                                                                        | SLL           | atosus sm all lym phocyticlym phom a                                                |\n| HCC                       | eTherapeutics,Inc.                                                                             | SOFR          | Secured Overnight Financing Rate                                                    |\n| HCM                       | hepatocellularcarcinom a hypertrophiccardiom yopathy                                           | SPC           | Supplem entary Protection Certif icate                                              |\n| IMDC                      | International MetastaticRenal Cell Carcinom aDatabaseConsortium                                | SystIm mune   | SystIm mune,Inc.                                                                    |\n| Im matics                 | Im matics N.V.                                                                                 | Takeda        | TakedaPharm aceuticalCom panyLim ited                                               |\n| IO                        | im muno-oncology                                                                               | TCJA          | theTaxCuts and Jobs Act of2017                                                      |\n| IPF                       | idiopathicpulm onary f ibrosis                                                                 | Turning Point | Turning Point Therapeutics,Inc.                                                     |\n| IPRD                      | in-process research and developm ent                                                           | UC            | ulcerativecolitis                                                                   |\n| IRA                       | Inf lation Reduction Act of2022                                                                | UK            | UnitedKingdom                                                                       |\n| IRS                       | Internal RevenueServices                                                                       |               | United States                                                                       |\n|                           |                                                                                                | U.S.          | valueadded tax                                                                      |\n| JIA Karuna                | JuvenileIdiopathicArthritis KarunaTherapeutics,Inc.                                            | VAT           |                                                                                     |\n| LBCL                      | largeB-cell lym phom a                                                                         |               |                                                                                     |\n|                           |                                                                                                | WTO           | WorldTradeOrganization                                                              |\n| Lilly                     | Eli LillyandCom pany                                                                           |               |                                                                                     |",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 211,
      "question": "How does Amgen's selection of an 8.5-year straight-line amortization period for the developed-product-technology rights related to Otezla align with the drug's current market indications and lifecycle expectations as reflected in the product pipeline disclosures?",
      "answer": "Amgen is amortizing the developed-product-technology rights for Otezla over 8.5 years using the straight-line method (page 112). These rights were valued based on the present value of incremental after-tax cash flows attributable to the intangible asset. On page 25, Otezla is shown to be approved for mild-to-moderate psoriasis and had a terminated indication for COVID-19. The 8.5-year amortization period suggests management's view of Otezla's expected economic life at the time of valuation, which appears to be primarily based on its core psoriasis indication, as no new major indications were actively being pursued at the time of the report. This alignment indicates that Amgen's amortization assumption reflects the established market position of Otezla for psoriasis rather than speculative expansion into other therapeutic areas like COVID-19.",
      "reasoning_steps": [
        "Hop 1: AMGN(page112) \u2192 Developed Product Technology Rights: Amgen is amortizing the intangible asset related to Otezla over 8.5 years using the straight-line method, based on a multiperiod excess earnings income approach that values the incremental after-tax cash flows from the asset.",
        "Hop 2: Developed Product Technology Rights \u2192 Otezla: The developed-product-technology rights are specifically tied to Otezla, indicating that the financial valuation and amortization schedule directly reflect expectations about Otezla\u2019s market performance and lifecycle.",
        "Hop 3: Otezla \u2190 AMGN(page25): Otezla is disclosed as being approved for mild-to-moderate psoriasis and having a terminated indication for COVID-19, showing its current therapeutic focus and limiting near-term pipeline-driven revenue expectations for the drug."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Amortizes]-> PRODUCT -[Relates_To]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Developed Product Technology Rights",
        "node_3": "Otezla",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset  acquisition.  Rather,  the  excess  of  the  accumulated  cost  over  the  fair  value  of  the  net  assets  acquired  is  reallocated  to  the nonfinancial assets acquired.\n\nThe developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multiperiod excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.",
          "relationship": "Amortizes"
        },
        "node_2": {
          "id": "Developed_Product_Technology_Rights",
          "name": "Developed Product Technology Rights",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAmgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset  acquisition.  Rather,  the  excess  of  the  accumulated  cost  over  the  fair  value  of  the  net  assets  acquired  is  reallocated  to  the nonfinancial assets acquired.\n\nThe developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multiperiod excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.",
          "relationship": "Relates_To"
        },
        "node_3": {
          "id": "Otezla",
          "name": "Otezla",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                                | Program change                                                  |\n|-------------------|-----------------------------------------------------------|-----------------------------------------------------------------|\n| LUMAKRAS/LUMYKRAS | NSCLC with KRAS G12C mutations                            | Approved by the FDAand conditional marketing approval by the EC |\n| Otezla            | Mild-to-moderate psoriasis                                | Approved by the FDA                                             |\n| RIABNI            | Non-Hodgkin's lymphoma                                    | Approved by the FDA                                             |\n| AMJEVITA          | Interchangeability                                        | Initiated phase 3 study                                         |\n| Bemarituzumab     | GEJ adenocarcinoma                                        | Initiated phase 3 study                                         |\n| BLINCYTO          | Ph-negative B-cell precursor Acute lymphoblastic leukemia | Initiated phase 3 study                                         |\n| TEZSPIRE          | Chronic rhinosinusitis with nasal polyps                  | Initiated phase 3 study                                         |\n| Otezla            | COVID-19                                                  | Terminated                                                      |\n",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 212,
      "question": "How does Amgen's appeal of the PTAB's decision on the '138 Patent relate to Zydus's separate appeal of its apremilast patent infringement judgment, and what does this reveal about Amgen's overall strategy in managing patent litigation risks across different drug franchises?",
      "answer": "Amgen's appeal of the PTAB's decision on the '138 Patent, which was remanded following the Federal Circuit's ruling in Arthrex Inc. v. Smith & Nephew, Inc., reflects its active defense of patent rights in the face of biosimilar challenges. Separately, Zydus filed a notice of appeal to the Federal Circuit Court regarding the '638 Patent after the New Jersey District Court ruled in Amgen's favor on certain claims of apremilast-related patents. Both appeals demonstrate Amgen's strategy of aggressively pursuing legal recourse to extend market exclusivity and protect revenue streams. However, while the '138 Patent appeal centers on procedural validity before the PTAB, the Zydus litigation involves direct infringement claims and injunctions tied to FDA approval timelines, showing a dual approach to patent risk management\u2014procedural defense in inter partes reviews and assertive enforcement in district court judgments.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_147) \u2192 Notice of Appeal: Amgen filed a notice of appeal to the Federal Circuit Court regarding the PTAB's decision on U.S. Patent No. 8,952,138 ('138 Patent), which was remanded due to procedural concerns raised in Arthrex Inc. v. Smith & Nephew, Inc.",
        "Hop 2: Notice of Appeal \u2192 Zydus: Zydus also filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent after the New Jersey District Court ruled in favor of Amgen on certain apremilast-related patent claims.",
        "Hop 3: Zydus \u2190 AMGN(page_145): Amgen faced Zydus in a consolidated patent infringement trial over apremilast, where the court issued an injunction against Zydus on multiple patents, with Zydus appealing the decision on the '638 Patent."
      ],
      "difficulty": "hard",
      "idf_score": 5.397992538378906,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> LITIGATION -[Files]-> COMP <-[Faces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Notice of Appeal",
        "node_3": "Zydus",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_147",
          "chunk_id": "chunk_1",
          "chunk_text": "In  February  2016,  the  European  Patent  Office  (EPO)  granted  European  Patent  No.  2,215,124  (EP  2,215,124)  to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the  EPO  seeking  to  invalidate  it.  In  November  2016,  Sanofi-Aventis  Deutschland  GmbH,  Sanofi-Aventis  Groupe  S.A.  and  Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen's patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen's patent. In November 2018, the EPO confirmed the validity of Amgen's EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA's decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA's October 29, 2020 ruling.\n\nOn April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.'s appeals making final the Japanese High Court's decisions  that  PRALUENT  infringes Amgen's  valid  patent  rights  in  Japan.  On  June  24,  2020, Amgen  filed  written  answers  to  the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen's Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron's invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan.\n\n## NEUPOGEN (filgrastim)/Neulasta Patent Litigation\n\n## Amgen Inc., et al. v. Hospira Inc. et al.\n\nOn February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit  in  the  Delaware  District  Court  against  Hospira  Inc.  and  Pfizer  Inc.  (collectively,  Pfizer).  This  lawsuit  stems  from  Pfizer's submission of an application  for  FDA  licensure  of  a  pegfilgrastim  product  as  biosimilar  to Amgen's  Neulasta. Amgen  has  asserted infringement of U.S. Patent No. 8,273,707 (the '707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the '707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the '707 Patent. In June 2020, the FDA approved Pfizer's NYVEPRIA, a biosimilar to Amgen's Neulasta.\n\nOn April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction. Currently pending before the Delaware District Court is Pfizer's motion for summary judgment of noninfringement, which has been fully briefed. No date has been set for argument on the motion.\n\n## Patent Trial and Appeal Board (PTAB) Challenge\n\n## Apotex PTAB Challenge\n\nIn February 2017, the PTAB of the USPTO granted Apotex's petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the '138 Patent), challenging claims of the '138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the '138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018.\n\nOn May 20, 2019, the PTAB issued a decision denying Apotex's request for rehearing on the PTAB's finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen's '138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court's decision in Arthrex Inc. v. Smith &amp; Nephew, Inc ., 941 F.3d 1320 (Fed. Cir. 2019).\n\nOn July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the '138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the '138 Patent, for proceedings consistent with its decision in Arthrex Inc. v. Smith &amp; Nephew, Inc. ,  requesting  that  such  remanded  cases  be  held  pending  the  U.S. Supreme Court's disposition of the petition for writ of certiorari in United States v. Arthrex, Inc. ,  No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government's petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.",
          "relationship": "Faces"
        },
        "node_2": {
          "id": "Notice_of_Appeal",
          "name": "Notice of Appeal",
          "type": "LITIGATION",
          "idf_score": 4.222304909797168
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Files"
        },
        "node_3": {
          "id": "Zydus",
          "name": "Zydus",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_145",
          "chunk_id": "chunk_1",
          "chunk_text": "injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience's apremilast product during the term of the '243, '940, '638, '302, '101, '536, '330 and '541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL's apremilast product during the term of the '638, '101, '536 and '541 Patents, unless authorized pursuant to a confidential settlement agreement.\n\nTrial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021.\n\nOn September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 2 and 27 of the '283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the '101 Patent and claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus's ANDA must be after expiration of the three infringed patents (the '638, '536 and '283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus's generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the '638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\nOn October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the '638 Patent, claim 6 of the '536 Patent and claims 1 and 15 of the '101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the '541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz's ANDA must be after expiration of the three infringed patents (the '638, '536 and '101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz's generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the '638 and '101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.\n\n## ENBREL Patent Litigation\n\n## Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.\n\nOn April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along  with  Hoffmann-La  Roche  Inc.  (Roche),  filed  a  lawsuit  in  the  New  Jersey  District  Court  against  Samsung  Bioepis  Co.,  Ltd. (Bioepis). This lawsuit stems from Bioepis' submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen's ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the '522 Patent),  7,915,225,  8,119,605  and  8,722,631.  By  their  complaint,  Amgen  and  Roche  seek  an  injunction  to  prohibit  Bioepis  from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District  Court  entered  a  consent  injunction  that  prohibits  Bioepis  from  making,  using,  offering  to  sell,  selling  or  importing  into  the United  States  Bioepis'  etanercept  product.  Amgen  and  Bioepis  entered  into  an  agreement  with  respect  to  an  injunction  regarding etanercept as set out in the New Jersey District Court's order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.\n\nOn November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche's '522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties' submission.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 213,
      "question": "How does BMY's reliance on regulatory exclusivity for Eliquis, including its composition of matter patents and SPCs, reconcile with the risk of rapid revenue decline due to early generic entry in the EU, and how does this affect the company's broader market exclusivity assumptions used in financial guidance?",
      "answer": "BMY emphasizes its reliance on both patent rights and regulatory exclusivity to maintain market exclusivity for Eliquis (page 27), noting that legal challenges and adverse judicial decisions in the UK and Netherlands have already led to generic versions entering those markets before patent expiration. This early loss of exclusivity contradicts the company's assumption that products will enjoy the full market exclusivity period outlined in the 10-K (page 28), which directly impacts revenue projections and financial guidance. The interplay between the legal strength of Eliquis\u2019s patents (Entity1) and the practical erosion of market exclusivity (Entity2) highlights a critical risk in how BMY models future revenue streams based on expected exclusivity timelines.",
      "reasoning_steps": [
        "Hop 1: BMY(page_27) \u2192 Regulatory Exclusivity: BMY depends on regulatory exclusivity and patent rights (including Eliquis\u2019s composition of matter patents and SPCs) to protect revenue and delay generic competition.",
        "Hop 2: Regulatory Exclusivity \u2192 Market Exclusivity: Regulatory exclusivity is a key determinant of market exclusivity, and its erosion\u2014either through legal challenges or settlements\u2014directly shortens the period of protected revenue.",
        "Hop 3: Market Exclusivity \u2190 BMY(page_28): BMY acknowledges that it cannot predict whether products will maintain market exclusivity for the full period assumed in financial guidance, citing Eliquis\u2019s early generic entry in the EU as a real-world example."
      ],
      "difficulty": "hard",
      "idf_score": 5.397992538378906,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT -[Positively_Impacts]-> REGULATORY_REQUIREMENT <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Regulatory Exclusivity",
        "node_3": "Market Exclusivity",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_27",
          "chunk_id": "chunk_1",
          "chunk_text": "not\tmeet\tone\tor\tmore\tof\tits\tprimary\tendpoints,\tour\tstock\tprice\tcould\tdecline\tsignificantly\tand\tthere\tmay\tbe\tan\tadverse\timpact on\tour\tbusiness,\tfinancial\tcondition\tor\tresults\tof\toperations.\n\nWe\tmust\tmaintain\ta\tcontinuous\tflow\tof\tsuccessful\tnew\tproducts\tand\tsuccessful\tnew\tindications\tfor\texisting\tproducts\tsufficient both\tto\tcover\tour\tsubstantial\tresearch\tand\tdevelopment\tcosts\tand\tto\treplace\tsales\tthat\tare\tlost\tas\tprofitable\tproducts\tlose market\texclusivity\tor\tare\tdisplaced\tby\tcompeting\tproducts\tor\ttherapies.\tFailure\tto\tdo\tso\tin\tthe\tshort-term\tor\tlong-term\tcan have\ta\tmaterial\tadverse\teffect\ton\tour\tbusiness,\tresults\tof\toperations,\tcash\tflow,\tfinancial\tcondition\tand\tprospects.\tThere can\tbe\tno\tassurance\tthat\tour\tkey\tproduct\tcandidates\twould\tprove\tto\tbe\tsafe\tand\teffective\tor\tas\tsafe\tand\teffective\tas\tother competing\t products,\t or\t that,\t even\t if\t approved,\t any\t such\t products\t will\t become\t commercially\t successful\t for\t all\t approved indications.\n\n## We\tcould\tlose\tmarket\texclusivity\tof\ta\tproduct\tearlier\tthan\texpected.\n\nIn\t the\t pharmaceutical\t and\t biotechnology\t industries,\t the\t majority\t of\t an\t innovative\t product's\t commercial\t value\t is\t realized during\tits\tmarket\texclusivity\tperiod.\tIn\tthe\tU.S.\tand\tin\tsome\tother\tcountries,\twhen\tmarket\texclusivity\texpires\tand\tgeneric versions\t are\t approved\t and\t marketed\t or\t when\t biosimilars\t are\t introduced\t (even\t if\t only\t for\t a\t competing\t product),\t there\t are usually\tvery\tsubstantial\tand\trapid\tdeclines\tin\ta\tproduct's\trevenues.\n\nMarket\texclusivity\tfor\tour\tproducts\tis\tbased\tupon\tpatent\trights\tand\tcertain\tregulatory\tforms\tof\texclusivity.\tThe\tscope\tof\tour patent\t rights,\t if\t any,\t varies\t from\t country\t to\t country\t and\t may\t also\t be\t dependent\t on\t the\t availability\t of\t meaningful\t legal remedies\tin\ta\tcountry.\tThe\tfailure\tto\tobtain\tor\tmaintain\tpatent\tand\tother\tintellectual\tproperty\trights,\tor\tlimitations\ton\tthe use\tor\tloss\tof\tsuch\trights,\tcould\tresult\tin\ta\trapid\tloss\tof\tsales\tfor\tany\taffected\tproducts\twhich\tcould\tbe\tmaterial\tto\tus.\tIn some\tcountries,\tincluding\tcertain\tEU\tmember\tstates,\tbasic\tpatent\tprotections\tfor\tour\tproducts\tmay\tnot\texist\tbecause\tcertain countries\tdid\tnot\thistorically\toffer\tthe\tright\tto\tobtain\tspecific\ttypes\tof\tpatents\tand/or\twe\t(or\tour\tlicensors)\tdid\tnot\tfile in\tthose\tcountries.\tIn\taddition,\tthe\tpatent\tenvironment\tcan\tbe\tunpredictable\tand\tthe\tvalidity\tand\tenforceability\tof\tpatents cannot\tbe\tpredicted\twith\tcertainty.\tFor\texample,\tfor\tEliquis,\tgenerics\thave\tchallenged\tthe\tcomposition\tof\tmatter\tpatents\tand related\t SPCs\t in\t various\t jurisdictions\t and\t trials\t have\t taken\t place,\t or\t are\t scheduled\t to\t take\t place,\t in\t certain\t European countries.\tWhile\tthese\tlegal\tproceedings\tare\tpending,\tgeneric\tmanufacturers\thave\tbegun\tmarketing\tgeneric\tversions\tof\tEliquis in\tcertain\tEU\tcountries\tand\tmay\tseek\tto\tmarket\tgeneric\tversions\tof\tEliquis\tin\tother\tEU\tcountries\tprior\tto\tthe\texpiration\tdate of\tapplicable\tpatents\tand\trelated\tSPCs.\tFurthermore,\tmanufacturers\tof\tinnovative\tdrugs\tas\twell\tas\tgeneric\tdrug\tmanufacturers may\tbe\table\tto\tdesign\ttheir\tproducts\taround\tour\towned\tor\tlicensed\tpatents\tand\tcompete\twith\tus\tusing\tthe\tresulting\talternative technology.\tAbsent\trelevant\tpatent\tprotection\tfor\ta\tproduct,\tonce\tthe\tdata\texclusivity\tperiod\texpires,\tgeneric\tor\talternative versions\tcan\tbe\tapproved\tand\tmarketed.\n\nGeneric\tand\tbiosimilar\tproduct\tmanufacturers\tas\twell\tas\tother\tgroups\tseeking\tfinancial\tgain\tare\talso\tincreasingly\tseeking\tto challenge\t patents\t before\t they\t expire,\t and\t we\t could\t face\t earlier-than-expected\t competition\t for\t any\t products\t at\t any\t time. Patents\t covering\t our\t key\t products\t have\t been,\t and\t are\t likely\t to\t continue\t to\t be,\t subject\t to\t validity,\t enforceability\t and infringement\tchallenges\tin\tpatent\tlitigations\tand\tpost-grant\treview\tpatent\toffice\tproceedings.\tAlthough\twe\tare\tconfident\tin the\tstrength\tof\tour\tintellectual\tproperty\trights,\tit\tmay\tbe\tpossible\tfor\tgeneric\tdrug\tcompanies\tto\tsuccessfully\tchallenge\tour rights\t and\t launch\t their\t generic\t versions\t of\t our\t drugs\t prior\t to\t the\t expiration\t of\t our\t intellectual\t property\t rights.\t For example,\t following\t certain\t adverse\t judicial\t decisions\t in\t the\t UK\t and\t the\t Netherlands,\t generic\t manufacturers\t have\t begun marketing\t generic\t versions\t of\t Eliquis\t in\t the\t UK\t and\t Netherlands,\t and\t may\t seek\t to\t market\t generic\t versions\t of\t Eliquis\t in additional\t countries\t in\t Europe,\t prior\t to\t the\t expiration\t of\t our\t patents,\t which\t may\t lead\t to\t additional\t infringement\t and invalidity\tactions\tinvolving\tEliquis\tpatents\tbeing\tfiled\tin\tvarious\tcountries\tin\tEurope.\tIn\taddition,\tin\torder\tto\tavoid\tthe uncertainty\t and\t expense\t of\t litigation,\t among\t other\t reasons,\t we\t may\t decide\t to\t enter\t into\t settlements\t with\t generic manufacturers\tthat\tpermit\tgeneric\tmarket\tentry\tprior\tto\tthe\texpiration\tof\tour\tintellectual\tproperty\trights.\tFor\texample,\tas\ta result\tof\tpatent\tsettlements,\tgeneric\tentry\tfor\tRevlimid\tin\tthe\tUnited\tKingdom\tbegan\ton\tJanuary\t18,\t2022,\tand\tin\tvarious other\tEuropean\tcountries\ton\tFebruary\t18,\t2022.\tSimilarly,\tin\tthe\tU.S.,\tfollowing\tpatent\tsettlements,\tcertain\tcompanies\twere granted\tvolume-limited\tlicenses\tto\tsell\tgeneric\tlenalidomide\tin\tthe\tU.S.\tcommencing\tin\tMarch\t2022\tor\tthereafter.\n\nIn\tsome\tcases,\tmanufacturers\tmay\tseek\tregulatory\tapproval\tby\tsubmitting\ttheir\town\tclinical\tstudy\tdata\tto\tobtain\tmarketing approval\tor\tchoose\tto\tlaunch\ta\tgeneric\tproduct\t'at\trisk'\tbefore\tthe\texpiration\tof\tthe\tapplicable\tpatent(s)\tand/or\tbefore\tthe final\tresolution\tof\trelated\tpatent\tlitigation.\tIn\taddition,\tsome\tcountries\tare\tallowing\tmanufacturers\tto\tmanufacture\tand\tsell generic\tproducts,\twhich\tnegatively\timpacts\tthe\tprotections\tafforded\tthe\tCompany.\tLower-priced\tgenerics\tor\tbiosimilars\tfor\tBMS biologic\tproducts\tor\tcompeting\tbiologics\tcould\tnegatively\timpact\tour\tvolumes\tand\tprices.\n\nIn\taddition,\tboth\tthe\tU.S.\tCongress\tand\tthe\tU.S.\tFDA\thave\ttaken\tsteps\tto\tpromote\tthe\tdevelopment\tand\tapproval\tof\tgeneric drugs\tand\tbiosimilar\tbiologics,\tincluding\tby\tproviding\tgeneric\tand\tbiosimilar\tdevelopers\ta\tprivate\tright\tof\taction\tto\tobtain sufficient\t quantities\t of\t drug\t samples\t from\t the\t reference\t product's\t manufacturer\t in\t order\t to\t conduct\t testing\t necessary\t to obtain\tapproval\tfor\tgeneric\tor\tbiosimilar\tproducts.\n\nIn\taddition,\tin\tDecember\t2023,\tthe\tBiden\tAdministration\treleased\ta\tproposed\tframework\tthat\tfor\tthe\tfirst\ttime\tproposed\tthat\ta drug's\tprice\tcan\tbe\ta\tfactor\tin\tdetermining\tthat\tthe\tdrug\tis\tnot\taccessible\tto\tthe\tpublic\tand\ttherefore\tthat\tthe\tgovernment could\texercise\t'march-in\trights'\tand\tlicense\tit\tto\ta\tthird\tparty\tto\tmanufacture.\tA\tcomment\tperiod\ton\tthe\tproposal\tran\tthrough February\t6,\t2024,",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Regulatory_Exclusivity",
          "name": "Regulatory Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "In\t the\t pharmaceutical\t industry,\t the\t majority\t of\t an\t innovative\t product's\t commercial\t value\t is\t usually\t realized\t during\t the period\tin\twhich\tthe\tproduct\thas\tmarket\texclusivity.\tA\tproduct's\tmarket\texclusivity\tis\tgenerally\tdetermined\tby\ttwo\tforms\tof intellectual\t property:\t patent\t rights\t held\t by\t the\t innovator\t company\t and\t any\t regulatory\t forms\t of\t exclusivity\t to\t which\t the innovative\tdrug\tis\tentitled.\n\nPatents\tare\ta\tkey\tdeterminant\tof\tmarket\texclusivity\tfor\tmost\tbranded\tpharmaceuticals.\tPatents\tprovide\tthe\tinnovator\twith\tthe right\tto\texclude\tothers\tfrom\tpracticing\tan\tinvention\trelated\tto\tthe\tmedicine.\tPatents\tmay\tcover,\tamong\tother\tthings,\tthe active\tingredient(s),\tvarious\tuses\tof\ta\tdrug\tproduct,\tpharmaceutical\tformulations,\tdrug\tdelivery\tmechanisms\tand\tprocesses\tfor (or\tintermediates\tuseful\tin)\tthe\tmanufacture\tof\tproducts.\tProtection\tfor\tindividual\tproducts\textends\tfor\tvarying\tperiods\tin accordance\twith\tthe\texpiration\tdates\tof\tpatents\tin\tthe\tvarious\tcountries.\tThe\tprotection\tafforded,\twhich\tmay\talso\tvary\tfrom country\tto\tcountry,\tdepends\tupon\tthe\ttype\tof\tpatent,\tits\tscope\tof\tcoverage\tand\tthe\tavailability\tof\tmeaningful\tlegal\tremedies in\tthe\tcountry.\n\nMarket\texclusivity\tis\talso\tsometimes\tprovided\tby\tRDP,\ta\tperiod\tof\ttime\tafter\tthe\tapproval\tof\ta\tnew\tdrug\tduring\twhich\tthe regulatory\tagency\tmay\tnot\trely\tupon\tthe\tinnovator's\tdata\tto\tapprove\ta\tcompetitor's\tgeneric\tcopy.\tMany\tdeveloped\tcountries provide\tcertain\tnon-patent\tincentives\tfor\tthe\tdevelopment\tof\tmedicines.\tFor\texample,\tin\tthe\tU.S.,\tEU,\tJapan\tand\tcertain\tother countries,\tRDP\texclusivity\trights\tare\toffered\tas\tincentives\tfor\tresearch\ton\tmedicines\tfor\trare\tdiseases,\tor\torphan\tdrugs,\tand on\tmedicines\tuseful\tin\ttreating\tpediatric\tpatients.\tThese\tincentives\tcan\tprovide\ta\tmarket\texclusivity\tperiod\ton\ta\tproduct that\texpires\tbeyond\tthe\tpatent\tterm.\n\nWhen\tthese\tpatent\trights\tand\tother\tforms\tof\texclusivity\texpire\tand\tgeneric\tversions\tof\ta\tmedicine\tare\tapproved\tand\tmarketed, there\tare\toften\tsubstantial\tand\trapid\tdeclines\tin\tthe\tsales\tof\tthe\toriginal\tinnovative\tproduct.\tFor\tfurther\tdiscussion\tof\tthe impact\tof\tgeneric\tmedicines\ton\tour\tbusiness,\trefer\tto\t'-Competition'\tbelow.\n\nSpecific\taspects\tof\tthe\tlaw\tgoverning\tmarket\tpatent\tprotection\tand\tRDP\tfor\tpharmaceuticals\tvary\tfrom\tcountry\tto\tcountry.\tThe following\tsummarizes\tkey\texclusivity\trules\tin\tmarkets\trepresenting\tsignificant\tsales:\n\n## United\tStates\n\nIn\tthe\tU.S.,\tmost\tof\tour\tkey\tproducts\tare\tprotected\tby\tpatents\twith\tvarying\tterms\tdepending\ton\tthe\ttype\tof\tpatent\tand\tthe filing\tdate.\tA\tsignificant\tportion\tof\ta\tproduct's\tpatent\tlife,\thowever,\tis\tlost\tduring\tthe\ttime\tit\ttakes\tan\tinnovator\tcompany to\tdevelop\tand\tobtain\tregulatory\tapproval\tof\ta\tnew\tdrug.\tAs\tcompensation\tat\tleast\tin\tpart\tfor\tthe\tlost\tpatent\tterm\tdue\tto regulatory\t review\t periods,\t the\t innovator\t may,\t depending\t on\t a\t number\t of\t factors,\t apply\t to\t the\t government\t to\t restore\t lost patent\tterm\tby\textending\tthe\texpiration\tdate\tof\tone\tpatent\tup\tto\ta\tmaximum\tterm\tof\tfive\tyears,\tprovided\tthat\tthe\textension cannot\tcause\tthe\tpatent\tto\tbe\tin\teffect\tfor\tmore\tthan\t14\tyears\tfrom\tthe\tdate\tof\tdrug\tapproval.\n\nA\tcompany\tseeking\tto\tmarket\tan\tinnovative\tpharmaceutical\tin\tthe\tU.S.\tmust\tsubmit\ta\tcomplete\tset\tof\tsafety\tand\tefficacy\tdata to\tthe\tFDA.\tIf\tthe\tinnovative\tpharmaceutical\tis\ta\tchemical\tproduct,\tthe\tcompany\tfiles\tan\tNDA.\tIf\tthe\tmedicine\tis\ta\tbiological product,\ta\tBLA\tis\tfiled.\tBoth\ttypes\tof\tapplications\tcan\treceive\tcertain\tperiods\tof\tregulatory\texclusivity.\tAn\tNDA\tor\ta\tBLA for\ta\tcompound\tthat\tis\tdesignated\tas\tan\torphan\tdrug\tcan\treceive\tseven\tyears\tof\texclusivity\tfor\tan\torphan\tdrug\tindication. During\tthis\tperiod,\tthe\tFDA\tgenerally\tmay\tnot\tapprove\tanother\tapplication\tfor\tthe\tsame\tdrug\tproduct\tfor\tthe\tsame\torphan\tuse. A\tcompany\tmay\talso\tearn\tsix\tmonths\tof\tadditional\texclusivity\tfor\ta\tdrug\twhere\tspecific\tclinical\tstudies\tare\tconducted\tat\tthe written\trequest\tof\tthe\tFDA\tto\tstudy\tthe\tuse\tof\tthe\tmedicine\tto\ttreat\tpediatric\tpatients,\tand\tsubmission\tto\tthe\tFDA\tis\tmade prior\t to\t the\t loss\t of\t basic\t exclusivity.\t The\t type\t of\t application\t filed\t (NDA\t or\t BLA)\t can\t affect\t RDP\t exclusivity\t rights\t as discussed\tbelow.\n\n## Chemical\tproducts\n\nA\tcompetitor\tseeking\tto\tlaunch\ta\tgeneric\tsubstitute\tof\ta\tchemical\tinnovative\tdrug\tin\tthe\tU.S.\tmust\tfile\tan\tANDA\twith\tthe\tFDA. In\t the\t ANDA,\t the\t generic\t manufacturer\t needs\t to\t demonstrate\t only\t 'bioequivalence'\t between\t the\t generic\t substitute\t and\t the approved\tNDA\tdrug.\tThe\tANDA\trelies\tupon\tthe\tsafety\tand\tefficacy\tdata\tpreviously\tfiled\tby\tthe\tinnovator\tin\tits\tNDA.\n\nAn\tinnovator\tcompany\tis\trequired\tto\tlist\tcertain\tof\tits\tpatents\tcovering\tthe\tmedicine\twith\tthe\tFDA\tin\twhat\tis\tcommonly\tknown as\tthe\tOrange\tBook.\tAbsent\ta\tsuccessful\tpatent\tchallenge,\tthe\tFDA\tcannot\tapprove\tan\tANDA\tuntil\tafter\tthe\tinnovator's\tlisted patents\texpire.\tHowever,\tafter\tthe\tinnovator\thas\tmarketed\tits\tproduct\tfor\tfour\tyears,\ta\tgeneric\tmanufacturer\tmay\tfile\tan\tANDA and\tallege\tthat\tone\tor\tmore\tof\tthe\tpatents\tlisted\tin\tthe\tOrange\tBook\tunder\tan\tinnovator's\tNDA\tis\tinvalid,\tunenforceable,\tor will\t not\t be\t infringed\t by\t the\t generic\t product.\t This\t allegation\t is\t commonly\t known\t as\t a\t Paragraph\t IV\t certification.\t The innovator\tthen\tmust\tdecide\twhether\tto\tfile\ta\tpatent\tinfringement\tsuit\tagainst\tthe\tgeneric\tmanufacturer.\tFrom\ttime\tto\ttime, ANDAs\tincluding\tParagraph\tIV\tcertifications\tare\tfiled\twith\trespect\tto\tcertain\tof\tour\tproducts.\tWe\tevaluate\tthese\tANDAs\ton\ta case-by-case\tbasis\tand,\twhere\twarranted,\tfile\tsuit\tagainst\tthe\tgeneric\tmanufacturer\tto\tprotect\tour\tpatent\trights.",
          "relationship": "Positively_Impacts"
        },
        "node_3": {
          "id": "Market_Exclusivity",
          "name": "Market Exclusivity",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "and\twe\tare\tnot\table\tto\tpredict\twhether\ta\tfinal\trule\twill\tbe\tadopted\talong\tthe\tlines\tproposed\tand,\tif\tadopted,\twhether\tthe government\twould\tseek\tto\texercise\tmarch-in\trights\tfor\tany\tof\tour\tproducts.\n\nThere\tis\tno\tassurance\tthat\ta\tparticular\tproduct\twill\tenjoy\tmarket\texclusivity\tfor\tthe\tfull\ttime\tperiod\tthat\tappears\tin\tthe estimates\tdisclosed\tin\tthis\t2023\tForm\t10-K\tor\tthat\twe\tassume\twhen\twe\tprovide\tour\tfinancial\tguidance.\n\n## We\tface\tintense\tcompetition\tfrom\tother\tmanufacturers\tand\texpect\tto\tsee\tincreasing\tmarket\tpenetration\tof\tlower-priced\tgeneric products.\n\nThe\t future\t growth\t of\t BMS\t is\t dependent\t on\t the\t market\t access,\t uptake\t and\t expansion\t for\t marketed\t brands,\t new\t product introductions,\tnew\tindications,\tproduct\textensions\tand\tco-promotional\tactivities\twith\talliance\tpartners.\tCompetition\tis\tkeen and\t as\t we\t lose\t exclusivity\t for\t some\t of\t our\t marketed\t brands\t lower-priced\t generic\t products\t will\t increasingly\t penetrate\t our markets.\tGeneric\tchallenges\tto\tour\tproducts\tcan\talso\tarise\tat\tany\ttime,\tand\tour\tpatents\tmay\tnot\tprevent\tthe\temergence\tof generic\tcompetition\tfor\tour\tproducts.\tIn\tsome\tcountries,\tpatent\tprotection\tis\tsignificantly\tweaker\tthan\tin\tthe\tU.S.\tor\tin\tthe EU;\t political\t and\t social\t pressure\t has\t also\t pushed\t legislation\t and\t other\t measures\t that\t promote\t the\t use\t of\t generic\t and biosimilar\tproducts.\tFor\tadditional\tinformation,\tsee\t'Item\t1A.\tRisk\tFactors-We\tcould\tlose\tmarket\texclusivity\tof\ta\tproduct earlier\tthan\texpected.'\n\nIn\taddition,\twe\tface\tcompetition\tfrom\tnew\tproducts\tentering\tthe\tmarket,\tparticularly\tin\tIO.\tNew\tproducts\tmay\thave\t(i)\tlower prices,\t (ii)\t superior\t efficacy\t (benefit)\t or\t safety\t (risk)\t profiles\t (whether\t actual\t or\t perceived),\t (iii)\t technological advantages\tthat\tmay\tmake\tsuch\tproducts\tmore\tconvenient\tto\tuse,\t(iv)\tbetter\tinsurance\tcoverage\tor\treimbursement\tlevels,\t(v) more\teffective\tmarketing\tprograms\tand/or\tother\tdifferentiating\tfactors\tthat\tmake\tit\tharder\tfor\tour\tproducts\tto\tcompete.\tWe cannot\t predict\t with\t accuracy\t the\t timing\t or\t impact\t of\t the\t introduction\t of\t competitive\t products\t that\t treat\t diseases\t and conditions\tlike\tthose\ttreated\tby\tour\tproducts\tand\tproduct\tcandidates.\tBusiness\tcombinations\tamong\tour\tcompetitors\tand\tmajor third-party\t payers\t may\t also\t increase\t competition\t for\t our\t products.\t If\t we\t are\t unable\t to\t compete\t successfully\t against\t our competitors'\tproducts\tin\tthe\tmarketplace,\tthis\tcould\thave\ta\tmaterial\tnegative\timpact\ton\tour\trevenues\tand\tearnings.\n\n## We\tcould\texperience\tdifficulties,\tdelays\tand\tdisruptions\tin\tour\tsupply\tchain\tas\twell\tas\tin\tthe\tmanufacturing,\tdistribution and\tsale\tof\tour\tproducts.\n\nOur\tproduct\tsupply\tand\trelated\tpatient\taccess\thas\tbeen,\tand\tcould\tin\tthe\tfuture\tbe,\tnegatively\timpacted\tby\tdifficulties, delays\t and\t disruptions\t in\t the\t manufacturing,\t distribution\t and\t sale\t of\t our\t products.\t Some\t of\t the\t difficulties,\t delays\t and disruptions\tinclude:\t(i)\tproduct\tseizures\tor\trecalls\tor\tforced\tclosings\tof\tmanufacturing\tplants;\t(ii)\tour\tfailure,\tor\tthe failure\t of\t any\t of\t our\t vendors\t or\t suppliers,\t to\t comply\t with\t cGMP\t and\t other\t applicable\t regulations\t or\t quality\t assurance guidelines\t that\t could\t lead\t to\t manufacturing\t shutdowns,\t product\t shortages\t or\t delays\t in\t product\t manufacturing;\t (iii) manufacturing,\t quality\t assurance/quality\t control,\t supply\t problems\t or\t governmental\t approval\t delays;\t (iv)\t the\t failure\t of\t a supplier,\t including\t sole\t source\t or\t single\t source\t suppliers,\t to\t provide\t us\t with\t the\t necessary\t raw\t materials,\t supplies\t or finished\t goods\t within\t a\t reasonable\t timeframe\t and\t with\t required\t quality;\t (v)\t the\t failure\t of\t a\t third-party\t manufacturer\t to supply\tus\twith\tbulk\tactive\tor\tfinished\tproduct\ton\ttime;\t(vi)\tconstruction\tor\tregulatory\tapproval\tdelays\tfor\tnew\tfacilities\tor the\texpansion\tof\texisting\tfacilities,\tincluding\tthose\tintended\tto\tsupport\tfuture\tdemand\tfor\tour\tbiologics\tproducts,\tsuch\tas Opdivo;\t(vii)\tthe\tfailure\tto\tmeet\tnew\tand\temerging\tregulations\trequiring\tproducts\tto\tbe\ttracked\tthroughout\tthe\tdistribution channels\t using\t unique\t identifiers\t to\t verify\t their\t authenticity\t in\t the\t supply\t chain;\t (viii)\t other\t manufacturing\t or distribution\t issues,\t including\t limits\t to\t manufacturing\t capacity\t and\t changes\t in\t the\t types\t of\t products\t produced,\t such\t as biologics,\tphysical\tlimitations,\tlabor\tdisputes\tor\tshortages,\tor\tother\tbusiness\tinterruptions;\tand\t(ix)\tdisruptions\tin\tsupply chain\tcontinuity,\tincluding\tfrom\tmarket\tforces\t(such\tas\tthe\trecent\tstress\ton\tglobal\tlogistics),\tnatural\tdisasters,\tglobal disease\toutbreaks\tor\tpandemics\t(including\tCOVID-19),\tacts\tof\twar\tor\tterrorism\tor\tother\tunforeseeable\tor\tunavoidable\tevents that\tmaterially\timpact\tone\tor\tmore\tof\tour\tfacilities\tor\ta\tcritical\tsupplier.\n\nIn\taddition,\tmanufacturing\tprocesses\tfor\tnovel\tcell-based\ttherapies,\tsuch\tas\tCAR-T\tcell\ttherapies,\tare\tstill\tevolving,\tand our\tprocesses\tmay\tbe\tmore\tcomplicated\tor\tmore\texpensive\tthan\tthe\tapproaches\ttaken\tby\tour\tcurrent\tand\tfuture\tcompetitors.\tOur ability\t to\t source\t raw\t materials\t and\t supplies\t used\t to\t manufacture\t our\t CAR-T\t cell\t therapies\t and\t to\t develop\t consistent\t and reliable\tmanufacturing\tprocesses\tand\tdistribution\tnetworks\twith\tan\tattractive\tcost\tof\tgoods\tcould\timpact\tfuture\tanticipated revenue\tand\tgross\tprofit\tfor\tour\tCAR-T\tcell\ttherapies.\tFurthermore,\twe\tmay\tface\tchallenges\twith\tsourcing\traw\tmaterials\tand supplies\tfor\tclinical\tand,\tif\tapproved,\tcommercial\tmanufacturing.\tLogistical\tand\tshipment\tdelays\tand\tother\tfactors\tnot\tin\tour control\tcould\tprevent\tor\tdelay\tthe\tdelivery\tof\tour\tproduct\tcandidates\tand\tmarketed\tproducts\tto\tpatients.\tAdditionally,\twe\tare required\tto\tmaintain\ta\tcomplex\tchain\tof\tidentity\tand\tcustody\twith\trespect\tto\tpatient\tmaterial\tas\tsuch\tmaterial\tenters\tinto and\tmoves\tthrough\tthe\tmanufacturing\tprocess.\tAs\ta\tresult,\teven\tslight\tdeviations\tat\tany\tpoint\tin\tthe\tproduction\tprocess\tfor our\t CAR-T\t cell\t therapies\t or\t in\t material\t used\t in\t our\t CAR-T\t cell\t therapies\t could\t result\t in\t loss\t of\t product\t or\t regulatory remedial\taction,\twhich\tcould\tadversely\taffect\tour\tfuture\tanticipated\trevenues\tand/or\tprofitability\trelated\tto\tour\tCAR-T\tcell therapies.",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 214,
      "question": "How does Gilead's option to license Merck's investigational oral integrase inhibitors relate to its commercialization strategy for long-acting oral HIV products, and what financial implications would exercising that option have on Gilead's cost-sharing and revenue-sharing arrangements with Merck?",
      "answer": "Gilead's option to license Merck's investigational oral integrase inhibitors (mentioned on page 75) is directly tied to its collaboration with Merck around long-acting oral HIV products (discussed on page 74), which are part of a broader joint development and commercialization strategy. If Gilead exercises the option within five years after the first Phase 1 trial, the companies will split development costs and revenues unless one party opts out, in which case the non-exercising party receives a royalty. This aligns with the existing cost- and revenue-sharing structure already defined in the long-acting oral product collaboration, where Gilead and Merck share development and commercialization costs at 60% and 40%, respectively, and split global revenues equally until certain revenue thresholds are met ($2.0 billion for oral products). Exercising the option could expand Gilead\u2019s portfolio of combination therapies, but it would also extend the financial commitments and revenue-sharing dynamics already in place, potentially increasing both cost exposure and upside if the products reach commercial success.",
      "reasoning_steps": [
        "Hop 1: GILD(page_75) \u2192 Merck: Gilead has the option to license Merck's investigational oral integrase inhibitors for combination development with lenacapavir, with cost and revenue sharing triggered upon option exercise.",
        "Hop 2: Merck \u2192 Long-Acting Oral Products: Merck is a co-developer and commercialization partner with Gilead for long-acting oral and injectable HIV products, including defined cost and revenue splits.",
        "Hop 3: Long-Acting Oral Products \u2190 GILD(page_74): The long-acting oral products are part of a joint development and commercialization strategy with Merck, with detailed financial terms including cost-sharing (60%/40%) and revenue-sharing thresholds."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Commercializes]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Merck",
        "node_3": "Long-Acting Oral Products",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_1",
          "chunk_text": "We will also have the option to license certain of Merck's investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of G ilead's investigational oral integrase inhibitors to develop in combination with islatravir. Each company may ex ercise its option for such investigational oral integrase inhibitor of the other company within the first five years after ex ecution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon ex ercise of an option, the companies will split development costs and revenues, unless the non-ex ercising company decides to opt out, in which case the non-exercising company will be paid a royalty.\n\n## Arcus\n\nIn  May 2020, we entered into a transaction, and have since entered into various amending transactions, with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (as amended, the 'Collaboration Agreement'), with G ilead having the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the initial transaction, and a common stock purchase agreement and an investor rights agreement (together, as amended, the 'Stock Purchase Agreements').\n\nAs part of the November 2021 amendment, we exercised our options to three of Arcus' clinical stage programs and made related collaboration opt-in payments of $725 million to Arcus in 2022, which were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows.\n\nAs part of the May 2023 amendment, we paid a $35 million upfront fee to initiate research programs against up to four targets jointly selected by the parties that are  applicable  to  inflammatory  diseases,  which  was  charged  to  Acquired  in-process  research  and  development  ex penses  on  our  Consolidated  Statements  of Operations.\n\nAs part of the January 2024 amendment, we committed to a $100 million continuation fee, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations and paid later in 2024.\n\nUnder the Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $243 million, $189 million  and  $187  million  of  such  costs  primarily  in  Research  and  development  ex penses  on  our  Consolidated  Statements  of  Operations  for  the  years  ended December 31, 2024, 2023 and 2022, respectively. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. G ilead will hold ex clusive commercialization rights outside the U.S., subject to any rights of Arcus's ex isting collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. For the research programs applicable to inflammatory diseases, G ilead may exercise an option to license each program at two separate, prespecified time points. If G ilead exercises its option at the earlier time point for the first two target programs, Arcus would be eligible to receive up to $420 million in future option and milestone payments and tiered royalties for each optioned program. For any other option exercise by G ilead for the four target programs, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the U.S. for optioned programs. We may also pay as much as an additional $100 million at our option in 2026 and again in 2028, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term.\n\nUnder the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We have made various purchases of shares since the original closing of the agreement, including a purchase of shares at a premium for $320 million in 2024 whereby we recorded $233 million for the fair value of the equity investment in Prepaid and other current assets on our Consolidated Balance Sheets and $87 million for the premium in Other (income) expense, net on our Consolidated Statements of Operations for the year ended December 31, 2024. Following this transaction, we owned a total of 30.1 million shares, which represented approximately 33% of the issued and outstanding voting stock of Arcus at that time. As of December 31, 2024, we had three designees on Arcus' board of directors.\n\n## Galapagos\n\nIn August 2019, we closed a 10-year option, license and collaboration agreement (the 'OLCA') and a subscription agreement (the 'Subscription Agreement'), each with Galapagos, a clinical-stage biotechnology company based in Belgium, pursuant to which the parties entered into a global collaboration that covers certain programs in Galapagos' current and future product portfolio.\n\nUnder the OLCA, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, G alapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each G alapagos product optioned by us. If we exercise our option for a program, the parties will share  equally  in  development  costs  and  mutually  agreed  commercialization  costs  incurred  subsequent  to  our  ex ercise  of  the  option.  We  may  terminate  the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events.",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Merck",
          "name": "Merck",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Long-Acting_Oral_Products",
          "name": "Long-Acting Oral Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Arcellx\n\nIn January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future nextgeneration  autologous  and  non-autologous  products.  In  December  2023,  we  amended  the  agreement  and  expanded  the  scope  of  the  collaboration  to  include lymphomas and exercised our option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with the collaboration, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Operations in 2023, primarily related to upfront payments. We also recorded a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2024. The companies will share development, clinical  trial  and  commercialization  costs  for  CART-ddBCMA  and  will  jointly  commercialize  the  product  and  split  U.S.  profits 50/50.  Outside  the  U.S.,  we  will commercialize  the  product  and Arcellx  will  receive  royalties  on  sales.  Under  the  agreement, Arcellx   is  eligible  to  receive  performance-based  development  and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future nonautologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the year ended December 31, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well.\n\n## Dragonfly\n\nIn April  2022,  we  entered  into  a  strategic  research  collaboration  agreement  (the  'Dragonfly  Collaboration Agreement')  with  Dragonfly  Therapeutics,  Inc. ('Dragonfly') to develop natural killer ('NK') cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as  options,  after  the  completion  of  certain  preclinical  activities,  to  license  ex clusive,  worldwide  rights  to  develop  and  commercialize  additional  NK  cell  engager programs using the  Dragonfly  Tri-specific  NK  Engager  platform.  Upon  the  closing  of  the  Dragonfly  Collaboration Agreement,  we  made  a  $300  million  upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Operations during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs.\n\n## Merck\n\nIn March 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc. ('Merck') to jointly develop  and  commercialize  long-acting  investigational  treatments  in  HIV   that  combine  G ilead's  investigational  capsid  inhibitor,  lenacapavir,  and  Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations.\n\nUnder  the  terms  of  the  agreement,  as  amended,  G ilead  and  Merck  will  mostly  share  global  development  and  commercialization  costs  at 60%  and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, G ilead would lead commercialization in the U.S., and Merck would lead  commercialization  in  the  European  Union  ('EU')  and  rest  of  the  world.  For  long-acting  injectable  products,  if  approved,  Merck  would  lead commercialization in the U.S. and G ilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, G ilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the years ended December 31, 2024, 2023 and 2022. No revenues have been recognized under the agreement for the years ended December 31, 2024, 2023 and 2022.",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 215,
      "question": "How does the potential market exclusivity timeline for MK-7962 (sotatercept), which includes a 12-year biologic data exclusivity period and a patent expiration in 2037, align with Merck's broader dependency on patent protection and the risks associated with loss of exclusivity for key products?",
      "answer": "Merck disclosed that MK-7962 (sotatercept) is eligible for 12 years of data exclusivity upon approval in the U.S., with its key patent covering treatment methods expiring in 2037. This creates a long-term exclusivity window that could extend beyond the initial 2027 expiration of its current regulatory submission timeline. However, in another section of the 10-K, Merck emphasizes its overall dependency on patent rights and warns that if those rights are invalidated or circumvented, its business could be materially affected. Additionally, the company notes that upon loss of exclusivity, sales of key products typically decline rapidly. Therefore, while MK-7962 has a potentially robust exclusivity timeline, Merck's broader risk profile around patent protection suggests that legal, regulatory, or competitive challenges could still significantly impact the product\u2019s long-term revenue potential.",
      "reasoning_steps": [
        "Hop 1: MRK(page_16) \u2192 MK-7962 (sotatercept): Discloses that MK-7962 is eligible for 12 years of data exclusivity upon approval and has a key patent expiring in 2037.",
        "Hop 2: MK-7962 (sotatercept) \u2192 Patent Protection: The product is subject to U.S. patent protection, with a key patent covering its method of treating pulmonary arterial hypertension.",
        "Hop 3: Patent Protection \u2190 MRK(page_28): Merck emphasizes its dependency on patent rights and warns of material adverse effects if those rights are invalidated or circumvented, and notes the rapid sales decline that typically follows loss of exclusivity."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Subject_To]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "MK-7962 (sotatercept)",
        "node_3": "Patent Protection",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Under Review in the U.S.        | Year of Expiration (in the U.S.)   |\n|---------------------------------|------------------------------------|\n| MK-7264 (gefapixant) (1)        | 2027                               |\n| MK-7962 (sotatercept)           | 2027 (2)                           |\n| MK-1022 (patritumab deruxtecan) | 2035                               |\n| V116 (pneumococcal vaccine)     | 2038                               |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "MK-7962_(sotatercept)",
          "name": "MK-7962 (sotatercept)",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_3",
          "chunk_text": "\nReceived\ta\tComplete\tResponse\tLetter\tfrom\tthe\tFDA\tin\tDecember\t2023. (1)\n\nAs\ta\tbiologic\tproduct,\tMK-7962\t(sotatercept)\twill\tbe\teligible\tfor\t12\tyears\tof\tdata\texclusivity\tupon\tapproval\tin\tthe\tU.S.\tGranted\tpatents\tcovering\tmethods\tof\ttreating\tpulmonary arterial\thypertension\twith\tMK-7962\t(sotatercept),\twhich\twill\texpire\tin\t2037\t(absent\tPTE),\tmay\talso\tprovide\tadditional\texclusivity. (2)\n\nThe\tCompany\talso\thas\tthe\tfollowing\tkey\tU.S.\tpatent\tprotection\tfor\tdrug\tcandidates\tin\tPhase\t3\tdevelopment:\n\nCurrently\tAnticipated\n\n",
          "relationship": "Subject_To"
        },
        "node_3": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 216,
      "question": "How does Pfizer's financial commitment to Valneva through the VLA15 Lyme disease vaccine co-development agreement align with its broader strategic emphasis on collaborative R&D partnerships and cost-sharing models?",
      "answer": "Pfizer committed up to $308 million to Valneva through the VLA15 co-development agreement, including a $130 million upfront payment and shared development costs, reflecting a structured cost-sharing model. This aligns with Pfizer's broader R&D strategy that emphasizes collaborative partnerships to share risk, access external innovation, and enhance pipeline productivity. The Valneva collaboration is specifically highlighted in the R&D section as part of Pfizer's approach to leveraging external partnerships to advance high-impact therapies while managing internal R&D costs and risk exposure.",
      "reasoning_steps": [
        "Hop 1: PFE(page_77) \u2192 VLA15 Development: Pfizer committed up to $308 million to Valneva for the co-development and commercialization of VLA15, including a $130 million upfront payment and shared development costs.",
        "Hop 2: VLA15 Development \u2192 Valneva: The agreement outlines a cost-sharing model where Valneva funds 30% of development costs and receives tiered royalties, indicating a structured partnership to reduce financial risk.",
        "Hop 3: Valneva \u2190 PFE(page_13): The R&D section emphasizes Pfizer's strategic focus on collaborative models to access innovation, share risk and cost, and accelerate development\u2014highlighting the Valneva Lyme disease vaccine collaboration as a specific example."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Funds]-> PRODUCT -[Funds]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "VLA15 Development",
        "node_3": "Valneva",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_7",
          "chunk_text": "\n## D. Licensing Arrangements\n\n## Agreement with Valneva\n\nOn April 30, 2020, we signed an agreement to co-develop and commercialize Valneva's Lyme disease vaccine candidate, VLA15, which covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of up to $308 million in cash payments from us consisting of a $130 million upfront payment, which was paid and recorded in Research and development expenses in our second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.\n\n## Agreement with Akcea\n\nOn October 4, 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a wholly-owned subsidiary of Ionis. The transaction closed in November 2019 and we made an upfront payment of $250 million to Akcea, which was recorded in Research and development expenses in our fourth quarter of 2019. On January 31, 2022, we and Ionis announced the discontinuation of the Pfizer-led clinical development program for the licensed product and that we would be returning the rights to the licensed product to Ionis.\n\nPfizer Inc.",
          "relationship": "Funds"
        },
        "node_2": {
          "id": "VLA15_Development",
          "name": "VLA15 Development",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_7",
          "chunk_text": "\n## D. Licensing Arrangements\n\n## Agreement with Valneva\n\nOn April 30, 2020, we signed an agreement to co-develop and commercialize Valneva's Lyme disease vaccine candidate, VLA15, which covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of up to $308 million in cash payments from us consisting of a $130 million upfront payment, which was paid and recorded in Research and development expenses in our second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.\n\n## Agreement with Akcea\n\nOn October 4, 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a wholly-owned subsidiary of Ionis. The transaction closed in November 2019 and we made an upfront payment of $250 million to Akcea, which was recorded in Research and development expenses in our fourth quarter of 2019. On January 31, 2022, we and Ionis announced the discontinuation of the Pfizer-led clinical development program for the licensed product and that we would be returning the rights to the licensed product to Ionis.\n\nPfizer Inc.",
          "relationship": "Funds"
        },
        "node_3": {
          "id": "Valneva",
          "name": "Valneva",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for heavy menstrual bleeding associated with uterine fibroids in premenopausal women and the management of moderate to severe pain associated with endometriosis. The companies will equally share profits and allowable expenses in the U.S. and Canada for Orgovyx and Myfembree, with Myovant bearing our share of allowable expenses up to a maximum of $50 million in 2022. Myovant will remain responsible for regulatory interactions and drug supply and continue to lead clinical development for the relugolix combination tablet.\n\nRevenues associated with these arrangements are included in Alliance revenues (except in certain markets where we have direct sales and except for the majority of revenues for Comirnaty/BNT162b2, which are included as direct product revenues). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline products that are in development stage, including, among others, (i) with BioNTech to develop a modified mRNA-based vaccine for the prevention of varicella zoster (Shingles), and (ii) with Valneva to co-develop and commercialize Valneva's Lyme disease vaccine candidate, VLA15. For further discussion of collaboration and co-promotion agreements, see the Item 1A. Risk Factors-Collaborations and Other Relationships with Third Parties section in this Form 10-K and Notes 2 and 17 .\n\n## RESEARCH AND DEVELOPMENT\n\nR&amp;D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients' lives as we work to translate advanced science and technologies into the therapies that may be the most impactful for patients. The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. In addition to discovering and developing new products, our R&amp;D efforts seek to add value to our existing products by improving their effectiveness and ease of dosing and by discovering potential new indications.\n\nOur R&amp;D Priorities and Strategy. Our R&amp;D priorities include:\n\n- delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;\n- advancing our capabilities that can position us for long-term R&amp;D leadership; and\n- advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.\n\nTo that end, our R&amp;D primarily focuses on our main therapeutic areas.\n\nWhile a significant portion of our R&amp;D is internal, we also seek promising chemical and biological lead molecules and innovative technologies developed by others to incorporate into our discovery and development processes or projects, as well as our product lines. We do so by entering into collaboration, alliance and license agreements with universities, biotechnology companies and other firms as well as through acquisitions and investments. These collaboration, alliance and license agreements and investments allow us to share knowledge, risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and in-licensed or acquired products. For information on certain of these collaborations, alliances and license arrangements and investments, see Note 2 .\n\nOur R&amp;D Operations. In 2021, we continued to strengthen our global R&amp;D operations and pursue strategies to improve R&amp;D productivity to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time. Our R&amp;D activity is conducted through various platform functions that operate in parallel within our global operations, including the following:\n\n- WRDM. Research units within WRDM are generally responsible for research and early-stage development assets for our business (assets that have not yet achieved proof-of-concept) and are organized by therapeutic area to enhance flexibility, cohesiveness and focus. We can rapidly redeploy resources within a research unit and between various projects to leverage, as necessary, common skills, expertise or focus.\n- GPD. Our GPD organization is a unified center for clinical development and regulatory activities that is generally responsible for the clinical development strategy and operational execution of clinical trials for late-stage clinical assets in Pfizer's pipeline.\n- Science-based platform-services organizations within WRDM. These organizations provide technical expertise and other services to various R&amp;D projects, and are organized into science-based functions. These organizations allow us to react more quickly and effectively to evolving needs by sharing resources among projects, candidates and targets across therapeutic areas and phases of development. Examples of these platform organizations include Pharmaceutical Sciences and Medicine Design, and Worldwide Medical and Safety.\n\nWe manage R&amp;D operations on a total-company basis through our platform functions described above. Specifically, the Portfolio Strategy &amp; Investment committee, composed of senior executives, is accountable for aligning resources among all of our WRDM, GPD and R&amp;D projects and for seeking to ensure optimal capital allocation across the innovative R&amp;D portfolio. We believe that this approach also serves to maximize accountability and flexibility.\n\nWe do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we do not manage our R&amp;D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.\n\nFor additional information, see the Costs and Expenses -Research and Development (R&amp;D) Expenses section within MD&amp;A and Note 17 .\n\nPfizer Inc.\n\n2021 Form 10-K\n\n5",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 217,
      "question": "How does Amgen's acknowledgment of reduced patient access to Prolia during the pandemic reconcile with their stated partnership approach to payers, especially considering ongoing access challenges with Repatha?",
      "answer": "Amgen has acknowledged that the pandemic significantly reduced patient access to Prolia, which requires in-office administration, due to healthcare facility limitations and patient avoidance of medical settings (page 35). Meanwhile, the company has also detailed how commercial payers have imposed formulary restrictions, prior authorization requirements, and cost-sharing measures that have historically limited access to Repatha, contributing to prescription abandonment and reduced sales (page 41). Despite these challenges, Amgen states on page 18 that it is committed to 'partnering with payers to share risk and accountability for health outcomes' as part of its broader strategy to ensure patient access and facilitate innovation. The tension between these realities\u2014systemic access limitations from both public health crises and payer policies\u2014suggests a strategic challenge: while Amgen aims to collaborate with payers to improve access, the structural constraints and financial incentives on the payer side continue to pose material barriers to product uptake, particularly for high-cost biologics like Repatha and in-person administered therapies like Prolia.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_35) \u2192 Patient Access: Amgen reports that the pandemic reduced access to Prolia, which requires in-office administration, due to healthcare facility limitations and patient behavior changes.",
        "Hop 2: Patient Access \u2192 Payers: Commercial payers have implemented cost-control measures such as prior authorization, step therapy, and high copays that have historically restricted access to Repatha, leading to prescription abandonment and lower sales.",
        "Hop 3: Payers \u2190 AMGN(page_18): Amgen explicitly states its commitment to 'partner with payers to share risk and accountability for health outcomes' as part of its strategy to ensure patient access and support innovation."
      ],
      "difficulty": "hard",
      "idf_score": 5.768961210743596,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR -[Negatively_Impacts]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Patient Access",
        "node_3": "Payers",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "RISK_FACTOR",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_35",
          "chunk_id": "chunk_1",
          "chunk_text": "appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. For example, an NPR/Harvard poll in 2021 found that, with hospitals crowded from COVID-19, one in five U.S. households has had to delay care for serious illnesses. These measures and challenges will likely continue to varying degrees for the duration of the pandemic and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia requires administration by a healthcare provider in doctors' offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia instructs healthcare professionals who discontinue Prolia to transition  the  patient  to  an  alternative  antiresorptive,  including  oral  treatments  that  do  not  require  administration  by  a  healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive or therapies that do not require administration in a hospital setting, potentially adversely affecting sales of certain of our products. Also, new patients have been, and are expected to continue to be, less likely to be diagnosed and/or to start therapeutics during the pandemic, and these effects, together with the lower treatment rates during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decrease in diagnoses over the course  of  the  pandemic  has  suppressed  the  volume  of  new  patients  starting  treatment,  which  we  expect  to  continue  to  impact  our business. Once the pandemic subsides, we anticipate there could be a backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate lower provider capacity, and this lower provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences  among  healthcare  professionals  and  patients  toward  treatments  that  do  not  require  administration  by  healthcare professionals or visits to medical facilities.\n\nAs  the  pandemic  continues,  and  if  conditions  worsen  or  if  the  duration  of  the  pandemic  extends  significantly,  we  expect  to experience  additional  adverse  effects  on  our  development,  operational  and  commercial  activities,  customer  purchases  and  our collections of accounts receivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections as conditions begin to improve. There was a resurgence in COVID19 infections in numerous jurisdictions in 2021, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions, including in the United States, Europe and Asia Pacific regions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. New variants of the SARS-CoV-2 virus have emerged, including the delta and omicron variants, and have been shown to be present in many geographies and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain  their  efficacy  against  future  variants  of  the  virus.  Further,  even  while  vaccine  booster  shots  are  available  for  certain  patients, persistent vaccine hesitancy may result in under-vaccinated populations which may prolong the duration of the COVID-19 pandemic and  continue  to  disrupt  the  availability  of  healthcare  services  to  the  patients  we  serve.  Jurisdictions  may  implement,  continue  or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity. These measures could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain,  and  further  prevent  or  discourage  patients  from  participating  in  our  clinical  trials,  seeking  healthcare  services  and  the administration of certain of our products. The increased availability of remote working arrangements in response to the COVID-19 pandemic has expanded the pool of companies that can compete for our employees and employment candidates. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the United States, on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 (including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of COVID-19 antibody therapies for Lilly) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of,  materials  or  components  used  in  the  development,  manufacturing,  distribution,  or  administration  of  our  products.  For  example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our clinical trials has developed that we are actively monitoring and managing. We have also experienced challenges in obtaining certain COVID-19-related supplies, including COVID-19 antigen rapid test kits for our staff, as a result of high demand and limited supplies during the omicron variant surge. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.\n\nThe COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in this 'Risk Factors' section, which could materially adversely affect our business, operations and",
          "relationship": "Negatively_Impacts"
        },
        "node_2": {
          "id": "Patient_Access",
          "name": "Patient Access",
          "type": "RISK_FACTOR",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_41",
          "chunk_id": "chunk_1",
          "chunk_text": "## -U.S. commercial payer actions have affected and may continue to affect access to and sales of our products\n\nPayers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from the consolidation of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With  increasing  frequency,  payers  are  adopting  benefit  plan  changes  that  shift  a  greater  proportion  of  drug  costs  to  patients.  Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant  limitations  on  patients'  use  of  manufacturer  commercial  copay  assistance  programs.  Further,  government  regulation  of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, and  remains  standing  policy  for  2022)  that  has  caused  commercial  payers  to  more  widely  adopt  copay  accumulator  adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their  formularies or those they manage, particularly in treatment areas where the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer's prior authorization before covering the product or that patients use a mailorder  pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain  indications  for  which  our  products  are  approved  or  chosen  to  exclude  coverage  entirely.  For  example,  some  payers  require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria,  and  these  requirements  have  limited,  and  may  continue  to  limit,  patient  access  to  Repatha  treatment.  In  an  effort  to  reduce barriers  to  access,  we  reduced  the  net  price  of  Repatha  by  providing  greater  discounts  and  rebates  to  payers,  including  PBMs  that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than pay their co-pay payment, we introduced a set of new National Drug Codes to make Repatha available at a lower list price to attempt to address affordability for patients, particularly those on Medicare, and on December 31,  2019,  we  discontinued  the  higher  list  price  option  for  Repatha.  Despite  these  net  and  list  price  reductions,  some  payers  have restricted,  and  may  continue  to  restrict,  patient  access  and  have  and  may  continue  to  change  formulary  coverage  for  Repatha,  seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, and negatively affect Repatha sales.\n\nFurther, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements  and  limiting  patient  access  and  usage.  For  example,  in  the  United  States,  as  of  the  beginning  of  2021,  the  top  five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage or plan changes, restrictions or exclusions imposed by these commercial  payers  could  have  a  material  adverse  effect  on  our  product  sales,  business  and  results  of  operations.  Policy  reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or  consequences  for  our  business  and  how  we  interact  with  these  entities.  See Concentration  of  sales  at  certain  of  our  wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.\n\n-Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products\n\nOutside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1.  Business-Reimbursement. IRP has been widely used by many countries outside the United States to control costs based on an external  benchmark  of  a  product's  price  in  other  countries.  IRP  policies  can  change  quickly  and  frequently  and  may  not  reflect differences  in  the  burden  of  disease,  indications,  market  structures,  or  affordability  differences  across  countries  or  regions.  Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are  used  in  various  foreign  jurisdictions  as  well.  In  addition,  countries  may  refuse  to  reimburse  or  may  restrict  the  reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA's approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to 2020 was limited to a narrower patient population (such as those with HoFH) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "Payers",
          "name": "Payers",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_18",
          "chunk_id": "chunk_1",
          "chunk_text": "The dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. Given the diverse interests in play between payers, biopharmaceutical manufacturers, policy makers, healthcare providers and independent organizations, if and whether the parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:\n\n- investing billions of dollars annually in R&amp;D;\n- pricing our medicines to reflect the value they provide;\n- developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;\n- partnering with payers to share risk and accountability for health outcomes;\n- providing patient support and education programs;\n- helping patients in financial need access our medicines; and\n- working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.\n\nSee  Item  1A.  Risk  FactorsOur sales  depend  on  coverage  and  reimbursement  from  government  and  commercial  third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability and Item 1A. Risk FactorsGuidelines and recommendations published by various organizations can reduce the use of our products.\n\n## Manufacturing, Distribution and Raw Materials\n\n## Manufacturing\n\nWe  believe  we  are  a  leader  in  the  manufacture  of  biologics  and  that  our  manufacturing  capabilities  represent  a  competitive advantage. The products we manufacture consist of both biologics and small molecule drugs. The majority of our products are biologics that are produced in living cells and that are inherently complex due to naturally occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory-scale processes into reproducible commercial  manufacturing  processes.  Further,  our  expertise  in  the  manufacture  of  biologics  positions  us  well  for  leadership  in  the global biosimilars market. For additional information regarding manufacturing facilities, see Item 2. Properties.\n\nWe  have  been  innovating  our  manufacturing  facilities  designed  to  extend  our  manufacturing  advantage  by  optimizing  our manufacturing  network  and/or  by  mitigating  risks  while  continuing  to  ensure  adequate  supply  of  our  products.  For  example,  our licensed next-generation biomanufacturing plant operating in Singapore, and our recently FDA approved facility in West Greenwich, Rhode  Island,  incorporate  multiple  innovative  technologies  into  a  single  facility.  Next-generation  biomanufacturing  plants  require smaller  manufacturing  footprints  and  offer  greater  environmental  benefits,  including  reduced  consumption  of  water  and  energy  and lower levels  of  carbon  emissions. Within  such  plants,  the  equipment  is  portable  and  smaller,  which  provides  greater  flexibility  and speed in the manufacture of different medicines simultaneously. This enables Amgen to respond to changing demands for its medicines with increased agility. The Singapore site also has a plant that has been approved by several agencies, including the FDA and EMA, to produce small molecule drugs for commercial manufacturing.\n\nOur  internal  manufacturing  network  has  commercial  production  capabilities  for  bulk  manufacturing,  formulation,  fill,  finish, tableting and device assembly. These activities are performed within the United States and its territories in our Puerto Rico, Rhode Island and California facilities as well as internationally in our Ireland, Netherlands and Singapore facilities. In addition, we use thirdparty contract manufacturers to supplement the capacity or capability of our commercial manufacturing network.\n\nTo support our clinical trials, we manufacture product candidates primarily at our California facilities. We also use third-party contract manufacturers to supplement the capacity or capability of our overall clinical manufacturing network.\n\nSee Item 1A. Risk Factors for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 218,
      "question": "How does GILD's financial exposure to Symtuza through its revenue-sharing arrangement with Janssen compare with the strategic importance of Symtuza in GILD's HIV portfolio, given the structure of their collaboration and GILD's role as exclusive supplier of the Gilead Compounds?",
      "answer": "GILD's financial exposure to Symtuza is indirect and contingent on Janssen's pricing and sales performance, as GILD recognizes its share of Symtuza revenue as Product Sales only when Janssen sells the product. This revenue share is based on the net selling prices of each party's components, and GILD does not directly control the commercialization or pricing strategy of Symtuza, which is managed entirely by Janssen. Despite this limited financial control, Symtuza remains strategically significant to GILD as it incorporates Gilead's proprietary compounds (cobicistat, emtricitabine, and tenofovir alafenamide), and GILD retains exclusive supply responsibility and intellectual property rights over these components. This dual role\u2014limited financial control but core scientific and supply involvement\u2014highlights a strategic dependency on Janssen for market success, while maintaining technical and operational influence over the product\u2019s foundational elements.",
      "reasoning_steps": [
        "Hop 1: GILD(page_77) \u2192 Janssen: GILD depends on Janssen for Symtuza pricing and revenue recognition, with revenue recognized only when Janssen sells the product.",
        "Hop 2: Janssen \u2192 Symtuza: Janssen commercializes Symtuza globally, with full control over manufacturing, registration, distribution, and commercialization.",
        "Hop 3: Symtuza \u2190 GILD(page_76): GILD retains exclusive supply and intellectual property rights over the Gilead Compounds used in Symtuza, underscoring its scientific contribution and ongoing operational role in the product\u2019s lifecycle."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Commercializes]-> PRODUCT <-[Commercializes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Symtuza",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Commercializes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 219,
      "question": "How does AbbVie's cost-sharing arrangement with Janssen Biotech, Inc. under the Imbruvica collaboration impact the financial treatment of development costs, and how does this compare to AbbVie's general accounting policy for collaboration-related development milestones paid to third parties?",
      "answer": "Under the Imbruvica collaboration, AbbVie and Janssen share development costs, with Janssen covering approximately 60% and AbbVie covering 40% of these costs, which are reported net of Janssen's share. In 2024, AbbVie incurred $130 million in development milestone payments under other collaboration agreements, which were expensed to acquired IPR&D and milestones expense. This contrasts with the Imbruvica arrangement, where cost-sharing is structured and ongoing, rather than milestone-based. The general policy is that development milestones paid prior to regulatory approval are expensed immediately, while regulatory and commercial milestones post-approval are capitalized and amortized. The Imbruvica collaboration does not follow this exact pattern due to its unique joint cost-sharing structure.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_71) \u2192 [Pharmacyclics]: AbbVie, through its wholly-owned subsidiary Pharmacyclics, entered into a collaboration with Janssen Biotech, Inc. for the development and commercialization of Imbruvica, including a structured cost-sharing arrangement where AbbVie bears 40% of development costs.",
        "Hop 2: [Pharmacyclics] \u2192 [Janssen Biotech, Inc.]: The collaboration agreement between Pharmacyclics and Janssen Biotech, Inc. involves shared development costs and profit-sharing, with Janssen covering approximately 60% of development costs, a unique arrangement compared to typical milestone-based collaborations.",
        "Hop 3: [Janssen Biotech, Inc.] \u2190 [ABBV](page_60): AbbVie's general accounting policy for collaboration-related development milestones (e.g., $130 million in 2024) is to expense them immediately if paid pre-approval, unlike the structured cost-sharing under the Janssen collaboration."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Partners_With]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Pharmacyclics",
        "node_3": "Janssen Biotech, Inc.",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_71",
          "chunk_id": "chunk_1",
          "chunk_text": "## Juvise Pharmaceuticals\n\nIn June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the consolidated statement of earnings in the second quarter of 2022.\n\n## Other Arrangements\n\nIn addition to the significant arrangements described above, AbbVie entered into several other arrangements resulting in charges related to upfront payments of $975 million in 2024, $582 million in 2023 and $315 million in 2022. In connection with the other individually insignificant early-stage arrangements entered into in 2024, AbbVie could make additional payments of up to $10.1 billion upon the achievement of certain development, regulatory and commercial milestones. Acquired IPR&amp;D and milestones expense also included development milestones of $130 million in 2024, $196 million in 2023 and $252 million in 2022.\n\n## Note 6 Collaborations\n\nThe company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2024, 2023 and 2022.\n\n## Collaboration with Janssen Biotech, Inc.\n\nIn December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson &amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.\n\nThe collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.\n\nIn the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line i tems, net of Janssen's share.\n\nOutside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and l osses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.\n\n2024 Form 10-K\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Pharmacyclics",
          "name": "Pharmacyclics",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_71",
          "chunk_id": "chunk_1",
          "chunk_text": "## Juvise Pharmaceuticals\n\nIn June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the consolidated statement of earnings in the second quarter of 2022.\n\n## Other Arrangements\n\nIn addition to the significant arrangements described above, AbbVie entered into several other arrangements resulting in charges related to upfront payments of $975 million in 2024, $582 million in 2023 and $315 million in 2022. In connection with the other individually insignificant early-stage arrangements entered into in 2024, AbbVie could make additional payments of up to $10.1 billion upon the achievement of certain development, regulatory and commercial milestones. Acquired IPR&amp;D and milestones expense also included development milestones of $130 million in 2024, $196 million in 2023 and $252 million in 2022.\n\n## Note 6 Collaborations\n\nThe company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2024, 2023 and 2022.\n\n## Collaboration with Janssen Biotech, Inc.\n\nIn December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson &amp; Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.\n\nThe collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.\n\nIn the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line i tems, net of Janssen's share.\n\nOutside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and l osses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.\n\n2024 Form 10-K\n\n",
          "relationship": "Partners_With"
        },
        "node_3": {
          "id": "Janssen_Biotech,_Inc.",
          "name": "Janssen Biotech, Inc.",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "page_id": "page_60",
          "chunk_id": "chunk_1",
          "chunk_text": "product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant.\n\nIn addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography.\n\n## Research and Development Expenses\n\nInternal R&amp;D costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed.\n\n## Acquired IPR&amp;D and Milestones Expenses\n\nIn an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&amp;D projects are expensed as acquired IPR&amp;D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&amp;D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.\n\n## Business Combinations\n\nAbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in AbbVie's results of operations beginning on the acquisition date and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair value of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and l i a bi l i ti es  a s s umed i n certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.\n\nIn a business combination, the fair value of IPR&amp;D projects acquired is capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off. R&amp;D costs incurred by the company after the acquisition are expensed to R&amp;D as incurred.\n\n## Collaborations and Other Arrangements\n\nThe company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include j oi nt research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements and subsequent payments made to the partner for the achievement of development milestones prior to regulatory approval are expensed to acquired IPR&amp;D and milestones expense in the consolidated statements of earnings. Regulatory and commercial milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred.\n\n## Advertising\n\nCosts associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&amp;A) expense in the consolidated statements of earnings. Advertising expenses were $2.1 billion in 2024, $2.2 billion in 2023 and $2.0 billion in 2022.\n\n## 57 | 2024 Form 10-K",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 220,
      "question": "How does the difference in U.S. patent expiration dates for 'methods of making' between KYPROLIS (2033) and Parsabiv (2035) impact Amgen\u2019s product lifecycle management strategy for these therapies?",
      "answer": "Amgen holds U.S. patent protection for 'methods of making' KYPROLIS until 2033 and for Parsabiv until 2035, indicating a two-year gap in lifecycle protection. This difference may influence how Amgen allocates resources for lifecycle extension strategies, such as formulation improvements or secondary patents, particularly for KYPROLIS, which faces earlier market exposure to potential biosimilar competition.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_13) \u2192 Methods of making: Discloses U.S. patent expiration for KYPROLIS 'methods of making' as 2033",
        "Hop 2: Methods of making \u2192 Parsabiv (etelcalcetide) \u00ae: Parsabiv\u2019s 'methods of making' patent is protected in the U.S. until 2035, creating a two-year extension beyond KYPROLIS",
        "Hop 3: Parsabiv (etelcalcetide) \u00ae \u2190 AMGN(page_14): Parsabiv is listed as a product with detailed patent expiration timelines in the U.S. and Europe"
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> REGULATORY_REQUIREMENT -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Methods of making",
        "node_3": "Parsabiv (etelcalcetide) \u00ae",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "REGULATORY_REQUIREMENT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product                       | Territory   | General subject matter                                                          | Expiration   |\n|-------------------------------|-------------|---------------------------------------------------------------------------------|--------------|\n|                               | U.S.        | Methods of treatment using aqueous formulations                                 | 6/8/2023     |\n| Enbrel (etanercept) \u00ae         | U.S.        | Formulations                                                                    | 10/19/2037   |\n|                               | U.S.        | Fusion protein and pharmaceutical compositions                                  | 11/22/2028   |\n|                               | U.S.        | DNAencoding fusion protein and methods of making fusion protein                 | 4/24/2029    |\n| Prolia /XGEVA (denosumab) \u00ae \u00ae | U.S.        | Methods of treatment                                                            | 6/25/2022    |\n| Prolia /XGEVA (denosumab) \u00ae \u00ae | U.S.        | Nucleic acids encoding RANKLantibodies and methods of producing RANKLantibodies | 11/30/2023   |\n| Prolia /XGEVA (denosumab) \u00ae \u00ae | U.S.        | RANKLantibodies, including sequences                                            | 2/19/2025    |\n| Prolia /XGEVA (denosumab) \u00ae \u00ae | Europe      | RANKLantibodies, including sequences (1)                                        | 6/25/2022    |\n| Otezla (apremilast) \u00ae         | U.S.        | Compositions and compounds                                                      | 2/16/2028    |\n| Otezla (apremilast) \u00ae         | U.S.        | Crystalline form                                                                | 12/9/2023    |\n| Otezla (apremilast) \u00ae         | U.S.        | Methods of treatment (2)                                                        | 5/29/2034    |\n| Otezla (apremilast) \u00ae         | Europe      | Compositions, compounds and methods of treatment (1)                            | 3/20/2023    |\n| Aranesp (darbepoetin alfa) \u00ae  | U.S.        | Glycosylation analogs of erythropoietin proteins                                | 5/15/2024    |\n| KYPROLIS (carfilzomib) \u00ae      | U.S.        | Compositions and compounds                                                      | 12/7/2027    |\n|                               | U.S.        | Methods of treatment                                                            | 4/14/2025    |\n|                               | U.S.        | Methods of making                                                               | 5/8/2033     |\n|                               | Europe      | Compositions, compounds and methods of treatment (1)                            | 12/7/2025    |\n| Repatha (evolocumab) \u00ae        | U.S.        | Antibodies (3)                                                                  | 10/25/2029   |\n| Repatha (evolocumab) \u00ae        | U.S.        | Methods of treatment                                                            | 10/8/2030    |\n| Repatha (evolocumab) \u00ae        | Europe      | Compositions (1)                                                                | 8/22/2028    |\n| Repatha (evolocumab) \u00ae        | Europe      | Methods of treatment                                                            | 5/10/2032    |\n| Repatha (evolocumab) \u00ae        | Europe      | Formulation                                                                     | 5/3/2033     |\n| Nplate (romiplostim) \u00ae        | U.S.        | Formulation                                                                     | 2/12/2028    |\n| Nplate (romiplostim) \u00ae        | Europe      | Thrombopoietic compounds (1)                                                    | 10/22/2019   |\n| Nplate (romiplostim) \u00ae        | Europe      | Formulation                                                                     | 4/20/2027    |\n| Vectibix (panitumumab) \u00ae      | Europe      | Human monoclonal antibodies to epidermal growth factor receptor (1)             | 5/5/2018     |\n| EVENITY (romosozumab-aqqg) \u00ae  | U.S.        | Antibodies (3)                                                                  | 4/25/2026    |\n| EVENITY (romosozumab-aqqg) \u00ae  | U.S.        | Methods of treatment (3)                                                        | 1/11/2029    |\n| EVENITY (romosozumab-aqqg) \u00ae  | U.S.        | Formulation and methods of using formulation                                    | 5/11/2031    |\n| EVENITY (romosozumab-aqqg) \u00ae  | Europe      | Antibodies (1)                                                                  | 4/28/2026    |\n|                               | Europe      | Methods of treatment                                                            | 4/18/2032    |\n|                               | Europe      | Formulation and methods of using formulation                                    | 5/11/2031    |\n| BLINCYTO (blinatumomab) \u00ae     | U.S.        | Pharmaceutical compositions and bifunctional polypeptides                       | 4/6/2030     |\n| BLINCYTO (blinatumomab) \u00ae     | U.S.        | Method of administration                                                        | 9/28/2027    |\n| BLINCYTO (blinatumomab) \u00ae     | Europe      | Bifunctional polypeptides (1)                                                   | 11/26/2024   |\n| BLINCYTO (blinatumomab) \u00ae     | Europe      | Method of administration                                                        | 11/6/2029    |",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Methods_of_making",
          "name": "Methods of making",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_14",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product                          | Territory   | General subject matter                                                 | Expiration   |\n|----------------------------------|-------------|------------------------------------------------------------------------|--------------|\n| Aimovig (erenumab-aooe) \u00ae        | U.S.        | CGRPreceptor antibodies                                                | 5/17/2032    |\n| Aimovig (erenumab-aooe) \u00ae        | U.S.        | Methods of treatment                                                   | 4/22/2036    |\n| Aimovig (erenumab-aooe) \u00ae        | Europe      | CGRPreceptor antibodies (1)                                            | 12/18/2029   |\n| Aimovig (erenumab-aooe) \u00ae        | Europe      | Methods of treatment                                                   | 8/10/2035    |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Compound and pharmaceutical composition                                | 2/7/2031     |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Formulation                                                            | 6/27/2034    |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Methods of making                                                      | 8/9/2035     |\n| Parsabiv (etelcalcetide) \u00ae       | Europe      | Compound and pharmaceutical composition (1)                            | 7/29/2030    |\n| Parsabiv (etelcalcetide) \u00ae       | Europe      | Formulation                                                            | 6/27/2034    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | U.S.        | Compounds and pharmaceutical compositions                              | 5/21/2038    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | U.S.        | Crystalline form, pharmaceutical compositions and methods of treatment | 5/20/2040    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | Europe      | Compounds, pharmaceutical compositions and methods of treatment        | 5/21/2038    |\n| TEZSPIRE (tezepelumab-ekko) \u2122    | U.S.        | Polypeptides (3)                                                       | 2/3/2029     |\n|                                  | U.S.        | Methods of treatment                                                   | 8/23/2038    |\n|                                  | Europe      | Polypeptides                                                           | 9/9/2028     |\n",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Parsabiv_(etelcalcetide)_\u00ae",
          "name": "Parsabiv (etelcalcetide) \u00ae",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_14",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product                          | Territory   | General subject matter                                                 | Expiration   |\n|----------------------------------|-------------|------------------------------------------------------------------------|--------------|\n| Aimovig (erenumab-aooe) \u00ae        | U.S.        | CGRPreceptor antibodies                                                | 5/17/2032    |\n| Aimovig (erenumab-aooe) \u00ae        | U.S.        | Methods of treatment                                                   | 4/22/2036    |\n| Aimovig (erenumab-aooe) \u00ae        | Europe      | CGRPreceptor antibodies (1)                                            | 12/18/2029   |\n| Aimovig (erenumab-aooe) \u00ae        | Europe      | Methods of treatment                                                   | 8/10/2035    |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Compound and pharmaceutical composition                                | 2/7/2031     |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Formulation                                                            | 6/27/2034    |\n| Parsabiv (etelcalcetide) \u00ae       | U.S.        | Methods of making                                                      | 8/9/2035     |\n| Parsabiv (etelcalcetide) \u00ae       | Europe      | Compound and pharmaceutical composition (1)                            | 7/29/2030    |\n| Parsabiv (etelcalcetide) \u00ae       | Europe      | Formulation                                                            | 6/27/2034    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | U.S.        | Compounds and pharmaceutical compositions                              | 5/21/2038    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | U.S.        | Crystalline form, pharmaceutical compositions and methods of treatment | 5/20/2040    |\n| LUMAKRAS /LUMYKRAS\u2122(sotorasib) \u00ae | Europe      | Compounds, pharmaceutical compositions and methods of treatment        | 5/21/2038    |\n| TEZSPIRE (tezepelumab-ekko) \u2122    | U.S.        | Polypeptides (3)                                                       | 2/3/2029     |\n|                                  | U.S.        | Methods of treatment                                                   | 8/23/2038    |\n|                                  | Europe      | Polypeptides                                                           | 9/9/2028     |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 221,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products reconcile with the inclusion of sales to Organon in Merck's 'Other' revenue category, which also reflects third-party manufacturing arrangements?",
      "answer": "Merck continues to manufacture and supply certain formulated pharmaceutical products to Organon under long-term manufacturing and supply agreements (MSAs) established after Organon's spin-off in 2021. These agreements, which have terms ranging from four to ten years, generated $394 million in sales for Merck in 2023. Despite Organon being a spun-off entity, these manufacturing arrangements are treated similarly to third-party relationships and are included within Merck's 'Other' revenue category, which also encompasses revenue from third-party manufacturing arrangements, including sales to Organon. This indicates that Merck views the supply of formulated pharmaceutical products to Organon as part of its broader contract manufacturing services, rather than as a core pharmaceutical segment activity.",
      "reasoning_steps": [
        "Hop 1: MRK(page_91) \u2192 Formulated Pharmaceutical Products: Merck discloses that it is manufacturing and supplying certain formulated pharmaceutical products to Organon under MSAs established post-spin-off, with $394 million in sales recorded in 2023.",
        "Hop 2: Formulated Pharmaceutical Products \u2192 Organon: Organon receives these formulated pharmaceutical products from Merck under long-term MSAs, indicating a continued operational interdependence despite the spin-off.",
        "Hop 3: Organon \u2190 MRK(page_126): Merck includes sales to Organon within its 'Other' revenue category, which also reflects revenue from third-party manufacturing arrangements, signaling how these intercompany transactions are now treated externally."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Supplies]-> PRODUCT -[Manufactures]-> COMP <-[Supplies]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Formulated Pharmaceutical Products",
        "node_3": "Organon",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Supplies"
        },
        "node_2": {
          "id": "Formulated_Pharmaceutical_Products",
          "name": "Formulated Pharmaceutical Products",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nother\texpenses\tas\twell\tas\tprofits\tworldwide.\tMerck\twill\tinclude\tits\tshare\tof\tdevelopment\tcosts\tassociated\twith\tthe\tcollaboration\tas\tpart of Research\tand\tdevelopment expenses.\n\nIn\tconjunction\twith\tthis\ttransaction,\tMerck\trecorded\tan\taggregate\tpretax\tcharge\tof\t$5.5\tbillion\tto Research\tand\tdevelopment expenses\t in\t 2023\t for\t the\t $4.0\t billion\t of\t upfront\t payments\t and\t the\t $1.5\t billion\t of\t continuation\t payments.\t Merck\t determined\t it\t was appropriate\t to\t expense\t the\t $1.0\t billion\t refundable\t portion\t of\t the\t consideration\t because\t the\t significant\t number\t of\t clinical\t studies currently\t underway\t and\t planned\t in\t the\t near\t future,\t as\t well\t as\t certain\t studies\t in\t advanced\t stages,\t makes\t it\t highly\t likely\t that\t the programs\twill\tcontinue\tto\tprogress\tand\tincur\tsubstantial\texpenses,\tand\ttherefore\tthe\tlikelihood\tof\tthe\tprograms\tterminating\tbefore\tthe end\t of\t the\t refundable\t period\t is\t remote.\t Merck\t also\t determined\t that\t it\t was\t appropriate\t to\t expense\t the\t continuation\t payments\t upon execution\tof\tthe\tagreement\tbecause\tsuch\tpayments\tdo\tnot\tresult\tin\tthe\tCompany\tgaining\tany\tadditional\tintellectual\tproperty\trights.\tIn addition,\t the\t significant\t number\t of\t ongoing\t and\t planned\t clinical\t studies\t and\t the\t short-term\t nature\t of\t the\t option\t period\t makes\t the likelihood\tof\tMerck\tnot\tmaking\tthese\tpayments\tremote.\n\n## 5.\t\t\t\tSpin-Off\tof\tOrganon\t&amp;\tCo.\n\nOn\tJune\t2,\t2021,\tMerck\tcompleted\tthe\tspin-off\tof\tOrganon\tthrough\ta\tdistribution\tof\tOrganon's\tpublicly\ttraded\tstock\tto\tCompany shareholders.\tIn\tconnection\twith\tthe\tspin-off,\teach\tMerck\tshareholder\treceived\tone-tenth\tof\ta\tshare\tof\tOrganon's\tcommon\tstock\tfor\teach share\tof\tMerck\tcommon\tstock\theld\tby\tsuch\tshareholder.\tThe\tdistribution\thas\tbeen\ttreated\tas\ttax\tfree\tto\tMerck\tand\tits\tshareholders\tfor U.S.\tfederal\tincome\ttax\tpurposes.\tIndebtedness\tof\t$9.5\tbillion\tprincipal\tamount,\tconsisting\tof\tterm\tloans\tand\tsenior\tnotes,\twas\tissued in\t 2021\t in\t connection\t with\t the\t spin-off\t and\t assumed\t by\t Organon.\t Merck\t is\t no\t longer\t the\t obligor\t of\t any\t Organon\t debt\t or\t financing arrangements.\tCash\tproceeds\tof\t$9.0\tbillion\twere\tdistributed\tby\tOrganon\tto\tMerck\tin\tconnection\twith\tthe\tspin-off.\n\nAlso\tin\tconnection\twith\tthe\tspin-off,\tMerck\tand\tOrganon\tentered\tinto\ta\tseparation\tand\tdistribution\tagreement\tand\talso\tentered into\tvarious\tother\tagreements\tto\teffect\tthe\tspin-off\tand\tprovide\ta\tframework\tfor\tthe\trelationship\tbetween\tMerck\tand\tOrganon\tafter\tthe spin-off,\tincluding\ta\ttransition\tservices\tagreement\t(TSA),\tmanufacturing\tand\tsupply\tagreements\t(MSAs),\ttrademark\tlicense\tagreements, intellectual\t property\t license\t agreements,\t an\t employee\t matters\t agreement,\t a\t tax\t matters\t agreement\t and\t certain\t other\t commercial agreements.\tUnder\tthe\tTSA,\tMerck\tis\tproviding\tOrganon\tvarious\tservices\tand,\tsimilarly,\tOrganon\tis\tproviding\tMerck\tvarious\tservices.\tA majority\tof\tthe\tservices\tprovided\tunder\tthe\tTSA\tterminated\twithin\t25\tmonths\tfollowing\tthe\tspin-off;\ta\tmajority\tof\tthe\tremaining\tservices will\tterminate\twithin\t35\tmonths\tfollowing\tthe\tspin-off.\tMerck\tand\tOrganon\talso\tentered\tinto\ta\tseries\tof\tinterim\toperating\tagreements pursuant\tto\twhich\tin\tvarious\tjurisdictions\twhere\tMerck\theld\tlicenses,\tpermits\tand\tother\trights\tin\tconnection\twith\tmarketing,\timport and/or\tdistribution\tof\tOrganon\tproducts\tprior\tto\tthe\tseparation,\tMerck\tcontinued\tto\tmarket,\timport\tand\tdistribute\tsuch\tproducts\tuntil such\ttime\tas\tthe\trelevant\tlicenses\tand\tpermits\ttransferred\tto\tOrganon.\tUnder\tsuch\tinterim\toperating\tagreements\tand\tin\taccordance\twith the\t separation\t and\t distribution\t agreement,\t Merck\t continued\t operations\t in\t the\t affected\t markets\t on\t behalf\t of\t Organon,\t with\t Organon receiving\tall\tof\tthe\teconomic\tbenefits\tand\tburdens\tof\tsuch\tactivities.\tAs\tof\tDecember\t31,\t2023,\tonly\tone\tjurisdiction\tremains\tunder\tan interim\toperating\tagreement.\tAdditionally,\tMerck\tand\tOrganon\tentered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tMerck\tis\t(a)\tmanufacturing and\tsupplying\tcertain\tactive\tpharmaceutical\tingredients\tfor\tOrganon,\t(b)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical products\tfor\tOrganon,\tand\t(c)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tOrganon.\tSimilarly,\tOrganon\tand\tMerck entered\tinto\ta\tnumber\tof\tMSAs\tpursuant\tto\twhich\tOrganon\tis\t(a)\tmanufacturing\tand\tsupplying\tcertain\tformulated\tpharmaceutical\tproducts for\tMerck,\tand\t(b)\tpackaging\tand\tlabeling\tcertain\tfinished\tpharmaceutical\tproducts\tfor\tMerck.\tThe\tterms\tof\tthe\tMSAs\trange\tin\tinitial duration\tfrom\tfour\tyears\tto\tten\tyears.\n\nThe\tamounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tabove\tMSAs\tinclude\tsales\tof\t$394\tmillion,\t$383\tmillion\tand $219\tmillion\tin\t2023,\t2022\tand\t2021,\trespectively,\tand\trelated\tcost\tof\tsales\tof\t$422\tmillion,\t$404\tmillion\tand\t$195\tmillion\tin\t2023, 2022\tand\t2021,\trespectively.\tAmounts\tincluded\tin\tthe\tconsolidated\tstatement\tof\tincome\tfor\tthe\tTSAs\twere\timmaterial\tin\t2023,\t2022\tand 2021.\tThe\tamounts\tdue\tfrom\tOrganon\tunder\tall\tof\tthe\tabove\tagreements\twere\t$632\tmillion\tand\t$511\tmillion\tat\tDecember\t31,\t2023\tand\t2022, respectively,\t and\t are\t reflected\t in Other\t current\t assets .\t The\t amounts\t due\t to\t Organon\t under\t these\t agreements\t were\t $598\t million\t and $345\tmillion\tat\tDecember\t31,\t2023\tand\t2022,\trespectively,\tand\tare\tincluded\tin Accrued\tand\tother\tcurrent\tliabilities .\n\nThe\t results\t of\t the\t women's\t health,\t biosimilars\t and\t established\t brands\t businesses\t (previously\t included\t in\t the\t Pharmaceutical segment)\tthat\twere\tcontributed\tto\tOrganon\tin\tthe\tspin-off,\tas\twell\tas\tinterest\texpense\trelated\tto\tthe\tdebt\tissuance\tin\t2021,\thave\tbeen reflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tconsolidated\tstatement\tof\tincome\tas Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand\tAmounts\tAttributable\tto\tNoncontrolling\tInterests for\tperiods\tprior\tto\tthe\tspin-off\ton\tJune\t2,\t2021.\tMerck\tincurred\tseparation costs\tof\t$556\tmillion\tin\t2021\trelated\tto\tthe\tspin-off\tof\tOrganon,\twhich\tare\talso\tincluded\tin Income\tfrom\tDiscontinued\tOperations,\tNet\tof Taxes\tand",
          "relationship": "Manufactures"
        },
        "node_3": {
          "id": "Organon",
          "name": "Organon",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_126",
          "chunk_id": "chunk_3",
          "chunk_text": "\nU.S.\tplus\tinternational\tmay\tnot\tequal\ttotal\tdue\tto\trounding.\n\nAlliance\trevenue\tfor\tLynparza\tand\tLenvima\trepresents\tMerck's\tshare\tof\tprofits,\twhich\tare\tproduct\tsales\tnet\tof\tcost\tof\tsales\tand\tcommercialization\tcosts\t(see\tNote\t4). (1)\n\nAlliance\trevenue\tfor\tReblozyl\trepresents\troyalties\tand,\tfor\t2022,\talso\tincludes\ta\tpayment\treceived\trelated\tto\tthe\tachievement\tof\ta\tregulatory\tapproval\tmilestone\t(see\tNote\t4). (2)\n\nAlliance\t revenue\t for\t Adempas/Verquvo\t represents\t Merck's\t share\t of\t profits\t from\t sales\t in\t Bayer's\t marketing\t territories,\t which\t are\t product\t sales\t net\t of\t cost\t of\t sales\t and commercialization\tcosts\t(see\tNote\t4). (3)\n\nOther\tpharmaceutical\tprimarily\treflects\tsales\tof\tother\thuman\thealth\tpharmaceutical\tproducts,\tincluding\tproducts\twithin\tthe\tfranchises\tnot\tlisted\tseparately. (4)\n\nOther\tis\tprimarily\tcomprised\tof\tmiscellaneous\tcorporate\trevenue,\tincluding\trevenue\thedging\tactivities\twhich\tincreased\t(decreased)\tsales\tby\t$244\tmillion,\t$810\tmillion\tand\t$(203) million\tin\t2023,\t2022\tand\t2021,\trespectively,\tas\twell\tas\trevenue\tfrom\tthird-party\tmanufacturing\tarrangements\t(including\tsales\tto\tOrganon).\tOther\tfor\t2023,\t2022\tand\t2021\talso includes\t$118\tmillion,\t$165\tmillion\tand\t$218\tmillion,\trespectively,\trelated\tto\tupfront\tand\tmilestone\tpayments\treceived\tby\tMerck\tfor\tout-licensing\tarrangements. (5)",
          "relationship": "Supplies"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 222,
      "question": "How does Amgen's patent protection timeline for Dazodalibep align with its strategic development focus on Sj\u00f6gren's Syndrome, particularly given the molecule's expiration dates in the U.S. and Europe and its acquisition through Horizon?",
      "answer": "Amgen's patent protection for Dazodalibep extends until 2034 in the U.S. and 2032 in Europe (page 26, chunk 4), which provides a relatively long runway for commercialization in key markets. This aligns with the company's strategic development focus on Sj\u00f6gren's Syndrome, a therapeutic area acquired through the Horizon transaction (page 26, chunk 2), where Dazodalibep is now positioned as a key investigational asset. The extended patent life supports a longer-term investment horizon for clinical development and market positioning in an autoimmune disease with high unmet need. Given the strategic importance of Horizon-acquired molecules like Dazodalibep, the patent expiration dates suggest Amgen has secured sufficient IP protection to justify ongoing investment in this indication.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_13) \u2192 Polypeptides: Discloses patent expiration timelines for various polypeptide-based products, including those in development.",
        "Hop 2: Polypeptides \u2192 Dazodalibep: Dazodalibep is specifically listed as a polypeptide with U.S. and European patent protection expiring in 2034 and 2032 respectively.",
        "Hop 3: Dazodalibep \u2190 AMGN(page_26): Dazodalibep is highlighted as a Horizon-acquired molecule under development for Sj\u00f6gren's Syndrome, indicating strategic prioritization."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Polypeptides",
        "node_3": "Dazodalibep",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_13",
          "chunk_id": "chunk_1",
          "chunk_text": "| Product                           | Territory   | General subject matter                                                    | Expiration         |\n|-----------------------------------|-------------|---------------------------------------------------------------------------|--------------------|\n|                                   | U.S.        | Formulations and methods of preparing formulations                        | 10/19/2037         |\n| Enbrel (etanercept) \u00ae             | U.S.        | Fusion protein and pharmaceutical compositions                            | 11/22/2028         |\n|                                   | U.S.        | DNA encoding fusion protein and methods of making fusion protein          | 4/24/2029          |\n| Otezla (apremilast) \u00ae             | U.S.        | Compositions and compounds                                                | 2/16/2028          |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 3/20/2023          |\n| \u00ae                                 | U.S.        | Antibodies (2)                                                            | 8/22/2028          |\n|                                   | U.S.        | Methods of treatment                                                      | 11/22/2030         |\n| Repatha (evolocumab)              | Europe      | Compositions (1)                                                          | 8/22/2028          |\n| Repatha (evolocumab)              | Europe      | Methods of treatment                                                      | 5/10/2032          |\n|                                   | Europe      | Formulation                                                               | 5/3/2033           |\n| Nplate (romiplostim) \u00ae            | U.S.        | Formulation                                                               | 2/12/2028          |\n|                                   | Europe      | Thrombopoietic compounds (1)                                              | 10/22/2019         |\n|                                   | Europe      | Formulation                                                               | 4/20/2027          |\n|                                   | U.S.        | Compositions and compounds                                                | 12/7/2027          |\n| \u00ae                                 | U.S.        | Methods of treatment                                                      | 4/14/2025          |\n| KYPROLIS (carfilzomib)            | U.S.        | Methods of making                                                         | 5/8/2033           |\n|                                   | Europe      | Compositions, compounds and methods of treatment (1)                      | 12/7/2025          |\n| Aranesp (darbepoetin alfa) \u00ae      | U.S.        | Glycosylation analogs of erythropoietin proteins                          | 5/15/2024          |\n|                                   | U.S.        | Antibodies                                                                | 4/25/2026          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/9/2033           |\n| EVENITY (romosozumab-aqqg) \u00ae      | Europe      | Antibodies (1)                                                            | 4/28/2026          |\n|                                   | Europe      | Methods of treatment                                                      | 4/18/2032          |\n|                                   | Europe      | Formulation and methods of using formulation                              | 5/11/2031          |\n|                                   | U.S.        | Pharmaceutical compositions and bifunctional polypeptides                 | 4/6/2030           |\n| \u00ae                                 | U.S.        | Method of administration                                                  | 9/28/2027          |\n| BLINCYTO (blinatumomab)           | Europe      | Bifunctional polypeptides (1)                                             | 11/26/2024         |\n|                                   | Europe      | Method of administration                                                  | 11/6/2029          |\n| TEZSPIRE (tezepelumab-ekko) \u00ae     | U.S.        | Polypeptides (2)                                                          | 2/3/2029           |\n|                                   | U.S.        | Methods of treatment                                                      | 8/23/2038          |\n|                                   | Europe      | Polypeptides (1)                                                          | 9/9/2028           |\n| TEPEZZA (teprotumumab-trbw) \u00ae     | U.S.        | IGF-1R antibodies (3)                                                     | 3/3/2029           |\n| \u00ae                                 | U.S.        | Compound and pharmaceutical composition                                   | 2/7/2031           |\n| Parsabiv (etelcalcetide)          | U.S.        | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | Methods of making                                                         | 8/9/2035           |\n|                                   | Europe      | Compound and pharmaceutical composition (1)                               | 7/29/2030          |\n|                                   | Europe      | Formulation                                                               | 6/27/2034          |\n|                                   | U.S.        | CGRP receptor antibodies                                                  | 5/17/2032          |\n|                                   | U.S.        | Methods of treatment                                                      | 4/22/2036          |\n| Aimovig (erenumab-aooe) \u00ae         | U.S.        | Compositions and pharmaceutical formulations                              | 4/1/2039           |\n|                                   | Europe      | CGRP receptor antibodies (1)                                              | 12/18/2029         |\n|                                   | Europe      | Methods of treatment                                                      | 8/10/2035          |\n|                                   | U.S.        | Compounds and pharmaceutical compositions                                 | 5/21/2038          |\n| LUMAKRAS /LUMYKRAS\u2122 (sotorasib) \u00ae | U.S.        | Crystalline form, pharmaceutical compositions and methods of treatment    | 5/20/2040          |\n|                                   | U.S.        | Methods of treatment                                                      | 9/15/2040          |\n|                                   | Europe      | Compounds, pharmaceutical compositions and methods of treatment           | 5/21/2038          |\n|                                   | U.S.        | Polypeptides and pharmaceutical compositions                              | 4/11/2026          |\n| KRYSTEXXA (pegloticase) \u00ae         | U.S.        | Methods of treatment                                                      |                    |\n|                                   | U.S.        | Compounds and pharmaceutical compositions (2)                             | 6/25/2030 2/3/2031 |\n| TAVNEOS (avacopan) \u00ae              | U.S.        | Crystalline and amorphous forms and pharmaceutical compositions           | 5/29/2041          |\n| UPLIZNA (inebilizumab-cdon) \u00ae     | U.S.        | CD19 antibodies and pharmaceutical compositions (2)                       | 3/7/2030           |\n|                                   | Europe      | CD19 antibodies, pharmaceutical compositions and methods of treatment (1) | 9/7/2027           |\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Polypeptides",
          "name": "Polypeptides",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_4",
          "chunk_text": "| Molecule      | Territory   | General subject matter   |   Estimated expiration* |\n|---------------|-------------|--------------------------|-------------------------|\n| Bemarituzumab | U.S.        | Polypeptides             |                    2029 |\n| Bemarituzumab | Europe      | Polypeptides             |                    2029 |\n| Dazodalibep   | U.S.        | Polypeptides             |                    2034 |\n| Dazodalibep   | Europe      | Polypeptides             |                    2032 |\n| Olpasiran     | U.S.        | Compounds                |                    2036 |\n| Olpasiran     | Europe      | Compounds                |                    2036 |\n| Rocatinlimab  | U.S.        | Polypeptides             |                    2027 |\n| Rocatinlimab  | Europe      | Polypeptides             |                    2026 |\n| Tarlatamab    | U.S.        | Polypeptides             |                    2036 |\n| Tarlatamab    | Europe      | Polypeptides             |                    2036 |\n",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Dazodalibep",
          "name": "Dazodalibep",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_2",
          "chunk_text": "| Molecule          | Investigational indication                         | Program change                                      |\n|-------------------|----------------------------------------------------|-----------------------------------------------------|\n| Dazodalibep       | Sj\u00f6gren's Syndrome                                 | Horizon acquired program                            |\n| KYPROLIS          | Weekly dosing for relapsed multiple myeloma        | Concluded-program did not meet its primary endpoint |\n| LUMAKRAS/LUMYKRAS | NSCLC in combination with chemotherapy             | Initiated phase 3 study                             |\n| Otezla            | Genital psoriasis                                  | Approved by the FDA                                 |\n| Tarlatamab        | Small cell lung cancer                             | Initiated phase 3 study                             |\n| TEPEZZA           | Active TED (OPTIC-J); Chronic/Low CAS TED in Japan | Horizon acquired programs                           |\n| UPLIZNA           | IgG4-related disease; Myasthenia gravis            | Horizon acquired programs                           |\n| ABP 206           | Biosimilar to OPDIVO                               | Initiated phase 3 study                             |\n",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 223,
      "question": "How does Amgen's strategic restructuring of the Aimovig collaboration with Novartis in 2022 align with the competitive pressures Amgen faces from Novartis in other therapeutic areas, particularly in light of the royalty and rights retention provisions in the modified agreement?",
      "answer": "Amgen restructured its Aimovig collaboration with Novartis effective January 1, 2022, ending Novartis's U.S. commercialization role and royalty obligations while retaining its ex-U.S. rights and royalty payments on international sales. This shift likely reflects strategic recalibration following litigation and changing market dynamics. At the same time, Amgen faces direct competition from Novartis in multiple therapeutic areas\u2014such as with Otezla and Nplate\u2014where Novartis markets competing products. The modified agreement allows Amgen full U.S. control and eliminates royalty burdens domestically, while still benefiting from Novartis's international commercial infrastructure and royalty contributions abroad. This dual positioning enables Amgen to strengthen its competitive stance in the U.S. while maintaining a revenue stream from Novartis in international markets.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_28) \u2192 Aimovig: Amgen restructured the Aimovig collaboration with Novartis in 2022, ending U.S. cost-sharing and royalty payments by Amgen, while Novartis continues to pay double-digit royalties on ex-U.S. sales.",
        "Hop 2: Aimovig \u2192 Novartis: Novartis retains exclusive commercial rights outside the U.S. and Japan for Aimovig and continues to pay royalties on international sales post-2022.",
        "Hop 3: Novartis \u2190 AMGN(page_16): Novartis competes directly with Amgen in multiple therapeutic areas, including Otezla (against Cosentyx) and Nplate (against PROMACTA/REVOLADE)."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Holds_Rights_To]-> COMP <-[Competes_With]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Aimovig",
        "node_3": "Novartis",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Aimovig",
          "name": "Aimovig",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Holds_Rights_To"
        },
        "node_3": {
          "id": "Novartis",
          "name": "Novartis",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_2",
          "chunk_text": "| Product      | Territory    | Competitor-marketed product                      | Competitors                            |\n|--------------|--------------|--------------------------------------------------|----------------------------------------|\n| ENBREL       | U.S. &Canada | HUMIRA                                           | AbbVie                                 |\n| ENBREL       | U.S.         | Xeljanz                                          | Pfizer Inc.                            |\n| ENBREL       | U.S. &Canada | RINVOQ                                           | AbbVie                                 |\n| Prolia       | U.S. &Europe | Alendronate, raloxifene and zoledronate generics | Various                                |\n| Otezla       | U.S. &Europe | HUMIRA \u2020                                         | AbbVie                                 |\n| Otezla       | U.S. &Europe | Cosentyx                                         | Novartis                               |\n| Otezla       | U.S. &Europe | Taltz                                            | Lilly                                  |\n| Otezla       | U.S. &Europe | Tremfya                                          | Janssen (1)                            |\n| Otezla       | U.S. &Europe | Skyrizi (2)                                      | AbbVie                                 |\n| Otezla       | U.S. &Europe | Methotrexate generics                            | Various                                |\n| XGEVA        | U.S. &Europe | Zoledronate generics                             | Various                                |\n| Neulasta (3) | U.S.         | UDENYCA                                          | Coherus BioSciences, Inc.              |\n| Neulasta (3) | U.S.         | Fulphila                                         | Mylan Institutional Inc.               |\n| Neulasta (3) | U.S. &Europe | Filgrastim biosimilars                           | Various                                |\n| Aranesp      | U.S.         | PROCRIT (4)                                      | Janssen (1)                            |\n| Aranesp      | U.S. &Europe | Epoetin alfa biosimilars                         | Various                                |\n| Repatha      | U.S. &Europe | PRALUENT                                         | Regeneron Pharmaceuticals, Inc. Sanofi |\n| KYPROLIS (5) | U.S.         | VELCADE                                          | Millennium Pharmaceuticals, Inc. (6)   |\n| KYPROLIS (5) | U.S. &Europe | REVLIMID                                         | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | POMALYST/IMNOVID                                 | Celgene (7)                            |\n| KYPROLIS (5) | U.S. &Europe | DARZALEX                                         | Janssen (1)                            |\n| Nplate       | U.S. &Europe | PROMACTA/REVOLADE                                | Novartis                               |\n",
          "relationship": "Competes_With"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 224,
      "question": "How does Pfizer's collaboration with payors to improve healthcare access reconcile with the competitive threat posed by biosimilars that payors are actively promoting, and what impact does this dynamic have on Pfizer's ability to maintain favorable formulary placement for its existing products?",
      "answer": "Pfizer collaborates with payors to support and expand patient access to reliable, affordable healthcare (page 36), while also recognizing that payors are actively promoting biosimilars to generate savings and stimulate price competition (page 19). This creates a dual dynamic where payors\u2014whom Pfizer partners with to improve access\u2014are simultaneously advancing products that directly compete with Pfizer's own therapies. The 10-K further notes that Pfizer faces challenges in maintaining favorable formulary placement and timely pricing for its products amid trends toward healthcare cost containment (page 8). Therefore, while collaboration with payors is aimed at improving access, the aggressive promotion of biosimilars by those same payors undermines Pfizer\u2019s ability to sustain premium pricing and optimal market positioning for its branded products.",
      "reasoning_steps": [
        "Hop 1: [PFE](page 36) \u2192 [Payors]: Pfizer collaborates with payors to support and expand patient access to reliable, affordable healthcare.",
        "Hop 2: [Payors] \u2192 [Biosimilars]: Payors are actively promoting biosimilars to generate savings and stimulate price competition.",
        "Hop 3: [Biosimilars] \u2190 [PFE](page 8): Biosimilars are cited as a significant competitive threat, complicating Pfizer\u2019s ability to maintain favorable formulary placement and pricing for its products."
      ],
      "difficulty": "hard",
      "idf_score": 5.947298682712962,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> COMP -[Promotes]-> PRODUCT <-[Impacted_By]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Payors",
        "node_3": "Biosimilars",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_1",
          "chunk_text": "## ITEM\t7.\n\n## GENERAL\n\nThe\tfollowing\tMD&amp;A\tis\tintended\tto\tassist\tthe\treader\tin\tunderstanding\tour\tfinancial\tcondition\tand\tresults\tof\toperations,\tincluding\tan\tevaluation\tof the\tamounts\tand\tcertainty\tof\tcash\tflows\tfrom\toperations\tand\tfrom\toutside\tsources,\tand\tis\tprovided\tas\ta\tsupplement\tto\tand\tshould\tbe\tread\tin conjunction\twith\tthe\tconsolidated\tfinancial\tstatements\tand\trelated\tnotes\tin Item\t8.\tFinancial\tStatements\tand\tSupplementary\tData in\tthis\tForm\t10-K. Discussions\tof\t2021\titems\tand\tyear-to-year\tcomparisons\tbetween\t2022\tand\t2021\tthat\tare\tnot\tincluded\tin\tthis\tForm\t10-K\tcan\tbe\tfound\twithin\tMD&amp;A\tin\tour 2022\tForm\t10-K.\n\n## OVERVIEW\tOF\tOUR\tPERFORMANCE,\tOPERATING\tENVIRONMENT,\tSTRATEGY\tAND\tOUTLOOK\n\nFinancial\tHighlights --The\tfollowing\tis\ta\tsummary\tof\tcertain\tfinancial\tperformance\tmetrics\t(in\tbillions,\texcept\tper\tshare\tdata):\n\n2023\tTotal\tRevenues--$58.5\tbillion\n\n2023\tNet\tCash\tFlow\tfrom\tOperations--$8.7\tbillion\n\nA\tdecrease\tof\t42%\tcompared\tto\t2022\n\n2023\tReported\tDiluted\tEPS--$0.37\n\nA\tdecrease\tof\t70%\tcompared\tto\t2022\n\n2023\tAdjusted\tDiluted\tEPS\t(Non-GAAP)--$1.84*\n\nA\tdecrease\tof\t93%\tcompared\tto\t2022\n\nA\tdecrease\tof\t72%\tcompared\tto\t2022\n\n* For\tadditional\tinformation\tregarding\tAdjusted\tdiluted\tEPS\t(which\tis\ta\tnon-GAAP\tfinancial\tmeasure),\tincluding\treconciliations\tof\tcertain\tGAAP\tReported\tto\tnon-GAAP\tAdjusted information,\tsee\tthe Non-GAAP\tFinancial\tMeasure:\tAdjusted\tIncome section\twithin\tMD&amp;A.\n\nReferences\tto\toperational\tvariances\tpertain\tto\tperiod-over-period\tchanges\tthat\texclude\tthe\timpact\tof\tforeign\texchange\trates.\tAlthough\tforeign exchange\trate\tchanges\tare\tpart\tof\tour\tbusiness,\tthey\tare\tnot\twithin\tour\tcontrol\tand\tsince\tthey\tcan\tmask\tpositive\tor\tnegative\ttrends\tin\tthe\tbusiness, we\tbelieve\tpresenting\toperational\tvariances\texcluding\tthese\tforeign\texchange\tchanges\tprovides\tuseful\tinformation\tto\tevaluate\tour\tresults.\n\nOur\tBusiness\tand\tStrategy --Pfizer\tInc.\tis\ta\tresearch-based,\tglobal\tbiopharmaceutical\tcompany.\tWe\tapply\tscience\tand\tour\tglobal\tresources\tto\tbring therapies\tto\tpeople\tthat\textend\tand\tsignificantly\timprove\ttheir\tlives.\tSee\tthe Item\t1.\tBusiness--About\tPfizer section.\tAs\ta\tscience-driven\tglobal biopharmaceutical\tcompany,\twe\tremain\tfocused\ton\tadvancing\tour\tpipeline,\tsupporting\tour\tmarketed\tbrands\tand\tdeploying\tcapital\tresponsibly,\twith\ta focus\ton\tinitiatives\tthat\tcan\thelp\tcontribute\tto\tour\tlong-term\trevenue\tand\tfuture\tgrowth.\tMost\tof\tour\trevenues\tcome\tfrom\tthe\tmanufacture\tand\tsale\tof biopharmaceutical\tproducts.\tWe\tbelieve\tthat\tour\tmedicines\tand\tvaccines\tprovide\tsignificant\tvalue\tfor\thealthcare\tproviders\tand\tpatients\tand continuously\tevaluate\thow\twe\tcan\tbest\tcollaborate\twith\tpatients,\tphysicians\tand\tpayors\tto\tsupport\tand\texpand\tpatient\taccess\tto\treliable,\taffordable healthcare\taround\tthe\tworld.\tIn\taddition,\twe\tcontinually\tseek\tto\texpand\tand\tbroaden\tour\tproduct\tportfolio\tofferings\tthrough\tprioritized\tdevelopment of\tour\tpipeline\tand\tbusiness\tdevelopment\topportunities\ttargeted\tat\tcritical\tunmet\tpatient\tneeds.\tAs\ta\tresult,\tour\tcommercial\torganizational structure\tand\tR&amp;D\toperations\tare\tcritical\tto\tthe\tsuccessful\texecution\tof\tour\tbusiness\tstrategy.\tOur\tability\tto\tfulfill\tour\tpurpose, Breakthroughs that\tchange\tpatients'\tlives ,\tremains\ta\tcore\tfocus\tand\tunderscores\tour\tcommitment\tto\taddressing\tthe\tneeds\tof\tsociety\tto\thelp\tsustain\tlong-term\tvalue creation\tfor\tall\tstakeholders.\tOur\t2024\tkey\tpriorities\tare:\n\n- Achieve\tworld-class\toncology\tleadership\n- Deliver\tnext\twave\tof\tpipeline\tinnovation\n- Maximize\tperformance\tof\tour\tnew\tproducts\n- Expand\tmargins\tby\trealigning\tour\tcost\tbase\n- Allocate\tcapital\tto\tenhance\tshareholder\tvalue\n\nPfizer\tInc.\n\n30",
          "relationship": "Partners_With"
        },
        "node_2": {
          "id": "Payors",
          "name": "Payors",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "review\tor\tare\tthe\tsubject\tof\tcurrent\tregulatory\tactivity\tand/or\tlitigation,\tand\ttheir\tstatus\tis\tunclear.\tIn\t2022,\twe\timplemented\ta\tpolicy\tthat\twill help\timprove\tcontract\tpharmacy\tintegrity.\tThe\tHHS\tHealth\tResources\tand\tServices\tAdministration\t(HRSA),\twhich\tadministers\tthe\t340B\tProgram,\thas\tsent letters\tto\tnumerous\tmanufacturers\tthat\thave\talso\timplemented\tcontract\tpharmacy\tpolicies\tand\tintegrity\tinitiatives;\tthe\tletters\texpress\tHRSA's\tview that\tthose\tmanufacturers'\tpolicies\tare\tin\tviolation\tof\tthe\t340B\tstatute.\tHRSA\talso\thas\treferred\tsome\tof\tthose\tother\tmanufacturers\tto\tthe\tHHS\tOffice of\tInspector\tGeneral\t(OIG)\tfor\tpotential\tenforcement\taction.\tPfizer\thas\tnot\treceived\tan\tenforcement\tletter\tfrom\tHRSA\tto\tdate\trelating\tto\tour\t340B Program\tintegrity\tinitiative.\tSeveral\tmanufacturers\thave\tchallenged\tHRSA's\tenforcement\tletters\tin\tfederal\tcourt\tand\tlitigation\tis\tongoing\tin\tthose cases.\tWe\tbelieve\tthat\tour\tpolicy\tis\tconsistent\twith\tthe\tstatute.\tIn\taddition,\tsome\tstates\thave\tenacted\tlaws\tseeking\tto\trestrict\tmanufacturer policies\trelated\tto\tcontract\tpharmacy\ttransactions\tin\ttheir\tstates.\tAt\tleast\tone\tstate\thas\tbegun\tto\tpursue\tenforcement\tproceedings\tunder\tits\tlaw. Several\tstakeholders\thave\tchallenged\tsuch\tlaws\tin\tcertain\tstates.\tOther\tstates\thave\tconsidered\tand\tcould\tenact\tsimilar\tlaws\tgoing\tforward,\talthough any\tsuch\tlaws\talso\tmay\tbe\tsubject\tto\tlegal\tchallenges.\tAdditional\tlegal\tor\tlegislative\tdevelopments\tat\tthe\tfederal\tor\tstate\tlevel\twith\trespect\tto the\t340B\tProgram\tmay\thave\tan\tadverse\timpact\ton\tour\tintegrity\tinitiative,\tand\twe\tmay\tface\tenforcement\taction\tor\tpenalties,\tdepending\tupon\tsuch developments.\tThe\t340B\tProgram\tcontinues\tto\tbe\ta\tsubject\tof\tregulatory\tactivity,\tcongressional\tscrutiny\tand\tinquiries,\tlitigation,\tand\tother developments,\tany\tor\tall\tof\twhich\tcould\taffect\tthe\tscope\tof\tthe\tprogram\tand\tPfizer's\tobligation\tto\toffer\tdiscounts\tto\t340B\tProgram\tcovered\tentities under\tthe\tprogram.\tSee\tthe Item\t1A.\tRisk\tFactors -Pricing\tand\tReimbursement section.\n\nStates\tseek\tto\tcontrol\thealthcare\tcosts\trelated\tto\tMedicaid\tand\tother\tstate\tregulated\thealthcare\tprograms.\tA\tmajority\tof\tstates\tuse\tpreferred\tdrug lists\tto\tmanage\taccess\tto\tpharmaceutical\tproducts\tunder\tMedicaid,\tincluding\tsome\tof\tour\tproducts.\tStates\tmay\tseek\tto\tnegotiate\tsupplemental\trebate agreements\tthat\tare\tlarger\tthan\tthe\tminimum\tfederal\trequirement\tfor\tpreferred\tformulary\taccess.\tPreferred\taccess\tto\tour\tproducts\tunder\tthe\tMedicaid managed\tcare\tprograms\tare\toften\tdetermined\tby\tthe\tmanaged\tcare\thealth\tplans\tcontracted\tby\tthe\tstate\tto\tadminister\tbenefits,\twhich\tmay\talso\trequire supplemental\trebates\tfor\tpreferred\tformulary\taccess.\tWe\texpect\tstates\twill\tcontinue\tto\tseek\tcost\tcutting,\twhich\tmay\tfocus\ton\tmanaged\tcare\tcapitation payments,\tsupplemental\trebates,\tand/or\tformulary\tmanagement.\n\nWe\texpect\tto\tsee\tcontinued\tfocus\tby\tCongress\tand\tthe\tBiden\tAdministration\ton\tregulating\tpricing\tand\taccess\tto\tmedicine,\tin\taddition\tto\tactions already\ttaken,\twhich\tcould\tresult\tin\tlegislative\tand\tregulatory\tchanges.\tGovernment\tand\tprivate\tpayors\troutinely\tseek\tto\tmanage\tutilization\tand control\tthe\tcosts\tof\tour\tproducts.\tThere\tis\tconsiderable\tpublic\tand\tgovernment\tscrutiny\tof\tpharmaceutical\tpricing\tand\tactions\tbeing\ttaken\tat\tthe state\tand\tfederal\tlevel.\tFurther\tefforts\tby\tstates\tand\tthe\tfederal\tgovernment\tto\tregulate\tprices\tor\tpayment\tfor\tpharmaceutical\tproducts,\tincluding proposed\tactions\tto\tfacilitate\tdrug\timportation,\tsuch\tas\tFlorida's\tdrug\timportation\tprogram\twhich\twas\trecently\tauthorized\tby\tthe\tFDA,\tlimit reimbursement\tto\tlower\treference\tprices,\trequire\tdeep\tdiscounts,\timpose\tfinancial\tpenalties\trelated\tto\tpricing\tpractices,\tand\trequire\tmanufacturers to\treport\tand\tmake\tpublic\tprice\tincreases\tand\tsometimes\ta\twritten\tjustification\tfor\tthe\tincrease,\tcould\tadversely\taffect\tour\tbusiness\tif implemented.\tFurther,\tcommercial\tpayors\toften\tfollow\tMedicare\tcoverage\tand\treimbursement\tpolicies\twhen\tsetting\ttheir\town\tpayment\trates.\tAny reduction\tin\tcost\tor\tother\tcontainment\tmeasures\tmay\tsimilarly\tbe\tadopted\tby\tcommercial\tplans.\tPayors\tmay\tcontinue\tto\tpromote\tgeneric\tdrugs\tand biosimilars\tmore\taggressively\tto\tgenerate\tsavings\tand\tattempt\tto\tstimulate\tadditional\tprice\tcompetition.\tIn\taddition,\twe\texpect\tthat\tconsolidation and\tintegration\tamong\tpharmacy\tchains,\twholesalers\tand\tPBMs\twill\tincrease\tpricing\tpressures\tin\tthe\tindustry.\tSee\tthe Item\t1A.\tRisk\tFactors -Managed Care\tTrends section.\n\nAnti-Corruption. The\tFCPA\tprohibits\tU.S.\tcorporations\tand\ttheir\trepresentatives\tfrom\toffering,\tpromising,\tauthorizing\tor\tmaking\tpayments\tto\tany foreign\tgovernment\tofficial,\tgovernment\tstaff\tmember,\tpolitical\tparty\tor\tpolitical\tcandidate\tto\tobtain\tor\tretain\tbusiness\tabroad.\tThe\tscope\tof\tthe FCPA\tincludes\tinteractions\twith\tcertain\thealthcare\tprofessionals\tin\tmany\tcountries.\tOther\tcountries\thave\tenacted\tsimilar\tanti-corruption\tlaws\tand/or regulations.\n\nData\tPrivacy. The\tnumber\tof\tprivacy\tand\tdata\tsecurity\tlaws\tand\tregulations\tin\tthe\tU.S.\tto\twhich\twe\tare\tsubject\ton\tthe\tfederal\tand\tstate\tlevel continues\tto\tincrease.\tWe\troutinely\tcollect\tand\tuse\tsensitive\tpersonal\tinformation\trelating\tto\tdigital\thealth.\tThe\tlegislative,\tregulatory\tand litigation\tlandscape\tfor\tprivacy\tand\tdata\tprotection\trequirements\tis\trapidly\tevolving\tand\tchanging.\tThese\trequirements\tare\tnot\tuniversal\tand\tcan conflict\tbetween\tjurisdictions.\tCompliance\twith\tthose\tlaws\tand\tregulations\tis\tmade\tmore\tcomplex\tby\tthe\tlack\tof\tconsistent\tstandards,\tcommon definitions,\tor\tclear\tregulatory\texpectations.\tAt\tthe\tsame\ttime,\tenforcement\tof\tthese\tlaws\tand\tregulations\tis\tincreasing\tand\tlitigation\tis\tbecoming more\tcommon.\tAny\tfailure\tor\tperceived\tfailure\tby\tus\tto\tcomply\twith\tapplicable\tprivacy\tand\tdata\tprotection\tlaws\tand\tregulations,\tincluding cybersecurity\tbreaches\tor\tincidents,\tcould\tsubject\tus\tto\tsignificant\tfines\tand\tpenalties,\tlitigation,\tand\tnegatively\timpact\tour\treputation.\n\n## Outside\tthe\tU.S.\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Biosimilars",
          "name": "Biosimilars",
          "type": "PRODUCT",
          "idf_score": 5.320917198465278
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_8",
          "chunk_id": "chunk_1",
          "chunk_text": "- the\tsuccess\tand\timpact\tof\texternal\tbusiness\tdevelopment\tactivities,\tsuch\tas\tthe\trecent\tacquisition\tof\tSeagen,\tincluding\tthe\tability\tto identify\tand\texecute\ton\tpotential\tbusiness\tdevelopment\topportunities;\tthe\tability\tto\tsatisfy\tthe\tconditions\tto\tclosing\tof\tannounced transactions\tin\tthe\tanticipated\ttime\tframe\tor\tat\tall;\tthe\tability\tto\trealize\tthe\tanticipated\tbenefits\tof\tany\tsuch\ttransactions\tin\tthe anticipated\ttime\tframe\tor\tat\tall;\tthe\tpotential\tneed\tfor\tand\timpact\tof\tadditional\tequity\tor\tdebt\tfinancing\tto\tpursue\tthese\topportunities, which\thas\tin\tthe\tpast\tand\tcould\tin\tthe\tfuture\tresult\tin\tincreased\tleverage\tand/or\ta\tdowngrade\tof\tour\tcredit\tratings\tand\tcould\tlimit\tour ability\tto\tobtain\tfuture\tfinancing;\tchallenges\tintegrating\tthe\tbusinesses\tand\toperations;\tdisruption\tto\tbusiness\tand\toperations relationships;\trisks\trelated\tto\tgrowing\trevenues\tfor\tcertain\tacquired\tor\tpartnered\tproducts;\tsignificant\ttransaction\tcosts;\tand\tunknown liabilities;\n- competition,\tincluding\tfrom\tnew\tproduct\tentrants,\tin-line\tbranded\tproducts,\tgeneric\tproducts,\tprivate\tlabel\tproducts,\tbiosimilars\tand product\tcandidates\tthat\ttreat\tor\tprevent\tdiseases\tand\tconditions\tsimilar\tto\tthose\ttreated\tor\tintended\tto\tbe\tprevented\tby\tour\tin-line products\tand\tproduct\tcandidates;\n- the\tability\tto\tsuccessfully\tmarket\tboth\tnew\tand\texisting\tproducts,\tincluding\tbiosimilars;\n- difficulties\tor\tdelays\tin\tmanufacturing,\tsales\tor\tmarketing;\tsupply\tdisruptions,\tshortages\tor\tstock-outs\tat\tour\tfacilities\tor\tthird-party facilities\tthat\twe\trely\ton;\tand\tlegal\tor\tregulatory\tactions;\n- the\timpact\tof\tpublic\thealth\toutbreaks,\tepidemics\tor\tpandemics\t(such\tas\tCOVID-19)\ton\tour\tbusiness,\toperations\tand\tfinancial\tcondition\tand results,\tincluding\timpacts\ton\tour\temployees,\tmanufacturing,\tsupply\tchain,\tsales\tand\tmarketing,\tR&amp;D\tand\tclinical\ttrials;\n- risks\tand\tuncertainties\trelated\tto\tour\tefforts\tto\tcontinue\tto\tdevelop\tand\tcommercialize\tComirnaty\tand\tPaxlovid\tor\tany\tpotential\tfuture COVID-19\tvaccines,\ttreatments\tor\tcombinations,\tas\twell\tas\tchallenges\trelated\tto\ttheir\tmanufacturing,\tsupply\tand\tdistribution,\tincluding, among\tothers,\tthe\trisk\tthat\tas\tthe\tmarket\tfor\tCOVID-19\tproducts\tcontinues\tto\tbecome\tmore\tendemic\tand\tseasonal,\tdemand\tfor\tour\tCOVID-19 products\thas\tand\tmay\tcontinue\tto\tbe\treduced\tor\tnot\tmeet\texpectations,\tor\tmay\tno\tlonger\texist,\twhich\thas\tand\tmay\tcontinue\tto\tlead\tto\treduced revenues,\texcess\tinventory\ton-hand\tand/or\tin\tthe\tchannel\twhich,\tfor\tPaxlovid\tand\tComirnaty,\tresulted\tin\tsignificant\tinventory\twrite-offs\tin 2023\tand\tcould\tcontinue\tto\tresult\tin\tinventory\twrite-offs,\tor\tother\tunanticipated\tcharges;\tchallenges\trelated\tto\tthe\ttransition\tto\tthe commercial\tmarket\tfor\tour\tCOVID-19\tproducts;\tuncertainties\trelated\tto\tthe\tpublic's\tadherence\tto\tvaccines,\tboosters,\ttreatments\tor combinations;\tand\trisks\trelated\tto\tour\tability\tto\taccurately\tpredict\tor\tachieve\tour\trevenue\tforecasts\tfor\tComirnaty\tand\tPaxlovid\tor\tany potential\tfuture\tCOVID-19\tvaccines\tor\ttreatments;\n- trends\ttoward\tmanaged\tcare\tand\thealthcare\tcost\tcontainment,\tand\tour\tability\tto\tobtain\tor\tmaintain\ttimely\tor\tadequate\tpricing\tor\tfavorable formulary\tplacement\tfor\tour\tproducts;\n- interest\trate\tand\tforeign\tcurrency\texchange\trate\tfluctuations,\tincluding\tthe\timpact\tof\tcurrency\tdevaluations\tand\tmonetary\tpolicy\tactions\tin countries\texperiencing\thigh\tinflation\tor\tdeflation\trates;\n- any\tsignificant\tissues\tinvolving\tour\tlargest\twholesale\tdistributors\tor\tgovernment\tcustomers,\twhich\taccount\tfor\ta\tsubstantial\tportion\tof\tour revenues;\n- the\timpact\tof\tthe\tincreased\tpresence\tof\tcounterfeit\tmedicines,\tvaccines\tor\tother\tproducts\tin\tthe\tpharmaceutical\tsupply\tchain;\n- any\tsignificant\tissues\trelated\tto\tthe\toutsourcing\tof\tcertain\toperational\tand\tstaff\tfunctions\tto\tthird\tparties;\n- any\tsignificant\tissues\trelated\tto\tour\tJVs\tand\tother\tthird-party\tbusiness\tarrangements,\tincluding\tmodifications\trelated\tto\tsupply\tagreements or\tother\tcontracts\twith\tcustomers\tincluding\tgovernments\tor\tother\tpayors;\n- uncertainties\trelated\tto\tgeneral\teconomic,\tpolitical,\tbusiness,\tindustry,\tregulatory\tand\tmarket\tconditions\tincluding,\twithout\tlimitation, uncertainties\trelated\tto\tthe\timpact\ton\tus,\tour\tcustomers,\tsuppliers\tand\tlenders\tand\tcounterparties\tto\tour\tforeign-exchange\tand\tinterestrate\tagreements\tof\tchallenging\tglobal\teconomic\tconditions,\tsuch\tas\tinflation\tor\tinterest\trate\tfluctuations,\tand\trecent\tand\tpossible\tfuture changes\tin\tglobal\tfinancial\tmarkets;\n- the\texposure\tof\tour\toperations\tglobally\tto\tpossible\tcapital\tand\texchange\tcontrols,\teconomic\tconditions,\texpropriation,\tsanctions\tand/or other\trestrictive\tgovernment\tactions,\tchanges\tin\tintellectual\tproperty\tlegal\tprotections\tand\tremedies,\tunstable\tgovernments\tand\tlegal systems\tand\tinter-governmental\tdisputes;\n- the\timpact\tof\tdisruptions\trelated\tto\tclimate\tchange\tand\tnatural\tdisasters,\tincluding\tuncertainties\trelated\tto\tthe\timpact\tof\tthe\ttornado\tat our\tmanufacturing\tfacility\tin\tRocky\tMount,\tNC\tin\t2023;\n- any\tchanges\tin\tbusiness,\tpolitical\tand\teconomic\tconditions\tdue\tto\tactual\tor\tthreatened\tterrorist\tactivity,\tgeopolitical\tinstability, political\tor\tcivil\tunrest\tor\tmilitary\taction,\tincluding\tthe\tongoing\tconflicts\tbetween\tRussia\tand\tUkraine\tand\tin\tthe\tMiddle\tEast\tand\tthe resulting\teconomic\tor\tother\tconsequences;\n- the\timpact\tof\tproduct\trecalls,\twithdrawals\tand\tother\tunusual\titems,\tincluding\tuncertainties\trelated\tto\tregulator-directed\trisk\tevaluations and\tassessments,\tincluding\tour\tongoing\tevaluation\tof\tour\tproduct\tportfolio\tfor\tthe\tpotential\tpresence\tor\tformation\tof\tnitrosamines;\n- trade\tbuying\tpatterns;\n- the\trisk\tof\tan\timpairment\tcharge\trelated\tto\tour\tintangible\tassets,\tgoodwill\tor\tequity-method\tinvestments;\n- the\timpact\tof,\tand\trisks\tand\tuncertainties\trelated\tto,\trestructurings\tand\tinternal\treorganizations,\tas\twell\tas\tany\tother\tcorporate strategic\tinitiatives\tand\tgrowth\tstrategies,\tand\tcost-reduction\tand\tproductivity\tinitiatives,\teach\tof\twhich\trequires\tupfront\tcosts\tbut\tmay fail\tto\tyield\tanticipated\tbenefits\tand\tmay\tresult\tin\tunexpected\tcosts,\torganizational\tdisruption,\tadverse\teffects\ton\temployee\tmorale, retention\tissues\tor\tother\tunintended\tconsequences;\n- the\tability\tto\tsuccessfully\tachieve\tour\tclimate\tgoals\tand\tprogress\tour\tenvironmental\tsustainability\tand\tother\tESG\tpriorities;\n\n## Risks\tRelated\tto\tGovernment\tRegulation\tand\tLegal\tProceedings :\n\n- the\timpact\tof\tany\tU.S.\thealthcare\treform\tor\tlegislation\tor\tany\tsignificant\tspending\treduction\tor\tcost\tcontrol\tefforts\taffecting\tMedicare, Medicaid\tor\tother\tpublicly\tfunded\tor\tsubsidized\thealth\tprograms,\tincluding\tthe\tIRA,\tor\tchanges\tin\tthe\ttax\ttreatment\tof\temployer-sponsored health\tinsurance\tthat\tmay\tbe\timplemented;\n- U.S.\tfederal\tor\tstate\tlegislation\tor\tregulatory\taction\tand/or\tpolicy\tefforts\taffecting,\tamong\tother\tthings,\tpharmaceutical\tproduct\tpricing, intellectual\tproperty,\treimbursement\tor\taccess\tor\trestrictions\ton\tU.S.\tdirect-to-consumer\tadvertising;\tlimitations\ton\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n2",
          "relationship": "Impacted_By"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 225,
      "question": "How does the elimination of the FFS Adjuster in the RADV Audit Rule, which increases the Company's liability for payment errors, reconcile with the ongoing litigation risk and potential financial exposure highlighted in the legal proceedings section?",
      "answer": "The elimination of the FFS Adjuster in the RADV Audit Rule, as disclosed on page 24, increases the Company's liability for extrapolated payment errors during RADV audits by removing a historical buffer that limited repayment obligations. This regulatory change introduces significant financial risk, particularly for payment years 2018 and beyond, where CMS may apply extrapolation without the adjuster. The ongoing litigation around the RADV Audit Rule, mentioned in the middle section, adds uncertainty to how CMS will enforce the rule and whether the industry will face broader financial penalties. Meanwhile, page 184 underscores the Company's exposure to regulatory audits\u2014including RADV audits\u2014and the potential material adverse effects on operating results, cash flows, and financial condition. Together, these disclosures indicate that the removal of the FFS Adjuster, combined with unresolved litigation and audit risk, could lead to substantial financial liabilities for the Company, particularly if CMS applies strict extrapolation methodologies in its audits.",
      "reasoning_steps": [
        "Hop 1: CVS(page_24) \u2192 Ongoing Litigation: Discloses the elimination of the FFS Adjuster in the RADV Audit Rule, which increases the Company's liability for payment errors during CMS audits.",
        "Hop 2: Ongoing Litigation \u2192 RADV Audit Rule: The RADV Audit Rule is subject to ongoing litigation, creating uncertainty around CMS enforcement and the potential financial impact on Medicare Advantage plans.",
        "Hop 3: RADV Audit Rule \u2190 CVS(page_184): The Company faces material financial exposure from regulatory audits, including those under the RADV program, which could significantly affect operating results and cash flows."
      ],
      "difficulty": "hard",
      "idf_score": 5.912802246969486,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> LITIGATION -[Negatively_Impacts]-> REGULATORY_REQUIREMENT <-[Faces]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Ongoing Litigation",
        "node_3": "RADV Audit Rule",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_24",
          "chunk_id": "chunk_1",
          "chunk_text": "The Company's Medicaid, dual eligible and dual eligible special needs plan products also are heavily regulated by CMS and state Medicaid agencies, which have the right to audit the Company's performance to determine compliance with CMS contracts and regulations. The Company's Medicaid products, dual eligible products and CHIP contracts also are subject to complex federal and state regulations and oversight by state Medicaid agencies regarding the services provided to Medicaid enrollees, payment for those services, network requirements (including mandatory inclusion of specified high-cost providers), and other aspects of these programs, and by external review organizations which audit Medicaid plans on behalf of state Medicaid agencies. The laws, regulations and contractual requirements applicable to the Company and other participants in Medicaid and dual eligible programs, including requirements that the Company submit encounter data to the applicable state agency, are extensive, complex and subject to change. For example, in April 2024, CMS finalized the Managed Care Rule, which addresses five primary areas: (1) access in managed care, including network adequacy; (2) state directed payments; (3) medical loss ratio standards; (4) in lieu of services and settings and (5) quality and performance assessment. The Company has invested significant resources to comply with these standards, and its Medicaid and dual eligible program compliance efforts will continue to require significant resources. CMS and/or state Medicaid agencies may fine the Company, withhold payments to the Company, seek premium and other refunds, terminate the Company's existing contracts, elect not to award the Company new contracts or not to renew the Company's existing contracts, prohibit the Company from continuing to market and/or enroll members in or refuse to automatically assign members to one or more of the Company's Medicaid or dual eligible products, exclude the Company from participating in one or more Medicaid or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS or state regulations or contractual requirements. CMS has proposed requiring that health plans offering certain dual eligible programs must also offer Medicaid programs, which has resulted in the Company refraining from bidding in certain jurisdictions and could impact the Company's ability to obtain or retain membership in its dual eligible programs.\n\nThe Company cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid program, nor can it predict the impact those changes will have on its business operations or operating results, but the effects could be materially adverse.\n\nMedicare and Medicaid Audits - CMS regularly audits the Company's performance to determine its compliance with CMS' regulations and its contracts with CMS and to assess the quality of services it provides to Medicare Advantage and PDP beneficiaries. For example, CMS conducts risk adjustment data validation ('RADV') audits of a subset of Medicare Advantage contracts for each contract year. Since 2011, CMS has selected certain of the Company's Medicare Advantage contracts for various years for RADV audit, and the number of RADV audits continues to increase. The OIG also is auditing the Company's risk adjustment data and that of other companies, and the Company expects CMS and the OIG to continue auditing risk adjustment data. The Company also has received Civil Investigative Demands ('CIDs') from, and provided documents and information to, the Civil Division of the DOJ in connection with investigations of the Company's identification and/or submission of diagnosis codes related to risk adjustment payments, including patient chart review processes, under Parts C and D of the Medicare program.\n\nOn January 30, 2023, CMS released the final rule concerning Part C contract-level Risk Adjustment Data Validation Audits (the 'RADV Audit Rule'). The RADV Audit Rule eliminated the application of a fee-for-service adjuster ('FFS Adjuster') in contract-level RADV audits but continued the use of extrapolation in such audits of Medicare Advantage organizations. The FFS Adjuster that was announced in 2012 was to be used by CMS to determine a permissible level of payment error. By applying the FFS Adjuster, Medicare Advantage organizations would have been liable for repayments only to the extent that their extrapolated payment errors ex ceeded the error rate in Original Medicare, which could have impacted the extrapolated repayments to which Medicare Advantage organizations are subject. CMS is conducting RADV audits of Medicare Advantage organizations, including the Company's Medicare Advantage plans, for payment year 2018 and subsequent payment years and may use extrapolation without the application of a FFS Adjuster. The RADV Audit Rule may have potential adverse effects, which could be material, on the Company's operating results, financial condition, and cash flows. CMS also has announced that it will not conduct RADV audits on all contracts; instead, it will only audit contracts it believes are at the highest risk for overpayments based on its statistical modeling. The RADV Audit Rule is subject to ongoing litigation and the outcome and future impacts are uncertain.\n\nIn addition, state Medicaid agencies regularly audit, and state Attorneys General regularly investigate, the Company's performance across all areas of its contractual obligations to the state to determine compliance and quality of services. The Company may be subject to, among other penalties, significant fines, sanctions, corrective actions, and enrollment freezes depending on the findings of these audits and reviews. The Company's ongoing performance and compliance with program requirements can impact our ability to expand and retain Medicaid business. State Medicaid agencies are also increasingly using the audit process to challenge the legality of PBM practices, such as guaranteed effective rate reconciliations with retail pharmacies and transmission fees.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Ongoing_Litigation",
          "name": "Ongoing Litigation",
          "type": "LITIGATION",
          "idf_score": 4.558777146418381
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_53",
          "chunk_id": "chunk_1",
          "chunk_text": "- Data Validation Audits ('RADV Audit Rule') issued in January 2023 or other changes that may result from enforcement or audit actions, could: materially affect the amount of our Medicare reimbursement, require us to raise prices or reduce the benefits we offer to Medicare beneficiaries, impact the services provided by, or the financial performance of, Oak Street Health and Signify Health and potentially limit our (and the industry's) participation in the Medicare program.\n- The RADV Audit Rule creates uncertainty for Medicare Advantage plans. The lack of detail provided with respect to how CMS will select contracts and claims to audit, the methodology CMS will use, and how it will extrapolate as part of the RADV Audit Rule may impact future Medicare Advantage bids and result in other implications. The RADV Audit Rule also permits extrapolation of OIG contract level audits for payment years 2018 forward. The RADV Audit Rule is subject to ongoing litigation and the outcome and future impacts are uncertain.\n- Medicare Part D has resulted in increased utilization of prescription medications and puts pressure on our pharmacy gross margin rates due to regulatory and competitive pressures. Further, as a result of the ACA and changes to the retiree drug subsidy rules, clients of our PBM business could decide to discontinue providing prescription drug benefits to their Medicare-eligible members. To the extent this phenomenon occurs, the adverse effects of increasing customer migration into Medicare Part D may outweigh the benefits we realize from growth of our Medicare Part D products.\n- Our Medicare Part D operating results and our ability to expand our Medicare Part D business could be adversely affected if: the cost and complexity of Medicare Part D exceed management's expectations or prevent effective program implementation or administration; further changes to the regulations regarding how drug costs are reported for Medicare Part D (including changes related to the IRA) are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the applicable regulations impact our ability to retain fees from third parties including network pharmacies; the government alters Medicare Part D program requirements or reduces funding because of the higher-than-anticipated cost to taxpayers of Medicare Part D or for other reasons; or reinsurance thresholds are reduced.\n- The IRA contains significant changes to the Part D program that began in 2023 and will continue to 2032 that shifts more of the claim liability to plans and away from the government, including a complete redesign of the Part D standard benefit effective in 2025.\n- We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, and some states mandate that certain amounts be included or excluded from encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to bid for, and continue to participate in, certain Medicaid programs.\n- If we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs, and on our operating results, cash flows and financial condition.\n- The resumption of Medicaid eligibility redeterminations after being suspended during the COVID-19 pandemic has negatively impacted the number of members eligible for the Company's Medicaid plans, which could impact our operating results and cash flows from the Medicaid business.\n- Certain of our Medicaid contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our Medicaid programs because more states are using encounter data to determine compliance with performance standards and, in part, to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect accurate, or to correct inaccurate or incomplete, encounter data and have been and could be exposed to premium withholding, operating sanctions and financial fines and penalties for noncompliance.\n- CMS has proposed requiring that health plans offering certain dual eligible programs must also offer Medicaid programs, which could further impact the Company's ability to obtain or retain membership in its dual eligible programs. In addition, states are increasingly requiring companies to offer Medicaid within a state and conducting competitive bid processes to qualify to offer dual eligible products.\n\nPrograms funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase.",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "RADV_Audit_Rule",
          "name": "RADV Audit Rule",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_184",
          "chunk_id": "chunk_1",
          "chunk_text": "from regulatory audits, whether as a result of RADV, Public Exchange-related or other audits by CMS, the OIG or otherwise, including audits of the Company's minimum loss ratio rebates, methodology and/or reports, could be material and could adversely affect the Company's operating results, cash flows and/or financial condition.\n\nThe RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS RADV programs.\n\n## Medicare and Medicaid Litigation and Investigations\n\nThe Company has received CIDs from the Civil Division of the DOJ in connection with investigations of the Company's identification and/or submission of diagnosis codes related to risk adjustment payments, including patient chart review processes, under Parts C and D of the Medicare program. The Company is cooperating with the government and providing documents and information in response to these CIDs.\n\nIn May 2017, the Company received a CID from the U.S. Attorney's Office for the Southern District of New York requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.\n\nSince January 2022, the U.S. Attorney's Office for the District of Massachusetts has issued subpoenas to Aetna Life Insurance Company seeking, among other things, information in connection with its relationship and compensation arrangements with certain brokers, and the Company may receive similar inquiries in the future. The Company is cooperating with the investigation.\n\n## Stockholder Matters\n\nBeginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company's LTC business unit. Since filing, several of the cases have been consolidated, and two have resolved. In February 2025, the District of Rhode Island granted the Company's motion to dismiss In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford ). A derivative case in the District of Rhode Island, Lovoi v. Aguirre , had been stayed pending the outcome of the Waterford case, and the court has scheduled a status conference. In In re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich ), the Rhode Island Supreme Court affirmed the superior court's order granting the Company's motion to dismiss in January 2025. The Company and its current and former officers and directors are defending themselves against remaining claims.\n\nBeginning in December 2021, the Company has received three demands for inspection of books and records pursuant to Delaware General Corporation Law Section 220 ('Section 220 demands'), as well as a derivative complaint ( Vladimir Gusinsky Revocable Trust v. Lynch, et al. ) that was filed in January 2023, which the defendants moved to dismiss. The Section 220 demands and the complaint purport to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids. Following the Company's response to the Section 220 demands, two of the three stockholders sent demand letters to the Board containing allegations substantially similar to those made in the earlier Section 220 demands and the derivative matter, and requested that it take certain actions, including consideration of its governance and policies with respect to controlled substances. The Board deferred consideration of these two demands until after the motion to dismiss the Gusinsky case was decided. In July 2024, the court granted the defendants' motion to dismiss the Gusinsky case. In September 2024, the Board received a third demand letter containing similar allegations and requesting the Board take action. The Board has formed a demand review committee to evaluate the demands.\n\nIn January 2022, a shareholder class action complaint was filed in the Northern District of Illinois, Allison v. Oak Street Health, Inc., et al. Defendants include Oak Street Health and certain of its pre-acquisition officers and directors. The putative plaintiffs assert causes of action under various securities laws premised on allegations that defendants made omissions and misrepresentations to investors relating to marketing conduct they allege may violate the False Claims Act. In May 2024, the parties reached agreement in principle to settle this action for an amount immaterial to the Company. The court granted approval of the settlement in December 2024.\n\nBeginning in July 2024, two purported class action complaints, as well as multiple derivative complaints, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws and state law that are premised on allegations that the defendants made certain",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 226,
      "question": "How does Amgen's strategic investment in BeiGene align with the commercialization timeline and revenue-sharing structure for KYPROLIS in China, particularly considering the initial profit-sharing arrangement and potential reversion of product rights?",
      "answer": "Amgen's $2.8 billion strategic investment in BeiGene in 2020 was part of a collaboration to expand its oncology presence in China. As part of this arrangement, BeiGene began selling KYPROLIS in early 2022 in China, with Amgen sharing profits and losses equally during the initial commercialization period. After this phase, product rights may revert to Amgen, at which point Amgen would pay royalties to BeiGene on Chinese sales. This structure aligns the upfront investment with a phased commercialization and profit-sharing model, balancing risk and reward between the two companies while securing long-term royalty potential for BeiGene and market access for Amgen.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_12) \u2192 KYPROLIS: KYPROLIS is introduced as a key oncology product launched in 2012, indicated for relapsed or refractory multiple myeloma, and later commercialized in China by BeiGene in early 2022.",
        "Hop 2: KYPROLIS \u2192 BeiGene: BeiGene is identified as the commercialization partner for KYPROLIS in China under a collaboration where profits and losses are shared equally during the initial phase.",
        "Hop 3: BeiGene \u2190 AMGN(page_28): Amgen's $2.8 billion investment in BeiGene in 2020 is framed as a strategic move to expand oncology presence in China, with product rights potentially reverting to Amgen after the initial commercialization period, followed by royalty payments from Amgen to BeiGene."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Supplies]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "KYPROLIS",
        "node_3": "BeiGene",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_12",
          "chunk_id": "chunk_1",
          "chunk_text": "## ENBREL\n\nWe market ENBREL, a tumor necrosis factor blocker, in the United States and Canada. ENBREL was launched in 1998 and is used primarily in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis.\n\n## Prolia\n\nWe market Prolia in many countries around the world. Prolia contains the same active ingredient as XGEVA but is approved for different indications, patient populations, doses and frequencies of administration. Prolia was launched in the United States and Europe in 2010. In the United States, it is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant  to  other  available  osteoporosis  therapy.  In  Europe,  Prolia  is  used  primarily  for  the  treatment  of  osteoporosis  in postmenopausal women at increased risk of fracture.\n\n## Otezla\n\nWe market Otezla, a small molecule that inhibits PDE4, in many countries around the world. Otezla was acquired from BMS in November 2019 after their acquisition of Celgene. Otezla is an oral therapy approved for the treatment of adult patients with plaque psoriasis  across  all  severities  for  whom  phototherapy  or  systemic  therapy  is  appropriate,  patients  with  active  psoriatic  arthritis  and patients with oral ulcers associated with Beh\u00e7et's disease. In Europe, Otezla is approved for second-line use in the treatment of psoriatic arthritis and psoriasis and for patients with oral ulcers associated with Beh\u00e7et's disease who are candidates for systemic therapy.\n\n## XGEVA\n\nWe market XGEVA in many countries around the world. XGEVA was launched in 2010 and is used primarily in the indication for prevention  of  SREs  (pathological  fracture,  radiation  to  bone,  spinal  cord  compression  or  surgery  to  bone)  in  patients  with  bone metastases from solid tumors and multiple myeloma.\n\n## Neulasta\n\nWe market Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta was launched in 2002 and is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer (nonmyeloid) who receive anticancer medicines (chemotherapy) that can cause fever and a low blood cell count. In 2015, the Neulasta Onpro kit became available in the United States. The Neulasta Onpro kit provides physicians the opportunity to initiate administration of Neulasta on the same day as chemotherapy, with drug delivery of the recommended dose of Neulasta at home the day after chemotherapy, thereby saving the patient a trip back to the doctor.\n\n## Aranesp\n\nWe market Aranesp primarily in the United States and Europe. It was launched in 2001 and is indicated to treat a lower-thannormal number of red blood cells (anemia) caused by CKD in both patients on dialysis and patients not on dialysis. Aranesp is also indicated  for  the  treatment  of  anemia  due  to  concomitant  myelosuppressive  chemotherapy  in  certain  patients  with  nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp.\n\n## Repatha\n\nWe market Repatha, a PCSK9 inhibitor, in many countries around the world. Repatha was launched in 2015 and is indicated to reduce the risks of myocardial infarction, stroke and coronary revascularization in adults with established CV disease. Repatha is also indicated to reduce LDL-C in adults with primary hyperlipidemia, including HeFH; in pediatric patients aged 10 years and older with HeFH; and in adults and pediatric patients aged 10 years and older with HoFH.\n\n## KYPROLIS\n\nWe  market  KYPROLIS  primarily  in  the  United  States  and  Europe.  KYPROLIS was  launched  in  2012  and  is  indicated  in combination with (i) dexamethasone, (ii) lenalidomide plus dexamethasone and (iii) DARZALEX plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. It is also approved as a single agent for patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "KYPROLIS",
          "name": "KYPROLIS",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_121",
          "chunk_id": "chunk_3",
          "chunk_text": "\nFor each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.\n\n## 8. Collaborations\n\nA collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.\n\nFrom time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or  product  candidates.  These  collaborations  generally  provide  for  nonrefundable  upfront  license  fees,  development  and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary  of  significant  accounting  policies,  for  additional  discussion  of  revenues  recognized  under  these  types  of  arrangements. Operating  expenses  for  costs  incurred  pursuant  to  these  arrangements  are  reported  in  their  respective  expense  line  items  in  the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand  our  oncology  presence  in  China.  For  additional  information  regarding  our  equity  investment  in  BeiGene,  see  Note  9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.",
          "relationship": "Supplies"
        },
        "node_3": {
          "id": "BeiGene",
          "name": "BeiGene",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Business Relationships\n\nFrom time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D  capabilities, product pipeline and marketed-product  base.  These arrangements  generally provide for nonrefundable,  upfront  license  fees,  development  and  commercial-performance  milestone  payments,  cost  sharing,  royalty  payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.\n\nTrade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we  generally  require  counterparties  to  execute  confidentiality  agreements  upon  commencement  of  a  business  relationship  with  us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.\n\n## BeiGene, Ltd.\n\nOn January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.\n\nIn addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash  and  development  services  of  up  to  $1.25  billion.  Upon  regulatory  approval,  BeiGene  will  assume  commercialization  rights  in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.\n\n## Novartis\n\nWe are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IVNote 19, Contingencies and commitments, to the Consolidated Financial Statements.\n\n## Arrangement through December 31, 2021\n\nIn the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal,  recognized  product  sales  of  Aimovig  in  the  United  States,  shared  U.S.  commercialization  costs  with  Novartis  and  paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to  make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States.\n\n## Arrangement after January 1, 2022\n\nPursuant  to  the  amendment  effective  January  1,  2022,  Novartis  retains  the  ex-U.S.  Novartis  Rights  and  will  continue  to  pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide.\n\nAmgen manufactures and supplies Aimovig worldwide.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 227,
      "question": "What are the implications of Amgen's declining Aranesp sales due to internal transitions to EPOGEN on its long-term position in the anemia management market, particularly in light of its U.S. market focus for EPOGEN and the historical volume growth of Aranesp outside the U.S.?",
      "answer": "The transition from Aranesp to EPOGEN within Amgen's product portfolio, particularly in the U.S. dialysis market, suggests a potential shift in internal strategy that could impact Amgen\u2019s long-term positioning in anemia management. While global Aranesp sales remained relatively flat in 2024 due to volume growth outside the U.S., U.S. sales declined in 2023 as independent and medium-sized dialysis organizations switched to EPOGEN. This internal substitution indicates that Amgen may be prioritizing EPOGEN in its core U.S. market, which could consolidate its position in domestic anemia treatment but may risk diluting Aranesp\u2019s broader global presence. Given that Amgen markets Aranesp primarily in the U.S. and Europe and EPOGEN is listed among its core U.S.-focused products, this shift may reflect a strategic realignment toward optimizing product utilization in key markets rather than maintaining parallel offerings, potentially affecting competitive differentiation and revenue diversification in the anemia therapeutic area.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_11) \u2192 Aranesp: Amgen markets Aranesp primarily in the U.S. and Europe for treating anemia caused by chronic kidney disease, with specific indications for both dialysis and non-dialysis patients.",
        "Hop 2: Aranesp \u2192 EPOGEN: U.S. Aranesp sales declined in 2023 due to lower unit demand as dialysis organizations transitioned to EPOGEN, indicating a direct competitive or substitution relationship between the two products within Amgen\u2019s own portfolio.",
        "Hop 3: EPOGEN \u2190 AMGN(page_5): EPOGEN is listed among Amgen\u2019s core products in the U.S. market, suggesting a strategic focus on this product, which may underpin the observed internal shift away from Aranesp in certain segments."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Negatively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Aranesp",
        "node_3": "EPOGEN",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## Nplate\n\nWe  market  Nplate  in  many  countries  around  the  world.  Nplate  was  launched  in  2008  and  is  indicated  to  treat  thrombocytopenia  in  patients  with  immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.\n\n## Aranesp\n\nWe market Aranesp primarily in the United States and Europe. Aranesp was launched in 2001 and is indicated to treat a lower-than-normal number of red blood cells (anemia) caused by chronic kidney disease (CKD) in both patients on dialysis and patients not on dialysis. Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in certain patients with nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp.\n\n## BLINCYTO\n\nWe market BLINCYTO in many countries around the world. BLINCYTO was launched in 2014 and has proven efficacy in a wide range of patients with CD19positive  B-ALL,  including  those  who  are  MRD(-)  or  MRD(+)  in  frontline  consolidation,  and  those  with  relapsed  or  refractory  (R/R)  disease. Acute  lymphoblastic leukemia (ALL) is a cancer of the blood in which a particular kind of white blood cell is growing out of control.\n\n## KRYSTEXXA\n\nWe market KRYSTEXXA in the United States. KRYSTEXXA was acquired through our Horizon acquisition in October 2023. KRYSTEXXA is the first and only FDA-approved medicine for the treatment of chronic refractory gout.\n\n## Vectibix\n\nWe market V ectibix in many countries around the world. V ectibix was launched in 2006 and is indicated for the treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC, cancer that has spread outside the colon and rectum) and in the United States, in combination with LUMAKRAS, for the treatment of adult patients with KRAS G12C-mutated mCRC, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. RAS status is determined by an FDA-approved test.\n\n## TEZSPIRE\n\nTogether with our collaboration partner, we market TEZSPIRE in many countries around the world. TEZSPIRE is currently approved for the treatment of severe asthma in the United States, Europe, Japan and more than 50 countries across the globe. TEZSPIRE is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults.\n\n## Other Marketed Products\n\nWe also market a number of other products in various markets worldwide, including but not limited to AMJEVITA/AMGEVITA, MV ASI, Neulasta, RAVICTI, UPLIZNA, Parsabiv, LUMAKRAS/LUMYKRAS, Aimovig, TAVNEOS, PROCYSBI, EPOGEN and IMDELLTRA.\n\n## Patents\n\nThe following  table  lists  our  outstanding  material  patents  for  the  indicated  product  by  territory,  general  subject  matter  and  latest  ex piry  date.  Certain  of  the European patents are subjects of supplemental protection certificates that provide additional protection for the products in certain European countries beyond the dates listed in the table. See footnotes to the patent table below.\n\nOne or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.\n\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Aranesp",
          "name": "Aranesp",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_73",
          "chunk_id": "chunk_7",
          "chunk_text": "\nGlobal Aranesp sales for 2024 remained relatively unchanged as unfavorable changes to both estimated sales deductions and foreign currency exchange rates were offset by volume growth outside the United States.\n\nThe decrease in global Aranesp sales for 2023 was driven by unfavorable changes to foreign currency exchange rates and lower net selling price. U.S. Aranesp sales for 2023 decreased due to lower unit demand as a result of independent and medium-sized dialysis organizations transitioning from Aranesp to EPOGEN.",
          "relationship": "Negatively_Impacts"
        },
        "node_3": {
          "id": "EPOGEN",
          "name": "EPOGEN",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_2",
          "chunk_text": "| Term                | Description                                            |\n|---------------------|--------------------------------------------------------|\n| ACTIMMUNE           | ACTIMMUNE (interferon gamma-1b) \u00ae                      |\n| Aimovig             | Aimovig (erenumab-aooe) \u00ae                              |\n| AMJEVITA/AMGEVITA   | AMJEVITA (adalimumab-atto)/AMGEVITA (adalimumab) \u00ae \u2122   |\n| Aranesp             | Aranesp (darbepoetin alfa) \u00ae                           |\n| AutoTouch           | AutoTouch \u00ae                                            |\n| AVSOLA              | AVSOLA (infliximab-axxq) \u00ae                             |\n| BKEMV/BEKEMV        | BKEMV (eculizumab-aeeb)/BEKEMV (eculizumab) \u2122 \u2122        |\n| BLINCYTO            | BLINCYTO (blinatumomab) \u00ae                              |\n| BUPHENYL            | BUPHENYL (sodiumphenylbutyrate) \u00ae                      |\n| ConfiPen            | ConfiPen \u2122                                             |\n| Corlanor            | Corlanor (ivabradine) \u00ae                                |\n| DUEXIS              | DUEXIS (ibuprofen and famotidine) \u00ae                    |\n| ENBREL              | Enbrel (etanercept) \u00ae                                  |\n| ENBRELMini          | ENBRELMini \u00ae                                           |\n| EPOGEN              | EPOGEN (epoetin alfa) \u00ae                                |\n| EVENITY             | EVENITY (romosozumab-aqqg) \u00ae                           |\n| IMDELLTRA/IMDYLLTRA | IMDELLTRA (tarlatamab-dlle)/IMDYLLTRA (tarlatamab) \u00ae \u00ae |\n| IMLYGIC             | IMLYGIC (talimogene laherparepvec) \u00ae                   |\n| KANJINTI            | KANJINTI (trastuzumab-anns) \u00ae                          |\n| KRYSTEXXA           | KRYSTEXXA (pegloticase) \u00ae                              |\n| KYPROLIS            | KYPROLIS (carfilzomib) \u00ae                               |\n| LUMAKRAS/LUMYKRAS   | LUMAKRAS /LUMYKRAS (sotorasib) \u00ae \u2122                     |\n| MariTide            | Maridebart cafraglutide (formerly AMG133)              |\n| MVASI               | MVASI (bevacizumab-awwb) \u00ae                             |\n| Neulasta            | Neulasta (pegfilgrastim) \u00ae                             |\n| NEUPOGEN            | NEUPOGEN (filgrastim) \u00ae                                |\n| Nplate              | Nplate (romiplostim) \u00ae                                 |\n| Onpro               | Onpro \u00ae                                                |\n| Otezla              | Otezla (apremilast) \u00ae                                  |\n| Parsabiv            | Parsabiv (etelcalcetide) \u00ae                             |\n| PAVBLU              | PAVBLU (aflibercept-ayyh, formerly ABP938) \u2122           |\n| PENNSAID            | PENNSAID (diclofenac sodiumtopical solution)2% \u00ae       |\n| PROCYSBI            | PROCYSBI (cysteamine bitartrate) \u00ae                     |\n| Prolia              | Prolia (denosumab) \u00ae                                   |\n| Pushtronex          | Pushtronex \u00ae                                           |\n| QUINSAIR            | QUINSAIR (levofloxacin) \u00ae                              |\n| RAVICTI             | RAVICTI (glycerol phenylbutyrate) \u00ae                    |\n| RAYOS               | RAYOS (prednisone) \u00ae                                   |\n| Repatha             | Repatha (evolocumab) \u00ae                                 |\n| RIABNI              | RIABNI (rituximab-arrx) \u00ae                              |\n| Sensipar/Mimpara    | Sensipar /Mimpara (cinacalcet) \u00ae \u2122                     |\n| SureClick           | SureClick \u00ae                                            |",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 228,
      "question": "How does BMY's litigation risk related to the CAR T patent dispute with Kite, involving Juno's $1.2 billion judgment award, reconcile with the company's strategic emphasis on Juno's CAR T programs as a key growth driver in its long-term pipeline?",
      "answer": "BMY faces significant litigation risk stemming from Juno's involvement in a CAR T patent infringement case against Kite, where Juno and SKI were awarded approximately $1.2 billion in royalties, interest, and enhanced damages, with an additional 27.6% running royalty on Yescarta* sales through August 2024. However, this favorable judgment was overturned in August 2021 when the Federal Circuit found the '190 Patent invalid, and the company plans to appeal to the U.S. Supreme Court. Despite the uncertainty of this legal outcome, BMY highlights its acquisition of Juno's CAR T programs\u2014including Breyanzi and Abecma\u2014as central to its long-term strategic growth, emphasizing the potential of these therapies despite the operational, regulatory, and market access challenges they face. The juxtaposition of litigation exposure and strategic investment underscores the dual-edged nature of BMY\u2019s reliance on Juno\u2019s technology, where legal uncertainty could impact both financial outcomes and the broader commercial viability of its CAR T portfolio.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_156) \u2192 [CAR T Litigation]: BMY is involved in a high-stakes patent litigation tied to Juno\u2019s CAR T technology, with a $1.2 billion judgment awarded (later overturned), exposing the company to legal and financial risk.",
        "Hop 2: [CAR T Litigation] \u2192 [Juno]: Juno was a key plaintiff in the litigation, asserting infringement of its patented CAR T technology, which underpins its strategic value to BMY post-acquisition.",
        "Hop 3: [Juno] \u2190 [BMY](page_38): BMY acquired Juno\u2019s CAR T programs (Breyanzi and Abecma) in 2019, positioning them as critical growth assets despite acknowledged risks in manufacturing, regulatory approval, and market adoption."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> LITIGATION -[Involved_In]-> COMP <-[Involved_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "CAR T Litigation",
        "node_3": "Juno",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "LITIGATION",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_156",
          "chunk_id": "chunk_1",
          "chunk_text": "While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that  there  will  not  be  an  increase  in  the  scope  of  one  or  more  of  these  pending  matters  or  any  other  or  future  lawsuits,  claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will  be  incurred  and  the  amount  of  the  related  loss  can  be  reasonably  estimated.  Developments  in  legal  proceedings  and  other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS's tax contingencies, see '-Note 7. Income Taxes'.\n\n## INTELLECTUAL PROPERTY\n\n## Anti-PD-1 Antibody Litigation\n\nIn September 2015, Dana-Farber Cancer Institute ('Dana-Farber') filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer  was  allowed  to  intervene  in  this  case  alleging  that  one  of  the  scientists  identified  by  Dana-Farber  was  employed  by  a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the District Court issued an opinion ruling that the two scientists should be added as inventors to the patents which was affirmed on appeal. In May 2021, the U.S. Supreme Court declined to consider the case. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the District Court's decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss the complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber's claims for damages before May 17, 2019-the date of the District Court's ruling that Dana-Farber was a co-inventor of the patents-are preempted by federal patent law. No trial date has been scheduled.\n\n## CAR T\n\nIn October 2017, Juno and Sloan Kettering Institute for Cancer Research ('SKI') filed a complaint for patent infringement against Kite  Pharma,  Inc.  ('Kite')  in  the  U.S.  District  Court  for  the  Central  District  of  California.  The  complaint  alleged  that  Kite's Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the ''190 Patent') concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the '190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite's defenses, finding that Kite willfully infringed the '190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite's sales of Yescarta* through the expiration of the '190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite's motions in their entirety. In April 2020, the Court granted in part Juno's motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest  and  enhanced damages and a 27.6% running royalty on Kite's sales of Yescarta * from December 13, 2019 through the expiration of the '190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the '190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit  for  panel  and  en  banc  rehearing  which  the  Federal  Circuit  denied  on  January  14,  2022. The  Company  intends  to  file  a petition for a writ of certiorari with the U.S. Supreme Court.",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "CAR_T_Litigation",
          "name": "CAR T Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_156",
          "chunk_id": "chunk_1",
          "chunk_text": "While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that  there  will  not  be  an  increase  in  the  scope  of  one  or  more  of  these  pending  matters  or  any  other  or  future  lawsuits,  claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition.\n\nUnless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will  be  incurred  and  the  amount  of  the  related  loss  can  be  reasonably  estimated.  Developments  in  legal  proceedings  and  other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS's tax contingencies, see '-Note 7. Income Taxes'.\n\n## INTELLECTUAL PROPERTY\n\n## Anti-PD-1 Antibody Litigation\n\nIn September 2015, Dana-Farber Cancer Institute ('Dana-Farber') filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer  was  allowed  to  intervene  in  this  case  alleging  that  one  of  the  scientists  identified  by  Dana-Farber  was  employed  by  a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the District Court issued an opinion ruling that the two scientists should be added as inventors to the patents which was affirmed on appeal. In May 2021, the U.S. Supreme Court declined to consider the case. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the District Court's decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss the complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber's claims for damages before May 17, 2019-the date of the District Court's ruling that Dana-Farber was a co-inventor of the patents-are preempted by federal patent law. No trial date has been scheduled.\n\n## CAR T\n\nIn October 2017, Juno and Sloan Kettering Institute for Cancer Research ('SKI') filed a complaint for patent infringement against Kite  Pharma,  Inc.  ('Kite')  in  the  U.S.  District  Court  for  the  Central  District  of  California.  The  complaint  alleged  that  Kite's Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the ''190 Patent') concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the '190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite's defenses, finding that Kite willfully infringed the '190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite's sales of Yescarta* through the expiration of the '190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite's motions in their entirety. In April 2020, the Court granted in part Juno's motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest  and  enhanced damages and a 27.6% running royalty on Kite's sales of Yescarta * from December 13, 2019 through the expiration of the '190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the '190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit  for  panel  and  en  banc  rehearing  which  the  Federal  Circuit  denied  on  January  14,  2022. The  Company  intends  to  file  a petition for a writ of certiorari with the U.S. Supreme Court.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Juno",
          "name": "Juno",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "generic products, which negatively impacts the protections afforded the Company. Lower-priced generics or biosimilars for BMS biologic products or competing biologics could negatively impact our volumes and prices.\n\nIn  addition,  both  the  U.S.  Congress  and  the  U.S.  FDA  have  taken  steps  to  promote  the  development  and  approval  of generic drugs and biosimilar biologics. For example, in December 2019, the U.S. Congress enacted legislation intended to  facilitate  generic  companies'  access  to  drug  samples.  Section  610  of  the  Further  Consolidated  Appropriations  Act, 2020, provides generic and biosimilar developers a private right of action to obtain sufficient quantities of drug samples from  the  reference  product' s  manufacturer  in  order  to  conduct  testing  necessary  to  obtain  approval  for  generic  or biosimilar products. This law has the potential to have an adverse impact on our business.\n\nThere is no assurance that a particular product will enjoy market exclusivity for the full time period that appears in the estimates disclosed in this 2021 Form 10-K or that we assume when we provide our financial guidance.\n\n## Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor ('CAR') T cell therapy, may present significant challenges and risks for us.\n\nThe  development  of  novel  approaches  for  the  treatment  of  diseases,  such  as  our  acquisition  in  November  2019  of Celgene's and Juno's CAR T cell therapy programs, including Breyanzi (liso-cel) and Abecma (ide-cel), presents many new challenges and risks due to the unique nature of genetic modification of patient cells ex vivo using certain viruses to reengineer  these  cells  to  ultimately  treat  diseases,  including  obtaining  regulatory  approval  from  U.S.  FDA  and  other regulatory agencies that have limited experience with the development of cellular therapies involving genetic modification of patient cells; developing and deploying consistent and reliable processes, while limiting contamination, for engineering a patient's cells ex vivo and infusing genetically modified cells back into the patient; developing processes for the safe administration of cellular therapies, including long-term follow-up for patients receiving cellular therapies; and sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process our potential CAR T products. The use of reengineered cells as a potential cancer treatment is a recent development and may not be broadly accepted by the regulatory, patient or medical communities.\n\nFurther, we may not be able to satisfactorily establish the safety and efficacy or the reliability of these therapies through health  authority  approval,  or  demonstrate  the  potential  advantages  and  side  effects  compared  to  existing  and  future therapies. Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Furthermore, certain payment models could impact the financial feasibility of making CAR T cell therapies available in certain markets or by certain treatment sites, thereby limiting patient access. To date, only a few products  that  involve  the  genetic  modification  of  patient  cells  have  been  approved  for  commercial  sale.  Moreover,  the safety profiles of cellular therapies may adversely influence public perception and may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians and payers to subscribe to these novel treatment approaches. If we fail to overcome these and other challenges, or if significant adverse events are reported from similar therapies,  our  development  of  these  novel  treatment  approaches  may  be  hampered  or  delayed,  which  could  adversely affect our future anticipated revenues and/or profitability related to these therapeutic programs. In addition, we could also face  difficulties  in  manufacturing  CAR  T  cell  therapies,  which  could  adversely  affect  our  future  anticipated  revenues and/or profitability related to our CAR T cell therapies. See ' -We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.'\n\n## We face intense competition from other manufacturers and expect to see increasing market penetration of lower-priced generic products.\n\nThe future growth of BMS is dependent on the market access, uptake and expansion for marketed brands, new product introductions,  new  indications,  product  extensions  and  co-promotional  activities  with  alliance  partners.  Competition  is keen and as we lose exclusivity for some of our marketed brands lower-priced generic products will increasingly penetrate our  markets.  Generic  challenges  to  our  products  can  also  arise  at  any  time,  and  our  patents  may  not  prevent  the emergence of generic competition for our products. For example, if we receive an adverse litigation decision in a country in the EU where our Eliquis composition of matter patents and related Supplementary Protection Certificates are being challenged (see 'Item 8. Financial Statements and Supplementary Data-Note 19. Legal Proceedings and Contingencies'), we may not be able to prevent generic apixaban products from being introduced in such country prior to our estimated minimum market exclusivity date. In some countries, patent protection is significantly weaker than in the United States or in the EU; political and social pressure has also pushed legislation and other measures that promote the use  of  generic  and  biosimilar  products.  In  addition,  we  face  competition  from  new  products  entering  the  market, particularly in IO. New products may have (i) lower prices, (ii) superior efficacy (benefit) or safety (risk) profiles (whether actual  or  perceived),  (iii)  technological  advantages  that  may  make  such  products  more  convenient  to  use,  (iv)  better insurance coverage or reimbursement levels, (v) more effective marketing programs and/or other differentiating factors that make it harder for our products to compete. We also face intense competition for external partnerships, joint ventures and  acquisition  targets  that  can  help  develop  and  bring  new  products  to  markets.  Business  combinations  among  our competitors and major third-party payers may increase competition",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 229,
      "question": "How does BMY's regulatory exclusivity risk for Orencia, as a biologic with 12 years of exclusivity, interact with its joint commercialization arrangement with Ono in Japan, particularly in light of BMY's broader strategic collaborations listed in the development partnerships section?",
      "answer": "BMY faces regulatory exclusivity risk for Orencia, a biologic product that is entitled to 12 years of exclusivity in the U.S., after which biosimilars may be approved. This risk is heightened by increasing challenges to innovator patents and evolving regulatory frameworks that may limit BMY's ability to maintain market exclusivity. Orencia is jointly commercialized with Ono in Japan, where BMY and Ono share responsibilities: BMY handles supply and intravenous formulation fulfillment, while Ono manages the subcutaneous formulation, and both promote the product with assigned customer accounts. A co-promotion fee of 60% is paid when a sale is made to the other party's assigned customer. Given BMY's broader strategic development partnerships\u2014such as those with Ono for OPDIVO, YERVOY, and other investigational compounds\u2014this joint promotion model with Ono appears to be a recurring strategic structure that BMY leverages in key markets. The interplay between Orencia\u2019s limited exclusivity window and the shared commercialization model with Ono suggests BMY must balance maximizing revenue during the exclusivity period with the operational complexity and revenue-sharing dynamics inherent in its partnership framework.",
      "reasoning_steps": [
        "Hop 1: BMY(page_7) \u2192 Orencia: Orencia is listed as a marketed biologic product, which is entitled to 12 years of regulatory exclusivity in the U.S., after which biosimilar versions may be approved, posing a risk to continued market exclusivity.",
        "Hop 2: Orencia \u2192 Ono: BMY and Ono jointly develop and commercialize Orencia in Japan, with defined roles: BMY handles supply and intravenous formulation fulfillment, Ono manages the subcutaneous formulation, and both promote the product with a co-promotion fee of 60% on cross-assigned sales.",
        "Hop 3: Ono \u2190 BMY(page_15): Ono is listed as a key development partner in BMY's broader pipeline collaborations, including for OPDIVO, YERVOY, and other investigational compounds, indicating a strategic and recurring partnership structure in the Japanese market."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT -[Promotes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Orencia",
        "node_3": "Ono",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "An innovator company is required to list certain of its patents covering the medicine with the FDA in what is commonly known as the Orange Book. Absent a successful patent challenge, the FDA cannot approve an ANDA until after the innovator's listed patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA and allege that one or more of the patents listed in the Orange Book under an innovator's NDA is invalid, unenforceable, or will not be infringed by the generic product. This allegation is commonly known as a Paragraph IV  certification. The innovator then must decide whether to file a patent infringement suit against the generic manufacturer. From time to time, ANDAs including Paragraph IV  certifications are filed with respect to certain of our products. We evaluate these ANDAs on a case-by-case basis and, where warranted, file suit against the generic manufacturer to protect our patent rights.\n\nMedicines can also receive several types of regulatory exclusivity. An innovative chemical pharmaceutical product is entitled to five years of regulatory exclusivity in the U.S., during which the FDA cannot approve generic substitutes. If an innovator's patent is challenged, a generic manufacturer may file its ANDA after the fourth year  of  the  five-year  regulatory  ex clusivity  period.  Our  marketed  chemical  products  include Eliquis,  Revlimid,  Pomalyst,  Sprycel,  Zeposia,  Camzyos,  Sotyktu , Augtyro, Krazati, and Cobenfy .\n\n## Biologic products (includes CAR-T cell therapy products)\n\nQualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative  biological  product  was  first  approved  by  the  FDA.  Our  marketed  biologic  products  include Opdivo , Opdivo  Qvantig, Orencia, Yervoy,  Reblozyl, Opdualag, Breyanzi, Abecma and Abraxane.\n\nIn the U.S., medicines (chemically synthesized or biologically derived) may also receive an additional six months of market exclusivity (added to certain patent terms and regulatory exclusivities) if certain agreed-upon pediatric studies are completed by the applicant.\n\nThe increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market ex clusivity. First, generic companies have increasingly sought to challenge innovators' patents covering major pharmaceutical products. Second, statutory and regulatory provisions may limit the ability of an innovator company to prevent generic and biosimilar drugs from being approved and launched while patent litigation is ongoing. As a result of these developments, among others, it is not possible to predict the length of market exclusivity for a particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory ex clusivity.\n\n## European Union\n\nPatents on pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended for up to five years to compensate for the patent term lost during the regulatory review process, provided that the extension cannot cause the patent to be in effect for more than 15 years from the date of drug approval. Such extensions are granted on a country-by-country basis. The EU provides an additional six months of exclusivity added to the extended patent term if certain pediatric studies are completed by the applicant.\n\nThe  primary  route  we  use  to  obtain  marketing  authorization  of  pharmaceutical  products  in  the  EU  is  through  the  'centralized  procedure.'  This  procedure  is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of an MAA with the EMA. After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA.\n\nAfter obtaining marketing authorization approval, a company must obtain pricing and reimbursement for the pharmaceutical product, which is typically subject to member state law. In certain EU countries, this process can take place simultaneously while the product is marketed but in other EU countries, this process must be completed before the company can market the new product. The pricing and reimbursement procedure can take months and sometimes years to complete.\n\nThroughout  the  EU,  all  products  for  which  marketing  authorizations  have  been  filed  after  October  and  November  2005  are  subject  to  an  '8+2+1'  regulatory exclusivity regime. Eight years after the innovator has received its first community authorization for a medicinal product, a generic company may file a MAA for that product with the health authorities. If the MAA is approved, the generic company may not commercialize the product until after either 10 or 11 years have elapsed from the initial marketing authorization granted to the innovator. The possible extension to 11 years is available if the innovator, during the first eight years of the marketing authorization, obtains an additional indication that is of significant clinical benefit in comparison with ex isting treatments.",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "Orencia",
          "name": "Orencia",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_3",
          "chunk_text": "\n## Ono\n\nBMS  and  Ono  jointly  develop  and  commercialize Opdivo , Yervoy and  several  BMS  investigational  compounds  in  Japan,  South  Korea  and  Taiwan.  BMS  is responsible for supply of the products. Profits, losses and development costs are shared equally for all combination therapies involving compounds of both parties. Otherwise, sharing is 80% and 20% for activities involving only one of the party's compounds.\n\nBMS and Ono also jointly develop and commercialize Orencia in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. A co-promotion fee of 60% is paid when a sale is made to the other party's assigned customer.\n\nSummarized financial information related to this alliance was as follows:\n\n",
          "relationship": "Promotes"
        },
        "node_3": {
          "id": "Ono",
          "name": "Ono",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNote: Above pipeline ex cludes clinical collaborations\n\n- Development  Partnerships: AUGTYRO: Zai  Lab;  BMS-986495:  Prothena; COBENFY :  Zai  Lab;  iza-bren  (EGFRxHER3  ADC):  SystImmune; KRAZATI :  Zai  Lab; milvexian: Johnson &amp; Johnson; obexelimab: Zenas BioPharma; OPDIVO , YERVOY , OPDUALAG, nivolumab + relatlimab HD, Anti-CCR8 + nivolumab: Ono; PKC\u03b8 Inhibitor: Ex scientia; REBLOZYL : Merck; rHuPH20: Halozyme \u00aa\n\n# Partner-run study\n\nThe following are our registrational study readouts anticipated through 2025/2026:\n\n",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 230,
      "question": "Given Oak Street Health's dependence on third-party payors and the $6.6 billion in cumulative goodwill impairments as of December 31, 2024, how does the $189 million decrease in CVS\u2019s adjusted operating income in 2024 reflect the financial risks associated with reimbursement pressures impacting both the broader Pharmacy & Consumer Wellness segment and Oak Street Health specifically?",
      "answer": "The $189 million decrease in CVS\u2019s adjusted operating income in 2024 was primarily driven by continued pharmacy reimbursement pressure, which is a risk also specifically highlighted for Oak Street Health. Oak Street Health, which contributed to the goodwill increases in 2023, is explicitly noted as being dependent on third-party payors for a significant portion of its revenue. This dependence subjects it to reimbursement delays and changes in payment terms, mirroring the broader reimbursement challenges faced by the Pharmacy & Consumer Wellness segment. The $6.6 billion in cumulative goodwill impairments as of December 31, 2024, indicates that the company has already experienced significant value erosion from prior acquisitions, potentially linked to similar operational and reimbursement risks. Therefore, the 2024 financial performance reflects a continuation of these systemic reimbursement pressures, impacting both legacy operations and newly acquired entities like Oak Street Health, which in turn heightens the risk of further goodwill impairment.",
      "reasoning_steps": [
        "Hop 1: CVS(page_150) \u2192 Oak Street Health: CVS acquired Oak Street Health in 2023, which contributed to an increase in goodwill, and as of 2024, cumulative goodwill impairments totaled $6.6 billion.",
        "Hop 2: Oak Street Health \u2192 Third-Party Payors: Oak Street Health is heavily dependent on third-party payors for a significant portion of its revenue, exposing it to reimbursement delays and contractual changes.",
        "Hop 3: Third-Party Payors \u2190 CVS(page_86): The Pharmacy & Consumer Wellness segment experienced a $189 million decrease in adjusted operating income in 2024, largely due to pharmacy reimbursement pressure from third-party payors."
      ],
      "difficulty": "hard",
      "idf_score": 6.462108391303541,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> COMP -[Depends_On]-> COMP <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "CVS",
        "node_2": "Oak Street Health",
        "node_3": "Third-Party Payors",
        "end": "CVS"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_150",
          "chunk_id": "chunk_5",
          "chunk_text": "\nThere were no changes to the carrying amount of the Company's goodwill during the year ended December 31, 2024.\n\nDuring the year ended December 31, 2023, the increase in the carrying amount of goodwill was primarily driven by the acquisitions of Oak Street Health and Signify Health. See Note 2 ''Acquisitions, Divestitures and Asset Sales'' for additional information.\n\nDuring the fourth quarter of 2024 and 2023, and the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of these impairment tests indicated that there was no impairment of goodwill.\n\nAt December 31, 2024 and 2023, cumulative goodwill impairments were $6.6 billion.",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Oak_Street_Health",
          "name": "Oak Street Health",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_1",
          "chunk_text": "- dependence on a concentrated number of key health plan customers;\n- the quality of the information received about plan members of such health plans for whom Signify Health will seek to provide in-home evaluations and other services, and the regulatory restrictions and requirements associated with directly contacting plan members;\n- ability to perform and ensure the quality of health risk assessments;\n- ability to achieve and receive shared health care cost savings;\n- the regulatory and business risks associated with participation in certain government health care programs, including, among others, the MSSP and ACO REACH models, and identification of diagnosis codes related to risk adjustment payments under Part C of the Medicare program;\n- health reform initiatives and changes in the rules governing government health care programs, including rules related to the use of in-home health risk assessments for the purpose of capturing individual risk use to calculate an individual's risk adjustment factor or a change to how patient-level risk is determined for CMS programs;\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;\n- impacts of fraud or anomalous billing on shared savings in CMS Innovation Center models;\n- use of 'open source' software in its technology, which may make it easier for others to gain access or compromise its proprietary technology;\n- success in large, national ACOs is dependent on the collective efforts and compliance of a wide range of participating clients, and for those clients to be able to meet new and changing requirements such as changes to interoperability and reporting requirements; and\n- challenges in rural and post-acute reimbursement due to their significant dependence on fee-for-service revenue.\n\nOur Oak Street Health business is subject to additional risks including, but not limited to, the following:\n\n- ability to attract new Medicare-eligible patients and credentialed, high-quality physicians and other providers for senior-focused primary care in a highly competitive market for such patients and providers;\n- satisfying the enrollment requirements under government health care programs for physicians and other providers in a timely manner;\n- dependence on a significant portion of revenue from Medicare or Medicare Advantage plans, which subjects Oak Street Health to reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;\n- dependence for a significant portion of revenue from agreements with a limited number of key payors with whom Oak Street Health contracts to provide services under terms that may permit a payor to amend the compensation arrangements or terminate the agreements without cause;\n- dependence on reimbursements from third-party payors, which can result in substantial delay, and on patients, through copayments and deductibles, which subjects Oak Street Health to additional reimbursement risk;\n- under the fix ed fee (or capitated) agreements Oak Street Health enters into with health plans, the assumption of the risk that the actual cost of a service it provides to a patient exceeds the reimbursement provided by the health plan;\n- reductions in the quality ratings of Medicare health plans Oak Street Health serves could result in a shift of patients from, or the termination of, a health plan Oak Street Health serves;\n- submission of inaccurate, incomplete or erroneous data, including risk adjustment data, to health plans and government payors could result in inaccuracies in the revenue Oak Street Health records or receipt of overpayments, which may subject it to repayment obligations and penalties;\n- geographic concentration of its primary care centers;\n- risks associated with its ex isting legal proceedings and litigations;\n- laws regulating the corporate practice of medicine and the associated agreements entered into with physician practice groups restrict the manner in which the Oak Street Health business is able to direct the operations and otherwise exercise control of its physician practice groups\n- participation in CMS Innovation Center models, such as ACO REACH, which are subject to changes annually, generally in ways meant to reduce available payments to participants, including benchmarks that can be changed after the end of the performance year, and which has an end date without a plan for ongoing participation in a model by those participating;",
          "relationship": "Depends_On"
        },
        "node_3": {
          "id": "Third-Party_Payors",
          "name": "Third-Party Payors",
          "type": "COMP",
          "idf_score": 5.657389435086491
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_1",
          "chunk_text": "- front store volume, including the impact of a decrease in store count and lower contributions from COVID-19 over-the-counter ('OTC') test kits since the expiration of the public health emergency in May 2023.\n- Pharmacy same store sales increased 12.3% in 2024 compared to 2023. The increase was primarily driven by the 6.8% increase in pharmacy same store prescription volume on a 30-day equivalent basis, including increased contributions from vaccinations, and pharmacy drug mix, including branded GLP-1 drugs. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions.\n- Front store same store sales decreased 2.1% in 2024 compared to 2023 primarily due to general softening of consumer demand and lower contributions from COVID-19 OTC test kits compared to the prior year.\n\n## Operating expenses\n\n- Operating expenses in the Pharmacy &amp; Consumer Wellness segment include payroll, employee benefits and occupancy costs associated with the segment's stores and pharmacy fulfillment operations; selling expenses; advertising expenses; depreciation and amortization expense and certain administrative expenses.\n- Operating expenses remained relatively consistent in 2024 compared to the prior year at $19.6 billion, as the absence of gains from anti-trust legal settlements and increased investments in the segment's operations and capabilities were substantially offset by the decrease in store count.\n\n## Restructuring charges\n\n- During 2024, the Company recorded $747 million of restructuring charges related to the write-down of lease right-of-use assets and property and equipment in connection with the Company's restructuring program. See Note 3 ''Restructuring'' included in Item 8 of this 10-K for additional information.\n\n## Loss on assets held for sale\n\n- During 2023, the Company recorded losses on assets held for sale of $349 million related to the write-down of its LTC business. See Note 2 ''Acquisitions, Divestitures and Asset Sales'' included in Item 8 of this 10-K for additional information.\n\n## Adjusted operating income\n\n- Adjusted operating income decreased $189 million, or 3.2%, in 2024 compared to 2023 primarily driven by continued pharmacy reimbursement pressure and decreased front store volume, including lower contributions from COVID-19 OTC test kits, largely offset by increased prescription volume, including increased contributions from vaccinations, as well as improved drug purchasing.\n- As you review the Pharmacy &amp; Consumer Wellness segment's performance in this area, you should consider the following important information about the business:\n- The segment's adjusted operating income has been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix  of business within the pharmacy portion of the Pharmacy &amp; Consumer Wellness segment. If the pharmacy reimbursement pressure accelerates, the segment may not be able to grow revenues, and its adjusted operating income could be adversely affected.\n\n## Prescriptions filled\n\n- Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy &amp; Consumer Wellness segment's retail and long-term care pharmacies and infusion services operations. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.\n- Prescriptions filled increased 4.0% on a 30-day equivalent basis in 2024 compared to 2023 primarily driven by increased utilization, partially offset by the decrease in store count.\n\n## Generic dispensing rate\n\n- Generic dispensing rate is calculated by dividing the Pharmacy &amp; Consumer Wellness segment's generic drug prescriptions filled by its total prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "CVS",
          "name": "CVS",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 231,
      "question": "How does Bravecto's recent EC approval for a 12-month injectable flea and tick formulation support Merck's strategy to maintain profitability in light of upcoming patent expirations for major products like Keytruda?",
      "answer": "Bravecto's EC approval for a 12-month injectable formulation in January 2024 provides Merck with an extended duration product that can enhance market differentiation and customer retention in the competitive animal health space. This is strategically important as Merck's key products, including Keytruda and Gardasil/Gardasil 9, accounted for 56% of total sales in 2023. With Keytruda expected to lose U.S. market exclusivity in 2028, Bravecto's innovation helps diversify revenue streams and offset potential declines from oncology and vaccine franchises. The approval aligns with Merck's broader strategy of leveraging product lifecycle management to maintain profitability amid looming patent cliffs.",
      "reasoning_steps": [
        "Hop 1: MRK(page_7) \u2192 Bravecto: EC approval of 12-month injectable flea and tick formulation in January 2024 enhances product differentiation",
        "Hop 2: Bravecto \u2192 Key Products: Bravecto is specifically listed among key products driving 56% of Merck's sales in 2023",
        "Hop 3: Key Products \u2190 MRK(page_28): Key products like Keytruda (U.S. exclusivity ends 2028) and Gardasil/Gardasil 9 are central to profitability, but face patent expiration risks"
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> PRODUCT -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Bravecto",
        "node_3": "Key Products",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_7",
          "chunk_id": "chunk_1",
          "chunk_text": "| Keytruda     | November 2023   | FDA approval in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.                                                                                                               |\n|--------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Keytruda     | December 2023   | FDA full approval in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer) and Astellas. |\n| Keytruda     | December 2023   | EC approval in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1, based on the KEYNOTE- 859 trial.                                                                                      |\n| Keytruda     | December 2023   | EC approval in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on the KEYNOTE-966 trial.                                                                                                                                                                    |\n| Keytruda     | December 2023   | China's NMPA approval in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.                                                                                                     |\n| Keytruda     | January 2024    | FDA approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.                                                                                                                                                           |\n| Keytruda     | January 2024    | FDA full approval for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an accelerated to full (regular) approval is based on the KEYNOTE-394 trial.                                                                                                     |\n| Keytruda     | February 2024   | China's NMPA approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the KEYNOTE-966 trial.                                                                                                                                                                   |\n| Lynparza (1) | May 2023        | FDA approval in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated ( BRCAm ) metastatic castration-resistant prostate cancer (mCRPC), based on the PROpel trial.                                                                                                        |\n| Lynparza (1) | August 2023     | Japan's MHLW approval in combination with abiraterone and prednisolone for treatment of adult patients with BRCAm mCRPC with distant metastasis, based on the PROpel trial.                                                                                                                                                                                                 |\n| Prevymis     | June 2023       | FDA approval for CMV prophylaxis in Donor CMV-seropositive/Recipient CMV-seronegative adult kidney transplant recipients, based on the P002 trial.                                                                                                                                                                                                                          |\n| Prevymis     | November 2023   | EC approval for CMV prophylaxis Donor CMV-seropositive/Recipient CMV-seronegative adult kidney transplant recipients, based on the P002 trial.                                                                                                                                                                                                                              |\n| Ervebo       | August 2023     | FDA approval of an expanded indication for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older.                                                                                                                                            |\n| Ervebo       | September 2023  | EC approval of an expanded indication for active immunization of individuals one year of age or older to protect against Ebola Virus Disease caused by Zaire ebolavirus . The vaccine was previously approved for use in the EU for individuals 18 years of age or older.                                                                                                   |\n| Welireg      | December 2023   | FDA approval for the treatment of adult patients with advanced RCC following both a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor, based on the LITESPARK-005 trial.                                                                                                                                                           |\n| Bravecto     | January 2024    | EC approval of injectable formulation for dogs for the persistent killing of fleas and ticks for 12 months after treatment.                                                                                                                                                                                                                                                 |\n",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Bravecto",
          "name": "Bravecto",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 232,
      "question": "How does AbbVie's financial exposure to Imbruvica, including its collaboration with Janssen Biotech, reconcile with the $3.6 billion intangible asset impairment charge primarily related to the product in 2023?",
      "answer": "AbbVie's collaboration with Janssen Biotech involves joint development and commercialization of Imbruvica, with both parties sharing pre-tax profits and losses equally in the U.S. and globally. Despite this shared risk model, AbbVie reported a $3.6 billion intangible asset impairment charge in 2023 primarily tied to Imbruvica, indicating that the financial burden of declining product value fell disproportionately on AbbVie\u2019s balance sheet. This suggests that while Janssen shares in the profits and development costs, AbbVie holds the majority of the associated intangible asset risk, potentially due to its principal role in U.S. sales and consolidated revenue reporting.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_68) \u2192 [Janssen Biotech]: AbbVie has a long-standing collaboration with Janssen Biotech for the joint development and commercialization of Imbruvica, with shared costs (60% Janssen, 40% AbbVie) and equal profit/loss sharing in both U.S. and international markets.",
        "Hop 2: [Janssen Biotech] \u2192 [Imbruvica]: Janssen Biotech holds exclusive or co-exclusive rights to commercialize Imbruvica under the collaboration, and both parties are financially tied to the product\u2019s performance through cost-sharing and profit-sharing arrangements.",
        "Hop 3: [Imbruvica] \u2190 [ABBV](page_44): In 2023, AbbVie recorded a $3.6 billion intangible asset impairment charge primarily related to Imbruvica, which significantly impacted gross margin percentages despite the shared collaboration model."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Has_Stake_In]-> PRODUCT <-[Depends_On]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Janssen Biotech",
        "node_3": "Imbruvica",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen_Biotech",
          "name": "Janssen Biotech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "## Note\t6\tCollaborations\n\nThe\tcompany\thas\tongoing\ttransactions\twith\tother\tentities\tthrough\tcollaboration\tagreements.\tThe\tfollowing\trepresent\tthe significant\tcollaboration\tagreements\timpacting\t2023,\t2022\tand\t2021.\n\n## Collaboration\twith\tJanssen\tBiotech,\tInc.\n\nIn\tDecember\t2011,\tPharmacyclics,\ta\twholly-owned\tsubsidiary\tof\tAbbVie,\tentered\tinto\ta\tworldwide\tcollaboration\tand\tlicense agreement\twith\tJanssen\tBiotech,\tInc.\tand\tits\taffiliates\t(Janssen),\tone\tof\tthe\tJanssen\tPharmaceutical\tcompanies\tof\tJohnson\t&amp; Johnson,\tfor\tthe\tjoint\tdevelopment\tand\tcommercialization\tof\tImbruvica,\ta\tnovel,\torally\tactive,\tselective\tcovalent\tinhibitor\tof Bruton's\ttyrosine\tkinase\tand\tcertain\tcompounds\tstructurally\trelated\tto\tImbruvica,\tfor\toncology\tand\tother\tindications,\texcluding all\timmune\tand\tinflammatory\tmediated\tdiseases\tor\tconditions\tand\tall\tpsychiatric\tor\tpsychological\tdiseases\tor\tconditions,\tin\tthe United\tStates\tand\toutside\tthe\tUnited\tStates.\n\nThe\tcollaboration\tprovides\tJanssen\twith\tan\texclusive\tlicense\tto\tcommercialize\tImbruvica\toutside\tof\tthe\tUnited\tStates\tand\tcoexclusively\twith\tAbbVie\tin\tthe\tUnited\tStates.\tBoth\tparties\tare\tresponsible\tfor\tthe\tdevelopment,\tmanufacturing\tand\tmarketing\tof\tany products\tgenerated\tas\ta\tresult\tof\tthe\tcollaboration.\tThe\tcollaboration\thas\tno\tset\tduration\tor\tspecific\texpiration\tdate\tand provides\tfor\tpotential\tfuture\tdevelopment,\tregulatory\tand\tapproval\tmilestone\tpayments\tof\tup\tto\t$200\tmillion\tto\tAbbVie.\tThe collaboration\talso\tincludes\ta\tcost\tsharing\tarrangement\tfor\tassociated\tcollaboration\tactivities.\tExcept\tin\tcertain\tcases,\tJanssen is\tresponsible\tfor\tapproximately\t60%\tof\tcollaboration\tdevelopment\tcosts\tand\tAbbVie\tis\tresponsible\tfor\tthe\tremaining\t40%\tof collaboration\tdevelopment\tcosts.\n\nIn\tthe\tUnited\tStates,\tboth\tparties\thave\tco-exclusive\trights\tto\tcommercialize\tthe\tproducts;\thowever,\tAbbVie\tis\tthe\tprincipal\tin the\tend-customer\tproduct\tsales.\tAbbVie\tand\tJanssen\tshare\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof products.\tSales\tof\tImbruvica\tare\tincluded\tin\tAbbVie's\tnet\trevenues.\tJanssen's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's\tcost\tof products\tsold.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nOutside\tthe\tUnited\tStates,\tJanssen\tis\tresponsible\tfor\tand\thas\texclusive\trights\tto\tcommercialize\tImbruvica.\tAbbVie\tand\tJanssen share\tpre-tax\tprofits\tand\tlosses\tequally\tfrom\tthe\tcommercialization\tof\tproducts.\tAbbVie's\tshare\tof\tprofits\tis\tincluded\tin\tAbbVie's net\trevenues.\tOther\tcosts\tincurred\tunder\tthe\tcollaboration\tare\treported\tin\ttheir\trespective\texpense\tline\titems,\tnet\tof\tJanssen's share.\n\nThe\tfollowing\ttable\tshows\tthe\tprofit\tand\tcost\tsharing\trelationship\tbetween\tJanssen\tand\tAbbVie:\n\n",
          "relationship": "Has_Stake_In"
        },
        "node_3": {
          "id": "Imbruvica",
          "name": "Imbruvica",
          "type": "PRODUCT",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_44",
          "chunk_id": "chunk_3",
          "chunk_text": "\nGross\tmargin\tas\ta\tpercentage\tof\tnet\trevenues\tin\t2023\tdecreased\tcompared\tto\t2022.\tGross\tmargin\tpercentage\tfor\t2023\twas unfavorably\timpacted\tby\tintangible\tasset\timpairment\tcharges\tof\t$3.6\tbillion\tprimarily\trelated\tto\tImbruvica,\tCoolSculpting\tand Liletta,\thigher\tamortization\tof\tintangibles\tand\tchanges\tin\tproduct\tmix,\tpartially\toffset\tby\tthe\tfavorable\ttax\tlaw\tchanges\tin Puerto\tRico.\n\n## Selling,\tGeneral\tand\tAdministrative\n\n",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 233,
      "question": "How does Merck's strategic emphasis on combining Lenvima with Keytruda for esophageal and gastric cancers align with the financial and developmental disclosures regarding Keytruda's broader pipeline and collaboration strategy?",
      "answer": "Merck's strategic emphasis on combining Lenvima with Keytruda for esophageal and gastric cancers, as stated in the Phase 3 oncology programs under the Precision Molecular Targeting pillar (page 48), aligns with the financial and developmental disclosures that show Lenvima is already approved in combination with Keytruda for other indications such as advanced endometrial carcinoma and RCC. This strategic direction is further reinforced by Keytruda's deep integration into multiple collaborations, including the joint development with Moderna for V940 in combination with Keytruda in Phase 3 trials, and the shared cost and profit structure in that partnership (page 90). The 10% growth in alliance revenue from Lenvima (page 52) indicates the financial traction of this combination therapy, supporting Merck's broader oncology strategy centered on Keytruda's versatility and pipeline expansion.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_48) \u2192 [Lenvima]: Merck's Phase 3 oncology programs under the Precision Molecular Targeting pillar include Lenvima in combination with Keytruda for certain types of esophageal and gastric cancers.",
        "Hop 2: [Lenvima] \u2192 [Keytruda]: Lenvima is approved in combination with Keytruda for advanced endometrial carcinoma and RCC, indicating Keytruda's central role in combination therapies.",
        "Hop 3: [Keytruda] \u2190 [MRK](page_90): Keytruda is being evaluated in combination with V940 in multiple Phase 3 trials, and Merck has a shared cost and profit collaboration with Moderna, emphasizing Keytruda's strategic importance in oncology development."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Approved_For]-> PRODUCT <-[Discloses]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Lenvima",
        "node_3": "Keytruda",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- V116,\t an\t investigational\t 21-valent\t pneumococcal\t conjugate\t vaccine\t for\t the\t prevention\t of\t invasive\t pneumococcal\t disease\t and pneumococcal\tpneumonia\tin\tadults,\tis\talso\tunder\tpriority\treview\tby\tthe\tFDA.\n- MK-1022,\tpatritumab\tderuxtecan,\tis\tan\tADC\tbeing\tevaluated\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tNSCLC\tunder\tpriority\treview\tby the\tFDA.\tPatritumab\tderuxtecan\tis\tpart\tof\ta\tcollaboration\twith\tDaiichi\tSankyo.\n- Additionally, Keytruda is\t under\t review\t in\t the\t U.S.\t and/or\t in\t international\t markets\t for\t supplemental\t indications\t for\t the treatment\tof\tcertain\tpatients\twith\tbiliary\ttract,\tcervical,\tendometrial,\tgastric,\tnon-small-cell\tlung\tand\turothelial\tcancers.\n- Welireg is\tunder\treview\tin\tthe\tEU\tfor\tthe\ttreatment\tof\tcertain\tpatients\twith\tadvanced\tRCC\tand\tfor\tthe\ttreatment\tof\tvon\tHippelLindau\tdisease.\n\nDuring\t2023,\tthe\tCompany\tinitiated\tmore\tthan\t20\tPhase\t3\tstudies\tacross\tmultiple\tasset\tclasses,\tincluding\tthe\tprogression\tof eight\tnovel\tcandidates.\n\nThe\t Company\t is\t diversifying\t its\t oncology\t portfolio\t and\t executing\t on\t its\t strategy\t which\t is\t broadly\t based\t on\t three\t strategic pillars:\timmuno-oncology,\tprecision\tmolecular\ttargeting\tand\ttissue\ttargeting.\tMerck's\tPhase\t3\toncology\tprograms\twithin\tthese\tpillars\tare as\tfollows:\n\n## Immuno-oncology\n\n- Keytruda in\t the\t therapeutic\t areas\t of\t cutaneous\t squamous\t cell,\t hepatocellular,\t mesothelioma,\t ovarian\t and\t small-cell\t lung cancers;\n- MK-1308A,\tthe\tcoformulation\tof\tquavonlimab,\tMerck's\tnovel\tinvestigational\tanti-CTLA-4\tantibody,\tand\tpembrolizumab\tfor\tRCC;\n- MK-3475A,\tthe\tsubcutaneous\tcoformulation\tof\tpembrolizumab\twith\thyaluronidase\tfor\tcertain\ttypes\tof\tNSCLC;\n- MK-4280A,\tthe\tcoformulation\tof\tfavezelimab,\tMerck's\tnovel\tinvestigational\tanti-LAG3\ttherapy,\tand\tpembrolizumab\tfor\tcolorectal cancer\tand\thematological\tmalignancies;\n- MK-7684A,\t the\t coformulation\t of\t vibostolimab,\t an\t anti-TIGIT\t therapy,\t and\t pembrolizumab\t for\t certain\t types\t of\t melanoma,\t non-\n- small-cell\tand\tsmall-cell\tlung\tcancers;\tand\n- V940,\tan\tinvestigational\tindividualized\tneoantigen\ttherapy,\tin\tcombination\twith Keytruda ,\tfor\tcertain\ttypes\tof\tmelanoma\tand NSCLC,\tbeing\tdeveloped\tin\tcollaboration\twith\tModerna.\n\n## Precision\tmolecular\ttargeting\n\n- Lynparza\tin\tcombination\twith Keytruda for\tnon-small-cell\tlung\tand\tsmall-cell\tlung\tcancers;\n- Lenvima,\tbeing\tdeveloped\tin\tcollaboration\twith\tEisai\tCo.,\tLtd.\t(Eisai),\tin\tcombination\twith Keytruda for\tcertain\ttypes\tof esophageal\tand\tgastric\tcancers;\n- MK-1026,\t nemtabrutinib,\t an\t oral,\t reversible,\t non-covalent\t Bruton's\t tyrosine\t kinase\t (BTK)\t inhibitor,\t for\t hematological malignancies;\n- MK-3543,\t bomedemstat,\t an\t investigational\t orally\t available\t lysine-specific\t demethylase\t 1\t inhibitor\t for\t myeloproliferative disorders;\tand\n- MK-5684,\tan\tinvestigational\tcytochrome\tP450\t11A1\t(CYP11A1)\tinhibitor\tbeing\tdeveloped\tin\tcollaboration\twith\tOrion\tCorporation (Orion)\tfor\tmCRPC.\n\n## Tissue\ttargeting\n\n- MK-2870,\t an\t investigational\t trophoblast\t cell-surface\t antigen\t 2\t (TROP2)-directed\t ADC\t being\t developed\t in\t collaboration\t with Kelun-Biotech\tfor\tendometrial\tcarcinoma\tand\tcertain\ttypes\tof\tNSCLC.\n\nAdditionally,\tthe\tCompany\tcurrently\thas\tcandidates\tin\tPhase\t3\tclinical\tdevelopment\tin\tseveral\tother\ttherapeutic\tareas\tincluding:\n\n- MK-0616,\tan\tinvestigational,\toral\tproprotein\tconvertase\tsubtilisin/kexin\ttype\t9\t(PCSK9)\tinhibitor\tfor\thypercholesterolemia;\n- MK-1654,\tclesrovimab,\ta\thuman\tmonoclonal\tantibody\tfor\tthe\tprevention\tof\trespiratory\tsyncytial\tvirus\t(RSV);\n- MK-7240,\ttulisokibart,\ta\thumanized\tmonoclonal\tantibody\tdirected\tto\ttumor\tnecrosis\tfactor-like\tligand\t1A,\ta\ttarget\tassociated with\tboth\tintestinal\tinflammation\tand\tfibrosis,\tfor\tulcerative\tcolitis;",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Lenvima",
          "name": "Lenvima",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_5",
          "chunk_text": "\nLenvima\tis\tan\toral\treceptor\ttyrosine\tkinase\tinhibitor\tbeing\tdeveloped\tas\tpart\tof\ta\tcollaboration\twith\tEisai\t(see\tNote\t4\tto\tthe consolidated\tfinancial\tstatements).\tLenvima\tis\tapproved\tfor\tthe\ttreatment\tof\tcertain\ttypes\tof\tthyroid\tcancer,\tRCC,\tHCC,\tin\tcombination with\teverolimus\tfor\tcertain\tpatients\twith\tadvanced\tRCC,\tand\tin\tcombination\twith Keytruda for\tcertain\tpatients\twith\tadvanced\tendometrial carcinoma\tor\tadvanced\tRCC.\tAlliance\trevenue\trelated\tto\tLenvima\tgrew\t10%\tin\t2023\treflecting\thigher\tdemand\tand\tpricing\tin\tthe\tU.S.\tand higher\tdemand\tin\tEurope,\tpartially\toffset\tby\tlower\tdemand\tin\tChina.\n\nSales\tof Welireg ,\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tcertain\tvon\tHippel-Lindau\tdisease-associated\ttumors\tand\tcertain\tadult patients\twith\tpreviously\ttreated\tadvanced\tRCC,\tincreased\t77%\tin\t2023\tdue\tto\tcontinued\tuptake\tin\tthe\tU.S.\tfollowing\tlaunch\tin\t2021.\tIn December\t2023,\tthe\tFDA\tapproved\ta\tsupplemental\tnew\tdrug\tapplication\t(NDA)\tfor Welireg for\tthe\ttreatment\tof\tadult\tpatients\twith\tadvanced RCC\tfollowing\ta\tPD-1\tor\tPD-L1\tinhibitor\tand\ta\tVEGF-TKI,\tbased\ton\tthe\tLITESPARK-005\tclinical\ttrial.\n\nReblozyl\t is\t a\t first-in-class\t erythroid\t maturation\t recombinant\t fusion\t protein\t obtained\t as\t part\t of\t Merck's\t November\t 2021 acquisition\tof\tAcceleron\tPharma\tInc.\t(Acceleron)\tthat\tis\tbeing\tcommercialized\tthrough\ta\tglobal\tcollaboration\twith\tBristol\tMyers\tSquibb Company\t(BMS)\t(see\tNote\t4\tto\tthe\tconsolidated\tfinancial\tstatements).\tReblozyl\tis\tapproved\tfor\tthe\ttreatment\tof\tanemia\tin\tcertain\trare blood\tdisorders.\tAlliance\trevenue\trelated\tto\tthis\tcollaboration\tconsists\tof\troyalties\tand,\tfor\t2022,\talso\tincludes\tthe\treceipt\tof\ta regulatory\tapproval\tmilestone\tpayment\tof\t$20\tmillion.\tAlliance\trevenue\tincreased\t28%\tin\t2023\tdue\tto\tstrong\tunderlying\tsales\tperformance, partially\toffset\tby\tthe\treceipt\tof\tthe\tregulatory\tapproval\tmilestone\tin\t2022\tas\tnoted\tabove.",
          "relationship": "Approved_For"
        },
        "node_3": {
          "id": "Keytruda",
          "name": "Keytruda",
          "type": "PRODUCT",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_90",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n## Bristol-Myers\tSquibb\tCompany\n\nReblozyl\t(luspatercept-aamt)\tis\ta\tfirst-in-class\terythroid\tmaturation\trecombinant\tfusion\tprotein\tobtained\tas\tpart\tof\tMerck's November\t2021\tacquisition\tof\tAcceleron\tthat\tis\tbeing\tcommercialized\tthrough\ta\tglobal\tcollaboration\twith\tBMS.\tReblozyl\tis\tapproved\tin\tthe U.S.,\tEurope,\tand\tcertain\tother\tmarkets\tfor\tthe\ttreatment\tof\tanemia\tin\tcertain\trare\tblood\tdisorders\tand\tis\talso\tbeing\tevaluated\tfor additional\tindications\tfor\thematology\ttherapies.\tBMS\tis\tthe\tprincipal\ton\tsales\ttransactions\tfor\tReblozyl;\thowever,\tMerck\tco-promotes Reblozyl\t(and\twill\tco-promote\tall\tfuture\tproducts\tapproved\tunder\tthis\tcollaboration)\tin\tNorth\tAmerica,\twhich\tis\treimbursed\tby\tBMS.\tMerck receives\ta\t20%\tsales\troyalty\tfrom\tBMS\twhich\tcould\tincrease\tto\ta\tmaximum\tof\t24%\tbased\ton\tsales\tlevels.\tThis\troyalty\twill\tbe\treduced\tby 50%\t upon\t the\t earlier\t of\t patent\t expiry\t or\t generic\t entry\t on\t an\t indication-by-indication\t basis\t in\t each\t market.\t Additionally,\t Merck\t is eligible\t to\t receive\t future\t contingent\t sales-based\t milestone\t payments\t of\t up\t to\t $80\t million.\t Alliance\t revenue\t related\t to\t this collaboration\t(recorded\twithin Sales )\tconsists\tof\troyalties\tand,\tfor\t2022,\talso\tincludes\tthe\treceipt\tof\ta\tregulatory\tapproval\tmilestone payment\tof\t$20\tmillion.\tMerck\trecorded\talliance\trevenue\trelated\tto\tthis\tcollaboration\tof\t$212\tmillion\tin\t2023,\t$166\tmillion\tin\t2022\tand $17\tmillion\tin\t2021.\n\n## Moderna,\tInc.\n\nIn\t September\t 2022,\t Merck\t exercised\t its\t option\t to\t jointly\t develop\t and\t commercialize\t V940\t (mRNA-4157),\t an\t investigational individualized\tneoantigen\ttherapy,\tpursuant\tto\tthe\tterms\tof\tan\texisting\tcollaboration\tand\tlicense\tagreement\twith\tModerna,\twhich\tresulted in\ta\t$250\tmillion\tpayment\tthat\twas\tcharged\tto Research\tand\tdevelopment expenses\tin\t2022.\tV940\t(mRNA-4157)\tis\tcurrently\tbeing\tevaluated in\tcombination\twith Keytruda in\tmultiple\tPhase\t3\tclinical\ttrials.\tMerck\tand\tModerna\twill\tshare\tcosts\tand\tany\tprofits\tequally\tunder\tthis worldwide\t collaboration.\t Merck\t records\t its\t share\t of\t development\t costs\t associated\t with\t the\t collaboration\t as\t part\t of Research\t and development expenses.\tAny\treimbursements\treceived\tfrom\tModerna\tfor\tresearch\tand\tdevelopment\texpenses\twill\tbe\trecognized\tas\treductions\tto Research\tand\tdevelopment costs.\n\nSummarized\tfinancial\tinformation\trelated\tto\tthis\tcollaboration\tis\tas\tfollows:\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 234,
      "question": "Given that Elahere received accelerated FDA approval for a specific ovarian cancer indication, how does AbbVie's acquisition of ImmunoGen align with its strategic positioning in the oncology market?",
      "answer": "AbbVie's acquisition of ImmunoGen for $10.1 billion highlights its strategic intent to strengthen its oncology portfolio through the addition of Elahere, which received accelerated FDA approval on November 14, 2022, for treating FR\u03b1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. As ImmunoGen\u2019s flagship product, Elahere represents a first-in-class antibody-drug conjugate (ADC) targeting a niche but high-need oncology indication. This aligns with AbbVie\u2019s broader oncology strategy, as Elahere is now positioned alongside key therapies like Imbruvica and Venclexta, which target blood cancers. The acquisition not only diversifies AbbVie\u2019s oncology pipeline into solid tumors but also underscores its focus on innovation in areas with high unmet medical need, despite the conditional nature of Elahere\u2019s approval pending confirmatory trials.",
      "reasoning_steps": [
        "Hop 1: ABBV (page 66) \u2192 ImmunoGen, Inc.: AbbVie acquired ImmunoGen for $10.1 billion, a company focused on antibody-drug conjugates, with Elahere as its flagship product.",
        "Hop 2: ImmunoGen, Inc. \u2192 Elahere: ImmunoGen developed Elahere, an ADC approved for platinum-resistant ovarian cancer under accelerated FDA review.",
        "Hop 3: Elahere \u2190 ABBV (page 6): Elahere is now part of AbbVie\u2019s oncology portfolio and is positioned as a novel therapy for a specific subset of ovarian cancer, complementing its existing oncology offerings."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> COMP -[Produces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "ImmunoGen,Inc.",
        "node_3": "Elahere",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_1",
          "chunk_text": "## Acquisition\tof\tImmunoGen,\tInc.\n\nSubsequent\tto\t2023,\ton\tFebruary\t12,\t2024,\tAbbVie\tcompleted\tits\tpreviously\tannounced\tacquisition\tof\tImmunoGen,\tInc. (ImmunoGen).\tUnder\tthe\tterms\tof\tthe\tagreement,\tAbbVie\tacquired\tall\toutstanding\tshares\tof\tImmunoGen\tfor\t$31.26\tper\tshare\tin\tcash for\ta\ttotal\tvalue\tof\tapproximately\t$10.1\tbillion.\n\nDue\tto\tthe\tproximity\tof\tthe\tclosing\tdate\tof\tthe\tacquisition\tto\tthe\tdate\tof\tfiling\tthis\tAnnual\tReport\ton\tForm\t10-K,\tthe\tinitial accounting\tfor\tthe\tacquisition\tis\tnot\tcomplete.\tSignificant,\trelevant\tinformation\tneeded\tto\tcomplete\tthe\tinitial\taccounting, including\tthe\tidentification\tand\tmeasurement\tof\tthe\tfair\tvalue\tof\tassets\tacquired\tand\tliabilities\tassumed,\tis\tpending.\tAs\ta result,\tit\tis\tnot\tpracticable\tto\tdisclose\tthe\tpreliminary\tallocation\tof\tthe\tpurchase\tprice\tto\tassets\tacquired\tand\tliabilities assumed\tor\tprovide\tother\trelated\tdisclosures.\tThe\taccounting\timpact\tof\tthis\tacquisition\tand\tthe\toperating\tresults\tof\tImmunoGen will\tbe\tincluded\tin\tthe\tconsolidated\tfinancial\tstatements\tbeginning\tin\tthe\tfirst\tquarter\tof\t2024.\n\nImmunoGen\tis\ta\tcommercial-stage\tbiotechnology\tcompany\tfocused\ton\tthe\tdiscovery,\tdevelopment\tand\tcommercialization\tof\tantibodydrug\tconjugates\t(ADC)\tfor\tcancer\tpatients.\tImmunoGen's\toncology\tportfolio\tincludes\tits\tflagship\tcancer\ttherapy\tElahere,\ta\tfirstin-class\tADC\tapproved\tfor\tplatinum-resistant\tovarian\tcancer,\tand\ta\tpipeline\tof\tpromising\tnext-generation\tADC's\ttargeting hematologic\tmalignancies\tand\tsolid\ttumors.\n\nIn\tconnection\twith\tthese\tacquisitions,\tAbbVie\tentered\tinto\tseveral\tdebt\tand\tfinancing\tarrangements.\tSee\tNote\t10\tfor\tadditional information.\n\n## Acquisition\tof\tDJS\tAntibodies\tLtd\n\nIn\tOctober\t2022,\tAbbVie\tentered\tinto\tan\tagreement\tto\tacquire\tDJS\tAntibodies\tLtd\t(DJS)\tincluding\tits\tlead\tprogram\tDJS-002\tand proprietary\tHEPTAD\tplatform.\tDJS-002\tis\tan\tLPAR1\tantagonist\tantibody\tcurrently\tin\tpreclinical\tstudies\tfor\tthe\ttreatment\tof Idiopathic\tPulmonary\tFibrosis\tand\tother\tfibrotic\tdiseases.\tHEPTAD\tplatform\tis\ta\tpotential\tnovel\tapproach\tto\tantibody\tdiscovery with\tspecific\tcapabilities\ttargeting\ttransmembrane\tprotein\ttargets.\tThe\taggregate\tpurchase\tprice\tof\t$287\tmillion\twas\tcomprised\tof a\t$255\tmillion\tupfront\tcash\tpayment\tand\t$32\tmillion\tfor\tthe\tacquisition\tdate\tfair\tvalue\tof\tcontingent\tconsideration\tliabilities, for\twhich\tAbbVie\tmay\towe\tup\tto\t$95\tmillion\tin\tfuture\tpayments\tupon\tachievement\tof\tcertain\tdevelopment\tmilestones.\tThe\ttransaction was\taccounted\tfor\tas\ta\tbusiness\tcombination\tusing\tthe\tacquisition\tmethod\tof\taccounting.\tAs\tof\tthe\tacquisition\tdate,\tAbbVie acquired\t$233\tmillion\tof\tintangible\tassets\tfor\tin-process\tresearch\tand\tdevelopment,\t$22\tmillion\tof\tintangible\tassets\tfor\tdeveloped product\trights\tand\t$60\tmillion\tof\tdeferred\ttax\tliabilities.\tOther\tassets\tand\tliabilities\tassumed\twere\tinsignificant.\tThe acquisition\tresulted\tin\tthe\trecognition\tof\t$92\tmillion\tof\tgoodwill\twhich\tis\tnot\tdeductible\tfor\ttax\tpurposes.\n\n## Acquisition\tof\tSoliton,\tInc.\n\nIn\tDecember\t2021,\tAbbVie\tcompleted\tits\tpreviously\tannounced\tacquisition\tof\tSoliton,\tInc.\t(Soliton).\tSoliton's\tRESONIC\t(Rapid Acoustic\tPulse\tdevice)\thas\tU.S.\tFood\tand\tDrug\tAdministration\t(FDA)\t510(k)\tclearance\tfor\tthe\tlong-term\timprovement\tin\tthe appearance\tof\tcellulite\tup\tto\tone\tyear.\tThe\ttransaction\twas\taccounted\tfor\tas\ta\tbusiness\tcombination\tusing\tthe\tacquisition\tmethod of\taccounting.\tTotal\tconsideration\ttransferred\tallocated\tto\tthe\tpurchase\tprice\tconsisted\tof\tcash\tconsideration\tof\t$535\tmillion paid\tto\tholders\tof\tSoliton\tcommon\tstock,\tequity-based\tawards\tand\twarrants.\tAs\tof\tthe\ttransaction\tdate,\tAbbVie\tacquired\t$407 million\tof\tintangible\tassets\tfor\tdeveloped\tproduct\trights\tand\tassumed\tdeferred\ttax\tliabilities\ttotaling\t$63\tmillion.\tOther\tassets and\tliabilities\twere\tinsignificant.\tThe\tacquisition\tresulted\tin\tthe\trecognition\tof\t$177\tmillion\tof\tgoodwill\twhich\tis\tnot deductible\tfor\ttax\tpurposes.\n\n## Other\tLicensing\t&amp;\tAcquisitions\tActivity\n\nCash\toutflows\trelated\tto\tother\tacquisitions\tand\tinvestments\ttotaled\t$1.2\tbillion\tin\t2023,\t$539\tmillion\tin\t2022\tand\t$1.4 billion\tin\t2021.\tAbbVie\trecorded\tacquired\tIPR&amp;D\tand\tmilestones\texpense\tof\t$778\tmillion\tin\t2023,\t$697\tmillion\tin\t2022\tand\t$1.1 billion\tin\t2021.\tSignificant\tarrangements\timpacting\t2023,\t2022\tand\t2021,\tsome\tof\twhich\trequire\tcontingent\tmilestone\tpayments,\tare summarized\tbelow.\n\n## Syndesi\tTherapeutics\tSA\n\nIn\tFebruary\t2022,\tAbbVie\tacquired\tSyndesi\tTherapeutics\tSA\tand\tits\tportfolio\tof\tnovel\tmodulators\tof\tthe\tsynaptic\tvesicle protein\t2A,\tincluding\tits\tlead\tmolecule\tABBV-552,\tpreviously\tnamed\tSDI-118,\tand\taccounted\tfor\tthe\ttransaction\tas\tan\tasset acquisition.\tABBV-552\tis\ta\tsmall\tmolecule,\twhich\tis\tbeing\tevaluated\tto\ttarget\tnerve\tterminals\tto\tenhance\tsynaptic\tefficiency. Under\tthe\tterms\tof\tthe\tagreement,\tAbbVie\tmade\tan\tupfront\tpayment\tof\t$130\tmillion\twhich\twas\trecorded\tto\tacquired\tIPR&amp;D\tand milestones\texpense\tin\tthe\tconsolidated\tstatement\tof\tearnings\tin\tthe\tfirst\tquarter\tof\t2022.\tThe\tagreement\talso\tincludes\n\n## 63 | 2023\tForm\t10-K",
          "relationship": "Has_Stake_In"
        },
        "node_2": {
          "id": "ImmunoGen,Inc.",
          "name": "ImmunoGen,Inc.",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_1",
          "chunk_text": "## Acquisition\tof\tImmunoGen,\tInc.\n\nSubsequent\tto\t2023,\ton\tFebruary\t12,\t2024,\tAbbVie\tcompleted\tits\tpreviously\tannounced\tacquisition\tof\tImmunoGen,\tInc. (ImmunoGen).\tUnder\tthe\tterms\tof\tthe\tagreement,\tAbbVie\tacquired\tall\toutstanding\tshares\tof\tImmunoGen\tfor\t$31.26\tper\tshare\tin\tcash for\ta\ttotal\tvalue\tof\tapproximately\t$10.1\tbillion.\n\nDue\tto\tthe\tproximity\tof\tthe\tclosing\tdate\tof\tthe\tacquisition\tto\tthe\tdate\tof\tfiling\tthis\tAnnual\tReport\ton\tForm\t10-K,\tthe\tinitial accounting\tfor\tthe\tacquisition\tis\tnot\tcomplete.\tSignificant,\trelevant\tinformation\tneeded\tto\tcomplete\tthe\tinitial\taccounting, including\tthe\tidentification\tand\tmeasurement\tof\tthe\tfair\tvalue\tof\tassets\tacquired\tand\tliabilities\tassumed,\tis\tpending.\tAs\ta result,\tit\tis\tnot\tpracticable\tto\tdisclose\tthe\tpreliminary\tallocation\tof\tthe\tpurchase\tprice\tto\tassets\tacquired\tand\tliabilities assumed\tor\tprovide\tother\trelated\tdisclosures.\tThe\taccounting\timpact\tof\tthis\tacquisition\tand\tthe\toperating\tresults\tof\tImmunoGen will\tbe\tincluded\tin\tthe\tconsolidated\tfinancial\tstatements\tbeginning\tin\tthe\tfirst\tquarter\tof\t2024.\n\nImmunoGen\tis\ta\tcommercial-stage\tbiotechnology\tcompany\tfocused\ton\tthe\tdiscovery,\tdevelopment\tand\tcommercialization\tof\tantibodydrug\tconjugates\t(ADC)\tfor\tcancer\tpatients.\tImmunoGen's\toncology\tportfolio\tincludes\tits\tflagship\tcancer\ttherapy\tElahere,\ta\tfirstin-class\tADC\tapproved\tfor\tplatinum-resistant\tovarian\tcancer,\tand\ta\tpipeline\tof\tpromising\tnext-generation\tADC's\ttargeting hematologic\tmalignancies\tand\tsolid\ttumors.\n\nIn\tconnection\twith\tthese\tacquisitions,\tAbbVie\tentered\tinto\tseveral\tdebt\tand\tfinancing\tarrangements.\tSee\tNote\t10\tfor\tadditional information.\n\n## Acquisition\tof\tDJS\tAntibodies\tLtd\n\nIn\tOctober\t2022,\tAbbVie\tentered\tinto\tan\tagreement\tto\tacquire\tDJS\tAntibodies\tLtd\t(DJS)\tincluding\tits\tlead\tprogram\tDJS-002\tand proprietary\tHEPTAD\tplatform.\tDJS-002\tis\tan\tLPAR1\tantagonist\tantibody\tcurrently\tin\tpreclinical\tstudies\tfor\tthe\ttreatment\tof Idiopathic\tPulmonary\tFibrosis\tand\tother\tfibrotic\tdiseases.\tHEPTAD\tplatform\tis\ta\tpotential\tnovel\tapproach\tto\tantibody\tdiscovery with\tspecific\tcapabilities\ttargeting\ttransmembrane\tprotein\ttargets.\tThe\taggregate\tpurchase\tprice\tof\t$287\tmillion\twas\tcomprised\tof a\t$255\tmillion\tupfront\tcash\tpayment\tand\t$32\tmillion\tfor\tthe\tacquisition\tdate\tfair\tvalue\tof\tcontingent\tconsideration\tliabilities, for\twhich\tAbbVie\tmay\towe\tup\tto\t$95\tmillion\tin\tfuture\tpayments\tupon\tachievement\tof\tcertain\tdevelopment\tmilestones.\tThe\ttransaction was\taccounted\tfor\tas\ta\tbusiness\tcombination\tusing\tthe\tacquisition\tmethod\tof\taccounting.\tAs\tof\tthe\tacquisition\tdate,\tAbbVie acquired\t$233\tmillion\tof\tintangible\tassets\tfor\tin-process\tresearch\tand\tdevelopment,\t$22\tmillion\tof\tintangible\tassets\tfor\tdeveloped product\trights\tand\t$60\tmillion\tof\tdeferred\ttax\tliabilities.\tOther\tassets\tand\tliabilities\tassumed\twere\tinsignificant.\tThe acquisition\tresulted\tin\tthe\trecognition\tof\t$92\tmillion\tof\tgoodwill\twhich\tis\tnot\tdeductible\tfor\ttax\tpurposes.\n\n## Acquisition\tof\tSoliton,\tInc.\n\nIn\tDecember\t2021,\tAbbVie\tcompleted\tits\tpreviously\tannounced\tacquisition\tof\tSoliton,\tInc.\t(Soliton).\tSoliton's\tRESONIC\t(Rapid Acoustic\tPulse\tdevice)\thas\tU.S.\tFood\tand\tDrug\tAdministration\t(FDA)\t510(k)\tclearance\tfor\tthe\tlong-term\timprovement\tin\tthe appearance\tof\tcellulite\tup\tto\tone\tyear.\tThe\ttransaction\twas\taccounted\tfor\tas\ta\tbusiness\tcombination\tusing\tthe\tacquisition\tmethod of\taccounting.\tTotal\tconsideration\ttransferred\tallocated\tto\tthe\tpurchase\tprice\tconsisted\tof\tcash\tconsideration\tof\t$535\tmillion paid\tto\tholders\tof\tSoliton\tcommon\tstock,\tequity-based\tawards\tand\twarrants.\tAs\tof\tthe\ttransaction\tdate,\tAbbVie\tacquired\t$407 million\tof\tintangible\tassets\tfor\tdeveloped\tproduct\trights\tand\tassumed\tdeferred\ttax\tliabilities\ttotaling\t$63\tmillion.\tOther\tassets and\tliabilities\twere\tinsignificant.\tThe\tacquisition\tresulted\tin\tthe\trecognition\tof\t$177\tmillion\tof\tgoodwill\twhich\tis\tnot deductible\tfor\ttax\tpurposes.\n\n## Other\tLicensing\t&amp;\tAcquisitions\tActivity\n\nCash\toutflows\trelated\tto\tother\tacquisitions\tand\tinvestments\ttotaled\t$1.2\tbillion\tin\t2023,\t$539\tmillion\tin\t2022\tand\t$1.4 billion\tin\t2021.\tAbbVie\trecorded\tacquired\tIPR&amp;D\tand\tmilestones\texpense\tof\t$778\tmillion\tin\t2023,\t$697\tmillion\tin\t2022\tand\t$1.1 billion\tin\t2021.\tSignificant\tarrangements\timpacting\t2023,\t2022\tand\t2021,\tsome\tof\twhich\trequire\tcontingent\tmilestone\tpayments,\tare summarized\tbelow.\n\n## Syndesi\tTherapeutics\tSA\n\nIn\tFebruary\t2022,\tAbbVie\tacquired\tSyndesi\tTherapeutics\tSA\tand\tits\tportfolio\tof\tnovel\tmodulators\tof\tthe\tsynaptic\tvesicle protein\t2A,\tincluding\tits\tlead\tmolecule\tABBV-552,\tpreviously\tnamed\tSDI-118,\tand\taccounted\tfor\tthe\ttransaction\tas\tan\tasset acquisition.\tABBV-552\tis\ta\tsmall\tmolecule,\twhich\tis\tbeing\tevaluated\tto\ttarget\tnerve\tterminals\tto\tenhance\tsynaptic\tefficiency. Under\tthe\tterms\tof\tthe\tagreement,\tAbbVie\tmade\tan\tupfront\tpayment\tof\t$130\tmillion\twhich\twas\trecorded\tto\tacquired\tIPR&amp;D\tand milestones\texpense\tin\tthe\tconsolidated\tstatement\tof\tearnings\tin\tthe\tfirst\tquarter\tof\t2022.\tThe\tagreement\talso\tincludes\n\n## 63 | 2023\tForm\t10-K",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Elahere",
          "name": "Elahere",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "page_id": "page_6",
          "chunk_id": "chunk_1",
          "chunk_text": "Oncology\tproducts. AbbVie's\toncology\tproducts\ttarget\tsome\tof\tthe\tmost\tcomplex\tand\tdifficult-to-treat\tcancers.\tThese\tproducts are:\n\nImbruvica. Imbruvica\t(ibrutinib)\tis\tan\toral,\tonce-daily\ttherapy\tthat\tinhibits\ta\tprotein\tcalled\tBruton's\ttyrosine\tkinase. Imbruvica\twas\tone\tof\tthe\tfirst\tmedicines\tto\treceive\ta\tUnited\tStates\tFood\tand\tDrug\tAdministration\t(FDA)\tapproval\tafter\tbeing granted\ta\tBreakthrough\tTherapy\tDesignation\tand\tis\tone\tof\tthe\tfew\ttherapies\tto\treceive\tfour\tseparate\tdesignations.\tImbruvica currently\tis\tapproved\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tblood\tcancers\tsuch\tas\tchronic\tlymphocytic\tleukemia\t(CLL),\tas\twell as\tcertain\tforms\tof\tnon-Hodgkin\tlymphoma.\tImbruvica\tis\tapproved\tin\tadult\tand\tpediatric\tpatients\tone\tyear\tand\tolder\twith\tchronic graft\tversus\thost\tdisease\tafter\tfailure\tof\tone\tor\tmore\tlines\tof\tsystemic\ttherapy.\n\nVenclexta/Venclyxto. Venclexta\t(venetoclax)\tis\ta\tB-cell\tlymphoma\t2\t(BCL-2)\tinhibitor\tused\tto\ttreat\tblood\tcancers.\tVenclexta is\tapproved\tby\tthe\tFDA\tfor\tadults\twith\tCLL\tor\tsmall\tlymphocytic\tlymphoma.\tIn\taddition,\tVenclexta\tis\tapproved\tin\tcombination\twith azacitidine,\tor\tdecitabine,\tor\tlow-dose\tcytarabine\tto\ttreat\tadults\twith\tnewly-diagnosed\tacute\tmyeloid\tleukemia\twho\tare\t75\tyears of\tage\tor\tolder\tor\thave\tother\tmedical\tconditions\tthat\tprevent\tthe\tuse\tof\tstandard\tchemotherapy.\n\nEpkinly .\t Epkinly\t (epcoritimab)\t is\t a\t product\t used\t to\t treat\t adults\t with\t certain\t types\t of\t diffuse\t large\t B-cell\t lymphoma (DLBCL)\tand\thigh-grade\tB-cell\tlymphoma\tthat\thas\trecurred\tor\tthat\tdoes\tnot\trespond\tto\tprevious\ttreatment\tafter\treceiving\ttwo\tor more\ttreatments.\tEpkinly\tis\tadministered\tas\ta\tsubcutaneous\tinjection.\n\nElahere. Elahere\t(mirvetuximab\tsoravtansine-gynx)\tis\tan\tantibody-drug\tconjugate\t(ADC)\tused\tto\ttreat\tcertain\ttypes\tof cancer.\tOn\tNovember\t14,\t2022,\tthe\tFDA\tgranted\taccelerated\tapproval\tfor\tthe\ttreatment\tof\tadult\tpatients\twith\tFR\u03b1\tpositive, platinum-resistant\tepithelial\tovarian,\tfallopian\ttube,\tor\tprimary\tperitoneal\tcancer,\twho\thave\treceived\tone\tto\tthree\tprior systemic\ttreatment\tregimens.\tContinued\tapproval\tmay\tbe\tcontingent\tupon\tverification\tand\tdescription\tof\tclinical\tbenefit\tin\ta confirmatory\ttrial.\n\nAesthetics\tproducts. AbbVie's\tAesthetics\tportfolio\tconsists\tof\tfacial\tinjectables,\tplastics\tand\tregenerative\tmedicine,\tbody contouring\tand\tskincare\tproducts,\twhich\thold\tmarket-leading\tpositions\tin\tthe\tU.S.\tand\tin\tkey\tmarkets\taround\tthe\tworld.\tThese products\tare:\n\nBotox\tCosmetic. Botox\tCosmetic\tis\tan\tacetylcholine\trelease\tinhibitor\tand\ta\tneuromuscular\tblocking\tagent\tindicated\tfor treatment\tin\tthree\tareas:\ttemporary\timprovement\tin\tthe\tappearance\tof\tmoderate\tto\tsevere\tglabellar\tlines\t(frown\tlines\tbetween\tthe eyebrows),\tmoderate\tto\tsevere\tcrow's\tfeet\tand\tmoderate\tto\tsevere\tforehead\tlines\tin\tadults.\tHaving\treceived\tits\tinitial\tFDA approval\tin\t2002,\tBotox\tCosmetic\tis\tnow\tapproved\tfor\tuse\tin\tall\tmajor\tmarkets\taround\tthe\tworld.\n\nThe\tJuvederm\tCollection\tof\tFillers. The\tJuvederm\tCollection\tof\tFillers\tis\ta\tportfolio\tof\thyaluronic\tacid-based\tdermal fillers\twith\ta\tvariety\tof\tapproved\tindications\tin\tthe\tU.S.\tand\tin\tother\tmajor\tmarkets\taround\tthe\tworld\tto\taugment\tor\ttreat volume\tloss\tin\tthe\tcheeks,\tchin,\tlips\tand\tlower\tface.\n\nOther\taesthetics. Other\taesthetics\tproducts\tinclude,\tbut\tare\tnot\tlimited\tto,\tAlloderm\tregenerative\tdermal\ttissue, CoolSculpting\tbody\tcontouring\ttechnology,\tNatrelle\tbreast\timplants,\tthe\tSkinMedica\tskincare\tline,\tLatisse\teyelash\tsolution\tand DiamondGlow\tdermabrasion\ttechnology.\n\nNeuroscience\tproducts. AbbVie's\tneuroscience\tproducts\taddress\tsome\tof\tthe\tmost\tdifficult-to-treat\tneurologic\tdiseases.\tThese products\tare:\n\nBotox\tTherapeutic. Botox\tTherapeutic\t(onabotulinumtoxinA\tinjection)\tis\tan\tacetylcholine\trelease\tinhibitor\tand\ta neuromuscular\tblocking\tagent\tthat\tis\tinjected\tinto\tmuscle\ttissue.\tIn\tthe\tUnited\tStates,\tit\tis\tapproved\tto\ttreat\tnumerous indications,\tincluding\tchronic\tmigraine,\toveractive\tbladder\tin\tadults\twho\thave\tan\tinadequate\tresponse\tto\tan\tanticholinergic medication,\tand\turinary\tincontinence\tdue\tto\tdetrusor\toveractivity\tassociated\twith\ta\tneurologic\tcondition\tin\tadults\twho\thave\tan inadequate\tresponse\tto\tan\tanticholinergic\tmedication.\tIn\taddition,\tBotox\tTherapeutic\tis\tapproved\tto\ttreat\tspasticity\tin\tpatients two\tyears\tof\tage\tand\tolder,\tcervical\tdystonia\tin\tadults,\tas\twell\tas\tother\tconditions.\tBotox\tis\tmarketed\tin\tother\tcountries around\tthe\tworld\tand\tlicenses\twill\tvary.\tBotox\tTherapeutic\tis\tmarketed\tby\tGSK\tin\tJapan.\n\nVraylar. Vraylar\t(cariprazine)\tis\ta\tdopamine\tD3-preferring\tD3/D2\treceptor\tpartial\tagonist\tand\ta\t5-HT1A\treceptor\tpartial agonist.\tVraylar\tis\tindicated\tfor\tacute\tand\tmaintenance\ttreatment\tof\tschizophrenia\tin\tadults,\tacute\ttreatment\tof\tmanic\tor\tmixed episodes\tassociated\twith\tbipolar\tdisorder\tin\tadults,\tacute\ttreatment\tof\tdepressive\tepisodes\tassociated\twith\tbipolar\tI\tdisorder in\tadults\tand\tas\tan\tadjunctive\ttreatment\tin\tmajor\tdepressive\tdisorder.\n\nDuopa\tand\tDuodopa (carbidopa\tand\tlevodopa).\t\t\t\tAbbVie's\tlevodopa-carbidopa\tintestinal\tgel\tfor\tthe\ttreatment\tof\tadvanced Parkinson's\tdisease\tis\tmarketed\tas\tDuopa\tin\tthe\tUnited\tStates\tand\tas\tDuodopa\toutside\tof\tthe\tUnited\tStates.\n\n## 3 | 2023\tForm\t10-K",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 235,
      "question": "How does AbbVie's clinical progress with Vraylar in major depressive disorder in 2021 relate to its legal strategy involving Forest Laboratories Holdings Limited and patent enforcement against generic competitors?",
      "answer": "AbbVie announced in October 2021 that Vraylar, an adjunctive treatment for major depressive disorder (MDD), met its primary endpoint in one of two Phase 3 trials (Study 3111-301-001), showing statistically significant improvement in depressive symptoms compared to placebo. This clinical progress positions Vraylar as a potentially valuable asset in AbbVie\u2019s neuroscience portfolio. However, protecting this asset is critical, which explains the involvement of Forest Laboratories Holdings Limited\u2014a wholly owned AbbVie subsidiary\u2014in enforcing patent rights for cariprazine (Vraylar). In December 2019, litigation was initiated against multiple generic drug manufacturers (e.g., Sun Pharmaceutical, Aurobindo Pharma) alleging infringement of Vraylar-related patents. The legal actions, led by Forest Laboratories Holdings Limited and Allergan, aim to prevent market entry of generic versions, thereby safeguarding the commercial potential of Vraylar following its positive clinical results in MDD.",
      "reasoning_steps": [
        "Hop 1: [ABBV](page_60) \u2192 [Vraylar]: AbbVie announced clinical trial results showing Vraylar's efficacy in treating major depressive disorder, with one trial meeting its primary endpoint and another showing numerical improvement.",
        "Hop 2: [Vraylar] \u2192 [Forest Laboratories Holdings Limited]: Forest Laboratories Holdings Limited is a wholly owned AbbVie subsidiary involved in enforcing Vraylar\u2019s patent rights, indicating its central role in protecting the drug\u2019s intellectual property.",
        "Hop 3: [Forest Laboratories Holdings Limited] \u2190 [ABBV](page_136): AbbVie, through Forest Laboratories Holdings Limited, is engaged in litigation against multiple generic drug manufacturers to prevent infringement of Vraylar-related patents."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Announces]-> PRODUCT -[Produces]-> COMP <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "ABBV",
        "node_2": "Vraylar",
        "node_3": "Forest Laboratories Holdings Limited",
        "end": "ABBV"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_60",
          "chunk_id": "chunk_1",
          "chunk_text": "- In July 2021, AbbVie announced that the FDA granted Breakthrough Therapy Designation to Venclexta in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.\n\n## Teliso-V\n\n- In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of cMet overexpression whose disease has progressed on or after platinum-based therapy.\n\n## Neuroscience\n\n## Botox Therapeutic\n\n- In February 2021, AbbVie received FDA approval of Botox for the treatment of detrusor overactivity associated with a neurological condition in certain pediatric patients 5 years of age and older.\n\n## Qulipta\n\n- In September 2021, AbbVie announced that the FDA approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.\n\n## Vraylar\n\n- In October 2021, AbbVie announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). In Study 3111-301-001, Vraylar met its primary endpoint demonstrating statistically significant change from baseline to week six in the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score compared with placebo in patients with MDD. In Study 3111-302-001, Vraylar demonstrated numerical improvement in depressive symptoms from baseline to week six in MADRS total score compared with placebo but did not achieve statistical significance. Safety data were consistent with the established safety profile of Vraylar across indications with no new safety signals identified.\n\n## ABBV-951\n\n- In October 2021, AbbVie announced that results from its pivotal Phase 3 M15-736 study of ABBV-951 (foslevodopa/foscarbidopa) in patients with advanced Parkinson's disease met its primary endpoint in a 12week study.\n\n## Eye Care\n\n## Vuity\n\n- In October 2021, AbbVie announced that the FDA approved Vuity (pilocarpine HCl ophthalmic solution) for the treatment of presbyopia.",
          "relationship": "Announces"
        },
        "node_2": {
          "id": "Vraylar",
          "name": "Vraylar",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Forest_Laboratories_Holdings_Limited",
          "name": "Forest Laboratories Holdings Limited",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_136",
          "chunk_id": "chunk_1",
          "chunk_text": "Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.\n\n2021 Form 10-K\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 236,
      "question": "How does Gilead's financial exposure to Janssen through the Symtuza revenue-sharing arrangement compare with its cost of goods sold related to Complera/Eviplera, and what does this reveal about the relative profitability and dependency of these HIV product collaborations?",
      "answer": "Gilead's financial exposure to Janssen through the Symtuza collaboration involves recognizing revenue from the sale of Gilead compounds used in Symtuza, while Janssen sets the price and handles global commercialization. In contrast, under the Complera/Eviplera agreement, Gilead is responsible for manufacturing and leads commercialization in most markets, retaining up to 30% of Janssen\u2019s share of revenues, with Janssen\u2019s share recorded as a cost of goods sold\u2014amounting to $403 million in 2024. The Symtuza arrangement appears to involve less direct commercial control by Gilead, but it still benefits from steady supply revenue. This comparison reveals that Gilead has a more operationally involved and cost-exposed position with Complera/Eviplera, while Symtuza reflects a more asset-based revenue model, highlighting differing strategic dependencies and profitability profiles across these collaborations.",
      "reasoning_steps": [
        "Hop 1: [GILD](page_77) \u2192 [Janssen]: Gilead recognizes its share of Symtuza revenue as Product sales when Janssen sells the product, with Gilead supplying the active compounds.",
        "Hop 2: [Janssen] \u2192 [Complera/Eviplera]: Janssen retains distribution rights in certain countries for Complera/Eviplera, and the revenue-sharing model results in Janssen's share being recorded as a cost of goods sold by Gilead.",
        "Hop 3: [Complera/Eviplera] \u2190 [GILD](page_76): Gilead is the primary manufacturer and commercializer of Complera/Eviplera in most markets and records Janssen's revenue share as a cost of goods sold, which was $403 million in 2024."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Distributes]-> PRODUCT <-[Distributes]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Janssen",
        "node_3": "Complera/Eviplera",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the G ilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Operations primarily because we supply the Gilead Compounds to Janssen for Symtuza.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause.\n\n## Japan Tobacco\n\nIn 2005, Japan Tobacco, Inc. ('Japan Tobacco') granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV  integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV  portfolio in Japan and to ex pand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.\n\nWe are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Operations. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Operations. Royalty expenses recognized were $139 million, $167 million and $198 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nUnder the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are ex pected to be derived from the applicable products in our HIV  portfolio. The amortization ex pense is classified as selling ex pense and recorded in Selling, general and administrative expenses on our Consolidated Statements of Operations.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.\n\n## Everest\n\nIn April 2019, Everest Medicines ('Everest') and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in  G reater  China,  South  Korea,  Singapore,  Indonesia,  Philippines,  V ietnam,  Thailand,  Malaysia  and  Mongolia  (the  'Territories').  G ilead  subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to  be  made to  G ilead  and  was  recorded  as  a  $175  million  finite-lived  asset  as  part  of  the  purchase  accounting.  In  the  fourth  quarter  of  2022,  we  reacquired  all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, G ilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Operations during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Complera/Eviplera",
          "name": "Complera/Eviplera",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "page_id": "page_76",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant to the Subscription Agreement, we purchased new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by G alapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of G alapagos ex ceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We have two designees appointed to Galapagos' board of directors as of December 31, 2024.\n\nIn January 2025, we agreed to amend the OLCA commensurate with Galapagos' announcement for a planned separation of G alapagos into two entities: a newly to be formed company (to be named at a later date, herein 'SpinCo') with an initial capital allocation of up to approximately \u20ac2.45 billion (approximately $2.54 billion) and Galapagos. At the time of separation, should it occur, G alapagos' and our rights and responsibilities under the OLCA would transfer to SpinCo, and G alapagos would gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to G ilead on net sales of certain products. This separation is expected to occur by mid-2025. With respect to G ilead's ownership stake in G alapagos, upon separation, G ilead will hold approximately 25% of the outstanding shares in both G alapagos and SpinCo and will be subject to a lock-up of G alapagos shares through March 2027 and of SpinCo shares until six months after the separation, subject to certain customary exceptions and early termination provisions. The two G ilead designees appointed to G alapagos' board of directors will step down upon the separation and Gilead will be entitled to nominate two directors to SpinCo's board.\n\n## Janssen\n\n## Complera/Eviplera and Odefsey\n\nIn  2009,  we  entered  into  a  license  and  collaboration  agreement  with  Janssen  to  develop  and  commercialize  a  fix ed-dose  combination  of  our  Truvada  and Janssen's non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen's rilpivirine and our emtricitabine and tenofovir alafenamide ('Odefsey').\n\nUnder the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.\n\nWe are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.\n\nUnder the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party's component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen's share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen's share of revenues is included in Cost of goods sold on our Consolidated Statements of Operations. Cost of goods sold relating to Janssen's share was $403 million, $430 million and $483 million for the years ended December 31, 2024, 2023 and 2022, respectively.\n\nTermination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products.\n\n## Symtuza\n\nIn 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen's darunavir and our cobicistat, emtricitabine and tenofovir alafenamide ('G ilead Compounds'). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza.\n\nUnder the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the G ilead Compounds and are the exclusive supplier  of  the  G ilead  Compounds.  Neither  party  is  restricted  from  combining  its  drugs  with  any  other  drug  products  ex cept  those  which  are  similar  to  the components of Symtuza.",
          "relationship": "Distributes"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 237,
      "question": "Given BMY's integration challenges with Celgene that could impact operational efficiency and financial reporting, and the ongoing BCBSA litigation related to Celgene's legacy practices, how might these combined factors affect BMY's ability to manage its $89 million environmental remediation liability while maintaining compliance with legal and financial obligations in FY2022?",
      "answer": "BMY highlights on page 40 that integration challenges with Celgene\u2014such as inconsistencies in standards, controls, and internal processes\u2014could adversely affect its ability to meet financial reporting obligations and maintain operational stability. Meanwhile, page 166 reveals that BMY is entangled in litigation with BCBSA, among others, which stems largely from Celgene\u2019s legacy practices, including allegations related to off-label marketing of Revlimid and Thalomid. These legal proceedings, combined with the integration risks, could strain BMY\u2019s legal and financial infrastructure. Additionally, BMY discloses an $89 million liability tied to environmental remediation under CERCLA obligations. If integration challenges disrupt internal controls or divert management focus, BMY may face difficulties in accurately accounting for and managing both its litigation exposure and environmental liabilities, potentially impacting its ability to meet compliance requirements or properly allocate capital in FY2022.",
      "reasoning_steps": [
        "Hop 1: [BMY](page_40) \u2192 [Celgene]: BMY expresses concern that integration challenges with Celgene could disrupt internal controls and financial reporting processes.",
        "Hop 2: [Celgene] \u2192 [BCBSA]: Celgene, now part of BMY, is involved in litigation with BCBSA over legacy practices, including off-label marketing claims, which remains unresolved and requires legal and financial oversight.",
        "Hop 3: [BCBSA] \u2190 [BMY](page_166): BMY is directly involved in the BCBSA litigation and also discloses a separate $89 million liability for environmental remediation, raising concerns about resource allocation and compliance capacity when combined with integration and litigation pressures."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Involved_In]-> COMP <-[Involved_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Celgene",
        "node_3": "BCBSA",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_40",
          "chunk_id": "chunk_1",
          "chunk_text": "for our products. If we are unable to compete successfully against our competitors' products in the marketplace, this could have a material negative impact on our revenues and earnings.\n\n## We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.\n\nOur product supply and related patient access has been, and could in the future be, negatively impacted by difficulties, delays and disruptions in the manufacturing, distribution and sale of our products. Some of the difficulties, delays and disruptions  include:  (i)  product  seizures  or  recalls  or  forced  closings  of  manufacturing  plants;  (ii)  our  failure,  or  the failure of any of our vendors or suppliers, to comply with cGMP and other applicable regulations or quality assurance guidelines  that  could  lead  to  manufacturing  shutdowns,  product  shortages  or  delays  in  product  manufacturing;  (iii) manufacturing, quality assurance/quality control, supply problems or governmental approval delays; (iv) the failure of a supplier,  including  sole  source  or  single  source  suppliers,  to  provide  us  with  the  necessary  raw  materials,  supplies  or finished goods within a reasonable timeframe and with required quality; (v) the failure of a third-party manufacturer to supply us with bulk active or finished product on time; (vi) construction or regulatory approval delays for new facilities or the expansion of existing facilities, including those intended to support future demand for our biologics products, such as Opdivo;  (vii)  the  failure  to  meet  new  and  emerging  regulations  requiring  products  to  be  tracked  throughout  the distribution channels using unique identifiers to verify their authenticity in the supply chain; (viii) other manufacturing or distribution  issues,  including  limits  to  manufacturing  capacity  and  changes  in  the  types  of  products  produced,  such  as biologics, physical limitations or other business interruptions; and (ix) disruptions in supply chain continuity, including from market forces (such as the recent stress on global logistics), natural disasters (such as hurricanes), global disease outbreaks (such as COVID-19), acts of war or terrorism or other unforeseeable or unavoidable events that materially impact one or more of our facilities or a critical supplier.\n\nIn addition, manufacturing processes for novel cell-based therapies, such as CAR T cell therapies, are still evolving, and our  processes  may  be  more  complicated  or  more  expensive  than  the  approaches  taken  by  our  current  and  future competitors.  Our  ability  to  source  raw  materials  and  supplies  used  to  manufacture  our  CAR  T  cell  therapies  and  to develop consistent and reliable manufacturing processes and distribution networks with an attractive cost of goods could impact future anticipated revenue and gross profit for our CAR T cell therapies. Furthermore, we may face challenges with  sourcing  raw  materials  and  supplies  for  clinical  and,  if  approved,  commercial  manufacturing.  Logistical  and shipment delays and other factors not in our control could prevent or delay the delivery of our product candidates and marketed products to patients. Additionally, we are required to maintain a complex chain of identity and custody with respect to patient material as such material enters into and moves through the manufacturing process. As a result, even slight deviations at any point in the production process for our CAR T cell therapies or in material used in our CAR T cell therapies could result in loss of product or regulatory remedial action, which could adversely affect our future anticipated revenues and/or profitability related to our CAR T cell therapies.\n\n## We may encounter difficulties integrating ours and Celgene's businesses and operations and, therefore, may not fully realize the projected benefits from our acquisition of Celgene.\n\nThe ultimate success of our acquisition of Celgene and our ability to realize the anticipated benefits from the acquisition, including the expected cost savings and avoidance from synergies, innovation opportunities and operational efficiencies, depends on, among other things, how effective we are in integrating the Bristol Myers Squibb and Celgene operations, products and employees.\n\nWe are in the process of integrating a large number of manufacturing, operational and administrative systems to achieve consistency  throughout  the  combined  company,  including  with  respect  to  human  capital  management,  portfolio rationalization,  finance  and  accounting  systems,  sales  operations  and  product  distribution,  pricing  systems  and methodologies,  cybersecurity  systems,  compliance  programs  and  internal  controls  processes.  This  integration  is  a complex, costly and time-consuming process. If any difficulties in the integration of our operations were to occur, they could adversely affect our business, including, among other ways, causing a failure to meet demand for our products, or adversely affect our ability to meet our financial reporting obligations. Inconsistencies in standards, controls, procedures and policies may adversely affect our ability to maintain relationships with customers, suppliers, distributors, alliance partners, creditors, clinical trial investigators and managers of our clinical trials.\n\nEvents outside our control, including changes in regulation and laws as well as economic trends, also could adversely affect our ability to realize the expected benefits from this acquisition.\n\n## Regulatory, Intellectual Property, Litigation, Tax and Legal Compliance Risks\n\n## Litigation  claiming  infringement  of  intellectual  property  may  adversely  affect  our  future  revenues  and  operating earnings.\n\nWe and certain of our subsidiaries are, and in the future may be, involved in various legal proceedings, including patent litigation, such as claims that our patents are invalid, unenforceable and/or do not cover the product of the generic drug manufacturer or where third parties seek damages and/or injunctive relief to compensate for alleged infringement of their",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "BCBSA",
          "name": "BCBSA",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 238,
      "question": "How does BMY's financial exposure to Otsuka through the Sprycel co-promotion arrangement relate to its ongoing legal liability in the Abilify* litigation, particularly given the settlement progress outlined in the litigation disclosures?",
      "answer": "BMY's financial relationship with Otsuka through the Sprycel co-promotion arrangement, which generated $1.8 billion in revenues in 2019 and involved $302 million in payments to Otsuka, directly connects to its legal exposure in the Abilify* litigation, where both companies are co-defendants. In the litigation disclosures, it is noted that BMY and Otsuka entered a master settlement agreement in February 2019 to resolve over 2,500 Abilify*-related cases alleging compulsive gambling and impulse control disorders. Approximately 2,700 cases (3,900 plaintiffs) have since been dismissed through the settlement program or non-compliance, with only a few remaining in the U.S. and 11 in Canada. Despite significant progress, the ongoing nature of two active class actions in Canada indicates continued legal risk. Therefore, while the Sprycel collaboration was financially significant, it also ties BMY to shared liability with Otsuka in a complex and high-profile litigation matter that has not been fully resolved.",
      "reasoning_steps": [
        "Hop 1: BMY(page_116) \u2192 Otsuka: BMY had a co-promotion agreement with Otsuka for Sprycel, generating $1.8 billion in 2019 and involving $302 million in payments to Otsuka.",
        "Hop 2: Otsuka \u2192 Abilify* Litigation: Otsuka is a co-defendant with BMY in the Abilify* litigation, where plaintiffs allege impulse control disorders linked to the drug.",
        "Hop 3: Abilify* Litigation \u2190 BMY(page_160): BMY and Otsuka entered a master settlement in 2019 covering over 2,500 cases, with most dismissed but some remaining in Canada."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Invests_In]-> COMP -[Involved_In]-> LITIGATION <-[Involved_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Otsuka",
        "node_3": "Abilify* Litigation",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "node_2": {
          "id": "Otsuka",
          "name": "Otsuka",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Abilify*_Litigation",
          "name": "Abilify* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 239,
      "question": "How does the Fast Track designation for PR001, acquired from Prevail, align with Eli Lilly's risk factors related to regulatory pathways for new therapies?",
      "answer": "PR001, a gene therapy for Parkinson\u2019s disease with GBA1 mutations and neuronopathic Gaucher disease, was acquired from Prevail in 2021 as part of a $747.4 million transaction that included contingent value rights (CVRs) tied to regulatory approval by December 31, 2024. PR001 was granted Fast Track designation by the FDA, which is intended to expedite the development and review of therapies addressing serious conditions and unmet medical needs. However, Eli Lilly\u2019s risk factors section highlights that even with expedited designations like Fast Track, there are significant uncertainties and high failure rates in drug development, including the risk of delays, failure to obtain regulatory approvals, or commercial viability issues. This creates a tension between the optimism signaled by the Fast Track status and the cautionary note in the risk factors, which emphasize that most R&D investments, including those with accelerated pathways, may not generate financial returns. The CVR tied to PR001\u2019s regulatory approval by 2024 further underscores the financial stakes of this regulatory timeline.",
      "reasoning_steps": [
        "Hop 1: LLY(page_66) \u2192 PR001: LLY acquired PR001 from Prevail in 2021 for $747.4 million, plus contingent value rights (CVRs) of up to $160 million tied to regulatory approval by 2024.",
        "Hop 2: PR001 \u2192 Fast Track Designation: PR001 received Fast Track designation from the FDA, intended to expedite development and review for therapies addressing serious conditions and unmet medical needs.",
        "Hop 3: Fast Track Designation \u2190 LLY(page_39): LLY\u2019s risk factors section notes that despite expedited designations like Fast Track, drug development remains highly uncertain, with most R&D investments failing to generate financial returns due to regulatory, clinical, or commercial risks."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Complies_With]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "PR001",
        "node_3": "Fast Track Designation",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "PR001",
          "name": "PR001",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers may not add due to rounding.\n\nRevenue is attributed to the countries based on the location of the customer. (1)\n\n## Note 3: Acquisitions and Divestiture\n\nIn January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.\n\nWe also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December 31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6 million, respectively.\n\n## Acquisitions of Businesses\n\n## Prevail Acquisition\n\n## Overview of Transaction\n\nIn January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.\n\nUnder the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).",
          "relationship": "Complies_With"
        },
        "node_3": {
          "id": "Fast_Track_Designation",
          "name": "Fast Track Designation",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 6.168215058852481
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_3",
          "chunk_text": "\nIn collaboration with Boehringer Ingelheim. (1)\n\nBreakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. (2)\n\nFast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs. (3)\n\nThe FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients. (4)\n\nThere are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 240,
      "question": "How does Merck's revenue growth from Adempas sales in its marketing territories in 2021 relate to the sales-based milestone payments made to Bayer AG under their sGC modulator collaboration agreement?",
      "answer": "Merck reported that sales of Adempas in its marketing territories grew 14% in 2021, primarily due to higher demand in Europe. This growth likely contributed to the momentum that triggered a $375 million sales-based milestone payment to Bayer in 2020, and increased the probability of triggering an additional $400 million in milestone payments based on future sales performance. The collaboration agreement includes joint development and profit-sharing on sales of both Adempas and Verquvo, with Merck recording alliance revenue from Bayer's sales in addition to its own product sales.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_62) \u2192 [Adempas]: Merck reports 14% growth in Adempas sales in its marketing territories in 2021, driven by demand in Europe.",
        "Hop 2: [Adempas] \u2192 [Bayer AG]: Adempas is a product developed and commercialized under a joint collaboration agreement between Merck and Bayer, with Bayer commercializing the drug in the Americas and Merck in the rest of the world.",
        "Hop 3: [Bayer AG] \u2190 [MRK](page_103): Merck made a $375 million milestone payment to Bayer in 2020 under the same collaboration agreement, with an additional $400 million in contingent payments likely due to future sales performance, including growth in Adempas sales."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Introduces]-> PRODUCT -[Commercializes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Adempas",
        "node_3": "Bayer AG",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAlliance revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5 to the consolidated financial statements). (1)\n\nAdempas  and  Verquvo  are  part  of  a  worldwide  collaboration  with  Bayer  to  market  and  develop  soluble  guanylate cyclase (sGC) modulators (see Note 5 to the consolidated financial statements). Adempas is approved for the treatment of certain types  of  PAH.  Verquvo  was  approved  in  the  U.S.  in  January  2021  to  reduce  the  risk  of  cardiovascular  death  and  heart  failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. These approvals were based on the results of the VICTORIA trial. Alliance revenue from the collaboration grew 22% in 2021 and rose 38% in 2020. Revenue from the collaboration also includes sales of Adempas and Verquvo in Merck's marketing territories. Sales of Adempas in Merck's marketing territories grew 14% in 2021 primarily reflecting higher demand in Europe.\n\n## Diabetes\n\n",
          "relationship": "Introduces"
        },
        "node_2": {
          "id": "Adempas",
          "name": "Adempas",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Commercializes"
        },
        "node_3": {
          "id": "Bayer_AG",
          "name": "Bayer AG",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone and future option payments. (2)\n\nIncludes accrued milestone payments. (3)\n\n## Bayer AG\n\nIn 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and  develop  soluble  guanylate  cyclase  (sGC)  modulators  including  Bayer's  Adempas  (riociguat).  The  two  companies  have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer's Verquvo (vericiguat),  which  was  approved  in  the  U.S.  in  January  2021,  in  Japan  in  June  2021  and  in  the  EU  in  July  2021.  Under  the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck's share of profits from sales of Adempas and Verquvo in Bayer's marketing territories, which are product sales  net  of  cost  of  sales  and  commercialization  costs.  Cost  of  sales  includes  Bayer's  share  of  profits  from  sales  in  Merck's marketing territories.\n\nIn addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375 million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 241,
      "question": "How does BMY's financial dependence on AstraZeneca through post-divestiture royalty payments relate to its shared legal exposure with AstraZeneca in the Onglyza* litigation, particularly in light of the ongoing motions and court decisions affecting liability risk?",
      "answer": "BMY receives tiered royalty payments from AstraZeneca ranging from 10% to 25% on net sales through 2025, amounting to $725 million in 2021, as part of the 2014 diabetes business divestiture. However, despite divesting Onglyza*, BMY remains a co-defendant with AstraZeneca in ongoing product liability litigation involving approximately 270 plaintiffs as of June 2021, with court decisions in early 2022 excluding plaintiffs' causation experts, which may reduce liability risk. The financial benefits from the royalty agreement with AstraZeneca must be weighed against the potential for shared liability exposure in the Onglyza* litigation, although recent legal developments suggest a favorable trend for the defendants.",
      "reasoning_steps": [
        "Hop 1: BMY(page_119) \u2192 AstraZeneca: BMY receives tiered royalty payments from AstraZeneca on net sales through 2025, with $725 million received in 2021 following the 2014 diabetes business divestiture.",
        "Hop 2: AstraZeneca \u2192 Onglyza* Litigation: AstraZeneca is a co-defendant with BMY in the Onglyza* litigation, which involves approximately 270 plaintiffs as of June 2021, with liability expected to be shared.",
        "Hop 3: Onglyza* Litigation \u2190 BMY(page_160): BMY is a co-defendant in the Onglyza* litigation, with court decisions in August 2021 and January 2022 excluding plaintiffs' general causation experts, potentially limiting liability exposure."
      ],
      "difficulty": "hard",
      "idf_score": 6.717521203186536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> COMP -[Involved_In]-> LITIGATION <-[Faces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "AstraZeneca",
        "node_3": "Onglyza* Litigation",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "LITIGATION",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_119",
          "chunk_id": "chunk_5",
          "chunk_text": "\n(a)    Includes royalties received subsequent to the related sale of the asset or business.\n\n## Diabetes Business\n\nIn  February  2014,  BMS and AstraZeneca terminated their diabetes business alliance agreements and BMS sold to AstraZeneca substantially all of the diabetes business comprising the alliance. Consideration for the transaction included tiered royalty payments ranging from 10% to 25% based on net sales through 2025. Royalties were $725 million in 2021, $673 million in 2020 and $533 million in 2019.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "AstraZeneca",
          "name": "AstraZeneca",
          "type": "COMP",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Onglyza*_Litigation",
          "name": "Onglyza* Litigation",
          "type": "LITIGATION",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_160",
          "chunk_id": "chunk_1",
          "chunk_text": "## PRODUCT LIABILITY LITIGATION\n\nBMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged  personal  injury  and  economic  loss.  As  previously  disclosed,  in  addition  to  lawsuits,  BMS  also  faces  unfiled  claims involving its products.\n\n## Abilify*\n\nBMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional  cases  are  pending  in  Canada.  The  Judicial  Panel  on  Multidistrict  Litigation  consolidated  the  federal  court  cases  for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master  settlement  agreement  establishing  a  proposed  settlement  program  to  resolve  all Abilify* compulsivity  claims  filed  as  of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., no cases remain in the MDL and less than 5 cases remain pending in state courts  (New  Jersey  and  Massachusetts).  There  are  eleven  cases  pending  in  Canada  (four  class  actions,  seven  individual  injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a pending further appeal of the Ontario class certification decision.\n\n## Byetta*\n\nAmylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles ('JCCP'). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals  in  the  JCCP. As  of  December  31,  2021,  Plaintiffs'  counsel  have  submitted  dismissals  with  prejudice  in  exchange  for  a waiver of costs on behalf of nearly 60% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta * to AstraZeneca in February 2014 as part of BMS's global diabetes business divestiture and any additional liability to Amylin with respect to Byetta * is expected to be shared with AstraZeneca.\n\n## Onglyza*\n\nBMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of June 2021, claims are pending in state and federal court on behalf of approximately 270 individuals who allege they ingested the product  and  suffered  an  injury.  In  February  2018,  the  Judicial  Panel  on  Multidistrict  Litigation  ordered  all  federal  cases  to  be transferred  to  an  MDL  in  the  U.S.  District  Court  for  the  Eastern  District  of  Kentucky. A  significant  majority  of  the  claims  are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ('JCCP'). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties' motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants' motion to exclude plaintiffs' only general causation expert and largely denied plaintiffs' motions to exclude defendants' general causation experts; on January 5, 2022, the MDL court likewise granted defendants' motion to exclude plaintiffs' expert and denied entirely plaintiffs' motions. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 242,
      "question": "How does Gilead's revenue recognition strategy for Symtuza, as a product containing Gilead compounds, align with the financial obligations and risk-sharing structure defined in the collaboration agreement with Janssen?",
      "answer": "Gilead recognizes its share of Symtuza revenue as Product sales when Janssen's sales occur, reflecting its exclusive supply of the Gilead compounds. This aligns with the collaboration agreement where Janssen sets the price and leads manufacturing and commercialization, while Gilead receives revenue based on the net selling price ratio of its components. However, the agreement also includes risk-sharing provisions, such as the right for Gilead to become the selling party in certain countries if Janssen terminates the agreement without cause, which introduces operational and financial risks that are not directly reflected in the revenue recognition pattern but are embedded in the contractual terms.",
      "reasoning_steps": [
        "Hop 1: GILD(page_40) \u2192 Symtuza: Gilead reports revenue from cobicistat, emtricitabine, and tenofovir alafenamide in Symtuza, which is commercialized by Janssen, and notes the collaboration details are further described in Note 7.",
        "Hop 2: Symtuza \u2192 Janssen: Gilead granted Janssen an exclusive license to Symtuza globally, and Janssen is responsible for manufacturing, registration, distribution, and commercialization, while Gilead supplies the Gilead compounds and retains related intellectual property rights.",
        "Hop 3: Janssen \u2190 GILD(page_79): Gilead recognizes its share of Symtuza revenue in the period of Janssen\u2019s sales, as the license is deemed the predominant item; Janssen sets the price and shares revenue based on the net selling price ratio, with provisions allowing Gilead to take over sales in certain countries if Janssen terminates the agreement."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Manufactures]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Symtuza",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_40",
          "chunk_id": "chunk_5",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nRepresents\tour\trevenue\tfrom\tcobicistat\t('C'),\temtricitabine\t('FTC')\tand\ttenofovir\talafenamide\t('TAF')\tin\tSymtuza\t(darunavir/C/FTC/TAF),\ta\tfixed dose\t combination\t product\t commercialized\t by\t Janssen\t Sciences\t Ireland\t Unlimited\t Company\t ('Janssen').\t See\t Note\t 7.\t Collaborations\t and\t Other Arrangements\tof\tthe\tNotes\tto\tConsolidated\tFinancial\tStatements\tincluded\tin\tItem\t8\tof\tthis\tAnnual\tReport\ton\tForm\t10-K\tfor\tadditional\tinformation. Includes\tAtripla,\tEmtriva,\tSunlenca\tand\tTybost. (1) (2)\n\nHIV\t product\t sales\t increased\t 6%\t to\t $18.2\t billion\t in\t 2023,\t compared\t to\t 2022,\t primarily\t due\t to\t higher\t demand\t across treatment\t and\t prevention,\t in\t addition\t to\t higher\t average\t realized\t price\t and\t favorable\t channel\t inventory\t dynamics.\t In particular,\tBiktarvy\tsales\tincreased\tprimarily\treflecting\thigher\tdemand,\tincluding\tpatients\tswitching\tfrom\tother\tGilead\tHIV products,\t as\t well\t as\t higher\t average\t realized\t price.\t Also,\t Descovy\t sales\t increased\t primarily\t driven\t by\t favorable\t channel inventory\tdynamics\tand\thigher\tdemand.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Manufactures"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen\t sets\t the\t price\t of\t Symtuza\t and\t the\t parties\t share\t revenue\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the party's\t component(s),\t subject\t to\t certain\t restrictions\t and\t adjustments.\t The\t intellectual\t property\t license\t and\t supply obligations\trelated\tto\tthe\tGilead\tCompounds\tare\taccounted\tfor\tas\ta\tsingle\tperformance\tobligation.\tAs\tthe\tlicense\twas\tdeemed to\tbe\tthe\tpredominant\titem\tto\twhich\tthe\trevenue\tshare\trelates,\twe\trecognize\tour\tshare\tof\tthe\tSymtuza\trevenue\tin\tthe\tperiod when\tthe\tcorresponding\tsales\tof\tSymtuza\tby\tJanssen\toccur.\tWe\trecord\tour\tshare\tof\tthe\tSymtuza\trevenue\tas\tProduct\tsales\ton\tour Consolidated\tStatements\tof\tIncome\tprimarily\tbecause\twe\tsupply\tthe\tGilead\tCompounds\tto\tJanssen\tfor\tSymtuza.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tJanssen may\tterminate\tthe\tagreement\twithout\tcause\ton\ta\tcountry-by-country\tbasis,\tin\twhich\tcase\tGilead\thas\tthe\tright\tto\tbecome\tthe selling\tparty\tfor\tsuch\tcountry(ies)\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10\tyears.\tJanssen may\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Japan\tTobacco\n\nIn\t2005,\tJapan\tTobacco,\tInc.\t('Japan\tTobacco')\tgranted\tus\texclusive\trights\tto\tdevelop\tand\tcommercialize\telvitegravir,\ta novel\t HIV\t integrase\t inhibitor,\t in\t all\t countries\t of\t the\t world,\t excluding\t Japan,\t where\t Japan\t Tobacco\t retained\t such\t rights. Effective\t December\t 2018,\t we\t entered\t into\t an\t agreement\t with\t Japan\t Tobacco\t to\t acquire\t the\t rights\t to\t market\t and\t distribute certain\tproducts\tin\tour\tHIV\tportfolio\tin\tJapan\tand\tto\texpand\tour\trights\tto\tdevelop\tand\tcommercialize\telvitegravir\tto\tinclude Japan.\tWe\tare\tresponsible\tfor\tthe\tmarketing\tof\tthe\tproducts\tas\tof\tJanuary\t1,\t2019.\n\nWe\t are\t responsible\t for\t seeking\t regulatory\t approval\t in\t our\t territories\t and\t are\t required\t to\t use\t diligent\t efforts\t to commercialize\t elvitegravir\t for\t the\t treatment\t of\t HIV\t infection.\t We\t bear\t all\t costs\t and\t expenses\t associated\t with\t such commercialization\tefforts\tand\tpay\ta\troyalty\tto\tJapan\tTobacco\tbased\ton\tour\tproduct\tsales.\tOur\tsales\tof\tthese\tproducts\tare included\tin\tProduct\tsales\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalties\tdue\tto\tJapan\tTobacco\tare\tincluded\tin\tCost\tof goods\tsold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalty\texpenses\trecognized\twere\t$167\tmillion,\t$198\tmillion\tand\t$250 million\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nUnder\tthe\tterms\tof\tthe\t2018\tagreement,\twe\tpaid\tJapan\tTobacco\t$559\tmillion\tin\tcash\tand\trecognized\tan\tintangible\tasset\tof $550\tmillion\treflecting\tthe\testimated\tfair\tvalue\tof\tthe\tmarketing-related\trights\tacquired\tfrom\tJapan\tTobacco.\tThe\tintangible asset\tis\tbeing\tamortized\tover\tnine\tyears,\trepresenting\tthe\tperiod\tover\twhich\tthe\tmajority\tof\tthe\tbenefits\tare\texpected\tto\tbe derived\t from\t the\t applicable\t products\t in\t our\t HIV\t portfolio.\t The\t amortization\t expense\t is\t classified\t as\t selling\t expense\t and recorded\tas\tSelling,\tgeneral\tand\tadministrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including material\tbreach\tby\teither\tparty\tor\texpiry\tof\troyalty\tpayment\tterm.\tWe\tmay\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Everest\n\nIn\tApril\t2019,\tEverest\tMedicines\t('Everest')\tand\tImmunomedics\tentered\tinto\tan\tagreement\tgranting\tEverest\tan\texclusive license\t to\t develop\t and\t commercialize\t Trodelvy\t in\t Greater\t China,\t South\t Korea,\t Singapore,\t Indonesia,\t Philippines,\t Vietnam, Thailand,\tMalaysia\tand\tMongolia\t(the\t'Territories').\tGilead\tsubsequently\tacquired\tImmunomedics\tin\tOctober\t2020\tand\tassumed the\tEverest\tlicense\tand\tsupply\tagreement,\twhich\tprovided\tfor\tcertain\tsales\tmilestones\tand\troyalties\tpayments\tto\tbe\tmade\tto Gilead\tand\twas\trecorded\tas\ta\t$175\tmillion\tfinite-lived\tasset\tas\tpart\tof\tthe\tpurchase\taccounting.\tIn\tthe\tfourth\tquarter\tof 2022,\t we\t reacquired\t all\t development\t and\t commercialization\t rights\t for\t Trodelvy\t from\t Everest\t and\t terminated\t the\t previous agreement.\tUnder\tthe\tterms\tof\tthe\tnew\tagreement,\tGilead\tmade\t$280\tmillion\tin\tupfront\ttermination\tpayments\tto\tEverest,\tof which\t$84\tmillion\twas\tmade\tin\t2022\tand\t$196\tmillion\twas\tmade\tin\t2023.\tIn\taddition,\tEverest\tis\teligible\tto\treceive\tup\tto\t$175 million\tin\tpotential\tadditional\tpayments\tupon\tachievement\tof\tcertain\tregulatory\tand\tcommercial\tmilestones.\tWe\taccounted\tfor the\tnew\tagreement\tas\ta\tcontract\ttermination,\twhich\tincludes\tthe\treacquisition\tof\tcommercial\trights\tand\tthe\tsettlement\tof\tour pre-existing\t relationship\t with\t Everest.\t As\t a\t result,\t we\t recorded\t an\t expense\t of\t $406\t million\t in\t Selling,\t general\t and administrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome\tduring\tthe\tyear\tended\tDecember\t31,\t2022,\twhich\tprimarily represents\tthe\tupfront\tcosts\tand\twrite-off\tof\tthe\tremaining\tvalue\tof\tthe\tpre-existing\tasset\trelated\tto\tthe\tprior\tagreement. Simultaneously,\t we\t recorded\t an\t acquired\t finite-lived\t asset\t with\t a\t fair\t value\t of\t $50\t million\t for\t the\t commercial\t rights reacquired\tfor\tproducts\tapproved\tin\tthe\tTerritories.\n\n## Abingworth\n\nIn\tDecember\t2023,\twe\tentered\tinto\tan\tarrangement\twith\tfunds\tmanaged\tby\tAbingworth\tLLP\t('Abingworth')\tunder\twhich\twe\twill receive\tup\tto\t$210\tmillion\tto\tco-fund\tour\tdevelopment\tcosts\tfor\tTrodelvy\tfor\tnon-small\tcell\tlung\tcancer\tin\t2023\tthrough\t2026. As\t there\t is\t substantive\t transfer\t of\t risk\t to\t the\t financial\t partner,\t the\t development\t funding\t is\t recognized\t by\t us\t as\t an obligation\tto\tperform\tcontractual\tservices.\tIn\t2023,\twe\treceived\t$50\tmillion\tfrom\tAbingworth.\tWe\tare\trecognizing\tthe\tfunding as\ta\treduction\tof\tResearch\tand\tdevelopment\texpenses\tusing\tan\tattribution\tmodel\tover\tthe\tperiod\tof\tthe\trelated\texpenses.\tIf successful,\t upon\t regulatory\t approval\t in\t the\t U.S.\t for\t the\t specified\t indication,\t Abingworth\t will\t be\t eligible\t to\t receive\t an approval-based\tfixed\tmilestone\tpayment\tof\tup\tto\t$84\tmillion\tand\troyalties\tbased\ton\tthe\tapplicable\tnet\tsales.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 243,
      "question": "How do the legal risks associated with Comirnaty's patent infringement lawsuits impact Pfizer's international revenue commitments with BioNTech under the EU supply agreements?",
      "answer": "The legal risks associated with Comirnaty's patent infringement lawsuits, involving both U.S. and European jurisdictions and multiple plaintiffs seeking unspecified monetary damages, create uncertainty around the product's continued revenue generation and global distribution. This uncertainty directly affects Pfizer's ability to meet its international commitments with BioNTech, particularly under the amended EU supply agreement that extends deliveries through 2026 but includes a reduced aggregate volume and rephased delivery schedule. Given that Comirnaty is a key component of Pfizer's international revenue\u2014contributing to over $500 million in 11 countries in 2024\u2014the legal exposure could constrain the execution of these agreements and affect future revenue projections.",
      "reasoning_steps": [
        "Hop 1: [PFE](page_101) \u2192 [Comirnaty]: Legal risks from multiple lawsuits alleging patent infringement against Comirnaty are detailed, including U.S. and European actions seeking monetary damages.",
        "Hop 2: [Comirnaty] \u2192 [BioNTech]: BioNTech is named as a co-defendant in these lawsuits, indicating shared legal exposure and strategic dependency on Comirnaty\u2019s continued market presence.",
        "Hop 3: [BioNTech] \u2190 [PFE](page_107): Pfizer and BioNTech have ongoing international supply agreements, including a modified EU contract through 2026 with rephased deliveries and reduced volumes, which are central to international revenue commitments."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Impacts]-> PRODUCT -[Impacts]-> COMP <-[Depends_On]- ORG",
      "entities": {
        "start": "PFE",
        "node_2": "Comirnaty",
        "node_3": "BioNTech",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "node_2": {
          "id": "Comirnaty",
          "name": "Comirnaty",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_2",
          "chunk_text": "I n April 2024, G laxoSm ithKline Biologicals SA and G laxoSm ithKline LLC  (collectively, G SK G roup) sued P fizer and P harm acia &amp; U pjohn C om pany LLC , BioN T ech, BioN T ech Manufacturing Gm bH  and BioN Tech U S Inc. in the U .S. D istrict C ourt for the D istrict of D elaware, alleging that C om irnaty infringes five U .S. patents and seeking unspecified m oney damages. In August 2024, GSK Group filed an am ended com plaint alleging that C om irnaty infringes three additional U .S. patents.\n\nI n J anuary 2025, P rom osom e LLC  filed a com plaint in the U nified P atent C ourt, Local D ivision M unich, against P fizer and BioN T ech and certain of their subsidiaries alleging that Comirnaty infringes a E uropean patent that is in force only in F rance, G erm any and Sweden, and seeking unspecified m onetary dam ages in connection with the m anufacture and sale of C om irnaty in F rance, G erm any and Sweden.\n\nPfizer Inc.\n\n2024 Form 10-K\n\n95",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "BioNTech",
          "name": "BioNTech",
          "type": "COMP",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "page_id": "page_107",
          "chunk_id": "chunk_5",
          "chunk_text": "\nRevenues exceeded $500 m illion in each of 11, 14 and 24 countries outside the U .S. in 2024, 2023 and 2022, respectively. T he U .S. is the only country to contribute m ore than 10% of total revenue in 2024, 2023 and 2022. As a percentage of Total revenues , C hina was our largest m arket outside the U .S. (representing 4% of total revenues) in 2024, and Japan was our largest m arket outside the U .S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively).\n\n## C. Other Revenue Information\n\n## Significant Customers\n\nWe and our collaboration partner, BioN T ech, have entered into agreem ents to supply pre-specified doses of C om irnaty with m ultiple developed and em erging nations around the world and are continuing to deliver doses of C om irnaty under such agreem ents. T his includes supply agreem ents entered into in N ovem ber 2020 and F ebruary and M ay 2021 with the E C  for Comirnaty on behalf of the different E U  m em ber states and certain other countries. E ach E U  m em ber state subm its its own C om irnaty vaccine order to us and is responsible for paym ent pursuant to term s of the supply agreem ents negotiated by the E C . In M ay 2023, we and BioN T ech am ended our contract with the E C  to deliver C O VID -19 vaccines to the E U . The am ended agreem ent includes rephasing of delivery of doses annually through 2026 and an aggregate volum e reduction, providing additional flexibility for those E U  m em ber states who agreed to the am ended agreem ent. The E C  will m aintain access to future adapted C O VID -19 vaccines and the ability to donate doses, in alignm ent with the original agreem ent.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 244,
      "question": "How does the decline in Aranesp sales due to biosimilar competition compare with Amgen's broader concerns about biosimilars impacting future revenue streams, as outlined in the risk factors section?",
      "answer": "Aranesp sales declined in 2023 due to lower unit demand, particularly in the U.S., where independent and medium-sized dialysis organizations transitioned to EPOGEN and its biosimilars, which are expected to continue impacting volume and net selling prices. This specific decline aligns with Amgen's broader risk factor disclosure that biosimilars and generics pose a significant threat to marketed products, as seen in the past with Sensipar, where loss of patent exclusivity led to a rapid loss of market share and revenues. The biosimilar threat, therefore, is both a current reality for Aranesp and a systemic risk highlighted in the company's strategic outlook.",
      "reasoning_steps": [
        "Hop 1: AMGN(page_74) \u2192 Aranesp: Aranesp sales decreased in 2023 due to lower U.S. unit demand driven by transition to EPOGEN and biosimilars",
        "Hop 2: Aranesp \u2192 Biosimilars: Biosimilars of EPOGEN are expected to continue impacting Aranesp's volume and net selling price",
        "Hop 3: Biosimilars \u2190 AMGN(page_15): Amgen highlights in risk factors that biosimilars and generics pose a major competitive threat, citing the example of Sensipar's rapid revenue loss post-patent expiration"
      ],
      "difficulty": "hard",
      "idf_score": 6.293872272992934,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Impacts]-> PRODUCT <-[Faces]- ORG",
      "entities": {
        "start": "AMGN",
        "node_2": "Aranesp",
        "node_3": "Biosimilars",
        "end": "AMGN"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "## Aranesp\n\nTotal\tAranesp\tsales\tby\tgeographic\tregion\twere\tas\tfollows\t(dollar\tamounts\tin\tmillions):\n\n",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Aranesp",
          "name": "Aranesp",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe\tdecrease\tin\tglobal\tAranesp\tsales\tfor\t2023\twas\tdriven\tby\tunfavorable\tchanges\tto\tforeign\tcurrency\texchange\trates\tand\tlower net\tselling\tprice.\tU.S.\tAranesp\tsales\tfor\t2023\tdecreased\tdue\tto\tlower\tunit\tdemand\tas\ta\tresult\tof\tindependent\tand\tmedium-sized dialysis\torganizations\ttransitioning\tfrom\tAranesp\tto\tEPOGEN.\n\nThe\t decrease\t in\t global\t Aranesp\t sales\t for\t 2022\t was\t driven\t by\t lower\t net\t selling\t price\t and\t unfavorable\t changes\t to\t foreign currency\texchange\trates,\tpartially\toffset\tby\tfavorable\tchanges\tto\testimated\tsales\tdeductions\tand\tvolume\tgrowth.\n\nWe\texpect\tAranesp\tto\tcontinue\tto\tface\tcompetition\tfrom\tEPOGEN\tand\tits\tbiosimilars,\twhich\twill\timpact\tvolume\tand\tnet\tselling price\tin\tthe\tfuture.\n\n## EVENITY\n\nTotal\tEVENITY\tsales\tby\tgeographic\tregion\twere\tas\tfollows\t(dollar\tamounts\tin\tmillions):\n\n",
          "relationship": "Impacts"
        },
        "node_3": {
          "id": "Biosimilars",
          "name": "Biosimilars",
          "type": "PRODUCT",
          "idf_score": 5.320917198465278
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "page_id": "page_15",
          "chunk_id": "chunk_1",
          "chunk_text": "Although most of our products are biologics, some are small molecule products, including Otezla, KYPROLIS and LUMAKRAS/LUMYKRAS.\tBecause\tthe\tFDA\tapproval\tprocess\tpermits\tgeneric\tmanufacturers\tto\trely\ton\tthe\tsafety\tand\tefficacy\tdata\tof\tthe innovator\tproduct\trather\tthan\thaving\tto\tconduct\ttheir\town\tcostly\tand\ttime-consuming\tclinical\ttrials,\tgeneric\tmanufacturers\tcan often\tdevelop\tand\tmarket\ttheir\tcompeting\tversions\tof\tour\tsmall\tmolecule\tproducts\tat\tmuch\tlower\tprices.\tFor\texample,\tfollowing loss\tof\texclusivity\tof\tpatents\tdirected\tto\tcinacalcet,\tthe\tactive\tingredient\tin\tour\tsmall\tmolecule\tcalcimimetic\tSensipar,\twe lost\t a\t significant\t share\t of\t the\t market\t and\t corresponding\t revenues\t in\t a\t very\t short\t period\t of\t time.\t See\t Part\t IV-Note\t 20, Contingencies\tand\tcommitments,\tto\tthe\tConsolidated\tFinancial\tStatements.\n\nThe\tintroduction\tof\tnew\tproducts,\tthe\tdevelopment\tof\tnew\tprocesses\tor\ttechnologies\tby\tcompetitors\tor\tthe\temergence\tof\tnew information\tabout\texisting\tproducts\tmay\tresult\tin\t(i)\tincreased\tcompetition\tfor\tour\tmarketed\tproducts,\teven\tfor\tthose\tprotected by\t patents\t and/or\t (ii)\t reductions\t in\t the\t prices\t we\t receive\t from\t selling\t our\t products.\t In\t addition,\t the\t development\t of\t new treatment\toptions\tor\tstandards\tof\tcare\tmay\treduce\tthe\tuse\tof\tour\tproducts\tor\tmay\tlimit\tthe\tutility\tand\tapplication\tof\tongoing clinical\ttrials\tof\tour\tproduct\tcandidates.\t(As\tused\tin\tthis\tdocument,\tthe\tterm clinical\ttrials may\tinclude\tprospective\tclinical trials,\t observational\t studies,\t registries\t and\t other\t studies.)\t See\t Item\t 1A.\t Risk\t FactorsOur\t products\t face\t substantial competition\tand\tour\tproduct\tcandidates\tare\talso\tlikely\tto\tface\tsubstantial\tcompetition and\tItem\t1A.\tRisk\tFactorsWe\tcurrently face\tcompetition\tfrom\tbiosimilars\tand\tgenerics\tand\texpect\tto\tface\tincreasing\tcompetition\tfrom\tbiosimilars\tand\tgenerics\tin\tthe future .",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "AMGN",
          "name": "AMGN",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 245,
      "question": "How does Merck's financial commitment to Lenvima through milestone payments to Eisai compare with the revenue generated from Lenvima during the co-commercialization period in 2021?",
      "answer": "Merck had accrued $600 million in sales-based milestone payments not yet paid to Eisai as of December 31, 2021, with potential future payments reaching $2.6 billion. During the same year, Merck's alliance revenue from Lenvima totaled $704 million globally, indicating a significant portion of that revenue was offset by ongoing and anticipated payments tied to the collaboration agreement.",
      "reasoning_steps": [
        "Hop 1: [MRK](page_103) \u2192 [Eisai]: Merck made multiple milestone payments to Eisai for Lenvima, including $200 million in 2021, with $600 million accrued but unpaid and potential future payments of $2.6 billion.",
        "Hop 2: [Eisai] \u2192 [Lenvima]: Eisai is the originator of Lenvima and collaborates with Merck for its global co-development and co-commercialization, with Merck sharing profits equally but recording its share as alliance revenue.",
        "Hop 3: [Lenvima] \u2190 [MRK](page_141): In 2021, Merck reported $704 million in alliance revenue from Lenvima globally, which represents its share of the product's sales under the collaboration agreement."
      ],
      "difficulty": "hard",
      "idf_score": 6.920253757240618,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> COMP -[Produces]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Eisai",
        "node_3": "Lenvima",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_103",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nshareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.\n\nUnder the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain  option  rights  (of  which  the  final  $125  million  option  payment  was  made  in  March  2021).  In  addition,  the  agreement provides  for  contingent  payments  from  Merck  to  Eisai  related  to  the  successful  achievement  of  sales-based  and  regulatory milestones. Merck made sales-based milestone payments to Eisai aggregating $200 million, $500 million and $50 million in 2021, 2020  and  2019,  respectively.  As  of  December  31,  2021,  sales-based  milestone  payments  accrued  but  not  yet  paid  totaled $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.\n\nIn 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $75 million and $10 million, respectively, from Merck to Eisai. As of December 31, 2021, a regulatory approval milestone payment of $25 million was accrued but not yet paid. Potential future regulatory milestone payments of $25 million remain under the agreement.\n\nThe  intangible  asset  balance  related  to  Lenvima  (which  includes  capitalized  sales-based  and  regulatory  milestone payments) was $1.0 billion at December 31, 2021 and is included in Other Intangibles, Net . The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.\n\nSummarized financial information related to this collaboration is as follows:\n\n",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Eisai",
          "name": "Eisai",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_102",
          "chunk_id": "chunk_3",
          "chunk_text": "\nRepresents amortization of capitalized milestone payments. (1)\n\nIncludes accrued milestone payments. (2)\n\n## Eisai\n\nIn 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization  of  Lenvima  (lenvatinib),  an  orally  available  tyrosine  kinase  inhibitor  discovered  by  Eisai.  Under  the agreement,  Merck  and  Eisai  will  develop  and  commercialize  Lenvima  jointly,  both  as  monotherapy  and  in  combination  with Keytruda . Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as  alliance  revenue.  Expenses  incurred  during  co-development  are  shared  by  the  two  companies  in  accordance  with  the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not",
          "relationship": "Produces"
        },
        "node_3": {
          "id": "Lenvima",
          "name": "Lenvima",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "page_id": "page_141",
          "chunk_id": "chunk_2",
          "chunk_text": "| Years Ended December 31                | 2021     | 2021     | 2021     | 2020     | 2020     | 2020     | 2019     | 2019     | 2019     |\n|----------------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|\n|                                        | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    |\n| Pharmaceutical:                        |          |          |          |          |          |          |          |          |          |\n| Oncology                               |          |          |          |          |          |          |          |          |          |\n| Keytruda                               | $ 9,765  | $ 7,421  | $ 17,186 | $ 8,352  | $ 6,028  | $ 14,380 | $ 6,305  | $ 4,779  | $ 11,084 |\n| Alliance revenue - Lynparza (1)        | 515      | 473      | 989      | 417      | 308      | 725      | 269      | 176      | 444      |\n| Alliance revenue - Lenvima (1)         | 417      | 287      | 704      | 359      | 220      | 580      | 239      | 165      | 404      |\n| Vaccines                               |          |          |          |          |          |          |          |          |          |\n| Gardasil/Gardasil 9                    | 1,881    | 3,792    | 5,673    | 1,755    | 2,184    | 3,938    | 1,831    | 1,905    | 3,737    |\n| ProQuad/M-M-R II/Varivax               | 1,629    | 506      | 2,135    | 1,378    | 500      | 1,878    | 1,683    | 592      | 2,275    |\n| Pneumovax 23                           | 547      | 346      | 893      | 727      | 359      | 1,087    | 679      | 247      | 926      |\n| RotaTeq                                | 473      | 334      | 807      | 486      | 311      | 797      | 506      | 284      | 791      |\n| Vaqta                                  | 100      | 79       | 179      | 103      | 67       | 170      | 130      | 108      | 238      |\n| Hospital Acute Care                    |          |          |          |          |          |          |          |          |          |\n| Bridion                                | 762      | 770      | 1,532    | 583      | 615      | 1,198    | 533      | 598      | 1,131    |\n| Prevymis                               | 153      | 218      | 370      | 119      | 162      | 281      | 84       | 81       | 165      |\n| Primaxin                               | 2        | 258      | 259      | 2        | 248      | 251      | 2        | 271      | 273      |\n| Noxafil                                | 60       | 199      | 259      | 42       | 287      | 329      | 282      | 380      | 662      |\n| Cancidas                               | 4        | 208      | 212      | 7        | 207      | 213      | 6        | 242      | 249      |\n| Invanz                                 | (5)      | 207      | 202      | 9        | 202      | 211      | 30       | 233      | 263      |\n| Zerbaxa                                | 4        | (5)      | (1)      | 74       | 56       | 130      | 63       | 58       | 121      |\n| Immunology                             |          |          |          |          |          |          |          |          |          |\n| Simponi                                | -        | 825      | 825      | -        | 838      | 838      | -        | 830      | 830      |\n| Remicade                               | -        | 299      | 299      | -        | 330      | 330      | -        | 411      | 411      |\n| Neuroscience                           |          |          |          |          |          |          |          |          |          |\n| Belsomra                               | 78       | 241      | 318      | 81       | 247      | 327      | 92       | 214      | 306      |\n| Virology                               |          |          |          |          |          |          |          |          |          |\n| Molnupiravir                           | 632      | 320      | 952      | -        | -        | -        | -        | -        | -        |\n| Isentress/Isentress HD                 | 294      | 474      | 769      | 326      | 531      | 857      | 398      | 576      | 975      |\n| Cardiovascular                         |          |          |          |          |          |          |          |          |          |\n| Alliance revenue - Adempas/Verquvo (2) | 312      | 30       | 342      | 259      | 22       | 281      | 194      | 10       | 204      |\n| Adempas                                | -        | 252      | 252      | -        | 220      | 220      | -        | 215      | 215      |\n| Diabetes                               |          |          |          |          |          |          |          |          |          |\n| Januvia                                | 1,404    | 1,920    | 3,324    | 1,470    | 1,836    | 3,306    | 1,724    | 1,758    | 3,482    |\n| Janumet                                | 367      | 1,597    | 1,964    | 477      | 1,494    | 1,971    | 589      | 1,452    | 2,041    |\n| Other pharmaceutical (3)               | 1,007    | 1,302    | 2,310    | 984      | 1,328    | 2,312    | 1,215    | 1,661    | 2,873    |\n| Total Pharmaceutical segment sales     | 20,401   | 22,353   | 42,754   | 18,010   | 18,600   | 36,610   | 16,854   | 17,246   | 34,100   |\n| Animal Health:                         |          |          |          |          |          |          |          |          |          |\n| Livestock                              | 667      | 2,628    | 3,295    | 612      | 2,327    | 2,939    | 582      | 2,201    | 2,784    |\n| Companion Animals                      | 1,091    | 1,182    | 2,273    | 872      | 892      | 1,764    | 724      | 885      | 1,609    |\n| Total Animal Health segment sales      | 1,758    | 3,810    | 5,568    | 1,484    | 3,219    | 4,703    | 1,306    | 3,086    | 4,393    |\n| Other segment sales (4)                | -        | -        | -        | 23       | -        | 23       | 174      | 1        | 175      |\n| Total segment sales                    | 22,159   | 26,163   | 48,322   | 19,517   | 21,819   | 41,336   | 18,334   | 20,333   | 38,668   |\n| Other (5)                              | 266      | 116      | 382      | 71       | 111      | 182      | 86       | 368      | 453      |\n|                                        | $ 22,425 | $ 26,279 | $ 48,704 | $ 19,588 | $ 21,930 | $ 41,518 | $ 18,420 | $ 20,701 | $ 39,121 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 246,
      "question": "How does Gilead's revenue recognition model for Symtuza, where Janssen sets the price and revenue is shared based on component net selling prices, compare with the Japan Tobacco partnership where royalty expenses are based on product sales and an intangible asset is amortized over nine years?",
      "answer": "In Gilead's partnership with Janssen for Symtuza, Janssen sets the price and revenue is shared based on the ratio of the net selling prices of each party's components. Gilead recognizes its share of Symtuza revenue as Product sales when Janssen makes corresponding sales, as the license is deemed the predominant item. In contrast, Gilead's partnership with Japan Tobacco involves royalty expenses based on product sales, with Gilead paying royalties on elvitegravir-related sales. Additionally, Gilead acquired marketing rights in Japan for $559 million, which it amortizes over nine years as an intangible asset. These models differ significantly in how revenue is recognized (direct revenue share vs. royalty expense) and the treatment of acquired rights (amortized intangible asset vs. no such asset).",
      "reasoning_steps": [
        "Hop 1: GILD(page_40) \u2192 Symtuza: Gilead receives revenue from cobicistat, emtricitabine, and tenofovir alafenamide in Symtuza, a product commercialized by Janssen, with revenue recognized as Product sales when Janssen sells.",
        "Hop 2: Symtuza \u2192 Janssen: Janssen is responsible for manufacturing, registration, distribution, and commercialization of Symtuza worldwide, and Gilead supplies the Gilead compounds, with revenue shared based on the ratio of net selling prices.",
        "Hop 3: Janssen \u2190 GILD(page_79): Gilead's partnership with Japan Tobacco involves royalty payments based on product sales, and Gilead amortizes a $550 million intangible asset over nine years related to the acquisition of marketing rights in Japan."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Distributes]-> COMP <-[Partners_With]- ORG",
      "entities": {
        "start": "GILD",
        "node_2": "Symtuza",
        "node_3": "Janssen",
        "end": "GILD"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_40",
          "chunk_id": "chunk_5",
          "chunk_text": "\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nRepresents\tour\trevenue\tfrom\tcobicistat\t('C'),\temtricitabine\t('FTC')\tand\ttenofovir\talafenamide\t('TAF')\tin\tSymtuza\t(darunavir/C/FTC/TAF),\ta\tfixed dose\t combination\t product\t commercialized\t by\t Janssen\t Sciences\t Ireland\t Unlimited\t Company\t ('Janssen').\t See\t Note\t 7.\t Collaborations\t and\t Other Arrangements\tof\tthe\tNotes\tto\tConsolidated\tFinancial\tStatements\tincluded\tin\tItem\t8\tof\tthis\tAnnual\tReport\ton\tForm\t10-K\tfor\tadditional\tinformation. Includes\tAtripla,\tEmtriva,\tSunlenca\tand\tTybost. (1) (2)\n\nHIV\t product\t sales\t increased\t 6%\t to\t $18.2\t billion\t in\t 2023,\t compared\t to\t 2022,\t primarily\t due\t to\t higher\t demand\t across treatment\t and\t prevention,\t in\t addition\t to\t higher\t average\t realized\t price\t and\t favorable\t channel\t inventory\t dynamics.\t In particular,\tBiktarvy\tsales\tincreased\tprimarily\treflecting\thigher\tdemand,\tincluding\tpatients\tswitching\tfrom\tother\tGilead\tHIV products,\t as\t well\t as\t higher\t average\t realized\t price.\t Also,\t Descovy\t sales\t increased\t primarily\t driven\t by\t favorable\t channel inventory\tdynamics\tand\thigher\tdemand.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Symtuza",
          "name": "Symtuza",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_78",
          "chunk_id": "chunk_1",
          "chunk_text": "Pursuant\t to\t the\t Galapagos\t Subscription\t Agreement,\t we\t purchased\t 6.8\t million\t new\t ordinary\t shares\t of\t Galapagos\t and\t were issued\twarrants\tthat\tconfer\tthe\tright\tto\tsubscribe,\tfrom\ttime\tto\ttime,\tfor\ta\tnumber\tof\tnew\tshares\tto\tbe\tissued\tby\tGalapagos sufficient\t to\t bring\t the\t number\t of\t shares\t owned\t by\t us\t to\t 29.9%\t of\t the\t issued\t and\t outstanding\t shares\t at\t the\t time\t of\t our exercises.\tWe\tcurrently\town\t16.7\tmillion\tshares\tor\tapproximately\t25.8%\tof\tthe\tshares\tissued\tand\toutstanding\tat\tthe\ttime\tof last\t purchase\t in\t 2019.\t We\t are\t subject\t to\t a\t 10-year\t standstill\t restricting\t our\t ability\t to\t acquire\t voting\t securities\t of Galapagos\t exceeding\t more\t than\t 29.9%\t of\t the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos.\t We\t agreed\t not\t to, without\tthe\tprior\tconsent\tof\tGalapagos,\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tprior\tto\tthe\tsecond\tanniversary\tof\tthe closing\tof\tthe\tGalapagos\tSubscription\tAgreement\tor\tdispose\tof\tany\tequity\tsecurities\tof\tGalapagos\tthereafter\tuntil\tthe\tfifth anniversary\tof\tthe\tclosing\tof\tthe\tGalapagos\tSubscription\tAgreement,\tif\tafter\tsuch\tdisposal\twe\twould\town\tless\tthan\t20.1%\tof the\t then-issued\t and\t outstanding\t voting\t securities\t of\t Galapagos,\t subject\t to\t certain\t exceptions\t and\t termination\t events.\t In April\t2021,\twe\tamended\tthe\tGalapagos\tSubscription\tAgreement\tto\textend\tthe\tinitial\tlock-up\tprovision\tfor\tcertain\tGalapagos shares\tfrom\tAugust\t2021\tto\tAugust\t2024.\n\nWith\trespect\tto\tprograms\tin\tGalapagos'\tcurrent\tand\tfuture\tpipeline,\tif\twe\texercise\tour\toption\tto\ta\tprogram,\twe\twill\tpay\ta $150\tmillion\toption\texercise\tfee\tper\tprogram.\tIn\taddition,\tGalapagos\twill\treceive\ttiered\troyalties\tranging\tfrom\t20%\tto\t24%\ton net\tsales\tin\tour\tterritories\tof\teach\tGalapagos\tproduct\toptioned\tby\tus.\tIf\twe\texercise\tour\toption\tfor\ta\tprogram,\tthe\tparties will\tshare\tequally\tin\tdevelopment\tcosts\tand\tmutually\tagreed\tcommercialization\tcosts\tincurred\tsubsequent\tto\tour\texercise\tof the\toption.\tWe\tmay\tterminate\tthe\tcollaboration\tin\tits\tentirety\tor\ton\ta\tprogram-by-program\tand\tcountry-by-country\tbasis\twith advance\tnotice\tas\twell\tas\tfollowing\tother\tcustomary\ttermination\tevents.\tWe\thave\ttwo\tdesignees\tappointed\tto\tGalapagos'\tboard of\tdirectors.\n\n## Janssen\n\n## Complera/Eviplera\tand\tOdefsey\n\nIn\t2009,\twe\tentered\tinto\ta\tlicense\tand\tcollaboration\tagreement\twith\tJanssen\tto\tdevelop\tand\tcommercialize\ta\tfixed-dose combination\tof\tour\tTruvada\tand\tJanssen's\tnon-nucleoside\treverse\ttranscriptase\tinhibitor,\trilpivirine.\tThis\tcombination\twas approved\tin\tthe\tU.S.\tand\tEU\tin\t2011,\tand\tis\tsold\tunder\tthe\tbrand\tname\tComplera\tin\tthe\tU.S.\tand\tEviplera\tin\tthe\tEU.\tThe agreement\twas\tamended\tin\t2014\tto\texpand\tthe\tcollaboration\tto\tinclude\tanother\tproduct\tcontaining\tJanssen's\trilpivirine\tand\tour emtricitabine\tand\ttenofovir\talafenamide\t('Odefsey').\n\nUnder\t the\t amended\t agreement,\t Janssen\t granted\t us\t an\t exclusive\t license\t to\t Complera/Eviplera\t and\t Odefsey\t worldwide,\t but retained\trights\tto\tdistribute\tboth\tcombination\tproducts\tin\tcertain\tcountries\toutside\tof\tthe\tU.S.\tNeither\tparty\tis\trestricted from\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof\tComplera/Eviplera and\tOdefsey.\n\nWe\tare\tresponsible\tfor\tmanufacturing\tComplera/Eviplera\tand\tOdefsey\tand\thave\tthe\tlead\trole\tin\tregistration,\tdistribution and\tcommercialization\tof\tboth\tproducts\texcept\tin\tthe\tcountries\twhere\tJanssen\tdistributes.\tJanssen\thas\texercised\ta\tright\tto co-detail\tthe\tcombination\tproduct\tin\tsome\tof\tthe\tcountries\twhere\twe\tare\tthe\tselling\tparty.\n\nUnder\tthe\tfinancial\tprovisions\tof\tthe\t2014\tamendment,\tthe\tselling\tparty\tsets\tthe\tprice\tof\tthe\tcombined\tproducts\tand\tthe parties\t share\t revenues\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the\t party's\t component(s),\t subject\t to\t certain restrictions\tand\tadjustments.\tWe\tretain\ta\tspecified\tpercentage\tof\tJanssen's\tshare\tof\trevenues,\tincluding\tup\tto\t30%\tin\tmajor markets.\tSales\tof\tthese\tproducts\tare\tincluded\tin\tProduct\tsales\tand\tJanssen's\tshare\tof\trevenues\tis\tincluded\tin\tCost\tof\tgoods sold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tCost\tof\tgoods\tsold\trelating\tto\tJanssen's\tshare\twas\t$430\tmillion,\t$483\tmillion and\t$530\tmillion\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tWe\tmay terminate\tthe\tagreement\twithout\tcause\twith\trespect\tto\tthe\tcountries\twhere\twe\tsell\tthe\tproducts,\tin\twhich\tcase\tJanssen\thas\tthe right\tto\tbecome\tthe\tselling\tparty\tfor\tsuch\tcountry\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10 years.\n\n## Symtuza\n\nIn\t 2014,\t we\t amended\t a\t license\t and\t collaboration\t agreement\t with\t Janssen\t to\t develop\t and\t commercialize\t a\t fixed-dose combination\t of\t Janssen's\t darunavir\t and\t our\t cobicistat,\t emtricitabine\t and\t tenofovir\t alafenamide\t ('Gilead\t Compounds').\t This combination\twas\tapproved\tin\tthe\tU.S.\tand\tEU\tin\tJuly\t2018\tand\tSeptember\t2017,\trespectively,\tand\tis\tsold\tunder\tthe\tbrand\tname Symtuza.\n\nUnder\t the\t terms\t of\t the\t 2014\t amendment,\t we\t granted\t Janssen\t an\t exclusive\t license\t to\t Symtuza\t worldwide.\t Janssen\t is responsible\tfor\tmanufacturing,\tregistration,\tdistribution\tand\tcommercialization\tof\tSymtuza\tworldwide.\tWe\tare\tresponsible\tfor the\tintellectual\tproperty\trelated\tto\tthe\tGilead\tCompounds\tand\tare\tthe\texclusive\tsupplier\tof\tthe\tGilead\tCompounds.\tNeither party\tis\trestricted\tfrom\tcombining\tits\tdrugs\twith\tany\tother\tdrug\tproducts\texcept\tthose\twhich\tare\tsimilar\tto\tthe\tcomponents\tof Symtuza.",
          "relationship": "Distributes"
        },
        "node_3": {
          "id": "Janssen",
          "name": "Janssen",
          "type": "COMP",
          "idf_score": 5.8805329864007
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "Janssen\t sets\t the\t price\t of\t Symtuza\t and\t the\t parties\t share\t revenue\t based\t on\t the\t ratio\t of\t the\t net\t selling\t prices\t of\t the party's\t component(s),\t subject\t to\t certain\t restrictions\t and\t adjustments.\t The\t intellectual\t property\t license\t and\t supply obligations\trelated\tto\tthe\tGilead\tCompounds\tare\taccounted\tfor\tas\ta\tsingle\tperformance\tobligation.\tAs\tthe\tlicense\twas\tdeemed to\tbe\tthe\tpredominant\titem\tto\twhich\tthe\trevenue\tshare\trelates,\twe\trecognize\tour\tshare\tof\tthe\tSymtuza\trevenue\tin\tthe\tperiod when\tthe\tcorresponding\tsales\tof\tSymtuza\tby\tJanssen\toccur.\tWe\trecord\tour\tshare\tof\tthe\tSymtuza\trevenue\tas\tProduct\tsales\ton\tour Consolidated\tStatements\tof\tIncome\tprimarily\tbecause\twe\tsupply\tthe\tGilead\tCompounds\tto\tJanssen\tfor\tSymtuza.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including withdrawal\tof\ta\tproduct\tfrom\tthe\tmarket,\tmaterial\tbreach\tby\teither\tparty\tor\texpiry\tof\tthe\trevenue\tshare\tpayment\tterm.\tJanssen may\tterminate\tthe\tagreement\twithout\tcause\ton\ta\tcountry-by-country\tbasis,\tin\twhich\tcase\tGilead\thas\tthe\tright\tto\tbecome\tthe selling\tparty\tfor\tsuch\tcountry(ies)\tif\tthe\tproduct\thas\tlaunched\tbut\thas\tbeen\ton\tthe\tmarket\tfor\tfewer\tthan\t10\tyears.\tJanssen may\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Japan\tTobacco\n\nIn\t2005,\tJapan\tTobacco,\tInc.\t('Japan\tTobacco')\tgranted\tus\texclusive\trights\tto\tdevelop\tand\tcommercialize\telvitegravir,\ta novel\t HIV\t integrase\t inhibitor,\t in\t all\t countries\t of\t the\t world,\t excluding\t Japan,\t where\t Japan\t Tobacco\t retained\t such\t rights. Effective\t December\t 2018,\t we\t entered\t into\t an\t agreement\t with\t Japan\t Tobacco\t to\t acquire\t the\t rights\t to\t market\t and\t distribute certain\tproducts\tin\tour\tHIV\tportfolio\tin\tJapan\tand\tto\texpand\tour\trights\tto\tdevelop\tand\tcommercialize\telvitegravir\tto\tinclude Japan.\tWe\tare\tresponsible\tfor\tthe\tmarketing\tof\tthe\tproducts\tas\tof\tJanuary\t1,\t2019.\n\nWe\t are\t responsible\t for\t seeking\t regulatory\t approval\t in\t our\t territories\t and\t are\t required\t to\t use\t diligent\t efforts\t to commercialize\t elvitegravir\t for\t the\t treatment\t of\t HIV\t infection.\t We\t bear\t all\t costs\t and\t expenses\t associated\t with\t such commercialization\tefforts\tand\tpay\ta\troyalty\tto\tJapan\tTobacco\tbased\ton\tour\tproduct\tsales.\tOur\tsales\tof\tthese\tproducts\tare included\tin\tProduct\tsales\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalties\tdue\tto\tJapan\tTobacco\tare\tincluded\tin\tCost\tof goods\tsold\ton\tour\tConsolidated\tStatements\tof\tIncome.\tRoyalty\texpenses\trecognized\twere\t$167\tmillion,\t$198\tmillion\tand\t$250 million\tfor\tthe\tyears\tended\tDecember\t31,\t2023,\t2022\tand\t2021,\trespectively.\n\nUnder\tthe\tterms\tof\tthe\t2018\tagreement,\twe\tpaid\tJapan\tTobacco\t$559\tmillion\tin\tcash\tand\trecognized\tan\tintangible\tasset\tof $550\tmillion\treflecting\tthe\testimated\tfair\tvalue\tof\tthe\tmarketing-related\trights\tacquired\tfrom\tJapan\tTobacco.\tThe\tintangible asset\tis\tbeing\tamortized\tover\tnine\tyears,\trepresenting\tthe\tperiod\tover\twhich\tthe\tmajority\tof\tthe\tbenefits\tare\texpected\tto\tbe derived\t from\t the\t applicable\t products\t in\t our\t HIV\t portfolio.\t The\t amortization\t expense\t is\t classified\t as\t selling\t expense\t and recorded\tas\tSelling,\tgeneral\tand\tadministrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome.\n\nTermination\t of\t the\t agreement\t may\t be\t on\t a\t product\t or\t country\t basis\t and\t will\t depend\t on\t the\t circumstances,\t including material\tbreach\tby\teither\tparty\tor\texpiry\tof\troyalty\tpayment\tterm.\tWe\tmay\talso\tterminate\tthe\tentire\tagreement\twithout\tcause.\n\n## Everest\n\nIn\tApril\t2019,\tEverest\tMedicines\t('Everest')\tand\tImmunomedics\tentered\tinto\tan\tagreement\tgranting\tEverest\tan\texclusive license\t to\t develop\t and\t commercialize\t Trodelvy\t in\t Greater\t China,\t South\t Korea,\t Singapore,\t Indonesia,\t Philippines,\t Vietnam, Thailand,\tMalaysia\tand\tMongolia\t(the\t'Territories').\tGilead\tsubsequently\tacquired\tImmunomedics\tin\tOctober\t2020\tand\tassumed the\tEverest\tlicense\tand\tsupply\tagreement,\twhich\tprovided\tfor\tcertain\tsales\tmilestones\tand\troyalties\tpayments\tto\tbe\tmade\tto Gilead\tand\twas\trecorded\tas\ta\t$175\tmillion\tfinite-lived\tasset\tas\tpart\tof\tthe\tpurchase\taccounting.\tIn\tthe\tfourth\tquarter\tof 2022,\t we\t reacquired\t all\t development\t and\t commercialization\t rights\t for\t Trodelvy\t from\t Everest\t and\t terminated\t the\t previous agreement.\tUnder\tthe\tterms\tof\tthe\tnew\tagreement,\tGilead\tmade\t$280\tmillion\tin\tupfront\ttermination\tpayments\tto\tEverest,\tof which\t$84\tmillion\twas\tmade\tin\t2022\tand\t$196\tmillion\twas\tmade\tin\t2023.\tIn\taddition,\tEverest\tis\teligible\tto\treceive\tup\tto\t$175 million\tin\tpotential\tadditional\tpayments\tupon\tachievement\tof\tcertain\tregulatory\tand\tcommercial\tmilestones.\tWe\taccounted\tfor the\tnew\tagreement\tas\ta\tcontract\ttermination,\twhich\tincludes\tthe\treacquisition\tof\tcommercial\trights\tand\tthe\tsettlement\tof\tour pre-existing\t relationship\t with\t Everest.\t As\t a\t result,\t we\t recorded\t an\t expense\t of\t $406\t million\t in\t Selling,\t general\t and administrative\texpenses\ton\tour\tConsolidated\tStatements\tof\tIncome\tduring\tthe\tyear\tended\tDecember\t31,\t2022,\twhich\tprimarily represents\tthe\tupfront\tcosts\tand\twrite-off\tof\tthe\tremaining\tvalue\tof\tthe\tpre-existing\tasset\trelated\tto\tthe\tprior\tagreement. Simultaneously,\t we\t recorded\t an\t acquired\t finite-lived\t asset\t with\t a\t fair\t value\t of\t $50\t million\t for\t the\t commercial\t rights reacquired\tfor\tproducts\tapproved\tin\tthe\tTerritories.\n\n## Abingworth\n\nIn\tDecember\t2023,\twe\tentered\tinto\tan\tarrangement\twith\tfunds\tmanaged\tby\tAbingworth\tLLP\t('Abingworth')\tunder\twhich\twe\twill receive\tup\tto\t$210\tmillion\tto\tco-fund\tour\tdevelopment\tcosts\tfor\tTrodelvy\tfor\tnon-small\tcell\tlung\tcancer\tin\t2023\tthrough\t2026. As\t there\t is\t substantive\t transfer\t of\t risk\t to\t the\t financial\t partner,\t the\t development\t funding\t is\t recognized\t by\t us\t as\t an obligation\tto\tperform\tcontractual\tservices.\tIn\t2023,\twe\treceived\t$50\tmillion\tfrom\tAbingworth.\tWe\tare\trecognizing\tthe\tfunding as\ta\treduction\tof\tResearch\tand\tdevelopment\texpenses\tusing\tan\tattribution\tmodel\tover\tthe\tperiod\tof\tthe\trelated\texpenses.\tIf successful,\t upon\t regulatory\t approval\t in\t the\t U.S.\t for\t the\t specified\t indication,\t Abingworth\t will\t be\t eligible\t to\t receive\t an approval-based\tfixed\tmilestone\tpayment\tof\tup\tto\t$84\tmillion\tand\troyalties\tbased\ton\tthe\tapplicable\tnet\tsales.",
          "relationship": "Partners_With"
        },
        "end_node": {
          "id": "GILD",
          "name": "GILD",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 247,
      "question": "Given Trulicity's 32% U.S. revenue decline in 2024, how does the product's current market performance align with the company's strategic reliance on patent protection mechanisms that are set to expire in the next few years?",
      "answer": "Trulicity's U.S. revenue declined by 32% in 2024 due to competitive dynamics and supply constraints, signaling early market pressures. This decline is likely exacerbated by the impending expiration of its patent and data protections, which are expected to occur in the next few years and will open the door to generic competition. Given that LLY's business model heavily depends on maintaining strong intellectual property rights to secure market exclusivity and revenue stability, the current performance of Trulicity highlights a misalignment between its strategic reliance on patent protection and the reality of its near-term loss of exclusivity. This creates a critical window for LLY to either extend exclusivity through alternative patents or prepare for a significant revenue drop once generics enter the market.",
      "reasoning_steps": [
        "Hop 1: LLY(page_49) \u2192 Trulicity: Trulicity's U.S. revenue declined by 32% in 2024 due to competitive dynamics and supply constraints.",
        "Hop 2: Trulicity \u2192 Patent Protection: Trulicity is expected to lose significant patent and data protections in the next few years, increasing exposure to generic competition.",
        "Hop 3: Patent Protection \u2190 LLY(page_10): LLY depends heavily on intellectual property rights, including data protection and patent term extensions, to maintain market exclusivity and revenue for its pharmaceutical products."
      ],
      "difficulty": "hard",
      "idf_score": 5.6778004323466185,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> PRODUCT -[Expires]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "entities": {
        "start": "LLY",
        "node_2": "Trulicity",
        "node_3": "Patent Protection",
        "end": "LLY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "REGULATORY_REQUIREMENT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        },
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_3",
          "chunk_text": "\nNumbers m ay not add due to rounding.\n\nNM - not m eaningful\n\nJardiance revenue includes Glyxam bi,Synjardy, and Trijardy XR . (1)\n\nHumalog revenue includes insulin lispro. (2)\n\nBasaglar revenue includes R ezvoglar. (3)\n\nZyprexa revenue includes sale of the rights for the olanzapine portfolio in 2023. (4)\n\nRevenue of Mounjaro increased 85 percent in the U.S., primarily driv en by strong demand and increased supply. Rev enue outside of the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023, primarily driv en by v olume growth in launched markets.\n\nRevenue of Verzenio increased 36 percent in the U.S., driv en by increased demand, wholesaler buying patterns and, to a lesser extent, higher realized prices. Rev enue outside the U.S. increased 39 percent, driv en by increased demand.\n\nRevenue of Trulicity decreased 32 percent in the U.S., driv en by decreased v olume primarily due to competitiv e dynamics and supply constraints during the first half of 2024. Rev enue outside the U.S. decreased 8 percent, driv en by decreased v olume primarily due to competitiv e dynamics and actions we have taken to manage demand.\n\nRevenue of Zepbound in the U.S. in 2024 was $4.93 billion, compared to $175.8 million in 2023. Zepbound launched in the U.S. for the treatment of adult patients with obesity or ov erweight with weight-related comorbidities in Nov ember 2023.\n\nRevenue of Jardiance remained relativ ely flat in the U.S. as increased demand was offset by lower realized prices. Rev enue outside the U.S. increased 52 percent, driv en by increased v olume and a one-time payment receiv ed of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim. Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim inv olv ing Jardiance.\n\nRevenue of Taltz increased 18 percent in the U.S., driv en by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand. Revenue outside the U.S. increased 19 percent, primarily driv en by increased demand.",
          "relationship": "Produces"
        },
        "node_2": {
          "id": "Trulicity",
          "name": "Trulicity",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain entities has increased due to consolidation, regulatory, and other market impacts, and they, along with gov ernments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or fav orable formulary placement. Such stakeholders hav e also increasingly imposed utilization management tools to limit access to our products. As these practices expand, including due to potential further consolidation of U.S. priv ate third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. We expect that consolidation of supply chain entities will continue to increase competitiv e and pricing pressures on pharmaceutical manufacturers.\n\nPharmacy benefit manager practices hav e come under increased scrutiny from U.S. policymakers at the federal and state lev el who hav e proposed legislation intended to address concerns regarding the impact that these intermediaries hav e on drug pricing and patients' out of pocket costs. If promulgated, such legislation could hav e resultant implications, costs, or consequences for our business and how we interact with these entities. For additional information on pricing and reimbursement for our pharmaceutical products, see Item 1, \"Business-U.S. Priv ate Sector Dynamics\" and \"Regulations and Priv ate Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.\"\n\n## Risks Related to Our Intellectual Property\n\n- We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.\n\nIn the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time. For example, Trulicity will lose significant patent and remaining data protections in the next few years. Some products also lose patent protection as a result of successful third-party challenges. We hav e faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection.\n\nFor non-biologic products, loss of exclusiv ity typically results in the entry of one or more generic competitors, leading to a rapid and sev ere decline in rev enues, especially in the U.S. Generic pharmaceutical companies hav e in some cases introduced a generic product before resolution of any related patent litigation. For biologics, loss of exclusiv ity may or may not result in the near-term entry of competitor v ersions (i.e., biosimilars) due to many factors, including dev elopment timelines, manufacturing challenges, and/or uncertainties regarding the regulatory approv al pathways.\n\nOur success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often inv olv e complex legal, scientific and factual questions. There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found v alid and enforceable if challenged. Third parties may challenge, inv alidate, or circumv ent our patents and patent applications relating to our products, product candidates, and technologies. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not be deemed to infringe our patents. Moreover, patents relating to particular products, uses, formulations, or processes may not preclude other manufacturers from employing alternativ e processes or marketing alternativ e products or formulations that compete with our patented products. Patents held by third-parties hav e also contributed, and may in the future contribute, to a decision by us to not pursue all potential indications for a product candidate. In addition, competitors or other third parties may assert claims that our activ ities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item 7, \"Management's Discussion and Analysis-Executiv e Ov erv iew-Other Matters-Patent Matters\" and Item 1, \"Business-Patents, Trademarks, and Other Intellectual Property Rights,\" for more details.",
          "relationship": "Expires"
        },
        "node_3": {
          "id": "Patent_Protection",
          "name": "Patent Protection",
          "type": "REGULATORY_REQUIREMENT",
          "idf_score": 4.088773517172645
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "page_id": "page_10",
          "chunk_id": "chunk_1",
          "chunk_text": "## Patents, Trademarks, and Other Intellectual Property Rights\n\n## Overview\n\nIntellectual property protection is critical to our ability to successfully commercialize our life sciences innov ations and inv est in the search for new medicines and uses. Loss of effectiv e patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effectiv e market exclusiv ity for the product, often leading to a sev ere and rapid decline in rev enues for the product. We own, hav e applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, for some products we hav e effectiv e intellectual property protection in the form of data protection under pharmaceutical regulatory laws.\n\nThe patent protection generally anticipated to be of most relev ance to pharmaceuticals is prov ided by patents claiming the activ e ingredient (the compound patent) for our products, particularly those in major markets such as the U.S., major European countries, and Japan. In general, patents in each relev ant country last for a period of 20 years from their filing date, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:\n\n- Patent term adjustment is av ailable to all U.S. patent applicants to prov ide relief in the ev ent that a patent grant is delayed during examination by the U.S. Patent and Trademark Office (USPTO).\n- Patent term restoration for a single patent for a pharmaceutical product is prov ided to U.S. patent holders to compensate for a portion of the time inv ested in clinical trials and the U.S. Food and Drug Administration (FDA) rev iew process. There is a fiv e-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from initial FDA approv al. Some countries outside the U.S. similarly offer forms of patent term restoration. For example, Supplementary Protection Certificates are av ailable to extend the life of a European patent up to an additional fiv e years (subject to a 15-year cap from European Medicines Agency (EMA) approv al) and in Japan patent terms can be extended up to fiv e years.\n\nIn some cases, the innov ator company may retain exclusiv ity despite approv al of the generic, biosimilar, or other follow-on v ersions of a new medicine beyond the expiration of the compound patent through market dynamics and challenges, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be av ailable under pharmaceutical regulatory laws. The primary forms of data protection are as follows:\n\n- Data package protection generally prohibits regulatory approv al of other manufacturers' applications for marketing approv al if they rely on the innov ator company's regulatory submission data for the drug. The base period is generally fiv e years in the U.S. (12 years for new biologics under the BPCIA, subject to certain conditions), effectiv ely 10 years in Europe, and eight years in Japan, which can be extended to 10 years with qualifying pediatric studies. The period begins on the date of product approv al and runs concurrently with the patent term for any relev ant patents. Legislativ e bodies in the European Union (EU) are discussing proposed reductions in data protection periods but it remains uncertain if, or when, these proposals might be adopted.\n- In the U.S., the FDA has the authority to grant additional data protection for approv ed drugs where the sponsor conducts specified testing in pediatric populations within a specified time period. If granted, this \"pediatric exclusiv ity\" prov ides an additional six months of exclusiv ity, which is added to the term of data protection, orphan drug exclusiv ity and, for products other than biologics, pediatric exclusiv ity is also added to the term of any relev ant and non-expired patents.\n- A specific use of a drug or biologic can receiv e \"orphan\" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recov er dev elopment and marketing costs through U.S. sales. Orphan designation entitles a particular use of the drug to sev en years of market exclusiv ity, which runs in parallel with any applicable patents.\n\nOutside the major markets, the adequacy and effectiv eness of intellectual property protection for pharmaceuticals v ary widely. International and U.S. free trade agreements like the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs Agreement) administered by the World Trade Organization prov ide global protection of certain intellectual property rights. But in a number of markets we are unable to patent our products or to enforce the patents that we receiv e for our products. Further, many dev eloping countries, and some dev eloped countries, do not prov ide effectiv e data package protection ev en though it is specified in the TRIPs Agreement.",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "LLY",
          "name": "LLY",
          "type": "ORG",
          "year": 2024
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 248,
      "question": "Given MRK's heavy dependence on key products for profitability and the specific decline in Bridion sales following loss of EU market exclusivity, how does the company's financial exposure to Bridion compare between its qualitative risk disclosures and the quantitative revenue trends presented in the financial tables?",
      "answer": "MRK discloses in its risk factors that key products like Bridion generate a significant portion of its profits and cash flows, and that the loss of market exclusivity for Bridion in the EU in 2023 led to a substantial decline in sales in those markets. This qualitative risk is supported by the quantitative evidence from the financial tables, which show Bridion's total sales declining from $1,842 million in 2022 to $1,532 million in 2021 (with a slight rebound in 2023 at $1,842 million, but with anticipated future declines as exclusivity is lost in other regions). The contrast between the risk disclosure and the revenue data highlights that while Bridion remains a material product, its financial contribution is under pressure due to patent expirations, reinforcing the company's stated risk of material adverse effects from such events.",
      "reasoning_steps": [
        "Hop 1: MRK(page_28) \u2192 Key Products: MRK states that key products generate a significant amount of its profits and cash flows and that the loss of market exclusivity for Bridion in the EU in 2023 caused a substantial sales decline.",
        "Hop 2: Key Products \u2192 Bridion: Bridion is explicitly listed among MRK\u2019s key products, and its loss of market exclusivity is highlighted as a material risk to future sales.",
        "Hop 3: Bridion \u2190 MRK(page_126): Financial tables show Bridion\u2019s sales trended downward in recent years, with total sales at $1,532 million in 2021, $1,685 million in 2022, and $1,842 million in 2023, indicating volatility but an overall exposure to future declines as exclusivity is lost in Japan and the U.S."
      ],
      "difficulty": "hard",
      "idf_score": 6.370947612906564,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> PRODUCT -[Includes]-> PRODUCT <-[Produces]- ORG",
      "entities": {
        "start": "MRK",
        "node_2": "Key Products",
        "node_3": "Bridion",
        "end": "MRK"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\n- The\tCompany\tis\tdependent\ton\tits\tpatent\trights,\tand\tif\tits\tpatent\trights\tare\tinvalidated\tor\tcircumvented,\tits\tbusiness\tcould be\tmaterially\tadversely\taffected.\n- As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales from\tthose\tproducts.\n- Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial condition.\n- The\t Company's\t research\t and\t development\t efforts\t may\t not\t succeed\t in\t developing\t commercially\t successful\t products\t and\t the Company\tmay\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table to\treplace\tsales\tof\tsuccessful\tproducts\tthat\tlose\tpatent\tprotection.\n- The\t Company's\t success\t is\t dependent\t on\t the\t successful\t development\t and\t marketing\t of\t new\t products,\t which\t are\t subject\t to substantial\trisks.\n- The\tCompany\tfaces\tcontinued\tpricing\tpressure\twith\trespect\tto\tits\tproducts.\n- Unfavorable\t or\t uncertain\t economic\t conditions,\t together\t with\t cost-reduction\t measures\t being\t taken\t by\t certain\t governments, could\tnegatively\taffect\tthe\tCompany's\toperating\tresults.\n- The\tCompany\tfaces\tintense\tcompetition\tfrom\tboth\tlower\tcost\tgeneric\tproducts\tand\tcompetitors'\tproducts.\n- The\t Company\t has\t significant\t global\t operations,\t which\t expose\t it\t to\t additional\t risks,\t and\t any\t adverse\t event\t could\t have\t a material\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n- Climate\t change\t or\t legal,\t regulatory\t or\t market\t measures\t to\t address\t climate\t change\t may\t negatively\t affect\t the\t Company's business,\tresults\tof\toperations,\tcash\tflows\tand\tprospects.\n- Environmental,\tsocial\tand\tgovernance\t(ESG)\tmatters\tmay\timpact\tthe\tCompany's\tbusiness\tand\treputation.\n- Failure\t to\t attract\t and\t retain\t highly\t qualified\t personnel\t could\t affect\t the\t Company's\t ability\t to\t successfully\t develop\t and commercialize\tproducts.\n- The\tCompany\tmay\texperience\tdifficulties\tand\tdelays\tin\tmanufacturing\tcertain\tof\tits\tproducts,\tincluding\tvaccines.\n- The\tCompany\tmay\tnot\tbe\table\tto\trealize\tthe\texpected\tbenefits\tof\tits\tinvestments\tin\temerging\tmarkets.\n- The\tCompany\tis\texposed\tto\tmarket\trisk\tfrom\tfluctuations\tin\tcurrency\texchange\trates\tand\tinterest\trates.\n- Pharmaceutical\tproducts\tcan\tdevelop\tunexpected\tsafety\tor\tefficacy\tconcerns.\n- Reliance\ton\tthird-party\trelationships\tand\toutsourcing\tarrangements\tcould\tmaterially\tadversely\taffect\tthe\tCompany's\tbusiness.\n- Negative\t events\t in\t the\t animal\t health\t industry\t could\t have\t a\t material\t adverse\t effect\t on\t future\t results\t of\t operations\t and financial\tcondition\tof\tthe\tCompany\tor\tits\tAnimal\tHealth\tbusiness.\n- Biologics\tand\tvaccines\tcarry\tunique\trisks\tand\tuncertainties,\twhich\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's future\tresults\tof\toperations\tand\tfinancial\tcondition.\n- The\t health\t care\t industry\t in\t the\t U.S.\t has\t been,\t and\t will\t continue\t to\t be,\t subject\t to\t increasing\t regulation\t and\t political action.\n- The\t Company's\t products,\t including\t products\t in\t development,\t cannot\t be\t marketed\t unless\t the\t Company\t obtains\t and\t maintains regulatory\tapproval.\n- Developments\tfollowing\tregulatory\tapproval\tmay\tadversely\taffect\tsales\tof\tthe\tCompany's\tproducts.\n- The\tCompany\tis\tsubject\tto\ta\tvariety\tof\tU.S.\tand\tinternational\tlaws\tand\tregulations.",
          "relationship": "Depends_On"
        },
        "node_2": {
          "id": "Key_Products",
          "name": "Key Products",
          "type": "PRODUCT",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table\tof\tContents\n\nA\t chart\t listing\t the\t key\t patent\t protection\t for\t certain\t of\t the\t Company's\t marketed\t products,\t and\t U.S.\t patent\t protection\t for candidates\tin\tPhase\t3\tclinical\tdevelopment\tis\tset\tforth\tabove\tin\tItem\t1.\t'Business\t-\tPatents,\tTrademarks\tand\tLicenses.'\n\n## As\tthe\tCompany's\tproducts\tlose\tmarket\texclusivity,\tthe\tCompany\tgenerally\texperiences\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfrom those\tproducts.\n\nThe\tCompany\tdepends\tupon\tpatents\tto\tprovide\tit\twith\texclusive\tmarketing\trights\tfor\tits\tproducts\tfor\tsome\tperiod\tof\ttime.\tLoss\tof patent\tprotection\tfor\tone\tof\tthe\tCompany's\tproducts\ttypically\tleads\tto\ta\tsignificant\tand\trapid\tloss\tof\tsales\tfor\tthat\tproduct\tas\tlower priced\tgeneric\tversions\tof\tthat\tdrug\tbecome\tavailable.\tIn\tthe\tcase\tof\tproducts\tthat\tcontribute\tsignificantly\tto\tthe\tCompany's\tsales,\tthe loss\tof\tmarket\texclusivity\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tbusiness,\tcash\tflow,\tresults\tof\toperations,\tfinancial condition\t and\t prospects.\t In\t 2023,\t the\t Company\t lost\t market\t exclusivity\t for Bridion in\t the\t EU\t and\t the\t Company\t has\t experienced\t a substantial\tdecline\tin Bridion sales\tin\tthose\tmarkets. Bridion lost\tmarket\texclusivity\tin\tJapan\tin\tJanuary\t2024\tand\twill\tlose\tmarket exclusivity\tin\tthe\tU.S.\tin\t2026\t(subject\tto\tpatent\tlitigation\tdiscussed\tbelow)\tand\tthe\tCompany\texpects\tthat\tsales\tin\tthose\tmarkets\twill decline\tsubstantially\tthereafter.\tIn\taddition,\tthe\tCompany\texpects\tto\tlose\tmarket\texclusivity\tin\tthe\tU.S.\tfor Keytruda in\t2028\tand\tthe Company\tanticipates\tthat\tsales\tof Keytruda in\tthe\tU.S.\twill\tdecline\tsubstantially\tthereafter.\n\n## Key\tproducts\tgenerate\ta\tsignificant\tamount\tof\tthe\tCompany's\tprofits\tand\tcash\tflows,\tand\tany\tevents\tthat\tadversely\taffect\tthe markets\tfor\tits\tleading\tproducts\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tCompany's\tresults\tof\toperations\tand\tfinancial\tcondition.\n\nThe\t Company's\t ability\t to\t generate\t profits\t and\t operating\t cash\t flow\t depends\t largely\t upon\t the\t continued\t profitability\t of\t the Company's\t key\t products,\t such\t as Keytruda , Gardasil/Gardasil 9,\t Lynparza, Bravecto , and Bridion .\t In\t 2023,\t the\t Company's\t oncology portfolio,\t led\t by Keytruda ,\t and\t its\t vaccines\t portfolio,\t led\t by Gardasil/Gardasil\t 9 ,\t represented\t substantially\t all\t of\t the\t Company's revenue\tgrowth.\tIn\tparticular,\tin\tthe\taggregate,\tin\t2023,\tsales\tof Keytruda and Gardasil/Gardasil\t9 represented\t56%\tof\tthe\tCompany's total\tsales.\tAs\ta\tresult\tof\tthe\tCompany's\tdependence\ton\tkey\tproducts,\tany\tevent\tthat\tadversely\taffects\tany\tof\tthese\tproducts\tor\tthe markets\tfor\tany\tof\tthese\tproducts\tcould\thave\ta\tsignificant\tadverse\timpact\ton\tresults\tof\toperations\tand\tfinancial\tcondition.\tThese\tevents could\tinclude\tloss\tof\tpatent\tprotection,\tincreased\tcosts\tassociated\twith\tmanufacturing,\tgeneric\tor\tover-the-counter\tavailability\tof\tthe Company's\tproduct\tor\ta\tcompetitive\tproduct,\tthe\tdiscovery\tof\tpreviously\tunknown\tside\teffects,\tresults\tof\tpost-approval\ttrials,\tincreased competition\tfrom\tthe\tintroduction\tof\tnew,\tmore\teffective\ttreatments\tand\tdiscontinuation\tor\tremoval\tfrom\tthe\tmarket\tof\tthe\tproduct\tfor any\treason.\tSuch\tevents\tcould\thave\ta\tmaterial\tadverse\teffect\ton\tthe\tsales\tof\tany\tsuch\tproducts.\n\n## The\tCompany's\tresearch\tand\tdevelopment\tefforts\tmay\tnot\tsucceed\tin\tdeveloping\tcommercially\tsuccessful\tproducts\tand\tthe\tCompany may\tnot\tbe\table\tto\tacquire\tcommercially\tsuccessful\tproducts\tin\tother\tways;\tconsequently,\tthe\tCompany\tmay\tnot\tbe\table\tto\treplace\tsales\tof successful\tproducts\tthat\tlose\tpatent\tprotection.\n\nIn\torder\tto\tremain\tcompetitive,\tthe\tCompany,\tlike\tother\tmajor\tpharmaceutical\tcompanies,\tmust\tcontinue\tto\tlaunch\tnew\tproducts. Expected\tdeclines\tin\tsales\tof\tproducts\tafter\tthe\tloss\tof\tmarket\texclusivity\tmean\tthat\tthe\tCompany's\tfuture\tsuccess\tis\tdependent\ton\tits pipeline\tof\tnew\tproducts,\tincluding\tnew\tproducts\tthat\tit\tmay\tdevelop\tthrough\tcollaborations\tand\tjoint\tventures\tand\tproducts\tthat\tit\tis able\tto\tobtain\tthrough\tlicense\tor\tacquisition.\tTo\taccomplish\tthis,\tthe\tCompany\tcommits\tsubstantial\teffort,\tfunds\tand\tother\tresources\tto research\tand\tdevelopment,\tboth\tthrough\tits\town\tdedicated\tresources\tand\tthrough\tvarious\tcollaborations\twith\tthird\tparties.\tThere\tis\ta high\trate\tof\tfailure\tinherent\tin\tthe\tresearch\tand\tdevelopment\tprocess\tfor\tnew\tdrugs\tand\tvaccines.\tAs\ta\tresult,\tthere\tis\ta\thigh\trisk\tthat funds\tinvested\tby\tthe\tCompany\tin\tresearch\tprograms\twill\tnot\tgenerate\tfinancial\treturns.\tThis\trisk\tprofile\tis\tcompounded\tby\tthe\tfact\tthat this\tresearch\thas\ta\tlong\tinvestment\tcycle.\tTo\tbring\ta\tpharmaceutical\tcompound\tfrom\tthe\tdiscovery\tphase\tto\tmarket\tmay\ttake\ta\tdecade\tor more\tand\tfailure\tcan\toccur\tat\tany\tpoint\tin\tthe\tprocess,\tincluding\tlater\tin\tthe\tprocess\tafter\tsignificant\tfunds\thave\tbeen\tinvested.\n\nFor\ta\tdescription\tof\tthe\tresearch\tand\tdevelopment\tprocess,\tsee\tItem\t1.\t'Business\t-\tResearch\tand\tDevelopment'\tabove.\tEach\tphase of\ttesting\tis\thighly\tregulated\tand\tduring\teach\tphase\tthere\tis\ta\tsubstantial\trisk\tthat\tthe\tCompany\twill\tencounter\tserious\tobstacles\tor will\t not\t achieve\t its\t goals.\t Therefore,\t the\t Company\t may\t abandon\t a\t product\t in\t which\t it\t has\t invested\t substantial\t amounts\t of\t time\t and resources.\tSome\tof\tthe\trisks\tencountered\tin\tthe\tresearch\tand\tdevelopment\tprocess\tinclude\tthe\tfollowing:\tpreclinical\ttesting\tof\ta\tnew compound\tmay\tyield\tdisappointing\tresults;\tcompeting\tproducts\tfrom\tother\tmanufacturers\tmay\treach\tthe\tmarket\tfirst;\tclinical\ttrials\tof\ta new\tdrug\tmay\tnot\tbe\tsuccessful;\ta\tnew\tdrug\tmay\tnot\tbe\teffective\tor\tmay\thave\tharmful\tside\teffects;\ta\tnew\tdrug\tmay\tnot\tbe\tapproved\tby\tthe regulators\tfor\tits\tintended\tuse;\tit\tmay\tnot\tbe\tpossible\tto\tobtain\ta\tpatent\tfor\ta\tnew\tdrug;\tpayers\tmay\trefuse\tto\tcover\tor\treimburse\tthe new\tproduct;\tor\tsales\tof\ta\tnew\tproduct\tmay\tbe\tdisappointing.",
          "relationship": "Includes"
        },
        "node_3": {
          "id": "Bridion",
          "name": "Bridion",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "page_id": "page_126",
          "chunk_id": "chunk_2",
          "chunk_text": "| Years Ended December 31                | 2023     | 2023     | 2023     | 2022     | 2022     | 2022     | 2021     | 2021     | 2021     |\n|----------------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|\n|                                        | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    | U.S.     | Int'l    | Total    |\n| Pharmaceutical:                        |          |          |          |          |          |          |          |          |          |\n| Oncology                               |          |          |          |          |          |          |          |          |          |\n| Keytruda                               | $ 15,114 | $ 9,897  | $ 25,011 | $ 12,686 | $ 8,251  | $ 20,937 | $ 9,765  | $ 7,421  | $ 17,186 |\n| Alliance revenue - Lynparza (1)        | 607      | 592      | 1,199    | 584      | 532      | 1,116    | 515      | 473      | 989      |\n| Alliance revenue - Lenvima (1)         | 657      | 303      | 960      | 579      | 297      | 876      | 417      | 287      | 704      |\n| Welireg                                | 209      | 10       | 218      | 123      | -        | 123      | 13       | -        | 13       |\n| Alliance revenue - Reblozyl (2)        | 168      | 43       | 212      | 123      | 43       | 166      | -        | 17       | 17       |\n| Vaccines                               |          |          |          |          |          |          |          |          |          |\n| Gardasil/Gardasil 9                    | 2,083    | 6,803    | 8,886    | 2,065    | 4,832    | 6,897    | 1,881    | 3,792    | 5,673    |\n| ProQuad/M-M-R II/Varivax               | 1,837    | 531      | 2,368    | 1,724    | 518      | 2,241    | 1,629    | 506      | 2,135    |\n| RotaTeq                                | 493      | 276      | 769      | 508      | 275      | 783      | 473      | 334      | 807      |\n| Vaxneuvance                            | 561      | 103      | 665      | 163      | 7        | 170      | 3        | -        | 3        |\n| Pneumovax 23                           | 127      | 285      | 412      | 346      | 256      | 602      | 547      | 346      | 893      |\n| Vaqta                                  | 119      | 61       | 180      | 95       | 78       | 173      | 100      | 79       | 179      |\n| Hospital Acute Care                    |          |          |          |          |          |          |          |          |          |\n| Bridion                                | 1,156    | 686      | 1,842    | 922      | 762      | 1,685    | 762      | 770      | 1,532    |\n| Prevymis                               | 264      | 341      | 605      | 188      | 240      | 428      | 153      | 218      | 370      |\n| Dificid                                | 274      | 28       | 302      | 241      | 22       | 263      | 166      | 10       | 175      |\n| Zerbaxa                                | 119      | 100      | 218      | 89       | 79       | 169      | 4        | (5)      | (1)      |\n| Noxafil                                | 32       | 181      | 213      | 51       | 187      | 238      | 60       | 199      | 259      |\n| Primaxin                               | 1        | 211      | 213      | 1        | 238      | 239      | 2        | 258      | 259      |\n| Cardiovascular                         |          |          |          |          |          |          |          |          |          |\n| Alliance revenue - Adempas/Verquvo (3) | 350      | 16       | 367      | 329      | 12       | 341      | 312      | 30       | 342      |\n| Adempas                                | -        | 255      | 255      | -        | 238      | 238      | -        | 252      | 252      |\n| Virology                               |          |          |          |          |          |          |          |          |          |\n| Lagevrio                               | 10       | 1,418    | 1,428    | 1,523    | 4,161    | 5,684    | 632      | 320      | 952      |\n| Isentress/Isentress HD                 | 215      | 268      | 483      | 274      | 359      | 633      | 294      | 474      | 769      |\n| Neuroscience                           |          |          |          |          |          |          |          |          |          |\n| Belsomra                               | 81       | 150      | 231      | 79       | 179      | 258      | 78       | 241      | 318      |\n| Immunology                             |          |          |          |          |          |          |          |          |          |\n| Simponi                                | -        | 710      | 710      | -        | 706      | 706      | -        | 825      | 825      |\n| Remicade                               | -        | 187      | 187      | -        | 207      | 207      | -        | 299      | 299      |\n| Diabetes                               |          |          |          |          |          |          |          |          |          |\n| Januvia                                | 1,151    | 1,039    | 2,189    | 1,248    | 1,565    | 2,813    | 1,404    | 1,920    | 3,324    |\n| Janumet                                | 223      | 954      | 1,177    | 355      | 1,344    | 1,700    | 367      | 1,597    | 1,964    |\n| Other pharmaceutical (4)               | 688      | 1,596    | 2,283    | 693      | 1,628    | 2,319    | 824      | 1,690    | 2,516    |\n| Total Pharmaceutical segment sales     | 26,539   | 27,044   | 53,583   | 24,989   | 27,016   | 52,005   | 20,401   | 22,353   | 42,754   |\n| Animal Health:                         |          |          |          |          |          |          |          |          |          |\n| Livestock                              | 700      | 2,637    | 3,337    | 710      | 2,590    | 3,300    | 667      | 2,628    | 3,295    |\n| Companion Animal                       | 1,104    | 1,184    | 2,288    | 1,112    | 1,138    | 2,250    | 1,091    | 1,182    | 2,273    |\n| Total Animal Health segment sales      | 1,804    | 3,821    | 5,625    | 1,822    | 3,728    | 5,550    | 1,758    | 3,810    | 5,568    |\n| Total segment sales                    | 28,343   | 30,865   | 59,208   | 26,811   | 30,744   | 57,555   | 22,159   | 26,163   | 48,322   |\n| Other (5)                              | 137      | 770      | 907      | 395      | 1,333    | 1,728    | 266      | 116      | 382      |\n|                                        | $ 28,480 | $ 31,635 | $ 60,115 | $ 27,206 | $ 32,077 | $ 59,283 | $ 22,425 | $ 26,279 | $ 48,704 |\n",
          "relationship": "Produces"
        },
        "end_node": {
          "id": "MRK",
          "name": "MRK",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 249,
      "question": "How does the litigation risk posed by MSP in the District of New Jersey relate to BMY's strategic investment in Celgene, and what impact could this have on the $35.7 billion Celgene acquisition cost already recognized in BMY's financials?",
      "answer": "The litigation risk involving MSP in the District of New Jersey stems from claims that mirror those in the Celgene class action litigation, where BMY (as a successor to Celgene) faces potential liabilities tied to the sale and reimbursement of drugs like Thalomid and Revlimid. This risk is directly connected to Celgene, which BMY acquired in 2019 for $35.7 billion in cash. The acquisition was intended to strengthen BMY\u2019s position in oncology and immunology, but it also assumed legacy liabilities such as the ongoing legal disputes. If the MSP litigation results in a significant judgment or settlement, it could materially affect the financial return on the Celgene acquisition, which was already a major capital outlay funded through cash and debt. The $89 million environmental liability noted in the CERCLA section further illustrates BMY's exposure to legacy costs post-acquisition, suggesting that additional legal liabilities like those from MSP could compound the financial burden.",
      "reasoning_steps": [
        "Hop 1: BMY(page_166) \u2192 MSP: BMY, through its Celgene acquisition, is named in a lawsuit by MSP in the District of New Jersey, where MSP claims damages related to the reimbursement of Celgene drugs, mirroring prior class action litigation.",
        "Hop 2: MSP \u2192 Celgene: The litigation involving MSP is directly tied to Celgene\u2019s legacy business practices, particularly around the marketing and reimbursement of Thalomid and Revlimid, and BMY inherited these liabilities post-acquisition.",
        "Hop 3: Celgene \u2190 BMY(page_116): BMY made a strategic decision to acquire Celgene for $35.7 billion in 2019, a move that significantly expanded its oncology portfolio but also assumed Celgene's legal and regulatory risks, including those now being pursued by MSP."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Involved_In]-> COMP -[Involved_In]-> COMP <-[Invests_In]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "MSP",
        "node_3": "Celgene",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "COMP",
        "node_3": "COMP",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_2": {
          "id": "MSP",
          "name": "MSP",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_166",
          "chunk_id": "chunk_1",
          "chunk_text": "In  May  2020,  Celgene  filed  suit  against  Humana  Pharmacy,  Inc.  ('HPI'),  a  Humana  subsidiary,  in  Delaware  Superior  Court. Celgene's complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI's breach as well as a declaratory judgment. A trial has been scheduled for March 2023.\n\nIn July 2020, Blue Cross Blue Shield Association ('BCBSA') sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA's complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn August 2020, BCBSM Inc., Health Care Service Corporation ('HCSC'), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. ('Molina') sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid . In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs' motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants' motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.\n\nIn  January  2021,  Cigna  Corporation  ('Cigna')  sued  Celgene  and  BMS  in  the  U.S.  District  Court  for  the  Eastern  District  of Pennsylvania. Cigna's complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna's complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties' joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.\n\nIn May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina's complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina's motion to remand to San Francisco Superior Court. No trial date has been scheduled.\n\nIn December 2021, a group of plaintiffs-MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, 'MSP')-sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP's complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid ,  and purports to bring direct and indirect purchaser claims. No trial date has been scheduled.\n\n## GOVERNMENT INVESTIGATIONS\n\nLike other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.\n\n## ENVIRONMENTAL PROCEEDINGS\n\nAs previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.\n\n## CERCLA Matters\n\nWith respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other 'potentially responsible parties,' and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at December 31, 2021, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.",
          "relationship": "Involved_In"
        },
        "node_3": {
          "id": "Celgene",
          "name": "Celgene",
          "type": "COMP",
          "idf_score": 6.573680166960646
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "page_id": "page_116",
          "chunk_id": "chunk_1",
          "chunk_text": "## Eisai\n\nIn 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of  MORAb-202, a selective folate  receptor  alpha  antibody-drug  conjugate  being  investigated  in  endometrial,  ovarian,  lung  and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors.\n\nThe parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the 'collaboration territory'). Eisai will be responsible for the global manufacturing and supply.  Profits,  research  and  development  and  commercialization  costs  are  shared  in  the  collaboration  territories.  BMS  will  be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales.\n\nA $650 million up-front collaboration fee was included in Research and development expense in 2021. BMS is also obligated to pay  up  to $2.5 billion upon  the achievement  of  contingent development,  regulatory and  sales-based milestones.  Cost reimbursements were not material.\n\n## Otsuka\n\nBMS and Otsuka  co-promoted Sprycel in  the  U.S.  and  the  EU  through  2019.  BMS  was  responsible  for  the  development  and manufacture of the product and was also the principal in the end customer product sales. A fee was paid to Otsuka through 2020 based on net sales levels in the Oncology Territory (U.S., Japan and the EU) that equated to $294 million on the first $1.0 billion of annual net sales plus 1% of net sales in excess of $1.0 billion.\n\nEffective January 1, 2020, Otsuka was no longer co-promoting Sprycel in the U.S. and as a result, this arrangement was no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2021 and 2020 are not included in the selected financial information table above.\n\nIn 2019, revenues earned from the Otsuka alliance were $1.8 billion and payments to Otsuka of $302 million were recorded in Cost of product sold.\n\n## Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS\n\n## Acquisitions\n\n## Business Combination\n\n## Celgene\n\nOn November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical  company  for  sustained  innovation  and  long-term  growth  and  to  address  the  needs  of  patients  with  cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. Each share of Celgene common stock was converted into a right to receive one share of BMS common stock and $50.00 in cash. Celgene  shareholders  also  received  one  tradeable  contingent  value  right  ('CVR')  for  each  share  of  Celgene  common  stock representing the right to receive $9.00 in cash, subject to the achievement of future regulatory milestones.\n\nThe aggregate cash paid in connection with the Celgene acquisition was $35.7 billion (or $24.6 billion net of cash acquired). BMS funded the acquisition through cash on-hand and debt proceeds.\n\nThe  transaction  was  accounted  for  as  a  business  combination  which  requires  that  assets  acquired  and  liabilities  assumed  be recognized at their fair value as of the acquisition date. The assessment of the fair value of assets acquired and liabilities assumed was finalized in 2020.",
          "relationship": "Invests_In"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 250,
      "question": "What does the successful FDA approval of repotrectinib (marketed as Augtyro) suggest about the effectiveness of BMY's acquisition-driven strategy in expanding its oncology portfolio, particularly in light of the $4.1 billion investment in Turning Point and the broader strategic focus on launching new medicines?",
      "answer": "The successful FDA approval of repotrectinib, now marketed as Augtyro, underscores the effectiveness of BMY's acquisition-driven strategy in rapidly expanding its oncology portfolio with high-value assets. The $4.1 billion acquisition of Turning Point in 2022 directly enabled BMY to bring Augtyro to market, aligning with the company's strategic focus on launching new medicines and diversifying beyond IO, as highlighted in the strategy section. This outcome reflects the company\u2019s broader ambition to accelerate the development of next-wave oncology mechanisms and deliver transformative treatments for refractory oncology patients. The approval not only validates the strategic fit of the Turning Point acquisition but also demonstrates BMY's ability to integrate and advance externally sourced assets into its commercial portfolio efficiently.",
      "reasoning_steps": [
        "Hop 1: BMY(page_43) \u2192 Augtyro: BMY's strategy section emphasizes the importance of launching new medicines and diversifying its oncology portfolio beyond IO, with a focus on accelerating next-wave oncology mechanisms and treatments for refractory patients.",
        "Hop 2: Augtyro \u2192 Repotrectinib: Augtyro is the marketed form of repotrectinib, which BMY acquired through the $4.1 billion purchase of Turning Point in 2022.",
        "Hop 3: Repotrectinib \u2190 BMY(page_88): The FDA approved repotrectinib in November 2023, marking a successful regulatory outcome that validates BMY's acquisition strategy and its ability to bring externally developed assets to market."
      ],
      "difficulty": "hard",
      "idf_score": 7.266827347520591,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> PRODUCT -[Related_To]-> PRODUCT <-[Introduces]- ORG",
      "entities": {
        "start": "BMY",
        "node_2": "Augtyro",
        "node_3": "Repotrectinib",
        "end": "BMY"
      },
      "entity_types": {
        "start": "ORG",
        "node_2": "PRODUCT",
        "node_3": "PRODUCT",
        "end": "ORG"
      },
      "hop_count": 3,
      "document_relationship": "intra_document",
      "path_data": {
        "start_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_43",
          "chunk_id": "chunk_1",
          "chunk_text": "## Strategy\n\nOur\tprincipal\tstrategy\tis\tto\tcombine\tthe\tresources,\tscale\tand\tcapability\tof\ta\tlarge\tpharmaceutical\tcompany\twith\tthe\tspeed, agility\tand\tfocus\ton\tinnovation\ttypically\tfound\tin\tthe\tbiotech\tindustry.\tOur\tpriorities\tare\t(i)\tto\tcontinue\tto\trenew\tand diversify\t our\t portfolio\t through\t launching\t new\t medicines,\t (ii)\t advancing\t our\t early,\t mid\t and\t late-stage\t pipeline\t and\t (iii) executing\tdisciplined\tbusiness\tdevelopment.\tAs\twe\tundergo\ta\tperiod\tof\trenewal,\tour\tstrategy\twill\tbe\tfocused\ton\tdriving\tnearterm\t growth,\t minimizing\t the\t impact\t of\t a\t transition\t period\t that\t follows\t and\t delivering\t growth\t in\t the\t late\t 2020s\t by accelerating\t opportunities\t that\t enhance\t productivity\t and\t efficiency,\t advance\t our\t pipeline,\t and\t drive\t strong\t commercial execution\tthat\tmove\tour\tbusiness\tforward.\tWe\tremain\tcommitted\tto\ta\tstrategic\tbusiness\tdevelopment\tand\tmaintaining\ta\tstrong investment\tgrade\tcredit\trating,\tgrowing\tthe\tdividend\tand\treducing\tadditional\tdebt\tthat\twill\tbe\tissued\tin\tsupport\tof\trecent transactions.\n\nOur\tfocus\tis\ton\tdiscovering,\tdeveloping\tand\tdelivering\ttransformational\tmedicines\tfor\tpatients\tfacing\tserious\tdiseases\tin\tthe following\tfive\tcore\ttherapeutic\tareas:\t(i)\toncology\twith\ta\tpriority\tin\tcertain\ttumor\ttypes,\tincluding\tdiversification\tbeyond IO;\t(ii)\thematology\twith\topportunities\tto\texpand\tleadership\tposition\tin\tmultiple\tmyeloma,\tas\twell\tas\tbroaden\tour\tportfolio across\t leukemias,\t lymphomas\t and\t non-malignant\t hematologic\t diseases;\t (iii)\t immunology\t with\t priorities\t in\t strengthening presence\tin\tdermatology,\trheumatology\tand\tgastrointestinal\tdisorders,\testablishing\tnew\tstandards\tof\tcare\tin\tpulmonology\tand rapidly\t advance\t cell\t therapy\t into\t immunology\t diseases;\t (iv)\t cardiovascular\t diseases\t with\t focus\t on\t cardiomyopathies,\t heart failures and thrombotic diseases; and (v) neuroscience with a focus on neuropsychiatry, neurodegenerative and neuroinflammation\tdiseases.\n\nWe\t are\t working\t towards\t expanding\t our\t pipeline\t of\t registrational\t assets\t from\t six\t to\t up\t to\t twelve.\t In\t addition,\t we\t are positioned\t to\t support\t continued\t innovation\t and\t expand\t treatment\t options\t across\t several\t different\t diseases\t based\t on\t our differentiated\tresearch\tplatforms.\tWe\thave\ta\tbroad\tportfolio\tand\tpipeline\twhen\tit\tcomes\tto\tautologous\tCAR-T\tcell\ttherapies. We\thave\ttwo\tapproved\tcell\ttherapies\tagainst\ttwo\tdistinct\ttargets\tand\tare\tcontinuing\tto\tbuild\tour\tleadership\tin\tthis\tspace.\tWe are\t expanding\t manufacturing\t capacity,\t exploring\t innovative\t technologies\t such\t as\t dual-targeting\t CAR-Ts\t and\t allogenic approaches,\tadvancing\tmultiple\tnext-generation\tassets\tincluding\tnew\ttargets\tand\trapidly\texpanding\tinto\timmunology,\tincluding lupus\tand\tmultiple\tsclerosis.\tWe\talso\thave\ta\tstrong\tposition\tin\tthe\tprotein\tdegradation\tfield\tand\thave\tbeen\tadvancing\tour pipeline\twith\tan\texpansive\tlibrary\tof\tassets\twith\ttwo\tin\tregistrational\ttrials,\tan\tadditional\tfive\tin\tclinical\tphase\tstudies and\t more\t than\t fifteen\t being\t studied\t pre-clinically.\t This\t growing\t platform\t has\t potential\t across\t several\t diseases\t and\t is positioned\tto\tdeliver\tapproximately\tfour\tINDs\teach\tyear.\tTogether\twith\tour\tproven\ttrack\trecord,\trapidly\tadvancing\tpipeline and\tgrowth\twith\tmarketed\tproducts,\twe\tincreased\tand\tsustained\tour\tR&amp;D\tproductivity\tenabling\tus\tto\tidentify\tmore\thigh-quality candidates\t and\t increase\t their\t probability\t of\t reaching\t patients\t in\t need.\t Specifically,\t our\t ambition\t is\t to:\t (i)\t deliver approximately\tten\tINDs\tper\tyear;\t(ii)\tincrease\tsuccess\trates\tfrom\tfirst-in-human\ttrials\tto\tapproval\tto\tapproximately\t20%; (iii)\treduce\ttimelines\tto\tachieve\ta\tmedian\tof\t6.5\tyears\tfrom\tfirst-in-human\ttrials\tto\tapproval.\tOur\tR&amp;D\tstrategy\twill\thelp ensure\t we\t maintain\t a\t strong\t legacy\t of\t scientific\t innovation,\t bringing\t first-in\t class\t and/or\t best-in-class\t treatments\t to patients\tat\tan\taccelerated\tspeed.\n\nOur\tcommercial\tmodel\thas\tbeen\tsuccessful\twith\trevenues\tfrom\tour\tin-line\tbrands\tand\tnew\tproduct\tportfolio\tcontinuing\tto\tgrow, which\tdemonstrates\tstrong\texecution\tof\tour\tstrategy.\tWe\tremain\tfocused\tand\twell-resourced\tin\tour\tcancer\tdevelopment\tprograms and\tseek\tto\tbroaden\tthe\tuse\tof Opdivo in\tearlier\tlines\tof\ttherapy,\texpand\tinto\tnew\ttumors,\taccelerate\tnext\twave\toncology mechanisms\t and\t develop\t treatment\t options\t for\t refractory\t oncology\t patients.\t We\t are\t encouraged\t that\t our\t investigational subcutaneous\t formulation\t for Opdivo has\t the\t potential\t to\t bring\t enhanced\t benefits\t to\t patients\t into\t the\t next\t decade,\t with positive\tregistrational\tdata\tnow\tin-house.\tWe\tcontinue\tto\tdrive\tadoption\tof Opdivo by\texpanding\tinto\tadditional\tindications and\t tumor\t types\t both\t as\t a\t monotherapy\t and\t in\t combination\t with Yervoy and\t other\t anti-cancer\t agents.\t We\t are\t further strengthening\t our\t IO\t portfolio\t with Opdualag for\t the\t treatment\t of\t melanoma\t and\t potential\t expanded\t opportunities\t in\t other indications.\t We\t are\t growing\t a\t differentiated\t NSCLC\t portfolio,\t which\t includes\t the\t launch\t of Augtyro and\t includes Krazati , (acquired\t through\t Mirati),\t which\t demonstrates\t a\t strategic\t fit\t into\t our\t oncology\t portfolio.\t We\t are\t also\t strengthening\t our neuroscience\tportfolio\twith\tthe\tplanned\tacquisition\tof\tKaruna.\tMoreover, Eliquis continues\tto\tgrow,\tleveraging\tits\tbest\tin class\t clinical\t profile\t and\t extensive\t real\t world\t data\t and\t remains\t the\t number\t one\t novel\t oral\t anticoagulant\t in\t total prescriptions\tglobally. Camzyos continues\tto\tdemonstrate\tbenefits\tas\tshared\tthrough\tour\tlong-term\tfollow-up\tdata\tfrom\ttwo Phase\tIII\tstudies.\tIn\timmunology, Sotyktu is\tthe\tkey\tgrowth\tdriver\tfor\tBMS\tand\twe\tcontinue\tto\tmake\tfurther\tinvestments\tto accelerate\t the\t launch\t through\t direct\t to\t consumer\t advertising\t and\t adding\t field\t force\t support.\t In\t addition,\t our\t Phase\t III registrational\t clinical\t trials\t are\t underway\t for Sotyktu in\t PsA,\t SLE\t and\t Sj\u00f6gren's\t Syndrome.\t We\t are\t able\t to\t leverage\t our leading\tcapabilities\tin\thematological\tmalignancies\tand\tour\trobust\tpipeline\tto\tprovide\topportunities\tfor\tlong-term\tgrowth\tto offset\tthe\timpact\tof\tcurrent\tand\tfuture\tpatent\texpiries\tfor Revlimid and Pomalyst .\tAs\twe\tlook\tat\tour\tcell\ttherapy\tfranchise, we\tcontinue\tto\texplore\tnew\tindications\twith Breyanzi to\tinclude\tthe\ttreatment\tof\tCLL,\tFL\tand\tMCL.\tIf\tindication\tfor\tCLL\tis approved,\t it\t would\t be\t the\t first\t and\t only\t CAR-T\t available\t for\t this\t patient\t population. Reblozyl is\t advancing\t into\t new indications\twith\tan\tongoing\tregistrational\ttrial\tfor\tchronic\tanemia\tassociated\twith\tmyelofibrosis.\n\nThe\t evolution\t in\t our\t operating\t model,\t which\t focuses\t on\t maintaining\t a\t disciplined\t approach\t in\t marketing,\t selling\t and administrative\texpenses,\twill\tenable\tus\tto\tdeliver\tthe\tnecessary\tstrategic,\tfinancial\tand\toperational\tflexibility\tto\tinvest in\tthe\thighest\tpriority\topportunities\twithin\tour\tportfolio.",
          "relationship": "Discloses"
        },
        "node_2": {
          "id": "Augtyro",
          "name": "Augtyro",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_88",
          "chunk_id": "chunk_1",
          "chunk_text": "BMS\t acquired\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Mirati's\t common\t stock\t for\t $58.00\t per\t share\t in\t an\t all-cash transaction\tfor\ta\ttotal\tconsideration\tof\t$4.8\tbillion\tor\t$4.1\tbillion,\tnet\tof\testimated\tcash\tacquired.\tMirati\tstockholders will\t also\t receive\t one\t non-tradeable\t contingent\t value\t right\t for\t each\t share\t of\t Mirati\t common\t stock\t held,\t potentially\t worth $12.00\tper\tshare\tin\tcash\tfor\ta\ttotal\tvalue\tof\tapproximately\t$1.0\tbillion.\tThe\tpayout\tof\tthe\tcontingent\tvalue\tright\tis\tsubject to\tthe\tFDA\tacceptance\tof\tan\tNDA\tfor\tMRTX1719\tfor\tthe\ttreatment\tof\tspecific\tindications\twithin\tseven\tyears\tof\tthe\tclosing\tof the\ttransaction.\tThe\ttransaction\twill\tbe\taccounted\tfor\tas\ta\tbusiness\tcombination\tin\twhich\tall\tassets\tacquired\tand\tliabilities assumed\t will\t be\t recognized\t at\t fair\t value\t as\t of\t the\t acquisition\t date.\t The\t purchase\t price\t allocation\t of\t the\t consideration transferred\tto\tthe\tassets\tacquired\tand\tliabilities\tassumed\thas\tnot\tyet\tbeen\tfinalized.\tThe\tacquisition\twas\tfunded\tthrough\ta combination\tof\tcash\ton\thand\tand\tdebt\tproceeds.\n\n## Karuna\n\nIn\t December\t 2023,\t BMS\t entered\t into\t a\t definitive\t merger\t agreement\t to\t acquire\t Karuna,\t a\t clinical-stage\t biopharmaceutical company\tdriven\tto\tdiscover,\tdevelop,\tand\tdeliver\ttransformative\tmedicines\tfor\tpeople\tliving\twith\tpsychiatric\tand\tneurological conditions.\tThe\tacquisition\twill\tprovide\tBMS\twith\trights\tto\tKaruna's\tlead\tasset,\tKarXT\t(xanomeline-trospium).\tKarXT\tis\tan antipsychotic\twith\ta\tnovel\tmechanism\tof\taction\tand\tdifferentiated\tefficacy\tand\tsafety,\tis\tcurrently\tunder\treview\tby\tthe\tFDA for\tthe\ttreatment\tof\tschizophrenia\tin\tadults\twith\ta\tPDUFA\tdate\tof\tSeptember\t26,\t2024.\tKarXT\tis\talso\tin\tregistrational\ttrials for\t both\t adjunctive\t therapy\t to\t existing\t standard\t of\t care\t agents\t in\t schizophrenia\t and\t for\t the\t treatment\t of\t psychosis\t in patients\twith\tAlzheimer's\tdisease.\n\nBMS\t will\t acquire\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Karuna's\t common\t stock\t for\t $330.00\t per\t share\t in\t an\t all-cash transaction\t for\t a\t total\t consideration\t of\t $14.0\t billion.\t The\t accounting\t treatment\t as\t a\t business\t combination\t or\t asset acquisition\twill\tbe\tdetermined\tin\tthe\tperiod\tthe\ttransaction\tcloses.\tThe\ttransaction\tis\texpected\tto\tclose\tin\tthe\tfirst\thalf of\t 2024,\t subject\t to\t customary\t closing\t conditions,\t including\t approval\t of\t Karuna\t stockholders\t and\t receipt\t of\t regulatory approvals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## RayzeBio\n\nIn\tDecember\t2023,\tBMS\tentered\tinto\ta\tdefinitive\tmerger\tagreement\tto\tacquire\tRayzeBio,\ta\tclinical-stage\tradiopharmaceutical therapeutics\t (RPT)\t company\t with\t actinium-based\t RPTs\t for\t solid\t tumors.\t The\t acquisition\t will\t provide\t BMS\t with\t rights\t to RayzeBio's\t actinium-based\t radiopharmaceutical\t platform\t and\t lead\t asset,\t RYZ101,\t which\t is\t in\t Phase\t III\t development\t for treatment\tof\tgastroenteropancreatic\tneuroendocrine\ttumors.\n\nBMS\twill\tacquire\tall\tof\tthe\tissued\tand\toutstanding\tshares\tof\tRayzeBio's\tcommon\tstock\tfor\t$62.50\tper\tshare\tin\tan\tall-cash transaction\t for\t a\t total\t consideration\t of\t $4.1\t billion.\t The\t transaction\t is\t expected\t to\t be\t accounted\t for\t as\t a\t business combination\tand\tis\tanticipated\tto\tclose\tin\tthe\tfirst\thalf\tof\t2024,\tsubject\tto\tfulfillment\tof\tcustomary\tclosing\tconditions, including\treceipt\tof\trequired\tregulatory\tapprovals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## Orum\n\nIn\tNovember\t2023,\tBMS\tacquired\tthe\trights\tto\tOrum's\tORM-6151\tprogram,\twhich\tis\tin\tpreclinical\tdevelopment.\tORM-6151\tis\ta anti-CD33\tantibody-enabled\tGSPT1\tdegrader\tthat\thas\treceived\tthe\tFDA's\tclearance\tfor\tPhase\tI\tfor\tthe\ttreatment\tof\tpatients with\t acute\t myeloid\t leukemia\t or\t high-risk\t myelodysplastic\t syndromes.\t The\t consideration\t included\t an\t upfront\t payment\t of $100\tmillion,\tas\twell\tas\tcontingent\tdevelopment\tmilestone\tpayments\tup\tto\t$80\tmillion.\tThe\tupfront\tpayment\twas\texpensed\tto Acquired\tIPRD.\n\n## Turning\tPoint\n\nIn\t2022,\tBMS\tacquired\tTurning\tPoint\tfor\t$4.1\tbillion\tof\tcash\t(or\t$3.3\tbillion\tnet\tof\tcash\tacquired).\tTurning\tPoint\twas\ta clinical-stage\t precision\t oncology\t company\t with\t a\t pipeline\t of\t investigational\t medicines\t designed\t to\t target\t the\t common mutations\t and\t alterations\t that\t drive\t cancer\t growth.\t The\t acquisition\t provided\t BMS\t rights\t to\t Turning\t Point's\t lead\t asset, repotrectinib,\tand\tother\tclinical\tand\tpre-clinical\tstage\tassets.\tRepotrectinib\twas\tapproved\tby\tthe\tFDA\tin\tNovember\t2023\tand is\tmarketed\tunder\tthe\tbrand\tname Augtyro.\n\nThe\t transaction\t was\t accounted\t for\t as\t a\t business\t combination\t in\t which\t all\t assets\t acquired\t and\t liabilities\t assumed\t were recognized\tat\tfair\tvalue\tas\tof\tthe\tacquisition\tdate.",
          "relationship": "Related_To"
        },
        "node_3": {
          "id": "Repotrectinib",
          "name": "Repotrectinib",
          "type": "PRODUCT",
          "idf_score": 7.266827347520591
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "page_id": "page_88",
          "chunk_id": "chunk_1",
          "chunk_text": "BMS\t acquired\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Mirati's\t common\t stock\t for\t $58.00\t per\t share\t in\t an\t all-cash transaction\tfor\ta\ttotal\tconsideration\tof\t$4.8\tbillion\tor\t$4.1\tbillion,\tnet\tof\testimated\tcash\tacquired.\tMirati\tstockholders will\t also\t receive\t one\t non-tradeable\t contingent\t value\t right\t for\t each\t share\t of\t Mirati\t common\t stock\t held,\t potentially\t worth $12.00\tper\tshare\tin\tcash\tfor\ta\ttotal\tvalue\tof\tapproximately\t$1.0\tbillion.\tThe\tpayout\tof\tthe\tcontingent\tvalue\tright\tis\tsubject to\tthe\tFDA\tacceptance\tof\tan\tNDA\tfor\tMRTX1719\tfor\tthe\ttreatment\tof\tspecific\tindications\twithin\tseven\tyears\tof\tthe\tclosing\tof the\ttransaction.\tThe\ttransaction\twill\tbe\taccounted\tfor\tas\ta\tbusiness\tcombination\tin\twhich\tall\tassets\tacquired\tand\tliabilities assumed\t will\t be\t recognized\t at\t fair\t value\t as\t of\t the\t acquisition\t date.\t The\t purchase\t price\t allocation\t of\t the\t consideration transferred\tto\tthe\tassets\tacquired\tand\tliabilities\tassumed\thas\tnot\tyet\tbeen\tfinalized.\tThe\tacquisition\twas\tfunded\tthrough\ta combination\tof\tcash\ton\thand\tand\tdebt\tproceeds.\n\n## Karuna\n\nIn\t December\t 2023,\t BMS\t entered\t into\t a\t definitive\t merger\t agreement\t to\t acquire\t Karuna,\t a\t clinical-stage\t biopharmaceutical company\tdriven\tto\tdiscover,\tdevelop,\tand\tdeliver\ttransformative\tmedicines\tfor\tpeople\tliving\twith\tpsychiatric\tand\tneurological conditions.\tThe\tacquisition\twill\tprovide\tBMS\twith\trights\tto\tKaruna's\tlead\tasset,\tKarXT\t(xanomeline-trospium).\tKarXT\tis\tan antipsychotic\twith\ta\tnovel\tmechanism\tof\taction\tand\tdifferentiated\tefficacy\tand\tsafety,\tis\tcurrently\tunder\treview\tby\tthe\tFDA for\tthe\ttreatment\tof\tschizophrenia\tin\tadults\twith\ta\tPDUFA\tdate\tof\tSeptember\t26,\t2024.\tKarXT\tis\talso\tin\tregistrational\ttrials for\t both\t adjunctive\t therapy\t to\t existing\t standard\t of\t care\t agents\t in\t schizophrenia\t and\t for\t the\t treatment\t of\t psychosis\t in patients\twith\tAlzheimer's\tdisease.\n\nBMS\t will\t acquire\t all\t of\t the\t issued\t and\t outstanding\t shares\t of\t Karuna's\t common\t stock\t for\t $330.00\t per\t share\t in\t an\t all-cash transaction\t for\t a\t total\t consideration\t of\t $14.0\t billion.\t The\t accounting\t treatment\t as\t a\t business\t combination\t or\t asset acquisition\twill\tbe\tdetermined\tin\tthe\tperiod\tthe\ttransaction\tcloses.\tThe\ttransaction\tis\texpected\tto\tclose\tin\tthe\tfirst\thalf of\t 2024,\t subject\t to\t customary\t closing\t conditions,\t including\t approval\t of\t Karuna\t stockholders\t and\t receipt\t of\t regulatory approvals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## RayzeBio\n\nIn\tDecember\t2023,\tBMS\tentered\tinto\ta\tdefinitive\tmerger\tagreement\tto\tacquire\tRayzeBio,\ta\tclinical-stage\tradiopharmaceutical therapeutics\t (RPT)\t company\t with\t actinium-based\t RPTs\t for\t solid\t tumors.\t The\t acquisition\t will\t provide\t BMS\t with\t rights\t to RayzeBio's\t actinium-based\t radiopharmaceutical\t platform\t and\t lead\t asset,\t RYZ101,\t which\t is\t in\t Phase\t III\t development\t for treatment\tof\tgastroenteropancreatic\tneuroendocrine\ttumors.\n\nBMS\twill\tacquire\tall\tof\tthe\tissued\tand\toutstanding\tshares\tof\tRayzeBio's\tcommon\tstock\tfor\t$62.50\tper\tshare\tin\tan\tall-cash transaction\t for\t a\t total\t consideration\t of\t $4.1\t billion.\t The\t transaction\t is\t expected\t to\t be\t accounted\t for\t as\t a\t business combination\tand\tis\tanticipated\tto\tclose\tin\tthe\tfirst\thalf\tof\t2024,\tsubject\tto\tfulfillment\tof\tcustomary\tclosing\tconditions, including\treceipt\tof\trequired\tregulatory\tapprovals.\tThe\tacquisition\twill\tbe\tfunded\tprimarily\twith\tfuture\tdebt\tproceeds.\n\n## Orum\n\nIn\tNovember\t2023,\tBMS\tacquired\tthe\trights\tto\tOrum's\tORM-6151\tprogram,\twhich\tis\tin\tpreclinical\tdevelopment.\tORM-6151\tis\ta anti-CD33\tantibody-enabled\tGSPT1\tdegrader\tthat\thas\treceived\tthe\tFDA's\tclearance\tfor\tPhase\tI\tfor\tthe\ttreatment\tof\tpatients with\t acute\t myeloid\t leukemia\t or\t high-risk\t myelodysplastic\t syndromes.\t The\t consideration\t included\t an\t upfront\t payment\t of $100\tmillion,\tas\twell\tas\tcontingent\tdevelopment\tmilestone\tpayments\tup\tto\t$80\tmillion.\tThe\tupfront\tpayment\twas\texpensed\tto Acquired\tIPRD.\n\n## Turning\tPoint\n\nIn\t2022,\tBMS\tacquired\tTurning\tPoint\tfor\t$4.1\tbillion\tof\tcash\t(or\t$3.3\tbillion\tnet\tof\tcash\tacquired).\tTurning\tPoint\twas\ta clinical-stage\t precision\t oncology\t company\t with\t a\t pipeline\t of\t investigational\t medicines\t designed\t to\t target\t the\t common mutations\t and\t alterations\t that\t drive\t cancer\t growth.\t The\t acquisition\t provided\t BMS\t rights\t to\t Turning\t Point's\t lead\t asset, repotrectinib,\tand\tother\tclinical\tand\tpre-clinical\tstage\tassets.\tRepotrectinib\twas\tapproved\tby\tthe\tFDA\tin\tNovember\t2023\tand is\tmarketed\tunder\tthe\tbrand\tname Augtyro.\n\nThe\t transaction\t was\t accounted\t for\t as\t a\t business\t combination\t in\t which\t all\t assets\t acquired\t and\t liabilities\t assumed\t were recognized\tat\tfair\tvalue\tas\tof\tthe\tacquisition\tdate.",
          "relationship": "Introduces"
        },
        "end_node": {
          "id": "BMY",
          "name": "BMY",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    }
  ]
}